PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	KASMAN, DL				KASMAN, DL			WHEN A HEART STOPS	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											KASMAN, DL (corresponding author), PROVIDENCE RAINIER MED CLIN, 8444 RAINIER AVE S, SEATTLE, WA 98118 USA.								0	2	2	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1994	120	5					432	433		10.7326/0003-4819-120-5-199403010-00012	http://dx.doi.org/10.7326/0003-4819-120-5-199403010-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY497	8304662				2022-12-01	WOS:A1994MY49700012
J	LAL, RB; OWEN, SM; SEGURADO, AAC; GONGORABIACHI, RA				LAL, RB; OWEN, SM; SEGURADO, AAC; GONGORABIACHI, RA			MOTHER-TO-CHILD TRANSMISSION OF HUMAN T-LYMPHOTROPIC VIRUS TYPE-II (HTLV-II)	ANNALS OF INTERNAL MEDICINE			English	Note							CELL LEUKEMIA-VIRUS; MILK		CTR INVEST REG MERIDA, YUCATAN, MEXICO		LAL, RB (corresponding author), CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV VIRAL & RICKETTSIAL DIS, ATLANTA, GA 30333 USA.		Segurado, Aluisio C/K-2229-2012	Segurado, Aluisio C/0000-0002-6311-8036				BRODINE SK, IN PRESS TRANSFUSION; GONGORABIACHI RA, 1992, J ACQ IMMUN DEF SYND, V5, P104; HENEINE W, 1992, LANCET, V340, P1157, DOI 10.1016/0140-6736(92)93182-M; HJELLE B, 1992, ANN INTERN MED, V116, P90, DOI 10.7326/0003-4819-116-1-90; KAJIYAMA W, 1986, J INFECT DIS, V154, P851, DOI 10.1093/infdis/154.5.851; KAPLAN JE, 1992, J INFECT DIS, V166, P892, DOI 10.1093/infdis/166.4.892; KHABBAZ RF, 1993, ANN INTERN MED, V118, P448; LAL RB, 1992, BLOOD, V80, P544; MANNS A, 1991, BLOOD, V77, P896; YAMANOUCHI K, 1985, JPN J CANCER RES, V76, P481	10	8	9	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 15	1994	120	4					300	301		10.7326/0003-4819-120-4-199402150-00007	http://dx.doi.org/10.7326/0003-4819-120-4-199402150-00007			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW103	8291823				2022-12-01	WOS:A1994MW10300007
J	SCHIEVINK, WI; MOKRI, B; OFALLON, WM				SCHIEVINK, WI; MOKRI, B; OFALLON, WM			RECURRENT SPONTANEOUS CERVICAL-ARTERY DISSECTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTERNAL CAROTID-ARTERY; SYNDROME TYPE-IV; INTRACRANIAL ANEURYSMS; STROKE	Background. Spontaneous dissection of the internal carotid and vertebral arteries is increasingly recognized as a cause of ischemic stroke in young people. An underlying arteriopathy is often suspected in the pathogenesis of such dissection, but the frequency of recurrent dissection is unknown. Methods. We describe the long-term follow-up of 200 consecutive patients (104 women and 96 men) with spontaneous cervical-artery dissections evaluated at the Mayo Clinic between 1970 and 1990. All diagnoses were confirmed by angiography. Results. The mean age of the patients was 44.9 years (range, 16 to 76). Internal carotid arteries were affected in 150 patients, vertebral arteries in 37, and both in 13. Multivessel dissections were present in 28 percent of the patients. The mean follow-up was 7.4 years. Recurrent dissection occurred only in arteries not previously involved by dissection. A recurrent arterial dissection developed in 16 patients (8 percent) - within a month after the initial dissection in 4 patients (2 percent) and between 1.4 and 8.6 years later in 12 patients (a rate of 1 percent per year). The cumulative rate of recurrent dissection among patients followed for 10 years was 11.9 percent. Younger patients had a greater risk of recurrent dissection. Conclusions. Although dissections in multiple cervical vessels are common at presentation, after the first month the risk of recurrent dissection is only about 1 percent per year.	MAYO CLIN & MAYO FDN,DEPT NEUROL,200 1ST ST SW,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT NEUROL SURG,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic								ANDERSON RM, 1959, J NEUROL NEUROSUR PS, V22, P195, DOI 10.1136/jnnp.22.3.195; AUSTIN MG, 1957, ARCH PATHOL, V64, P205; BOGOUSSLAVSKY J, 1987, ARCH NEUROL-CHICAGO, V44, P817; BOGOUSSLAVSKY J, 1987, ARCH NEUROL-CHICAGO, V44, P137, DOI 10.1001/archneur.1987.00520140009010; BOGOUSSLAVSKY J, 1987, ARCH NEUROL-CHICAGO, V44, P479, DOI 10.1001/archneur.1987.00520170009012; BOSTROM K, 1967, NEUROLOGY, V17, P179, DOI 10.1212/WNL.17.2.179; BRICE JG, 1964, BRIT MED J, V2, P790; BROWN OL, 1973, AM J ROENTGENOL, V118, P648, DOI 10.2214/ajr.118.3.648; CHATILLON JD, 1990, PRESSE MED, V19, P661; COX DR, 1972, J R STAT SOC B, V34, P187; Cronqvist S E, 1986, Acta Radiol Suppl, V369, P34; FISHER CM, 1978, CAN J NEUROL SCI, V5, P9, DOI 10.1017/S0317167100024690; Hart R G, 1983, Neurol Clin, V1, P155; HOUSER OW, 1984, AM J NEURORADIOL, V5, P27; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MANTEL N, 1967, BIOMETRICS, V23, P65, DOI 10.2307/2528282; MAS JL, 1987, STROKE, V18, P1037, DOI 10.1161/01.STR.18.6.1037; MOKRI B, 1987, STROKE, V18, P246, DOI 10.1161/01.STR.18.1.246; MOKRI B, 1990, J NEUROL, V237, P356, DOI 10.1007/BF00315659; MOKRI B, 1985, STROKE, V16, P959, DOI 10.1161/01.STR.16.6.959; MOKRI B, 1986, ANN NEUROL, V19, P126, DOI 10.1002/ana.410190204; MOKRI B, 1992, ARCH OTOLARYNGOL, V118, P431; MOKRI B, 1988, NEUROLOGY, V38, P880, DOI 10.1212/WNL.38.6.880; Mokri B, 1991, J Stroke Cerebrovasc Dis, V1, P117, DOI 10.1016/S1052-3057(10)80002-3; Mokri B, 1992, J Stroke Cerebrovasc Dis, V2, P100, DOI 10.1016/S1052-3057(10)80214-9; Mokri B, 1987, OCCLUSIVE CEREBROVAS, P38; ROHR J, 1987, REV NEUROL, V143, P115; SCHIEVINK WI, 1991, J NEUROSURG, V74, P991, DOI 10.3171/jns.1991.74.6.0991; SCHIEVINK WI, 1990, STROKE, V21, P626, DOI 10.1161/01.STR.21.4.626; SCHIEVINK WI, 1993, NEUROLOGY, V43, P1938, DOI 10.1212/WNL.43.10.1938; SCHIEVINK WI, 1993, STROKE, V24, P1678, DOI 10.1161/01.STR.24.11.1678; SCHIEVINK WI, 1991, STROKE, V22, P1426, DOI 10.1161/01.STR.22.11.1426; SCHIEVINK WI, 1992, J NEUROSURG, V76, P62, DOI 10.3171/jns.1992.76.1.0062; YOUL BD, 1990, STROKE, V21, P618, DOI 10.1161/01.STR.21.4.618	34	346	361	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	1994	330	6					393	397		10.1056/NEJM199402103300604	http://dx.doi.org/10.1056/NEJM199402103300604			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV279	8284004				2022-12-01	WOS:A1994MV27900004
J	MILLER, EK; DESIMONE, R				MILLER, EK; DESIMONE, R			PARALLEL NEURONAL MECHANISMS FOR SHORT-TERM-MEMORY	SCIENCE			English	Article							INFERIOR TEMPORAL CORTEX; HIPPOCAMPAL-FORMATION; RECOGNITION MEMORY; MONKEYS; TASKS	Although objects that have just been seen may persist in memory automatically for a time and interact passively with incoming stimulation, some tasks require that the memory be actively maintained and used. To test for the existence of separate automatic and volitional mechanisms of short-term memory, recordings were made from neurons in the inferior temporal cortex of monkeys while the monkeys held a sample picture ''in mind'' and signaled when it was repeated in a sequence of pictures, ignoring other stimulus repetitions. Some neurons were suppressed by any picture repetition, regardless of relevance, whereas others were enhanced, but only when a picture matched the sample. Short-term memory appears to reflect the parallel operation of these two mechanisms-one being automatic and the other active.			MILLER, EK (corresponding author), NIMH,NEUROPSYCHOL LAB,BLDG 49,ROOM 1B80,BETHESDA,MD 20892, USA.		Desimone, Robert/G-1121-2018; Miller, Earl K./AAE-8187-2019	Miller, Earl K./0000-0002-0582-6958				Baddeley A.D., 1986, WORKING MEMORY; BAYLIS GC, 1987, EXP BRAIN RES, V65, P614; Chelazzi L., 1993, Society for Neuroscience Abstracts, V19, P975; ESKANDAR EN, 1992, J NEUROPHYSIOL, V68, P1277, DOI 10.1152/jn.1992.68.4.1277; FUSTER JM, 1982, EXP NEUROL, V77, P679, DOI 10.1016/0014-4886(82)90238-2; FUSTER JM, 1981, SCIENCE, V212, P952, DOI 10.1126/science.7233192; GAFFAN D, 1992, BEHAV NEUROSCI, V106, P30, DOI 10.1037/0735-7044.106.1.30; GROSS CG, 1979, NEUROPSYCHOLOGIA, V17, P215, DOI 10.1016/0028-3932(79)90012-5; HOREL JA, 1987, BEHAV BRAIN RES, V23, P29, DOI 10.1016/0166-4328(87)90240-3; MEUNIER M, 1993, J NEUROSCI, V13, P5419; MILLER EK, 1993, J NEUROSCI, V13, P1460; MILLER EK, 1991, SCIENCE, V254, P1377, DOI 10.1126/science.1962197; RICHES IP, 1991, J NEUROSCI, V11, P1763; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; WILSON FAW, 1993, SCIENCE, V260, P1955, DOI 10.1126/science.8316836; ZOLAMORGAN S, 1989, J NEUROSCI, V9, P4355	16	435	437	2	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 28	1994	263	5146					520	522		10.1126/science.8290960	http://dx.doi.org/10.1126/science.8290960			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT966	8290960				2022-12-01	WOS:A1994MT96600033
J	WEBSTER, NR; WARD, MJ				WEBSTER, NR; WARD, MJ			BATTLEFIELD TRANSFUSIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter											WEBSTER, NR (corresponding author), ARMED SERV BLOOD PROGRAM OFF,FALLS CHURCH,VA, USA.								0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	1994	271	4					319	319						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR221	8295296				2022-12-01	WOS:A1994MR22100033
J	LILFORD, R				LILFORD, R			FORMAL MEASUREMENT OF CLINICAL UNCERTAINTY - PRELUDE TO A TRIAL IN PERINATAL MEDICINE	BMJ-BRITISH MEDICAL JOURNAL			English	Article									MALMO GEN HOSP, S-21401 MALMO, SWEDEN; QUEENS MED CTR, NOTTINGHAM NG7 2UH, ENGLAND; GEN INFIRM, LEEDS LS1 3EX, W YORKSHIRE, ENGLAND; N MANCHESTER GRP HOSP, MANCHESTER, ENGLAND; ST GEORGE HOSP, LONDON, ENGLAND; UNIV TURIN, I-10124 TURIN, ITALY; MRC, BIOSTAT UNIT, CAMBRIDGE, ENGLAND; UNIV GLASGOW, GLASGOW G12 8QQ, SCOTLAND	University of Nottingham; Leeds General Infirmary; St Georges University London; University of Turin; MRC Biostatistics Unit; University of Glasgow	LILFORD, R (corresponding author), UNIV LEEDS, INST EPIDEMIOL & HLTH SERV RES, LEEDS LS2 9LN, ENGLAND.		Thornton, Jim/B-8336-2008	Thornton, Jim/0000-0001-9764-6876; Walker, James/0000-0002-8922-083X; Todros, Tullia/0000-0003-3016-1510	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		[Anonymous], 1988, LANCET, V2, P349; JOHNSON N, 1991, J MED ETHICS, V17, P30, DOI 10.1136/jme.17.1.30; ODENDAAL HJ, 1990, OBSTET GYNECOL, V76, P1070; POCOCK SJ, 1990, STAT MED, V9, P657, DOI 10.1002/sim.4780090612; Williams C, 1992, INTRO NEW TREATMENTS, P49	5	31	31	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 8	1994	308	6921					111	112		10.1136/bmj.308.6921.111	http://dx.doi.org/10.1136/bmj.308.6921.111			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR173	8298380	Green Published			2022-12-01	WOS:A1994MR17300015
J	SMITH, RM; NEUMAN, TS				SMITH, RM; NEUMAN, TS			ELEVATION OF SERUM CREATINE-KINASE IN DIVERS WITH ARTERIAL GAS EMBOLIZATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AIR-EMBOLISM; ISOENZYME; BRAIN	Background. Arterial gas embolism due to pulmonary barotrauma and the resultant cerebral gas embolism are catastrophic complications of diving. Previous studies have only rarely noted evidence of gas embolism to noncranial sites. Methods. Among 142 persons with diving-related injuries evaluated between January 1982 and July 1991, we identified 29 who had arterial gas embolism and who underwent biochemical studies indicative of muscle injury. Of the 29 patients, 4 were excluded because cardiopulmonary resuscitation had been performed and 3 were excluded because the duration of their dives met or exceeded standard limits set for dives not requiring staged decompression. The outcome at the time of hospital discharge in the remaining 22 patients was correlated with clinical factors and the results of biochemical studies. We also studied 22 subjects after uncomplicated dives and 11 patients who had sustained blunt trauma. Results. All the patients with diving-associated gas embolism had elevated serum creatine kinase activity (normal, less-than-or-equal-to 175 U per liter); the values were markedly elevated (> 900 U per liter) in 14. The MB isoenzyme of creatine kinase was detected in the serum of 13 of 20 patients in whom it was measured and was greater-than-or-equal-to 4 percent of total creatine kinase activity in 6 patients. In three patients electrocardiography showed myocardial injury. Changes in serum creatine kinase activity of similar magnitude were not present in the subjects who had uncomplicated dives or in the patients with blunt trauma. Thirteen patients recovered fully, four had minor residual neurologic deficits, three were severely impaired, and two died. Logistic-regression analysis revealed a significant correlation between peak serum creatine kinase values and clinical outcome. Conclusions. Biochemical evidence of muscle injury is frequently found after diving-associated arterial gas embolism. The correlation between serum creatine kinase activity and outcome suggests that serum creatine kinase is a marker of the size and severity of arterial gas embolism.	UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,DIV PULM & CRIT CARE MED,SAN DIEGO,CA 92103; UNIV CALIF SAN DIEGO,SCH MED,DEPT MED,DIV EMERGENCY MED,SAN DIEGO,CA 92103	University of California System; University of California San Diego; University of California System; University of California San Diego								BENDZ R, 1981, SCAND J THORAC CARD, V15, P199, DOI 10.3109/14017438109101046; BERRY CC, 1990, AM J ROENTGENOL, V154, P477, DOI 10.2214/ajr.154.3.2106207; BUTLER BD, 1988, ANN THORAC SURG, V45, P198, DOI 10.1016/S0003-4975(10)62437-X; DAWSON DM, 1967, ARCH NEUROL-CHICAGO, V16, P175, DOI 10.1001/archneur.1967.00470200063005; DICK APK, 1985, NEUROLOGY, V35, P667, DOI 10.1212/WNL.35.5.667; EVANS DE, 1981, STROKE, V12, P338; FEINSTEIN EI, 1981, ARCH INTERN MED, V141, P753, DOI 10.1001/archinte.141.6.753; GHOSH PK, 1985, J CARDIOVASC SURG, V26, P248; Glantz SA., 1987, PRIMER BIOSTATISTICS; HAMBURG RJ, 1990, J BIOL CHEM, V265, P6403; HORROW JC, 1982, ANESTHESIOLOGY, V56, P212, DOI 10.1097/00000542-198203000-00012; Hosmer D, 2013, APPL LOGISTIC REGRES; INGWALL JS, 1985, NEW ENGL J MED, V313, P1050, DOI 10.1056/NEJM198510243131704; KASTE M, 1977, ARCH NEUROL-CHICAGO, V34, P142, DOI 10.1001/archneur.1977.00500150028004; KING MW, 1984, J TRAUMA, V24, P753, DOI 10.1097/00005373-198408000-00012; LEITCH DR, 1986, AVIAT SPACE ENVIR MD, V57, P931; LONGSTRETH WT, 1981, NEUROLOGY, V31, P455; NEUMAN TS, 1964, CLIN SPORTS MED, V6, P647; ROBERTS R, 1975, AM J CARDIOL, V36, P433, DOI 10.1016/0002-9149(75)90890-5; TRAINER TD, 1968, CLIN CHIM ACTA, V21, P151, DOI 10.1016/0009-8981(68)90023-5; TRASK RV, 1990, BIOCHIM BIOPHYS ACTA, V1049, P182, DOI 10.1016/0167-4781(90)90039-5; Whitcraft D D 3rd, 1976, JACEP, V5, P355, DOI 10.1016/S0361-1124(76)80061-5; WILLIAMS J, 1988, CLIN CHEM, V34, P1514	23	42	45	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	1994	330	1					19	24		10.1056/NEJM199401063300104	http://dx.doi.org/10.1056/NEJM199401063300104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP649	8259140	Bronze			2022-12-01	WOS:A1994MP64900004
J	NUNNARI, J; FOX, TD; WALTER, P				NUNNARI, J; FOX, TD; WALTER, P			A MITOCHONDRIAL PROTEASE WITH 2 CATALYTIC SUBUNITS OF NONOVERLAPPING SPECIFICITIES	SCIENCE			English	Article							MICROSOMAL SIGNAL PEPTIDASE; CYTOCHROME-C1 HEME LYASE; COLI LEADER PEPTIDASE; YEAST SEC11 PROTEIN; SACCHAROMYCES-CEREVISIAE; INTERMEMBRANE SPACE; ESCHERICHIA-COLI; NUCLEAR GENE; PROCESSING PROTEASE; MEMBRANE-PROTEIN	The mitochondrial inner membrane protease is required for the maturation of mitochondrial proteins that are delivered to the intermembrane space. In the yeast Saccharomyces cerevisiae, this protease is now shown to be a complex that contains two catalytic subunits, Imp2p and the previously identified Imp1p. Primary structure similarity indicates that Imp1p and Imp2p are related to each other and to the family of eubacterial and eukaryotic signal peptidases. Imp1p and Imp2p have separate, nonoverlapping substrate specificities. In addition to its catalyzing the cleavage of intermembrane space sorting signals, Imp2p is required for the stable and functional expression of Imp1p. Thus, inner membrane protease, and by analogy eukaryotic multisubunit signal peptidases, may have acquired multiple catalytic subunits by gene duplication to broaden their range of substrate specificity.	CORNELL UNIV, GENET & DEV SECT, ITHACA, NY 14853 USA	Cornell University	NUNNARI, J (corresponding author), UNIV CALIF SAN FRANCISCO, SCH MED, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.			Fox, Thomas/0000-0001-7629-3661				BAKER RK, 1987, BIOCHEMISTRY-US, V26, P8561, DOI 10.1021/bi00400a010; BEASLEY EM, 1993, EMBO J, V12, P2303, DOI 10.1002/j.1460-2075.1993.tb05884.x; BEHRENS M, 1991, MOL GEN GENET, V228, P167, DOI 10.1007/BF00282462; BILGIN N, 1990, EMBO J, V9, P2717, DOI 10.1002/j.1460-2075.1990.tb07458.x; BLACK MT, 1992, BIOCHEM J, V282, P539, DOI 10.1042/bj2820539; BOHNI PC, 1988, J CELL BIOL, V106, P1035, DOI 10.1083/jcb.106.4.1035; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARKSON GHD, 1989, J BIOL CHEM, V264, P10114; COSTANZO MC, 1986, EMBO J, V5, P3637, DOI 10.1002/j.1460-2075.1986.tb04693.x; COX JS, 1993, CELL, V73, P1197, DOI 10.1016/0092-8674(93)90648-A; CRIVELLONE MD, 1988, J BIOL CHEM, V263, P14323; DALBEY RE, 1992, TRENDS BIOCHEM SCI, V17, P474, DOI 10.1016/0968-0004(92)90492-R; DAUM G, 1982, J BIOL CHEM, V257, P3028; EVANS EA, 1986, P NATL ACAD SCI USA, V83, P581, DOI 10.1073/pnas.83.3.581; EVANS EA, 1986, J BIOL CHEM, V103, P291; FOLLEY LS, 1991, GENETICS, V129, P659; GASSER SM, 1982, P NATL ACAD SCI-BIOL, V79, P267, DOI 10.1073/pnas.79.2.267; GLICK BS, 1992, CELL, V69; GREENBURG G, 1989, J BIOL CHEM, V264, P15762; GUIARD B, 1985, EMBO J, V4, P3265, DOI 10.1002/j.1460-2075.1985.tb04076.x; HANN BC, 1991, CELL, V67, P131, DOI 10.1016/0092-8674(91)90577-L; HARTL FU, 1987, CELL, V51, P1027, DOI 10.1016/0092-8674(87)90589-7; HARTL FU, 1990, SCIENCE, V247, P930, DOI 10.1126/science.2406905; HORTIN G, 1981, CELL, V24, P453, DOI 10.1016/0092-8674(81)90336-6; JENSEN RE, 1988, EMBO J, V7, P3863, DOI 10.1002/j.1460-2075.1988.tb03272.x; KOHRER K, 1991, METHOD ENZYMOL, V194, P398; KOLL H, 1992, CELL, V68, P1163, DOI 10.1016/0092-8674(92)90086-R; MULERO JJ, IN PRESS MOL GEN GEN; NGUYEN M, 1988, J CELL BIOL, V106, P1499, DOI 10.1083/jcb.106.5.1499; NICHOLSON DW, 1989, J BIOL CHEM, V264, P10156; OHASHI A, 1982, J BIOL CHEM, V257, P3042; PRATJE E, 1986, EMBO J, V5, P1313, DOI 10.1002/j.1460-2075.1986.tb04361.x; PRATJE E, 1983, EMBO J, V2, P1049, DOI 10.1002/j.1460-2075.1983.tb01544.x; REID GA, 1982, J BIOL CHEM, V257, P3068; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; SADLER I, 1984, EMBO J, V3, P2137, DOI 10.1002/j.1460-2075.1984.tb02103.x; SANMILLAN JL, 1989, J BACTERIOL, V171, P5536, DOI 10.1128/jb.171.10.5536-5541.1989; SCHNEIDER A, 1991, EMBO J, V10, P247, DOI 10.1002/j.1460-2075.1991.tb07944.x; SCHWARZ E, 1993, EMBO J, V12, P2295, DOI 10.1002/j.1460-2075.1993.tb05883.x; SEVARINO KA, 1980, P NATL ACAD SCI-BIOL, V77, P142, DOI 10.1073/pnas.77.1.142; SHELNESS GS, 1990, J BIOL CHEM, V265, P9512; SHELNESS GS, 1993, J BIOL CHEM, V268, P5201; Sherman F., 1986, METHODS YEAST GENETI; SIKORSKI RS, 1989, GENETICS, V122, P19; THOMAS PE, 1976, ANAL BIOCHEM, V75, P168, DOI 10.1016/0003-2697(76)90067-1; VANDIJL JM, 1992, EMBO J, V11, P2819, DOI 10.1002/j.1460-2075.1992.tb05349.x; VANLOON APGM, 1987, EMBO J, V6, P2433, DOI 10.1002/j.1460-2075.1987.tb02522.x; VANLOON APGM, 1986, CELL, V44, P801, DOI 10.1016/0092-8674(86)90846-9; WAKABAYASHI S, 1980, BIOCHEM BIOPH RES CO, V97, P1548, DOI 10.1016/S0006-291X(80)80042-8; WITTE C, 1988, EMBO J, V7, P1439, DOI 10.1002/j.1460-2075.1988.tb02961.x; WOLFE PB, 1983, J BIOL CHEM, V258, P2073; YADEAU JT, 1991, P NATL ACAD SCI USA, V88, P517, DOI 10.1073/pnas.88.2.517; YANG M, 1988, EMBO J, V7, P3857, DOI 10.1002/j.1460-2075.1988.tb03271.x; ZOLLNER A, 1992, EUR J BIOCHEM, V207, P1093, DOI 10.1111/j.1432-1033.1992.tb17146.x	54	193	197	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1993	262	5142					1997	2004		10.1126/science.8266095	http://dx.doi.org/10.1126/science.8266095			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266095				2022-12-01	WOS:A1993MN10800028
J	SILVER, JR				SILVER, JR			THE DANGERS OF SLEDGING	BRITISH MEDICAL JOURNAL			English	Article											SILVER, JR (corresponding author), STOKE MANDEVILLE HOSP,NATL SPINAL INJURIES CTR,AYLESBURY HP21 8AL,BUCKS,ENGLAND.							Gissane W, 1970, INJURY, V1, P195; HEDGES JR, 1980, ANN EMERG MED, V9, P131, DOI 10.1016/S0196-0644(80)80267-8; KLINE DG, 1985, SPORTS INJURIES MECH; SILVER JR, 1993, BRIT J SPORT MED, V27, P115, DOI 10.1136/bjsm.27.2.115; SLOAN JP, 1985, BRIT MED J, V290, P821, DOI 10.1136/bmj.290.6471.821	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1602	1603		10.1136/bmj.307.6919.1602	http://dx.doi.org/10.1136/bmj.307.6919.1602			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292954	Bronze, Green Published			2022-12-01	WOS:A1993MN10700017
J	NEEFJES, JJ; MOMBURG, F; HAMMERLING, GJ				NEEFJES, JJ; MOMBURG, F; HAMMERLING, GJ			SELECTIVE AND ATP-DEPENDENT TRANSLOCATION OF PEPTIDES BY THE MHC-ENCODED TRANSPORTER	SCIENCE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-I MOLECULES; ANTIGEN PRESENTATION	Major histocompatibility complex (MHC) class I molecules present peptides derived from nuclear and cytosolic proteins to CD8+ T cells. These peptides are translocated into the lumen of the endoplasmic reticulum (ER) to associate with class I molecules. Two MHC-encoded putative transporter proteins, TAP1 and TAP2, are required for efficient assembly of class I molecules and presentation of endogenous peptides. Expression of TAP1 and TAP2 in a mutant cell line resulted in the delivery of an 11-amino acid oligomer model peptide to the ER. Peptide translocation depended on the sequence of the peptide, was adenosine triphosphate (ATP)-dependent, required ATP hydrolysis, and was inhibited in a concentration-dependent manner.	GERMAN CANC RES CTR,TUMOR IMMUNOL PROGRAM,NEUENHEIMER FELD 280,W-6900 HEIDELBERG,GERMANY; NETHERLANDS CANC INST,1066 CX AMSTERDAM,NETHERLANDS	Helmholtz Association; German Cancer Research Center (DKFZ); Netherlands Cancer Institute			Neefjes, Jacques J.C./H-8780-2017	Neefjes, Jacques J.C./0000-0001-6763-2211				ARNOLD D, 1992, NATURE, V360, P171, DOI 10.1038/360171a0; ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KOPPELMAN B, 1992, P NATL ACAD SCI USA, V89, P3908, DOI 10.1073/pnas.89.9.3908; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.bi.54.070185.003215; LEVY F, 1991, CELL, V67, P25; MOMBURG F, 1992, NATURE, V360, P174, DOI 10.1038/360174a0; MONACO JJ, 1992, IMMUNOL TODAY, V13, P173, DOI 10.1016/0167-5699(92)90122-N; NEEFJES JJ, UNPUB; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; SPIES T, 1992, NATURE, V355, P644, DOI 10.1038/355644a0	14	516	522	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 6	1993	261	5122					769	771		10.1126/science.8342042	http://dx.doi.org/10.1126/science.8342042			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ730	8342042				2022-12-01	WOS:A1993LQ73000042
J	COLLINS, S				COLLINS, S			THE NEED FOR ADULT THERAPEUTIC CARE IN EMERGENCY FEEDING PROGRAMS - LESSONS FROM SOMALIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CHRONIC ENERGY DEFICIENCY				COLLINS, S (corresponding author), CONCERN WORLDWIDE, 248-250 LAVENDER HILL, LONDON SW11 1LJ, ENGLAND.							DRUMMOND J, 1945, LANCET, V1, P282; FERROLUZZI A, 1992, EUR J CLIN NUTR, V46, P173; GOLDEN B, IN PRESS PRIMARY PRO; GOLDEN MHN, 1991, ACTA PAEDIATR SCAND, P95; GOPALAN C, 1975, Progress in Food and Nutrition Science, V1, P207; JAMES WPT, 1988, EUR J CLIN NUTR, V42, P969; Keys A, 1950, BIOL HUMAN STARVATIO, V2, DOI DOI 10.1017/S1352465801003010; LIPSCOMB FM, 1945, LANCET, V249, P313; MCCANCE R, 1951, MED RES COUNCIL SPEC, V275; MOORE PS, 1993, LANCET, V341, P935, DOI 10.1016/0140-6736(93)91223-9; SHETTY P, IN PRESS BODY MASS I; 1992, MMWR MORB MORTAL WKL, V41, P913	13	10	10	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1993	270	5					637	638						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP436	8331768				2022-12-01	WOS:A1993LP43600034
J	HUNTER, DJ; MANSON, JE; COLDITZ, GA; STAMPFER, MJ; ROSNER, B; HENNEKENS, CH; SPEIZER, FE; WILLETT, WC				HUNTER, DJ; MANSON, JE; COLDITZ, GA; STAMPFER, MJ; ROSNER, B; HENNEKENS, CH; SPEIZER, FE; WILLETT, WC			A PROSPECTIVE-STUDY OF THE INTAKE OF VITAMIN-C, VITAMIN-E, AND VITAMIN-A AND THE RISK OF BREAST-CANCER	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ALPHA-TOCOPHEROL LEVELS; BETA-CAROTENE; DIETARY-FAT; QUESTIONNAIRE; CARCINOGENESIS; ISOTRETINOIN; EPIDEMIOLOGY; CONSUMPTION; VALIDATION; INHIBITION	Background. Although it has been hypothesized that large intakes of the antioxidant vitamins C, E, and A reduce the risk of breast cancer, few prospective data are available. Methods. We prospectively studied 89,494 women who were 34 to 59 years old in 1980 and who did not have diagnosed cancer. Their intakes of vitamins C, E, and A from foods and supplements were assessed at base line and in 1984 with the use of a validated semiquantitative food-frequency questionnaire. Results. Breast cancer was diagnosed in 1439 women during eight years of follow-up. After multivariate adjustment for known risk factors, the relative risk among women in the highest quintile group for intake of vitamin C as compared with the risk among those in the lowest quintile group was 1.03 (95 percent confidence interval, 0.87 to 1.21); for vitamin E, after vitamin A intake had been controlled for, the relative risk was 0.99 (95 percent confidence interval, 0.83 to 1.19). In contrast, among women in the highest quintile group for intake of total vitamin A the relative risk was 0.84 (95 percent confidence interval, 0.71 to 0.98; P for trend = 0.001). Among women in the lowest quintile group for intake of vitamin A from food, consumption of vitamin A from supplements was associated with a reduced risk (P = 0.03). The significant inverse association of vitamin A intake with the risk of breast cancer was also found on study of data based on the 1984 questionnaire and four years of follow-up. Conclusions. Large intakes of vitamin C or E did not protect women in our study from breast cancer. A low intake of vitamin A may increase the risk of this disease; any benefit of vitamin A supplements may be limited to women with diets low in vitamin A.	BRIGHAM & WOMENS HOSP, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT PREVENT MED, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT EPIDEMIOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT NUTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT BIOSTAT, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School	HUNTER, DJ (corresponding author), HARVARD UNIV, SCH MED, CHANNING LAB, DEPT MED, 180 LONGWOOD AVE, BOSTON, MA 02115 USA.		Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R01CA050597, R37CA040356] Funding Source: NIH RePORTER; NCI NIH HHS [CA-40356, CA-50597] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABRAMS AA, 1965, NEW ENGL J MED, V272, P1080; [Anonymous], 1982, EPIDEMIOLOGIC RES; ARMSTRONG B, 1975, INT J CANCER, V15, P617, DOI 10.1002/ijc.2910150411; BIERI JG, 1983, NEW ENGL J MED, V308, P1063, DOI 10.1056/NEJM198305053081805; BLOMHOFF R, 1990, SCIENCE, V250, P399, DOI 10.1126/science.2218545; CAMERON E, 1979, CANCER RES, V39, P663; COX DR, 1972, J R STAT SOC B, V34, P187; DOLL R, 1981, JNCI-J NATL CANCER I, V66, P1191, DOI 10.1093/jnci/66.6.1192; EWERTZ M, 1990, INT J CANCER, V46, P779, DOI 10.1002/ijc.2910460505; FRAKER LD, 1984, CANCER RES, V44, P5757; GRAHAM S, 1982, AM J EPIDEMIOL, V116, P68, DOI 10.1093/oxfordjournals.aje.a113403; GRAHAM S, 1991, AM J EPIDEMIOL, V134, P552, DOI 10.1093/oxfordjournals.aje.a116129; HARMAN D, 1969, Clinical Medicine, V17, P125; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HOWE GR, 1991, J NATL CANCER I, V83, P336, DOI 10.1093/jnci/83.5.336; HOWE GR, 1990, JNCI-J NATL CANCER I, V82, P561, DOI 10.1093/jnci/82.7.561; JONES DY, 1987, JNCI-J NATL CANCER I, V79, P465; KATSOUYANNI K, 1988, CANCER-AM CANCER SOC, V61, P181, DOI 10.1002/1097-0142(19880101)61:1<181::AID-CNCR2820610130>3.0.CO;2-J; KING MM, 1983, CANCER RES, V43, P2485; KRAEMER KH, 1988, NEW ENGL J MED, V318, P1633, DOI 10.1056/NEJM198806233182501; KUSHI LH, 1992, J NATL CANCER I, V84, P1092, DOI 10.1093/jnci/84.14.1092; LEE C, 1979, P AM ASSOC CANC RES, V20, P132; LIPPMAN SM, 1987, CANCER TREAT REP, V71, P391; MARUBINI E, 1988, CANCER, V61, P173, DOI 10.1002/1097-0142(19880101)61:1&lt;173::AID-CNCR2820610129&gt;3.0.CO;2-P; MCCORMICK DL, 1981, J NATL CANCER I, V66, P559; MILLS P, 1989, CANCER-AM CANCER SOC, V64, P582, DOI 10.1002/1097-0142(19890801)64:3&lt;582::AID-CNCR2820640304&gt;3.0.CO;2-V; MOON RC, 1977, NATURE, V267, P620, DOI 10.1038/267620a0; MOON RC, 1983, CANCER RES, V43, P2469; PAGANINIHILL A, 1987, JNCI-J NATL CANCER I, V79, P443; PETO R, 1981, NATURE, V290, P201, DOI 10.1038/290201a0; POTISCHMAN N, 1990, AM J CLIN NUTR, V52, P909, DOI 10.1093/ajcn/52.5.909; PRASAD KN, 1990, J AM COLL NUTR, V9, P28; PRENTICE RL, 1989, CANCER RES, V49, P3147; ROHAN TE, 1988, AM J EPIDEMIOL, V128, P478, DOI 10.1093/oxfordjournals.aje.a114996; SALVINI S, 1989, INT J EPIDEMIOL, V18, P858, DOI 10.1093/ije/18.4.858; STAMPFER MJ, 1984, AM J EPIDEMIOL, V119, P837, DOI 10.1093/oxfordjournals.aje.a113804; STAMPFER MJ, 1985, NEW ENGL J MED, V313, P1044, DOI 10.1056/NEJM198510243131703; STRYKER WS, 1988, AM J EPIDEMIOL, V127, P283, DOI 10.1093/oxfordjournals.aje.a114804; WILLETT W, 1986, AM J EPIDEMIOL, V124, P17, DOI 10.1093/oxfordjournals.aje.a114366; Willett W, 1990, MONOGRAPHS EPIDEMIOL, V15; WILLETT WC, 1990, NEW ENGL J MED, V323, P1664, DOI 10.1056/NEJM199012133232404; WILLETT WC, 1988, AM J EPIDEMIOL, V127, P188, DOI 10.1093/oxfordjournals.aje.a114780; WILLETT WC, 1983, AM J CLIN NUTR, V38, P631, DOI 10.1093/ajcn/38.4.631; WILLETT WC, 1987, NEW ENGL J MED, V316, P22, DOI 10.1056/NEJM198701013160105; WILLETT WC, 1992, JAMA-J AM MED ASSOC, V268, P2037, DOI 10.1001/jama.268.15.2037; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086; 1963, COMPOSITION FOODS RA; [No title captured]	48	250	250	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1993	329	4					234	240		10.1056/NEJM199307223290403	http://dx.doi.org/10.1056/NEJM199307223290403			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM682	8292129				2022-12-01	WOS:A1993LM68200003
J	MCINTIRE, SL; JORGENSEN, E; HORVITZ, HR				MCINTIRE, SL; JORGENSEN, E; HORVITZ, HR			GENES REQUIRED FOR GABA FUNCTION IN CAENORHABDITIS-ELEGANS	NATURE			English	Article							NERVOUS-SYSTEM; C-ELEGANS; ACID; ASCARIS	Gamma-AMINOBUTYRIC acid (GABA) neurotransmission is widespread in vertebrate and invertebrate nervous systems1. Here we use a genetic approach to identify molecules specific to GABA function. On the basis of the known in vivo roles of GABAergic neurons in controlling behaviour of the nematode Caenorhabditis elegans2, we identified mutants defective in GABA-mediated behaviours. Five genes are necessary either for GABAergic neuronal differentiation or for pre- or postsynaptic GABAergic function. The gene unc-30 is required for the differentiation of a specific type of GABAergic neuron, the type-D inhibitory motor neuron. The gene unc-25 is necessary for GABA expression and probably encodes the GABA biosynthetic enzyme glutamic acid decarboxylase. The genes unc-46 and unc-47 seem to be required for normal GABA release. Finally, the gene unc-49 is apparently necessary postsynaptically for the inhibitory effect of GABA on the body muscles and might encode a protein needed for the function of a GABA(A)-like receptor. Some of these genes are likely to encode previously unidentified proteins required for GABA function.	MIT,DEPT BIOL,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School								AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; BRENNER S, 1974, GENETICS, V77, P71; BURGER PM, 1991, NEURON, V7, P287, DOI 10.1016/0896-6273(91)90267-4; COOPER JR, 1991, BIOCH BASIS NEUROPHA, V1, P133; ERLANDER MG, 1991, NEUROCHEM RES, V16, P215, DOI 10.1007/BF00966084; FERGUSON EL, 1985, GENETICS, V110, P17; FFRENCHCONSTANT RH, 1991, P NATL ACAD SCI USA, V88, P7209, DOI 10.1073/pnas.88.16.7209; GUASTELLA J, 1991, J COMP NEUROL, V307, P598, DOI 10.1002/cne.903070407; Hedgecock E, 1976, GABA METABOLISM CAEN; HODGKIN J, 1983, GENETICS, V103, P43; KASS IS, 1984, MOL BIOCHEM PARASIT, V13, P213, DOI 10.1016/0166-6851(84)90114-2; MCINTIRE SL, 1993, NATURE, V364, P337, DOI 10.1038/364337a0; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; MEIR E, 1991, NEUROCHEM INT, V19, P1; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; THOMAS JH, 1990, GENETICS, V124, P855; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; Wood WB, 1988, NEMATODE CAENORHABDI	18	235	246	1	26	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 22	1993	364	6435					334	337		10.1038/364334a0	http://dx.doi.org/10.1038/364334a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	8332190				2022-12-01	WOS:A1993LN57000056
J	MEADOR, CK				MEADOR, CK			THE LAST WELL PERSON	NEW ENGLAND JOURNAL OF MEDICINE			English	Note									VANDERBILT UNIV,NASHVILLE,TN 37205	Vanderbilt University								BARSKY AJ, 1988, WORRIED SICK OUR TRO; MEADOR CK, 1991, JAMA-J AM MED ASSOC, V265, P1374, DOI 10.1001/jama.265.11.1374	2	33	32	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	1994	330	6					440	441		10.1056/NEJM199402103300618	http://dx.doi.org/10.1056/NEJM199402103300618			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV279	8284021				2022-12-01	WOS:A1994MV27900032
J	DYCK, JA; MAUL, GG; MILLER, WH; CHEN, JD; KAKIZUKA, A; EVANS, RM				DYCK, JA; MAUL, GG; MILLER, WH; CHEN, JD; KAKIZUKA, A; EVANS, RM			A NOVEL MACROMOLECULAR STRUCTURE IS A TARGET OF THE PROMYELOCYTE-RETINOIC ACID RECEPTOR ONCOPROTEIN	CELL			English	Article							RAR-ALPHA; T(15-17) TRANSLOCATION; NUCLEAR ANTIGEN; LEUKEMIA FUSES; CELL-LINE; T-CELLS; EXPRESSION; GENE; FINGER; PURIFICATION	Acute promyelocytic leukemia (APL) is associated with a t(15;17) translocation that creates the promyelocyte-retinoic acid receptor alpha (PML-RARalpha) fusion gene. Immunohistochemistry demonstrates that PML is a part of a novel macromolecular organelle (including at least three other nuclear proteins) referred to as PML oncogenic domains (PODs). In APL cells, the POD is disrupted into a microparticulate pattern as a consequence of the expression of the PML-RAR oncoprotein. RA treatment of APL cells triggers a reorganization of PML to generate normal-appearing PODs. We propose that PML-RAR is a dominant negative oncoprotein that exerts its putative leukomogenic effect by inhibiting assembly of the POD. According to this proposal, not only is the POD a novel structure, but it can be ascribed an imputed function such that its disruption leads to altered myeloid maturation; this may represent a novel oncogenic target.	SALK INST BIOL STUDIES, HOWARD HUGHES MED INST, LA JOLLA, CA 92037 USA; WISTAR INST ANAT & BIOL, PHILADELPHIA, PA 19104 USA; KYOTO UNIV, FAC MED, KYOTO 606, JAPAN	Howard Hughes Medical Institute; Salk Institute; The Wistar Institute; Kyoto University	DYCK, JA (corresponding author), UNIV CALIF SAN DIEGO, GRAD PROGRAM BIOMED SCI, LA JOLLA, CA 92037 USA.		Evans, Ronald/AAF-4001-2019	Evans, Ronald/0000-0002-9986-5965	NCI NIH HHS [CA10815] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA010815] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; BASCH RS, 1982, EUR J IMMUNOL, V12, P359, DOI 10.1002/eji.1830120502; BELLINI M, 1993, EMBO J, V12, P107, DOI 10.1002/j.1460-2075.1993.tb05636.x; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BRAVO R, 1987, J CELL BIOL, V105, P1549, DOI 10.1083/jcb.105.4.1549; BREITMAN TR, 1980, P NATL ACAD SCI-BIOL, V77, P2936, DOI 10.1073/pnas.77.5.2936; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; CARTER KC, 1993, SCIENCE, V259, P1330, DOI 10.1126/science.8446902; CARTER KC, 1991, J CELL BIOL, V115, P1191, DOI 10.1083/jcb.115.5.1191; CHAN EKL, 1991, J CLIN INVEST, V87, P68, DOI 10.1172/JCI115003; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; CLEARY ML, 1991, CELL, V66, P619, DOI 10.1016/0092-8674(91)90105-8; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; DAMM K, 1993, P NATL ACAD SCI USA, V90, P2989, DOI 10.1073/pnas.90.7.2989; de The G., 1960, B ASSOC FR ETUD CANC, V47, P570; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EPSTEIN AL, 1984, J VIROL, V50, P372, DOI 10.1128/JVI.50.2.372-379.1984; FAKAN S, 1984, J CELL BIOL, V98, P358, DOI 10.1083/jcb.98.1.358; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; HANSON IM, 1991, GENOMICS, V10, P417, DOI 10.1016/0888-7543(91)90327-B; HARLOW E, 1988, ANTIBODIES LABORATOR; HINGLA.N, 1961, B ASSOC FR ETUD CANC, V48, P283; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KAMPS MP, 1993, MOL CELL BIOL, V13, P351, DOI 10.1128/MCB.13.1.351; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; LANOTTE M, 1991, BLOOD, V77, P1080; LONGO L, 1990, J EXP MED, V172, P1571, DOI 10.1084/jem.172.6.1571; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MAUL GG, 1993, J GEN VIROL, V74, P2679, DOI 10.1099/0022-1317-74-12-2679; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; Mitelman F., 1988, CATALOG CHROMOSOME A; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; RABBITTS TH, 1991, CELL, V67, P641, DOI 10.1016/0092-8674(91)90057-6; REDDY BA, 1991, DEV BIOL, V148, P107, DOI 10.1016/0012-1606(91)90321-S; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; RIVIER J, 1984, SCIENCE, V224, P889, DOI 10.1126/science.6326264; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; SPECTOR DL, 1992, MOL BIOL CELL, V3, P555, DOI 10.1091/mbc.3.5.555; STAUFENBIEL M, 1984, J CELL BIOL, V98, P1886, DOI 10.1083/jcb.98.5.1886; STUURMAN N, 1992, J CELL SCI, V101, P773; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; TSAI S, 1993, P NATL ACAD SCI USA, V90, P7153, DOI 10.1073/pnas.90.15.7153; VAUGHAN JM, 1989, METHOD ENZYMOL, V168, P588; WURDEN S, 1993, J HISTOCHEM CYTOCHEM, V41, P627, DOI 10.1177/41.4.8450202; XIE KW, 1993, MOL CELL BIOL, V13, P6170, DOI 10.1128/MCB.13.10.6170; YANG N, 1991, P NATL ACAD SCI USA, V88, P3559, DOI 10.1073/pnas.88.9.3559	57	742	752	0	14	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 28	1994	76	2					333	343		10.1016/0092-8674(94)90340-9	http://dx.doi.org/10.1016/0092-8674(94)90340-9			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	8293467				2022-12-01	WOS:A1994MU67800016
J	APPLEWHITE, MP; JANSEN, GR; MARRIOTT, BM; BREEN, VM				APPLEWHITE, MP; JANSEN, GR; MARRIOTT, BM; BREEN, VM			THE EFFECTS OF DIET ON PERFORMANCE - AN INITIAL REVIEW	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									INST MED,FOOD & NUTR BOARD,2101 CONSTITUT AVE NW,WASHINGTON,DC 20418									1990, JAMA-J AM MED ASSOC, V264, P1656; 1990, JAMA-J AM MED ASSOC, V264, P1655; 1990, JAMA-J AM MED ASSOC, V264, P1698	3	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	1994	271	2					98	98		10.1001/jama.271.2.98	http://dx.doi.org/10.1001/jama.271.2.98			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ083	8264076				2022-12-01	WOS:A1994MQ08300004
J	LYNN, JT				LYNN, JT			LAPHROAIG	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	1994	271	1					18	18						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN725	8258875				2022-12-01	WOS:A1994MN72500008
J	FEAVER, WJ; SVEJSTRUP, JQ; BARDWELL, L; BARDWELL, AJ; BURATOWSKI, S; GULYAS, KD; DONAHUE, TF; FRIEDBERG, EC; KORNBERG, RD				FEAVER, WJ; SVEJSTRUP, JQ; BARDWELL, L; BARDWELL, AJ; BURATOWSKI, S; GULYAS, KD; DONAHUE, TF; FRIEDBERG, EC; KORNBERG, RD			DUAL ROLES OF A MULTIPROTEIN COMPLEX FROM SACCHAROMYCES-CEREVISIAE IN TRANSCRIPTION AND DNA-REPAIR	CELL			English	Article							RNA POLYMERASE-II; YEAST RAD3 PROTEIN; SACCHAROMYCES-CEREVISIAE; XERODERMA-PIGMENTOSUM; PYRIMIDINE DIMERS; MUTANT ALLELES; CTD KINASE; FACTOR-B; GENE; HELICASE	Yeast RNA polymerase II initiation factor b, homolog of human TFIIH, is a protein kinase capable of phosphorylating the C-terminal repeat domain of the polymerase; it possesses a DNA-dependent ATPase activity as well. The 85 kd and 50 kd subunits of factor b are now identified as RAD3 and SSL1 proteins, respectively; both are known to be involved in DNA repair. Factor b interacts specifically with another DNA repair protein, SSL2. The ATPase activity of factor b may be due entirely to that associated with a helicase function of RAD3. Factor b transcriptional activity was unaffected, however, by amino acid substitution at a conserved residue in the RAD3 nucleotide-binding domain, suggesting that the ATPase/helicase function is not required for transcription. These results identify factor b as a core repairosome, which may be responsible for the preferential repair of actively transcribed genes in eukaryotes.	UNIV TEXAS, SW MED CTR, DEPT PATHOL, MOLEC PATHOL LAB, DALLAS, TX 75235 USA; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; INDIANA UNIV, DEPT BIOL, BLOOMINGTON, IN 47405 USA	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Massachusetts Institute of Technology (MIT); Whitehead Institute; Indiana University System; Indiana University Bloomington	FEAVER, WJ (corresponding author), STANFORD UNIV, MED CTR, SCH MED, DEPT CELL BIOL, STANFORD, CA 94305 USA.		Bardwell, Lee/I-8284-2019	Bardwell, Lee/0000-0002-2393-8363; Svejstrup, Jesper/0000-0003-4964-6147	NCI NIH HHS [CA12428] Funding Source: Medline; NIGMS NIH HHS [GM46498, GM36659] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA012428, R37CA012428] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046498, R29GM046498, R01GM036659, R37GM036659] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARDWELL L, 1992, MOL CELL BIOL, V12, P3041, DOI 10.1128/MCB.12.7.3041; BARDWELL L, 1992, THESIS STANDARD U ST; BARDWELL L, 1994, IN PRESS P NATL ACAD; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BURATOWSKI S, 1993, SCIENCE, V260, P37, DOI 10.1126/science.8465198; CHASMAN DI, 1990, MOL CELL BIOL, V10, P2916, DOI 10.1128/MCB.10.6.2916; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CONAWAY JW, 1992, J BIOL CHEM, V267, P10142; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; FEAVER WJ, 1991, CELL, V67, P1223, DOI 10.1016/0092-8674(91)90298-D; FEAVER WJ, 1991, J BIOL CHEM, V266, P1900; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FRIEDBERG EC, 1991, MOL CELLULAR BIOL YE, V1, P147; GERARD M, 1991, J BIOL CHEM, V266, P20940; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GULYAS KD, 1992, CELL, V69, P1031, DOI 10.1016/0092-8674(92)90621-I; HANAWALT P, 1993, CURR BIOL, V3, P67, DOI 10.1016/0960-9822(93)90156-I; HAROSH I, 1989, J BIOL CHEM, V264, P20532; HOCHULI E, 1987, J CHROMATOGR, V411, P177, DOI 10.1016/S0021-9673(00)93969-4; HOEIJMAKERS JHJ, 1993, J CHROMATOGR, V9, P211; KASSAVETIS GA, 1993, SCIENCE, V259, P944, DOI 10.1126/science.7679800; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; LEADON SA, 1992, J BIOL CHEM, V267, P23175; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; LUE NF, 1991, METHOD ENZYMOL, V194, P545; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MELLON I, 1989, NATURE, V342, P95, DOI 10.1038/342095a0; NAEGELI H, 1992, J BIOL CHEM, V267, P392; NAUMOVSKI L, 1988, MOL GEN GENET, V213, P400, DOI 10.1007/BF00339609; NAUMOVSKI L, 1985, MOL CELL BIOL, V5, P17, DOI 10.1128/MCB.5.1.17; NICOLET CM, 1987, YEAST, V3, P149, DOI 10.1002/yea.320030303; PARK E, 1992, P NATL ACAD SCI USA, V89, P11416, DOI 10.1073/pnas.89.23.11416; SADOWSKI I, 1992, GENE, V118, P137, DOI 10.1016/0378-1119(92)90261-M; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SERIZAWA H, 1993, NATURE, V363, P371, DOI 10.1038/363371a0; SONG JM, 1990, J BACTERIOL, V172, P6620, DOI 10.1128/jb.172.12.6620-6630.1990; SUNG P, 1987, P NATL ACAD SCI USA, V84, P8951, DOI 10.1073/pnas.84.24.8951; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; SWEDER KS, 1993, SCIENCE, V262, P439, DOI 10.1126/science.8211165; SWEDER KS, 1992, P NATL ACAD SCI USA, V89, P10696, DOI 10.1073/pnas.89.22.10696; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WEBER CA, 1990, EMBO J, V9, P1437, DOI 10.1002/j.1460-2075.1990.tb08260.x; WEEDA G, 1990, CELL, V62, P777, DOI 10.1016/0092-8674(90)90122-U; YOON H, 1992, GENE DEV, V6, P2463, DOI 10.1101/gad.6.12b.2463	48	298	302	0	7	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 31	1993	75	7					1379	1387		10.1016/0092-8674(93)90624-Y	http://dx.doi.org/10.1016/0092-8674(93)90624-Y			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	8269516				2022-12-01	WOS:A1993MP86900016
J	KUROKI, R; WEAVER, LH; MATTHEWS, BW				KUROKI, R; WEAVER, LH; MATTHEWS, BW			A COVALENT ENZYME-SUBSTRATE INTERMEDIATE WITH SACCHARIDE DISTORTION IN A MUTANT T4 LYSOZYME	SCIENCE			English	Article							BACTERIOPHAGE-T4 LYSOZYME; ACTIVE-SITE; BETA-GLUCOSIDASE; EGG-WHITE; BINDING; HEN; REFINEMENT; CATALYSIS; MECHANISM; PROTEINS	The glycosyl-enzyme intermediate in lysozyme action has long been considered to be an oxocarbonium ion, although precedent from other glycosidases and theoretical considerations suggest it should be a covalent enzyme-substrate adduct. The mutation of threonine 26 to glutamic acid in the active site cleft of phage T4 lysozyme (T4L) produced an enzyme that cleaved the cell wall of Escherichia coli but left the product covalently bound to the enzyme. The crystalline complex was nonisomorphous with wild-type T4L, and analysis of its structure showed a covalent linkage between the product and the newly introduced glutamic acid 26. The covalently linked sugar ring was substantially distorted, suggesting that distortion of the substrate toward the transition state is important for catalysis, as originally proposed by Phillips. It is also postulated that the adduct formed by the mutant is an intermediate, consistent with a double displacement mechanism of action in which the glycosidic linkage is cleaved with retention of configuration as originally proposed by Koshland. The peptide part of the cell wall fragment displays extensive hydrogen-bonding interactions with the carboxyl-terminal domain of the enzyme, consistent with previous studies of mutations in T4L.	UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA; UNIV OREGON, DEPT PHYS, EUGENE, OR 97403 USA; UNIV OREGON, HOWARD HUGHES MED INST, EUGENE, OR 97403 USA	University of Oregon; University of Oregon; Howard Hughes Medical Institute; University of Oregon					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021967] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM21967] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON WF, 1981, J MOL BIOL, V147, P523, DOI 10.1016/0022-2836(81)90398-3; BELL JA, 1991, PROTEINS, V10, P10, DOI 10.1002/prot.340100103; BLAKE CCF, 1965, NATURE, V206, P757, DOI 10.1038/206757a0; DAHLQUIS.FW, 1969, BIOCHEMISTRY-US, V8, P694, DOI 10.1021/bi00830a035; GEBLER JC, 1992, J BIOL CHEM, V267, P11126; GHUYSEN JM, 1968, BACTERIOL REV, V32, P425, DOI 10.1128/MMBR.32.4_Pt_2.425-464.1968; GRUTTER MG, 1983, NATURE, V303, P828, DOI 10.1038/303828a0; GRUTTER MG, 1982, J MOL BIOL, V154, P525, DOI 10.1016/S0022-2836(82)80011-9; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HARDY LW, 1991, BIOCHEMISTRY-US, V30, P9457, DOI 10.1021/bi00103a010; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JENSEN B, 1976, EUR J BIOCHEM, V66, P319; KEMPTON JB, 1992, BIOCHEMISTRY-US, V31, P9961, DOI 10.1021/bi00156a015; KOSHLAND DE, 1953, BIOL REV, V28, P416, DOI 10.1111/j.1469-185X.1953.tb01386.x; KUROKI R, 1989, P NATL ACAD SCI USA, V86, P6903, DOI 10.1073/pnas.86.18.6903; KUROKI R, 1992, P NATL ACAD SCI USA, V89, P6803, DOI 10.1073/pnas.89.15.6803; LUMB KJ, 1992, FEBS LETT, V296, P153, DOI 10.1016/0014-5793(92)80368-Q; MALCOLM BA, 1989, P NATL ACAD SCI USA, V86, P133, DOI 10.1073/pnas.86.1.133; MATTHEWS BW, 1981, NATURE, V290, P334, DOI 10.1038/290334a0; MATTHEWS BW, 1974, P NATL ACAD SCI USA, V71, P4178, DOI 10.1073/pnas.71.10.4178; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; PHILLIPS DC, 1967, P NATL ACAD SCI USA, V57, P484; POST CB, 1986, J AM CHEM SOC, V108, P1317, DOI 10.1021/ja00266a044; POTEETE AR, 1991, BIOCHEMISTRY-US, V30, P1425, DOI 10.1021/bi00219a037; RENNELL D, 1991, J MOL BIOL, V222, P67, DOI 10.1016/0022-2836(91)90738-R; SCHLEIFER KH, 1972, BACTERIOL REV, V36, P407, DOI 10.1128/MMBR.36.4.407-477.1972; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; STREET IP, 1992, BIOCHEMISTRY-US, V31, P9970, DOI 10.1021/bi00156a016; STRYNADKA NCJ, 1991, J MOL BIOL, V220, P401, DOI 10.1016/0022-2836(91)90021-W; SVENSSON B, 1993, J BIOTECHNOL, V29, P1, DOI 10.1016/0168-1656(93)90038-O; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TRONRUD DE, 1992, ACTA CRYSTALLOGR A, V48, P912, DOI 10.1107/S0108767392005415; WEAVER LH, 1985, J MOL EVOL, V21, P97, DOI 10.1007/BF02100084; WEAVER LH, 1987, J MOL BIOL, V193, P189, DOI 10.1016/0022-2836(87)90636-X; ZHANG XJ, 1993, J APPL CRYSTALLOGR, V26, P457, DOI 10.1107/S0021889892013165	35	178	183	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1993	262	5142					2030	2033		10.1126/science.8266098	http://dx.doi.org/10.1126/science.8266098			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266098				2022-12-01	WOS:A1993MN10800037
J	MASSUNG, RF; ESPOSITO, JJ; LIU, LI; QI, J; UTTERBACK, TR; KNIGHT, JC; AUBIN, L; YURAN, TE; PARSONS, JM; LOPAREV, VN; SELIVANOV, NA; CAVALLARO, KF; KERLAVAGE, AR; MAHY, BWJ; VENTER, JC				MASSUNG, RF; ESPOSITO, JJ; LIU, LI; QI, J; UTTERBACK, TR; KNIGHT, JC; AUBIN, L; YURAN, TE; PARSONS, JM; LOPAREV, VN; SELIVANOV, NA; CAVALLARO, KF; KERLAVAGE, AR; MAHY, BWJ; VENTER, JC			POTENTIAL VIRULENCE DETERMINANTS IN TERMINAL REGIONS OF VARIOLA SMALLPOX VIRUS GENOME	NATURE			English	Article								SMALLPox eradication culminated the most successful antimicrobial campaign in medical history1. To characterize further the linear double-stranded DNA genome of the aetiological agent of smallpox, we have determined the entire nucleotide sequence of the highly virulent variola major virus, strain Bangladesh-1975 (VA R-BSH; 186,102 base pairs, 33.7% G + C; Genbank accession number, L22579). Here we highlight features of the molecule and focus on a few of the 187 putative proteins that probably contribute to pathogenicity and virus host-range properties. One hundred and fifty proteins were markedly similar to those of vaccinia virus (smallpox vaccine), for which a complete sequence has been reported2,3 for strain Copenhagen (VAC-CPN; 191,636 base pairs, 33.3% G + C). The remaining 37 proteins reflected variola-specific sequences or open reading frame divergences for variant proteins, which are often truncated or elongated compared with their vaccinia counterparts.	CTR DIS CONTROL & PREVENT, NATL CTR INFECT DIS, DIV VIRAL & RICKETTSIAL DIS, ATLANTA, GA 30333 USA; NINCDS, BETHESDA, MD 20892 USA; INST GENOM RES, GAITHERSBURG, MD 20878 USA	Centers for Disease Control & Prevention - USA; National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); J. Craig Venter Institute				Kerlavage, Anthony/0000-0002-3954-9653				AGUADO B, 1992, J GEN VIROL, V73, P2887, DOI 10.1099/0022-1317-73-11-2887; BEATTIE E, 1991, VIROLOGY, V183, P419, DOI 10.1016/0042-6822(91)90158-8; BULLER RML, 1991, MICROBIOL REV, V55, P80, DOI 10.1128/MMBR.55.1.80-122.1991; ESPOSITO JJ, 1985, VIROLOGY, V143, P230, DOI 10.1016/0042-6822(85)90111-4; ESPOSITO JJ, 1991, CLASSIFICATION NOM S, V2, P91; Fenner F., 1989, MONKEYPOX VIRUS ORTH, P227; Fenner F., 1988, SMALLPOX ITS ERADICA; GOCAYNE J, 1987, P NATL ACAD SCI USA, V84, P8296, DOI 10.1073/pnas.84.23.8296; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; HENIKOFF S, 1984, GENE, V28, P351, DOI 10.1016/0378-1119(84)90153-7; JOHNSON GP, 1993, VIROLOGY, V196, P381, DOI 10.1006/viro.1993.1494; KOTWAL GJ, 1989, J VIROL, V63, P600, DOI 10.1128/JVI.63.2.600-606.1989; KOTWAL GJ, 1988, VIROLOGY, V167, P524, DOI 10.1016/S0042-6822(88)90115-8; MAHY BWJ, 1993, REV MED VIROL, V3, P131, DOI 10.1002/rmv.1980030302; MAHY BWJ, 1991, ASM NEWS, V57, P577; MARTINGALLARDO A, 1992, NAT GENET, V1, P34, DOI 10.1038/ng0492-34; MOSS B, 1990, CURR TOP MICROBIOL, V163, P41; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERKUS ME, 1990, VIROLOGY, V179, P276, DOI 10.1016/0042-6822(90)90296-4; RUOSLAHTI E, 1986, CELL, V44, P517, DOI 10.1016/0092-8674(86)90259-X; Sambrook J., 1989, MOL CLONING LAB MANU; SCCHELKUNOV SN, 1993, VIRUS RES, V27, P25; SHCHELKUNOV SN, 1993, FEBS LETT, V319, P80, DOI 10.1016/0014-5793(93)80041-R; SHCHELKUNOV SN, 1993, DOKL AKAD NAUK+, V328, P629; SHCHELKUNOV SN, 1993, FEBS LETT, V319, P163, DOI 10.1016/0014-5793(93)80059-4; SMITH GL, 1993, J GEN VIROL, V74, P1725, DOI 10.1099/0022-1317-74-9-1725; SMITH GL, 1991, J GEN VIROL, V72, P1349, DOI 10.1099/0022-1317-72-6-1349	27	149	380	0	10	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 23	1993	366	6457					748	751		10.1038/366748a0	http://dx.doi.org/10.1038/366748a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN264	8264798				2022-12-01	WOS:A1993MN26400030
J	FOSS, M; MCNALLY, FJ; LAURENSON, P; RINE, J				FOSS, M; MCNALLY, FJ; LAURENSON, P; RINE, J			ORIGIN RECOGNITION COMPLEX (ORC) IN TRANSCRIPTIONAL SILENCING AND DNA-REPLICATION IN SACCHAROMYCES-CEREVISIAE	SCIENCE			English	Article							ACTIVE-SITE TYROSINE; MATING TYPE LOCUS; SACCHAROMYCES-CEREVISIAE; BINDING PROTEIN; TOPOISOMERASE-I; GENETIC-ANALYSIS; YEAST SILENCER; REPRESSION; MUTAGENESIS; HISTONE-H4	In Saccharomyces cerevisiae, the HMR-E silencer blocks site-specific interactions between proteins and their recognition sequences in the vicinity of the silencer. Silencer function is correlated with the firing of an origin of replication at HMR-E. An essential gene with a role in transcriptional silencing was identified by means of a screen for mutations affecting expression of HMR. This gene, known as ORC2, was shown to encode a component of the origin recognition complex that binds yeast origins of replication. A temperature-sensitive mutation in ORC2 disrupted silencing in cells grown at the permissive temperature. At the restrictive temperature, the orc2-1 mutation caused cell cycle arrest at a point in the cell cycle indicative of blocks in DNA replication. The orc2-1 mutation also resulted in the enhanced mitotic loss of a plasmid, suggestive of a defect in replication. These results provide strong evidence for an in vivo role of ORC in both chromosomal replication and silencing, and provide a link between the mechanism of silencing and DNA replication.			FOSS, M (corresponding author), UNIV CALIF BERKELEY,DEPT MOLEC & CELLULAR BIOL,DIV GENET,401 BARKER HALL,BERKELEY,CA 94720, USA.				NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES001896] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031105, R37GM031105] Funding Source: NIH RePORTER; NIEHS NIH HHS [P30ES01896-12] Funding Source: Medline; NIGMS NIH HHS [GM31105] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAHAM J, 1982, COLD SPRING HARB SYM, V47, P989, DOI 10.1101/SQB.1983.047.01.113; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BRAND AH, 1985, CELL, V41, P41, DOI 10.1016/0092-8674(85)90059-5; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P5086, DOI 10.1128/MCB.8.12.5086; BUCHMAN AR, 1990, MOL CELL BIOL, V10, P887, DOI 10.1128/MCB.10.3.887; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DUBLEY DD, 1991, MOL CELL BIOL, V11, P5346; ENG WK, 1989, J BIOL CHEM, V264, P13373; FELDMAN JB, 1984, J MOL BIOL, V178, P815, DOI 10.1016/0022-2836(84)90313-9; HERSKOWITZ J, 1992, MOL CELLULAR BIOL YE, P583; HIETER P, 1985, CELL, V40, P381, DOI 10.1016/0092-8674(85)90152-7; HRYCYNA CA, 1991, EMBO J, V10, P1699, DOI 10.1002/j.1460-2075.1991.tb07694.x; HUBERMAN JA, 1988, NUCLEIC ACIDS RES, V16, P6373, DOI 10.1093/nar/16.14.6373; HUISMAN O, 1987, GENETICS, V116, P191; JOHNSON LM, 1990, P NATL ACAD SCI USA, V87, P6286, DOI 10.1073/pnas.87.16.6286; KAYNE PS, 1988, CELL, V55, P27, DOI 10.1016/0092-8674(88)90006-2; KIMMERLY W, 1988, EMBO J, V7, P2241, DOI 10.1002/j.1460-2075.1988.tb03064.x; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURTZ S, 1991, GENE DEV, V5, P616, DOI 10.1101/gad.5.4.616; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LO ST, UNPUB; LONGTINE MS, 1989, CURR GENET, V16, P225, DOI 10.1007/BF00422108; LYNN RM, 1989, P NATL ACAD SCI USA, V86, P3559, DOI 10.1073/pnas.86.10.3559; MCNALLY FJ, 1991, MOL CELL BIOL, V11, P5648, DOI 10.1128/MCB.11.11.5648; MEGEE PC, 1990, SCIENCE, V247, P841, DOI 10.1126/science.2106160; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; MULLEN JR, 1989, EMBO J, V8, P2067, DOI 10.1002/j.1460-2075.1989.tb03615.x; PARK EC, 1990, MOL CELL BIOL, V10, P4932, DOI 10.1128/MCB.10.9.4932; RINE J, 1987, GENETICS, V116, P9; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; SHUMAN S, 1989, P NATL ACAD SCI USA, V86, P9793, DOI 10.1073/pnas.86.24.9793; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGH J, 1992, GENE DEV, V6, P186, DOI 10.1101/gad.6.2.186; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; SPENCER F, 1990, GENETICS, V124, P237; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749	41	288	292	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 17	1993	262	5141					1838	1844		10.1126/science.8266071	http://dx.doi.org/10.1126/science.8266071			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266071				2022-12-01	WOS:A1993MM51100026
J	RUSSELL, SM; KEEGAN, AD; HARADA, N; NAKAMURA, Y; NOGUCHI, M; LELAND, P; FRIEDMANN, MC; MIYAJIMA, A; PURI, RK; PAUL, WE; LEONARD, WJ				RUSSELL, SM; KEEGAN, AD; HARADA, N; NAKAMURA, Y; NOGUCHI, M; LELAND, P; FRIEDMANN, MC; MIYAJIMA, A; PURI, RK; PAUL, WE; LEONARD, WJ			INTERLEUKIN-2 RECEPTOR GAMMA-CHAIN - A FUNCTIONAL COMPONENT OF THE INTERLEUKIN-4 RECEPTOR	SCIENCE			English	Article							GROWTH SIGNAL TRANSDUCTION; HUMAN IL-2 RECEPTOR; T-CELL LINE; BETA-CHAIN; LIGAND-BINDING; GM-CSF; SUBUNIT; PROLIFERATION; EXPRESSION; CLONING	The interleukin-2 (IL-2) receptor gamma chain (IL-2Rgamma) is an essential component of high- and intermediate-affinity IL-2 receptors. IL-2Rgamma was demonstrated to be a component of the IL-4 receptor on the basis of chemical cross-linking data, the ability of IL-2Rgamma to augment IL-4 binding affinity, and the requirement for IL-2Rgamma in IL-4-mediated phosphorylation of insulin receptor substrate-1. The observation that IL-2Rgamma is a functional component of the IL-4 receptor, together with the finding that IL-2Rgamma associates with the IL-7 receptor, begins to elucidate why deficiency of this common gamma chain (gamma(c)) has a profound effect on lymphoid function and development, as seen in X-linked severe combined immunodeficiency.	NHLBI,PULM & MOLEC IMMUNOL SECT,BETHESDA,MD 20892; NIAID,IMMUNOL LAB,BETHESDA,MD 20892; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304; US FDA,CTR BIOL EVALUAT & RES,DIV CELLULAR & GENE THERAPIES,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.; US Food & Drug Administration (FDA)			Leonard, Warren/AAA-1397-2022; Russell, Sarah M/B-9341-2009	Russell, Sarah M/0000-0001-5826-9641				BAULA JL, 1992, J BIOL CHEM, V267, P20525; BOULAY JL, 1993, CURR BIOL, V3, P573, DOI 10.1016/0960-9822(93)90002-6; CAO XQ, 1993, P NATL ACAD SCI USA, V90, P8464, DOI 10.1073/pnas.90.18.8464; CARRISON M, 1989, EUR J IMMUNOL, V19, P913; CONLEY ME, 1992, ANNU REV IMMUNOL, V10, P215; COOPER MD, 1989, FUNDAMENTAL IMMUNOLO, P1034; DEFRANCE T, 1988, J EXP MED, V168, P1321, DOI 10.1084/jem.168.4.1321; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FERNANDEZBOTRAN R, 1989, J EXP MED, V169, P379, DOI 10.1084/jem.169.2.379; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; GALIZZI JP, 1990, INT IMMUNOL, V2, P669, DOI 10.1093/intimm/2.7.669; Gelfand E W, 1983, Birth Defects Orig Artic Ser, V19, P65; GNARRA JR, 1990, P NATL ACAD SCI USA, V87, P3440, DOI 10.1073/pnas.87.9.3440; HARADA N, 1992, J BIOL CHEM, V267, P22752; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HULI J, 1989, J IMMUNOL, V142, P800; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; ISUHARA K, 1993, BIOCHEM BIOPH RES CO, V190, P992; KEEGAN AD, 1991, J IMMUNOL, V146, P2272; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; LEONARD WJ, 1992, INTERLEUKIN 2, P29; LICHTMAN AH, 1987, P NATL ACAD SCI USA, V84, P824, DOI 10.1073/pnas.84.3.824; MIGLIORATI G, 1991, CELL IMMUNOL, V136, P194, DOI 10.1016/0008-8749(91)90394-Q; MITCHELL LC, 1989, J IMMUNOL, V142, P1548; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, J BIOL CHEM, V268, P13601; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; OTANI H, 1992, P NATL ACAD SCI USA, V89, P2789, DOI 10.1073/pnas.89.7.2789; PAUL WE, 1991, BLOOD, V77, P1859; PURI RK, 1993, CANCER INVEST, V11, P479; RIGLEY KP, 1991, INT IMMUNOL, V3, P197, DOI 10.1093/intimm/3.2.197; RUSSELL SM, UNPUB; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; SMITH KA, 1989, ANNU REV CELL BIOL, V5, P397; SPITS H, 1987, J IMMUNOL, V139, P1142; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAVERNIER J, 1991, CELL, V66, P1174; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALLE A, 1991, INT IMMUNOL, V3, P229, DOI 10.1093/intimm/3.3.229; VAZQUEZ A, 1989, J IMMUNOL, V142, P94; WALDMANN TA, 1989, ANNU REV BIOCHEM, V58, P875, DOI 10.1146/annurev.bi.58.070189.004303; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WLODAWER A, 1993, PROTEIN SCI, V2, P1373, DOI 10.1002/pro.5560020902; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x; [No title captured]	51	808	837	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 17	1993	262	5141					1880	1883		10.1126/science.8266078	http://dx.doi.org/10.1126/science.8266078			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266078	Green Submitted			2022-12-01	WOS:A1993MM51100038
J	GULYAS, AI; MILES, R; SIK, A; TOTH, K; TAMAMAKI, N; FREUND, TF				GULYAS, AI; MILES, R; SIK, A; TOTH, K; TAMAMAKI, N; FREUND, TF			HIPPOCAMPAL PYRAMIDAL CELLS EXCITE INHIBITORY NEURONS THROUGH A SINGLE RELEASE SITE	NATURE			English	Article							MINIATURE SYNAPTIC CURRENTS; LONG-TERM POTENTIATION; PROTEIN PARVALBUMIN; RAT HIPPOCAMPUS; SLICES; CORTEX; IDENTIFICATION; TRANSMISSION; VARIABILITY; SYSTEM	MORPHOLOGICALLY a synapse consists of a presynaptic release site containing vesicles, a postsynaptic element with membrane specialization, and a synaptic cleft between them1. The number of release sites shapes the properties of synaptic transmission between neurons2-4. Although excitatory interactions between cortical neurons have been examined5-9, the number of release sites remains unknown. We have now recorded excitatory postsynaptic potentials evoked by single pyramidal cells in hippocampal interneurons and visualized both cells using biocytin injections. Light and electron microscopy showed that excitatory postsynaptic potentials were mediated by a single synapse. We also reconstructed the entire axon arborization of single pyramidal cells, filled in vivo, in sections counterstained for parvalbumin, which selectively marks basket and axo-axonic cells10,11. Single synaptic contacts between pyramidal cells and parvalbumin-containing neurons were dominant (>80%), providing evidence for high convergence and divergence in hippocampal networks12.	HUNGARIAN ACAD SCI,INST EXPTL MED,POB 67,H-1450 BUDAPEST,HUNGARY; INST PASTEUR,INSERM,U261,NEUROBIOL LAB,F-75264 PARIS 15,FRANCE; FUKUI MED SCH,DEPT ANAT,FUKUI 91011,JAPAN	Hungarian Academy of Sciences; Hungarian Institute of Experimental Medicine; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; University of Fukui				Gulyas, Attila/0000-0003-4961-636X				BAIMBRIDGE KG, 1982, BRAIN RES, V239, P519, DOI 10.1016/0006-8993(82)90526-1; BEKKERS JM, 1990, P NATL ACAD SCI USA, V87, P5359, DOI 10.1073/pnas.87.14.5359; BUSCH C, 1990, COLD SPRING HARB SYM, V55, P69; BUZSAKI G, 1983, BRAIN RES REV, V6, P139, DOI 10.1016/0165-0173(83)90037-1; FREUND TF, 1985, J COMP NEUROL, V242, P275, DOI 10.1002/cne.902420209; HESTRIN S, 1992, NEURON, V9, P991, DOI 10.1016/0896-6273(92)90250-H; Heuser JE, 1977, HDB PHYSL, VI, P261; KAWAGUCHI Y, 1987, BRAIN RES, V416, P369, DOI 10.1016/0006-8993(87)90921-8; Korn H., 1987, SYNAPTIC FUNCTION, P57; KOSAKA T, 1987, BRAIN RES, V419, P119, DOI 10.1016/0006-8993(87)90575-0; LI XG, IN PRESS J COMP NEUR; LLINAS R, 1969, J NEUROPHYSIOL, V32, P847, DOI 10.1152/jn.1969.32.6.847; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MANABE T, 1992, NATURE, V355, P50, DOI 10.1038/355050a0; McClelland J. L., 1986, PARALLEL DISTRIBUTED, V2; MCNAUGHTON BL, 1987, TRENDS NEUROSCI, V10, P408, DOI 10.1016/0166-2236(87)90011-7; MILES R, 1990, J PHYSIOL-LONDON, V428, P61, DOI 10.1113/jphysiol.1990.sp018200; MILES R, 1986, J PHYSIOL-LONDON, V373, P397, DOI 10.1113/jphysiol.1986.sp016055; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; REDMAN S, 1990, PHYSIOL REV, V70, P165, DOI 10.1152/physrev.1990.70.1.165; SAYER RJ, 1989, J NEUROSCI, V9, P840; SCHWARTZKROIN PA, 1978, BRAIN RES, V157, P1, DOI 10.1016/0006-8993(78)90991-5; SCHWARTZKROIN PA, 1993, BRAIN RES, V9, P991; SIK A, IN PRESS EUR J NEURO; SOMOGYI P, 1983, NEUROSCIENCE, V10, P261, DOI 10.1016/0306-4522(83)90133-1; STERN P, 1992, J PHYSIOL-LONDON, V449, P247, DOI 10.1113/jphysiol.1992.sp019085; STEVENS CF, 1993, NEURON S, V10, P55; TAMAMAKI N, 1984, BRAIN RES, V307, P336, DOI 10.1016/0006-8993(84)90489-X; Traub R.D., 1991, NEURONAL NETWORKS HI; WHITE EL, 1987, J COMP NEUROL, V262, P13, DOI 10.1002/cne.902620103	31	283	284	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 16	1993	366	6456					683	687		10.1038/366683a0	http://dx.doi.org/10.1038/366683a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	8259211				2022-12-01	WOS:A1993MM26500069
J	SERRANO, M; HANNON, GJ; BEACH, D				SERRANO, M; HANNON, GJ; BEACH, D			A NEW REGULATORY MOTIF IN CELL-CYCLE CONTROL CAUSING SPECIFIC-INHIBITION OF CYCLIN-D/CDK4	NATURE			English	Article							PROTEIN-KINASES	THE division cycle of eukaryotic cells is regulated by a family of protein kinases known as the cyclin-dependent kinases (CDKs)1,2. The sequential activation of individual members of this family and their consequent phosphorylation of critical substrates promotes orderly progression through the cell cycle3,4. The complexes formed by CDK4 and the D-type cyclins have been strongly implicated in the control of cell proliferation during the G1 phase3-6. CDK4 exists, in part, as a multi-protein complex with a D-type cyclin, proliferating cell nuclear antigen and a protein, p21 (refs 7-9). CDK4 associates separately with a protein of M(r) 16K, particularly in cells lacking a functional retinoblastoma protein9. Here we report the isolation of a human p16 complementary DNA and demonstrate that p16 binds to CDK4 and inhibits the catalytic activity of the CDK4/cyclin D enzymes. p16 seems to act in a regulatory feedback circuit with CDK4, D-type cyclins and retino-blastoma protein.	COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, POB 100, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute			Serrano, Manuel/H-2634-2015; Hannon, Gregory/AAB-3568-2019	Serrano, Manuel/0000-0001-7177-9312; 				CHEN XS, 1993, EUR J BIOCHEM, V214, P845, DOI 10.1111/j.1432-1033.1993.tb17988.x; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HARLOW E, 1988, ANTIBODIES LABORATOR; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; KATO J, 1993, GENE DEV, V7, P331; LEES EM, 1993, MOL CELL BIOL, V13, P1194, DOI 10.1128/MCB.13.2.1194; LI Y, 1993, GENE DEV, V7, P2366, DOI 10.1101/gad.7.12a.2366; LUKAS J, IN PRESS ONCOGENE; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; Michaely P, 1992, Trends Cell Biol, V2, P127, DOI 10.1016/0962-8924(92)90084-Z; MOTOKURA T, 1993, BIOCHIM BIOPHYS ACTA, V1155, P63, DOI 10.1016/0304-419X(93)90022-5; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SOLOMON M, 1993, J CURR OPIN CELL BIO, V5, P180; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHENG XF, 1993, CELL, V75, P155, DOI 10.1016/S0092-8674(05)80092-3; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	23	3366	3579	5	142	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1993	366	6456					704	707		10.1038/366704a0	http://dx.doi.org/10.1038/366704a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	8259215				2022-12-01	WOS:A1993MM26500075
J	HARDIE, RM; WATSON, JM				HARDIE, RM; WATSON, JM			SCREENING MIGRANTS AT RISK OF TUBERCULOSIS	BRITISH MEDICAL JOURNAL			English	Article											HARDIE, RM (corresponding author), PUBL HLTH LAB SERV,COMMUNICABLE DIS SURVEILLANCE CTR,LONDON NW9 5EQ,ENGLAND.							ORMEROD LP, 1990, RESP MED, V84, P269, DOI 10.1016/S0954-6111(08)80051-0; WATSON JM, 1993, BRIT MED J, V306, P221, DOI 10.1136/bmj.306.6872.221; 1992, SERIES MN, V17; 1990, BMJ, V300, P995; 1992, THORAX, V47, P770	5	41	42	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1993	307	6918					1539	1540		10.1136/bmj.307.6918.1539	http://dx.doi.org/10.1136/bmj.307.6918.1539			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML869	8274925	Green Published, Bronze			2022-12-01	WOS:A1993ML86900024
J	COUTAVAS, E; REN, MD; OPPENHEIM, JD; DEUSTACHIO, P; RUSH, MG				COUTAVAS, E; REN, MD; OPPENHEIM, JD; DEUSTACHIO, P; RUSH, MG			CHARACTERIZATION OF PROTEINS THAT INTERACT WITH THE CELL-CYCLE REGULATORY PROTEIN RAN/TC4	NATURE			English	Article							RCC1; POLYPEPTIDE; EXPRESSION; MITOSIS; GTPASE; GENES	THE human Ras-related nuclear protein Ran/TC4 (refs 1-4) is the prototype of a well conserved family of GTPases that can regulate both cell-cycle progression5-8 and messenger RNA transport9. Ran has been proposed to undergo tightly controlled cycles of GTP binding and hydrolysis, to operate as a GTPase switch10,11 whose GTP- and GDP-bound forms interact differentially with regulators and effectors. One known regulator, the protein RCC1 (refs 12, 13), interacts with Ran to catalyse guanine nucleotide exchange, and both RCC1 and Ran are components of an intrinsic checkpoint control that prevents the premature initiation of mitosis. To test and extend the GTPase-switch model, we searched for a Ran-specific GTPase-activating protein (GAP), and for putative effectors (proteins that interact specifically with Ran/TC4-GTP). We report here the identification of a Ran GAP and its use to characterize the GTP-hydrolysing properties of mutant Ran proteins, and the identification and cloning of a binding protein specific for Ran/TC4-GTP.	NYU MED CTR,DEPT BIOCHEM,NEW YORK,NY 10016; NYU MED CTR,DEPT CELL BIOL,NEW YORK,NY 10016; NYU MED CTR,DEPT MICROBIOL,NEW YORK,NY 10016; NYU MED CTR,KAPLAN CTR,NEW YORK,NY 10016	New York University; New York University; New York University; New York University				Oppenheim, Joel/0000-0002-6920-5624; D'Eustachio, Peter/0000-0002-5494-626X; Coutavas, Elias/0000-0003-4904-0081				AMBERG DC, 1993, EMBO J, V12, P233, DOI 10.1002/j.1460-2075.1993.tb05649.x; Barbacid M., 1987, REV BIOCH, V56, P779; BELHUMEUR P, 1993, MOL CELL BIOL, V13, P2152, DOI 10.1128/MCB.13.4.2152; BISCHOFF FR, 1991, NATURE, V354, P80, DOI 10.1038/354080a0; BISCHOFF FR, 1991, P NATL ACAD SCI USA, V88, P10830, DOI 10.1073/pnas.88.23.10830; BISCHOFF FR, 1993, 13 WASH INT S; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRESSAN A, 1991, GENE, V103, P201, DOI 10.1016/0378-1119(91)90274-F; CONNOLLY T, 1989, CELL, V57, P599, DOI 10.1016/0092-8674(89)90129-3; DASSO M, 1993, TRENDS BIOCHEM SCI, V18, P96, DOI 10.1016/0968-0004(93)90161-F; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; KADOWAKI T, 1992, P NATL ACAD SCI USA, V89, P2312, DOI 10.1073/pnas.89.6.2312; MARGOLIS B, 1992, P NATL ACAD SCI USA, V89, P8894, DOI 10.1073/pnas.89.19.8894; MATSUMOTO T, 1993, MOL BIOL CELL, V4, P337, DOI 10.1091/mbc.4.3.337; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MCCORMICK F, 1992, PHILOS T ROY SOC B, V336, P43, DOI 10.1098/rstb.1992.0042; MOORE MS, 1993, NATURE, V365, P661, DOI 10.1038/365661a0; NISHITANI H, 1991, EMBO J, V10, P1555, DOI 10.1002/j.1460-2075.1991.tb07675.x; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; REN MD, 1993, J CELL BIOL, V120, P313, DOI 10.1083/jcb.120.2.313; ROBERGE M, 1992, TRENDS CELL BIOL, V2, P177; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; UCHIDA S, 1990, MOL CELL BIOL, V10, P577, DOI 10.1128/MCB.10.2.577	23	246	250	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 9	1993	366	6455					585	587		10.1038/366585a0	http://dx.doi.org/10.1038/366585a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	8255297				2022-12-01	WOS:A1993ML21800076
J	LARSSON, K; OHLSEN, P; LARSSON, L; MALMBERG, P; RYDSTROM, PO; ULRIKSEN, H				LARSSON, K; OHLSEN, P; LARSSON, L; MALMBERG, P; RYDSTROM, PO; ULRIKSEN, H			HIGH PREVALENCE OF ASTHMA IN CROSS-COUNTRY SKIERS	BRITISH MEDICAL JOURNAL			English	Article							BRONCHIAL HYPERRESPONSIVENESS; SKELETAL-MUSCLE; COLD AIR; TERBUTALINE; SALBUTAMOL; EXERCISE; BRONCHODILATOR; RESPONSIVENESS; AGONIST; TESTS	Objectives-To study the prevalence of asthma (asthma symptoms and bronchial hyperresponsiveness) in Swedish cross country skiers compared with non-skiers and monitor changes in symptoms and bronchial hyperresponsiveness during the year. Design-Cross sectional study during the winter ski season and in the summer. Setting-Six ski clubs for elite skiers (total 47) in two different areas of Sweden. Subjects-42 elite cross country skiers and 29 non-skiing referents. Main outcome measures-Bronchial responsiveness, asthma symptoms, and lung function. Results-Bronchial responsiveness was significantly greater and asthma symptoms more prevalent in the skiers than in the referents. There was no difference in bronchial responsiveness within either group between winter and summer. 15 of the 42 skiers used antiasthmatic drugs regularly and 23 had a combination of asthma symptoms and hyperresponsive airways or physician diagnosed asthma, or both. Altogether 33 skiers had symptoms of asthma or bronchial hyperresponsiveness. One of the referents had symptoms of asthma and bronchial hyperresponsiveness, and none used antiasthmatic drugs regularly. Conclusions-Asthma, asthma-like symptoms, and bronchial hyperresponsiveness are much more common in cross country skiers than in the general population and non-skiers. Strenuous exercise at low temperatures entailing breathing large volumes of cold air is the most probable explanation of persistent asthma in skiers.	SWEDISH SKI ASSOC,CTR ATHLET,STOCKHOLM,SWEDEN; HOSP OSTERSUND,DEPT INTERNAL MED,OSTERSUND,SWEDEN		LARSSON, K (corresponding author), NATL INST OCCUPAT HLTH,IFL,DIV RESP,S-17184 SOLNA,SWEDEN.							AMARIV I, 1989, AM REV RESPIR DIS, V140, P1416; BEERMANN DH, 1987, J ANIM SCI, V65, P1514, DOI 10.2527/jas1987.6561514x; CHOO JJ, 1992, AM J PHYSIOL, V263, pE50, DOI 10.1152/ajpendo.1992.263.1.E50; DOSMAN JA, 1991, AM REV RESPIR DIS, V144, P45, DOI 10.1164/ajrccm/144.1.45; DROBNIC F, 1992, EUR RESPIR J S15, V5, pS456; FREEMAN W, 1989, THORAX, V44, P942, DOI 10.1136/thx.44.11.942; GOMES I, 1992, EUR RESPIR J S15, V5, pS455; HEDENSTROM H, 1985, B EUR PHYSIOPATH RES, V21, P551; HENDENSTROM H, 1986, UPPSALA MED SCI, V91, P299; KERREBIJN KF, 1987, J ALLERGY CLIN IMMUN, V79, P653, DOI 10.1016/S0091-6749(87)80163-X; KRAAN J, 1985, J ALLERGY CLIN IMMUN, V76, P628, DOI 10.1016/0091-6749(85)90786-9; LARSSON K, 1992, CHEST, V101, P953, DOI 10.1378/chest.101.4.953; LARSSON K, 1987, RESPIRATION, V51, P214, DOI 10.1159/000195204; LARSSON L, 1993, EUR RESPIR J, V6, P198; LARSSON L, IN PRESS THORAX; LARSSON L, IN PRESS SCANDINAVIA; LITMANEN H, 1992, EUR RESPIR J S15, V5, pS445; LUNDBACK B, 1991, EUR RESPIR J, V4, P257; MALMBERG P, 1991, EUR RESPIR J, V4, P890; MARTINEAU L, 1992, CLIN SCI, V83, P615, DOI 10.1042/cs0830615; MARTINEZ JA, 1991, HORM METAB RES, V23, P590, DOI 10.1055/s-2007-1003762; MCKENZIE DC, 1993, MED SCI SPORTS EXERC, V15, P520; Morton AR, 1992, CLIN J SPORT MED, V2, P93; SIGNORILE JF, 1992, MED SCI SPORT EXER, V24, P638; STRAUSS RH, 1978, J CLIN INVEST, V61, P433, DOI 10.1172/JCI108954; STRAUSS RH, 1977, NEW ENGL J MED, V297, P743, DOI 10.1056/NEJM197710062971402; TOREN K, IN PRESS CHEST; VANSCHAYCK CP, 1990, J ALLERGY CLIN IMMUN, V86, P793, DOI 10.1016/S0091-6749(05)80185-X; VATHENEN AS, 1988, LANCET, V1, P554; VOY RO, 1984, MED SCI SPORTS EXERC, V18, P328; WEILER JM, 1986, CHEST, V90, P23, DOI 10.1378/chest.90.1.23	31	240	243	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1993	307	6915					1326	1329		10.1136/bmj.307.6915.1326	http://dx.doi.org/10.1136/bmj.307.6915.1326			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH556	8257888	Green Published, Bronze			2022-12-01	WOS:A1993MH55600022
J	EVERY, NR; LARSON, EB; LITWIN, PE; MAYNARD, C; FIHN, SD; EISENBERG, MS; HALLSTROM, AP; MARTIN, JS; WEAVER, WD				EVERY, NR; LARSON, EB; LITWIN, PE; MAYNARD, C; FIHN, SD; EISENBERG, MS; HALLSTROM, AP; MARTIN, JS; WEAVER, WD			THE ASSOCIATION BETWEEN ON-SITE CARDIAC-CATHETERIZATION FACILITIES AND THE USE OF CORONARY ANGIOGRAPHY AFTER ACUTE MYOCARDIAL-INFARCTION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SMALL-AREA VARIATIONS; INTERVENTION-REGISTRY; TRIAGE	Background. During the past decade the use of coronary angiography after acute myocardial infarction has substantially increased. Among the possible contributing factors, the increasing availability of cardiac catheterization facilities was the focus of our investigation. Methods. We investigated whether the availability of cardiac catheterization facilities at an admitting hospital was associated with the likelihood that a patient would undergo coronary angiography. After adjusting for age, sex, cardiac history, and cardiac complications during hospitalization, we evaluated this association in 5867 consecutive patients with acute myocardial infarction admitted to 19 Seattle-area hospitals. We also assessed the association between the presence of on-site cardiac catheterization facilities and in-hospital mortality. Results. Patients admitted to hospitals with on-site cardiac catheterization facilities were far more likely to undergo coronary angiography (odds ratio, 3.21; 95 percent confidence interval, 2.81 to 3.67) than patients admitted to hospitals where transfer to another institution would be required to perform cardiac catheterization. Admission to a hospital with on-site facilities was more strongly associated with the use of coronary angiography than any characteristic of the patient. Although our study had limited power to detect differences in mortality, the availability of coronary angiography had no discernible association with in-hospital mortality rates (odds ratio for mortality among patients admitted to hospitals with on-site facilities vs. patients admitted to hospitals without such facilities, 0.88; 95 percent confidence interval, 0.71 to 1.09). Conclusions. In this community-wide study, the availability of on-site cardiac catheterization facilities was associated with a higher likelihood that a patient would undergo coronary angiography. However, admission to hospitals with these facilities did not appear to be associated with lower short-term mortality.	VET AFFAIRS MED CTR, NW HLTH SERV RES & DEV FIELD PROGRAM, SEATTLE, WA USA; UNIV WASHINGTON, DEPT MED CARDIOL, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT BIOSTAT, SEATTLE, WA 98195 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle			Fihn, Stephan/ABA-1040-2020; Maynard, Charles/N-3906-2015	Maynard, Charles/0000-0002-1644-7814	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL038454] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL-38454] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Altman DG, 1991, PRACTICAL STAT MED R, P179; [Anonymous], 1991, BMJ, V302, P555; [Anonymous], 1989, NEW ENGL J MED, V320, P618; BENGTSON JR, 1992, J AM COLL CARDIOL, V20, P1482, DOI 10.1016/0735-1097(92)90440-X; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2543, DOI 10.1001/jama.258.18.2543; DEFEYTER PJ, 1982, CIRCULATION, V66, P527, DOI 10.1161/01.CIR.66.3.527; DEWOOD MA, 1989, J AM COLL CARDIOL, V14, P65, DOI 10.1016/0735-1097(89)90055-7; FEILD DJ, 1987, J AM COLL CARDIOL, V10, P935, DOI 10.1016/S0735-1097(87)80294-2; HILLMAN BJ, 1990, NEW ENGL J MED, V323, P1604, DOI 10.1056/NEJM199012063232306; Kulick D L, 1990, Cardiovasc Clin, V21, P3; LEAPE LL, 1990, JAMA-J AM MED ASSOC, V263, P669, DOI 10.1001/jama.263.5.669; MAYNARD C, 1991, AM J CARDIOL, V67, P18, DOI 10.1016/0002-9149(91)90092-Y; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; MITCHELL JB, 1982, REGIONAL VARIATIONS, P103; MOSS AJ, 1983, NEW ENGL J MED, V309, P331, DOI 10.1056/nejm198308113090602; NICOD P, 1991, CIRCULATION, V84, P1004, DOI 10.1161/01.CIR.84.3.1004; ROBINSON JC, 1987, NEW ENGL J MED, V317, P85, DOI 10.1056/NEJM198707093170205; ROULEAU JL, 1993, NEW ENGL J MED, V328, P779, DOI 10.1056/NEJM199303183281108; SHAIN M, 1959, Mod Hosp, V92, P71; SIMPSON JB, 1985, AM J PUBLIC HEALTH, V75, P1225, DOI 10.2105/AJPH.75.10.1225; WEAVER WD, 1990, J AM COLL CARDIOL, V15, P925, DOI 10.1016/0735-1097(90)90218-E; WENNBERG J, 1973, SCIENCE, V182, P1102, DOI 10.1126/science.182.4117.1102; 1990, SPSS PC PLUS ADV STA; 1992, CONSUM REP, P435; 1991, HOSPITAL STATISTICS, P209	25	203	204	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1993	329	8					546	551		10.1056/NEJM199308193290807	http://dx.doi.org/10.1056/NEJM199308193290807			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR892	8336755				2022-12-01	WOS:A1993LR89200007
J	DEKARIS, D; SABIONCELLO, A; MAZURAN, R; RABATIC, S; SVOBODABEUSAN, I; RACUNICA, NL; TOMASIC, J				DEKARIS, D; SABIONCELLO, A; MAZURAN, R; RABATIC, S; SVOBODABEUSAN, I; RACUNICA, NL; TOMASIC, J			MULTIPLE CHANGES OF IMMUNOLOGICAL PARAMETERS IN PRISONERS OF WAR - ASSESSMENTS AFTER RELEASE FROM A CAMP IN MANJACA, BOSNIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PROTEIN-CALORIE MALNUTRITION; PITUITARY-ADRENAL AXIS; STRESS; DISORDERS; RESPONSES; DISEASE; SYSTEM; AGE	Objective.-To assess immune reactivity in men just released from a war prisoner camp. Participants.-Random sample of 29 men from a group of 764 liberated detainees in war prisoner camp in Bosnia, 15 matched healthy control subjects, and pre-war historical control subjects. Main Outcome Measures.-Report on immune reactivity parameters, such as lymphocyte immunophenotypes, natural killer cell and phagocyte function, serum cytokines, and hormones. Results.-Compared with control subjects, detainees had significantly lowered red blood cell count, hemogLobin mass concentration, hematocrit, total serum proteins, and albumin level, while the percentage and count of monocytes and nonsegmented neutrophils were increased. Flow cytometry revealed a significant increase in percentage of activated lymphocytes, activated T lymphocytes, Tc/s lymphocytes, B lymphocytes, and total HLA-DR lymphocytes. The absolute counts of activated lymphocytes and activated T lymphocytes were also significantly increased. The percentages of naive Th/i lymphocytes and the ratio of CD4:CD8 lymphocytes were decreased. The in vitro natural killer cell cytotoxic activity and phagocytic functions of ingestion and digestion were significantly depressed. Serum interferon, serum cortisol, and prolactin were also significantly lowered. Serum tumor necrosis factor was increased. Conclusions.-Alterations in the main parameters of the immune system and depression of important immune effector functions may have resulted from the psychological stress, physical deprivation, and malnutrition experienced by these war camp prisoners during their detainment.			DEKARIS, D (corresponding author), UNIV ZAGREB, INST IMMUNOL, ROCKEFELLEROVA 10, 41000 ZAGREB, CROATIA.							AOKI T, 1987, NAT IMMUN CELL GROW, V6, P116; AUSMAN LM, 1989, AM J CLIN NUTR, V50, P19, DOI 10.1093/ajcn/50.1.19; BALLIEUX RE, 1991, J CLIN PERIODONTOL, V18, P427, DOI 10.1111/j.1600-051X.1991.tb02311.x; BENTDAL OH, 1991, CLIN NUTR, V10, P167, DOI 10.1016/0261-5614(91)90053-F; BORCIC D, 1992, CROATIAN MED J S, V2, P93; CERAMI A, 1992, CLIN IMMUNOL IMMUNOP, V62, pS3, DOI 10.1016/0090-1229(92)90035-M; CHANDRA RK, 1992, J NUTR, V122, P597, DOI 10.1093/jn/122.suppl_3.597; CHANDRA RK, 1991, AM J CLIN NUTR, V53, P1087, DOI 10.1093/ajcn/53.5.1087; CHROUSOS GP, 1992, JAMA-J AM MED ASSOC, V267, P1244, DOI 10.1001/jama.267.9.1244; DEKARIS D, 1992, M EUROPEAN GROUP IMM, P110; DEKARIS D, IN PRESS WIEN MED WO; DENIZOT F, 1986, J IMMUNOL METHODS, V89, P271, DOI 10.1016/0022-1759(86)90368-6; DEZAN D, 1992, CROATIAN MED J S, V2, P97; GEARING AJH, 1987, LYMPHOKINES INTERFER, P291; HANSEN MB, 1990, J IMMUNOL METHODS, V127, P241, DOI 10.1016/0022-1759(90)90074-6; HARBUZ MS, 1992, J ENDOCRINOL, V134, P327, DOI 10.1677/joe.0.1340327; HOMODELARCHE F, 1991, J STEROID BIOCHEM, V40, P616; KHANSARI DN, 1990, IMMUNOL TODAY, V11, P170, DOI 10.1016/0167-5699(90)90069-L; Kiecolt-Glaser JK, 1991, PSYCHONEUROIMMUNOLOG, P849; LAW DK, 1973, ANN INTERN MED, V79, P545, DOI 10.7326/0003-4819-79-4-545; LEVY SM, 1991, NAT IMMUN CELL GROW, V10, P289; MALOZOWSKI S, 1990, CLIN ENDOCRINOL, V32, P461, DOI 10.1111/j.1365-2265.1990.tb00886.x; MATTHEWS N, 1987, LYMPHOKINES INTERFER, P221; MAZOWIECKI T, 1992, COMMUNICATION, P18; NOVOTNY Z, 1992, CROATIAN MED J S, V2, P90; OLEARY A, 1990, PSYCHOL BULL, V108, P363, DOI 10.1037/0033-2909.108.3.363; PETERSON PK, 1991, REV INFECT DIS, V13, P710; POLLOCK RE, 1991, ARCH SURG-CHICAGO, V126, P338; RABATIC S, 1988, MECH AGEING DEV, V45, P223, DOI 10.1016/0047-6374(88)90004-8; REDMOND HP, 1991, SURGERY, V110, P311; REICHERT T, 1991, CLIN IMMUNOL IMMUNOP, V60, P190, DOI 10.1016/0090-1229(91)90063-G; SAKSELA E, 1979, IMMUNOL REV, V44, P71, DOI 10.1111/j.1600-065X.1979.tb00268.x; Serban G, 1991, Methods Achiev Exp Pathol, V15, P200; THEODORSSONNORHEIM E, 1986, COMPUT METH PROG BIO, V23, P57, DOI 10.1016/0169-2607(86)90081-7; WAAGE A, 1992, IMMUNOL REV, V127, P221, DOI 10.1111/j.1600-065X.1992.tb01416.x; WEIGENT DA, 1987, IMMUNOL REV, V100, P79, DOI 10.1111/j.1600-065X.1987.tb00528.x; XIE QW, 1991, NEUROENDOCRINOLOGY, V53, P52, DOI 10.1159/000125796; YANG KD, 1991, J PEDIATR-US, V119, P343, DOI 10.1016/S0022-3476(05)82044-X	38	69	70	1	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1993	270	5					595	599		10.1001/jama.270.5.595	http://dx.doi.org/10.1001/jama.270.5.595			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP436	8331758				2022-12-01	WOS:A1993LP43600024
J	CHANSON, P; WEINTRAUB, BD; HARRIS, AG				CHANSON, P; WEINTRAUB, BD; HARRIS, AG			OCTREOTIDE THERAPY FOR THYROID-STIMULATING HORMONE-SECRETING PITUITARY-ADENOMAS - A FOLLOW-UP OF 52 PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Review							ACTING SOMATOSTATIN ANALOG; SMS 201-995; INAPPROPRIATE SECRETION; GROWTH-HORMONE; THYROTROPIN; SMS-201-995; TSH; IMPROVEMENT; INHIBITION; RECEPTORS	Objective: To evaluate the efficacy of octreotide in the treatment of pituitar Data Sources. Combination of review and original data. Review data included information supplied by Sandoz Pharmaceuticals from patient case report forms and information from abstracts and articles published in the French or English language between 1987 and 1991. Original data included follow-up data on 15 of 37 previously reported cases and data on 15 new cases provided by 11 investigators. Study Selection: Fifty-two cases from 24 medical centers in nine countries reported between 1987 and 1991. Data Extraction: Chief clinical characteristics of the patients; dose and duration of octreotide treatment; serum TSH, thyroid hormone, and free alpha-subunit levels before and during treatment; serial anatomic evaluation of the pituitary gland by either computed tomographic scanning or magnetic resonance imaging; and side effects. Data Synthesis: After the first octreotide dose (50 to 100 mug), TSH levels decreased in all but 2 patients (mean decrease for the whole group, 55.8% +/- 27%). Levels of alpha-subunit decreased in 15 of the 19 patients who had alpha-subunit assessments (mean decrease, 37.5% +/- 24%). Reduction of TSH levels after short-term treatment (50 or 100 mug two or three times daily) was observed in 30 of 33 patients (mean decrease, 74.1%). Thyroid hormone levels were reduced in all patients and returned to normal in 73%. Despite an initial response to therapy, thyroid hormone levels continued to rise (''true escape'') in 2 patients receiving short-term therapy and in 3 patients receiving long-term therapy. Partial shrinkage of the adenoma occurred in 11 patients. Conclusions: Octreotide is an effective treatment for TSH-secreting adenomas. Thyroid-stimulating hormone levels almost always decreased, and thyroid hormone levels reverted to normal in about three quarters of patients. Partial tumor shrinkage was observed in one third of patients receiving long-term octreotide treatment.	NIH, BETHESDA, MD 20892 USA; CEDARS SINAI MED CTR, LOS ANGELES, CA 90048 USA	National Institutes of Health (NIH) - USA; Cedars Sinai Medical Center	CHANSON, P (corresponding author), HOP LARIBOISIERE, DEPT INTERNAL MED & ENDOCRINOL, 2 RUE AMBROISE PARE, F-75475 PARIS 10, FRANCE.		Chanson, Philippe/F-8511-2013	Chanson, Philippe/0000-0001-5096-5722; Harris, Alan/0000-0002-6618-2092				ASAI J, 1988, 8TH INT C END; BECKERS A, 1988, Revue Medicale de Liege, V43, P396; BECKERS A, 1991, J CLIN ENDOCR METAB, V72, P477, DOI 10.1210/jcem-72-2-477; BECKPECCOZ P, 1988, HORM RES, V29, P121, DOI 10.1159/000180986; BECKPECCOZ P, 1989, J CLIN ENDOCR METAB, V68, P208, DOI 10.1210/jcem-68-1-208; BELDENT V, 1988, ANN ENDOCRINOL-PARIS, V50, P282; BERTHERAT J, 1992, J CLIN ENDOCR METAB, V75, P540, DOI 10.1210/jc.75.2.540; BRENNERGATI L, 1985, PITUITARY GLAND, P467; BUCHFELDER M, 1990, ACTA ENDOCR-COP   S1, V122, P140; CHANSON P, 1987, PRESSE MED, V16, P1644; CHAPMAN C, 1989, J ENDOCRINOL S, V12, P137; COMI RJ, 1987, NEW ENGL J MED, V317, P12, DOI 10.1056/NEJM198707023170103; FRANCAVILLA TL, 1991, NEUROSURGERY, V28, P826, DOI 10.1227/00006123-199106000-00007; FRANCIA G, 1989, J ENDOCRINOL INVE S1, V12, P42; GESUNDHEIT N, 1989, ANN INTERN MED, V111, P827, DOI 10.7326/0003-4819-111-10-827; GIRELLI ME, 1989, J ENDOCRINOL INVE S1, V12, P37; GUILLAUSSEAU PJ, 1987, NEW ENGL J MED, V317, P53; HIRASAWA R, 1991, ACTA MED OKAYAMA, V45, P107; HOUDENT C, 1989, ANN ENDOCRINOL-PARIS, V50, P227; LEVY A, 1989, J NEUROENDOCRINOL, V1, P321, DOI 10.1111/j.1365-2826.1989.tb00123.x; LINQUETTE M, 1989, B ACAD NAT MED PARIS, V173, P217; MALARKEY WB, 1989, NEUROENDOCRINOLOGY, V49, P267, DOI 10.1159/000125127; MCCUTCHEON IE, 1990, J NEUROSURG, V73, P674, DOI 10.3171/jns.1990.73.5.0674; MONTINI M, 1988, ADV PITUITARY ADENOM, V69, P429; MUHR C, 1990, J ENDOCRINOL INVE S2, V13, pS79; POLAK M, 1991, ACTA ENDOCRINOL-COP, V124, P479, DOI 10.1530/acta.0.1240479; RESCHINI E, 1976, J CLIN ENDOCR METAB, V43, P924, DOI 10.1210/jcem-43-4-924; ROGER P, 1988, 8TH INT C END; SASSOLAS G, 1988, HORM RES, V29, P124, DOI 10.1159/000180987; SHAKER JL, 1991, 73RD M END SOC, P1138; SILER TM, 1974, J CLIN ENDOCR METAB, V38, P742, DOI 10.1210/jcem-38-5-742; SMALLRIDGE RC, 1987, ENDOCRIN METAB CLIN, V16, P765, DOI 10.1016/S0889-8529(18)30473-0; VANCE ML, 1991, ARCH INTERN MED, P8; VUILLERMET P, 1991, ANN ENDOCRINOL-PARIS, V532, P36; WARNET A, 1991, ACTA ENDOCRINOL-COP, V124, P487, DOI 10.1530/acta.0.1240487; WEEKE J, 1975, J CLIN ENDOCR METAB, V41, P168, DOI 10.1210/jcem-41-1-168; WEINTRAUB BD, 1981, ANN INTERN MED, V95, P339, DOI 10.7326/0003-4819-95-3-339; WEMEAU JL, 1988, J CLIN ENDOCR METAB, V66, P636, DOI 10.1210/jcem-66-3-636	38	162	168	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1993	119	3					236	240		10.7326/0003-4819-119-3-199308010-00010	http://dx.doi.org/10.7326/0003-4819-119-3-199308010-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU903	8323093				2022-12-01	WOS:A1993LU90300010
J	ZHENG, LB; COLLINS, FH; KUMAR, V; KAFATOS, FC				ZHENG, LB; COLLINS, FH; KUMAR, V; KAFATOS, FC			A DETAILED GENETIC-MAP FOR THE X-CHROMOSOME OF THE MALARIA VECTOR, ANOPHELES-GAMBIAE	SCIENCE			English	Article							ESTERASE LOCUS; DNA; POLYMORPHISMS; COMPLEX; REPEAT	Anopheles gambiae, the primary vector of human malaria in Africa, is responsible for approximately a million deaths per year, mostly of children. Despite its significance in disease transmission, this mosquito has not been studied extensively by genetic or molecular techniques. To facilitate studies on this vector, a genetic map has been developed that covers the X chromosome at an average resolution of 2 centimorgans. This map has been integrated with the chromosome banding pattern and used to localize a recessive, sex-linked mutation (white eye) to within 1 centimorgan of flanking markers.	HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138; FORTH,INST MOLEC BIOL & BIOTECHNOL,GR-71110 IRAKLION,GREECE; UNIV CRETE,DEPT BIOL,GR-71110 IRAKLION,GREECE; CTR DIS CONTROL,MALARIA BRANCH F12,ATLANTA,GA 30333	Harvard University; Foundation for Research & Technology - Hellas (FORTH); University of Crete; Centers for Disease Control & Prevention - USA								BAKER RH, 1961, AM ZOOL, V1, P435; BENDER W, 1983, J MOL BIOL, V168, P17, DOI 10.1016/S0022-2836(83)80320-9; BESANSKY NJ, COMMUNICATION; COLLINS FH, 1986, SCIENCE, V234, P607, DOI 10.1126/science.3532325; COLUZZI M, 1979, T ROY SOC TROP MED H, V73, P483, DOI 10.1016/0035-9203(79)90036-1; CURTIS CF, 1976, R SOC TROP MED HYG, V70, P281; GREEN CA, 1980, GENETICA, V51, P187, DOI 10.1007/BF00121610; HUDSON TJ, 1992, GENOMICS, V13, P622, DOI 10.1016/0888-7543(92)90133-D; KITZMILLER JB, 1967, GENETICS INSECT VECT, P3; LITT M, 1989, AM J HUM GENET, V44, P397; MASON GF, 1967, GENET RES, V10, P205, DOI 10.1017/S001667230001096X; MILLER LH, 1987, SCIENCE, V237, P779, DOI 10.1126/science.3039658; ROMANS P, 1991, J MED ENTOMOL, V28, P147, DOI 10.1093/jmedent/28.1.147; Sambrook J., 1989, MOL CLONING; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEVERSON DW, IN PRESS J HERED; VERNICK KD, 1989, AM J TROP MED HYG, V40, P593, DOI 10.4269/ajtmh.1989.40.593; WEBER JL, 1989, AM J HUM GENET, V44, P388; ZHENG LB, 1991, P NATL ACAD SCI USA, V88, P11187, DOI 10.1073/pnas.88.24.11187	19	83	88	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 30	1993	261	5121					605	608		10.1126/science.8342025	http://dx.doi.org/10.1126/science.8342025			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	8342025				2022-12-01	WOS:A1993LP72800038
J	OSENSAND, A; CATSICAS, M; STAPLE, JK; JONES, KA; AYALA, G; KNOWLES, J; GRENNINGLOH, G; CATSICAS, S				OSENSAND, A; CATSICAS, M; STAPLE, JK; JONES, KA; AYALA, G; KNOWLES, J; GRENNINGLOH, G; CATSICAS, S			INHIBITION OF AXONAL GROWTH BY SNAP-25 ANTISENSE OLIGONUCLEOTIDES IN-VITRO AND IN-VIVO	NATURE			English	Article							SYNAPTOSOMAL-ASSOCIATED PROTEIN; RAT-BRAIN; EXPRESSION; TERMINALS; RETINA; CELLS	AXONAL elongation and the transformation of growth cones to synaptic terminals are major steps of brain development and the molecular mechanisms involved form the basis of the correct wiring of the nervous system. The same mechanisms may also contribute to the remodelling of nerve terminals that occurs in the adult brain, as a morphological substrate to memory and learning1. We have investigated the function of the nerve terminal protein SNAP-25 (ref. 2) during development. We report here that SNAP-25 is expressed in axonal growth cones during late stages of elongation and that selective inhibition of SNAP-25 expression prevents neurite elongation by rat cortical neurons and PC-12 cells in vitro and by amacrine cells of the developing chick retina in vivo. These results demonstrate that SNAP-25 plays a key role in axonal growth. They also suggest that high levels of SNAP-25 expression in specific areas of the adult brain2 may contribute to nerve terminal plasticity.	GLAXO INST MOLEC BIOL SA,14 CHEMIN AULX,CASE POSTALE 674,CH-1228 PLAN LES OUATES,SWITZERLAND; INST ANAT,CH-1005 LAUSANNE,SWITZERLAND	GlaxoSmithKline			Ayala, Gustavo/ABC-6625-2020					ALVAREZBOLADO G, 1991, ABSTR SOC NEUROSCI, V17, P215; BARK C, 1991, ABSTR SOC NEUROSCI, V17, P531; BAUGHMAN RW, 1991, CULTURING NERVE CELL, P227; CATSICAS S, 1991, P NATL ACAD SCI USA, V88, P785, DOI 10.1073/pnas.88.3.785; CATSICAS S, 1992, J NEUROSCI RES, V33, P1, DOI 10.1002/jnr.490330102; CATSICAS S, 1987, J COMP NEUROL, V262, P512, DOI 10.1002/cne.902620405; CELIO MR, 1990, NEUROSCIENCE, V35, P375, DOI 10.1016/0306-4522(90)90091-H; ELLIS JH, 1991, CELL TISSUE RES, V264, P197, DOI 10.1007/BF00313956; GEDDES JW, 1990, NEUROSCIENCE, V38, P515, DOI 10.1016/0306-4522(90)90047-8; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; GUNNING PW, 1981, J CELL BIOL, V89, P240, DOI 10.1083/jcb.89.2.240; HESS DT, 1992, J NEUROSCI, V12, P4634; HESS EJ, 1992, J NEUROSCI, V12, P2865; LOEWY A, 1991, J NEUROSCI, V11, P3412; MASLIAH E, 1990, J HISTOCHEM CYTOCHEM, V38, P837, DOI 10.1177/38.6.2110586; OYLER GA, 1991, P NATL ACAD SCI USA, V88, P5247, DOI 10.1073/pnas.88.12.5247; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; OYLER GA, 1992, DEV BRAIN RES, V65, P133, DOI 10.1016/0165-3806(92)90172-S; PFENNINGER KH, 1991, GROWTH CONE, P111; SANNA PP, 1991, DEV BRAIN RES, V59, P104, DOI 10.1016/0165-3806(91)90035-H; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; WALLACE SW, 1991, LONG TERM POTENTIATI, P189	23	362	377	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 29	1993	364	6436					445	448		10.1038/364445a0	http://dx.doi.org/10.1038/364445a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP640	8332215				2022-12-01	WOS:A1993LP64000055
J	STEEL, MA; LOCKHART, PJ; PENNY, D				STEEL, MA; LOCKHART, PJ; PENNY, D			CONFIDENCE IN EVOLUTIONARY TREES FROM BIOLOGICAL SEQUENCE DATA	NATURE			English	Article							INFLUENZA-VIRUSES; GENOME; ORIGINS; GENES	THE reliable construction of evolutionary trees from nucleotide sequences often depends on randomization tests such as the boot-strap1 and PTP (cladistic permutation tail probability) tests2-6. The genomes of bacteria7, viruses8, animals7,9,10 and plants11, however, vary widely in their nucleotide frequencies. Where genomes have independently acquired similar G+C base compositions, signals in the data arise that cause methods of evolutionary tree reconstruction to estimate the wrong tree by grouping together sequences with similar G+C content12-14. Under these conditions randomization tests can lead to both the rejection of the correct evolutionary hypothesis and acceptance of an incorrect hypothesis (such as with the contradictory inferences from the photosynthetic rbcS and rbcL sequences14). We have proposed one approach to testing for the G+C content problem15. Here we present a formalization of this method, a frequency-dependent significance test, which has general application.	MASSEY UNIV,MOLEC GENET UNIT,PALMERSTON NORTH,NEW ZEALAND	Massey University	STEEL, MA (corresponding author), MASSEY UNIV,DEPT MATH,PALMERSTON NORTH,NEW ZEALAND.		Penny, David/E-9410-2011; Lockhart, Peter J/E-6624-2011	Steel, Mike/0000-0001-7015-4644				ARCHIE JW, 1989, SYST ZOOL, V38, P239, DOI 10.2307/2992285; BERNARDI G, 1986, J MOL EVOL, V24, P1, DOI 10.1007/BF02099946; CROZIER RH, 1993, GENETICS, V133, P97; FAITH DP, 1991, CLADISTICS, V7, P1, DOI 10.1111/j.1096-0031.1991.tb00020.x; FELSENSTEIN J, 1985, EVOLUTION, V39, P783, DOI 10.1111/j.1558-5646.1985.tb00420.x; HASEGAWA M, 1993, NATURE, V361, P23, DOI 10.1038/361023b0; HENDERSON IM, 1987, NATURE, V326, P22, DOI 10.1038/326022a0; HENDERSON IM, 1989, J THEOR BIOL, V140, P289, DOI 10.1016/S0022-5193(89)80087-6; JUKES TH, 1986, J MOL EVOL, V24, P39, DOI 10.1007/BF02099949; KEESE P, 1989, VIROLOGY, V172, P536, DOI 10.1016/0042-6822(89)90196-7; Lockhart P., 1992, RES PHOTOSYNTHESIS, V3, P499; LOCKHART PJ, 1992, J MOL EVOL, V34, P153; LOCKHART PJ, 1992, FEBS LETT, V301, P127, DOI 10.1016/0014-5793(92)81231-A; LOCKHART PJ, IN PRESS PHOTOSYN RE; OLIVER JL, 1990, NUCLEIC ACIDS RES, V18, P65, DOI 10.1093/nar/18.1.65; PENNY D, 1990, Australian Systematic Botany, V3, P21, DOI 10.1071/SB9900021; SACCONE C, 1989, J MOL EVOL, V29, P407, DOI 10.1007/BF02602910; STEEL MA, 1992, J CLASSIF, V9, P71, DOI 10.1007/BF02618469	18	150	152	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 29	1993	364	6436					440	442		10.1038/364440a0	http://dx.doi.org/10.1038/364440a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP640	8332213				2022-12-01	WOS:A1993LP64000053
J	SIMONDS, RJ; OXTOBY, MJ; CALDWELL, MB; GWINN, ML; ROGERS, MF				SIMONDS, RJ; OXTOBY, MJ; CALDWELL, MB; GWINN, ML; ROGERS, MF			PNEUMOCYSTIS-CARINII PNEUMONIA AMONG UNITED-STATES CHILDREN WITH PERINATALLY ACQUIRED HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-SYNDROME; SURVIVAL; HYPOGAMMAGLOBULINEMIA; CHEMOPROPHYLAXIS; PREVALENCE; PATTERNS; SAMPLES; AIDS	Objective.-To describe epidemiologic characteristics of Pneumocystis carinii pneumonia (PCP) among children with perinatally acquired human immunodeficiency virus (HIV) infection to guide prevention efforts. Design.-National acquired immunodeficiency syndrome (AIDS) surveillance of children aged 0 through 12 years, a multisite surveillance study of HIV infection in children aged 0 through 12 years, and the national HIV serosurvey of childbearing women. Setting.-Surveillance conducted by state and local health departments and reported to the Centers for Disease Control and Prevention 1982 through 1992. Results.-Pneumocystis carinii pneumonia was reported in 1374 (37%) of 3665 perinatally acquired AIDS cases. Over half of these cases occurred between 3 and 6 months of age. In 183 (64%) of 275 PCP cases reported in the special surveillance study, PCP was the first or only AIDS-defining condition diagnosed, and in 44% of cases, the child had not been evaluated for HIV infection before diagnosis of PCP. The estimated median survival after diagnosis of PCP was 19 months. Conclusions.-Pneumocystis carinii pneumonia is a common and serious opportunistic infection that affects young children with HIV infection. Effective efforts to prevent PCP in this population will require identification as early as possible of children who may be infected with HIV.			SIMONDS, RJ (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,1600 CLIFTON RD,MAILSTOP E-45,ATLANTA,GA 30333, USA.							[Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BERNSTEIN LJ, 1989, AM J DIS CHILD, V143, P775, DOI 10.1001/archpedi.1989.02150190025013; BLANCHE S, 1990, AM J DIS CHILD, V144, P1210, DOI 10.1001/archpedi.1990.02150350042021; BRESLOW N, 1970, BIOMETRIKA, V57, P579, DOI 10.1093/biomet/57.3.579; BROOKMEYER R, 1982, BIOMETRICS, V38, P29, DOI 10.2307/2530286; BURKE BA, 1973, MEDICINE, V52, P23, DOI 10.1097/00005792-197301000-00002; Centers for Disease Control (CDC), 1987, MMWR Morb Mortal Wkly Rep, V36, P509; CHUSID MJ, 1967, PEDIATRICS, V62, P1031; CONNOR E, 1991, JAMA-J AM MED ASSOC, V265, P1693, DOI 10.1001/jama.265.13.1693; Dutz W, 1976, Natl Cancer Inst Monogr, V43, P31; FISCHL MA, 1988, JAMA-J AM MED ASSOC, V259, P1185, DOI 10.1001/jama.259.8.1185; GAJDUSEK DC, 1957, PEDIATRICS, V19, P543; GWINN M, 1991, JAMA-J AM MED ASSOC, V265, P1704, DOI 10.1001/jama.265.13.1704; HARDY AM, 1984, J INFECT DIS, V149, P143, DOI 10.1093/infdis/149.2.143; HOOVER DR, 1991, AM REV RESPIR DIS, V144, P756, DOI 10.1164/ajrccm/144.4.756; HSU H, 1990, 30TH ANN M INT C ANT; HUGHES WT, 1977, NEW ENGL J MED, V297, P1419, DOI 10.1056/NEJM197712292972602; HUGHES WT, 1984, J INFECT DIS, V150, P305, DOI 10.1093/infdis/150.2.305-a; HUGHES WT, 1974, AM J DIS CHILD, V128, P44, DOI 10.1001/archpedi.1974.02110260046008; HUGHES WT, 1973, J PEDIATR-US, V82, P404, DOI 10.1016/S0022-3476(73)80113-1; LEGGIADRO RJ, 1981, J PEDIATR-US, V99, P96, DOI 10.1016/S0022-3476(81)80967-5; LEOUNG GS, 1990, NEW ENGL J MED, V323, P769, DOI 10.1056/NEJM199009203231201; MILLER RF, 1992, LANCET, V339, P747, DOI 10.1016/0140-6736(92)90650-R; OXTOBY MJ, 1991, PEDIATRIC AIDS CHALL, P3; RAO CP, 1983, J PEDIATR-US, V103, P410, DOI 10.1016/S0022-3476(83)80415-6; ROSENBLUM L, 1992, AM J PUBLIC HEALTH, V82, P1495, DOI 10.2105/AJPH.82.11.1495; SAULSBURY FT, 1979, J PEDIATR-US, V95, P559, DOI 10.1016/S0022-3476(79)80766-0; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; SINGER C, 1975, ANN INTERN MED, V82, P772, DOI 10.7326/0003-4819-82-6-722; THOMAS P, 1992, PEDIATR INFECT DIS J, V11, P34, DOI 10.1097/00006454-199201000-00009; WALZER PD, 1974, ANN INTERN MED, V80, P83, DOI 10.7326/0003-4819-80-1-83; 1991, MMWR MORB MORTAL WKL, V40, P1; 1987, MMWR MORB MORTAL WKL, V36, P225; 1992, PEDIATRICS, V89, P791; 1993, HIV AIDS SURVEIL FEB, P1; 1990, LIFE TABLES SURVIVOR; 1987, MMWR MORB MORTAL WKL, V36, pS1; 1991, HIV SCREENING PREGNA, P33; 1982, MMWR MORB MORTAL WKL, V31, P507; 1991, LANCET, V337, P253; 1982, MMWR MORB MORTAL WKL, V31, P513	41	111	112	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1993	270	4					470	473		10.1001/jama.270.4.470	http://dx.doi.org/10.1001/jama.270.4.470			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN426	8320786				2022-12-01	WOS:A1993LN42600026
J	ZHOU, YX; BAKER, CL				ZHOU, YX; BAKER, CL			A PROCESSING STREAM IN MAMMALIAN VISUAL-CORTEX NEURONS FOR NON-FOURIER RESPONSES	SCIENCE			English	Article							CATS STRIATE CORTEX; SPATIAL-FREQUENCY; COMPLEX CELLS; GRATINGS; PATTERNS; SYSTEM; DISCRIMINATION; THRESHOLDS; HYPOTHESIS; STIMULI	Mammalian striate and circumstriate cortical neurons have long been understood as coding spatially localized retinal luminance variations, providing a basis for computing motion, stereopsis, and contours from the retinal image. However, such perceptual attributes do not always correspond to the retinal luminance variations in natural vision. Recordings from area 17 and 18 neurons of the cat revealed a specialized nonlinear processing stream that responds to stimulus attributes that have no corresponding luminance variations. This nonlinear stream acts in parallel to the conventional luminance processing of single cortical neurons. The two streams were consistent in their preference for orientation and direction of motion but distinct in processing spatial variations of the stimulus attributes.	MCGILL UNIV,DEPT OPHTHALMOL,MCGILL VIS RES UNIT,MONTREAL H3A 1A1,QUEBEC,CANADA; MCGILL UNIV,DEPT PSYCHOL,MONTREAL H3A 1B1,QUEBEC,CANADA	McGill University; McGill University			Baker, Curtis/A-8794-2011					ALBRECHT DG, 1980, SCIENCE, V207, P88, DOI 10.1126/science.6765993; ALBRECHT DG, 1981, J PHYSIOL-LONDON, V319, P497, DOI 10.1113/jphysiol.1981.sp013922; ALBRIGHT TD, 1992, SCIENCE, V255, P1141, DOI 10.1126/science.1546317; BAKER CL, 1990, VISUAL NEUROSCI, V4, P101, DOI 10.1017/S0952523800002273; BLAKE R, 1974, VISION RES, V14, P1211, DOI 10.1016/0042-6989(74)90218-1; BOULTON JC, IN PRESS VISION RES; BURTON GJ, 1973, VISION RES, V13, P1211, DOI 10.1016/0042-6989(73)90198-3; CAMPBELL FW, 1968, J PHYSIOL-LONDON, V197, P551, DOI 10.1113/jphysiol.1968.sp008574; CHEN B, 1993, VISION RES, V33, P413, DOI 10.1016/0042-6989(93)90095-E; CHUBB C, 1988, J OPT SOC AM A, V5, P1986, DOI 10.1364/JOSAA.5.001986; DERRINGTON AM, 1987, VISION RES, V27, P1377, DOI 10.1016/0042-6989(87)90214-8; DERRINGTON AM, 1985, VISION RES, V25, P1869, DOI 10.1016/0042-6989(85)90010-0; GROSOF DH, 1992, INVEST OPHTH VIS SCI, V33, P1257; HENNING GB, 1975, VISION RES, V15, P887, DOI 10.1016/0042-6989(75)90228-X; HESS RF, 1992, VISION RES, V32, P1085, DOI 10.1016/0042-6989(92)90009-8; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; MOVSHON JA, 1978, J PHYSIOL-LONDON, V283, P53, DOI 10.1113/jphysiol.1978.sp012488; MOVSHON JA, 1978, J PHYSIOL-LONDON, V283, P79, DOI 10.1113/jphysiol.1978.sp012489; NACHMIAS J, 1989, VISION RES, V29, P137, DOI 10.1016/0042-6989(89)90180-6; PETERHANS E, 1991, TRENDS NEUROSCI, V14, P112, DOI 10.1016/0166-2236(91)90072-3; POLLEN DA, 1988, VISION RES, V28, P25, DOI 10.1016/0042-6989(88)90004-1; REDIES C, 1986, EXP BRAIN RES, V61, P469; Robson J. G., 1980, VISUAL CODING ADAPTA, P177; SHAPLEY R, 1985, ANNU REV NEUROSCI, V8, P547, DOI 10.1146/annurev.ne.08.030185.002555; SKOTTUN BC, 1991, VISION RES, V31, P1079, DOI 10.1016/0042-6989(91)90033-2; SPITZER H, 1988, PROG NEUROBIOL, V31, P285, DOI 10.1016/0301-0082(88)90016-0; TOET A, 1988, VISION RES, V28, P133, DOI 10.1016/S0042-6989(88)80013-0; TURANO K, 1989, VISION RES, V29, P207, DOI 10.1016/0042-6989(89)90125-9; WILSON HR, 1991, J OPT SOC AM A, V8, P229, DOI 10.1364/JOSAA.8.000229; 1989, 1989 P IEEE WORKSH V, P126	30	184	186	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					98	101		10.1126/science.8316862	http://dx.doi.org/10.1126/science.8316862			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	8316862				2022-12-01	WOS:A1993LK43400041
J	KLONOFF, EA; FRITZ, JM; LANDRINE, H; RIDDLE, RW; TULLYPAYNE, L				KLONOFF, EA; FRITZ, JM; LANDRINE, H; RIDDLE, RW; TULLYPAYNE, L			THE PROBLEM AND SOCIOCULTURAL CONTEXT OF SINGLE-CIGARETTE SALES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							SMOKING PREVENTION; FOLLOW-UP; MINORS; CHILDREN	Objective.-To provide data on the sale of single cigarettes to adults and miners and to examine the sociocultural context in which these sales occur. Design.-A naturalistic observation study using repeated measures. Two hundred six stores in a convenience sample were visited by one minor and one adult who each attempted to purchase a single cigarette. Main Outcome Measures.-Single-cigarette sales to an adult and/or minor. Data were obtained on type of store and, if a sale occurred, on the price, brand, and packaging of the cigarette. The ethnic composition of the neighborhood surrounding each store was determined. Results.-One hundred one (49.1%) of the stores sold single cigarettes. Singles were sold significantly more often to miners than to adults, and when both could make a purchase, miners paid more for these singles than did adults. Singles were least likely to be sold in white neighborhoods, more likely to be sold in integrated neighborhoods, and most likely to be sold in minority neighborhoods. Miners were able to purchase single cigarettes during 34.4% of the visits to white neighborhoods but could do so during 71.2% of the visits to minority neighborhoods; adults were able to make similar purchases during 24% of the visits to white neighborhoods and 37.3% of the visits to minority neighborhoods. Conclusions.-The illegal sale of single cigarettes involves complex sociocultural factors heretofore unexamined. An understanding of such factors may be useful in planning merchant education programs and drafting policy to control illegal sales.	UNIV CINCINNATI, SCH PLANNING, CINCINNATI, OH USA; PUBL HLTH FDN ENTERPRISES, CITY OF INDUSTRY, CA USA	University of Cincinnati	KLONOFF, EA (corresponding author), CALIF STATE COLL SAN BERNARDINO, INST BEHAV HLTH, 5500 UNIV PKWY, SAN BERNARDINO, CA 92407 USA.							ALTMAN DG, 1991, AM J PUBLIC HEALTH, V81, P891, DOI 10.2105/AJPH.81.7.891; ALTMAN DG, 1989, JAMA-J AM MED ASSOC, V261, P80, DOI 10.1001/jama.261.1.80; ARCHBALD C, 1993, PEDIATRICS, V91, P851; BIGLAN A, 1987, J BEHAV MED, V10, P613, DOI 10.1007/BF00846658; BIGLAN A, 1987, J BEHAV MED, V10, P159, DOI 10.1007/BF00846424; DIFRANZA JR, 1990, JAMA-J AM MED ASSOC, V263, P2784, DOI 10.1001/jama.263.20.2784; FLAY BR, 1989, AM J PUBLIC HEALTH, V79, P1371, DOI 10.2105/AJPH.79.10.1371; FLAY BR, 1985, HEALTH PSYCHOL, V4, P449, DOI 10.1037/0278-6133.4.5.449; FOSTER JL, 1992, PREV MED, V21, P320; HANSEN WB, 1988, PREV MED, V17, P135, DOI 10.1016/0091-7435(88)90059-X; JOHNSON P R L, 1986, Journal of Biochemical Toxicology, V1, P15, DOI 10.1002/jbt.2570010104; KIRN TF, 1987, JAMA-J AM MED ASSOC, V257, P3323; MURRAY DM, 1987, J BEHAV MED, V10, P595, DOI 10.1007/BF00846657; WARNER KE, 1986, JAMA-J AM MED ASSOC, V255, P1028, DOI 10.1001/jama.255.8.1028; 1991, DHHS CDC923316 US DE; 1989, DHHS CDC898411 US DE; 1990, TAX BURDEN TOBACCO H, P25; 1990, MMWR MORB MORTAL WKL, V39, P349	18	39	39	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	1994	271	8					618	620		10.1001/jama.271.8.618	http://dx.doi.org/10.1001/jama.271.8.618			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW477	8301795				2022-12-01	WOS:A1994MW47700026
J	VASCONCELLOS, CA; ALLEN, PG; WOHL, ME; DRAZEN, JM; JANMEY, PA; STOSSEL, TP				VASCONCELLOS, CA; ALLEN, PG; WOHL, ME; DRAZEN, JM; JANMEY, PA; STOSSEL, TP			REDUCTION IN VISCOSITY OF CYSTIC-FIBROSIS SPUTUM IN-VITRO BY GELSOLIN	SCIENCE			English	Article							D-BINDING-PROTEIN; F-ACTIN; PLASMA GELSOLIN; BREVIN; SERUM; VISCOELASTICITY; FILAMENTS; PLATELETS; DISEASE; CONTAIN	Obstruction of airways by viscous sputum causes lung damage in patients with cystic fibrosis (CF). Sputum samples from OF patients were shown to contain filamentous actin. Human plasma gelsolin, a protein that severs actin filaments, rapidly decreased the viscosity of CF sputum samples in vitro. Gc globulin and deoxyribonuclease I, proteins that sequester monomeric actin but do not sever actin filaments, were less efficient than gelsolin in diminishing sputum viscosity. These results suggest that gelsolin may have therapeutic potential as a mucolytic agent in CF patients.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV EXPTL MED,BOSTON,MA 02115; HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT PEDIAT,DIV RESP MED,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DIV RESP MED,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Boston Children's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Drazen, Jeffrey M/E-5841-2012		NHLBI NIH HHS [HL19429, HL19170] Funding Source: Medline; NIAMS NIH HHS [AR38910] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL019170, R37HL019429, R01HL019429] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038910, R29AR038910] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AITKEN ML, 1992, JAMA-J AM MED ASSOC, V267, P1947, DOI 10.1001/jama.267.14.1947; Asakura S., 1975, THERMODYNAMICS POLYM; CHAPONNIER C, 1989, AM J PATHOL, V134, P597; CHARMAN J, 1973, Biorheology, V10, P295; COUE M, 1986, EUR J BIOCHEM, V160, P273, DOI 10.1111/j.1432-1033.1986.tb09967.x; HANSON J, 1963, J MOL BIOL, V6, P46, DOI 10.1016/S0022-2836(63)80081-9; HITCHCOCK SE, 1976, CELL, V7, P531, DOI 10.1016/0092-8674(76)90203-8; HOWARD TH, 1985, CELL MOTIL CYTOSKEL, V5, P545, DOI 10.1002/cm.970050609; JANMEY PA, 1991, J BIOCHEM BIOPH METH, V22, P41, DOI 10.1016/0165-022X(91)90080-G; JANMEY PA, 1986, BIOCHEM BIOPH RES CO, V136, P72, DOI 10.1016/0006-291X(86)90878-8; JANMEY PA, 1987, BLOOD, V70, P524; JANMEY PA, 1988, BIOCHEMISTRY-US, V27, P8218, DOI 10.1021/bi00421a035; JANMEY PA, 1992, BLOOD, V80, P928; KOUYAMA T, 1981, EUR J BIOCHEM, V114, P33; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; LAZARIDES E, 1974, P NATL ACAD SCI USA, V71, P4742, DOI 10.1073/pnas.71.12.4742; LEE WM, 1992, NEW ENGL J MED, V326, P1335; LEES A, 1984, BIOCHEMISTRY-US, V23, P3038, DOI 10.1021/bi00308a030; LETHEM MI, 1990, AM REV RESPIR DIS, V142, P1053, DOI 10.1164/ajrccm/142.5.1053; LIEBERMAN J, 1968, J AMER MED ASSOC, V205, P312, DOI 10.1001/jama.205.5.312; LIND SE, 1982, J CLIN INVEST, V69, P1384, DOI 10.1172/JCI110578; MARKEY F, 1982, BIOCHIM BIOPHYS ACTA, V709, P122, DOI 10.1016/0167-4838(82)90429-0; MARKS MI, 1981, J PEDIATR-US, V98, P173, DOI 10.1016/S0022-3476(81)80631-2; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; MORNET D, 1984, P NATL ACAD SCI-BIOL, V81, P3680, DOI 10.1073/pnas.81.12.3680; NEWMAN J, 1985, BIOCHEMISTRY-US, V24, P1538, DOI 10.1021/bi00327a037; PICOT R, 1978, THORAX, V33, P235, DOI 10.1136/thx.33.2.235; PUCHELLE E, 1985, EUR J CLIN INVEST, V15, P389, DOI 10.1111/j.1365-2362.1985.tb00290.x; ROSENBLUTH M, 1974, ARCH DIS CHILD, V49, P606, DOI 10.1136/adc.49.8.606; SHAK S, 1990, P NATL ACAD SCI USA, V87, P9188, DOI 10.1073/pnas.87.23.9188; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STOSSEL TP, 1992, INFLAMMATION BASIC P, P459; VANBAELEN H, 1980, J BIOL CHEM, V255, P270; WOOD RE, 1976, AM REV RESPIR DIS, V113, P833; YIN HL, 1979, NATURE, V281, P583, DOI 10.1038/281583a0	36	157	167	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 18	1994	263	5149					969	971		10.1126/science.8310295	http://dx.doi.org/10.1126/science.8310295			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX165	8310295				2022-12-01	WOS:A1994MX16500036
J	LUCAS, R; MAGEZ, S; DELEYS, R; FRANSEN, L; SCHEERLINCK, JP; RAMPELBERG, M; SABLON, E; DEBAETSELIER, P				LUCAS, R; MAGEZ, S; DELEYS, R; FRANSEN, L; SCHEERLINCK, JP; RAMPELBERG, M; SABLON, E; DEBAETSELIER, P			MAPPING THE LECTIN-LIKE ACTIVITY OF TUMOR-NECROSIS-FACTOR	SCIENCE			English	Article							COLONY-STIMULATING FACTOR; FACTOR-ALPHA; FACTOR-BETA; MUTATIONAL ANALYSIS; BINDING-PROPERTIES; FACTOR RECEPTORS; PROTEINS; EXPRESSION; UROMODULIN; SITES	Tumor necrosis factor (TNF), but not lymphotoxin (LT), is directly trypanolytic for salivarian trypanosomes. This activity was not blocked by soluble 55-kilodalton and 75-kilodalton TNF receptors, but was potently inhibited by N,N'-diacetylchitobiose, an oligosaccharide that binds TNF. Comparative sequence analysis of TNF and LT localized the trypanocidal region, and synthetic peptides were trypanolytic. TNF molecules in which the trypanocidal region was mutated or deleted retained tumoricidal activity. Thus, trypanosome-TNF interactions occur via a TNF domain, probably with lectin-like affinity, which is functionally and spatially distinct from the mammalian TNF receptor binding sites.	VRIJE UNIV BRUSSELS,GEN BIOL LAB,B-1640 RHODE ST GENESE,BELGIUM; INNOGENET NV,B-9052 ZWIJNAARDE,BELGIUM	Vrije Universiteit Brussel; Innogenetics NV	LUCAS, R (corresponding author), VRIJE UNIV BRUSSELS,CELLULAR IMMUNOL LAB,CAMPUS RODE,PAARDENSTR 65,B-1640 RHODE ST GENESE,BELGIUM.		Magez, Stefan/D-9497-2014; Lucas, Rudolf/ABA-3011-2020; Magez, Stefan/AAC-5682-2021; De Baetselier, Patrick/D-3866-2014; Lucas, Rudolf/G-5197-2012	Magez, Stefan/0000-0003-3760-7968; Magez, Stefan/0000-0003-3760-7968; Lucas, Rudolf/0000-0003-3805-8868; Scheerlinck, Jean-Pierre/0000-0002-8385-353X				AMIRI P, 1992, NATURE, V356, P604, DOI 10.1038/356604a0; CICCO NA, 1990, BLOOD, V75, P2049; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; FIELDS GB, 1990, INT J PEPT PROT RES, V35, P161, DOI 10.1111/j.1399-3011.1990.tb00939.x; FRANSEN L, 1986, EUR J CANCER CLIN ON, V22, P419, DOI 10.1016/0277-5379(86)90107-0; Goldstein I J, 1978, Adv Carbohydr Chem Biochem, V35, P127; HESSION C, 1987, SCIENCE, V237, P1479, DOI 10.1126/science.3498215; KOEFFLER HP, 1987, BLOOD, V70, P55; KONGSHAVN PAL, 1988, PARASITE IMMUNOL, V10, P581, DOI 10.1111/j.1365-3024.1988.tb00245.x; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; LOCKSLEY RM, 1987, J IMMUNOL, V139, P1891; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; Lucas R., UNPUB; LUO G, 1983, INFECT IMMUN, V61, P830; MAGEZ S, 1993, PARASITE IMMUNOL, V15, P635, DOI 10.1111/j.1365-3024.1993.tb00577.x; OSTER W, 1987, BLOOD, V70, P1700; REMAUT E, 1983, GENE, V22, P103, DOI 10.1016/0378-1119(83)90069-0; SCHOENFELD HJ, 1991, J BIOL CHEM, V266, P3863; SHERBLOM AP, 1988, J BIOL CHEM, V263, P5418; SHIBUYA N, 1988, J BIOL CHEM, V263, P728; SHIBUYA N, 1986, ARCH BIOCHEM BIOPHYS, V249, P215, DOI 10.1016/0003-9861(86)90577-1; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; VANOSTADE X, 1991, EMBO J, V10, P827, DOI 10.1002/j.1460-2075.1991.tb08015.x; WELLS JA, 1985, GENE, V34, P315, DOI 10.1016/0378-1119(85)90140-4; WERTMAN KF, 1986, GENE, V49, P253, DOI 10.1016/0378-1119(86)90286-6; WOOD C, 1979, ARCH BIOCHEM BIOPHYS, V198, P1, DOI 10.1016/0003-9861(79)90389-8; YAMAGISHI J, 1990, PROTEIN ENG, V3, P713, DOI 10.1093/protein/3.8.713	29	174	187	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 11	1994	263	5148					814	817		10.1126/science.8303299	http://dx.doi.org/10.1126/science.8303299			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV866	8303299				2022-12-01	WOS:A1994MV86600037
J	SPOLAR, RS; RECORD, MT				SPOLAR, RS; RECORD, MT			COUPLING OF LOCAL FOLDING TO SITE-SPECIFIC BINDING OF PROTEINS TO DNA	SCIENCE			English	Article							STREPTOMYCES SUBTILISIN INHIBITOR; REPRESSOR-OPERATOR INTERACTION; GENE ACTIVATOR PROTEIN; HEAT-CAPACITY CHANGES; COLI RNA-POLYMERASE; LAMBDA-PR PROMOTER; ESCHERICHIA-COLI; CRYSTAL-STRUCTURE; TRP REPRESSOR; GLUCOCORTICOID RECEPTOR	Thermodynamic studies have demonstrated the central importance of a large negative heat capacity change (DELTAC(assoc)degrees) in site-specific protein-DNA recognition. Dissection of the large negative DELTAC(assoc)degrees and the entropy change of protein-ligand and protein-DNA complexation provide a thermodynamic signature identifying processes in which local folding is coupled to binding. Estimates of the number of residues that fold on binding obtained from this analysis agree with structural data. Structural comparisons indicate that these local folding transitions create key parts of the protein-DNA interface. The energetic implications of this ''induced fit'' model for DNA site recognition are considered.	UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	SPOLAR, RS (corresponding author), UNIV WISCONSIN, DEPT CHEM, MADISON, WI 53706 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM023467, R37GM023467] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM23467] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Abola E. E., 1987, CRYSTALLOGRAPHIC DAT; ALBER T, 1993, CURR BIOL, V3, P182, DOI 10.1016/0960-9822(93)90268-S; ALBER T, 1981, THESIS MIT; ALBER T, 1982, MOBILITY FUNCTION PR, P4; ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; ARROWSMITH C, 1991, EUR J BIOCHEM, V202, P53, DOI 10.1111/j.1432-1033.1991.tb16344.x; ARROWSMITH CH, 1991, J AM CHEM SOC, V113, P4020, DOI 10.1021/ja00010a070; AUNE KC, 1971, BIOCHEMISTRY-US, V10, P1617; BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BAUGH RJ, 1972, J BIOL CHEM, V247, P7498; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOWIE JU, 1989, BIOCHEMISTRY-US, V28, P7139, DOI 10.1021/bi00444a001; BRENNAN RG, 1990, P NATL ACAD SCI USA, V87, P8165, DOI 10.1073/pnas.87.20.8165; Brennan RG, 1991, CURR OPIN STRUC BIOL, V1, P80, DOI 10.1016/0959-440X(91)90015-L; BRENOWITZ M, 1990, BIOCHEMISTRY-US, V29, P3374, DOI 10.1021/bi00465a033; CLARKE ND, 1991, SCIENCE, V254, P267, DOI 10.1126/science.1833818; CONNELLY PR, 1992, P NATL ACAD SCI USA, V89, P4781, DOI 10.1073/pnas.89.11.4781; CREAMER TP, 1992, P NATL ACAD SCI USA, V89, P5937, DOI 10.1073/pnas.89.13.5937; CREIGHTON TE, 1983, PROTEINS; DILL KA, 1989, BIOCHEMISTRY-US, V28, P5439, DOI 10.1021/bi00439a019; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DILL KA, 1985, BIOCHEMISTRY-US, V24, P1501, DOI 10.1021/bi00327a032; EBRIGHT RH, 1989, NUCLEIC ACIDS RES, V17, P10295, DOI 10.1093/nar/17.24.10295; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; ERICKSON HP, 1989, J MOL BIOL, V206, P465, DOI 10.1016/0022-2836(89)90494-4; FILIMONOV VV, 1978, BIOPHYS CHEM, V8, P117, DOI 10.1016/0301-4622(78)80003-9; FINKELSTEIN AV, 1989, PROTEIN ENG, V3, P1, DOI 10.1093/protein/3.1.1; FORMISANO S, 1977, P NATL ACAD SCI USA, V74, P3340, DOI 10.1073/pnas.74.8.3340; FRANKEL AD, 1991, CELL, V65, P717, DOI 10.1016/0092-8674(91)90378-C; FRANKEL AD, 1992, P NATL ACAD SCI USA, V89, P11653, DOI 10.1073/pnas.89.24.11653; FUKADA H, 1985, BIOCHEMISTRY-US, V24, P5109, DOI 10.1021/bi00340a023; GARCIA KC, 1992, SCIENCE, V257, P502, DOI 10.1126/science.1636085; GRIKO YV, 1992, BIOCHEMISTRY-US, V31, P12701, DOI 10.1021/bi00165a022; GROSS CA, 1992, TRANSCRIPTIONAL REGU, P129; HA JH, 1989, J MOL BIOL, V209, P801, DOI 10.1016/0022-2836(89)90608-6; HA JH, 1992, J MOL BIOL, V228, P252, DOI 10.1016/0022-2836(92)90504-D; HARD T, 1990, BIOCHEMISTRY-US, V29, P9015; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HARD T, 1990, BIOCHEMISTRY-US, V29, P5358; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.biochem.59.1.933; HERSCHLAG D, 1988, BIOORG CHEM, V16, P62, DOI 10.1016/0045-2068(88)90038-7; JANIN J, 1978, BIOCHEMISTRY-US, V17, P2943, DOI 10.1021/bi00608a001; JARDETZKY O, COMMUNICATION; JENJACOBSON L, 1983, J BIOL CHEM, V258, P4638; JIN LH, 1993, BIOCHEMISTRY-US, V32, P7302, DOI 10.1021/bi00079a029; KARPLUS M, 1987, BIOPHYS J, V52, P1083, DOI 10.1016/S0006-3495(87)83303-9; KIM EE, 1992, BIOCHEMISTRY-US, V31, P12304, DOI 10.1021/bi00164a004; KIM J, 1993, P NATL ACAD SCI USA, V90, P4513, DOI 10.1073/pnas.90.10.4513; KIM KS, 1993, PROTEIN SCI, V2, P588; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KOBLAN KS, 1992, BIOCHEMISTRY-US, V31, P57, DOI 10.1021/bi00116a010; KOSHLAND DE, 1958, P NATL ACAD SCI USA, V44, P98, DOI 10.1073/pnas.44.2.98; LAWSON CL, 1988, PROTEINS, V3, P18, DOI 10.1002/prot.340030103; LESSER DR, 1990, SCIENCE, V250, P776, DOI 10.1126/science.2237428; LIVINGSTONE JR, 1991, BIOCHEMISTRY-US, V30, P4237, DOI 10.1021/bi00231a019; LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; LUNDBACK T, 1993, BIOCHEMISTRY-US, V32, P5074, DOI 10.1021/bi00070a015; MCCLARIN JA, 1986, SCIENCE, V234, P1526, DOI 10.1126/science.3024321; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MOSSING MC, 1985, J MOL BIOL, V186, P295, DOI 10.1016/0022-2836(85)90106-8; MURPHY KP, 1990, SCIENCE, V247, P559, DOI 10.1126/science.2300815; MURPHY KP, 1993, PROTEINS, V15, P113, DOI 10.1002/prot.340150203; MURPHY KP, 1991, J MOL BIOL, V222, P699, DOI 10.1016/0022-2836(91)90506-2; OBEYSEKARE U, UNPUB; OHLENDORF D, UNPUB; ONEIL KT, 1990, SCIENCE, V249, P774, DOI 10.1126/science.2389143; ONEIL KT, 1991, BIOCHEMISTRY-US, V30, P9030, DOI 10.1021/bi00101a017; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PAGE MI, 1971, P NATL ACAD SCI USA, V68, P1678, DOI 10.1073/pnas.68.8.1678; PICKETT SD, 1993, J MOL BIOL, V231, P825, DOI 10.1006/jmbi.1993.1329; POST CB, UNPUB; Privalov P L, 1979, Adv Protein Chem, V33, P167, DOI 10.1016/S0065-3233(08)60460-X; PRIVALOV PL, 1988, ADV PROTEIN CHEM, V39, P191; PRIVALOV PL, 1992, J MOL BIOL, V224, P715, DOI 10.1016/0022-2836(92)90555-X; Record Jr M. T., 1990, BIOL NONSPECIFIC DNA, P33; RECORD MT, 1977, BIOCHEMISTRY-US, V16, P4791, DOI 10.1021/bi00641a005; RECORD MT, 1991, METHOD ENZYMOL, V208, P291; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; RECORD MT, 1988, UNUSUAL DNA STRUCTUR, P237; ROE JH, 1985, BIOCHEMISTRY-US, V24, P4721, DOI 10.1021/bi00339a002; ROE JH, 1985, J MOL BIOL, V184, P441, DOI 10.1016/0022-2836(85)90293-1; Rosenberg JM, 1991, CURR OPIN STRUC BIOL, V1, P104, DOI 10.1016/0959-440X(91)90018-O; SASAKI K, 1975, NATURE, V257, P751, DOI 10.1038/257751a0; SAUDEK V, 1991, BIOCHEMISTRY-US, V30, P1310, DOI 10.1021/bi00219a022; SCHEVITZ RW, 1985, NATURE, V317, P782, DOI 10.1038/317782a0; SCHOLTZ JM, 1991, BIOPOLYMERS, V31, P1463, DOI 10.1002/bip.360311304; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SPOLAR RS, 1992, BIOCHEMISTRY-US, V31, P3947, DOI 10.1021/bi00131a009; SPOLAR RS, 1989, P NATL ACAD SCI USA, V86, P8382, DOI 10.1073/pnas.86.21.8382; STURTEVANT JM, 1977, P NATL ACAD SCI USA, V74, P2236, DOI 10.1073/pnas.74.6.2236; SUSSMAN J, UNPUB; SUURKUUSK J, 1972, EUR J BIOCHEM, V28, P438, DOI 10.1111/j.1432-1033.1972.tb01930.x; TAKAHASHI K, 1981, BIOCHEMISTRY-US, V20, P4693, DOI 10.1021/bi00519a026; TAKAHASHI K, 1985, BIOCHEMISTRY-US, V24, P297, DOI 10.1021/bi00323a009; TAKEDA Y, 1992, P NATL ACAD SCI USA, V89, P8180, DOI 10.1073/pnas.89.17.8180; TANFORD C, 1980, HYDROPHOBIC EFFECT; TERRY BJ, 1983, J BIOL CHEM, V258, P9820; TERWILLIGER TC, 1982, J BIOL CHEM, V257, P6016; VARADARAJAN R, 1992, BIOCHEMISTRY-US, V31, P1421, DOI 10.1021/bi00120a019; VERSHON AK, 1987, J MOL BIOL, V195, P311, DOI 10.1016/0022-2836(87)90652-8; WEBER IT, 1987, J MOL BIOL, V198, P311, DOI 10.1016/0022-2836(87)90315-9; WEISS MA, 1990, NATURE, V347, P575, DOI 10.1038/347575a0; WEISS MA, 1990, BIOCHEMISTRY-US, V29, P8020, DOI 10.1021/bi00487a004; WHITSON PA, 1986, BIOCHEMISTRY-US, V25, P3852, DOI 10.1021/bi00361a017; WILCOX W, 1992, PROTEIN SCI, V1, P641, DOI 10.1002/pro.5560010510; WINKLER FK, 1993, EMBO J, V12, P1781, DOI 10.1002/j.1460-2075.1993.tb05826.x; ZHANG RG, 1987, NATURE, V327, P591, DOI 10.1038/327591a0; ZHAO D, 1993, J MOL BIOL, V229, P735, DOI 10.1006/jmbi.1993.1076	112	1363	1372	1	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	1994	263	5148					777	784		10.1126/science.8303294	http://dx.doi.org/10.1126/science.8303294			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV866	8303294				2022-12-01	WOS:A1994MV86600026
J	STURGILLKOSZYCKI, S; SCHLESINGER, PH; CHAKRABORTY, P; HADDIX, PL; COLLINS, HL; FOK, AK; ALLEN, RD; GLUCK, SL; HEUSER, J; RUSSELL, DG				STURGILLKOSZYCKI, S; SCHLESINGER, PH; CHAKRABORTY, P; HADDIX, PL; COLLINS, HL; FOK, AK; ALLEN, RD; GLUCK, SL; HEUSER, J; RUSSELL, DG			LACK OF ACIDIFICATION IN MYCOBACTERIUM PHAGOSOMES PRODUCED BY EXCLUSION OF THE VESICULAR PROTON-ATPASE	SCIENCE			English	Article							LYSOSOME FUSION; PATHOGENIC MYCOBACTERIUM; PARASITOPHOROUS VACUOLES; COMPLEMENT RECEPTORS; HUMAN MACROPHAGES; TUBERCULOSIS; LEPRAE; INHIBITION; AVIUM; PHAGOCYTOSIS	The success of Mycobacterium species as pathogens depends on their ability to maintain an infection inside the phagocytic vacuole of the macrophage. Although the bacteria are reported to modulate maturation of their intracellular vacuoles, the nature of such modifications is unknown. In this study, vacuoles formed around Mycobacterium avium failed to acidify below pH 6.3 to 6.5. Immunoelectron microscopy of infected macrophages and immunoblotting of isolated phagosomes showed that Mycobacterium vacuoles acquire the lysosomal membrane protein LAMP-1, but not the vesicular proton-adenosine triphosphatase (ATPase) responsible for phagosomal acidification. This suggests either a selective inhibition of fusion with proton-ATPase-containing vesicles or a rapid removal of the complex from Mycobacterium phagosomes.	WASHINGTON UNIV, MED CTR, DEPT MOLEC MICROBIOL, ST LOUIS, MO 63130 USA; WASHINGTON UNIV, MED CTR, DEPT CELL BIOL & PHYSIOL, ST LOUIS, MO 63130 USA; WASHINGTON UNIV, MED CTR, DEPT LOW TEMP ENGN PHYS, ST LOUIS, MO 63130 USA; UNIV HAWAII, DEPT MICROBIOL, HONOLULU, HI 96822 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); University of Hawaii System			Russell, David G/N-5280-2019; Russell, David G/D-4533-2009; Schlesinger, Paul H/C-6049-2012	Russell, David G/0000-0002-9748-750X; Russell, David G/0000-0002-9748-750X; 	NIAID NIH HHS [AI34207, AI26889] Funding Source: Medline; NIAMS NIH HHS [AR42370] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI026889, R01AI034207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR042370] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANTOINE JC, 1990, INFECT IMMUN, V58, P779, DOI 10.1128/IAI.58.3.779-787.1990; APPELBERG R, 1993, IMMUNOLOGY, V80, P352; BLOOM BR, 1992, NATURE, V358, P538, DOI 10.1038/358538b0; Chakraborty A., UNPUB; CHAN J, 1991, INFECT IMMUN, V59, P1755, DOI 10.1128/IAI.59.5.1755-1761.1991; CHEN JW, 1986, BIOCHEM SOC SYMP, P97; CROWLE AJ, 1991, INFECT IMMUN, V59, P1823, DOI 10.1128/IAI.59.5.1823-1831.1991; DECHASTELLIER C, 1993, INFECT IMMUN, V61, P3775, DOI 10.1128/IAI.61.9.3775-3784.1993; EISSENBERG LG, 1993, J EXP MED, V177, P1605, DOI 10.1084/jem.177.6.1605; FOK AK, IN PRESS J CELL SCI; FREHEL C, 1986, INFECT IMMUN, V52, P252, DOI 10.1128/IAI.52.1.252-262.1986; FREHEL C, 1987, INFECT IMMUN, V55, P2916, DOI 10.1128/IAI.55.12.2916-2921.1987; GORDON AH, 1980, NATURE, V286, P79, DOI 10.1038/286079a0; HART PD, 1991, J EXP MED, V174, P881, DOI 10.1084/jem.174.4.881; HEUSER J, 1993, J CELL BIOL, V121, P1311, DOI 10.1083/jcb.121.6.1311; JOINER KA, 1990, SCIENCE, V249, P641, DOI 10.1126/science.2200126; MARQUEZSTERLING N, 1991, EUR J CELL BIOL, V56, P19; MELLMAN I, 1992, J EXP BIOL, V172, P39; NELSON N, 1992, Current Opinion in Cell Biology, V4, P654, DOI 10.1016/0955-0674(92)90086-R; NELSON RD, 1992, P NATL ACAD SCI USA, V89, P3541, DOI 10.1073/pnas.89.8.3541; PERIN MS, 1991, J BIOL CHEM, V266, P3877; RASTOGI N, 1992, FEMS MICROBIOL IMMUN, V89, P273, DOI 10.1111/j.1574-6968.1992.tb05006.x; RUSSELL DG, 1992, J CELL SCI, V103, P1193; SCHLESINGER LS, 1991, J IMMUNOL, V147, P1983; SCHLESINGER LS, 1990, J IMMUNOL, V144, P2771; SIBLEY LD, 1987, INFECT IMMUN, V55, P680, DOI 10.1128/IAI.55.3.680-685.1987; STEINHOFF U, 1989, INFECT IMMUN, V57, P1008, DOI 10.1128/IAI.57.3.1008-1010.1989; Xu S., UNPUB; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0	29	987	1017	0	59	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	1994	263	5147					678	681		10.1126/science.8303277	http://dx.doi.org/10.1126/science.8303277			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8303277				2022-12-01	WOS:A1994MU96400048
J	ZELISSEN, PMJ; CROUGHS, RJM; VANRIJK, PP; RAYMAKERS, JA				ZELISSEN, PMJ; CROUGHS, RJM; VANRIJK, PP; RAYMAKERS, JA			EFFECT OF GLUCOCORTICOID REPLACEMENT THERAPY ON BONE-MINERAL DENSITY IN PATIENTS WITH ADDISON-DISEASE	ANNALS OF INTERNAL MEDICINE			English	Article							OSTEOPOROSIS	Objective: To study the influence of glucocorticoid replacement therapy on bone mineral density. Design: Cross-sectional. Setting: University hospital in the Netherlands. Patients: 91 patients with Addison disease who had been receiving glucocorticoid replacement therapy for a mean of 10.6 years (range, 0.5 to 36.5 years). Measurements: Bone mineral density of the lumbar spine and both femoral necks using a dual-energy x-ray absorptiometer and basal serum concentrations of adrenocorticotropin, gonadal hormones, and adrenal androgens. Results: Decreased bone mineral density (less than 2 standard deviations [SD] of the mean value of an age-matched reference population) was found in 10 of 31 men (32%; 95% CI, 17% to 51%) and in 4 of 60 women (7%; CI, 2% to 16%). No statistically significant differences were found between men and women with regard to age, duration of glucocorticoid substitution, or glucocorticoid dose, either in absolute quantities or when expressed per kilogram of body weight. However, in men with decreased bone mineral density, the daily hydrocortisone dose per kilogram of body weight (0.43 +/- 0.08 mg/kg; mean +/- SD) was significantly (P = 0.032) higher than in men with normal bone mineral density (0.35 +/- 0.10 mg/kg). After correction for possible confounding variables, a significant linear correlation was found between hydrocortisone dose per kilogram of body weight and bone mineral density of the lumbar spine in the men (regression coefficient, -0.86; CI, -1.60 to -0.13; P = 0.029) but not in the women. Conclusions; Long-term treatment with standard replacement doses of glucocorticoids may induce bone loss in men with Addison disease. Adjustment of glucocorticoid therapy to the lowest acceptable dose is mandatory in Addison disease, and regular measurement of bone mineral density may be helpful in identifying men at risk for the development of osteoporosis.	UNIV HOSP UTRECHT, DEPT NUCL MED, 3508 GA UTRECHT, NETHERLANDS; UNIV HOSP UTRECHT, DEPT INTERNAL MED & GERIATR, 3508 GA UTRECHT, NETHERLANDS	Utrecht University; Utrecht University Medical Center; Utrecht University; Utrecht University Medical Center	ZELISSEN, PMJ (corresponding author), UNIV HOSP UTRECHT, DEPT ENDOCRINOL, POB 85500, 3508 GA UTRECHT, NETHERLANDS.							ANDERSON DC, 1992, BRIT MED J, V305, P489, DOI 10.1136/bmj.305.6852.489; BOYCE BF, 1991, J BONE MINER RES  S1, V6, pS108; BURKE CW, 1992, CLIN ENDOCRINOL, P393; DEVOGELAER JP, 1987, BRIT MED J, V294, P798, DOI 10.1136/bmj.294.6575.798; ESTEBAN NV, 1991, J CLIN ENDOCR METAB, V72, P39, DOI 10.1210/jcem-72-1-39; HAHN TJ, 1978, ARCH INTERN MED, V138, P882; LUKERT BP, 1992, J BONE MINER RES, V7, P1063; MANNING PJ, 1992, CLIN ENDOCRINOL, V36, P229, DOI 10.1111/j.1365-2265.1992.tb01437.x; MASON AS, 1968, LANCET, V2, P744; RYAN PJ, 1992, BRIT J RHEUMATOL, V31, P823; SCHOT LPC, 1990, J STEROID BIOCHEM, V37, P167, DOI 10.1016/0960-0760(90)90325-F; STALL GM, 1990, ANN INTERN MED, V113, P265, DOI 10.7326/0003-4819-113-4-265	12	166	169	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	FEB 1	1994	120	3					207	210		10.7326/0003-4819-120-3-199402010-00005	http://dx.doi.org/10.7326/0003-4819-120-3-199402010-00005			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU303	8273983				2022-12-01	WOS:A1994MU30300005
J	KEMBLE, GW; DANIELI, T; WHITE, JM				KEMBLE, GW; DANIELI, T; WHITE, JM			LIPID-ANCHORED INFLUENZA HEMAGGLUTININ PROMOTES HEMIFUSION, NOT COMPLETE FUSION	CELL			English	Article							MEDIATED MEMBRANE-FUSION; VIRUS HEMAGGLUTININ; CONFORMATIONAL CHANGE; DISULFIDE BONDS; PROTEIN; LIPOSOMES; PEPTIDE; EVENTS; CELLS; ERYTHROCYTES	It has been proposed that membrane fusion events such as virus-cell fusion proceed through a hemifusion intermediate, a state where lipids but not contents of the fusing compartments mix. We engineered the influenza hemagglutinin (HA) such that it would be anchored in membranesvia a glycosylphosphatidylinositol (GPI) tail. GPI-anchored HA forms a trimer that can bind red blood cells (RBCs) and change conformation under fusion-inducing conditions. Using RBCs labeled with fluorescent lipid or fluorescent soluble content probes, we found that GPI-anchored HA mediated lipid mixing with similar time course and efficiency as wt-HA, yet did not mediate transfer of soluble contents. Hence, GPI-anchored HA appears to initiate, but not complete, a fusion reaction. We interpret our results as evidence for uncoupling a physiological fusion reaction, for trapping a hemifusion intermediate, and for assigning a role to a transmembrane domain in a fusion event.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,CELL BIOL PROGRAM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI022470] Funding Source: NIH RePORTER; NIAID NIH HHS [AI22470] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALMERS W, 1990, ANNU REV PHYSIOL, V52, P607, DOI 10.1146/annurev.ph.52.030190.003135; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BENTZ J, 1990, FEBS LETT, V276, P1, DOI 10.1016/0014-5793(90)80492-2; BLOBEL CP, 1992, NATURE, V356, P248, DOI 10.1038/356248a0; BNROWN D, 1992, CELL, V68, P533; BODIAN DL, 1993, BIOCHEMISTRY-US, V32, P2967, DOI 10.1021/bi00063a007; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; CHANDLER DE, 1980, J CELL BIOL, V86, P666, DOI 10.1083/jcb.86.2.666; CURRAN MJ, 1993, J MEMBRANE BIOL, V133, P61; DETOLEDO GA, 1993, NATURE, V363, P554, DOI 10.1038/363554a0; DISIMONE C, 1992, VIROLOGY, V191, P338, DOI 10.1016/0042-6822(92)90196-V; DOMS RW, 1985, J BIOL CHEM, V260, P2973; DONG JY, 1992, J VIROL, V66, P7374, DOI 10.1128/JVI.66.12.7374-7382.1992; Edidin Michael, 1992, Trends in Cell Biology, V2, P376, DOI 10.1016/0962-8924(92)90050-W; ELLENS H, 1985, BIOCHEMISTRY-US, V24, P3099, DOI 10.1021/bi00334a005; ELLENS H, 1990, BIOCHEMISTRY-US, V29, P9697, DOI 10.1021/bi00493a027; GETHING MJ, 1986, J CELL BIOL, V102, P11, DOI 10.1083/jcb.102.1.11; GODLEY L, 1992, CELL, V68, P635, DOI 10.1016/0092-8674(92)90140-8; GUY HR, 1992, BIOPHYS J, V62, P95, DOI 10.1016/S0006-3495(92)81790-3; HARTER C, 1989, J BIOL CHEM, V264, P6459; KALDERON N, 1979, J CELL BIOL, V81, P411, DOI 10.1083/jcb.81.2.411; KEMBLE GW, 1993, J CELL BIOL, V122, P1253, DOI 10.1083/jcb.122.6.1253; KEMBLE GW, 1992, J VIROL, V66, P4940, DOI 10.1128/JVI.66.8.4940-4950.1992; LAZAROWITZ SG, 1975, VIROLOGY, V68, P440, DOI 10.1016/0042-6822(75)90285-8; LEVENTIS R, 1986, BIOCHEMISTRY-US, V25, P6978, DOI 10.1021/bi00370a600; MONCK JR, 1992, J CELL BIOL, V119, P1395, DOI 10.1083/jcb.119.6.1395; NICHOLS JW, 1982, BIOCHEMISTRY-US, V21, P1720, DOI 10.1021/bi00537a003; ORNBERG RL, 1981, J CELL BIOL, V90, P40, DOI 10.1083/jcb.90.1.40; PALADE GE, 1968, J CELL BIOL, V37, P633, DOI 10.1083/jcb.37.3.633; Pinto da Silva P., 1977, J CELL BIOL, V73, P161; ROTH MG, 1986, J CELL BIOL, V102, P1271, DOI 10.1083/jcb.102.4.1271; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHEKMAN R, 1992, Current Opinion in Cell Biology, V4, P587, DOI 10.1016/0955-0674(92)90076-O; SIEGEL DP, 1993, VIRAL FUSION MECHANI, P475; SIMPSON DA, 1992, J VIROL, V66, P790, DOI 10.1128/JVI.66.2.790-803.1992; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SONG LY, 1991, BIOCHIM BIOPHYS ACTA, V1065, P54, DOI 10.1016/0005-2736(91)90010-6; SPRUCE AE, 1989, NATURE, V342, P555, DOI 10.1038/342555a0; SPRUCE AE, 1991, P NATL ACAD SCI USA, V88, P3623, DOI 10.1073/pnas.88.9.3623; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STEGMANN T, 1987, EMBO J, V6, P2651, DOI 10.1002/j.1460-2075.1987.tb02556.x; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; STEGMANN T, 1990, EMBO J, V9, P4231, DOI 10.1002/j.1460-2075.1990.tb07871.x; TSE FW, 1993, J CELL BIOL, V121, P543, DOI 10.1083/jcb.121.3.543; WHARTON SA, 1986, VIROLOGY, V149, P27, DOI 10.1016/0042-6822(86)90083-8; WHITE J, 1982, NATURE, V300, P658, DOI 10.1038/300658a0; WHITE JM, 1987, J CELL BIOL, V105, P2887, DOI 10.1083/jcb.105.6.2887; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON DW, 1989, NATURE, V339, P355, DOI 10.1038/339355a0; WUNDERLIALLENSPACH H, 1990, BIOCHEMISTRY-US, V29, P1990, DOI 10.1021/bi00460a005	51	460	468	0	24	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 28	1994	76	2					383	391		10.1016/0092-8674(94)90344-1	http://dx.doi.org/10.1016/0092-8674(94)90344-1			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	8293471				2022-12-01	WOS:A1994MU67800020
J	BARRETTCONNOR, E; CHANG, JC; EDELSTEIN, SL				BARRETTCONNOR, E; CHANG, JC; EDELSTEIN, SL			COFFEE-ASSOCIATED OSTEOPOROSIS OFFSET BY DAILY MILK CONSUMPTION - THE RANCHO-BERNARDO STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BONE-MINERAL CONTENT; ELDERLY WOMEN; HIP FRACTURE; CAFFEINE; CALCIUM; RISK; MASS	Objective.-To describe the association of lifetime intake of caffeinated coffee, in cup-years, to bone mineral density (BMD) of the hip and spine in postmenopausal women; and to determine the effect of regular milk intake on this association. Design.-Women from an established epidemiologic cohort had measures of BMD and gave a medical and behavioral history that included caffeinated coffee and daily milk intake between the ages of 12 and 18 years, 20 and 50 years, and 50 years of age and older. Setting.-A community-based population of older women, Rancho Bernardo, Calif. Participants.-All 980 postmenopausal women aged 50 to 98 years (mean age, 72.7 years) who participated between 1988 and 1991. Main Outcome Measures.-Bone density at the hip and lumbar spine measured by dual energy x-ray absorptiometry. Main Results.-There was a statistically significant graded association between increasing lifetime intake of caffeinated coffee and decreasing BMD at both the hip and spine, independent of age, obesity, parity, years since menopause, and the use of tobacco, alcohol, estrogen, thiazides, and calcium supplements. Bone density did not vary by lifetime coffee intake in women who reported drinking at least one glass of milk per day during most of their adult lives. Conclusions.-Lifetime caffeinated coffee intake equivalent to two cups per day is associated with decreased bone density in older women who do not drink milk on a daily basis.			BARRETTCONNOR, E (corresponding author), UNIV CALIF SAN DIEGO,DEPT FAMILY & PREVENT MED,9500 GILMAN DR,LA JOLLA,CA 92093, USA.				NIA NIH HHS [R37AG07181-06] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R37AG007181] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BARGERLUX MJ, 1990, AM J CLIN NUTR, V52, P722, DOI 10.1093/ajcn/52.4.722; Barone J.J., 1984, CAFFEINE; BARRETTCONNOR E, 1989, CALCIFIED TISSUE INT, V44, P303, DOI 10.1007/BF02556308; BAUER DC, 1991, CLIN RES, V39, pA571; CHAPUY MC, 1992, NEW ENGL J MED, V327, P1637, DOI 10.1056/NEJM199212033272305; COOPER C, 1992, J BONE MINER RES, V7, P465; ELIEL LP, 1983, CALCIFIED TISSUE INT, V35, P669; FLEISS JL, 1973, STATISTICAL METHODS; GILBERT RM, 1976, CAN MED ASSOC J, V114, P205; HEANEY RP, 1993, NEW ENGL J MED, V328, P503, DOI 10.1056/NEJM199302183280710; HEANEY RP, 1982, J LAB CLIN MED, V99, P46; HERNANDEZAVILA M, 1991, AM J CLIN NUTR, V54, P157, DOI 10.1093/ajcn/54.1.157; HOLBROOK TL, 1988, LANCET, V2, P1046, DOI 10.1016/S0140-6736(88)90065-7; JOHANNSON CH, 1990, 3RD P INT S OST ALB, P10; KIEL DP, 1990, AM J EPIDEMIOL, V132, P675, DOI 10.1093/oxfordjournals.aje.a115709; KREIGER N, 1992, INT J EPIDEMIOL, V21, P953, DOI 10.1093/ije/21.5.953; MASSEY LK, 1991, J BONE MINER RES, V6, P1149; MASSEY LK, 1989, J BONE MINER RES SS1, V4, P249; PICARD D, 1988, BONE MINER, V4, P299; RECKER RR, 1992, JAMA-J AM MED ASSOC, V268, P2403, DOI 10.1001/jama.268.17.2403; REID IR, 1993, NEW ENGL J MED, V328, P460, DOI 10.1056/NEJM199302183280702; SLEMENDA CW, 1990, ANN INTERN MED, V112, P96, DOI 10.7326/0003-4819-112-2-96; SMITH S, 1989, ARCH INTERN MED, V149, P2517, DOI 10.1001/archinte.149.11.2517; SOROKO S, 1993, AM J EPIDEMIOL, V138, P6; YANO K, 1985, AM J CLIN NUTR, V42, P877, DOI 10.1093/ajcn/42.5.877	25	129	134	1	13	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	1994	271	4					280	283		10.1001/jama.271.4.280	http://dx.doi.org/10.1001/jama.271.4.280			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR221	8295286				2022-12-01	WOS:A1994MR22100023
J	KOSNETT, MJ; BECKER, CE; OSTERLOH, JD; KELLY, TJ; PASTA, DJ				KOSNETT, MJ; BECKER, CE; OSTERLOH, JD; KELLY, TJ; PASTA, DJ			FACTORS INFLUENCING BONE LEAD CONCENTRATION IN A SUBURBAN COMMUNITY ASSESSED BY NONINVASIVE K-X-RAY FLUORESCENCE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD LEAD; HUMAN TISSUES; EXPOSURE; CHILDREN; INDUSTRY; SMOKING; BURDEN; POPULATION; CADMIUM; ALCOHOL	Objective.-To determine the influence of demographic, exposure, and medical factors on the bone lead concentration of subjects with background (nonindustrial) environmental lead exposure. Design.-Survey. Setting.-Suburban residential community. Participants.-A total of 101 subjects (49 males, 52 females; aged 11 to 78 years) were recruited from 49 of 123 households geographically located in a suburban residential neighborhood unexposed to any major source of industrial lead emissions. Main Outcome Measurements.-Cortical bone lead concentrations in the mid-shaft of the tibia were noninvasively measured by in vivo K x-ray fluorescence. Blood lead concentrations were measured by anodic stripping voltammetry. An administered questionnaire assessed potential sources of lead exposure and medical conditions affecting bone metabolism. Results.-After the exclusion of one outlier, log-transformed bone lead concentration was highly correlated with age (r=.71; P less-than-or-equal-to .0001). Bone lead concentration showed no significant change up to age 20 years, increased with the same slope in men and women between ages 20 and 55 years, and then increased at a faster rate in men older than 55 years. In addition to the variables age and sex, the best fitting multiple regression model for bone lead concentration (R2=.66; P less-than-or-equal-to .0001) revealed a positive correlation with total pack-years of cigarette smoking and a negative correlation with a history of having nursed an infant for longer than 2 weeks. Blood lead concentrations of the subjects were low (geometric mean, 0.24 mumol/L [4.9 mug/dL]) and after log transformation were weakly correlated with log-transformed bone lead concentration (r=.23; P=.02). Conclusions.-The age- and sex-related increases in bone lead concentration found by K x-ray fluorescence concur with published postmortem studies of bone lead concentration and are consistent with the kinetics of bone turnover and secular trends in lead exposure. These data help to establish a reference range for assessing the lead burden of other populations with environmental or occupational lead exposure.	DMA CORP, LOS ALTOS, CA USA; SAN FRANCISCO GEN HOSP, DIV OCCUPAT & ENVIRONM MED, SAN FRANCISCO, CA 94110 USA	San Francisco General Hospital Medical Center	KOSNETT, MJ (corresponding author), UNIV CALIF SAN FRANCISCO, CTR OCCUPAT & ENVIRONM HLTH, BOX 0843, SAN FRANCISCO, CA 94143 USA.				NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH [K01OH000108] Funding Source: NIH RePORTER; NIOSH CDC HHS [1 K01 OH001 08-01] Funding Source: Medline	NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH(United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USANational Institute for Occupational Safety & Health (NIOSH)); NIOSH CDC HHS		APPEL BR, 1990, AM J PUBLIC HEALTH, V80, P560, DOI 10.2105/AJPH.80.5.560; BARRY PSI, 1975, BRIT J IND MED, V32, P119; BELLINGER D, 1991, PEDIATRICS, V87, P219; BERODE M, 1991, ENVIRON RES, V55, P1, DOI 10.1016/S0013-9351(05)80136-7; BOHM J, 1986, THESIS U MUNCHEN; BRANGSTRUPHANSE.JP, 1981, J OCCUP MED, V23, P39; Burger D E, 1990, Basic Life Sci, V55, P287; CHAN GM, 1987, AM J CLIN NUTR, V46, P319, DOI 10.1093/ajcn/46.2.319; CHRISTOFFERSSON JO, 1984, AM J IND MED, V6, P447, DOI 10.1002/ajim.4700060608; COHEN J., 1983, APPL MULTIPLE REGRES, V2; DRASCH GA, 1987, SCI TOTAL ENVIRON, V64, P303, DOI 10.1016/0048-9697(87)90252-X; EMMERSON BT, 1961, MED J AUSTRALIA, V1, P243, DOI 10.5694/j.1326-5377.1961.tb82436.x; ERKKILA J, 1992, BRIT J IND MED, V49, P631; FROINES JR, 1990, AM J IND MED, V18, P1; GRANDJEAN P, 1981, INT ARCH OCC ENV HEA, V48, P391, DOI 10.1007/BF00378687; GROSS SB, 1975, TOXICOL APPL PHARM, V32, P638, DOI 10.1016/0041-008X(75)90127-1; HEANEY RP, 1978, J LAB CLIN MED, V92, P964; HU H, 1989, ENVIRON RES, V49, P295, DOI 10.1016/S0013-9351(89)80074-X; HU H, 1990, ARCH ENVIRON HEALTH, V45, P335, DOI 10.1080/00039896.1990.10118752; HU H, 1991, AM J IND MED, V20, P723, DOI 10.1002/ajim.4700200603; HU H, 1991, ENVIRON HEALTH PERSP, V94, P107, DOI 10.2307/3431301; JONES KW, 1987, IN VIVO BODY COMPOSI, P363; KAYE WE, 1987, ARCH ENVIRON HEALTH, V42, P161, DOI 10.1080/00039896.1987.9935815; KELLER CA, 1980, TOXICOL APPL PHARM, V55, P220, DOI 10.1016/0041-008X(80)90083-6; KERIEY ER, 1965, AM J PHYS ANTHROPOL, V23, P149; MANTON WI, 1985, BRIT J IND MED, V42, P168; MASSIE HR, 1992, GERONTOLOGY, V38, P13; MORGAN WD, 1990, BIOL TRACE ELEM RES, V26-7, P407, DOI 10.1007/BF02992695; NEEDLEMAN HL, 1990, JAMA-J AM MED ASSOC, V263, P673, DOI 10.1001/jama.263.5.673; NEEDLEMAN HL, 1979, NEW ENGL J MED, V300, P689, DOI 10.1056/NEJM197903293001301; NUSBAUM RE, 1965, ARCH ENVIRON HEALTH, V10, P227, DOI 10.1080/00039896.1965.10663989; OFLAHERTY EJ, 1991, TOXICOL APPL PHARM, V111, P313, DOI 10.1016/0041-008X(91)90033-B; OSTERLOH JD, 1990, J ANAL TOXICOL, V14, P8, DOI 10.1093/jat/14.1.8; OTT J, 1987, THESIS U MUNCHEN; PRICE J, 1984, BRIT J RADIOL, V57, P29, DOI 10.1259/0007-1285-57-673-29; QUINN MJ, 1989, HUM TOXICOL, V8, P205, DOI 10.1177/096032718900800302; RABINOWITZ MB, 1991, ENVIRON HEALTH PERSP, V91, P33, DOI 10.2307/3430979; RABINOWITZ MB, 1976, J CLIN INVEST, V58, P260, DOI 10.1172/JCI108467; SALTZMAN BE, 1990, ENVIRON RES, V52, P126, DOI 10.1016/S0013-9351(05)80248-8; SCHUTZ A, 1987, SCI TOTAL ENVIRON, V61, P201, DOI 10.1016/0048-9697(87)90367-6; SHAPER AG, 1982, BMJ-BRIT MED J, V284, P299, DOI 10.1136/bmj.284.6312.299; SHARP DS, 1987, MED TOXICOL ADV DRUG, V2, P210, DOI 10.1007/BF03259865; SHARP DS, 1991, AM IND HYG ASSOC J, V52, P409, DOI 10.1080/15298669191364956; SIEBER WK, 1991, AM J IND MED, V20, P163, DOI 10.1002/ajim.4700200204; SILBERGELD EK, 1991, ENVIRON HEALTH PERSP, V91, P63, DOI 10.2307/3430984; SOMERVAILLE LJ, 1985, PHYS MED BIOL, V30, P929, DOI 10.1088/0031-9155/30/9/005; SOMERVAILLE LJ, 1988, BRIT J IND MED, V45, P174; TELL I, 1992, SCAND J WORK ENV HEA, V18, P113, DOI 10.5271/sjweh.1603; TODD AC, 1992, ENVIRON RES, V57, P117, DOI 10.1016/S0013-9351(05)80073-8; TOLA S, 1973, BRIT J IND MED, V30, P134; Tukey J.W., 1977, EXPLORATORY DATA ANA, P61, DOI 10.1007/978-0-387-32833-1_136; WEDEEN RP, 1979, ARCH INTERN MED, V139, P53, DOI 10.1001/archinte.139.1.53; WEDEEN RP, 1987, IN VIVO BODY COMPOSI, P357; WILLERS S, 1988, SCAND J WORK ENV HEA, V14, P385, DOI 10.5271/sjweh.1905; WITTMERS LE, 1988, ARCH ENVIRON HEALTH, V43, P381, DOI 10.1080/00039896.1988.9935855; 1986, US EPA SW846 PUBL; 1991, DRAFT TOXIOLOGICAL P; 1984, NATIONAL CTR HLTH ST, V11; 1977, TASK GROUP ENV HLTH; 1973, ALKALINE EARTH METAB; 1986, US EPA600883028F PUB	61	95	97	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	1994	271	3					197	203		10.1001/jama.271.3.197	http://dx.doi.org/10.1001/jama.271.3.197			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ645	8277545				2022-12-01	WOS:A1994MQ64500032
J	SCHWACHA, A; KLECKNER, N				SCHWACHA, A; KLECKNER, N			IDENTIFICATION OF JOINT MOLECULES THAT FORM FREQUENTLY BETWEEN HOMOLOGS BUT RARELY BETWEEN SISTER CHROMATIDS DURING YEAST MEIOSIS	CELL			English	Article							DOUBLE-STRAND BREAKS; SYNAPTONEMAL COMPLEX-FORMATION; SACCHAROMYCES-CEREVISIAE; MEIOTIC RECOMBINATION; CHROMOSOME SYNAPSIS; GENE CONVERSION; INITIATION SITE; RECA PROTEIN; DNA; EXCHANGE	We have investigated DNA interactions between homologs and between sister chromatids during meiosis in S. cerevisiae. We have detected a DNA species containing information from both parental chromosomes at a specific hotspot for melotic recombination and double strand breaks (DSBs). These joint molecules are a prominent feature of melotic prophase. They appear to be a major intermediate stage in DSB-promoted recombination, because they occur with appropriate timing and require known recombination functions. Other possibilities cannot be completely dismissed, however. Most or all joint molecules contain two full-length nonrecombinant strands from each parental duplex and thus do not consist of single Holliday junctions. Joint molecules form between sister chromatids at approximately 10% the interhomolog level. Also, joint molecule formation is aberrant in a mutant defective in the HOP1 gene, which encodes a melotic chromosome structure component. General models for discrimination between homologs and sisters during meiosis are discussed.			SCHWACHA, A (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA.				NIGMS NIH HHS [GM44794] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BEACHAM IR, 1984, GENE, V29, P271, DOI 10.1016/0378-1119(84)90056-8; BELL L, 1979, P NATL ACAD SCI USA, V76, P3445, DOI 10.1073/pnas.76.7.3445; BELL LR, 1982, COLD SPRING HARB SYM, V47, P829, DOI 10.1101/SQB.1983.047.01.095; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BORTS RH, 1986, GENETICS, V113, P551; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CANCER CELL, V6, P229; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; CARPENTER ATC, 1987, BIOESSAYS, V6, P232, DOI 10.1002/bies.950060510; CHAMPOUX JJ, 1977, P NATL ACAD SCI USA, V74, P5328, DOI 10.1073/pnas.74.12.5328; CHENG S, 1988, J BIOL CHEM, V263, P15110; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLLINS I, 1994, CELL, V76, P65, DOI 10.1016/0092-8674(94)90173-2; CUNNINGHAM RP, 1981, CELL, V24, P213, DOI 10.1016/0092-8674(81)90517-1; FARNET C, 1988, UCLA S MOL CELL BIOL, V83, P201; GAME JC, 1989, GENETICS, V123, P695; GOYON C, 1993, MOL CELL BIOL, V13, P373, DOI 10.1128/MCB.13.1.373; HABER JE, 1984, GENETICS, V106, P185; HABER JE, 1991, P NATL ACAD SCI USA, V88, P1120, DOI 10.1073/pnas.88.4.1120; HOLLINGSWORTH NM, 1989, GENETICS, V121, P445; HOLLINGSWORTH NM, 1990, CELL, V61, P73, DOI 10.1016/0092-8674(90)90216-2; HOLM C, 1986, GENE, V42, P169, DOI 10.1016/0378-1119(86)90293-3; JACKSON JA, 1985, GENETICS, V109, P303; KLAPHOLZ S, 1985, GENETICS, V110, P187; KLECKNER N, 1991, COLD SH Q B, V56, P729; KLECKNER N, 1994, IN PRESS COLD SPRING, V58; MALONE RE, 1981, MOL CELL BIOL, V1, P891, DOI 10.1128/MCB.1.10.891; MALONE RE, 1983, MOL GEN GENET, V189, P405, DOI 10.1007/BF00325902; MCGAVIN S, 1971, J MOL BIOL, V55, P293, DOI 10.1016/0022-2836(71)90201-4; NAG DK, 1993, MOL CELL BIOL, V13, P2324, DOI 10.1128/MCB.13.4.2324; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; ROCKMILL B, 1990, GENETICS, V126, P563; ROEDER GS, 1990, TRENDS GENET, V6, P385, DOI 10.1016/0168-9525(90)90297-J; Sambrook J., 1989, MOL CLONING LAB MANU; SENA EP, 1986, MOL GEN GENET, V202, P421, DOI 10.1007/BF00333272; SHI YB, 1988, BIOCHEMISTRY-US, V27, P5174, DOI 10.1021/bi00414a034; SHINOHARA A, 1992, CELL, V69, P457, DOI 10.1016/0092-8674(92)90447-K; SIKORSKI RS, 1989, GENETICS, V122, P19; SMITHIES O, 1986, PHILOS T ROY SOC B, V312, P291, DOI 10.1098/rstb.1986.0008; STACK SM, 1991, GENOME, V34, P900, DOI 10.1139/g91-138; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SUNDIN O, 1980, CELL, V21, P103, DOI 10.1016/0092-8674(80)90118-X; SZOSTAK JW, 1983, CELL, V33, P25, DOI 10.1016/0092-8674(83)90331-8; THALER DS, 1988, ANNU REV GENET, V22, P169, DOI 10.1146/annurev.ge.22.120188.001125; THORNE LW, 1993, GENETICS, V134, P29; UMLAUF SW, 1990, J BIOL CHEM, V265, P16898; UZAWA S, 1992, J CELL SCI, V101, P267; VONWETTS.D, 1971, P NATL ACAD SCI USA, V68, P851, DOI 10.1073/pnas.68.4.851; WAGSTAFF JE, 1985, MOL CELL BIOL, V5, P3532, DOI 10.1128/MCB.5.12.3532; WU TC, 1993, MEIOSIS, V2; WU TC, 1994, IN PRESS SCIENCE; ZENVIRTH D, 1992, EMBO J, V11, P3441, DOI 10.1002/j.1460-2075.1992.tb05423.x	55	287	291	1	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	1994	76	1					51	63		10.1016/0092-8674(94)90172-4	http://dx.doi.org/10.1016/0092-8674(94)90172-4			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287479				2022-12-01	WOS:A1994MR49500006
J	DEODHAR, HA; MARSHALL, RJ; BARNES, JN				DEODHAR, HA; MARSHALL, RJ; BARNES, JN			LESSON OF THE WEEK - INCREASED RISK OF SEPSIS AFTER SPLENECTOMY	BRITISH MEDICAL JOURNAL			English	Article							POSTSPLENECTOMY SEPSIS; PNEUMOCOCCAL VACCINE		ROYAL CORNWALL HOSP,RENAL UNIT,TRURO TR1 3LJ,CORNWALL,ENGLAND; ROYAL CORNWALL HOSP,DEPT PATHOL,TRURO TR1 3LJ,CORNWALL,ENGLAND	Royal Cornwall Hospital; Royal Cornwall Hospital								ADDIEGO JE, 1980, LANCET, V2, P450; BADDELEY PG, 1993, HOSPITAL UPDATE, V19, P365; FOSTER PN, 1987, J ROY COLL PHYS LOND, V21, P188; KING H, 1952, ANN SURG, V136, P239, DOI 10.1097/00000658-195208000-00006; ONEAL BJ, 1981, ANN SURG, V194, P775, DOI 10.1097/00000658-198112000-00020; SHAPIRO ED, 1984, ANN INTERN MED, V101, P325, DOI 10.7326/0003-4819-101-3-325; SHAW JHF, 1989, BRIT J SURG, V76, P1074, DOI 10.1002/bjs.1800761029; SIMS RV, 1988, ANN INTERN MED, V108, P653, DOI 10.7326/0003-4819-108-5-653; TRAUB A, 1987, NEW ENGL J MED, V317, P1559, DOI 10.1056/NEJM198712173172503; ZARRABI MH, 1986, ARCH INTERN MED, V146, P1207, DOI 10.1001/archinte.146.6.1207; 1985, LANCET, V2, P928; 1992, IMMUNISATION INFECTI, P100; 1989, JAMA-J AM MED ASSOC, V261, P1265	13	65	65	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1993	307	6916					1408	1409		10.1136/bmj.307.6916.1408	http://dx.doi.org/10.1136/bmj.307.6916.1408			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK420	8274896	Green Published, Bronze			2022-12-01	WOS:A1993MK42000026
J	WORKOWSKI, KA; LAMPE, MF; WONG, KG; WATTS, MB; STAMM, WE				WORKOWSKI, KA; LAMPE, MF; WONG, KG; WATTS, MB; STAMM, WE			LONG-TERM ERADICATION OF CHLAMYDIA-TRACHOMATIS GENITAL-INFECTION AFTER ANTIMICROBIAL THERAPY - EVIDENCE AGAINST PERSISTENT INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMERASE CHAIN-REACTION; ENZYME-IMMUNOASSAY; URETHRITIS; WOMEN	Objective.-To determine whether Chlamydia trachomatis urogenital infections persist or relapse after antimicrobial therapy by serial measurement of chlamydial-specific DNA using the polymerase chain reaction (PCR), cell cultures, and serological studies. Design.-Prospective evaluation of an inception cohort. Setting.-University student health clinic. Participants.-Twenty women with culture-proven and PCR-proven C trachomatis urogenital infections. Measurements.-Incidence of persistent infection as determined by PCR, culture, and serial measurement of local and systemic antibody to C trachomatis for 5 months after doxycycline therapy. Results.-Prior to therapy, C trachomatis was isolated in cell culture from the cervix in 19 of 20 women, from the urethra in 13 women, and from the rectum in 13 women. All culture-positive specimens were also PCR-positive. Immediately after completion of antimicrobial therapy, all women had negative cell cultures for chlamydia. Ten of 20 culture-negative cervical specimens and two culture-negative urethral specimens had chlamydial DNA present immediately after treatment. In addition, three women had detectable DNA from cervical specimens 1 week after treatment. The presence of cervicitis (P=.01), high inclusion counts (P=.004), and serological evidence of recent infection (P=.0004) were each significantly associated with PCR positivity after treatment. All 384 subsequent cervical, rectal, and urethral specimens collected over 5 months were negative by both PCR and culture with the exception of one woman who was reinfected. Serum immunoglobulin M (IgM) titers, geometric mean serum immunoglobulin G (IgG) titers, and prevalence of local antibody to chlamydia progressively declined after treatment. Conclusions.-Standard antimicrobial therapy is effective in the long-term microbiologic eradication of uncomplicated C trachomatis urogenital infections. The presence of chlamydial DNA after antimicrobial therapy is of short duration and reflects excretion of nonviable organisms rather than persistent infection.			WORKOWSKI, KA (corresponding author), EMORY UNIV, DIV INFECT DIS, 20 LINDEN AVE NE, SUITE 101-G, ATLANTA, GA 30308 USA.				NIAID NIH HHS [AI-27456] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BATTEIGER BE, 1989, J INFECT DIS, V159, P661, DOI 10.1093/infdis/159.4.661; BELL TA, 1992, JAMA-J AM MED ASSOC, V267, P400, DOI 10.1001/jama.267.3.400; BOBO L, 1991, LANCET, V338, P847, DOI 10.1016/0140-6736(91)91502-L; Cerin A, 1991, Int J STD AIDS, V2, P176; HATCH TP, 1975, INFECT IMMUN, V12, P211, DOI 10.1128/IAI.12.1.211-220.1975; HOOTON TM, 1990, JAMA-J AM MED ASSOC, V264, P1418, DOI 10.1001/jama.264.11.1418; LOEFFELHOLZ MJ, 1992, J CLIN MICROBIOL, V30, P2847, DOI 10.1128/JCM.30.11.2847-2851.1992; MARTIN DH, 1992, NEW ENGL J MED, V327, P921, DOI 10.1056/NEJM199209243271304; MCCORMACK WM, 1979, NEW ENGL J MED, V300, P123, DOI 10.1056/NEJM197901183000305; NACHAMKIN I, 1987, J CLIN MICROBIOL, V25, P1774, DOI 10.1128/JCM.25.9.1774-1775.1987; Oriel J D, 1982, Eur J Clin Microbiol, V1, P69, DOI 10.1007/BF02014194; OSTERGAARD L, 1990, J CLIN MICROBIOL, V28, P1254, DOI 10.1128/JCM.28.6.1254-1260.1990; PATTON DL, 1987, J INFECT DIS, V155, P292; SANDERS LL, 1986, JAMA-J AM MED ASSOC, V255, P1750, DOI 10.1001/jama.255.13.1750; SCHACHTER J, 1978, NEW ENGL J MED, V298, P540, DOI 10.1056/NEJM197803092981005; SCHACHTER J, 1978, NEW ENGL J MED, V298, P428, DOI 10.1056/NEJM197802232980805; SCHACHTER J, 1978, NEW ENGL J MED, V298, P490, DOI 10.1056/NEJM197803022980905; SHEPARD MK, 1989, FERTIL STERIL, V52, P232; SOREN K, 1989, AM J DIS CHILD, V143, P51, DOI 10.1001/archpedi.1989.02150130061015; STAMM WE, 1983, J CLIN MICROBIOL, V17, P666, DOI 10.1128/JCM.17.4.666-668.1983; SUCHLAND RJ, 1991, J CLIN MICROBIOL, V29, P1333, DOI 10.1128/JCM.29.7.1333-1338.1991; TOOMEY KE, 1990, REV INFECT DIS, V12, pS645; WANG SP, 1975, J CLIN MICROBIOL, V1, P250, DOI 10.1128/JCM.1.3.250-255.1975; Ward ME, 1988, MICOBIOLOGY CHLAMYDI, P71; WASHINGTON AE, 1987, JAMA-J AM MED ASSOC, V257, P2070, DOI 10.1001/jama.257.15.2070	25	88	88	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 3	1993	270	17					2071	2075		10.1001/jama.270.17.2071	http://dx.doi.org/10.1001/jama.270.17.2071			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MD882	8305018				2022-12-01	WOS:A1993MD88200026
J	ALFONSO, A; GRUNDAHL, K; DUERR, JS; HAN, HP; RAND, JB				ALFONSO, A; GRUNDAHL, K; DUERR, JS; HAN, HP; RAND, JB			THE CAENORHABDITIS-ELEGANS UNC-17 GENE - A PUTATIVE VESICULAR ACETYLCHOLINE TRANSPORTER	SCIENCE			English	Article							C-ELEGANS; CHOLINE-ACETYLTRANSFERASE; MESSENGER-RNA; NEMATODE; RESISTANCE; SEQUENCES; ENCODES; CELLS	Mutations in the unc-17 gene of the nematode Caenorhabditis elegans produce deficits in neuromuscular function. This gene was cloned and complementary DNAs were sequenced. On the basis of sequence similarity to mammalian vesicular transporters of biogenic amines and of localization to synaptic vesicles of cholinergic neurons in C. elegans, unc-17 likely encodes the vesicular transporter of acetylcholine. Mutations that eliminated all unc-17 gene function were lethal, suggesting that the acetylcholine transporter is essential. Molecular analysis of unc-17 mutations will allow the correlation of specific parts of the gene (and the protein) with observed functional defects. The mutants will also be useful for the isolation of extragenic suppressors, which could identify genes encoding proteins that interact with UNC-17.	OKLAHOMA MED RES FDN,PROGRAM MOLEC & CELL BIOL,825 NE 13TH ST,OKLAHOMA CITY,OK 73104	Oklahoma Medical Research Foundation					NIGMS NIH HHS [R01 GM038679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038679] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; ALFONSO A, UNPUB; ALFONSO A, IN PRESS J NEUROSCI; AVERY L, 1990, J EXP ZOOL, V253, P263, DOI 10.1002/jez.1402530305; BARSTEAD RJ, 1989, J BIOL CHEM, V264, P10177; Bektesh S., 1988, GENE DEV, V2, P527; BITTNER M, 1980, ANAL BIOCHEM, V102, P459, DOI 10.1016/0003-2697(80)90182-7; BRENNER S, 1974, GENETICS, V77, P71; Chalfie M., 1988, NEMATODE CAENORHABDI, P337; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; ERICKSON JD, 1992, P NATL ACAD SCI USA, V89, P10993, DOI 10.1073/pnas.89.22.10993; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FERGUSON EL, 1985, GENETICS, V110, P17; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HEDGECOCK EM, 1990, NEURON, V4, P61, DOI 10.1016/0896-6273(90)90444-K; HOSONO R, 1989, ZOOL SCI, V6, P697; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LIU YJ, 1992, CELL, V70, P539, DOI 10.1016/0092-8674(92)90425-C; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; NEYFAKH AA, 1991, P NATL ACAD SCI USA, V88, P4781, DOI 10.1073/pnas.88.11.4781; Nguyen M. A., UNPUB; NONET ML, IN PRESS CELL; OTSUKA AJ, 1991, NEURON, V6, P113, DOI 10.1016/0896-6273(91)90126-K; PALATNIK CM, 1979, J MOL BIOL, V128, P371, DOI 10.1016/0022-2836(79)90093-7; RAND JB, 1985, J NEUROCHEM, V44, P189, DOI 10.1111/j.1471-4159.1985.tb07130.x; RAND JB, 1984, GENETICS, V106, P227; RAND JB, 1989, GENETICS, V122, P73; ROSS J, 1976, J MOL BIOL, V106, P403, DOI 10.1016/0022-2836(76)90093-0; Sambrook J., 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; THOMAS JH, 1990, GENETICS, V124, P855; YOSHIDA H, 1990, J BACTERIOL, V172, P6942, DOI 10.1128/jb.172.12.6942-6949.1990	32	318	332	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 30	1993	261	5121					617	619		10.1126/science.8342028	http://dx.doi.org/10.1126/science.8342028			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	8342028				2022-12-01	WOS:A1993LP72800042
J	SAUER, F; JACKLE, H				SAUER, F; JACKLE, H			DIMERIZATION AND THE CONTROL OF TRANSCRIPTION BY KRUPPEL	NATURE			English	Article							ALCOHOL-DEHYDROGENASE GENE; CULTURED DROSOPHILA CELLS; ACTIVATION; PROTEIN; REPRESSION; BINDING; PRODUCT; EMBRYO; STRIPE; YEAST	KRUPPEL (KR), a Drosophila zinc finger-type1 transcription factor2-4, can both activate and repress gene expression through interaction with a single DNA-binding site4. The opposite regulatory effects of KR are concentration-dependent, and they require distinct portions of KR such as the N-terminal region for activation and the C-terminal region for repression4. Here we show that KR is able to form homodimers through sequences located within the C terminus. When these sequences were fused to separated functional parts of the yeast transcription factor GAL4(5), they reconstituted a functional transcriptional activator on dimerization in vivo. Our results suggest that the KR monomer is a transcriptional activator. At higher concentration KR forms a homodimer and becomes a repressor that functions through the same target sequences as the activator.			SAUER, F (corresponding author), MAX PLANCK INST BIOPHYS CHEM,MOLEK ENTWICKLUNGSBIOL ABT,POSTFACH 2841,D-37018 GOTTINGEN,GERMANY.							BENSON M, 1987, EMBO J, V6, P1387, DOI 10.1002/j.1460-2075.1987.tb02379.x; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GAUL U, 1987, CELL, V50, P639, DOI 10.1016/0092-8674(87)90037-7; HAN KY, 1993, GENE DEV, V7, P491, DOI 10.1101/gad.7.3.491; HEBERLEIN U, 1985, CELL, V41, P965, DOI 10.1016/S0092-8674(85)80077-5; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; INGRAHAM HA, 1990, CELL, V61, P1021, DOI 10.1016/0092-8674(90)90067-O; KAKIDANI H, 1988, CELL, V52, P161, DOI 10.1016/0092-8674(88)90504-1; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LICHT JD, 1990, NATURE, V346, P76, DOI 10.1038/346076a0; MA J, 1987, CELL, V51, P113, DOI 10.1016/0092-8674(87)90015-8; MA J, 1987, CELL, V48, P847, DOI 10.1016/0092-8674(87)90081-X; MANIATIS T, 1990, MOL CLONING; PANKRATZ MJ, 1989, NATURE, V341, P337, DOI 10.1038/341337a0; PANKRATZ MJ, 1993, DEV DROSOPHILIA MELA; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROSENBERG UB, 1986, NATURE, V319, P336, DOI 10.1038/319336a0; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SCHNEIDER I, 1972, J EMBRYOL EXP MORPH, V27, P353; SMALL S, 1991, GENE DEV, V5, P827, DOI 10.1101/gad.5.5.827; SORGER PK, 1987, EMBO J, V6, P3035, DOI 10.1002/j.1460-2075.1987.tb02609.x; STANOJEVIC D, 1991, SCIENCE, V254, P1385, DOI 10.1126/science.1683715; ZUO P, 1991, GENE DEV, V5, P254, DOI 10.1101/gad.5.2.254	24	96	102	1	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 29	1993	364	6436					454	457		10.1038/364454a0	http://dx.doi.org/10.1038/364454a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP640	8332216				2022-12-01	WOS:A1993LP64000058
J	VOGT, MT; CAULEY, JA; NEWMAN, AB; KULLER, LH; HULLEY, SB				VOGT, MT; CAULEY, JA; NEWMAN, AB; KULLER, LH; HULLEY, SB			DECREASED ANKLE ARM BLOOD-PRESSURE INDEX AND MORTALITY IN ELDERLY WOMEN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To evaluate the relationship of the ankle/arm blood pressure index to short-term mortality in women 65 years of age or older. Design.-Prospective cohort study with average follow-up of 4.3 years. Setting.-Rural community near Pittsburgh, Pa. Participants.-A total of 1492 white women 65 years of age or older, living in the community and ambulatory without the help of another person. Outcome Measures.-All-cause and cause-specific mortality. Results.-The ankle/arm index (the systolic pressure in the posterior tibial artery divided by that in the brachial artery) was measured in 1986 through 1988 and found to be 0.9 or less in 82 (5.5%) of the women, 67 of whom reported no symptoms of claudication. Comparing women with an index of 0.9 or less with those with an index greater than 0.9, the relative risk for all-cause mortality 4 years later (after adjustment for age, smoking, and other risk factors) was 3.1 (95% confidence interval [CI], 1.7 to 5.5); for heart disease, 3.7 (95% CI, 1.2 to 11.6); for cardiovascular diseases, 4.0 (95% CI, 1.3 to 8.5); for cancer, 3.3 (95% CI, 1.3 to 8.5); and for all other causes, 1.1 (95% CI, 0.1 to 9.2). Similar levels of risk were found after excluding women with symptoms of claudication and/or a history of cardiovascular disease at baseline. Conclusions.-Healthy, older women with an ankle/arm index of 0.9 or less are at high risk of death and therefore may be considered for aggressive therapy to modify cardiovascular risk factors.	MED COLL PENN, DEPT MED, PITTSBURGH, PA USA; UNIV CALIF SAN FRANCISCO, DEPT EPIDEMIOL & BIOSTAT, DIV CLIN EPIDEMIOL, SAN FRANCISCO, CA 94143 USA	Drexel University; University of California System; University of California San Francisco	VOGT, MT (corresponding author), UNIV PITTSBURGH, GRAD SCH PUBL HLTH, DEPT EPIDEMIOL, 130 DESOTO ST, PITTSBURGH, PA 15261 USA.		Cauley, Jane A/N-4836-2015; Newman, Anne B./C-6408-2013	Cauley, Jane A/0000-0003-0752-4408; Newman, Anne B./0000-0002-0106-1150	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007011, R29HL040489] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR035582] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 40489, 5T32 HL 07011] Funding Source: Medline; NIAMS NIH HHS [AR 35582] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BERNSTEIN EF, 1982, SURG CLIN N AM, V62, P473; BRESLOW NE, 1987, IARC SCI PUBL, V82, pCH2; COX DR, 1972, J R STAT SOC B, V34, P187; CRIQUI MH, 1985, CIRCULATION, V71, P516, DOI 10.1161/01.CIR.71.3.516; CRIQUI MH, 1992, NEW ENGL J MED, V326, P381, DOI 10.1056/NEJM199202063260605; CUTLER SJ, 1958, J CHRON DIS, V8, P699; FOWKES FGR, 1989, BRIT MED J, V298, P405, DOI 10.1136/bmj.298.6671.405; FOWKES FGR, 1991, INT J EPIDEMIOL, V20, P384, DOI 10.1093/ije/20.2.384; FOWKES FGR, 1988, INT J EPIDEMIOL, V17, P248, DOI 10.1093/ije/17.2.248; GOFIN R, 1987, ISRAEL J MED SCI, V23, P157; HIATT WR, 1990, J CLIN EPIDEMIOL, V43, P597, DOI 10.1016/0895-4356(90)90164-K; JELNES R, 1986, BRIT MED J, V293, P1137, DOI 10.1136/bmj.293.6555.1137; JONASON T, 1987, ACTA MED SCAND, V221, P253; KALBFLEISCH JD, 1980, STATISTICAL ANAL FAI; KALLERO KS, 1981, J CHRON DIS, V34, P455, DOI 10.1016/0021-9681(81)90005-9; KANNEL WB, 1985, J AM GERIATR SOC, V33, P13, DOI 10.1111/j.1532-5415.1985.tb02853.x; KAPANTAIS GH, 1989, PHS891250 US DEP HLT; MALONE JM, 1977, SURGERY, V81, P551; Manolio T A, 1992, Ann Epidemiol, V2, P161, DOI 10.1016/1047-2797(92)90051-Q; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MCKENNA M, 1991, ATHEROSCLEROSIS, V87, P119, DOI 10.1016/0021-9150(91)90014-T; NEWMAN AB, 1991, J CLIN EPIDEMIOL, V44, P15, DOI 10.1016/0895-4356(91)90196-G; Prineas RJ, 1982, CIRCULATION, V65, p1561A; REUNANEN A, 1982, ACTA MED SCAND, V211, P249; SCHROLL M, 1981, J CHRON DIS, V34, P261, DOI 10.1016/0021-9681(81)90031-X; SILBERT S, 1958, JAMA-J AM MED ASSOC, V166, P1816, DOI 10.1001/jama.1958.02990150012002; STRANDNESS DE, 1991, PERIPHERAL VASCULAR, P39; VOGT MT, 1993, AM J EPIDEMIOL, V137, P559, DOI 10.1093/oxfordjournals.aje.a116709; [No title captured]; 1990, PHS901232 US DEP HLT; 1989, PHS891260 US DEP HLT	31	301	312	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1993	270	4					465	469		10.1001/jama.270.4.465	http://dx.doi.org/10.1001/jama.270.4.465			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN426	8320785				2022-12-01	WOS:A1993LN42600025
J	CLOS, J; RABINDRAN, S; WISNIEWSKI, J; WU, C				CLOS, J; RABINDRAN, S; WISNIEWSKI, J; WU, C			INDUCTION TEMPERATURE OF HUMAN HEAT-SHOCK FACTOR IS REPROGRAMMED IN A DROSOPHILA CELL ENVIRONMENT	NATURE			English	Article							BINDING	HEAT shock factor (HSF)1,2, the transcriptional activator of eukaryotic heat shock genes, is induced to bind DNA by a monomer to trimer transition involving leucine zipper interactions3,4. Although this mode of regulation is shared among many eukaryotic species, there is variation in the temperature at which HSF binding activity is induced. We investigated the basis of this variation by analysing the response of a human HSF expressed in Drosophila cells and Drosophila HSF expressed in human cells. We report here that the temperature that induces DNA binding and trimerization of human HSF in Drosophila was decreased by approximately 10-degrees-C to the induction temperature for the host cell, whereas Drosophila HSF expressed in human cells was constitutively active. The results indicate that the activity of HSF in vivo is not a simple function of the absolute environmental temperature.	NCI,BIOCHEM LAB,BLDG 37,RM 4C-09,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)								ABRAVAYA K, 1991, GENE DEV, V5, P2117, DOI 10.1101/gad.5.11.2117; ABRAVAYA K, 1992, GENE DEV, V6, P1153, DOI 10.1101/gad.6.7.1153; BALER R, 1992, J CELL BIOL, V117, P1151, DOI 10.1083/jcb.117.6.1151; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; CRAIG EA, 1991, TRENDS BIOCHEM SCI, V16, P135, DOI 10.1016/0968-0004(91)90055-Z; HIGHTOWER LE, 1991, CELL, V66, P191, DOI 10.1016/0092-8674(91)90611-2; LIS JT, 1992, TRANSCRIPTIONAL REGU, V2, P907; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RABINDRAN SK, 1993, SCIENCE, V259, P230, DOI 10.1126/science.8421783; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; TREUTER E, IN PRESS MOL GEN GEN; WESTWOOD JT, 1993, MOL CELL BIOL, V13, P3481, DOI 10.1128/MCB.13.6.3481; WESTWOOD JT, 1991, NATURE, V353, P822, DOI 10.1038/353822a0; ZIMARINO V, 1987, NATURE, V327, P727, DOI 10.1038/327727a0	16	75	75	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 15	1993	364	6434					252	255		10.1038/364252a0	http://dx.doi.org/10.1038/364252a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM683	8321322				2022-12-01	WOS:A1993LM68300062
J	DOVER, JS; ARNDT, KA				DOVER, JS; ARNDT, KA			DERMATOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, BOSTON, MA 02215 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	DOVER, JS (corresponding author), NEW ENGLAND DEACONESS HOSP, BOSTON, MA 02215 USA.							CAPEWELL S, 1990, BRIT MED J, V300, P1548, DOI 10.1136/bmj.300.6739.1548; DEMARCHI S, 1992, NEW ENGL J MED, V326, P969; GELLER A C, 1992, Morbidity and Mortality Weekly Report, V41, P20; KOH HK, 1992, J AM ACAD DERMATOL, V26, P914, DOI 10.1016/0190-9622(92)70132-Y; MCHENRY PM, 1992, BRIT MED J, V304, P746, DOI 10.1136/bmj.304.6829.746; OLERUD JE, 1992, ARCH DERMATOL, V128, P501, DOI 10.1001/archderm.128.4.501; PETZELBAUER P, 1992, BRIT J DERMATOL, V126, P542; SCHLAGHECKE R, 1992, NEW ENGL J MED, V326, P226, DOI 10.1056/NEJM199201233260403; SEPPALA H, 1992, NEW ENGL J MED, V326, P292, DOI 10.1056/NEJM199201303260503; SPRUANCE SL, 1991, J INFECT DIS, V163, P728, DOI 10.1093/infdis/163.4.728	10	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					197	198		10.1001/jama.270.2.197	http://dx.doi.org/10.1001/jama.270.2.197			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL368	8315728				2022-12-01	WOS:A1993LL36800014
J	KARP, JE; BRODER, S				KARP, JE; BRODER, S			ONCOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER; DISOMY				KARP, JE (corresponding author), NCI,BETHESDA,MD 20892, USA.							BROWN KW, 1992, CANCER GENET CYTOGEN, V58, P66, DOI 10.1016/0165-4608(92)90136-V; CATTANACH BM, 1992, NAT GENET, V2, P270, DOI 10.1038/ng1292-270; ENGEL E, 1980, AM J MED GENET, V6, P137, DOI 10.1002/ajmg.1320060207; FERGUSONSMITH AC, 1990, CANCER SURV, V9, P487; HAAS OA, 1992, NATURE, V359, P414, DOI 10.1038/359414a0; HENRY I, 1991, NATURE, V351, P665, DOI 10.1038/351665a0; Junien C, 1992, CURR OPIN GENET DEV, V2, P431, DOI 10.1016/S0959-437X(05)80154-6; KOUFOS A, 1989, AM J HUM GENET, V44, P711; LEFF SE, 1992, NAT GENET, V2, P259, DOI 10.1038/ng1292-259; MASCARI MJ, 1992, NEW ENGL J MED, V326, P1599, DOI 10.1056/NEJM199206113262404; MAW MA, 1992, CANCER RES, V52, P3094; OZCELIK T, 1992, NAT GENET, V2, P265, DOI 10.1038/ng1292-265; PING AJ, 1989, AM J HUM GENET, V44, P720; REIK W, 1989, TRENDS GENET, V5, P331, DOI 10.1016/0168-9525(89)90138-8; REIK W, 1992, NATURE, V359, P362, DOI 10.1038/359362a0; VILJOEN D, 1992, J MED GENET, V29, P221, DOI 10.1136/jmg.29.4.221	16	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					237	239		10.1001/jama.270.2.237	http://dx.doi.org/10.1001/jama.270.2.237			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315746				2022-12-01	WOS:A1993LL36800032
J	RUSSELL, RM				RUSSELL, RM			NUTRITION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											RUSSELL, RM (corresponding author), TUFTS UNIV,BOSTON,MA 02111, USA.							[Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; DONGWANG X, 1991, ARCH BIOCHEM BIOPHYS, V285, P8; GAZIANO JM, 1992, ANN NY ACAD SCI, V669, P249; GERSTER H, 1991, INT J VITAM NUTR RES, V61, P277; JANERO DR, 1991, FREE RADICAL BIO MED, V11, P129, DOI 10.1016/0891-5849(91)90193-7; LEE IM, 1992, JAMA-J AM MED ASSOC, V268, P2045, DOI 10.1001/jama.268.15.2045; LEHMANN JM, 1992, SCIENCE, V258, P1944, DOI 10.1126/science.1335166; LICHTMAN SW, 1992, NEW ENGL J MED, V327, P1893, DOI 10.1056/NEJM199212313272701; PALOZZA P, 1992, ARCH BIOCHEM BIOPHYS, V297, P184, DOI 10.1016/0003-9861(92)90658-J; RIMM EB, 1993, NEW ENGL J MED, V328, P1450, DOI 10.1056/NEJM199305203282004; RUSSELL RM, IN PRESS AM J CLIN N; STAMPFER MJ, 1993, NEW ENGL J MED, V328, P1444, DOI 10.1056/NEJM199305203282003; STAMPFER MJ, 1992, JAMA-J AM MED ASSOC, V268, P877, DOI 10.1001/jama.268.7.877; SUTER PM, 1992, NEW ENGL J MED, V326, P983, DOI 10.1056/NEJM199204093261503; WERLER MM, 1993, JAMA-J AM MED ASSOC, V269, P1257, DOI 10.1001/jama.269.10.1257; 1991, LANCET, V336, P131; 1992, NUTR REV, V50, P340	18	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					233	234		10.1001/jama.270.2.233	http://dx.doi.org/10.1001/jama.270.2.233			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315744				2022-12-01	WOS:A1993LL36800030
J	HANSEN, RS; CANFIELD, TK; LAMB, MM; GARTLER, SM; LAIRD, CD				HANSEN, RS; CANFIELD, TK; LAMB, MM; GARTLER, SM; LAIRD, CD			ASSOCIATION OF FRAGILE-X SYNDROME WITH DELAYED REPLICATION OF THE FMR1 GENE	CELL			English	Article							MAMMALIAN-CELLS; CPG ISLAND; DNA-REPLICATION; REGION; EXPRESSION; METHYLATION; SEQUENCES; LOCUS; DEMETHYLATION; INSTABILITY	The fragile X syndrome is commonly associated with mutant alleles of the FMR1 gene that are hypermethylated and have large expansions of CGG repeats. We present data here on the replication timing of FMR1 that confirm predictions of delayed replication of alleles from affected males. The normal FMR1 allele replicates late in S phase, while alleles from affected males replicate later, the major peak of replication occurring in the flow cytometry fraction usually referred to as G2/M. The delayed timing of replication is not the direct result of a single replication fork stalling at the expanded CGG repeat, because delayed replication was observed for regions on both sides of the repeat. The domain of altered replication timing includes sites at least 150 kb 5' and 34 kb 3' of the repeat, indicating that genes in addition to FMR1 may be affected.	UNIV WASHINGTON,DEPT ZOOL,SEATTLE,WA 98195; UNIV WASHINGTON,DEPT GENET,SEATTLE,WA 98195; FRED HUTCHINSON CANC RES CTR,PROGRAM MOLEC MED,SEATTLE,WA 98104	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; Fred Hutchinson Cancer Center	HANSEN, RS (corresponding author), UNIV WASHINGTON,DEPT MED,SEATTLE,WA 98195, USA.				NICHD NIH HHS [HD16659] Funding Source: Medline; NIGMS NIH HHS [GM19179] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD016659, R01HD016659] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ATKINS L, 1962, J CELL BIOL, V15, P390, DOI 10.1083/jcb.15.2.390; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; BROWN EH, 1987, MOL CELL BIOL, V7, P450, DOI 10.1128/MCB.7.1.450; CLARKE A, 1992, AM J MED GENET, V43, P299, DOI 10.1002/ajmg.1320430146; COLLINS M, 1987, J MOL BIOL, V198, P737, DOI 10.1016/0022-2836(87)90214-2; DHAR V, 1989, MOL CELL BIOL, V9, P3524, DOI 10.1128/MCB.9.8.3524; DIETRICH A, 1991, NUCLEIC ACIDS RES, V19, P2567, DOI 10.1093/nar/19.10.2567; ERSTER SH, 1992, HUM GENET, V90, P55; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; FURST A, 1981, P NATL ACAD SCI-BIOL, V78, P1023, DOI 10.1073/pnas.78.2.1023; GALE JM, 1992, J MOL BIOL, V224, P343, DOI 10.1016/0022-2836(92)90999-Z; Gartler S M, 1992, Mol Genet Med, V2, P121; GILBERT DM, 1987, CELL, V50, P59, DOI 10.1016/0092-8674(87)90662-3; GOLDMAN MA, 1984, SCIENCE, V224, P686, DOI 10.1126/science.6719109; GOLDMAN MA, 1988, BIOESSAYS, V9, P50, DOI 10.1002/bies.950090204; HANSEN RS, 1990, P NATL ACAD SCI USA, V87, P4174, DOI 10.1073/pnas.87.11.4174; HANSEN RS, 1988, MOL CELL BIOL, V8, P4692, DOI 10.1128/MCB.8.11.4692; HANSEN RS, 1992, HUM MOL GENET, V1, P571, DOI 10.1093/hmg/1.8.571; HATTON KS, 1990, MOL CELL BIOL, V10, P4314, DOI 10.1128/MCB.10.8.4314; HATTON KS, 1988, MOL CELL BIOL, V8, P2149, DOI 10.1128/MCB.8.5.2149; HEITZ D, 1991, SCIENCE, V251, P1236, DOI 10.1126/science.2006411; HEITZ D, 1992, J MED GENET, V29, P794, DOI 10.1136/jmg.29.11.794; HINDS HL, 1993, NAT GENET, V3, P36, DOI 10.1038/ng0193-36; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LAIRD C, 1987, TRENDS GENET, V3, P274, DOI 10.1016/0168-9525(87)90268-X; LAIRD CD, 1987, GENETICS, V117, P587; LIMADEFARIA A, 1961, CANCER GENET CYTOGEN, V3, P171; LOESCH DZ, 1992, AM J MED GENET, V44, P543, DOI 10.1002/ajmg.1320440502; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; OPSTELTEN RJG, 1989, CHROMOSOMA, V98, P422, DOI 10.1007/BF00292787; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; REIK W, 1990, DEVELOPMENT S, V90, P99; RIGGINS GJ, 1992, AM J MED GENET, V43, P237, DOI 10.1002/ajmg.1320430138; ROSENSTRAUS M, 1975, P NATL ACAD SCI USA, V72, P493, DOI 10.1073/pnas.72.2.493; SASAKI H, 1991, DEVELOPMENT, V111, P573; SCHMIDT M, 1990, P NATL ACAD SCI USA, V87, P3685, DOI 10.1073/pnas.87.10.3685; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; SPACK EG, 1992, MOL CELL BIOL, V12, P5174, DOI 10.1128/MCB.12.11.5174; Sutcliffe James S., 1992, Human Molecular Genetics, V1, P397, DOI 10.1093/hmg/1.6.397; TAYLOR JH, 1960, J BIOPHYS BIOCHEM CY, V7, P455, DOI 10.1083/jcb.7.3.455; TENHAGEN KG, 1990, MOL CELL BIOL, V10, P6348, DOI 10.1128/MCB.10.12.6348; VASSILEV LT, 1990, MOL CELL BIOL, V10, P4685, DOI 10.1128/MCB.10.9.4685; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WARBURTON PE, 1991, GENOMICS, V11, P324, DOI 10.1016/0888-7543(91)90139-6; WEBB T, 1992, AM J MED GENET, V43, P1057, DOI 10.1002/ajmg.1320430633; YU S, 1992, AM J HUM GENET, V50, P968; YU WD, 1990, HUM GENET, V85, P590	52	214	218	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 2	1993	73	7					1403	1409		10.1016/0092-8674(93)90365-W	http://dx.doi.org/10.1016/0092-8674(93)90365-W			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	LL209	8324827	Bronze			2022-12-01	WOS:A1993LL20900014
J	SILAGY, C; MUIR, J; COULTER, A; THOROGOOD, M; ROE, L				SILAGY, C; MUIR, J; COULTER, A; THOROGOOD, M; ROE, L			CARDIOVASCULAR RISK AND ATTITUDES TO LIFE-STYLE - WHAT DO PATIENTS THINK	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine the relation between subjects' level of cardiovascular risk and their beliefs about the harmfulness of their smoking habit, current diet, and level of exercise, together with their stated desire to modify such behaviour. Design-Self administered postal health and life-style questionnaire followed by a structured health check conducted by a nurse. Setting-Five general practices in Luton and Dunstable, Bedfordshire. Subjects-5803 people aged 35-64 years enrolled in the OXCHECK trial who attended for a health check before 1 March 1992. Main outcome measures-Perceived risk to health of lifestyle behaviours, desire to modify behaviour, and a reported serious attempt to modify behaviour in the preceding year. Results-A high proportion of smokers and those who were physically inactive perceived their behaviour to be harmful (1020; (76%; 95% confidence interval 74% to 79%) and 350 (74%; 70% to 78%) respectively) and wished to modify it (1212 (79%; 77% to 81%) and 375 (74%; 71% to 78%) respectively). In contrast, only 289 (45%; 41% to 48%) of obese people and 188 (14%; 12% to 16%) of people with a high dietary fat intake perceived their current diet to be harmful. The more cardiovascular risk factors present, the more likely subjects were to perceive a health risk attached to their diet and lack of exercise (p < 0.01 in both cases) and to want to improve their diet. Conclusion-Awareness of the health risk from smoking and motivation to stop is high. Further efforts are required, however, to educate the public about the risks associated with a high dietary fat intake. Although the health risks of inactivity were widely recognised, motivation to take more exercise needs to be increased.	RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,HLTH SERV RES UNIT,OXFORD OX2 6HE,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT PUBL HLTH & POLICY,HLTH PROMOT SCI UNIT,LONDON WC1E 7HT,ENGLAND	Radcliffe Infirmary; University of Oxford; University of London; London School of Hygiene & Tropical Medicine	SILAGY, C (corresponding author), UNIV OXFORD,RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX2 6HE,ENGLAND.		Coulter, Angela/N-6998-2019	Coulter, Angela/0000-0002-6308-8375				Anderson K, 1990, AM HEART J, V121, P293; [Anonymous], 1980, CLASSIFICATION OCCUP; ARMITAGE P, 1987, STATISTICAL METHODS, P372; COULTER A, 1987, J ROY COLL GEN PRACT, V37, P533; JAMROZIK K, 1984, BRIT MED J, V288, P1499, DOI 10.1136/bmj.288.6429.1499; KANNEL WB, 1987, AM HEART J, V114, P213, DOI 10.1016/0002-8703(87)90964-1; KEYS A, 1986, AM J EPIDEMIOL, V124, P903, DOI 10.1093/oxfordjournals.aje.a114480; MANSON JE, 1992, NEW ENGL J MED, V326, P1406, DOI 10.1056/NEJM199205213262107; Prochaska JO, 1986, TREATING ADDICTIVE B, P3, DOI DOI 10.1007/978-1-4613-2191-0_; SILAGY C, 1992, BRIT MED J, V305, P871, DOI 10.1136/bmj.305.6858.871; THOROGOOD M, 1992, WOMENS HLTH MATTERS; TUCKETT D, 1985, M EXPERTS APPROACH S, P173; 1993, NEW HLTH PROMOTION P; [No title captured]; 1991, BMJ, V302, P1057; 1991, 41 COMM MED ASP FOOD	16	48	49	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1993	306	6893					1657	1660		10.1136/bmj.306.6893.1657	http://dx.doi.org/10.1136/bmj.306.6893.1657			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ337	8324437	Bronze, Green Published			2022-12-01	WOS:A1993LJ33700025
J	KOTLOFF, KL; JOHNSON, JP; NAIR, P; HICKMAN, D; LIPPINCOTT, P; WILSON, PD; CLEMENS, JD				KOTLOFF, KL; JOHNSON, JP; NAIR, P; HICKMAN, D; LIPPINCOTT, P; WILSON, PD; CLEMENS, JD			DIARRHEAL MORBIDITY DURING THE 1ST 2 YEARS OF LIFE AMONG HIV-INFECTED INFANTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; LONGITUDINAL DATA-ANALYSIS; PERSISTENT DIARRHEA; SYNDROME AIDS; VIRUS TYPE-1; CHILDREN; WOMEN; ENTEROPATHY; COMMUNITY; PATTERNS	Objective.-To determine the incidence, cause, and patterns of diarrhea during the first 2 years of life among infants infected perinatally with the human immunodeficiency virus (HIV). Design.-A cohort study in which infants were enrolled shortly after birth and followed up longitudinally using biweekly surveillance for the occurrence of diarrhea. Stool specimens collected at the onset of diarrhea were evaluated for enteropathogens. Infants who were infected with HIV were compared with uninfected infants. Subjects.-Infants born to HIV-infected women at the University of Maryland Hospital, Baltimore, were recruited at 0 to 3 months of age. This analysis included 58 infants enrolled in the cohort and followed up at least 15 months (unless death intervened) whose HIV status was established (18 HIV-infected infants and 40 HIV-uninfected infants). Measurements and Results.-The overall incidence of diarrhea in HIV-infected infants was 3.2 episodes per 12 child-months compared with 1.5 episodes per 12 child-months among HIV-uninfected infants (incidence density ratio, 2.2; P<.05). An enteropathogen was identified in stool specimens collected during 20% of diarrheal episodes occurring in HIV-infected infants and during 25% of diarrheal episodes occurring in HIV-uninfected infants. Episodes that persisted tor 14 days or longer were significantly more common among HIV-infected infants. The peak incidence of diarrhea occurred at 0 to 5 months of age for HIV-infected infants compared with 6 to 11 months for HIV-uninfected infants. Early onset of diarrhea (<6 months old) in HIV-infected infants was associated with the later development of persistent episodes of diarrhea, and those with persistent episodes had more severe HIV infection, characterized by a significantly higher frequency of opportunistic infections and lower CD4+ T-lymphocyte counts by 1 year of age. Conclusions.-Both acute and persistent episodes of diarrhea are major sources of morbidity in HIV-infected infants. Moreover, persistent diarrhea is a marker for rapid progression of HIV disease.	UNIV MARYLAND,SCH MED,DIV INFECT DIS,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DIV TROP PEDIAT,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DIV PEDIAT IMMUNOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DIV PEDIAT EDUC,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT EPIDEMIOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,DEPT PREVENT MED,BALTIMORE,MD 21201; NICHHD,EPIDEMIOL BRANCH,BETHESDA,MD 20892	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	KOTLOFF, KL (corresponding author), UNIV MARYLAND,SCH MED,CTR VACCINE DEV,10 S PINE ST,BALTIMORE,MD 21201, USA.		kotloff, karen l/E-7768-2012	kotloff, karen l/0000-0003-1808-6431	NICHD NIH HHS [1R01 HD26691] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD026691] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Balows A, 1991, MANUAL CLIN MICROBIO; CRAVIOTO A, 1991, LANCET, V337, P262, DOI 10.1016/0140-6736(91)90868-P; DWORKIN B, 1985, AM J GASTROENTEROL, V80, P774; GILLIN JS, 1985, ANN INTERN MED, V102, P619, DOI 10.7326/0003-4819-102-5-619; GREENSON JK, 1991, ANN INTERN MED, V114, P366, DOI 10.7326/0003-4819-114-5-366; GURWITH M, 1981, J INFECT DIS, V144, P218, DOI 10.1093/infdis/144.3.218; JOHANSON JF, 1990, ANN INTERN MED, V112, P942, DOI 10.7326/0003-4819-112-12-942; JOHNSON JP, 1989, AM J DIS CHILD, V143, P1147, DOI 10.1001/archpedi.1989.02150220037017; KOOPMAN JS, 1984, AM J EPIDEMIOL, V119, P114, DOI 10.1093/oxfordjournals.aje.a113712; KOSTER FT, 1987, AM J CLIN NUTR, V46, P115, DOI 10.1093/ajcn/46.1.115; KOTLER DP, 1984, ANN INTERN MED, V101, P421, DOI 10.7326/0003-4819-101-4-421; KOTLER DP, 1985, AM J CLIN NUTR, V42, P1255, DOI 10.1093/ajcn/42.6.1255; KRASINSKI K, 1989, PEDIATR INFECT DIS J, V8, P216; LANATA CF, 1991, J PEDIATR GASTR NUTR, V12, P82, DOI 10.1097/00005176-199101000-00017; LAUGHON BE, 1988, GASTROENTEROLOGY, V94, P984, DOI 10.1016/0016-5085(88)90557-4; LIANG KY, 1986, BIOMETRIKA, V73, P13, DOI 10.2307/2336267; LIMA AAM, 1992, EPIDEMIOL REV, V14, P222, DOI 10.1093/oxfordjournals.epirev.a036088; LINDAN CP, 1992, ANN INTERN MED, V116, P320, DOI 10.7326/0003-4819-116-4-320; MONTO AS, 1983, J INFECT DIS, V148, P284, DOI 10.1093/infdis/148.2.284; OLESKE J, 1983, JAMA-J AM MED ASSOC, V249, P2345, DOI 10.1001/jama.249.17.2345; ROGERS MF, 1987, PEDIATRICS, V79, P1008; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SALISBURY FT, 1980, J PEDIATR, V97, P61; SCOTT GB, 1984, NEW ENGL J MED, V310, P76, DOI 10.1056/NEJM198401123100202; SCOTT GB, 1989, NEW ENGL J MED, V321, P1791, DOI 10.1056/NEJM198912283212604; SHADID NS, 1988, BRIT MED J, V297, P1096; SMITH PD, 1988, ANN INTERN MED, V108, P328, DOI 10.7326/0003-4819-108-3-328; THOMAS JC, 1992, INT J EPIDEMIOL, V21, P589, DOI 10.1093/ije/21.3.589; ULLRICH R, 1989, ANN INTERN MED, V111, P1; WALKER BD, 1990, BASIC VIROLOGIC TECH, P57; YOLKEN RH, 1991, J INFECT DIS, V164, P61, DOI 10.1093/infdis/164.1.64; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248; 1987, MMWR MORB MORTAL WKL, V36, P224; 1988, LANCET, V1, P1043	34	20	20	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	1994	271	6					448	452		10.1001/jama.271.6.448	http://dx.doi.org/10.1001/jama.271.6.448			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU491	8295320				2022-12-01	WOS:A1994MU49100032
J	LIEU, TA; COCHI, SL; BLACK, SB; HALLORAN, ME; SHINEFIELD, HR; HOLMES, SJ; WHARTON, M; WASHINGTON, AE				LIEU, TA; COCHI, SL; BLACK, SB; HALLORAN, ME; SHINEFIELD, HR; HOLMES, SJ; WHARTON, M; WASHINGTON, AE			COST-EFFECTIVENESS OF A ROUTINE VARICELLA VACCINATION PROGRAM FOR UNITED-STATES CHILDREN	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HEALTHY-CHILDREN; ACYCLOVIR TREATMENT; IMMUNIZATION; CHICKENPOX; ZOSTER; LEUKEMIA; COMPLICATIONS; ADOLESCENTS; EFFICACY; BENEFITS	Objective.-To evaluate the economic consequences of a routine varicella vaccination program that targets healthy children, Methods.-Decision analysis was used to compare the costs, outcomes, and cost-effectiveness of a routine vaccination program with no intervention. Clinical outcomes were based on a mathematical model of vaccine efficacy that relied on published and unpublished data and on expert opinion. Medical utilization rates and costs were collected from multiple sources, including the Kaiser Permanente Medical Care Program and the California Hospital Discharge Database. Results.-A routine varicella vaccination program for healthy children would prevent 94% of all potential cases of chickenpox, provided the vaccination coverage rate is 97% at school entry. lt would cost approximately $162 million annually if one dose of vaccine per child were recommended at a cost of $35 per dose. From the societal perspective, which includes work-loss costs as well as medical costs, the program would save more than $5 for every dollar invested in vaccination. However, from the health care payer's perspective (medical costs only), the program would cost approximately $2 per chickenpox case prevented, or $2500 per life-year saved. The medical cost of disease prevention was sensitive to the vaccination coverage rate and vaccine price but was relatively insensitive to assumptions about vaccine efficacy within plausible ranges. An additional program for catch-up vaccination of 12-year-olds would have high incremental costs if the vaccination coverage rate of children of preschool age were 97%, but would result in net savings at a coverage rate of 50%. Conclusions.-A routine varicella vaccination program for healthy children would result in net savings from the societal perspective, which includes work-loss costs as well as medical costs. Compared with other prevention programs, it would also be relatively cost-effective from the health care payers perspective.	UNIV CALIF SAN FRANCISCO,ROBERT WOOD JOHNSON CLIN SCHOLARS PROGRAM,SAN FRANCISCO,CA 94143; CTR DIS CONTROL & PREVENT,NATL IMMUNIZAT PROGRAM,SURVEILLANCE INVEST & RES BRANCH,ATLANTA,GA; KAISER PERMANENTE PEDIAT VACCINE STUDY CTR,OAKLAND,CA; UNIV CALIF SAN FRANCISCO,DEPT PEDIAT,DIV GEN PEDIAT,SAN FRANCISCO,CA 94143; EMORY UNIV,SCH PUBL HLTH,DIV BIOSTAT,ATLANTA,GA 30322; UNIV CALIF SAN FRANCISCO,DEPT OBSTET GYNECOL & REPROD SCI,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,MEDTEP RES CTR MINOR POPULAT,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; Centers for Disease Control & Prevention - USA; Kaiser Permanente; University of California System; University of California San Francisco; Emory University; University of California System; University of California San Francisco; University of California System; University of California San Francisco	LIEU, TA (corresponding author), PERMANENTE MED GRP INC,DIV RES,3451 PIEDMONT AVE,OAKLAND,CA 94611, USA.							ARBETER AM, 1986, PEDIATRICS, V78, P748; ASANO Y, 1985, PEDIATRICS, V75, P667; BALFOUR HH, 1990, J PEDIATR-US, V116, P633, DOI 10.1016/S0022-3476(05)81618-X; BALFOUR HH, 1992, J PEDIATR-US, V120, P627, DOI 10.1016/S0022-3476(05)82495-3; BLOOM BS, 1993, ANN INTERN MED, V118, P298, DOI 10.7326/0003-4819-118-4-199302150-00009; BRUNELL PA, 1986, PEDIATRICS, V77, P53; COCHI SL, 1988, AM J DIS CHILD, V142, P499, DOI 10.1001/archpedi.1988.02150050037025; COCHI SL, 1985, JAMA-J AM MED ASSOC, V253, P521, DOI 10.1001/jama.253.4.521; CUTTS FT, 1992, JAMA-J AM MED ASSOC, V267, P1952, DOI 10.1001/jama.267.14.1952; DUNKLE LM, 1991, NEW ENGL J MED, V325, P1539, DOI 10.1056/NEJM199111283252203; FLEISHER G, 1981, AM J DIS CHILD, V135, P896, DOI 10.1001/archpedi.1981.02130340008004; GRABOWSKY M, 1991, J INFECT DIS, V164, P1237, DOI 10.1093/infdis/164.6.1237; GUESS HA, 1984, AM J DIS CHILD, V138, P1055, DOI 10.1001/archpedi.1984.02140490055013; HALLORAN ME, IN PRESS MATH BIOSCI; HARDY I, 1991, NEW ENGL J MED, V325, P1545, DOI 10.1056/NEJM199111283252204; HAY JW, 1990, PEDIATR INFECT DIS J, V9, P246, DOI 10.1097/00006454-199004000-00005; HINMAN AR, 1984, JAMA-J AM MED ASSOC, V251, P3109, DOI 10.1001/jama.251.23.3109; JACKSON MA, 1992, PEDIATR INFECT DIS J, V11, P441, DOI 10.1097/00006454-199206000-00004; JOHNSON CD, 1992, PEDIATR RES 2, V31, P165; KELLEY PW, 1991, JAMA-J AM MED ASSOC, V266, P2724, DOI 10.1001/jama.266.19.2724; KINOSIAN BP, 1988, JAMA-J AM MED ASSOC, V259, P2249, DOI 10.1001/jama.259.15.2249; KUTER BJ, 1991, VACCINE, V9, P643, DOI 10.1016/0264-410X(91)90189-D; LAWRENCE R, 1988, NEW ENGL J MED, V318, P543, DOI 10.1056/NEJM198803033180904; LIEU TA, IN PRESS PEDIATR INF; LITTENBERG B, 1990, ANN INTERN MED, V112, P192, DOI 10.7326/0003-4819-112-3-192; OSTER G, 1986, JAMA-J AM MED ASSOC, V256, P1315, DOI 10.1001/jama.256.10.1315; PLOTKIN SA, 1989, J INFECT DIS, V159, P1000, DOI 10.1093/infdis/159.5.1000; PREBLUD SR, 1985, POSTGRAD MED J, V61, P17; PREBLUD SR, 1986, PEDIATRICS S, V78, P738; SISK JE, 1986, ANN INTERN MED, V104, P79, DOI 10.7326/0003-4819-104-1-79; SULLIVANBOLYAI JZ, 1987, PEDIATR INFECT DIS J, V6, P33, DOI 10.1097/00006454-198701000-00009; WAGNER JL, 1991, ANN INTERN MED, V115, P807, DOI 10.7326/0003-4819-115-10-807; WATSON BM, 1993, PEDIATRICS, V91, P17; WEIBEL RE, 1984, NEW ENGL J MED, V310, P1409, DOI 10.1056/NEJM198405313102201; WHARTON M, 1990, 30TH INT C ANT AG CH; WHITE CC, 1985, AM J PUBLIC HEALTH, V75, P739, DOI 10.2105/AJPH.75.7.739; WHITE CJ, 1992, PEDIATR INFECT DIS J, V11, P19, DOI 10.1097/00006454-199201000-00006; WHITE CJ, 1991, PEDIATRICS, V87, P604; 1992, 1990 DISCHARGE DATA; 1988, OTAH345 US C OFF TEC; 1993, COST EFFECTIVENESS V	41	311	319	1	23	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	1994	271	5					375	381		10.1001/jama.271.5.375	http://dx.doi.org/10.1001/jama.271.5.375			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR983	8283587				2022-12-01	WOS:A1994MR98300033
J	SHORR, RI; FOUGHT, RL; RAY, WA				SHORR, RI; FOUGHT, RL; RAY, WA			CHANGES IN ANTIPSYCHOTIC DRUG-USE IN NURSING-HOMES DURING IMPLEMENTATION OF THE OBRA-87 REGULATIONS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PSYCHOACTIVE-DRUGS; IMPACT; RESIDENTS; MEDICARE; QUALITY; CARE; RISK	Objectives.-To describe the changes in antipsychotic drug use in nursing homes during the period surrounding the implementation of federal legislation designed to reduce unnecessary use (the Omnibus Budget Reconciliation Act of 1987 [OBRA-87]) and to identify nursing home characteristics associated with such changes. Design.-Longitudinal study of 9432 Tennessee Medicaid enrollees 65 years of age or older who continuously resided in Tennessee from April 1, 1989, to September 30,1991, a 30-month period surrounding implementation of OBRA-87. Main Outcome Measures.-Changes in the use of antipsychotic and other psychotropic drugs. Results.-During the 30-month period, antipsychotic drug use decreased from 23.9 to 17.5 days per 100 days of residence, a 26.7% decline (P<.001), which resulted from both a decrease in new users (P<.001) and a reduction in long-term use of antipsychotic drugs (P<.001). There was no concomitant increase in other psychotropic drug use. A multivariate analysis revealed that changes in antipsychotic use were strongly associated with baseline antipsychotic use (P=.001) and third-shift staffing levels (P=.003). Nursing homes with baseline antipsychotic drug use and third-shift staffing above the median reduced antipsychotic drug use by 41%, compared with a 2% increase in nursing homes where both of these factors were below the median (P<.0001). Conclusions.-A substantial decrease in antipsychotic drug use coincided with the implementation of OBRA-87. Although this decrease is consistent with an improvement in quality of nursing home care, further research is needed to determine the effects of this legislation on resident outcomes.			SHORR, RI (corresponding author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT PREVENT MED,DIV PHARMACOEPIDEMIOL,NASHVILLE,TN 37232, USA.				PHS HHS [K08-00559] Funding Source: Medline; FDA HHS [FD-U-000073] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); FDA HHS		AVORN J, 1992, NEW ENGL J MED, V327, P168, DOI 10.1056/NEJM199207163270306; BALDESSARINI RJ, 1985, GOODMAN GILMANS PHAR, P387; BEARDSLEY RS, 1989, J AM GERIATR SOC, V37, P327, DOI 10.1111/j.1532-5415.1989.tb05499.x; BEERS M, 1988, JAMA-J AM MED ASSOC, V260, P3016, DOI 10.1001/jama.260.20.3016; BRAUN BI, 1991, J AM GERIATR SOC, V39, P329, DOI 10.1111/j.1532-5415.1991.tb02896.x; BUCK JA, 1988, J AM GERIATR SOC, V36, P409, DOI 10.1111/j.1532-5415.1988.tb02379.x; BURKE WJ, 1991, AM FAM PHYSICIAN, V43, P2125; DOANE KW, 1989, CONSULTANT PHARM, V4, P367; DRAPER NR, 1981, APPLIED REGRESSION A; ELON R, 1992, J AM GERIATR SOC, V40, P958, DOI 10.1111/j.1532-5415.1992.tb01996.x; GARRARD J, 1992, J GERONTOL, V47, pM183, DOI 10.1093/geronj/47.6.M183; GARRARD J, 1991, JAMA-J AM MED ASSOC, V265, P463, DOI 10.1001/jama.265.4.463; GURWITZ JH, 1990, J AM GERIATR SOC, V38, P542, DOI 10.1111/j.1532-5415.1990.tb02406.x; KATZ IR, 1992, NEW ENGL J MED, V327, P1392; KIDDER SW, 1987, CONSULT PHARM, V2, P394; LINN MW, 1977, AM J PUBLIC HEALTH, V67, P337, DOI 10.2105/AJPH.67.4.337; LYLES YM, 1986, J AM GERIATR SOC, V34, P573, DOI 10.1111/j.1532-5415.1986.tb05762.x; NEEL AB, 1993, CONSULT PHARM, V8, P245; PIES R, 1992, NEW ENGL J MED, V327, P1392; RAY WA, 1993, ARCH INTERN MED, V153, P713, DOI 10.1001/archinte.153.6.713; RAY WA, 1989, AM J EPIDEMIOL, V129, P837, DOI 10.1093/oxfordjournals.aje.a115198; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; RAY WA, 1980, AM J PUBLIC HEALTH, V70, P485, DOI 10.2105/AJPH.70.5.485; ROVNER BW, 1992, AM J PSYCHIAT, V149, P1390; SAGER MA, 1989, NEW ENGL J MED, V320, P433, DOI 10.1056/NEJM198902163200705; SALZMAN C, 1987, PSYCHOPHARMACOLOGY 3, P1167; SCHNEIDER LS, 1990, J AM GERIATR SOC, V38, P553, DOI 10.1111/j.1532-5415.1990.tb02407.x; Spector W D, 1991, J Aging Health, V3, P427, DOI 10.1177/089826439100300401; STERNBERG J, 1990, Journal of Geriatric Drug Therapy, V4, P47; SVARSTAD BL, 1991, J AM GERIATR SOC, V39, P869, DOI 10.1111/j.1532-5415.1991.tb04453.x; TINETTI ME, 1986, AM J MED, V80, P429, DOI 10.1016/0002-9343(86)90717-5; WINOGRAD CH, 1991, J AM GERIATR SOC, V39, P724, DOI 10.1111/j.1532-5415.1991.tb03629.x; WOLLSTADT LJ, 1992, CLIN RES, V40, pA575; 1989, SAS STAT USERS GUIDE, P890; 1992, J AM GERIATR SOC, V40, P946	35	153	154	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	1994	271	5					358	362						5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MR983	8283585				2022-12-01	WOS:A1994MR98300030
J	NOCTON, JJ; DRESSLER, F; RUTLEDGE, BJ; RYS, PN; PERSING, DH; STEERE, AC				NOCTON, JJ; DRESSLER, F; RUTLEDGE, BJ; RYS, PN; PERSING, DH; STEERE, AC			DETECTION OF BORRELIA-BURGDORFERI DNA BY POLYMERASE CHAIN-REACTION IN SYNOVIAL-FLUID FROM PATIENTS WITH LYME ARTHRITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							IXODES-DAMMINI TICKS; CEREBROSPINAL-FLUID; RHEUMATOID-ARTHRITIS; DISEASE SPIROCHETE; SKIN BIOPSIES; JOINT FLUID; DIAGNOSIS; AMPLIFICATION; INFECTION; NEUROBORRELIOSIS	Background. Borrelia burgdorferi is difficult to detect in synovial fluid, which limits our understanding of the pathogenesis of Lyme arthritis, particularly when arthritis persists despite antibiotic therapy. Methods. Using the polymerase chain reaction (PCR), we attempted to detect B. burgdorferi DNA in joint-fluid samples obtained over a 17-year period. The samples were tested in two separate laboratories with four sets of primers and probes, three of which target plasmid DNA that encodes outer-surface protein A (OspA). Results. B. burgdorferi DNA was detected in 75 of 88 patients with Lyme arthritis (85 percent) and in none of 64 control patients. Each of the three OspA primer-probe sets was sensitive, and the results were moderately concordant in the two laboratories (kappa = 0.54 to 0.73). Of 73 patients with Lyme arthritis that was untreated or treated with only short courses of oral antibiotics, 70 (96 percent) had positive PCR results. In contrast, of 19 patients who received either parenteral antibiotics or long courses of oral antibiotics (greater-than-or-equal-to 1 month), only 7 (37 percent) had positive tests (P<0.001). None of these seven patients had received more than two months of oral antibiotic treatment or more than three weeks of intravenous antibiotic treatment. Of 10 patients with chronic arthritis (continuous joint inflammation for one year or more) despite multiple courses of antibiotics, 7 had consistently negative tests in samples obtained three months to two years after treatment. Conclusions. PCR testing can detect B. burgdorferi DNA in synovial fluid. This test may be able to show whether Lyme arthritis that persists after antibiotic treatment is due to persistence of the spirochete.	TUFTS UNIV NEW ENGLAND MED CTR,DEPT PEDIAT RHEUMATOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,BOSTON,MA 02111; MAYO CLIN & MAYO FDN,CLIN MICROBIOL SECT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,INFECT DIS SECT,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,EXPTL PATHOL SECT,ROCHESTER,MN 55905	Tufts Medical Center; Tufts University; Mayo Clinic; Mayo Clinic; Mayo Clinic	NOCTON, JJ (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR,DIV RHEUMATOL IMMUNOL,750 WASHINGTON ST,BOSTON,MA 02111, USA.			Steere, Allen/0000-0002-5268-9853; Nocton, James/0000-0003-3560-6099	NIAMS NIH HHS [AR-20358, AR-07570, AR-40576] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007570, R01AR040576, R01AR020358] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AURELIUS E, 1991, LANCET, V337, P189, DOI 10.1016/0140-6736(91)92155-U; BERGER BW, 1985, J AM ACAD DERMATOL, V13, P444, DOI 10.1016/S0190-9622(85)70187-9; BERGSTROM S, 1992, RES MICROBIOL, V143, P623, DOI 10.1016/0923-2508(92)90120-D; CIMINO GD, 1991, NUCLEIC ACIDS RES, V19, P99, DOI 10.1093/nar/19.1.99; DATTWYLER RJ, 1988, LANCET, V1, P1191; GARON CF, 1989, SCANNING MICROSCOPY, V3, P109; GOODMAN JL, 1991, INFECT IMMUN, V59, P269, DOI 10.1128/IAI.59.1.269-278.1991; GUY EC, 1991, J CLIN PATHOL, V44, P610, DOI 10.1136/jcp.44.7.610; HOLODNIY M, 1991, J CLIN MICROBIOL, V29, P676, DOI 10.1128/JCM.29.4.676-679.1991; JAULHAC B, 1991, NEW ENGL J MED, V324, P1440; KALISH RA, 1993, INFECT IMMUN, V61, P2774, DOI 10.1128/IAI.61.7.2774-2779.1993; KELLER TL, 1992, NEUROLOGY, V42, P32, DOI 10.1212/WNL.42.1.32; KRUGER WH, 1991, J MED MICROBIOL, V35, P98, DOI 10.1099/00222615-35-2-98; LEBECH AM, 1991, J CLIN MICROBIOL, V29, P731, DOI 10.1128/JCM.29.4.731-737.1991; LEBECH AM, 1992, J CLIN MICROBIOL, V30, P1646, DOI 10.1128/JCM.30.7.1646-1653.1992; LIEBLING MR, 1993, ARTHRITIS RHEUM-US, V36, P665, DOI 10.1002/art.1780360514; LUFT BJ, 1992, JAMA-J AM MED ASSOC, V267, P1364, DOI 10.1001/jama.267.10.1364; LUFT BJ, 1992, JAMA-J AM MED ASSOC, V268, P872; MALAWISTA SE, 1992, ARTHRITIS RHEUM, V35, P246, DOI 10.1002/art.1780350220; MALLOY DC, 1990, J CLIN MICROBIOL, V28, P1089, DOI 10.1128/JCM.28.6.1089-1093.1990; MELCHERS W, 1991, J CLIN MICROBIOL, V29, P2401, DOI 10.1128/JCM.29.11.2401-2406.1991; NIELSEN SL, 1990, CLIN RES, V38, pA402; NIELSEN SL, 1990, MOL CELL PROBE, V4, P73, DOI 10.1016/0890-8508(90)90041-W; PERSING DH, 1990, SCIENCE, V249, P1420, DOI 10.1126/science.2402635; PERSING DH, 1990, J CLIN MICROBIOL, V28, P566, DOI 10.1128/JCM.28.3.566-572.1990; PERSING DH, 1992, J CLIN MICROBIOL, V30, P2097, DOI 10.1128/JCM.30.8.2097-2103.1992; PERSING DH, 1994, J INFECT DIS, V169, P664; RABB DC, 1992, J AM ACAD DERMATOL, V26, P267, DOI 10.1016/S0190-9622(08)80309-X; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; ROSA PA, 1989, J INFECT DIS, V160, P1018, DOI 10.1093/infdis/160.6.1018; ROTBART HA, 1987, MOL CELL PROBE, V1, P347, DOI 10.1016/0890-8508(87)90016-8; SCHMIDLI J, 1988, J INFECT DIS, V158, P905, DOI 10.1093/infdis/158.4.905; SCHWARTZ I, 1992, J CLIN MICROBIOL, V30, P3082, DOI 10.1128/JCM.30.12.3082-3088.1992; SNYDMAN DR, 1986, ANN INTERN MED, V104, P798, DOI 10.7326/0003-4819-104-6-798; STEERE AC, 1990, NEW ENGL J MED, V323, P219, DOI 10.1056/NEJM199007263230402; STEERE AC, 1985, NEW ENGL J MED, V312, P869, DOI 10.1056/NEJM198504043121401; STEERE AC, 1979, ANN INTERN MED, V90, P896, DOI 10.7326/0003-4819-90-6-896; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; STEERE AC, 1988, ARTHRITIS RHEUM, V31, P487, DOI 10.1002/art.1780310405; STEERE AC, 1993, ARTHRITIS RHEUM, V36, pS40; STEERE AC, 1987, ANN INTERN MED, V107, P725, DOI 10.7326/0003-4819-107-5-725; SZER IS, 1991, NEW ENGL J MED, V325, P159, DOI 10.1056/NEJM199107183250304; WHITMIRE WM, 1993, INFECT IMMUN, V61, P1460, DOI 10.1128/IAI.61.4.1460-1467.1993; WILLIAMS WV, 1992, DNA CELL BIOL, V11, P207, DOI 10.1089/dna.1992.11.207; 1991, PEDIATRICS, V88, P176; 1991, PEDIATRICS, V88, P840	46	441	459	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 27	1994	330	4					229	234		10.1056/NEJM199401273300401	http://dx.doi.org/10.1056/NEJM199401273300401			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR496	8272083				2022-12-01	WOS:A1994MR49600001
J	LISTOKIN, T				LISTOKIN, T			HES STILL ALIVE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											LISTOKIN, T (corresponding author), NYU MED CTR, 333 E 30TH ST, NEW YORK, NY 10016 USA.								0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1994	120	2					159	160		10.7326/0003-4819-120-2-199401150-00009	http://dx.doi.org/10.7326/0003-4819-120-2-199401150-00009			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ671	8256975				2022-12-01	WOS:A1994MQ67100009
J	COLLINS, I; NEWLON, CS				COLLINS, I; NEWLON, CS			MEIOSIS-SPECIFIC FORMATION OF JOINT DNA-MOLECULES CONTAINING SEQUENCES FROM HOMOLOGOUS CHROMOSOMES	CELL			English	Article							MEIOTIC GENE CONVERSION; DOUBLE-STRAND BREAKS; SACCHAROMYCES-CEREVISIAE CHROMOSOME; INITIATION SITE; ESCHERICHIA-COLI; MISMATCH-REPAIR; S-CEREVISIAE; PHYSICAL MAP; RECOMBINATION; YEAST	All recombination models postulate one or more recombination intermediates that are joint molecules containing two homologous parental molecules. A spike of branched DNA molecules not seen in DNA from mitotic cells was found in the two-dimensional gel analysis of melotic DNA from S. cerevisiae. The mass of molecules in the spike, the timing of its appearance and disappearance, and its absence from a recombination-defective spo11 mutant are consistent with the hypothesis that it contains recombination intermediates. The spike changes in mass as predicted for joint molecules containing DNA from homologous chromosomes rather than sister chromatids in a strain heterozygous for an RFLP. Finally, joint molecules containing DNA from homeologous chromosomes were not found, suggesting that the block to recombination between homeologous sequences occurs prior to the formation of joint molecules.	UNIV MED & DENT NEW JERSEY, GRAD SCH BIOMED SCI, NEWARK, NJ 07103 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center	COLLINS, I (corresponding author), UNIV MED & DENT NEW JERSEY, NEW JERSEY MED SCH, DEPT MICROBIOL & MOLEC GENET, NEWARK, NJ 07103 USA.							ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; BAILIS AM, 1990, GENETICS, V126, P535; BELL L, 1983, ANAL BIOCHEM, V130, P527, DOI 10.1016/0003-2697(83)90628-0; BELL L, 1979, P NATL ACAD SCI USA, V76, P3445, DOI 10.1073/pnas.76.7.3445; BELL LR, 1982, COLD SPRING HARB SYM, V47, P829, DOI 10.1101/SQB.1983.047.01.095; BORTS RH, 1990, GENETICS, V124, P573; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1988, CANCER CELL, V6, P229; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; COLEMAN KG, 1986, MOL CELL BIOL, V6, P4516, DOI 10.1128/MCB.6.12.4516; DUNDERDALE HJ, 1991, NATURE, V354, P506, DOI 10.1038/354506a0; FOGEL S, 1981, MOL BIOL YEAST SACCH, P289; GOLDWAY M, 1993, GENETICS, V133, P159; GOYON C, 1993, MOL CELL BIOL, V13, P373, DOI 10.1128/MCB.13.1.373; GREENFEDER SA, 1992, MOL BIOL CELL, V3, P999, DOI 10.1091/mbc.3.9.999; HABER JE, 1993, P NATL ACAD SCI USA, V90, P3363, DOI 10.1073/pnas.90.8.3363; HOLMBERG S, 1982, CARLSBERG RES COMMUN, V47, P233, DOI 10.1007/BF02907875; JACKSON JA, 1985, GENETICS, V109, P303; JINKSROBERTSON S, 1985, P NATL ACAD SCI USA, V82, P3350, DOI 10.1073/pnas.82.10.3350; JOHNSON RD, 1993, J MOL BIOL, V229, P812, DOI 10.1006/jmbi.1993.1087; JOHNSTON LH, 1982, EXP CELL RES, V141, P53, DOI 10.1016/0014-4827(82)90067-2; KABACK DB, 1989, P NATL ACAD SCI USA, V86, P3694, DOI 10.1073/pnas.86.10.3694; KANE SM, 1974, J BACTERIOL, V118, P8, DOI 10.1128/JB.118.1.8-14.1974; KLAPHOLZ S, 1985, GENETICS, V110, P187; LICHTEN M, 1990, P NATL ACAD SCI USA, V87, P7653, DOI 10.1073/pnas.87.19.7653; LICHTEN M, 1987, GENETICS, V115, P233; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; MORTIMER RK, 1989, YEAST, V5, P321, DOI 10.1002/yea.320050503; NAG DK, 1993, MOL CELL BIOL, V13, P2324, DOI 10.1128/MCB.13.4.2324; NEWLON CS, 1991, GENETICS, V129, P343; NICOLAS A, 1989, NATURE, V338, P35, DOI 10.1038/338035a0; NILSSONTILLGREN T, 1981, CARLSBERG RES COMMUN, V46, P65, DOI 10.1007/BF02906199; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; Petes T. D., 1991, MOL CELLULAR BIOL YE, P407; PORTER SE, 1993, GENETICS, V134, P5; POTTER H, 1976, P NATL ACAD SCI USA, V73, P3000, DOI 10.1073/pnas.73.9.3000; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; RESNICK MA, 1989, P NATL ACAD SCI USA, V86, P2276, DOI 10.1073/pnas.86.7.2276; ROTH R, 1969, J BACTERIOL, V98, P831, DOI 10.1128/JB.98.2.831-832.1969; Sambrook J., 1989, MOL CLONING LAB MANU; SCHULTES NP, 1990, GENETICS, V126, P813; SCHWACHA A, 1994, CELL, V76, P51, DOI 10.1016/0092-8674(94)90172-4; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SMITH GE, 1980, ANAL BIOCHEM, V109, P123, DOI 10.1016/0003-2697(80)90019-6; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SYMINGTON LS, 1988, MOL CELL BIOL, V8, P595, DOI 10.1128/MCB.8.2.595; TSANEVA IR, 1992, CELL, V69, P1171, DOI 10.1016/0092-8674(92)90638-S; WAGSTAFF JE, 1985, MOL CELL BIOL, V5, P3532, DOI 10.1128/MCB.5.12.3532; Williamson D H, 1975, Methods Cell Biol, V12, P335; WILLIAMSON DH, 1983, EXP CELL RES, V145, P209, DOI 10.1016/S0014-4827(83)80022-6; ZENVIRTH D, 1992, EMBO J, V11, P3441, DOI 10.1002/j.1460-2075.1992.tb05423.x	53	86	87	0	4	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	1994	76	1					65	75		10.1016/0092-8674(94)90173-2	http://dx.doi.org/10.1016/0092-8674(94)90173-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287480				2022-12-01	WOS:A1994MR49500007
J	JEFFERY, R; JEFFERY, A				JEFFERY, R; JEFFERY, A			METACHROMATIC LEUKODYSTROPHY - 2 SIDES OF A COIN	BRITISH MEDICAL JOURNAL			English	Article											JEFFERY, R (corresponding author), HOPE HOSP,DEPT ORTHOPAED SURG,CLIN SCI BLDG,ECCLES OLD RD,SALFORD M6 8HD,LANCS,ENGLAND.			Jeffery, Alison/0000-0001-7539-5957					0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1631	1632		10.1136/bmj.307.6919.1631	http://dx.doi.org/10.1136/bmj.307.6919.1631			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292966	Green Published, Bronze			2022-12-01	WOS:A1993MN10700034
J	HUANG, XY; MORIELLI, AD; PERALTA, EG				HUANG, XY; MORIELLI, AD; PERALTA, EG			TYROSINE KINASE-DEPENDENT SUPPRESSION OF A POTASSIUM CHANNEL BY THE G-PROTEIN-COUPLED M1-MUSCARINIC ACETYLCHOLINE-RECEPTOR	CELL			English	Article							GLIOMA HYBRID-CELLS; TISSUE-SPECIFIC EXPRESSION; SWISS 3T3 CELLS; MUSCARINIC RECEPTOR; MOLECULAR-BASIS; PHOSPHORYLATION; SUBTYPES; HYDROLYSIS; ACTIVATION; CLONING	Neurotransmitter receptors alter membrane excitability and synaptic efficacy by generating intracellular signals that ultimately change the properties of ion channels. Through expression studies in Xenopus oocytes and mammalian cells, we found that the G protein-coupled m1 muscarinic acetylcholine receptor potently suppresses a cloned delayed rectifier K+ channel through a pathway involving phospholipase C activation and direct tyrosine phosphorylation of the K+ channel. Furthermore, analysis of neuroblastoma cells revealed that a similar tyrosine kinase-dependent pathway links endogenous G protein-coupled receptors to suppression of the native RAK channel. These results suggest a novel mechanism by which neurotransmitters and hormones may regulate a specific type of K+ channel that is widely expressed in the mammalian brain and heart.			HUANG, XY (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA.							AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ASHKENAZI A, 1989, NATURE, V340, P146, DOI 10.1038/340146a0; ASHKENAZI A, 1989, CELL, V56, P487, DOI 10.1016/0092-8674(89)90251-1; ASHKENAZI A, 1994, IN PRESS CRC HDB REC, V1; BEECH DJ, 1991, P NATL ACAD SCI USA, V88, P652, DOI 10.1073/pnas.88.2.652; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BROWN AM, 1990, ANNU REV PHYSIOL, V52, P197, DOI 10.1146/annurev.ph.52.030190.001213; BROWN DA, 1988, J PHYSIOL-LONDON, V397, P185, DOI 10.1113/jphysiol.1988.sp016995; BROWN DA, 1980, NATURE, V283, P673, DOI 10.1038/283673a0; CATARSI S, 1993, NATURE, V363, P353, DOI 10.1038/363353a0; CATTERALL WA, 1984, SCIENCE, V223, P653, DOI 10.1126/science.6320365; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P15180; COLE AE, 1984, J PHYSIOL-LONDON, V352, P173, DOI 10.1113/jphysiol.1984.sp015285; CONKLIN BR, 1988, P NATL ACAD SCI USA, V85, P8698, DOI 10.1073/pnas.85.22.8698; DELLACQUA ML, 1993, J BIOL CHEM, V268, P5676; DISALVO J, 1993, BIOCHEM BIOPH RES CO, V190, P968, DOI 10.1006/bbrc.1993.1144; ENRIGHT WJ, 1991, FOCUS, V13, P79; FELDER CC, 1989, J BIOL CHEM, V264, P20356; FELDER CC, 1993, P NATL ACAD SCI USA, V90, P1706, DOI 10.1073/pnas.90.5.1706; FORCE T, 1991, J BIOL CHEM, V266, P6650; FUKUDA K, 1988, NATURE, V335, P355, DOI 10.1038/335355a0; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HAN HQ, 1991, NATURE, V349, P697, DOI 10.1038/349697a0; HILLE B, 1992, NEURON, V9, P187, DOI 10.1016/0896-6273(92)90158-A; Hille B., 1992, IONIC CHANNELS EXCIT; HOGER JH, 1991, NEURON, V6, P227, DOI 10.1016/0896-6273(91)90358-7; HUGANIR RL, 1984, P NATL ACAD SCI USA, V81, P6963; Kaczmarek LK, 1987, NEUROMODULATION BIOC; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; KUNKEL MT, 1993, EMBO J, V12, P3809, DOI 10.1002/j.1460-2075.1993.tb06059.x; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LEEBLUNDBERG LMF, 1991, J BIOL CHEM, V266, P7746; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LOGOTHETIS DE, 1987, NATURE, V325, P321, DOI 10.1038/325321a0; MALENKA RC, 1986, J NEUROSCI, V6, P475; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MCKINNON D, 1989, J BIOL CHEM, V264, P8230; MELTON DA, 1984, NUCLEIC ACIDS RES, V12, P7035, DOI 10.1093/nar/12.18.7035; NATHANSON NM, 1987, ANNU REV NEUROSCI, V10, P195, DOI 10.1146/annurev.ne.10.030187.001211; NITSCH RM, 1992, SCIENCE, V258, P304, DOI 10.1126/science.1411529; PAULMICHL M, 1991, P NATL ACAD SCI USA, V88, P7892, DOI 10.1073/pnas.88.17.7892; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; PERALTA EG, 1988, NATURE, V334, P434, DOI 10.1038/334434a0; PERALTA EG, 1987, SCIENCE, V236, P600, DOI 10.1126/science.3107123; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; PERNEY TM, 1989, J BIOL CHEM, V264, P7317; PFAFFINGER PJ, 1988, NEURON, V1, P477, DOI 10.1016/0896-6273(88)90178-X; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; REPP H, 1993, P NATL ACAD SCI USA, V90, P3403, DOI 10.1073/pnas.90.8.3403; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; SANDMANN J, 1991, J BIOL CHEM, V266, P6031; SCHAFER S, 1991, PFLUG ARCH EUR J PHY, V418, P581, DOI 10.1007/BF00370575; STANSFELD CE, 1993, NEURON, V10, P639, DOI 10.1016/0896-6273(93)90166-O; STRATTON KR, 1989, P NATL ACAD SCI USA, V86, P2498, DOI 10.1073/pnas.86.7.2498; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TAYLOR P, 1990, PHARMACOL BASIS THER, P122; TREJO J, 1991, J BIOL CHEM, V266, P7876; YOKOYAMA S, 1989, FEBS LETT, V259, P37, DOI 10.1016/0014-5793(89)81488-7; ZACHARY I, 1992, CELL, V71, P891, DOI 10.1016/0092-8674(92)90385-P; ZACHARY I, 1992, J BIOL CHEM, V267, P19031	62	258	263	0	5	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 17	1993	75	6					1145	1156		10.1016/0092-8674(93)90324-J	http://dx.doi.org/10.1016/0092-8674(93)90324-J			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	8261514				2022-12-01	WOS:A1993MM89300013
J	SIRUMCONNOLLY, K; MASON, TL				SIRUMCONNOLLY, K; MASON, TL			FUNCTIONAL REQUIREMENT OF A SITE-SPECIFIC RIBOSE METHYLATION IN RIBOSOMAL-RNA	SCIENCE			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; MITOCHONDRIAL RIBOSOME; NUCLEAR GENE; YEAST MITOCHONDRIA; PROTEIN; EXPRESSION; SEQUENCE; SUBUNIT; CONSTRUCTION	The product of the PET56 nuclear gene of Saccharomyces cerevisiae was shown to be required for ribose methylation ata universally conserved nucleotide in the peptidyl transferase center of the mitochondrial large ribosomal RNA (21S rRNA). Cells reduced i n this activity were deficient in formation of functional large subunits of the mitochondrial ribosome. The purified Pet56 protein catalyzed the site-specific formation of 2'-O-methylguanosine on in vitro transcripts of both mitochondrial 21S rRNA and Escherichia coli 23S rRNA. These results provide evidence for an essential modified nucleotide in rRNA.	UNIV MASSACHUSETTS, DEPT BIOCHEM & MOLEC BIOL, AMHERST, MA 01003 USA; UNIV MASSACHUSETTS, GRAD PROGRAM MOLEC & CELLULAR BIOL, AMHERST, MA 01003 USA	University of Massachusetts System; University of Massachusetts Amherst; University of Massachusetts System; University of Massachusetts Amherst								ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALARIF A, 1972, ANAL BIOCHEM, V48, P386, DOI 10.1016/0003-2697(72)90091-7; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BAER RJ, 1981, NUCLEIC ACIDS RES, V9, P323, DOI 10.1093/nar/9.2.323; BRANLANT C, 1981, NUCLEIC ACIDS RES, V9, P4303, DOI 10.1093/nar/9.17.4303; BRIMACOMBE R, 1993, FASEB J, V7, P161, DOI 10.1096/fasebj.7.1.8422963; CHELBIALIX MK, 1981, EUR J BIOCHEM, V115, P627; CHIU MI, 1992, GENETICS, V132, P987; CUNDLIFFE E, 1981, J GEN MICROBIOL, V126, P185; CUNNINGHAM PR, 1991, BIOCHIMIE, V73, P789, DOI 10.1016/0300-9084(91)90058-9; DAUM G, 1982, J BIOL CHEM, V257, P3028; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUBIN DT, 1978, J MOL BIOL, V121, P523, DOI 10.1016/0022-2836(78)90398-4; EICHLER DC, 1987, BIOCHEMISTRY-US, V26, P1639, DOI 10.1021/bi00380a023; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FAYE G, 1976, FEBS LETT, V69, P167, DOI 10.1016/0014-5793(76)80678-3; FEARON K, 1988, MOL CELL BIOL, V8, P3636, DOI 10.1128/MCB.8.9.3636; FEARON K, 1992, J BIOL CHEM, V267, P5162; HOESS A, 1988, BIO-TECHNOL, V6, P1214, DOI 10.1038/nbt1088-1214; KLOOTWIJK J, 1975, J MOL BIOL, V97, P337, DOI 10.1016/S0022-2836(75)80044-1; KOERNER TJ, 1991, METHOD ENZYMOL, V194, P477; KRZYZOSIAK W, 1987, BIOCHEMISTRY-US, V26, P2353, DOI 10.1021/bi00382a042; KUECHLER E, 1988, METHOD ENZYMOL, V164, P361; LAMBOWITZ AM, 1976, J BIOL CHEM, V251, P3081; MADEN BEH, 1974, J MOL BIOL, V88, P133, DOI 10.1016/0022-2836(74)90299-X; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MELANCON P, 1987, BIOCHEM CELL BIOL, V65, P1022, DOI 10.1139/o87-134; MERTEN S, 1980, P NATL ACAD SCI-BIOL, V77, P1417, DOI 10.1073/pnas.77.3.1417; MOAZED D, 1991, P NATL ACAD SCI USA, V88, P3725, DOI 10.1073/pnas.88.9.3725; MOAZED D, 1989, CELL, V57, P585, DOI 10.1016/0092-8674(89)90128-1; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; NOLLER HF, 1992, SCIENCE, V256, P1416, DOI 10.1126/science.1604315; NOLLER HF, 1991, ANNU REV BIOCHEM, V60, P191, DOI 10.1146/annurev.biochem.60.1.191; PARIKH VS, 1987, SCIENCE, V235, P576, DOI 10.1126/science.3027892; PARTALEDIS JA, 1988, MOL CELL BIOL, V8, P3647, DOI 10.1128/MCB.8.9.3647; Sambrook J., 1989, MOL CLONING LAB MANU; SIRUMCONNOLLY K, UNPUB; SMITH JE, 1992, BIOCHEMISTRY-US, V31, P10825, DOI 10.1021/bi00159a025; STRUHL K, 1985, NUCLEIC ACIDS RES, V13, P8587, DOI 10.1093/nar/13.23.8587; STRUHL K, 1985, P NATL ACAD SCI USA, V82, P8419, DOI 10.1073/pnas.82.24.8419; THOMPSON J, 1991, BIOCHIMIE, V73, P1131, DOI 10.1016/0300-9084(91)90156-U; ZHU H, 1987, MOL CELL BIOL, V7, P2530, DOI 10.1128/MCB.7.7.2530	42	107	108	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1993	262	5141					1886	1889		10.1126/science.8266080	http://dx.doi.org/10.1126/science.8266080			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266080				2022-12-01	WOS:A1993MM51100040
J	COUPLAND, RM				COUPLAND, RM			HAND GRENADE INJURIES AMONG CIVILIANS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							WAR WOUND EXCISION; RED-CROSS; INTERNATIONAL-COMMITTEE; ANTIPERSONNEL MINES; EXPERIENCE; MANAGEMENT	Objectives.-To describe how noncombatants are injured by hand grenades in camps for displaced people, and to categorize grenade wounds according to the Red Cross wound classification. Design.-Case series. Setting.-A surgical hospital in Khao I Dang refugee camp on the Thailand-Cambodia border. Patients.-Seventy-four patients injured by hand grenades. Interventions.-Intravenous antibiotics and primary wound surgery. Main Outcome Measures.-Combatant status of the patients, categorization of the wounds, surgical outcome, number of operations, and number of blood transfusions. Results.-Only 7% of the patients sustained their wounds in battle and 50% were women, children, or older men. Seventy had 91 wounds that could be categorized; 59% of the wounds were small, affecting only soft tissue. Few wounds were associated with fractures and none with comminuted fractures. Twenty-four soft-tissue wounds were treated conservatively with minimal morbidity and no mortality. Conclusions.-Missiles (fragments or bullets) from hand grenades tend to produce wounds with little tissue damage. Serious injury is due to penetration of vital structures. The results permit a recommendation that certain small and uncomplicated fragment wounds can be treated initially without surgery.			COUPLAND, RM (corresponding author), INT COMM RED CROSS,DIV MED,17 AV DE LA PAIX,CH-1202 GENEVA,SWITZERLAND.							ADAMS DB, 1990, J TRAUMA S, V6, P48; COOPER GJ, 1990, BRIT J SURG, V77, P606, DOI 10.1002/bjs.1800770604; Coupland R.M., 1991, RED CROSS WOUND CLAS, P18; COUPLAND RM, 1990, BRIT J SURG, V77, P833, DOI 10.1002/bjs.1800770738; COUPLAND RM, 1992, WORLD J SURG, V16, P910, DOI 10.1007/BF02066991; COUPLAND RM, 1989, BRIT J SURG, V76, P663, DOI 10.1002/bjs.1800760704; COUPLAND RM, 1992, LANCET, V339, P35, DOI 10.1016/0140-6736(92)90152-S; COUPLAND RM, 1991, BMJ-BRIT MED J, V303, P1509, DOI 10.1136/bmj.303.6816.1509; COUPLAND RM, 1992, BRIT MED J, V304, P1509, DOI 10.1136/bmj.304.6840.1509-c; DUFOUR D, 1988, SURGERY VICTIMS WAR; ESHAYACHAUVIN B, 1992, BRIT J ANAESTH, V68, P221, DOI 10.1093/bja/68.2.221; Fackler M. L., 1990, J TRAUMA CHINA, V6, P32; FACKLER ML, 1989, SURGERY, V105, P576; FACKLER ML, 1989, BRIT J SURG, V76, P1217, DOI 10.1002/bjs.1800761133; HAYWOOD IR, 1991, BRIT J SURG, V78, P123; HOGG IV, 1991, JANES INFANTRY WEAPO, P570; SMITH MSO, 1981, HIGH VELOCITY MISSIL; WANG ZG, 1988, J TRAUMA, V28, pS89, DOI 10.1097/00005373-198801001-00020	18	24	25	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1993	270	5					624	626		10.1001/jama.270.5.624	http://dx.doi.org/10.1001/jama.270.5.624			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP436	8331764				2022-12-01	WOS:A1993LP43600030
J	ARGETSINGER, LS; CAMPBELL, GS; YANG, XN; WITTHUHN, BA; SILVENNOINEN, O; IHLE, JN; CARTERSU, C				ARGETSINGER, LS; CAMPBELL, GS; YANG, XN; WITTHUHN, BA; SILVENNOINEN, O; IHLE, JN; CARTERSU, C			IDENTIFICATION OF JAK2 AS A GROWTH-HORMONE RECEPTOR-ASSOCIATED TYROSINE KINASE	CELL			English	Article							BINDING-PROTEIN; CELLS; METABOLISM; GH; PHOSPHORYLATION; PURIFICATION; DOMAINS; PRODUCT; SERUM; DNA	Growth hormone receptor (GHR) forms a complex with a tyrosine kinase, suggesting involvement of a ligand-activated tyrosine kinase in intracellular signaling by growth hormone (GH). Here we identify JAK2, a nonreceptor tyrosine kinase, as a GHR-associated tyrosine kinase. Immunological approaches were used to establish GH-dependent complex formation between JAK2 and GHR, activation of JAK2 tyrosine kinase activity, and tyrosyl phosphorylation of both JAK2 and GHR. The JAK2-GHR and JAK2-erythropoietin receptor interactions described here and in the accompanying paper provide a molecular basis for involvement of tyrosyl phosphorylation in physiological responses to these ligands and suggest a shared signaling mechanism among members of the cytokine/hematopoietin receptor family.	HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA; ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA	Harvard University; Harvard Medical School; St Jude Children's Research Hospital	ARGETSINGER, LS (corresponding author), UNIV MICHIGAN, SCH MED, DEPT PHYSIOL, ANN ARBOR, MI 48109 USA.		witthuhn, bruce/GSE-3193-2022		NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK034171, R01DK042932] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline; NIDDK NIH HHS [R01 DK042932, R01-DK42932, R01 DK034171, R01-DK34171] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BILLESTRUP N, 1990, P NATL ACAD SCI USA, V87, P7210, DOI 10.1073/pnas.87.18.7210; CAMPBELL GS, 1993, J BIOL CHEM, V268, P7427; CARTERSU C, 1989, J BIOL CHEM, V264, P18654; CHEEK DB, 1974, HDB PHYSIOLOGY END 2, V4, P159; DAVIDSON MB, 1987, ENDOCR REV, V8, P115, DOI 10.1210/edrv-8-2-115; EMTNER M, 1990, MOL ENDOCRINOL, V4, P2014, DOI 10.1210/mend-4-12-2014; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FUKUNAGA R, 1991, EMBO J, V10, P2855, DOI 10.1002/j.1460-2075.1991.tb07835.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; HUNTER T, 1980, P NATL ACAD SCI-BIOL, V77, P1311, DOI 10.1073/pnas.77.3.1311; ISAKSSON OGP, 1987, ENDOCR REV, V8, P426, DOI 10.1210/edrv-8-4-426; ISHIZAKAIKEDA E, 1993, P NATL ACAD SCI USA, V90, P123, DOI 10.1073/pnas.90.1.123; KAPLAN DR, 1991, SCIENCE, V252, P554, DOI 10.1126/science.1850549; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LEUNG DW, 1987, NATURE, V330, P537, DOI 10.1038/330537a0; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; MOLLER C, 1992, THESIS NOVUM HUDDING, P1; PANG DT, 1985, ARCH BIOCHEM BIOPHYS, V242, P176, DOI 10.1016/0003-9861(85)90491-6; SADEGHI H, 1990, MOL ENDOCRINOL, V4, P1799, DOI 10.1210/mend-4-12-1799; SCHWARTZ J, 1988, ENDOCRINOLOGY, V122, P2247; SILVA CM, 1993, ENDOCRINOLOGY, V132, P101, DOI 10.1210/en.132.1.101; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STRED SE, 1990, ENDOCRINOLOGY, V127, P2506, DOI 10.1210/endo-127-5-2506; STRED SE, 1992, ENDOCRINOLOGY, V130, P1626, DOI 10.1210/en.130.3.1626; TAI PKK, 1990, J BIOL CHEM, V265, P21828; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WANG XY, 1992, J BIOL CHEM, V267, P17390; WANG XY, 1993, J BIOL CHEM, V268, P3573; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1990, P NATL ACAD SCI USA, V87, P4139, DOI 10.1073/pnas.87.11.4139	34	853	872	0	19	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674			CELL	Cell	JUL 30	1993	74	2					237	244		10.1016/0092-8674(93)90415-M	http://dx.doi.org/10.1016/0092-8674(93)90415-M			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343952	Green Submitted			2022-12-01	WOS:A1993LP72600005
J	CHENG, XD; KUMAR, S; POSFAI, J; PFLUGRATH, JW; ROBERTS, RJ				CHENG, XD; KUMAR, S; POSFAI, J; PFLUGRATH, JW; ROBERTS, RJ			CRYSTAL-STRUCTURE OF THE HHAL DNA METHYLTRANSFERASE COMPLEXED WITH S-ADENOSYL-L-METHIONINE	CELL			English	Article							TARGET-RECOGNIZING DOMAINS; MACROMOLECULAR CRYSTALLOGRAPHY; DETERMINES METHYLATION; CATALYTIC MECHANISM; ESCHERICHIA-COLI; SEQUENCE MOTIFS; MET REPRESSOR; BINDING; PROTEIN; EXPRESSION	The first three-dimensional structure of a DNA methyltransferase is presented. The crystal structure of the DNA (cytosine-5)-methyltransferase, M.Hhal (recognition sequence: GCGC), complexed with S-adenosyl-L-methionine has been determined and refined at 2.5 angstrom resolution. The core of the structure is dominated by sequence motifs conserved among all DNA (cytosine-5)-methyltransferases, and these are responsible for cofactor binding and methyltransferase function.	NEW ENGLAND BIOLABS INC,BEVERLY,MA 01915		CHENG, XD (corresponding author), COLD SPRING HARBOR LAB,WM KECK STRUCT BIOL LAB,COLD SPRING HARBOR,NY 11724, USA.		Kumar, Sanjay/AAO-2593-2021	Roberts, Richard/0000-0002-4348-0169	NCI NIH HHS [CA 45508] Funding Source: Medline; NIGMS NIH HHS [GM 46127, GM 49245] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA045508] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046127, R01GM049245] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS RLP, 1990, BIOCHEM J, V265, P309, DOI 10.1042/bj2650309; ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; BALGANESH TS, 1987, EMBO J, V6, P3543, DOI 10.1002/j.1460-2075.1987.tb02681.x; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CASERTA M, 1987, J BIOL CHEM, V262, P4770; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; FRIEDMAN S, 1992, NUCLEIC ACIDS RES, V20, P3241, DOI 10.1093/nar/20.12.3241; FRIEDMAN S, 1986, NUCLEIC ACIDS RES, V14, P4543, DOI 10.1093/nar/14.11.4543; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GUNTHERT U, 1986, EUR J BIOCHEM, V159, P485, DOI 10.1111/j.1432-1033.1986.tb09912.x; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; INGROSSO D, 1989, J BIOL CHEM, V264, P20130; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KLIMASAUSKAS S, 1991, NUCLEIC ACIDS RES, V19, P6183, DOI 10.1093/nar/19.22.6183; KLIMASAUSKAS S, 1989, NUCLEIC ACIDS RES, V17, P9823, DOI 10.1093/nar/17.23.9823; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUMAR S, 1992, BIOCHEMISTRY-US, V31, P8648, DOI 10.1021/bi00151a035; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; MANN MB, 1979, P C TRANSMETHYLATION, P483; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MI S, 1993, NUCLEIC ACIDS RES, V21, P2459, DOI 10.1093/nar/21.10.2459; MI S, 1992, NUCLEIC ACIDS RES, V20, P4811, DOI 10.1093/nar/20.18.4811; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; RAFFERTY JB, 1989, NATURE, V341, P705, DOI 10.1038/341705a0; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; REMINGTON S, 1982, J MOL BIOL, V158, P111, DOI 10.1016/0022-2836(82)90452-1; ROBERTS RJ, 1992, NUCLEIC ACIDS RES, V20, P2167, DOI 10.1093/nar/20.suppl.2167; ROBERTS RJ, 1976, J MOL BIOL, V103, P199, DOI 10.1016/0022-2836(76)90060-7; ROSSMANN MG, 1974, NATURE, V250, P194, DOI 10.1038/250194a0; SANTI DV, 1987, BIOCHEMISTRY-US, V26, P8599, DOI 10.1021/bi00400a016; SANTI DV, 1984, FOLATES PTERIDINES, V1, P343; SMITH HO, 1990, P NATL ACAD SCI USA, V87, P826, DOI 10.1073/pnas.87.2.826; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; STEIGEMANN W, 1974, THESIS TU MUNCHEN; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISSMAN L, 1982, COMPUTATIONAL CRYSTA, P56; WIERENGA RK, 1986, J MOL BIOL, V187, P101, DOI 10.1016/0022-2836(86)90409-2; WILKE K, 1988, EMBO J, V7, P2601, DOI 10.1002/j.1460-2075.1988.tb03110.x; WILSON GG, 1991, ANNU REV GENET, V25, P585, DOI 10.1146/annurev.ge.25.120191.003101; WU JC, 1987, J BIOL CHEM, V262, P4778; WU JC, 1988, NUCLEIC ACIDS RES, V16, P703, DOI 10.1093/nar/16.2.703; WU JC, 1985, BIOCH BIOL DNA METHY, P119; WYSZYNSKI MW, 1992, NUCLEIC ACIDS RES, V20, P319, DOI 10.1093/nar/20.2.319; YEN RWC, 1992, NUCLEIC ACIDS RES, V20, P2287, DOI 10.1093/nar/20.9.2287	53	364	370	0	17	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					299	307		10.1016/0092-8674(93)90421-L	http://dx.doi.org/10.1016/0092-8674(93)90421-L			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343957				2022-12-01	WOS:A1993LP72600011
J	CREASE, RP				CREASE, RP			BIOMEDICINE IN THE AGE OF IMAGING	SCIENCE			English	Editorial Material																		Hall S., 1992, MAPPING NEXT MILLENN; [No title captured]; [No title captured]; [No title captured]	4	19	22	0	10	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 30	1993	261	5121					554	&		10.1126/science.8342016	http://dx.doi.org/10.1126/science.8342016			0	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	8342016				2022-12-01	WOS:A1993LP72800024
J	HIRT, RP; HUGHES, GJ; FRUTIGER, S; MICHETTI, P; PERREGAUX, C; POULAINGODEFROY, O; JEANGUENAT, N; NEUTRA, MR; KRAEHENBUHL, JP				HIRT, RP; HUGHES, GJ; FRUTIGER, S; MICHETTI, P; PERREGAUX, C; POULAINGODEFROY, O; JEANGUENAT, N; NEUTRA, MR; KRAEHENBUHL, JP			TRANSCYTOSIS OF THE POLYMERIC IG RECEPTOR REQUIRES PHOSPHORYLATION OF SERINE-664 IN THE ABSENCE BUT NOT THE PRESENCE OF DIMERIC IGA	CELL			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; TRANS-EPITHELIAL TRANSPORT; SODIUM DODECYL-SULFATE; AMINO-ACID CHANGE; CYTOPLASMIC DOMAIN; IMMUNOGLOBULIN RECEPTOR; MDCK CELLS; SECRETORY COMPONENT; COATED PITS; PROTEINS	MDCK cells expressing the polymeric immunoglobulin (poly-Ig) receptor, cocultured with IgA-producing hybridoma cells, transported dimeric IgA (dIgA) from the basolateral into the lumenal compartment, where it was recovered as secretory component-dIgA complexes. The tail of the receptor was phosphorylated on serines 664 and 726. Each serine was mutated to alanine. Appearance of A726 receptor at the basolateral surface was reduced approximately 5-fold. This was accompanied by a approximately 5-fold reduction in dIgA transcytosis. Basolateral delivery of receptor was not affected by mutation A664, and in the absence of dIgA, the receptor accumulated in recycling basolateral endosomes. In coculture, however, dIgA transcytosis by A664 receptor was normal. Thus, entry of receptor into the transcytotic pathway requires Ser-664 phosphorylation only in the absence of dIgA.	SWISS INST EXPTL CANC RES, CH-1066 EPALINGES, SWITZERLAND; UNIV LAUSANNE, INST BIOCHEM, CH-1066 EPALINGES, SWITZERLAND; UNIV GENEVA, CTR MED, DEPT MED BIOCHEM, CH-1211 GENEVA, SWITZERLAND; CHILDRENS HOSP MED CTR, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Swiss Institute Experimental Cancer Research; University of Lausanne; University of Geneva; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School			Poulain-Godefroy, Odile/AAF-5474-2021; Hirt, Robert/R-5429-2017	Hirt, Robert/0000-0002-3760-9958; POULAIN-GODEFROY, Odile/0000-0001-8805-9450	NICHD NIH HHS [HD17557] Funding Source: Medline; NIDDK NIH HHS [DK21505] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD017557, R01HD017557] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK021505] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARR FA, 1991, FEBS LETT, V294, P239, DOI 10.1016/0014-5793(91)81438-E; Breitfeld PP, 1989, CURR OPIN CELL BIOL, V1, P617, DOI 10.1016/0955-0674(89)90024-0; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CASANOVA JE, 1990, SCIENCE, V248, P742, DOI 10.1126/science.2110383; CASANOVA JE, 1991, CELL, V66, P65, DOI 10.1016/0092-8674(91)90139-P; CORVERA S, 1988, P NATL ACAD SCI USA, V85, P7567, DOI 10.1073/pnas.85.20.7567; EGGERT M, 1991, FEBS LETT, V292, P205, DOI 10.1016/0014-5793(91)80868-4; FRUTIGER S, 1986, J BIOL CHEM, V261, P6673; FULLER S, 1984, CELL, V38, P65, DOI 10.1016/0092-8674(84)90527-0; GEUZE HJ, 1984, CELL, V37, P195, DOI 10.1016/0092-8674(84)90315-5; HANLY WC, 1987, J IMMUNOL, V139, P1597; HIRT RP, 1992, GENE, V111, P199, DOI 10.1016/0378-1119(92)90687-K; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; HUNZIKER W, 1991, CELL, V66, P907, DOI 10.1016/0092-8674(91)90437-4; JING SQ, 1990, J CELL BIOL, V110, P283, DOI 10.1083/jcb.110.2.283; KONIGSBERG WH, 1983, METHOD ENZYMOL, V91, P254; KRAEHENBUHL JP, 1992, PHYSIOL REV, V72, P853, DOI 10.1152/physrev.1992.72.4.853; KTISTAKIS NT, 1990, J CELL BIOL, V111, P1393, DOI 10.1083/jcb.111.4.1393; KUHN LC, 1981, J BIOL CHEM, V256, P2490; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LARKIN JM, 1986, P NATL ACAD SCI USA, V83, P4759, DOI 10.1073/pnas.83.13.4759; LAZAROVITS J, 1988, CELL, V53, P743, DOI 10.1016/0092-8674(88)90092-X; LEBIVIC A, 1991, J CELL BIOL, V115, P607, DOI 10.1083/jcb.115.3.607; MATTER K, 1992, CELL, V71, P741, DOI 10.1016/0092-8674(92)90551-M; MEYER HE, 1986, FEBS LETT, V204, P61, DOI 10.1016/0014-5793(86)81388-6; MOSTOV K, 1992, J CELL BIOL, V116, P577, DOI 10.1083/jcb.116.3.577; MOSTOV KE, 1986, CELL, V47, P359, DOI 10.1016/0092-8674(86)90592-1; MOSTOV KE, 1986, CELL, V46, P613, DOI 10.1016/0092-8674(86)90887-1; MOSTOV KE, 1984, NATURE, V308, P37, DOI 10.1038/308037a0; NISHIMOTO I, 1991, J BIOL CHEM, V266, P12747; OKAMOTO CT, 1992, J BIOL CHEM, V267, P9925; PACCOLAT MP, 1987, AM J PHYSIOL, V252, pC468, DOI 10.1152/ajpcell.1987.252.5.C468; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; PEARSON RB, 1991, METHOD ENZYMOL, V200, P62; RODRIGUEZBOULAN E, 1989, METHOD CELL BIOL, V32, P37; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAERER E, 1990, J CELL BIOL, V110, P987, DOI 10.1083/jcb.110.4.987; SCHAERER E, 1991, J MEMBRANE BIOL, V123, P93, DOI 10.1007/BF01998081; SCHULTE TH, 1978, BIOCHIM BIOPHYS ACTA, V508, P425, DOI 10.1016/0005-2736(78)90089-5; SOLARI R, 1984, CELL, V36, P61, DOI 10.1016/0092-8674(84)90074-6; SOLARI R, 1985, J BIOL CHEM, V260, P1141; Solari R., 1987, The mammary gland. Development, regulation, and function., P269; SOLARI R, 1985, IMMUNOL TODAY, V6, P17, DOI 10.1016/0167-5699(85)90163-X; SZTUL E, 1991, CELL, V64, P81, DOI 10.1016/0092-8674(91)90210-P; TOWBIN H, 1984, J IMMUNOL METHODS, V72, P313, DOI 10.1016/0022-1759(84)90001-2; WELTZIN R, 1989, J CELL BIOL, V108, P1673, DOI 10.1083/jcb.108.5.1673; WINNER L, 1991, INFECT IMMUN, V59, P977, DOI 10.1128/IAI.59.3.977-982.1991	47	83	86	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 30	1993	74	2					245	255		10.1016/0092-8674(93)90416-N	http://dx.doi.org/10.1016/0092-8674(93)90416-N			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343953				2022-12-01	WOS:A1993LP72600006
J	SAKA, Y; YANAGIDA, M				SAKA, Y; YANAGIDA, M			FISSION YEAST CUT5+, REQUIRED FOR S-PHASE ONSET AND M-PHASE RESTRAINT, IS IDENTICAL TO THE RADIATION-DAMAGE REPAIR GENE RAD4+	CELL			English	Article							CELL-DIVISION CYCLE; SISTER-CHROMATID EXCHANGE; DNA TOPOISOMERASE-II; STRAND-BREAK REPAIR; SCHIZOSACCHAROMYCES-POMBE; PROTEIN-KINASE; TYROSINE PHOSPHATASE; ACTIVATES P34CDC2; CDC25 PROTEIN; MITOSIS	Fission yeast cut5 mutants cause cytokinesis in the absence of normal nuclear division. We show here that cut5+ is required for both the onset of S phase and the restraint of M phase before the completion of S phase. The primary defects in cut5 mutants occur prior to S phase, but cells suffer lethal damage during M phase. Mitosis and cytokinesis occur in the presence of hydroxyurea or in the double mutant cdc10-cut5 (the cdc10 mutation alone blocks progression from G1 to S). Gene cloning shows that cut5+ is identical to the fission yeast rad4+ gene, which is similar to human XRCC1. The rad4+/cut5+ gene is unique in its positive role for replication/repair and in its negative role for mitosis/cytokinesis. We propose a single/twin chromatid marking model for rad4+/cut5+ function in cell cycle control.			SAKA, Y (corresponding author), KYOTO UNIV,FAC SCI,DEPT BIOPHYS,KITASHIRAKAWA OIWAKECHO,SAKYO KU,KYOTO 606,JAPAN.							ADACHI Y, 1989, J CELL BIOL, V108, P1195, DOI 10.1083/jcb.108.4.1195; ALKHODAIRY F, 1992, EMBO J, V11, P1343, DOI 10.1002/j.1460-2075.1992.tb05179.x; ALKHODAIRY F, 1992, EMBO J, V114, P59; BARBET N, 1992, GENE, V114, P59, DOI 10.1016/0378-1119(92)90707-V; BEACH D, 1981, NATURE, V290, P140, DOI 10.1038/290140a0; BUENO A, 1992, EMBO J, V11, P2167, DOI 10.1002/j.1460-2075.1992.tb05276.x; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; COSTELLO G, 1986, CURR GENET, V11, P119, DOI 10.1007/BF00378203; DASSO M, 1992, MOL CELL BIOL, V12, P3337, DOI 10.1128/MCB.12.8.3337; DUCK P, 1976, J BACTERIOL, V128, P536, DOI 10.1128/JB.128.2.536-539.1976; DUNPHY WG, 1991, CELL, V67, P189, DOI 10.1016/0092-8674(91)90582-J; ENOCH T, 1990, CELL, V60, P665, DOI 10.1016/0092-8674(90)90669-6; ENOCH T, 1992, GENE DEV, V6, P2035, DOI 10.1101/gad.6.11.2035; FAN JB, 1988, NUCLEIC ACIDS RES, V17, P2801; FENECH M, 1991, NUCLEIC ACIDS RES, V19, P6737, DOI 10.1093/nar/19.24.6737; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GAUTIER J, 1991, CELL, V67, P197, DOI 10.1016/0092-8674(91)90583-K; GOEBL M, 1991, TRENDS BIOCHEM SCI, V16, P173, DOI 10.1016/0968-0004(91)90070-C; HAGAN I, 1992, NATURE, V356, P74, DOI 10.1038/356074a0; HAGAN I, 1990, NATURE, V347, P563, DOI 10.1038/347563a0; HAGAN IM, 1988, J CELL SCI, V89, P343; HARTWELL LH, 1989, SCIENCE, V246, P629, DOI 10.1126/science.2683079; HIRANO T, 1988, J CELL BIOL, V106, P1171, DOI 10.1083/jcb.106.4.1171; HIRANO T, 1986, EMBO J, V5, P2973, DOI 10.1002/j.1460-2075.1986.tb04594.x; HONDA R, 1992, BIOCHEM BIOPH RES CO, V186, P1333, DOI 10.1016/S0006-291X(05)81552-9; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KINOSHITA N, 1991, MOL CELL BIOL, V11, P5839, DOI 10.1128/MCB.11.12.5839; KINOSHITA N, 1990, CELL, V63, P405, DOI 10.1016/0092-8674(90)90173-C; LOWNDES NF, 1992, NATURE, V355, P449, DOI 10.1038/355449a0; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MATSUMOTO T, 1991, CELL, V66, P347, DOI 10.1016/0092-8674(91)90624-8; MILLAR JBA, 1991, EMBO J, V10, P4301, DOI 10.1002/j.1460-2075.1991.tb05008.x; Mitchison JM, 1970, METHOD CELL PHYSIOL, V4, P131; MIZUKAMI T, 1993, CELL, V73, P121, DOI 10.1016/0092-8674(93)90165-M; MORENO S, 1989, CELL, V58, P361, DOI 10.1016/0092-8674(89)90850-7; NASMYTH K, 1981, MOL GEN GENET, V182, P119, DOI 10.1007/BF00422777; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; OHKURA H, 1989, CELL, V57, P997, DOI 10.1016/0092-8674(89)90338-3; PARKER LL, 1992, P NATL ACAD SCI USA, V89, P2917, DOI 10.1073/pnas.89.7.2917; Phipps J, 1985, Adv Genet, V23, P1, DOI 10.1016/S0065-2660(08)60511-8; ROWLEY R, 1992, NATURE, V356, P353, DOI 10.1038/356353a0; ROWLEY R, 1992, EMBO J, V11, P1335, DOI 10.1002/j.1460-2075.1992.tb05178.x; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SAMEJIMA I, 1993, IN PRESS J CELL SCI; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STONE EM, 1993, CURR BIOL, V3, P13, DOI 10.1016/0960-9822(93)90140-J; STRAUSFELD U, 1991, NATURE, V351, P242, DOI 10.1038/351242a0; THOMPSON LH, 1982, MUTAT RES, V95, P427, DOI 10.1016/0027-5107(82)90276-7; THOMPSON LH, 1990, MOL CELL BIOL, V10, P6160, DOI 10.1128/MCB.10.12.6160; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; UEMURA T, 1986, EMBO J, V5, P1003, DOI 10.1002/j.1460-2075.1986.tb04315.x; UEMURA T, 1986, EMBO J, V5, P2355, DOI 10.1002/j.1460-2075.1986.tb04504.x; UZAWA S, 1990, CELL, V62, P913, DOI 10.1016/0092-8674(90)90266-H; WEINERT TA, 1988, SCIENCE, V241, P317, DOI 10.1126/science.3291120	56	205	209	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					383	393		10.1016/0092-8674(93)90428-S	http://dx.doi.org/10.1016/0092-8674(93)90428-S			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343962				2022-12-01	WOS:A1993LP72600018
J	DODDS, L; MARRETT, LD; TOMKINS, DJ; GREEN, B; SHERMAN, G				DODDS, L; MARRETT, LD; TOMKINS, DJ; GREEN, B; SHERMAN, G			CASE-CONTROL STUDY OF CONGENITAL-ANOMALIES IN CHILDREN OF CANCER-PATIENTS	BRITISH MEDICAL JOURNAL			English	Article							CHILDHOOD-CANCER; SURVIVORS; PREGNANCY; POPULATION; FERTILITY; MUTATION; MICE	Objectives-To determine whether the offspring of cancer survivors are at an increased risk of congenital anomalies and whether cancer therapy before conception is associated with such an increase. Design-Case-control study using computerised record linkage. Setting-Ontario, Canada. Subjects-Parents of children born during April 1979 to December 1986 who had a congenital anomaly diagnosed within the first year of life (45 200 mothers and 41 158 fathers) and a matched sample of parents whose children did not have a congenital anomaly (45 200 mothers and 41 158 fathers). Main outcome measures-Cancer diagnosed in either parent before conception and radiotherapy to the pelvis or abdomen or chemotherapy with an alkylating agent. Results-Among the mothers, 54 cases and 52 controls were identified as having had cancer diagnosed in Ontario (relative risk=1.04, 95% confidence interval 0.7 to 1.5) and among the fathers, 61 cases and 65 controls were identified (0.9, 0.7 to 1.4). No significant associations were found between congenital anomalies in the offspring and any type of cancer treatment in either the mothers or the fathers. Conclusions-The risk of congenital anomalies among liveborn offspring whose parents have had cancer or been treated for cancer is not higher than that in the general population.	ONTARIO CANC TREATMENT & RES FDN,TORONTO M4H 1A8,ON,CANADA; HLTH & WELF CANADA,LAB CTR DIS CONTROL,OTTAWA K1A 0L2,ONTARIO,CANADA; UNIV TORONTO,DEPT PREVENT MED & BIOSTAT,TORONTO M5S 1A8,ONTARIO,CANADA; MCMASTER UNIV,DEPT PEDIAT,HAMILTON L8N 3Z5,ONTARIO,CANADA	University of Toronto; McMaster University								BAIRD PA, 1988, AM J HUM GENET, V42, P677; BALIS FM, 1989, PRINCIPLES PRACTICE, P165; BLATT J, 1989, PRINCIPLES PRACTICE, P1003; BRESLOW NE, 1980, IARC32 INT AG RES CA; BYRNE J, 1987, NEW ENGL J MED, V317, P1315, DOI 10.1056/NEJM198711193172104; Chabner B. A., 1982, CANCER PRINCIPLES PR, P156; CZEIZEL A, 1989, MUTAT RES, V212, P3, DOI 10.1016/0027-5107(89)90017-1; GARDNER MJ, 1990, BRIT MED J, V300, P423, DOI 10.1136/bmj.300.6722.423; GREEN DM, 1991, NEW ENGL J MED, V325, P141, DOI 10.1056/NEJM199107183250301; HAWKINS MM, 1991, J NATL CANCER I, V83, P1643, DOI 10.1093/jnci/83.22.1643; HAWKINS MM, 1989, ARCH DIS CHILD, V64, P798, DOI 10.1136/adc.64.6.798; HAWKINS MM, 1989, INT J CANCER, V43, P399, DOI 10.1002/ijc.2910430309; HOWE GR, 1981, COMPUT BIOMED RES, V14, P327, DOI 10.1016/0010-4809(81)90004-5; KIRK M, 1982, MUTAT RES, V106, P73, DOI 10.1016/0027-5107(82)90191-9; LI FP, 1987, JAMA-J AM MED ASSOC, V257, P216, DOI 10.1001/jama.257.2.216; MULVIHILL JJ, 1987, CANCER, V60, P1143, DOI 10.1002/1097-0142(19870901)60:5<1143::AID-CNCR2820600537>3.0.CO;2-E; MULVIHILL JJ, 1990, PROG CLIN BIOL RES, V340, P179; NOMURA T, 1988, MUTAT RES, V198, P309, DOI 10.1016/0027-5107(88)90008-5; ROTHMAN KJ, 1986, MODERN EPIDMIOLOGY; TRASLER JM, 1985, NATURE, V316, P144, DOI 10.1038/316144a0; YOUNG J L JR, 1986, Cancer, V58, P598, DOI 10.1002/1097-0142(19860715)58:2+<598::AID-CNCR2820581332>3.0.CO;2-C; 1985, SAS VERSION 5; 1977, INT CLASSIFICATION C; 1988, EGRET	24	70	71	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1993	307	6897					164	168		10.1136/bmj.307.6897.164	http://dx.doi.org/10.1136/bmj.307.6897.164			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN184	8343744	Green Published, Bronze			2022-12-01	WOS:A1993LN18400019
J	VOJTEK, AB; HOLLENBERG, SM; COOPER, JA				VOJTEK, AB; HOLLENBERG, SM; COOPER, JA			MAMMALIAN RAS INTERACTS DIRECTLY WITH THE SERINE THREONINE KINASE RAF	CELL			English	Article							GTPASE-ACTIVATING PROTEIN; NEUROFIBROMATOSIS TYPE-1 GENE; SACCHAROMYCES-CEREVISIAE; ADENYLATE-CYCLASE; TYROSINE KINASE; SIGNAL TRANSDUCTION; VULVAR INDUCTION; MAP KINASE; V-RAF; YEAST	We have identified proteins that interact with H-Ras using a two hybrid system screen of a mouse cDNA library. Approximately 50% of the clones identified encoded portions of the c-Raf and A-Raf serine/threonine kinases. Overlaps among these clones define a conserved 81 residue region of the N-terminus of Raf as the Ras interaction region. We show that Raf interacts with wild-type and activated Ras, but not with an effector domain mutant of Ras or with a dominant-interfering Ras mutant. Using purified bacterially expressed fusion proteins, we show, furthermore, that Ras and the N-terminal region of Raf associate directly in vitro and that this interaction is dependent on GTP bound to Ras.			VOJTEK, AB (corresponding author), FRED HUTCHINSON CANC RES CTR,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.							ADARI H, 1988, SCIENCE, V240, P518, DOI 10.1126/science.2833817; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BECKNER SK, 1985, NATURE, V317, P71, DOI 10.1038/317071a0; BEITEL GJ, 1990, NATURE, V348, P503, DOI 10.1038/348503a0; BIRCHMEIER C, 1985, CELL, V43, P615, DOI 10.1016/0092-8674(85)90233-8; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BROEK D, 1987, CELL, V48, P789, DOI 10.1016/0092-8674(87)90076-6; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; CALES C, 1988, NATURE, V332, P548, DOI 10.1038/332548a0; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; DALTON S, 1992, CELL, V68, P597, DOI 10.1016/0092-8674(92)90194-H; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DOLE HJ, 1993, GENE DEV, V7, P633; DOMINGUEZ I, 1991, EMBO J, V10, P3215, DOI 10.1002/j.1460-2075.1991.tb04884.x; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; FEDORCHAIKEN M, 1990, CELL, V61, P329, DOI 10.1016/0092-8674(90)90813-T; FEIG LA, 1993, SCIENCE, V260, P767, DOI 10.1126/science.8484117; FIELD J, 1990, SCIENCE, V247, P464, DOI 10.1126/science.2405488; FIELD J, 1990, CELL, V61, P319, DOI 10.1016/0092-8674(90)90812-S; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FORTINI ME, 1992, NATURE, V355, P559, DOI 10.1038/355559a0; FUKUI Y, 1986, CELL, V44, P329, DOI 10.1016/0092-8674(86)90767-1; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; HAN M, 1990, CELL, V63, P921, DOI 10.1016/0092-8674(90)90495-Z; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HAN M, 1993, CELL, V363, P133; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; KATAOKA T, 1985, CELL, V40, P19, DOI 10.1016/0092-8674(85)90304-6; KAZLAUSKAS A, 1991, CELL REGUL, V2, P413, DOI 10.1091/mbc.2.6.413; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAI CC, 1993, MOL CELL BIOL, V13, P1345, DOI 10.1128/MCB.13.3.1345; LEEVERS S J, 1992, Trends in Cell Biology, V2, P283, DOI 10.1016/0962-8924(92)90105-V; LU XY, 1993, GENE DEV, V7, P621, DOI 10.1101/gad.7.4.621; MACNICOL AM, 1993, CELL, V73, P571, DOI 10.1016/0092-8674(93)90143-E; MATVIW H, 1992, MOL CELL BIOL, V12, P5033, DOI 10.1128/MCB.12.11.5033; MELNICK MB, 1993, DEVELOPMENT, V118, P127; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MORRISON DK, 1988, P NATL ACAD SCI USA, V85, P8855, DOI 10.1073/pnas.85.23.8855; MORRISON DK, 1990, CANCER CELL-MON REV, V2, P377; MUNDER T, 1992, MOL CELL BIOL, V12, P2091, DOI 10.1128/MCB.12.5.2091; NADINDAVIS SA, 1986, EMBO J, V5, P2963, DOI 10.1002/j.1460-2075.1986.tb04593.x; POWERS S, 1989, MOL CELL BIOL, V9, P390, DOI 10.1128/MCB.9.2.390; REED JC, 1991, CELL GROWTH DIFFER, V2, P235; ROSE MD, 1990, LABORATORY COURSE MA; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SIGAL IS, 1986, P NATL ACAD SCI USA, V83, P4725, DOI 10.1073/pnas.83.13.4725; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; SOZERI O, 1992, ONCOGENE, V7, P2259; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STORM SM, 1990, ONCOGENE, V5, P345; TODA T, 1985, CELL, V40, P27, DOI 10.1016/0092-8674(85)90305-8; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; VOJTEK AB, 1993, IN PRESS J CELL SCI; WHITMAN M, 1992, NATURE, V357, P252, DOI 10.1038/357252a0; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922; WILLUMSEN BM, 1986, MOL CELL BIOL, V6, P2646, DOI 10.1128/MCB.6.7.2646; WOOD KW, 1993, P NATL ACAD SCI USA, V90, P5016, DOI 10.1073/pnas.90.11.5016; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; YATANI A, 1990, CELL, V61, P769, DOI 10.1016/0092-8674(90)90187-J; YOCUM RR, 1984, MOL CELL BIOL, V4, P1985, DOI 10.1128/MCB.4.10.1985; ZAKIAN VA, 1982, MOL CELL BIOL, V2, P221, DOI 10.1128/MCB.2.3.221; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	73	1752	1817	0	50	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					205	214		10.1016/0092-8674(93)90307-C	http://dx.doi.org/10.1016/0092-8674(93)90307-C			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8334704				2022-12-01	WOS:A1993LN62500020
J	WILSON, FAW; SCALAIDHE, SPO; GOLDMANRAKIC, PS				WILSON, FAW; SCALAIDHE, SPO; GOLDMANRAKIC, PS			DISSOCIATION OF OBJECT AND SPATIAL PROCESSING DOMAINS IN PRIMATE PREFRONTAL CORTEX	SCIENCE			English	Article							INFERIOR TEMPORAL CORTEX; RHESUS-MONKEY; VISUAL NEURONS; UNIT-ACTIVITY; PERFORMANCE; MACAQUE; MEMORY; SEGREGATION; ANATOMY; COLOR	Areas and pathways subserving object and spatial vision are segregated in the visual system. Experiments show that the primate prefrontal cortex is similarly segregated into object and spatial domains. Neurons that code information related to stimulus identity are dissociable, both by function and region, from those that code information related to stimulus location. These findings indicate that the prefrontal cortex contains separate processing mechanisms for remembering ''what'' and ''where'' an object is.			WILSON, FAW (corresponding author), YALE UNIV, SCH MED, NEUROBIOL SECT, NEW HAVEN, CT 06511 USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH038546, R37MH038546] Funding Source: NIH RePORTER; NIMH NIH HHS [MH38546] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BARBAS H, 1988, J COMP NEUROL, V276, P313, DOI 10.1002/cne.902760302; BOCH RA, 1989, J NEUROPHYSIOL, V61, P1064, DOI 10.1152/jn.1989.61.5.1064; BRUCE CJ, 1985, J NEUROPHYSIOL, V53, P603, DOI 10.1152/jn.1985.53.3.603; CAVADA C, 1989, J COMP NEUROL, V287, P422, DOI 10.1002/cne.902870403; CORBETTA M, 1991, J NEUROSCI, V11, P2383; DESIMONE R, 1984, J NEUROSCI, V4, P2051; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FUNAHASHI S, 1989, J NEUROPHYSIOL, V61, P331, DOI 10.1152/jn.1989.61.2.331; FUSTER JM, 1973, J NEUROPHYSIOL, V36, P61, DOI 10.1152/jn.1973.36.1.61; Goldman-Rakic P. S., 1987, HDB PHYSL, V5, P373, DOI DOI 10.1002/CPHY.CP010509; GROSS CG, 1972, J NEUROPHYSIOL, V35, P96, DOI 10.1152/jn.1972.35.1.96; INCISADELLAROCCHETTA A, 1986, CORTEX, V22, P189, DOI 10.1016/S0010-9452(86)80045-4; KAWAMURA K, 1984, Neuroscience Research, V1, P89, DOI 10.1016/S0168-0102(84)80007-3; KOWALSKA DM, 1991, NEUROPSYCHOLOGIA, V29, P583, DOI 10.1016/0028-3932(91)90012-W; KUBOTA K, 1971, J NEUROPHYSIOL, V34, P337, DOI 10.1152/jn.1971.34.3.337; LIVINGSTONE M, 1988, SCIENCE, V240, P740, DOI 10.1126/science.3283936; MACKO KA, 1982, SCIENCE, V218, P394, DOI 10.1126/science.7123241; MCCARTHY RA, 1990, COGNITIVE NEUROPSYCH; MIKAMI A, 1982, J NEUROPHYSIOL, V47, P593, DOI 10.1152/jn.1982.47.4.593; MILLER EK, 1991, SCIENCE, V254, P1377, DOI 10.1126/science.1962197; MOREL A, 1990, VISUAL NEUROSCI, V4, P555, DOI 10.1017/S0952523800005769; PASSINGHAM R, 1975, BRAIN RES, V92, P89, DOI 10.1016/0006-8993(75)90529-6; PERRETT DI, 1982, EXP BRAIN RES, V47, P329; PETRIDES M, 1984, J COMP NEUROL, V228, P105, DOI 10.1002/cne.902280110; QUINTANA J, 1993, CEREB CORTEX, V3, P122, DOI 10.1093/cercor/3.2.122; RICHES IP, 1991, J NEUROSCI, V11, P1763; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; SCHWARTZ ML, 1984, J COMP NEUROL, V226, P403, DOI 10.1002/cne.902260309; SELEMON LD, 1988, J NEUROSCI, V8, P4049; STAMM JS, 1973, NEUROPSYCHOLOGIA, V11, P181, DOI 10.1016/0028-3932(73)90006-7; SUZUKI H, 1983, EXP BRAIN RES, V53, P47; Ungerleider L, 1982, ANAL VISUAL BEHAV, P549; WEINBERGER DR, 1986, ARCH GEN PSYCHIAT, V43, P114; ZEKI S, 1988, NATURE, V335, P311, DOI 10.1038/335311a0	34	1033	1045	4	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1993	260	5116					1955	1958		10.1126/science.8316836	http://dx.doi.org/10.1126/science.8316836			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ349	8316836				2022-12-01	WOS:A1993LJ34900047
J	HAYNES, MR; STURA, EA; HILVERT, D; WILSON, IA				HAYNES, MR; STURA, EA; HILVERT, D; WILSON, IA			ROUTES TO CATALYSIS - STRUCTURE OF A CATALYTIC ANTIBODY AND COMPARISON WITH ITS NATURAL COUNTERPART	SCIENCE			English	Article							CHORISMATE MUTASE REACTION; CLAISEN REARRANGEMENT; TRANSITION-STATE; CRYSTAL-STRUCTURES; ENZYMIC CATALYSIS; PREPHENATE; MECHANISM; STEREOCHEMISTRY; REFINEMENT; BINDING	The three-dimensional structure of a catalytic antibody (1F7) with chorismate mutase activity has been determined to 3.0 angstrom resolution as a complex with a transition state analog. The structural data suggest that the antibody stabilizes the same conformationally restricted pericyclic transition state as occurs in the uncatalyzed reaction. Overall shape and charge complementarity between the combining site and the transition state analog dictate preferential binding of the correct substrate enantiomer in a conformation appropriate for reaction. Comparison with the structure of a chorismate mutase enzyme indicates an overall similarity between the catalytic mechanism employed by the two proteins. Differences in the number of specific interactions available for restricting the rotational degrees of freedom in the transition state, and the lack of multiple electrostatic interactions that might stabilize charge separation in this highly polarized metastable species, are likely to account for the observed 10(4) times lower activity of the antibody relative to that of the natural enzymes that catalyze this reaction. The structure of the 1F7 Fab'-hapten complex provides confirmation that the properties of an antibody catalyst faithfully reflect the design of the transition state analog.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA	Scripps Research Institute	HAYNES, MR (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA.		Stura, Enrico A./A-2793-2010	Stura, Enrico A./0000-0001-6718-2118	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023498] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038273, R01GM038273] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-23498] Funding Source: Medline; NIGMS NIH HHS [GM-38273] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADDADI L, 1983, BIOCHEMISTRY-US, V22, P4494, DOI 10.1021/bi00288a022; ANDREWS PR, 1973, BIOCHEMISTRY-US, V12, P3492, DOI 10.1021/bi00742a022; AVIES DR, 1990, ANNU REV BIOCHEM, V59, P439; BARTLETT PA, 1988, J ORG CHEM, V53, P3195, DOI 10.1021/jo00249a013; BARTLETT PA, 1985, J AM CHEM SOC, V107, P7792, DOI 10.1021/ja00311a111; BRESLOW R, 1972, J AM CHEM SOC, V94, P2110, DOI 10.1021/ja00761a051; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURROWS CJ, 1981, J AM CHEM SOC, V103, P6983, DOI 10.1021/ja00413a045; CAMPBELL AP, 1993, P NATL ACAD SCI USA, V90, P8663, DOI 10.1073/pnas.90.18.8663; CHOOK YM, 1993, P NATL ACAD SCI USA, V90, P8600, DOI 10.1073/pnas.90.18.8600; CHOOK YM, COMMUNICATION; COATES RM, 1987, J AM CHEM SOC, V109, P1160, DOI 10.1021/ja00238a028; CONNOLLY ML, 1985, J MOL GRAPHICS, V3, P19, DOI 10.1016/0263-7855(85)80009-6; CONNOLLY ML, 1983, J APPL CRYSTALLOGR, V16, P548, DOI 10.1107/S0021889883010985; COPLEY SD, 1985, J AM CHEM SOC, V107, P5306, DOI 10.1021/ja00304a064; COPLEY SD, 1987, J AM CHEM SOC, V109, P5008, DOI 10.1021/ja00250a040; DAVIES D R, 1992, Current Biology, V2, P254, DOI 10.1016/0960-9822(92)90369-L; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; GAJEWSKI JJ, 1987, J AM CHEM SOC, V109, P1170, DOI 10.1021/ja00238a029; GORISCH H, 1978, BIOCHEMISTRY-US, V17, P3700, DOI 10.1021/bi00611a004; GRAY JV, 1990, BIOCHEMISTRY-US, V29, P8872, DOI 10.1021/bi00489a051; GUILFORD WJ, 1987, J AM CHEM SOC, V109, P5013, DOI 10.1021/ja00250a041; HARADA Y, 1981, ACTA CRYSTALLOGR A, V37, P398, DOI 10.1107/S0567739481000867; HARRISON SC, 1968, J APPL CRYSTALLOGR, V1, P84, DOI 10.1107/S0021889868005054; HAYNES MR, 1994, PROTEINS, V18, P201; HILVERT D, 1988, P NATL ACAD SCI USA, V85, P4953, DOI 10.1073/pnas.85.14.4953; HILVERT D, 1988, J AM CHEM SOC, V110, P5593, DOI 10.1021/ja00224a066; HILVERT D, 1993, ACCOUNTS CHEM RES, V26, P552, DOI 10.1021/ar00034a006; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HOWARD AJ, 1987, J APPL CRYSTALLOGR, V20, P383, DOI 10.1107/S0021889887086436; JACKSON DY, 1992, ANGEW CHEM INT EDIT, V31, P182, DOI 10.1002/anie.199201821; JACKSON DY, 1988, J AM CHEM SOC, V110, P4841, DOI 10.1021/ja00222a060; Jencks W, 1969, CATALYSIS CHEM ENZYM, P288; JENCKS WP, 1975, ADV ENZYMOL RAMB, V43, P219; JONES TA, 1978, J APL CRYSTALLOGR, V11, P262; KABAT EA, 1991, J IMMUNOL, V147, P1709; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MATTHEWS BW, 1968, J MOL BIOL, V33, P491, DOI 10.1016/0022-2836(68)90205-2; PAWLAK JL, 1989, J AM CHEM SOC, V111, P3374, DOI 10.1021/ja00191a040; RINI JM, 1992, SCIENCE, V255, P959, DOI 10.1126/science.1546293; SCHULTZ PG, 1993, ACCOUNTS CHEM RES, V26, P391, DOI 10.1021/ar00032a001; SEVERANCE DL, 1992, J AM CHEM SOC, V114, P10966, DOI 10.1021/ja00053a046; SOGO SG, 1984, J AM CHEM SOC, V106, P2701, DOI 10.1021/ja00321a039; STANFIELD RL, 1993, STRUCTURE, V1, P83, DOI 10.1016/0969-2126(93)90024-B; STANFIELD RL, 1990, SCIENCE, V248, P712, DOI 10.1126/science.2333521; STEWART JD, 1993, ACCOUNTS CHEM RES, V26, P396, DOI 10.1021/ar00032a002; TANG Y, 1991, P NATL ACAD SCI USA, V88, P8784, DOI 10.1073/pnas.88.19.8784; UPSON C, 1989, IEEE COMPUT GRAPH, V9, P30, DOI 10.1109/38.31462; WESTHEIMER FH, 1962, ADV ENZYMOL REL S BI, V24, P441; WILSON IA, 1993, CURR OPIN STRUC BIOL, V3, P113, DOI 10.1016/0959-440X(93)90210-C	52	152	152	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 4	1994	263	5147					646	652		10.1126/science.8303271	http://dx.doi.org/10.1126/science.8303271			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8303271				2022-12-01	WOS:A1994MU96400037
J	WULFSBERG, EA; HOFFMANN, DE; COHEN, MM				WULFSBERG, EA; HOFFMANN, DE; COHEN, MM			ALPHA-1-ANTITRYPSIN DEFICIENCY - IMPACT OF GENETIC DISCOVERY ON MEDICINE AND SOCIETY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							TISSUE-SPECIFIC EXPRESSION; NATURAL-HISTORY; NEUTROPHIL ELASTASE; TRANSGENIC MICE; EMPHYSEMA; ALPHA1-ANTITRYPSIN; DISCRIMINATION; ANTITRYPSIN; INSURANCE; LUNG	An increasing body of molecular information resulting from advances in basic research is being incorporated into clinical practice by medical genetics. The process by which these research advances progress from the laboratory to the bedside and their medical, social, and legal impact is a topic of intense current interest. Some authors have claimed that new genetic information may lead to discrimination in insurance and employment; change the way courts allocate responsibility for injury and resultant damages; and be inappropriately interpreted by the medical profession. To address some of these issues, we chose, as a model, to review alpha1-antitrypsin deficiency, described over 30 years ago. At this time, such concerns with respect to alpha1-antitrypsin deficiency have not yet been realized, perhaps for the following reasons: (1) knowledge of alpha1-antitrypsin deficiency, while common among geneticists and pulmonologists, has not been well disseminated in the medical community; (2) insurers, employers, lawyers, and judges are not generally aware of the deficiency and its implications; (3) insurers, if they are aware of the deficiency, have not found it cost-effective to screen for the condition; and (4) in the legal context, case law involving other types of preexisting conditions is being applied to genetic predispositions.	UNIV MARYLAND, SCH LAW, BALTIMORE, MD 21201 USA; UNIV MARYLAND, CTR MED BIOTECHNOL, BALTIMORE, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	WULFSBERG, EA (corresponding author), UNIV MARYLAND, SCH MED, DIV HUMAN GENET, SUITE 400, 405 W REDWOOD ST, BALTIMORE, MD 21201 USA.				NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000419] Funding Source: NIH RePORTER; NHGRI NIH HHS [R01-HG00419] Funding Source: Medline	NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI))		ALLEN RC, 1974, AM J CLIN PATHOL, V62, P732; BEECHAM L, 1992, BRIT MED J, V305, P1244; BILLINGS PR, 1992, AM J HUM GENET, V50, P476; BROCK DJH, 1993, LANCET, V341, P495, DOI 10.1016/0140-6736(93)90249-G; BUIST AS, 1990, LUNG, V168, P543, DOI 10.1007/BF02718177; BUIST AS, 1990, AM REV RESPIR DIS, V141, P1078, DOI 10.1164/ajrccm/141.4_Pt_1.1078a; CARRELL RW, 1982, NATURE, V298, P329, DOI 10.1038/298329a0; COURTNEY M, 1984, P NATL ACAD SCI-BIOL, V81, P669, DOI 10.1073/pnas.81.3.669; COX DW, 1982, NATURE, V297, P428, DOI 10.1038/297428a0; COX DW, 1980, HUM GENET, V53, P429, DOI 10.1007/BF00287070; EBERT RV, 1963, ARCH INTERN MED, V111, P34, DOI 10.1001/archinte.1963.03620250038006; ERIKSSON S, 1965, ACTA MED SCAND, VS177, P5; ERIKSSON S, 1964, ACTA MED SCAND, V175, P197; Eriksson S., 1991, ANN N Y ACAD SCI, V624, P1; FAGERHOL MK, 1967, CLIN CHIM ACTA, V16, P199, DOI 10.1016/0009-8981(67)90181-7; FELLS G, 1987, American Review of Respiratory Disease, V135, pA291; Gadek J., 1982, METABOLIC BASIS INHE, P1450; GADEK JE, 1981, J CLIN INVEST, V68, P889, DOI 10.1172/JCI110344; GADEK JE, 1990, LUNG, V168, P552, DOI 10.1007/BF02718178; GADEK JE, 1980, CLIN RES PROC, V16, P27; GEORGE PM, 1984, LANCET, V2, P1426; GOSTIN L, 1991, AM J LAW MED, V17, P109; HARPER PS, 1993, LANCET, V341, P224, DOI 10.1016/0140-6736(93)90080-Z; HEIMBURGER N, 1970, P INT RES C PROTEINA, P1; HUBBARD RC, 1990, LUNG, V168, P565, DOI 10.1007/BF02718179; HUBBARD RC, 1988, JAMA-J AM MED ASSOC, V260, P1259, DOI 10.1001/jama.260.9.1259; HUTCHISON DCS, 1990, LUNG, V168, P535, DOI 10.1007/BF02718176; JANOFF A, 1972, AM REV RESPIR DIS, V105, P121; JUENGST ET, 1991, JAMA-J AM MED ASSOC, V266, P1835, DOI 10.1001/jama.266.13.1835; KELSEY GD, 1987, GENE DEV, V1, P161, DOI 10.1101/gad.1.2.161; KUEPPERS F, 1974, AM REV RESPIR DIS, V110, P176; LAENNEC RTH, 1838, TREATISE DISEASES CH, P161; LARSON A, 1992, LAW WORKMENS COMPENS; LARSSON C, 1978, ACTA MED SCAND, V204, P345, DOI 10.1111/j.0954-6820.1978.tb08452.x; LAURELL CB, 1963, SCAND J CLIN LAB INV, V15, P132, DOI 10.3109/00365516309051324; LI Y, 1988, MOL CELL BIOL, V8, P4362, DOI 10.1128/MCB.8.10.4362; LIEBERMAN J, 1990, PRINCIPLES PRACTICES, P1179; LOWDEN JA, 1992, AM J HUM GENET, V51, P901; MCEWEN JE, 1992, AM J HUM GENET, V51, P785; MCKUSICK VA, 1989, NEW ENGL J MED, V320, P910, DOI 10.1056/NEJM198904063201406; MCKUSICK VA, 1991, HOSP PRACT, V26, P74; MCNEIL TF, 1988, THORAX, V43, P505, DOI 10.1136/thx.43.7.505; OLSEN GN, 1975, J CLIN INVEST, V55, P427, DOI 10.1172/JCI107947; OSTRER H, 1993, AM J HUM GENET, V52, P565; PIERCE JA, 1988, JAMA-J AM MED ASSOC, V259, P2890, DOI 10.1001/jama.259.19.2890; REYNOLDS MA, 1993, LANCET, V341, P495; SHEN RF, 1987, NUCLEIC ACIDS RES, V15, P8399, DOI 10.1093/nar/15.20.8399; SHOENBORN CA, 1988, VITAL HLTH STAT, V166, P85; SIFERS RN, 1987, NUCLEIC ACIDS RES, V15, P1459, DOI 10.1093/nar/15.4.1459; SIFERS RN, 1989, MOL BIOL MED, V6, P127; SNIDER GL, 1985, AM REV RESPIR DIS, V132, P182; SNIDER GL, 1991, ANN NY ACAD SCI, V624, P45, DOI 10.1111/j.1749-6632.1991.tb17005.x; STOLLER JK, 1993, AM REV RESPIR DIS, V147, pA871; SVEGER T, 1988, ACTA PAEDIATR SCAND, V77, P847, DOI 10.1111/j.1651-2227.1988.tb10767.x; SVEGER T, 1990, BIRTH DEFECTS ENCY, P90; TETLEY TD, 1992, RESP MED, V86, P187, DOI 10.1016/S0954-6111(06)80053-3; THELIN T, 1985, ACTA PAEDIATR SCAND, V74, P841, DOI 10.1111/j.1651-2227.1985.tb10046.x; TOBIN MJ, 1983, BRIT J DIS CHEST, V77, P14, DOI 10.1016/S0007-0971(83)80054-0; TURINO GM, 1991, ANN NY ACAD SCI, V624, P18, DOI 10.1111/j.1749-6632.1991.tb17002.x; TURINO GM, 1980, CLIN RES PROC, V16, P43; WEWERS MD, 1987, NEW ENGL J MED, V316, P1055, DOI 10.1056/NEJM198704233161704; WEWERS MD, 1989, AM J RESP CELL MOL, V1, P423, DOI 10.1165/ajrcmb/1.5.423; WIMPFHEIMER F, 1961, AM REV RESPIR DIS, V83, P697; 1992, GENETIC TESTS HLTH I	64	19	19	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	1994	271	3					217	222		10.1001/jama.271.3.217	http://dx.doi.org/10.1001/jama.271.3.217			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ645	8277549				2022-12-01	WOS:A1994MQ64500036
J	PITT, WR; THOMAS, S; NIXON, J; CLARK, R; BATTISTUTTA, D; ACTON, C				PITT, WR; THOMAS, S; NIXON, J; CLARK, R; BATTISTUTTA, D; ACTON, C			TRENDS IN HEAD-INJURIES AMONG CHILD BICYCLISTS	BRITISH MEDICAL JOURNAL			English	Article									QUEENSLAND INST MED RES,DEPT EPIDEMIOL,HERSTON,QLD 4029,AUSTRALIA; UNIV QUEENSLAND,DEPT CHILD HLTH,HERSTON,QLD 4029,AUSTRALIA; ROYAL CHILDRENS HOSP,HERSTON,QLD 4029,AUSTRALIA; QUEENSLAND RADIUM INST,HERSTON,QLD 4029,AUSTRALIA	QIMR Berghofer Medical Research Institute; University of Queensland; Royal Children's Hospital Brisbane	PITT, WR (corresponding author), MATER CHILDRENS HOSP,BRISBANE,QLD 4101,AUSTRALIA.							ARMSON CJ, 1986, MED J AUSTRALIA, V44, P144; DIX W, 1992, 6 MONTHS REV COMPULS; THOMAS S, 1994, BRIT MED J, V308, P173, DOI 10.1136/bmj.308.6922.173; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; VULCAN AP, 1992, WORLD J SURG, V16, P389, DOI 10.1007/BF02104437	5	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	1994	308	6922					177	177		10.1136/bmj.308.6922.177	http://dx.doi.org/10.1136/bmj.308.6922.177			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR974	8312769	Green Published			2022-12-01	WOS:A1994MR97400021
J	STAHL, N; BOULTON, TG; FARRUGGELLA, T; IP, NY; DAVIS, S; WITTHUHN, BA; QUELLE, FW; SILVENNOINEN, O; BARBIERI, G; PELLEGRINI, S; IHLE, JN; YANCOPOULOS, GD				STAHL, N; BOULTON, TG; FARRUGGELLA, T; IP, NY; DAVIS, S; WITTHUHN, BA; QUELLE, FW; SILVENNOINEN, O; BARBIERI, G; PELLEGRINI, S; IHLE, JN; YANCOPOULOS, GD			ASSOCIATION AND ACTIVATION OF JAK-TYK KINASES BY CNTF-LIF-OSM-IL-6 BETA-RECEPTOR COMPONENTS	SCIENCE			English	Article							LEUKEMIA-INHIBITORY FACTOR; IL-6 SIGNAL TRANSDUCER; PROTEIN-TYROSINE KINASES; ONCOSTATIN-M; GP130; INTERLEUKIN-6; FAMILY; CYTOKINES; MEMBER	A recently defined family of cytokines, consisting of ciliary neurotrophic factor (CNTF), leukemia inhibitory factor (LIF), oncostatin M (OSM), and interleukin-6 (IL-6), utilize the Jak-Tyk family of cytoplasmic tyrosine kinases. The beta receptor components for this cytokine family, gp130 and LIF receptor beta, constitutively associate with Jak-Tyk kinases. Activation of these kinases occurs as a result of ligand-induced dimerization of the receptor beta components. Unlike other cytokine receptors studied to date, the receptors for the CNTF cytokine family utilize all known members of the Jak-Tyk family, but induce distinct patterns of Jak-Tyk phosphorylation in different cell lines.	ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38105 USA; INST PASTEUR, INSERM, U276, F-75724 PARIS 15, FRANCE	St Jude Children's Research Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	STAHL, N (corresponding author), REGENERON PHARMACEUT INC, 777 OLD SAW MILL RIVER RD, TARRYTOWN, NY 10591 USA.		Pellegrini, Sandra -/G-5546-2015; Pellegrini, Sandra/Y-6351-2019; Barbieri, Giovanna/AAH-3645-2019; witthuhn, bruce/GSE-3193-2022	Pellegrini, Sandra -/0000-0001-5837-7589; Pellegrini, Sandra/0000-0001-5837-7589; BARBIERI, GIOVANNA/0000-0002-5895-1795; Quelle, Frederick/0000-0002-1184-6170	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline; NIDDK NIH HHS [R01 DK42932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BEYERS AD, 1992, P NATL ACAD SCI USA, V89, P2945, DOI 10.1073/pnas.89.7.2945; BOLEN JB, 1993, ONCOGENE, V8, P2025; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; EISEMAN E, 1992, NATURE, V355, P78; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; HARPUR AG, 1992, ONCOGENE, V7, P1347; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAJIMA K, 1991, MOL CELL BIOL, V11, P1409, DOI 10.1128/MCB.11.3.1409; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SILVENNOINEN O, UNPUB; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STAHL N, UNPUB; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L	33	919	945	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 7	1994	263	5143					92	95		10.1126/science.8272873	http://dx.doi.org/10.1126/science.8272873			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ301	8272873				2022-12-01	WOS:A1994MQ30100038
J	HEEMELS, MT; SCHUMACHER, TNM; WONIGEIT, K; PLOEGH, HL				HEEMELS, MT; SCHUMACHER, TNM; WONIGEIT, K; PLOEGH, HL			PEPTIDE TRANSLOCATION BY VARIANTS OF THE TRANSPORTER ASSOCIATED WITH ANTIGEN-PROCESSING	SCIENCE			English	Article							CLASS-I MOLECULE; MHC; EXPRESSION; PROTEINS; REGION; GENES; CIM	Major histocompatibility complex (MHC) class I molecules associate with peptides that are delivered from the cytosol to the lumen of the endoplasmic reticulum by the transporter associated with antigen processing (TAP). Liver microsomes of SHR and Lewis rats, which express different alleles of TAP (cim(b) and cim(a), respectively), accumulate different sets of peptides. Use of MHC congenic rats assigned this difference to the MHC, independent of the class I products expressed. Both the cim(a) and cim(b) TAP complexes translocate peptides with a hydrophobic carboxyl terminus, but translocation of peptides with a carboxyl-terminal His, Lys, or Arg residue is unique to cim(a). Thus, the specificity of the TAP peptide translocator restricts the peptides available for antigen presentation.	MIT,CTR CANC RES,DEPT BIOL,CAMBRIDGE,MA 02139; HANNOVER MED SCH,ABDOMINAL & TRANSPLANTAT CHIRURG KLIN,D-30625 HANNOVER,GERMANY	Massachusetts Institute of Technology (MIT); Hannover Medical School			Schumacher, Ton/Y-2432-2019	Schumacher, Ton/0000-0003-0517-8804; Heemels, Marie Therese/0000-0002-4364-3116	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033456] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI3 3456-01] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BIJLMAKERS MJ, 1993, CURR OPIN IMMUNOL, V5, P21, DOI 10.1016/0952-7915(93)90076-5; BIJLMAKERS MJE, 1993, EUR J IMMUNOL, V23, P1305, DOI 10.1002/eji.1830230618; COLONNA M, 1992, P NATL ACAD SCI USA, V89, P3932, DOI 10.1073/pnas.89.9.3932; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; FUKUMOTO T, 1982, EUR J IMMUNOL, V12, P237, DOI 10.1002/eji.1830120313; GASKINS HR, 1992, SCIENCE, V256, P1826, DOI 10.1126/science.1352067; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HOWARD JC, 1993, P NATL ACAD SCI USA, V90, P3777, DOI 10.1073/pnas.90.9.3777; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; LIVINGSTONE AM, 1991, IMMUNOGENETICS, V34, P157, DOI 10.1007/BF00205818; LIVINGSTONE AM, 1989, J EXP MED, V170, P777, DOI 10.1084/jem.170.3.777; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; NEEFJES JJ, 1986, HUM IMMUNOL, V16, P169, DOI 10.1016/0198-8859(86)90046-7; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; PARHAM P, 1990, NATURE, V348, P674, DOI 10.1038/348674a0; POWIS SJ, 1991, J EXP MED, V173, P913, DOI 10.1084/jem.173.4.913; POWIS SJ, 1992, NATURE, V357, P211, DOI 10.1038/357211a0; RAMMENSEE HG, 1993, ANNU REV IMMUNOL, V11, P213, DOI 10.1146/annurev.iy.11.040193.001241; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHUMACHER TNM, 1992, EUR J IMMUNOL, V22, P1405, DOI 10.1002/eji.1830220612; SCHUMACHER TNM, IN PRESS J EXP MED; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; TOWNSEND A, 1989, ANNU REV IMMUNOL, V7, P601, DOI 10.1146/annurev.iy.07.040189.003125; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; TSOMIDES TJ, 1993, ANAL BIOCHEM, V210, P129, DOI 10.1006/abio.1993.1162; WALTER P, 1983, METHOD ENZYMOL, V96, P84	27	194	195	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					2059	2063		10.1126/science.8266106	http://dx.doi.org/10.1126/science.8266106			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266106				2022-12-01	WOS:A1993MN10800046
J	BREWER, BJ; FANGMAN, WL				BREWER, BJ; FANGMAN, WL			INITIATION AT CLOSELY SPACED REPLICATION ORIGINS IN A YEAST CHROMOSOME	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE CHROMOSOME; S-PHASE; ACTIVATION; TIME; MAP	Replication of eukaryotic chromosomes involves initiation at origins spaced an average of 50 to 100 kilobase pairs. In yeast, potential origins can be recognized as autonomous replication sequences (ARSs) that allow maintenance of plasmids. However, there are more ARS elements than active chromosomal origins. The possibility was examined that close spacing of ARSs can lead to inactive origins. Two ARSs located 6.5 kilobase pairs apart can indeed interfere with each other. Replication is initiated from one or the other ARS with equal probability, but rarely (<5%) from both ARSs on the same DNA molecule.			BREWER, BJ (corresponding author), UNIV WASHINGTON,DEPT GENET SK50,SEATTLE,WA 98195, USA.				PHS HHS [18926] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BREWER B, UNPUB; BREWER BJ, 1987, CELL, V51, P463, DOI 10.1016/0092-8674(87)90642-8; BREWER BJ, 1992, CELL, V71, P267, DOI 10.1016/0092-8674(92)90355-G; CLARKE L, 1980, NATURE, V287, P504, DOI 10.1038/287504a0; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; FERGUSON BM, 1992, CELL, V68, P333, DOI 10.1016/0092-8674(92)90474-Q; GREENFEDER SA, 1992, MOL BIOL CELL, V3, P999, DOI 10.1091/mbc.3.9.999; HAMLIN JL, 1992, BIOESSAYS, V14, P651, DOI 10.1002/bies.950141002; HUBERMAN JA, 1968, J MOL BIOL, V32, P327, DOI 10.1016/0022-2836(68)90013-2; HUBERMAN JA, 1987, CELL, V51, P473, DOI 10.1016/0092-8674(87)90643-X; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; NEWLON CS, 1991, GENETICS, V129, P343; NEWLON CS, 1980, ICN UCLA S MOL CELL, V19, P211; RIVIN CJ, 1980, J CELL BIOL, V85, P108, DOI 10.1083/jcb.85.1.108	16	88	89	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 10	1993	262	5140					1728	1731		10.1126/science.8259517	http://dx.doi.org/10.1126/science.8259517			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	8259517				2022-12-01	WOS:A1993ML22000040
J	SELKER, EU; FRITZ, DY; SINGER, MJ				SELKER, EU; FRITZ, DY; SINGER, MJ			DENSE NONSYMMETRICAL DNA METHYLATION RESULTING FROM REPEAT-INDUCED POINT MUTATION IN NEUROSPORA	SCIENCE			English	Article							CRASSA; GENE; SEQUENCE; CPG; INACTIVATION; BINDING; DENOVO; RIP	Cytosine methylation has been implicated in epigenetic control of gene expression in animals, plants, and fungi. It has been assumed that all methylation in eukaryotes is at symmetrical sequences such as CpG/GpC, because this can explain perpetuation of methylation states. Here the bisulfite genomic sequencing method was used to examine methylation in DNA from a Neurospora gene exposed to repeat-induced point mutation. 5-Methylcytosine was not limited to symmetrical sites and individual molecules showed different patterns and amounts of modification. The methylation extended beyond the mutated region and even beyond the edge of the duplicated segment.	UNIV OREGON, DEPT BIOL, EUGENE, OR 97403 USA	University of Oregon	SELKER, EU (corresponding author), UNIV OREGON, INST MOLEC BIOL, EUGENE, OR 97403 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM035690, R01GM035690] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35690] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Antequera F., 1993, Experientia Supplementum (Basel), V64, P169; CAMBARERI EB, 1991, GENETICS, V127, P699; Finnegan E J, 1993, EXS, V64, P218; FROMMER M, 1992, P NATL ACAD SCI USA, V89, P1827, DOI 10.1073/pnas.89.5.1827; GRAYBURN WS, 1989, MOL CELL BIOL, V9, P4416, DOI 10.1128/MCB.9.10.4416; GRUENBAUM Y, 1981, NATURE, V292, P860, DOI 10.1038/292860a0; HOLLIDAY R, 1975, SCIENCE, V187, P226, DOI 10.1126/science.1111098; KINNAIRD JH, 1983, GENE, V26, P253, DOI 10.1016/0378-1119(83)90195-6; MARGOLIN B, UNPUB; MIAO V, UNPUB; PALUH JL, 1988, P NATL ACAD SCI USA, V85, P3728, DOI 10.1073/pnas.85.11.3728; RHOUNIM L, 1992, EMBO J, V11, P4451, DOI 10.1002/j.1460-2075.1992.tb05546.x; RIGGS AD, 1975, CYTOGENET CELL GENET, V14, P9, DOI 10.1159/000130315; Saluz H, 1993, EXS, V64, P11; Sasaki H., 1993, DNA methylation: molecular biology and biological significance., P469; SCHWEIZER M, 1981, P NATL ACAD SCI-BIOL, V78, P5086, DOI 10.1073/pnas.78.8.5086; SELKER E, UNPUB; SELKER EU, 1987, SCIENCE, V238, P48, DOI 10.1126/science.2958937; SELKER EU, 1985, P NATL ACAD SCI USA, V82, P8114, DOI 10.1073/pnas.82.23.8114; SELKER EU, 1990, TRENDS BIOCHEM SCI, V15, P103, DOI 10.1016/0968-0004(90)90193-F; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SELKER EU, 1988, P NATL ACAD SCI USA, V85, P6870, DOI 10.1073/pnas.85.18.6870; SELKER EU, 1993, DNA METHYLATION MOL, P212; TOTH M, 1990, J MOL BIOL, V214, P673, DOI 10.1016/0022-2836(90)90285-T; TURKER MS, 1989, J BIOL CHEM, V264, P11632; WOODCOCK DM, 1987, BIOCHEM BIOPH RES CO, V145, P888, DOI 10.1016/0006-291X(87)91048-5; YISRAELI J, 1984, DNA METHYLATION BIOC, P353	27	115	119	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1993	262	5140					1724	1728		10.1126/science.8259516	http://dx.doi.org/10.1126/science.8259516			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	8259516				2022-12-01	WOS:A1993ML22000039
J	BARSAGI, D; ROTIN, D; BATZER, A; MANDIYAN, V; SCHLESSINGER, J				BARSAGI, D; ROTIN, D; BATZER, A; MANDIYAN, V; SCHLESSINGER, J			SH3 DOMAINS DIRECT CELLULAR-LOCALIZATION OF SIGNALING MOLECULES	CELL			English	Article							PHOSPHOLIPASE-C-GAMMA; RECEPTOR TYROSINE KINASES; ACTIN-BINDING PROTEIN; EGF RECEPTOR; ESCHERICHIA-COLI; POINT MUTATION; PHOSPHORYLATION; SITE; GAP; TRANSDUCTION	In this study we describe the cellular distribution of the SH2 and SH3 domains of phospholipase C-gamma (PLC-gamma) and of the adaptor protein GRB2 following their microinjection into living rat embryo fibroblasts. Using immunofluorescence microscopy, we show that a truncated protein composed of the SH2 and SH3 domains of PLC-gamma was localized to the actin cytoskeleton. A similar localization pattern was observed when only the SH3 domain of PLC-gamma was microinjected. In contrast, a truncated protein composed of only the SH2 domains of PLC-gamma exhibited diffuse cytoplasmic distribution. Microinjected GRB2 protein was localized primarily to membrane ruffles, as was GRB2 protein containing SH2 loss-of-function point mutations. Hence, the localization of GRB2 to membrane ruffles does not require interaction with tyrosine-phosphorylated moieties. However, GRB2 proteins with SH3 loss-of-function point mutations exhibited diffuse cytoplasmic distribution. These results indicate that SH3 domains are responsible for the targeting of signaling molecules to specific subcellular locations.	NYU MED CTR,DEPT PHARMACOL,NEW YORK,NY 10016	New York University	BARSAGI, D (corresponding author), COLD SPRING HARBOR LAB,1 BUNGTOWN RD,COLD SPRING HARBOR,NY 11724, USA.			Bar-Sagi, Dafna/0000-0003-2597-8948	NCI NIH HHS [CA46370, CA55360] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA046370, R37CA055360, R01CA055360] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BARSAGI D, 1988, J CELL BIOL, V106, P1649, DOI 10.1083/jcb.106.5.1649; BERRIDGE MJ, 1989, NATURE, V341, P197, DOI 10.1038/341197a0; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; DRUBIN DG, 1990, NATURE, V343, P288, DOI 10.1038/343288a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; GOLDSCHMIDTCLERMONT PJ, 1990, SCIENCE, V247, P1575, DOI 10.1126/science.2157283; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GROSS M, 1985, MOL CELL BIOL, V5, P1015, DOI 10.1128/MCB.5.5.1015; HIRAI J, 1990, MOL CELL BIOL, V10, P1307; JACKSON P, 1989, EMBO J, V8, P449, DOI 10.1002/j.1460-2075.1989.tb03397.x; JUNG G, 1987, P NATL ACAD SCI USA, V84, P6720, DOI 10.1073/pnas.84.19.6720; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KIM HK, 1991, CELL, V65, P435, DOI 10.1016/0092-8674(91)90461-7; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARGOLIS B, 1989, CELL, V57, P1101, DOI 10.1016/0092-8674(89)90047-0; MARGOLIS B, 1990, EMBO J, V9, P4375, DOI 10.1002/j.1460-2075.1990.tb07887.x; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MCBRIDE K, 1991, P NATL ACAD SCI USA, V88, P7111, DOI 10.1073/pnas.88.16.7111; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODAWAY ARF, 1989, NATURE, V342, P624, DOI 10.1038/342624a0; ROTIN D, 1992, EMBO J, V11, P559, DOI 10.1002/j.1460-2075.1992.tb05087.x; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SEIDELDUGAN C, 1992, MOL CELL BIOL, V12, P1835, DOI 10.1128/MCB.12.4.1835; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VANDERGEER P, 1991, MOL CELL BIOL, V11, P4698, DOI 10.1128/MCB.11.9.4698; WANG K, 1982, METHOD ENZYMOL, V85, P514	41	336	346	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					83	91		10.1016/0092-8674(93)90296-3	http://dx.doi.org/10.1016/0092-8674(93)90296-3			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8334708				2022-12-01	WOS:A1993LN62500009
J	RAWLINGS, DJ; SAFFRAN, DC; TSUKADA, S; LARGAESPADA, DA; GRIMALDI, JC; COHEN, L; MOHR, RN; BAZAN, JF; HOWARD, M; COPELAND, NG; JENKINS, NA; WITTE, ON				RAWLINGS, DJ; SAFFRAN, DC; TSUKADA, S; LARGAESPADA, DA; GRIMALDI, JC; COHEN, L; MOHR, RN; BAZAN, JF; HOWARD, M; COPELAND, NG; JENKINS, NA; WITTE, ON			MUTATION OF UNIQUE REGION OF BRUTONS TYROSINE KINASE IN IMMUNODEFICIENT XID MICE	SCIENCE			English	Article							X-LINKED AGAMMAGLOBULINEMIA; B-CELLS; LYMPHOCYTES-B; BONE-MARROW; CHROMOSOME; EXPRESSION; GENE	The cytoplasmic tyrosine kinase, Bruton's tyrosine kinase (Btk, formerly bpk or atk), is crucial for B cell development. Loss of kinase activity results in the human immunodeficiency, X-linked agammaglobulinemia, characterized by a failure to produce B cells. In the murine X-linked immunodeficiency (XID), B cells are present but respond abnormally to activating signals. The Btk gene, btk, was mapped to the xid region of the mouse X chromosome by interspecific backcross analysis. A single conserved residue within the amino terminal unique region of Btk was mutated in XID mice. This change in xid probably interferes with normal B cell signaling mediated by Btk protein interactions.	UNIV CALIF LOS ANGELES,HOWARD HUGHES MED INST,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT MICROBIOL & MOLEC GENET,LOS ANGELES,CA 90024; NCI,FREDERICK CANC RES & DEV CTR,ABL BASIC RES PROGRAM,MAMMALIAN GENET LAB,FREDERICK,MD 21702; DNAX RES INST MOLEC & CELLULAR BIOL INC,MOLEC & CELLULAR BIOL RES INST,PALO ALTO,CA 94304	Howard Hughes Medical Institute; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.			Largaespada, David/C-9832-2014; Bazan, J. Fernando/B-4562-2010; Jones, Jeffrey A/E-9827-2013		NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036834] Funding Source: NIH RePORTER; OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline; NIAMS NIH HHS [AR36834] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BENNER SA, 1992, CURR OPIN STRUC BIOL, V2, P402; BROWN SDM, 1992, MAMM GENOME, V3, pS274, DOI 10.1007/BF00648438; CHUNG HY, 1992, J IMMUNOL, V149, P3456; CLARK EA, 1991, ANNU REV IMMUNOL, V9, P97; CONLEY ME, 1986, NEW ENGL J MED, V315, P564, DOI 10.1056/NEJM198608283150907; CONLEY ME, 1985, J IMMUNOL, V134, P3070; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DEFRANCO AL, 1992, EUR J BIOCHEM, V210, P381, DOI 10.1111/j.1432-1033.1992.tb17432.x; FORRESTER LM, 1987, J EXP MED, V165, P949, DOI 10.1084/jem.165.4.949; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GO NF, 1990, J EXP MED, V172, P1625, DOI 10.1084/jem.172.6.1625; Green EL, 1981, GENETICS PROBABILITY, P77; GREGORY RJ, 1987, MOL CELL BIOL, V7, P2119, DOI 10.1128/MCB.7.6.2119; GRIBSKOV M, 1990, METHOD ENZYMOL, V183, P146; Hardy R R, 1990, Semin Immunol, V2, P197; HARDY RR, 1983, NATURE, V306, P270, DOI 10.1038/306270a0; HEYECK SD, 1993, P NATL ACAD SCI USA, V90, P669, DOI 10.1073/pnas.90.2.669; HILLYARD AL, 1992, MOUSE GENOME, V90, P8; Innis M. A., 1990, PCR PROTOCOLS GUIDE, P3; KITOSHI Y, IN PRESS INT IMMKUNO; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; MANO H, 1990, ONCOGENE, V5, P1781; MANO H, 1993, ONCOGENE, V8, P417; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MOSIER DE, 1985, J MOL CELL IMMUNOL, V2, P70; NAHM MH, 1983, J EXP MED, V158, P920, DOI 10.1084/jem.158.3.920; RAWLINGS DE, UNPUB; ROLINK A, 1991, CELL, V66, P1081, DOI 10.1016/0092-8674(91)90032-T; ROST B, 1992, NATURE, V360, P540, DOI 10.1038/360540b0; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHER I, 1982, ADV IMMUNOL, V33, P1, DOI 10.1016/S0065-2776(08)60834-2; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; TAKEMORI T, 1987, EMBO J, V6, P951, DOI 10.1002/j.1460-2075.1987.tb04844.x; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WEISS R, 1984, RNA TUMOR VIRUSES MO; WHITLOCK CA, 1982, P NATL ACAD SCI-BIOL, V79, P3608, DOI 10.1073/pnas.79.11.3608; WICKER LS, 1986, CURR TOP MICROBIOL, V124, P87; [No title captured]; 1990, HDB GENETICALLY STAN, P9	40	780	799	1	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 16	1993	261	5119					358	361		10.1126/science.8332901	http://dx.doi.org/10.1126/science.8332901			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM678	8332901				2022-12-01	WOS:A1993LM67800038
J	STEINE, S				STEINE, S			WILL IT HURT, DOCTOR - FACTORS PREDICTING PATIENTS EXPERIENCE OF PAIN DURING DOUBLE-CONTRAST EXAMINATION OF THE COLON	BRITISH MEDICAL JOURNAL			English	Article											STEINE, S (corresponding author), UNIV OSLO,DEPT GEN PRACTICE,N-0264 OSLO 2,NORWAY.							FORK FT, 1982, DIAGNOSTIC VALUE LAR; Hosmer D, 2013, APPL LOGISTIC REGRES; MORIARTY KJ, 1992, BRIT MED J, V304, P1166, DOI 10.1136/bmj.304.6835.1166; STEINE S, 1992, Scandinavian Journal of Primary Health Care, V10, P134, DOI 10.3109/02813439209014050; 1990, INCIDENCE CANCER NOR	5	7	7	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1993	307	6896					100	100		10.1136/bmj.307.6896.100	http://dx.doi.org/10.1136/bmj.307.6896.100			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM585	8343703	Green Published, Bronze			2022-12-01	WOS:A1993LM58500025
J	HE, SY; HUANG, HC; COLLMER, A				HE, SY; HUANG, HC; COLLMER, A			PSEUDOMONAS-SYRINGAE PV SYRINGAE HARPIN (PSS) - A PROTEIN THAT IS SECRETED VIA THE HRP PATHWAY AND ELICITS THE HYPERSENSITIVE RESPONSE IN PLANTS	CELL			English	Article							AVIRULENCE GENE; ERWINIA-RUBRIFACIENS; CULTIVAR SPECIFICITY; YOP PROTEINS; CLUSTER; TOBACCO; PATHOGENICITY; MEMBRANE; CLONING; CELLS	The ability of P. syringae to elicit the hypersensitive response in nonhost plants or pathogenesis in hosts is controlled by hrp genes. The P. syringae pv. syringae 61 hrpZ gene encodes harpin(Pss), a 34.7 kd extracellular protein that elicits hypersensitive necrosis in tobacco and other plants. Harpin(Pss) is heat stable, glycine rich, dissimilar in amino acid sequence to any known protein, produced only in apoplastic fluid-mimicking minimal media, and secreted in a HrpH-dependent manner. The carboxy-terminal 148 amino acid portion of harpin(Pss) contains two directly repeated sequences of GGGLGTP and QTGT and is sufficient and necessary for elicitor activity. The necrosis elicited by harpin(Pss) is an active response of the plant, which can be inhibited by alpha-amanitin, cycloheximide, lanthanum chloride, or sodium vanadate.	CORNELL UNIV,DEPT PLANT PATHOL,ITHACA,NY 14853; NATL CHUNGHSING UNIV,AGR BIOTECHNOL LABS,TAICHUNG 40227,TAIWAN	Cornell University; National Chung Hsing University				He, Sheng Yang/0000-0003-1308-498X				ALLAOUI A, 1993, MOL MICROBIOL, V7, P59, DOI 10.1111/j.1365-2958.1993.tb01097.x; ALLEN C, 1991, MOL PLANT MICROBE IN, V4, P147, DOI 10.1094/MPMI-4-147; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; ARLAT M, 1991, MOL PLANT MICROBE IN, V4, P593, DOI 10.1094/MPMI-4-593; ATKINSON MM, 1990, PLANT PHYSIOL, V92, P215, DOI 10.1104/pp.92.1.215; Ausubel M., 1989, MOL REPROD DEV, V1, P146, DOI [10.1002/mrd.1080010210, DOI 10.1002/MRD.1080010210]; AZAD HR, 1984, PHYTOPATHOLOGY, V74, P61, DOI 10.1094/Phyto-74-61; BEER SV, 1993, ADV MOL GENETICS PLA, V2, P281; BRADLEY DJ, 1992, CELL, V70, P21, DOI 10.1016/0092-8674(92)90530-P; COLLMER A, 1993, IN PRESS BIOTECHNOLO; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWIT PJGM, 1982, PHYSIOL PLANT PATHOL, V21, P1, DOI 10.1016/0048-4059(82)90002-9; FENSELAU S, 1992, MOL PLANT MICROBE IN, V5, P390, DOI 10.1094/MPMI-5-390; GALAN JE, 1992, J BACTERIOL, V174, P4338; GARDNER JM, 1976, J BACTERIOL, V127, P451, DOI 10.1128/JB.127.1.451-460.1976; GENIN S, 1993, MOL GENETICS PLANT M, V2, P259; GOUGH CL, 1992, MOL PLANT MICROBE IN, V5, P384, DOI 10.1094/MPMI-5-384; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; HE SY, 1991, J BACTERIOL, V173, P4310, DOI 10.1128/JB.173.14.4310-4317.1991; HIRANO SS, 1990, ANNU REV PHYTOPATHOL, V28, P155, DOI 10.1146/annurev.py.28.090190.001103; HUANG HC, 1991, MOL PLANT MICROBE IN, V4, P469, DOI 10.1094/MPMI-4-469; HUANG HC, 1988, J BACTERIOL, V170, P4748, DOI 10.1128/jb.170.10.4748-4756.1988; HUANG HC, 1992, J BACTERIOL, V174, P6878, DOI 10.1128/JB.174.21.6878-6885.1992; HUANG HC, 1993, IN PRESS MOL PLANT M; HUANG Y, 1989, Molecular Plant-Microbe Interactions, V2, P132, DOI 10.1094/MPMI-2-132; HUYNH TV, 1989, SCIENCE, V245, P1374, DOI 10.1126/science.2781284; KEEN NT, 1990, ANNU REV GENET, V24, P447, DOI 10.1146/annurev.ge.24.120190.002311; KEEN NT, 1990, MOL PLANT MICROBE IN, V3, P112, DOI 10.1094/MPMI-3-112; KEEN NT, 1981, PHYSIOL PLANT PATHOL, V18, P325; KING EO, 1954, J LAB CLIN MED, V44, P301; KLEMENT Z, 1963, NATURE, V199, P299, DOI 10.1038/199299b0; KLEMENT Z, 1964, PHYTOPATHOLOGY, V54, P474; Klement Z., 1982, PHYTOPATHOGENIC PROK, V2, P149; KNOOP V, 1991, J BACTERIOL, V173, P7142, DOI 10.1128/jb.173.22.7142-7150.1991; KOBAYASHI DY, 1989, P NATL ACAD SCI USA, V86, P157, DOI 10.1073/pnas.86.1.157; LABY RJ, 1992, MOL PLANT MICROBE IN, V5, P412, DOI 10.1094/MPMI-5-412; LINDGREN PB, 1988, MOL GEN GENET, V211, P499, DOI 10.1007/BF00425707; LINDGREN PB, 1986, J BACTERIOL, V168, P512, DOI 10.1128/jb.168.2.512-522.1986; LINDOW SE, 1993, IN PRESS BIOTECHNOLO; MICHIELS T, 1991, J BACTERIOL, V173, P4994, DOI 10.1128/jb.173.16.4994-5009.1991; MICHIELS T, 1990, INFECT IMMUN, V58, P2840, DOI 10.1128/IAI.58.9.2840-2849.1990; MICHIELS T, 1991, J BACTERIOL, V173, P1677, DOI 10.1128/jb.173.5.1677-1685.1991; NIEPOLD F, 1985, P NATL ACAD SCI USA, V82, P406, DOI 10.1073/pnas.82.2.406; PEARCE G, 1991, SCIENCE, V253, P895, DOI 10.1126/science.253.5022.895; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; RAHME LG, 1992, J BACTERIOL, V174, P3499, DOI 10.1128/JB.174.11.3499-3507.1992; Sambrook J., 1989, MOL CLONING LAB MANU; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHOTTENSTOMA IMJ, 1988, PHYSIOL MOL PLANT P, V33, P59, DOI 10.1016/0885-5765(88)90043-4; SEQUEIRA L, 1976, SPECIFICITY PLANT DI, P289; SEQUEIRA L, 1979, USDA TECH B, V1586, P111; Silhavy T.J., 1984, EXPT GENE FUSIONS; STASKAWICZ BJ, 1984, P NATL ACAD SCI-BIOL, V81, P6024, DOI 10.1073/pnas.81.19.6024; TARTOF KD, 1987, FOCUS, V9, P12; TURNER JG, 1974, PHYTOPATHOLOGY, V64, P885, DOI 10.1094/Phyto-64-885; WEI ZM, 1992, SCIENCE, V257, P85, DOI 10.1126/science.1621099; WEI ZM, 1991, ADV MOL GENETICS PLA, P53; WHALEN MC, 1991, PLANT CELL, V3, P49, DOI 10.1105/tpc.3.1.49; WILLIS DK, 1991, MOL PLANT MICROBE IN, V4, P132, DOI 10.1094/MPMI-4-132; XIAO YX, 1992, J BACTERIOL, V174, P1734, DOI 10.1128/jb.174.6.1734-1741.1992; YUCEL I, 1989, APPL ENVIRON MICROB, V55, P1724, DOI 10.1128/AEM.55.7.1724-1729.1989; [No title captured]	62	397	462	2	22	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 2	1993	73	7					1255	1266		10.1016/0092-8674(93)90354-S	http://dx.doi.org/10.1016/0092-8674(93)90354-S			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Biochemistry & Molecular Biology; Cell Biology	LL209	8324821	Bronze			2022-12-01	WOS:A1993LL20900003
J	GODIN, IE; GARCIAPORRERO, JA; COUTINHO, A; DIETERLENLIEVRE, F; MARCOS, MAR				GODIN, IE; GARCIAPORRERO, JA; COUTINHO, A; DIETERLENLIEVRE, F; MARCOS, MAR			PARAAORTIC SPLANCHNOPLEURA FROM EARLY MOUSE EMBRYOS CONTAINS B1A CELL PROGENITORS	NATURE			English	Article							YOLK-SAC; B-CELLS; MONOCLONAL-ANTIBODY; STEM-CELLS; ORIGIN; LYMPHOPOIESIS; ONTOGENY; SYSTEM; MICE	DEFINITIVE erythropoiesis in birds originates from stem cells that emerge in the splanchnopleural mesoderm near the embryonic aorta1-4. The yolk sac is still generally held to be the unique provider of haematopoietic stem cells during mammalian ontogeny5, although there may be an alternative intraembryonic source of stem cells in the mouse fetus6,7. Here we search for a possible non-yolk-sac source of stem cells by grafting intraembryonic splanchnopleura from 10- to 18-somite mouse embryos into adult immunodeficient SCID mice. We find significant amounts of donor-derived serum IgM, normal numbers of IgM-secreting plasma cells, and the B1a (IgM(bright)(a)B220(dull)CD5+) cell subset to be fully reconstituted by donor progenitors 3 to 6 months after engraftment. The haematogenic capacity revealed in our experiments is present in a previously unrecognized site, the earliest described in the embryo, 12 hours before fetal liver colonization.	COLL FRANCE, F-94130 NOGENT SUR MARNE, FRANCE; UNIV CANTABRIA, DEPT ANAT & CELL BIOL, E-39011 SANTANDER, SPAIN; INST PASTEUR, CNRS, UNITE IMMUNOBIOL 357, F-75724 PARIS 15, FRANCE; UNIV SALAMANCA, DEPT MED, E-37007 SALAMANCA, SPAIN	UDICE-French Research Universities; PSL Research University Paris; College de France; Universidad de Cantabria; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Universite Paris Cite; University of Salamanca	GODIN, IE (corresponding author), CNRS, INST EMBRYOL CELLULAIRE, F-94130 NOGENT SUR MARNE, FRANCE.		GODIN, Isabelle/K-5769-2013	GODIN, Isabelle/0000-0001-8577-8388; Coutinho, Antonio/0000-0002-0857-9227				COFFMAN RL, 1981, J EXP MED, V153, P269, DOI 10.1084/jem.153.2.269; CORMIER F, 1988, DEVELOPMENT, V102, P279; DIETERLENLIEVRE F, 1975, J EMBRYOL EXP MORPH, V33, P607; DIETERLENLIEVRE F, 1984, DEV COMP IMMUNOL S, V3, P75; FOSTER I, 1987, EUR J IMMUNOL, V17, P521; GRANDIEN A, 1992, INT IMMUNOL, V4, P1153, DOI 10.1093/intimm/4.10.1153; HARDY RR, 1991, P NATL ACAD SCI USA, V88, P11550, DOI 10.1073/pnas.88.24.11550; HAYAKAWA K, 1988, ANNU REV IMMUNOL, V6, P197, DOI 10.1146/annurev.iy.06.040188.001213; KANTOR AB, 1991, IMMUNOL TODAY, V12, P389, DOI 10.1016/0167-5699(91)90136-H; KANTOR AB, 1992, P NATL ACAD SCI USA, V89, P3320, DOI 10.1073/pnas.89.8.3320; Kroese FGM, 1989, INT IMMUNOL, V1, P75, DOI 10.1093/intimm/1.1.75; LASSILA O, 1978, NATURE, V272, P353, DOI 10.1038/272353a0; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; MARCOS MAR, 1992, ANN NY ACAD SCI, V651, P433; MARCOS MAR, 1991, SCAND J IMMUNOL, V34, P129, DOI 10.1111/j.1365-3083.1991.tb01529.x; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; NISHIKAWA SI, 1986, IMMUNOGENETICS, V23, P137, DOI 10.1007/BF00377976; OGAWA M, 1988, EMBO J, V7, P1337, DOI 10.1002/j.1460-2075.1988.tb02949.x; PAIGE CJ, 1979, J EXP MED, V150, P548, DOI 10.1084/jem.150.3.548; SCHUPPEL R, 1987, EUR J IMMUNOL, V17, P739, DOI 10.1002/eji.1830170527; SEDGWICK JD, 1983, J IMMUNOL METHODS, V57, P301, DOI 10.1016/0022-1759(83)90091-1; SOLVASON N, 1991, INT IMMUNOL, V3, P543, DOI 10.1093/intimm/3.6.543	22	309	314	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	1993	364	6432					67	70		10.1038/364067a0	http://dx.doi.org/10.1038/364067a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK818	8316299				2022-12-01	WOS:A1993LK81800059
J	HULSKAMP, M; MISERA, S; JURGENS, G				HULSKAMP, M; MISERA, S; JURGENS, G			GENETIC DISSECTION OF TRICHOME CELL-DEVELOPMENT IN ARABIDOPSIS	CELL			English	Article							SIGNAL TRANSDUCTION; C-ELEGANS; DROSOPHILA; THALIANA; FATE; MAP	Trichomes are specialized epidermal cells that are regularly distributed on the leaves of Arabidopsis plants. During leaf development, each trichome undergoes cell morphogenesis, resulting in a very precise architecture. We have isolated and characterized more than 70 trichome mutants that represent 21 different genes. By analyzing their cellular phenotypes, it has been possible to define specific steps in trichome development. Although these steps normally occur in a temporal sequence, genetic dissection indicates that the morphology of the mature cell is largely assembled in independent events. The results suggest a model of how a specialized cell type originates from a uniform cell layer.	UNIV MUNICH, INST GENET & MIKROBIOL, LEHRSTUHL GENET, D-80638 MUNICH, GERMANY	University of Munich				Hulskamp, Martin/0000-0003-4165-6754				APPEL LF, 1993, P NATL ACAD SCI USA, V90, P4937, DOI 10.1073/pnas.90.11.4937; Chant J, 1991, CURR OPIN GENET DEV, V1, P342, DOI 10.1016/S0959-437X(05)80298-9; COUSO JP, 1993, SCIENCE, V259, P484, DOI 10.1126/science.8424170; DRUBIN DG, 1991, CELL, V65, P1093, DOI 10.1016/0092-8674(91)90001-F; FEENSTRA WJ, 1978, INFORM SERV, V15, P35; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; HAUGHN GW, 1988, DEV GENET, V9, P73, DOI 10.1002/dvg.1020090202; HILL RJ, 1992, NATURE, V358, P470, DOI 10.1038/358470a0; HOLSTEIN TW, 1990, DEV BIOL, V142, P392, DOI 10.1016/0012-1606(90)90360-U; IRISH VF, 1992, DEVELOPMENT, V115, P745; KOORNNEEF M, 1983, J HERED, V74, P265, DOI 10.1093/oxfordjournals.jhered.a109781; KOORNNEEF M, 1982, MUTAT RES, V93, P109, DOI 10.1016/0027-5107(82)90129-4; Koornneef M., 1987, ARABID INF SERV, V1987, P46; Koornneef M., 1981, ARABID INF SERV, V18, P45; KOORNNEEF M, 1983, ARABID INF SERV, V20, P89; Kramer Helmut, 1993, Trends in Cell Biology, V3, P103, DOI 10.1016/0962-8924(93)90165-W; LEECHEN S, 1967, CAN J GENET CYTOL, V9, P381, DOI 10.1139/g67-039; LLOYD AM, 1992, SCIENCE, V258, P1773, DOI 10.1126/science.1465611; Marks M D, 1991, Symp Soc Exp Biol, V45, P77; MAYER U, 1991, NATURE, V353, P402, DOI 10.1038/353402a0; MAYER U, 1993, DEVELOPMENT, V117, P149; MEDFORD JI, 1992, PLANT CELL, V4, P1029, DOI 10.1105/tpc.4.9.1029; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; POETHIG S, 1989, TRENDS GENET, V5, P273, DOI 10.1016/0168-9525(89)90101-7; Poodry C.A., 1980, Genetics and Biology of Drosophila, V2d, P443; REDEI GP, 1962, Z VEREBUNGSL, V93, P164; RUBIN GM, 1991, TRENDS GENET, V7, P372, DOI 10.1016/0168-9525(91)90258-R; SIMPSON P, 1990, DEVELOPMENT, V109, P509; SMITH LG, 1992, PLANT CELL, V4, P1017, DOI 10.1105/tpc.4.9.1017; STERNBERG PW, 1991, TRENDS GENET, V7, P366, DOI 10.1016/0168-9525(91)90257-Q; Uphof J.C.T., 1962, ENCYCL PLANT ANAT, V5, P1; WOODS DF, 1992, ANNU REV GENET, V26, P305	32	500	539	5	127	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 11	1994	76	3					555	566		10.1016/0092-8674(94)90118-X	http://dx.doi.org/10.1016/0092-8674(94)90118-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	8313475				2022-12-01	WOS:A1994MX20700015
J	SCHILD, H; MAVADDAT, N; LITZENBERGER, C; EHRICH, EW; DAVIS, MM; BLUESTONE, JA; MATIS, L; DRAPER, RK; CHIEN, YH				SCHILD, H; MAVADDAT, N; LITZENBERGER, C; EHRICH, EW; DAVIS, MM; BLUESTONE, JA; MATIS, L; DRAPER, RK; CHIEN, YH			THE NATURE OF MAJOR HISTOCOMPATIBILITY COMPLEX RECOGNITION BY GAMMA-DELTA-T-CELLS	CELL			English	Article							ANTIGEN-PROCESSING MUTANT; INVARIANT CHAIN PEPTIDES; LIPID-LINKED FORM; HLA-DR MOLECULES; CLASS-I; MONOCLONAL-ANTIBODIES; RECEPTOR; BINDING; EXPRESSION; GENE	Despite intensive efforts, the general rules for gammadelta T cell recognition remain undefined. Here, we take advantage of the detailed knowledge of the molecular structure and biosynthetic pathways of major histocompatibility complex (MHC) molecules to analyze the recognition properties of the gammadelta T cell clones LBK5 (specific for the class II MHC, IE(k)) and G8 (specific for the nonclassical class I MHC, TL10b). We find that the activation of these clones requires neither class I nor class II antigen-processing and that peptides do not confer specificity. Epitope mapping also shows that the topology of gammadelta T cell receptor interaction with the MHC is distinct from that of alphabeta T cells. These results suggest that the molecular nature of gammadelta T cell recognition is fundamentally different than that of alphabeta T cells.	STANFORD UNIV,MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,STANFORD,CA 94305; UNIV WESTERN AUSTRALIA,DEPT MED,NEDLANDS,WA 6009,AUSTRALIA; STANFORD UNIV,HOWARD HUGHES MED INST,STANFORD,CA 94305; UNIV CHICAGO,COMM IMMUNOL,CHICAGO,IL 60637; ALEXION PHARMACEUT,NEW HAVEN,CT 06511; UNIV TEXAS,PROGRAM MOLEC & CELLULAR BIOL,RICHARDSON,TX 75083	Stanford University; University of Western Australia; Howard Hughes Medical Institute; Stanford University; University of Chicago; University of Texas System; University of Texas Dallas				Davis, Mark/0000-0001-6868-657X; Mavaddat, Nasim/0000-0003-0307-055X				ATTAYA M, 1992, NATURE, V355, P647, DOI 10.1038/355647a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BRAM RJ, 1993, MOL CELL BIOL, V13, P4760, DOI 10.1128/MCB.13.8.4760; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BUUS S, 1986, CELL, V47, P1071, DOI 10.1016/0092-8674(86)90822-6; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0; COLBAUGH PA, 1993, ENDOSOMES LYSOSOMES, V1, P169; DAVIES DR, 1990, ANNU REV BIOCHEM, V59, P439, DOI 10.1146/annurev.biochem.59.1.439; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; EHRICH EW, 1993, J EXP MED, V178, P713, DOI 10.1084/jem.178.2.713; GERMAIN RN, 1993, ANNU REV IMMUNOL, V11, P403, DOI 10.1146/annurev.iy.11.040193.002155; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GILLIS S, 1978, J IMMUNOL, V120, P2027; HAAS W, 1993, ANNU REV IMMUNOL, V11, P637, DOI 10.1146/annurev.iy.11.040193.003225; HOULDEN BA, 1989, COLD SH Q B, V54, P45; ITO K, 1990, CELL, V62, P549, DOI 10.1016/0092-8674(90)90019-B; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; JOLY E, 1991, GENE, V97, P213, DOI 10.1016/0378-1119(91)90054-F; JORGENSEN JL, 1992, NATURE, V355, P224, DOI 10.1038/355224a0; KABELITZ D, 1990, J IMMUNOL, V145, P2827; KANE KP, 1989, MOL IMMUNOL, V26, P759, DOI 10.1016/0161-5890(89)90036-9; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAI MZ, 1987, J IMMUNOL, V139, P3973; LIN AY, 1990, SCIENCE, V249, P677, DOI 10.1126/science.1696397; LORENZ RG, 1988, P NATL ACAD SCI USA, V85, P5220, DOI 10.1073/pnas.85.14.5220; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MALNATI MS, 1992, NATURE, V357, P702, DOI 10.1038/357702a0; MATIS LA, 1989, SCIENCE, V245, P746, DOI 10.1126/science.2528206; MATZINGER P, 1977, CELL IMMUNOL, V29, P1, DOI 10.1016/0008-8749(77)90269-6; MCCOY KL, 1989, J IMMUNOL, V143, P29; MEHRINGER JH, 1991, J IMMUNOL, V146, P920; NEEFJES JJ, 1992, IMMUNOL TODAY, V13, P179, DOI 10.1016/0167-5699(92)90123-O; OZATO K, 1980, J IMMUNOL, V124, P533; PFEFFER K, 1992, J IMMUNOL, V148, P575; PFEFFER K, 1990, EUR J IMMUNOL, V20, P1175, DOI 10.1002/eji.1830200534; REAY PA, 1992, EMBO J, V11, P2829, DOI 10.1002/j.1460-2075.1992.tb05350.x; RIBERDY JM, 1992, J IMMUNOL, V148, P2586; RIBERDY JM, 1992, NATURE, V360, P474, DOI 10.1038/360474a0; ROCK EP, 1994, J EXP MED, V179, P985; SAMELSON LE, 1983, P NATL ACAD SCI-BIOL, V80, P6972, DOI 10.1073/pnas.80.22.6972; Schrader J W, 1983, Lymphokine Res, V2, P83; SETTE A, 1992, SCIENCE, V258, P1801, DOI 10.1126/science.1465617; SHERMAN LA, 1993, ANNU REV IMMUNOL, V11, P385, DOI 10.1146/annurev.immunol.11.1.385; SPIES T, 1991, NATURE, V351, P323, DOI 10.1038/351323a0; THOMAS JR, 1990, BIOCHEMISTRY-US, V29, P5413, DOI 10.1021/bi00475a001; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; WETTSTEIN DA, 1991, J EXP MED, V174, P219, DOI 10.1084/jem.174.1.219; YAGI JJ, 1990, J IMMUNOL, V144, P892; ZEMMOUR J, 1992, J IMMUNOL, V148, P1941	50	384	393	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 14	1994	76	1					29	37		10.1016/0092-8674(94)90170-8	http://dx.doi.org/10.1016/0092-8674(94)90170-8			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287478				2022-12-01	WOS:A1994MR49500004
J	GWALTNEY, JM; PHILLIPS, CD; MILLER, RD; RIKER, DK				GWALTNEY, JM; PHILLIPS, CD; MILLER, RD; RIKER, DK			COMPUTED TOMOGRAPHIC STUDY OF THE COMMON COLD	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FREQUENCY; INFECTIONS; VOLUNTEERS	Background. Colds are common, but the abnormalities they produce in the nasal passages and sinus cavities have not been well defined. Methods. We studied healthy adult volunteers with self-diagnosed colds of 48 to 96 hours' duration and obtained the following data: information on symptoms, computed tomographic (CT) studies of the nasal passages and sinuses, mucosal-transport times, measures of nasal-airway resistance, and viral-culture studies. Thirty-one subjects (mean age, 24 years) had complete evaluations, including CT scans, which were read without knowledge of the clinical data. An additional 79 subjects underwent the same evaluations, except the CT scans. Results. Of the 31 subjects with CT scans, 24 (77 percent) had occlusion of the ethmoid infundibulum; 27 (87 percent) had abnormalities of one or both maxillary-sinus cavities; 20 (65 percent) had abnormalities of the ethmoid sinuses; 10 (32 percent) had abnormalities of the frontal sinuses; and 12 (39 percent) had abnormalities of the sphenoid sinuses. Infraorbital air cells were present in 14 subjects (45 percent), and pneumatization of the middle turbinate (concha bullosa) was noted in 11 subjects (35 percent). Also common were engorged turbinates (in 7 subjects) and thickening of the walls of the nasal passages (in 13). After two weeks, the CT studies were repeated in 14 subjects, none of whom received antibiotics. In 11 of these subjects (79 percent) the abnormalities of the infundibula and sinuses had cleared or markedly improved. Nasal-airway resistance was abnormal in 29 (94 percent) and mucosal transport in 19 (61 percent) of the 31 subjects who had CT scans. Rhinovirus was detected in nasal secretions from 24 (27 percent) of 90 subjects. Conclusions. The common cold is associated with frequent and variable anatomical involvement of the upper airways, including occlusion and abnormalities in the sinus cavities.	UNIV VIRGINIA,HLTH SCI CTR,DEPT RADIOL,CHARLOTTESVILLE,VA 22908; PROCTER & GAMBLE CO,CINCINNATI,OH 45239	University of Virginia; Procter & Gamble	GWALTNEY, JM (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,DEPT INTERNAL MED,CHARLOTTESVILLE,VA 22908, USA.		Riker, Donald/AAR-8380-2020					BOLGER WE, 1991, LARYNGOSCOPE, V101, P56; CALHOUN KH, 1991, OTOLARYNG HEAD NECK, V104, P480, DOI 10.1177/019459989110400409; Clark S, 1989, AM J RHINOL, P11; CONNELL JT, 1982, ANN ALLERGY, V49, P179; CONNELL JT, 1987, AM J RHINOL, V1, P87; DINGLE JH, 1964, ILLNESS HOME STUDY 2, P347; DOYLE W J, 1987, Rhinology (Utrecht), V25, P167; DUCHATEAU GSMJE, 1985, LARYNGOSCOPE, V95, P854; EVANS FO, 1975, NEW ENGL J MED, V293, P735, DOI 10.1056/NEJM197510092931502; Fox J.P., 1980, VIRUSES FAMILIES SUR; Gwaltney J.M., 1989, DIAGNOSTIC PROCEDURE, P579; GWALTNEY JM, 1966, NEW ENGL J MED, V275, P1261, DOI 10.1056/NEJM196612082752301; HENDLEY JO, 1972, J INFECT DIS, V125, P243, DOI 10.1093/infdis/125.3.243; JACKSON GG, 1958, ARCH INTERN MED, V101, P267, DOI 10.1001/archinte.1958.00260140099015; MONTO AS, 1987, J INFECT DIS, V156, P43, DOI 10.1093/infdis/156.1.43; PUCHELLE E, 1981, ACTA OTO-LARYNGOL, V91, P297, DOI 10.3109/00016488109138511; WALD ER, 1991, PEDIATRICS, V87, P129	17	449	467	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	1994	330	1					25	30		10.1056/NEJM199401063300105	http://dx.doi.org/10.1056/NEJM199401063300105			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP649	8259141				2022-12-01	WOS:A1994MP64900005
J	COHEN, D; CHUMAKOV, I; WEISSENBACH, J				COHEN, D; CHUMAKOV, I; WEISSENBACH, J			A 1ST-GENERATION PHYSICAL MAP OF THE HUMAN GENOME	NATURE			English	Article							YEAST ARTIFICIAL CHROMOSOMES; HUMAN Y-CHROMOSOME; DNA; STRATEGY; CLONES; LIBRARY; ELEGANS; VECTORS	SETS of ordered overlapping cloned genomic DNA fragments that span each of the human chromosomes are urgently needed for identification of human disease genes. Such a physical map also provides unique material to study the structure and function of the genome. We have therefore exhaustively analysed the CEPH yeast artificial chromosome (YAC) library, which contains 33,000 clones, whose insert size was individually determined. These YACs have an average length of 0.9 megabases and cover the equivalent of 10 haploid genomes. Several mapping techniques were combined to provide multiple sources of structural information for most of these clones. Finally, the library was screened with more than 2,000 genetic markers quasiuniformly distributed over 90% of the genome. These results should allow the scientific community to construct detailed maps of all human chromosomes. Moreover, we propose a data analysis strategy that produces a first-generation integrated map covering most of the human genome.	GENETHON,F-91002 EVRY,FRANCE; INST PASTEUR,CNRS,URA 1445,F-75014 PARIS,FRANCE	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	COHEN, D (corresponding author), FDN JEAN DAUSSET,CEPH,27 RUE JULIETTE DODU,F-75010 PARIS,FRANCE.							BARILLOT E, 1991, P NATL ACAD SCI USA, V88, P3917, DOI 10.1073/pnas.88.9.3917; BELLANNECHANTELOT C, 1992, CELL, V70, P1059, DOI 10.1016/0092-8674(92)90254-A; BURKE DT, 1987, SCIENCE, V236, P806, DOI 10.1126/science.3033825; CHUMAKOV I, 1992, NATURE, V359, P380, DOI 10.1038/359380a0; CHUMAKOV IM, 1992, NAT GENET, V1, P222, DOI 10.1038/ng0692-222; COULSON A, 1986, P NATL ACAD SCI USA, V83, P7821, DOI 10.1073/pnas.83.20.7821; DEJONG PJ, 1989, CYTOGENET CELL GENET, V51, P985; FOOTE S, 1992, SCIENCE, V258, P60, DOI 10.1126/science.1359640; GREEN ED, 1991, GENOMICS, V11, P658, DOI 10.1016/0888-7543(91)90073-N; KOHARA Y, 1987, CELL, V50, P495, DOI 10.1016/0092-8674(87)90503-4; MULLIVOR RA, 1991, AM J HUM GENET S, V49, P370; NELSON DL, 1989, P NATL ACAD SCI USA, V86, P6686, DOI 10.1073/pnas.86.17.6686; OLSON M, 1989, SCIENCE, V245, P1434, DOI 10.1126/science.2781285; OLSON MV, 1986, P NATL ACAD SCI USA, V83, P7826, DOI 10.1073/pnas.83.20.7826; RIED T, 1992, P NATL ACAD SCI USA, V89, P1388, DOI 10.1073/pnas.89.4.1388; SULSTON J, 1992, NATURE, V356, P37, DOI 10.1038/356037a0; VANOMMEN GJ, 1993, HUGO B; VOLLRATH D, 1992, SCIENCE, V258, P52, DOI 10.1126/science.1439769; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	19	476	500	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 16	1993	366	6456					698	701		10.1038/366698a0	http://dx.doi.org/10.1038/366698a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	8259213				2022-12-01	WOS:A1993MM26500073
J	BALDWIN, EP; HAJISEYEDJAVADI, O; BAASE, WA; MATTHEWS, BW				BALDWIN, EP; HAJISEYEDJAVADI, O; BAASE, WA; MATTHEWS, BW			THE ROLE OF BACKBONE FLEXIBILITY IN THE ACCOMMODATION OF VARIANTS THAT REPACK THE CORE OF T4-LYSOZYME	SCIENCE			English	Article							ACID SIDE-CHAINS; PROTEIN STRUCTURES; T4 LYSOZYME; PACKING ARRANGEMENTS; HYDROPHOBIC CORE; SEQUENCES; STABILITY; CONFORMATION; REFINEMENT; MUTATIONS	To understand better how the packing of side chains within the core influences protein structure and stability, the crystal structures were determined for eight variants of T4 lysozyme, each of which contains three to five substitutions at adjacent interior sites. Concerted main-chain and side-chain displacements, with movements of helical segments as large as 0.8 angstrom, were observed. In contrast, the angular conformations of the mutated side chains tended to remain unchanged, with torsion angles within 20-degrees of those in the wild-type structure. These observations suggest that not only the rotation of side chains but also movements of the main chain must be considered in the evaluation of which amino acid sequences are compatible with a given protein fold.	UNIV OREGON, HOWARD HUGHES MED INST, INST MOLEC BIOL, EUGENE, OR 97403 USA; UNIV OREGON, DEPT PHYS, EUGENE, OR 97403 USA	Howard Hughes Medical Institute; University of Oregon; University of Oregon				Baldwin, Enoch/0000-0002-1472-0944	NIGMS NIH HHS [GM12989, GM21967] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM012989, R01GM021967] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALDWIN EP, 1993, TECHNIQUES PROTEIN C, V4, P499; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; CHANDRASEKARAN R, 1970, INT J PROT RES, V2, P223; DAOPIN S, 1991, J MOL BIOL, V221, P647, DOI 10.1016/0022-2836(91)80079-A; DESMET J, 1992, NATURE, V356, P539, DOI 10.1038/356539a0; DUNBRACK RL, 1993, J MOL BIOL, V230, P543, DOI 10.1006/jmbi.1993.1170; ERIKSSON AE, 1992, SCIENCE, V255, P178, DOI 10.1126/science.1553543; ERIKSSON AE, 1993, J MOL BIOL, V229, P747, DOI 10.1006/jmbi.1993.1077; FAUCHERE JL, 1983, EUR J MED CHEM, V18, P369; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HURLEY JH, 1992, J MOL BIOL, V224, P1143, DOI 10.1016/0022-2836(92)90475-Y; JANIN J, 1978, J MOL BIOL, V125, P357, DOI 10.1016/0022-2836(78)90408-4; KELLIS JT, 1988, NATURE, V333, P784, DOI 10.1038/333784a0; LEE C, 1991, J MOL BIOL, V217, P373, DOI 10.1016/0022-2836(91)90550-P; LESK AM, 1980, J MOL BIOL, V136, P225, DOI 10.1016/0022-2836(80)90373-3; LESK AM, 1986, PHILOS T R SOC A, V317, P345, DOI 10.1098/rsta.1986.0044; LIM WA, 1992, BIOCHEMISTRY-US, V31, P4324, DOI 10.1021/bi00132a025; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LIM WA, IN PRESS P NATL ACAD; MATSUMURA M, 1988, NATURE, V334, P406, DOI 10.1038/334406a0; MATSUMURA M, 1989, SCIENCE, V243, P792, DOI 10.1126/science.2916125; MUCHMORE DC, 1989, METHOD ENZYMOL, V177, P44; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; POTEETE AR, 1991, BIOCHEMISTRY-US, V30, P1425, DOI 10.1021/bi00219a037; RENNELL D, 1985, VIROLOGY, V143, P280, DOI 10.1016/0042-6822(85)90115-1; RICHARDS FM, 1974, J MOL BIOL, V82, P1, DOI 10.1016/0022-2836(74)90570-1; SERRANO L, 1990, BIOCHEMISTRY-US, V29, P9343, DOI 10.1021/bi00492a006; SHORTLE D, 1990, BIOCHEMISTRY-US, V29, P8033, DOI 10.1021/bi00487a007; SUMMERS NL, 1987, J MOL BIOL, V196, P175, DOI 10.1016/0022-2836(87)90520-1; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TRONRUD DE, 1992, ACTA CRYSTALLOGR A, V48, P912, DOI 10.1107/S0108767392005415; TUFFERY P, 1991, J BIOMOL STRUCT DYN, V8, P1267, DOI 10.1080/07391102.1991.10507882; WILSON C, 1993, J MOL BIOL, V229, P996, DOI 10.1006/jmbi.1993.1100; ZHANG XJ, 1991, BIOCHEMISTRY-US, V30, P2012, DOI 10.1021/bi00222a001; 1970, J MOL BIOL, V52, P4	36	117	119	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1993	262	5140					1715	1718		10.1126/science.8259514	http://dx.doi.org/10.1126/science.8259514			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	8259514	Green Submitted			2022-12-01	WOS:A1993ML22000036
J	NELSON, KE; CELENTANO, DD; SUPRASERT, S; WRIGHT, N; EIUMTRAKUL, S; TULVATANA, S; MATANASARAWOOT, A; AKARASEWI, P; KUNTOLBUTRA, S; ROMYEN, S; SIRISOPANA, N; THEETRANONT, C				NELSON, KE; CELENTANO, DD; SUPRASERT, S; WRIGHT, N; EIUMTRAKUL, S; TULVATANA, S; MATANASARAWOOT, A; AKARASEWI, P; KUNTOLBUTRA, S; ROMYEN, S; SIRISOPANA, N; THEETRANONT, C			RISK-FACTORS FOR HIV-INFECTION AMONG YOUNG-ADULT MEN IN NORTHERN THAILAND	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNODEFICIENCY-VIRUS-INFECTION; TRANSMISSION; WOMEN	Objective.-To determine the sociodemographic and behavioral risk factors associated with human immunodeficiency virus (HIV) infection in two cohorts of young men selected for military service in northern Thailand. Design.-Military conscripts were studied cross-sectionally after conscription in May 1991 and November 1991. Risk factors were assessed by interview with trained nonmilitary interviewers. Setting.-Two military training bases in Chiang Mai, Thailand. Participants.-A total of 2417 young men aged 19 to 23 years (mean age, 21 years) conscripted by lottery into military service in the Royal Thai Army or Royal Thai Air Force from six provinces in northern Thailand. Main Outcome Measures.-Human immunodeficiency virus seroprevalence by enzyme-linked immunosorbent assay confirmed by Western blot and univariate and multivariate analyses of sociodemographic and behavioral risk factors associated with HIV seroprevalence. Results.-Overall, 289 (12.0%) of 2417 men were HIV-seropositive at baseline. The strongest associations with being HIV positive were heterosexual activities. History of sex with a female commercial sex worker (CSW) was frequent (96.5% of men who were HIV-positive and 79.0% of men who were HIV-negative) and strongly associated with HIV infection on univariate and multivariate analyses (adjusted odds ratio, 1.60 to 2.07, depending on the frequency of CSW contact). Also, sexually transmitted diseases were common and associated with HIV infection in both univariate and multivariate analyses (adjusted odds ratio, 3.36). Sex with other males and injection drug use were uncommon and not associated with HIV infection. Condom use was reported in 61.5% of men at last sex with a CSW but was not shown to be protective of prevalent HIV infection. Conclusion.-The epidemic of HIV infection has spread widely among young men in northern Thailand, despite reported frequent and recent use of condoms during sex with female CSWs. Control of HIV infection in this population will probably require more regular and effective use of condoms, prevention and treatment of sexually transmitted diseases, and reduction in the frequency of CSW contact.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21205; CHIANG MAI UNIV,DEPT FAMILY MED,CHIANG MAI,THAILAND; CHIANG MAI UNIV,DEPT PATHOL,CHIANG MAI,THAILAND; MINIST PUBL HLTH,CHIANG MAI,THAILAND; ROYAL THAI ARMY,CHIANG MAI,THAILAND; ROYAL THAI AF,CHIANG MAI,THAILAND; ROBERT WOOD JOHNSON MED SCH,PISCATAWAY,NJ; ARMED FORCES RES INST MED SCI,BANGKOK,THAILAND	Johns Hopkins University; Chiang Mai University; Chiang Mai University; Ministry of Public Health - Thailand; Rutgers State University New Brunswick; Rutgers State University Medical Center; United States Department of Defense; United States Army; Walter Reed Army Institute of Research (WRAIR); Armed Forces Research Institute of Medical Science (AFRIMS)	NELSON, KE (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT EPIDEMIOL,624 N BROADWAY,BALTIMORE,MD 21205, USA.							ALLEN S, 1991, JAMA-J AM MED ASSOC, V266, P1657, DOI 10.1001/jama.266.12.1657; BAGASRA O, 1993, J INFECT DIS, V167, P789, DOI 10.1093/infdis/167.4.789; BERKLEY SF, 1989, J INFECT DIS, V160, P22, DOI 10.1093/infdis/160.1.22; FORD N, 1991, SOC SCI MED, V33, P405, DOI 10.1016/0277-9536(91)90321-3; GREENBLATT RM, 1988, AIDS, V2, P47, DOI 10.1097/00002030-198802000-00008; HALSEY NA, 1992, JAMA-J AM MED ASSOC, V267, P2062, DOI 10.1001/jama.267.15.2062; JOHNSON AM, 1988, AIDS, V2, pS49, DOI 10.1097/00002030-198800001-00008; MUECKE MA, 1992, SOC SCI MED, V35, P891, DOI 10.1016/0277-9536(92)90103-W; PADIAN NS, 1987, REV INFECT DIS, V9, P947; Phongpaichit Pasuk, 1982, PEASANT GIRLS BANGKO, P71; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; SIMONSEN JN, 1988, NEW ENGL J MED, V319, P274, DOI 10.1056/NEJM198808043190504; SIRAPRAPASIRI T, 1991, AIDS, V5, P579, DOI 10.1097/00002030-199105000-00017; SIRISOPANA N, 1992, 8 INT C AIDS AMST; TAWEESAK N, 1992, 8TH INT C AIDS AMST; THONGCHAROEN P, 1989, HUMAN IMMUNODEFICIEN; UNGACHASAK K, 1990, 6TH INT C AIDS SAN F; UNGCHUSAK K, 1991, 7 INT C AIDS FLOR; WANGROONGSARB Y, 1985, Southeast Asian Journal of Tropical Medicine and Public Health, V16, P517; Weniger B G, 1991, AIDS, V5 Suppl 2, pS71, DOI 10.1097/00002030-199101001-00011	20	132	134	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 25	1993	270	8					955	960		10.1001/jama.270.8.955	http://dx.doi.org/10.1001/jama.270.8.955			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LT567	8345647				2022-12-01	WOS:A1993LT56700026
J	NOVELLO, AC				NOVELLO, AC			UNITED-STATES PUBLIC-HEALTH-SERVICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									OFF SURGEON GEN,WASHINGTON,DC 20201										0	5	5	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1993	270	7					806	806		10.1001/jama.270.7.806	http://dx.doi.org/10.1001/jama.270.7.806			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LR612	8340968				2022-12-01	WOS:A1993LR61200006
J	UJHELYI, MR; ROBERT, S; CUMMINGS, DM; COLUCCI, RD; GREEN, PJ; SAILSTAD, J; VLASSES, PH; ZAROWITZ, BJ				UJHELYI, MR; ROBERT, S; CUMMINGS, DM; COLUCCI, RD; GREEN, PJ; SAILSTAD, J; VLASSES, PH; ZAROWITZ, BJ			INFLUENCE OF DIGOXIN IMMUNE FAB THERAPY AND RENAL DYSFUNCTION ON THE DISPOSITION OF TOTAL AND FREE DIGOXIN	ANNALS OF INTERNAL MEDICINE			English	Article						DIGOXIN; IMMUNOGLOBULINS, FAB; KIDNEY FAILURE, CHRONIC; DRUG TOXICITY; KIDNEY DISEASES	DIGITALIS INTOXICATION; ANTIBODY FRAGMENTS; TOXIC PATIENTS; SERUM; KINETICS; PHARMACOKINETICS; FAILURE	Objective: To characterize the disposition of total and free serum digoxin following the administration of digoxin Fab antibody in patients with varying degrees of renal function. Design: Observational study of pharmacokinetics and pharmacodynamics. Setting: Critical care and telemetry units of two university-affiliated teaching institutions, Hartford Hospital and Henry Ford Hospital. Patients: Fourteen digoxin-intoxicated patients (baseline total digoxin > 3.2 nmol/mL) with mean (+/- SD) serum creatinine of 380.1 +/- 212.2 mumol/L who received digoxin Fab antibody therapy. Measurements: Serum was drawn every 12 to 24 hours for 80 to 327 hours after Fab administration. Total and free digoxin were assayed in serum by fluorescence polarization immunoassay or modified immunofluorometric assay. Results: Before Fab was administered, total digoxin ranged from 3.5 to 10,5 nmol/mL. After treatment with Fab, total digoxin increased rapidly to a mean (+/- SD) maximum of 51.8 +/- 22.7 nmol/mL and decreased to 7.2 +/- 4.7 nmol/mL at the last measurement. Total digoxin was eliminated in a two-phase fashion. The half-life of the initial phase of total digoxin decline was 11.6 +/- 4.1 hours, and the half-life of the second or terminal elimination phase was 118 +/- 57 hours. Free digoxin levels decreased rapidly following Fab therapy, to a mean nadir of 0.6 +/- 1.1 nmol/mL, but rebounded to a mean maximum free digoxin concentration of 1.7 +/- 1.3 nmol/mL in 77 +/- 46 hours. The time to maximum free digoxin rebound occurred later in patients with end-stage renal disease (n = 4) compared with other patients (127 +/- 40 hours compared with 55 +/- 28 hours). Conclusion: Elimination of digoxin following Fab therapy is prolonged in digoxin-toxic patients with renal dysfunction. In addition, rebound of free digoxin is delayed in anephric patients. Monitoring free digoxin following the administration of Fab may be of value in selected patients to guide additional Fab dosing, confirm possible rebound toxicity, or guide the reinitiation of digoxin therapy.	HARTFORD HOSP, HARTFORD, CT 06115 USA; UNIV CONNECTICUT, HARTFORD, CT 06112 USA; UNIV CONNECTICUT, STORRS, CT 06268 USA; HENRY FORD HOSP, COLL PHARM, DETROIT, MI 48202 USA; WAYNE STATE UNIV, DETROIT, MI 48202 USA; E CAROLINA UNIV, SCH MED, GREENVILLE, NC 27834 USA; THOMAS JEFFERSON UNIV, JEFFERSON MED COLL, PHILADELPHIA, PA 19107 USA; UNIV HOSP CONSORTIUM, OAK BROOK, IL USA; WELLCOME RES LABS, RES TRIANGLE PK, NC 27709 USA	Hartford Hospital; University of Connecticut; University of Connecticut; Henry Ford Health System; Henry Ford Hospital; Wayne State University; University of North Carolina; East Carolina University; Jefferson University; Wellcome Research Laboratories			Ujhelyi, Michael/AAL-1844-2020	CUMMINGS, DOYLE/0000-0002-8237-7885				ALLEN NM, 1991, DICP ANN PHARMAC, V25, P1315, DOI 10.1177/106002809102501205; ALLEN NM, 1990, DICP ANN PHARMAC, V24, P991, DOI 10.1177/106002809002401015; ANTMAN EM, 1990, CIRCULATION, V81, P1744, DOI 10.1161/01.CIR.81.6.1744; BUTLER VP, 1977, J CLIN INVEST, V59, P345, DOI 10.1172/JCI108647; COLE PL, 1986, DRUG INTEL CLIN PHAR, V20, P267, DOI 10.1177/106002808602000403; COLUCCI R D, 1989, Pharmacotherapy, V9, P175; ERDMANN E, 1989, KLIN WOCHENSCHR, V67, P16, DOI 10.1007/BF01736529; HURSTING MJ, 1987, CLIN CHEM, V33, P1652; KOUP JR, 1975, CLIN PHARMACOL THER, V18, P9; MAHDYOON H, 1990, AM HEART J, V120, P1189, DOI 10.1016/0002-8703(90)90135-K; NUWAYHID NF, 1989, THER DRUG MONIT, V11, P680, DOI 10.1097/00007691-198911000-00012; OHNHAUS EE, 1972, EUR J CLIN PHARMACOL, V5, P34, DOI 10.1007/BF00560893; RABETOY GM, 1990, AM J NEPHROL, V10, P518, DOI 10.1159/000168179; REUNING RH, 1973, J CLIN PHARMACOL, V13, P127, DOI 10.1002/j.1552-4604.1973.tb00074.x; SCHAUMANN W, 1986, EUR J CLIN PHARMACOL, V30, P527, DOI 10.1007/BF00542410; SINCLAIR AJ, 1989, BRIT J CLIN PHARMACO, V28, P352, DOI 10.1111/j.1365-2125.1989.tb05437.x; SMITH TW, 1976, NEW ENGL J MED, V294, P797, DOI 10.1056/NEJM197604082941501; SMOLARZ A, 1985, J TOXICOL-CLIN TOXIC, V23, P327, DOI 10.3109/15563658508990641; Ujhelyi M, 1990, Conn Med, V54, P63; UJHELYI MR, 1988, DRUG INTEL CLIN PHAR, V22, P345, DOI 10.1177/106002808802200421; UJHELYI MR, 1990, THER DRUG MONIT, V12, P288, DOI 10.1097/00007691-199005000-00014; UJHELYI MR, 1991, DICP ANN PHARMAC, V25, P1047, DOI 10.1177/106002809102501002; UJHELYI MR, 1992, THER DRUG MONIT, V14, P147, DOI 10.1097/00007691-199204000-00013; WENGER TL, 1985, J AM COLL CARDIOL, V5, pA118, DOI 10.1016/S0735-1097(85)80471-X; WENGER TL, 1988, PRIMARY CARDIOL, V1, P19; 1988, DIGIBIND PRODUCT INF	26	24	24	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1993	119	4					273	277		10.7326/0003-4819-119-4-199308150-00004	http://dx.doi.org/10.7326/0003-4819-119-4-199308150-00004			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV525	8328735				2022-12-01	WOS:A1993LV52500004
J	WEISS, RB; VOGELZANG, NJ; PETERSON, BA; PANASCI, LC; CARPENTER, JT; GAVIGAN, M; SARTELL, K; FREI, E; MCINTYRE, OR				WEISS, RB; VOGELZANG, NJ; PETERSON, BA; PANASCI, LC; CARPENTER, JT; GAVIGAN, M; SARTELL, K; FREI, E; MCINTYRE, OR			A SUCCESSFUL SYSTEM OF SCIENTIFIC-DATA AUDITS FOR CLINICAL-TRIALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MISCONDUCT; PROGRAM	Objective.-To report on data collected during on-site audits of source documents in the Cancer and Leukemia Group B (CALGB). Design.-A retrospective review of audit reports in four audit cycles. Setting.-A cooperative group of institutions conducting clinical trials in cancer treatment. Participants.-Patients taking part in clinical trials at collaborating CALGB institutions, members of the CALGB Data Audit Committee, and group chairmen of CALGB. Main Outcome Measure.-The results of 691 institutional audits conducted by the CALGB in 1982 through 1992 with comparisons of main CALGB institutions vs affiliates. Results.-In four full reviews of all participating institutions in the CALGB, 3787 patients have had their on-site medical records compared with data submitted to the CALGB Data Management Center. Compliance with federal regulations for oversight by an institutional review board improved from a deficiency rate of 28.0% among the main institutions and 49.6% of the affiliate institutions in the first audit cycle to respective figures of 13.3% and 28.2% in the fourth cycle. Consent form deficiencies also dropped overall from 18.5% in the first cycle to 3.9% in the fourth. Patient eligibility was verified by auditors in 94.5%, and assessment of tumor changes in response to treatment was verified in 96.4% in the fourth cycle; both figures were only slightly lower in the first cycle. Two instances of scientific impropriety were discovered for a rate of only 0.28% of all audits. Both occurred prior to 1984, and none have occurred since. Major protocol deviations in drug dosing have held steady at about 11% over four audit cycles. Over the 11-year period of audits, three main institutions and 96 affiliate institutions have discontinued CALGB membership due solely, or at least partly, to unfavorable audit results. Conclusion.-Scientific improprieties have occurred very rarely in clinical trials conducted by the CALGB. Protocol compliance in assessing patient eligibility and tumor responses has been high. Attention to administrative matters of consent forms, institutional review board approval, and ancillary data submission has measurably improved in the CALGB, which is at least partly due to the pressure from this on-site peer review of investigator performance.	MCGILL CANC CTR,DEPT MED,MONTREAL,PQ,CANADA; UNIFORMED SERV UNIV HLTH SCI,DEPT MED,BETHESDA,MD 20814; UNIV CHICAGO,DEPT MED,CHICAGO,IL 60637; CANC & LEUKEMIA GRP B,CENT OFF,LEBANON,NH; UNIV MINNESOTA,DEPT MED,MINNEAPOLIS,MN 55455; UNIV ALABAMA,DEPT MED,BIRMINGHAM,AL 35294; UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27514; HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV MED ONCOL,BOSTON,MA 02115; DARTMOUTH COLL,HITCHCOCK MED CTR,DARTMOUTH MED SCH,DEPT MED,HANOVER,NH 03756	McGill University; Uniformed Services University of the Health Sciences - USA; University of Chicago; University of Minnesota System; University of Minnesota Twin Cities; University of Alabama System; University of Alabama Birmingham; University of North Carolina; University of North Carolina Chapel Hill; Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Dartmouth College	WEISS, RB (corresponding author), WALTER REED ARMY MED CTR,DEPT MED,MED ONCOL SECT,WASHINGTON,DC 20307, USA.				NATIONAL CANCER INSTITUTE [U10CA016450, U10CA041287, U10CA026806] Funding Source: NIH RePORTER; NCI NIH HHS [CA 26806, CA 16450, CA 41287] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BROAD WJ, 1983, SCIENCE, V121, P137; CHEUNG NKV, 1992, J CLIN ONCOL, V10, P671, DOI 10.1200/JCO.1992.10.4.671; CULLITON BJ, 1986, SCIENCE, V234, P1069, DOI 10.1126/science.3535072; GREENBERG DS, 1991, J NATL I HLTH RES, V3, P32; HOLDEN C, 1986, SCIENCE, V124, P1488; Knox R, 1983, JAMA, V249, P1797, DOI 10.1001/jama.249.14.1797; KOSHLAND DE, 1987, SCIENCE, V235, P141, DOI 10.1126/science.3798097; KOSHLAND DE, 1991, SCIENCE, V3, P32; MAUER JK, 1985, CANCER TREAT REP, V69, P1177; RENNIE D, 1989, JAMA-J AM MED ASSOC, V261, P2543, DOI 10.1001/jama.261.17.2543; SHAPIRO MF, 1989, JAMA-J AM MED ASSOC, V261, P2505, DOI 10.1001/jama.261.17.2505; SHAPIRO MF, 1985, NEW ENGL J MED, V312, P731, DOI 10.1056/NEJM198503143121128; SUNDERLAND M, 1990, P AN M AM SOC CLIN, V9, P60; SYLVESTER RJ, 1981, NEW ENGL J MED, V305, P852, DOI 10.1056/NEJM198110083051503; WEISS GR, 1987, P AM SOC CLIN ONCOL, V6, P227; WEISS RB, 1992, ACCOUNTABIL RES POL, V2, P13; 1982, NEW ENGL J MED, V306, P1076	17	56	57	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1993	270	4					459	464		10.1001/jama.270.4.459	http://dx.doi.org/10.1001/jama.270.4.459			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN426	8320783				2022-12-01	WOS:A1993LN42600024
J	SCHMIDT, GA; WOOD, LDH				SCHMIDT, GA; WOOD, LDH			CRITICAL CARE MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OBSTRUCTIVE PULMONARY-DISEASE; END-EXPIRATORY PRESSURE; AIRWAY PRESSURE; TIDAL VOLUME; VENTILATION; PEEP				SCHMIDT, GA (corresponding author), UNIV CHICAGO,CHICAGO,IL 60637, USA.			Schmidt, Gregory/0000-0002-5013-6323				CORBRIDGE TC, 1990, AM REV RESPIR DIS, V142, P311, DOI 10.1164/ajrccm/142.2.311; CURTIS SE, 1992, AM REV RESPIR DIS, V145, P348, DOI 10.1164/ajrccm/145.2_Pt_1.348; DREYFUSS D, 1988, AM REV RESPIR DIS, V137, P1159, DOI 10.1164/ajrccm/137.5.1159; GUTIERREZ G, 1992, CRIT CARE MED, V20, P451, DOI 10.1097/00003246-199204000-00004; GUTIERREZ G, 1992, LANCET, V339, P195, DOI 10.1016/0140-6736(92)90002-K; HALL JB, 1992, PRINCIPLES CRITICAL, P1617; HALUSZKA J, 1990, AM REV RESPIR DIS, V141, P1194, DOI 10.1164/ajrccm/141.5_Pt_1.1194; HICKLING KG, 1990, INTENS CARE MED, V16, P372, DOI 10.1007/BF01735174; HUMPHREY H, 1990, CHEST, V97, P1176, DOI 10.1378/chest.97.5.1176; KIISKI R, 1992, AM REV RESPIR DIS, V146, P1131, DOI 10.1164/ajrccm/146.5_Pt_1.1131; LEE PC, 1990, CHEST, V97, P430, DOI 10.1378/chest.97.2.430; MARINI JJ, 1992, AM REV RESPIR DIS, V146, P2, DOI 10.1164/ajrccm/146.1.2; MIRO AM, 1993, CHEST, V103, P266, DOI 10.1378/chest.103.1.266; MITCHELL JP, 1992, AM REV RESPIR DIS, V145, P990, DOI 10.1164/ajrccm/145.5.990; PETROF BJ, 1990, AM REV RESPIR DIS, V141, P281, DOI 10.1164/ajrccm/141.2.281; RONCO JJ, 1992, AM REV RESPIR DIS, V141, P25; TUCHSCHMIDT J, 1992, CHEST, V102, P216, DOI 10.1378/chest.102.1.216; WALLEY KR, 1990, CRIT CARE MED, V18, P336, DOI 10.1097/00003246-199003000-00019; YOUNES M, 1992, AM REV RESPIR DIS, V145, P121, DOI 10.1164/ajrccm/145.1.121; ZIEGLER EJ, 1991, NEW ENGL J MED, V324, P429, DOI 10.1056/NEJM199102143240701	20	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					194	196		10.1001/jama.270.2.194	http://dx.doi.org/10.1001/jama.270.2.194			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315727				2022-12-01	WOS:A1993LL36800013
J	BEATTY, OL; HARPER, R; SHERIDAN, B; ATKINSON, AB; BELL, PM				BEATTY, OL; HARPER, R; SHERIDAN, B; ATKINSON, AB; BELL, PM			INSULIN-RESISTANCE IN OFFSPRING OF HYPERTENSIVE PARENTS	BMJ-BRITISH MEDICAL JOURNAL			English	Article							DEPENDENT DIABETES-MELLITUS; PIMA-INDIANS; GLUCOSE-INTOLERANCE; FAMILY HISTORY; BLOOD-PRESSURE; METABOLISM; SENSITIVITY; RECEPTOR; OBESITY; GENE	Objective-To determine if insulin resistance is present in normotensive adults at increased risk of developing hypertension. Design-Normotensive subjects with at least one hypertensive parent were paired with offspring of normotensive parents (controls), being matched for age, sex, social class, and physical activity. Setting-Outpatient clinic. Subjects-30 paired subjects (16 men and 14 women) with and without a family history of hypertension, aged 18-32, with a body mass index <25 kg/m2, with blood pressure < 130/85 mm Hg, and not taking drugs. Interventions-Euglycaemic glucose clamp (two hour infusion of insulin 1 mU/kg/min) and intravenous glucose tolerance test (injection of 100 ml 20% glucose). Main outcome measures-Insulin mediated glucose disposal and insulin secretion. Results-The offspring of hypertensive parents had slightly higher blood pressure than did the controls (mean 117 (SD 6) v 108 (5) mm Hg systolic, p=0.013; 76 (7) v 67 (6) mm Hg diastolic, p=0.017). Their insulin mediated glucose disposal was lower than that of controls (29.5 (6.5) v 40.1 (8.6) mumol/kg/min, p=0.002), but, after adjustment for blood pressure, the difference was not significant (difference 6.9 (95% confidence interval -1.5 to 15.3), p=0.10). Insulin secretion in the first hour after injection of glucose was slightly but not significantly higher in the offspring of hypertensive patients (9320 (5484) v 6723 (3751) pmol.min/l). The two groups had similar concentrations of plasma glucose (5.2 (0.3) v 5.1 (0.4) mmol/l), serum cholesterol (4.4 (0.8) v 4.6 (0.8) mmol/l), serum triglyceride (0.89 (0.52) v 0.68 (0.27) mmol/l), and serum low density lipoprotein cholesterol (2.81 (0.65) v 2.79 (0.61) mmol/l). The offspring of hypertensive parents, however, had lower serum concentrations of high density lipoprotein cholesterol (1.24 (0.31) v 1.56 (0.35) mmol/l, p=0.002) and higher serum concentrations of non-esterified fatty acids (0.7 (0.4) v 0.4 (0.4) mmol/l, p=0.039). Conclusions-Young normotensive subjects who are at increased risk of developing hypertension are insulin resistant.	ROYAL VICTORIA HOSP, SIR GEORGE E CLARK METAB UNIT, BELFAST BT12 6BA, NORTH IRELAND; ROYAL VICTORIA HOSP, REG ENDOCRINE LAB, BELFAST BT12 6BA, NORTH IRELAND									BOGARDUS C, 1989, DIABETES, V38, P1423, DOI 10.2337/diabetes.38.11.1423; BOGARDUS C, 1984, J CLIN INVEST, V74, P1238, DOI 10.1172/JCI111533; DEFRONZO RA, 1982, INT J OBESITY, V6, P73; DEFRONZO RA, 1981, DIABETOLOGIA, V21, P165, DOI 10.1007/BF00252649; DEFRONZO RA, 1979, AM J PHYSIOL, V237, pE214; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; FERRARI P, 1991, AM J MED, V91, P589, DOI 10.1016/0002-9343(91)90211-F; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; HALES CN, 1963, BIOCHEM J, V88, P137, DOI 10.1042/bj0880137; JARRETT RJ, 1992, LANCET, V340, P469, DOI 10.1016/0140-6736(92)91781-3; JULIUS S, 1991, J HYPERTENS, V9, P983, DOI 10.1097/00004872-199111000-00001; KOLTERMAN OG, 1980, J CLIN INVEST, V65, P1272, DOI 10.1172/JCI109790; KUSARI J, 1991, J CLIN INVEST, V88, P1323, DOI 10.1172/JCI115437; LAAKSO M, 1990, J CLIN INVEST, V85, P1844, DOI 10.1172/JCI114644; LAAKSO M, 1991, DIABETES S1, V40, pA100; LILLIOJA S, 1987, DIABETES, V36, P1329, DOI 10.2337/diabetes.36.11.1329; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; MOORE RD, 1983, BIOCHIM BIOPHYS ACTA, V737, P1, DOI 10.1016/0304-4157(83)90013-8; MUNGER RG, 1988, J HYPERTENS, V6, P647, DOI 10.1097/00004872-198808000-00008; NATALI A, 1991, HYPERTENSION, V17, P170, DOI 10.1161/01.HYP.17.2.170; OELBAUM RS, 1991, DIABETOLOGIA, V34, P260, DOI 10.1007/BF00405085; POLLARE T, 1989, BRIT MED J, V298, P1152, DOI 10.1136/bmj.298.6681.1152; POLLARE T, 1988, DIABETOLOGIA, V31, P415, DOI 10.1007/BF00271585; POLLARE T, 1989, NEW ENGL J MED, V321, P868, DOI 10.1056/NEJM198909283211305; RABEN N, 1991, DIABETES, V40, P118, DOI 10.2337/diabetes.40.1.118; RANDLE PJ, 1963, LANCET, V1, P785; REAVEN G, 1968, DIABETES, V17, P560, DOI 10.2337/diab.17.9.560; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; RIZZA RA, 1981, DIABETES, V30, P990, DOI 10.2337/diabetes.30.12.990; ROONEY DP, 1991, EUR J CLIN INVEST, V21, P430, DOI 10.1111/j.1365-2362.1991.tb01391.x; ROONEY DP, 1992, METABOLISM, V41, P317, DOI 10.1016/0026-0495(92)90278-I; ROWE JW, 1981, DIABETES, V30, P219, DOI 10.2337/diab.30.3.219; SALTIN B, 1968, CIRCULATION, V38, P1104, DOI 10.1161/01.CIR.38.6.1104; SHEN DC, 1988, J CLIN ENDOCR METAB, V66, P580, DOI 10.1210/jcem-66-3-580; STAMLER R, 1979, JAMA-J AM MED ASSOC, V241, P43, DOI 10.1001/jama.241.1.43; SWISLOCKI ALM, 1989, AM J HYPERTENS, V2, P419, DOI 10.1093/ajh/2.6.419; VALDES CT, 1991, J CLIN ENDOCR METAB, V72, P642, DOI 10.1210/jcem-72-3-642; WATT G, 1986, J HYPERTENS, V4, P1, DOI 10.1097/00004872-198602000-00001; WILLIAMS RR, 1988, JAMA-J AM MED ASSOC, V259, P3579, DOI 10.1001/jama.259.24.3579; WILLIAMS RR, 1989, J HYPERTENS       S6, V7, P8; 1990, CHALLENGE 90S CHANGE	41	102	105	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	1993	307	6896					92	96		10.1136/bmj.307.6896.92	http://dx.doi.org/10.1136/bmj.307.6896.92			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM585	8343735	Green Published, Bronze			2022-12-01	WOS:A1993LM58500022
J	BORCHJOHNSEN, K; WENZEL, H; VIBERTI, GC; MOGENSEN, CE				BORCHJOHNSEN, K; WENZEL, H; VIBERTI, GC; MOGENSEN, CE			IS SCREENING AND INTERVENTION FOR MICROALBUMINURIA WORTHWHILE IN PATIENTS WITH INSULIN-DEPENDENT DIABETES	BRITISH MEDICAL JOURNAL			English	Article							ALBUMIN EXCRETION; KIDNEY-FUNCTION; NEPHROPATHY; PREDICTOR; MELLITUS; RISK; PROTEINURIA; MORTALITY	Objective-To analyse the cost-benefit of screening for and antihypertensive treatment of early renal disease indicated by microalbuminuria in patients with insulin dependent diabetes mellitus. Design-Previously published data were used to estimate transition probabilities for each step from normoalbuminuria until death. The effect of intervention on urinary albumin excretion rate by antihypertensive treatment was arbitrarily set at three different levels. All direct costs (screening, antihypertensive treatment, treatment of end stage renal failure) were included in the cost-benefit analysis by using real discount rates of 2.5% and 6%. Setting-Computer simulation. Subjects-Simulated cohort of 8000 patients. Main outcome measures-Mortality, incidence of diabetic nephropathy, incidence of end stage renal failure, and costs versus savings. Results-Assuming treatment effects of 33% and 67% median life expectancy increased by four to 14 years, respectively, and the need for dialysis or transplantation decreased by 21% to 63%. Costs and savings would balance if the annual rate of increase of albuminuria was decreased from 20% to 18% a year. Conclusions-Screening and intervention programmes are likely to have life saving effects and lead to considerable economic savings.	UNIV BIELEFELD,SCH PUBL HLTH,W-4800 BIELEFELD,GERMANY; UNITED MED & DENT SCH GUYS & ST THOMAS HOSP,METAB MED UNIT,LONDON,ENGLAND; UNIV HOSP ARHUS,ARHUS KOMMUNEHOSP,MED DEPT M,DK-8000 AARHUS,DENMARK	University of Bielefeld; University of London; King's College London; Aarhus University	BORCHJOHNSEN, K (corresponding author), KOMMUNE HOSP COPENHAGEN,INST PREVENT MED,DK-1399 COPENHAGEN K,DENMARK.							BORCHJOHNSEN K, 1985, DIABETOLOGIA, V28, P590, DOI 10.1007/BF00281993; BORCHJOHNSEN K, 1987, BMJ-BRIT MED J, V294, P1651, DOI 10.1136/bmj.294.6588.1651; BORCHJOHNSEN K, 1989, DAN MED BULL, V36, P336; Christensen C K, 1987, J Diabet Complications, V1, P45, DOI 10.1016/S0891-6632(87)80079-X; CHRISTENSEN CK, 1991, DAN MED BULL, V38, P145; DAMSGAARD EM, 1992, KIDNEY INT, V41, P731; DAMSGAARD EM, 1990, BRIT MED J, V300, P297, DOI 10.1136/bmj.300.6720.297; Deckerf T., 1987, SCAND ACTUAR J, V1, P19; Doubilet P, 1985, Med Decis Making, V5, P157, DOI 10.1177/0272989X8500500205; Feldt-Rasmussen B, 1984, DIABETIC NEPHROPATHY, V3, P101; FELDTRASMUSSEN B, 1991, DIABETOLOGIA, V34, P164, DOI 10.1007/BF00418270; HALLAB M, 1993, BRIT MED J, V306, P175, DOI 10.1136/bmj.306.6871.175; JENSEN T, 1987, DIABETOLOGIA, V30, P144, DOI 10.1007/BF00274218; Kofoed-Enevoldsen A, 1987, J Diabet Complications, V1, P96, DOI 10.1016/S0891-6632(87)80064-8; KOFOEDENEVOLDSEN A, 1987, DIABETES, V36, P205, DOI 10.2337/diabetes.36.2.205; KRANS HMJ, 1992, GIORN ITAL DIABET S2, V12, P1; KROLEWSKI AS, 1986, DIABETES CARE, V9, P443, DOI 10.2337/diacare.9.5.443; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; MARRE M, 1988, BMJ-BRIT MED J, V297, P1092, DOI 10.1136/bmj.297.6656.1092; MARSHALL SM, 1989, Q J MED, V70, P61; MATHIESEN ER, 1989, DIABETOLOGIA, V32, P884, DOI 10.1007/BF00297455; MATHIESEN ER, 1991, BMJ-BRIT MED J, V303, P81, DOI 10.1136/bmj.303.6794.81; MATHIESEN ER, 1984, DIABETOLOGIA, V26, P406; MOGENSEN CE, 1982, BRIT MED J, V285, P685, DOI 10.1136/bmj.285.6343.685; MOGENSEN CE, 1984, NEW ENGL J MED, V311, P89, DOI 10.1056/NEJM198407123110204; MOGENSEN CE, 1992, DIABETES CARE, V15, P1192, DOI 10.2337/diacare.15.9.1192; MOGENSEN CE, 1992, J HYPERTENS, V10, pS43, DOI 10.1097/00004872-199204001-00009; MOGENSEN CE, 1992, J AM SOC NEPHROL, V3, pA336; MOGENSEN CE, 1986, UREMIA INVEST, V9, P85; PARVING HH, 1983, LANCET, V1, P1175; PARVING HH, 1982, ACTA ENDOCRINOL-COP, V100, P550, DOI 10.1530/acta.0.1000550; SIEGEL JE, 1992, J AM SOC NEPHROL, V3, P3111; VIBERTI GC, 1982, LANCET, V1, P1430; 1991, BMJ, V302, P210; 1990, STATISTISCHES JB 199	35	133	133	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1993	306	6894					1722	1723		10.1136/bmj.306.6894.1722	http://dx.doi.org/10.1136/bmj.306.6894.1722			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK367	8343628	Green Published, Bronze			2022-12-01	WOS:A1993LK36700019
J	NEWMAN, LJ; PLATTSMILLS, TAE; PHILLIPS, CD; HAZEN, KC; GROSS, CW				NEWMAN, LJ; PLATTSMILLS, TAE; PHILLIPS, CD; HAZEN, KC; GROSS, CW			CHRONIC SINUSITIS - RELATIONSHIP OF COMPUTED TOMOGRAPHIC FINDINGS TO ALLERGY, ASTHMA, AND EOSINOPHILIA	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MAXILLARY SINUSITIS; CHILDREN; SINUSES; SURGERY; BACTERIOLOGY; DISEASE	Objective.-To develop a technique for evaluating the severity of chronic sinus disease and to examine the correlation with allergy, asthma, and eosinophilia. Design.-A survey of 104 patients undergoing surgery for chronic sinusitis. Setting.-A university hospital ear, nose, and throat clinic. Patients.-A referral population of adult patients being scheduled for endoscopic sinus surgery was eligible; 104 completed questionnaires and agreed to participate. Main Outcome Measures.-Computed tomographic scans were reviewed and scored for extent of disease. Serum samples were assayed for total IgE and specific IgE antibodies to common inhalant allergens. Peripheral blood samples were analyzed for total eosinophil count. Surgical biopsy specimens were examined for eosinophilia and cultured for bacteria and fungi. Results.-Extensive disease was present in 39% of subjects and correlated well with asthma, specific IgE antibodies, and eosinophilia, but not with elevated total IgE. Among patients with peripheral eosinophilia, 87% had extensive disease. All cultures grew aerobic bacteria; anaerobes and fungi were uncommon. Conclusions.-We present a system for quantitation of disease extent using computed tomographic scans of patients with chronic sinusitis. The well-accepted associations of chronic sinusitis with asthma and allergy appear to be restricted to the group with extensive disease. The presence of peripheral eosinophilia in patients with sinusitis indicates a high likelihood of extensive disease.	UNIV VIRGINIA,HLTH SCI CTR,DEPT MED,CHARLOTTESVILLE,VA 22903; UNIV VIRGINIA,HLTH SCI CTR,DEPT RADIOL,CHARLOTTESVILLE,VA 22903; UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,CHARLOTTESVILLE,VA 22903; UNIV VIRGINIA,HLTH SCI CTR,DEPT OTOLARYNGOL,CHARLOTTESVILLE,VA 22903	University of Virginia; University of Virginia; University of Virginia; University of Virginia				Platts-Mills, Thomas/0000-0002-1263-329X	NIAID NIH HHS [AI-30840, AI-20562] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI030840] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBERT A, 1987, MULTIVARIATE INTERPR, P76; Balows A, 1991, MANUAL CLIN MICROBIO; BOLGER WE, 1991, LARYNGOSCOPE, V101, P56; BROOK I, 1981, JAMA-J AM MED ASSOC, V246, P967, DOI 10.1001/jama.246.9.967; FORD AW, 1985, INT ARCH ALLER A IMM, V76, P58, DOI 10.1159/000233662; FREDERICK J, 1974, NEW ENGL J MED, V290, P135, DOI 10.1056/NEJM197401172900304; GELBER LE, 1993, AM REV RESPIR DIS, V147, P573, DOI 10.1164/ajrccm/147.3.573; GWALTNEY JM, 1992, J ALLERGY CLIN IMMUN, V90, P457, DOI 10.1016/0091-6749(92)90169-3; HAMILOS DL, 1993, J ALLERGY CLIN IMMUN, V92, P39, DOI 10.1016/0091-6749(93)90035-E; HARLIN SL, 1988, J ALLERGY CLIN IMMUN, V81, P867, DOI 10.1016/0091-6749(88)90944-X; KANAI N, IN PRESS AM REV RESP; KENNEDY DW, 1985, ARCH OTOLARYNGOL, V111, P576; MINGS R, 1988, AM J RHINOL, V71, P123; MUNTZ HR, 1991, ARCH OTOLARYNGOL, V117, P179; PELIKAN Z, 1990, J ALLERGY CLIN IMMUN, V86, P484, DOI 10.1016/S0091-6749(05)80203-9; POLLART SM, 1989, J ALLERGY CLIN IMMUN, V83, P875, DOI 10.1016/0091-6749(89)90100-0; RACHELEFSKY GS, 1984, PEDIATRICS, V73, P526; SHAPIRO ED, 1982, J INFECT DIS, V146, P589, DOI 10.1093/infdis/146.5.589; SLAVIN RG, 1982, ANN ALLERGY, V49, P76; SLAVIN RG, 1992, J ALLERGY CLIN IMMUN, V90, P534, DOI 10.1016/0091-6749(92)90180-A; VAN DISHOECK H A, 1957, Pract Otorhinolaryngol (Basel), V19, P502; VANDISHOECK HAE, 1961, ADV OTORHINOLARYNGOL, V10, P1; WALD ER, 1981, NEW ENGL J MED, V304, P749, DOI 10.1056/NEJM198103263041302; ZINREICH SJ, 1987, RADIOLOGY, V163, P769, DOI 10.1148/radiology.163.3.3575731; 1990, 901261 US DEP HLTH H	25	260	269	0	9	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	1994	271	5					363	367		10.1001/jama.271.5.363	http://dx.doi.org/10.1001/jama.271.5.363			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR983	8283586				2022-12-01	WOS:A1994MR98300031
J	ALLSHIRE, RC; JAVERZAT, JP; REDHEAD, NJ; CRANSTON, G				ALLSHIRE, RC; JAVERZAT, JP; REDHEAD, NJ; CRANSTON, G			POSITION EFFECT VARIEGATION AT FISSION YEAST CENTROMERES	CELL			English	Article							MATING-TYPE LOCI; NONHISTONE CHROMOSOMAL PROTEIN; SATELLITE DNA-SEQUENCES; TRANSFER-RNA GENES; DROSOPHILA-MELANOGASTER; SCHIZOSACCHAROMYCES-POMBE; CHROMATIN STRUCTURE; SACCHAROMYCES-CEREVISIAE; HETEROCHROMATIN; TRANSCRIPTION	Chromatin structure at Schizosaccharomyces pombe centromeres is unusual. The insertion of the ura4 gene within these centromeres resulted in genetically identical cells mosaic for its expression. Placement of the ade6 gene within cen1 or cen3 resulted in red-white sectored colonies, demonstrating the instability of gene expression. The occurrence of pink colonies implied that intermediate levels of repression were established. Repression of both genes within centromeres was temperature sensitive. The chromatin structure of the ura4 gene at centromeres was altered, suggesting that the unusual chromatin encroaches into the gene and inhibits normal expression. These repressive effects at S. pombe centromeres resemble the classical phenomenon of position effect variegation imposed by Drosophila heterochromatin on nearby genes. However, since the epigenetic states can be set at intermediate levels of expression, a purely euchromatin-heterochromatin dichotomy does not apply. A model for the epigenetic regulation of genes placed within S. pombe centromeres is presented.			ALLSHIRE, RC (corresponding author), WESTERN GEN HOSP, MRC, HUMAN GENET UNIT, CREWE RD, EDINBURGH EH4 2XU, MIDLOTHIAN, SCOTLAND.			Allshire, Robin/0000-0002-8005-3625	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BARIGOZZI C, 1966, EXP CELL RES, V43, P231, DOI 10.1016/0014-4827(66)90399-5; BISHOP CP, 1992, GENETICS, V132, P1063; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; CHIKASHIGE Y, 1989, CELL, V57, P739, DOI 10.1016/0092-8674(89)90789-7; CLARKE L, 1990, MOL CELL BIOL, V10, P1863, DOI 10.1128/MCB.10.5.1863; Demerec M, 1940, GENETICS, V25, P618; DIMITRI P, 1989, GENETICS, V122, P793; EGEL R, 1984, CURR GENET, V8, P199, DOI 10.1007/BF00417816; EISSENBERG JC, 1992, GENETICS, V131, P345; FERGUSON BM, 1992, CELL, V68, P333, DOI 10.1016/0092-8674(92)90474-Q; FUNABIKI H, 1993, J CELL BIOL, V121, P961, DOI 10.1083/jcb.121.5.961; GOTTSCHLING DE, 1992, P NATL ACAD SCI USA, V89, P4062, DOI 10.1073/pnas.89.9.4062; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Gowen JW, 1933, SCIENCE, V77, P312, DOI 10.1126/science.77.1995.312; Gowen JW, 1934, GENETICS, V19, P0189; HAHNENBERGER KM, 1991, MOL CELL BIOL, V11, P2206, DOI 10.1128/MCB.11.4.2206; HAHNENBERGER KM, 1989, P NATL ACAD SCI USA, V86, P577, DOI 10.1073/pnas.86.2.577; HARTMANN.IJ, 1967, GENET RES, V10, P143, DOI 10.1017/S0016672300010880; HAZELRIGG T, 1984, CELL, V36, P469, DOI 10.1016/0092-8674(84)90240-X; HENIKOFF S, 1990, TRENDS GENET, V6, P422, DOI 10.1016/0168-9525(90)90304-O; HENIKOFF S, 1979, GENETICS, V93, P105; HILLIKER AJ, 1980, CELL, V21, P607, DOI 10.1016/0092-8674(80)90424-9; HOCHSTRASSER M, 1986, J CELL BIOL, V102, P112, DOI 10.1083/jcb.102.1.112; JAMES TC, 1989, EUR J CELL BIOL, V50, P170; JAMES TC, 1986, MOL CELL BIOL, V6, P3862, DOI 10.1128/MCB.6.11.3862; KLAR AJS, 1992, TRENDS GENET, V8, P208, DOI 10.1016/0168-9525(92)90100-I; KLAR AJS, 1981, NATURE, V289, P239, DOI 10.1038/289239a0; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; KUHN RM, 1991, P NATL ACAD SCI USA, V88, P1306, DOI 10.1073/pnas.88.4.1306; LEVIS R, 1985, SCIENCE, V229, P558, DOI 10.1126/science.2992080; LOCKE J, 1988, GENETICS, V120, P181; LOHE AR, 1986, P NATL ACAD SCI USA, V83, P696, DOI 10.1073/pnas.83.3.696; MCCARROLL RM, 1988, CELL, V54, P505, DOI 10.1016/0092-8674(88)90072-4; Miklos GLG, 1985, MOL EVOLUTIONARY GEN, P241; MORENO S, 1991, METHOD ENZYMOL, V194, P795; Muller HJ, 1930, J GENET, V22, P299, DOI 10.1007/BF02984195; MURAKAMI S, 1991, CHROMOSOMA, V101, P214, DOI 10.1007/BF00365153; NAKASEKO Y, 1986, EMBO J, V5, P1011, DOI 10.1002/j.1460-2075.1986.tb04316.x; NASMYTH KA, 1982, CELL, V30, P567, DOI 10.1016/0092-8674(82)90253-7; NASMYTH KA, 1981, NATURE, V289, P244, DOI 10.1038/289244a0; OKEEFE RT, 1992, J CELL BIOL, V116, P1095, DOI 10.1083/jcb.116.5.1095; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; POLIZZI C, 1991, J CELL BIOL, V112, P191, DOI 10.1083/jcb.112.2.191; PONCE MR, 1992, NUCLEIC ACIDS RES, V20, P623, DOI 10.1093/nar/20.3.623; REUTER G, 1990, NATURE, V344, P219, DOI 10.1038/344219a0; REUTER G, 1982, CHROMOSOMA, V85, P539, DOI 10.1007/BF00327349; Sambrook J., 1989, MOL CLONING LAB MANU; Schultz J, 1936, P NATL ACAD SCI USA, V22, P27, DOI 10.1073/pnas.22.1.27; SINCLAIR DAR, 1983, MOL GEN GENET, V191, P326, DOI 10.1007/BF00334834; SINGH J, 1992, GENE DEV, V6, P186, DOI 10.1101/gad.6.2.186; SPOFFORD JB, 1967, GENETICS, V57, P751; SPOFFORD JB, 1976, GENETICS BIOL DROS C, V1, P955; SPRADLING AC, 1990, GENETICS, V126, P779; STEWART AF, 1991, NUCLEIC ACIDS RES, V19, P3157, DOI 10.1093/nar/19.11.3157; TAKAHASHI K, 1991, J MOL BIOL, V218, P13, DOI 10.1016/0022-2836(91)90867-6; TAKAHASHI K, 1992, MOL BIOL CELL, V3, P819, DOI 10.1091/mbc.3.7.819; TARTOF KD, 1990, DEVELOPMENT, P35; TARTOF KD, 1989, DEV GENET, V10, P162, DOI 10.1002/dvg.1020100306; THON G, 1992, GENETICS, V131, P287; WILLARD HF, 1990, TRENDS GENET, V6, P410, DOI 10.1016/0168-9525(90)90302-M; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197	62	279	284	0	11	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	1994	76	1					157	169		10.1016/0092-8674(94)90180-5	http://dx.doi.org/10.1016/0092-8674(94)90180-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287474				2022-12-01	WOS:A1994MR49500014
J	COHEN, CB; JONSEN, AR				COHEN, CB; JONSEN, AR			THE FUTURE OF THE FETAL TISSUE-BANK	SCIENCE			English	Article							PARKINSONS-DISEASE; TRANSPLANTATION; PREVALENCE; CELLS				COHEN, CB (corresponding author), NATL ADVISORY BOARD ETH REPROD,409 12TH ST SW,WASHINGTON,DC 20024, USA.							ANNAS GJ, 1989, NEW ENGL J MED, V320, P1079, DOI 10.1056/NEJM198904203201610; [Anonymous], 1989, REV GUIDANCE RES USE; CAMPBELL CS, 1992, HASTINGS CENT REP, V22, P34, DOI 10.2307/3562143; FANTEL A, COMMUNICATION; FREED CR, 1992, NEW ENGL J MED, V327, P1549, DOI 10.1056/NEJM199211263272202; GLADWELL M, 1992, WASH POST       0714, pA3; GOLDBERG DJ, 1992, BMJ-BRIT MED J, V304, P1082, DOI 10.1136/bmj.304.6834.1082; HAMILTON DP, 1992, SCIENCE, V257, P869, DOI 10.1126/science.1502549; LEVALLOIS P, 1987, CAN MED ASSOC J, V137, P33; LEWIS SH, 1990, LANCET, V335, P565, DOI 10.1016/0140-6736(90)90349-A; Oskarsson T, 1990, ACTA OBSTET GYN SCAN, V69, P635, DOI 10.3109/00016349009028709; Polkinghorne J., 1992, FETAL TISSUE TRANSPL, P323; SPENCER DD, 1992, NEW ENGL J MED, V327, P1541, DOI 10.1056/NEJM199211263272201; VAWTER DE, 1990, USE HUMAN FETAL TISS, P66; WONG L, 1992, FETAL TISSUE TRANSPL, P129; ZOLER ML, 1993, OB GYN NEWS, V1, P24; 1988, REPORT HUMAN FETAL T; 1993, NIH GUIDE, V22; 1991, LANCET, V337, P253	19	19	19	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 10	1993	262	5140					1663	1665		10.1126/science.8259510	http://dx.doi.org/10.1126/science.8259510			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	ML220	8259510				2022-12-01	WOS:A1993ML22000025
J	INGHAM, PW				INGHAM, PW			LOCALIZED HEDGEHOG ACTIVITY CONTROLS SPATIAL LIMITS OF WINGLESS TRANSCRIPTION IN THE DROSOPHILA EMBRYO	NATURE			English	Article								CELL patterning in the body segments of the Drosophila embryo requires activity of the segment polarity genes, a molecularly heterogeneous group defined by a generic mutant phenotype1. Two of these genes, wingless (wg) and hedgehog (hh), encode proteins that enter the secretory pathway2-4, implicating them as signals that instruct the fates of neighbouring cells5. Genetic analysis has identified wg transcription as one of the targets of hh activity6,7 and it has been suggested that the spatial control of wg expression depends on the limited range of the hh signal and the differential competence of responding cells8. I have tested this model by driving ubiquitous expression of the hh gene using the Hsp70 promoter. Here I report that, as predicted, this causes the ectopic activation of wg in only a subset of the cells of each parasegment. Using another target of hh activity as a probe, I demonstrate that the competence of cells to express wg is independent of their ability to receive the hh signal. Finally, I show that wg activation requires the function of the segment polarity gene fused, suggesting that the putative hh signal is transduced by the serine/threonine kinase that fused encodes.			INGHAM, PW (corresponding author), ICRF, DEV BIOL UNIT, DEPT ZOOL, MOLEC EMBRYOL LAB, S PARKS RD, OXFORD OX1 3PS, ENGLAND.		Ingham, Philip W/E-6710-2010; Ingham, Philip W/G-9903-2011; Ingham, Philip William/AAH-5884-2020	Ingham, Philip W/0000-0001-8224-9958; Ingham, Philip William/0000-0001-8224-9958				ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1993, DEVELOPMENT, V117, P283; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LIMBOURGBOUCHON B, 1991, DEVELOPMENT, V112, P417; MARTINEZARIAS A, 1985, J EMBRYOL EXP MORPH, V87, P99; MARTINEZARIAS A, 1985, NATURE, V313, P639, DOI 10.1038/313639a0; MOHLER J, 1992, DEVELOPMENT, V115, P957; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; Roberts D.B., 1986, P1; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TASHIRO S, 1993, GENE, V124, P183; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2	28	166	176	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	1993	366	6455					560	562		10.1038/366560a0	http://dx.doi.org/10.1038/366560a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	8255293				2022-12-01	WOS:A1993ML21800068
J	KITSBERG, D; SELIG, S; KESHET, I; CEDAR, H				KITSBERG, D; SELIG, S; KESHET, I; CEDAR, H			REPLICATION STRUCTURE OF THE HUMAN BETA-GLOBIN GENE DOMAIN	NATURE			English	Article							DIHYDROFOLATE-REDUCTASE DOMAIN; DNA-REPLICATION; CHROMOSOME-REPLICATION; NUCLEOSOME SEGREGATION; MAMMALIAN-CELLS; ORIGIN; LOCUS; IDENTIFICATION; ACTIVATION; ELEMENT	THE animal cell genome is organized into a series of replicons with an average size of 50-300 kilobases1; each of these units is characterized by its own origin of replication which serves as the point of initiation for DNA synthesis. In animal viruses, origin usage can be regulated by cis-acting elements2, and in some cases, replication may be cell-type specific3. Little is known, however, about the organization and control of endogenous tissue-specific gene replication. To understand this process, we have used a replication direction assay to examine DNA fragments covering more than 200 kilobases of the human beta-like globin domain, and have identified a single bidirectional origin located upstream of the beta-globin itself. This locus is used to initiate DNA synthesis in expressing cells, where the globin domain replicates early, and in non-expressing cells, which are characterized by late replication of the same region4,5. Deletion of this origin sequence, as occurs in the haemoglobin Lepore syndrome6, cancels bidirectional DNA synthesis at this site and leads to a striking reversal of replication direction upstream to the locus. This represents the first genetic proof of the existence of specific, discrete origins of replication in animal cells.			KITSBERG, D (corresponding author), HEBREW UNIV JERUSALEM,SCH MED,DEPT CELLULAR BIOCHEM,IL-91010 JERUSALEM,ISRAEL.							ANACHKOVA B, 1989, MOL CELL BIOL, V9, P532, DOI 10.1128/MCB.9.2.532; BERGEMANN AD, 1992, MOL CELL BIOL, V12, P1257, DOI 10.1128/MCB.12.3.1257; BURHANS WC, 1991, EMBO J, V10, P4351, DOI 10.1002/j.1460-2075.1991.tb05013.x; BURHANS WC, 1990, CELL, V62, P955, DOI 10.1016/0092-8674(90)90270-O; DEPAMPHILIS ML, 1988, CELL, V52, P635, DOI 10.1016/0092-8674(88)90398-4; DEVILLIERS J, 1984, NATURE, V312, P242, DOI 10.1038/312242a0; DHAR V, 1988, MOL CELL BIOL, V8, P4958, DOI 10.1128/MCB.8.11.4958; EDENBERG HJ, 1975, ANNU REV GENET, V9, P245, DOI 10.1146/annurev.ge.09.120175.001333; EPNER E, 1988, P NATL ACAD SCI USA, V85, P8081, DOI 10.1073/pnas.85.21.8081; FERGUSON BM, 1991, CELL, V65, P507, DOI 10.1016/0092-8674(91)90468-E; FERGUSON BM, 1992, CELL, V68, P333, DOI 10.1016/0092-8674(92)90474-Q; FLAVELL RA, 1978, CELL, V15, P25, DOI 10.1016/0092-8674(78)90080-6; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; HANDELI S, 1989, CELL, V57, P909, DOI 10.1016/0092-8674(89)90329-2; HATTON KS, 1988, MOL CELL BIOL, V8, P2149, DOI 10.1128/MCB.8.5.2149; KIOUSSIS D, 1983, NATURE, V306, P662, DOI 10.1038/306662a0; MEARS JG, 1978, P NATL ACAD SCI USA, V75, P1222, DOI 10.1073/pnas.75.3.1222; ROUFA DJ, 1982, P NATL ACAD SCI-BIOL, V79, P1810, DOI 10.1073/pnas.79.6.1810; SEIDMAN MM, 1979, CELL, V18, P439, DOI 10.1016/0092-8674(79)90063-1; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; TARMELLI R, 1986, NUCLEIC ACIDS RES, V15, P7017; TREMPE JP, 1988, MOL CELL BIOL, V8, P1657, DOI 10.1128/MCB.8.4.1657; VANIN EF, 1983, CELL, V35, P701, DOI 10.1016/0092-8674(83)90103-4; VASSILEV LT, 1990, MOL CELL BIOL, V10, P4685, DOI 10.1128/MCB.10.9.4685; VAUGHN JP, 1990, CELL, V61, P1075, DOI 10.1016/0092-8674(90)90071-L	25	256	260	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 9	1993	366	6455					588	590		10.1038/366588a0	http://dx.doi.org/10.1038/366588a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	8255298				2022-12-01	WOS:A1993ML21800077
J	LINDGREN, S; BOHLIN, AB; FORSGREN, M; ARNEBORN, M; OTTENBLAD, C; LIDMAN, K; ANZEN, B; VONSYDOW, M; BOTTIGER, M				LINDGREN, S; BOHLIN, AB; FORSGREN, M; ARNEBORN, M; OTTENBLAD, C; LIDMAN, K; ANZEN, B; VONSYDOW, M; BOTTIGER, M			SCREENING FOR HIV-1 ANTIBODIES IN PREGNANCY - RESULTS FROM THE SWEDISH NATIONAL PROGRAM	BRITISH MEDICAL JOURNAL			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; CHILDBEARING WOMEN; INFECTION; TRANSMISSION; PREVALENCE; TYPE-1; SEROPREVALENCE; KNOWLEDGE; CONTINUE; NEWBORNS	Objective-To determine the effectiveness of a national screening programme for HIV infection in pregnant women. Design-Observational study. Subjects-All pregnant women presenting to antenatal or abortion clinics. Setting-Sweden, September 1987 to December 1991. Main outcome measures-Number and characteristics of infected women. Results-By the end of the study period 510000 tests had been performed and 54 women with HIV infection identified (1.06/10000). Of the 33 women identified in Stockholm, 14 women (4.4/10000) had attended abortion clinics and 19 antenatal clinics (1.8/10000; p < 0.05). Three women had been intravenous drug users, one was infected through a blood transfusion, and 50 were probably infected sexually. Of the 20 women who attended antenatal clinics early enough to allow an abortion, 12 continued with their pregnancies. Conclusions-Testing of all women, not just those perceived to be at risk, probably contributed to the high uptake of HIV testing. With high uptake such screening provides valuable data on spread of HIV in the heterosexual population and presents opportunity for preventing transmission of HIV to children and partners.	STOCKHOLM CTY COUNCIL,DEPT CLIN VIROL,CENT MICROBIOL LAB,S-10726 STOCKHOLM,SWEDEN; NATL BACTERIOL LAB,DEPT EPIDEMIOL,S-10521 STOCKHOLM,SWEDEN; DANDERYD HOSP,S-18288 DANDERYD,SWEDEN	Stockholm County Council; Danderyds Hospital	LINDGREN, S (corresponding author), HUDDINGE HOSP,FAMILY SOCIAL CLIN,S-14186 HUDDINGE,SWEDEN.							ADES AE, 1991, LANCET, V337, P1562, DOI 10.1016/0140-6736(91)93260-G; BARBACCI M, 1991, LANCET, V337, P7509; BLANCHE S, 1989, NEW ENGL J MED, V320, P1643, DOI 10.1056/NEJM198906223202502; BLAXHULT A, IN PRESS AIDS; BOYD KM, 1990, J MED ETHICS, V16, P173, DOI 10.1136/jme.16.4.173; DUNN DT, 1992, LANCET, V340, P585, DOI 10.1016/0140-6736(92)92115-V; GAINES H, 1987, LANCET, V1, P1249; GOLDBERG DJ, 1992, BMJ-BRIT MED J, V304, P1082, DOI 10.1136/bmj.304.6834.1082; HOFF R, 1988, NEW ENGL J MED, V318, P525, DOI 10.1056/NEJM198803033180901; HULL HF, 1988, JAMA-J AM MED ASSOC, V260, P935, DOI 10.1001/jama.260.7.935; JOHNSTONE FD, 1990, BRIT MED J, V300, P23, DOI 10.1136/bmj.300.6716.23; LANDESMAN S, 1987, JAMA-J AM MED ASSOC, V258, P2701, DOI 10.1001/jama.258.19.2701; LARSSON G, 1990, AIDS Care, V2, P223, DOI 10.1080/09540129008257734; LARSSON G, 1987, J ADV NURS, V12, P441; Larsson G, 1988, Lakartidningen, V85, P332; LINDGREN S, 1991, AIDS, V5, P1111, DOI 10.1097/00002030-199109000-00009; LINDSAY MK, 1989, OBSTET GYNECOL, V74, P289; MEADOWS J, 1990, AIDS Care, V2, P229, DOI 10.1080/09540129008257735; MITCHELL J, 1990, PEDIATRIC AIDS HIF I, V1, P78; NOVICK LF, 1989, JAMA-J AM MED ASSOC, V261, P1745, DOI 10.1001/jama.261.12.1745; QUINN TC, 1988, NEW ENGL J MED, V318, P197, DOI 10.1056/NEJM198801283180401; RYDER RW, 1989, NEW ENGL J MED, V320, P1637, DOI 10.1056/NEJM198906223202501; SELWYN PA, 1989, JAMA-J AM MED ASSOC, V261, P3567, DOI 10.1001/jama.261.24.3567; SHERR L, 1991, HIV AIDS MOTHERS BAB, P57; TAPPIN DM, 1991, LANCET, V337, P1565; TOVO PA, 1992, LANCET, V339, P1249, DOI 10.1016/0140-6736(92)91592-V; VANDEPERRE P, 1991, NEW ENGL J MED, V325, P593, DOI 10.1056/NEJM199108293250901; WENSTROM KD, 1989, OBSTET GYNECOL, V74, P558; 1991, EPIDAKTUELLT, V14, P6; 1987, SOCIALSTYRELSENS FOR, V22, P1; 1991, LANCET, V337, P253	31	52	52	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1993	307	6917					1447	1451		10.1136/bmj.307.6917.1447	http://dx.doi.org/10.1136/bmj.307.6917.1447			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK797	8281085	Green Published, Bronze			2022-12-01	WOS:A1993MK79700018
J	ROONEY, C; BERAL, V; MACONOCHIE, N; FRASER, P; DAVIES, G				ROONEY, C; BERAL, V; MACONOCHIE, N; FRASER, P; DAVIES, G			CASE-CONTROL STUDY OF PROSTATIC-CANCER IN EMPLOYEES OF THE UNITED-KINGDOM-ATOMIC-ENERGY-AUTHORITY	BRITISH MEDICAL JOURNAL			English	Article							NUCLEAR-FUELS; MORTALITY; WORKERS; FACILITY	Objective-To investigate the relation between risk of prostatic cancer and occupational exposures, especially to radionuclides, in employees of the United Kingdom Atomic Energy Authority. Design-Case-control study of men with prostatic cancer and matched controls. Information about sociodemographic factors and exposures to radionuclides and other substances was abstracted and classified for each subject from United Kingdom Atomic Energy Authority records without knowledge of who had cancer. Subjects-136 men with prostatic cancer diagnosed between 1946 and 1986 and 404 matched controls, all employees of United Kingdom Atomic Energy Authority. Main outcome measures-Documented or possible contamination with specific radionuclides. Results-Risk of prostatic cancer was significantly increased in men who were internally contaminated with or who worked in environments potentially contaminated by tritium, chromium-51, iron-59, cobalt-60, or zinc-65. Internal contamination with at least one of the five radionuclides was detected in 14 men with prostatic cancer (10%) and 12 controls (3%) (relative risk 5.32 (95% confidence interval 1.87 to 17.24). Altogether 28 men with prostatic cancer (21%) and 46 controls (11%) worked in environments potentially contaminated by at least one of the five radionuclides (relative risk 2.36 (1.26 to 4.43)); about two thirds worked at heavy water reactors (19 men with prostatic cancer and 32 controls (relative risk 2.13 (1.00 to 4.52)). Relative risk of prostatic cancer increased with increasing duration of work in places potentially contaminated by these radionuclides and with increasing level of probable contamination. Prostatic cancer was not associated with exposure to plutonium, uranium, cadmium, boron, beryllium, or organic or inorganic chemicals. Conclusions-Risk of prostatic cancer risk was increased in United Kingdom Atomic Energy Authority workers who were occupationally exposed to tritium, C-51, Fe-59, Co-60, or Zn-65. Exposure to these radionuclides was infrequent, and their separate effects could not be evaluated.	RADCLIFFE INFIRM,CANC EPIDEMIOL UNIT,IMPERIAL CANC RES FUND,OXFORD OX2 6HE,ENGLAND; UNIV LONDON LONDON SCH HYG & TROP MED,DEPT EPIDEMIOL & POPULAT SCI,EPIDEMIOL MONITORING UNIT,LONDON WC1E 7HT,ENGLAND	Radcliffe Infirmary; University of Oxford; University of London; London School of Hygiene & Tropical Medicine								BERAL V, 1985, BRIT MED J, V291, P440, DOI 10.1136/bmj.291.6493.440; BERAL V, 1988, BRIT MED J, V297, P757, DOI 10.1136/bmj.297.6651.757; BRESLOW NE, 1980, IARC SCI PUBLICATION, V82; BYAR DP, 1969, INVEST UROL, V7, P57; BYAR DP, 1974, MALE ACCESSORY SEX O, P161; COSTELLO LC, 1991, PROSTATE, V18, P25, DOI 10.1002/pros.2990180104; CRAGLE DL, 1988, AM J IND MED, V14, P379, DOI 10.1002/ajim.4700140404; FRASER P, 1993, BRIT J CANCER, V67, P615, DOI 10.1038/bjc.1993.113; FRASER P, 1985, BRIT MED J, V291, P435, DOI 10.1136/bmj.291.6493.435; GILBERT ES, 1989, HEALTH PHYS, V56, P11, DOI 10.1097/00004032-198901000-00001; GILBERT ES, 1979, RADIAT RES, V79, P122, DOI 10.2307/3575027; MARTIN MJ, 1970, RADIOACTIVE ATOMS AU; NOMURA AMY, 1991, EPIDEMIOL REV, V13, P200, DOI 10.1093/oxfordjournals.epirev.a036069; SCHROEDER HA, 1967, J CHRON DIS, V20, P179, DOI 10.1016/0021-9681(67)90002-1; SHIMIZU Y, 1987, RAD EFFECTS RES F TE, V12, P1; SMITH PG, 1986, BRIT MED J, V293, P845, DOI 10.1136/bmj.293.6551.845; THUN MJ, 1985, J NATL CANCER I, V74, P325; WILKINSON GS, 1987, AM J EPIDEMIOL, V125, P231, DOI 10.1093/oxfordjournals.aje.a114523; WING S, 1991, JAMA-J AM MED ASSOC, V265, P1397, DOI 10.1001/jama.265.11.1397; 1985, LANCET, V2, P533; 1990, EGRET EPIDEMIOLOGICA	21	60	63	1	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1993	307	6916					1391	1397		10.1136/bmj.307.6916.1391	http://dx.doi.org/10.1136/bmj.307.6916.1391			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK420	8274891	Bronze, Green Published			2022-12-01	WOS:A1993MK42000020
J	MAXWELL, M; HEANEY, D; HOWIE, JGR; NOBLE, S				MAXWELL, M; HEANEY, D; HOWIE, JGR; NOBLE, S			GENERAL-PRACTICE FUNDHOLDING - OBSERVATIONS ON PRESCRIBING PATTERNS AND COSTS USING THE DEFINED DAILY DOSE METHOD	BRITISH MEDICAL JOURNAL			English	Article							BUDGET	Objective-To compare prescribing patterns between a group of fundholding practices and a group of non-fundholding practices in north east Scotland using a method which provides more accurate statements about volumes prescribed than standard NHS statistics. Design-The pharmacy practice division of the National Health Service in Scotland provided data for selected British National Formulary sections over two years. Each prescription issued was converted using the World Health Organisation ''defined daily dose'' mechanism. Setting-Six fundholding groups (nine practices) in Grampian and Tayside regions and six non-fundholding practices in Grampian. Results-During the past two years both fund-holding and control practices reduced the volume of their prescribing for the classes of drug analysed. The unit costs of drugs in some classes, however, rose substantially, contributing to higher costs per patient. The unit costs rose more in the control practices (24%) than in the fundholding practices (11% in Tayside, 16% in Grampian). Conclusion-The use of defined daily doses helped identify cost and volume trends in specific areas of prescribing in fundholding and control practices. The basis on which funds are set needs improving, and defined daily doses may prove useful for setting volume targets within drug classes for all practices, whether fundholding or not.	LOTHIAN HLTH BOARD,EDINBURGH EH8 9RS,SCOTLAND		MAXWELL, M (corresponding author), UNIV EDINBURGH,DEPT GEN PRACTICE,EDINBURGH EH8 9DX,SCOTLAND.			Maxwell, Margaret/0000-0003-3318-9500				BAIN J, 1993, BRIT MED J, V306, P1185, DOI 10.1136/bmj.306.6886.1185; BAIN J, 1992, BRIT MED J, V304, P971, DOI 10.1136/bmj.304.6832.971; BAIN J, 1991, BRIT MED J, V302, P771, DOI 10.1136/bmj.302.6779.771; COULTER A, 1993, BRIT MED J, V306, P433, DOI 10.1136/bmj.306.6875.433; GLENNERSTER H, 1992, FOOTHOLD FUNDHOLDING; Howie J G, 1993, Health Bull (Edinb), V51, P94; Howie J G, 1992, Health Bull (Edinb), V50, P316; NEWTON J, 1993, BRIT MED J, V306, P375, DOI 10.1136/bmj.306.6874.375; PURVES IN, 1993, BRIT MED J, V306, P496, DOI 10.1136/bmj.306.6876.496; SLEATOR DJD, 1993, BRIT J GEN PRACT, V43, P102; WUATT TD, 1990, BMJ, V300, P441; 1986, NORDIC STATISTICS 1; 1989, WORKING PATIENTS; 1985, NORDIC STATISTICS 3; 1991, GUIDELINES DEFINED D; 1990, FUNDING GENERAL PRAC; 1985, NORDIC STATISTICS 2; 1993, TREATMENT DEPRESSION	18	115	117	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 6	1993	307	6913					1190	1194		10.1136/bmj.307.6913.1190	http://dx.doi.org/10.1136/bmj.307.6913.1190			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MF824	8305075	Bronze, Green Published			2022-12-01	WOS:A1993MF82400027
J	WALTER, HJ; VAUGHAN, RD				WALTER, HJ; VAUGHAN, RD			AIDS RISK REDUCTION AMONG A MULTIETHNIC SAMPLE OF URBAN HIGH-SCHOOL-STUDENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; SEXUALLY-TRANSMITTED DISEASES; UNITED-STATES; PRIMARY PREVENTION; SELF-EFFICACY; ADOLESCENTS; BEHAVIORS; HIV; INTERVENTION; INFECTION	Objective.-To evaluate the effectiveness of a teacher-delivered curriculum in favorably modifying acquired immunodeficiency syndrome (AIDS)-related knowledge and beliefs, self-efficacy related to AIDS-preventive actions, and involvement in AIDS risk behaviors among an eligible population of 1316 New York City high school students. Design.-Students in two pairs of demographically similar high schools were assigned to receive either a special six-lesson AIDS-preventive curriculum (intervention group) or no formal AIDS-preventive curriculum (comparison group). Participants.-Study participants were ninth- and 11th-grade students, 12 to 20 years of age (mean, 15.7 years), 41.5% male, and 72.1% black or Hispanic. Intervention.-The special curriculum focused on conveying facts about AIDS, fostering theoretically derived beliefs favorable to AIDS prevention, and teaching skills necessary for the successful performance of AIDS-preventive behaviors. Main Outcome Measures.-AIDS-related knowledge, beliefs, self-efficacy, and behaviors were assessed among students in intervention and comparison groups at study baseline and at 3 months' follow-up. Results.-Significant (albeit modest) effects favoring intervention were observed for knowledge, beliefs, self-efficacy, and risk behavior scores. Conclusions.-School-based AIDS-preventive curricula may play a role in curtailing transmission of the human immunodeficiency virus among multiethnic groups of urban adolescents; however, such curricula may need supplementation by a broader-based prevention effort to achieve substantial risk behavior change.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PSYCHIAT,NEW YORK,NY 10032	Columbia University	WALTER, HJ (corresponding author), COLUMBIA UNIV,SCH PUBL HLTH,CTR POPULAT & FAMILY HLTH,60 HAVEN AVE,NEW YORK,NY 10032, USA.				NIMH NIH HHS [5-P50-MH43520] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [P50MH043520] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BANDURA A, 1986, SOCIAL F THOUGHT ACT; BASENENGQUIST K, 1992, HEALTH EDUC QUART, V19, P263, DOI 10.1177/109019819201900209; Becker MH, 1974, HLTH ED MONOGR, V2; BIGLAN A, 1990, J BEHAV MED, V13, P245, DOI 10.1007/BF00846833; BROWN LK, 1989, J ADOLESC HLTH CARE, V10, P286; BURKE DS, 1990, JAMA-J AM MED ASSOC, V263, P2074, DOI 10.1001/jama.263.15.2074; COHEN J, 1988, STATISTICAL POWER AN; COHEN J., 1983, APPL MULTIPLE REGRES, V2; DICLEMENTE RJ, 1989, J SEX RES, V26, P188, DOI 10.1080/00224498909551505; DICLEMENTE RJ, 1989, HLTH ED, V2, P39; ELLICKSON PL, 1990, SCIENCE, V247, P1299, DOI 10.1126/science.2180065; FISHER JD, 1988, AM PSYCHOL, V43, P914, DOI 10.1037/0003-066X.43.11.914; FLAY BR, 1986, PREV MED, V15, P451, DOI 10.1016/0091-7435(86)90024-1; FRIEDLAND GH, 1987, NEW ENGL J MED, V317, P1125, DOI 10.1056/NEJM198710293171806; GLADIS MM, 1992, HEALTH PSYCHOL, V11, P307, DOI 10.1037/0278-6133.11.5.307; GOODMAN E, 1989, PEDIATRICS, V84, P36; Green L. W., 1980, HLTH ED PLANNING DIA; HANSEN WB, 1985, J BEHAV MED, V8, P261, DOI 10.1007/BF00870313; HEARST N, 1988, JAMA-J AM MED ASSOC, V259, P2428, DOI 10.1001/jama.259.16.2428; HINGSON RW, 1990, AM J PUBLIC HEALTH, V80, P295, DOI 10.2105/AJPH.80.3.295; HOSMER DW, 1981, APPLIED LOGISTIC REG; HUSZTI HC, 1989, PEDIATRICS, V84, P986; JEMMOTT JB, 1992, AM J PUBLIC HEALTH, V82, P372, DOI 10.2105/AJPH.82.3.372; JOHNSON JA, 1988, J MED EDUC, V63, P522; KASEN S, 1992, HEALTH EDUC QUART, V19, P187, DOI 10.1177/109019819201900204; KELLER SE, 1991, J ADOLESCENT HEALTH, V12, P44, DOI 10.1016/0197-0070(91)90040-S; KILLEN JD, 1988, JAMA-J AM MED ASSOC, V260, P1728, DOI 10.1001/jama.260.12.1728; KIRBY D, 1991, FAM PLANN PERSPECT, V23, P253, DOI 10.2307/2135776; KIRBY D, 1992, ADOLESCENTS AIDS GEN; PENTZ MA, 1989, JAMA-J AM MED ASSOC, V261, P3259, DOI 10.1001/jama.261.22.3259; QUINN TC, 1988, NEW ENGL J MED, V318, P197, DOI 10.1056/NEJM198801283180401; ROTHERAMBORUS MJ, 1991, JAMA-J AM MED ASSOC, V266, P1237, DOI 10.1001/jama.266.9.1237; RUDER AM, 1990, NEW YORK STATE J MED, V90, P129; SELIK RM, 1988, AM J PUBLIC HEALTH, V78, P1539, DOI 10.2105/AJPH.78.12.1539; SHAFER MA, 1991, J PEDIATR-US, V119, P826, DOI 10.1016/S0022-3476(05)80312-9; STLOUIS ME, 1991, JAMA-J AM MED ASSOC, V266, P2387, DOI 10.1001/jama.266.17.2387; UPCHURCH DM, 1991, AM J EPIDEMIOL, V134, P1159, DOI 10.1093/oxfordjournals.aje.a116019; VAUGHAN RD, 1991, AIDS, V5, P112, DOI 10.1097/00002030-199101000-00021; WALTER HJ, 1991, PEDIATRICS, V88, P846; WALTER HJ, 1991, J AM ACAD CHILD PSY, V30, P556, DOI 10.1097/00004583-199107000-00005; WALTER HJ, 1992, AM J PUBLIC HEALTH, V82, P528, DOI 10.2105/AJPH.82.4.528; WALTER HJ, 1988, NEW ENGL J MED, V318, P1093, DOI 10.1056/NEJM198804283181704; WALTER HJ, 1989, J NATL CANCER I, V81, P995, DOI 10.1093/jnci/81.13.995; WALTER HJ, IN PRESS J AM ACAD C; WALTER HJ, IN PRESS AIDS ED PRE; WALTER HJ, INPRESS J APPL SOC P; WALTER HJ, IN PRESS PREV MED; WALTER HJ, IN PRESS HLTH ED Q; 1988, CDC HHS888404 US DEP; 1992, HIV AIDS SURVEILLANC; 1991, CHANCELLORS EXPANDED	51	135	135	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1993	270	6					725	730		10.1001/jama.270.6.725	http://dx.doi.org/10.1001/jama.270.6.725			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LQ338	8336374				2022-12-01	WOS:A1993LQ33800027
J	CLARK, KL; HALAY, ED; LAI, ES; BURLEY, SK				CLARK, KL; HALAY, ED; LAI, ES; BURLEY, SK			CO-CRYSTAL STRUCTURE OF THE HNF-3/FORK HEAD DNA-RECOGNITION MOTIF RESEMBLES HISTONE-H5	NATURE			English	Article							GENE FORK-HEAD; TRANSCRIPTION FACTORS; PROTEIN STRUCTURES; OPERATOR COMPLEX; BINDING DOMAINS; TRP REPRESSOR; REFINEMENT; RESOLUTION; HOMOLOGY; SEQUENCE	The three-dimensional structure of an HNF-3/fork head DNA-recognition motif complexed with DNA has been determined by X-ray crystallography at 2.5 angstrom resolution. This alpha/beta protein binds B-DNA as a monomer, through interactions with the DNA backbone and through both direct and water-mediated major and minor groove base contacts, inducing a 13-degrees bend. The transcription factor fold is very similar to the structure of histone H5. In its amino-terminal half, three alpha-helices adopt a compact structure that presents the third helix to the major groove. The remainder of the protein includes a twisted, antiparallel beta-structure and random coil that interacts with the minor groove.	ROCKEFELLER UNIV, MOLEC BIOPHYS LABS, 1230 YORK AVE, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, HOWARD HUGHES MED INST, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, CELL BIOL & GENET PROGRAM, NEW YORK, NY 10021 USA; MEM SLOAN KETTERING CANC CTR, ENDOCRINOL SERV, NEW YORK, NY 10021 USA	Rockefeller University; Howard Hughes Medical Institute; Rockefeller University; Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center				Burley, Stephen/0000-0002-2487-9713				ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOWIE JU, 1991, SCIENCE, V253, P164, DOI 10.1126/science.1853201; BRENNAN RG, 1989, J BIOL CHEM, V264, P1903; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, XPLOR V 3 0 MANUAL; BURLEY SK, 1988, ADV PROTEIN CHEM, V39, P125; BURLEY SK, 1986, J AM CHEM SOC, V108, P7995, DOI 10.1021/ja00285a019; CHAIT BT, 1992, SCIENCE, V257, P1885, DOI 10.1126/science.1411504; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; CRANEROBINSON C, 1989, PROTEIN ENG, V2, P577, DOI 10.1093/protein/2.8.577; DEKKER N, 1993, NATURE, V362, P852, DOI 10.1038/362852a0; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; GROSSNIKLAUS U, 1992, GENE DEV, V6, P1030, DOI 10.1101/gad.6.6.1030; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HARAN TE, 1992, EMBO J, V11, P3021, DOI 10.1002/j.1460-2075.1992.tb05372.x; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; IP YT, 1990, MOL CELL BIOL, V10, P3770, DOI 10.1128/MCB.10.7.3770; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUO CJ, 1992, NATURE, V355, P457, DOI 10.1038/355457a0; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LAI E, IN PRESS P NATN ACAD; LI C, 1992, GENOMICS, V13, P658, DOI 10.1016/0888-7543(92)90138-I; LI C, 1991, P NATL ACAD SCI USA, V88, P7739, DOI 10.1073/pnas.88.17.7739; LIU JK, 1991, MOL CELL BIOL, V11, P773, DOI 10.1128/MCB.11.2.773; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PANI L, 1992, MOL CELL BIOL, V12; PUGLISI JD, 1989, METHOD ENZYMOL, V180, P304; RAMACHANDRAN GN, 1963, J MOL BIOL, V7, P95, DOI 10.1016/S0022-2836(63)80023-6; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; REID KSC, 1985, FEBS LETT, V190, P209, DOI 10.1016/0014-5793(85)81285-0; RICHARDSON JS, 1985, METHOD ENZYMOL, V115, P359; SANDER C, 1991, PROTEINS, V9, P56, DOI 10.1002/prot.340090107; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TAO W, 1992, NEURON, V8, P957, DOI 10.1016/0896-6273(92)90210-5; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	49	1093	1119	3	52	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 29	1993	364	6436					412	420		10.1038/364412a0	http://dx.doi.org/10.1038/364412a0			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP640	8332212				2022-12-01	WOS:A1993LP64000045
J	RABIZADEH, S; OH, J; ZHONG, LT; YANG, J; BITLER, CM; BUTCHER, LL; BREDESEN, DE				RABIZADEH, S; OH, J; ZHONG, LT; YANG, J; BITLER, CM; BUTCHER, LL; BREDESEN, DE			INDUCTION OF APOPTOSIS BY THE LOW-AFFINITY NGF RECEPTOR	SCIENCE			English	Article							NERVE GROWTH-FACTOR; TUMOR-NECROSIS-FACTOR; ALZHEIMERS-DISEASE; TRK PROTOONCOGENE; MOLECULAR-CLONING; BASAL FOREBRAIN; GENE-TRANSFER; EXPRESSION; ANTIBODY; SYSTEM	Nerve growth factor (NGF) binding to cellular receptors is required for the survival of some neural cells. In contrast to Trk A, the high-affinity NGF receptor that transduces NGF signals for survival and differentiation, the function of the low-affinity NGF receptor, p75NGFR, remains uncertain. Expression of p75NGFR induced neural cell death constitutively when p75NGFR was unbound; binding by NGF or monoclonal antibody, however, inhibited cell death induced by p75NGFR. Thus, expression of p75NGFR may explain the dependence of some neural cells on NGF for survival. These findings also suggest that p75NGFR has some functional similarities to other members of a superfamily of receptors that include tumor necrosis factor receptors, Fas (Apo-1), and CD40.	UNIV CALIF LOS ANGELES,DEPT NEUROL,LOS ANGELES,CA 90024; STANFORD RES INST,MENLO PK,CA 94025; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT PSYCHOL,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; SRI International; Stanford University; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS010928] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG010671] Funding Source: NIH RePORTER; NIA NIH HHS [AG10671] Funding Source: Medline; NINDS NIH HHS [NS10928] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BANCHEREAU J, 1991, SCIENCE, V251, P70, DOI 10.1126/science.1702555; Chan-Palay V., 1990, DEMENT GERIATR COGN, V1, P138, DOI [DOI 10.1159/0001, 10.1159/000107133, DOI 10.1159/000107133]; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DISANTO JP, 1993, NATURE, V361, P541, DOI 10.1038/361541a0; DURAND M M, 1990, Society for Neuroscience Abstracts, V16, P40; GOEDERT M, 1989, MOL BRAIN RES, V5, P1, DOI 10.1016/0169-328X(89)90011-9; GREENBERG ME, 1984, P NATL ACAD SCI-BIOL, V81, P969, DOI 10.1073/pnas.81.3.969; HEMPSTEAD BL, 1991, NATURE, V350, P678, DOI 10.1038/350678a0; IBANEZ CF, 1992, CELL, V69, P329, DOI 10.1016/0092-8674(92)90413-7; IP NY, 1993, NEURON, V10, P137, DOI 10.1016/0896-6273(93)90306-C; ITOH N, 1991, CELL, V66, P233, DOI 10.1016/0092-8674(91)90614-5; KERR JFR, 1991, APOPTOSIS, V3, P321; KLEIN R, 1991, CELL, V65, P189, DOI 10.1016/0092-8674(91)90419-Y; KORDOWER JH, 1989, NEUROBIOL AGING, V10, P67, DOI 10.1016/S0197-4580(89)80013-2; LARGE TH, 1989, NEURON, V2, P1123, DOI 10.1016/0896-6273(89)90179-7; LEVI-MONTALCINI RITA, 1966, HARVEY LECT, V60, P217; LEVIMONTALCINI R, 1987, SCIENCE, V237, P1154, DOI 10.1126/science.3306916; LIU YJ, 1989, NATURE, V342, P21; MAH SP, 1993, J NEUROCHEM, V60, P1183, DOI 10.1111/j.1471-4159.1993.tb03275.x; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MORGENSTERN JP, 1990, NUCLEIC ACIDS RES, V18, P3587, DOI 10.1093/nar/18.12.3587; RABIZADEH S, UNPUB; RADEKE MJ, 1987, NATURE, V325, P593, DOI 10.1038/325593a0; RUKENSTEIN A, 1991, J NEUROSCI, V11, P2552; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SCHULZEOSTHOFF K, 1992, J BIOL CHEM, V267, P5317; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SUTTER A, 1979, J BIOL CHEM, V254, P5972; TRAUTH BC, 1989, SCIENCE, V245, P301, DOI 10.1126/science.2787530; WOOLE NJ, 1989, NEUROSCIENCE, V30, P143, DOI 10.1016/0306-4522(89)90360-6; WOOLF NJ, 1989, NEUROSCI LETT, V96, P277, DOI 10.1016/0304-3940(89)90391-1; Zhong L. T., 1992, Society for Neuroscience Abstracts, V18, P44; ZHONG LT, 1993, P NATL ACAD SCI USA, V90, P4533, DOI 10.1073/pnas.90.10.4533	33	754	804	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 16	1993	261	5119					345	348		10.1126/science.8332899	http://dx.doi.org/10.1126/science.8332899			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM678	8332899				2022-12-01	WOS:A1993LM67800034
J	NOWAK, M; SIGMUND, K				NOWAK, M; SIGMUND, K			A STRATEGY OF WIN STAY, LOSE SHIFT THAT OUTPERFORMS TIT-FOR-TAT IN THE PRISONERS-DILEMMA GAME	NATURE			English	Article							EVOLUTION; COOPERATION	THE Prisoner's Dilemma is the leading metaphor for the evolution of cooperative behaviour in populations of selfish agents, especially since the well-known computer tournaments of Axelrod1 and their application to biological communities2,3. In Axelrod's simulations, the simple strategy tit-for-tat did outstandingly well and subsequently became the major paradigm for reciprocal altruism4-12. Here we present extended evolutionary simulations of heterogeneous ensembles of probabilistic strategies including mutation and selection, and report the unexpected success of another protagonist: Pavlov. This strategy is as simple as tit-for-tat and embodies the fundamental behavioural mechanism win-stay, lose-shift, which seems to be a widespread rule13. Pavlov's success is based on two important advantages over tit-for-tat: it can correct occasional mistakes and exploit unconditional cooperators. This second feature prevents Pavlov populations from being undermined by unconditional cooperators, which in turn invite defectors. Pavlov seems to be more robust than tit-for-tat, suggesting that cooperative behaviour in natural situations may often be based on win-stay, lose-shift.	UNIV VIENNA, INST MATH, A-1090 VIENNA, AUSTRIA	University of Vienna	NOWAK, M (corresponding author), UNIV OXFORD, DEPT ZOOL, S PARKS RD, OXFORD OX1 3PS, ENGLAND.		Nowak, Martin A/A-6977-2008					AXELROD R, 1988, SCIENCE, V242, P1385, DOI 10.1126/science.242.4884.1385; AXELROD R, 1981, SCIENCE, V211, P1390, DOI 10.1126/science.7466396; Axelrod R., 1987, GENETIC ALGORITHMS S; Axelrod Robert K., 1984, EVOLUTION COOPERATIO, DOI DOI 10.2307/3323905; BOYD R, 1989, J THEOR BIOL, V136, P47, DOI 10.1016/S0022-5193(89)80188-2; BOYD R, 1987, NATURE, V327, P58, DOI 10.1038/327058a0; Dawkins R, 1988, SELFISH GENE; Domjan M., 1986, PRINCIPLES LEARNING, V2nd; DUGATKIN LA, 1988, BEHAV ECOL SOCIOBIOL, V23, P395, DOI 10.1007/BF00303714; Hofbauer J., 1988, THEORY EVOLUTION DYN; KRAINES D, 1989, THEOR DECIS, V26, P47, DOI 10.1007/BF00134056; KREBS JR, 1981, INTRO BEHAVIOURAL EC; LINDGREN K, 1991, ARTIFICIAL LIFE, V2; LOMBARDO MP, 1985, SCIENCE, V227, P1363, DOI 10.1126/science.227.4692.1363; MAY RM, 1987, NATURE, V327, P15, DOI 10.1038/327015a0; Maynard Smith J., 1982, pi; MILINSKI M, 1987, NATURE, V325, P433, DOI 10.1038/325433a0; NOWAK M, 1993, P NATL ACAD SCI USA, V90, P5091, DOI 10.1073/pnas.90.11.5091; NOWAK M, 1990, ACTA APPL MATH, V20, P247, DOI 10.1007/BF00049570; NOWAK MA, 1992, NATURE, V355, P250, DOI 10.1038/355250a0; NOWAK MA, 1992, NATURE, V359, P826, DOI 10.1038/359826a0; Rapoport A, 1965, PRISONERS DILEMMA; REBOREDA JC, 1993, J EXP ANIMAL BEHAV, V60, P176; SELTEN R, 1984, BEHAV BRAIN SCI, V7, P115, DOI 10.1017/S0140525X00026479; Sigmund K., 1993, GAMES LIFE; SMITH JM, 1984, BEHAV BRAIN SCI, V7, P95, DOI 10.1017/S0140525X00026327; WILKINSON GS, 1984, NATURE, V308, P181, DOI 10.1038/308181a0	27	1010	1033	5	205	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	JUL 1	1993	364	6432					56	58		10.1038/364056a0	http://dx.doi.org/10.1038/364056a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK818	8316296				2022-12-01	WOS:A1993LK81800055
J	SHANNON, KM; OCONNELL, P; MARTIN, GA; PADERANGA, D; OLSON, K; DINNDORF, P; MCCORMICK, F				SHANNON, KM; OCONNELL, P; MARTIN, GA; PADERANGA, D; OLSON, K; DINNDORF, P; MCCORMICK, F			LOSS OF THE NORMAL NF1 ALLELE FROM THE BONE-MARROW OF CHILDREN WITH TYPE-1 NEUROFIBROMATOSIS AND MALIGNANT MYELOID DISORDERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							COLONY-STIMULATING FACTOR; POLYMORPHIC CDNA PROBE; VONRECKLINGHAUSEN NEUROFIBROMATOSIS; MYELODYSPLASTIC SYNDROMES; CHILDHOOD MONOSOMY-7; RAS P21; GENE; LEUKEMIA; MUTATIONS; PROTEIN	Background. Children with type 1 neurofibromatosis (NF-1) are at increased risk for malignant myeloid disorders. Analysis of the NF-1 gene (NF1) suggests that the function of its product, neurofibromin, is reduced in affected persons and that NF1 belongs to the tumor-suppressor class of recessive cancer genes. This model is consistent with evidence that neurofibromin accelerates the intrinsic guanosine triphosphate-hydrolyzing activity of the Ras family of regulatory proteins. Loss of constitutional heterozygosity has not been reported in the benign tumors associated with NF-1, however, and has only been detected in a few malignant neural-crest tumors and in some tumor-derived cell lines. Methods. We studied DNA extracted from the bone marrow of 11 children with NF-1 in whom malignant myeloid disorders developed and from parental leukocytes. We used a series of polymorphic markers within and near NF1 to determine whether leukemogenesis was associated with structural alterations of the gene. Results. Bone marrow samples from five patients showed loss of heterozygosity. In each case, the NF1 allele was inherited from a parent with NF-1 and the normal allele was deleted. Conclusions. These data provide evidence that NF1 may function as a tumor-suppressor allele in malignant myeloid diseases in children with NF-1 and that neurofibromin is a regulator of Ras in early myelopoiesis.	UNIV TEXAS, HLTH SCI CTR, DEPT PATHOL, SAN ANTONIO, TX 78284 USA; ONYX PHARMACEUT, RICHMOND, CA USA; CHILDRENS NATL MED CTR, WASHINGTON, DC 20010 USA	University of Texas System; University of Texas Health San Antonio; Children's National Health System	SHANNON, KM (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT PEDIAT, RM U-432, SAN FRANCISCO, CA 94143 USA.							ANDERSEN LB, 1993, HUM MOL GENET, V2, P1083, DOI 10.1093/hmg/2.7.1083-a; ANDERSEN LB, 1991, NUCLEIC ACIDS RES, V19, P3754, DOI 10.1093/nar/19.13.3754; ANDERSEN LB, 1993, NAT GENET, V3, P118, DOI 10.1038/ng0293-118; ANDERSEN LB, 1991, NUCLEIC ACIDS RES, V19, P197, DOI 10.1093/nar/19.1.197-a; BADER JL, 1978, J PEDIATR-US, V92, P925, DOI 10.1016/S0022-3476(78)80362-X; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BARSAGI D, 1985, CELL, V42, P841, DOI 10.1016/0092-8674(85)90280-6; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BUCHBERG AM, 1990, NATURE, V347, P291, DOI 10.1038/347291a0; CASTROMALASPINA H, 1984, CANCER, V54, P675, DOI 10.1002/1097-0142(1984)54:4<675::AID-CNCR2820540415>3.0.CO;2-Q; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; EMANUEL PD, 1991, BLOOD, V77, P925; FONG C, 1987, CANCER GENET CYTOGEN, V28, P55, DOI 10.1016/0165-4608(87)90354-2; FREEDMAN MH, 1992, BRIT J HAEMATOL, V80, P40, DOI 10.1111/j.1365-2141.1992.tb06398.x; FUTREAL PA, 1991, NUCLEIC ACIDS RES, V19, P6977, DOI 10.1093/nar/19.24.6977; GADNER H, 1992, HEMATOL ONCOL CLIN N, V6, P655, DOI 10.1016/S0889-8588(18)30334-4; GLOVER TW, 1991, GENE CHROMOSOME CANC, V3, P62, DOI 10.1002/gcc.2870030111; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840; LEGIUS E, 1993, NAT GENET, V3, P122, DOI 10.1038/ng0293-122; LUBBERT M, 1992, ONCOGENE, V7, P263; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MENON AG, 1990, P NATL ACAD SCI USA, V87, P5435, DOI 10.1073/pnas.87.14.5435; NAKAMURA Y, 1988, NUCLEIC ACIDS RES, V16, P5707, DOI 10.1093/nar/16.12.5707; NEUBAUER A, 1991, BLOOD, V77, P594; NODA M, 1985, NATURE, V318, P73, DOI 10.1038/318073a0; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; Riccardi VM., 1993, PLASTIC RECONST SURG, V91, P561, DOI [10.1097/00006534-199303000-00029, DOI 10.1097/00006534-199303000-00029]; Rodenhuis S, 1992, Semin Cancer Biol, V3, P241; SATOH T, 1991, P NATL ACAD SCI USA, V88, P3314, DOI 10.1073/pnas.88.8.3314; SHANNON KM, 1989, J CLIN INVEST, V84, P984, DOI 10.1172/JCI114262; SHANNON KM, 1992, BLOOD, V79, P1311; SKUSE GR, 1989, GENE CHROMOSOME CANC, V1, P36, DOI 10.1002/gcc.2870010107; THE I, 1993, NAT GENET, V3, P62, DOI 10.1038/ng0193-62; VOGELSTEIN B, 1990, GENE CHROMOSOME CANC, V2, P159, DOI 10.1002/gcc.2870020212; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEISS K, 1987, LEUKEMIA, V1, P97; XU GF, 1991, NUCLEIC ACIDS RES, V19, P3764, DOI 10.1093/nar/19.13.3764; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9; XU W, 1992, GENE CHROMOSOME CANC, V4, P337, DOI 10.1002/gcc.2870040411	42	344	352	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAR 3	1994	330	9					597	601		10.1056/NEJM199403033300903	http://dx.doi.org/10.1056/NEJM199403033300903			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY573	8302341				2022-12-01	WOS:A1994MY57300003
J	MOLITERNO, DJ; WILLARD, JE; LANGE, RA; NEGUS, BH; BOEHRER, JD; GLAMANN, DB; LANDAU, C; ROSSEN, JD; WINNIFORD, MD; HILLIS, LD				MOLITERNO, DJ; WILLARD, JE; LANGE, RA; NEGUS, BH; BOEHRER, JD; GLAMANN, DB; LANDAU, C; ROSSEN, JD; WINNIFORD, MD; HILLIS, LD			CORONARY-ARTERY VASOCONSTRICTION INDUCED BY COCAINE, CIGARETTE-SMOKING, OR BOTH	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INTRANASAL COCAINE; NICOTINE; DISEASE; DIMENSIONS; TERM	Background. In humans, the use of cocaine and cigarette smoking each increases the heart's metabolic need for oxygen but may also decrease the supply of oxygen. As cocaine abuse has proliferated, cocaine-associated chest pain, myocardial infarction, and sudden death have occurred, especially among smokers. We assessed the influence of intranasal cocaine and cigarette smoking, alone and together, on myocardial oxygen demand and coronary arterial dimensions in subjects with and subjects without coronary atherosclerosis. Methods. In 42 smokers (28 men and 14 women; age, 34 to 79 years; 36 with angiographically demonstrable coronary artery disease), we measured the product of the heart rate and systolic arterial pressure (rate-pressure product) and coronary arterial diameters before and after intranasal cocaine at a dose of 2 mg per kilogram of body weight (n = 6), one cigarette (n = 12), or intranasal cocaine at a dose of 2 mg per kilogram followed by one cigarette (n = 24). Results. No patient had chest pain or ischemic electrocardiographic changes after cocaine use or smoking. The mean (+/-SE) rate-pressure product increased by 11+/-2 percent after cocaine use (n = 30, P<0.001), by 12+/-4 percent after one cigarette (n = 12, P = 0.021), and by 45+/-5 percent after both cocaine use and smoking (n = 24, P<0.001). As compared with base-line measurements, the diameters of nondiseased coronary arterial segments decreased on average by 7+/-1 percent after cocaine use (P<0.001), by 7+/-1 percent after smoking (P<0.001), and by 6+/-2 percent after cocaine use and smoking (P<0.001). The diameters of diseased segments decreased by 9+/-2 percent after cocaine use (n = 18, P<0.001), by 5+/-5 percent after smoking (n = 12, P = 0.322), and by 19+/-4 percent after cocaine use and smoking (n = 12, P<0.001). The increase in the rate-pressure product and the decrease in the diameters of diseased segments caused by cocaine use and smoking together were greater (P<0.001 and P = 0.037, respectively) than the changes caused by either alone. Conclusions. The deleterious effects of cocaine on myocardial oxygen supply and demand are exacerbated by concomitant cigarette smoking. This combination substantially increases the metabolic requirement of the heart for oxygen but simultaneously decreases the diameter of diseased coronary arterial segments.	UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DIV CARDIOVASC,DALLAS,TX 75235; UNIV IOWA,DEPT INTERNAL MED,DIV CARDIOVASC,IOWA CITY,IA 52242	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Iowa			Lange, Richard/AAM-9594-2021	Rossen, James/0000-0001-7287-7088				BOEHRER JD, 1992, J AM COLL CARDIOL, V20, P90, DOI 10.1016/0735-1097(92)90142-A; BROGAN WC, 1992, ANN INTERN MED, V116, P556, DOI 10.7326/0003-4819-116-7-556; BROGAN WC, 1991, J AM COLL CARDIOL, V18, P581, DOI 10.1016/0735-1097(91)90617-I; CRYER PE, 1976, NEW ENGL J MED, V295, P573, DOI 10.1056/NEJM197609092951101; FLORES ED, 1990, J AM COLL CARDIOL, V16, P74, DOI 10.1016/0735-1097(90)90459-3; KLEIN LW, 1984, J AM COLL CARDIOL, V3, P879, DOI 10.1016/S0735-1097(84)80344-7; KUHN FE, 1990, J AM COLL CARDIOL, V16, P1481, DOI 10.1016/0735-1097(90)90396-7; LANGE RA, 1989, NEW ENGL J MED, V321, P1557, DOI 10.1056/NEJM198912073212301; LANGE RA, 1990, ANN INTERN MED, V112, P897, DOI 10.7326/0003-4819-112-12-897; MAOUAD J, 1986, CATHETER CARDIO DIAG, V12, P366, DOI 10.1002/ccd.1810120603; MINOR RL, 1991, ANN INTERN MED, V115, P797, DOI 10.7326/0003-4819-115-10-797; MOREYRA AE, 1992, AM HEART J, V124, P392, DOI 10.1016/0002-8703(92)90603-S; NICOD P, 1984, J AM COLL CARDIOL, V4, P964, DOI 10.1016/S0735-1097(84)80058-3; QUILLEN JE, 1993, J AM COLL CARDIOL, V22, P642, DOI 10.1016/0735-1097(93)90170-6; RABINOWITZ BD, 1979, CIRCULATION, V60, P752, DOI 10.1161/01.CIR.60.4.752; REIBER JHC, 1985, CIRCULATION, V71, P280, DOI 10.1161/01.CIR.71.2.280; REINDERS JH, 1986, ARTERIOSCLEROSIS, V6, P15, DOI 10.1161/01.ATV.6.1.15; SONNENFELD T, 1980, BRIT J PHARMACOL, V71, P609, DOI 10.1111/j.1476-5381.1980.tb10980.x; THOMAS CB, 1956, ANN INTERN MED, V44, P874, DOI 10.7326/0003-4819-44-5-874; WINER BJ, 1971, STATISTICAL PRINCIPL, P185; ZIMMERMAN M, 1987, ATHEROSCLEROSIS, V63, P33, DOI 10.1016/0021-9150(87)90079-7; 1988, DHHS ADM881584 PUBL	22	193	207	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	1994	330	7					454	459		10.1056/NEJM199402173300702	http://dx.doi.org/10.1056/NEJM199402173300702			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW480	8289850				2022-12-01	WOS:A1994MW48000002
J	RHYU, MS; JAN, LY; JAN, YN				RHYU, MS; JAN, LY; JAN, YN			ASYMMETRIC DISTRIBUTION OF NUMB PROTEIN DURING DIVISION OF THE SENSORY ORGAN PRECURSOR CELL CONFERS DISTINCT FATES TO DAUGHTER CELLS	CELL			English	Article							DROSOPHILA NERVOUS-SYSTEM; CAENORHABDITIS-ELEGANS; MONOCLONAL-ANTIBODIES; NOTCH LOCUS; GENE; MELANOGASTER; EMBRYOS; DIFFERENTIATION; EXPRESSION; HAIRLESS	The four cells of an external sense organ in the Drosophila peripheral nervous system, the neuron, its sheath cell, and two ''outer support cells'' that form the hair and socket, are derived from a common precursor, the sensory organ precursor (SOP), after two rounds of division. We determined by immunocytochemistry that numb is a membrane-associated protein which localizes asymmetrically to one-half of the predivisional SOP cell. Upon division, numb segregates differentially to one daughter. Loss of numb function causes the descendants of the SOP to differentiate inappropriately, producing four outer support cells and no neuron or sheath. Ectopic expression of numb during the time of SOP division results in a transformation that is opposite to the null mutant transformation. Thus, numb functions to determine the fates of the secondary precursors; the differential distribution of numb as the SOP divides generates an asymmetric division in which the daughter cells acquire distinct identities.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco	RHYU, MS (corresponding author), UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143, USA.			Jan, Lily/0000-0003-3938-8498; Jan, Yuh Nung/0000-0003-1367-6299				ANDERSON KV, 1987, TRENDS GENET, V3, P91, DOI 10.1016/0168-9525(87)90191-0; ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; ARTAVANISTSAKONAS S, 1988, TRENDS GENET, V4, P95, DOI 10.1016/0168-9525(88)90096-0; ASHBURNER M, 1982, GENETICS, V101, P447; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BANG AG, 1991, DEVELOPMENT, V111, P89; BANG AG, 1992, GENE DEV, V6, P1752, DOI 10.1101/gad.6.9.1752; Bate C.M., 1978, HDB SENSORY PHYSL, V9, P1, DOI [10.1007/978-3-642-66880-7_1, DOI 10.1007/978-3-642-66880-7_1]; Bauer V, 1904, ZOOL JB ABT ANAT ONT, V20, P123; BLOCHLINGER K, 1990, GENE DEV, V4, P1322, DOI 10.1101/gad.4.8.1322; BLOCHLINGER K, 1991, GENE DEV, V5, P1124, DOI 10.1101/gad.5.7.1124; BODMER R, 1987, ROUX ARCH DEV BIOL, V196, P69, DOI 10.1007/BF00402027; BODMER R, 1987, CELL, V51, P293, DOI 10.1016/0092-8674(87)90156-5; BODMER R, 1989, NEURON, V3, P21, DOI 10.1016/0896-6273(89)90112-8; BOWERMAN B, 1993, CELL, V74, P443, DOI 10.1016/0092-8674(93)80046-H; BOWERMAN B, 1992, CELL, V68, P1062; BRAND M, 1993, DEVELOPMENT, V119, P1; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CAMPOSORTEGA JA, 1991, ANNU REV NEUROSCI, V14, P399, DOI 10.1146/annurev.ne.14.030191.002151; CAMPOSORTEGA JA, 1988, TRENDS NEUROSCI, V11, P400, DOI 10.1016/0166-2236(88)90077-X; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CANAL I, 1986, J NEUROGENET, V3, P293, DOI 10.3109/01677068609106856; Davidson E. H., 1986, GENE ACTIVITY EARLY; DOE CQ, 1992, DEVELOPMENT, V116, P855; FERGUSON EL, 1985, GENETICS, V110, P17; FUJITA SC, 1982, P NATL ACAD SCI-BIOL, V79, P7929, DOI 10.1073/pnas.79.24.7929; GHYSEN A, 1986, ROUX ARCH DEV BIOL, V195, P281, DOI 10.1007/BF00376060; GHYSEN A, 1989, DEVELOPMENT, V105, P35; GOBER JW, 1991, BIOESSAYS, V13, P277, DOI 10.1002/bies.950130604; GOLIC KG, 1989, CELL, V59, P499, DOI 10.1016/0092-8674(89)90033-0; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HARTENSTEIN V, 1988, DEVELOPMENT, V102, P869; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; HIGASHIJIMA S, 1992, GENE DEV, V6, P1005, DOI 10.1101/gad.6.6.1005; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; JARMAN AP, 1993, DEVELOPMENT, V119, P19; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; Lees AD, 1942, PROC R SOC SER B-BIO, V131, P87, DOI 10.1098/rspb.1942.0019; LEPTIN M, 1990, DEVELOPMENT, V110, P73; Lindsley D.L., 1992, GENOME DROSOPHILA ME; LOSICK R, 1992, NATURE, V355, P601, DOI 10.1038/355601a0; MALER D, 1992, MECH DEVELOP, V38, P143; McIver S.B., 1985, P71; NASH D, 1970, GENETICS, V64, P471; NASH D, 1965, GENET RES, V6, P175, DOI 10.1017/S0016672300004079; PARKS AL, 1993, DEV BIOL, V157, P484, DOI 10.1006/dbio.1993.1151; POINDEXTER JS, 1964, BACTERIOL REV, V28, P231, DOI 10.1128/MMBR.28.3.231-295.1964; RAO Y, 1991, GENE DEV, V5, P1577, DOI 10.1101/gad.5.9.1577; SCHWEISGUTH F, 1992, CELL, V69, P1199, DOI 10.1016/0092-8674(92)90641-O; Spradling AC, 1986, DROSOPHILA PRACTICAL, P175; STERNBERG PW, 1988, DEV BIOL, V130, P67, DOI 10.1016/0012-1606(88)90414-9; STRATHERN JN, 1979, CELL, V17, P371, DOI 10.1016/0092-8674(79)90163-6; STROME S, 1983, CELL, V35, P15, DOI 10.1016/0092-8674(83)90203-9; UEMURA T, 1989, CELL, V58, P349, DOI 10.1016/0092-8674(89)90849-0; VAESSIN H, 1991, CELL, V67, P941, DOI 10.1016/0092-8674(91)90367-8; XU T, 1993, DEVELOPMENT, V117, P1223; Zacharuk R.Y., 1985, COMPREHENSIVE INSECT, V6, P1; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2	58	630	650	0	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 11	1994	76	3					477	491		10.1016/0092-8674(94)90112-0	http://dx.doi.org/10.1016/0092-8674(94)90112-0			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	8313469				2022-12-01	WOS:A1994MX20700009
J	TAKAI, T; LI, M; SYLVESTRE, D; CLYNES, R; RAVETCH, JV				TAKAI, T; LI, M; SYLVESTRE, D; CLYNES, R; RAVETCH, JV			FCR GAMMA-CHAIN DELETION RESULTS IN PLEIOTROPIC EFFECTOR CELL DEFECTS	CELL			English	Article							NATURAL-KILLER-CELLS; IGG FC; T-CELL; HIGH-AFFINITY; RECEPTOR; MACROPHAGE; HETEROGENEITY; EXPRESSION; RIII; LYMPHOCYTES	The gamma subunit of immunoglobulin Fc receptors is an essential component of the high-affinity receptor for IgE (Fc epsilon RI) and the low-affinity receptor for IgG (Fc gamma RIII) and is associated with the high-affinity receptor for IgG (Fc gamma RI) and the T cell receptor-CD3 complex. It is required for both receptor assembly and signal transduction. Targeted disruption of this subunit results in immunocompromised mice. Activated macrophages from gamma chain-deficient mice unexpectedly lack the ability to phagocytose antibody-coated particles, despite normal binding. Defects in NK cell-mediated antibody-dependent cytotoxicity and mast cell-mediated allergic responses are evident in these animals, establishing the indispensable role of FcRs in these responses. However, loss of gamma chain does not appear to perturb T cell development, since both thymic and peripheral T cell populations appear normal. These mice thus represent an important tool for evaluating the role of these receptors in humoral and cellular immune responses.	SLOAN KETTERING INST, DEWITT WALLACE RES LAB, NEW YORK, NY 10021 USA	Memorial Sloan Kettering Cancer Center			Ravetch, Jeffrey/Z-1596-2019	Ravetch, Jeffrey/0000-0003-2024-9041				ALCARAZ G, 1987, BIOCHEMISTRY-US, V26, P2569, DOI 10.1021/bi00383a024; ALLEN JM, 1989, SCIENCE, V243, P378, DOI 10.1126/science.2911749; ASKENASE PW, 1974, IMMUNOLOGY, V27, P563; BEAVEN MA, 1993, IMMUNOL TODAY, V14, P222, DOI 10.1016/0167-5699(93)90167-J; BROOKS DG, 1989, J EXP MED, V170, P1369, DOI 10.1084/jem.170.4.1369; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAERON M, 1992, J IMMUNOL, V149, P1365; DIAMOND B, 1978, J IMMUNOL, V121, P1329; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; ERNST LK, 1993, P NATL ACAD SCI USA, V90, P6023, DOI 10.1073/pnas.90.13.6023; HEUSSER CH, 1977, J EXP MED, V145, P1316, DOI 10.1084/jem.145.5.1316; HOOPER M, 1987, NATURE, V326, P292, DOI 10.1038/326292a0; KINET JP, IN PRESS COMMUNICATI; KUROSAKI T, 1991, P NATL ACAD SCI USA, V88, P3837, DOI 10.1073/pnas.88.9.3837; KUROSAKI T, 1989, NATURE, V342, P805, DOI 10.1038/342805a0; KUROSAKI T, 1994, IN PRESS NATURE; LANIER LL, 1989, NATURE, V342, P803, DOI 10.1038/342803a0; LEE F, 1986, P NATL ACAD SCI USA, V83, P2061, DOI 10.1073/pnas.83.7.2061; LOVE PE, 1993, SCIENCE, V261, P918, DOI 10.1126/science.7688481; MARSH JL, 1984, GENE, V32, P481, DOI 10.1016/0378-1119(84)90022-2; MATSUDA H, 1990, J IMMUNOL, V144, P259; MERCEP M, 1989, SCIENCE, V246, P1162, DOI 10.1126/science.2531464; MIETTINEN HM, 1989, CELL, V58, P317, DOI 10.1016/0092-8674(89)90846-5; NATHAN CF, 1980, NEW ENGL J MED, V303, P622, DOI 10.1056/NEJM198009113031106; NOMA Y, 1986, NATURE, V319, P640, DOI 10.1038/319640a0; PARKER CW, 1987, ANNU REV IMMUNOL, V5, P65, DOI 10.1146/annurev.iy.05.040187.000433; PERUSSIA B, 1989, J EXP MED, V170, P73, DOI 10.1084/jem.170.1.73; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; QIU WQ, 1990, SCIENCE, V248, P732, DOI 10.1126/science.2139735; RA C, 1989, NATURE, V341, P752, DOI 10.1038/341752a0; RA C, 1989, J BIOL CHEM, V264, P15323; Ravetch J.V., 1990, FC RECEPTORS ACTION, P211; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RAVETCH JV, 1986, SCIENCE, V234, P718, DOI 10.1126/science.2946078; RIELE HT, 1990, NATURE, V348, P649, DOI 10.1038/348649a0; RODEWALD HR, 1992, CELL, V69, P139, DOI 10.1016/0092-8674(92)90125-V; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; STUART SG, 1989, EMBO J, V8, P3657, DOI 10.1002/j.1460-2075.1989.tb08540.x; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; UHER F, 1985, CELL IMMUNOL, V95, P368, DOI 10.1016/0008-8749(85)90324-7; UNKELESS JC, 1979, J EXP MED, V150, P580, DOI 10.1084/jem.150.3.580; WEINSHANK RL, 1988, J EXP MED, V167, P1909, DOI 10.1084/jem.167.6.1909; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WIRTHMUELLER U, 1992, J EXP MED, V175, P1381, DOI 10.1084/jem.175.5.1381	44	812	879	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 11	1994	76	3					519	529		10.1016/0092-8674(94)90115-5	http://dx.doi.org/10.1016/0092-8674(94)90115-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	8313472				2022-12-01	WOS:A1994MX20700012
J	KLIMASAUSKAS, S; KUMAR, S; ROBERTS, RJ; CHENG, XD				KLIMASAUSKAS, S; KUMAR, S; ROBERTS, RJ; CHENG, XD			HHAL METHYLTRANSFERASE FLIPS ITS TARGET BASE OUT OF THE DNA HELIX	CELL			English	Article							COLI THYMIDYLATE SYNTHASE; CRYSTAL-STRUCTURE; MACROMOLECULAR CRYSTALLOGRAPHY; DETERMINES METHYLATION; DIFFRACTION ANALYSIS; RECOGNIZING DOMAINS; MAMMALIAN NUCLEI; MISMATCH REPAIR; GENE-EXPRESSION; MECHANISM		NEW ENGLAND BIOLABS INC,BEVERLY,MA 01915; INST BIOTECHNOL FERMENTAS,VILNIUS 232028,LITHUANIA		KLIMASAUSKAS, S (corresponding author), COLD SPRING HARBOR LAB,WM KECK STRUCT BIOL LAB,COLD SPRING HARBOR,NY 11724, USA.		Kumar, Sanjay/AAO-2593-2021; Klimasauskas, Saulius/M-3053-2016	Klimasauskas, Saulius/0000-0002-1395-2030; Roberts, Richard/0000-0002-4348-0169	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM049245, R01GM046127] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM49245, GM46127] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANTEQUERA F, 1989, CELL, V58, P509, DOI 10.1016/0092-8674(89)90431-5; BALGANESH TS, 1987, EMBO J, V6, P3543, DOI 10.1002/j.1460-2075.1987.tb02681.x; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BROWN TC, 1987, CELL, V50, P945, DOI 10.1016/0092-8674(87)90521-6; BROWN TC, 1988, CELL, V54, P705, DOI 10.1016/S0092-8674(88)80015-1; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CHEN L, 1991, BIOCHEMISTRY-US, V30, P11018, DOI 10.1021/bi00110a002; CHEN L, 1993, J AM CHEM SOC, V115, P5318, DOI 10.1021/ja00065a063; CHENG XD, 1990, ACTA CRYSTALLOGR B, V46, P195, DOI 10.1107/S0108768189012607; CHENG XD, 1993, CELL, V74, P299, DOI 10.1016/0092-8674(93)90421-L; COOPER DN, 1988, HUM GENET, V78, P151, DOI 10.1007/BF00278187; CUNIASSE P, 1990, J MOL BIOL, V213, P303, DOI 10.1016/S0022-2836(05)80192-5; FEDOROFF NV, 1989, CELL, V56, P181, DOI 10.1016/0092-8674(89)90891-X; FITZGERALD PMD, 1988, J APPL CRYSTALLOGR, V21, P273, DOI 10.1107/S0021889887012299; FRIEDMAN S, 1992, NUCLEIC ACIDS RES, V20, P3241, DOI 10.1093/nar/20.12.3241; GARTLER SM, 1983, ANNU REV GENET, V17, P155, DOI 10.1146/annurev.ge.17.120183.001103; GRAVES KL, 1992, BIOCHEMISTRY-US, V31, P10315, DOI 10.1021/bi00157a020; HARDY LW, 1992, P NATL ACAD SCI USA, V89, P9725, DOI 10.1073/pnas.89.20.9725; HARDY LW, 1987, SCIENCE, V235, P448, DOI 10.1126/science.3099389; HARE JT, 1985, P NATL ACAD SCI USA, V82, P7350, DOI 10.1073/pnas.82.21.7350; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HEINEMANN U, 1992, EMBO J, V11, P1931, DOI 10.1002/j.1460-2075.1992.tb05246.x; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1990, SCIENCE, V249, P1307, DOI 10.1126/science.2399465; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLIMASAUSKAS S, 1991, NUCLEIC ACIDS RES, V19, P6183, DOI 10.1093/nar/19.22.6183; KUMAR S, 1992, BIOCHEMISTRY-US, V31, P8648, DOI 10.1021/bi00151a035; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LAUSTER R, 1989, J MOL BIOL, V206, P305, DOI 10.1016/0022-2836(89)90480-4; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; LEWIS J, 1991, FEBS LETT, V285, P155, DOI 10.1016/0014-5793(91)80795-5; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LIU L, 1992, BIOCHEMISTRY-US, V31, P5100, DOI 10.1021/bi00137a002; MANN MB, 1979, P C TRANSMETHYLATION, P483; MATTHEWS DA, 1990, J MOL BIOL, V214, P923, DOI 10.1016/0022-2836(90)90346-N; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; MI S, 1993, NUCLEIC ACIDS RES, V21, P2459, DOI 10.1093/nar/21.10.2459; MI S, 1992, NUCLEIC ACIDS RES, V20, P4811, DOI 10.1093/nar/20.18.4811; MILLER M, 1988, NATURE, V334, P85, DOI 10.1038/334085a0; MORDEN KM, 1990, BIOCHEMISTRY-US, V29, P8835, DOI 10.1021/bi00489a047; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; OSTERMAN DG, 1988, BIOCHEMISTRY-US, V27, P5204, DOI 10.1021/bi00414a039; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PABO CO, 1992, ANNU REV BIOCHEM, V61, P1053, DOI 10.1146/annurev.bi.61.070192.005201; PFEIFER GP, 1990, P NATL ACAD SCI USA, V87, P8252, DOI 10.1073/pnas.87.21.8252; Phillips SEV, 1991, CURR OPIN STRUC BIOL, V1, P89, DOI 10.1016/0959-440X(91)90016-M; POSFAI J, 1989, NUCLEIC ACIDS RES, V17, P2421, DOI 10.1093/nar/17.7.2421; REIK W, 1987, NATURE, V328, P248, DOI 10.1038/328248a0; ROBERTS RJ, 1976, J MOL BIOL, V103, P199, DOI 10.1016/0022-2836(76)90060-7; ROBERTS RJ, 1993, IN PRESS NUCLEASES; SELIG S, 1988, EMBO J, V7, P419, DOI 10.1002/j.1460-2075.1988.tb02829.x; SMITH SS, 1992, P NATL ACAD SCI USA, V89, P4744, DOI 10.1073/pnas.89.10.4744; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WEISSMAN L, 1982, COMPUTATIONAL CRYSTA, P56; WILKE K, 1988, EMBO J, V7, P2601, DOI 10.1002/j.1460-2075.1988.tb03110.x; WU JC, 1987, J BIOL CHEM, V262, P4778; WU JC, 1985, BIOCH BIOL DNA METHY, P119; WYSZYNSKI MW, 1992, NUCLEIC ACIDS RES, V20, P319, DOI 10.1093/nar/20.2.319	65	889	914	0	52	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 28	1994	76	2					357	369		10.1016/0092-8674(94)90342-5	http://dx.doi.org/10.1016/0092-8674(94)90342-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	8293469				2022-12-01	WOS:A1994MU67800018
J	ROBINSON, BH; HAAS, DA; MAILER, C				ROBINSON, BH; HAAS, DA; MAILER, C			MOLECULAR-DYNAMICS IN LIQUIDS - SPIN-LATTICE RELAXATION OF NITROXIDE SPIN LABELS	SCIENCE			English	Article							ELECTRON-PARAMAGNETIC RESONANCE; SATURATION-RECOVERY; MOTION	Time domain pulsed saturation recovery and electron-electron double resonance spectroscopies were used to measure the spin-lattice relaxation rates of the electron and the nitrogen nucleus in nitroxide spin labels in liquids. The rotational correlation time range covered is from picoseconds to milliseconds. These rates are quantitatively explained by isotropic rotational Brownian dynamics, which modulate the interactions between the electron spin and the molecular angular momentum; the nitrogen and electron spins; and the solvent protons with both the electron and the nitrogen spins. This solves a 20-year-old problem that has limited scientific applications of nitroxides.			ROBINSON, BH (corresponding author), UNIV WASHINGTON,DEPT CHEM,SEATTLE,WA 98195, USA.				NIGMS NIH HHS [GM-32681] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [P01GM032681] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAGAM A, 1961, PRINCIPLES NUCLEAR M, pCH8; ALTENBACH C, 1989, BIOPHYS J, V56, P1183, DOI 10.1016/S0006-3495(89)82765-1; ALTENBACH C, 1990, SCIENCE, V248, P1088, DOI 10.1126/science.2160734; ATKINS PW, 1966, J CHEM PHYS, V44, P169, DOI 10.1063/1.1726440; BEECHAM M, 1991, FLUORESCENCE SPECTRO, V2, pCH5; Berliner L., 1989, BIOL MAGNETIC RESONA, V8; Berliner L., 1976, SPIN LABELING THEORY, V1; Berliner L. J., 1979, SPIN LABELING THEORY, V2; BLUMBERG WE, 1960, PHYS REV, V119, P79, DOI 10.1103/PhysRev.119.79; FAJER P, 1986, BIOPHYS J, V50, P1195, DOI 10.1016/S0006-3495(86)83562-7; FEIX JB, 1984, BIOCHEMISTRY-US, V23, P2293, DOI 10.1021/bi00305a032; FREED JH, 1979, MULTIPLE ELECTRON RE, P112; HAAS DA, 1993, BIOPHYS J, V64, P594, DOI 10.1016/S0006-3495(93)81418-8; HAAS DA, 1993, J PHYS CHEM-US, V97, P2914, DOI 10.1021/j100114a014; HAAS DA, 1993, THESIS U WASHINGTON; HORNAK JP, 1983, CHEM PHYS LETT, V101, P115, DOI 10.1016/0009-2614(83)87353-9; HUBBARD PS, 1963, PHYS REV, V131, P1155, DOI 10.1103/PhysRev.131.1155; HUISJEN M, 1974, REV SCI INSTRUM, V45, P669, DOI 10.1063/1.1686710; HUNT BI, 1966, P PHYS SOC LOND, V88, P513, DOI 10.1088/0370-1328/88/2/321; HWANG JS, 1975, J PHYS CHEM-US, V79, P489, DOI 10.1021/j100572a017; Hyde J.S., 1990, BIOL MAGNETIC RESONA, P399; HYDE JS, 1984, CHEM PHYS LETT, V110, P621, DOI 10.1016/0009-2614(84)85474-3; HYDE JS, 1979, SPIN LABELING, V2, pCH1; LARSEN DW, 1984, J PHYS CHEM-US, V88, P4015, DOI 10.1021/j150662a031; MAILER C, 1992, B MAGN RESON, V14, P30; MILLER C, 1991, J MAGN RESON, V91, P475; PERCIVAL PW, 1976, J MAGN RESON, V23, P249, DOI 10.1016/0022-2364(76)90206-7; ROBINSON BH, 1992, J CHEM PHYS, V96, P2609, DOI 10.1063/1.462869; ROBINSON BH, 1993, 35TH EPR S MOUNT INT; ROBINSON BH, 1985, EPR ADV EPR STUDIES, P192; SARNA T, 1978, J CHEM PHYS, V69, P1945, DOI 10.1063/1.436833; SUGANO T, 1987, THESIS U WASHINGTON, P283; TORREY HC, 1953, PHYS REV, V92, P962, DOI 10.1103/PhysRev.92.962; YIN JJ, 1992, 34TH EPR S ROCK MOUN	34	130	130	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 28	1994	263	5146					490	493		10.1126/science.8290958	http://dx.doi.org/10.1126/science.8290958			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT966	8290958				2022-12-01	WOS:A1994MT96600024
J	SIKORA, K				SIKORA, K			ENRAGED ABOUT RADIOTHERAPY	BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER	The use of radiotherapy in treating breast cancer has meant that many women are able to avoid mastectomy, which is both physically and psychologically damaging. The side effects of radiotherapy, however, are given little attention. Many women have developed brachial plexus injury after radiotherapy for breast cancer, often resulting in severe pain and loss of use of the arm. There is no effective treatment for this injury and little help can be offered. In addition, many of the women did not require radiotherapy of nodal areas. A pressure group has been formed to support these women, to establish the right to compensation, and to ensure that radiotherapy regimens given to future patients will not damage the brachial plexus.			SIKORA, K (corresponding author), HAMMERSMITH HOSP,ROYAL POSTGRAD MED SCH,LONDON W12 0NN,ENGLAND.							CUZICK J, 1987, CANCER TREAT REP, V71, P15; HARRIS JR, 1993, CANC PRINCIPLES PRAC, P1264; POWELL S, 1990, RADIOTHER ONCOL, V18, P213, DOI 10.1016/0167-8140(90)90057-4; Priestman T J, 1989, Clin Oncol (R Coll Radiol), V1, P39, DOI 10.1016/S0936-6555(89)80010-X; STOLL BA, 1966, BRIT MED J, V1, P834, DOI 10.1136/bmj.1.5491.834; SVENSSON H, 1975, ACTA RADIOL, V15, P228; YARNOLD JR, 1984, RADIOTHER ONCOL, V2, P79, DOI 10.1016/S0167-8140(84)80043-2; 1991, MED MANPOWER WORKLOA	8	14	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	1994	308	6922					188	189		10.1136/bmj.308.6922.188	http://dx.doi.org/10.1136/bmj.308.6922.188			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR974	8312773	Green Published			2022-12-01	WOS:A1994MR97400025
J	JARLAIS, DCD; FRIEDMAN, SR; SOTHERAN, JL; WENSTON, J; MARMOR, M; YANCOVITZ, SR; FRANK, B; BEATRICE, S; MILDVAN, D				JARLAIS, DCD; FRIEDMAN, SR; SOTHERAN, JL; WENSTON, J; MARMOR, M; YANCOVITZ, SR; FRANK, B; BEATRICE, S; MILDVAN, D			CONTINUITY AND CHANGE WITHIN AN HIV EPIDEMIC - INJECTING DRUG-USERS IN NEW-YORK-CITY, 1984 THROUGH 1992	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; AIDS; INFECTION; HEROIN; DISEASE; TRIAL	Objectives.-To examine trends in acquired immunodeficiency syndrome (AIDS) risk behavior and human immunodeficiency virus (HIV) seroprevalence among injecting drug users (IDUs) in New York City from 1984 through 1992. Design and Setting.-Comparisons were made between two surveys of IDUs at the same hospital-based New York City drug abuse detoxification program: 141 IDUs in 1984 and 974 IDUs in 1990 through 1992. National Death Registry, New York City Health Department, and drug treatment program records were also used. Participants.-Persons attending detoxification program randomly selected for participation. Eligibility was based on injection within previous 2 months; 99% acceptance rates were obtained. Participants in the 1984 and 1990 through 1992 surveys were 66% and 79% men, 21% and 19% white, 33% and 34% African American, and 45% and 46% Latin American, respectively. Interventions.-Community-based AIDS prevention programs, including underground syringe exchanges. Main Outcome Measures.-Acquired immunodeficiency syndrome risk behaviors; HIV serostatus; CD4+ cell counts; death rates among 1984 subjects; and injection and intranasal routes of drug administration. Results.-The HIV seroprevalence remained stable at slightly more than 50%. Mean CD4+ cell counts declined from 0.716x10(9)/L (716/muL) to 0.575x10(9)/L (P<.009). Annual death rate among 1984 subjects was 3%, with a significantly higher rate among HIV-seropositive subjects (relative risk, 2.57; 95% exact binomial confidence interval, 1.12 to 6.61). Large-scale declines were observed in AIDS risk behaviors, eg, use of potentially contaminated syringes declined from 51% to 7% of injections (P<.001). Recent additional risk reduction was associated with use of the underground syringe exchanges. Intranasal heroin use was the primary route of drug administration for 46% of heroin admissions to New York City drug treatment programs. Conclusions.-The HIV seroprevalence has remained stable among this population of New York City IDUs for almost a decade. Continuation of current trends should lead to further reduction in HIV transmission, although reversal of the trend to intranasal use could lead to substantially increased transmission.	NYU, NEW YORK STATE OFF ALCOHOLISM & SUBST ABUSE SERV, DEPT ENVIRONM MED, NEW YORK, NY 10003 USA; NEW YORK CITY DEPT HLTH, NEW YORK, NY 10013 USA	New York University; New York City Department of Health & Mental Hygiene	JARLAIS, DCD (corresponding author), BETH ISRAEL MED CTR, NATL DEV & RES INST INC, INST AIDS RES, 11 BEACH ST, NEW YORK, NY 10013 USA.			Marmor, Michael/0000-0001-6605-2661	NIDA NIH HHS [DA06001, DA03574] Funding Source: Medline; NATIONAL INSTITUTE ON DRUG ABUSE [R01DA003574] Funding Source: NIH RePORTER	NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission)		ABDULQUADER AS, 1987, CONTEMP DRUG PROBL, V14, P425; ANDERSON W, 1991, AM J PUBLIC HEALTH, V81, P1506, DOI 10.2105/AJPH.81.11.1506; [Anonymous], 1993, NEW YORK CITY AIDS S; BLIX O, 1988, 4TH INT C AIDS STOCK; BLOWER SM, 1991, PHILOS T R SOC B, V331, P171, DOI 10.1098/rstb.1991.0006; BROWN LS, 1988, 5TH INT C AIDS MONTR; CASRIEL C, 1990, J SUBST ABUSE TREAT, V7, P1, DOI 10.1016/0740-5472(90)90031-K; DESJARLAIS DC, 1992, BRIT J ADDICT, V87, P493; DESJARLAIS DC, 1989, JAMA-J AM MED ASSOC, V261, P1008, DOI 10.1001/jama.261.7.1008; DESJARLAIS DC, 1992, ANN AM ACAD POLIT SS, V521, P42; DESJARLAIS DC, 1992, SCI CHALLENGING AIDS, P207; FRANK B, 1992, EPIDEMIOLOGIC TRENDS, P220; FRENCH JF, 1989, LANCET, V1, P1082, DOI 10.1016/S0140-6736(89)92483-5; FRIEDMAN SR, 1987, INT J ADDICT, V22, P201, DOI 10.3109/10826088709027425; FRIEDMAN SR, 1992, 120TH ANN M AM PUBL; FRIEDMAN SR, 1993, 9TH INT C AIDS BERL; GALLI M, 1992, 8TH INT C AIDS AMST; GRIFFITHS P, 1992, BRIT J ADDICT, V87, P485; HAGAN H, 1992, 8TH INT C AIDS AMST; HARTEL D, 1988, 4TH INT C AIDS STOCK; JARLAIS DCD, 1992, AM J PUBLIC HEALTH, V82, P1531, DOI 10.2105/AJPH.82.11.1531; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; MARMOR M, 1987, AIDS, V1, P39; Nicolosi A, 1990, Epidemiology, V1, P453, DOI 10.1097/00001648-199011000-00007; SCHOTTENFELD RS, 1993, J SUBST ABUSE TREAT, V10, P5, DOI 10.1016/0740-5472(93)90092-G; SELWYN PA, 1992, NEW ENGL J MED, V327, P1697, DOI 10.1056/NEJM199212103272401; SOTHERAN JL, 1992, 8TH INT C AIDS AMST; STONEBURNER RL, 1988, SCIENCE, V242, P916, DOI 10.1126/science.3187532; VLAHOV D, 1991, AM J DRUG ALCOHOL AB, V17, P39, DOI 10.3109/00952999108992808; 1985, SAS USERS GUIDE STAT; 1993, HIV AIDS SURVEILLANC	31	177	180	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	1994	271	2					121	127		10.1001/jama.1994.03510260053028	http://dx.doi.org/10.1001/jama.1994.03510260053028			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ083	8264066				2022-12-01	WOS:A1994MQ08300021
J	WATTERS, JK; ESTILO, MJ; CLARK, GL; LORVICK, J				WATTERS, JK; ESTILO, MJ; CLARK, GL; LORVICK, J			SYRINGE AND NEEDLE EXCHANGE AS HIV AIDS-PREVENTION FOR INJECTION-DRUG USERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ETHNIC-DIFFERENCES; RISK BEHAVIOR; SAN-FRANCISCO; INFECTION; PROGRAM; INITIATION; AMSTERDAM; RACE	Objective.-To evaluate an all-volunteer syringe exchange program in San Francisco, Calif. Data Sources.-Syringe exchange program records and 11 semiannual surveys administered during a 5.5-year period, using standard questionnaires. Interviews (N=5644) were conducted with injection drug users recruited in two 21-day drug detoxification clinics and three street settings. Main Outcome Measures.-Use of the syringe exchange program and self-reported data regarding sources of syringes, frequency of injection, initiation into drug injection, and frequency of syringe sharing. Results.-In spring 1992, 45% reported ''usually'' obtaining injection equipment from the syringe exchange, and 61% reported using the program within the past year. During the period from December 1986 through June 1992, the median reported frequency of injection declined from 1.9 injections per day to 0.7 injection per day, the mean age increased from 36 to 42 years, and the percentage of new initiates into injection drug use decreased from 3% to 1%. In logistic regression analysis (of fall 1991 through spring 1992 interviews; n=752), we found six independent factors associated with syringe sharing. Protective from syringe sharing were use of the syringe exchange program, having received human immunodeficiency virus (HIV) testing and counseling, condom use, older age, and African-American race. Injection of cocaine was a predictor for syringe sharing. The strength of association between use of the syringe exchange program and not sharing syringes was greatest in injection drug users younger than the median age of 40 years. Conclusions.-The syringe exchange program was rapidly adopted by injection drug users. Health interventions associated with not sharing needles included use of the syringe exchange program and voluntary, confidential HIV testing and counseling. Our data did not support the hypothesis that a syringe exchange program would stimulate increased drug abuse in terms of frequency of injection or recruitment of new and/or younger users.	UNIV CALIF SAN FRANCISCO,SCH MED,DEPT FAMILY & COMMUNITY MED,SAN FRANCISCO,CA 94143; PREVENT POINT RES GRP,SAN FRANCISCO,CA	University of California System; University of California San Francisco	WATTERS, JK (corresponding author), UNIV CALIF SAN FRANCISCO,SCH MED,INST HLTH POLICY STUDIES,URBAN HLTH STUDY,BOX 1304,SAN FRANCISCO,CA 94143, USA.			Lorvick, Jennifer/0000-0002-2836-3028	NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004212] Funding Source: NIH RePORTER; NIDA NIH HHS [R01-DA04212] Funding Source: Medline; PHS HHS [U62-CCU902017, 83-0706] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BUZOLIC A, 1988, NEEDLE SYRINGE AVAIL; CARVELL AM, 1990, BRIT J ADDICT, V85, P235; CATALANO RF, 1992, J STUD ALCOHOL, V53, P208, DOI 10.15288/jsa.1992.53.208; CHAISSON RE, 1989, JAMA-J AM MED ASSOC, V261, P561, DOI 10.1001/jama.261.4.561; CHOOPANYA K, 1991, AIDS, V5, P1509, DOI 10.1097/00002030-199112000-00014; DAQUILA RT, 1989, J ACQ IMMUN DEF SYND, V2, P503; DESJARLAIS DC, 1989, 5 INT C AIDS MONTR; Dinwiddie S H, 1992, J Subst Abuse, V4, P1, DOI 10.1016/0899-3289(92)90022-P; DINWIDDIE SH, 1992, COMPR PSYCHIAT, V33, P172; DONOGHOE MC, 1991, 7 INT C AIDS FLOR; ELLICKSON PL, 1992, J ABNORM PSYCHOL, V101, P441, DOI 10.1037/0021-843X.101.3.441; GRUND JPC, 1990, AIDS, V4, P819, DOI 10.1097/00002030-199008000-00020; GUYDISH J, 1993, AIDS, V7, P871, DOI 10.1097/00002030-199306000-00017; GUYDISH J, 1992, AIDS, V6, P739, DOI 10.1097/00002030-199207000-00021; HART GJ, 1989, AIDS, V3, P261, DOI 10.1097/00002030-198905000-00002; HARTGERS C, 1989, AIDS, V3, P571, DOI 10.1097/00002030-198909000-00003; HARTGERS C, 1992, PUBLIC HEALTH REP, V107, P675; KAPLAN EH, 1992, J ACQ IMMUN DEF SYND, V5, P163; KOBLIN BA, 1990, AM J EPIDEMIOL, V132, P837, DOI 10.1093/oxfordjournals.aje.a115726; KOZEL NJ, 1986, SCIENCE, V234, P970, DOI 10.1126/science.3490691; LAMPINEN T, 1989, JAMA-J AM MED ASSOC, V262, P1331, DOI 10.1001/jama.1989.03430100065027; LJUNGBERG B, 1991, J ACQ IMMUN DEF SYND, V4, P890; LURIE P, 1993, PUBLIC HLTH IMPACT N, V1; MANN J, 1993, AIDS WORLD; MORRISON V, 1991, DRUG ALCOHOL DEPEN, V27, P213, DOI 10.1016/0376-8716(91)90003-H; NELSON KE, 1991, JAMA-J AM MED ASSOC, V266, P2259, DOI 10.1001/jama.266.16.2259; PURCHASE D, 1989, 5 INT C AIDS MONTR; PYE M, 1989, 5TH INT C AIDS MONTR; Schlesselman J.J., 1982, CASE CONTROL STUDIES; SCHOENBAUM EE, 1989, NEW ENGL J MED, V321, P874, DOI 10.1056/NEJM198909283211306; STIMSON GV, 1989, AIDS, V3, P253, DOI 10.1097/00002030-198905000-00001; STIMSON GV, 1992, 8TH INT C AIDS AMST; VANDENHOEK JA, 1989, AM J PUBLIC HEALTH, V10, P1355; WATTERS JK, 1990, AM J COMMUN PSYCHOL, V18, P587, DOI 10.1007/BF00938061; WATTERS JK, 1991, INT J ADDICT, V26, P1247, DOI 10.3109/10826089109062158; WATTERS JK, 1992, JAMA-J AM MED ASSOC, V268, P2374, DOI 10.1001/jama.268.17.2374; WILEY JA, 1989, AIDS S1, V3, P71; WODAK A, 1990, AIDS (London), V4, pS105; [No title captured]; 1990, SPSS REFERENCE GUIDE; 1989, PILOT NEEDLE EXCHANG; 1993, HIV AIDS SURVEILLANC, V5; 1991, TWIN EPIDEMICS SUBST	43	252	253	0	11	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	1994	271	2					115	120		10.1001/jama.271.2.115	http://dx.doi.org/10.1001/jama.271.2.115			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MQ083	8264065				2022-12-01	WOS:A1994MQ08300020
J	IFUDU, O; MAYERS, J; MATTHEW, J; TAN, CC; CAMBRIDGE, A; FRIEDMAN, EA				IFUDU, O; MAYERS, J; MATTHEW, J; TAN, CC; CAMBRIDGE, A; FRIEDMAN, EA			DISMAL REHABILITATION IN GERIATRIC INNER-CITY HEMODIALYSIS-PATIENTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							STAGE RENAL-DISEASE; RECOMBINANT HUMAN ERYTHROPOIETIN; FUNCTIONAL STATUS; CLINICAL-TRIAL; DIALYSIS; LIFE; MORTALITY; SURVIVAL; THERAPY; QUALITY	Objective.-To assess the extent of functional and vocational rehabilitation achieved by elderly inner-city patients sustained on maintenance hemodialysis. Design.-Inception cohort study of elderly patients who have end-stage renal disease using a modified Karnofsky rating system. The need for a wheelchair, participation in household activities, and effect of comorbid conditions were noted. Current status was compared with patient's recollection of functional activity level 2 years before commencing maintenance hemodialysis. Setting.-Seven outpatient, hospital-affiliated and private hemodialysis units in Brooklyn, NY. Patients.-One hundred four patients aged 65 years or older who were receiving maintenance hemodialysis for at least 6 months. Main Outcome Measures.-A score of 76 or greater on a modified Karnofsky scale indicated independent function at a level that permitted participation in activities beyond those mandated by the hemodialysis regimen. A comorbidity score 6 or greater on a newly constructed index correlated with severe debility. Employment status was also recorded. Results.-Present functional activity had deteriorated to a modified Karnofsky score of 66+/-12.3 (+/-SD) compared with patients' recollection of a mean score of 84+/-14.3 (P<.001) 2 years before initiation of hemodialysis. Diabetic patients had a lower score than nondiabetic patients. The mean comorbidity index of the entire study group was 7.8+/-2.9 (mean+/-SD). Within the diabetic subset, severe debility constrained 71 patients (68%) to limit all activity to their residence with the exception of travel to and from their dialysis facility. By contrast, 2 years prior to commencing dialytic therapy, 81 diabetic patients (78%) had interests and activities that took them outside their homes (P<.001). Generalized weakness was the most common explanation given for the lack of outside activity by nine patients (9%) who were wheelchair bound. Erythropoietin, though regularly administered to 87 patients (84%) in the study group, was unsuccessful in raising mean hematocrit reading above 0.28+/-0.05 (mean+/-SD). Conclusions.-Maintenance hemodialysis does not return inner-city elderly patients to their predialysis level of functioning. Few elderly, diabetic hemodialysis patients conduct any substantive portion of their lives outside their homes. For nondiabetic patients, the modified Karnofsky score of whites (70.4+/-11.9) and blacks (66.5+/-15.3), though low, was equivalent (P<.4).			IFUDU, O (corresponding author), SUNY HLTH SCI CTR,DEPT MED,DIV RENAL DIS,BOX 52,450 CLARKSON AVE,BROOKLYN,NY 11203, USA.							AVRAM MR, 1991, AM J KIDNEY DIS, V26, P342; BONNEY S, 1978, ARCH INTERN MED, V138, P1510, DOI 10.1001/archinte.138.10.1510; BRANCHE GC, 1991, AM J MED, V91, P37; CANTOR M, 1976, GERONTOLOGIST, V16, P17, DOI 10.1093/geront/16.1_Part_1.17; CARDENAS DD, 1982, NEPHRON, V62, P626; CARLSON DM, 1987, MAYO CLIN PROC, V62, P338, DOI 10.1016/S0025-6196(12)65436-6; CHESTER AC, 1979, ARCH INTERN MED, V139, P1001, DOI 10.1001/archinte.139.9.1001; EASTERLING RE, 1977, T AM SOC ART INT ORG, V23, P28; Eggers P W, 1984, Health Care Financ Rev, V5, P69; EGGERS PW, 1990, AM J KIDNEY DIS, V15, P414, DOI 10.1016/S0272-6386(12)70359-1; ESCHBACH JW, 1987, NEW ENGL J MED, V316, P73, DOI 10.1056/NEJM198701083160203; ESCHBACH JW, 1989, ANN INTERN MED, V111, P992, DOI 10.7326/0003-4819-111-12-992; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; FRANCIS CK, 1990, AM J MED, V91, P29; GILLUM RF, 1974, JAMA-J AM MED ASSOC, V228, P1563; GUTMAN RA, 1988, ANN INTERN MED, V108, P898, DOI 10.7326/0003-4819-108-6-898; GUTMAN RA, 1981, NEW ENGL J MED, V304, P309, DOI 10.1056/NEJM198102053040601; GUTMAN RA, 1978, POSTGRAD MED, V64, P183, DOI 10.1080/00325481.1978.11714980; HELD PJ, 1987, JAMA-J AM MED ASSOC, V257, P645, DOI 10.1001/jama.257.5.645; HUTCHINSON TA, 1979, J CHRON DIS, V32, P661, DOI 10.1016/0021-9681(79)90096-1; IGLEHART JK, 1993, NEW ENGL J MED, V328, P366, DOI 10.1056/NEJM199302043280528; JULIUS M, 1989, AM J KIDNEY DIS, V13, P61, DOI 10.1016/S0272-6386(89)80118-0; KARNOFSKY DA, 1949, EVALUATION CHEMOTHER, P191; KRAUS JF, 1980, AM J EPIDEMIOL, V111, P407, DOI 10.1093/oxfordjournals.aje.a112915; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; MCCLELLAN WM, 1991, J CLIN EPIDEMIOL, V44, P83, DOI 10.1016/0895-4356(91)90204-M; MCKEVITT PM, 1990, AJKD, V26, P346; NEU S, 1986, NEW ENGL J MED, V314, P14, DOI 10.1056/NEJM198601023140103; PORT FK, 1989, AM J NEPHROL, V9, P145, DOI 10.1159/000167954; PRETCHERS MK, 1988, GERONTOLOGIST, V28, P213; REUBEN DB, 1992, AM J MED, V93, P663, DOI 10.1016/0002-9343(92)90200-U; RICHARDSON YW, 1987, TRANSPLANT P, V19, P111; ROSTAND SG, 1982, NEW ENGL J MED, V306, P1276, DOI 10.1056/NEJM198205273062106; SHAPIRO FL, 1983, AM SOC ARTIF INT ORG, V6, P176; SHIDEMAN JR, 1976, ARCH INTERN MED, V136, P1126, DOI 10.1001/archinte.136.10.1126; Uva J L, 1990, JAMA, V263, P139, DOI 10.1001/jama.263.1.135; WESTLIE L, 1984, T AM SOC ART INT ORG, V30, P21; WRIGHT LF, 1991, AM J KIDNEY DIS, V17, P25, DOI 10.1016/S0272-6386(12)80245-9; 1990, USRDS NIH1990 NAT I	39	89	91	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	1994	271	1					29	33		10.1001/jama.271.1.29	http://dx.doi.org/10.1001/jama.271.1.29			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN725	8258883				2022-12-01	WOS:A1994MN72500026
J	HABER, DA; PARK, S; MAHESWARAN, S; ENGLERT, C; RE, GG; HAZENMARTIN, DJ; SENS, DA; GARVIN, AJ				HABER, DA; PARK, S; MAHESWARAN, S; ENGLERT, C; RE, GG; HAZENMARTIN, DJ; SENS, DA; GARVIN, AJ			WT1-MEDIATED GROWTH SUPPRESSION OF WILMS-TUMOR CELLS EXPRESSING A WT1 SPLICING VARIANT	SCIENCE			English	Article							GENOMIC STRUCTURE; GENE WT1; RB GENE; FORM; TUMORIGENICITY; TRANSFORMATION; CHROMOSOME-11; PROTEIN; BINDING; FOSB	A human Wilms tumor cell line (RM1) was developed to test the tumor suppressor activity of WT1, a zinc finger transcription factor that is expressed in the developing human kidney and is mutationally inactivated in a subset of Wilms tumors. Transfection of each of four wild-type WT1 isoforms suppressed the growth of RM1 cells. The endogenous WT1 transcript in these cells was devoid of exon 2 sequences, a splicing alteration that was also detected in varying amounts in all Wilms tumors tested but not in normal kidney. Production of this abnormal transcript, which encodes a functionally altered protein, may represent a distinct mechanism for inactivating WT1 in Wilms tumors.	HARVARD UNIV,SCH MED,BOSTON,MA 02129; MED UNIV S CAROLINA,DEPT PATHOL & LAB MED,CHARLESTON,SC 29425	Harvard University; Harvard Medical School; Medical University of South Carolina	HABER, DA (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC GENET LAB,BOSTON,MA 02129, USA.			Englert, Christoph/0000-0002-5931-3189	NCI NIH HHS [CA37887, CA58596] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA058596, R01CA037887, R23CA037887, R37CA058596] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BICKMORE WA, 1992, SCIENCE, V257, P235, DOI 10.1126/science.1321494; BOOKSTEIN R, 1990, SCIENCE, V247, P712, DOI 10.1126/science.2300823; BUCKLER AJ, 1991, MOL CELL BIOL, V11, P1707, DOI 10.1128/MCB.11.3.1707; CHEN PL, 1990, SCIENCE, V250, P1576, DOI 10.1126/science.2274789; DILLER L, 1990, MOL CELL BIOL, V10, P5772, DOI 10.1128/MCB.10.11.5772; DOWDY SF, 1991, SCIENCE, V254, P293, DOI 10.1126/science.1656527; GARVIN AJ, 1993, AM J PATHOL, V142, P375; HABER DA, 1992, ADV CANCER RES, V59, P41, DOI 10.1016/S0065-230X(08)60302-4; HABER DA, 1992, P NATL ACAD SCI USA, V89, P6010, DOI 10.1073/pnas.89.13.6010; HABER DA, 1990, CELL, V61, P1257, DOI 10.1016/0092-8674(90)90690-G; HABER DA, 1991, P NATL ACAD SCI USA, V88, P9618, DOI 10.1073/pnas.88.21.9618; HAZENMARTIN D, UNPUB; HAZENMARTIN DJ, 1993, AM J PATHOL, V142, P893; HUANG HJS, 1988, SCIENCE, V242, P1563, DOI 10.1126/science.3201247; KOI M, 1993, SCIENCE, V260, P361, DOI 10.1126/science.8469989; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; NAKABEPPU Y, 1991, CELL, V64, P751, DOI 10.1016/0092-8674(91)90504-R; PARK S, 1993, CANCER RES, V53, P4757; PARK S, 1993, NAT GENET, V4, P415, DOI 10.1038/ng0893-415; PARK S, IN PRESS NATURE GENE; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; RAUSCHER FJ, 1990, SCIENCE, V250, P1259, DOI 10.1126/science.2244209; ROMAN C, 1991, SCIENCE, V254, P94, DOI 10.1126/science.1840705; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; WANG ZY, 1993, J BIOL CHEM, V268, P9172; WEISSMAN BE, 1987, SCIENCE, V236, P175, DOI 10.1126/science.3031816; YAMAMOTO KK, 1990, CELL, V60, P611, DOI 10.1016/0092-8674(90)90664-Z; YEN J, 1991, P NATL ACAD SCI USA, V88, P5077, DOI 10.1073/pnas.88.12.5077	30	173	174	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					2057	2059		10.1126/science.8266105	http://dx.doi.org/10.1126/science.8266105			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266105				2022-12-01	WOS:A1993MN10800045
J	PARSONS, R; LI, GM; LONGLEY, MJ; FANG, WH; PAPADOPOULOS, N; JEN, J; DELACHAPELLE, A; KINZLER, KW; VOGELSTEIN, B; MODRICH, P				PARSONS, R; LI, GM; LONGLEY, MJ; FANG, WH; PAPADOPOULOS, N; JEN, J; DELACHAPELLE, A; KINZLER, KW; VOGELSTEIN, B; MODRICH, P			HYPERMUTABILITY AND MISMATCH REPAIR DEFICIENCY IN RER+ TUMOR-CELLS	CELL			English	Article							ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; DNA; MUTATION; MUTANTS; CARCINOGENESIS; EXTRACTS; SYSTEM; LINES	A subset of sporadic colorectal tumors and most tumors developing in hereditary nonpolyposis colorectal cancer patients display frequent alterations in microsatellite sequences. Such tumors have been thought to manifest replication errors (RER+), but the basis for the alterations has remained conjectural. We demonstrate that the mutation rate of (CA)n repeats in RER+ tumor cells is at least 100-fold that in RER- tumor cells and show by in vitro assay that increased mutability of RER+ cells is associated with a profound defect in strand-specific mismatch repair. This deficiency was observed with microsatellite heteroduplexes as well as with heteroduplexes containing single base-base mismatches and affected an early step in the repair pathway. Thus, a true mutator phenotype exists in a subset of tumor cells, the responsible defect is likely to cause transitions and transversions in addition to microsatellite alterations, and a biochemical basis for this phenotype has been identified.	JOHNS HOPKINS ONCOL CTR, BALTIMORE, MD 21231 USA; UNIV HELSINKI, DEPT MED GENET, SF-00014 HELSINKI, FINLAND; NATL TAIWAN UNIV, INST MED TECHNOL, TAIPEI 10016, TAIWAN	Johns Hopkins University; Johns Hopkins Medicine; University of Helsinki; National Taiwan University	PARSONS, R (corresponding author), DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA.		Papadopoulos, Nickolas/K-7272-2012; Li, Guo-Min/I-5016-2014	FANG, WOEI-HORNG/0000-0003-4728-5931; Parsons, Ramon/0000-0002-6656-3514; Li, Guo-Min/0000-0002-9842-4578; Modrich, Paul/0000-0001-8708-9885	NCI NIH HHS [CA09320, CA35494] Funding Source: Medline; NIGMS NIH HHS [GM45190] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA035494, R01CA035494] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045190] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121; BRATTAIN MG, 1981, CANCER RES, V41, P1751; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; FANG WH, 1993, J BIOL CHEM, V268, P11838; FANG WH, 1993, IN PRESS COLD SPRING, V58; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; GOELZ SE, 1985, BIOCHEM BIOPH RES CO, V130, P118, DOI 10.1016/0006-291X(85)90390-0; GOLDMACHER VS, 1986, J BIOL CHEM, V261, P2462; GRILLEY M, 1993, J BIOL CHEM, V268, P11830; GROGER RK, 1989, GENE, V81, P285, DOI 10.1016/0378-1119(89)90189-3; HARWOOD J, 1991, MOL CELL BIOL, V11, P3163, DOI 10.1128/MCB.11.6.3163; HENDERSON ST, 1992, MOL CELL BIOL, V12, P2749, DOI 10.1128/MCB.12.6.2749; HOLMES J, 1990, P NATL ACAD SCI USA, V87, P5837, DOI 10.1073/pnas.87.15.5837; IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0; IVANOV EL, 1989, MUTAT RES, V213, P105, DOI 10.1016/0027-5107(89)90141-3; KAT A, 1993, P NATL ACAD SCI USA, V90, P6424, DOI 10.1073/pnas.90.14.6424; KUHL DPA, 1993, CURR OPIN GENET DEV, V3, P404, DOI 10.1016/0959-437X(93)90112-3; KUNKEL TA, 1993, NATURE, V365, P207, DOI 10.1038/365207a0; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LEACH FS, 1993, CELL, V75, P1215, DOI 10.1016/0092-8674(93)90330-S; LEIBOVITZ A, 1976, CANCER RES, V36, P4562; LEVINSON G, 1987, MOL BIOL EVOL, V4, P203; LEVINSON G, 1987, NUCLEIC ACIDS RES, V15, P5323, DOI 10.1093/nar/15.13.5323; LINDBLOM A, 1993, NAT GENET, V5, P279, DOI 10.1038/ng1193-279; LOEB LA, 1991, CANCER RES, V51, P3075; MESELSON M, 1988, RECOMBINATION GENETI, P91; MODRICH P, 1991, ANNU REV GENET, V25, P229, DOI 10.1146/annurev.ge.25.120191.001305; PARKER BO, 1992, P NATL ACAD SCI USA, V89, P1730, DOI 10.1073/pnas.89.5.1730; PELTOMAKI P, 1993, SCIENCE, V260, P810, DOI 10.1126/science.8484120; PETIT MA, 1991, GENETICS, V129, P327; RAYSSIGUIER C, 1989, NATURE, V342, P396, DOI 10.1038/342396a0; STANBRIDGE EJ, 1990, ANNU REV GENET, V24, P615; STRAND M, 1993, NATURE, V365, P274, DOI 10.1038/365274a0; SU SS, 1986, P NATL ACAD SCI USA, V83, P5057, DOI 10.1073/pnas.83.14.5057; SU SS, 1988, J BIOL CHEM, V263, P6829; THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122; THOMAS DC, 1991, J BIOL CHEM, V266, P3744; ULLMANN A, 1967, J MOL BIOL, V24, P339, DOI 10.1016/0022-2836(67)90341-5; WEBER JL, 1993, HUM MOL GENET, V2, P1123, DOI 10.1093/hmg/2.8.1123; WEINBERG RA, 1989, CANCER RES, V49, P3713; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0	41	983	1024	26	163	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 17	1993	75	6					1227	1236		10.1016/0092-8674(93)90331-J	http://dx.doi.org/10.1016/0092-8674(93)90331-J			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	8261516				2022-12-01	WOS:A1993MM89300020
J	SHAW, A; MCREE, DE; VACQUIER, VD; STOUT, CD				SHAW, A; MCREE, DE; VACQUIER, VD; STOUT, CD			THE CRYSTAL-STRUCTURE OF LYSIN, A FERTILIZATION PROTEIN	SCIENCE			English	Article							ABALONE; SPERMATOZOA; DOMAIN	Lysin, a protein from abalone sperm, creates a hole in the envelope of the egg, permitting the sperm to pass through the envelope and fuse with the egg. The structure of lysin, refined at 1.9 angstroms resolution, reveals an alpha-helical, amphipathic molecule. The surface of the protein exhibits three features: two tracks of basic residues that span the length of the molecule, a solvent-exposed cluster of aromatic and aliphatic amino acids, and an extended amino-terminal hypervariable domain that is species-specific. The structure suggests possible mechanisms of action.	SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA; UNIV CALIF SAN DIEGO, SCRIPPS INST OCEANOG, CTR MARINE BIOMED & BIOTECHNOL, LA JOLLA, CA 92093 USA	Scripps Research Institute; University of California System; University of California San Diego; Scripps Institution of Oceanography					NICHD NIH HHS [HD12986] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R37HD012986, R01HD012986] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		BAGINSKY ML, 1990, J BIOL CHEM, V265, P4958; BRUNGER AT, 1989, ACTA CRYSTALLOGR A, V45, P50, DOI 10.1107/S0108767388009195; CONNOLLY ML, 1983, SCIENCE, V221, P709, DOI 10.1126/science.6879170; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; HOESS A, 1993, EMBO J, V12, P3351, DOI 10.1002/j.1460-2075.1993.tb06008.x; HONG KL, 1986, BIOCHEMISTRY-US, V25, P543, DOI 10.1021/bi00351a004; HOWARD AJ, 1985, METHODS ENZYMOLOGY A, V114, pCH28; JONES TA, 1986, EMBO J, V5, P819, DOI 10.1002/j.1460-2075.1986.tb04287.x; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; LEE Y, 1992, BIOL BULL, V182, P97, DOI 10.2307/1542183; LEWIS CA, 1982, DEV BIOL, V92, P227, DOI 10.1016/0012-1606(82)90167-1; McRee DE, 1992, J MOL GRAPHICS, V10, P44, DOI DOI 10.1016/0263-7855(92)80022-6; MIAN IS, 1991, J MOL BIOL, V217, P133, DOI 10.1016/0022-2836(91)90617-F; PARKER MW, 1992, J MOL BIOL, V224, P639, DOI 10.1016/0022-2836(92)90550-4; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; VACQUIER VD, 1990, P NATL ACAD SCI USA, V87, P5792, DOI 10.1073/pnas.87.15.5792; VACQUIER VD, IN PRESS ZYGOTE; WILSON C, 1991, SCIENCE, V252, P1817, DOI 10.1126/science.2063194	18	57	61	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 17	1993	262	5141					1864	1867		10.1126/science.8266073	http://dx.doi.org/10.1126/science.8266073			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266073				2022-12-01	WOS:A1993MM51100033
J	HIRST, SJ; HAYES, NA; BURRIDGE, J; PEARCE, FL; FOREMAN, JC				HIRST, SJ; HAYES, NA; BURRIDGE, J; PEARCE, FL; FOREMAN, JC			HUMAN BASOPHIL DEGRANULATION IS NOT TRIGGERED BY VERY DILUTE ANTISERUM AGAINST HUMAN IGE	NATURE			English	Article								We have attempted to reproduce the findings of Benveniste and co-workers, who reported in 1988 that degranulation of human basophil leukocytes is triggered by very dilute (10(2)-10(120)) antiserum against IgE. The results were contrary to conventional scientific theory and were not satisfactorily explained. Following as closely as possible the methods of the original study, we can find no evidence for any periodic or polynomial change of degranulation as a function of anti-IgE dilution. Our results contain a source of variation for which we cannot account, but no aspect of the data is consistent with the previously published claims.	UNIV LONDON UNIV COLL,DEPT PHARMACOL,GOWER ST,LONDON WC1E 6BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT CHEM,LONDON WC1E 6BT,ENGLAND; UNIV LONDON UNIV COLL,DEPT STAT SCI,LONDON WC1E 6BT,ENGLAND	University of London; University College London; University of London; University College London; University of London; University College London								DAVENAS E, 1988, NATURE, V333, P816, DOI 10.1038/333816a0	1	71	74	2	37	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 9	1993	366	6455					525	527		10.1038/366525a0	http://dx.doi.org/10.1038/366525a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	8255290				2022-12-01	WOS:A1993ML21800058
J	WHITTLE, J; CONIGLIARO, J; GOOD, CB; LOFGREN, RP				WHITTLE, J; CONIGLIARO, J; GOOD, CB; LOFGREN, RP			RACIAL-DIFFERENCES IN THE USE OF INVASIVE CARDIOVASCULAR PROCEDURES IN THE DEPARTMENT-OF-VETERANS-AFFAIRS MEDICAL SYSTEM	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY-ARTERY DISEASE; ACUTE MYOCARDIAL-INFARCTION; PROSPECTIVE-PAYMENT SYSTEM; ISCHEMIC HEART-DISEASE; PREHOSPITAL DELAY; SURGERY; CARE; BLACKS; RATES; INEQUALITIES	Background. Previous studies have found racial differences in the use of invasive cardiovascular procedures, which may be due in part to the greater financial incentives to perform such procedures in white patients. In Department of Veterans Affairs hospitals, direct financial incentives affecting use of the procedures are minimized for both patients and physicians. Methods. We analyzed retrospectively the use of cardiovascular procedures among black and white male veterans discharged from Veterans Affairs hospitals with primary diagnoses of cardiovascular disease or chest pain during fiscal years 1987 through 1991. We used coded discharge data to determine whether cardiac catheterization, percutaneous transluminal coronary angioplasty, or coronary artery bypass grafting was performed during or immediately after such admissions. We used logistic-regression analysis to adjust for the primary discharge diagnosis, the presence of coexisting conditions, age, marital status, type of eligibility to receive care at Veterans Affairs hospitals, geographic region, and whether the hospital was equipped to perform bypass surgery. We classified the primary diagnosis as myocardial infarction, unstable angina, angina, chronic ischemia, chest pain, or ''other'' cardiovascular diagnosis. Results. After we adjusted for all the potential confounders, we found that white veterans were more likely than black veterans to undergo cardiac catheterization (odds ratio, 1.38; 95 percent confidence interval, 1.34 to 1.42), angioplasty (odds ratio, 1.50; 95 percent confidence interval, 1.38 to 1.64), and coronary artery bypass surgery (odds ratio, 2.22; 95 percent confidence interval, 2.09 to 2.36). Conclusions. Even when financial incentives are absent, whites are more likely than blacks to undergo invasive cardiac procedures. These findings suggest that social or clinical factors affect the use of these procedures differently in blacks and whites.	UNIV PITTSBURGH,MED CTR,DEPT MED,GEN INTERNAL MED SECT,PITTSBURGH,PA 15260	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	WHITTLE, J (corresponding author), VET AFFAIRS MED CTR,GEN INTERNAL MED SECT,11A,UNIV DR C,PITTSBURGH,PA 15240, USA.		Good, Chester B/K-2818-2019	Good, Chester B/0000-0003-4388-4558; Whittle, Jeff/0000-0002-9544-838X				ADAY LA, 1984, AM J PUBLIC HEALTH, V74, P1331, DOI 10.2105/AJPH.74.12.1331; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; Breslow NE., 1980, IARC SCI PUBLICATION, V32; CLARK LT, 1992, J NATL MED ASSOC, V84, P931; CONCATO J, 1992, JAMA-J AM MED ASSOC, V267, P1077, DOI 10.1001/jama.267.8.1077; COOPER RS, 1986, AM J CARDIOL, V57, P208, DOI 10.1016/0002-9149(86)90892-1; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; FORD E, 1989, AM J PUBLIC HEALTH, V79, P437, DOI 10.2105/AJPH.79.4.437; GILLUM RF, 1987, AM HEART J, V113, P1255, DOI 10.1016/0002-8703(87)90952-5; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; HANNAN EL, 1991, MED CARE, V29, P430, DOI 10.1097/00005650-199105000-00004; HOLMES MD, 1989, JAMA-J AM MED ASSOC, V261, P3242, DOI 10.1001/jama.261.22.3242; HSIA DC, 1992, JAMA-J AM MED ASSOC, V268, P896, DOI 10.1001/jama.268.7.896; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; IEZZONI LI, 1988, ANN INTERN MED, V109, P745, DOI 10.7326/0003-4819-109-9-745; JENCKS SF, 1988, JAMA-J AM MED ASSOC, V260, P2240, DOI 10.1001/jama.260.15.2240; KAHN HA, 1983, INTRO EPIDEMIOLOGIC; LLOYD SS, 1985, JAMA-J AM MED ASSOC, V254, P1330, DOI 10.1001/jama.254.10.1330; MAYNARD C, 1986, AM J PUBLIC HEALTH, V76, P1446, DOI 10.2105/AJPH.76.12.1446; MAYNARD C, 1991, AM J CARDIOL, V67, P18, DOI 10.1016/0002-9149(91)90092-Y; MAYNARD C, 1986, CIRCULATION, V74, P64, DOI 10.1161/01.CIR.74.1.64; OBERMAN A, 1984, AM HEART J, V108, P688, DOI 10.1016/0002-8703(84)90656-2; PARK RE, 1986, AM J PUBLIC HEALTH, V76, P766, DOI 10.2105/AJPH.76.7.766; STROGATZ DS, 1990, AM J PUBLIC HEALTH, V80, P290, DOI 10.2105/AJPH.80.3.290; UDVARHELYI IS, 1992, JAMA-J AM MED ASSOC, V268, P2530, DOI 10.1001/jama.268.18.2530; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; 1977, RELIABILITY HOSPITAL; 1985, SAS USERS GUIDE STAT; 1985, SAS USERS GUIDE BASI; 1980, DHHS PHS801260 PUBL	30	390	390	0	3	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1993	329	9					621	627		10.1056/NEJM199308263290907	http://dx.doi.org/10.1056/NEJM199308263290907			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU217	8341338				2022-12-01	WOS:A1993LU21700007
J	THOMSEN, GH; MELTON, DA				THOMSEN, GH; MELTON, DA			PROCESSED VG1 PROTEIN IS AN AXIAL MESODERM INDUCER IN XENOPUS	CELL			English	Article							MATERNAL MESSENGER-RNA; ERYTHROID-DIFFERENTIATION FACTOR; BONE MORPHOGENETIC PROTEIN-4; DORSAL-VENTRAL POLARITY; EARLY AMPHIBIAN EMBRYOS; TGF-BETA FAMILY; DROSOPHILA EMBRYO; ACTIVIN-A; CRESCENT FORMATION; SPEMANN ORGANIZER	Vg1 is a TGFbeta-related growth factor encoded by a maternal mRNA localized to vegetal blastomeres in Xenopus embryos. Vg1 precursor protein is abundant in vegetal cells, but the processed mature form has not been readily detected and no activity has been demonstrated for the putative Vg1 mature protein. We have engineered a BMP2-Vg1 fusion (BVg1) that promotes formation of mature Vg1 protein in vivo. Injection of BVg1 mRNA induces dorsal mesoderm in animal cap cells, and BVg1 expression in ultraviolet-ventralized embryos fully restores a normal dorsal axis. Blastomeres expressing BVg1 act as a Nieuwkoop center, the region that induces the Spemann organizer. Our results lead us to suggest that localized posttranslational processing of Vg1 precursor protein on the future dorsal side of the embryo is a key step in generating dorsal mesoderm and the body axis in Xenopus.	HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Harvard University			Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647				ASASHIMA M, 1991, P NATL ACAD SCI USA, V88, P6511, DOI 10.1073/pnas.88.15.6511; ASASHIMA M, 1990, ROUX ARCH DEV BIOL, V198, P330, DOI 10.1007/BF00383771; BOLCE ME, 1992, DEVELOPMENT, V115, P681; CHASAN R, 1992, DEVELOPMENT, V115, P607; CHASAN R, 1989, CELL, V56, P391, DOI 10.1016/0092-8674(89)90242-0; CHO KWY, 1991, CELL, V65, P55, DOI 10.1016/0092-8674(91)90407-P; CHRISTIAN JL, 1992, EMBO J, V11, P33, DOI 10.1002/j.1460-2075.1992.tb05024.x; CHRISTIAN JL, 1991, DEV BIOL, V143, P230, DOI 10.1016/0012-1606(91)90073-C; DALE L, 1989, EMBO J, V8, P1057, DOI 10.1002/j.1460-2075.1989.tb03473.x; DALE L, 1992, DEVELOPMENT, V115, P573; ELINSON RP, 1989, DEV GROWTH DIFFER, V31, P423; FERGUSON EL, 1991, CURR TOP DEV BIOL, V25, P17; GALLAGHER BC, 1991, DEVELOPMENT, V112, P1103; GERHART J, 1986, ANNU REV CELL BIOL, V2, P201, DOI 10.1146/annurev.cb.02.110186.001221; GERHART J, 1989, DEVELOPMENT, V107, P37; GIMLICH RL, 1984, DEV BIOL, V104, P117, DOI 10.1016/0012-1606(84)90042-3; GRAY AM, 1990, SCIENCE, V247, P1328, DOI 10.1126/science.2315700; Hamburger V, 1988, HERITAGE EXPT EMBRYO; HARLOW E, 1989, ANTIBODIES LABORATOR, V106, P611; HEMMATIBRIVANLO.A, 1989, DEVELOPMENT, V106, P611; HEMMATIBRIVANLOU A, 1992, NATURE, V359, P609, DOI 10.1038/359609a0; ISAACS HV, 1992, DEVELOPMENT, V114, P711; JONES CM, 1992, DEVELOPMENT, V115, P639; KAO K, 1991, METHOD CELL BIOL, V36, P271; KAO KR, 1988, DEV BIOL, V127, P64, DOI 10.1016/0012-1606(88)90189-3; KIMELMAN D, 1992, DEVELOPMENT, V116, P1; KINTNER CR, 1984, NATURE, V308, P67, DOI 10.1038/308067a0; KORNER J, 1991, P NATL ACAD SCI USA, V88, P11393, DOI 10.1073/pnas.88.24.11393; KOSTER M, 1991, MECH DEVELOP, V33, P191, DOI 10.1016/0925-4773(91)90027-4; KRIEG PA, 1989, DEV BIOL, V133, P93, DOI 10.1016/0012-1606(89)90300-X; KRIEG PA, 1987, METHOD ENZYMOL, V155, P397; LYONS KM, 1991, TRENDS GENET, V7, P408, DOI 10.1016/0168-9525(91)90265-R; MANES ME, 1980, ROUX ARCH DEV BIOL, V189, P73, DOI 10.1007/BF00848569; MASSAGUE J, 1987, CELL, V49, P437, DOI 10.1016/0092-8674(87)90443-0; MELTON DA, 1987, NATURE, V328, P80, DOI 10.1038/328080a0; MOODY SA, 1987, DEV BIOL, V119, P560, DOI 10.1016/0012-1606(87)90059-5; New HV, 1991, CURR OPIN GENET DEV, V1, P196, DOI 10.1016/S0959-437X(05)80070-X; NIEUWKOOP P D, 1969, Wilhelm Roux' Archiv fuer Entwicklungsmechanik der Organismen, V162, P341, DOI 10.1007/BF00578701; NISHIMATSU S, 1992, BIOCHEM BIOPH RES CO, V186, P1487, DOI 10.1016/S0006-291X(05)81574-8; NUSSLEINVOLHARD C, 1991, DEVELOPMENT, P1; REBAGLIATI MR, 1985, CELL, V42, P769, DOI 10.1016/0092-8674(85)90273-9; SAMBROOK J, 1990, MOL CLONING LABORATO; SHIMELL MJ, 1991, CELL, V67, P469, DOI 10.1016/0092-8674(91)90522-Z; SHIURBA RA, 1991, DEVELOPMENT, V113, P487; SIVE HL, 1993, GENE DEV, V7, P1, DOI 10.1101/gad.7.1.1; SMITH JC, 1990, NATURE, V345, P729, DOI 10.1038/345729a0; SMITH JC, 1991, CELL, V67, P79, DOI 10.1016/0092-8674(91)90573-H; SMITH WC, 1993, NATURE, V361, P547, DOI 10.1038/361547a0; SMITH WC, 1992, CELL, V70, P829, DOI 10.1016/0092-8674(92)90316-5; SMITH WC, 1991, CELL, V67, P753, DOI 10.1016/0092-8674(91)90070-F; SOKOL S, 1991, CELL, V67, P741, DOI 10.1016/0092-8674(91)90069-B; SOKOL SY, 1992, DEV BIOL, V154, P348, DOI 10.1016/0012-1606(92)90073-P; STEIN D, 1992, CELL, V68, P429, DOI 10.1016/0092-8674(92)90181-B; TANNAHILL D, 1989, DEVELOPMENT, V106, P775; THOMSEN G, 1990, CELL, V63, P485, DOI 10.1016/0092-8674(90)90445-K; VINCENT JP, 1986, DEV BIOL, V113, P484, DOI 10.1016/0012-1606(86)90184-3; VIZE PD, 1991, METHOD CELL BIOL, V36, P367; WEEKS DL, 1987, CELL, V51, P861, DOI 10.1016/0092-8674(87)90109-7; WOZNEY JM, 1988, SCIENCE, V242, P1528, DOI 10.1126/science.3201241; WU M, 1991, METHOD CELL BIOL, V36, P3; YOUN BW, 1981, DEV BIOL, V83, P339, DOI 10.1016/0012-1606(81)90479-6	61	390	405	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	AUG 13	1993	74	3					433	441		10.1016/0092-8674(93)80045-G	http://dx.doi.org/10.1016/0092-8674(93)80045-G			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8348610				2022-12-01	WOS:A1993LT73900005
J	ROGERS, DE; OSBORN, JE				ROGERS, DE; OSBORN, JE			AIDS POLICY - 2 DIVISIVE ISSUES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									NATL COMMISS AIDS,WASHINGTON,DC									1993, HIV AIDS PANDEMIC 19; 1993, SOCIAL IMPACT AIDS U; 1993, NEEDLE EXCHANGE PROG; 1993, AIDS EXPANDING TRAGE; 1991, TWIN EPIDEMICS SUBST	5	15	15	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1993	270	4					494	495						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN426	8320790				2022-12-01	WOS:A1993LN42600031
J	HAUSER, MD				HAUSER, MD			RIGHT-HEMISPHERE DOMINANCE FOR THE PRODUCTION OF FACIAL EXPRESSION IN MONKEYS	SCIENCE			English	Article							SPECIES-SPECIFIC VOCALIZATIONS; MACAQUES; PERCEPTION; FACES	In humans, the left side of the face (right hemisphere of the brain) is dominant in emotional expression. In rhesus monkeys, the left side of the face begins to display facial expression earlier than the right side and is more expressive. Humans perceive rhesus chimeras created by pairing the left half of the face with its mirror-reversed duplicate as more expressive than chimeras created by right-right pairings. That the right hemisphere determines facial expression, and the left hemisphere processes species-typical vocal signals, suggests that human and nonhuman primates exhibit the same pattern of brain asymmetry for communication.	HARVARD UNIV,PROGRAM NEUROSCI,DEPT PSYCHOL,CAMBRIDGE,MA 02138	Harvard University	HAUSER, MD (corresponding author), HARVARD UNIV,PROGRAM NEUROSCI,DEPT BIOL ANTHROPOL,CAMBRIDGE,MA 02138, USA.							Bradshaw JL., 1993, EVOLUTION LATERAL AS; Cheney D.L., 1990, MONKEYS SEE WORLD IN; CORBALLIS M, 1991, LOPSIDED APE; DAVIDSON RJ, 1992, PSYCHOL SCI, V3, P39, DOI 10.1111/j.1467-9280.1992.tb00254.x; DEWAAL FBM, 1988, BEHAVIOUR, V106, P183, DOI 10.1163/156853988X00269; DIMOND S, 1984, NEUROPSYCHOLOGIA, V26, P445; FALK D, 1986, FOLIA PRIMATOL, V46, P98, DOI 10.1159/000156242; Goodall J, 1986, CHIMPANZEES GOMBE, DOI DOI 10.1002/AJPA.1330730313; HAMILTON CR, 1991, CEREBRAL LATERALITY, P19; HAUSER MD, 1991, ETHOLOGY, V89, P29; HAUSER MD, 1993, ANIM BEHAV, V45, P423, DOI 10.1006/anbe.1993.1054; HEFFNER HE, 1984, SCIENCE, V226, P75, DOI 10.1126/science.6474192; HEILBRONER PL, 1988, AM J PHYS ANTHROPOL, V76, P39, DOI 10.1002/ajpa.1330760105; Hellige J. B., 1993, HEMISPHERIC ASYMMETR; IFUNE CK, 1985, BEHAV NEURAL BIOL, V41, P231; LEVY J, 1983, BRAIN COGNITION, V2, P404, DOI 10.1016/0278-2626(83)90021-0; MacNeilage Peter F., 1991, P165; MARIER P, 1992, HUMAN NONHUMAN ANIMA, P66; NOTTEBOHM F, 1990, PHILOS T R SOC LON B, V292, P205; OVERMAN WH, 1982, NEUROPSYCHOLOGIA, V20, P113, DOI 10.1016/0028-3932(82)90002-1; PETERSEN MR, 1978, SCIENCE, V202, P324, DOI 10.1126/science.99817	21	161	162	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 23	1993	261	5120					475	477		10.1126/science.8332914	http://dx.doi.org/10.1126/science.8332914			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8332914				2022-12-01	WOS:A1993LN62300037
J	GELLERT, GA; WAGNER, GA; MAXWELL, RM; MOORE, D; FOSTER, L				GELLERT, GA; WAGNER, GA; MAXWELL, RM; MOORE, D; FOSTER, L			LEAD-POISONING AMONG LOW-INCOME CHILDREN IN ORANGE-COUNTY, CALIFORNIA - A NEED FOR REGIONALLY DIFFERENTIATED POLICY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To estimate the prevalence of elevated lead levels among children in Orange County, California, and to evaluate the appropriateness of a universal pediatric blood lead screening policy in this community. Design.-Venous blood lead testing was conducted and results were analyzed according to seven blood lead strata ranging from less than 0.50 mumol/L (10 mug/dL) to 3.35 mumol/L (70 mug/dL) or higher. A cost analysis of the lead-testing program in Orange County was conducted. Setting.-Children meeting poverty eligibility criteria and attending the Child Health and Disability Prevention Program, the state's implementation of the federal Early and Periodic Screening, Diagnosis and Treatment (EPSDT) services program. Participants.-A total of 5115 Orange County children between 12 and 72 months of age using EPSDT services from March through December 1992. Main Outcome Measures.-Blood lead levels and associated costs of the testing program stratified by level of blood lead elevation. Results.-Blood lead levels of 0.50 mumol/L (10 mug/dL) or higher were found in 371 children (7.25%; 95% confidence interval, 6.66% to 7.85%), but only six children (0.12%; 95% confidence interval, 0.04% to 0.20%) had elevations greater than 1.20 mumol/L (25 mug/dL). Five children (83.3%) had histories of lead consumption unrelated to ingestion of lead-containing paint but related to the use of lead-containing folk remedies and cooking utensils. Costs for detection of children with blood levels elevated to 0.50 mumol/L (10 mug/dL) or higher was $310 per child and for levels of 1.20 mumol/L (25 mug/dL) or higher was $19 139 per child. Conclusions.-These data suggest that lead poisoning is not a major public health problem among Orange County children and detection of infrequent cases would involve a high cost per child. In jurisdictions with newer housing, initial screening for a history of possible lead exposure alone may offer reasonable efficacy that is cost-effective. The scope of lead-testing programs should be determined according to local needs and conditions.	ORANGE CTY HLTH CARE AGCY,SANTA ANA,CA									[Anonymous], 1991, PREVENTING LEAD POIS; 1992, MANAGEMENT SUMMARY R; 1980, SELECTED POPULATIO B, V5; 1991, 9110 DEP HLTH SERV C; 1992, MMWR MORB MORTAL WKL, V41, P291; 1991, 9111 DEP HLTH SERV C	6	47	47	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 7	1993	270	1					69	71		10.1001/jama.270.1.69	http://dx.doi.org/10.1001/jama.270.1.69			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK366	8305000				2022-12-01	WOS:A1993LK36600026
J	OHYA, Y; BOTSTEIN, D				OHYA, Y; BOTSTEIN, D			DIVERSE ESSENTIAL FUNCTIONS REVEALED BY COMPLEMENTING YEAST CALMODULIN MUTANTS	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; PEPTIDE COMPLEX; CELL-GROWTH; MUTATIONS; PROTEIN; MITOSIS; MYOSIN; CYCLE; GENE	Calmodulin, a cytoplasmic calcium-binding protein, is indispensable for eukaryotic cell growth. Examination of 14 temperature-sensitive yeast mutants bearing one or more phenylalanine to alanine substitutions in the single essential calmodulin gene of yeast (CMD1) revealed diverse essential functions. Mutations could be classified into four intragenic complementation groups. Each group showed different characteristic functional defects in actin organization, calmodulin localization, nuclear division, or bud emergence. Phenylalanine residues implicated in calmodulin localization and nuclear division are located in the amino-terminal half of the protein, whereas those implicated in actin organization and bud emergence are located in the carboxyl-terminal half.	STANFORD UNIV, SCH MED, DEPT GENET, STANFORD, CA 94305 USA	Stanford University					NIGMS NIH HHS [GM46888, GM46406] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046888, R01GM046406, R37GM046406] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS AEM, 1984, J CELL BIOL, V98, P934, DOI 10.1083/jcb.98.3.934; AIREY JA, 1993, BIOCHEMISTRY-US, V32, P5739, DOI 10.1021/bi00073a003; BIGELIS R, 1977, ICN UCLA S MOL CELL, V8, P179; BROCKERHOFF SE, 1992, J CELL BIOL, V118, P619, DOI 10.1083/jcb.118.3.619; COHEN P, 1988, CALMODULIN MOL ASPEC, V5; DAVIS TN, 1992, CELL CALCIUM, V13, P435, DOI 10.1016/0143-4160(92)90056-X; DAVIS TN, 1992, J CELL BIOL, V118, P607, DOI 10.1083/jcb.118.3.607; DAVIS TN, 1989, P NATL ACAD SCI USA, V86, P7909, DOI 10.1073/pnas.86.20.7909; DAVIS TN, 1986, CELL, V47, P423, DOI 10.1016/0092-8674(86)90599-4; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; FINK GR, 1966, GENETICS, V53, P445; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JOHNSTON GC, 1991, J CELL BIOL, V113, P539, DOI 10.1083/jcb.113.3.539; KINK JA, 1990, CELL, V62, P165, DOI 10.1016/0092-8674(90)90250-I; LU KP, 1993, J CELL BIOL, V121, P621, DOI 10.1083/jcb.121.3.621; MATTHIES HJ, 1993, J BIOL CHEM, V268; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MILLER HC, 1993, J BIOL CHEM, V268; OHYA Y, 1987, EUR J BIOCHEM, V168, P13, DOI 10.1111/j.1432-1033.1987.tb13380.x; OHYA Y, 1989, BIOCHEM BIOPH RES CO, V158, P541, DOI 10.1016/S0006-291X(89)80083-X; OHYA Y, 1992, CELL CALCIUM, V13, P445, DOI 10.1016/0143-4160(92)90057-Y; OHYA Y, UNPUB; PRINGLE JR, 1989, METHOD CELL BIOL, V31, P357; RASMUSSEN CD, 1989, EMBO J, V8, P73, DOI 10.1002/j.1460-2075.1989.tb03350.x; REHAKRANTZ LJ, 1990, GENETICS, V124, P213; SANJOSE E, 1992, J BIOL CHEM, V267, P15237; SCHLESINGER MJ, 1963, COLD SPRING HARB SYM, V28, P539, DOI 10.1101/SQB.1963.028.01.072; STAROVASNIK MA, 1993, BIOCHEMISTRY-US, V32, P3261, DOI 10.1021/bi00064a008; SUN GH, 1992, J CELL BIOL, V119, P1625, DOI 10.1083/jcb.119.6.1625; SUN GH, 1992, PROTOPLASMA, V166, P110, DOI 10.1007/BF01320150	30	132	134	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	1994	263	5149					963	966		10.1126/science.8310294	http://dx.doi.org/10.1126/science.8310294			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX165	8310294				2022-12-01	WOS:A1994MX16500034
J	ABELIOVICH, A; CHEN, C; GODA, Y; SILVA, AJ; STEVENS, CF; TONEGAWA, S				ABELIOVICH, A; CHEN, C; GODA, Y; SILVA, AJ; STEVENS, CF; TONEGAWA, S			MODIFIED HIPPOCAMPAL LONG-TERM POTENTIATION IN PKC-GAMMA-MUTANT MICE	CELL			English	Article							PROTEIN-KINASE-C; INDUCTION; EXPRESSION; CALMODULIN; LTP; CA1; TRANSMISSION; MAINTENANCE; ACTIVATION; CURRENTS	Calcium-phospholipid-dependent protein kinase (PKC) has long been suggested to play an important role in modulating synaptic efficacy. We have created a strain of mice that lacks the gamma subtype of PKC to evaluate the significance of this brain-specific PKC isozyme in synaptic plasticity. Mutant mice are viable, develop normally, and have synaptic transmission that is indistinguishable from wild-type mice. Long-term potentiation (LTP), however, is greatly diminished in mutant animals, while two other forms of synaptic plasticity, long-term depression and paired-pulse facilitation, are normal. Surprisingly, when tetanus to evoke LTP was preceded by a low frequency stimulation, mutant animals displayed apparently normal LTP. We propose that PKCgamma is not part of the molecular machinery that produces LTP but is a key regulatory component.	MIT,HOWARD HUGHES MED INST,DEPT BIOL,CAMBRIDGE,MA 02139; SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,LA JOLLA,CA 92037	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Salk Institute	ABELIOVICH, A (corresponding author), MIT,CTR CANC RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139, USA.		Silva, Alcino/ABD-7684-2021; Goda, Yukiko/A-6576-2016; Goda, Yukiko/AAR-5641-2020	Silva, Alcino/0000-0002-1587-4558; Goda, Yukiko/0000-0003-0352-9498; Goda, Yukiko/0000-0003-0352-9498; Silva, Alcino/0000-0001-5525-0494	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS012961] Funding Source: NIH RePORTER; NINDS NIH HHS [5 RO1 NS 12961-17] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABELIOVICH A, 1993, CELL, V75, P1263, DOI 10.1016/0092-8674(93)90614-V; AKERS RF, 1986, SCIENCE, V231, P587, DOI 10.1126/science.3003904; BENARI Y, 1992, TRENDS NEUROSCI, V15, P333, DOI 10.1016/0166-2236(92)90049-E; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; COAN EJ, 1989, NEUROSCI LETT, V105, P205, DOI 10.1016/0304-3940(89)90038-4; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; FREISEWINKEL I, 1991, FEBS LETT, V280, P262, DOI 10.1016/0014-5793(91)80307-O; FUJII S, 1991, BRAIN RES, V555, P112, DOI 10.1016/0006-8993(91)90867-U; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HU GY, 1987, NATURE, V328, P426, DOI 10.1038/328426a0; HUANG FL, 1988, J NEUROSCI, V8, P4734; HUANG YY, 1992, SCIENCE, V255, P730, DOI 10.1126/science.1346729; JAHR CE, 1990, J NEUROSCI, V10, P3178; KLANN E, 1991, J BIOL CHEM, V266, P24253; KNOPF JL, 1986, CELL, V46, P491, DOI 10.1016/0092-8674(86)90874-3; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MALLART A, 1968, J PHYSIOL-LONDON, V196, P593, DOI 10.1113/jphysiol.1968.sp008525; MULKEY RM, 1993, SCIENCE, V261, P1051, DOI 10.1126/science.8394601; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; RAASTAD M, 1992, EUR J NEUROSCI, V4, P113, DOI 10.1111/j.1460-9568.1992.tb00114.x; REYMANN KG, 1968, BRAIN RES, V463, P388; SACKTOR TC, 1993, P NATL ACAD SCI USA, V90, P8342, DOI 10.1073/pnas.90.18.8342; SAE K, 1988, J NEUROSCI, V8, P3850; SCHWARTZ JH, 1993, P NATL ACAD SCI USA, V90, P8310, DOI 10.1073/pnas.90.18.8310; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; THOMPSON S, 1989, CELL, V56, P313, DOI 10.1016/0092-8674(89)90905-7; WANG JH, 1992, P NATL ACAD SCI USA, V89, P2576, DOI 10.1073/pnas.89.7.2576; YASUDA I, 1990, BIOCHEM BIOPH RES CO, V166, P1220, DOI 10.1016/0006-291X(90)90996-Z	32	407	415	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 31	1993	75	7					1253	1262		10.1016/0092-8674(93)90613-U	http://dx.doi.org/10.1016/0092-8674(93)90613-U			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	8269509				2022-12-01	WOS:A1993MP86900005
J	SONTHEIMER, EJ; STEITZ, JA				SONTHEIMER, EJ; STEITZ, JA			THE U5 AND U6 SMALL NUCLEAR RNAS AS ACTIVE-SITE COMPONENTS OF THE SPLICEOSOME	SCIENCE			English	Article							PRE-MESSENGER-RNA; BASE-PAIRING INTERACTION; SELF-SPLICING INTRONS; GROUP-I INTRONS; RIBONUCLEOPROTEIN-PARTICLES; MUTATIONAL ANALYSIS; CATALYTIC CORE; HELA-CELLS; P-SITE; YEAST	Five small nuclear RNAs (U1, U2, U4, U5, and U6) participate in precursor messenger RNA (pre-mRNA) splicing. To probe their interactions within the active center of the mammalian spliceosome, substrates containing a single photoactivatable 4-thiouridine residue adjacent to either splice site were synthesized, and crosslinks were induced during the course of in vitro splicing. An invariant loop sequence in U5 small nuclear RNA contacts exon 1 before and after the first step of splicing because a crosslink between U5 and the last residue of exon 1 appeared in the pre-mRNA and then in the cutoff exon 1 intermediate. Both of these crosslinked species could undergo subsequent splicing, indicating that the crosslinks reflect afunctional interaction that is maintained through both reaction steps. The same U5 loop aligns the two exons for ligation since the first residue of exon 2 also became crosslinked to U5 in the lariat intermediate. An invariant sequence in U6 RNA became crosslinked to the conserved second position of the intron within both the lariat intermediate and the lariat intron product. On the basis of these results, several conformational arrangements of small nuclear RNAs within the spliceosomal active center can be distinguished, and additional mechanistic parallels between the spliceosome and self-splicing introns can be drawn.	YALE UNIV, SCH MED,BOYER CTR MOLEC MED,HOWARD HUGHES MED INST, DEPT MOLEC BIOPHYS & BIOCHEM, NEW HAVEN, CT 06536 USA	Howard Hughes Medical Institute; Yale University				Sontheimer, Erik/0000-0002-0881-0310	NIGMS NIH HHS [GM26514] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABMAYR SM, 1988, P NATL ACAD SCI USA, V85, P7216, DOI 10.1073/pnas.85.19.7216; AEBI M, 1986, CELL, V47, P555, DOI 10.1016/0092-8674(86)90620-3; BEEN MD, 1986, CELL, V47, P207, DOI 10.1016/0092-8674(86)90443-5; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; CHABOT B, 1987, MOL CELL BIOL, V7, P281, DOI 10.1128/MCB.7.1.281; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; CORTES JJ, IN PRESS EMBO J; DATTA B, 1993, MOL CELL BIOL, V13, P5377, DOI 10.1128/MCB.13.9.5377; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; DENMAN R, 1988, NUCLEIC ACIDS RES, V16, P165, DOI 10.1093/nar/16.1.165; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ERICSON G, 1988, ANAL BIOCHEM, V174, P215, DOI 10.1016/0003-2697(88)90538-6; FABRIZIO P, 1992, NUCLEIC ACIDS RES, V20, P3659, DOI 10.1093/nar/20.14.3659; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HANNA MM, 1989, METHOD ENZYMOL, V180, P383; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; HEINTZ N, 1984, P NATL ACAD SCI-BIOL, V81, P2713, DOI 10.1073/pnas.81.9.2713; HEUER TS, 1991, P NATL ACAD SCI USA, V88, P11105, DOI 10.1073/pnas.88.24.11105; HUTTENHOFER A, 1992, P NATL ACAD SCI USA, V89, P7851, DOI 10.1073/pnas.89.17.7851; JACQUIER A, 1990, J MOL BIOL, V213, P437, DOI 10.1016/S0022-2836(05)80206-2; JACQUIER A, 1991, J MOL BIOL, V219, P415, DOI 10.1016/0022-2836(91)90183-7; JACQUIER A, 1987, CELL, V50, P17, DOI 10.1016/0092-8674(87)90658-1; JAMISON SF, 1992, P NATL ACAD SCI USA, V89, P5482, DOI 10.1073/pnas.89.12.5482; KANDELSLEWIS S, 1993, SCIENCE, V262, P2035, DOI 10.1126/science.8266100; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; LAMOND AI, 1987, GENE DEV, V1, P532, DOI 10.1101/gad.1.6.532; LATHAM JA, 1989, SCIENCE, V245, P276, DOI 10.1126/science.2501870; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MARCINIEC TE, COMMUNICATION; MCPHEETERS DS, 1992, CELL, V71, P819, DOI 10.1016/0092-8674(92)90557-S; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; Moore M., 1993, RNA WORLD, P303; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NAKASHIMA K, 1980, NATURE, V286, P226, DOI 10.1038/286226a0; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; PARKER R, 1993, NATURE, V361, P660, DOI 10.1038/361660a0; PEEBLES CL, 1986, CELL, V44, P213, DOI 10.1016/0092-8674(86)90755-5; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; RYMOND BC, 1988, GENE DEV, V2, P428, DOI 10.1101/gad.2.4.428; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; Smith Coby, UNPUB; SOLNICK D, 1985, CELL, V42, P157, DOI 10.1016/S0092-8674(85)80111-2; SONTHEIMER EJ, 1992, MOL CELL BIOL, V12, P734, DOI 10.1128/MCB.12.2.734; SONTHEIMER EJ, UNPUB; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; TANI T, 1991, GENE DEV, V5, P1022, DOI 10.1101/gad.5.6.1022; TEARE J, 1990, NUCLEIC ACIDS RES, V18, P855, DOI 10.1093/nar/18.4.855; VANDERVEEN R, 1986, CELL, V44, P225, DOI 10.1016/0092-8674(86)90756-7; WANG JF, 1993, SCIENCE, V260, P504, DOI 10.1126/science.7682726; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; WOLFF T, IN PRESS P NATL ACAD; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; YU YT, IN PRESS CELL; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; [No title captured]	66	318	344	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1993	262	5142					1989	1996		10.1126/science.8266094	http://dx.doi.org/10.1126/science.8266094			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266094				2022-12-01	WOS:A1993MN10800027
J	KIRSCH, J; WOLTERS, I; TRILLER, A; BETZ, H				KIRSCH, J; WOLTERS, I; TRILLER, A; BETZ, H			GEPHYRIN ANTISENSE OLIGONUCLEOTIDES PREVENT GLYCINE RECEPTOR CLUSTERING IN SPINAL NEURONS	NATURE			English	Article							NICOTINIC ACETYLCHOLINE-RECEPTORS; GAMMA-AMINOBUTYRIC ACID; MONOCLONAL-ANTIBODIES; POSTSYNAPTIC MEMBRANE; CENTRAL SYNAPSES; PROTEIN; TUBULIN; LOCALIZATION; POLYPEPTIDE; COMPLEX	EACH neuron in the mammalian brain carries many postsynaptic membrane specializations containing high densities of receptors that mediate signal transduction upon neurotransmitter release from the apposed nerve terminal1. Little is known about the mechanisms by which receptors are transported to and anchored at postsynaptic sites, but extracellular2 as well as intracellular3 components may be involved. Ultrastructural studies have shown that the peripheral membrane protein gephyrin4, Which co-purifies with the postsynaptic inhibitory glycine receptor (GlyR) upon affinity chromatography5,6, is situated on the cytoplasmic face of glycinergic postsynaptic membranes7-9. Moreover, gephyrin binds with high affinity to polymerized tubulin and has been postulated to link the GlyR to the subsynaptic cytoskeleton10. Here we report that treatment of rat spinal neurons in culture with gephyrin antisense oligonucleotides prevents the formation of GlyR clusters in the dendritic plasma membrane. Thus, gephyrin is essential for localizing the GlyR to presumptive postsynaptic plasma membrane specializations.	MAX PLANCK INST BRAIN RES,DEPT NEUROCHEM,DEUTSCHORDENSTR 46,D-60528 FRANKFURT,GERMANY; INST PASTEUR,DEPT BIOTECHNOL,INSERM,U261,F-750 PARIS 15,FRANCE	Max Planck Society; Institut National de la Sante et de la Recherche Medicale (Inserm)				TRILLER, Antoine/0000-0002-7530-1233				ALTSCHULER RA, 1986, BRAIN RES, V369, P316, DOI 10.1016/0006-8993(86)90542-1; BECKER CM, 1989, J NEUROCHEM, V53, P124, DOI 10.1111/j.1471-4159.1989.tb07303.x; BLOCH RJ, 1986, J CELL BIOL, V102, P1447, DOI 10.1083/jcb.102.4.1447; BLOMBERG F, 1977, J CELL BIOL, V74, P204, DOI 10.1083/jcb.74.1.204; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; BRIDGMAN PC, 1989, J CELL BIOL, V105, P1829; FROEHNER SC, 1993, ANNU REV NEUROSCI, V16, P347, DOI 10.1146/annurev.ne.16.030193.002023; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; HIROKAWA N, 1982, J NEUROCYTOL, V11, P487, DOI 10.1007/BF01257990; HOCH W, 1989, NEURON, V3, P339, DOI 10.1016/0896-6273(89)90258-4; JASMIN BJ, 1991, J NATURE, V344, P673; KIRSCH J, 1993, EUR J NEUROSCI, V5, P1109, DOI 10.1111/j.1460-9568.1993.tb00965.x; KIRSCH J, 1990, J NEUROCHEM, V55, P1031, DOI 10.1111/j.1471-4159.1990.tb04593.x; KIRSCH J, 1991, J BIOL CHEM, V266, P22242; KIRSCH J, 1993, BRAIN RES, V621, P301, DOI 10.1016/0006-8993(93)90120-C; LAROCHELLE WJ, 1990, J NEUROSCI, V10, P3460; MCMAHAN UJ, 1989, DEV NEUROSCI-BASEL, V11, P227, DOI 10.1159/000111903; NGHIEM HO, 1983, P NATL ACAD SCI-BIOL, V80, P6403, DOI 10.1073/pnas.80.20.6403; NICOLA MA, 1992, NEUROSCI LETT, V138, P173, DOI 10.1016/0304-3940(92)90499-W; PETERS A, 1992, FINE STRUCTURE NERVO; PFEIFFER F, 1982, J BIOL CHEM, V257, P9389; PFEIFFER F, 1984, P NATL ACAD SCI-BIOL, V81, P7224, DOI 10.1073/pnas.81.22.7224; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; PRIOR P, 1992, NEURON, V8, P1161, DOI 10.1016/0896-6273(92)90136-2; SCHMITT B, 1987, BIOCHEMISTRY-US, V26, P805, DOI 10.1021/bi00377a022; SEALOCK R, 1984, J CELL BIOL, V98, P2239, DOI 10.1083/jcb.98.6.2239; STEPHENS RE, 1986, BIOL CELL, V57, P95, DOI 10.1111/j.1768-322X.1986.tb00467.x; TRILLER A, 1987, J CELL BIOL, V104, P947, DOI 10.1083/jcb.104.4.947; TRILLER A, 1985, J CELL BIOL, V101, P683, DOI 10.1083/jcb.101.2.683; WALKER JH, 1984, EMBO J, V3, P2287, DOI 10.1002/j.1460-2075.1984.tb02127.x	30	368	377	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 23	1993	366	6457					745	748		10.1038/366745a0	http://dx.doi.org/10.1038/366745a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN264	8264797				2022-12-01	WOS:A1993MN26400029
J	UYEDA, TQP; SPUDICH, JA				UYEDA, TQP; SPUDICH, JA			A FUNCTIONAL RECOMBINANT MYOSIN-II LACKING A REGULATORY LIGHT-CHAIN BINDING-SITE	SCIENCE			English	Article							DICTYOSTELIUM-DISCOIDEUM; HEAVY-CHAIN; ELECTRON-MICROSCOPY; MUSCLE-CONTRACTION; NONMUSCLE MYOSIN; ACTIN-FILAMENTS; SCALLOP MYOSIN; PHOSPHORYLATION; GENE; SUBFRAGMENT-1	Myosin II, which converts the energy of adenosine triphosphate hydrolysis into the movement of actin filaments, is a hexamer of two heavy chains, two essential light chains, and two regulatory light chains (RLCs). Dictyostelium myosin II is known to be regulated in vitro by phosphorylation of the RLC. Cells in which the wild-type myosin II heavy chain was replaced with a recombinant form that lacks the binding site for RLC carried out cytokinesis and almost normal development, processes known to be dependent on functional myosin II. Characterization of the purified recombinant protein suggests that a complex of RLC and the RLC binding site of the heavy chain plays an inhibitory role for adenosine triphosphatase activity and a structural role for the movement of myosin along actin.	STANFORD UNIV, MED CTR, SCH MED, DEPT BIOCHEM, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA	Stanford University; Stanford University					NIGMS NIH HHS [GM46551] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM046551, R01GM046551] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAYLEY SA, 1986, EUR J CELL BIOL, V42, P10; BERLOT CH, 1985, CELL, V43, P307, DOI 10.1016/0092-8674(85)90036-4; BURTON K, 1992, J MUSCLE RES CELL M, V13, P590, DOI 10.1007/BF01738249; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHISHOLM RL, 1993, MAY INT DICT M NOORD; CLARKE M, 1974, J MOL BIOL, V86, P209, DOI 10.1016/0022-2836(74)90013-8; COOKE R, 1984, CONTRACTILE MECHANIS, P413; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; EGELHOFF TT, 1991, J CELL BIOL, V112, P677, DOI 10.1083/jcb.112.4.677; EGELHOFF TT, 1990, DEV BIOL, V137, P359, DOI 10.1016/0012-1606(90)90260-P; EGELHOFF TT, 1993, CELL, V75, P363, DOI 10.1016/0092-8674(93)80077-R; EGELHOFF TT, 1991, METHOD ENZYMOL, V196, P319; ELLIOTT A, 1978, J MOL BIOL, V123, P505, DOI 10.1016/0022-2836(78)90204-8; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; FERNANDEZ A, 1990, J CELL BIOL, V111, P103, DOI 10.1083/jcb.111.1.103; FLICKER PF, 1983, J MOL BIOL, V169, P723, DOI 10.1016/S0022-2836(83)80167-3; HADWIGER JA, 1992, GENE DEV, V6, P38, DOI 10.1101/gad.6.1.38; HARADA Y, 1990, J MOL BIOL, V216, P49, DOI 10.1016/S0022-2836(05)80060-9; HOSOYA H, 1991, J BIOL CHEM, V266, P22173; HUXLEY HE, 1985, J MUSCLE RES CELL M, V6, P153, DOI 10.1007/BF00713057; IKEBE M, 1985, BIOCHEMISTRY-US, V24, P2380, DOI 10.1021/bi00330a038; KARESS RE, 1991, CELL, V65, P1177, DOI 10.1016/0092-8674(91)90013-O; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KNECHT DA, 1986, MOL CELL BIOL, V6, P3973, DOI 10.1128/MCB.6.11.3973; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KORN ED, 1988, ANNU REV BIOPHYS BIO, V17, P23; KUBALEK EW, 1992, MOL BIOL CELL, V3, P1455, DOI 10.1091/mbc.3.12.1455; LOWEY S, 1993, NATURE, V365, P454, DOI 10.1038/365454a0; MAITA T, 1991, J BIOCHEM, V110, P75, DOI 10.1093/oxfordjournals.jbchem.a123546; MARGOSSIAN SS, 1973, J MOL BIOL, V74, P313, DOI 10.1016/0022-2836(73)90376-8; MERINO E, 1992, BIOTECHNIQUES, V12, P508; MOSS RL, 1992, CIRC RES, V70, P865, DOI 10.1161/01.RES.70.5.865; PASTRALANDIS SC, 1986, J BIOL CHEM, V261, P4811; PELTZ G, 1985, J CELL BIOL, V100, P1016, DOI 10.1083/jcb.100.4.1016; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; RUPPEL KM, UNPUB; SATTERWHITE L L, 1992, Current Opinion in Cell Biology, V4, P43, DOI 10.1016/0955-0674(92)90057-J; SCHRODER RR, 1993, NATURE, V364, P171, DOI 10.1038/364171a0; SPUDICH JA, 1989, CELL REGUL, V1, P11; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; TAN JL, 1992, ANNU REV BIOCHEM, V61, P721, DOI 10.1146/annurev.bi.61.070192.003445; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; UYEDA TQP, 1991, NATURE, V352, P307, DOI 10.1038/352307a0; UYEDA TQP, 1990, J MOL BIOL, V214, P699, DOI 10.1016/0022-2836(90)90287-V; UYEDA TQP, UNPUB; VALE RD, 1984, P NATL ACAD SCI-BIOL, V81, P6775, DOI 10.1073/pnas.81.21.6775; VIBERT P, 1982, J MOL BIOL, V157, P299, DOI 10.1016/0022-2836(82)90236-4; WAKABAYASHI K, 1992, SCIENCE, V258, P443, DOI 10.1126/science.1411537; WAKABAYASHI K, 1993, BIOCHEMISTRY-US, V32, P2455; WARMKE J, 1992, J CELL BIOL, V119, P1523, DOI 10.1083/jcb.119.6.1523; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cellbio.3.1.379; WARRICK HM, 1986, P NATL ACAD SCI USA, V83, P9433, DOI 10.1073/pnas.83.24.9433; WINKELMANN DA, 1991, J CELL BIOL, V114, P701, DOI 10.1083/jcb.114.4.701	54	114	114	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1993	262	5141					1867	1870		10.1126/science.8266074	http://dx.doi.org/10.1126/science.8266074			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266074				2022-12-01	WOS:A1993MM51100034
J	GIAEVER, I; KEESE, CR				GIAEVER, I; KEESE, CR			A MORPHOLOGICAL BIOSENSOR FOR MAMMALIAN-CELLS	NATURE			English	Article							TISSUE-CULTURE; ELECTRIC-FIELDS; BEHAVIOR; MONITOR	An electrical biosensor is described that can continuously track morphological changes of adherent cells providing quantitative data from both sparse and confluent cultures. The method is capable of detecting vertical motion of cells of the order of 1 nm, much below the resolution of an optical microscope.	RENSSELAER POLYTECH INST,DEPT BIOL,TROY,NY 12180	Rensselaer Polytechnic Institute	GIAEVER, I (corresponding author), RENSSELAER POLYTECH INST,SCH SCI,TROY,NY 12180, USA.							GHOSH PM, 1993, BIOPHYS J, V64, P1602, DOI 10.1016/S0006-3495(93)81531-5; GIAEVER I, 1989, PHYSICA D, V38, P128, DOI 10.1016/0167-2789(89)90182-6; GIAEVER I, 1984, P NATL ACAD SCI-BIOL, V81, P3761, DOI 10.1073/pnas.81.12.3761; GIAEVER I, 1986, IEEE T BIO-MED ENG, V33, P242, DOI 10.1109/TBME.1986.325896; GIAEVER I, 1991, P NATL ACAD SCI USA, V88, P7896, DOI 10.1073/pnas.88.17.7896; GIAEVER I, 1992, CHEMTECH, P116; KEESE CR, 1990, IEEE P BIOMED ENG, V12, P500; KOWOLENKO M, 1990, J IMMUNOL METHODS, V127, P71, DOI 10.1016/0022-1759(90)90342-S; LO CM, 1993, EXP CELL RES, V204, P102, DOI 10.1006/excr.1993.1014; MITRA P, 1991, BIOTECHNIQUES, V11, P504; TIRUPPATHI C, 1992, P NATL ACAD SCI USA, V89, P7919, DOI 10.1073/pnas.89.17.7919	11	599	622	3	90	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 9	1993	366	6455					591	592		10.1038/366591a0	http://dx.doi.org/10.1038/366591a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	8255299				2022-12-01	WOS:A1993ML21800078
J	BROWN, SJ; KELLETT, PJ; LIPPARD, SJ				BROWN, SJ; KELLETT, PJ; LIPPARD, SJ			IXR1, A YEAST PROTEIN THAT BINDS TO PLATINATED DNA AND CONFERS SENSITIVITY TO CISPLATIN	SCIENCE			English	Article							ANTICANCER DRUG CISPLATIN; SACCHAROMYCES-CEREVISIAE; INTRASTRAND D(GPG); NUCLEAR; MITOCHONDRIA; EXTRACTS; REPAIR; CELLS	Structure-specific recognition proteins (SSRPs) bind to DNA containing intrastrand cross-links formed by the anticancer drug cisplatin. A yeast gene encoding an SSRP, designated IXR1, was cloned and sequenced. The Ixr1 protein, a member of the high mobility group-box protein family, bound specifically to DNA modified with cisplatin but not inactive platinum compounds. A yeast strain with an inactivated IXR1 gene was half as sensitive to cisplatin and accumulated one-third as many platinum-DNA lesions after treatment with cisplatin as the parental strain. These findings suggest that SSRPs play a role in mediating the cytotoxicity of cisplatin.	MIT, DEPT CHEM, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)								BROWN SDM, UNPUB; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; BRUHN SL, 1990, PROG INORG CHEM, V38, P477; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIFFLEY JFX, 1992, J BIOL CHEM, V267, P3368; DIFFLEY JFX, 1991, P NATL ACAD SCI USA, V88, P7864, DOI 10.1073/pnas.88.17.7864; DONAHUE BA, 1990, BIOCHEMISTRY-US, V29, P5872, DOI 10.1021/bi00476a032; GIESE K, 1991, GENE DEV, V5, P2567, DOI 10.1101/gad.5.12b.2567; HUGHES EN, 1992, J BIOL CHEM, V267, P13520; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JANTZEN HM, 1990, NATURE, V344, P830, DOI 10.1038/344830a0; KELLEY SL, 1989, EUR J CANCER CLIN ON, V25, P1135, DOI 10.1016/0277-5379(89)90405-7; LOEHRER PJ, 1984, ANN INTERN MED, V100, P704, DOI 10.7326/0003-4819-100-5-704; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; RUDOLPH HK, 1989, CELL, V58, P133, DOI 10.1016/0092-8674(89)90410-8; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; SZYMKOWSKI DE, 1992, P NATL ACAD SCI USA, V89, P10772, DOI 10.1073/pnas.89.22.10772; TONEY JH, 1989, P NATL ACAD SCI USA, V86, P8328, DOI 10.1073/pnas.86.21.8328; WANG ZG, 1992, BIOCHEMISTRY-US, V31, P3694, DOI 10.1021/bi00129a019	22	181	187	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	1993	261	5121					603	605		10.1126/science.8342024	http://dx.doi.org/10.1126/science.8342024			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	8342024				2022-12-01	WOS:A1993LP72800037
J	REBAY, I; FEHON, RG; ARTAVANISTSAKONAS, S				REBAY, I; FEHON, RG; ARTAVANISTSAKONAS, S			SPECIFIC TRUNCATIONS OF DROSOPHILA NOTCH DEFINE DOMINANT ACTIVATED AND DOMINANT-NEGATIVE FORMS OF THE RECEPTOR	CELL			English	Article							EPIDERMAL GROWTH-FACTOR; GENE SERRATE ENCODES; CELL FATE; TRANSMEMBRANE PROTEIN; EXPRESSION PATTERN; EARLY NEUROGENESIS; LOCUS; MELANOGASTER; HOMOLOG; REPEATS	The Notch gene of Drosophila plays an important role in cell fate specification throughout development. To investigate the functions of specific structural domains of the Notch protein in vivo, a series of deletion mutants have been ectopically expressed under the hsp70 heat shock promoter. Two classes of dominant phenotypes are observed, one suggestive of Notch loss-of-function mutations and the other of Notch gain-of-function,mutations. Dominant activated phenotypes result from overexpression of a protein lacking most extracellular sequences, while dominant negative phenotypes result from overexpression of a protein lacking most intracellular sequences. These results support the notion that Notch functions as a receptor whose extracellular domain mediates ligand binding, resulting in the transmission of developmental signals by the cytoplasmic domain. Finally, the phenotypes observed suggest that the cdc10/ankyrin repeat region within the intracellular domain plays an essential role in the postulated signal transduction events.	YALE UNIV,DEPT BIOL,NEW HAVEN,CT 06536	Yale University	REBAY, I (corresponding author), YALE UNIV,DEPT CELL BIOL,HOWARD HUGHES MED INST,NEW HAVEN,CT 06536, USA.				NIGMS NIH HHS [GM29093] Funding Source: Medline; NINDS NIH HHS [NS26084] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026084, R37NS026084] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; APPELLA E, 1987, FEBS LETT, V231, P1; ARTAVANISTSAKONAS S, 1991, ANNU REV CELL BIOL, V7, P427; ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; BASLER K, 1991, CELL, V64, P1069, DOI 10.1016/0092-8674(91)90262-W; BLANK V, 1992, TRENDS BIOCHEM SCI, V17, P135, DOI 10.1016/0968-0004(92)90321-Y; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; DELAMO FF, 1992, DEVELOPMENT, V115, P737; DELIDAKIS C, 1991, GENETICS, V129, P803; DOWNWARD J, 1984, NATURE, V307, P521, DOI 10.1038/307521a0; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FLEMING RJ, 1990, GENE DEV, V4, P2188, DOI 10.1101/gad.4.12a.2188; GARCIABELLIDO A, 1971, DEV BIOL, V24, P61, DOI 10.1016/0012-1606(71)90047-9; GARCIABELLIDO A, 1978, GENETICS, V88, P469; HARTENSTEIN AY, 1992, DEVELOPMENT, V116, P1203; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; HARTLEY DA, 1987, EMBO J, V6, P3407, DOI 10.1002/j.1460-2075.1987.tb02664.x; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; KELLEY MR, 1987, CELL, V51, P539, DOI 10.1016/0092-8674(87)90123-1; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIDD S, 1989, GENE DEV, V3, P1113, DOI 10.1101/gad.3.8.1113; KOPCZYNSKI CC, 1988, GENE DEV, V2, P1723, DOI 10.1101/gad.2.12b.1723; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; Maniatis T, 1989, DECONTAMINATION DILU; MOFFAT KG, 1992, DEVELOPMENT, V114, P681; PALKA J, 1990, DEVELOPMENT, V109, P167; Poulson DF, 1940, J EXP ZOOL, V83, P271, DOI 10.1002/jez.1400830207; Poulson DF, 1937, P NATL ACAD SCI USA, V23, P133, DOI 10.1073/pnas.23.3.133; RAMOS RGP, 1989, GENETICS, V123, P337; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; ROBERTSON HM, 1988, GENETICS, V118, P461; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SHELLENBARGER DL, 1978, DEV BIOL, V62, P432, DOI 10.1016/0012-1606(78)90226-9; SMOLLER D, 1990, GENE DEV, V4, P1688, DOI 10.1101/gad.4.10.1688; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; THOMAS U, 1991, DEVELOPMENT, V111, P749; THOMPSON JN, 1974, HEREDITY, V33, P389, DOI 10.1038/hdy.1974.105; THUMMEL CS, 1991, DROSOPH INFO NEWS, V2; VAESSIN H, 1987, EMBO (European Molecular Biology Organization) Journal, V6, P3431; WEINMASTER G, 1991, DEVELOPMENT, V113, P199; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; XU T, 1992, DEVELOPMENT, V115, P913; YAMAMOTO T, 1986, NATURE, V319, P230, DOI 10.1038/319230a0; YARDEN Y, 1988, ANNU REV BIOCHEM, V57, P443, DOI 10.1146/annurev.bi.57.070188.002303	53	375	393	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					319	329		10.1016/0092-8674(93)90423-N	http://dx.doi.org/10.1016/0092-8674(93)90423-N			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343959				2022-12-01	WOS:A1993LP72600013
J	YAMASHITA, S; HISATAKE, K; KOKUBO, T; DOI, K; ROEDER, RG; HORIKOSHI, M; NAKATANI, Y				YAMASHITA, S; HISATAKE, K; KOKUBO, T; DOI, K; ROEDER, RG; HORIKOSHI, M; NAKATANI, Y			TRANSCRIPTION FACTOR TFIIB SITES IMPORTANT FOR INTERACTION WITH PROMOTER-BOUND TFIID	SCIENCE			English	Article							RNA POLYMERASE-II; INITIATION; SELECTION; COMPLEX; DOMAIN	Transcription initiation factor TFIIB recruits RNA polymerase II to the promoter subsequent to interaction with a preformed TFIID-promoter complex. The domains of TFIIB required for binding to the TFIID-promoter complex and for transcription initiation have been determined. The carboxyl-terminal two-thirds of TFIIB, which contains two direct repeats and two basic residue repeats, is sufficient for interaction with the TFIID-promoter complex. An extra 84-residue amino-terminal region, with no obvious known structural motifs, is required for basal transcription activity. Basic residues within the second basic repeat of TFIIB are necessary for stable interaction with the TFIID-promoter complex, whereas the basic character of the first basic repeat is not. Functional roles of other potential structural motifs are discussed in light of the present study.	NINCDS,BETHESDA,MD 20892; ROCKEFELLER UNIV,BIOCHEM & MOLEC BIOL LAB,NEW YORK,NY 10021; NIDCD,NEUROCHEM LAB,BETHESDA,MD 20892; UNIV TOKYO,INST APPL MICROBIOL,BUNKYO KU,TOKYO 113,JAPAN	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS); Rockefeller University; National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD); University of Tokyo				Hisatake, Koji/0000-0002-5795-3115	NCI NIH HHS [CA42567] Funding Source: Medline; NIAID NIH HHS [AI27397] Funding Source: Medline; NIGMS NIH HHS [GM45258] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA042567] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI027397] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM045258] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HISATAKE K, 1991, NUCLEIC ACIDS RES, V19, P6636; HOFFMANN A, 1990, NATURE, V346, P387, DOI 10.1038/346387a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; MALIK S, 1991, P NATL ACAD SCI USA, V88, P9553, DOI 10.1073/pnas.88.21.9553; NIKOLOV DB, 1992, NATURE, V360, P40, DOI 10.1038/360040a0; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; WAMPLER SL, 1992, GENE DEV, V6, P1542, DOI 10.1101/gad.6.8.1542; YAMAMOTO T, 1992, P NATL ACAD SCI USA, V89, P2844, DOI 10.1073/pnas.89.7.2844; YAMASHITA S, 1992, P NATL ACAD SCI USA, V89, P2839, DOI 10.1073/pnas.89.7.2839	16	50	50	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 23	1993	261	5120					463	466		10.1126/science.8332911	http://dx.doi.org/10.1126/science.8332911			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8332911				2022-12-01	WOS:A1993LN62300033
J	CAPPUCCIO, FP; STRAZZULLO, P; FARINARO, E; TREVISAN, M				CAPPUCCIO, FP; STRAZZULLO, P; FARINARO, E; TREVISAN, M			URIC-ACID METABOLISM AND TUBULAR SODIUM HANDLING - RESULTS FROM A POPULATION-BASED STUDY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RENAL LITHIUM CLEARANCE; ESSENTIAL-HYPERTENSION; COUNTERTRANSPORT; HYPERINSULINEMIA; INSULIN; MEN; RESISTANCE; EXCRETION; DISEASE	Objective.-To define the relationship, if any, between uric acid metabolism (serum and urinary levels) and proximal tubular sodium handling in a sample of general male population. Design.-Cross-sectional survey of a sample of the male working population conducted as part of a nationwide survey of the prevalence of cardiovascular risk factors. Setting.-The Olivetti factory in Pozzuoli, a suburb of Naples, Italy. Participants.-Five hundred sixty-eight untreated male workers aged 21 to 68 years (90.8% of those eligible). Measurements.-Anthropometry, blood pressure, blood tests, a detailed questionnaire, and urinary measurements on a fasting timed collection after a 300-mg lithium carbonate capsule was taken the night before the investigation. Results.-Serum uric acid level was inversely and significantly associated with the fractional excretion of lithium (r=-.22, P<.001), ie, the higher the serum uric acid level, the greater the amount of sodium reabsorbed at nephron sites proximal to the distal tubule. The association was graded and independent of possible confounders such as age, body mass, smoking, wine consumption, blood pressure, fractional excretion of sodium, and serum creatinine (R2=.34, P<.001). Conclusions.-High serum uric acid levels are independently associated with increased proximal tubular sodium reabsorption in men. This relationship suggests an altered tubular sodium handling and uric acid metabolism consistent with hyperinsulinemia, insulin resistance being the possible pathophysiological link.	UNIV NAPLES, SCH MED 2, INST INTERNAL MED & METAB DIS, I-80138 NAPLES, ITALY; SUNY Buffalo, DEPT SOCIAL & PREVENT MED, BUFFALO, NY 14260 USA	University of Naples Federico II; State University of New York (SUNY) System; State University of New York (SUNY) Buffalo	CAPPUCCIO, FP (corresponding author), ST GEORGE HOSP, SCH MED, DEPT MED, BLOOD PRESSURE UNIT, CRANMER TERRACE, LONDON SW17 0RE, ENGLAND.		Cappuccio, Francesco/D-3028-2009	Cappuccio, Francesco Paolo/0000-0002-7842-5493				BRAND FN, 1985, AM J EPIDEMIOL, V121, P11, DOI 10.1093/oxfordjournals.aje.a113972; BRECKENRIDGE A, 1966, LANCET, V1, P15; CANNON PJ, 1966, NEW ENGL J MED, V275, P457, DOI 10.1056/NEJM196609012750902; CAPPUCCIO FP, 1991, EUR J CLIN INVEST, V21, P40, DOI 10.1111/j.1365-2362.1991.tb01356.x; CAPPUCCIO FP, 1990, BRIT MED J, V300, P1234, DOI 10.1136/bmj.300.6734.1234; DEFRONZO RA, 1981, DIABETOLOGIA, V21, P165, DOI 10.1007/BF00252649; DOLLERY CT, 1960, BRIT MED J, V2, P832, DOI 10.1136/bmj.2.5202.832; DORIA A, 1991, AM J PHYSIOL, V261, pE684, DOI 10.1152/ajpendo.1991.261.6.E684; FACCHINI F, 1991, JAMA-J AM MED ASSOC, V266, P3008, DOI 10.1001/jama.266.21.3008; FERRANNINI E, 1987, NEW ENGL J MED, V317, P350, DOI 10.1056/NEJM198708063170605; GERTLER MM, 1951, ANN INTERN MED, V34, P1421, DOI 10.7326/0003-4819-34-6-1421; MAHNENSMITH RL, 1985, CIRC RES, V56, P773, DOI 10.1161/01.RES.56.6.773; MESSERLI FH, 1980, ANN INTERN MED, V93, P817, DOI 10.7326/0003-4819-93-6-817; MODAN M, 1987, DIABETOLOGIA, V30, P713, DOI 10.1007/BF00296994; MODAN M, 1985, J CLIN INVEST, V75, P809, DOI 10.1172/JCI111776; SELBY JV, 1990, AM J EPIDEMIOL, V131, P1017, DOI 10.1093/oxfordjournals.aje.a115593; SHIRLEY DG, 1991, CLIN SCI, V81, P59, DOI 10.1042/cs0810059; SHIRLEY DG, 1990, AM J MED SCI, V299, P326, DOI 10.1097/00000441-199005000-00007; SOLOMON LR, 1987, CLIN SCI, V72, P201, DOI 10.1042/cs0720201; STEELE TH, 1971, NEW ENGL J MED, V284, P1193, DOI 10.1056/NEJM197105272842106; STRAZZULLO P, 1989, CLIN SCI, V77, P337, DOI 10.1042/cs0770337; STRAZZULLO P, 1988, CLIN SCI, V74, P651, DOI 10.1042/cs0740651; STRAZZULLO P, 1989, AM J HYPERTENS, V2, P634, DOI 10.1093/ajh/2.8.634; THOMSEN K, 1984, NEPHRON, V37, P217, DOI 10.1159/000183252; TREVISAN M, 1991, CIRCULATION, V84, P2011, DOI 10.1161/01.CIR.84.5.2011; TUOMILEHTO J, 1988, AM J EPIDEMIOL, V127, P321, DOI 10.1093/oxfordjournals.aje.a114807; WEDER AB, 1986, NEW ENGL J MED, V314, P198, DOI 10.1056/NEJM198601233140402; ZAVARONI I, 1989, NEW ENGL J MED, V320, P702, DOI 10.1056/NEJM198903163201105	28	196	211	3	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1993	270	3					354	359		10.1001/jama.270.3.354	http://dx.doi.org/10.1001/jama.270.3.354			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM435	8315780				2022-12-01	WOS:A1993LM43500031
J	BURGESS, SM; GUTHRIE, C				BURGESS, SM; GUTHRIE, C			A MECHANISM TO ENHANCE MESSENGER-RNA SPLICING FIDELITY - THE RNA-DEPENDENT ATPASE PRP16 GOVERNS USAGE OF A DISCARD PATHWAY FOR ABERRANT LARIAT INTERMEDIATES	CELL			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR RIBONUCLEOPROTEIN; SACCHAROMYCES-CEREVISIAE; BRANCH SITE; TRANSLATION INITIATION; ESCHERICHIA-COLI; YEAST INTRON; SPLICEOSOME; PROTEIN; HELICASE	PRP16 encodes an RNA-dependent ATPase required for the second step of mRNA splicing in S. cerevisiae. We have isolated seven alleles of PRP16 that, like the original allele prp16-1, allow splicing of introns with a mutant branch site (UACUAAC to UACUACC), by forming lariat intermediates at the mutant C nucleotide. Every suppressor mutation maps to the region of PRP16 common to RNA-dependent ATPases. We purified three of the mutant proteins and found that all exhibit reduced ATPase activity, as does Prp16-1. An in vivo analysis of the steady-state levels of the splicing intermediates and products provides evidence for a pathway, under the genetic control of PRP16, to discard incorrectly branched substrates. We propose that decreasing the rate of ATP hydrolysis by Prp16 allows aberrantly formed lariat intermediates more time to proceed through the productive rather than the discard branch of this pathway.			BURGESS, SM (corresponding author), UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA.				NIGMS NIH HHS [GM21119] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021119, R37GM021119] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBERTS B, 1992, CELL, V68, P415, DOI 10.1016/0092-8674(92)90179-G; BILGIN N, 1992, J MOL BIOL, V224, P1011, DOI 10.1016/0022-2836(92)90466-W; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BURGESS S, 1990, CELL, V60, P705, DOI 10.1016/0092-8674(90)90086-T; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CHEN JH, 1990, NUCLEIC ACIDS RES, V18, P6447, DOI 10.1093/nar/18.21.6447; CHENG SC, 1986, P NATL ACAD SCI USA, V83, P2387, DOI 10.1073/pnas.83.8.2387; CHENG SC, 1987, GENE DEV, V1, P1014, DOI 10.1101/gad.1.9.1014; COMPANY M, 1991, NATURE, V349, P487, DOI 10.1038/349487a0; COUTO JR, 1987, GENE DEV, V1, P445, DOI 10.1101/gad.1.5.445; DALBADIEMCFARLAND G, 1990, P NATL ACAD SCI USA, V87, P4236, DOI 10.1073/pnas.87.11.4236; Dowdy S, 1983, STAT RES; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; FOUSER LA, 1986, CELL, V45, P81, DOI 10.1016/0092-8674(86)90540-4; GRABOWSKI PJ, 1984, CELL, V37, P415, DOI 10.1016/0092-8674(84)90372-6; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; Guthrie C., 1991, METHODS ENZYMOLOGY G, V194; HAMM J, 1987, EMBO J, V6, P3479, DOI 10.1002/j.1460-2075.1987.tb02672.x; HARLOW E, 1988, ANTIBODIES LABORATOR; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P4135, DOI 10.1073/pnas.71.10.4135; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KIM SH, 1992, EMBO J, V11, P2319, DOI 10.1002/j.1460-2075.1992.tb05291.x; KONARSKA MM, 1987, CELL, V49, P763, DOI 10.1016/0092-8674(87)90614-3; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; KONARSKA MM, 1985, NATURE, V313, P552, DOI 10.1038/313552a0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURODA MI, 1991, CELL, V66, P935, DOI 10.1016/0092-8674(91)90439-6; KUTCHA RD, 1988, BIOCHEMISTRY-US, V27, P6716; LEGRAIN P, 1988, MOL CELL BIOL, V8, P3755, DOI 10.1128/MCB.8.9.3755; LESSER CF, 1993, GENETICS, V133, P851; LIN RJ, 1985, J BIOL CHEM, V260, P4780; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; Maniatis T., 1982, MOL CLONING; MENDENHALL MD, 1988, P NATL ACAD SCI USA, V85, P4426, DOI 10.1073/pnas.85.12.4426; MOORE MJ, 1992, SCIENCE, V256, P992, DOI 10.1126/science.1589782; PADGETT RA, 1984, SCIENCE, V225, P898, DOI 10.1126/science.6206566; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; PATTERSON B, 1987, CELL, V49, P613, DOI 10.1016/0092-8674(87)90537-X; PATTERSON B, 1991, CELL, V64, P181, DOI 10.1016/0092-8674(91)90219-O; PEEBLES CL, 1986, CELL, V44, P213, DOI 10.1016/0092-8674(86)90755-5; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; ROZEN F, 1990, MOL CELL BIOL, V10, P1134, DOI 10.1128/MCB.10.3.1134; RUBY SW, 1988, SCIENCE, V242, P1028, DOI 10.1126/science.2973660; RUSKIN B, 1984, CELL, V38, P317, DOI 10.1016/0092-8674(84)90553-1; RYMOND BC, 1983, N PRESS MOL CELL BIO, V2; SACHS AB, 1990, SCIENCE, V247, P1077, DOI 10.1126/science.2408148; SAWA H, 1988, NUCLEIC ACIDS RES, V16, P3157; SCHENA M, 1991, METHOD ENZYMOL, V194, P389; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCHWER B, 1992, MOL CELL BIOL, V12, P3540, DOI 10.1128/MCB.12.8.3540; SCHWER B, 1992, EMBO J, V11, P5033, DOI 10.1002/j.1460-2075.1992.tb05610.x; SCHWER B, 1991, NATURE, V349, P494, DOI 10.1038/349494a0; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SILICIANO PG, 1987, SCIENCE, V237, P1484, DOI 10.1126/science.3306922; STRATHERN JN, 1991, METHOD ENZYMOL, V194, P319; STRAUSS EJ, 1991, GENE DEV, V5, P629, DOI 10.1101/gad.5.4.629; Taylor J.R, 1982, INTRO ERROR ANAL STU; THOMPSON RC, 1988, TRENDS BIOCHEM SCI, V13, P91, DOI 10.1016/0968-0004(88)90047-3; TSCHUMPER G, 1980, GENE, V10, P157, DOI 10.1016/0378-1119(80)90133-X; VANDERVEEN R, 1986, CELL, V44, P225, DOI 10.1016/0092-8674(86)90756-7; VIJAYRAGHAVAN U, 1989, GENE DEV, V3, P1206, DOI 10.1101/gad.3.8.1206; VIJAYRAGHAVAN U, 1990, MOL CELL BIOL, V10, P324, DOI 10.1128/MCB.10.1.324; VIJAYRAGHAVAN U, 1986, EMBO J, V5, P1683, DOI 10.1002/j.1460-2075.1986.tb04412.x; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; YARUS M, 1992, TRENDS BIOCHEM SCI, V17, P130, DOI 10.1016/0968-0004(92)90320-9; YOUDERIAN P, 1983, CELL, V35, P777, DOI 10.1016/0092-8674(83)90110-1; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	71	148	152	0	4	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 2	1993	73	7					1377	1391		10.1016/0092-8674(93)90363-U	http://dx.doi.org/10.1016/0092-8674(93)90363-U			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LL209	8324826	Bronze			2022-12-01	WOS:A1993LL20900012
J	OLIVECRONA, H; ERICSSON, S; BERGLUND, L; ANGELIN, B				OLIVECRONA, H; ERICSSON, S; BERGLUND, L; ANGELIN, B			INCREASED CONCENTRATIONS OF SERUM LIPOPROTEIN(A) IN RESPONSE TO GROWTH-HORMONE TREATMENT	BRITISH MEDICAL JOURNAL			English	Article									KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT MED,METAB UNIT,S-14186 HUDDINGE,SWEDEN; KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT SURG,S-14186 HUDDINGE,SWEDEN; KAROLINSKA INST,HUDDINGE UNIV HOSP,DEPT CLIN CHEM,S-14186 HUDDINGE,SWEDEN	Karolinska Institutet; Karolinska Institutet; Karolinska Institutet				Berglund, Lars/0000-0001-6705-1791				HENRIKSSON P, 1992, J CLIN INVEST, V89, P1166, DOI 10.1172/JCI115699; ROSEN T, 1990, LANCET, V336, P285, DOI 10.1016/0140-6736(90)91812-O; RUDLING M, 1992, P NATL ACAD SCI USA, V89, P6983, DOI 10.1073/pnas.89.15.6983; SALOMON F, 1989, NEW ENGL J MED, V321, P1797, DOI 10.1056/NEJM198912283212605; SCANU AM, 1992, JAMA-J AM MED ASSOC, V267, P3326, DOI 10.1001/jama.267.24.3326	5	69	69	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1993	306	6894					1726	1727		10.1136/bmj.306.6894.1726-a	http://dx.doi.org/10.1136/bmj.306.6894.1726-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK367	8343630	Bronze, Green Published			2022-12-01	WOS:A1993LK36700021
J	DOLPH, PJ; RANGANATHAN, R; COLLEY, NJ; HARDY, RW; SOCOLICH, M; ZUKER, CS				DOLPH, PJ; RANGANATHAN, R; COLLEY, NJ; HARDY, RW; SOCOLICH, M; ZUKER, CS			ARRESTIN FUNCTION IN INACTIVATION OF G-PROTEIN COUPLED RECEPTOR RHODOPSIN INVIVO	SCIENCE			English	Article							LIGHT-DEPENDENT PHOSPHORYLATION; A-BINDING-PROTEIN; VISUAL-SYSTEM; DROSOPHILA PHOTORECEPTOR; GENE ENCODES; S-ANTIGEN; HOMOLOG; UVEITIS; PHOTOTRANSDUCTION; TRANSDUCTION	Arrestins have been implicated in the regulation of many G protein-coupled receptor signaling cascades. Mutations in two Drosophila photoreceptor-specific arrestin genes, arrestin 1 and arrestin 2, were generated. Analysis of the light response in these mutants shows that the Arr1 and Arr2 proteins are mediators of rhodopsin inactivation and are essential for the termination of the phototransduction cascade in vivo. The saturation of arrestin function by an excess of activated rhodopsin is responsible for a continuously activated state of the photoreceptors known as the prolonged depolarized afterpotential. In the absence of arrestins, photoreceptors undergo light-dependent retinal degeneration as a result of the continued activity of the phototransduction cascade. These results demonstrate the fundamental requirement for members of the arrestin protein family in the regulation of G protein-coupled receptors and signaling cascades in vivo.	UNIV CALIF SAN DIEGO,HOWARD HUGHES MED INST,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT NEUROSCI,LA JOLLA,CA 92093	Howard Hughes Medical Institute; University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego				Socolich, Michael/0000-0002-0702-1061	NATIONAL EYE INSTITUTE [R01EY008768] Funding Source: NIH RePORTER; NEI NIH HHS [R01 EY008768] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ATTRAMADA H, 1982, J BIOL CHEM, V267, P17882; BAYLOR DA, 1974, J PHYSIOL-LONDON, V242, P729, DOI 10.1113/jphysiol.1974.sp010732; BLOOMQUIST BT, 1988, CELL, V54, P723, DOI 10.1016/S0092-8674(88)80017-5; Bockaert J, 1991, Curr Opin Neurobiol, V1, P32, DOI 10.1016/0959-4388(91)90008-U; COLLEY N, UNPUB; COLLEY NJ, 1991, CELL, V67, P255, DOI 10.1016/0092-8674(91)90177-Z; COLLINS S, 1990, BIOCHEM SOC T, V18, P541, DOI 10.1042/bst0180541; DOHLMAN HG, 1991, ANNU REV BIOCHEM, V60, P653, DOI 10.1146/annurev.biochem.60.1.653; DOLPH PJ, UNPUB; FAIN GL, 1990, TRENDS NEUROSCI, V13, P378, DOI 10.1016/0166-2236(90)90023-4; FEILER R, 1992, J NEUROSCI, V12, P3862; FUORTES MGF, 1964, J PHYSIOL-LONDON, V172, P239, DOI 10.1113/jphysiol.1964.sp007415; Grigliati T., 1986, DROSOPHILA PRACTICAL, P39; GUREVICH VV, 1992, J BIOL CHEM, V267, P21919; HYDE DR, 1990, P NATL ACAD SCI USA, V87, P1008, DOI 10.1073/pnas.87.3.1008; KALSOW CM, 1977, INVEST OPHTH VIS SCI, V16, P181; KUHN H, 1972, FEBS LETT, V20, P1, DOI 10.1016/0014-5793(72)80002-4; KUHN H, 1987, J RECEPTOR RES, V7, P298; KUHN H, 1984, PROGR RETINAL RES, V3, P124; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE YJ, 1990, NEURON, V5, P889, DOI 10.1016/0896-6273(90)90349-K; LEVINE H, 1991, MECH DEVELOP, V33, P19; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; LOHSE MJ, 1990, SCIENCE, V248, P1547, DOI 10.1126/science.2163110; MATSUMOTO H, 1991, BIOCHEM BIOPH RES CO, V177, P1306, DOI 10.1016/0006-291X(91)90683-X; MATSUMOTO H, 1987, P NATL ACAD SCI USA, V84, P985, DOI 10.1073/pnas.84.4.985; MINKE B, 1986, MOL MECHANISM PHOTOR, P241; MINKE B, 1992, PROGR RETINAL RES, V11, P99; MIRSHAHI M, 1991, THROMB RES, V64, P551, DOI 10.1016/S0049-3848(05)80004-0; MONTELL C, 1988, CELL, V52, P757, DOI 10.1016/0092-8674(88)90413-8; NUSSENBLATT RB, 1981, ARCH OPHTHALMOL-CHIC, V99, P1090, DOI 10.1001/archopht.1981.03930011090021; NUSSENBLATT RB, 1980, AM J OPHTHALMOL, V89, P173, DOI 10.1016/0002-9394(80)90108-7; ONDEK B, 1992, J BIOL CHEM, V267, P16460; OTOUSA JE, 1985, CELL, V40, P839, DOI 10.1016/0092-8674(85)90343-5; Pak W.L., 1979, P67; PALCZEWSKI K, 1989, J BIOL CHEM, V264, P15770; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P15334; PALCZEWSKI K, 1992, NEURON, V8, P117, DOI 10.1016/0896-6273(92)90113-R; PALCZEWSKI K, 1991, TRENDS BIOCHEM SCI, V16, P387, DOI 10.1016/0968-0004(91)90157-Q; PITCHER J, 1992, BIOCHEMISTRY-US, V31, P3193, DOI 10.1021/bi00127a021; RANGANATHAN R, 1991, TRENDS NEUROSCI, V14, P486, DOI 10.1016/0166-2236(91)90060-8; RANGANATHAN RS, UNPUB; RAPOPORT B, 1992, MOL CELL ENDOCRINOL, V84, pR39, DOI 10.1016/0303-7207(92)90038-8; RICHARD EA, 1992, NATURE, V356, P336, DOI 10.1038/356336a0; ROTH NS, 1991, ADV EXP MED BIOL, V308, P223; SCHEURING U, 1990, FEBS LETT, V276, P192, DOI 10.1016/0014-5793(90)80540-Y; SCHNEUWLY S, 1989, P NATL ACAD SCI USA, V86, P5390, DOI 10.1073/pnas.86.14.5390; SHIEH BH, 1989, NATURE, V338, P67, DOI 10.1038/338067a0; SMITH DP, 1990, P NATL ACAD SCI USA, V87, P1003, DOI 10.1073/pnas.87.3.1003; SMITH DP, 1991, SCIENCE, V254, P1478, DOI 10.1126/science.1962207; SMITH DP, 1991, ANNU REV CELL BIOL, V7, P161; STEPHENSON RS, 1983, BIOL PHOTORECEPTION, P477; STRYER L, 1991, J BIOL CHEM, V266, P10711; VANVACTOR D, 1988, CELL, V52, P281, DOI 10.1016/0092-8674(88)90517-X; WACKER WB, 1977, J IMMUNOL, V119, P1949; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YAMADA T, 1990, SCIENCE, V248, P483, DOI 10.1126/science.2158671; Zuker Charles S., 1992, Current Opinion in Neurobiology, V2, P622, DOI 10.1016/0959-4388(92)90029-K; ZUKER CS, 1985, CELL, V40, P851, DOI 10.1016/0092-8674(85)90344-7	59	268	271	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 25	1993	260	5116					1910	1916		10.1126/science.8316831	http://dx.doi.org/10.1126/science.8316831			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ349	8316831				2022-12-01	WOS:A1993LJ34900033
J	CHERIAN, T; STEINHOFF, MC; HARRISON, LH; ROHN, D; MCDOUGAL, LK; DICK, J				CHERIAN, T; STEINHOFF, MC; HARRISON, LH; ROHN, D; MCDOUGAL, LK; DICK, J			A CLUSTER OF INVASIVE PNEUMOCOCCAL DISEASE IN YOUNG-CHILDREN IN CHILD-CARE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							RESISTANT STREPTOCOCCUS-PNEUMONIAE	Objective.-To investigate a cluster of invasive pneumococcal disease in children 8 to 26 months of age, using standard microbiological procedures and ribosomal DNA gene-restriction patterns to characterize the outbreak strain. Design.-Outbreak investigation. Setting.-A family child-care home with six children in Baltimore, Md. Results.-During an 8-day period, three of the six children in the family child-care home had febrile illnesses with pneumococcal bacteremia, and a fourth had purulent pneumococcal conjunctivitis. Type 12F Streptococcus pneumoniae was isolated from the four ill children and from the nasopharynges of the two healthy children. Ribotyping revealed all outbreak isolates had an identical ribotype pattern. Administration of rifampin to the children did not eradicate carriage of the organism. Conclusions.-Our data demonstrate that child care provides an opportunity for outbreak of invasive pneumococcal disease in young child ren. This observation suggests a need for increased alertness for clusters of pneumococcal disease in young children in child-care facilities and underscores the necessity for a pneumococcal vaccine that is effective in infants and young children.	JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,DEPT INT HLTH,CTR IMMUNIZAT RES,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH PUBL HLTH,DEPT EPIDEMIOL,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT PEDIAT,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205; JOHNS HOPKINS UNIV,SCH MED,DEPT LAB MED,BALTIMORE,MD 21205; MARYLAND DEPT HLTH & MENTAL HYG,BALTIMORE,MD; NATL CTR INFECT DIS,HOSP INFECT PROGRAM,NOSOCOMIAL PATHOGENS LAB BRANCH,ATLANTA,GA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Maryland Department of Health & Mental Hygiene; Centers for Disease Control & Prevention - USA								AUSTRIAN R, 1981, REV INFECT DIS, V3, pS1; DEMARIA A, 1980, JAMA-J AM MED ASSOC, V244, P1446, DOI 10.1001/jama.244.13.1446; DOYLE MG, 1992, PEDIATR INFECT DIS J, V11, P831, DOI 10.1097/00006454-199210000-00005; HARRISON LH, 1991, ARCH INTERN MED, V151, P1005, DOI 10.1001/archinte.151.5.1005; HODGES RG, 1946, AM J HYG, V44, P183, DOI 10.1093/oxfordjournals.aje.a119088; Holle HA, 1940, NEW ENGL J MED, V223, P887, DOI 10.1056/NEJM194011282232203; KLEIN JO, 1981, REV INFECT DIS, V3, P246; KOORNHOF HJ, 1979, MICROBIOLOGY 1979, P286; LODA FA, 1975, J PEDIATR-US, V87, P1087, DOI 10.1016/S0022-3476(75)80120-X; MCDOUGAL LK, 1992, ANTIMICROB AGENTS CH, V36, P2176, DOI 10.1128/AAC.36.10.2176; MERCAT A, 1991, CHEST, V99, P147, DOI 10.1378/chest.99.1.147; OSTERHOLM MT, 1990, SEMIN PEDIATR INFECT, V1, P222; RAUCH AM, 1990, AM J DIS CHILD, V144, P923, DOI 10.1001/archpedi.1990.02150320087033; REICHLER M, 1991, 31ST INT C ANT AG CH; REICHLER MR, 1992, J INFECT DIS, V166, P1346, DOI 10.1093/infdis/166.6.1346; RIEDO F, 1991, 31ST INT C ANT AG CH; Smillie WG, 1938, AM J PUBLIC HEALTH N, V28, P293, DOI 10.2105/AJPH.28.3.293; STEINHOFF MC, IN PRESS PEDIATR INF; Strom A, 1932, J INFECT DIS, V50, P430, DOI 10.1093/infdis/50.5-6.430; 1990, M7A2 NAT COMM CLIN L; 1991, REPORT COMMITTEE INF, P373; 1989, MMWR MORB MORTAL WKL, V38, P733	22	83	84	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	MAR 2	1994	271	9					695	697		10.1001/jama.271.9.695	http://dx.doi.org/10.1001/jama.271.9.695			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX570	8309033				2022-12-01	WOS:A1994MX57000031
J	WASSENEGGER, M; HEIMES, S; RIEDEL, L; SANGER, HL				WASSENEGGER, M; HEIMES, S; RIEDEL, L; SANGER, HL			RNA-DIRECTED DE-NOVO METHYLATION OF GENOMIC SEQUENCES IN PLANTS	CELL			English	Article							TUBER VIROID PSTV; TOMATO LEAF TISSUE; DNA METHYLATION; GENE-EXPRESSION; CO-SUPPRESSION; HOMOLOGOUS GENES; TOBACCO PLANTS; INACTIVATION; RECOGNITION; PETUNIA	One monomeric and three oligomeric potato spindle tuber viroid (PSTVd) cDNA units were introduced into the tobacco genome via the Agrobacterium-mediated leaf-disc transformation. Southern analysis of the integrates revealed that only their PSTVd-specific sequences become fully methylated, whereas the flanking T-DNA and the genomic plant DNA remain unaltered. Viroid cDNA methylation could only be observed after autonomous viroid RNA-RNA replication had taken place in these plants. These findings demonstrate that a mechanism of de novo methylation of genes might exist that can be induced and targeted in a sequence-specific manner by their own mRNA.			WASSENEGGER, M (corresponding author), MAX PLANCK INST BIOCHEM,VIROIDFORSCH ABT,D-82152 MARTINSRIED,GERMANY.		Wassenegger, Michael/AAF-6507-2020	Wassenegger, Michael/0000-0002-7926-2454				AMASINO RM, 1986, ANAL BIOCHEM, V152, P304, DOI 10.1016/0003-2697(86)90413-6; BEDBROOK J, 1981, PLANT MOL BIOL NEWSL, V2, P24; BOLDEN A, 1984, J BIOL CHEM, V259, P2437; CEDAR H, 1990, BIOCHIM BIOPHYS ACTA, V1049, P1, DOI 10.1016/0167-4781(90)90076-E; DOERFLER W, 1983, ANNU REV BIOCHEM, V52, P93, DOI 10.1146/annurev.bi.52.070183.000521; ESCUDE C, 1992, CR ACAD SCI III-VIE, V315, P521; GRIERSON D, 1991, TRENDS BIOTECHNOL, V9, P122, DOI 10.1016/0167-7799(91)90042-G; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; HAAS B, 1988, EMBO J, V7, P4063, DOI 10.1002/j.1460-2075.1988.tb03300.x; HARDERS J, 1989, EMBO J, V8, P3941, DOI 10.1002/j.1460-2075.1989.tb08577.x; HOBBS SLA, 1993, PLANT MOL BIOL, V21, P17, DOI 10.1007/BF00039614; HORSCH RB, 1985, SCIENCE, V227, P1229, DOI 10.1126/science.227.4691.1229; JORGENSEN R, 1990, TRENDS BIOTECHNOL, V8, P340, DOI 10.1016/0167-7799(90)90220-R; JORGENSEN R, 1991, TRENDS BIOTECHNOL, V9, P266, DOI 10.1016/0167-7799(91)90087-X; Jorgensen R, 1992, AGBIOTECH NEWS INFOR, V4, P265; KAFRI T, 1992, GENE DEV, V6, P705, DOI 10.1101/gad.6.5.705; KONOZ C, 1986, MOL GEN GENET, V204, P383; KOOTER JM, 1993, BIOTECHNOLOGY, V4, P166; LINN F, 1990, MOL GEN GENET, V222, P329, DOI 10.1007/BF00633837; LOGEMANN J, 1987, ANAL BIOCHEM, V163, P16, DOI 10.1016/0003-2697(87)90086-8; MATZKE MA, 1991, PLANT MOL BIOL, V16, P821, DOI 10.1007/BF00015074; MATZKE MA, 1989, EMBO J, V8, P643, DOI 10.1002/j.1460-2075.1989.tb03421.x; MOL J, 1991, TRENDS BIOTECHNOL, V9, P182, DOI 10.1016/0167-7799(91)90060-U; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; NAPOLI C, 1990, PLANT CELL, V2, P279, DOI 10.1105/tpc.2.4.279; PALOMARES R, 1991, J PHOTOCH PHOTOBIO B, V11, P151, DOI 10.1016/1011-1344(91)80257-I; PFITZNER UM, 1987, NUCLEIC ACIDS RES, V15, P4449; RAZIN A, 1991, MICROBIOL REV, V55, P451, DOI 10.1128/MMBR.55.3.451-458.1991; Sambrook J., 1989, MOL CLONING LAB MANU; SCHEID OM, 1991, MOL GEN GENET, V228, P104, DOI 10.1007/BF00282454; SCHMIDTPUCHTA W, 1989, MOL GEN GENET, V219, P17, DOI 10.1007/BF00261152; SCHNOLZER M, 1985, EMBO J, V4, P2181, DOI 10.1002/j.1460-2075.1985.tb03913.x; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; SMITH SS, 1991, J MOL BIOL, V217, P39, DOI 10.1016/0022-2836(91)90609-A; SMITH SS, 1992, BIOCHEMISTRY-US, V31, P850, DOI 10.1021/bi00118a030; SPLESMACHER E, 1985, BIOSCIENCE REP, V5, P251; TABLER M, 1985, EMBO J, V4, P2191, DOI 10.1002/j.1460-2075.1985.tb03914.x; TABLER M, 1984, EMBO J, V3, P3055, DOI 10.1002/j.1460-2075.1984.tb02257.x; VANDERKROL AR, 1990, PLANT CELL, V2, P291, DOI 10.1105/tpc.2.4.291; [No title captured]	40	663	736	0	99	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 11	1994	76	3					567	576		10.1016/0092-8674(94)90119-8	http://dx.doi.org/10.1016/0092-8674(94)90119-8			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	8313476				2022-12-01	WOS:A1994MX20700016
J	MIYATA, T; YAMADA, N; IIDA, Y; NISHIMURA, J; TAKEDA, J; KITANI, T; KINOSHITA, T				MIYATA, T; YAMADA, N; IIDA, Y; NISHIMURA, J; TAKEDA, J; KITANI, T; KINOSHITA, T			ABNORMALITIES OF PIG-A TRANSCRIPTS IN GRANULOCYTES FROM PATIENTS WITH PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ANCHORED PROTEINS; CELLS; BIOSYNTHESIS; EXPRESSION; DEFICIENT	Background. Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired disorder in which there is a deficiency in the synthesis by hematopoietic cells of the glycosyl-phosphatidylinositol molecules that anchor proteins to the cell membrane. Recently, we demonstrated that a gene termed PIG-A (for phosphatidylinositol glycan class A), a component of glycosyl-phosphatidylinositol biosynthesis, was responsible for PNH in two patients. The present study was undertaken to elucidate whether PIG-A is the gene responsible for all cases of PNH and to characterize further the somatically acquired abnormalities of this gene. Methods. We studied granulocytes from 15 patients with PNH. The cell content of CD55 and CD59 was assessed by fluorescence-activated flow cytometry. PIG-A transcripts were reverse-transcribed, amplified by the polymerase chain reaction, and cloned into plasmids. The structure of the cloned complementary DNA was analyzed by nucleotide sequencing, and its function was assessed on the basis of its ability to restore to normal the abnormal phenotype of a PIG-A-deficient cell line after transfection. Results. Three patients had size abnormalities of PIG-A transcripts with different patterns, and in one patient a very low level of the PIG-A transcript was found. Eleven patients had transcripts of normal size, but the transfection assay revealed that in each patient some of them were nonfunctional. The percentage of nonfunctional PIG-A transcripts was correlated with the percentage of affected granulocytes (P<0.001). Sequence analysis demonstrated somatic mutations in two of the patients. Conclusions. PIG-A is the gene responsible for PNH in all patients studied to date.	OSAKA UNIV,MICROBIAL DIS RES INST,DEPT IMMUNOREGULAT,3-1 YAMADA OKA,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,MICROBIAL DIS RES INST,DEPT INTERNAL MED,SUITA,OSAKA 565,JAPAN; NAGOYA UNIV,SCH MED,BRANCH HOSP,DEPT INTERNAL MED,NAGOYA,AICHI 466,JAPAN	Osaka University; Osaka University; Nagoya University			Kinoshita, Taroh/C-7353-2009; Miyata, Toshio/A-4872-2010					ARMSTRONG C, 1992, J BIOL CHEM, V267, P25347; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; HILLMEN P, 1993, BLOOD, V81, P193; HJIROSE S, 1992, P NATL ACAD SCI USA, V89, P6025; HOLLANDER N, 1988, J IMMUNOL, V141, P4283; KINOSHITA T, 1985, J EXP MED, V162, P75, DOI 10.1084/jem.162.1.75; MAHONEY JF, 1992, BLOOD, V79, P1400; MARGOLSKEE RF, 1988, MOL CELL BIOL, V8, P2837, DOI 10.1128/MCB.8.7.2837; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MIYATA T, 1993, SCIENCE, V259, P1318, DOI 10.1126/science.7680492; ROSSE WF, 1989, BLOOD REV, V3, P192, DOI 10.1016/0268-960X(89)90016-7; ROSSE WF, 1991, BLOOD, V78, P547, DOI 10.1182/blood.V78.3.547.bloodjournal783547; Rotoli B, 1989, Baillieres Clin Haematol, V2, P113, DOI 10.1016/S0950-3536(89)80010-1; TAKAHASHI M, 1993, J EXP MED, V177, P517, DOI 10.1084/jem.177.2.517; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; TARTAKOFF AM, 1992, TRENDS BIOCHEM SCI, V17, P470, DOI 10.1016/0968-0004(92)90491-Q; UEDA E, 1992, INT IMMUNOL, V4, P1263, DOI 10.1093/intimm/4.11.1263	18	205	207	0	2	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 27	1994	330	4					249	255		10.1056/NEJM199401273300404	http://dx.doi.org/10.1056/NEJM199401273300404			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR496	8272086	Bronze			2022-12-01	WOS:A1994MR49600004
J	PORTER, DL; ROTH, MS; MCGARIGLE, C; FERRARA, JLM; ANTIN, JH				PORTER, DL; ROTH, MS; MCGARIGLE, C; FERRARA, JLM; ANTIN, JH			INDUCTION OF GRAFT-VERSUS-HOST DISEASE AS IMMUNOTHERAPY FOR RELAPSED CHRONIC MYELOID-LEUKEMIA	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BONE-MARROW TRANSPLANTATION; CHRONIC MYELOGENOUS LEUKEMIA; DONOR LEUKOCYTE INFUSIONS; POLYMERASE CHAIN-REACTION; CHRONIC PHASE; SELECTIVE DEPLETION; LYMPHOCYTES-T; INTERFERON; CELLS; TRANSFUSIONS	Background. The ability of allogeneic bone marrow transplantation to cure chronic myeloid leukemia (CML) is due to both the conditioning regimen and the antileukemic effects of the lymphocytes in the grafted marrow. We studied the ability of interferon alfa-2b and infusions of mononuclear cells from the marrow donor to induce a graft-versus-leukemia reaction in patients with CML in relapse after bone marrow transplantation. Methods. Eleven patients with relapsed CML after allogeneic bone marrow transplantation were treated with interferon alfa-2b and infusions of mononuclear cells. The patients were monitored for toxic effects, for hematologic and cytogenetic responses, and, with use of the polymerase chain reaction, for elimination of cells containing the bcr/abl messenger RNA transcript characteristic of the leukemic cells. Results. Six of the eight patients with stable CML after relapse had complete remissions according to molecular genetic criteria, since no cells with bcr/abl messenger RNA transcripts were detected (the method can identify 1 leukemic cell among 1 million normal cells). The three patients with accelerated CML after relapse did not enter remission. Myelosuppression was prominent in eight patients. Grade I acute graft-versus-host disease (GVHD) occurred in six patients, and grade III acute GVHD occurred in three. Limited chronic GVHD developed in five patients. Conclusions. The induction of a graft-versus-leukemia reaction with interferon alfa-2b and infusions of donor mononuclear cells in patients with CML in relapse after bone marrow transplantation is an effective antileukemic therapy that may off er an alternative to a second marrow transplantation.	BRIGHAM & WOMENS HOSP,DIV HEMATOL ONCOL,75 FRANCIS ST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV MICHIGAN,MED CTR,DIV HEMATOL ONCOL,ANN ARBOR,MI 48109	Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; University of Michigan System; University of Michigan					NATIONAL CANCER INSTITUTE [P01CA039542, R01CA058661] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007623] Funding Source: NIH RePORTER; NCI NIH HHS [CA39542, CA58661] Funding Source: Medline; NHLBI NIH HHS [T32-HL07623] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS PT, 1992, BLOOD, V80, P551; ANTIN JH, 1992, BLOOD, V80, P2964; ANTIN JH, 1991, BLOOD, V78, P2139; APPERLEY JF, 1988, BRIT J HAEMATOL, V69, P239, DOI 10.1111/j.1365-2141.1988.tb07628.x; BALKWILL FR, 1989, CYTOKINES CANCER THE, P8; BARNES DWH, 1957, BRIT J HAEMATOL, V3, P241, DOI 10.1111/j.1365-2141.1957.tb05793.x; COLLINS RH, 1992, BONE MARROW TRANSPL, V10, P391; CULLIS JO, 1992, BLOOD, V79, P1379; DROBYSKI WR, 1992, BONE MARROW TRANSPL, V10, P301; FERRARA JLM, 1992, BLOOD SA, V80, pA270; GLUCKSBERG H, 1974, TRANSPLANTATION, V18, P295, DOI 10.1097/00007890-197410000-00001; GOLDMAN JM, 1988, ANN INTERN MED, V108, P806, DOI 10.7326/0003-4819-108-6-806; HAUCH M, 1990, BLOOD, V75, P2250; HENDY GN, 1981, P NATL ACAD SCI-BIOL, V78, P7365, DOI 10.1073/pnas.78.12.7365; HERBERMAN RB, 1981, J CLIN IMMUNOL, V1, P149, DOI 10.1007/BF00922756; HIGANO CS, 1992, BLOOD, V80, P1437; HOROWITZ MM, 1990, BLOOD, V75, P555; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOLB HJ, 1990, BLOOD, V76, P2462, DOI 10.1182/blood.V76.12.2462.2462; MCGLAVE P, 1987, J CLIN ONCOL, V5, P1033, DOI 10.1200/JCO.1987.5.7.1033; MRSIC M, 1992, BONE MARROW TRANSPL, V9, P269; MYERS JD, 1987, ANN INTERN MED, V107, P809; OPALKA B, 1991, BLOOD, V78, P2188, DOI 10.1182/blood.V78.9.2188.bloodjournal7892188; ROTH MS, 1990, TRANSPLANTATION, V49, P714, DOI 10.1097/00007890-199004000-00012; ROTH MS, 1992, BLOOD, V79, P276; SHULMAN HM, 1980, AM J MED, V69, P204, DOI 10.1016/0002-9343(80)90380-0; SHULMAN HM, 1988, HEPATOLOGY, V8, P463, DOI 10.1002/hep.1840080305; SOIFFER RJ, 1992, J CLIN ONCOL, V10, P1191, DOI 10.1200/JCO.1992.10.7.1191; SPECK B, 1984, LANCET, V1, P665; STORB R, 1986, NEW ENGL J MED, V314, P729, DOI 10.1056/NEJM198603203141201; SULLIVAN KM, 1989, NEW ENGL J MED, V320, P828, DOI 10.1056/NEJM198903303201303; SULLIVAN KM, 1989, BLOOD, V73, P1720; SULLIVAN KM, 1989, BLOOD, V74, P1180; TALPAZ M, 1991, ANN INTERN MED, V114, P532, DOI 10.7326/0003-4819-114-7-532; TRUITT RL, 1990, GRAFT VS HOST DISEAS, P177; UPADHYAYA G, 1991, J CLIN INVEST, V88, P2131, DOI 10.1172/JCI115543; WAGNER JE, 1990, BLOOD, V75, P1370; WEIDEN PL, 1976, J IMMUNOL, V116, P1212	38	431	445	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 13	1994	330	2					100	106		10.1056/NEJM199401133300204	http://dx.doi.org/10.1056/NEJM199401133300204			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ670	8259165	Bronze			2022-12-01	WOS:A1994MQ67000004
J	LESSER, CF; GUTHRIE, C				LESSER, CF; GUTHRIE, C			MUTATIONS IN U6 SNRNA THAT ALTER SPLICE-SITE SPECIFICITY - IMPLICATIONS FOR THE ACTIVE-SITE	SCIENCE			English	Article							PRE-MESSENGER-RNA; BASE-PAIRING INTERACTION; SMALL NUCLEAR-RNA; U1 SNRNA; ASSEMBLY PATHWAY; YEAST; U2; SELECTION; CLEAVAGE; RIBONUCLEOPROTEIN	What determines the precise sites of cleavage in the two transesterification reactions of messenger RNA (mRNA) splicing is a major unsolved question. Mutation of the invariant G (guanosine) at position 5 of 5' splice sites in Saccharomyces cerevisiae introns activates cleavage at nearby aberrant sites. A genetic approach was used to test the hypothesis that a base-pairing interaction between the 5' splice site and the invariant ACAGAG sequence of U6 is a determinant of 5' splice site choice. Mutations in U6 or the intron (or both) that were predicted to stabilize the interaction suppressed aberrant cleavage and increased normal cleavage. In addition, a mutation in the ACAGAG sequence suppressed mutations of the 3' splice site dinucleotide. These data can fit a model for the spliceosomal active site comprised of a set of RNA-RNA interactions between the intron, U2 and U6.	UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,MED SCIENTIST TRAINING PROGRAM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NIGMS NIH HHS [GM21119] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM021119, R37GM021119] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; FOUSER LA, 1986, CELL, V45, P81, DOI 10.1016/0092-8674(86)90540-4; FRANK D, UNPUB; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1988, ANNU REV GENET, V22, P387, DOI 10.1146/annurev.ge.22.120188.002131; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; GUTHRIE CC, UNPUB; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; JACQUIER A, 1985, CELL, V43, P423, DOI 10.1016/0092-8674(85)90172-2; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; Johnson SL, 1991, THESIS U WASHINGTON; LEGRAIN P, 1988, MOL CELL BIOL, V8, P3755, DOI 10.1128/MCB.8.9.3755; LESSER C, UNPUB; LESSER CF, 1993, GENETICS, V133, P851; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; Moore M., 1993, RNA WORLD, P303; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NEWMAN AJ, 1985, CELL, V42, P335, DOI 10.1016/S0092-8674(85)80129-X; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; PARKER R, 1985, CELL, V41, P107, DOI 10.1016/0092-8674(85)90065-0; PARKER R, 1993, NATURE, V361, P660, DOI 10.1038/361660a0; PARKER R, 1987, CELL, V49, P220; RYMOND BC, 1992, MOL CELLULAR BIOL YE, P143; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SERAPHIN B, 1989, CELL, V59, P349, DOI 10.1016/0092-8674(89)90296-1; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; SIKORSKI RS, 1989, GENETICS, V122, P19; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; VIJAYRAGHAVAN U, 1986, EMBO J, V5, P1683, DOI 10.1002/j.1460-2075.1986.tb04412.x; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WOLFF T, 1993, GENE DEV, V7, P1377, DOI 10.1101/gad.7.7b.1377; WOOLFORD JL, 1989, YEAST, V5, P439, DOI 10.1002/yea.320050604; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; YU YT, IN PRESS CELL; ZHUANG Y, 1986, CELL, V46, P827, DOI 10.1016/0092-8674(86)90064-4; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	45	265	267	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					1982	1988		10.1126/science.8266093	http://dx.doi.org/10.1126/science.8266093			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266093				2022-12-01	WOS:A1993MN10800026
J	MARKBY, DW; ONRUST, R; BOURNE, HR				MARKBY, DW; ONRUST, R; BOURNE, HR			SEPARATE GTP-BINDING AND GTPASE-ACTIVATING DOMAINS OF A G-ALPHA-SUBUNIT	SCIENCE			English	Article							ADENYLATE-CYCLASE; ESCHERICHIA-COLI; G-PROTEIN; MOLECULAR-CLONING; TERMINAL DOMAIN; CHOLERA-TOXIN; RAS PROTEINS; WILD-TYPE; EF-TU; SITE	Most members of the guanosine triphosphatase (GTPase) superfamily hydrolyze guanosine triphosphate (GTP) quite slowly unless stimulated by a GTPase activating protein or GAP. The alpha subunits (Galpha) of the heterotrimeric G proteins hydrolyze GTP much more rapidly and contain an approximately 120-residue insert not found in other GTPases. Interactions between a Galpha insert domain and a Galpha GTP-binding core domain, both expressed as recombinant proteins, show that the insert acts biochemically as a GAP. The results suggest a general mechanism for GAP-dependent hydrolysis of GTP by other GTPases.	UNIV CALIF SAN FRANCISCO, DEPT PHARMACOL, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, DEPT MED, CELL BIOL PROGRAM, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NATIONAL CANCER INSTITUTE [R01CA054427] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM013918, R01GM027800, R37GM027800] Funding Source: NIH RePORTER; NCI NIH HHS [CA54427] Funding Source: Medline; NIGMS NIH HHS [GM27800, 5F32-GM13918] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; BENJAMIN D, UNPUB; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BOURNE HR, 1975, SCIENCE, V187, P750, DOI 10.1126/science.163487; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRODSKY MH, 1990, J IMMUNOL, V144, P3078; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; CASSEL D, 1977, P NATL ACAD SCI USA, V74, P3307, DOI 10.1073/pnas.74.8.3307; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; CREIGHTON TE, 1993, PROTEIN STRUCTURES M, P307; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; ECCLESTON JF, 1985, J BIOL CHEM, V260, P6237; ELWELL ML, 1977, BIOCHIM BIOPHYS ACTA, V494, P367, DOI 10.1016/0005-2795(77)90166-0; FERGUSON KM, 1986, J BIOL CHEM, V261, P7393; FEUERSTEIN J, 1989, J BIOL CHEM, V264, P6188; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GILBERT W, 1978, NATURE, V271, P501, DOI 10.1038/271501a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; GREEN N, 1982, CELL, V28, P477, DOI 10.1016/0092-8674(82)90202-1; HARRIS BA, 1985, SCIENCE, V229, P1274, DOI 10.1126/science.3839937; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P757; ITOH H, 1991, J BIOL CHEM, V266, P16226; ITOH H, 1988, J BIOL CHEM, V263, P6656; JONES DT, 1987, J BIOL CHEM, V262, P14241; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KJELDGAARD M, 1992, J MOL BIOL, V223, P721, DOI 10.1016/0022-2836(92)90986-T; KOZASA T, 1988, P NATL ACAD SCI USA, V85, P2081, DOI 10.1073/pnas.85.7.2081; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LEVIS MJ, 1992, J CELL BIOL, V119, P1297, DOI 10.1083/jcb.119.5.1297; LYONS J, 1990, SCIENCE, V249, P655, DOI 10.1126/science.2116665; MARKBY DW, UNPUB; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MASTERS SB, 1988, SCIENCE, V241, P448, DOI 10.1126/science.2899356; MASTERS SB, 1989, J BIOL CHEM, V264, P15467; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NEAL SE, 1990, P NATL ACAD SCI USA, V87, P3562, DOI 10.1073/pnas.87.9.3562; NORTHUP JK, 1982, J BIOL CHEM, V257, P1416; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; PRIVE GG, 1992, P NATL ACAD SCI USA, V89, P3649, DOI 10.1073/pnas.89.8.3649; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; ROBISHAW JD, 1986, J BIOL CHEM, V261, P9587; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; SKINNER RH, 1991, J BIOL CHEM, V266, P14163; STROM M, 1993, NATURE, V361, P736, DOI 10.1038/361736a0; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Summers MD, 1987, TEXAS AGR EXPT STATI; VANDOP C, 1984, J BIOL CHEM, V259, P696; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; YOSHIHISA T, 1993, SCIENCE, V259, P1466, DOI 10.1126/science.8451644	61	150	159	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1993	262	5141					1895	1901		10.1126/science.8266082	http://dx.doi.org/10.1126/science.8266082			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266082				2022-12-01	WOS:A1993MM51100043
J	CHARYCH, DH; NAGY, JO; SPEVAK, W; BEDNARSKI, MD				CHARYCH, DH; NAGY, JO; SPEVAK, W; BEDNARSKI, MD			DIRECT COLORIMETRIC DETECTION OF A RECEPTOR-LIGAND INTERACTION BY A POLYMERIZED BILAYER ASSEMBLY	SCIENCE			English	Article							LANGMUIR-BLODGETT-FILMS; GAS-WATER INTERFACE; POLYDIACETYLENE FILMS; COLOR TRANSITIONS; PHASE-TRANSITIONS; ACID MONOLAYERS; GLUCOSE SENSOR; DIACETYLENE	Detection of receptor-ligand interactions is generally accomplished by indirect assays such as enzyme-linked immunosorbent assay. A direct colorimetric detection method based on a polydiacetylene bilayer assembled on glass microscope slides has been developed. The bilayer is composed of a self-assembled monolayer of octadecylsilane and a Langmuir-Blodgett monolayer of polydiacetylene. The polydiacetylene layer is functionalized with an analog of sialic acid, the receptor-specific ligand for the influenza virus hemagglutinin. The sialic acid ligand serves as a molecular recognition element and the conjugated polymer backbone signals binding at the surface by a chromatic transition. The color transition is readily visible to the naked eye as a blue to red color change and can be quantified by visible absorption spectroscopy. Direct colorimetric detection by polydiacetylene films offers new possibilities for diagnostic applications and screening for new drug candidates or binding ligands.	UNIV CALIF BERKELEY,DEPT CHEM,BERKELEY,CA 94720	University of California System; University of California Berkeley	CHARYCH, DH (corresponding author), LAWRENCE BERKELEY LAB,CTR ADV MAT,BERKELEY,CA 94720, USA.							AIR GM, 1989, PROTEINS, V6, P341, DOI 10.1002/prot.340060402; ANZAI JI, 1990, SELECT ELECTR REV, V12, P3; ARISAWA S, 1992, THIN SOLID FILMS, V210, P443; BESWICK RB, 1988, J COLLOID INTERF SCI, V124, P146, DOI 10.1016/0021-9797(88)90335-9; BILEWICZ R, 1991, LANGMUIR, V7, P2794, DOI 10.1021/la00059a063; CHANCE RR, 1979, J CHEM PHYS, V71, P206, DOI 10.1063/1.438117; DAY D, 1980, MACROMOLECULES, V13, P1478, DOI 10.1021/ma60078a023; DAY D, 1978, J POLYM SCI POL LETT, V16, P205, DOI 10.1002/pol.1978.130160501; DEPALMA V, 1989, LANGMUIR, V5, P868, DOI 10.1021/la00087a049; FISCHETTI RF, 1988, PHYS REV B, V37, P4714, DOI 10.1103/PhysRevB.37.4714; FODOR SPA, 1991, SCIENCE, V251, P767, DOI 10.1126/science.1990438; FURUKI M, 1992, THIN SOLID FILMS, V210, P471, DOI 10.1016/0040-6090(92)90315-3; Gaines Jr. G. L., 1966, INSOLUBLE MONOLAYERS; KANEKO F, 1992, THIN SOLID FILMS, V210, P548, DOI 10.1016/0040-6090(92)90338-C; KEPLEY LJ, 1992, ANAL CHEM, V64, P3191, DOI 10.1021/ac00048a018; LIESER G, 1980, THIN SOLID FILMS, V68, P77, DOI 10.1016/0040-6090(80)90138-8; MAOZ R, 1984, J COLLOID INTERF SCI, V100, P465, DOI 10.1016/0021-9797(84)90452-1; MINO N, 1992, LANGMUIR, V8, P594, DOI 10.1021/la00038a047; MINO N, 1991, LANGMUIR, V7, P2336, DOI 10.1021/la00058a060; MIYASAKA T, 1990, CHEM LETT, P627, DOI 10.1246/cl.1990.627; NOVOTNY V, 1989, LANGMUIR, V5, P485, DOI 10.1021/la00086a034; OKAHATA Y, 1989, THIN SOLID FILMS, V180, P65, DOI 10.1016/0040-6090(89)90055-2; ROBERTS GG, 1990, LANGMUIRBLODGETT FIL; SHIBATA M, 1989, THIN SOLID FILMS, V179, P433, DOI 10.1016/0040-6090(89)90217-4; SPEVAK W, 1993, J AM CHEM SOC, V115, P1146, DOI 10.1021/ja00056a047; SWALEN JD, 1987, LANGMUIR, V3, P932, DOI 10.1021/la00078a011; TIEKE B, 1977, COLLOID POLYM SCI, V255, P36; WENZEL M, 1989, J AM CHEM SOC, V111, P6123, DOI 10.1021/ja00198a020; WHITESIDES GM, 1990, LANGMUIR, V6, P87, DOI 10.1021/la00091a013; ZHAO S, 1992, LANGMUIR, V8, P2785, DOI 10.1021/la00047a034	30	669	717	5	212	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 30	1993	261	5121					585	588		10.1126/science.8342021	http://dx.doi.org/10.1126/science.8342021			4	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	8342021				2022-12-01	WOS:A1993LP72800031
J	TRAYNOR, MP; BEGAY, ME; GLANTZ, SA				TRAYNOR, MP; BEGAY, ME; GLANTZ, SA			NEW TOBACCO INDUSTRY STRATEGY TO PREVENT LOCAL TOBACCO CONTROL	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CALIFORNIA	We examined the tobacco industry's new strategy to defeat and then repeal tobacco control ordinances in California and the efforts of health professionals to pass and defend these ordinances. Case studies were conducted in California communities in 1991 and 1992, using published reports, public documents, attendance at public meetings, and interviews. The tobacco industry is spending millions of dollars to intervene in California communities to oppose legislation protecting nonsmokers from secondhand smoke. The tobacco industry has moved beyond organizing smokers to use professional public affairs and political campaign firms to defeat or weaken local tobacco control ordinances. The industry used front groups to conceal its involvement because public knowledge of the industry's involvement increases support for legislation controlling smoking. Some firms closely monitor developing ordinances, while others actively organize and direct local opposition. If these efforts do not weaken or defeat an ordinance, the tobacco industry initiates a referendum petition drive to suspend it to pressure local elected officials to repeal or weaken it. If this tactic fails, the industry often finances an election campaign to repeal the ordinance by popular vote. Although the tobacco industry's new strategy has hindered the passage of some local tobacco control ordinances, when health professionals and elected officials remained active and committed, the industry's efforts have failed and the ordinances have been upheld.	UNIV CALIF SAN FRANCISCO,INST HLTH POLICY STUDIES,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								ANGUS D, 1991, COMMUNICATION   0625; ANGUS D, 1991, COMMUNICATION   1025; BONTA D, 1991, MAR LONG BEACH CAL C; BONTA D, 1991, COMMUNICATION   0703; BORLAND R, 1992, JAMA-J AM MED ASSOC, V268, P749, DOI 10.1001/jama.268.6.749; CAVIGLIA L, 1991, COMMUNICATION   1028; COLE R, 1991, COMMUNICATION   0522; EDISON C, 1991, LONG BEACH BUSI 0521; FONTAINE V, 1991, AUBURN J        1115; FREEDMAN A, 1988, WALL STREET J   0411; GAMBEE P, 1991, EC IMPACTS SMOKING B; GLANTZ S, 1992, U CALIFORNIA MONOGRA; GLANTZ S, 1992, TOBACCO CONTROL, V3, P166; GRISWOLD L, 1991, VISALIA TIMES D 0921; MALMGREN K, 1992, COMMUNICATION   0401; MEGALLI M, 1991, ESSENTIAL INFORM DEC; MOORE J, 1992, METHODS; PRICE C, 1992, CALIF J          NOV; RHODES K, 1991, FAIR EQUITABLE SMOKI; ROGERS D, 1991, COMMUNICATION   0524; ROGERS DA, 1991, FAIR EQUITABLE SMOKI; SAMUELS B, 1991, JAMA-J AM MED ASSOC, V266, P2110, DOI 10.1001/jama.266.15.2110; SAMUELS BE, 1991, U CALIFORNIA MONOGRA; SIMPSON J, 1991, COMMUNICATION   1108; SIMPSON J, 1992, COMMUNICATION   0117; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V267, P2723; SKOLNICK AA, 1992, JAMA-J AM MED ASSOC, V267, P2721, DOI 10.1001/jama.267.20.2721; WOODRUFF T, IN PRESS ARCH INTERN; 1992, WISCONSIN STATE 1013; 1982, KERN COUNTY SMOKING; 1990, IND GOAL IS OBJECTIV; 1992, EPA600690006F PUBL; 1992, BUSINESS J      0413; 1978, PUBLIC ATTITUDES CIG	34	66	66	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1993	270	4					479	486		10.1001/jama.270.4.479	http://dx.doi.org/10.1001/jama.270.4.479			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LN426	8320788				2022-12-01	WOS:A1993LN42600028
J	BRUNET, AP; HUANG, ES; HUFFINE, ME; LOEB, JE; WELTMAN, RJ; HECHT, MH				BRUNET, AP; HUANG, ES; HUFFINE, ME; LOEB, JE; WELTMAN, RJ; HECHT, MH			THE ROLE OF TURNS IN THE STRUCTURE OF AN ALPHA-HELICAL PROTEIN	NATURE			English	Article							FOLDING UNFOLDING PATHWAYS; MONTE-CARLO SIMULATIONS; PEPTIDE-FRAGMENTS; ESCHERICHIA-COLI; DENOVO DESIGN; MUTAGENESIS; SEQUENCE; CYTOCHROME-B562; CONFORMATION; PENTAPEPTIDES	THE turns joining segments of secondary structure have been proposed to be key elements in dictating the folded structures of native proteins1-9. An alternative view assumes that turns play a passive role and are merely default structures that occur as a consequence of interactions between antiparallel segments of secondary structure, with chain reversal being dictated by the context surrounding the turn and not by the sequence of the turn itself10,11. The solvent-exposure of turns and their tolerance to evolutionary variance suggests that they may have little or no effect on the formation of native structures. Previous investigations have focused on various types of beta-turns that connect antiparallel beta-strands1-3,12,13, with comparatively little reported on the structural role of interhelical turns. Here we probe the structural importance of such a turn in an antiparallel 4-helix bundle by randomly substituting an interhelical tripeptide in cytochrome b-562 with many different amino-acid sequences. Thirty-one of the resulting substituted proteins were characterized and all of them were shown to fold into stable, native-like structures. These results suggest that this interhelical turn does not does not play a dominant role in determining the folded structure of this antiparallel 4-helix bundle.	PRINCETON UNIV, DEPT CHEM, PRINCETON, NJ 08544 USA; PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	Princeton University; Princeton University				Hecht, Michael/0000-0002-5538-9813				ARGOS P, 1987, J MOL BIOL, V197, P331, DOI 10.1016/0022-2836(87)90127-6; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; CHOU KC, 1992, P NATL ACAD SCI USA, V89, P7315, DOI 10.1073/pnas.89.16.7315; CHOU PY, 1974, BIOCHEMISTRY-US, V13, P222, DOI 10.1021/bi00699a002; DENTE L, 1987, METHOD ENZYMOL, V155, P111; DILL KA, 1991, REV BIOCH, V60, P795; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; EISENBEIS SJ, 1985, P NATL ACAD SCI USA, V82, P1084, DOI 10.1073/pnas.82.4.1084; FEDOROV AN, 1992, J MOL BIOL, V225, P927, DOI 10.1016/0022-2836(92)90092-X; FISHER MT, 1991, BIOCHEMISTRY-US, V30, P10012, DOI 10.1021/bi00105a028; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HAHN KW, 1990, SCIENCE, V248, P1544, DOI 10.1126/science.2360048; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; HERTZBERG O, 1990, PROTEIN-STRUCT FUNCT, V11, P223; HYNES TR, 1989, NATURE, V339, P73, DOI 10.1038/339073a0; ITAGAKI E, 1966, J BIOL CHEM, V241, P3687; KABSCH W, 1984, P NATL ACAD SCI-BIOL, V81, P1075, DOI 10.1073/pnas.81.4.1075; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEDERER F, 1981, J MOL BIOL, V148, P427, DOI 10.1016/0022-2836(81)90185-6; MATHEWS FS, 1979, J BIOL CHEM, V254, P1699; MILBURN PJ, 1988, INT J PEPT PROT RES, V31, P311; NIKKILA H, 1991, EUR J BIOCHEM, V202, P309, DOI 10.1111/j.1432-1033.1991.tb16377.x; RAMAKRISHNAN C, 1965, BIOPHYS J, V5, P909, DOI 10.1016/S0006-3495(65)86759-5; REGAN L, 1988, SCIENCE, V241, P976, DOI 10.1126/science.3043666; REIDHAAROLSON JF, 1991, METHOD ENZYMOL, V208, P564; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; ROSE GD, 1985, ADV PROTEIN CHEM, V37, P1, DOI 10.1016/S0065-3233(08)60063-7; SAMBROOK J, 1990, MOL CLONING LABORATO; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHORTLE D, 1989, BIOCHEMISTRY-US, V28, P936, DOI 10.1021/bi00429a003; SIBANDA BL, 1989, J MOL BIOL, V206, P759, DOI 10.1016/0022-2836(89)90583-4; SIKORSKI A, 1990, J MOL BIOL, V212, P819, DOI 10.1016/0022-2836(90)90238-H; SKOLNICK J, 1990, J MOL BIOL, V212, P787, DOI 10.1016/0022-2836(90)90237-G; WELLS JA, 1985, GENE, V34, P315, DOI 10.1016/0378-1119(85)90140-4; WRIGHT PE, 1988, BIOCHEMISTRY-US, V27, P7167, DOI 10.1021/bi00419a001; YOUNG HD, 1962, STATISTICAL TREATMEN, pCH2	37	104	105	0	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 22	1993	364	6435					355	358		10.1038/364355a0	http://dx.doi.org/10.1038/364355a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	8332196				2022-12-01	WOS:A1993LN57000063
J	PETERS, LL; BARKER, JE				PETERS, LL; BARKER, JE			NOVEL INHERITANCE OF THE MURINE SEVERE COMBINED ANEMIA AND THROMBOCYTOPENIA (SCAT) PHENOTYPE	CELL			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; NATURAL-KILLER-CELLS; BONE-MARROW; MOUSE; PURPURA; MICE; EXPRESSION; DISEASE; GENE; ASSOCIATION	The phenotype of the autosomal recessive mutation scat includes severe intermittent bleeding, depletion of platelets, and circulating anti-platelet antibodies. In this study, we have mapped the scat mutation to mouse chromosome 8 and shown that the immune component is a secondary consequence of the gene defect. Surprisingly, the phenotype of the scat/scat pups depends on the genotype of the mother. Maternal homozygosity prevents disease transmission; crosses between scat homozygotes produce few affected young, while the expected frequency is generated from normal (+/+) mice bearing scat/scat ovaries. The results suggest a novel method of maternal-fetal interaction that relies neither on transfer of maternal mitochondria nor on parental imprinting. We conclude that contribution from the maternal wild-type allele is required for expression of the scat phenotype in homozygotes.	JACKSON LAB, BAR HARBOR, ME 04609 USA	Jackson Laboratory				Peters, Luanne/0000-0002-0784-0534	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049761, R01HL029305] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027726] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49761, HL29305] Funding Source: Medline; NIDDK NIH HHS [DK27726] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BALLEM PJ, 1987, J CLIN INVEST, V80, P33, DOI 10.1172/JCI113060; BOSMA GC, 1983, NATURE, V301, P527, DOI 10.1038/301527a0; BRANEHOG I, 1975, BLOOD, V45, P551; BROWN B, 1984, HEMATOLOGY PRINCIPLE; CANFIELD VA, 1990, J BIOL CHEM, V265, P19878; CHRISTIANSON SW, 1993, DIABETES, V42, P44, DOI 10.2337/diabetes.42.1.44; CZITROM AA, 1985, J IMMUNOL, V134, P2276; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; EISENBERG RA, 1980, J IMMUNOL, V125, P1032; FRANKEL WN, 1989, J VIROL, V63, P1763, DOI 10.1128/JVI.63.4.1763-1774.1989; GARNIWAGNER BA, 1990, J IMMUNOL, V144, P796; HALLER JA, 1964, TRANSPLANTATION, V2, P287, DOI 10.1097/00007890-196403000-00016; HAYES MM, 1985, J CLIN PATHOL, V38, P985, DOI 10.1136/jcp.38.9.985; HOLME S, 1988, BRIT J HAEMATOL, V68, P431, DOI 10.1111/j.1365-2141.1988.tb04231.x; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; JOHNSON KR, 1991, MAMM GENOME, V1, P260, DOI 10.1007/BF00352334; JYONOUCHI H, 1981, J IMMUNOL, V127, P1232; KARPATKIN S, 1985, SEMIN HEMATOL, V22, P260; KARPATKIN S, 1972, BRIT J HAEMATOL, V23, P167, DOI 10.1111/j.1365-2141.1972.tb03470.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAI WC, 1990, J INFECT DIS, V161, P1269, DOI 10.1093/infdis/161.6.1269; LYNCH DM, 1986, BRIT J HAEMATOL, V63, P301; MCMILLAN R, 1976, IMMUNOASPECTS SPLEEN, P227; NAIDU S, 1983, ARCH NEUROL-CHICAGO, V40, P552, DOI 10.1001/archneur.1983.04050080052009; PETERS LL, 1990, BLOOD, V76, P745; Robertson GG, 1940, P SOC EXP BIOL MED, V44, P302; RODER JC, 1979, J IMMUNOL, V123, P2168; Sambrook J., 1989, MOL CLONING LAB MANU; SASAKI H, 1992, GENE DEV, V6, P1843, DOI 10.1101/gad.6.10.1843; SOUTHERN EM, 1975, J MOL BIOL, V98, P503, DOI 10.1016/S0022-2836(75)80083-0; STOYE JP, 1988, J VIROL, V62, P168, DOI 10.1128/JVI.62.1.168-175.1988; THEOFILOPOULOS AN, 1989, ADV IMMUNOL, V46, P61, DOI 10.1016/S0065-2776(08)60651-3; THEOFILOPOULOS AN, 1985, J EXP MED, V162, P1, DOI 10.1084/jem.162.1.1; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGSTAFF J, 1992, NAT GENET, V1, P291, DOI 10.1038/ng0792-291; WALLACE DC, 1992, ANNU REV BIOCHEM, V61, P1175, DOI 10.1146/annurev.bi.61.070192.005523; WHITE RA, 1992, MAMM GENOME, V3, P281, DOI 10.1007/BF00292156	37	30	31	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 16	1993	74	1					135	142		10.1016/0092-8674(93)90301-6	http://dx.doi.org/10.1016/0092-8674(93)90301-6			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8334700				2022-12-01	WOS:A1993LN62500014
J	WITHERS, GS; FAHRBACH, SE; ROBINSON, GE				WITHERS, GS; FAHRBACH, SE; ROBINSON, GE			SELECTIVE NEUROANATOMICAL PLASTICITY AND DIVISION-OF-LABOR IN THE HONEYBEE	NATURE			English	Article							MUSHROOM BODIES; APIS-MELLIFERA; SYNAPTOGENESIS; MORPHOLOGY; CORTEX; BRAIN; BEE	THE mushroom bodies in the protocerebrum are believed to be the structures of the insect brain most closely associated with higher-order sensory integration and learning1. Drosophila melanogaster mutants with olfactory learning deficit have anatomically abnormal mushroom bodies or altered patterns of gene expression in mushroom body neurons2-4. In addition, anatomical reorganization of the mushroom bodies occurs in adult flies5, and possibly in adult honeybees6,7; disturbance of electrical activity in this region disrupts memory formation in honeybees8. Little is known, however, about the relationship of naturally occurring anatomical changes in the mushroom bodies to naturally occurring behavioural plasticity. We now report that age-based division of labour in adult worker honeybees (Apis mellifera) is associated with substantial changes in certain brain regions, notably the mushroom bodies. Moreover, these striking changes in brain structure are dependent, not on the age of the bee, but on its foraging experience, thus demonstrating a robust anatomical plasticity associated with complex behaviour in an adult insect.	UNIV ILLINOIS,DEPT ENTOMOL,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign	WITHERS, GS (corresponding author), UNIV ILLINOIS,NEUROSCI PROGRAM,URBANA,IL 61801, USA.			Withers, Ginger/0000-0002-7004-7846				BLACK JE, 1990, P NATL ACAD SCI USA, V87, P5568, DOI 10.1073/pnas.87.14.5568; BRANDON JG, 1982, BRAIN RES, V252, P51, DOI 10.1016/0006-8993(82)90977-5; COSS RG, 1980, BRAIN RES, V192, P49, DOI 10.1016/0006-8993(80)91007-0; DEVOOGD TJ, 1985, BRAIN RES, V329, P304, DOI 10.1016/0006-8993(85)90539-6; ERBER J, 1980, PHYSIOL ENTOMOL, V5, P343, DOI 10.1111/j.1365-3032.1980.tb00244.x; ERBER J, 1987, ARTHROPOD BRAIN ITS, P484; GOULD JL, 1986, ANNU REV PSYCHOL, V37, P163; GUNDERSEN HJG, 1988, APMIS, V96, P379, DOI 10.1111/j.1699-0463.1988.tb05320.x; HAN PL, 1992, NEURON, V9, P619, DOI 10.1016/0896-6273(92)90026-A; HEISENBERG M, 1985, J NEUROGENET, V2, P1, DOI 10.3109/01677068509100140; HUANG ZY, 1993, P NATL ACAD SCI USA, V89, P11726; Kenyon F., 1896, J COMP NEUROL, V6, P133, DOI DOI 10.1002/CNE.910060302; LAIDLAW HH, 1977, INSTRUMENTAL INSEMIN; Menzel R., 1990, NEUROBIOLOGY COMP CO, P237; MICHEL RP, 1988, J MICROSC-OXFORD, V150, P117, DOI 10.1111/j.1365-2818.1988.tb04603.x; MOBBS PG, 1984, J INSECT PHYSIOL, V30, P43, DOI 10.1016/0022-1910(84)90107-0; MOBBS PG, 1982, PHILOS T ROY SOC B, V298, P309, DOI 10.1098/rstb.1982.0086; NIGHORN A, 1991, NEURON, V6, P455, DOI 10.1016/0896-6273(91)90253-V; Ramon y Cajal S., 1894, P ROY SOC LOND B BIO, V55, P444, DOI DOI 10.1098/RSPL.1894.0063; ROBINSON GE, 1992, ANNU REV ENTOMOL, V37, P637, DOI 10.1146/annurev.en.37.010192.003225; ROBINSON GE, 1989, SCIENCE, V246, P109, DOI 10.1126/science.246.4926.109; Tanzi E., 1893, RIV SPER FRENIAT MED, V19, P419; Technau GM, 1984, J NEUROGENET, V1, P113, DOI 10.3109/01677068409107077; TURNER AM, 1985, BRAIN RES, V329, P195, DOI 10.1016/0006-8993(85)90525-6; von Frisch K., 1967, DANCE LANGUAGE ORIEN; WINSTON ML, 1987, BIOL HONEY BEE, P89; 1985, SAS USERS GUIDE STAT	27	311	314	1	43	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 15	1993	364	6434					238	240		10.1038/364238a0	http://dx.doi.org/10.1038/364238a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM683	8321320				2022-12-01	WOS:A1993LM68300057
J	BARASH, PG				BARASH, PG			ANESTHESIOLOGY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									YALE NEW HAVEN MED CTR,NEW HAVEN,CT	Yale University	BARASH, PG (corresponding author), YALE UNIV,SCH MED,NEW HAVEN,CT 06510, USA.							ALON E, 1992, ANESTH ANALG, V75, P561; [Anonymous], 1993, ANESTHESIOLOGY, V78, P597; [Anonymous], 1992, ACUTE PAIN MANAGEMEN; BENNETT JA, 1992, J CLIN ANESTH, V4, P378, DOI 10.1016/0952-8180(92)90159-X; EJLERSEN E, 1992, ANESTH ANALG, V74, P495; GABA DM, 1992, ANESTHESIOLOGY, V76, P491; HALPERN NA, 1992, CRIT CARE MED, V20, P1637, DOI 10.1097/00003246-199212000-00006; HOWARD SK, 1992, AVIAT SPACE ENVIR MD, V63, P763; KATZ J, 1992, ANESTHESIOLOGY, V77, P439, DOI 10.1097/00000542-199209000-00006; MATHEW JP, 1992, ANESTHESIOLOGY, V77, P635, DOI 10.1097/00000542-199210000-00004; MCLINTIC AJ, 1992, ANESTH ANALG, V74, P51; MCQUAY HJ, 1992, BRIT J ANAESTH, V69, P1, DOI 10.1093/bja/69.1.1; ROBIN ED, 1992, CHEST, V102, P1842, DOI 10.1378/chest.102.6.1842; SCHWID HA, 1992, ANESTHESIOLOGY, V76, P495, DOI 10.1097/00000542-199204000-00002; ZAKOWSKI MI, 1993, ANESTH ANALG, V76, P162; 1993, ANESTHESIOLOGY, V78, P380	16	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					188	190		10.1001/jama.270.2.188	http://dx.doi.org/10.1001/jama.270.2.188			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315724				2022-12-01	WOS:A1993LL36800010
J	FRANKLIN, JE				FRANKLIN, JE			ADDICTION MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article											FRANKLIN, JE (corresponding author), NORTHWESTERN UNIV, SCH MED, CHICAGO, IL 60611 USA.							ARNDT IO, 1992, ARCH GEN PSYCHIAT, V49, P888; BRESLAU N, 1993, ARCH GEN PSYCHIAT, V50, P31; BRESLAU N, 1992, AM J PSYCHIAT, V149, P464; CARMELLI D, 1992, NEW ENGL J MED, V327, P829, DOI 10.1056/NEJM199209173271201; DAUNNO T, 1992, JAMA-J AM MED ASSOC, V267, P253, DOI 10.1001/jama.267.2.253; GOODMAN AC, 1992, MED CARE, V30, P795, DOI 10.1097/00005650-199209000-00004; GRAHAM NMH, 1992, JAMA-J AM MED ASSOC, V267, P369, DOI 10.1001/jama.267.3.369; JOHNSON RE, 1992, JAMA-J AM MED ASSOC, V267, P2750, DOI 10.1001/jama.267.20.2750; KENDLER KS, 1993, ARCH GEN PSYCHIAT, V50, P36; KENDLER KS, 1992, JAMA-J AM MED ASSOC, V268, P1877, DOI 10.1001/jama.268.14.1877; KOSTEN TR, 1992, ARCH GEN PSYCHIAT, V49, P894; LITT MD, 1992, ARCH GEN PSYCHIAT, V49, P609; MANN K, 1992, ALCOHOL CLIN EXP RES, V16, P1052, DOI 10.1111/j.1530-0277.1992.tb00698.x; MCLELLAN AT, 1993, JAMA-J AM MED ASSOC, V269, P1953, DOI 10.1001/jama.269.15.1953; NARANJO CA, 1992, CLIN PHARMACOL THER, V51, P729, DOI 10.1038/clpt.1992.85; OMALLEY SS, 1992, ARCH GEN PSYCHIAT, V49, P881; REGIER DA, 1993, ARCH GEN PSYCHIAT, V50, P85; SELWYN PA, 1992, JAMA-J AM MED ASSOC, V268, P504, DOI 10.1001/jama.268.4.504; VOLPICELLI JR, 1992, ARCH GEN PSYCHIAT, V49, P876; WEISNER C, 1992, JAMA-J AM MED ASSOC, V268, P1872, DOI 10.1001/jama.268.14.1872	20	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					184	185		10.1001/jama.270.2.184	http://dx.doi.org/10.1001/jama.270.2.184			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LL368	8315722				2022-12-01	WOS:A1993LL36800008
J	CHILVERS, CED				CHILVERS, CED			BREAST-FEEDING AND RISK OF BREAST-CANCER IN YOUNG-WOMEN	BRITISH MEDICAL JOURNAL			English	Article							LACTATION	Objective-To investigate whether breast feeding is related to subsequent risk of breast cancer. Design-Population based case-control study designed primarily to investigate the relation between oral contraceptives and risk of breast cancer; data obtained from questionnaires administered by interviewers, general practitioner notes, and family planning clinic records. Setting-11 health regions in Britain. Subjects-Women diagnosed with breast cancer before age 36 living in the defined study areas. One control per case, matched for age, was selected from the list of the case's general practitioner. 755 case-control pairs were interviewed. Main outcome measures-Duration of breast feeding each liveborn infant; timing of return of menses; hormone use; other risk factors for breast cancer. Results-Risk of breast cancer fell with increasing duration of breast feeding (relative risk=0.94 per three months' breast feeding; test for trend p=0.026) and with number of babies breast fed (relative risk=0.86; test for trend, p=0.017). Breast feeding each baby for longer than three months conferred no additional benefit. Breast feeding was more strongly negatively associated with risk of breast cancer than duration of postpartum amenorrhoea (chi2 test for trend, p=0.69). Hormonal suppression of lactation was unrelated to risk of breast cancer (relative risk=0.96 per episode of suppressed lactation; test for trend, p=0.72). Conclusions-These results suggest that breast feeding protects against the development of breast cancer in young women.			CHILVERS, CED (corresponding author), UNIV NOTTINGHAM,SCH MED,DEPT PUBL HLTH MED & EPIDEMIOL,NOTTINGHAM NG7 2UH,ENGLAND.							ADAMI HO, 1990, BRIT J CANCER, V62, P122, DOI 10.1038/bjc.1990.242; Breslow NE., 1980, IARC SCI PUBLICATION, V32; GRAY RH, 1990, LANCET, V335, P25, DOI 10.1016/0140-6736(90)90147-W; KVALE G, 1987, J EPIDEMIOL COMMUN H, V42, P30; LAYDE PM, 1989, J CLIN EPIDEMIOL, V42, P963, DOI 10.1016/0895-4356(89)90161-3; LONDON SJ, 1990, AM J EPIDEMIOL, V132, P17, DOI 10.1093/oxfordjournals.aje.a115629; MCTIERNAN A, 1986, AM J EPIDEMIOL, V124, P353, DOI 10.1093/oxfordjournals.aje.a114405; SISKIND V, 1989, AM J EPIDEMIOL, V130, P229; 1990, LANCET, V335, P1507; 1989, LANCET, V1, P973	10	49	52	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1993	307	6895					17	20						4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL369	8343660	Green Published, Bronze			2022-12-01	WOS:A1993LL36900018
J	HO, RK; KIMMEL, CB				HO, RK; KIMMEL, CB			COMMITMENT OF CELL FATE IN THE EARLY ZEBRAFISH EMBRYO	SCIENCE			English	Article							LINEAGE; GASTRULATION; XENOPUS	When do single cells in the early zebrafish embryo become irreversibly committed to a specific fate? Work with lineage tracing and fate mapping has shown that the marginal cells of the blastoderm give rise to hypoblast-derived fates (mesoderm and endoderm). However, experiments described here show that these marginal blastoderm cells remain pluripotent and uncommitted throughout the late blastula and early gastrula stages. Embryonic cells become committed to a hypoblast-derived fate at mid-gastrulation. Time-lapse photographic analysis reveals that committed cells, when transplanted heterotopically and heterochronically, can migrate along atypical pathways to reposition themselves within a more correct environment.	UNIV OREGON,INST NEUROSCI,EUGENE,OR 97403	University of Oregon					NICHD NIH HHS [HD22486] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD022486] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		DAVIS RL, 1987, CELL, V56, P607; EISEN JS, 1991, SCIENCE, V252, P569, DOI 10.1126/science.1708527; GURDON JB, 1988, NATURE, V336, P772, DOI 10.1038/336772a0; HATTA K, 1991, NATURE, V350, P39; HEASMAN J, 1985, PHILOS T ROY SOC B, V312, P145, DOI 10.1098/rstb.1985.0184; HEASMAN J, 1984, CELL, V37, P185, DOI 10.1016/0092-8674(84)90314-3; HO RK, 1990, NATURE, V348, P728, DOI 10.1038/348728a0; HOLTFRETER JOHANNES, 1939, WILHELM ROUX ARCH ENTWICKLUNGSMECH ORGAN, V139, P110, DOI 10.1007/BF00576387; HOPWOOD ND, 1989, EMBO J, V8, P3409, DOI 10.1002/j.1460-2075.1989.tb08505.x; KELLER R, 1992, DEV DYNAM, V193, P199, DOI 10.1002/aja.1001930302; KIMMEL CB, 1990, DEVELOPMENT, V108, P581; KIMMEL CB, 1986, SCIENCE, V231, P365, DOI 10.1126/science.231.4736.365; KIMMEL CB, 1987, DEV BIOL, V124, P269, DOI 10.1016/0012-1606(87)90478-7; Lawrence P., 1992, MAKING FLY GENETICS; LIN S, 1992, P NATL ACAD SCI USA, V89, P4519, DOI 10.1073/pnas.89.10.4519; Spemann H, 1924, ARCH MIKROSK ANAT EN, V100, P599, DOI 10.1007/BF02108133; STEINBERG MS, 1963, SCIENCE, V141, P401, DOI 10.1126/science.141.3579.401; STENT GS, 1985, PHILOS T R SOC B, V312, P3, DOI 10.1098/rstb.1985.0174; TECHNAU G M, 1986, Wilhelm Roux's Archives of Developmental Biology, V195, P445; TECHNAU GM, 1986, ROUX ARCH DEV BIOL, V195, P489, DOI 10.1007/BF00375889; TOWNES PL, 1955, J EXP ZOOL, V128, P53, DOI 10.1002/jez.1401280105; Trinkaus J.P., 1984, CELLS ORGANS; WARGA RM, 1990, DEVELOPMENT, V108, P569; WEISBLAT DA, 1988, MESSAGE MIND; WILSON P, 1991, DEVELOPMENT, V112, P289	25	150	150	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					109	111		10.1126/science.8316841	http://dx.doi.org/10.1126/science.8316841			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	8316841				2022-12-01	WOS:A1993LK43400045
J	HARRIS, H; SCOTCHER, D; HARTLEY, N; WALLACE, A; CRAUFURD, D; HARRIS, R				HARRIS, H; SCOTCHER, D; HARTLEY, N; WALLACE, A; CRAUFURD, D; HARRIS, R			CYSTIC-FIBROSIS CARRIER TESTING IN EARLY-PREGNANCY BY GENERAL-PRACTITIONERS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To assess the feasibility of genetic counselling in general practice by using cystic fibrosis carrier screening at the booking appointment as an integral part of routine antenatal care and as a paradigm for the wider participation of general practitioners in medical genetics. Design-Maternal testing (male partner tested only if woman screens positive) and couple testing for cystic fibrosis carrier status in the antenatal population attending one general practice and, later, in a further six (outreach) practices also. Setting-Two partner urban training practice (pilot practice) in south Manchester, and six north west practices (two inner city, three urban, one rural dispensing). Subjects-Total practice population of 50 000 (pilot practice plus six outreach practices) with an estimated 500-800 pregnancies per year. Main outcome measures-(a) Proportion of carriers of cystic fibrosis identified, counselled, and appropriately managed within the first trimester of pregnancy; (b) questionnaire and interview measures of patient satisfaction and stress. Results-Eleven carriers of cystic fibrosis were detected including one carrier couple. This carrier couple, after extensive counselling, elected to have prenatal diagnosis by chorionic villus biopsy. The fetus was homozygous normal. Conclusions-General practitioners can successfully integrate genetic counselling and cystic fibrosis carrier screening into the first antenatal booking appointment. When a carrier couple is identified clinical geneticists can help with the discussion of reproductive options, and prenatal diagnosis by chorionic villus biopsy can be completed within the first trimester. The results suggest that general practitioners will have an increasingly important role in medical genetics, subject to continuing evaluation of patient acceptability and stress.	BROOKLANDS MED PRACTICE,MANCHESTER M23 9JH,ENGLAND				Craufurd, David/G-5277-2013					FERRIE RM, 1992, AM J HUM GENET, V51, P251; HARRIS HJ, 1992, LANCET, V339, P1539, DOI 10.1016/0140-6736(92)91303-P; RIORDAN JR, 1989, SCIENCE, V245, P1066; SPIELBERGER CD, 1970, MANUAL STATE TRAIT A; WILLIAMSON R, IN PRESS NATURE GENE; 1992, CYSTIC FIBROSIS DNA	6	63	63	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1580	1583		10.1136/bmj.306.6892.1580	http://dx.doi.org/10.1136/bmj.306.6892.1580			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329921	Bronze, Green Published			2022-12-01	WOS:A1993LH12800021
J	RODIN, A; THAKKAR, H; TAYLOR, N; CLAYTON, R				RODIN, A; THAKKAR, H; TAYLOR, N; CLAYTON, R			HYPERANDROGENISM IN POLYCYSTIC-OVARY-SYNDROME - EVIDENCE OF DYSREGULATION OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							GONADOTROPIN-RELEASING HORMONE; INSULIN RESISTANCE; 21-HYDROXYLASE DEFICIENCY; ANDROGEN OVERPRODUCTION; MALE-TRANSSEXUALS; ADRENAL-FUNCTION; HIRSUTE WOMEN; DISEASE; ENDOCRINE; CATHETERIZATION	Background. Hyperandrogenemia is the hallmark of the polycystic ovary syndrome, yet the relative contributions of the adrenal cortex and ovary to the overproduction of androgen remain unclear. To identify possible causes of adrenocortical overactivity, we studied the metabolism of adrenal and ovarian steroid hormones in women with this disorder. Methods, We measured 24-hour urinary excretion of steroid hormone metabolites by high-resolution capillary gas chromatography in 65 women with the polycystic ovary syndrome and 45 normal women matched for body-mass index. Results. After adjustment for body-mass index, the urinary excretion of testosterone and androstenedione metabolites was 1.9 times higher in the women with the syndrome than in the normal women, and the excretion of dehydroepiandrosterone metabolites (C19 steroid sulfates) and cortisol metabolites was 1.5 and 1.3 times higher, respectively (P<0.01 for all comparisons). The affected women also had significantly higher ratios of 11-oxo (oxygenated) metabolites to 11-hydroxy metabolites of cortisol (1.4 times higher, P<0.001) and of 11-oxo to 11-hydroxy metabolites of corticosterone (1.8 times higher, P<0.001). In the group with the polycystic ovary syndrome, 55 percent of the nonobese women and 24 percent of the obese women had ratios above the upper limit of normal; the ratios in the obese women did not differ significantly from those in the nonobese women. Conclusions. Adrenal secretion of cortisol and androgens is increased in women with the polycystic ovary syndrome. The increases may be explained by dysregulation of 11 beta-hydroxysteroid dehydrogenase causing increased oxidation of cortisol to cortisone, which cannot be accounted for by obesity.	ROYAL LONDON HOSP,DEPT CLIN BIOCHEM,LONDON,ENGLAND; KINGS COLL,SCH MED,DEPT CLIN BIOCHEM,LONDON,ENGLAND; ST GEORGE HOSP,SCH MED,DIV BIOCHEM MED,LONDON,ENGLAND	Barts Health NHS Trust; Royal London Hospital; University of London; King's College London; St Georges University London	RODIN, A (corresponding author), N STAFFORDSHIRE ROYAL INFIRM,DEPT ENDOCRINOL,HARTSHILL,STOKE ON TRENT ST4 7LN,STAFFS,ENGLAND.							ABRAHAM GE, 1975, OBSTET GYNECOL, V46, P169; ADAMS J, 1985, LANCET, V2, P1375; AXELROD LR, 1962, J CLIN ENDOCR METAB, V22, P431, DOI 10.1210/jcem-22-4-431; BARDIN CW, 1968, J CLIN ENDOCR METAB, V28, P1300, DOI 10.1210/jcem-28-9-1300; BARNES R, 1989, ANN INTERN MED, V110, P386, DOI 10.7326/0003-4819-110-5-386; CARMINA E, 1990, GYNECOL ENDOCRINOL, V4, P225, DOI 10.3109/09513599009024976; CHANG RJ, 1983, J CLIN ENDOCR METAB, V57, P356, DOI 10.1210/jcem-57-2-356; CHANG RJ, 1983, J CLIN ENDOCR METAB, V56, P897, DOI 10.1210/jcem-56-5-897; CLAYTON RN, 1992, CLIN ENDOCRINOL, V37, P127, DOI 10.1111/j.1365-2265.1992.tb02296.x; CONWAY GS, 1989, CLIN ENDOCRINOL, V30, P459, DOI 10.1111/j.1365-2265.1989.tb00446.x; DUNAIF A, 1989, DIABETES, V38, P1165, DOI 10.2337/diabetes.38.9.1165; FERRIMAN D, 1961, J CLIN ENDOCR METAB, V21, P1440, DOI 10.1210/jcem-21-11-1440; FEUILLAN P, 1988, J CLIN ENDOCR METAB, V67, P154, DOI 10.1210/jcem-67-1-154; FOX R, 1991, CLIN ENDOCRINOL, V34, P127, DOI 10.1111/j.1365-2265.1991.tb00282.x; FRANKS S, 1989, CLIN ENDOCRINOL, V31, P87, DOI 10.1111/j.1365-2265.1989.tb00457.x; FUTTERWEIT W, 1986, J CLIN ENDOCR METAB, V62, P16, DOI 10.1210/jcem-62-1-16; FUTTERWEIT W, 1984, POLYCYSTIC OVARIAN D, P97; GADIR AA, 1990, CLIN ENDOCRINOL, V32, P749, DOI 10.1111/j.1365-2265.1990.tb00921.x; GIVENS JR, 1975, J CLIN ENDOCR METAB, V40, P988, DOI 10.1210/jcem-40-6-988; GOLDZIEHER JW, 1962, J CLIN ENDOCR METAB, V22, P325, DOI 10.1210/jcem-22-3-325; GROSS MD, 1986, J CLIN ENDOCR METAB, V62, P197, DOI 10.1210/jcem-62-1-197; HAGUE WM, 1986, J ENDOCRINOL, V111, P46; HORTON R, 1968, J CLIN ENDOCR METAB, V28, P479, DOI 10.1210/jcem-28-4-479; KIRSCHNER MA, 1971, J CLIN ENDOCR METAB, V33, P199, DOI 10.1210/jcem-33-2-199; LACHELIN GCL, 1979, J CLIN ENDOCR METAB, V49, P892, DOI 10.1210/jcem-49-6-892; LOBO RA, 1981, OBSTET GYNECOL, V57, P69; LOUGHLIN T, 1986, J CLIN ENDOCR METAB, V62, P142, DOI 10.1210/jcem-62-1-142; MIGEON CJ, 1989, ENDOCRINOLOGY, V2, P1676; MOLLER DE, 1988, NEW ENGL J MED, V319, P1526, DOI 10.1056/NEJM198812083192306; NELSON DH, 1989, ENDOCRINOLOGY, V2, P1660; NEW MI, 1983, J CLIN ENDOCR METAB, V57, P320, DOI 10.1210/jcem-57-2-320; ORSINI LF, 1985, FERTIL STERIL, V43, P709; PACHE TD, 1991, HISTOPATHOLOGY, V19, P445, DOI 10.1111/j.1365-2559.1991.tb00235.x; ROBINSON S, 1992, BRIT J OBSTET GYNAEC, V99, P232, DOI 10.1111/j.1471-0528.1992.tb14505.x; SHACKLETON CHL, 1980, CLIN CHIM ACTA, V107, P231, DOI 10.1016/0009-8981(80)90451-9; SOMMERS SC, 1956, AM J OBSTET GYNECOL, V72, P160, DOI 10.1016/S0002-9378(16)37526-3; STEWART PM, 1990, LANCET, V335, P431, DOI 10.1016/0140-6736(90)90664-Q; STRAIN GW, 1989, METABOLISM, V29, P980; WAJCHENBERG BL, 1986, J CLIN ENDOCR METAB, V63, P1204, DOI 10.1210/jcem-63-5-1204; WALKER BR, 1991, CLIN ENDOCRINOL, V35, P281, DOI 10.1111/j.1365-2265.1991.tb03537.x; YEN SSC, 1980, CLIN ENDOCRINOL, V12, P177, DOI 10.1111/j.1365-2265.1980.tb02132.x	41	170	172	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 17	1994	330	7					460	465		10.1056/NEJM199402173300703	http://dx.doi.org/10.1056/NEJM199402173300703			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW480	8289851				2022-12-01	WOS:A1994MW48000003
J	RICE, WR				RICE, WR			DEGENERATION OF A NONRECOMBINING CHROMOSOME	SCIENCE			English	Article							EVOLUTIONARY ADVANTAGE; RECOMBINATION; RATCHET; GENES; MODEL; SEX	Comparative studies suggest that sex chromosomes begin as ordinary autosomes that happen to carry a major sex determining locus. Over evolutionary time the Y chromosome is selected to stop recombining with the X chromosome, perhaps in response to accumulation of alleles beneficial to the heterogametic but harmful to the homogametic sex. Population genetic theory predicts that a nonrecombining Y chromosome should degenerate. Here this prediction is tested by application of specific selection pressures to Drosophila melanogaster populations. Results demonstrate the decay of a nonrecombining, nascent Y chromosome and the capacity for recombination to ameliorate such decay.			RICE, WR (corresponding author), UNIV CALIF SANTA CRUZ,DEPT BIOL,SANTA CRUZ,CA 95064, USA.							Bull J.J., 1983, EVOLUTION SEX DETERM; CHAO L, 1990, NATURE, V348, P454, DOI 10.1038/348454a0; CHARLESWORTH B, 1978, P NATL ACAD SCI USA, V75, P5618, DOI 10.1073/pnas.75.11.5618; CHARLESWORTH B, 1990, GENET RES, V55, P199, DOI 10.1017/S0016672300025532; CROW J. F., 1970, Biomathematics. Volume 1. Mathematical topics in population genetics., P128; DOBZHANSKY T, 1947, EVOLUTION, V1, P191, DOI 10.2307/2405495; FELSENSTEIN J, 1974, GENETICS, V78, P737; HAIGH J, 1978, THEOR POPUL BIOL, V14, P251, DOI 10.1016/0040-5809(78)90027-8; KONDRASHOV AS, 1988, NATURE, V336, P435, DOI 10.1038/336435a0; Lindsley D.L., 1968, GENETIC VARIATIONS D; LYNCH M, 1990, EVOLUTION, V44, P1725, DOI 10.1111/j.1558-5646.1990.tb05244.x; MUKAI T, 1964, GENETICS, V50, P1; MULLER HJ, 1964, MUTAT RES, V1, P2, DOI 10.1016/0027-5107(64)90047-8; OHNISHI O, 1977, GENETICS, V87, P529; RICE WR, 1992, SCIENCE, V256, P1436, DOI 10.1126/science.1604317; RICE WR, 1990, BIOMETRICS, V46, P303, DOI 10.2307/2531435; RICE WR, 1987, GENETICS, V116, P161; RICE WR, 1988, BIOMETRICS, V44, P1, DOI 10.2307/2531892; Vrijenhoek R.C., 1990, P175	19	153	154	0	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 14	1994	263	5144					230	232		10.1126/science.8284674	http://dx.doi.org/10.1126/science.8284674			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ879	8284674				2022-12-01	WOS:A1994MQ87900036
J	WATKINS, KP; DUNGAN, JM; AGABIAN, N				WATKINS, KP; DUNGAN, JM; AGABIAN, N			IDENTIFICATION OF A SMALL RNA THAT INTERACTS WITH THE 5' SPLICE-SITE OF THE TRYPANOSOMA-BRUCEI SPLICED LEADER RNA IN-VIVO	CELL			English	Article							PRE-MESSENGER-RNA; NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; RIBOSOMAL-RNA; DISCONTINUOUS SYNTHESIS; TRANSCRIPTION UNIT; CROSS-LINKING; C-ELEGANS; GROUP-II; SNRNA; SEQUENCES	In vivo psoralen cross-linking of the trypanosome spliced leader (SL) RNA has led to the discovery of a small RNA that we provisionally call the spliced leader associated (SLA) RNA. The 72 nt SLA RNA is unlike any known small RNA except for a small region that resembles U5 snRNA. The SL/SLA RNA cross-links map to two regions, the predominant interactions occurring between the 5' splice site region of the SL RNA and a CUUUUA sequence in the SLA RNA. The resemblance between these cross-links and interactions of U5 snRNA with cis-spliced pre-mRNAs suggests that the SLA RNA may be the trans-splicing analog of U5 snRNA in trypanosomes.			WATKINS, KP (corresponding author), UNIV CALIF SAN FRANCISCO & UNIV CALIF BERKELEY, INTERCAMPUS PROGRAM MOLEC PARASITOL, SAN FRANCISCO, CA 94143 USA.							AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; BIENEN EJ, 1981, EXP PARASITOL, V51, P408, DOI 10.1016/0014-4894(81)90128-4; BLUMENTHAL T, 1988, TRENDS GENET, V4, P305, DOI 10.1016/0168-9525(88)90107-2; BOCHNIG P, 1987, EUR J BIOCHEM, V168, P461, DOI 10.1111/j.1432-1033.1987.tb13439.x; BONEN L, 1993, FASEB J, V7, P40, DOI 10.1096/fasebj.7.1.8422973; BRUZIK JP, 1990, CELL, V62, P889, DOI 10.1016/0092-8674(90)90264-F; BRUZIK JP, 1988, NATURE, V335, P559, DOI 10.1038/335559a0; CAMPBELL DA, 1987, J MOL BIOL, V196, P113, DOI 10.1016/0022-2836(87)90514-6; CAMPBELL DA, 1984, NATURE, V311, P350, DOI 10.1038/311350a0; CIMINO GD, 1985, ANNU REV BIOCHEM, V54, P1151, DOI 10.1146/annurev.bi.54.070185.005443; DELANGE T, 1984, NUCLEIC ACIDS RES, V12, P3777, DOI 10.1093/nar/12.9.3777; England T E, 1980, Methods Enzymol, V65, P65; ERICSON G, 1988, ANAL BIOCHEM, V174, P215, DOI 10.1016/0003-2697(88)90538-6; HANNON GJ, 1991, J BIOL CHEM, V266, P22792; HARTSHORNE T, 1990, GENE DEV, V4, P2121, DOI 10.1101/gad.4.12a.2121; HASAN G, 1984, GENE, V27, P75, DOI 10.1016/0378-1119(84)90240-3; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; JACQUIER A, 1990, TRENDS BIOCHEM SCI, V15, P351, DOI 10.1016/0968-0004(90)90075-M; JOHNSON PJ, 1987, CELL, V51, P273, DOI 10.1016/0092-8674(87)90154-1; KOOTER JM, 1984, EMBO J, V3, P2387, DOI 10.1002/j.1460-2075.1984.tb02144.x; KRAUSE M, 1987, CELL, V49, P753, DOI 10.1016/0092-8674(87)90613-1; LAIRD PW, 1987, EMBO J, V6, P1055, DOI 10.1002/j.1460-2075.1987.tb04858.x; LAIRD PW, 1989, TRENDS GENET, V5, P204, DOI 10.1016/0168-9525(89)90082-6; LUHRMANN R, 1982, NUCLEIC ACIDS RES, V10, P7103, DOI 10.1093/nar/10.22.7103; MACDONALD RJ, 1987, METHOD ENZYMOL, V152, P219; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MILHAUSEN M, 1984, CELL, V38, P721, DOI 10.1016/0092-8674(84)90267-8; MILLIGAN JF, 1989, METHOD ENZYMOL, V180, P51; Moore M., 1993, RNA WORLD, P303; MOTTRAM J, 1989, MOL CELL BIOL, V9, P1212, DOI 10.1128/MCB.9.3.1212; MUHICH ML, 1988, MOL CELL BIOL, V8, P3837, DOI 10.1128/MCB.8.9.3837; MURPHY WJ, 1986, CELL, V47, P517, DOI 10.1016/0092-8674(86)90616-1; NEWMAN A, 1991, CELL, V65, P115, DOI 10.1016/0092-8674(91)90413-S; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; NILSEN TW, 1989, EXP PARASITOL, V69, P413, DOI 10.1016/0014-4894(89)90191-4; ORUM H, 1991, J MOL BIOL, V222, P219, DOI 10.1016/0022-2836(91)90208-N; PARSONS M, 1984, CELL, V38, P309, DOI 10.1016/0092-8674(84)90552-X; PATZELT E, 1989, MOL CELL BIOL, V9, P4291, DOI 10.1128/MCB.9.10.4291; RAJKOVIC A, 1990, P NATL ACAD SCI USA, V87, P8879, DOI 10.1073/pnas.87.22.8879; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SERAPHIN B, 1993, CELL, V73, P803, DOI 10.1016/0092-8674(93)90258-R; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; SUTTON RE, 1986, CELL, V47, P527, DOI 10.1016/0092-8674(86)90617-3; TEARE J, 1990, NUCLEIC ACIDS RES, V18, P855, DOI 10.1093/nar/18.4.855; TESSIER LH, 1991, EMBO J, V10, P2621, DOI 10.1002/j.1460-2075.1991.tb07804.x; THOMPSON JF, 1983, CELL, V32, P1355, DOI 10.1016/0092-8674(83)90316-1; TSCHUDI C, 1990, GENE, V91, P71, DOI 10.1016/0378-1119(90)90164-M; TSCHUDI C, 1986, NUCLEIC ACIDS RES, V14, P8893, DOI 10.1093/nar/14.22.8893; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; TSCHUDI C, 1988, EMBO J, V7, P455, DOI 10.1002/j.1460-2075.1988.tb02833.x; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WATKINS KP, 1991, GENE DEV, V5, P1859, DOI 10.1101/gad.5.10.1859; WHITE TC, 1986, NUCLEIC ACIDS RES, V14, P9471, DOI 10.1093/nar/14.23.9471; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; ZUKER M, 1991, NUCLEIC ACIDS RES, V19, P2707, DOI 10.1093/nar/19.10.2707; ZWIEB C, 1980, NUCLEIC ACIDS RES, V8, P2397, DOI 10.1093/nar/8.11.2397	58	42	42	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	1994	76	1					171	182		10.1016/0092-8674(94)90181-3	http://dx.doi.org/10.1016/0092-8674(94)90181-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287476				2022-12-01	WOS:A1994MR49500015
J	RUDNICKI, MA; SCHNEGELSBERG, PNJ; STEAD, RH; BRAUN, T; ARNOLD, HH; JAENISCH, R				RUDNICKI, MA; SCHNEGELSBERG, PNJ; STEAD, RH; BRAUN, T; ARNOLD, HH; JAENISCH, R			MYOD OR MYF-5 IS REQUIRED FOR THE FORMATION OF SKELETAL-MUSCLE	CELL			English	Article							REGULATORY GENE; ACETYLCHOLINE-RECEPTOR; MESSENGER-RNAS; CDNA CLONE; EXPRESSION; FAMILY; MYOGENESIS; MEMBER; CELLS; INACTIVATION	Mice carrying null mutations in the myogenic regulatory factors Myf-5 or MyoD have apparently normal skeletal muscle. To address whether these two factors functionally substitute for one another in myogenesis, mice carrying mutant Myf-5 and MyoD genes were interbred. While mice lacking both MyoD and Myf-5 were born alive, they were immobile and died soon after birth. Northern blot and S1 nuclease analyses indicated that Myf-5(-/-);MyoD(-/-) mice expressed no detectable skeletal muscle-specific mRNAs. Histological examination of these mice revealed a complete absence of skeletal muscle. Immunohistochemical analysis indicated an absence of desmin-expressing myoblast-like cells. These observations suggest that either Myf-5 or MyoD is required for the determination of skeletal myoblasts, their propagation, or both during embryonic development and indicate that these factors play, at least in part, functionally redundant roles in myogenesis.	MIT,WHITEHEAD INST,CAMBRIDGE,MA 02142; MIT,DEPT BIOL,CAMBRIDGE,MA 02142; MCMASTER UNIV,DEPT PATHOL,HAMILTON L8S 4K1,ONTARIO,CANADA; INST BIOCHEM & BIOTECHNOL,ZELL & MOLEK BIOL ABT,D-38106 BRAUNSCHWEIG,GERMANY	Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT); McMaster University	RUDNICKI, MA (corresponding author), MCMASTER UNIV,INST MOLEC BIOL & BIOTECHNOL,HAMILTON L8S 4K1,ONTARIO,CANADA.		Braun, Thomas/B-2310-2008	Braun, Thomas/0000-0002-6165-4804	NATIONAL CANCER INSTITUTE [R35CA044339] Funding Source: NIH RePORTER; NCI NIH HHS [5R35CA44339] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADRA CN, 1988, SOMAT CELL MOLEC GEN, V14, P69, DOI 10.1007/BF01535050; AUFFRAY C, 1980, EUR J BIOCHEM, V107, P303; Bancroft JD, 1990, THEORY PRACTICE HIST; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BOBER E, 1991, J CELL BIOL, V113, P1255, DOI 10.1083/jcb.113.6.1255; BRAUN T, 1992, CELL, V71, P369, DOI 10.1016/0092-8674(92)90507-9; BRAUN T, 1990, EMBO J, V9, P821, DOI 10.1002/j.1460-2075.1990.tb08179.x; BRAUN T, 1989, EMBO J, V8, P3617, DOI 10.1002/j.1460-2075.1989.tb08535.x; BRAUN T, 1989, EMBO J, V8, P701, DOI 10.1002/j.1460-2075.1989.tb03429.x; BUCKINGHAM M, 1992, TRENDS GENET, V8, P144, DOI 10.1016/0168-9525(92)90373-C; EDMONDSON DG, 1989, GENE DEV, V3, P628, DOI 10.1101/gad.3.5.628; FRAIL DE, 1989, NEURON, V2, P1077, DOI 10.1016/0896-6273(89)90232-8; GEORGEWEINSTEIN M, 1993, DEV BIOL, V156, P209, DOI 10.1006/dbio.1993.1071; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; KOPPE RI, 1989, J BIOL CHEM, V264, P14327; LAPOLLA RJ, 1984, P NATL ACAD SCI-BIOL, V81, P7970, DOI 10.1073/pnas.81.24.7970; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; Maniatis T., 1982, MOL CLONING; MCLEOD MJ, 1980, TERATOLOGY, V22, P299, DOI 10.1002/tera.1420220306; MILLER JB, 1992, CELL, V69, P1, DOI 10.1016/0092-8674(92)90111-O; MINER JH, 1990, P NATL ACAD SCI USA, V87, P1089, DOI 10.1073/pnas.87.3.1089; MONTARRAS D, 1991, NEW BIOL, V3, P592; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; OLSON EN, 1990, GENE DEV, V4, P1454, DOI 10.1101/gad.4.9.1454; OTT MO, 1991, DEVELOPMENT, V111, P1097; RHODES SJ, 1989, GENE DEV, V3, P2050, DOI 10.1101/gad.3.12b.2050; RUDNICKI MA, 1992, CELL, V71, P383, DOI 10.1016/0092-8674(92)90508-A; SASSOON D, 1989, NATURE, V341, P303, DOI 10.1038/341303a0; STEAD RH, 1989, GASTROENTEROLOGY, V97, P575, DOI 10.1016/0016-5085(89)90627-6; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WRIGHT WE, 1989, CELL, V56, P607, DOI 10.1016/0092-8674(89)90583-7	31	1319	1369	4	60	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 31	1993	75	7					1351	1359		10.1016/0092-8674(93)90621-V	http://dx.doi.org/10.1016/0092-8674(93)90621-V			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	8269513				2022-12-01	WOS:A1993MP86900013
J	GU, Y; TURCK, CW; MORGAN, DO				GU, Y; TURCK, CW; MORGAN, DO			INHIBITION OF CDK2 ACTIVITY IN-VIVO BY AN ASSOCIATED 20K REGULATORY SUBUNIT	NATURE			English	Article							HUMAN CELL-CYCLE; DNA-REPLICATION; KINASES; ACTIVATION; PROTEINS	THE major events of the cell division cycle are triggered by periodic changes in the activity of cyclin-dependent protein kinases (CDKs). In mammals, the members of the CDK family include CDK2 and CDC2, which are thought to be involved in the control of DNA replication and mitosis, respectively1-3. The protein kinase activity of these enzymes is controlled by a complex array of mechanisms4-6. Activation of the CDK catalytic subunit requires association with a positive regulatory subunit (cyclin) and phosphorylation (at Thr 160 in CDK2). This activated complex can be inhibited by additional phosphorylation at Thr 14 and Tyr 15. Here we report the identification of a new mechanism for the regulation of CDK2 activity. We find that CDK2/cyclin complexes in mouse fibroblasts associate tightly with a 20K protein (CAP20). Complexes containing CAP20 were isolated from cell lysates and found to have negligible kinase activity, indicating that CAP20 association in vivo may inhibit CDK2 activity. We purified CAP20 from 3T3 cells and found that low concentrations of the protein completely inhibit the kinase activity of CDK2 in vitro. Thus CAP20 represents a new negative regulatory subunit that inhibits the activity of CDK2/cyclin complexes in mammalian cells.	UNIV CALIF SAN FRANCISCO,DEPT PHYSIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco				Morgan, David/0000-0001-8753-4416				DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; Draetta Giulio, 1993, Trends in Cell Biology, V3, P287, DOI 10.1016/0962-8924(93)90001-H; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GU Y, 1992, EMBO J, V11, P3995, DOI 10.1002/j.1460-2075.1992.tb05493.x; HAGER DA, 1980, ANAL BIOCHEM, V109, P76, DOI 10.1016/0003-2697(80)90013-5; HARPER JW, 1993, CELL, V75, P805; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; NODA A, IN PRESS EXP CELL RE; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OHTSUBO M, 1993, SCIENCE, V259, P1908, DOI 10.1126/science.8384376; PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PINES J, 1993, TRENDS BIOCHEM SCI, V18, P195, DOI 10.1016/0968-0004(93)90185-P; REED SI, 1992, ANNU REV CELL BIOL, V8, P529, DOI 10.1146/annurev.cb.08.110192.002525; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; Solomon MJ, 1993, CURR OPIN CELL BIOL, V5, P180, DOI 10.1016/0955-0674(93)90100-5; TSAI LH, 1993, ONCOGENE, V8, P1593; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	22	779	804	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 16	1993	366	6456					707	710		10.1038/366707a0	http://dx.doi.org/10.1038/366707a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	8259216				2022-12-01	WOS:A1993MM26500076
J	BECKER, LB; HAN, BH; MEYER, PM; WRIGHT, FA; RHODES, KV; SMITH, DW; BARRETT, J				BECKER, LB; HAN, BH; MEYER, PM; WRIGHT, FA; RHODES, KV; SMITH, DW; BARRETT, J			RACIAL-DIFFERENCES IN THE INCIDENCE OF CARDIAC-ARREST AND SUBSEQUENT SURVIVAL	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							AMERICAN-HEART-ASSOCIATION; CARDIOPULMONARY RESUSCITATION; MYOCARDIAL-INFARCTION; HEALTH-PROFESSIONALS; PREVALENCE; STATEMENT; DISEASE; DEATH	Background. Differences between blacks and whites have been reported in the incidence of several forms of cardiovascular disease, including hypertension and stroke. We examined racial differences in the incidence of cardiac arrest in a large urban population and in subsequent survival. Methods. We collected data on all nontraumatic, out-of-hospital cardiac arrests in Chicago from January 1, 1987, through December 31, 1988, and compared the incidence and survival rates for blacks and whites. We examined the association between survival and race and seven other known risk factors by logistic-regression analysis. We computed incidence rates by coupling our data with U.S. Census population data. Results. Our study population comprised 6451 patients: 3207 whites, 2910 blacks, and 334 persons of other races. The incidence of cardiac arrest was significantly higher tor blacks than for whites in every age group. The survival rate after cardiac arrest was 2.6 percent in whites as compared with 0.8 percent in blacks (P<0.001). Blacks were significantly less likely to have a witnessed cardiac arrest, bystander-initiated cardiopulmonary resuscitation, or a ''favorable'' initial rhythm or to be admitted to the hospital. When they were admitted, blacks were half as likely to survive. The association between race and survival persisted even when other recognized risk factors were taken into account. We did not find important differences between blacks and whites in the response times of the emergency medical services. Conclusions. The black community in our study was at higher risk for cardiac arrest and subsequent death than the white community, even after we controlled for other variables.	UNIV CHICAGO,DEPT MED,EMERGENCY MED SECT,CHICAGO,IL 60637; RESURRECT HOSP,DEPT EMERGENCY,CHICAGO,IL; CHICAGO FIRE DEPT,BUR EMERGENCY MED SERV,CHICAGO,IL; RUSH PRESBYTERIAN ST LUKES MED CTR,DEPT PREVENT MED,CHICAGO,IL 60612; UNIV CHICAGO,DEPT STAT,CHICAGO,IL 60637; UNIV OKLAHOMA HLTH SCI CTR,DEPT EPIDEMIOL & ST,OKLAHOMA CITY,OK	University of Chicago; Rush University; University of Chicago; University of Oklahoma System; University of Oklahoma Health Sciences Center								[Anonymous], GEN LINEAR MODELS; BECKER LB, 1991, ANN EMERG MED, V20, P355, DOI 10.1016/S0196-0644(05)81654-3; BECKER LB, 1993, ANN EMERG MED, V22, P86, DOI 10.1016/S0196-0644(05)80257-4; BRESLOW NE, 1987, IARC SCI PUBL, V32, P135; CASTANER A, 1988, ANN INTERN MED, V109, P33, DOI 10.7326/0003-4819-109-1-33; COBB LA, 1980, ANNU REV MED, V31, P453, DOI 10.1146/annurev.me.31.020180.002321; CUMMINS RO, 1985, AM J EMERG MED, V3, P114, DOI 10.1016/0735-6757(85)90032-4; CUMMINS RO, 1991, CIRCULATION, V84, P960, DOI 10.1161/01.CIR.84.2.960; CUMMINS RO, 1991, CIRCULATION, V83, P1832, DOI 10.1161/01.CIR.83.5.1832; EISENBERG MS, 1990, ANN EMERG MED, V19, P179, DOI 10.1016/S0196-0644(05)81805-0; GILLUM RF, 1989, CIRCULATION, V79, P756, DOI 10.1161/01.CIR.79.4.756; GILLUM RF, 1985, J NATL MED ASSOC, V77, P281; HAGSTROM RM, 1971, CIRCULATION, V44, P884, DOI 10.1161/01.CIR.44.5.884; HALLSTROM A, 1993, AM J PUBLIC HEALTH, V83, P245, DOI 10.2105/AJPH.83.2.245; KEIL JE, 1985, AM HEART J, V109, P776, DOI 10.1016/0002-8703(85)90638-6; LITWIN PE, 1987, ANN EMERG MED, V16, P787, DOI 10.1016/S0196-0644(87)80576-0; OALMANN MC, 1971, AM J EPIDEMIOL, V94, P546, DOI 10.1093/oxfordjournals.aje.a121353; SPRAFKA JM, 1988, AM J PUBLIC HEALTH, V78, P1546, DOI 10.2105/AJPH.78.12.1546; WILCOXGOK VL, 1991, MED CARE, V29, P104, DOI 10.1097/00005650-199102000-00003; 1991, CIRCULATION, V83, P1462; 1992, 1990 CENSUS POPULATI; 1980, 180 CENSUS POPULA 15, V1, pCHB; 1986, JAMA-J AM MED ASSOC, V255, P2905	23	311	316	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1993	329	9					600	606		10.1056/NEJM199308263290902	http://dx.doi.org/10.1056/NEJM199308263290902			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU217	8341333				2022-12-01	WOS:A1993LU21700002
J	RAVICHANDRAN, KG; BODDUPALLI, SS; HASEMANN, CA; PETERSON, JA; DEISENHOFER, J				RAVICHANDRAN, KG; BODDUPALLI, SS; HASEMANN, CA; PETERSON, JA; DEISENHOFER, J			CRYSTAL-STRUCTURE OF HEMOPROTEIN DOMAIN OF P450BM-3, A PROTOTYPE FOR MICROSOMAL P450S	SCIENCE			English	Article							2 FUNCTIONAL DOMAINS; ELECTRON-TRANSFER; BACILLUS-MEGATERIUM; BINDING-PROTEIN; CYTOCHROME-P-450; RESOLUTION; REFINEMENT; ENZYMES; COMPLEX; ERRORS	Cytochrome P450BM-3, a bacterial fatty acid monooxygenase, resembles the eukaryotic microsomal P450's and their flavoprotein reductase in primary structure and function. The three-dimensional structure of the hemoprotein domain of P450BM-3 was determined by x-ray diffraction and refined to an R factor of 16.9 percent at 2.0 angstrom resolution. The structure consists of an alpha and a beta domain. The active site heme is accessible through a long hydrophobic channel formed primarily by the beta domain and the B' and F helices of the alpha domain. The two molecules in the asymmetric unit differ in conformation around the substrate binding pocket. Substantial differences between P450BM-3 and P450cam, the only other P450 structure available, are observed around the substrate binding pocket and the regions important for redox partner binding. A general mechanism for proton transfer in P450's is also proposed.	UNIV TEXAS, SW MED CTR, HOWARD HUGHES MED INST, 5323 HARRY HINES BLVD, DALLAS, TX 75235 USA; UNIV TEXAS, SW MED CTR, DEPT BIOCHEM, DALLAS, TX 75235 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas					NIGMS NIH HHS [GM43479] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM043479] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BODDUPALLI SS, 1992, J BIOL CHEM, V267, P10375; BODDUPALLI SS, 1992, P NATL ACAD SCI USA, V89, P5567, DOI 10.1073/pnas.89.12.5567; BODDUPALLI SS, UNPUB; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CHOTHIA C, 1986, EMBO J, V5, P823, DOI 10.1002/j.1460-2075.1986.tb04288.x; DEMONTELANO PRO, 1986, CYTOCHROME, V450, P217; FULCO AJ, 1991, ANNU REV PHARMACOL, V31, P177; FURUYA H, 1989, BIOCHEMISTRY-US, V28, P6848, DOI 10.1021/bi00443a011; GERBER NC, 1992, J AM CHEM SOC, V114, P8742, DOI 10.1021/ja00048a081; GONZALEZ FJ, 1988, PHARMACOL REV, V40, P243; GUENGERICH FP, 1991, J BIOL CHEM, V266, P10019; GUNSALUS IC, 1974, MOL MECHANISMS OXYGE; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; LI HY, 1991, J BIOL CHEM, V266, P11909; LINDBERG RLP, 1989, NATURE, V339, P632, DOI 10.1038/339632a0; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; NARHI LO, 1987, J BIOL CHEM, V262, P6683; NELSON DR, 1993, DNA CELL BIOL, V12, P1, DOI 10.1089/dna.1993.12.1; NEWCOMER ME, 1984, EMBO J, V3, P1451, DOI 10.1002/j.1460-2075.1984.tb01995.x; OKEY AB, 1990, PHARMACOL THERAPEUT, V45, P241, DOI 10.1016/0163-7258(90)90030-6; OSTER T, 1991, J BIOL CHEM, V266, P22718; PELLETIER H, 1992, SCIENCE, V258, P1748, DOI 10.1126/science.1334573; PETERSON JA, 1992, CYTOCHROME P, V450, P708; PORTER TD, 1991, TRENDS BIOCHEM SCI, V16, P154, DOI 10.1016/0968-0004(91)90059-5; PORTER TD, 1991, J BIOL CHEM, V266, P13469; POULOS TL, 1987, J MOL BIOL, V195, P687, DOI 10.1016/0022-2836(87)90190-2; POULOS TL, 1992, FASEB J, V6, P674, DOI 10.1096/fasebj.6.2.1537455; POULOS TL, 1986, BIOCHEMISTRY-US, V25, P5314, DOI 10.1021/bi00366a049; POULOS TL, 1991, METHOD ENZYMOL, V206, P11; PRESNELL SR, 1989, P NATL ACAD SCI USA, V86, P6592, DOI 10.1073/pnas.86.17.6592; RAAG R, 1991, BIOCHEMISTRY-US, V30, P11420, DOI 10.1021/bi00112a008; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RUETTINGER RT, 1989, TRENDS BIOCHEM SCI, V264, P10987; SACCHETTINI JC, 1992, J BIOL CHEM, V267, P23534; SONO M, 1982, J BIOL CHEM, V257, P8308; STAYTON PS, 1989, BIOCHEMISTRY-US, V28, P8201, DOI 10.1021/bi00446a035; STEIGEMANN W, 1992, JUL AM CRYST ASS ANN	39	915	935	2	71	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 6	1993	261	5122					731	736		10.1126/science.8342039	http://dx.doi.org/10.1126/science.8342039			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ730	8342039				2022-12-01	WOS:A1993LQ73000030
J	TOOLE, MJ; WALDMAN, RJ				TOOLE, MJ; WALDMAN, RJ			REFUGEES AND DISPLACED PERSONS - WAR, HUNGER, AND PUBLIC-HEALTH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								The number of refugees and internally displaced persons in need of protection and assistance has increased from 30 million in 1990 to more than 43 million today. War and civil strife have been largely responsible for this epidemic of mass migration that has affected almost every region of the world, including Europe. Since 1990, crude death rates (CDRs) during the early influx of refugees who crossed international borders have been somewhat lower than CDRs reported earlier among Cambodian and Ethiopian refugees. Nevertheless, CDRs among refugees arriving in Ethiopia, Kenya, Nepal, Malawi, and Zimbabwe since 1990 ranged from five to 12 times the baseline CDRs in the countries of origin. Among internally displaced populations in northern Iraq, Somalia, and Sudan, CDRs were extremely high, ranging from 12 to 25 times the baseline CDRs for the nondisplaced. Among both refugees and internally displaced persons, death rates among children less than 5 years of age were far higher than among older children and adults. In Bangladesh, the death rate in female Rohingya refugees was several times higher than in males. Preventable conditions such as diarrheal disease, measles, and acute respiratory infections, exacerbated often by malnutrition, caused most deaths. Although relief programs for refugees have improved since 1990, the situation among the internally displaced may have worsened. The international community should intervene earlier in the evolution of complex disasters involving civil war, human rights abuses, food shortages, and mass displacement. Relief programs need to be based on sound health and nutrition information and should focus on the provision of adequate shelter, food, water, sanitation, and public health programs that prevent mortality from diarrhea, measles, and other communicable diseases, especially among young children and women.	WHO,DIV DIARRHOEAL & ACUTE RESP DISEASE CONTROL,CH-1211 GENEVA 27,SWITZERLAND	World Health Organization	TOOLE, MJ (corresponding author), CTR DIS CONTROL & PREVENT,INT HLTH PROGRAM OFF,MAILSTOP FO3,ATLANTA,GA 30333, USA.							[Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; HILDEBRAND K, 1991, JOINT NUTRITION MORT; ISAACSON M, 1993, LANCET, V341, P961, DOI 10.1016/0140-6736(93)91253-I; MANONCOURT S, 1992, LANCET, V340, P176, DOI 10.1016/0140-6736(92)93252-I; MOORE PS, 1993, LANCET, V341, P935, DOI 10.1016/0140-6736(93)91223-9; SUDETIC C, 1993, NY TIMES        0524, pA7; TOOLE MJ, 1992, LANCET, V339, P1214, DOI 10.1016/0140-6736(92)91143-V; TOOLE MJ, 1990, JAMA-J AM MED ASSOC, V263, P3296, DOI 10.1001/jama.263.24.3296; TOOLE MJ, 1993, LANCET, V341, P935; YIP R, 1993, JAMA-J AM MED ASSOC, V270, P587, DOI 10.1001/jama.270.5.587; 1968, HCRINF29 UN HIGH COM; 1982, HDB EMERGENCIES; 1992, NO MERCY MOGADISHU, P3; 1991, MMWR MORB MORTAL WKL, V40, P443; 1993, UNHCR IMPLEMENTATION; 1993, MMWR MORB MORTAL WKL, V42, P69; 1993, ECN4199350 PUBL; 1992, RESPONDING NUTRITION; 1992, REFUGES, V91, P4; 1993, MMWR MORB MORTAL WKL, V42, P304; 1992, INTERNALLY DISPLACED, P5; 1993, MMWR MORB MORTAL WKL, V42, P14; 1992, STATE WORLDS CHILDRE; 1993, MMWR MORB MORTAL WKL, V42, P468	24	147	149	1	113	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1993	270	5					600	605		10.1001/jama.270.5.600	http://dx.doi.org/10.1001/jama.270.5.600			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LP436	8331759				2022-12-01	WOS:A1993LP43600025
J	FRASER, I; HUGHES, D; GORDON, S				FRASER, I; HUGHES, D; GORDON, S			DIVALENT CATION-INDEPENDENT MACROPHAGE ADHESION INHIBITED BY MONOCLONAL-ANTIBODY TO MURINE SCAVENGER RECEPTOR	NATURE			English	Article							TYPE-3 COMPLEMENT RECEPTOR; RAT HYBRID MYELOMAS; MYELOMONOCYTIC CELLS; HUMAN MONOCYTE; PROTEINS; FAMILY; LIPOPROTEINS; RECRUITMENT; INTEGRINS; INVITRO	MACROPHAGES interact with other cells and components of the extracellular environment by means of adhesion receptors1,2. Adhesion to artificial substrata in vitro facilitates isolation of macrophages3, and has been used to generate antibodies that inhibit their migration in vivo4,5. Unlike other cell types, macrophages attach to tissue culture plastic in the absence of divalent cations. Here we use an adhesion assay exploiting this property to isolate a rat monoclonal antibody, 2F8, which totally inhibits divalent cation-independent adhesion of murine macrophages to tissue culture plastic in the presence of fetal calf serum. Immunoprecipitation from macrophages and stably transfected Chinese hamster ovary cells revealed that the antigen recognized by monoclonal 2F8 is identical to murine macrophage scavenger receptor6,7. We propose a novel function for this molecule, previously described as an endocytic receptor, thus providing a mechanism for mononuclear phagocyte recruitment to and retention in ligand-rich tissues such as in atherosclerotic lesions.			FRASER, I (corresponding author), UNIV OXFORD,SIR WILLIAM DUNN SCH PATHOL,S PARKS RD,OXFORD OX1 3RE,ENGLAND.		Hughes, Derralynn/J-8012-2013	Hughes, Derralynn/0000-0003-4531-9173				ASHKENAS J, 1993, J LIPID RES, V34, P983; BEVILACQUA M, 1991, CELL, V67, P233, DOI 10.1016/0092-8674(91)90174-W; DAVIS GE, 1992, EXP CELL RES, V200, P242, DOI 10.1016/0014-4827(92)90170-D; FREEMAN M, 1990, P NATL ACAD SCI USA, V87, P8810, DOI 10.1073/pnas.87.22.8810; GALFRE G, 1979, NATURE, V277, P131, DOI 10.1038/277131a0; GENG YJ, 1992, J CLIN INVEST, V89, P1322, DOI 10.1172/JCI115718; GODING JW, 1986, HDB EXPT IMMUNOLOGY; HALE G, 1987, J IMMUNOL METHODS, V103, P59, DOI 10.1016/0022-1759(87)90242-0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JOHNSON WD, 1977, J EXP MED, V146, P1613, DOI 10.1084/jem.146.5.1613; KRIEGER M, 1992, TRENDS BIOCHEM SCI, V17, P141, DOI 10.1016/0968-0004(92)90322-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEENEN PJM, 1986, DIFFERENTIATION, V32, P157, DOI 10.1111/j.1432-0436.1986.tb00568.x; PEARLSTEIN E, 1978, J CELL BIOL, V79, P263, DOI 10.1083/jcb.79.1.263; PENMAN M, 1991, J BIOL CHEM, V266, P23985; PITAS RE, 1981, ARTERIOSCLEROSIS, V1, P177, DOI 10.1161/01.ATV.1.3.177; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; RABINOVITCH M, 1976, J EXP MED, V143, P290, DOI 10.1084/jem.143.2.290; RASCHKE WC, 1978, CELL, V15, P261, DOI 10.1016/0092-8674(78)90101-0; ROSEN H, 1987, J EXP MED, V166, P1685, DOI 10.1084/jem.166.6.1685; ROSEN H, 1989, J EXP MED, V170, P27, DOI 10.1084/jem.170.1.27; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER TA, 1986, CIBA F SYMP, V118, P102, DOI 10.1002/9780470720998.ch8	23	315	327	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 22	1993	364	6435					343	345		10.1038/364343a0	http://dx.doi.org/10.1038/364343a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	8332192				2022-12-01	WOS:A1993LN57000059
J	MCINTIRE, SL; JORGENSEN, E; KAPLAN, J; HORVITZ, HR				MCINTIRE, SL; JORGENSEN, E; KAPLAN, J; HORVITZ, HR			THE GABAERGIC NERVOUS-SYSTEM OF CAENORHABDITIS-ELEGANS	NATURE			English	Article							NEMATODE ASCARIS; C-ELEGANS; INHIBITORY MOTONEURONS; GABA; NEURONS	Gamma-AMINOBUTYRIC acid (GABA) is the most abundant inhibitory neurotransmitter in vertebrates and invertebrates1. GABA receptors are the target of anxiolytic, antiepileptic and antispasmodic drugs2, as well as of commonly used insecticides3. How does a specific neurotransmitter such as GABA control animal behaviour? To answer this question, we identified all neurons that react with antisera raised against the neurotransmitter GABA in the nervous system of the nematode Caenorhabditis elegans. We determined the in vivo functions of 25 of the 26 GABAergic neurons by killing these cells with a laser microbeam in living animals and by characterizing a mutant defective in GABA expression. On the basis of the ultrastructurally defined connectivity of the C. elegans nervous system, we deduced how these GABAergic neurons act to control the body and enteric muscles necessary for different behaviours. Our findings provide evidence that GABA functions as an excitatory as well as an inhibitory neurotransmitter.	MIT,DEPT BIOL,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; HARVARD UNIV,SCH MED,PROGRAM NEUROSCI,BOSTON,MA 02115	Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); Harvard University; Harvard Medical School								AMBROS V, 1984, SCIENCE, V226, P409, DOI 10.1126/science.6494891; AVERY L, 1989, NEURON, V3, P473, DOI 10.1016/0896-6273(89)90206-7; BOWERY NG, 1991, SEMINARS NEUROSCI, V3, P241; BOWERY NG, 1989, GABA BASIC RES CLIN, P1; CHERUBINI E, 1991, TRENDS NEUROSCI, V14, P515, DOI 10.1016/0166-2236(91)90003-D; CHISHOLM A, 1991, DEVELOPMENT, V111, P921; Cooper J. R., 1991, BIOCH BASIS NEUROPHA, P133; GUASTELLA J, 1991, J COMP NEUROL, V307, P584, DOI 10.1002/cne.903070406; HALL DH, 1991, J NEUROSCI, V11, P1; HOSKINS SG, 1986, CELL TISSUE RES, V244, P243; JOHNSON CD, 1985, J NEUROSCI, V5, P1984; JOHNSON CD, 1987, J NEUROSCI, V7, P223; MCINTIRE SL, 1993, NATURE, V364, P334, DOI 10.1038/364334a0; MCINTIRE SL, 1992, NEURON, V8, P307, DOI 10.1016/0896-6273(92)90297-Q; Olsen RW, 1991, SEMIN NEUROSCI, V3, P175, DOI [10.1016/1044-5765(91)90014-F, DOI 10.1016/1044-5765(91)90014-F]; SATTELLE DB, 1991, NEUROCHEM RES, V16, P363, DOI 10.1007/BF00966100; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; THOMAS JH, 1990, GENETICS, V124, P855; WALROND JP, 1985, J NEUROSCI, V5, P9; WALROND JP, 1985, J NEUROSCI, V5, P1; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WHITE JG, 1976, PHILOS T R SOC B, V275, P327, DOI 10.1098/rstb.1976.0086; Wood WB, 1988, NEMATODE CAENORHABDI	25	337	343	2	29	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 22	1993	364	6435					337	341		10.1038/364337a0	http://dx.doi.org/10.1038/364337a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	8332191				2022-12-01	WOS:A1993LN57000057
J	MAROTTI, KR; CASTLE, CK; BOYLE, TP; LIN, AH; MURRAY, RW; MELCHIOR, GW				MAROTTI, KR; CASTLE, CK; BOYLE, TP; LIN, AH; MURRAY, RW; MELCHIOR, GW			SEVERE ATHEROSCLEROSIS IN TRANSGENIC MICE EXPRESSING SIMIAN CHOLESTERYL ESTER TRANSFER PROTEIN	NATURE			English	Article							DENSITY-LIPOPROTEIN LEVELS; PLASMA; SUSCEPTIBILITY; STRAINS; LESIONS; FAT	CHOLESTERYL ester transfer protein (CETP) is a plasma protein that mediates the exchange of neutral lipids among the lipoproteins1-3. Because the principal core lipid of very-low-density lipoprotein (VLDL) is triglyceride and that of high-density lipoprotein (HDL) is cholesterol ester, CETP mediates a 'heteroexchange' of cholesterol ester for triglyceride between those lipoproteins. As a result, animals that express CETP tend to have higher VLDL and low-density lipoprotein (LDL) cholesterol levels, whereas those with no CETP activity tend to have high HDL cholesterol levels2. Because VLDL and LDL are associated with the progression of atherosclerosis, and HDL are considered anti-atherogenic, CETP could be an 'atherogenic' protein, that is, given the other conditions required for atherosclerosis to develop, expression of CETP would accelerate the rate at which the arterial lesions progress. We report here that transgenic mice expressing CETP had much worse atherosclerosis than did non-expressing controls, and we suggest that the increase in lesion severity was due largely to CETP-induced alterations in the lipoprotein profile.			MAROTTI, KR (corresponding author), UPJOHN CO LABS,MOLEC BIOL RES & METAB DIS RES,7242-209-7,KALAMAZOO,MI 49001, USA.							CASTLE CK, 1993, ARTERIOSCLER THROMB, V13, P302, DOI 10.1161/01.ATV.13.2.302; MAHLEY RW, 1982, MED CLIN N AM, V66, P375, DOI 10.1016/S0025-7125(16)31426-2; MAROTTI KR, 1992, ARTERIOSCLER THROMB, V12, P736, DOI 10.1161/01.ATV.12.6.736; NISHINA PM, 1990, J LIPID RES, V31, P859; PAIGEN B, 1987, ATHEROSCLEROSIS, V64, P215, DOI 10.1016/0021-9150(87)90249-8; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4; PAPE ME, 1991, ARTERIOSCLER THROMB, V11, P1759, DOI 10.1161/01.ATV.11.6.1759; RYE KA, 1992, STRUCTURE FUNCTION A, P401; TALL AR, 1992, J INTERN MED, V231, P661, DOI 10.1111/j.1365-2796.1992.tb01255.x; ZILVERSMIT DB, 1975, BIOCHIM BIOPHYS ACTA, V409, P393, DOI 10.1016/0005-2760(75)90036-3	12	411	417	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 1	1993	364	6432					73	75		10.1038/364073a0	http://dx.doi.org/10.1038/364073a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK818	8316302				2022-12-01	WOS:A1993LK81800061
J	GUPTA, S; TRENHOLME, K; ANDERSON, RM; DAY, KP				GUPTA, S; TRENHOLME, K; ANDERSON, RM; DAY, KP			ANTIGENIC DIVERSITY AND THE TRANSMISSION DYNAMICS OF PLASMODIUM-FALCIPARUM	SCIENCE			English	Article							PAPUA-NEW-GUINEA; MALARIA; ERYTHROCYTES; SURFACE; MADANG	The average age of humans at their first infection with Plasmodium falciparum is typically less than 1 year in most endemic areas. This has been interpreted as evidence of the high transmissibility of the parasite, with the implication that control of malaria will require high levels of coverage with a potential vaccine. This interpretation is challenged by mathematical models that demonstrate that the long period required to develop immunity to malaria permits a high risk (or low average age) of infection even when parasite transmissibility is low. Patterns of seroconversion to five antigenically distinct isolates of P. falciparum in a highly malarious area of Papua New Guinea indicate that each is only mildly transmissible and that malaria, as a construct of several such independently transmitted strains, has a basic reproductive rate (or transmissibility) that is an order of magnitude lower than other estimates.	PAPUA NEW GUINEA INST MED RES, MADANG, PAPUA N GUINEA; WALTER & ELIZA HALL INST MED RES, PARKVILLE, VIC 3050, AUSTRALIA; IMPERIAL COLL SCI TECHNOL & MED, DEPT BIOL, LONDON SW7 2BB, ENGLAND	PNG Institute Of Medical Research; Walter & Eliza Hall Institute; Imperial College London	GUPTA, S (corresponding author), UNIV OXFORD, DEPT ZOOL, OXFORD OX1 3PS, OXON, ENGLAND.		Day, Karen/F-3697-2015; Trenholme, Katharine/C-9244-2013	Day, Karen/0000-0002-6115-6135; Anderson, Roy/0000-0002-9528-3175	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANDERSON R M, 1991; ANDERSON RM, 1989, PARASITOLOGY, V99, pS59, DOI 10.1017/S0031182000083426; Aron J.L., 1982, P139; BANG FB, 1947, T ROY SOC TROP MED H, V40, P809, DOI 10.1016/0035-9203(47)90039-4; BURKOT TR, 1988, AM J TROP MED HYG, V39, P135, DOI 10.4269/ajtmh.1988.39.135; CATTANI JA, 1986, AM J TROP MED HYG, V35, P3, DOI 10.4269/ajtmh.1986.35.3; DAVIDSON G, 1953, T ROY SOC TROP MED H, V47, P522, DOI 10.1016/S0035-9203(53)80005-2; DAY KP, 1993, P NATL ACAD SCI USA, V90, P8292, DOI 10.1073/pnas.90.17.8292; DAY KP, 1990, PARASITOL TODAY, V6, pA68; DE ZULUETA J, 1961, East Afr Med J, V38, P1; DELORON P, 1992, PARASITOL TODAY, V8, P375, DOI 10.1016/0169-4758(92)90174-Z; FORSYTH KP, 1989, AM J TROP MED HYG, V41, P259, DOI 10.4269/ajtmh.1989.41.259; Gibson F. D., 1958, West African Medical Journal NS, V7, P170; GRAVES PM, 1988, PARASITOLOGY, V96, P251, DOI 10.1017/S003118200005825X; GREENWOOD B, 1991, PARASITOL TODAY, V7, P277, DOI 10.1016/0169-4758(91)90096-7; LINDSAY SW, 1990, ANN TROP MED PARASIT, V84, P553, DOI 10.1080/00034983.1990.11812510; MARSH K, 1989, T ROY SOC TROP MED H, V83, P293, DOI 10.1016/0035-9203(89)90478-1; MARSH K, 1992, PARASITOLOGY, V104, pS53, DOI 10.1017/S0031182000075247; MARSH K, 1986, SCIENCE, V231, P150, DOI 10.1126/science.2417315; MBOGO CNM, 1993, AM J TROP MED HYG, V49, P245, DOI 10.4269/ajtmh.1993.49.245; MCLEAN AR, 1988, EPIDEMIOL INFECT, V100, P111, DOI 10.1017/S0950268800065614; Molineaux L, 1980, THE GARKI PROJECT; MUIRHEADTHOMSON RC, 1954, T ROY SOC TROP MED H, V48, P208, DOI 10.1016/0035-9203(54)90067-X; NEWBOLD CI, 1992, EXP PARASITOL, V75, P281, DOI 10.1016/0014-4894(92)90213-T; NOKES DJ, 1987, LANCET, V1, P1441; ROBERTS DJ, 1992, NATURE, V357, P689, DOI 10.1038/357689a0; WALLIKER D, 1987, SCIENCE, V236, P1661, DOI 10.1126/science.3299700; WILSON D B, 1962, East Afr Med J, V39, P593; YOUNG MARTIN D., 1949, JOUR NATION MALARIA SOC, V8, P247; 1960, REPORT PARETAVETA MA	30	161	161	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	1994	263	5149					961	963		10.1126/science.8310293	http://dx.doi.org/10.1126/science.8310293			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX165	8310293				2022-12-01	WOS:A1994MX16500033
J	THERIOT, JA; ROSENBLATT, J; PORTNOY, DA; GOLDSCHMIDTCLERMONT, PJ; MITCHISON, TJ				THERIOT, JA; ROSENBLATT, J; PORTNOY, DA; GOLDSCHMIDTCLERMONT, PJ; MITCHISON, TJ			INVOLVEMENT OF PROFILIN IN THE ACTIN-BASED MOTILITY OF L-MONOCYTOGENES IN CELLS AND IN CELL-FREE-EXTRACTS	CELL			English	Article							HEAVY-CHAIN GENE; LISTERIA-MONOCYTOGENES; DICTYOSTELIUM-DISCOIDEUM; FILAMENT NUCLEATION; CYCLIN SYNTHESIS; POLYMERIZATION; MOVEMENT; PROTEIN; SPREAD; END	Within hours of Listeria monocytogenes infection, host cell actin filaments form a dense cloud around the intracytoplasmic bacteria and then rearrange to form a polarized comet tail that is associated with moving bacteria. We have devised a cell-free extract system capable of faithfully reconstituting L. monocytogenes motility, and we have used this system to demonstrate that profilin, a host actin monomer-binding protein, is necessary for bacterial actin-based motility. We find that extracts from which profilin has been depleted do not support comet tail formation or bacterial motility. In extracts and host cells, profilin is localized to the back half of the surface of motile L. monocytogenes, the site of actin filament assembly in the tail. This association is not observed with L. monocytogenes mutants that do not express the ActA protein, a bacterial gene product necessary for motility and virulence. Profilin also fails to bind L. monocytogenes grown outside of host cytoplasm, suggesting that at least one other host cell factor is required for this association.	UNIV CALIF SAN FRANCISCO,DEPT PHARMACOL,SAN FRANCISCO,CA 94143; UNIV PENN,SCH MED,DEPT MICROBIOL,PHILADELPHIA,PA 19104; JOHNS HOPKINS UNIV,SCH MED,DEPT CARDIOL,BALTIMORE,MD 21205	University of California System; University of California San Francisco; University of Pennsylvania; Johns Hopkins University	THERIOT, JA (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM,SAN FRANCISCO,CA 94143, USA.		Rosenblatt, Jody/AAD-4260-2019	Rosenblatt, Jody/0000-0001-9460-5868; Theriot, Julie/0000-0002-2334-2535	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI036929] Funding Source: NIH RePORTER; NIAID NIH HHS [R37 AI036929] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BRUNDAGE RA, 1993, P NATL ACAD SCI USA, V90, P11890, DOI 10.1073/pnas.90.24.11890; BUSS F, 1992, CELL MOTIL CYTOSKEL, V22, P51, DOI 10.1002/cm.970220106; CAO LG, 1992, J CELL BIOL, V117, P1023, DOI 10.1083/jcb.117.5.1023; CARLSSON L, 1977, J MOL BIOL, V115, P465, DOI 10.1016/0022-2836(77)90166-8; CHAKRABORTY T, 1992, J BACTERIOL, V174, P568, DOI 10.1128/jb.174.2.568-574.1992; CONDEELIS JS, 1977, J CELL BIOL, V74, P901, DOI 10.1083/jcb.74.3.901; COOLEY L, 1992, CELL, V69, P173, DOI 10.1016/0092-8674(92)90128-Y; COX D, 1992, J CELL BIOL, V116, P943, DOI 10.1083/jcb.116.4.943; CUNNINGHAM CC, 1992, SCIENCE, V255, P325, DOI 10.1126/science.1549777; DABIRI GA, 1990, P NATL ACAD SCI USA, V87, P6068, DOI 10.1073/pnas.87.16.6068; DELOZANNE A, 1987, SCIENCE, V236, P1086, DOI 10.1126/science.3576222; DOMANN E, 1992, EMBO J, V11, P1981, DOI 10.1002/j.1460-2075.1992.tb05252.x; EDAMATSU M, 1992, J BIOCHEM-TOKYO, V112, P637, DOI 10.1093/oxfordjournals.jbchem.a123952; FINKEL T, 1994, IN PRESS P NATL ACAD; GELLIN BG, 1989, JAMA-J AM MED ASSOC, V261, P1313, DOI 10.1001/jama.261.9.1313; GOLDSCHMIDTCLERMONT PJ, 1992, MOL BIOL CELL, V3, P1015, DOI 10.1091/mbc.3.9.1015; GOLDSCHMIDTCLERMONT PJ, 1991, J CELL BIOL, V113, P1081, DOI 10.1083/jcb.113.5.1081; HAARER BK, 1990, J CELL BIOL, V110, P105, DOI 10.1083/jcb.110.1.105; HEATH JP, 1991, CELL MOTIL CYTOSKEL, V18, P245, DOI 10.1002/cm.970180402; KAISER DA, 1989, CELL MOTIL CYTOSKEL, V14, P251, DOI 10.1002/cm.970140211; KANE RE, 1980, J CELL BIOL, V86, P803, DOI 10.1083/jcb.86.3.803; KNECHT DA, 1987, SCIENCE, V236, P1081, DOI 10.1126/science.3576221; KOCKS C, 1993, J CELL SCI, V105, P699; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; LEIMEISTERWACHTER M, 1989, INFECT IMMUN, V57, P2350; MENGAUD J, 1991, MOL MICROBIOL, V5, P2273, DOI 10.1111/j.1365-2958.1991.tb02158.x; MITCHISON TJ, 1989, J CELL BIOL, V109, P637, DOI 10.1083/jcb.109.2.637; MOUNIER J, 1990, INFECT IMMUN, V58, P1048, DOI 10.1128/IAI.58.4.1048-1058.1990; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NIEBUHR K, 1993, INFECT IMMUN, V61, P2793, DOI 10.1128/IAI.61.7.2793-2802.1993; OSTER GF, 1987, J CELL SCI S, V8, P35; PANTALONI D, 1993, CELL, V75, P1007, DOI 10.1016/0092-8674(93)90544-Z; PESKIN CS, 1993, BIOPHYS J, V65, P316, DOI 10.1016/S0006-3495(93)81035-X; POLLARD TD, 1984, BIOCHEMISTRY-US, V23, P6631, DOI 10.1021/bi00321a054; POLLARD TD, 1976, J CELL BIOL, V68, P579, DOI 10.1083/jcb.68.3.579; PRING M, 1992, BIOCHEMISTRY-US, V31, P1827, DOI 10.1021/bi00121a035; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; SANGER JM, 1992, INFECT IMMUN, V60, P3609, DOI 10.1128/IAI.60.9.3609-3619.1992; SAWIN KE, 1991, J CELL BIOL, V112, P941, DOI 10.1083/jcb.112.5.941; SHARIFF A, 1992, SCIENCE, V256, P245, DOI 10.1126/science.1373523; SMITH SJ, 1988, SCIENCE, V242, P708, DOI 10.1126/science.3055292; STOSSEL TP, 1993, SCIENCE, V260, P1086, DOI 10.1126/science.8493552; SYMONS MH, 1991, J CELL BIOL, V114, P503, DOI 10.1083/jcb.114.3.503; TANAKA M, 1985, EUR J BIOCHEM, V151, P291, DOI 10.1111/j.1432-1033.1985.tb09099.x; THERIOT JA, 1991, NATURE, V352, P126, DOI 10.1038/352126a0; THERIOT JA, 1992, NATURE, V357, P257, DOI 10.1038/357257a0; Theriot Julie A., 1992, Trends in Cell Biology, V2, P219, DOI 10.1016/0962-8924(92)90298-2; TILNEY LG, 1990, J CELL BIOL, V111, P2979, DOI 10.1083/jcb.111.6.2979; TILNEY LG, 1992, J CELL BIOL, V118, P83, DOI 10.1083/jcb.118.1.83; TILNEY LG, 1983, J CELL BIOL, V97, P112, DOI 10.1083/jcb.97.1.112; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; VAZQUEZBOLAND JA, 1992, INFECT IMMUN, V60, P219, DOI 10.1128/IAI.60.1.219-230.1992	55	240	243	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 11	1994	76	3					505	517		10.1016/0092-8674(94)90114-7	http://dx.doi.org/10.1016/0092-8674(94)90114-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	8313471				2022-12-01	WOS:A1994MX20700011
J	LEE, KYC; KLINGLER, JF; MCCONNELL, HM				LEE, KYC; KLINGLER, JF; MCCONNELL, HM			ELECTRIC-FIELD-INDUCED CONCENTRATION GRADIENTS IN LIPID MONOLAYERS	SCIENCE			English	Article							TRANSITIONS; INTERFACE	Externally applied electric field gradients gave rise to lateral concentration gradients in monolayers of certain binary lipid mixtures. For binary mixtures of dihydrocholesterol and dimyristoylphosphatidylcholine, the application of an electric field gradient at pressures below the critical pressure produced a liquid-liquid phase separation in a monolayer that is otherwise homogenous. At pressures slightly above the critical pressure, a field gradient produced a large concentration gradient without phase separation. The lipid concentration gradients can be described by equilibrium thermodynamic chemical potentials. The observed effects appear to be relevant to the structure and composition of biological membranes.			LEE, KYC (corresponding author), STANFORD UNIV,DEPT CHEM,STANFORD,CA 94305, USA.							BEHANMARTIN MK, 1993, BIOCHIM BIOPHYS ACTA, V1151, P216, DOI 10.1016/0005-2736(93)90106-A; BENVEGNU DJ, 1993, J PHYS CHEM-US, V97, P6686, DOI 10.1021/j100127a019; DEUTICKE B, 1987, ANNU REV PHYSIOL, V49, P221; HECKL WM, 1988, THIN SOLID FILMS, V159, P125, DOI 10.1016/0040-6090(88)90624-4; HIRSHFELD CL, 1990, J PHYS-PARIS, V51, P1537, DOI 10.1051/jphys:0199000510140153700; Kirkwood J. G., 1961, CHEM THERMODYNAMICS; KLINGLER JF, 1993, J PHYS CHEM-US, V97, P2962, DOI 10.1021/j100114a023; KNOBLER CM, 1992, ANNU REV PHYS CHEM, V43, P207, DOI 10.1146/annurev.pc.43.100192.001231; LEE KYC, 1993, J PHYS CHEM-US, V97, P9532, DOI 10.1021/j100139a044; LINDEN CD, 1975, ACCOUNTS CHEM RES, V8, P321, DOI 10.1021/ar50094a001; MCCONNELL HM, 1991, ANNU REV PHYS CHEM, V42, P171, DOI 10.1146/annurev.physchem.42.1.171; MOHWALD H, 1990, ANNU REV PHYS CHEM, V41, P441, DOI 10.1146/annurev.pc.41.100190.002301; PHILLIPS MC, 1972, PROG SURF MEMBR SCI, V8, P184; RECTENWALD DJ, 1981, BIOCHEMISTRY-US, V20, P4505; RICE PA, 1989, P NATL ACAD SCI USA, V86, P6445, DOI 10.1073/pnas.86.17.6445; SEUL A, 1990, PHYS REV LETT, V64, P190; SHINITZKY M, 1984, PHYSL MEMBRANE FLUID, V1, pCH1; SUBRAMANIAM S, 1987, J PHYS CHEM-US, V91, P1715, DOI 10.1021/j100291a010; VOGEL V, 1988, THIN SOLID FILMS, V159, P73, DOI 10.1016/0040-6090(88)90618-9	19	85	87	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 4	1994	263	5147					655	658		10.1126/science.8303272	http://dx.doi.org/10.1126/science.8303272			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8303272				2022-12-01	WOS:A1994MU96400039
J	GEJMAN, PV; RAM, A; GELERNTER, J; FRIEDMAN, E; CAO, QH; PICKAR, D; BLUM, K; NOBLE, EP; KRANZLER, HR; OMALLEY, S; HAMER, DH; WHITSITT, F; RAO, P; DELISI, LE; VIRKKUNEN, M; LINNOILA, M; GOLDMAN, D; GERSHON, ES				GEJMAN, PV; RAM, A; GELERNTER, J; FRIEDMAN, E; CAO, QH; PICKAR, D; BLUM, K; NOBLE, EP; KRANZLER, HR; OMALLEY, S; HAMER, DH; WHITSITT, F; RAO, P; DELISI, LE; VIRKKUNEN, M; LINNOILA, M; GOLDMAN, D; GERSHON, ES			NO STRUCTURAL MUTATION IN THE DOPAMINE-D2 RECEPTOR GENE IN ALCOHOLISM OR SCHIZOPHRENIA - ANALYSIS USING DENATURING GRADIENT GEL-ELECTROPHORESIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYMERASE CHAIN-REACTION; ALPHA-SUBUNIT GENE; SCREENING-TEST; D2-DOPAMINE RECEPTOR; ALLELIC ASSOCIATION; DNA FRAGMENTS; GC-CLAMP; D2; FAMILY; DRUG	Objective.-To examine the dopamine D2 receptor (DRD2) gene coding sequences for abnormalities associated with schizophrenia or alcoholism and thereby help to resolve the controversy surrounding the reported association of alcoholism with a restriction fragment length polymorphism located close to the DRD2 gene. Design.-Mutational analysis of complete DRD2 gene coding sequences by denaturing gradient gel electrophoresis followed by direct nucleotide sequencing of detected variants. Setting.-Patients and controls from clinical and epidemiologic collections in the United States and Europe. Patients.-A total of 253 unrelated individuals, including 106 patients with schizophrenia, 113 with alcoholism, and 34 controls. For alcoholism we included patients from previously published series in which an association of illness with allele A1 was reported (Taq I site 3' to the DRD2 gene) and from other published series in which nonconfirmations of this association were reported. Nearly all persons examined were white. Main Outcome Measures.-Frequency of nonsilent variations in DRD2 gene DNA sequences in the different diagnostic groups. Results.-We found three infrequent DNA variants that predict altered amino acid sequence of the receptor. None of these is associated with either alcoholism or schizophrenia. Conclusion.-No structural coding abnormalities in the DRD2 gene are present in alcoholism or schizophrenia.	NIMH, EXPTL THERAPEUT BRANCH, BETHESDA, MD 20892 USA; YALE UNIV, MED CTR, DEPT PSYCHIAT, NEW HAVEN, CT 06520 USA; VET AFFAIRS MED CTR, W HAVEN, CT USA; KAROLINSKA HOSP, DEPT CLIN GENET, S-10401 STOCKHOLM 60, SWEDEN; UNIV TEXAS, HLTH SCI CTR, DEPT PHARMACOL, SAN ANTONIO, TX 78284 USA; UNIV CALIF LOS ANGELES, NEUROPSYCHIAT INST & BRAIN RES, ALCOHOL RES CTR, LOS ANGELES, CA USA; UNIV CONNECTICUT, CTR HLTH, ALCOHOL RES CTR, FARMINGTON, CT 06032 USA; NCI, BIOCHEM LAB, BETHESDA, MD 20892 USA; SUNY STONY BROOK, HLTH SCI CTR, DEPT PSYCHIAT & BEHAV SCI, STONY BROOK, NY 11794 USA; UNIV HELSINKI, DEPT PSYCHIAT, SF-00100 HELSINKI 10, FINLAND; NIAAA, DIV INTRAMURAL CLIN & BIOL RES, CLIN STUDIES LAB, BETHESDA, MD USA; NIAAA, NEUROGENET LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Mental Health (NIMH); Yale University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; Karolinska Institutet; Karolinska University Hospital; University of Texas System; University of Texas Health San Antonio; University of California System; University of California Los Angeles; University of Connecticut; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); State University of New York (SUNY) System; SUNY Community College; State University of New York (SUNY) Stony Brook; University of Helsinki; National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA); National Institutes of Health (NIH) - USA; NIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)	GEJMAN, PV (corresponding author), NIMH, CLIN & NEUROGENET BRANCH, 10-3N218, BETHESDA, MD 20892 USA.		kranzler, henry/AAS-1113-2020; Hamer, Dean H/L-1248-2015; Goldman, David/F-9772-2010	kranzler, henry/0000-0002-1018-0450; Hamer, Dean H/0000-0002-6211-5781; Goldman, David/0000-0002-1724-5405; Gelernter, Joel/0000-0002-4067-1859; Pickar, David/0000-0002-8596-3687	NIMH NIH HHS [MH00931] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [K20MH000931] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AMADEO S, 1993, J PSYCHIAT RES, V27, P173, DOI 10.1016/0022-3956(93)90005-M; ARINAMI T, 1993, BIOL PSYCHIAT, V33, P108, DOI 10.1016/0006-3223(93)90309-2; BARBETTI F, 1992, DIABETES, V41, P408, DOI 10.2337/diabetes.41.4.408; BLUM K, 1990, JAMA-J AM MED ASSOC, V263, P2055, DOI 10.1001/jama.263.15.2055; BOLOS A M, 1990, Journal of the American Medical Association, V264, P3156, DOI 10.1001/jama.264.24.3156; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; CATALANO M, 1992, NEUROPSYCHOBIOLOGY, V26, P1, DOI 10.1159/000118888; CLONINGER CR, 1991, JAMA-J AM MED ASSOC, V266, P1833; COMINGS DE, 1991, JAMA-J AM MED ASSOC, V266, P1793, DOI 10.1001/jama.266.13.1793; COOK BL, 1992, ALCOHOL CLIN EXP RES, V16, P806, DOI 10.1111/j.1530-0277.1992.tb00683.x; COON H, 1993, AM J HUM GENET, V52, P327; COOPER DN, 1992, ANN MED, V24, P427, DOI 10.3109/07853899209166991; DALTOSO R, 1989, EMBO J, V8, P4025, DOI 10.1002/j.1460-2075.1989.tb08585.x; DAUSSET J, 1990, GENOMICS, V6, P575, DOI 10.1016/0888-7543(90)90491-C; DEARRY A, 1991, CELL MOL NEUROBIOL, V11, P437, DOI 10.1007/BF00734808; DOHLMAN HG, 1987, BIOCHEMISTRY-US, V26, P2657, DOI 10.1021/bi00384a001; EUBANKS JH, 1992, GENOMICS, V14, P1010, DOI 10.1016/S0888-7543(05)80124-7; FINDLAY JBC, 1986, BIOCHEM J, V238, P625, DOI 10.1042/bj2380625; FISCHER SG, 1980, P NATL ACAD SCI-BIOL, V77, P4420, DOI 10.1073/pnas.77.8.4420; FRIEDMAN E, IN PRESS J CLIN ENDO; GANDELMAN KY, 1991, J NEUROCHEM, V56, P1024, DOI 10.1111/j.1471-4159.1991.tb02024.x; GEJMAN PV, 1991, GENOMICS, V9, P782, DOI 10.1016/0888-7543(91)90377-Q; GEJMAN PV, IN PRESS METHODS ENZ; GELERNLTER J, 1989, CYTOGENET CELL GENET, V1, P100; GELERNTER J, 1991, JAMA-J AM MED ASSOC, V266, P1801, DOI 10.1001/jama.266.13.1801; GELERNTER J, 1993, JAMA-J AM MED ASSOC, V269, P1673, DOI 10.1001/jama.269.13.1673; GERSHON ES, 1988, ARCH GEN PSYCHIAT, V45, P328; GIBBS LE, 1983, DRUG ALCOHOL DEPEN, V12, P279, DOI 10.1016/0376-8716(83)90071-6; GOLDMAN D, 1992, ACTA PSYCHIAT SCAND, V86, P351, DOI 10.1111/j.1600-0447.1992.tb03279.x; GOLDMAN D, 1993, ALCOHOL CLIN EXP RES, V17, P199, DOI 10.1111/j.1530-0277.1993.tb00749.x; GRANDY DK, 1989, P NATL ACAD SCI USA, V86, P9762, DOI 10.1073/pnas.86.24.9762; GRANDY DK, 1989, AM J HUM GENET, V45, P778; GREENBERG DA, 1993, AM J HUM GENET, V52, P135; HAUGE XY, 1991, GENOMICS, V10, P527, DOI 10.1016/0888-7543(91)90431-D; KARP RW, 1992, ALCOHOL CLIN EXP RES, V16, P786, DOI 10.1111/j.1530-0277.1992.tb00679.x; KOOB GF, 1988, SCIENCE, V242, P715, DOI 10.1126/science.2903550; LEMOAL M, 1991, PHYSIOL REV, V71, P155, DOI 10.1152/physrev.1991.71.1.155; LERMAN LS, 1987, METHOD ENZYMOL, V155, P482; MACDONALD ME, 1993, CELL, V72, P971, DOI 10.1016/0092-8674(93)90585-E; MITCHELL LG, 1989, ANAL BIOCHEM, V178, P239, DOI 10.1016/0003-2697(89)90631-3; MOISES HW, 1991, ARCH GEN PSYCHIAT, V48, P643; MYERS RM, 1985, NUCLEIC ACIDS RES, V13, P3131, DOI 10.1093/nar/13.9.3131; NAYLOR JA, 1992, LANCET, V340, P1066, DOI 10.1016/0140-6736(92)93080-7; NOBLE EP, 1991, ARCH GEN PSYCHIAT, V48, P648; NOBLE EP, 1993, BEHAV GENET, V23, P117; NOBLE EP, IN PRESS DRUG ALCOHO; PARSIAN A, 1991, ARCH GEN PSYCHIAT, V48, P655; PICKAR D, 1992, ARCH GEN PSYCHIAT, V49, P345; RIGGINS GJ, 1992, NAT GENET, V2, P186, DOI 10.1038/ng1192-186; SARKAR G, 1991, GENOMICS, V11, P8, DOI 10.1016/0888-7543(91)90096-W; SEEMAN P, 1993, NEUROPSYCHOPHARMACOL, V8, P137, DOI 10.1038/npp.1993.15; SELBIE LA, 1989, DNA-J MOLEC CELL BIO, V8, P683, DOI 10.1089/dna.1.1989.8.683; SELVIE LA, 1989, DNA CELL BIOL, V8, P683; SELZER ML, 1971, AM J PSYCHIAT, V127, P1653, DOI 10.1176/ajp.127.12.1653; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; SMITH SS, 1992, ARCH GEN PSYCHIAT, V49, P723; SNYDER SH, 1984, SCIENCE, V224, P22, DOI 10.1126/science.6322304; SNYDER SH, 1974, SCIENCE, V184, P1243, DOI 10.1126/science.184.4143.1243; SPITZER R, 1971, CRITICAL ISSUES PSYC; STCLAIR D, 1990, LANCET, V336, P13, DOI 10.1016/0140-6736(90)91520-K; SU Y, 1993, ARCH GEN PSYCHIAT, V50, P205; SWENSON WM, 1975, MAYO CLIN PROC, V50, P204; TURNER E, 1992, BIOL PSYCHIAT, V31, P285, DOI 10.1016/0006-3223(92)90052-2; UHL G, 1993, TRENDS NEUROSCI, V16, P83, DOI 10.1016/0166-2236(93)90128-9; WANG ZW, 1993, ARCH GEN PSYCHIAT, V50, P212; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; WEINSTEIN LS, 1990, P NATL ACAD SCI USA, V87, P8287, DOI 10.1073/pnas.87.21.8287; WISE RA, 1989, ANNU REV PSYCHOL, V40, P191, DOI 10.1146/annurev.ps.40.020189.001203; 1987, DIAGNOSTIC STATISTIC	69	203	204	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	1994	271	3					204	208		10.1001/jama.271.3.204	http://dx.doi.org/10.1001/jama.271.3.204			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ645	8277546				2022-12-01	WOS:A1994MQ64500033
J	TABATA, T; KORNBERG, TB				TABATA, T; KORNBERG, TB			HEDGEHOG IS A SIGNALING PROTEIN WITH A KEY ROLE IN PATTERNING DROSOPHILA IMAGINAL DISKS	CELL			English	Article							CELL-CELL COMMUNICATION; SEGMENT POLARITY GENES; ENGRAILED GENE; PATCHED GENE; BETA FAMILY; EXPRESSION; MELANOGASTER; COMPARTMENT; SHIBIRE; EMBRYO	The segment polarity genes hedgehog and engrailed are expressed in identical posterior-compartment-specific patterns in both Drosophila embryos and imaginal discs. We show here that the hedgehog protein is secreted, and it can cross embryo parasegment borders and the anterior-posterior compartment border of imaginal discs to neighboring cells that express neither engrailed nor hedgehog. In these cells, it is localized in discrete punctate structures that are sequestered within the polarized epithelium. Analysis of animals that have expressed hedgehog ectopically, or of a mutant that expresses hedgehog abnormally in the anterior compartment of the wing disc, indicates that hedgehog is involved in regulating patched. In the embryo, hedgehog regulation of patched apparently facilitates patched and wingless expression. In the discs, hedgehog regulation of patched and other genes in the anterior compartment helps to establish the proximodistal axis. We propose that the cell-cell communication mediated by hedgehog links the special properties of compartment borders with specification of the proximodistal axis in imaginal development.			TABATA, T (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143, USA.							ARIAS AM, 1988, DEVELOPMENT, V103, P157; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; BLAIR SS, 1992, DEVELOPMENT, V115, P21; BROOK WJ, 1993, DEVELOPMENT, V117, P1287; BRYANT SV, 1981, SCIENCE, V212, P993, DOI 10.1126/science.212.4498.993; CAMPBELL G, 1993, CELL, V74, P1113, DOI 10.1016/0092-8674(93)90732-6; CHEN MS, 1991, NATURE, V351, P583, DOI 10.1038/351583a0; DINARDO S, 1985, CELL, V43, P59, DOI 10.1016/0092-8674(85)90012-1; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; GARCIABELLIDO A, 1973, NATURE-NEW BIOL, V245, P251, DOI 10.1038/newbio245251a0; GRIGLIATTI TA, 1973, MOL GEN GENET, V120, P107, DOI 10.1007/BF00267238; GRONZALEZ F, 1991, MECH DEVELOP, V35, P43; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HIDALGO A, 1991, MECH DEVELOP, V35, P77, DOI 10.1016/0925-4773(91)90059-F; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOCH M, 1993, CURR OPIN GENET DEV, V3, P566, DOI 10.1016/0959-437X(93)90092-4; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1993, DEVELOPMENT, V117, P283; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KARLSSON J, 1980, J EMBRYOL EXP MORPH, V59, P315; KORNBERG T, 1981, P NATL ACAD SCI-BIOL, V78, P1095, DOI 10.1073/pnas.78.2.1095; KOSAKA T, 1983, J NEUROBIOL, V14, P207, DOI 10.1002/neu.480140305; LAWRENCE PA, 1976, DEV BIOL, V50, P321, DOI 10.1016/0012-1606(76)90155-X; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; MEINHARDT H, 1983, DEV BIOL, V96, P375, DOI 10.1016/0012-1606(83)90175-6; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; MORATA G, 1975, NATURE, V255, P614, DOI 10.1038/255614a0; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PHILLIPS RG, 1990, DEVELOPMENT, V110, P105; POODRY CA, 1979, J CELL BIOL, V81, P520, DOI 10.1083/jcb.81.3.520; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; RAFTERY LA, 1991, DEVELOPMENT, V113, P27; SCHUBIGER G, 1978, DEV BIOL, V67, P286, DOI 10.1016/0012-1606(78)90200-2; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; SPRADLING AC, 1982, SCIENCE, V218, P341, DOI 10.1126/science.6289435; STJOHNSTON D, 1992, CELL, V68, P201; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TARTAKOFF AM, 1983, CELL, V32, P1026, DOI 10.1016/0092-8674(83)90286-6; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; THUMMEL CS, 1988, GENE, V74, P445, DOI 10.1016/0378-1119(88)90177-1; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VANDERBLIEK AM, 1991, NATURE, V351, P411, DOI 10.1038/351411a0; WHARTON KA, 1993, DEVELOPMENT, V117, P807	51	562	591	0	21	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 14	1994	76	1					89	102		10.1016/0092-8674(94)90175-9	http://dx.doi.org/10.1016/0092-8674(94)90175-9			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287482				2022-12-01	WOS:A1994MR49500009
J	CLERICI, M; LEVIN, JM; KESSLER, HA; HARRIS, A; BERZOFSKY, JA; LANDAY, AL; SHEARER, GM				CLERICI, M; LEVIN, JM; KESSLER, HA; HARRIS, A; BERZOFSKY, JA; LANDAY, AL; SHEARER, GM			HIV-SPECIFIC T-HELPER ACTIVITY IN SERONEGATIVE HEALTH-CARE WORKERS EXPOSED TO CONTAMINATED BLOOD	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; POLYMERASE CHAIN-REACTION; CELL-MEDIATED-IMMUNITY; LYMPHOCYTES-T; SEROPOSITIVE INDIVIDUALS; INFECTED INDIVIDUALS; TYPE-1; SURVEILLANCE; RECOGNITION; RESPONSES	Objective.-To evaluate human immunodeficiency virus (HIV) type 1-specific cellular immune responses in HIV-seronegative health care workers with occupational high-risk exposures to HIV-infected (HIV-positive) patients. Design.-Peripheral blood mononuclear cells (PBMCs) were obtained after occupational exposures to HIV, and PBMCs from health care workers exposed to HIV-negative patients served as controls. The PBMCs were stimulated in vitro with HIV envelope synthetic peptides. Interleukin 2 (IL-2) production was measured in a bioassay. The HIV antibody status was determined by standard enzyme-linked immunosorbent assays. Exposed individuals were also evaluated for HIV proviral DNA by polymerase chain reaction techniques. Participants.-The PBMCs from eight health care workers with high-risk exposures and nine control health care workers were studied. Results.-The PBMCs from all individuals showed strong IL-2 production to control antigens, indicating intact T-helper function. Interleukin 2 production to HIV peptides was detected in PBMCs from six of eight HIV-exposed individuals, but in only one of the nine health care workers exposed to HIV-negative body fluids (P<.008). None of the HIV-exposed health care workers became infected as determined by negative HIV antibody and polymerase chain reaction analysis after follow-up evaluation that ranged from 8 to 64 weeks. Conclusion.-Human immunodeficiency virus-specific T-helper activity was detected in six (75%) of eight HIV-negative health care workers with exposure to HIV-positive body fluids. Potent HIV-specific T-helper activity was detectable 4 to 8 weeks after the exposure and was lost in individuals followed up for 8 to 64 weeks. Three health care workers remained responsive at 8, 19, and 24 weeks. Exposure to HIV without evidence of subsequent infection appears to result in activation of cellular immunity without activation of antibody production.	NCI, EXPTL IMMUNOL BRANCH, BLDG 10, ROOM 4B17, BETHESDA, MD 20892 USA; NCI, METAB BRANCH, BETHESDA, MD 20892 USA; RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT IMMUNOL MICROBIOL, CHICAGO, IL 60612 USA; RUSH PRESBYTERIAN ST LUKES MED CTR, DEPT MED, CHICAGO, IL 60612 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Rush University; Rush University				Clerici, Mario/0000-0001-5920-6191				AHEARNE PM, 1988, AIDS RES HUM RETROV, V4, P259, DOI 10.1089/aid.1988.4.259; BELL DM, 1991, AM J MED, V91, pS294, DOI 10.1016/0002-9343(91)90385-B; BERZOFSKY JA, 1988, NATURE, V334, P706, DOI 10.1038/334706a0; BRETSCHER PA, 1974, CELL IMMUNOL, V13, P171, DOI 10.1016/0008-8749(74)90237-8; BRETSCHER PA, 1992, SCIENCE, V257, P539, DOI 10.1126/science.1636090; Butcher A., 1992, Clinical Immunology Newsletter, V12, P73, DOI 10.1016/0197-1859(92)90008-T; CEASE KB, 1987, P NATL ACAD SCI USA, V84, P4249, DOI 10.1073/pnas.84.12.4249; Centers for Disease Control (CDC), 1988, MMWR Morb Mortal Wkly Rep, V37, P229; CHAMBERLAND ME, 1991, JAMA-J AM MED ASSOC, V266, P3459, DOI 10.1001/jama.266.24.3459; CLERICI M, 1991, EUR J IMMUNOL, V21, P1345, DOI 10.1002/eji.1830210603; CLERICI M, 1989, NATURE, V339, P383, DOI 10.1038/339383a0; CLERICI M, 1991, J INFECT DIS, V164, P178, DOI 10.1093/infdis/164.1.178; CLERICI M, 1992, J INFECT DIS, V165, P1012, DOI 10.1093/infdis/165.6.1012; CLERICI M, 1989, J CLIN INVEST, V84, P1892, DOI 10.1172/JCI114376; COURGNAUD V, 1991, AIDS RES HUM RETROV, V7, P337, DOI 10.1089/aid.1991.7.337; DEROSSI A, 1991, AIDS, V5, P15, DOI 10.1097/00002030-199101000-00002; DOLIN R, 1991, ANN INTERN MED, V114, P119, DOI 10.7326/0003-4819-114-2-119; Hale P M, 1989, Int Immunol, V1, P409, DOI 10.1093/intimm/1.4.409; HENDERSON DK, 1990, ANN INTERN MED, V113, P740, DOI 10.7326/0003-4819-113-10-740; KUNDU SK, 1992, AIDS, V6, P643, DOI 10.1097/00002030-199207000-00005; MARCUS R, 1988, NEW ENGL J MED, V319, P1118, DOI 10.1056/NEJM198810273191703; PALTER F, 1989, IMMUNODEFIC REV, V1, P227; PARISH CR, 1972, TRANSPLANT REV-DENMA, V13, P35; PIATAK M, 1993, SCIENCE, V259, P1749, DOI 10.1126/science.8096089; RANKI A, 1989, AIDS, V3, P63, DOI 10.1097/00002030-198902000-00002; TACKET CO, 1990, AIDS RES HUM RETROV, V6, P535, DOI 10.1089/aid.1990.6.535; UCHIYAMA T, 1981, J IMMUNOL, V126, P1393; WAHREN B, 1989, J ACQ IMMUN DEF SYND, V2, P448; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WALKER BD, 1988, SCIENCE, V240, P64, DOI 10.1126/science.2451288; WEISS RA, 1993, SCIENCE, V260, P1273, DOI 10.1126/science.8493571; 1987, MMWR MORB MORTAL WKL, V36, P285; 1992, MMWR MORB MORTAL WKL, V41, P501; 1992, MMWR MORB MORTAL WKL, V41, P823	34	184	190	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	1994	271	1					42	46		10.1001/jama.271.1.42	http://dx.doi.org/10.1001/jama.271.1.42			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN725	8258885				2022-12-01	WOS:A1994MN72500029
J	HAMPSON, NB; KRAMER, CC; DUNFORD, RG; NORKOOL, DM				HAMPSON, NB; KRAMER, CC; DUNFORD, RG; NORKOOL, DM			CARBON-MONOXIDE POISONING FROM INDOOR BURNING OF CHARCOAL BRIQUETS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note								Objective.-To describe the case characteristics of a series of patients poisoned with carbon monoxide (CO) resulting from indoor burning of charcoal briquets. Design.-Cases of patients with unintentional CO poisoning referred for treatment with hyperbaric oxygen were reviewed. Cases that occurred as the result of indoor burning of charcoal briquets were analyzed. Setting.-A private, urban, tertiary care center. Patients.-Seventy-nine patients ranging from 3 months to 87 years of age referred from 10 counties within the state of Washington between October 1982 and October 1993. Results.-Of 509 patients treated for acute unintentional CO poisoning, 79 cases occurred in 32 incidents as a result of indoor burning of charcoal briquets, for the purpose of either home heating or cooking. A majority of cases occurred in the months of October through January, commonly during power outages or when electricity was intentionally disconnected. Patients of minority races were disproportionately represented compared with the general population of the region. Conclusions.-Carbon monoxide poisoning is a significant hazard from indoor use of charcoal briquets. All cases are avoidable and public awareness of the risk should be enhanced.	VIRGINIA MASON RES CTR,DEPT HYPERBAR,SEATTLE,WA 98101; VIRGINIA MASON MED CTR,DEPT MED,SEATTLE,WA 98101	Virginia Mason Medical Center; Virginia Mason Medical Center								BARON RC, 1989, AM J PUBLIC HEALTH, V79, P1656, DOI 10.2105/AJPH.79.12.1656; BARRET L, 1985, CLIN TOXICOL, V23, P309; COBB N, 1991, JAMA-J AM MED ASSOC, V266, P659, DOI 10.1001/jama.266.5.659; FAIN DB, 1988, AM J FOREN MED PATH, V9, P301, DOI 10.1097/00000433-198812000-00006; FINCK PA, 1966, MIL MED, V131, P1513, DOI 10.1093/milmed/131.12.1513; GASMAN JD, 1990, WESTERN J MED, V153, P656; GEEHR EC, 1989, AM J EMERG MED, V7, P598, DOI 10.1016/0735-6757(89)90282-9; GRACE TW, 1981, JAMA-J AM MED ASSOC, V246, P1698; HAMPSON NB, 1992, JAMA-J AM MED ASSOC, V267, P538, DOI 10.1001/jama.267.4.538; KIM YS, 1985, J EPIDEMIOL COMMUN H, V39, P79, DOI 10.1136/jech.39.1.79; LIU KS, 1993, J EXPO ANAL ENV EPID, V3, P143; PIANTADOSI CA, 1990, UPDATE INTENSIVE CAR, V10, P460; RADFORD EP, 1982, PHS821250 US DEP HLT; STERNBACH G, 1991, WESTERN J MED, V154, P737; WILSON EF, 1972, J AMER MED ASSOC, V221, P405, DOI 10.1001/jama.221.4.405; YATES MW, 1967, J ENV HLTH, V29, P413; 1982, MMWR MORB MORTAL WKL, V31, P529; 1966, ANESTH ANALG, V45, P664; 1989, AIR CONTAMINANT 1910, P1000	19	42	43	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	1994	271	1					52	53		10.1001/jama.271.1.52	http://dx.doi.org/10.1001/jama.271.1.52			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN725	8258888				2022-12-01	WOS:A1994MN72500031
J	ALDRICH, FD				ALDRICH, FD			RADIATION FROM DIGITAL CLOCKS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Letter																		GAUGER JR, 1985, IEEE T POWER AP SYST, V104, P2436, DOI 10.1109/TPAS.1985.318988; 1989, BONNEVILLE POWER ADM	2	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1993	270	7					879	879						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR612	8340991				2022-12-01	WOS:A1993LR61200038
J	BOWERMAN, B; DRAPER, BW; MELLO, CC; PRIESS, JR				BOWERMAN, B; DRAPER, BW; MELLO, CC; PRIESS, JR			THE MATERNAL GENE SKN-1 ENCODES A PROTEIN THAT IS DISTRIBUTED UNEQUALLY IN EARLY C-ELEGANS EMBRYOS	CELL			English	Article							NEMATODE CAENORHABDITIS-ELEGANS; CELLULAR INTERACTIONS; ESCHERICHIA-COLI; LOCALIZATION; LINEAGES; REVERSAL; GLP-1; GUT	The autonomous or cell-intrinsic developmental properties of early embryonic blastomeres in nematodes are thought to result from the action of maternally provided determinants. After the first cleavage of the C. elegans embryo, only the posterior blastomere, P1, has a cell-intrinsic ability to produce pharyngeal cells. The product of the maternal gene skn-1 is required for P1 to produce pharyngeal cells. We show here that the Skn-1 protein is nuclear localized and that P1 appears to accumulate markedly higher levels of Skn-1 protein than its sister, the AB blastomere. We have examined the distribution of Skn-1 protein in embryos from mothers with maternal-effect mutations in the genes mex-1, par-1, and pie-1. These results suggest that mex-1(+) and par-1(+) activities are required for the unequal distribution of the Skn-1 protein and that pie-1(+) activity may function to regulate the activity of Skn-1 protein in the descendants of the posterior blastomere P1.	FRED HUTCHINSON CANC RES CTR,DEPT BASIC SCI,SEATTLE,WA 98104; UNIV WASHINGTON,DEPT ZOOL,SEATTLE,WA 98195	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle				Draper, Bruce W/0000-0002-4397-7749				ALBERTSON DG, 1976, PHILOS T ROY SOC B, V275, P299, DOI 10.1098/rstb.1976.0085; AUSTIN J, 1987, CELL, V51, P589, DOI 10.1016/0092-8674(87)90128-0; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; Boveri T., 1910, FESTSCHRIFT R HERTWI, VIII, P133; Boveri Th., 1899, Festschrift C von Kupffer, P383; BOWERMAN B, 1992, CELL, V68, P1061, DOI 10.1016/0092-8674(92)90078-Q; BOWERMAN B, 1992, DEVELOPMENT, V116, P1113; BRENNER S, 1974, GENETICS, V77, P71; DAVIDSON EH, 1991, DEVELOPMENT, V113, P1; EDGAR LG, 1986, DEV BIOL, V114, P109, DOI 10.1016/0012-1606(86)90387-8; GOLDSTEIN B, 1992, NATURE, V357, P255, DOI 10.1038/357255a0; HARLOW E, 1988, ANTIBODIES LABORATOR; HIRSH D, 1976, DEV BIOL, V49, P200, DOI 10.1016/0012-1606(76)90267-0; KEMPHUES KJ, 1988, CELL, V52, P311, DOI 10.1016/S0092-8674(88)80024-2; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; KIRBY C, 1990, DEV BIOL, V142, P203, DOI 10.1016/0012-1606(90)90164-E; KONAPKA JB, 1984, J VIROL, V51, P223; LAUFER JS, 1980, CELL, V19, P569, DOI 10.1016/S0092-8674(80)80033-X; MELLO CC, 1992, CELL, V70, P163, DOI 10.1016/0092-8674(92)90542-K; MILLER DM, 1983, CELL, V34, P477, DOI 10.1016/0092-8674(83)90381-1; PRIESS JR, 1987, CELL, V48, P241, DOI 10.1016/0092-8674(87)90427-2; PRIESS JR, 1987, CELL, V51, P601, DOI 10.1016/0092-8674(87)90129-2; Sambrook J., 1989, MOL CLONING LAB MANU; SCHIERENBERG E, 1985, COLD SPRING HARB SYM, V50, P59, DOI 10.1101/SQB.1985.050.01.010; SCHIERENBERG E, 1987, DEV BIOL, V122, P452, DOI 10.1016/0012-1606(87)90309-5; SCHNABEL R, 1991, MECH DEVELOP, V34, P85, DOI 10.1016/0925-4773(91)90046-9; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPINDLER KR, 1984, J VIROL, V49, P132, DOI 10.1128/JVI.49.1.132-141.1984; Stevens NM, 1909, ARCH ENTWICKLUNG ORG, V27, P622, DOI 10.1007/BF02161872; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; TAGGART RT, 1983, SCIENCE, V219, P1228, DOI 10.1126/science.6402815; WOOD WB, 1991, NATURE, V349, P536, DOI 10.1038/349536a0	33	208	214	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	AUG 13	1993	74	3					443	452		10.1016/0092-8674(93)80046-H	http://dx.doi.org/10.1016/0092-8674(93)80046-H			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LT739	8348611				2022-12-01	WOS:A1993LT73900006
J	SCHAPIRA, RM; SCHAPIRA, MM; FUNAHASHI, A; MCAULIFFE, TL; VARKEY, B				SCHAPIRA, RM; SCHAPIRA, MM; FUNAHASHI, A; MCAULIFFE, TL; VARKEY, B			THE VALUE OF THE FORCED EXPIRATORY TIME IN THE PHYSICAL DIAGNOSIS OF OBSTRUCTIVE AIRWAYS DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LIKELIHOOD RATIOS; HISTORY	Objective.-To evaluate the test characteristics-of the forced expiratory time (FET) in the diagnosis of obstructive airways disease. Design.-A cross-sectional diagnostic test study. The FET of 400 subjects was measured by a physician examiner and was compared with the criterion standard of spirometry. In a second sample of 100 subjects, the FET was measured by pairs of physician examiners to evaluate interexaminer agreement. Setting.-A pulmonary function test laboratory at a tertiary care hospital that receives referrals for preoperative evaluations, acute and chronic pulmonary disease, and occupational lung disease. Subjects.-A consecutive sample of patients who were referred to the pulmonary function laboratory from primary care internists, pulmonary physicians, and surgeons. Interventions.-None. Main Outcome Measures.-The sensitivity and specificity of the FET in the diagnosis of obstructive airways disease at cutoff values ranging from 2 to 14 seconds. A receiver operating characteristic curve was used to evaluate the diagnostic performance of the FET. Likelihood ratio lines were determined using a logistic regression model adjusting for the subjects age. Interexaminer agreement was evaluated with a kappa statistic. Results.-Using the FET maneuver with a cutoff value of 6 seconds will correctly diagnose the greatest number of subjects with obstructive airways disease. The FET maneuver is more discriminating for subjects 60 years or older compared with younger subjects. The positive likelihood ratio for a subject aged 60 years or older with an FET of 4 to 6 seconds is 0.42 (95% confidence interval [CI], 0.24 to 0.73); of 6 to 8 seconds, 2.19 (95% CI, 1.02 to 4.80); and of greater than 8 seconds, 4.08 (95% CI, 2.54 to 6.79). The kappa statistic for interexaminer agreement is 0.70. Conclusions.-The FET demonstrates moderately good performance as a diagnostic test for obstructive airways disease. The value of the test will depend on the pretest probability of disease and the clinical circumstances in which it is used.	MED COLL WISCONSIN,DEPT INTERNAL MED,MILWAUKEE,WI 53226; MED COLL WISCONSIN,DIV GEN INTERNAL MED,MILWAUKEE,WI 53226; CLEMENT J ZABLOCKI VET AFFAIRS MED CTR,GEN INTERNAL MED SECT,MILWAUKEE,WI 53295; MED COLL WISCONSIN,DIV PULM & CRIT CARE MED,MILWAUKEE,WI 53226	Medical College of Wisconsin; Medical College of Wisconsin; Medical College of Wisconsin	SCHAPIRA, RM (corresponding author), CLEMENT J ZABLOCKI VET AFFAIRS MED CTR,PULM & CRIT CARE MED SECT,111-E,5000 W NATL AVE,MILWAUKEE,WI 53295, USA.							ALBERT A, 1982, CLIN CHEM, V28, P1113; BADGETT RG, 1993, AM J MED, V94, P188, DOI 10.1016/0002-9343(93)90182-O; BARKUN AN, 1991, AM J MED, V91, P512, DOI 10.1016/0002-9343(91)90188-4; BATES B, 1991, GUIDE PHYSICAL EXAMI, P231; BURROWS B, 1992, MERCK MANUAL DIAGNOS, P646; CAMPBELL EJ, 1969, THORAX, V24, P1, DOI 10.1136/thx.24.1.1; CENTOR RM, 1992, MED DECIS MAKING, V12, P229, DOI 10.1177/0272989X9201200309; CHERNIAK RM, 1972, RESPIRATION HLTH DIS, P217; CHERNIAK RM, 1972, RESPIRATION HLTH DIS, P303; FITZGERALD FT, 1990, WESTERN J MED, V152, P377; GEORGOPOULOS D, 1991, CHRONIC OBSTRUCTIVE, P357; GODFREY S, 1969, THORAX, V24, P4, DOI 10.1136/thx.24.1.4; GODFREY S, 1970, THORAX, V25, P285, DOI 10.1136/thx.25.3.285; GOLDMAN HI, 1959, AM REV TUBERC PULM, V79, P457; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HOLLEMAN DR, 1993, J GEN INTERN MED, V8, P63, DOI 10.1007/BF02599985; HONIG E, 1990, CLIN METHODS, P193; KERN DG, 1991, CHEST, V100, P636, DOI 10.1378/chest.100.3.636; LAL S, 1964, BRIT MED J, V1, P814, DOI 10.1136/bmj.1.5386.814; MACDONALD JB, 1975, THORAX, V30, P554, DOI 10.1136/thx.30.5.554; MORRIS JF, 1973, AM REV RESPIR DIS, V108, P1000; MORRIS JF, 1971, AM REV RESPIR DIS, V103, P57; Paik, 2003, STAT METHODS RATES P, P598; PETERSON MC, 1992, WESTERN J MED, V156, P163; PETTY TL, 1988, HOSP PRACT, V23, P39; PETTY TL, 1989, TXB INTERNAL MED, P1884; Pingleton Susan K., 1993, P565; ROSENBLATT G, 1962, NEW ENGL J MED, V267, P432, DOI 10.1056/NEJM196208302670903; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2650, DOI 10.1001/jama.267.19.2650; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2683; SMITH JG, 1992, CURRENT DIAGNOSIS, V8, P343; SNIDER GL, 1988, TXB RESPIRATORY MED, P1069; TISI GM, 1980, PULMONARY PHYSL CLIN, P145; TISI GM, 1980, PULMONARY PHYSL CLIN, P53; TSI GM, 1980, PULMONARY PHYSL CLIN, P29; TSI GM, 1980, PULMONARY PHYSL CLIN, P131; WEG JG, 1989, CLIN DIAGNOSIS PHYSL, P197; WEINMANN GG, 1988, PRINCIPLES PRACTICE, P202; WILLIAMS JW, 1992, ANN INTERN MED, V117, P705, DOI 10.7326/0003-4819-117-9-705; WILLIAMS JW, 1992, JAMA-J AM MED ASSOC, V267, P2645, DOI 10.1001/jama.267.19.2645; [No title captured]; 1991, AM REV RESPIR DIS, V144, P1202	42	31	35	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 11	1993	270	6					731	736		10.1001/jama.270.6.731	http://dx.doi.org/10.1001/jama.270.6.731			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ338	8336375				2022-12-01	WOS:A1993LQ33800028
J	HALL, K; COLE, DG; YEH, Y; SCHOLEY, JM; BASKIN, RJ				HALL, K; COLE, DG; YEH, Y; SCHOLEY, JM; BASKIN, RJ			FORCE-VELOCITY RELATIONSHIPS IN KINESIN-DRIVEN MOTILITY	NATURE			English	Article							CENTRIFUGE MICROSCOPE; MOVEMENT; MOLECULES; INVITRO	KINESIN is a microtubule-based motor protein that uses energy released from Mg-ATP hydrolysis to generate force for the movement of intracellular membranes towards the fast-growing (plus) ends of microtubule tracks in cells1. Kinesin-driven microtubule movement can be visualized and quantified using light microscope motility assays2-5 but our understanding of how kinesin generates force and motion is incomplete6. Here we report the use of a centrifuge microscope7,8 to obtain force-velocity curves for kinesin-driven motility and to estimate that the maximal isometric force generated per kinesin is 0.12+/-0.03 pN per molecule.	UNIV CALIF DAVIS, MOLEC & CELLULAR BIOL SECT, BIOPHYS GRAD GRP, DAVIS, CA 95616 USA; UNIV CALIF DAVIS, DEPT APPL SCI, DAVIS, CA 95616 USA	University of California System; University of California Davis; University of California System; University of California Davis								BLOCK SM, 1990, NATURE, V348, P348, DOI 10.1038/348348a0; BLOOM G S, 1992, Current Opinion in Cell Biology, V4, P66, DOI 10.1016/0955-0674(92)90060-P; BUSTER D, 1991, J CELL SCI, P109; COHN SA, 1989, J BIOL CHEM, V264, P4290; DASILVA LB, 1992, SCIENCE, V258, P269, DOI 10.1126/science.1411525; GELLES J, 1988, NATURE, V331, P450, DOI 10.1038/331450a0; GITTES F, 1993, J CELL BIOL, V120, P923, DOI 10.1083/jcb.120.4.923; GOLDMAN AJ, 1967, CHEM ENG SCI, V22, P637, DOI 10.1016/0009-2509(67)80047-2; Hill AV, 1938, PROC R SOC SER B-BIO, V126, P136, DOI 10.1098/rspb.1938.0050; HOWARD J, 1989, NATURE, V342, P154, DOI 10.1038/342154a0; KAMIMURA S, 1992, J CELL BIOL, V118, P865, DOI 10.1083/jcb.118.4.865; KAMITSUBO E, 1989, PROTOPLASMA, V152, P148, DOI 10.1007/BF01323074; KUO SC, 1993, SCIENCE, V260, P232, DOI 10.1126/science.8469975; OIWA K, 1990, P NATL ACAD SCI USA, V87, P7893, DOI 10.1073/pnas.87.20.7893; ROMBERG L, 1993, NATURE, V361, P168, DOI 10.1038/361168a0; SCHOLEY JM, 1989, NATURE, V338, P355, DOI 10.1038/338355a0; VALE RD, 1993, SCIENCE, V260, P169, DOI 10.1126/science.8469971; YANG JT, 1990, SCIENCE, V249, P42, DOI 10.1126/science.2142332	18	24	24	0	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 29	1993	364	6436					457	459		10.1038/364457a0	http://dx.doi.org/10.1038/364457a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP640	8332217				2022-12-01	WOS:A1993LP64000059
J	BERRY, ZS; LYNN, J				BERRY, ZS; LYNN, J			HOSPICE MEDICINE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CANCER; PAIN		DARTMOUTH COLL,HITCHCOCK MED CTR,HANOVER,NH 03756	Dartmouth College	BERRY, ZS (corresponding author), GEORGE WASHINGTON UNIV,WASHINGTON,DC 20052, USA.							[Anonymous], 1992, J Clin Oncol, V10, P1976; Bonica JJ, 1953, MANAGEMENT PAIN; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; BURCHMAN SL, 1992, PRACTICAL MANAGEMENT; DAUT RL, 1982, CANCER-AM CANCER SOC, V50, P1913, DOI 10.1002/1097-0142(19821101)50:9<1913::AID-CNCR2820500944>3.0.CO;2-R; Fields HE, 1991, CORE CURRICULUM PROF; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; LYNN J, 1983, HASTINGS CENT REP, V13, P17, DOI 10.2307/3560572; MARKS RM, 1973, ANN INTERN MED, V78, P173, DOI 10.7326/0003-4819-78-2-173; PORTER J, 1980, NEW ENGL J MED, V302, P123; RHYMES J, 1990, JAMA-J AM MED ASSOC, V264, P369, DOI 10.1001/jama.264.3.369; SAUNDERS CM, 1981, THERAPY PAIN; SOLOMON MZ, 1993, AM J PUBLIC HEALTH, V83, P14, DOI 10.2105/AJPH.83.1.14; SULLIVAN RJ, 1993, J GEN INTERN MED, V8, P220, DOI 10.1007/BF02599271; TWYCROSS RG, 1974, INT J CLIN PHARM TH, V9, P184; TWYCROSS RG, 1982, PAIN, V14, P303, DOI 10.1016/0304-3959(82)90137-3; 1990, CANCER PAIN RELIEF P	17	8	8	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					221	223		10.1001/jama.270.2.221	http://dx.doi.org/10.1001/jama.270.2.221			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315738				2022-12-01	WOS:A1993LL36800024
J	TAUSSIG, R; INIGUEZLLUHI, JA; GILMAN, AG				TAUSSIG, R; INIGUEZLLUHI, JA; GILMAN, AG			INHIBITION OF ADENYLYL-CYCLASE BY G(I-ALPHA)	SCIENCE			English	Article							BINDING REGULATORY COMPONENT; G-PROTEIN SUBUNITS; SIGNAL TRANSDUCTION; ESCHERICHIA-COLI; BETA-GAMMA; ALPHA; EXPRESSION; PURIFICATION; MEMBRANES; RECEPTOR	Evidence suggests that both alpha and betagamma subunits of heterotrimeric guanine nucleotide-binding regulatory proteins (G proteins) inhibit adenylyl cyclase. Although type I adenylyl cyclase is inhibited directly by exogenous betagamma, inhibition of adenylyl cyclase by G(ialpha) has not been convincingly demonstrated in vitro. Concentration-dependent inhibition of adenylyl cyclases by purified G(ialpha) subunits is described. Activated G(ialpha) but not G(oalpha) was effective, and myristoylation of G(ialpha) was required. The characteristics of the inhibitory effect were dependent on the type of adenylyl cyclase and the nature of the activator of the enzyme. The concentrations of G(ialpha) required to inhibit adenylyl cyclase were substantially higher than those normally thought to be relevant physiologically. However, analysis indicates that these concentrations may be relevant and reasonable.			TAUSSIG, R (corresponding author), UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.			Iniguez-Lluhi, Jorge/0000-0001-7010-089X	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034497, R37GM034497] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34497] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERSTEIN G, 1992, CELL, V70, P41; BIRNBAUMER L, 1987, TRENDS PHARMACOL SCI, V8, P209, DOI 10.1016/0165-6147(87)90064-2; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BREITWIESER GE, 1988, J GEN PHYSIOL, V91, P469, DOI 10.1085/jgp.91.4.469; FREISSMUTH M, 1989, J BIOL CHEM, V264, P21907; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P9695, DOI 10.1073/pnas.89.20.9695; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; GRAZIANO MP, 1989, J BIOL CHEM, V264, P409; ISHIKAWA Y, 1992, J BIOL CHEM, V267, P13553; JAKOBS KH, 1979, N-S ARCH PHARMACOL, V310, P113, DOI 10.1007/BF00500275; KATADA T, 1984, J BIOL CHEM, V259, P3586; KATADA T, 1984, J BIOL CHEM, V259, P3568; LINDER ME, 1993, P NATL ACAD SCI USA, V90, P3675, DOI 10.1073/pnas.90.8.3675; LINDER ME, 1991, J BIOL CHEM, V266, P4654; LINDER ME, 1990, J BIOL CHEM, V265, P8243; MAY DC, 1985, J BIOL CHEM, V260, P5829; MUMBY SM, 1990, P NATL ACAD SCI USA, V87, P728, DOI 10.1073/pnas.87.2.728; MUNTZ KH, 1992, CIRCULATION, V86, P764; ROSS EM, 1977, J BIOL CHEM, V252, P5761; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMIGEL MD, 1986, J BIOL CHEM, V261, P1976; STERNWEIS PC, 1990, TRENDS NEUROSCI, V13, P122, DOI 10.1016/0166-2236(90)90002-R; STERNWEIS PC, 1984, J BIOL CHEM, V259, P3806; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TANG WJ, 1991, J BIOL CHEM, V266, P8595; TAUSSIG R, 1993, J BIOL CHEM, V268, P9; TAUSSIG R, UNPUB; WONG YH, 1992, SCIENCE, V255, P339, DOI 10.1126/science.1347957; WONG YH, 1991, NATURE, V351, P63, DOI 10.1038/351063a0; YATANI A, 1987, SCIENCE, V235, P207, DOI 10.1126/science.2432660	31	329	337	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 9	1993	261	5118					218	221		10.1126/science.8327893	http://dx.doi.org/10.1126/science.8327893			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL596	8327893				2022-12-01	WOS:A1993LL59600043
J	LEYSER, HMO; LINCOLN, CA; TIMPTE, C; LAMMER, D; TURNER, J; ESTELLE, M				LEYSER, HMO; LINCOLN, CA; TIMPTE, C; LAMMER, D; TURNER, J; ESTELLE, M			ARABIDOPSIS AUXIN-RESISTANCE GENE-AXR1 ENCODES A PROTEIN RELATED TO UBIQUITIN-ACTIVATING ENZYME-E1	NATURE			English	Article							THALIANA; SEQUENCE; GENE; TRANSFORMATION; EXPRESSION; MUTANTS; CLONING; LINKAGE	THE plant hormone auxin has a central role in many aspects of plant growth and development1,2. By screening for mutants of Arabidopsis that are resistant to exogenous auxin, we have identified several genes that are required for normal auxin response3. One of these genes, AXR1, is defined by recessive mutations that confer auxin resistance to the roots, rosettes and inflorescences of mutant plants4-6. In addition, axr1 mutants display a variety of morphological defects that are consistent with a reduction in auxin sensitivity5. Here we isolate the AXR1 gene using a map-based approach and report that AXR1 encodes a new protein with significant sequence similarity to the ubiquitin-activating enzyme E1. The AXR1 protein is highly diverged from previously characterized E1 enzymes, however, and lacks a key cysteine residue that is essential for E1 activity7. AXR1 may therefore define a new class of enzymes in the ubiquitin pathway or it may have a novel function in cellular regulation which is unrelated to ubiquitin conjugation.	INDIANA UNIV,DEPT BIOL,BLOOMINGTON,IN 47405	Indiana University System; Indiana University Bloomington			Leyser, Ottoline/AAC-5577-2019; Estelle, Mark/ABD-6742-2021	Leyser, Ottoline/0000-0003-2161-3829				CENCIARELLI C, 1992, SCIENCE, V257, P795, DOI 10.1126/science.1323144; CHANG C, 1988, P NATL ACAD SCI USA, V85, P6856, DOI 10.1073/pnas.85.18.6856; Davies P. J., 1988, PLANT HORMONES THEIR, P1; DELLAPORTA SL, 1983, PLANT MOL BIOL REP, V1, P181; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ESTELLE M, 1992, BIOESSAYS, V14, P439, DOI 10.1002/bies.950140703; ESTELLE MA, 1987, MOL GEN GENET, V206, P200, DOI 10.1007/BF00333575; EVANS ML, 1984, ENCY PLANT PHYSL, V10, P23; FINLEY K, 1991, REV CELL BIOL, V7, P25; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HATFIELD PM, 1990, J BIOL CHEM, V265, P15813; HATFIELD PM, 1992, J BIOL CHEM, V267, P14799; LINCOLN C, 1990, PLANT CELL, V2, P1071, DOI 10.1105/tpc.2.11.1071; LINCOLN C, 1991, IOWA ACAD SCI, V98, P68; MCGRATH JP, 1991, EMBO J, V10, P227, DOI 10.1002/j.1460-2075.1991.tb07940.x; MORI S, 1992, J BIOL CHEM, V267, P6429; NAIRN CJ, 1988, GENE, V65, P247, DOI 10.1016/0378-1119(88)90461-1; NAM HG, 1989, PLANT CELL, V1, P699, DOI 10.1105/tpc.1.7.699; OLSZEWSKI NE, 1988, NUCLEIC ACIDS RES, V16, P10765, DOI 10.1093/nar/16.22.10765; PAOLINI R, 1993, EMBO J, V12, P779, DOI 10.1002/j.1460-2075.1993.tb05712.x; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; Sambrook J., 1989, MOL CLONING LAB MANU; SUITER KA, 1983, J HERED, V74, P203, DOI 10.1093/oxfordjournals.jhered.a109766; VALVEKENS D, 1988, P NATL ACAD SCI USA, V85, P5536, DOI 10.1073/pnas.85.15.5536; WARD ER, 1990, PLANT MOL BIOL, V14, P561, DOI 10.1007/BF00027501	25	405	433	2	45	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 8	1993	364	6433					161	164		10.1038/364161a0	http://dx.doi.org/10.1038/364161a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL367	8321287				2022-12-01	WOS:A1993LL36700054
J	RAYMENT, I; RYPNIEWSKI, WR; SCHMIDTBASE, K; SMITH, R; TOMCHICK, DR; BENNING, MM; WINKELMANN, DA; WESENBERG, G; HOLDEN, HM				RAYMENT, I; RYPNIEWSKI, WR; SCHMIDTBASE, K; SMITH, R; TOMCHICK, DR; BENNING, MM; WINKELMANN, DA; WESENBERG, G; HOLDEN, HM			3-DIMENSIONAL STRUCTURE OF MYOSIN SUBFRAGMENT-1 - A MOLECULAR MOTOR	SCIENCE			English	Article							SKELETAL-MUSCLE MYOSIN; LIGHT-CHAINS; HEAVY-CHAIN; NUCLEOTIDE BINDING; 2.8-A RESOLUTION; TROPONIN-C; ACTIN; ATP; SITE; CONTRACTION	Directed movement is a characteristic of many living organisms and occurs as a result of the transformation of chemical energy into mechanical energy. Myosin is one of three families of molecular motors that are responsible for cellular motility. The three-dimensional structure of the head portion of myosin, or subfragment-1, which contains both the actin and nucleotide binding sites, is described. This structure of a molecular motor was determined by single crystal x-ray diffraction. The data provide a structural framework for understanding the molecular basis of motility.	UNIV WISCONSIN,INST ENZYME RES,MADISON,WI 53705; ROBERT WOOD JOHNSON MED SCH,DEPT PATHOL,PISCATAWAY,NJ 08854	University of Wisconsin System; University of Wisconsin Madison; Rutgers State University New Brunswick; Rutgers State University Medical Center	RAYMENT, I (corresponding author), UNIV WISCONSIN,DEPT BIOCHEM,1710 UNIV AVE,MADISON,WI 53705, USA.		rayment, ivan/A-2720-2008; Rypniewski, Wojciech/W-5330-2018	rayment, ivan/0000-0001-9279-7835; Rypniewski, Wojciech/0000-0002-6097-5518; Tomchick, Diana/0000-0002-7529-4643				ADELSTEIN RS, 1980, ANNU REV BIOCHEM, V49, P921, DOI 10.1146/annurev.bi.49.070180.004421; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BABU YS, 1985, NATURE, V315, P37, DOI 10.1038/315037a0; BRUNGER AT, 1990, X PLOR MANUAL VERSIO; BURKE M, 1977, BIOCHEMISTRY-US, V16, P5559, DOI 10.1021/bi00644a026; CITI S, 1987, BIOESSAYS, V7, P155, DOI 10.1002/bies.950070404; COLLINS JH, 1991, J MUSCLE RES CELL M, V12, P3, DOI 10.1007/BF01781170; CREMO CR, 1989, J BIOL CHEM, V264, P6608; ELLIOTT A, 1978, J MOL BIOL, V123, P505, DOI 10.1016/0022-2836(78)90204-8; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FOX GC, 1966, ACTA CRYSTALLOGR, V20, P886, DOI 10.1107/S0365110X66002007; GEEVES MA, 1991, BIOCHEM J, V274, P1; GOODY RS, 1977, EUR J BIOCHEM, V78, P317, DOI 10.1111/j.1432-1033.1977.tb11742.x; GRAMMER J, 1991, Biophysical Journal, V59, p226A; GRATZER WB, 1969, J BIOL CHEM, V244, P22; HERZBERG O, 1985, NATURE, V313, P653, DOI 10.1038/313653a0; HIBBERD MG, 1986, ANNU REV BIOPHYS BIO, V15, P119; HOLDEN HM, 1991, ARCH BIOCHEM BIOPHYS, V291, P187, DOI 10.1016/0003-9861(91)90122-Y; HUSTON EE, 1988, BIOCHEMISTRY-US, V27, P8945, DOI 10.1021/bi00425a011; HUXLEY AF, 1954, NATURE, V173, P971, DOI 10.1038/173971a0; HUXLEY H, 1954, NATURE, V173, P973, DOI 10.1038/173973a0; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LOWEY S, 1969, J MOL BIOL, V42, P1, DOI 10.1016/0022-2836(69)90483-5; LOWEY S, 1986, MYOLOGY, V19, P563; LYMM RW, 1971, BIOCHEMISTRY-US, V10, P4617; MAHMOOD R, 1989, BIOCHEMISTRY-US, V28, P3989, DOI 10.1021/bi00435a054; MAITA T, 1991, J BIOCHEM, V110, P75, DOI 10.1093/oxfordjournals.jbchem.a123546; MARGOSSIAN SS, 1981, BIOCHEMISTRY-US, V20, P2151, DOI 10.1021/bi00511a012; MATSUDA G, 1983, ADV BIOPHYS, V16, P185; MATSUDA G, 1977, FEBS LETT, V84, P53, DOI 10.1016/0014-5793(77)81055-7; MEADOR WE, 1992, SCIENCE, V257, P1251, DOI 10.1126/science.1519061; MORNET D, 1981, BIOCHEMISTRY-US, V20, P2110, DOI 10.1021/bi00511a007; MULLER CW, 1992, J MOL BIOL, V224, P159, DOI 10.1016/0022-2836(92)90582-5; MUSACCHIO A, 1992, NATURE, V359, P851, DOI 10.1038/359851a0; NABESHIMA YI, 1984, NATURE, V308, P333, DOI 10.1038/308333a0; OKAMOTO Y, 1985, P NATL ACAD SCI USA, V82, P1575, DOI 10.1073/pnas.82.6.1575; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.physiol.53.1.653; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1984, P NATL ACAD SCI-BIOL, V81, P4378; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RICE RH, 1971, J BIOL CHEM, V246, P831; ROSSMANN MG, 1960, ACTA CRYSTALLOGR, V13, P221, DOI 10.1107/S0365110X60000510; ROSSMANN MG, 1985, METHOD ENZYMOL, V114, P237; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RYPNIEWSKI WR, IN PRESS BIOCH; SELLERS JS, 1991, CURR OPIN CELL BIOL, V1, P98; SILBERSTEIN L, 1981, J MOL BIOL, V148, P153, DOI 10.1016/0022-2836(81)90510-6; SLEEP JA, 1981, J MUSCLE RES CELL M, V2, P373, DOI 10.1007/BF00711966; SMITH RE, UNPUB, P54011; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P4800, DOI 10.1021/bi00262a043; SZILAGYI L, 1979, BIOCHEM BIOPH RES CO, V87, P936, DOI 10.1016/0006-291X(79)92047-3; TAYLOR EW, 1979, CRC CR REV BIOCH MOL, V6, P103, DOI 10.3109/10409237909102562; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR B, V39, P913; TESI C, 1988, FEBS LETT, V236, P256, DOI 10.1016/0014-5793(88)80326-0; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; VALE RD, 1990, CELL, V60, P883, DOI 10.1016/0092-8674(90)90334-B; VIBERT P, 1988, J MUSCLE RES CELL M, V9, P296, DOI 10.1007/BF01773873; WAGNER PD, 1981, NATURE, V292, P560, DOI 10.1038/292560a0; WAKABAYASHI K, 1992, SCIENCE, V258, P443, DOI 10.1126/science.1411537; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WARRICK HM, 1987, ANNU REV CELL BIOL, V3, P379, DOI 10.1146/annurev.cellbio.3.1.379; WEEDS AG, 1971, J MOL BIOL, V61, P701, DOI 10.1016/0022-2836(71)90074-X; WELLS JA, 1982, METHOD ENZYMOL, V85, P93; WHITE H, IN PRESS BIOCH; WINKELMANN DA, 1985, J MOL BIOL, V181, P487, DOI 10.1016/0022-2836(85)90422-X; WINKELMANN DA, 1991, J CELL BIOL, V114, P701, DOI 10.1083/jcb.114.4.701; YAMAMOTO K, 1991, J MOL BIOL, V217, P229, DOI 10.1016/0022-2836(91)90535-E; YOUNT RG, 1992, PHILOS T ROY SOC B, V336, P55, DOI 10.1098/rstb.1992.0044	74	1905	1932	4	173	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					50	58		10.1126/science.8316857	http://dx.doi.org/10.1126/science.8316857			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	8316857				2022-12-01	WOS:A1993LK43400028
J	MORTONJONES, T; PRINGLE, M				MORTONJONES, T; PRINGLE, M			EXPLAINING VARIATIONS IN PRESCRIBING COSTS ACROSS ENGLAND	BRITISH MEDICAL JOURNAL			English	Article								Objective-To derive a predictive model for national prescribing behaviour in terms of basic morbidity and demographic factors. Design-24 demographic, morbidity, and practice factors were entered into a multiple regression analysis to determine the net ingredient cost per patient. Setting-The 90 family health service authorities in England for 1989. Results-For net ingredient cost per patient only two demographic factors (numbers of pensioners and the mobility of the registered population measured by list inflation) and two morbidity related factors (standardised mortality ratios and numbers of prepayment certificates issued) significantly contributed to a multiple regression model. This model explained 81% of the variation in net ingredient cost per registered patient between family health services authorities. The model also enabled a weighting factor of 4.6 (95% confidence interval 3.2 to 6.7) to be derived for the net ingredient cost for elderly patients (compared with the existing prescribing unit factor of 3). Conclusions-The model shows that variations in prescribing costs essentially reflect demand. It also suggests that the current prescribing unit value of 3 for patients aged 65 or more underestimates the extra costs of prescribing for elderly patients.			MORTONJONES, T (corresponding author), QUEENS MED CTR,DEPT GEN PRACTICE,NOTTINGHAM NG7 2UH,ENGLAND.							BAKER D, 1991, BRIT MED J, V303, P225, DOI 10.1136/bmj.303.6796.225; BRADLEY CP, 1991, FAM PRACT, V8, P276, DOI 10.1093/fampra/8.3.276; BRENNAN ME, 1980, J EPIDEMIOL COMMUN H, V34, P134, DOI 10.1136/jech.34.2.134; EDWARDS C, 1991, INT J PHARM PRACTICE, V1, P73; FORSTER DP, 1991, BRIT J GEN PRACT, V41, P67; GILLEGHAN JD, 1991, 54 ROYAL COLL GEN PR; HARRIS CM, 1984, RCGP24 OCC PAP; HARRIS CM, 1986, BR J GEN PRACT, V36, P148; HARRIS CM, 1990, ANAL PRESCRIBING GEN; HARRIS JF, 1990, SOMAT CELL MOLEC GEN, V16, P39, DOI 10.1007/BF01650478; Marinker M, 1973, J R Coll Gen Pract, V23 Suppl 2, P26; MAYS N, 1992, J EPIDEMIOL COMMUN H, V46, P38, DOI 10.1136/jech.46.1.38; MAYS N, 1989, J EPIDEMIOL COMMUN H, V43, P191, DOI 10.1136/jech.43.2.191; MORTONJONES AJ, 1993, BRIT MED J, V306, P1244; MORTONJONES AJ, IN PRESS BR J GEN PR; Taylor R J, 1977, J R Coll Gen Pract, V27, P79; TAYLOR RJ, 1991, BRIT J GEN PRACT, V41, P244; VIRJI A, 1991, FAM PRACT, V8, P314, DOI 10.1093/fampra/8.4.314; 1991, ANN REPORT 1 APRIL 1, P9; 1991, NHLTH SERVICES INDIC; 1991, REGIONAL TRENDS, V26	21	35	36	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1993	306	6894					1731	1734		10.1136/bmj.306.6894.1731	http://dx.doi.org/10.1136/bmj.306.6894.1731			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK367	8343631	Green Published, Bronze			2022-12-01	WOS:A1993LK36700024
J	NISTICO, A; YOUNG, NS				NISTICO, A; YOUNG, NS			GAMMA-INTERFERON GENE-EXPRESSION IN THE BONE-MARROW OF PATIENTS WITH APLASTIC-ANEMIA	ANNALS OF INTERNAL MEDICINE			English	Article						ANEMIA, APLASTIC; INTERFERON TYPE II; BONE MARROW; GENE EXPRESSION; LYMPHOKINES	CHRONIC MYELOGENOUS LEUKEMIA; LYMPHOCYTES-T; PROGENITOR CELLS; VIRUS-INFECTIONS; TRANSGENIC MICE; SUPPRESSION; DISEASES; INVITRO; HEMATOPOIESIS; PROLIFERATION	Objective: To determine gamma-interferon gene expression in the bone marrow of patients with aplastic anemia and controls. Most patients with acquired aplastic anemia respond to immunosuppressive therapy, implicating an immune pathophysiologic origin for this disease.			NISTICO, A (corresponding author), NHLBI, HEMATOL BRANCH, BLDG 10, ROOM 7C103, BETHESDA, MD 20892 USA.							ALLISON J, 1988, NATURE, V333, P529, DOI 10.1038/333529a0; BACIGALUPO A, 1980, J IMMUNOL, V125, P1449; BORDEN EC, 1992, CLIN IMMUNOL IMMUNOP, V62, pS18, DOI 10.1016/0090-1229(92)90037-O; BROXMEYER HE, 1983, J IMMUNOL, V131, P1300; CAMITTA BM, 1976, BLOOD, V48, P63; CAMPBELL IL, 1988, J IMMUNOL, V141, P2325; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; CAUX C, 1992, BLOOD, V79, P2628; CLANET M, 1989, BIOMED PHARMACOTHER, V43, P355, DOI 10.1016/0753-3322(89)90061-9; COLLART MA, 1986, J EXP MED, V164, P2113, DOI 10.1084/jem.164.6.2113; FRICKHOFEN N, 1991, NEW ENGL J MED, V324, P1297, DOI 10.1056/NEJM199105093241901; HINTERBERGER W, 1989, BLOOD, V74, P2713; HOFFMAN R, 1977, NEW ENGL J MED, V296, P10, DOI 10.1056/NEJM197701062960103; HOOKS JJ, 1988, INVEST OPHTH VIS SCI, V29, P1444; JOKLIK W K, 1990, P383; KAGAN WA, 1976, P NATL ACAD SCI USA, V73, P2890, DOI 10.1073/pnas.73.8.2890; KAWANO Y, 1991, BLOOD, V77, P2118; KOTT E, 1990, Q J MED, V76, P951; KURANE I, 1989, J EXP MED, V170, P763, DOI 10.1084/jem.170.3.763; KURANE I, 1991, J CLIN INVEST, V88, P1473, DOI 10.1172/JCI115457; LAVER J, 1988, BRIT J HAEMATOL, V69, P545, DOI 10.1111/j.1365-2141.1988.tb02413.x; NAKAO S, 1992, BLOOD, V79, P2532; PAZDERKA F, 1991, TRANSPLANT P, V23, P241; RIVIERE Y, 1977, P NATL ACAD SCI USA, V74, P2135, DOI 10.1073/pnas.74.5.2135; ROSENFELD S, 1992, BLOOD S, V80, pA282; SALGAME P, 1991, SCIENCE, V254, P279, DOI 10.1126/science.1681588; SAMUEL CE, 1991, VIROLOGY, V183, P1, DOI 10.1016/0042-6822(91)90112-O; SARVETNICK N, 1988, CELL, V52, P773, DOI 10.1016/0092-8674(88)90414-X; TAKAMATSU Y, 1993, BRIT J HAEMATOL, V83, P21, DOI 10.1111/j.1365-2141.1993.tb04625.x; TALPAZ M, 1986, EXP HEMATOL, V14, P668; TALPAZ M, 1992, CANCER, V69, P410, DOI 10.1002/1097-0142(19920115)69:2<410::AID-CNCR2820690222>3.0.CO;2-V; TOROKSTORB B, 1987, BLOOD, V69, P629; VIALE M, 1991, BLOOD, V78, P1268; VILCEK J, 1984, PROG MED VIROL, V30, P62; WALLACH D, 1982, NATURE, V299, P833, DOI 10.1038/299833a0; YOUNG NS, 1994, APLASTIC ANEMIA ACQU; ZOUMBOS NC, 1985, NEW ENGL J MED, V312, P257, DOI 10.1056/NEJM198501313120501; ZOUMBOS NC, 1985, P NATL ACAD SCI USA, V82, P188, DOI 10.1073/pnas.82.1.188; ZOUMBOS NC, 1984, J IMMUNOL, V133, P769; [No title captured]	40	106	114	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1994	120	6					463	469		10.7326/0003-4819-120-6-199403150-00003	http://dx.doi.org/10.7326/0003-4819-120-6-199403150-00003			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB625	8311369				2022-12-01	WOS:A1994NB62500003
J	MURNICK, DE; PEER, BJ				MURNICK, DE; PEER, BJ			LASER-BASED ANALYSIS OF CARBON-ISOTOPE RATIOS	SCIENCE			English	Article							OPTOGALVANIC SPECTROSCOPY; CO2	A laser technique for analysis of carbon-13:carbon-12 ratios with the specificity of laser resonance spectroscopy and the sensitivity and accuracy typical of isotope ratio mass spectrometers is reported. The technique is based on laser optogalvanic effect spectroscopy, in which an electrical (galvanic) signal is detected in response to the optical stimulation of a resonance transition in a gas discharge species. Carbon dioxide molecular gas lasers are used, with the probed transitions being identical to the lasing transitions. Measurements for carbon dioxide samples with 100-second averaging times yield isotopic ratios with a precision of better than 10 parts per million.			MURNICK, DE (corresponding author), RUTGERS STATE UNIV, DEPT PHYS, NEWARK, NJ 07102 USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [R03RR006976] Funding Source: NIH RePORTER; NCRR NIH HHS [R03 RR06976-01] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BARBIERI B, 1990, REV MOD PHYS, V62, P603, DOI 10.1103/RevModPhys.62.603; BRADLEY LC, 1986, IEEE J QUANTUM ELECT, V22, P234, DOI 10.1109/JQE.1986.1072967; CHAOHUA W, 1986, CHINESE PHYS LETT, V3, P501; CHAPMAN TE, 1991, STABLE ISOTOPES PAED; DULEY WW, 1976, CO2 LASERS EFFECTS A; GRAHAM DY, 1987, LANCET, V1, P1174; KELES T, 1991, STABLE ISOTOPES PAED, P279; KING WH, 1984, ISOTOPE SHIFTS ATOMI; KRUMBIEGEL P, 1991, STABLE ISOTOPE PHARM; LEE PS, 1986, APPL PHYS LETT, V48, P619, DOI 10.1063/1.96722; MAY RD, 1986, REV SCI INSTRUM, V57, P2242, DOI 10.1063/1.1138691; MUENCHAUSEN RE, 1984, OPT COMMUN, V48, P317, DOI 10.1016/0030-4018(84)90307-9; NELSON DE, 1991, SCIENCE, V251, P552, DOI 10.1126/science.1990430; PATEL CKN, 1964, PHYS REV LETT, V13, P617, DOI 10.1103/PhysRevLett.13.617; PLANAROSA P, 1984, J OPT SOC AM B, V1, P704; QUADE J, 1990, SCIENCE, V250, P1549, DOI 10.1126/science.250.4987.1549; QUAY PD, 1992, SCIENCE, V256, P74, DOI 10.1126/science.256.5053.74; SILVER M, 1970, J APPL PHYS, V41, P4566, DOI 10.1063/1.1658497; STEWART RS, 1991, OPTOGALVANIC SPECTRO, V113	19	70	78	2	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 18	1994	263	5149					945	947		10.1126/science.8310291	http://dx.doi.org/10.1126/science.8310291			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX165	8310291				2022-12-01	WOS:A1994MX16500028
J	FLAM, F				FLAM, F			CULTURAL SHIFTS - EX-DEFENSE SCIENTISTS COME IN FROM THE COLD	SCIENCE			English	Editorial Material								For many researchers who have spent their careers working on military projects, the end of the Cold War has brought an end to an era of secure funding. Uncertain new priorities such as ''technology transfer'' and ''economic competitiveness'' now determine whether their work will continue to be supported-and at what level. As a result, thousands of researchers who depended on defense money in national labs and universities are struggling to make the transition to civilian science in a research culture very different from the closed world of secret research, Many of them have found some seemingly unlikely uses for their skills The computer algorithms developed to detect incoming missiles can also identify errant cells in the human body, and the plasma physics vital to understanding the detonation of a hydrogen bomb can also be applied to pollution control. But these gentler research goals don't always mean a gentler research environment, say some ex-military scientists. Cold War veterans are finding that the civilian research world, rife with the struggle for funds and the search for ''spinoffs,'' can be a pretty cold place itself.											0	1	1	1	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 4	1994	263	5147					623	624		10.1126/science.8303268	http://dx.doi.org/10.1126/science.8303268			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8303268				2022-12-01	WOS:A1994MU96400027
J	GREENSPAN, SL; MYERS, ER; MAITLAND, LA; RESNICK, NM; HAYES, WC				GREENSPAN, SL; MYERS, ER; MAITLAND, LA; RESNICK, NM; HAYES, WC			FALL SEVERITY AND BONE-MINERAL DENSITY AS RISK-FACTORS FOR HIP FRACTURE IN AMBULATORY ELDERLY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OSTEOPOROSIS; WOMEN; AGE	Objective.-To determine the relative importance of fall characteristics, body habitus, and femoral bone mineral density (BMD) in predicting hip fracture in community-dwelling elderly. Design.-Prospective case-control study. Setting.-Community-based academic hospital. Participants.-A total of 149 ambulatory, community-dwelling fallers (126 women, 23 men) aged 65 years and older, including 72 case patients (fallers with hip fracture) and 77 control fallers (fallers with no hip fracture). Main Outcome Measures.-Fall characteristics, body habitus, femoral BMD. Results.-Significant and independent risk factors for hip fracture in both sexes were direction of the fall (adjusted odds ratio [OR], 5.7; 95% confidence interval [CI], 2.3 to 14.0; P<.001); femoral neck BMD (a decrease of 1 SD; adjusted OR, 2.795% CI, 1.6 to 4.6; P<.001); potential energy of the fall (an increase of 1 SD; adjusted OR, 2.8; 95% CI, 1.5 to 5.2; P<.001); and body mass index (a decrease of 1 SD; adjusted OR, 2.2; 95% CI, 1.2 to 3.8; P<.01). Importantly, the OR for the fall direction was unaffected by the addition or removal of BMD from the model. Conclusions.-We conclude that among elderly fallers-in most of whom hip BMD is already less than the fracture threshold-fall characteristics and body habitus are important risk factors for hip fracture and touch on a domain entirely missed by knowledge of BMD. These data suggest new targets for preventive therapy. In addition to the maintenance of bone density, reductions in fall severity (eg, by use of trochanteric padding or enhancement of muscle strength) may provide additional strategies for prevention of hip fracture in this age group.	BETH ISRAEL HOSP,DEPT MED,DIV GERONTOL,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT ORTHOPAED SURG,ORTHOPAED BIOMECH LAB,BOSTON,MA 02215; BETH ISRAEL HOSP,CHARLES A DANA RES INST,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV GERONTOL,BOSTON,MA 02115; VET ADM MED CTR W ROXBURY,CTR GERIATR RES EDUC & CLIN,BOSTON,MA 02132	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Geriatric Research Education & Clinical Center	GREENSPAN, SL (corresponding author), BETH ISRAEL HOSP,DEPT MED,DIV BONE & MINERAL METAB,330 BROOKLINE AVE,BOSTON,MA 02215, USA.				NCI NIH HHS [CA41295] Funding Source: Medline; NCRR NIH HHS [RR01032] Funding Source: Medline; ODCDC CDC HHS [CC102550] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA041295] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR001032] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); ODCDC CDC HHS; NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		BESDINE RW, 1983, J AM GERIATR SOC, V31, P651, DOI 10.1111/j.1532-5415.1983.tb04150.x; BOHR H, 1983, CLIN ORTHOP RELAT R, V179, P240; CHRISCHILLES EA, 1991, ARCH INTERN MED, V151, P2026, DOI 10.1001/archinte.151.10.2026; CHUMLEA WC, 1985, J AM GERIATR SOC, V33, P116, DOI 10.1111/j.1532-5415.1985.tb02276.x; CUMMINGS SR, 1985, EPIDEMIOL REV, V7, P178, DOI 10.1093/oxfordjournals.epirev.a036281; CUMMINGS SR, 1990, JAMA-J AM MED ASSOC, V263, P665, DOI 10.1001/jama.263.5.665; CUMMINGS SR, 1993, LANCET, V341, P72, DOI 10.1016/0140-6736(93)92555-8; CUMMINGS SR, 1985, AM J MED, V78, P487, DOI 10.1016/0002-9343(85)90343-2; FELSON DT, 1989, J AM GERIATR SOC, V37, P495, DOI 10.1111/j.1532-5415.1989.tb05678.x; GLUER CC, 1990, RADIOLOGY, V174, P223, DOI 10.1148/radiology.174.1.2294552; GRISSO JA, 1991, NEW ENGL J MED, V324, P1326, DOI 10.1056/NEJM199105093241905; GRYFE C I, 1977, Age and Ageing, V6, P201, DOI 10.1093/ageing/6.4.201; HAYES WC, 1993, CALCIFIED TISSUE INT, V52, P192, DOI 10.1007/BF00298717; Hayes WC, 1985, BONE MINERAL RES, P259; Hosmer D, 2013, APPL LOGISTIC REGRES; LAURITZEN JB, 1993, LANCET, V341, P11, DOI 10.1016/0140-6736(93)92480-H; MAITLAND LA, 1993, CALCIFIED TISSUE INT, V52, P85, DOI 10.1007/BF00308313; Melton L J 3rd, 1985, Clin Geriatr Med, V1, P525; MELTON LJ, 1992, J BONE MINER RES, V7, P1005, DOI 10.1002/jbmr.5650070902; MELTON LJ, 1990, ANN INTERN MED, V112, P516, DOI 10.7326/0003-4819-112-7-516; MELTON LJ, 1988, OSTEOPOROSIS ETIOLOG, P111; NEVITT MC, 1989, JAMA-J AM MED ASSOC, V261, P2663, DOI 10.1001/jama.261.18.2663; PRAEMER A, 1992, MUSCULOSKELETAL COND, P143; RAY WA, 1987, NEW ENGL J MED, V316, P363, DOI 10.1056/NEJM198702123160702; RESNICK NM, 1989, NEW ENGL J MED, V320, P1, DOI 10.1056/NEJM198901053200101; RESNICK NM, 1989, JAMA-J AM MED ASSOC, V261, P1025, DOI 10.1001/jama.261.7.1025; RIGGS BL, 1982, J CLIN INVEST, V70, P716, DOI 10.1172/JCI110667; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; ROSS PD, 1990, CALCIFIED TISSUE INT, V46, P149, DOI 10.1007/BF02555036; TINETTI ME, 1988, NEW ENGL J MED, V319, P1701, DOI 10.1056/NEJM198812293192604; 1992, HOLOGIC QDR 1000 XRA	31	447	451	0	20	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	1994	271	2					128	133		10.1001/jama.271.2.128	http://dx.doi.org/10.1001/jama.271.2.128			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MQ083	8264067				2022-12-01	WOS:A1994MQ08300022
J	ABELIOVICH, A; PAYLOR, R; CHEN, C; KIM, JJ; WEHNER, JM; TONEGAWA, S				ABELIOVICH, A; PAYLOR, R; CHEN, C; KIM, JJ; WEHNER, JM; TONEGAWA, S			PKC-GAMMA MUTANT MICE EXHIBIT MILD DEFICITS IN SPATIAL AND CONTEXTUAL LEARNING	CELL			English	Article							PROTEIN-KINASE-C; LONG-TERM POTENTIATION; RABBIT FOLLOWING STIMULATION; SYNAPTIC TRANSMISSION; LASTING POTENTIATION; PERFORANT PATH; DENTATE AREA; HIPPOCAMPAL; RATS; MEMORY	We are undertaking a genetic approach to investigate the role that synaptic modulation in the mammalian central nervous system plays in learning and memory and to identify relevant molecular components. We have generated mice deficient in the gamma isoform of protein kinase C (PKCgamma), an enzyme that has previously been implicated in both long-term potentiation (LTP) and learning and memory. These mice have a modified LTP of synaptic transmission in the hippocampus. We demonstrate that PKCgamma-mutant mice can learn to carry out hippocampus-dependent tasks, although mild deficits are evident. Thus, hippocampal CA1 LTP induced by the conventional tetanic stimulation is not essential for the mice to exhibit spatial and contextual learning. Furthermore, the modification of hippocampal synaptic plasticity correlates with the learning deficits we observe.	MIT,DEPT BIOL,CAMBRIDGE,MA 02139; MIT,CTR CANC RES,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02139; UNIV COLORADO,INST BEHAV GENET,BOULDER,CO 80309; UNIV COLORADO,SCH PHARM,BOULDER,CO 80309; UNIV SO CALIF,NEUROSCI PROGRAM,LOS ANGELES,CA 90089	Massachusetts Institute of Technology (MIT); Howard Hughes Medical Institute; Massachusetts Institute of Technology (MIT); University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; University of Southern California	ABELIOVICH, A (corresponding author), MIT,CTR CANC RES,CAMBRIDGE,MA 02139, USA.			Kim, Jeansok/0000-0001-7964-106X	NIAAA NIH HHS [AA-00141] Funding Source: Medline; NIMH NIH HHS [MH-48663] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH048663] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ABELIOVICH A, 1993, CELL, V75, P1253, DOI 10.1016/0092-8674(93)90613-U; BANK B, 1989, MOL NEUROBIOL, V3, P55, DOI 10.1007/BF02935588; BANK B, 1988, P NATL ACAD SCI USA, V85, P1988, DOI 10.1073/pnas.85.6.1988; BEKKERS JH, 1990, COLD SPRING HARB SYM, V50, P131; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P357, DOI 10.1113/jphysiol.1973.sp010274; BLISS TVP, 1973, J PHYSIOL-LONDON, V232, P331, DOI 10.1113/jphysiol.1973.sp010273; COLLINGRIDGE GL, 1990, TRENDS PHARMACOL SCI, V11, P290, DOI 10.1016/0165-6147(90)90011-V; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; EICHENBAUM H, 1992, BEHAV NEURAL BIOL, V57, P2, DOI 10.1016/0163-1047(92)90724-I; Eichenbaum H, 1991, MEMORY ORG LOCUS CHA, P163; Flourens P, 1824, RECHERCHES EXPT PROP; FORDYCE DE, 1993, BRAIN RES, V619, P111, DOI 10.1016/0006-8993(93)91602-O; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; HASHIMOTO T, 1988, J NEUROSCI, V8, P1678; HEBB DO, 1949, BEHAV BIOL, V12, P421; JARRARD LE, 1993, BEHAV NEURAL BIOL, V60, P9, DOI 10.1016/0163-1047(93)90664-4; KIM JJ, 1991, BEHAV NEUROSCI, V105, P126, DOI 10.1037/0735-7044.105.1.126; KIM JJ, 1992, SCIENCE, V256, P675, DOI 10.1126/science.1585183; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1989, SCIENCE, V245, P862, DOI 10.1126/science.2549638; MORRIS RGM, 1982, NATURE, V297, P681, DOI 10.1038/297681a0; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; Morris RGM, 1991, LONG TERM POTENTIATI, P267; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; O'Keefe J, 1978, HIPPOCAMPUS COGNITIV; OLDS JL, 1991, NEW BIOL, V3, P27; OLDS JL, 1990, J NEUROSCI, V10, P3707; PAYLOR R, 1993, PSYCHOBIOLOGY, V21, P11; PAYLOR R, 1992, BEHAV BRAIN RES, V52, P49, DOI 10.1016/S0166-4328(05)80324-9; PHILLIPS RG, 1992, BEHAV NEUROSCI, V106, P274, DOI 10.1037/0735-7044.106.2.274; Siegelbaum S A, 1991, Curr Opin Neurobiol, V1, P113, DOI 10.1016/0959-4388(91)90018-3; SILVA AJ, 1992, SCIENCE, V257, P206, DOI 10.1126/science.1321493; SILVA AJ, 1992, SCIENCE, V257, P201, DOI 10.1126/science.1378648; SQUIRE L, 1987, MEMORY HIPPOCAMPUS S; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; SUTHERLAND RJ, 1989, PSYCHOBIOLOGY, V17, P129; SUTHERLAND RJ, 1982, NEUROSCI LETT, V31, P271, DOI 10.1016/0304-3940(82)90032-5; VANDERZEE EA, 1992, J NEUROSCI, V12, P4808; WEHNER JM, 1990, BRAIN RES, V523, P181, DOI 10.1016/0006-8993(90)91485-Y	41	401	409	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 31	1993	75	7					1263	1271		10.1016/0092-8674(93)90614-V	http://dx.doi.org/10.1016/0092-8674(93)90614-V			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	8269510				2022-12-01	WOS:A1993MP86900006
J	KOBE, B; DEISENHOFER, J				KOBE, B; DEISENHOFER, J			CRYSTAL-STRUCTURE OF PORCINE RIBONUCLEASE INHIBITOR, A PROTEIN WITH LEUCINE-RICH REPEATS	NATURE			English	Article							KINETIC CHARACTERIZATION; TRANSMEMBRANE PROTEIN; GENE; DROSOPHILA; CEREVISIAE; SEQUENCE; HOMOLOGY; DOMAINS; CYCLASE; YEAST	RIBONUCLEASE inhibitor is a cytoplasmic protein that tightly binds and inhibits ribonucleases of the pancreatic ribonuclease superfamily1. The primary sequence of this inhibitor contains leucine-rich repeats2 (LRRs); these motifs are present in many proteins that participate in protein-protein interactions and have different functions and cellular locations. In vivo, ribonuclease inhibitor may have a role in the regulation of RNA turnover in mammalian cells3 and in angiogenesis4. To define the structural features of LRR proteins and to understand better the nature of the tight interaction of ribonuclease inhibitor with ribonucleases, we have determined the crystal structure of the porcine inhibitor. To our knowledge, this is the first three-dimensional structure of a protein containing LRRs and represents a new class of alpha/beta protein fold. Individual repeats constitute beta-alpha structural units that probably also occur in other proteins containing LRRs. The non-globular shape of the structure and the exposed face of the parallel beta-sheet may explain why LRRs are used to achieve strong protein-protein interactions. A possible ribonuclease-binding region incorporates the surface formed by the parallel beta-sheet and the betaalpha loops.	UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	KOBE, B (corresponding author), UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,5323 HARRY HINES BLVD,DALLAS,TX 75235, USA.		Kobe, Bostjan/D-1292-2009	Kobe, Bostjan/0000-0001-9413-9166				BODE W, 1985, BIOL CHEM H-S, V366, P287, DOI 10.1515/bchm3.1985.366.1.287; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CARSON M, 1987, J MOL GRAPHICS, V5, P105; FOMINAYA JM, 1992, J BIOL CHEM, V267, P24655; FRESCO LD, 1991, MOL CELL BIOL, V11, P1578, DOI 10.1128/MCB.11.3.1578; HAMLIN R, 1985, METHOD ENZYMOL, V114, P416; HASHIMOTO C, 1988, CELL, V52, P269, DOI 10.1016/0092-8674(88)90516-8; HOFSTEENGE J, 1988, BIOCHEMISTRY-US, V27, P8537, DOI 10.1021/bi00423a006; HOFSTEENGE J, 1991, J BIOL CHEM, V266, P24198; HOFSTEENGE J, 1991, BIOCHEM J, V275, P541, DOI 10.1042/bj2750541; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; JONES TA, 1990, CRYSTALLOGRAPHIC MOD, P189; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KATAOKA T, 1985, CELL, V43, P493, DOI 10.1016/0092-8674(85)90179-5; KOBE B, 1993, J MOL BIOL, V231, P137, DOI 10.1006/jmbi.1993.1263; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LASTERS I, 1988, P NATL ACAD SCI USA, V85, P3338, DOI 10.1073/pnas.85.10.3338; LEE FS, 1990, P NATL ACAD SCI USA, V87, P1879, DOI 10.1073/pnas.87.5.1879; LEE FS, 1993, PROG NUCLEIC ACID RE, V44, P1, DOI 10.1016/S0079-6603(08)60215-9; LEE FS, 1990, BIOCHEMISTRY-US, V29, P6633, DOI 10.1021/bi00480a012; LEUNG KY, 1989, J BACTERIOL, V171, P4623, DOI 10.1128/jb.171.9.4623-4632.1989; LOPEZ JA, 1987, P NATL ACAD SCI USA, V84, P5615, DOI 10.1073/pnas.84.16.5615; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MCFARLAND KC, 1989, SCIENCE, V245, P494, DOI 10.1126/science.2502842; NEUMANN U, 1993, J MOL BIOL, V231, P505, DOI 10.1006/jmbi.1993.1299; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; OLDBERG A, 1989, EMBO J, V8, P2601, DOI 10.1002/j.1460-2075.1989.tb08399.x; QUIRINSTRICKER C, 1968, BIOCHIM BIOPHYS ACTA, V159, P75, DOI 10.1016/0005-2744(68)90245-3; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; REINKE R, 1988, CELL, V52, P291, DOI 10.1016/0092-8674(88)90518-1; SCHNEIDER R, 1991, FEBS LETT, V283, P203, DOI 10.1016/0014-5793(91)80588-T; SCHNEIDER R, 1991, ONCOGENE, V6, P1807; SHAPIRO R, 1987, P NATL ACAD SCI USA, V84, P2238, DOI 10.1073/pnas.84.8.2238; STEIGEMANN W, 1992, PROTEIN PROGRAM SYST; TAN FL, 1990, J BIOL CHEM, V265, P13; VICENTINI AM, 1990, BIOCHEMISTRY-US, V29, P8827, DOI 10.1021/bi00489a046; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WILMOT CM, 1990, PROTEIN ENG, V3, P479, DOI 10.1093/protein/3.6.479; YODER MD, 1993, SCIENCE, V260, P1503, DOI 10.1126/science.8502994; YOUNG D, 1989, P NATL ACAD SCI USA, V86, P7989, DOI 10.1073/pnas.86.20.7989	40	535	552	1	20	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 23	1993	366	6457					751	756		10.1038/366751a0	http://dx.doi.org/10.1038/366751a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN264	8264799				2022-12-01	WOS:A1993MN26400031
J	MULLER, W; RINGSDORF, H; RUMP, E; WILDBURG, G; ZHANG, X; ANGERMAIER, L; KNOLL, W; LILEY, M; SPINKE, J				MULLER, W; RINGSDORF, H; RUMP, E; WILDBURG, G; ZHANG, X; ANGERMAIER, L; KNOLL, W; LILEY, M; SPINKE, J			ATTEMPTS TO MIMIC DOCKING PROCESSES OF THE IMMUNE-SYSTEM - RECOGNITION-INDUCED FORMATION OF PROTEIN MULTILAYERS	SCIENCE			English	Article							SURFACE RECOGNITION; STREPTAVIDIN; MONOLAYERS; LIPIDS	The assemblage of protein multilayers induced by molecular recognition, as seen, for example, in the immune cascade, has been mimicked by using streptavidin as a docking matrix. For these experiments, this protein matrix was organized on liposomes, monolayers at the air-water interface, and self-assembled layers on gold, all three containing biotin lipids. The docking of streptavidin to biotin at liposomal surfaces was confirmed by circular dichroism. Mixed double and triple layers of streptavidin, concanavalin A, antibody Fab fragments, and hormones were prepared at the air-water interface and on gold surfaces and were characterized by fluorescence microscopy and plasmon spectroscopy. With the use of biotin analogs that have lower binding constants it has been possible to achieve multiple formation and competitive replacement of the oriented protein assemblages.	INST ORGAN CHEM,JJ BECHERWEG 18-20,D-55099 MAINZ,GERMANY; MAX PLANCK INST POLYMER RES,D-55021 MAINZ,GERMANY	Max Planck Society			Zhang, Xi/AAF-9871-2021; Zhang, Xi/C-8136-2011					AHLERS M, 1990, ANGEW CHEM INT EDIT, V29, P1269, DOI 10.1002/anie.199012691; AHLERS M, 1991, MAKROMOL CHEM-M SYMP, V46, P307, DOI 10.1002/masy.19910460143; Ahlers M., 1990, ANGEW CHEM, V102, P1310, DOI [10.1002/ange.19901021114, DOI 10.1002/ANGE.19901021114]; BLANKENBURG R, 1989, BIOCHEMISTRY-US, V28, P8214, DOI 10.1021/bi00446a037; CHAIET L, 1964, ARCH BIOCHEM BIOPHYS, V106, P1, DOI 10.1016/0003-9861(64)90150-X; COOPER NR, 1985, ADV IMMUNOL, V37, P151, DOI 10.1016/S0065-2776(08)60340-5; DARST SA, 1991, BIOPHYS J, V59, P387, DOI 10.1016/S0006-3495(91)82232-9; EBATO H, 1992, ANGEW CHEM, V104, P1064; EBATO H, 1992, ANGEW CHEM INT EDIT, V31, P1078; EBERSOLE RC, 1990, J AM CHEM SOC, V112, P3239, DOI 10.1021/ja00164a070; Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8; GREEN NM, 1990, METHOD ENZYMOL, V184, P51; HAUSSLING L, 1991, MAKROMOL CHEM-M SYMP, V46, P145, DOI 10.1002/masy.19910460118; HAUSSLING L, 1991, ANGEW CHEM, V103, P568; HENDRICKSON WA, 1989, P NATL ACAD SCI USA, V86, P2190, DOI 10.1073/pnas.86.7.2190; HERRON JN, 1992, LANGMUIR, V8, P1413, DOI 10.1021/la00041a028; MORGAN H, 1992, BIOSENS BIOELECTRON, V7, P405, DOI 10.1016/0956-5663(92)85039-D; MULLEREBERHARD HJ, 1988, ANNU REV BIOCHEM, V57, P321, DOI 10.1146/annurev.biochem.57.1.321; SPINKE J, 1992, THESIS U MAINZ MAINZ	19	189	207	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 10	1993	262	5140					1706	1708		10.1126/science.8259513	http://dx.doi.org/10.1126/science.8259513			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	8259513				2022-12-01	WOS:A1993ML22000032
J	BRECKER, SJD; STEVENSON, RN; ROBERTS, R; UTHAYAKUMAR, S; TIMMIS, AD; BALCON, R				BRECKER, SJD; STEVENSON, RN; ROBERTS, R; UTHAYAKUMAR, S; TIMMIS, AD; BALCON, R			ACUTE MYOCARDIAL-INFARCTION IN PATIENTS WITH NORMAL CORONARY-ARTERIES	BRITISH MEDICAL JOURNAL			English	Article									LONDON CHEST HOSP,DEPT CARDIAC,LONDON E2 9JX,ENGLAND	University of London; Queen Mary University London								ARNETT EN, 1976, CIRCULATION, V53, P395, DOI 10.1161/01.CIR.53.3.395; BETRIU A, 1981, AM J CARDIOL, V48, P28, DOI 10.1016/0002-9149(81)90568-3; KHAN AH, 1974, NEW ENGL J MED, V291, P427, DOI 10.1056/NEJM197408292910901; RAYMOND R, 1988, J AM COLL CARDIOL, V11, P471, DOI 10.1016/0735-1097(88)91519-7; ROSENBLATT A, 1977, CIRCULATION, V55, P578, DOI 10.1161/01.CIR.55.4.578	5	23	23	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 13	1993	307	6914					1255	1256		10.1136/bmj.307.6914.1255	http://dx.doi.org/10.1136/bmj.307.6914.1255			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH001	8281058	Bronze, Green Published			2022-12-01	WOS:A1993MH00100022
J	BUNIN, GR; KUIJTEN, RR; BUCKLEY, JD; RORKE, LB; MEADOWS, AT				BUNIN, GR; KUIJTEN, RR; BUCKLEY, JD; RORKE, LB; MEADOWS, AT			RELATION BETWEEN MATERNAL DIET AND SUBSEQUENT PRIMITIVE NEUROECTODERMAL BRAIN-TUMORS IN YOUNG-CHILDREN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							NEURAL-TUBE DEFECTS; EXPLORATORY CASE-CONTROL; UNITED-STATES; RISK-FACTORS; CANCER; MEDULLOBLASTOMA; QUESTIONNAIRE; POPULATION; FOLATE	Background. It has been hypothesized that a high dietary intake of nitrosamines and their precursors, nitrites and nitrates, is a risk factor for brain tumors. Vitamins C and E inhibit the formation of nitrosamines and thus may be protective. Methods. We conducted a case-control study of maternal diet and the risk of primitive neuroectodermal tumors of the brain in children. The case patients were under the age of six years at diagnosis in 1986 to 1989. The controls were selected by random-digit telephone dialing and were matched for age and race to 166 case patients. Telephone interviews with the mothers included questions on the frequency of consumption of alcohol, vitamin and mineral supplements, and 53 foods during pregnancy. Results. Significant protective trends were observed for vegetables (odds ratio for the highest quartile group for intake relative to the lowest, 0.37; P for trend = 0.005), fruits and fruit juices (odds ratio, 0.28; P = 0.003), vitamin A (odds ratio, 0.59; P = 0.03), vitamin C (odds ratio, 0.42; P = 0.009), nitrate (odds ratio, 0.44; P = 0.002), and folate (odds ratio, 0.38; P = 0.005). A nonsignificant trend of increasing risk was observed for nitrosamine (odds ratio, 1.65; P = 0.15). The use of iron (odds ratio, 0.43; P = 0.004), calcium (odds ratio, 0.42; P = 0.05), and vitamin C (odds ratio, 0.35; P = 0.04) supplements at any time during the pregnancy and the use of multivitamins during the first six weeks (odds ratio, 0.56; P = 0.02) were associated with decreased risk. In multivariate analyses, folate, early multivitamin use, and iron supplements generally remained protective. Conclusions. These results do not support the hypothesis that nitrosamines have a role in the development of primitive neuroectodermal tumors in young children, but they do suggest that certain other aspects of maternal diet can influence the risk.	CHILDRENS HOSP PHILADELPHIA,DIV ONCOL,PHILADELPHIA,PA; UNIV PENN,SCH MED,PHILADELPHIA,PA 19104; UNIV SO CALIF,SCH MED,DEPT PREVENT MED,LOS ANGELES,CA 90033	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Southern California					NATIONAL CANCER INSTITUTE [R01CA029275, U10CA013539] Funding Source: NIH RePORTER; NCI NIH HHS [CA 29275, CA 13539] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BLOCK G, 1986, AM J EPIDEMIOL, V124, P453, DOI 10.1093/oxfordjournals.aje.a114416; BOWER C, 1989, MED J AUSTRALIA, V150, P613, DOI 10.5694/j.1326-5377.1989.tb136723.x; Breslow NE., 1980, IARC SCI PUBLICATION, V32; BURCH JD, 1987, J NATL CANCER I, V78, P601; CZEIZEL AE, 1992, NEW ENGL J MED, V327, P1832, DOI 10.1056/NEJM199212243272602; HAMMAR N, 1991, INT J EPIDEMIOL, V20, P621, DOI 10.1093/ije/20.3.621; HOWE GR, 1986, AM J EPIDEMIOL, V124, P595, DOI 10.1093/oxfordjournals.aje.a114432; HOWE GR, 1989, CANCER RES, V49, P4349; HUNTER DJ, 1988, AM J EPIDEMIOL, V127, P1240, DOI 10.1093/oxfordjournals.aje.a114916; KUIJTEN RR, 1990, CANCER RES, V50, P2608; Lindsted K D, 1990, Epidemiology, V1, P392, DOI 10.1097/00001648-199009000-00010; MAGEE PN, 1976, ACS MONOGR SER, V173, P491; MEALEY J, 1977, J NEUROSURG, V46, P56, DOI 10.3171/jns.1977.46.1.0056; MULINARE J, 1988, JAMA-J AM MED ASSOC, V260, P3141, DOI 10.1001/jama.260.21.3141; OLSON SH, 1992, AM J EPIDEMIOL, V135, P210, DOI 10.1093/oxfordjournals.aje.a116273; PRESTONMARTIN S, 1989, CANCER RES, V49, P6137; PRESTONMARTIN S, 1982, CANCER RES, V42, P5240; ROMIEU I, 1990, AM J EPIDEMIOL, V131, P864, DOI 10.1093/oxfordjournals.aje.a115577; RORKE LB, 1983, J NEUROPATH EXP NEUR, V42, P1, DOI 10.1097/00005072-198301000-00001; Sadler TW, 1985, LANGMANS MED EMBRYOL, P334; SCHOENBERG BS, 1976, AM J EPIDEMIOL, V104, P499, DOI 10.1093/oxfordjournals.aje.a112322; SUBAR AF, 1989, AM J CLIN NUTR, V50, P508, DOI 10.1093/ajcn/50.3.508; Tannenbaum S R, 1980, Ann N Y Acad Sci, V355, P267, DOI 10.1111/j.1749-6632.1980.tb21345.x; WARD EM, 1984, AM J EPIDEMIOL, V120, P582, DOI 10.1093/oxfordjournals.aje.a113920; WATTENBERG LW, 1983, CANCER RES, V43, P2448; WILKENS LR, 1992, AM J EPIDEMIOL, V136, P825, DOI 10.1093/aje/136.7.825; Willett W, 1990, NUTR EPIDEMIOLOGY, P92; YOUNG J L JR, 1986, Cancer, V58, P598, DOI 10.1002/1097-0142(19860715)58:2+<598::AID-CNCR2820581332>3.0.CO;2-C; 1991, LANCET, V338, P131; 1976, AGR HDB, V8; 1985, PHYSICIANS DESK REFE; 1981, HLTH EFFECTS NITRA 1	32	167	169	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 19	1993	329	8					536	541		10.1056/NEJM199308193290804	http://dx.doi.org/10.1056/NEJM199308193290804			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR892	8336753	Bronze			2022-12-01	WOS:A1993LR89200004
J	MARUSIC, M				MARUSIC, M			DO ANGELS CRY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1993	270	5					548	548						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LP436	8331742				2022-12-01	WOS:A1993LP43600001
J	MOLLICA, RF; DONELAN, K; TOR, S; LAVELLE, J; ELIAS, C; FRANKEL, M; BLENDON, RJ				MOLLICA, RF; DONELAN, K; TOR, S; LAVELLE, J; ELIAS, C; FRANKEL, M; BLENDON, RJ			THE EFFECT OF TRAUMA AND CONFINEMENT ON FUNCTIONAL HEALTH AND MENTAL-HEALTH STATUS OF CAMBODIANS LIVING IN THAILAND-CAMBODIA BORDER CAMPS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POSTTRAUMATIC-STRESS-DISORDER; SOUTHEAST-ASIAN REFUGEES; CULTURAL BEREAVEMENT; TORTURE; CARE; WAR; INSTRUMENT; DISABILITY; DEPRESSION; SITUATION	Objective.-To assess the long-term impact of trauma and confinement on the functional health and mental health status of Cambodian displaced persons living on the Thailand-Cambodia border. Design.-Household survey of 993 adults randomly selected from household rosters. Household sample selection by multistage area probability sample. Setting.-Site 2, the largest Cambodian displaced-persons camp on the Thailand-Cambodia border. Participants.-Adults 18 years of age and older selected at random within households; 98% of eligible persons selected agreed to participate. Results.-From 1975 through 1979 (Khmer Rouge regime), more than 85% reported lack of food, water, shelter, and medical care, brainwashing, and forced labor; 54% reported murder of a family member or friend; 36% reported torture; 18% reported head injury; and 17% reported rape or sexual abuse. During the refugee period between 1980 and 1990, 56% reported lack of food or water, 44% reported lack of shelter, 28% reported lack of medical care, 24% reported brainwashing, and 8% reported torture. Since 1980, reports of murder of a family member, head injury, and rape/sexual abuse have decreased to 5%. Reports of experiencing combat situations and shelling attacks have remained consistent between the two time periods, approximately 44% and 30%, respectively. From 1989 to 1990, 25% reported experiencing lack of food or water, and 5% to 10% reported serious injury, combat, and shelling conditions. More than 80% said they were in fair or poor health, felt depressed, and had a number of somatic complaints despite good access to medical services. Fifty-five percent and 15% had symptom scores that correlate with Western criteria for depression and posttraumatic stress disorder, respectively. Fifteen percent to 20% reported health impairments limiting activity, and moderate or severe bodily pain. Despite reported high levels of trauma and symptoms, social and work functioning were well preserved in the majority of respondents. Conclusions.-Reports of extensive trauma, poor health status, and depressive symptoms of this population are of concern in predicting future morbidity and mortality. The health and mental health needs of Cambodian displaced persons and their impact on social and economic behavior should be addressed now that the Cambodians have been repatriated.	HARVARD UNIV,SCH PUBL HLTH,HARVARD PROGRAM REFUGEE TRAUMA,BOSTON,MA 02115; POPULAT COUNCIL,NEW YORK,NY; HARVARD UNIV,SCH PUBL HLTH,DEPT HLTH POLICY & MANAGEMENT,BOSTON,MA 02115; CUNY BERNARD M BARUCH COLL,NEW YORK,NY 10010	Harvard University; Harvard T.H. Chan School of Public Health; Population Council; Harvard University; Harvard T.H. Chan School of Public Health; City University of New York (CUNY) System; Baruch College (CUNY)	MOLLICA, RF (corresponding author), ST ELIZABETH HOSP,INDOCHINESE PSYCHIAT CLIN,77 WARREN ST,BRIGHTON,MA 02135, USA.		Donelan, Karen/R-6162-2019					AGAKHAN S, 1986, REFUGEES DYNAMICS DI; BLENDON RJ, 1991, HEALTH AFFAIR, V10, P216, DOI 10.1377/hlthaff.10.3.216; DIEKSTRA RFW, 1988, PSYCHOSOCIAL MENTAL; DOHRENWEND BP, 1990, PSYCHOL MED, V20, P195, DOI 10.1017/S0033291700013374; EISENBRUCH M, 1992, J NERV MENT DIS, V180, P8, DOI 10.1097/00005053-199201000-00004; EISENBRUCH M, 1991, SOC SCI MED, V33, P673, DOI 10.1016/0277-9536(91)90021-4; Eitinger L., 1964, CONCENTRATION CAMP S; FLAHERTY JA, 1988, J NERV MENT DIS, V176, P257; GLASS RI, 1990, LANCET, V335, P868; GOLDFELD AE, 1988, JAMA-J AM MED ASSOC, V259, P2725, DOI 10.1001/jama.259.18.2725; HANNUM H, 1989, HUM RIGHTS QUART, V11, P82, DOI 10.2307/761936; HEARST N, 1986, NEW ENGL J MED, V314, P620, DOI 10.1056/NEJM198603063141005; IDLER EL, 1991, J GERONTOL SOC SCI, V2, P55; KHASIANI SA, 1990, INT MIGR, V28, P369, DOI 10.1111/j.1468-2435.1990.tb00482.x; Kiljunen K., 1984, KAMPUCHEA DECADE GEN; KILJUNEN K, 1985, B CONCERNED ASIAN SC, P1749; KINZIE JD, 1990, AM J PSYCHIAT, V147, P913; Kish L, 1965, SURVEY SAMPLING; KLAUS K, 1992, AM J PSYCHIAT, V149, P337; KLERMAN GL, 1989, ARCH GEN PSYCHIAT, V46, P856; KROLL J, 1989, AM J PSYCHIAT, V146, P1592; LYNCH JF, 1989, BORDER KHMER DEMOGRA; MECHANIC D, 1986, PSYCHOL MED, V16, P1, DOI 10.1017/S0033291700002476; MOLLICA R, 1991, PSYCHOL ASSESSMENT, V3, P1; MOLLICA RF, 1992, J NERV MENT DIS, V180, P111, DOI 10.1097/00005053-199202000-00008; MOLLICA RF, 1987, AM J PSYCHIAT, V144, P497; MOLLICA RF, 1989, PSYCHIAT CLIN N AM, V12, P363; MOLLICA RF, 1987, AM J PSYCHIAT, V144, P1567; MOLLICA RF, 1989, COMMUNITY CONFINEMEN; MOLLICA RF, 1989, TURNING POINT KHMER; MUSCAT RJ, 1989, CAMBODIA POST SETTLE; NGOR H, 1987, CAMBODIAN ODYSSEY; Reynell J., 1989, POLITICAL PAWNS REFU; ROGGE JR, 1992, REPATRIATIOON CONFLI; SANDLER RH, 1987, MED CARE REFUGEES; SEGAL J, 1976, INT SOC SCI J, V28, P593; STEIN BN, 1986, INT MIGR REV, V20, P264, DOI 10.2307/2546035; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; SZYMUSIAK M, 1986, STONES CRY OUT CAMBO; TAYLOR DC, 1979, LANCET, V2, P1008; THORN L, 1988, RICE TRUCK PADDY FIE; THYGESEN P, 1970, DAN MED BULL, V17, P65; TOOLE MJ, 1993, JAMA-J AM MED ASSOC, V270, P600, DOI 10.1001/jama.270.5.600; URSANO RJ, 1990, MIL MED, V155, P176, DOI 10.1093/milmed/155.4.176; VERNEZ G, 1991, AM PSYCHOL, V46, P627, DOI 10.1037/0003-066X.46.6.627; VONKORFF M, 1992, ARCH GEN PSYCHIAT, V49, P91; WELLS KB, 1989, JAMA-J AM MED ASSOC, V262, P914, DOI 10.1001/jama.262.7.914; 1991, AMNESTY INT REPORT, P224; 1987, DIAGNOSTIC STATISTIC; 1992, S23613 UN SEC COUNC; 1986, THAILAND TORTURE 3 K, P1; 1990, ECN619912 UN EC SOC; 1985, MONTHLY PROTECTION R; 1987, SEEKING SHELTER CAMB; 1990, ECN619914 UN EC SOC	55	238	239	0	35	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 4	1993	270	5					581	586		10.1001/jama.270.5.581	http://dx.doi.org/10.1001/jama.270.5.581			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LP436	8331755				2022-12-01	WOS:A1993LP43600021
J	KIM, SG; ASHE, J; HENDRICH, K; ELLERMANN, JM; MERKLE, H; UGURBIL, K; GEORGOPOULOS, AP				KIM, SG; ASHE, J; HENDRICH, K; ELLERMANN, JM; MERKLE, H; UGURBIL, K; GEORGOPOULOS, AP			FUNCTIONAL MAGNETIC-RESONANCE-IMAGING OF MOTOR CORTEX - HEMISPHERIC-ASYMMETRY AND HANDEDNESS	SCIENCE			English	Article							CEREBRAL BLOOD-FLOW; MOVEMENTS; DAMAGE; STROKE	A hemispheric asymmetry in the functional activation of the human motor cortex during contralateral (C) and ipsilateral (I) finger movements, especially in right-handed subjects, was documented with nuclear magnetic resonance imaging at high field strength (4 tesla). Whereas the right motor cortex was activated mostly during contralateral finger movements in both right-handed (C/I mean area of activation = 36.8) and left-handed (C/I = 29.9) subjects, the left motor cortex was activated substantially during ipsilateral movements in left-handed subjects (C/I = 5.4) and even more so in right-handed subjects (C/I = 1.3).	UNIV MINNESOTA, SCH MED, DEPT RADIOL, MINNEAPOLIS, MN 55455 USA; DEPT VET AFFAIRS MED CTR, CTR BRAIN SCI, MINNEAPOLIS, MN 55417 USA; UNIV MINNESOTA, SCH MED, DEPT NEUROL, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH MED, DEPT BIOCHEM, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH MED, DEPT MED, MINNEAPOLIS, MN 55455 USA; UNIV MINNESOTA, SCH MED, DEPT PHYSIOL, MINNEAPOLIS, MN 55455 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities	KIM, SG (corresponding author), UNIV MINNESOTA, SCH MED, CTR MAGNET RESONANCE RES, MINNEAPOLIS, MN 55455 USA.		Ugurbil, Kamil/AAD-6058-2022	Ellermann, Jutta/0000-0002-7109-9656	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033600, P01HL032427] Funding Source: NIH RePORTER; NCRR NIH HHS [RR08079] Funding Source: Medline; NHLBI NIH HHS [HL33600, HL32427] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		CHOLLET F, 1991, ANN NEUROL, V29, P63, DOI 10.1002/ana.410290112; COLEBATCH JG, 1991, J NEUROPHYSIOL, V65, P1392, DOI 10.1152/jn.1991.65.6.1392; De Renzi E., 1982, DISORDERS SPACE EXPL; GESCHWIN.N, 1965, BRAIN, V88, P237, DOI 10.1093/brain/88.2.237; Geschwind N, 1984, CEREBRAL DOMINANCE B; HAALAND KY, 1981, NEUROPSYCHOLOGIA, V19, P17; HAALAND KY, 1989, NEUROPSYCHOLOGIA, V27, P961, DOI 10.1016/0028-3932(89)90071-7; HAALAND KY, 1987, NEUROPSYCHOLOGIA, V25, P783, DOI 10.1016/0028-3932(87)90116-3; HAASE A, 1986, J MAGN RESON, V67, P258, DOI 10.1016/0022-2364(86)90433-6; HASLEY JH, 1979, NEUROLOGY, V29, P21; KIM SG, 1993, J NEUROPHYSIOL, V69, P297, DOI 10.1152/jn.1993.69.1.297; KIMURA D, 1977, BRAIN, V100, P527, DOI 10.1093/brain/100.3.527; NYBERGHANSEN R, 1963, ACTA NEUROL SCAND, V39, P1, DOI 10.1111/j.1600-0404.1963.tb05384.x; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; ROLAND PE, 1982, J NEUROPHYSIOL, V48, P467, DOI 10.1152/jn.1982.48.2.467; Springer S., 1981, LEFT BRAIN RIGHT BRA; WYKE M, 1966, ARCH NEUROL-CHICAGO, V15, P329, DOI 10.1001/archneur.1966.00470150107016; WYKE M, 1968, NEUROPSYCHOLOGIA, V6, P125, DOI 10.1016/0028-3932(68)90054-7; WYKE M, 1967, NEUROLOGY, V17, P1113, DOI 10.1212/WNL.17.11.1113	19	814	829	3	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	1993	261	5121					615	617		10.1126/science.8342027	http://dx.doi.org/10.1126/science.8342027			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	8342027				2022-12-01	WOS:A1993LP72800041
J	YE, M; GRANTHAM, JJ				YE, M; GRANTHAM, JJ			THE SECRETION OF FLUID BY RENAL CYSTS FROM PATIENTS WITH AUTOSOMAL-DOMINANT POLYCYSTIC KIDNEY-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INVITRO; EPITHELIUM; GROWTH	Background. The mechanism by which fluid accumulates in renal cysts of adults with autosomal dominant polycystic kidney disease is not known. This study was designed to determine whether transepithelial secretion of fluid may account for this accumulation. Methods. We studied in vitro intact cysts that were excised from kidneys removed from three patients with end-stage autosomal dominant polycystic kidney disease. The cysts were loaded with natural cyst fluid or with a combination of Dulbecco's modified Eagle's medium and Ham's F12 medium (DME-F12) and incubated in DME-F12 for 24 hours. Fluid secretion, determined by the change in the weight of the cysts, was expressed as the rate of fluid secretion per square centimeter of surface area per 24 hours, to correct for the wide variation in the sizes of the cysts. To test for endogenous secretagogues, cyst fluid was added to confluent monolayer cultures of canine- and human-kidney cells. Results. During the first 24 hours of incubation, the mean (+/-SE) rate of fluid secretion in nine cysts containing natural cyst fluid was 20.8+/-5.6 mul per square centimeter of surface area per 24 hours, as compared with 2.3+/-3.6 mul per square centimeter per 24 hours in nine cysts containing incubation medium. Each group of cysts was then incubated with forskolin, a nonspecific stimulator of adenylate cyclase activity, for an additional 24 hours. During this period the fluid-secretion rate of cysts containing natural cyst fluid did not change; however, the secretion rate of those containing incubation medium increased to 9.1+/-4.4 mul per square centimeter per 24 hours (mean change, 6.8+/-1.1; P<0.001). Cyst fluid stimulated fluid secretion by polarized monolayers of canine- and human-kidney cells. Conclusions. Renal cysts from patients with autosomal dominant polycystic kidney disease can secrete fluid, and net fluid secretion can be increased by unidentified secretagogues in the cyst fluid. These results suggest that the process of cyst enlargement may be susceptible to pharmacologic intervention.	UNIV KANSAS,MED CTR,SCH MED,DEPT MED,DIV NEPHROL,39TH & RAINBOW BLVD,KANSAS CITY,KS 66103	University of Kansas; University of Kansas Medical Center					NIDDK NIH HHS [DK 45614] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045614] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CUPPAGE FE, 1980, KIDNEY INT, V17, P372, DOI 10.1038/ki.1980.43; EVERSON GT, 1990, HEPATOLOGY, V11, P557, DOI 10.1002/hep.1840110406; GARDNER KD, 1969, NEW ENGL J MED, V281, P985, DOI 10.1056/NEJM196910302811804; GRANTHAM JJ, 1987, KIDNEY INT, V31, P1145, DOI 10.1038/ki.1987.121; GRANTHAM JJ, 1976, PHYSIOL REV, V56, P248, DOI 10.1152/physrev.1976.56.1.248; GRANTHAM JJ, 1983, AM J PHYSIOL, V244, pF3, DOI 10.1152/ajprenal.1983.244.1.F3; HUSEMAN R, 1980, KIDNEY INT, V18, P375, DOI 10.1038/ki.1980.148; MANGOOKARIM R, 1989, P NATL ACAD SCI USA, V86, P6007, DOI 10.1073/pnas.86.15.6007; MANGOOKARIM R, 1989, FASEB J, V3, P2629, DOI 10.1096/fasebj.3.14.2480260; Neufeld TK, 1991, J TISS CULT METHODS, V13, P229; PERRONE RD, 1985, J CLIN INVEST, V76, P1688, DOI 10.1172/JCI112155; YE M, 1992, J AM SOC NEPHROL, V3, P984; YE M, 1986, CHINESE J SURG, V24, P73	13	97	100	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JUL 29	1993	329	5					310	313		10.1056/NEJM199307293290503	http://dx.doi.org/10.1056/NEJM199307293290503			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN621	8321258	Bronze			2022-12-01	WOS:A1993LN62100003
J	MASUD, T; LANGLEY, S; WILTSHIRE, P; DOYLE, DV; SPECTOR, TD				MASUD, T; LANGLEY, S; WILTSHIRE, P; DOYLE, DV; SPECTOR, TD			EFFECT OF SPINAL OSTEOPHYTOSIS ON BONE-MINERAL DENSITY-MEASUREMENTS IN VERTEBRAL OSTEOPOROSIS	BRITISH MEDICAL JOURNAL			English	Article									WHIPPS CROSS HOSP & CHEST CLIN,DEPT RHEUMATOL,LONDON E11 1NR,ENGLAND	University of London; Queen Mary University London	MASUD, T (corresponding author), ST THOMAS HOSP,DEPT RHEUMATOL,LONDON SE1 7EH,ENGLAND.		Langley-Evans, Simon C/F-3564-2012; Spector, Tim D/F-6533-2012	Langley-Evans, Simon C/0000-0002-1969-8416; 	Arthritis Research UK [17489] Funding Source: Medline	Arthritis Research UK(Versus Arthritis)		DAWSONHUGHES B, 1990, CALCIFIED TISSUE INT, V46, P280, DOI 10.1007/BF02555008; DEQUEKER J, 1985, CLIN RHEUM DIS, V11, P271; LAWRENCE JS, 1969, ANN RHEUM DIS, V28, P6121; ORWOLL ES, 1990, J CLIN ENDOCR METAB, V70, P1202, DOI 10.1210/jcem-70-4-1202; REID IR, 1991, J CLIN ENDOCR METAB, V72, P1372, DOI 10.1210/jcem-72-6-1372	5	163	170	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1993	307	6897					172	173		10.1136/bmj.307.6897.172	http://dx.doi.org/10.1136/bmj.307.6897.172			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN184	8343746	Bronze, Green Published			2022-12-01	WOS:A1993LN18400021
J	SCHNUCHEL, A; WILTSCHECK, R; CZISCH, M; HERRLER, M; WILLIMSKY, G; GRAUMANN, P; MARAHIEL, MA; HOLAK, TA				SCHNUCHEL, A; WILTSCHECK, R; CZISCH, M; HERRLER, M; WILLIMSKY, G; GRAUMANN, P; MARAHIEL, MA; HOLAK, TA			STRUCTURE IN SOLUTION OF THE MAJOR COLD-SHOCK PROTEIN FROM BACILLUS-SUBTILIS	NATURE			English	Article							NUCLEAR MAGNETIC-RESONANCE; SPIN COUPLING-CONSTANTS; RNA-BINDING DOMAIN; DISTANCE GEOMETRY; TRYPSIN-INHIBITOR; ESCHERICHIA-COLI; IDENTIFICATION; CONFORMATIONS; SPECTROSCOPY; COSY	THE cold-shock domain (CSD) is found in many eukaryotic transcriptional factors and is responsible for the specific binding to DNA of a cis-element called the Y-box1-3. The same domain exists in the sequence of the Xenopus RNA-binding proteins FRG Y1 and FRG Y2 (refs 1, 3). The major cold-shock proteins of Escherichia coli (CS7.4)4-7 and B. subtilis (CspB)8 have sequences that are more than 40 per cent identical to the cold-shock domain. We present here the three-dimensional structure of CspB determined by nuclear magnetic resonance spectroscopy. The 67-residue protein consists of an antiparallel five-stranded beta-barrel with strands connected by turns and loops. The structure resembles that of staphylococcal nuclease and the gene-5 single-stranded-DNA-binding protein9-11. A three-stranded beta-sheet, which contains the conserved RNA-binding motif RNP1 as well as a motif similar to RNP2 in two neighbouring antiparallel beta-strands12-14, has basic and aromatic residues at its surface which could serve as a binding site for single-stranded DNA. CspB binds to single-stranded DNA in gel retardation experiments.	UNIV MARBURG,DEPT BIOCHEM,W-3550 MARBURG,GERMANY	Philipps University Marburg	SCHNUCHEL, A (corresponding author), MAX PLANCK INST BIOCHEM,W-8033 MARTINSRIED,GERMANY.		Willimsky, Gerald/AAA-2445-2021	Willimsky, Gerald/0000-0002-9693-948X; Graumann, Peter/0000-0002-8033-5171				ARUTYUNYAN E G, 1981, Doklady Biochemistry, V258, P189; BRAYER GD, 1983, J MOL BIOL, V169, P565, DOI 10.1016/S0022-2836(83)80065-5; BRUNGER AT, 1988, J MOL BIOL, V203, P803, DOI 10.1016/0022-2836(88)90211-2; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; GRIESINGER C, 1987, J MAGN RESON, V75, P474, DOI 10.1016/0022-2364(87)90102-8; HAVEL TF, 1985, J MOL BIOL, V182, P281, DOI 10.1016/0022-2836(85)90346-8; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HOLAK TA, 1989, J MOL BIOL, V210, P635, DOI 10.1016/0022-2836(89)90137-X; JONES PG, 1987, J BACTERIOL, V169, P2092, DOI 10.1128/jb.169.5.2092-2095.1987; JONES PG, 1992, J BACTERIOL, V174, P5798, DOI 10.1128/jb.174.18.5798-5802.1992; KLINE A, 1988, J MOL BIOL, V204, P657; LANDSMAN D, 1992, NUCLEIC ACIDS RES, V20, P2861, DOI 10.1093/nar/20.11.2861; LATEANA A, 1991, P NATL ACAD SCI USA, V88, P10907, DOI 10.1073/pnas.88.23.10907; MARION D, 1983, BIOCHEM BIOPH RES CO, V113, P967, DOI 10.1016/0006-291X(83)91093-8; MCPHERSON A, 1985, BIOL MACROMOL, V2, P323; MURZIN AG, 1992, CURR OPIN STRUC BIOL, V2, P895; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; PARDI A, 1984, J MOL BIOL, V180, P741, DOI 10.1016/0022-2836(84)90035-4; SCHINDELIN H, 1993, NATURE, V364, P164, DOI 10.1038/364164a0; TAFURI SR, 1992, NEW BIOL, V4, P349; TAFURI SR, 1990, P NATL ACAD SCI USA, V87, P9028, DOI 10.1073/pnas.87.22.9028; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WILLIMSKY G, 1992, J BACTERIOL, V174, P6326, DOI 10.1128/JB.174.20.6326-6335.1992; WISTOW G, 1990, NATURE, V344, P823, DOI 10.1038/344823c0; WOLFFE AP, 1992, NEW BIOL, V4, P290; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC	28	202	205	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 8	1993	364	6433					169	171		10.1038/364169a0	http://dx.doi.org/10.1038/364169a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL367	8321289				2022-12-01	WOS:A1993LL36700056
J	PINI, A				PINI, A			CHEMOREPULSION OF AXONS IN THE DEVELOPING MAMMALIAN CENTRAL-NERVOUS-SYSTEM	SCIENCE			English	Article							NEURONAL PROJECTIONS; GROWTH CONES; GUIDANCE; COLLAPSE; BRAIN	During development of the nervous system, distinct populations of nerve cells extend specialized processes, axons and dendrites, over considerable distances to locate their targets. There is strong evidence for two general mechanisms by which these connections are made. The first involves attractive and repulsive interactions, both between cells and between them and their extracellular matrix. The second depends on the release of diffusible chemoattractants by target structures. Evidence is now provided for a mechanism of axon guidance in which diffusible chemorepulsive factors create exclusion zones for developing axons, causing them to turn away from inappropriate territory.	MRC,MAMMALIAN DEV UNIT,LONDON NW1 2HE,ENGLAND				Pini, Adrian PJ/C-5342-2009					BAYER SA, 1983, EXP BRAIN RES, V50, P329; BOLZ J, 1990, NATURE, V346, P359, DOI 10.1038/346359a0; CAJAL SRY, 1909, HISTOLOGIE SYSTEME N, V1, P657; COX EC, 1990, NEURON, V4, P31, DOI 10.1016/0896-6273(90)90441-H; DAVIES JA, 1990, NEURON, V4, P11, DOI 10.1016/0896-6273(90)90439-M; DODD J, 1988, NEURON, V1, P105, DOI 10.1016/0896-6273(88)90194-8; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; HEFFNER CD, 1990, SCIENCE, V247, P217, DOI 10.1126/science.2294603; LUMSDEN AGS, 1986, NATURE, V323, P538, DOI 10.1038/323538a0; LUMSDEN AGS, 1983, NATURE, V306, P786, DOI 10.1038/306786a0; RAPER JA, 1990, NEURON, V4, P21, DOI 10.1016/0896-6273(90)90440-Q; SCHONFELD TA, 1989, J NEUROSCI, V98, P1712; SCHWOB JE, 1984, J COMP NEUROL, V223, P117; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; YAMAMOTO M, 1986, J NEUROSCI, V6, P3576	15	151	154	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					95	98		10.1126/science.8316861	http://dx.doi.org/10.1126/science.8316861			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	8316861				2022-12-01	WOS:A1993LK43400040
J	MARON, BJ				MARON, BJ			SUDDEN-DEATH IN YOUNG ATHLETES - LESSONS FROM THE GATHERS,HANK AFFAIR	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							HYPERTROPHIC CARDIOMYOPATHY; CARDIOVASCULAR-DISEASE				MARON, BJ (corresponding author), MINNEAPOLIS HEART INST FDN, MINNEAPOLIS, MN 55407 USA.							BURKE AP, 1991, AM HEART J, V121, P568, DOI 10.1016/0002-8703(91)90727-Y; CHEITLIN MD, 1974, CIRCULATION, V50, P780, DOI 10.1161/01.CIR.50.4.780; CORRADO D, 1990, AM J MED, V89, P588, DOI 10.1016/0002-9343(90)90176-E; FURLANELLO F, 1984, ANN NY ACAD SCI, V427, P253, DOI 10.1111/j.1749-6632.1984.tb20789.x; LEWIS JF, 1989, AM J CARDIOL, V64, P1029, DOI 10.1016/0002-9149(89)90802-3; MARON BJ, 1990, CIRCULATION, V82, P239; MARON BJ, 1987, J AM COLL CARDIOL, V10, P1214, DOI 10.1016/S0735-1097(87)80121-3; MARON BJ, 1985, J AM COLL CARDIOL, V6, P1189; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; MARON BJ, 1980, CIRCULATION, V62, P218, DOI 10.1161/01.CIR.62.2.218; MARON BJ, 1982, CIRCULATION, V65, P1388, DOI 10.1161/01.CIR.65.7.1388; NEUSPIEL DR, 1985, JAMA-J AM MED ASSOC, V254, P1321, DOI 10.1001/jama.254.10.1321; Noren G R, 1977, J Forensic Sci, V22, P188; SHAPIRO L, 1992, WASHINGTON POST 0404, pD1; SMALE D, 1991, OFFICIAL NATIONAL CO, P84; THIENE G, 1983, HUM PATHOL, V14, P704, DOI 10.1016/S0046-8177(83)80143-9; TSUNG SH, 1982, ARCH PATHOL LAB MED, V106, P168; [No title captured]	18	140	141	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 1	1993	329	1					55	57		10.1056/NEJM199307013290113	http://dx.doi.org/10.1056/NEJM199307013290113			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ338	8292123				2022-12-01	WOS:A1993LJ33800013
J	FORSYTH, JS; OGSTON, SA; CLARK, A; FLOREY, CD; HOWIE, PW				FORSYTH, JS; OGSTON, SA; CLARK, A; FLOREY, CD; HOWIE, PW			RELATION BETWEEN EARLY INTRODUCTION OF SOLID FOOD TO INFANTS AND THEIR WEIGHT AND ILLNESSES DURING THE 1ST 2 YEARS OF LIFE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BREAST; OVERNUTRITION; INFECTION; ECZEMA; ASTHMA; DIET	Objective-To assess the relations between early introduction of solid food and infant weight, gastrointestinal illness, and allergic illnesses during the first two years of life. Design-Prospective observational study of infants followed up for 24 months after birth. Setting-Community setting in Dundee. Patients-671 newborn infants, of whom 455 were still available for study at 2 years of age. Main outcome measures-Infants' diet, weight, and incidence of gastrointestinal illness, respiratory illness, napkin dermatitis, and eczema at 2 weeks and 2, 3, 4, 6, 9, 12, 15, 18, 21, and 24 months of age. Results-The infants given solid food at an early age (at < 8 weeks or 8-12 weeks) were heavier than those introduced to solids later (after 12 weeks) at 4, 8, 13, and 26 weeks of age (p < 0.01) but not at 52 and 104 weeks. At their first solid feed those given solids early were heavier than infants of similar age who had not yet received solids. The incidence of gastrointestinal illness, wheeze, and nappy dermatitis was not related to early introduction of solids. There was a significant but less than twofold increase in respiratory illness at 14-26 weeks of age and persistent cough at 14-26 and 27-39 weeks of age among the infants given solids early. The incidence of eczema was increased in the infants who received solids at 8-12 weeks of age. Conclusion-Early introduction of solid food to infants is less harmful than was previously reported. Longer follow up is needed, but, meanwhile, a more relaxed approach to early feeding with solids should be considered.	UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT EPIDEMIOL & PUBL HLTH, DUNDEE DD1 9SY, SCOTLAND; UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT OBSTET & GYNAECOL, DUNDEE DD1 9SY, SCOTLAND	University of Dundee; University of Dundee	FORSYTH, JS (corresponding author), UNIV DUNDEE, NINEWELLS HOSP & MED SCH, DEPT CHILD HLTH, DUNDEE DD1 9SY, SCOTLAND.							ABERG N, 1990, ACTA PAEDIATR SCAND, V79, P206, DOI 10.1111/j.1651-2227.1990.tb11440.x; AGRAS WS, 1990, J PEDIATR-US, V116, P805, DOI 10.1016/S0022-3476(05)82677-0; ANDRAE S, 1988, ARCH DIS CHILD, V63, P473, DOI 10.1136/adc.63.5.473; BAKER RJ, 1978, GLIM SYSTEM; CHANDRA RK, 1979, ACTA PAEDIATR SCAND, V68, P691, DOI 10.1111/j.1651-2227.1979.tb18439.x; COGSWELL JJ, 1987, ARCH DIS CHILD, V62, P338, DOI 10.1136/adc.62.4.338; FERGUSSON DM, 1990, PEDIATRICS, V86, P541; FERGUSSON DM, 1983, ARCH DIS CHILD, V58, P48, DOI 10.1136/adc.58.1.48; FERGUSSON DM, 1981, CLIN ALLERGY, V11, P325; HOWIE PW, 1990, BRIT MED J, V300, P11, DOI 10.1136/bmj.300.6716.11; JARRETT EEE, 1984, LANCET, V2, P797; KRAMER MS, 1988, J PEDIATR-US, V112, P181, DOI 10.1016/S0022-3476(88)80054-4; MARTIN J, 1988, INFANT FEEDING 1985; MILLA PJ, 1986, ACTA PAEDIATR SCAND, P5; POPKIN BM, 1990, PEDIATRICS, V86, P874; SHUKLA A, 1972, BMJ-BRIT MED J, V4, P507, DOI 10.1136/bmj.4.5839.507; STUFF JE, 1989, J PEDIATR-US, V115, P959, DOI 10.1016/S0022-3476(89)80750-4; TAITZ LS, 1971, BRIT MED J, V1, P315, DOI 10.1136/bmj.1.5744.315; TAYLOR B, 1973, LANCET, V2, P111; Thorogood M, 1979, J R Coll Gen Pract, V29, P427; WILKINSON PW, 1978, BRIT MED J, V1, P1682, DOI 10.1136/bmj.1.6128.1682; 1988, PRESENT DAY PRACTICE; 1980, PRESENT DAY PRACTICE; 1980, PEDIATRICS, V65, P1178; 1982, ACTA PAEDIATR SC   S, V302, P1; 1974, PRESENT DAY PRACTICE	26	103	103	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 12	1993	306	6892					1572	1576		10.1136/bmj.306.6892.1572	http://dx.doi.org/10.1136/bmj.306.6892.1572			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329916	Green Published, Bronze			2022-12-01	WOS:A1993LH12800016
J	PERMERT, J; LARSSON, J; WESTERMARK, GT; HERRINGTON, MK; CHRISTMANSON, L; POUR, PM; WESTERMARK, P; ADRIAN, TE				PERMERT, J; LARSSON, J; WESTERMARK, GT; HERRINGTON, MK; CHRISTMANSON, L; POUR, PM; WESTERMARK, P; ADRIAN, TE			ISLET AMYLOID POLYPEPTIDE IN PATIENTS WITH PANCREATIC-CANCER AND DIABETES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							INSULIN RESISTANCE; AMYLIN; GLUCOSE; CELLS; IMMUNOREACTIVITY; EXPRESSION; PEPTIDE; INVITRO; INVIVO; LIVER	Background. The diabetes mellitus that occurs in patients with pancreatic cancer is characterized by marked insulin resistance that declines after tumor resection. Islet amyloid polypeptide (IAPP), a hormonal factor secreted from the pancreatic beta cells, reduces insulin sensitivity in vivo and glycogen synthesis in vitro. In this study, we examined the relation between IAPP and diabetes in patients with pancreatic cancer. Methods. We measured IAPP in plasma from 30 patients with pancreatic cancer, 46 patients with other cancers, 23 patients with diabetes, and 25 normal subjects. IAPP immunoreactivity and IAPP messenger RNA were studied in pancreatic cancers, pancreatic tissue adjacent to cancers, and normal pancreatic tissue. Results. Plasma IAPP concentrations were elevated in the patients with pancreatic cancer as compared with the normal subjects (mean [+/-SD], 22.3+/-13.6 vs. 8.0+/-5.0 pmol per liter; P<0.001), normal in the patients with other cancers, and normal or low in the patients with diabetes. Among the patients with pancreatic cancer, the concentrations were 25.0+/-8.7 pmol per liter in the 7 patients with diabetes who required insulin, 31.4+/-12.6 pmol per liter in the 11 patients with diabetes who did not require insulin, and 12.2+/-2.4 pmol per liter in the 9 patients with normal glucose tolerance (3 patients had impaired glucose tolerance; their mean plasma IAPP concentration was 11.7+/-5.5 pmol per liter). Plasma IAPP concentrations decreased after surgery in the seven patients with pancreatic cancer who were studied before and after subtotal pancreatectomy (28.9+/-16.4 vs. 5.6+/-3.4 pmol per liter, P = 0.01). Pancreatic cancers contained IAPP, but the concentrations were lower than in normal pancreatic tissue (17+/-16 vs. 183+/-129 pmol per gram, P<0.001). In samples from the patients with both pancreatic cancer and diabetes, immunostaining for IAPP was reduced in islets of pancreatic tissue surrounding the tumor; in situ hybridization studies suggested that transcription occurred normally in these islets. Conclusions. Plasma IAPP concentrations are elevated in patients with pancreatic cancer who have diabetes. Since IAPP may cause insulin resistance, its overproduction may contribute to the diabetes that occurs in these patients.	CREIGHTON UNIV, SCH MED, DEPT BIOMED SCI, 2500 CALIF ST, OMAHA, NE 68178 USA; UNIV LINKOPING, DEPT SURG, LINKOPING, SWEDEN; UNIV LINKOPING, DEPT PATHOL, LINKOPING, SWEDEN; UNIV UPPSALA, DEPT PATHOL, S-75105 UPPSALA, SWEDEN; UNIV NEBRASKA, MED CTR, EPPLEY INST RES CANC, OMAHA, NE 68105 USA	Creighton University; Linkoping University; Linkoping University; Uppsala University; University of Nebraska System; University of Nebraska Medical Center			Adrian, Thomas E/D-8484-2012	Adrian, Thomas/0000-0002-5051-1111	NATIONAL CANCER INSTITUTE [R01CA044799] Funding Source: NIH RePORTER	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], 1985, World Health Organ Tech Rep Ser, V727, P1; ARNELO U, 1993, GASTROENTEROLOGY, V104, pA294; BERKOWITZ D, 1962, AM J MED SCI, V243, P228; BOYLE P, 1989, INT J PANCREATOL, V5, P327, DOI 10.1007/BF02924298; BRETHERTONWATT D, 1989, DIABETOLOGIA, V32, P881, DOI 10.1007/BF00297454; BRETHERTONWATT D, 1992, J CLIN ENDOCR METAB, V74, P1032, DOI 10.1210/jc.74.5.1032; BRETHERTONWATT D, 1990, DIABETOLOGIA, V33, P115, DOI 10.1007/BF00401050; BUTLER PC, 1990, DIABETES, V39, P752, DOI 10.2337/diabetes.39.6.752; CHANCE WT, 1991, BRAIN RES, V539, P352, DOI 10.1016/0006-8993(91)91644-G; CIARALDI TP, 1992, DIABETES, V41, P975, DOI 10.2337/diabetes.41.8.975; GREEN RC, 1958, DIABETES, V7, P308, DOI 10.2337/diab.7.4.308; HEDING LG, 1975, DIABETOLOGIA, V11, P541, DOI 10.1007/BF01222104; JOHNSON KH, 1989, AM J PATHOL, V135, P245; KOOPMANS SJ, 1991, DIABETOLOGIA, V34, P218, DOI 10.1007/BF00405079; LEIGHTON B, 1988, NATURE, V335, P632, DOI 10.1038/335632a0; MADSEN OD, 1991, MOL ENDOCRINOL, V5, P143, DOI 10.1210/mend-5-1-143; OBRIEN TD, 1991, DIABETES, V40, P1701, DOI 10.2337/diabetes.40.12.1701; PERMERT J, 1993, AM J SURG, V165, P61, DOI 10.1016/S0002-9610(05)80405-2; PERMERT J, 1993, BRIT J SURG, V80, P1047, DOI 10.1002/bjs.1800800841; PERMERT J, 1993, EUR J SURG, V159, P101; PERMERT J, 1992, INT J PANCREATOL, V11, P23; SANKE T, 1991, DIABETOLOGIA, V34, P129, DOI 10.1007/BF00500385; SCHWARTZ SS, 1978, AM J DIG DIS, V23, P1107, DOI 10.1007/BF01072886; SHERIFF S, 1992, BIOCHIM BIOPHYS ACTA, V1136, P219, DOI 10.1016/0167-4889(92)90260-I; SOWA R, 1990, DIABETOLOGIA, V33, P118, DOI 10.1007/BF00401051; Sternberger L. A., 1979, IMMUNOCYTOCHEMISTRY; TURNER RC, 1982, RECENT ADV ENDOCRINO, V2, P73; WESTERMARK GT, 1993, DIABETOLOGIA, V36, P323, DOI 10.1007/BF00400235; WESTERMARK P, 1987, P NATL ACAD SCI USA, V84, P3881, DOI 10.1073/pnas.84.11.3881; WESTERMARK P, 1987, DIABETOLOGIA, V30, P887	30	181	193	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 3	1994	330	5					313	318		10.1056/NEJM199402033300503	http://dx.doi.org/10.1056/NEJM199402033300503			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU489	8277951	Bronze			2022-12-01	WOS:A1994MU48900003
J	ZOU, ZQ; ANISOWICZ, A; HENDRIX, MJC; THOR, A; NEVEU, M; SHENG, SJ; RAFIDI, K; SEFTOR, E; SAGER, R				ZOU, ZQ; ANISOWICZ, A; HENDRIX, MJC; THOR, A; NEVEU, M; SHENG, SJ; RAFIDI, K; SEFTOR, E; SAGER, R			MASPIN, A SERPIN WITH TUMOR-SUPPRESSING ACTIVITY IN HUMAN MAMMARY EPITHELIAL-CELLS	SCIENCE			English	Article							DOWN-REGULATION; MESSENGER-RNAS; METASTASIS; GENES; LINES	A gene encoding a protein related to the serpin family of protease inhibitors was identified as a candidate tumor suppressor gene that may play a role in human breast cancer. The gene product, called maspin, is expressed in normal mammary epithelial cells but not in most mammary carcinoma cell lines. Transfection of MDA-MB-435 mammary carcinoma cells with the maspin gene did not alter the cells' growth properties in vitro, but reduced the cells' ability to induce tumors and metastasize in nude mice and to invade through a basement membrane matrix in vitro. Analysis of human breast cancer specimens revealed that loss of maspin expression occurred most frequently in advanced cancers. These results support the hypothesis that maspin functions as a tumor suppressor.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DIV CANC GENET,44 BINNEY ST,BOSTON,MA 02115; UNIV ARIZONA,CTR CANC,TUCSON,AZ 85724; MASSACHUSETTS GEN HOSP,DEPT PATHOL,BOSTON,MA 02114	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; University of Arizona; Harvard University; Massachusetts General Hospital					NATIONAL CANCER INSTITUTE [R35CA039814, P01CA022427, R01CA059702] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA59702, P01 CA22427, CA39814] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS JC, 1992, J HISTOCHEM CYTOCHEM, V40, P1457, DOI 10.1177/40.10.1527370; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; HARLOW E, 1988, ANTIBODIES LABORATOR, pCH8; HENDRIX MJC, 1987, CANCER LETT, V38, P137, DOI 10.1016/0304-3835(87)90209-6; HENDRIX MJC, UNPUB; HUBER R, 1989, BIOCHEMISTRY-US, V28, P8951, DOI 10.1021/bi00449a001; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; LEE SW, 1992, P NATL ACAD SCI USA, V89, P2504, DOI 10.1073/pnas.89.6.2504; LEE SW, 1991, P NATL ACAD SCI USA, V88, P2825, DOI 10.1073/pnas.88.7.2825; LEE SW, 1992, J CELL BIOL, V118, P1213, DOI 10.1083/jcb.118.5.1213; LIANG P, 1992, CANCER RES, V52, P6966; LIOTTA LA, 1991, CANCER RES, V51, pS5054; PRICE JE, 1990, CANCER RES, V50, P717; SAGER R, 1989, SCIENCE, V246, P1406, DOI 10.1126/science.2574499; SAGER R, 1993, FASEB J, V7, P964, DOI 10.1096/fasebj.7.10.8344495; SHENG S, UNPUB; STETLERSTEVENSON WG, 1993, ANNU REV CELL BIOL, V9, P541, DOI 10.1146/annurev.cellbio.9.1.541; TESTA JE, 1990, CANCER METAST REV, V9, P353, DOI 10.1007/BF00049524; TOMASETTO C, 1993, J CELL BIOL, V122, P157, DOI 10.1083/jcb.122.1.157; TRAVIS J, 1990, BIOL CHEM H-S, V371, P3; ZOU Z, UNPUB	21	806	893	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 28	1994	263	5146					526	529		10.1126/science.8290962	http://dx.doi.org/10.1126/science.8290962			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT966	8290962				2022-12-01	WOS:A1994MT96600035
J	ANDERSSON, R; HUGANDER, A; THULIN, A; NYSTROM, PO; OLAISON, G				ANDERSSON, R; HUGANDER, A; THULIN, A; NYSTROM, PO; OLAISON, G			INDICATIONS FOR OPERATION IN SUSPECTED APPENDICITIS AND INCIDENCE OF PERFORATION	BRITISH MEDICAL JOURNAL			English	Article							UNITED-STATES; APPENDECTOMY; RATES; AGE; ULTRASONOGRAPHY; POPULATION	Objective-To clarify poorly understood epidemiological features of appendicitis. Design-Retrospective study of consecutive cases from a defined population and analysis of data from published studies. Setting-County of Jonkoping, Sweden. 3029 patients who underwent operation in 1984-9 and 4717 patients from the county town who underwent operation in 1970-89, all for suspected appendicitis, plus 48 426 cases from six reported studies. Main outcome measures-Incidences specific for age and sex and temporal trends of perforating and non-perforating appendicitis and removal of a normal appendix. Associations between diagnostic accuracy, rate of perforation, and incidences of removal of a normal appendix and of perforating and non-perforating appendicitis. Results-The incidence of appendicitis was 116/100000 inhabitants. Appendicitis was more common in male patients. The incidence of perforating appendicitis was independent of age, stable over time, and uninfluenced by the rate of laparotomy, whereas the incidence of non-perforating appendicitis was age dependent, decreasing over time, and related to the diagnostic accuracy and rate of removal of a normal appendix. Conclusions-Perforating and non-perforating appendicitis seem to be separate entities, and appendicitis that resolves spontaneously is common. This may have important implications for managing suspected appendicitis.	LINKOPING UNIV HOSP,DEPT SURG,S-58185 LINKOPING,SWEDEN	Linkoping University	ANDERSSON, R (corresponding author), RYHOV HOSP,DEPT SURG,S-55185 JONKOPING,SWEDEN.			Andersson, Roland/0000-0002-1460-0248				ADDISS DG, 1990, AM J EPIDEMIOL, V132, P910, DOI 10.1093/oxfordjournals.aje.a115734; AMLAND PF, 1989, ACTA CHIR SCAND, V155, P185; ANDERSSON RE, 1992, EUR J SURG, V158, P37; ARNBJORNSSON E, 1983, ACTA CHIR SCAND, V149, P789; ARNBJORNSSON E, 1982, ACTA CHIR SCAND, V148, P461; ATTWOOD SE, 1987, J EPIDEMIOL COMMUN H, V41, P72, DOI 10.1136/jech.41.1.72; BARKER DJP, 1981, BMJ, V238, P1083; BUTSCH DW, 1973, POSTGRAD MED, V54, P132, DOI 10.1080/00325481.1973.11713586; Condon R. E., 1986, TXB SURG, P967; Dean A. G., 1990, EPI INFO VERSION 5 W; FOSTER HM, 1989, BRIT J SURG, V76, P368, DOI 10.1002/bjs.1800760417; GRAHAM DF, 1977, BRIT MED J, V2, P1375, DOI 10.1136/bmj.2.6099.1375; HELLER MB, 1993, AM J EMERG MED, V11, P51, DOI 10.1016/0735-6757(93)90060-O; HOWIE JGR, 1964, LANCET, V1, P1240; Lichtner S, 1971, Med Care, V9, P311, DOI 10.1097/00005650-197107000-00003; LUCKMANN R, 1989, AM J EPIDEMIOL, V129, P905, DOI 10.1093/oxfordjournals.aje.a115224; NOER T, 1975, ACTA CHIR SCAND, V141, P431; OLSEN JB, 1993, BRIT J SURG, V80, P922, DOI 10.1002/bjs.1800800744; PELTOKALLIO P, 1981, ARCH SURG-CHICAGO, V116, P153; PIEPER R, 1982, ACTA CHIR SCAND, V148, P45; PIEPER R, 1982, ACTA CHIR SCAND, V148, P51; PIEPER R, 1983, ANN SURG, V197, P368, DOI 10.1097/00000658-198303000-00019; PUYLAERT JBCM, 1987, NEW ENGL J MED, V317, P666, DOI 10.1056/NEJM198709103171103; RICCI MA, 1988, AM SURGEON, V54, P273; RUTKOW IM, 1981, SURGERY, V89, P151; THOMSON HJ, 1986, AM J SURG, V152, P522, DOI 10.1016/0002-9610(86)90220-5; VANDIEIJENVISSER MP, 1991, EUR J CLIN CHEM CLIN, V29, P749; WALDRON R, 1983, IRAN MED J, V6, P446; WEST RR, 1978, BRIT MED J, V1, P1662, DOI 10.1136/bmj.1.6128.1662; WILLIAMS GT, 1987, SYSTEMIC PATHOLOGY, V3, P292	30	182	183	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	1994	308	6921					107	110		10.1136/bmj.308.6921.107	http://dx.doi.org/10.1136/bmj.308.6921.107			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR173	8298378	Green Published			2022-12-01	WOS:A1994MR17300013
J	GOMMERSAMPT, JH; VANLEEUWEN, F; DEBEER, ALJ; VLIEGENTHART, JFG; DIZDAROGLU, M; KOWALAK, JA; CRAIN, PF; BORST, P				GOMMERSAMPT, JH; VANLEEUWEN, F; DEBEER, ALJ; VLIEGENTHART, JFG; DIZDAROGLU, M; KOWALAK, JA; CRAIN, PF; BORST, P			BETA-D-GLUCOSYL-HYDROXYMETHYLURACIL - A NOVEL MODIFIED BASE PRESENT IN THE DNA OF THE PARASITIC PROTOZOAN TRYPANOSOMA-BRUCEI	CELL			English	Article							TRYPANOSOMA-BRUCEI; HOMOLOGOUS RECOMBINATION; ANTIGENIC VARIATION; MAGNETIC-RESONANCE; MASS-SPECTROMETRY; HIGH-RESOLUTION; H-1-NMR; DAMAGE	We have previously shown that the DNA of the unicellular eukaryote T. brucei contains about 0.1% of a novel modified base, called J. The presence of J correlates with a DNA modification associated with the silencing of telomeric expression sites for the variant surface antigens of trypanosomes. Here we show that J is 5-((beta-D-glucopyranosyloxy)-methyl)-uracil (shortened to beta-D-glucosyl-hydroxymethyluracil), a base not previously found in DNA. We discuss putative pathways for the introduction of this base modification at specific positions in the DNA and the possible contribution of this modification to repression of surface antigen gene expression.	UNIV UTRECHT, BIJVOET CTR, DEPT BIOORGAN CHEM, 3584 CH UTRECHT, NETHERLANDS; NATL INST STANDARDS & TECHNOL, CHEM SCI & TECHNOL LAB, GAITHERSBURG, MD 20899 USA; UNIV UTAH, DEPT BIOCHEM, DEPT MED CHEM, SALT LAKE CITY, UT 84112 USA	Utrecht University; National Institute of Standards & Technology (NIST) - USA; Utah System of Higher Education; University of Utah	GOMMERSAMPT, JH (corresponding author), NETHERLANDS CANC INST, DIV MOLEC BIOL, PLESMANIAAN 121, 1066 CX AMSTERDAM, NETHERLANDS.		van Leeuwen, Fred/A-7698-2010	van Leeuwen, Fred/0000-0002-7267-7251	NIGMS NIH HHS [GM 29812] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029812] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BERNARDS A, 1981, CELL, V27, P497, DOI 10.1016/0092-8674(81)90391-3; BERNARDS A, 1984, NUCLEIC ACIDS RES, V12, P4153, DOI 10.1093/nar/12.10.4153; BIRD A, 1992, CELL, V70, P5, DOI 10.1016/0092-8674(92)90526-I; BORST P, 1991, IMMUNOPARASITOL TOD, pA29, DOI 10.1016/S0167-5699(05)80009-X; BRUN R, 1979, ACTA TROP, V36, P289; CROSS GAM, 1990, ANNU REV IMMUNOL, V8, P83, DOI 10.1146/annurev.iy.08.040190.000503; CROZATIER M, 1988, MOL BIOCHEM PARASIT, V31, P127, DOI 10.1016/0166-6851(88)90163-6; DIZDAROGLU M, 1991, FREE RADICAL BIO MED, V10, P225, DOI 10.1016/0891-5849(91)90080-M; DIZDAROGLU M, 1984, J CHROMATOGR, V295, P103, DOI 10.1016/S0021-9673(01)87602-0; EID J, 1991, P NATL ACAD SCI USA, V88, P2118, DOI 10.1073/pnas.88.6.2118; GAJEWSKI E, 1990, BIOCHEMISTRY-US, V29, P7876, DOI 10.1021/bi00486a014; GOMMERSAMPT J, 1991, NUCLEIC ACIDS RES, V19, P1745, DOI 10.1093/nar/19.8.1745; GOMMERSAMPT JH, 1993, NUCLEIC ACIDS RES, V21, P2039, DOI 10.1093/nar/21.9.2039; GUPTA RC, 1982, CARCINOGENESIS, V3, P1081, DOI 10.1093/carcin/3.9.1081; Kornberg A., 1992, DNA REPLICATION; KORNBERG S, 1961, J BIOL CHEM, V236, P1487; LEE MGS, 1990, SCIENCE, V250, P1583, DOI 10.1126/science.2177225; LEHMAN IR, 1960, J BIOL CHEM, V235, P3254; LICHTENSTEIN J, 1960, J BIOL CHEM, V235, P1134; LYON MF, 1993, TRENDS GENET, V9, P123, DOI 10.1016/0168-9525(93)90206-W; NISHIDA Y, 1984, TETRAHEDRON LETT, V25, P1575, DOI 10.1016/S0040-4039(01)90014-0; PAYS E, 1984, NUCLEIC ACIDS RES, V12, P5235, DOI 10.1093/nar/12.13.5235; PERKINS SJ, 1977, CARBOHYD RES, V59, P19, DOI 10.1016/S0008-6215(00)83289-9; RAE PMM, 1978, BIOSYSTEMS, V10, P37, DOI 10.1016/0303-2647(78)90027-8; SCHANBAC.FL, 1970, J BIOL CHEM, V245, P5057; SMITH RD, 1990, ANAL CHEM, V62, P882, DOI 10.1021/ac00208a002; TENASBROEK ALMA, 1990, NATURE, V348, P174, DOI 10.1038/348174a0; TENASBROEK ALMA, 1993, MOL BIOCHEM PARASIT, V59, P133, DOI 10.1016/0166-6851(93)90014-O; VANDERPLOEG LHT, 1987, CELL, V51, P159, DOI 10.1016/0092-8674(87)90140-1; VLIEGENTHART JFG, 1983, ADV CARBOHYD CHEM BI, V41, P209, DOI 10.1016/S0065-2318(08)60059-1; WOOD DJ, 1974, CAN J CHEM, V52, P3353, DOI 10.1139/v74-495; WYATT GR, 1953, BIOCHEM J, V55, P774, DOI 10.1042/bj0550774	32	157	162	0	6	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 17	1993	75	6					1129	1136		10.1016/0092-8674(93)90322-H	http://dx.doi.org/10.1016/0092-8674(93)90322-H			8	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	8261512	Green Submitted			2022-12-01	WOS:A1993MM89300011
J	KAMTEKAR, S; SCHIFFER, JM; XIONG, HY; BABIK, JM; HECHT, MH				KAMTEKAR, S; SCHIFFER, JM; XIONG, HY; BABIK, JM; HECHT, MH			PROTEIN DESIGN BY BINARY PATTERNING OF POLAR AND NONPOLAR AMINO-ACIDS	SCIENCE			English	Article							MOLTEN-GLOBULE STATE; HELIX-FORMING TENDENCIES; ESCHERICHIA-COLI; LAMBDA-REPRESSOR; GROWTH-HORMONE; DENOVO DESIGN; STABILITY; SEQUENCES; CONFORMATION; EXPRESSION	A general strategy is described for the de novo design of proteins. In this strategy the sequence locations of hydrophobic and hydrophilic residues were specified explicitly, but the precise identities of the side chains were not constrained and varied extensively. This strategy was tested by constructing a large collection of synthetic genes whose protein products were designed to fold into four-helix bundle proteins. Each gene encoded a different amino acid sequence, but all sequences shared the same pattern of polar and nonpolar residues. Characterization of the expressed proteins indicated that most of the designed sequences folded into compact alpha-helical structures. Thus, a simple binary code of polar and nonpolar residues arranged in the appropriate order can drive polypeptide chains to collapse into globular alpha-helical folds.	PRINCETON UNIV, DEPT CHEM, PRINCETON, NJ 08544 USA; PRINCETON UNIV, DEPT MOLEC BIOL, PRINCETON, NJ 08544 USA	Princeton University; Princeton University				Hecht, Michael/0000-0002-5538-9813				AHMAD F, 1986, BIOPOLYMERS, V25, P1623, DOI 10.1002/bip.360250906; ALTER JE, 1973, MACROMOLECULES, V6, P564, DOI 10.1021/ma60034a019; BAUM J, 1989, BIOCHEMISTRY-US, V28, P7, DOI 10.1021/bi00427a002; BETZ SF, 1993, CURR OPIN STRUC BIOL, V3, P601, DOI 10.1016/0959-440X(93)90090-8; BLABER M, 1993, SCIENCE, V260, P1637, DOI 10.1126/science.8503008; BOWIE JU, 1990, PROTEINS, V7, P257, DOI 10.1002/prot.340070307; BOWIE JU, 1989, P NATL ACAD SCI USA, V86, P2152, DOI 10.1073/pnas.86.7.2152; BOWIE JU, 1990, SCIENCE, V247, P1306, DOI 10.1126/science.2315699; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P33; BREMS DN, 1989, PROTEINS, V5, P93, DOI 10.1002/prot.340050110; BREYER RM, 1990, EMBO J, V9, P2679, DOI 10.1002/j.1460-2075.1990.tb07453.x; BRUNET AP, 1993, NATURE, V364, P355, DOI 10.1038/364355a0; BULLOCK PA, 1978, BIOCHEMISTRY-US, V17, P3084, DOI 10.1021/bi00608a022; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CARUTHERS MH, 1991, ACCOUNTS CHEM RES, V24, P278, DOI 10.1021/ar00009a005; CHAN HS, 1991, J CHEM PHYS, V95, P3775, DOI 10.1063/1.460828; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; de Boer HA., 1986, MAXIMIZING GENE EXPR, P225; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; DOLGIKH DA, 1984, FEBS LETT, V165, P88, DOI 10.1016/0014-5793(84)80020-4; GHADIRI MR, 1992, J AM CHEM SOC, V114, P4000, DOI 10.1021/ja00036a072; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; HAHN KW, 1990, SCIENCE, V248, P1544, DOI 10.1126/science.2360048; HANDEL TM, 1993, SCIENCE, V261, P879, DOI 10.1126/science.8346440; HECHT MH, 1984, P NATL ACAD SCI-BIOL, V81, P5685, DOI 10.1073/pnas.81.18.5685; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; HOLLADAY LA, 1974, BIOCHEMISTRY-US, V13, P1653, DOI 10.1021/bi00705a015; ITAGAKI E, 1966, J BIOL CHEM, V241, P3687; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; KAMTEKAR S, UNPUB; KAUZMANN W, 1959, ADV PROTEIN CHEM, V14, P1, DOI 10.1016/S0065-3233(08)60608-7; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LAU KF, 1990, P NATL ACAD SCI USA, V87, P638, DOI 10.1073/pnas.87.2.638; LIM WA, 1989, NATURE, V339, P31, DOI 10.1038/339031a0; LYU PC, 1990, SCIENCE, V250, P669, DOI 10.1126/science.2237416; MARSTON FAO, 1986, BIOCHEM J, V240, P1, DOI 10.1042/bj2400001; MCCALDON P, 1988, PROTEINS, V4, P99, DOI 10.1002/prot.340040204; MITRAKI A, 1989, BIO-TECHNOL, V7, P690, DOI 10.1038/nbt0789-690; NICHOLSON LK, 1992, BIOCHEMISTRY-US, V31, P5253, DOI 10.1021/bi00138a003; ONEIL KT, 1990, SCIENCE, V250, P646, DOI 10.1126/science.2237415; OSTERMAN DG, 1985, J CELL BIOCHEM, V29, P57, DOI 10.1002/jcb.240290202; PACE C N, 1975, Critical Reviews in Biochemistry, V3, P1, DOI 10.3109/10409237509102551; PACE CN, 1990, TRENDS BIOCHEM SCI, V15, P14, DOI 10.1016/0968-0004(90)90124-T; PADMANABHAN S, 1990, NATURE, V344, P268, DOI 10.1038/344268a0; PAKULA AA, 1986, P NATL ACAD SCI USA, V83, P8829, DOI 10.1073/pnas.83.23.8829; PARSELL DA, 1989, J BIOL CHEM, V264, P7590; RALEIGH DP, 1992, J AM CHEM SOC, V114, P10079, DOI 10.1021/ja00051a061; REGAN L, 1988, SCIENCE, V241, P976, DOI 10.1126/science.3043666; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; RICHARDSON JS, 1989, TRENDS BIOCHEM SCI, V14, P304, DOI 10.1016/0968-0004(89)90070-4; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; Richardson JS, 1987, PROTEIN ENG, P149; SASAKI T, 1989, J AM CHEM SOC, V111, P380, DOI 10.1021/ja00183a065; SCHIFFER M, 1967, BIOPHYS J, V7, P121, DOI 10.1016/S0006-3495(67)86579-2; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; UNSON CG, 1984, FED PROC, V93, P1837; WAGNER G, 1993, CURR OPIN STRUC BIOL, V3, P748, DOI 10.1016/0959-440X(93)90059-T; WEBER PC, 1980, NATURE, V287, P82, DOI 10.1038/287082a0; YBE JA, UNPUB; YUE K, 1992, P NATL ACAD SCI USA, V89, P4163, DOI 10.1073/pnas.89.9.4163; [No title captured]	63	626	652	1	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1993	262	5140					1680	1685		10.1126/science.8259512	http://dx.doi.org/10.1126/science.8259512			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	8259512				2022-12-01	WOS:A1993ML22000030
J	WARDEN, CH; HEDRICK, CC; QIAO, JH; CASTELLANI, LW; LUSIS, AJ				WARDEN, CH; HEDRICK, CC; QIAO, JH; CASTELLANI, LW; LUSIS, AJ			ATHEROSCLEROSIS IN TRANSGENIC MICE OVEREXPRESSING APOLIPOPROTEIN-A-II	SCIENCE			English	Article							HIGH-DENSITY-LIPOPROTEIN; LECITHIN-CHOLESTEROL ACYLTRANSFERASE; CELL-DERIVED CHOLESTEROL; ESTER TRANSFER PROTEIN; PLASMA-LIPOPROTEINS; HEART-DISEASE; ADIPOSE-CELLS; PARTICLES; SUBCLASSES; SUSCEPTIBILITY	Concentrations of plasma high density lipoprotein (HDL) are inversely correlated with atherosclerotic coronary artery disease. The two most abundant protein constituents of HDL are apolipoproteins A-I and A-II (apoA-I and apoA-II). ApoA-I is required for assembly of HDL and, when overexpressed in transgenic mice, confers resistance to early atherosclerosis. The present studies reveal that transgenic mice that overexpress mouse apoA-II had elevated HDL-cholesterol concentrations but, nevertheless, exhibited increased atherosclerotic lesion development as compared to normal mice. The HDL in the transgenic mice was larger and had an increased ratio of apoA-II to apoA-I. Thus, both the composition and amount of HDL appear to be important determinants of atherosclerosis.	UNIV CALIF LOS ANGELES, DEPT MED, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, DEPT MICROBIOL & MOLEC GENET, LOS ANGELES, CA 90024 USA; UNIV CALIF LOS ANGELES, INST MOLEC BIOL, LOS ANGELES, CA 90024 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles			Hedrick, Catherine/D-1106-2012		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL042488, R01HL042488, P01HL028481] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-28481, HL-42488, HL-07386] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARBARAS R, 1987, BIOCHEM BIOPH RES CO, V142, P63, DOI 10.1016/0006-291X(87)90451-7; BRESLOW JL, 1989, METABOLIC BASIS INHE, P1251; BURSTEIN M, 1970, J LIPID RES, V11, P583; CASTRO GR, 1988, BIOCHEMISTRY-US, V27, P25, DOI 10.1021/bi00401a005; CHEUNG MC, 1986, J LIPID RES, V27, P1135; CHEUNG MC, 1984, J BIOL CHEM, V259, P2201; DOOLITTLE MH, 1990, J BIOL CHEM, V265, P16380; FIELDING PE, 1980, P NATL ACAD SCI-BIOL, V77, P3327, DOI 10.1073/pnas.77.6.3327; FRANCONE OL, 1989, J BIOL CHEM, V264, P7066; GORDON T, 1977, AM J MED, V62, P707, DOI 10.1016/0002-9343(77)90874-9; Haberland ME, 1992, MOL GENETICS CORONAR, P35; HAYEK T, 1992, J CLIN INVEST, V90, P505, DOI 10.1172/JCI115887; HUGHES TA, 1992, J LAB CLIN MED, V119, P57; JIAO S, 1990, J LIPID RES, V31, P467; Karathanasis S. K., 1992, MONOGRAPHS HUMAN GEN, P140; KHOO JC, 1990, J LIPID RES, V31, P645; LEBOEUF RC, 1983, J BIOL CHEM, V258, P5063; MEHRABIAN M, 1991, ARTERIOSCLER THROMB, V11, P947, DOI 10.1161/01.ATV.11.4.947; MEHRABIAN M, 1993, ARTERIOSCLER THROMB, V13, P1, DOI 10.1161/01.ATV.13.1.1; MILLER NE, 1987, AM HEART J, V113, P589, DOI 10.1016/0002-8703(87)90638-7; MILLER NE, 1982, HIGH DENSITY LIPOPRO, P191; MOWRI H, 1990, CIRCULATION, V82, P558; NISHIDA HI, 1990, J BIOL CHEM, V265, P4876; NOWICKA G, 1990, J LIPID RES, V31, P1947; PAIGEN B, 1987, P NATL ACAD SCI USA, V84, P3763, DOI 10.1073/pnas.84.11.3763; PAIGEN B, 1985, ATHEROSCLEROSIS, V57, P65, DOI 10.1016/0021-9150(85)90138-8; PATSCH JR, 1987, PLASMA LIPOPROTEINS, P211; RUBIN EM, 1991, NATURE, V353, P265, DOI 10.1038/353265a0; RUBIN EM, 1991, P NATL ACAD SCI USA, V88, P434, DOI 10.1073/pnas.88.2.434; SCHULTZ JR, 1992, J BIOL CHEM, V267, P21630; SLOOP CH, 1987, J LIPID RES, V28, P225; STEINMETZ A, 1990, J BIOL CHEM, V265, P7859; TALL AR, 1990, J CLIN INVEST, V86, P379, DOI 10.1172/JCI114722; WALSH A, 1989, J BIOL CHEM, V264, P6488; YAMAZAKI S, 1983, J BIOL CHEM, V258, P5847	35	322	326	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 23	1993	261	5120					469	472		10.1126/science.8332912	http://dx.doi.org/10.1126/science.8332912			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8332912				2022-12-01	WOS:A1993LN62300035
J	FARABAUGH, PJ; ZHAO, H; VIMALADITHAN, A				FARABAUGH, PJ; ZHAO, H; VIMALADITHAN, A			A NOVEL PROGRAMMED FRAMESHIFT EXPRESSES THE POL3 GENE OF RETROTRANSPOSON-TY3 OF YEAST - FRAMESHIFTING WITHOUT TRANSFER-RNA SLIPPAGE	CELL			English	Article							SYNONYMOUS CODONS DIFFER; ELONGATION-FACTOR-TU; RELEASE FACTOR-II; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; BASE-PAIR; TY3; SUPPRESSION; TRANSLATION; RIBOSOMES	Most retroviruses and retrotransposons express their pol gene as a translational fusion to the upstream gag gene, often involving translational frameshifting. We describe here an unusual translational frameshift event occurring between the GAG3 and POL3 genes of the retrotransposon Ty3 of yeast. A + 1 frameshift occurs within the sequence GCG AGU U (shown as codons of GAG3), encoding alanine-valine (GCG A GUU). Unlike other programed translational frameshifts described, this event does not require tRNA slippage between cognate or near-cognate codons in the mRNA. Two features distal to the GCG codon stimulate frameshifting. The low availability of the tRNA specific for the ''hungry'' serine codon, AGU, induces a translational pause required for frameshifting. A sequence of 12 nt distal to the AGU codon (termed the Ty3 ''context'') also stimulates the event.			FARABAUGH, PJ (corresponding author), UNIV MARYLAND, DEPT BIOL SCI, CATONSVILLE, MD 21228 USA.			Farabaugh, Philip/0000-0002-5658-7141	NIGMS NIH HHS [GM 29480] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029480, R56GM029480] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATKINS JF, 1990, CELL, V62, P413, DOI 10.1016/0092-8674(90)90007-2; ATKINS JF, 1991, ANNU REV GENET, V25, P201; AYER D, 1986, SCIENCE, V231, P393, DOI 10.1126/science.3510456; BELCOURT MF, 1990, CELL, V62, P339, DOI 10.1016/0092-8674(90)90371-K; BENHAR I, 1993, CELL, V72, P121, DOI 10.1016/0092-8674(93)90056-V; BOSSI L, 1984, P NATL ACAD SCI-BIOL, V81, P6105, DOI 10.1073/pnas.81.19.6105; CHALKER DL, 1990, GENETICS, V126, P837; CRAIGEN WJ, 1986, NATURE, V322, P273, DOI 10.1038/322273a0; CURRAN JF, 1987, SCIENCE, V238, P1545, DOI 10.1126/science.3685992; CURRAN JF, 1988, J MOL BIOL, V203, P75, DOI 10.1016/0022-2836(88)90092-7; DIX DB, 1989, P NATL ACAD SCI USA, V86, P6888, DOI 10.1073/pnas.86.18.6888; FARABAUGH P, 1989, MOL CELL BIOL, V9, P4824, DOI 10.1128/MCB.9.11.4824; FARABAUGH PJ, 1993, MOL CELL BIOL, V13, P2081, DOI 10.1128/MCB.13.4.2081; GALLANT J, 1980, RIBOSOMES STRUCTURE, P615; GESTELAND RF, 1992, SCIENCE, V257, P1640, DOI 10.1126/science.1529352; HANSEN LJ, 1992, J VIROL, V66, P1414, DOI 10.1128/JVI.66.3.1414-1424.1992; HANSEN LJ, 1988, MOL CELL BIOL, V8, P5245, DOI 10.1128/MCB.8.12.5245; HANSEN LJ, 1990, J VIROL, V64, P2599, DOI 10.1128/JVI.64.6.2599-2607.1990; HUGHES D, 1987, EMBO J, V6, P4235, DOI 10.1002/j.1460-2075.1987.tb02772.x; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACKS T, 1990, CURR TOP MICROBIOL, V157, P93; KALNIK MW, 1989, J BIOL CHEM, V264, P3702; KIRCHNER J, 1992, J VIROL, V66, P6081, DOI 10.1128/JVI.66.10.6081-6092.1992; KURLAND CG, 1992, ANNU REV GENET, V26, P29, DOI 10.1146/annurev.ge.26.120192.000333; KURLAND CG, 1986, ACCURACY MOL PROCESS, P127; MOAZED D, 1989, NATURE, V342, P142, DOI 10.1038/342142a0; PETER K, 1992, NEW BIOL, V4, P520; QUIGLEY GJ, 1976, SCIENCE, V194, P796, DOI 10.1126/science.790568; ROSE MD, 1990, METHODS YEAST GENETI; SANDBAKEN MG, 1988, GENETICS, V120, P923; SMITH D, 1989, P NATL ACAD SCI USA, V86, P4397, DOI 10.1073/pnas.86.12.4397; SPANJAARD RA, 1988, P NATL ACAD SCI USA, V85, P7967, DOI 10.1073/pnas.85.21.7967; SPANJAARD RA, 1990, NUCLEIC ACIDS RES, V18, P5031, DOI 10.1093/nar/18.17.5031; ten Dam E B, 1990, Virus Genes, V4, P121, DOI 10.1007/BF00678404; THOMAS LK, 1988, P NATL ACAD SCI USA, V85, P4242, DOI 10.1073/pnas.85.12.4242; TU CL, 1992, P NATL ACAD SCI USA, V89, P8636, DOI 10.1073/pnas.89.18.8636; TUOHY TMF, 1992, J MOL BIOL, V228, P1042, DOI 10.1016/0022-2836(92)90313-9; TUOHY TMF, 1990, BIOCHIM BIOPHYS ACTA, V1050, P274, DOI 10.1016/0167-4781(90)90180-A; VIJGENBOOM E, 1989, J BIOL CHEM, V264, P13012; WEISS R, 1983, NATURE, V302, P389, DOI 10.1038/302389a0; WEISS R, 1988, J MOL BIOL, V203, P403, DOI 10.1016/0022-2836(88)90008-3; WEISS RB, 1990, CELL, V62, P117, DOI 10.1016/0092-8674(90)90245-A; WEISS RB, 1986, GENETICS, V112, P727; WEISS RB, 1987, COLD SPRING HARB SYM, V52, P687, DOI 10.1101/SQB.1987.052.01.078; WEISS RB, 1988, EMBO J, V7, P1503, DOI 10.1002/j.1460-2075.1988.tb02969.x; WILLIAMS JM, 1989, EUR J BIOCHEM, V186, P515, DOI 10.1111/j.1432-1033.1989.tb15237.x	46	134	138	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 16	1993	74	1					93	103		10.1016/0092-8674(93)90297-4	http://dx.doi.org/10.1016/0092-8674(93)90297-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8267715	Green Published, Bronze			2022-12-01	WOS:A1993LN62500010
J	HANSKI, I; TURCHIN, P; KORPIMAKI, E; HENTTONEN, H				HANSKI, I; TURCHIN, P; KORPIMAKI, E; HENTTONEN, H			POPULATION OSCILLATIONS OF BOREAL RODENTS - REGULATION BY MUSTELID PREDATORS LEADS TO CHAOS	NATURE			English	Article							MICROTINE CYCLES; PREY ABUNDANCE; LEAST WEASELS; NIVALIS; DYNAMICS; HYPOTHESIS; NUMBERS; SIZE	THE four-year cycle of microtine rodents in boreal and arctic regions was first described in 1924 (ref. 1). Competing hypotheses on the mechanisms underlying the small mammal cycle have been extensively tested2-5, but so far the sustained rodent oscillations are unexplained. Here we use two mutually supportive approaches to investigate this question. First, building on studies of the interaction between rodents and their mustelid predators6-9, we construct a predator-prey model with seasonality. Second, we use a new technique of nonlinear analysis10,11 to examine empirical time-series data, and compare them with the model dynamics. The model parameterized with field data predicts dynamics that closely resemble the observed dynamics of boreal rodent populations. Both the predicted and observed dynamics are chaotic, albeit with a statistically significant periodic component. Our results suggest that the multiannual oscillations of rodent populations in Fennoscandia are due to delayed density dependence imposed by mustelid predators, and are chaotic.	SO FOREST EXPT STN,PINEVILLE,LA 71360; UNIV TURKU,DEPT BIOL,ECOL ZOOL LAB,SF-20500 TURKU 50,FINLAND; FINNISH FOREST RES UNIT,DEPT FOREST ECOL,SF-01301 VANTAA,FINLAND	United States Department of Agriculture (USDA); United States Forest Service; University of Turku; Natural Resources Institute Finland (Luke)	HANSKI, I (corresponding author), UNIV HELSINKI,DEPT ZOOL,DIV ECOL,POB 17,P RAUTATIEKATU 13,SF-00014 HELSINKI,FINLAND.							BATZLI GO, 1992, WILDLIFE 2001 : POPULATIONS, P831; CHRISTIAN CJ, 1978, PYMATUNING LAB ECOL, V5, P143; Elton C., 1942, VOLES MICE LEMMINGS; ERLINGE S, 1974, OIKOS, V25, P308, DOI 10.2307/3543948; ERLINGE S, 1983, OIKOS, V40, P36, DOI 10.2307/3544197; ERLINGE S, 1975, OIKOS, V26, P378, DOI 10.2307/3543510; GILLINGHAM BJ, 1984, J MAMMAL, V65, P517, DOI 10.2307/1381110; HANSKI I, 1991, J ANIM ECOL, V60, P353, DOI 10.2307/5465; HANSKI I, 1991, TRENDS ECOL EVOL, V6, P141, DOI 10.1016/0169-5347(91)90052-Y; HANSSON L, 1988, TRENDS ECOL EVOL, V3, P195, DOI 10.1016/0169-5347(88)90006-7; HANSSON L, 1985, ANN ZOOL FENN, V22, P277; HANSSON L, 1984, SPEC PUBL CARNEGIE M, V10, P225; HENTTONEN H, 1987, OIKOS, V50, P353, DOI 10.2307/3565496; HENTTONEN H, 1987, OIKOS, V50, P366, DOI 10.2307/3565497; JEDRZEJEWSKA B, 1989, ACTA THERIOL, V34, P347; KAIKUSALO A, 1984, CARNEGIE MUS NAT HIS, V10, P243; KORPIMAKI E, 1989, OIKOS, V55, P205, DOI 10.2307/3565424; KORPIMAKI E, 1991, OECOLOGIA, V88, P552, DOI 10.1007/BF00317719; Krebs C.J., 1974, ADV ECOL RES, V8, P267, DOI DOI 10.1016/S0065-2504(08)60280-9; LAINE K, 1983, OIKOS, V40, P407, DOI 10.2307/3544313; LAINE KM, 1987, OIKOS, V50, P389, DOI 10.2307/3565500; May, 1973, COMPLEXITY STABILITY; MAY RM, 1974, SCIENCE, V186, P645, DOI 10.1126/science.186.4164.645; MAY RM, 1976, NATURE, V261, P459, DOI 10.1038/261459a0; OKSANEN L, 1992, ECOGRAPHY, V15, P226, DOI 10.1111/j.1600-0587.1992.tb00029.x; TAPPER S, 1979, J ANIM ECOL, V48, P603, DOI 10.2307/4182; TAPPER SC, 1976, J ZOOL, V179, P219; TURCHIN P, IN PRESS OIKOS; TURCHIN P, 1993, ECODYN RSM RESPONSE; WOLF A, 1985, PHYSICA D, V16, P285, DOI 10.1016/0167-2789(85)90011-9	30	370	381	0	77	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 15	1993	364	6434					232	235		10.1038/364232a0	http://dx.doi.org/10.1038/364232a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM683	8321318				2022-12-01	WOS:A1993LM68300055
J	RAYMENT, I; HOLDEN, HM; WHITTAKER, M; YOHN, CB; LORENZ, M; HOLMES, KC; MILLIGAN, RA				RAYMENT, I; HOLDEN, HM; WHITTAKER, M; YOHN, CB; LORENZ, M; HOLMES, KC; MILLIGAN, RA			STRUCTURE OF THE ACTIN-MYOSIN COMPLEX AND ITS IMPLICATIONS FOR MUSCLE-CONTRACTION	SCIENCE			English	Article							DEPENDENT ADENOSINE-TRIPHOSPHATASE; HEAVY-CHAIN; BINDING-SITES; SUBFRAGMENT-1; DISSOCIATION; MECHANISM; ASSOCIATION; SKELETAL; MEROMYOSIN; LOCATION	Muscle contraction consists of a cyclical interaction between myosin and actin driven by the concomitant hydrolysis of adenosine triphosphate (ATP). A model for the rigor complex of F actin and the myosin head was obtained by combining the molecular structures of the individual proteins with the low-resolution electron density maps of the complex derived by cryo-electron microscopy and image analysis. The spatial relation between the ATP binding pocket on myosin and the major contact area on actin suggests a working hypothesis for the crossbridge cycle that is consistent with previous independent structural and biochemical studies.	UNIV WISCONSIN, INST ENZYME RES, MADISON, WI 53705 USA; MAX PLANCK INST MED RES, DEPT BIOPHYS, W-6900 HEIDELBERG 1, GERMANY; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA	University of Wisconsin System; University of Wisconsin Madison; Max Planck Society; Scripps Research Institute	RAYMENT, I (corresponding author), UNIV WISCONSIN, DEPT BIOCHEM, 1710 UNIV AVE, MADISON, WI 53705 USA.		rayment, ivan/A-2720-2008	rayment, ivan/0000-0001-9279-7835; Yohn, Christopher/0000-0002-5937-8070; Holmes, Kenneth/0000-0001-8894-9453				BAGSHAW CR, 1974, BIOCHEM J, V141, P351, DOI 10.1042/bj1410351; BAGSHAW CR, 1974, BIOCHEM J, V141, P331, DOI 10.1042/bj1410331; BAGSHAW CR, 1973, BIOCHEM J, V133, P323, DOI 10.1042/bj1330323; BALINT M, 1978, ARCH BIOCHEM BIOPHYS, V190, P793, DOI 10.1016/0003-9861(78)90339-9; BETRAND R, 1992, BIOCHEMISTRY-US, V31, P12219; BOTTS J, 1989, P NATL ACAD SCI USA, V86, P2204, DOI 10.1073/pnas.86.7.2204; BRENNER B, 1986, BIOPHYS J, V50, P1101, DOI 10.1016/S0006-3495(86)83554-8; BRENNER B, 1982, P NATL ACAD SCI-BIOL, V79, P7288, DOI 10.1073/pnas.79.23.7288; CHEN T, 1991, BIOCHEMISTRY-US, V30, P4546, DOI 10.1021/bi00232a026; COMBEAU C, 1992, J BIOL CHEM, V267, P14038; Cooke R, 1990, CURR OPIN CELL BIOL, V2, P62, DOI 10.1016/S0955-0674(05)80032-8; COOKE R, 1986, CRIT REV BIOCHEM MOL, V21, P53, DOI 10.3109/10409238609113609; CUDA G, 1993, J CLIN INVEST, V91, P2861, DOI 10.1172/JCI116530; CURMI PMG, 1988, J MOL BIOL, V203, P781, DOI 10.1016/0022-2836(88)90209-4; DASGUPTA G, 1990, BIOCHEMISTRY-US, V29, P8503, DOI 10.1021/bi00488a043; EISENBERG E, 1980, ANNU REV PHYSIOL, V42, P293, DOI 10.1146/annurev.ph.42.030180.001453; GEEVES MA, 1991, BIOCHEM J, V274, P1; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; GOLDMAN YE, 1987, ANNU REV PHYSIOL, V49, P637, DOI 10.1146/annurev.ph.49.030187.003225; GOODY RS, 1983, BIOCHIM BIOPHYS ACTA, V726, P13, DOI 10.1016/0304-4173(83)90009-5; GREENE LE, 1980, J BIOL CHEM, V255, P543; Hill T.L., 1974, Progress Biophys Molec Biol, V28, P267, DOI 10.1016/0079-6107(74)90020-0; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; HUXLEY AF, 1974, J PHYSIOL-LONDON, V243, P1; HUXLEY AF, 1971, NATURE, V233, P533, DOI 10.1038/233533a0; HUXLEY HE, 1969, SCIENCE, V164, P1356, DOI 10.1126/science.164.3886.1356; IRVING M, 1992, NATURE, V357, P156, DOI 10.1038/357156a0; JOHARA M, 1993, P NATL ACAD SCI USA, V90, P2127, DOI 10.1073/pnas.90.6.2127; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LORENZ M, UNPUB; LYMM RW, 1971, BIOCHEMISTRY-US, V10, P4617; MAITA T, 1991, J BIOCHEM, V110, P75, DOI 10.1093/oxfordjournals.jbchem.a123546; MILLER L, 1988, J BIOL CHEM, V263, P1996; MILLIGAN RA, 1987, J CELL BIOL, V105, P29, DOI 10.1083/jcb.105.1.29; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MORNET D, 1979, BIOCHEM BIOPH RES CO, V89, P925, DOI 10.1016/0006-291X(79)91867-9; MORNET D, 1981, NATURE, V292, P801; ONISHI H, 1990, J BIOL CHEM, V265, P19362; PEPIN TM, 1985, BIOCHEMISTRY-US, V24, P3024; POLLARD TD, 1991, ANNU REV PHYSIOL, V53, P653, DOI 10.1146/annurev.physiol.53.1.653; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; ROSENFELD SS, 1984, J BIOL CHEM, V259, P1908; SUTOH K, 1989, J MOL BIOL, V206, P357, DOI 10.1016/0022-2836(89)90485-3; SUTOH K, 1991, P NATL ACAD SCI USA, V88, P7711, DOI 10.1073/pnas.88.17.7711; SUTOH K, 1982, BIOCHEMISTRY-US, V21, P4800, DOI 10.1021/bi00262a043; SUTOH K, 1983, BIOCHEMISTRY-US, V22, P1579, DOI 10.1021/bi00276a009; SZILAGYI L, 1979, BIOCHEM BIOPH RES CO, V87, P936, DOI 10.1016/0006-291X(79)92047-3; TAYLOR EW, 1991, J BIOL CHEM, V266, P294; TOKUNAGA M, 1986, J ELECTRON MICROSC S, V35, P3107; VALENTINRANC C, 1991, J BIOL CHEM, V266, P17872; VANDEKERCKHOVE J, 1978, EUR J BIOCHEM, V90, P451, DOI 10.1111/j.1432-1033.1978.tb12624.x; WAKABAYASHI K, 1992, SCIENCE, V258, P443, DOI 10.1126/science.1411537; Wakabayashi T, 1988, Adv Exp Med Biol, V226, P39; WHITTAKER M, UNPUB; 1988, 11 P YAM C EN TRANSD	57	1473	1496	2	211	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					58	65		10.1126/science.8316858	http://dx.doi.org/10.1126/science.8316858			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	8316858				2022-12-01	WOS:A1993LK43400029
J	MEDVINSKY, AL; SAMOYLINA, NL; MULLER, AM; DZIERZAK, EA				MEDVINSKY, AL; SAMOYLINA, NL; MULLER, AM; DZIERZAK, EA			AN EARLY PRE-LIVER INTRA-EMBRYONIC SOURCE OF CFU-S IN THE DEVELOPING MOUSE	NATURE			English	Article							HEMATOPOIETIC STEM-CELLS; COLONY-FORMING CELLS; YOLK-SAC; GROWTH-FACTOR; C-KIT; ONTOGENY; ORIGIN; LIGAND; PRECURSORS; EXPRESSION	IT is widely accepted that during murine embryogenesis, totipotent haematopoietic stem cells first originate in the yolk sac, then migrate to the fetal liver and finally colonize the bone marrow shortly before birth1,2. This view is based on in vitro studies showing that yolk sac cells can differentiate into various haematopoietic lineages1,3-7 and in vivo studies showing that yolk sac contains spleen colony-forming units (CFU-S) beginning at day 8 of gestation1. However, some investigators have failed to find statistically significant numbers of CFU-S arising from day 9 yolk sac3,8-11 and, although one group reported that yolk sac could repopulate the haematopoietic system of W mutant mice2, others have failed to confirm yolk sac-derived repopulation of adults3,12. In the avian and amphibian systems, the yolk sac gives rise only to early, transitory haematopoiesis whereas the definitive adult haematopoietic stem cells in these vertebrates are derived from the mesodermal region containing the dorsal aorta13-17. Because this analogous area of the mouse embryo has not been previously examined for haematopoietic activity, we directly compared the CFU-S activity of the aorta, gonad, mesonephros (AGM) region with the yolk sac and fetal liver during embryogenesis. Here we report that this intra-embryonic AGM region contains CFU-S activity at a higher frequency than that in embryonic yolk sac and that such activity appears in the AGM region before the fetal liver.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND	MRC National Institute for Medical Research	MEDVINSKY, AL (corresponding author), NATL RES CTR HEMATOL,PHYSIOL HEMATOPOIESIS LAB,NOVOZYKOVSKY PR 4A,MOSCOW 125167,RUSSIA.							BLUMEJENSEN P, 1991, EMBO J, V10, P4121, DOI 10.1002/j.1460-2075.1991.tb04989.x; BODINE DM, 1992, BLOOD, V79, P913; BOLSHEV LN, 1965, TABLES MATH STATISTI, V464; CORMIER F, 1988, DEVELOPMENT, V102, P279; DEVRIES P, 1991, J EXP MED, V173, P1205, DOI 10.1084/jem.173.5.1205; DIETERLENLIEVRE F, 1975, J EMBRYOL EXP MORPH, V33, P607; DIETERLENLIEVRE F, 1981, DEV BIOL, V88, P180, DOI 10.1016/0012-1606(81)90228-1; EREN R, 1987, IMMUNOL RES, V6, P279, DOI 10.1007/BF02935522; GIGUERE V, 1983, EMBO J, V8, P2017; HARRISON DE, 1979, BLOOD, V54, P1152; HOUSSAINT E, 1981, CELL DIFFER DEV, V10, P243, DOI 10.1016/0045-6039(81)90007-5; JOHNSON GR, 1985, EXP HEMATOL, V13, P200; JOHNSON GR, 1973, J EMBRYOL EXP MORPH, V30, P83; JONES RJ, 1990, NATURE, V347, P188, DOI 10.1038/347188a0; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; LIU CP, 1991, DEVELOPMENT, V113, P1315; MAENO M, 1985, DEV BIOL, V110, P503, DOI 10.1016/0012-1606(85)90108-3; MAGLI MC, 1982, NATURE, V295, P527, DOI 10.1038/295527a0; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; MOORE MAS, 1970, BRIT J HAEMATOL, V18, P279, DOI 10.1111/j.1365-2141.1970.tb01443.x; PERAH G, 1977, J CELL PHYSIOL, V91, P193, DOI 10.1002/jcp.1040910205; PLOEMACHER RE, 1988, EXP HEMATOL, V16, P21; Russell E S, 1979, Adv Genet, V20, P357, DOI 10.1016/S0065-2660(08)60549-0; SAMOYLINA NL, 1992, HAEMATOLOGY BLOOD TR, V35, P106; SAMOYLINA NL, 1990, SOV J DEVEL BIOL, V21, P127; SONODA T, 1983, DEV BIOL, V97, P89, DOI 10.1016/0012-1606(83)90066-0; STROUBOULIS J, 1992, GENE DEV, V6, P1857, DOI 10.1101/gad.6.10.1857; SYMANN M, 1978, EXP HEMATOL, V6, P749; TOLES JF, 1989, P NATL ACAD SCI USA, V86, P7456, DOI 10.1073/pnas.86.19.7456; TURPEN JB, 1981, DEV BIOL, V85, P99, DOI 10.1016/0012-1606(81)90239-6; WITTE ON, 1990, CELL, V63, P5, DOI 10.1016/0092-8674(90)90280-R; WOLF NS, 1986, EXP HEMATOL, V14, P676; WONG PMC, 1986, P NATL ACAD SCI USA, V83, P3851, DOI 10.1073/pnas.83.11.3851	33	393	401	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 1	1993	364	6432					64	67		10.1038/364064a0	http://dx.doi.org/10.1038/364064a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK818	8316298				2022-12-01	WOS:A1993LK81800058
J	GIBBINS, RL; RILEY, M; BRIMBLE, P				GIBBINS, RL; RILEY, M; BRIMBLE, P			EFFECTIVENESS OF PROGRAM FOR REDUCING CARDIOVASCULAR RISK FOR MEN IN ONE GENERAL-PRACTICE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BLOOD LIPID CONCENTRATIONS	Objectives-To assess the effectiveness of a programme for reducing cardiovascular risk in men in terms of clinical measurements and perceptions of patients. Design-Collection of paired data on men attending well person clinics over three to five years. Questionnaire to determine changes in risk related habits. Setting-Well person clinics in rural general practice with five partners in mid-Wales. Subjects-The first 687 men seen in the clinic: analysable data obtained on 520. Initial age range 28-60 years. Main outcome measures-Analysis of serum cholesterol concentration (mmol/l) and blood pressure (mm Hg). Changes in diet, exercise, smoking, and drinking. Results-Mean (SD) cholesterol concentration for all subjects increased from 5.8 (1.0) to 6.0 (1.0), p < 0.001. Overall percentage of ideal weight and mean systolic blood pressure also increased. Mean diastolic blood pressure was unchanged at 84 mm Hg. Professed dietary change, age, and number of visits atl had significant effects on final cholesterol concentration. Those seen more often showed a significant decrease in cholesterol concentrations (in those seen more than twice mean (SD) initial value 6.7 (0.9) mmol/l v final value 6.5 (1.0) mmol/l, p < 0.001). Those over 45 years at start of study showed a significant decrease in diastolic blood pressure (mean (SD) initial value 89 (9) mm Hg v final value 86 (7) mm Hg, p < 0.001). Conclusions-These clinics are not effective in achieving a reduction in mean cholesterol concentration or blood pressure, despite evidence that the message of reduction in risk had been successfully transmitted. Success was achieved in older patients and those in whom a definite problem was identified. Identification of high risk groups and clinical case finding with appropriate long term follow up may be more cost effective in reducing cardiovascular risk than non-specific screening of the whole population.			GIBBINS, RL (corresponding author), THE SURGERY, GLANDWR PARC, POWYS LD2 3DZ, ENGLAND.							BURSTEIN M, 1970, LIPID RES, V19, P583; HOLMEN J, 1991, BRIT MED J, V302, P219, DOI 10.1136/bmj.302.6770.219; KWITEROVICH P, 1989, J HOPKINS COMPLETE G, P293; LENTHER C, 1970, GEIGY TABLES, P553; MANN JI, 1988, BRIT MED J, V296, P1702, DOI 10.1136/bmj.296.6638.1702; MANT D, 1991, BRIT MED J, V302, P1057, DOI 10.1136/bmj.302.6784.1057; Parish R, 1987, Health Trends, V19, P23; RICHMOND W, 1973, CLIN CHEM, V19, P1350; SHEPHERD J, 1987, BRIT MED J, V295, P1245, DOI 10.1136/bmj.295.6608.1245; 1986, 4 WELSH HEART PROGR; 1989, TERMS SERVICE DOCTOR; 1986, HEART WALES; 1959, STATISTICAL B METROP, V40	13	27	27	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUN 19	1993	306	6893					1652	1656		10.1136/bmj.306.6893.1652	http://dx.doi.org/10.1136/bmj.306.6893.1652			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ337	8324436	Green Published, Bronze			2022-12-01	WOS:A1993LJ33700023
J	MINTZ, PD				MINTZ, PD			PARTICIPATION OF HIV-INFECTED PATIENTS IN AUTOLOGOUS BLOOD PROGRAMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HUMAN-IMMUNODEFICIENCY-VIRUS; CYTOMEGALO-VIRUS; TRANSFUSION; PROGRESSION; ANTIBODY; DISEASE; DONORS; AIDS		UNIV VIRGINIA,HLTH SCI CTR,DEPT INTERNAL MED,CHARLOTTESVILLE,VA 22908	University of Virginia	MINTZ, PD (corresponding author), UNIV VIRGINIA,HLTH SCI CTR,DEPT PATHOL,BLOOD BANK & TRANSFUS SERV,BOX 286,CHARLOTTESVILLE,VA 22908, USA.							ANDERSON BV, 1988, TRANSFUSION, V28, P394, DOI 10.1046/j.1537-2995.1988.28488265277.x; BALFOUR HH, 1993, TRANSFUSION, V33, P101, DOI 10.1046/j.1537-2995.1993.33293158038.x; BUSCH MP, 1992, BLOOD, V80, P2128; CHENGMAYER C, 1988, SCIENCE, V240, P80, DOI 10.1126/science.2832945; CREGAN P, 1991, TRANSFUSION, V31, P172, DOI 10.1046/j.1537-2995.1991.31291142950.x; DAVIS MG, 1987, P NATL ACAD SCI USA, V84, P8642, DOI 10.1073/pnas.84.23.8642; DONEGAN E, 1990, ANN INTERN MED, V113, P733, DOI 10.7326/0003-4819-113-10-733; DZIK WH, 1989, TRANSFUSION, V29, P743, DOI 10.1046/j.1537-2995.1989.29890020447.x; GROSSMAN BJ, 1988, TRANSFUSION, V28, P283, DOI 10.1046/j.1537-2995.1988.28388219162.x; HO DD, 1992, LANCET, V339, P1549, DOI 10.1016/0140-6736(92)91321-X; KENNEY S, 1988, P NATL ACAD SCI USA, V85, P1652, DOI 10.1073/pnas.85.5.1652; LANG DJ, 1989, J ACQ IMMUN DEF SYND, V2, P540; LEWIS WF, 1992, TRANSFUSION, V32, pS56; LINDEN JV, 1992, TRANSFUSION, V32, P601, DOI 10.1046/j.1537-2995.1992.32792391030.x; PARKMAN PD, 1989, GUIDANCE AUTOLOGOUS; PARKMAN PD, 1990, AUTOLOGOUS BLOOD COL; PHILLIPS RE, 1991, NATURE, V354, P453, DOI 10.1038/354453a0; QUINN TC, 1987, JAMA-J AM MED ASSOC, V257, P2617, DOI 10.1001/jama.257.19.2617; QUINNAN GV, 1991, FDA RECOMMENDATIONS; QUINNAN GV, 1991, DISPOSITION BLOOD PR; QUINNAN GV, 1990, TESTING ANTIBODY HEP; QUINNAN GV, 1991, CLARIFICATION FDA RE; SAZAMA K, 1990, TRANSFUSION, V30, P583, DOI 10.1046/j.1537-2995.1990.30790385515.x; SCHNITTMAN SM, 1990, ANN INTERN MED, V113, P328; STARKEY JM, 1989, JAMA-J AM MED ASSOC, V262, P3452, DOI 10.1001/jama.262.24.3452; SURGENOR DM, 1990, NEW ENGL J MED, V322, P1646, DOI 10.1056/NEJM199006073222306; TEGTMEIER GE, 1989, ARCH PATHOL LAB MED, V113, P236; TOY PTCY, 1987, NEW ENGL J MED, V316, P517, DOI 10.1056/NEJM198702263160906; TRIULZI DJ, 1990, TRANSFUSION MEDICINE IN THE 1990S, P1; WALLACE EL, 1993, TRANSFUSION, V33, P139, DOI 10.1046/j.1537-2995.1993.33293158046.x; WARD JW, 1989, NEW ENGL J MED, V321, P947, DOI 10.1056/NEJM198910053211406; WEBSTER A, 1989, LANCET, V2, P63; ZOON KC, 1992, REVISED RECOMMENDATI	33	9	9	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUN 9	1993	269	22					2892	2894		10.1001/jama.269.22.2892	http://dx.doi.org/10.1001/jama.269.22.2892			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE936	8292121				2022-12-01	WOS:A1993LE93600028
J	COCKCROFT, S; THOMAS, GMH; FENSOME, A; GENY, B; CUNNINGHAM, E; GOUT, I; HILES, I; TOTTY, NF; TRUONG, Q; HSUAN, JJ				COCKCROFT, S; THOMAS, GMH; FENSOME, A; GENY, B; CUNNINGHAM, E; GOUT, I; HILES, I; TOTTY, NF; TRUONG, Q; HSUAN, JJ			PHOSPHOLIPASE-D - A DOWNSTREAM EFFECTOR OF ARF IN GRANULOCYTES	SCIENCE			English	Article							ADP-RIBOSYLATION FACTOR; GTP-BINDING PROTEIN; GOLGI MEMBRANES; NEUTROPHILS; ACTIVATION; VESICLES; FLUORIDE; BOVINE; CELLS; BRAIN	Activation of the phospholipase D (PLD) pathway is a widespread response when cells are activated by agonists that bind receptors on the cell surface. A 16-kD cytosolic component can reconstitute guanosine triphosphate (GTP)-mediated activation of phospholipase D in HL60 cells depleted of their cytosol by permeabilization. This factor was purified and identified as two small GTP-binding proteins, ARF1 and ARF3. Recombinant ARF1 substituted for purified ARF proteins in the reconstitution assay. These results indicate that phospholipase D is a downstream effector of ARF1 and ARF3. The well-established role of ARF in vesicular traffic would suggest that alterations in lipid content by PLD are an important determinant in vesicular dynamics.	UCL, SCH MED, LUDWIG INST CANC RES, LONDON W1P 8BT, ENGLAND	Ludwig Institute for Cancer Research; University of London; University College London; UCL Medical School	COCKCROFT, S (corresponding author), UNIV LONDON UNIV COLL, DEPT PHYSIOL, ROCKEFELLER BLDG, UNIV ST, LONDON WC1E 6JJ, ENGLAND.		Cockcroft, Shamshad/F-9480-2011; Hsuan, Justin/C-8825-2009	Hsuan, Justin/0000-0001-6083-7564; Cockcroft, Shamshad/0000-0002-5731-476X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ANTHES JC, 1991, BIOCHEM BIOPH RES CO, V175, P236, DOI 10.1016/S0006-291X(05)81225-2; BALCH W E, 1992, Current Biology, V2, P157, DOI 10.1016/0960-9822(92)90276-G; BOMAN AL, 1992, NATURE, V358, P512, DOI 10.1038/358512a0; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; Cleves A, 1991, Trends Cell Biol, V1, P30, DOI 10.1016/0962-8924(91)90067-J; DEMATTEIS MA, 1993, NATURE, V364, P818, DOI 10.1038/364818a0; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; ENGLISH D, 1991, BLOOD, V77, P2746; GENY B, 1993, EUR J BIOCHEM, V215, P389, DOI 10.1111/j.1432-1033.1993.tb18045.x; GENY B, 1992, BIOCHEM J, V284, P531, DOI 10.1042/bj2840531; KAHN RA, 1984, J BIOL CHEM, V259, P6228; KAHN RA, 1991, J BIOL CHEM, V266, P15595; KAHN RA, 1986, J BIOL CHEM, V261, P1; KAHN RA, 1991, METHOD ENZYMOL, V195, P233; KANAHO Y, 1991, FEBS LETT, V279, P249, DOI 10.1016/0014-5793(91)80160-5; LENNARD JM, 1992, J BIOL CHEM, V267, P13047; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PAI JK, 1988, J BIOL CHEM, V263, P12472; PFANNER N, 1989, CELL, V59, P95, DOI 10.1016/0092-8674(89)90872-6; RANDAZZO PA, 1992, METHOD ENZYMOL, V219, P362; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SERAFINI T, 1991, CELL, V67, P239, DOI 10.1016/0092-8674(91)90176-Y; SEWELL JL, 1988, P NATL ACAD SCI USA, V85, P4620, DOI 10.1073/pnas.85.13.4620; STUTCHFIELD J, 1993, BIOCHEM J, V293, P649, DOI 10.1042/bj2930649; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; Thomas GWC, UNPUB; TSAI SC, 1988, J BIOL CHEM, V263, P1768; TSAI SC, 1992, P NATL ACAD SCI USA, V89, P9272, DOI 10.1073/pnas.89.19.9272; TSUCHIYA M, 1991, J BIOL CHEM, V266, P2772; YANG SF, 1967, J BIOL CHEM, V242, P477	30	626	633	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 28	1994	263	5146					523	526		10.1126/science.8290961	http://dx.doi.org/10.1126/science.8290961			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT966	8290961				2022-12-01	WOS:A1994MT96600034
J	BAUMGARTEN, M; HANLEY, JA; INFANTERIVARD, C; BATTISTA, RN; BECKER, R; GAUTHIER, S				BAUMGARTEN, M; HANLEY, JA; INFANTERIVARD, C; BATTISTA, RN; BECKER, R; GAUTHIER, S			HEALTH OF FAMILY MEMBERS CARING FOR ELDERLY PERSONS WITH DEMENTIA - A LONGITUDINAL-STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						DEMENTIA; SENILE; DEPRESSION; CAREGIVERS; ALZHEIMERS DISEASE; FAMILY HEALTH	DEPRESSIVE SYMPTOMS; PHYSICAL HEALTH; SOCIAL SUPPORT; SPOUSE CAREGIVERS; OLDER ADULTS; BURDEN; CARE; PEOPLE; STRESS; MODEL	Objective: To estimate the change in depression and physical symptoms during a 1-year period in a group of caregivers for elderly persons with dementia and in a group of comparison participants. Design: Cohort study with a comparison group. Setting: Outpatient geriatric assessment unit and ophthalmology service in an acute care hospital. Participants: 218 close family members of a consecutive sample of patients with dementia and patients having cataract surgery were interviewed to obtain a baseline assessment. Of these, 86 caregivers (family members of patients with dementia) and 95 comparison participants (family members of patients with cataracts) were interviewed again approximately 1 year later. Main Outcome Measures: Center for Epidemiologic Studies depression scale and Aday and Andersen's 24-item physical symptom checklist. Results: For the Center for Epidemiologic Studies depression score, the difference between caregivers and comparison participants with respect to change during the 1-year study period was 2.1 (95% CI, 1.0 to 5.2); for physical symptoms, the difference was 0.4 (CI, -0.3 to 1.1). A higher level of behavioral disturbance in the patients with dementia at time 1 and institutionalization of the patient between time 1 and time 2 were predictive of worsening caregiver depression and physical symptoms during the study period. The magnitude and direction of changes in caregiver health varied considerably. Conclusions: Overall mean changes in depression and physical symptoms during 1 year were small. The observed variability in the individual response to the caregiving situation suggests that future research should focus on the identification of salient prognostic factors.	MCGILL UNIV, DEPT EPIDEMIOL & BIOSTAT, MONTREAL H3A 1A2, PQ, CANADA; MCGILL UNIV, SCH OCCUPAT HLTH, MONTREAL H3A 1A3, PQ, CANADA; ST JUSTINE HOSP, MONTREAL, PQ, CANADA	McGill University; McGill University; Universite de Montreal; Centre Hospitalier Universitaire Sainte-Justine								ADAY LA, 1980, HLTH CARE US EQUITAB; BAUMGARTEN M, 1990, J AM GERIATR SOC, V38, P221, DOI 10.1111/j.1532-5415.1990.tb03495.x; BAUMGARTEN M, 1989, J CLIN EPIDEMIOL, V42, P1137, DOI 10.1016/0895-4356(89)90111-X; BAUMGARTEN M, 1992, J CLIN EPIDEMIOL, V45, P61, DOI 10.1016/0895-4356(92)90189-T; BECKER J, 1988, PSYCHOL AGING, V3, P300, DOI 10.1037/0882-7974.3.3.300; BERKMAN LF, 1986, AM J EPIDEMIOL, V124, P372, DOI 10.1093/oxfordjournals.aje.a114408; CORNONIHUNTLEY J, 1986, NIH862443 NAT I AG P; CUTRONA CE, 1986, J PERS SOC PSYCHOL, V50, P349, DOI 10.1037/0022-3514.50.2.349; DEFORGE BR, 1988, INT J PSYCHIAT MED, V18, P325, DOI 10.2190/8XGR-YUFH-0GVM-K4XB; EAGLES JM, 1987, BRIT J PSYCHIAT, V150, P293, DOI 10.1192/bjp.150.3.293; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GATZ M, 1990, PSYCHOL AGING, V5, P284, DOI 10.1037/0882-7974.5.2.284; GEORGE LK, 1985, J AM GERIATR SOC, V33, P607, DOI 10.1111/j.1532-5415.1985.tb06317.x; GEORGE LK, 1986, GERONTOLOGIST, V26, P253, DOI 10.1093/geront/26.3.253; Gilleard C J, 1982, Arch Gerontol Geriatr, V1, P151, DOI 10.1016/0167-4943(82)90015-2; GILLEARD CJ, 1984, J EPIDEMIOL COMMUN H, V38, P319, DOI 10.1136/jech.38.4.319; HALEY WE, 1988, GERONTOLOGICAL SOC A; JORM AF, 1987, ACTA PSYCHIAT SCAND, V76, P465, DOI 10.1111/j.1600-0447.1987.tb02906.x; KENNEDY GJ, 1989, AM J PSYCHIAT, V146, P220; KIECOLTGLASER JK, 1991, PSYCHOSOM MED, V53, P345, DOI 10.1097/00006842-199107000-00001; KINNEY JM, 1989, PSYCHOL AGING, V4, P402, DOI 10.1037/0882-7974.4.4.402; KOSBERG JI, 1990, GERONTOLOGIST, V30, P236, DOI 10.1093/geront/30.2.236; LIPTZIN B, 1988, GERONTOLOGIST, V28, P397, DOI 10.1093/geront/28.3.397; MORRIS RG, 1988, BRIT J PSYCHIAT, V153, P147, DOI 10.1192/bjp.153.2.147; MORTIMER JA, 1988, EPIDEMIOLOGY AGING I; MURRELL SA, 1984, J COMMUNITY PSYCHOL, V12, P301, DOI 10.1002/1520-6629(198410)12:4<301::AID-JCOP2290120403>3.0.CO;2-I; NORUSIS MJ, 1990, SPSS PC PLUS STATIST; OCONNOR DW, 1990, BRIT J PSYCHIAT, V156, P835, DOI 10.1192/bjp.156.6.835; OLSON DH, 1982, FAMILY INVENTORIES; PAGEL MD, 1985, J ABNORM PSYCHOL, V94, P169, DOI 10.1037/0021-843X.94.2.169; PHIFER JF, 1986, J ABNORM PSYCHOL, V95, P282; PRUCHNO RA, 1990, J GERONTOL, V45, pP192, DOI 10.1093/geronj/45.5.P192; RABINS PV, 1990, AGE AGEING, V19, P185; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; RADLOFF LS, 1986, CLIN GERONTOLOGY GUI; RUSSELL DW, 1991, PSYCHOL AGING, V6, P190, DOI 10.1037/0882-7974.6.2.190; SCHULZ R, 1990, J GERONTOL, V45, pP181, DOI 10.1093/geronj/45.5.P181; SCHULZ R, 1991, PSYCHOL AGING, V6, P569, DOI 10.1037/0882-7974.6.4.569; SHAPIRO MF, 1986, ANN INTERN MED, V104, P246, DOI 10.7326/0003-4819-104-2-246; STOKES JP, 1983, AM J COMMUN PSYCHOL, V11, P141, DOI 10.1007/BF00894363; STONE R, 1987, GERONTOLOGIST, V27, P616, DOI 10.1093/geront/27.5.616; TOWNSEND A, 1989, PSYCHOL AGING, V4, P393, DOI 10.1037/0882-7974.4.4.393; VITALIANO PP, 1991, GERONTOLOGIST, V31, P76, DOI 10.1093/geront/31.1.76; WILDER DE, 1983, DEMENTIAS; WILLIAMSON GM, 1990, PSYCHOL AGING, V5, P502, DOI 10.1037/0882-7974.5.4.502; ZARIT SH, 1986, GERONTOLOGIST, V26, P260, DOI 10.1093/geront/26.3.260; 1981, HLTH CANADIANS REPOR; 1980, DIAGNOSTIC STATISTIC; 1978, MULTIDIMENSIONAL FUN	49	86	87	0	8	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1994	120	2					126	132		10.7326/0003-4819-120-2-199401150-00005	http://dx.doi.org/10.7326/0003-4819-120-2-199401150-00005			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ671	8256971				2022-12-01	WOS:A1994MQ67100005
J	STANDISH, A; ENQUIST, LW; SCHWABER, JS				STANDISH, A; ENQUIST, LW; SCHWABER, JS			INNERVATION OF THE HEART AND ITS CENTRAL MEDULLARY ORIGIN DEFINED BY VIRAL TRACING	SCIENCE			English	Article							PSEUDORABIES VIRUS; VISUAL-SYSTEM; CAT; NEURONS	The vagus nerve exerts a profound influence on the heart, regulating the heart rate and rhythm. An extensive vagal innervation of the cardiac ventricles and the central origin and extent of this innervation was demonstrated by transynaptic transport of pseudorabies virus with a virulent and two attenuated pseudorabies viral strains. The neurons that innervate the ventricles are numerous, and their distribution within the nucleus ambiguus and dorsal motor nucleus of the vagus is similar to that of neurons innervating other cardiac targets, such as the sino-atrial node. These data provide a neuroanatomical correlate to the physiological influence of the vagus nerve on ventricular function.	DUPONT MERCK PHARMACEUT CO,EXPTL STN,WILMINGTON,DE 19880	DuPont	STANDISH, A (corresponding author), DUPONT CO INC,NEURAL COMPUTAT GRP,E323 130,WILMINGTON,DE 19880, USA.			schwaber, james/0000-0003-0598-7345	NATIONAL INSTITUTE OF MENTAL HEALTH [P01MH043787] Funding Source: NIH RePORTER; NIMH NIH HHS [MH-43787] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BURKHOLDER T, 1992, ANAT REC, V232, P44; CALARESU FR, 1965, J PHYSIOL-LONDON, V176, P252, DOI 10.1113/jphysiol.1965.sp007548; CARD JP, 1990, J NEUROSCI, V10, P1974; CARD JP, 1991, NEURON, V6, P957, DOI 10.1016/0896-6273(91)90236-S; CARD JP, 1993, J NEUROSCI, V13, P2515, DOI 10.1523/JNEUROSCI.13-06-02515.1993; CARD JP, 1992, J VIROL, V66, P3032, DOI 10.1128/JVI.66.5.3032-3041.1992; CIRIELLO J, 1980, AM J PHYSIOL, V238, pR57, DOI 10.1152/ajpregu.1980.238.1.R57; DEGEEST H, 1965, CIRC RES, V17, P222, DOI 10.1161/01.RES.17.3.222; ESCARDO J A, 1991, Society for Neuroscience Abstracts, V17, P993; GEIS GS, 1980, CIRC RES, V46, P606, DOI 10.1161/01.RES.46.5.606; HOFF H. E., 1936, ANN MED HIST, V8, P138; Hopkins D.A., 1987, CARDIOGENIC REFLEXES, P185; IZZO PN, 1993, J COMP NEUROL, V327, P572, DOI 10.1002/cne.903270408; Levy M.N., 1984, P68; Loewy AD, 1990, CENTRAL REGULATION A, P68; LOFFELHOLZ K, 1985, PHARMACOL REV, V37, P1; MCALLEN RM, 1976, J PHYSIOL-LONDON, V258, P187, DOI 10.1113/jphysiol.1976.sp011414; MCLEAN IW, 1974, J HISTOCHEM CYTOCHEM, V22, P1077, DOI 10.1177/22.12.1077; NOSAKA S, 1982, AM J PHYSIOL, V243, pR92, DOI 10.1152/ajpregu.1982.243.1.R92; STRACK AM, 1989, BRAIN RES, V491, P156, DOI 10.1016/0006-8993(89)90098-X; THOMAS MR, 1974, AM J PHYSIOL, V226, P1344, DOI 10.1152/ajplegacy.1974.226.6.1344; TODO K, 1977, BRAIN RES, V130, P545, DOI 10.1016/0006-8993(77)90116-0; UGOLINI G, 1987, BRAIN RES, V422, P242, DOI 10.1016/0006-8993(87)90931-0	23	133	134	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 14	1994	263	5144					232	234		10.1126/science.8284675	http://dx.doi.org/10.1126/science.8284675			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ879	8284675				2022-12-01	WOS:A1994MQ87900037
J	LOE, H				LOE, H			BROAD PAYOFFS FROM ORAL-TISSUE RESEARCH	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material											LOE, H (corresponding author), NIDR,BETHESDA,MD 20892, USA.							1992, BIOCHEM BIOPH RES CO, V188, P740; 1993, J PERIDONTOL S, V64, P819	2	3	3	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	1994	271	1					14	14		10.1001/jama.271.1.14	http://dx.doi.org/10.1001/jama.271.1.14			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN725	8258872				2022-12-01	WOS:A1994MN72500005
J	YAN, Y; WINOGRAD, E; VIEL, A; CRONIN, T; HARRISON, SC; BRANTON, D				YAN, Y; WINOGRAD, E; VIEL, A; CRONIN, T; HARRISON, SC; BRANTON, D			CRYSTAL-STRUCTURE OF THE REPETITIVE SEGMENTS OF SPECTRIN	SCIENCE			English	Article							HUMAN-ERYTHROCYTE SPECTRIN; CROSS-LINKING PROTEINS; RAY-DIFFRACTION DATA; COMPLETE SEQUENCE; HEREDITARY ELLIPTOCYTOSIS; ALPHA-SPECTRIN; COILED-COIL; REFINEMENT; DYSTROPHIN; DETECTOR	The elongated proteins of the spectrin family (dystrophin, alpha-actinin, and spectrin) contain tandemly repeated segments and form resilient cellular meshworks by cross-linking actin filaments. The structure of one of the repetitive segments of alpha-spectrin was determined at a 1.8 angstrom resolution. A segment consists of a three-helix bundle. A model of the interface between two tandem segments suggests that hydrophobic interactions between segments may constrain intersegment flexibility. The helix side chain interactions explain how mutations that are known to produce hemolytic anemias disrupt spectrin associations that sustain the integrity of the erythrocyte membrane.	HARVARD UNIV,HOWARD HUGHES MED INST,CAMBRIDGE,MA 02138; HARVARD UNIV,DEPT CELLULAR & DEV BIOL,CAMBRIDGE,MA 02138	Harvard University; Howard Hughes Medical Institute; Harvard University	YAN, Y (corresponding author), HARVARD UNIV,DEPT BIOCHEM & MOLEC BIOL,CAMBRIDGE,MA 02138, USA.				NATIONAL CANCER INSTITUTE [R37CA013202, R01CA013202] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL017411] Funding Source: NIH RePORTER; NCI NIH HHS [CA 13202] Funding Source: Medline; NHLBI NIH HHS [HL 17411] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANNER DW, 1987, J MOL BIOL, V196, P657, DOI 10.1016/0022-2836(87)90039-8; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BLUNDELL T, 1983, NATURE, V306, P281, DOI 10.1038/306281a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1990, ACTA CRYSTALLOGR A, V46, P585, DOI 10.1107/S0108767390002355; BRUNGER AT, 1992, XPLOR MANUAL VERSION; BYERS TJ, 1992, P NATL ACAD SCI USA, V89, P6187, DOI 10.1073/pnas.89.13.6187; CHOTHIA C, 1977, P NATL ACAD SCI USA, V74, P4130, DOI 10.1073/pnas.74.10.4130; COETZER TL, 1991, J CLIN INVEST, V88, P743, DOI 10.1172/JCI115371; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P89; CROSS RA, 1990, FEBS LETT, V262, P87, DOI 10.1016/0014-5793(90)80160-K; DUBREUIL RR, 1989, J CELL BIOL, V109, P2197, DOI 10.1083/jcb.109.5.2197; DUBREUIL RR, 1991, BIOESSAYS, V13, P219, DOI 10.1002/bies.950130504; ELGSAETER A, 1986, SCIENCE, V234, P1217, DOI 10.1126/science.3775380; HARRISON SC, 1968, J APPL CRYSTALLOGR, V1, P84, DOI 10.1107/S0021889868005054; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KOENIG M, 1988, CELL, V53, P219, DOI 10.1016/0092-8674(88)90383-2; KOTULA L, 1993, J BIOL CHEM, V268, P14788; LOVEJOY B, 1993, SCIENCE, V259, P1288, DOI 10.1126/science.8446897; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; PALEK J, 1990, HEMATOLOGY, P569; PARRY DAD, 1992, BIOPHYS J, V61, P858, DOI 10.1016/S0006-3495(92)81893-3; PARRY DAD, 1991, AIP CONF PROC, V226, P367; SHOTTON DM, 1979, J MOL BIOL, V131, P303, DOI 10.1016/0022-2836(79)90078-0; SPEICHER DW, 1984, NATURE, V311, P177, DOI 10.1038/311177a0; SPEICHER DW, 1993, J BIOL CHEM, V268, P4227; SPEICHER DW, 1980, P NATL ACAD SCI-BIOL, V77, P5673, DOI 10.1073/pnas.77.10.5673; TERWILLIGER TC, 1983, ACTA CRYSTALLOGR A, V39, P813, DOI 10.1107/S0108767383001592; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; TSE WT, 1990, J CLIN INVEST, V86, P909, DOI 10.1172/JCI114792; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788	33	335	342	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					2027	2030		10.1126/science.8266097	http://dx.doi.org/10.1126/science.8266097			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266097				2022-12-01	WOS:A1993MN10800036
J	JAGADEESH, B; WHEAT, HS; FERSTER, D				JAGADEESH, B; WHEAT, HS; FERSTER, D			LINEARITY OF SUMMATION OF SYNAPTIC POTENTIALS UNDERLYING DIRECTION SELECTIVITY IN SIMPLE CELLS OF THE CAT VISUAL-CORTEX	SCIENCE			English	Article							STRIATE CORTEX; NEURONS; INHIBITION; MECHANISM; MOTION	Intracellular recordings from simple cells of the cat visual cortex were used to test linear models for the generation of selectivity for the direction of visual motion. Direction selectivity has been thought to arise in part from nonlinear processes, as suggested by previous experiments that were based on extracellular recordings of action potentials. In intracellular recordings, however, the fluctuations in membrane potential evoked by moving stimuli were accurately predicted by the linear summation of responses to stationary stimuli. Nonlinear mechanisms were not required.	NORTHWESTERN UNIV,DEPT NEUROBIOL & PHYSIOL,EVANSTON,IL 60208	Northwestern University					NEI NIH HHS [R01 EY04726] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY004726] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI))		ALBRECHT DG, 1991, VISUAL NEUROSCI, V7, P531, DOI 10.1017/S0952523800010336; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; DOUGLAS RJ, 1988, NATURE, V332, P642, DOI 10.1038/332642a0; EMERSON RC, 1987, J NEUROPHYSIOL, V58, P33, DOI 10.1152/jn.1987.58.1.33; FERSTER D, 1987, J NEUROSCI, V7, P1780; FERSTER D, 1990, VISUAL NEUROSCI, V4, P115, DOI 10.1017/S0952523800002285; FERSTER D, 1988, J NEUROSCI, V8, P1172; GANZ L, 1984, J NEUROPHYSIOL, V51, P294, DOI 10.1152/jn.1984.51.2.294; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEEGER D, IN PRESS J NEUROPHYS; KOCH C, 1985, MODELS VISUAL CORTEX, P408; MCLEAN J, IN PRESS VISUAL NEUR; POGGIO T, 1973, KYBERNETIK, V13, P223, DOI 10.1007/BF00274887; REID RC, 1987, P NATL ACAD SCI USA, V84, P8740, DOI 10.1073/pnas.84.23.8740; REID RC, 1991, J NEUROPHYSIOL, V66, P505, DOI 10.1152/jn.1991.66.2.505; SAUL AB, 1992, J NEUROPHYSIOL, V68, P1190, DOI 10.1152/jn.1992.68.4.1190; TOLHURST DJ, 1991, VISUAL NEUROSCI, V6, P421, DOI 10.1017/S0952523800001280; TORRE V, 1978, PROC R SOC SER B-BIO, V202, P409, DOI 10.1098/rspb.1978.0075; WEHMEIER U J, 1988, Society for Neuroscience Abstracts, V14, P898	19	170	172	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 17	1993	262	5141					1901	1904		10.1126/science.8266083	http://dx.doi.org/10.1126/science.8266083			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266083				2022-12-01	WOS:A1993MM51100044
J	LEVIS, RW; GANESAN, R; HOUTCHENS, K; TOLAR, LA; SHEEN, FM				LEVIS, RW; GANESAN, R; HOUTCHENS, K; TOLAR, LA; SHEEN, FM			TRANSPOSONS IN-PLACE OF TELOMERIC REPEATS AT A DROSOPHILA TELOMERE	CELL			English	Article							MICROTUBULE-ASSOCIATED PROTEIN; BROKEN CHROMOSOME ENDS; DNA-SEQUENCES; SACCHAROMYCES-CEREVISIAE; GENOME EVOLUTION; CODING SEQUENCES; Y-CHROMOSOME; WHITE LOCUS; HET DNA; MELANOGASTER	We present the first isolation of the terminal DNA of an intact Drosophila telomere. lt differs from those isolated from other eukaryotes by the lack of short tandem repeats at the terminus. The terminal 14.5 kb is composed of four tandem elements derived from two families of non-long terminal repeat retrotransposons and is subject to slow terminal loss. One of these transposon families, TART (telomere-associated retrotransposon), is described for the first time here. The other element, HeT-A, has previously been shown to transpose to broken chromosome ends. Our results provide key evidence that these elements also transpose to natural chromosome ends. We propose that the telomere-associated repetitive DNA is maintained by saltatory expansions, including terminal transpositions of specialized retrotransposons, which serve to balance terminal loss.			LEVIS, RW (corresponding author), FRED HUTCHINSON CANC RES CTR,DIV BASIC SCI,1124 COLUMBIA ST,SEATTLE,WA 98104, USA.			Sheen, Fangmiin/0000-0002-5112-253X; Levis, Robert/0000-0003-3453-2390	NATIONAL CANCER INSTITUTE [P30CA015704] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM038259] Funding Source: NIH RePORTER; NCI NIH HHS [CA15704] Funding Source: Medline; NIGMS NIH HHS [GM38259] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLSHIRE RC, 1988, NATURE, V332, P656, DOI 10.1038/332656a0; Ashburner M, 1989, DROSOPHILA LABORATOR, P44; BALAKIREVA MD, 1992, NUCLEIC ACIDS RES, V20, P3731, DOI 10.1093/nar/20.14.3731; BIESSMANN H, 1993, CHROMOSOMA, V102, P297, DOI 10.1007/BF00661272; BIESSMANN H, 1992, ADV GENET, V30, P185, DOI 10.1016/S0065-2660(08)60321-1; BIESSMANN H, 1988, EMBO J, V7, P1081, DOI 10.1002/j.1460-2075.1988.tb02916.x; BIESSMANN H, 1992, EMBO J, V11, P4459, DOI 10.1002/j.1460-2075.1992.tb05547.x; BIESSMANN H, 1990, P NATL ACAD SCI USA, V87, P1758, DOI 10.1073/pnas.87.5.1758; BIESSMANN H, 1990, CELL, V61, P663, DOI 10.1016/0092-8674(90)90478-W; BIESSMANN H, 1992, MOL CELL BIOL, V12, P3910, DOI 10.1128/MCB.12.9.3910; BLACKBURN EH, 1984, CELL, V37, P7, DOI 10.1016/0092-8674(84)90295-2; BLACKBURN EH, 1993, REVERSE TRANSCRIPTAS, P411; BROSIUS J, 1991, SCIENCE, V251, P753, DOI 10.1126/science.1990437; BROWN W R A, 1992, Current Biology, V2, P127, DOI 10.1016/0960-9822(92)90248-9; CABOT EL, 1989, COMPUT APPL BIOSCI, V5, P233; CHARLESWORTH B, 1991, SCIENCE, V251, P1030, DOI 10.1126/science.1998119; CHARLESWORTH B, 1989, ANNU REV GENET, V23, P251, DOI 10.1146/annurev.ge.23.120189.001343; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; CLARK D, 1994, IN PRESS METH MOL BI, V31; DANILEVSKAYA O, 1993, GENETICS, V134, P531; DANILEVSKAYA ON, 1992, CHROMOSOMA, V102, P32, DOI 10.1007/BF00352288; DANILEVSKAYA ON, 1991, CHROMOSOMA, V100, P118, DOI 10.1007/BF00418245; DOOLITTLE RF, 1989, Q REV BIOL, V64, P1, DOI 10.1086/416128; DOOLITTLE WF, 1980, NATURE, V284, P601, DOI 10.1038/284601a0; EICHER EM, 1989, GENETICS, V122, P181; EICKBUSH TH, 1992, NEW BIOL, V4, P430; ENGELS WR, 1979, GENETICS, V92, P161; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FINNEGAN DJ, 1989, TRENDS GENET, V5, P103, DOI 10.1016/0168-9525(89)90039-5; GARZINO V, 1992, EMBO J, V11, P4471, DOI 10.1002/j.1460-2075.1992.tb05548.x; Gilson Eric, 1993, Trends in Cell Biology, V3, P128, DOI 10.1016/0962-8924(93)90175-Z; GOLDSTEIN LSB, 1986, J CELL BIOL, V102, P2076, DOI 10.1083/jcb.102.6.2076; GREIDER CW, 1991, CELL, V67, P645, DOI 10.1016/0092-8674(91)90058-7; GREIDER CW, 1985, CELL, V43, P405, DOI 10.1016/0092-8674(85)90170-9; HAZELRIGG T, 1984, CELL, V36, P469, DOI 10.1016/0092-8674(84)90240-X; HENIKOFF S, 1986, CELL, V44, P33, DOI 10.1016/0092-8674(86)90482-4; HENIKOFF S, 1987, GENETICS, V117, P711; HENNIG W, 1990, CHROMOSOMES EUKARYOT, P214; IRMINGERFINGER I, 1990, J CELL BIOL, V111, P2563, DOI 10.1083/jcb.111.6.2563; JOHNSONSCHLITZ D, 1987, GENETICS, V115, P701; KARPEN GH, 1992, GENETICS, V132, P737; LEVIS R, 1982, P NATL ACAD SCI-BIOL, V79, P564, DOI 10.1073/pnas.79.2.564; LEVIS RW, 1989, CELL, V58, P791, DOI 10.1016/0092-8674(89)90112-8; LEVIS RW, 1993, MOL GEN GENET, V236, P440, DOI 10.1007/BF00277145; LOUIS EJ, 1990, GENETICS, V124, P547; LUAN DD, 1993, CELL, V72, P595, DOI 10.1016/0092-8674(93)90078-5; LUNDBLAD V, 1993, CELL, V73, P347, DOI 10.1016/0092-8674(93)90234-H; MASON JM, 1984, P NATL ACAD SCI-BIOL, V81, P6090, DOI 10.1073/pnas.81.19.6090; McClintock B, 1941, GENETICS, V26, P234; MCCLINTOCK B, 1938, MO AGR EXP STN RES B, V163, P1; MCKEE BD, 1992, GENETICS, V132, P529; Muller H. J., 1941, Cold Spring Harbor Symposia on Quantitative Biology, V9, P151; MULLER HJ, 1938, COLLECTING NET, V13, P182; OHARE K, 1987, TRENDS GENET, V3, P87, DOI 10.1016/0168-9525(87)90186-7; OKAZAKI S, 1993, MOL CELL BIOL, V13, P1424, DOI 10.1128/MCB.13.3.1424; OLOVNIKOV AM, 1973, J THEOR BIOL, V41, P181, DOI 10.1016/0022-5193(73)90198-7; ORGEL LE, 1980, NATURE, V284, P604, DOI 10.1038/284604a0; PARDUE ML, 1992, DYNAMIC GENOME, P145; PEREIRA A, 1992, J CELL BIOL, V116, P377, DOI 10.1083/jcb.116.2.377; PETRACEK ME, 1990, P NATL ACAD SCI USA, V87, P8222, DOI 10.1073/pnas.87.21.8222; PLUTA AF, 1989, NATURE, V337, P429, DOI 10.1038/337429a0; PRIIMAGI AF, 1988, GENE, V70, P253, DOI 10.1016/0378-1119(88)90197-7; REED KC, 1985, NUCLEIC ACIDS RES, V13, P7207, DOI 10.1093/nar/13.20.7207; RICHARDS EJ, 1988, CELL, V53, P127, DOI 10.1016/0092-8674(88)90494-1; RICHARDS G, 1985, COMPREHENSIVE INSECT, V2, P255; RUBIN GM, 1978, COLD SPRING HARB SYM, V42, P1041; SANDELL LL, 1993, IN PRESS CELL, V75; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAMPAY J, 1988, P NATL ACAD SCI USA, V85, P534, DOI 10.1073/pnas.85.2.534; SIMON JA, 1985, CHROMOSOMA, V93, P26, DOI 10.1007/BF01259442; TOWER J, 1993, GENETICS, V133, P347; TRAVERSE KL, 1988, P NATL ACAD SCI USA, V85, P8116, DOI 10.1073/pnas.85.21.8116; VALGEIRSDOTTIR K, 1990, P NATL ACAD SCI USA, V87, P7998, DOI 10.1073/pnas.87.20.7998; VAURY C, 1989, CHROMOSOMA, V98, P215, DOI 10.1007/BF00329686; VIEIRA J, 1987, METHOD ENZYMOL, V153, P3; WANG SS, 1990, MOL CELL BIOL, V10, P4415, DOI 10.1128/MCB.10.8.4415; WANG SS, 1990, NATURE, V345, P456, DOI 10.1038/345456a0; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WERTMAN KF, 1986, GENE, V49, P253, DOI 10.1016/0378-1119(86)90286-6; WILLIAMSON JR, 1993, P NATL ACAD SCI USA, V90, P3214; XIONG Y, 1990, EMBO J, V9, P3353, DOI 10.1002/j.1460-2075.1990.tb07536.x; Yao MC, 1989, MOBILE DNA, P715; YOUNG BS, 1983, CELL, V34, P85, DOI 10.1016/0092-8674(83)90138-1; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579; ZHANG P, 1993, GENETICS, V133, P361	86	361	373	0	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 17	1993	75	6					1083	1093		10.1016/0092-8674(93)90318-K	http://dx.doi.org/10.1016/0092-8674(93)90318-K			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	8261510				2022-12-01	WOS:A1993MM89300007
J	NOEL, JP; HAMM, HE; SIGLER, PB				NOEL, JP; HAMM, HE; SIGLER, PB			THE 2.2-ANGSTROM CRYSTAL-STRUCTURE OF TRANSDUCIN-ALPHA COMPLEXED WITH GTP-GAMMA-S	NATURE			English	Article							AMINO-ACID-SEQUENCE; ROD OUTER SEGMENTS; G-PROTEIN; BIOCHEMICAL-PROPERTIES; ADENYLATE-CYCLASE; BINDING PROTEINS; CDNA SEQUENCE; RAS P21; SUBUNIT; IDENTIFICATION	The 2.2 angstrom crystal structure of activated rod transducin, G(talpha) . GTPgammaS, shows the bound GTPgammaS molecule occluded deep in a cleft between a domain structurally homologous to small GTPases and a helical domain unique to heterotrimeric G proteins. The structure, when combined with biochemical and genetic studies, suggests: how an activated receptor might open this cleft to allow nucleotide exchange; a mechanism for GTP-induced changes in effector and receptor binding surfaces; and a mechanism for GTPase activity not evident from previous data.	YALE UNIV, BOYER CTR MOLEC MED, DEPT MOLEC BIOPHYS & BIOCHEM, 295 CONGRESS AVE, NEW HAVEN, CT 06510 USA; YALE UNIV, BOYER CTR MOLEC MED, HOWARD HUGHES MED INST, NEW HAVEN, CT 06510 USA; UNIV ILLINOIS, DEPT PHYSIOL & BIOPHYS, CHICAGO, IL 60680 USA; UNIV SASSARI, IST FISIOL GEN & CHIM BIOL, I-07100 SASSARI, ITALY	Yale University; Howard Hughes Medical Institute; Yale University; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Sassari			Noel, Joseph P/A-9459-2009; Hamm, Heidi E/G-2374-2014					ARSHAVSKY VY, 1992, NATURE, V357, P416, DOI 10.1038/357416a0; ARTEMYEV NO, 1993, J BIOL CHEM, V268, P23611; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERLOT CH, 1992, CELL, V68, P911, DOI 10.1016/0092-8674(92)90034-A; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BLUMER KJ, 1991, ANNU REV PHYSIOL, V53, P37; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1993, XPLOR VERSION 3 1 MA; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CARSON M, 1991, J APPL CRYSTALLOGR, V24, P958, DOI 10.1107/S0021889891007240; CASEY PJ, 1990, J BIOL CHEM, V265, P2383; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; CONKLIN BR, 1993, CELL, V73, P631, DOI 10.1016/0092-8674(93)90245-L; DOWNWARD J, 1990, P NATL ACAD SCI USA, V87, P5998, DOI 10.1073/pnas.87.15.5998; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; FUNG BKK, 1983, J BIOL CHEM, V258, P503; GIBBS JB, 1985, TRENDS BIOCHEM SCI, V10, P350, DOI 10.1016/0968-0004(85)90110-0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; GUPTA SK, 1992, MOL CELL BIOL, V12, P190, DOI 10.1128/MCB.12.1.190; HAMM HE, 1988, SCIENCE, V241, P832, DOI 10.1126/science.3136547; HIGASHIJIMA T, 1987, J BIOL CHEM, V262, P752; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JURNAK F, 1985, SCIENCE, V230, P32, DOI 10.1126/science.3898365; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P916, DOI 10.1107/S0021889888007903; KABSCH W, 1988, J APPL CRYSTALLOGR, V21, P67, DOI 10.1107/S0021889887009737; KAZIRO Y, 1978, BIOCHIM BIOPHYS ACTA, V505, P95, DOI 10.1016/0304-4173(78)90009-5; LACOUR TFM, 1985, EMBO J, V4, P2385, DOI 10.1002/j.1460-2075.1985.tb03943.x; LANDIS CA, 1989, NATURE, V340, P692, DOI 10.1038/340692a0; LAURSEN RA, 1981, J BIOL CHEM, V256, P8102; LIEBMAN PA, 1987, ANNU REV PHYSIOL, V49, P765, DOI 10.1146/annurev.ph.49.030187.004001; MAZZONI MR, 1993, J PROTEIN CHEM, V12, P215, DOI 10.1007/BF01026043; MAZZONI MR, 1991, J BIOL CHEM, V266, P14072; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; MILLER RT, 1988, NATURE, V334, P712, DOI 10.1038/334712a0; NUKADA T, 1986, FEBS LETT, V197, P305, DOI 10.1016/0014-5793(86)80347-7; OTWINOWSKI Z, 1976, ML PHARE CCP4 P WARR, P80; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; PFISTER C, 1993, CELL SIGNAL, V5, P235, DOI 10.1016/0898-6568(93)90015-E; RARICK HM, 1992, SCIENCE, V256, P1031, DOI 10.1126/science.1317058; ROBISHAW JD, 1986, P NATL ACAD SCI USA, V83, P1251, DOI 10.1073/pnas.83.5.1251; SARASTE M, 1990, TRENDS BIOCHEM SCI, V15, P430, DOI 10.1016/0968-0004(90)90281-F; SIMONDS WF, 1989, P NATL ACAD SCI USA, V86, P7809, DOI 10.1073/pnas.86.20.7809; STEITZ TA, 1992, 36 F C CHEM RES REG, P173; STRATHMANN M, 1990, P NATL ACAD SCI USA, V87, P9113, DOI 10.1073/pnas.87.23.9113; STRYER L, 1986, ANNU REV CELL BIOL, V2, P391, DOI 10.1146/annurev.cb.02.110186.002135; TANG WJ, 1991, J BIOL CHEM, V266, P8595; VANDOP C, 1984, J BIOL CHEM, V259, P23; VANDOP C, 1984, J BIOL CHEM, V259, P696; VANMEURS KP, 1987, P NATL ACAD SCI USA, V84, P3107, DOI 10.1073/pnas.84.10.3107; YATSUNAMI K, 1985, P NATL ACAD SCI USA, V82, P4316, DOI 10.1073/pnas.82.13.4316; ZHANG KYJ, 1993, ACTA CRYSTALLOGR D, V49, P213, DOI 10.1107/S0907444992007911	52	723	737	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1993	366	6456					654	663		10.1038/366654a0	http://dx.doi.org/10.1038/366654a0			10	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	8259210				2022-12-01	WOS:A1993MM26500060
J	XIONG, Y; HANNON, GJ; ZHANG, H; CASSO, D; KOBAYASHI, R; BEACH, D				XIONG, Y; HANNON, GJ; ZHANG, H; CASSO, D; KOBAYASHI, R; BEACH, D			P21 IS A UNIVERSAL INHIBITOR OF CYCLIN KINASES	NATURE			English	Article							ACTIVATION	DEREGULATION of cell proliferation is a hallmark of neoplastic. transformation. Alteration in growth control pathways must translate into changes in the cell-cycle regulatory machinery, but the mechanism by which this occurs is largely unknown. Compared with normal human fibroblasts, cells transformed with a variety of viral oncoproteins show striking changes in the subunit composition of the cyclin-dependent kinases (CDKs)1. In normal cells, CDKs exist predominantly in multiple quaternary complexes, each containing a CDK, cyclin, proliferating cell nuclear antigen and the p21 protein. However, in many transformed cells, proliferating cell nuclear antigen and p21 are lost from these multiprotein enzymes. Here we have investigated the significance of this phenomenon by molecular cloning of p21 and in vitro reconstitution of the quaternary cell-cycle kinase complexes. We find that p21 inhibits the activity of each member of the cyclin/CDK family. Furthermore, overexpression of p21 inhibits the proliferation of mammalian cells. Our results indicate that p21 may be a universal inhibitor of cyclin kinases.	COLD SPRING HARBOR LAB, HOWARD HUGHES MED INST, 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA	Cold Spring Harbor Laboratory; Howard Hughes Medical Institute			Hannon, Gregory/AAB-3568-2019					DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; EWEN ME, 1993, CELL, V73, P487, DOI 10.1016/0092-8674(93)90136-E; HANNON GJ, 1993, GENE DEV, V7, P2378, DOI 10.1101/gad.7.12a.2378; HUI Z, 1993, MOL BIOL CELL, V4, P897, DOI 10.1091/mbc.4.9.897; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	13	3265	3380	3	122	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 16	1993	366	6456					701	704		10.1038/366701a0	http://dx.doi.org/10.1038/366701a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	8259214				2022-12-01	WOS:A1993MM26500074
J	RUBINFELD, B; SOUZA, B; ALBERT, I; MULLER, O; CHAMBERLAIN, SH; MASIARZ, FR; MUNEMITSU, S; POLAKIS, P				RUBINFELD, B; SOUZA, B; ALBERT, I; MULLER, O; CHAMBERLAIN, SH; MASIARZ, FR; MUNEMITSU, S; POLAKIS, P			ASSOCIATION OF THE APC GENE-PRODUCT WITH BETA-CATENIN	SCIENCE			English	Article							COLORECTAL TUMORIGENESIS; CYTOPLASMIC DOMAIN; CELL-ADHESION; E-CADHERIN; MUTATIONS; PLAKOGLOBIN; PROTEIN; CANCER; CHROMOSOME-5Q21; IDENTIFICATION	Mutations in the human APC gene are linked to familial adenomatous polyposis and to the progression of sporadic colorectal and gastric tumors. To gain insight into APC function, APC-associated proteins were identified by immunoprecipitation experiments. Antibodies to APC precipitated a 95-kilodalton protein that was purified and identified by sequencing as beta-catenin, a protein that binds to the cell adhesion molecule E-cadherin. An antibody specific to beta-catenin also recognized the 95-kilodalton protein in the immunoprecipitates. These results suggest that APC is involved in cell adhesion.	ONYX PHARMACEUT,3031 RES DR,RICHMOND,CA 94806; CHIRON CORP,PROT CHEM SECT,EMERYVILLE,CA 94608; UNIV CALIF SAN FRANCISCO,SAN FRANCISCO,CA 94143	Novartis; University of California System; University of California San Francisco				Rubinfeld, Bonnee/0000-0001-9861-6775				BUTZ S, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142-a; FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I; FUJIMORI T, 1993, MOL BIOL CELL, V4, P37, DOI 10.1091/mbc.4.1.37; GOYETTE MC, 1992, MOL CELL BIOL, V12, P1387, DOI 10.1128/MCB.12.3.1387; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; GRUSSENMEYER T, 1985, P NATL ACAD SCI USA, V82, P7952, DOI 10.1073/pnas.82.23.7952; HUELSKEN J, 1992, UNPUB; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; MARRS JA, 1993, J CELL BIOL, V123, P149, DOI 10.1083/jcb.123.1.149; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; NAKATSURU S, 1992, HUM MOL GENET, V1, P559, DOI 10.1093/hmg/1.8.559; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; RUBINFELD B, 1991, CELL, V65, P1033, DOI 10.1016/0092-8674(91)90555-D; RUBINFELD B, 1992, MOL CELL BIOL, V12, P4634, DOI 10.1128/MCB.12.10.4634; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; SU LK, 1993, CANCER RES, V53, P2728	23	1189	1219	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 10	1993	262	5140					1731	1734		10.1126/science.8259518	http://dx.doi.org/10.1126/science.8259518			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	8259518				2022-12-01	WOS:A1993ML22000041
J	PONSONBY, AL; DWYER, T; GIBBONS, LE; COCHRANE, JA; WANG, YG				PONSONBY, AL; DWYER, T; GIBBONS, LE; COCHRANE, JA; WANG, YG			FACTORS POTENTIATING THE RISK OF SUDDEN-INFANT-DEATH-SYNDROME ASSOCIATED WITH THE PRONE POSITION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							SLEEPING POSITION	Background. In several studies the sudden infant death syndrome (SIDS) has been significantly associated with sleeping in the prone position. It is not known how the prone position increases the risk of SIDS. Methods. We analyzed data from a case-control study (58 infants with SIDS and 120 control infants) and a prospective cohort study (22 infants with SIDS and 213 control infants) in Tasmania. Interactions were examined in matched analyses with a multiplicative model of interaction. Results. In the case-control study, SIDS was significantly associated with sleeping in the prone position, as compared with other positions (unadjusted odds ratio, 4.5; 95 percent confidence interval, 2.1 to 9.6). The strength of this association was increased among infants who slept on natural-fiber mattresses (P = 0.05), infants who were swaddled (P = 0.09), infants who slept in heated rooms (P = 0.006), and infants who had had a recent illness (P = 0.02). These variables had no significant effect on infants who did not sleep in the prone position. A history of recent illness was significantly associated with SIDS among infants who slept prone (odds ratio, 5.7; 95 percent confidence interval, 1.8 to 19) but not among infants who slept in other positions (odds ratio, 0.83). In the cohort study, the risk of SIDS was greater among infants who slept prone on natural-fiber mattresses (odds ratio, 6.6; 95 percent confidence interval, 1.3 to 33) than among infants who slept prone on other types of mattresses (odds ratio, 1.8). Conclusions. When infants sleep prone, the elevated risk of SIDS is increased by each of four factors: the use of natural-fiber mattresses, swaddling, recent illness, and the use of heating in bedrooms.			PONSONBY, AL (corresponding author), UNIV TASMANIA, MENZIES CTR POPULAT HLTH RES, 43 COLLINS ST, HOBART, TAS 7001, AUSTRALIA.		Wang, You-Gan/A-6059-2008; Ponsonby, Anne-Louise/AAE-4351-2019	Wang, You-Gan/0000-0003-0901-4671; Ponsonby, Anne-Louise/0000-0002-6581-3657				BEAL S, 1991, ACTA PAEDIATR SCAND, V80, P278, DOI 10.1111/j.1651-2227.1991.tb11850.x; BEAL S, 1991, MED J AUSTRALIA, V155, P507, DOI 10.5694/j.1326-5377.1991.tb93882.x; BEAL SM, 1991, J PAEDIATR CHILD H, V27, P334, DOI 10.1111/j.1440-1754.1991.tb00414.x; BRESLOW NE, 1980, STATISTICAL METHODS, V1, P196; CHECKOWAY H, 1989, MONOGRAPHS EPIDEMIOL, V13; CORBYN JA, 1992, ENV CAUSES SUDDEN IN; DWYER T, 1991, LANCET, V337, P1244, DOI 10.1016/0140-6736(91)92917-Q; DWYER T, 1992, IN PRESS 2ND P FAM I; EMERY JL, 1968, BRIT MED J, V3, P209, DOI 10.1136/bmj.3.5612.209; ENGELBERTS AC, 1990, ARCH DIS CHILD, V65, P462, DOI 10.1136/adc.65.4.462; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; GIBBONS LE, 1993, AM J EPIDEMIOL, V137, P654, DOI 10.1093/oxfordjournals.aje.a116723; GREENLAND S, 1989, AM J PUBLIC HEALTH, V79, P340, DOI 10.2105/AJPH.79.3.340; GUNTHEROTH WG, 1992, JAMA-J AM MED ASSOC, V267, P2359, DOI 10.1001/jama.267.17.2359; Hosmer D, 2013, APPL LOGISTIC REGRES; KAHN HA, 1989, MONOGRAPHS EPIDEMIOL, V12; KATTWINKEL J, 1992, PEDIATRICS, V89, P1120; KEMP JS, 1991, NEW ENGL J MED, V324, P1858, DOI 10.1056/NEJM199106273242605; KOOPMAN JS, 1981, AM J EPIDEMIOL, V113, P716, DOI 10.1093/oxfordjournals.aje.a113153; KUPPER LL, 1978, AM J EPIDEMIOL, V108, P447, DOI 10.1093/oxfordjournals.aje.a112643; LITTLE RE, 1990, EPIDEMIOL REV, V12, P241, DOI 10.1093/oxfordjournals.epirev.a036057; MIETTINEN O, 1974, AM J EPIDEMIOL, V100, P350, DOI 10.1093/oxfordjournals.aje.a112044; MITCHELL EA, 1991, NEW ZEAL MED J, V104, P71; NELSON EAS, 1989, LANCET, V1, P199; PONSONBY AL, 1992, BRIT MED J, V304, P277, DOI 10.1136/bmj.304.6822.277; RYAN E L, 1991, Australasian Physical and Engineering Sciences in Medicine, V14, P112; SCOTT S, 1990, BRIT MED J, V301, P493, DOI 10.1136/bmj.301.6750.493-b; TONKIN S, 1975, PEDIATRICS, V55, P650; 1992, PEDIATRICS, V90, P264	29	295	303	1	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 5	1993	329	6					377	382		10.1056/NEJM199308053290601	http://dx.doi.org/10.1056/NEJM199308053290601			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ339	8326970				2022-12-01	WOS:A1993LQ33900001
J	WINTERKORN, JMS; KUPERSMITH, MJ; WIRTSCHAFTER, JD; FORMAN, S				WINTERKORN, JMS; KUPERSMITH, MJ; WIRTSCHAFTER, JD; FORMAN, S			BRIEF REPORT - TREATMENT OF VASOSPASTIC AMAUROSIS FUGAX WITH CALCIUM-CHANNEL BLOCKERS	NEW ENGLAND JOURNAL OF MEDICINE			English	Note							SYSTEMIC LUPUS-ERYTHEMATOSUS; MIGRAINE; NIFEDIPINE; ATTACKS; TRIAL		NYU MED CTR,DEPT OPHTHALMOL & NEUROL,NEW YORK,NY 10016; UNIV MINNESOTA,DEPT NEUROL & NEUROSURG,MINNEAPOLIS,MN 55455; WESTCHESTER CTY MED CTR,DEPT OPHTHALMOL,VALHALLA,NY 10595	New York University; University of Minnesota System; University of Minnesota Twin Cities; Westchester Medical Center	WINTERKORN, JMS (corresponding author), N SHORE UNIV HOSP,CORNELL UNIV,MED COLL,DEPT OPHTHALMOL,300 COMMUNITY DR,MANHASSET,NY 11030, USA.							BRANDT KD, 1978, ARTHRITIS RHEUM, V21, P7, DOI 10.1002/art.1780210103; BRAUNWALD E, 1982, NEW ENGL J MED, V307, P1618; BURGER SK, 1991, NEW ENGL J MED, V325, P870, DOI 10.1056/NEJM199109193251207; Carpenter WM, 1938, ARCH OPHTHALMOL-CHIC, V19, P111, DOI 10.1001/archopht.1938.00850130123014; COHEN GR, 1984, OPHTHALMOLOGY, V91, P436; Corbett J J, 1983, Neurol Clin, V1, P973; FARACI FM, 1989, STROKE, V20, P242, DOI 10.1161/01.STR.20.2.242; FISHER CM, 1980, CAN J NEUROL SCI, V7, P9; FISHER CM, 1952, ARCH OPHTHALMOL-CHIC, V47, P167; HILLIS LD, 1978, NEW ENGL J MED, V299, P695, DOI 10.1056/NEJM197809282991305; HUPP SL, 1989, SURV OPHTHALMOL, V33, P221, DOI 10.1016/0039-6257(82)90149-7; KLINE LB, 1980, HEADACHE, V20, P253, DOI 10.1111/j.1526-4610.1980.hed2005253.x; KUPERSMITH M, 1993, NEUROVASCULAR NEURO, P441; KUPERSMITH MJ, 1979, STROKE, V10, P299, DOI 10.1161/01.STR.10.3.299; MILLER FW, 1984, NEW ENGL J MED, V311, P921; MOORE JB, 1985, THROMB RES, V40, P401, DOI 10.1016/0049-3848(85)90275-0; PICKARD JD, 1989, BRIT MED J, V298, P636, DOI 10.1136/bmj.298.6674.636; POOLE CJM, 1987, J NEUROL NEUROSUR PS, V50, P81, DOI 10.1136/jnnp.50.1.81; RODEHEFFER RJ, 1983, NEW ENGL J MED, V308, P880, DOI 10.1056/NEJM198304143081507; SHAW HE, 1979, AM J OPHTHALMOL, V87, P281, DOI 10.1016/0002-9394(79)90063-1; WILLIAMS JK, 1989, J CEREBR BLOOD F MET, V9, P111, DOI 10.1038/jcbfm.1989.15; WINTERKORN JMS, 1991, ANN NEUROL, V30, P423, DOI 10.1002/ana.410300317; 1990, STROKE, V21, P201; 1991, NEW ENGL J MED, V325, P445	24	94	95	0	4	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 5	1993	329	6					396	398		10.1056/NEJM199308053290604	http://dx.doi.org/10.1056/NEJM199308053290604			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LQ339	8326973	Bronze			2022-12-01	WOS:A1993LQ33900004
J	LONGO, ML; BISAGNO, AM; ZASADZINSKI, JAN; BRUNI, R; WARING, AJ				LONGO, ML; BISAGNO, AM; ZASADZINSKI, JAN; BRUNI, R; WARING, AJ			A FUNCTION OF LUNG SURFACTANT PROTEIN SP-B	SCIENCE			English	Article							MODEL MEMBRANE BILAYERS; AMINO-ACID SEQUENCES; PULMONARY SURFACTANT; BIOPHYSICAL ACTIVITY; MONOLAYERS; CDNA; INHIBITION; ADSORPTION; DOMAIN	The primary function of lung surfactant is to form monolayers at the alveolar interface capable of lowering the normal surface tension to near zero. To accomplish this process, the surfactant must be capable of maintaining a coherent, tight y packed monolayer that avoids collapse during expiration. The Positively charged amino-terminal peptide SP-B1-25 of lung surfactant-specific protein SP-B increases the collapse pressure of an important component of lung surfactant, palmitic acid (PA), to nearly 70 millinewtons per meter. This alteration of the PA isotherms removes the driving force for ''squeeze-out'' of the fatty acids from the primarily dipalmitoylphosphatidylcholine monolayers of lung surfactant. An uncharged mutant of SP-B1-25 induced little change in the isotherms, suggesting that a specific charge interaction between the cationic peptide and the anionic lipid is responsible for the stabilization. The effect of SP-B1-25 on fatty acid isotherms is remarkably similar to that of simple poly-cations, suggesting that such polymers might be useful as components of replacement surfactants for the treatment of respiratory distress syndrome.	UNIV CALIF SANTA BARBARA,DEPT CHEM & NUCL ENGN,SANTA BARBARA,CA 93106; UNIV CALIF LOS ANGELES,LOS ANGELES,CA 90024; DREW UNIV,KING MED CTR,DEPT PEDIAT,LOS ANGELES,CA 90059	University of California System; University of California Santa Barbara; University of California System; University of California Los Angeles					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL040666] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047334] Funding Source: NIH RePORTER; NCRR NIH HHS [G 12 RRO 302607] Funding Source: Medline; NHLBI NIH HHS [HL 40666] Funding Source: Medline; NIGMS NIH HHS [GM 47334] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMSON AW, 1990, PHYSICAL CHEM SURFAC, pCH4; AVERY ME, 1959, AM J DIS CHILD, V97, P917; BAATZ JE, 1990, BIOCHEMISTRY-US, V29, P6714, DOI 10.1021/bi00480a022; BAATZ JE, 1991, CHEM PHYS LIPIDS, V60, P163, DOI 10.1016/0009-3084(91)90039-E; BRUNI R, 1991, P NATL ACAD SCI USA, V88, P7451, DOI 10.1073/pnas.88.16.7451; CHI LF, 1991, LANGMUIR, V7, P2323, DOI 10.1021/la00058a058; CHI LF, 1993, SCIENCE, V259, P213, DOI 10.1126/science.259.5092.213; CHUNG JB, 1990, LANGMUIR, V6, P1647, DOI 10.1021/la00101a005; CLEMENTS J A, 1962, Physiologist, V5, P11; CLEMENTS JA, 1961, ARCH ENVIRON HEALTH, V2, P280; COCHRANE CG, 1991, SCIENCE, V254, P566, DOI 10.1126/science.1948032; COCKSHUTT AM, 1991, BIOCHIM BIOPHYS ACTA, V1085, P248, DOI 10.1016/0005-2760(91)90101-M; GLASSER SW, 1987, P NATL ACAD SCI USA, V84, P4007, DOI 10.1073/pnas.84.12.4007; GLASSER SW, 1988, J BIOL CHEM, V263, P9; HAWGOOD S, 1987, P NATL ACAD SCI USA, V84, P66, DOI 10.1073/pnas.84.1.66; HOLM BA, 1990, CHEM PHYS LIPIDS, V52, P243, DOI 10.1016/0009-3084(90)90120-G; JOBE A, 1987, AM REV RESPIR DIS, V136, P1256, DOI 10.1164/ajrccm/136.5.1256; KEOUGH KMW, 1988, CAN J PHYSIOL PHARM, V66, P1166, DOI 10.1139/y88-192; KNOBLER CM, 1990, ADV CHEM PHYS, V78, P398; LONGO ML, 1992, BIOPHYS J, V63, P760, DOI 10.1016/S0006-3495(92)81643-0; MATHIALAGAN N, 1990, BIOCHIM BIOPHYS ACTA, V1045, P121, DOI 10.1016/0005-2760(90)90140-S; MCCONNELL HM, 1991, ANNU REV PHYS CHEM, V42, P171, DOI 10.1146/annurev.physchem.42.1.171; MOHWALD H, 1990, ANNU REV PHYS CHEM, V41, P441, DOI 10.1146/annurev.pc.41.100190.002301; RIES HE, 1987, LANGMUIR, V3, P853, DOI 10.1021/la00077a048; SARIN VK, 1990, P NATL ACAD SCI USA, V87, P2633, DOI 10.1073/pnas.87.7.2633; SCHWARTZ DK, 1992, J PHYS CHEM-US, V96, P10444, DOI 10.1021/j100204a059; SEEGER W, 1992, AM J PHYSIOL, V262, pL286, DOI 10.1152/ajplung.1992.262.3.L286; Shapiro D. L, 1989, SURFACTANT REPLACEME; SMITH RD, 1980, J COLLOID INTERF SCI, V74, P273, DOI 10.1016/0021-9797(80)90190-3; SOLL RF, 1992, RESIDENT STAFF PHYSI, V38, P19; STUART JM, 1984, SOLID PHASE PEPTIDE; TANAKA Y, 1986, J LIPID RES, V27, P475; VANDENBUSSCHE G, 1992, BIOCHEMISTRY-US, V31, P9169, DOI 10.1021/bi00153a008; VENKITARAMAN AR, 1990, CHEM PHYS LIPIDS, V53, P157, DOI 10.1016/0009-3084(90)90041-O; VOLLHARDT D, 1992, LANGMUIR, V8, P309, DOI 10.1021/la00037a056; WARING A, 1989, Peptide Research, V2, P308; WARING A, 1991, BIOPHYS J, V59, P507; WARR RG, 1987, P NATL ACAD SCI USA, V84, P7915, DOI 10.1073/pnas.84.22.7915; WHITSETT JA, 1986, PEDIATR RES, V20, P460, DOI 10.1203/00006450-198605000-00016; YU SH, 1992, BIOCHIM BIOPHYS ACTA, V1126, P26, DOI 10.1016/0005-2760(92)90212-E; YU SH, 1986, BIOCHEM J, V236, P85, DOI 10.1042/bj2360085	41	160	163	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 23	1993	261	5120					453	456		10.1126/science.8332910	http://dx.doi.org/10.1126/science.8332910			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8332910				2022-12-01	WOS:A1993LN62300030
J	TUOMILEHTOWOLF, E; TUOMILEHTO, J; HITMAN, GA; NISSINEN, A; STENGARD, J; PEKKANEN, J; KIVINEN, P; KAARSALO, E; KARVONEN, MJ				TUOMILEHTOWOLF, E; TUOMILEHTO, J; HITMAN, GA; NISSINEN, A; STENGARD, J; PEKKANEN, J; KIVINEN, P; KAARSALO, E; KARVONEN, MJ			GENETIC SUSCEPTIBILITY TO NON-INSULIN-DEPENDENT DIABETES-MELLITUS AND GLUCOSE-INTOLERANCE ARE LOCATED IN HLA REGION	BRITISH MEDICAL JOURNAL			English	Article							ELDERLY MEN; A ANTIGENS; FREQUENCY; FINLAND; RISK	Objectives-To test the hypothesis that the genetic susceptibility to non-insulin dependent diabetes mellitus is the same as that to insulin dependent disease and to see whether glucose intolerance is associated with specific HLA haplotypes. Design-Population based study of men in 1989 first tested for glucose tolerance in 1984. HLA haplotypes, including HLA-A, C, B, DR, and DQ, were defined serologically. HLA haplotype data from a population based Finnish study of childhood diabetes were used for predicting non-insulin dependent diabetes and impaired glucose tolerance. Setting-Two communities in Finland. Subjects-Representative cohort of Finnish men aged 70-89, comprising 98 men with non-insulin dependent diabetes mellitus and a randomly selected group of 74 men, who served as controls, who were tested for glucose tolerance twice within five years. Main outcome measures-Non-insulin dependent diabetes, impaired glucose tolerance, blood glucose concentration. Results-Diabetes associated HLA haplotypes were present in 94% (85/90) of diabetic subjects, 79% (27/34) of subjects with impaired glucose tolerance, and only 13% (3/23) of non-diabetic subjects. In this group of elderly men sensitivity of the diabetes associated HLA haplotypes for non-insulin dependent diabetes and impaired glucose tolerance was 90%, specificity 87%, and predictive power 97%. Mean fasting blood glucose concentration was only just significantly higher in men with diabetes associated haplotypes than in men with no such haplotypes, but there was a substantial difference in blood glucose values two hours after glucose loading (10.4 and 6.4 mmol/l in men with diabetes associated HLA haplotypes and men with no such haplotypes, respectively (p<0.0001)). Conclusions-These findings support the hypothesis that specific HLA haplotypes exhibit a common genetic determinant for insulin dependent and non-insulin dependent diabetes. Furthermore, HLA is a major genetic determinant of glucose intolerance in elderly Finnish men. The belief that the HLA predisposition to diabetes is specific for insulin dependent diabetes mellitus is largely incorrect.	ROYAL LONDON HOSP,MED UNIT,LONDON E1 1BB,ENGLAND; UNIV KUOPIO,DEPT COMMUNITY HLTH & GEN PRACTICE,KUOPIO,FINLAND; LOIMAA DIST HOSP,LOIMAA,FINLAND; NATL PUBL HLTH INST,DEPT EPIDEMIOL,SF-00280 HELSINKI 28,FINLAND	Barts Health NHS Trust; Royal London Hospital; University of Eastern Finland; University of Turku; Finland National Institute for Health & Welfare					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037957] Funding Source: NIH RePORTER; NIA NIH HHS [AG087762] Funding Source: Medline; NIDDK NIH HHS [DK-37957] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ASMAL AC, 1981, S AFR MED J, V60, P3; BARNETT AH, 1981, DIABETOLOGIA, V20, P87, DOI 10.1007/BF00262007; BAUR MP, 1984, HISTOCOMPATIBILITY; BENNETT AH, 1992, INT TXB DIABETES MEL, P147; BHATIA K, 1984, DIABETOLOGIA, V27, P370, DOI 10.1007/BF00304852; BRIGGS BR, 1980, DIABETES, V29, P68, DOI 10.2337/diabetes.29.1.68; CUDWORTH AG, 1975, BRIT MED J, V3, P133, DOI 10.1136/bmj.3.5976.133; DAHLQUIST G, 1989, DIABETOLOGIA, V32, P2; Diabetes Epidemiology Research International Group, 1988, DIABETES, V37, P1113; GROOP L, 1983, ACTA ENDOCRINOL-COP, V104, P475, DOI 10.1530/acta.0.1040475; HARRIS H, 1950, ANN EUGENIC, V15, P95; KEYS A, 1970, CIRCULATION       S1, V41, P1; Neel J. V, 1976, GENETICS DIABETES ME, P1; NERUP J, 1974, LANCET, V2, P864; NISSINEN A, 1986, AGE AGEING, V15, P203, DOI 10.1093/ageing/15.4.203; OMAR MAK, 1988, DIABETES, V37, P796, DOI 10.2337/diabetes.37.6.796; PEKKANEN J, 1989, BRIT MED J, V299, P81, DOI 10.1136/bmj.299.6691.81; PYKE DA, 1977, CLIN ENDOCRINOL META, V6, P285, DOI 10.1016/S0300-595X(77)80039-X; REWERS M, 1988, World Health Statistics Quarterly, V41, P179; SERJEANTSOIN SW, 1981, MED J AUSTRALIA, V41, P462; SERJEANTSON SW, 1983, DIABETOLOGIA, V25, P13; SINGAL DP, 1973, DIABETES, V22, P429, DOI 10.2337/diab.22.6.429; SPEES EK, 1973, HISTOCOMPATIBILITY T, P345; TIENARI PJ, 1992, DIABETOLOGIA, V35, P254, DOI 10.1007/BF00400926; TIWARI JL, 1985, HLA DISEASE ASS, P210; TUOMILEHTO J, 1991, INT J EPIDEMIOL, V20, P1010, DOI 10.1093/ije/20.4.1010; TUOMILEHTO J, 1992, DIABETOLOGIA, V35, P70, DOI 10.1007/BF00400854; TUOMILEHTO J, 1986, DIABETOLOGIA, V29, P611, DOI 10.1007/BF00869258; TUOMILEHTOWOLF E, 1989, LANCET, V2, P299; TUOMILEHTOWOLF E, 1992, ANN MED, V24, P533, DOI 10.3109/07853899209167007; VELLENA AA, 1980, NEW ENGL J MED, V303, P1065; WILLIAMS RC, 1981, DIABETOLOGIA, V21, P460; WOLF E, 1981, DIABETOLOGIA, V21, pA80; ZHAO TM, 1982, CHINESE MED J-PEKING, V95, P609; 1985, WHO TECH REP SER, V727	35	67	67	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1993	307	6897					155	159		10.1136/bmj.307.6897.155	http://dx.doi.org/10.1136/bmj.307.6897.155			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN184	8343743	Green Published, Bronze			2022-12-01	WOS:A1993LN18400017
J	KOLCH, W; HEIDECKER, G; KOCHS, G; HUMMEL, R; VAHIDI, H; MISCHAK, H; FINKENZELLER, G; MARME, D; RAPP, UR				KOLCH, W; HEIDECKER, G; KOCHS, G; HUMMEL, R; VAHIDI, H; MISCHAK, H; FINKENZELLER, G; MARME, D; RAPP, UR			PROTEIN KINASE-C-ALPHA ACTIVATES RAF-1 BY DIRECT PHOSPHORYLATION	NATURE			English	Article								THE kinase Raf-1 can be activated by treatment of cells with mitogens and by the protein kinase C (PKC) activator 12-O-tetradecanoyl-phorbol-13-acetate (TPA) (reviewed in refs 1,2). Activated Raf-1 triggers a protein kinase cascade by direct phosphorylation of MAP kinase kinase3-5, resulting in phosphorylation of ternary complex factor6 and Jun7,8 by MAP kinase. Here we investigate the molecular mechanism and biological consequences of PKCalpha-mediated Raf-1 activation in NIH3T3 fibroblasts. PKCalpha directly phosphorylates and activates Raf-1 both in vitro and in vivo. PKCalpha induces Raf-1 phosphorylation at several sites, including a serine residue at position 499. Mutation of serine at this position or at residue 259 does not abrogate Raf-1 stimulation by a combination of Ras plus the src tyrosine kinase Lck, but severely impedes Raf-1 activation by PKCalpha. Consistent with such a direct interaction is the observation that Raf-1 and PKCalpha cooperate in the transformation of NIH3T3 cells. The Ser499 phosphorylation site is necessary for this synergism.	GODECKE AG,BIOL RES,W-7800 FREIBURG,GERMANY; NCI,FCRDC,VIRAL CARCINOGENESIS LAB,FREDERICK,MD 21702; UNIV FREIBURG,GOEDECKE AG,INST MOLEC CELL BIOL,W-7800 FREIBURG,GERMANY; NCI,GENET LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); University of Freiburg; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Kolch, Walter/ABF-2102-2021; Mischak, Harald/E-8685-2011	Kolch, Walter/0000-0001-5777-5016; Mischak, Harald/0000-0003-0323-0306				APP H, 1991, MOL CELL BIOL, V11, P913, DOI 10.1128/MCB.11.2.913; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; GILLE H, 1992, NATURE, V358, P414, DOI 10.1038/358414a0; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOCHS G, IN PRESS BIOCHEMICAL; KOLCH W, 1990, ONCOGENE, V5, P713; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LUO K, 1991, METHOD ENZYMOL, V201, pB149; MCGREW BR, 1992, ONCOGENE, V7, P33; PIWINICAWORMS H, 1987, CELL, V49, P75; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAPP UR, 1991, ONCOGENE, V6, P495; SMEAL T, 1992, MOL CELL BIOL, V12, P3507, DOI 10.1128/MCB.12.8.3507; SOZERI O, 1992, ONCOGENE, V7, P2259; Summers MD, 1987, MANUAL METHODS BACUL; THOMPSON PA, 1991, CELL GROWTH DIFFER, V2, P609; WILLIAMS NG, 1992, P NATL ACAD SCI USA, V89, P2922, DOI 10.1073/pnas.89.7.2922	19	1239	1263	0	28	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 15	1993	364	6434					249	252		10.1038/364249a0	http://dx.doi.org/10.1038/364249a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM683	8321321				2022-12-01	WOS:A1993LM68300061
J	EWEN, ME; SLUSS, HK; SHERR, CJ; MATSUSHIME, H; KATO, JY; LIVINGSTON, DM				EWEN, ME; SLUSS, HK; SHERR, CJ; MATSUSHIME, H; KATO, JY; LIVINGSTON, DM			FUNCTIONAL INTERACTIONS OF THE RETINOBLASTOMA PROTEIN WITH MAMMALIAN D-TYPE CYCLINS	CELL			English	Article							SV40 LARGE-T; ADENOVIRUS E1A PROTEINS; GENE-PRODUCT; CELL-CYCLE; SUSCEPTIBILITY GENE; RB PROTEIN; G1 PHASE; PHOSPHORYLATION; BINDING; ONCOGENE	The retinoblastoma gene product (Rb) can interact efficiently with two of three D-type G1 cyclins (D2 and D3) in vitro. Binding depended upon the minimal regions of Rb necessary for its growth-suppressive activity, as well as upon the D-type cyclin sequence motif shared with Rb-binding DNA tumor virus oncoproteins. Coexpression of the three D-type cyclins with the cyclin-dependent kinase (cdk4) in insect cells generated Rb kinase activity. By contrast, cyclins D2 and D3, but not D1, activated another such kinase, cdk2. Introduction of cyclin D2 and Rb into the Rb-deficient cell line SAOS-2 led to overt Rb hyperphosphorylation, whereas Rb, expressed alone or together with cyclin D1, remained unphosphorylated. Cyclin D2-dependent phosphorylation inhibited its binding to the transcription factor E2F and reversed the Rb G1 exit block in the cell cycle. Thus, all D-type cyclins do not function equivalently, and one of them plays a major role in reversing the cycle-blocking function of a known tumor suppressor.	HOWARD HUGHES MED INST, MEMPHIS, TN 38105 USA; ST JUDE CHILDRENS RES HOSP, DEPT TUMOR CELL BIOL, MEMPHIS, TN 38101 USA	Howard Hughes Medical Institute; St Jude Children's Research Hospital	EWEN, ME (corresponding author), HARVARD UNIV, SCH MED, DANA FARBER CANC INST, BOSTON, MA 02115 USA.		Sherr, Charles J/N-8074-2018	Sherr, Charles J/0000-0002-5516-6206	NCI NIH HHS [CA-47064] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA047064] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AJCHENBAUM F, 1993, IN PRESS J CELL BIOL; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DECAPRIO JA, 1989, CELL, V58, P1085, DOI 10.1016/0092-8674(89)90507-2; DECAPRIO JA, 1992, P NATL ACAD SCI USA, V89, P1795, DOI 10.1073/pnas.89.5.1795; DOWDY SF, 1993, CELL, V73, P499, DOI 10.1016/0092-8674(93)90137-F; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1989, CELL, V58, P249, DOI 10.1016/0092-8674(89)90839-8; EWEN ME, 1992, SCIENCE, V255, P85, DOI 10.1126/science.1532457; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; EWEN ME, 1989, CELL, V58, P257, DOI 10.1016/0092-8674(89)90840-4; FAHA B, 1992, SCIENCE, V255, P87, DOI 10.1126/science.1532458; FRIEND SH, 1986, NATURE, V323, P643, DOI 10.1038/323643a0; GOODRICH DW, 1991, CELL, V67, P293, DOI 10.1016/0092-8674(91)90181-W; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAMEL PA, 1992, MOL CELL BIOL, V12, P3431, DOI 10.1128/MCB.12.8.3431; HANNA Z, 1993, IN PRESS ONCOGENE; HELIN K, 1992, CELL, V70, P337, DOI 10.1016/0092-8674(92)90107-N; HIEBERT SW, 1992, GENE DEV, V6, P177, DOI 10.1101/gad.6.2.177; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; HU Q, 1992, MOL CELL BIOL, V12, P971, DOI 10.1128/MCB.12.3.971; HU QJ, 1991, MOL CELL BIOL, V11, P5792, DOI 10.1128/MCB.11.11.5792; INABA T, 1992, GENOMICS, V13, P565, DOI 10.1016/0888-7543(92)90126-D; JONES RE, 1990, J BIOL CHEM, V265, P12782; KAELIN WG, 1991, CELL, V64, P521, DOI 10.1016/0092-8674(91)90236-R; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KATO J, 1993, GENE DEV, V7, P331; KAYE FJ, 1990, P NATL ACAD SCI USA, V87, P6922, DOI 10.1073/pnas.87.17.6922; KIYOKAWA H, 1992, P NATL ACAD SCI USA, V89, P2444, DOI 10.1073/pnas.89.6.2444; KOFF A, 1991, CELL, V66, P1217, DOI 10.1016/0092-8674(91)90044-Y; KREK W, 1991, EMBO J, V10, P3331, DOI 10.1002/j.1460-2075.1991.tb04897.x; LAMMIE GA, 1992, ONCOGENE, V7, P2381; LAMMIE GA, 1991, ONCOGENE, V6, P439; LEES JA, 1991, EMBO J, V10, P4279, DOI 10.1002/j.1460-2075.1991.tb05006.x; LEW DJ, 1991, CELL, V66, P1197, DOI 10.1016/0092-8674(91)90042-W; LIN BTY, 1991, EMBO J, V10, P857, DOI 10.1002/j.1460-2075.1991.tb08018.x; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUDLOW JW, 1990, CELL, V60, P387, DOI 10.1016/0092-8674(90)90590-B; MATSUSHIME H, 1991, COLD SPRING HARB SYM, V56, P69; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MITTNACHT S, 1991, CELL, V65, P381, DOI 10.1016/0092-8674(91)90456-9; MOTOKURA T, 1991, NATURE, V350, P512, DOI 10.1038/350512a0; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; QIN XQ, 1992, GENE DEV, V6, P953, DOI 10.1101/gad.6.6.953; SCHUURING E, 1992, ONCOGENE, V7, P355; SHERR CJ, 1991, TRENDS GENET, V7, P398, DOI 10.1016/0168-9525(91)90263-P; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; TAYA Y, 1989, BIOCHEM BIOPH RES CO, V164, P580, DOI 10.1016/0006-291X(89)91759-2; WEINBERG RA, 1991, SCIENCE, V254, P1138, DOI 10.1126/science.1659741; WEINTRAUB SJ, 1992, NATURE, V358, P259, DOI 10.1038/358259a0; WHYTE P, 1989, CELL, V56, P67, DOI 10.1016/0092-8674(89)90984-7; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WILLIAMS RT, 1992, ONCOGENE, V7, P423; WITHERS DA, 1991, MOL CELL BIOL, V11, P4846, DOI 10.1128/MCB.11.10.4846; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, GENOMICS, V13, P575, DOI 10.1016/0888-7543(92)90127-E; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YUE X, 1991, CELL, V65, P691, DOI 10.1016/0092-8674(91)90100-D	61	1044	1076	0	23	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	MAY 7	1993	73	3					487	497		10.1016/0092-8674(93)90136-E	http://dx.doi.org/10.1016/0092-8674(93)90136-E			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LA743	8343202				2022-12-01	WOS:A1993LA74300010
J	HLA, KM; YOUNG, TB; BIDWELL, T; PALTA, MM; SKATRUD, B; DEMPSEY, J				HLA, KM; YOUNG, TB; BIDWELL, T; PALTA, MM; SKATRUD, B; DEMPSEY, J			SLEEP-APNEA AND HYPERTENSION - A POPULATION-BASED STUDY	ANNALS OF INTERNAL MEDICINE			English	Article						SLEEP APNEA SYNDROMES; HYPERTENSION; SNORING; POLYSOMNOGRAPHY; BLOOD PRESSURE MONITORS	AMBULATORY BLOOD-PRESSURE; LEFT-VENTRICULAR HYPERTROPHY; ARTERIAL-PRESSURE; RISK FACTOR; PREVALENCE; HYPERSOMNIA; MEN; CATECHOLAMINES; TRACHEOSTOMY; BORDERLINE	Objective: To measure the independent association of sleep-disordered breathing (sleep apnea and habitual snoring) and hypertension in a healthy adult population. Design: A cross-sectional study of blood pressure during wakefulness and sleep among participants with and without sleep-disordered breathing. Setting: Community-based study. Participants: 147 men and women, aged 30 to 60 years, selected from Wisconsin State employees enrolled in the Wisconsin Sleep Cohort Study, an ongoing, prospective, epidemiologic study of sleep-disordered breathing. Measurements: Sleep and medical history interview, nocturnal polysomnography, and 24-hour ambulatory blood pressure monitoring in all participants. Results: Mean blood pressures were significantly higher among participants with sleep apnea (greater than or equal to 5 apneas or hypopneas per hour of sleep) compared with those without (131/80 +/- 1.7/1.1 mm Hg compared with 122/75 +/- 1.9/1.2 mm Hg during wakefulness and 113/66 +/- 1.8/1.1 mm Hg compared with 104/62 +/- 2/1.3 mm Hg during sleep, respectively; P < 0.05). The variability of the blood pressure during sleep was significantly greater in participants with sleep apnea or a history of snoring compared with those without (P < 0.05). After controlling for obesity, age, and sex, sleep apnea was significantly associated with hypertension in a dose-response fashion, with odds ratios ranging from 2.0 for 5 apneic or hypopneic episodes per hour of sleep to 5.0 for 25 apneic or hypopneic episodes. Conclusions: Our data indicate an association between hypertension and sleep apnea independent of obesity, age, and sex in a nonselected, community-based adult population.			HLA, KM (corresponding author), UNIV WISCONSIN, CTR CLIN SCI, DEPT MED, J5-210, 600 HIGHLAND AVE, MADISON, WI 53792 USA.				NCRR NIH HHS [RR 03186] Funding Source: Medline; NHLBI NIH HHS [P01 HL 42242] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042242] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BURACK B, 1984, AM HEART J, V107, P543, DOI 10.1016/0002-8703(84)90098-X; BURACK B, 1977, CIRCULATION, V56, P177; CARSKADON MA, 1989, PRINCIPLES PRACTICE, P3; COCCAGNA G, 1972, B PHYSIO-PATHOL RESP, V8, P1159; CORNONIHUNTLEY J, 1989, ARCH INTERN MED, V149, P780, DOI 10.1001/archinte.149.4.780; DEMENT WC, 1993, JAMA-J AM MED ASSOC, V269, P1548, DOI 10.1001/jama.269.12.1548; DRAYER JIM, 1983, ARCH INTERN MED, V143, P90, DOI 10.1001/archinte.143.1.90; DRAYER JIM, 1987, HYPERTENSION, V9, P61; Drizd T, 1986, Vital Health Stat 11, P1; FLETCHER EC, 1985, ANN INTERN MED, V103, P190, DOI 10.7326/0003-4819-103-2-190; FLORAS JS, 1981, LANCET, V2, P107; GELLMAN M, 1990, PSYCHOPHYSIOLOGY, V27, P544, DOI 10.1111/j.1469-8986.1990.tb01972.x; GIFFORD RW, 1993, ARCH INTERN MED, V153, P154; GISLASON T, 1988, J CLIN EPIDEMIOL, V41, P571, DOI 10.1016/0895-4356(88)90061-3; GUILLEMINAULT C, 1981, ARCH INTERN MED, V141, P985, DOI 10.1001/archinte.141.8.985; Guilleminault C., 1978, SLEEP APNEAS SYNDROM, V1, P1; HALL JE, 1992, HYPERTENSION S, V19, P145; HOFFSTEIN V, 1988, LANCET, V2, P992; IRVING JB, 1976, POSTGRAD MED J, V52, P137; JENNUM P, 1989, AM J HYPERTENS, V2, P847, DOI 10.1093/ajh/2.11.847; KALES A, 1984, LANCET, V2, P1005; KHATRI IM, 1967, J APPL PHYSIOL, V22, P867, DOI 10.1152/jappl.1967.22.5.867; KOSKENVUO M, 1985, LANCET, V1, P893; LAVIE P, 1984, AM HEART J, V108, P373, DOI 10.1016/0002-8703(84)90628-8; Lugaresi E, 1978, Adv Exp Med Biol, V99, P35; MESSERLI FH, 1982, AM HEART J, V104, P109, DOI 10.1016/0002-8703(82)90649-4; MILLMAN RP, 1991, CHEST, V99, P861, DOI 10.1378/chest.99.4.861; MORGAN BJ, 1993, J APPL PHYSIOL, V74, P2969, DOI 10.1152/jappl.1993.74.6.2969; MOTTA J, 1978, ANN INTERN MED, V89, P454, DOI 10.7326/0003-4819-89-4-454; NORTON PG, 1985, BRIT MED J, V291, P630, DOI 10.1136/bmj.291.6496.630; PACK AI, 1993, SLEEP MED REV, V1, P1; PEISER J, 1984, ANN SURG, V199, P112, DOI 10.1097/00000658-198401000-00020; PERLOFF D, 1983, JAMA-J AM MED ASSOC, V249, P2792, DOI 10.1001/jama.249.20.2792; PICKERING TG, 1982, CLIN EXP HYPERTENS, V4, P675, DOI 10.3109/10641968209061606; PICKERING TG, 1982, JAMA-J AM MED ASSOC, V247, P992, DOI 10.1001/jama.247.7.992; RAUSCHER H, 1992, American Review of Respiratory Disease, V145, pA442; Rechtschaffen A, 1969, MANUAL STANDARDIZED, V26, P644; RINGLER J, 1990, J APPL PHYSIOL, V69, P2143, DOI 10.1152/jappl.1990.69.6.2143; ROWLANDS DB, 1981, CLIN SCI, V61, pS101, DOI 10.1042/cs061101s; SCHWAN A, 1992, J HYPERTENS, V10, P189; Snedecor GW, 1980, STATISTICAL METHODS, P98; SOKOLOW M, 1966, CIRCULATION, V34, P279; SOMERS VK, 1993, NEW ENGL J MED, V328, P303, DOI 10.1056/NEJM199302043280502; STAESSEN J, 1990, J HYPERTENS, V8, pS57; STAMLER R, 1978, JAMA-J AM MED ASSOC, V240, P1607, DOI 10.1001/jama.240.15.1607; STRADLING JR, 1991, THORAX, V46, P85, DOI 10.1136/thx.46.2.85; TILKIAN AG, 1976, ANN INTERN MED, V85, P714, DOI 10.7326/0003-4819-85-6-714; TURJANMAA V, 1991, J HYPERTENS, V9, P665, DOI 10.1097/00004872-199107000-00012; TURNER JR, 1991, J PSYCHOSOM RES, V35, P289; VEERMAN DP, 1988, J HYPERTENS, V6, pS77, DOI 10.1097/00004872-198812040-00020; WEBER MA, 1988, HYPERTENSION, V11, P288, DOI 10.1161/01.HYP.11.3.288; WHITE WB, 1989, JAMA-J AM MED ASSOC, V261, P873; WILCOX T, 1991, CIRCULATION S2, V84, P136; WILLIAMS AJ, 1985, AM J CARDIOL, V55, P1019, DOI 10.1016/0002-9149(85)90738-6; YOUNG T, 1993, NEW ENGL J MED, V328, P1230, DOI 10.1056/NEJM199304293281704; 1993, EXECUTIVE SUMMARY EX, V1	56	451	473	0	13	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 1	1994	120	5					382	388		10.7326/0003-4819-120-5-199403010-00005	http://dx.doi.org/10.7326/0003-4819-120-5-199403010-00005			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MY497	8304655				2022-12-01	WOS:A1994MY49700005
J	LI, YQ; ERZURUMLU, RS; CHEN, C; JHAVERI, S; TONEGAWA, S				LI, YQ; ERZURUMLU, RS; CHEN, C; JHAVERI, S; TONEGAWA, S			WHISKER-RELATED NEURONAL PATTERNS FAIL TO DEVELOP IN THE TRIGEMINAL BRAIN-STEM NUCLEI OF NMDAR1 KNOCKOUT MICE	CELL			English	Article							VIBRISSA-RELATED PATTERNS; SOMATOSENSORY CORTEX; RECEPTOR ANTAGONIST; STRIATE CORTEX; NEONATAL RAT; MOUSE; BLOCKADE; DISRUPT; SYSTEM; ORGANIZATION	Sensory pathways of the brain generally develop from crudely wired networks to precisely organized systems. Several studies have implicated neural activity-dependent mechanisms, including N-methyl-D-aspartate (NMDA) receptors, in this refinement process. We applied the gene targeting to the NMDAR1 gene and created a mutant mouse that lacks functional NMDA receptors. The development of whisker-related patterns in the trigeminal nuclei of the mutant mice and their normal littermates was compared. We show that in the mutant mice pathfinding, initial targeting, and crude topographic projection of trigeminal axons in the brainstem are unaffected, but that whisker-specific patches fail to form. Our results provide a direct demonstration of the involvement of the NMDA receptor in the formation of periphery-related neural patterns in the mammalian brain.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA; MIT, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	LI, YQ (corresponding author), MIT, CTR CANC RES, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02139 USA.		Li, Yuqing/G-1596-2011; Li, Yuqing/AAR-9383-2021	Li, Yuqing/0000-0003-1211-5529; Li, Yuqing/0000-0003-1211-5529	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027678] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 27678] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AMANO T, 1992, MOL BRAIN RES, V14, P35, DOI 10.1016/0169-328X(92)90007-X; BATES CA, 1985, J COMP NEUROL, V240, P265, DOI 10.1002/cne.902400305; BEAR MF, 1990, J NEUROSCI, V10, P909; BELFORD GR, 1980, J COMP NEUROL, V193, P335, DOI 10.1002/cne.901930203; BELFORD GR, 1979, J COMP NEUROL, V183, P305, DOI 10.1002/cne.901830207; Blue ME, 1991, CEREB CORTEX, V1, P380, DOI 10.1093/cercor/1.5.380; BRADLEY A, 1987, TERATOCARCINOMAS EMB, P113; CAPECCHI MR, 1989, SCIENCE, V244, P1288, DOI 10.1126/science.2660260; CHIAIA NL, 1992, NEUROSCIENCE, V49, P141, DOI 10.1016/0306-4522(92)90082-D; CHIAIA NL, 1993, J NEUROPHYSIOL, V69, P1171, DOI 10.1152/jn.1993.69.4.1171; CHIAIA NL, 1992, DEV BRAIN RES, V66, P244, DOI 10.1016/0165-3806(92)90086-C; CHIAIA NL, 1992, J NEUROSCI, V12, P62; CLINE HT, 1987, P NATL ACAD SCI USA, V84, P4342, DOI 10.1073/pnas.84.12.4342; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; CROSSIN KL, 1989, DEV BIOL, V136, P381, DOI 10.1016/0012-1606(89)90264-9; DURHAM D, 1984, J COMP NEUROL, V223, P424, DOI 10.1002/cne.902230308; EASTER SS, 1993, J NEUROSCI, V13, P285; ERZURUMLU RS, 1990, DEV BRAIN RES, V56, P229; ERZURUMLU RS, 1992, J NEUROSCI, V12, P3946; FAVARON M, 1993, NEUROREPORT, V4, P1171; GODEMENT P, 1987, DEVELOPMENT, V101, P697; GOODMAN CS, 1993, CELL, V72, P77, DOI 10.1016/S0092-8674(05)80030-3; GOSSLER A, 1986, P NATL ACAD SCI USA, V83, P9065, DOI 10.1073/pnas.83.23.9065; GWAG BJ, 1993, NEUROREPORT, V5, P125, DOI 10.1097/00001756-199311180-00007; GWAG BJ, 1993, EXP NEUROL, V121, P160, DOI 10.1006/exnr.1993.1083; HAHM JO, 1991, NATURE, V351, P568, DOI 10.1038/351568a0; HENDERSON TA, 1992, DEV BRAIN RES, V66, P146, DOI 10.1016/0165-3806(92)90152-M; HENDERSON TA, 1993, J COMP NEUROL, V336, P243, DOI 10.1002/cne.903360207; HENDERSON TA, 1994, IN PRESS J NEUROSCI; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; JEANMONOD D, 1981, NEUROSCIENCE, V6, P1503, DOI 10.1016/0306-4522(81)90222-0; JHAVERI S, 1991, P NATL ACAD SCI USA, V88, P4489, DOI 10.1073/pnas.88.10.4489; Jhaveri S, 1992, DEV CENTRAL NERVOUS, P167; Katz L C, 1993, Curr Opin Neurobiol, V3, P93, DOI 10.1016/0959-4388(93)90041-V; KATZ LC, 1993, NATURE, V364, P578, DOI 10.1038/364578a0; KLEINSCHMIDT A, 1987, SCIENCE, V238, P355, DOI 10.1126/science.2443978; MA PM, 1993, J COMP NEUROL, V327, P376, DOI 10.1002/cne.903270306; MA PM, 1991, J COMP NEUROL, V309, P161, DOI 10.1002/cne.903090202; MA PM, 1984, BRAIN RES, V306, P374, DOI 10.1016/0006-8993(84)90390-1; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; Schlaggar B L, 1993, Perspect Dev Neurobiol, V1, P81; SCHLAGGAR BL, 1993, NATURE, V364, P623, DOI 10.1038/364623a0; SHATZ CJ, 1990, NEURON, V5, P745, DOI 10.1016/0896-6273(90)90333-B; SIMON DK, 1992, P NATL ACAD SCI USA, V89, P10593, DOI 10.1073/pnas.89.22.10593; STAINIER DYR, 1990, P NATL ACAD SCI USA, V87, P923, DOI 10.1073/pnas.87.3.923; VANDERLOOS H, 1985, DEV ORG PROCESSING S, P53; VONGDOKMAI R, 1980, J COMP NEUROL, V191, P283, DOI 10.1002/cne.901910209; WHITFIELD HJ, 1990, CELL MOL NEUROBIOL, V10, P145, DOI 10.1007/BF00733641; WONGRILEY M, 1979, BRAIN RES, V171, P11, DOI 10.1016/0006-8993(79)90728-5; Woolsey T.A., 1990, P461; ZAFRA F, 1991, P NATL ACAD SCI USA, V88, P10037, DOI 10.1073/pnas.88.22.10037	52	391	395	0	5	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 11	1994	76	3					427	437		10.1016/0092-8674(94)90108-2	http://dx.doi.org/10.1016/0092-8674(94)90108-2			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	8313466				2022-12-01	WOS:A1994MX20700005
J	DEBELLE, JS; HEISENBERG, M				DEBELLE, JS; HEISENBERG, M			ASSOCIATIVE ODOR LEARNING IN DROSOPHILA ABOLISHED BY CHEMICAL ABLATION OF MUSHROOM BODIES	SCIENCE			English	Article							CYCLIC-AMP PHOSPHODIESTERASE; DEPENDENT PROTEIN-KINASE; SHORT-TERM-MEMORY; POSTEMBRYONIC NEUROBLASTS; APIS-MELLIFERA; MELANOGASTER; MUTANTS; GENE; BRAIN; RUTABAGA	The corpora pedunculata, or mushroom bodies (MBs), in the brain of Drosophila melanogaster adults consist of approximately 2500 parallel Kenyon cell fibers derived from four MB neuroblasts. Hydroxyurea fed to newly hatched larvae selectively deletes these cells, resulting in complete, precise MB ablation. Adult flies developing without MBs behave normally in most respects, but are unable to perform in a classical conditioning paradigm that tests associative learning of odor cues and electric shock. This deficit cannot be attributed to reductions in olfactory sensitivity, shock reactivity, or locomotor behavior. The results demonstrate that MBs mediate associative odor learning in flies.			DEBELLE, JS (corresponding author), UNIV WURZBURG, LEHRSTUHL GENET, THEODOR BOVERI INST BIOWISSENSCH, AM HUBLAND, D-97074 WURZBURG, GERMANY.							ASZODI A, 1991, P NATL ACAD SCI USA, V88, P5832, DOI 10.1073/pnas.88.13.5832; ASZTALOS Z, 1993, J NEUROSCI, V13, P924; BAILEY CH, 1993, ANNU REV PHYSIOL, V55, P397, DOI 10.1146/annurev.ph.55.030193.002145; BALLING A, 1987, J NEUROGENET, V4, P65, DOI 10.3109/01677068709102334; BELLEN HJ, 1987, GENETICS, V115, P153; BOYNTON S, 1992, GENETICS, V131, P655; BYERS D, 1981, NATURE, V289, P79, DOI 10.1038/289079a0; CORFAS G, 1991, P NATL ACAD SCI USA, V88, P7252, DOI 10.1073/pnas.88.16.7252; DEBELLE JS, 1993, J NEUROGENET, V8, P225; DEBELLE JS, UNPUB; DRAIN P, 1991, NEURON, V6, P71, DOI 10.1016/0896-6273(91)90123-H; DUDAI Y, 1988, ANNU REV NEUROSCI, V11, P537, DOI 10.1146/annurev.ne.11.030188.002541; DURST C, 1993, GENE BRAIN BEHAVIOUR; ERBER J, 1980, PHYSIOL ENTOMOL, V5, P343, DOI 10.1111/j.1365-3032.1980.tb00244.x; ERBER J, 1987, ARTHROPOD BRAIN ITS, pCH21; GOODWIN SF, 1993, J NEUROGENET, V8, P232; GRIFFITH LC, 1993, NEURON, V10, P501, DOI 10.1016/0896-6273(93)90337-Q; HAMMER M, 1993, NATURE, V366, P59, DOI 10.1038/366059a0; HAN PL, 1992, NEURON, V9, P619, DOI 10.1016/0896-6273(92)90026-A; HAWKINS RD, 1993, ANNU REV NEUROSCI, V16, P625, DOI 10.1146/annurev.ne.16.030193.003205; HEISENBERG M, 1989, FORTS ZOOL, V37, P3; HEISENBERG M, 1985, J NEUROGENET, V2, P1, DOI 10.3109/01677068509100140; HEISENBERG M, 1979, Z NATURFORSCH C, V34, P143; HEISENBERG M, 1980, DEV NEUROBIOLOGY DRO, P373; ITO K, 1992, DEV BIOL, V149, P134, DOI 10.1016/0012-1606(92)90270-Q; LEVIN LR, 1992, CELL, V68, P479, DOI 10.1016/0092-8674(92)90185-F; LIVINGSTONE MS, 1984, CELL, V37, P205, DOI 10.1016/0092-8674(84)90316-7; MAUELSHAGEN J, 1993, J NEUROPHYSIOL, V69, P609, DOI 10.1152/jn.1993.69.2.609; MENZEL R, 1991, BEHAVIOUR AND PHYSIOLOGY OF BEES, P323; MOBBS PG, 1982, PHILOS T ROY SOC B, V298, P309, DOI 10.1098/rstb.1982.0086; MULLER U, 1989, J NEUROGENET, V6, P95, DOI 10.3109/01677068909107104; NIGHORN A, 1991, NEURON, V6, P455, DOI 10.1016/0896-6273(91)90253-V; PROKOP A, 1991, DEVELOPMENT, V111, P79; PROKOP A, IN PRESS DEV BIOL; QUI Y, 1991, J MOL BIOL, V222, P553; SCHURMANN FW, 1987, ARTHROPOD BRAIN ITS, pCH11; SOKOLOWSKI MB, 1984, ANIM BEHAV, V32, P645, DOI 10.1016/S0003-3472(84)80139-6; SQUIRE LR, 1992, PSYCHOL REV, V99, P195, DOI 10.1037/0033-295X.99.2.195; STOCKER RF, 1990, CELL TISSUE RES, V262, P9, DOI 10.1007/BF00327741; STRAUSFELD NJ, 1976, ATLAS INSECT BRAIN, pCH3; STRAUSS R, 1993, J NEUROSCI, V13, P1852, DOI 10.1523/jneurosci.13-05-01852.1993; Strauss R, COMMUNICATION; TECHNAU G, 1982, NATURE, V295, P405, DOI 10.1038/295405a0; Technau GM, 1984, J NEUROGENET, V1, P113, DOI 10.3109/01677068409107077; TECHNAU GM, 1983, THESIS U WURZBURG; TIMSON J, 1975, MUTAT RES, V32, P115, DOI 10.1016/0165-1110(75)90002-0; TRUMAN JW, 1988, DEV BIOL, V125, P145, DOI 10.1016/0012-1606(88)90067-X; TULLY T, 1985, J COMP PHYSIOL A, V157, P263, DOI 10.1007/BF01350033; TULLY T, 1991, TRENDS NEUROSCI, V14, P163, DOI 10.1016/0166-2236(91)90096-D; TULLY T, 1991, PERSPECTIVES COGNITI, P46; WITHERS GS, 1993, NATURE, V364, P238, DOI 10.1038/364238a0; WOLF R, 1991, J COMP PHYSIOL A, V169, P699; ZAR JH, 1984, BIOSTATISTICAL ANAL, pCH8; ZAR JH, 1985, SAS USERS GUIDE STAT; ZHONG Y, 1992, J NEUROSCI, V12, P644	55	598	606	3	74	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	FEB 4	1994	263	5147					692	695		10.1126/science.8303280	http://dx.doi.org/10.1126/science.8303280			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8303280				2022-12-01	WOS:A1994MU96400053
J	RAINNIE, DG; GRUNZE, HCR; MCCARLEY, RW; GREENE, RW				RAINNIE, DG; GRUNZE, HCR; MCCARLEY, RW; GREENE, RW			ADENOSINE INHIBITION OF MESOPONTINE CHOLINERGIC NEURONS - IMPLICATIONS FOR EEG AROUSAL	SCIENCE			English	Article							CENTRAL-NERVOUS-SYSTEM; SLOW-WAVE SLEEP; CEREBRAL-CORTEX; BRAIN; CAFFEINE; RECEPTOR; SLICES; NUCLEI; RATS; MECHANISMS	Increased discharge activity of mesopontine cholinergic neurons participates in the production of electroencephalographic (EEG) arousal; such arousal diminishes as a function of the duration of prior wakefulness or of brain hyperthermia. Whole-cell and extracellular recordings in a brainstem slice show that mesopontine cholinergic neurons are under the tonic inhibitory control of endogenous adenosine, a neuromodulator released during brain metabolism. This inhibitory tone is mediated postsynaptically by an inwardly rectifying potassium conductance and by an inhibition of the hyperpolarization-activated current. These data provide a coupling mechanism linking neuronal control of EEG arousal with the effects of prior wakefulness, brain hyperthermia, and the use of the adenosine receptor blockers caffeine and theophylline.	HARVARD UNIV, DEPT PSYCHIAT, CAMBRIDGE, MA 02138 USA; VET ADM MED CTR, BROCKTON, MA 02401 USA	Harvard University; US Department of Veterans Affairs; Veterans Health Administration (VHA)			Rainnie, Donald/L-3853-2016; Grunze, Heinz/J-1198-2019; McCarley, Robert W/N-5562-2014; Shenton, Martha/V-8780-2019	Rainnie, Donald/0000-0003-0758-0530; Grunze, Heinz/0000-0003-4712-8979; McCarley, Robert W/0000-0001-5705-7495; Greene, Robert/0000-0003-1355-9797	NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH039683] Funding Source: NIH RePORTER; NIMH NIH HHS [R01 MH039683] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BERNE RM, 1982, CEREBRAL HYPOXIA PAT, P89; BLANTON MG, 1989, J NEUROSCI METH, V30, P203, DOI 10.1016/0165-0270(89)90131-3; Borbely A A, 1982, Hum Neurobiol, V1, P195; BRUNS RF, 1981, BIOCHEM PHARMACOL, V30, P325, DOI 10.1016/0006-2952(81)90062-9; BRUNS RF, 1980, P NATL ACAD SCI-BIOL, V77, P5547, DOI 10.1073/pnas.77.9.5547; BRUNS RF, 1986, MOL PHARMACOL, V29, P331; CHOI OH, 1988, LIFE SCI, V43, P387, DOI 10.1016/0024-3205(88)90517-6; DESANCHEZ VC, 1993, BRAIN RES, V612, P115, DOI 10.1016/0006-8993(93)91651-8; DUNWIDDIE TV, 1985, INT REV NEUROBIOL, V27, P63, DOI 10.1016/S0074-7742(08)60556-5; DUNWIDDIE TV, 1981, N-S ARCH PHARMACOL, V316, P326, DOI 10.1007/BF00501365; FEINBERG I, 1985, ELECTROEN CLIN NEURO, V61, P134, DOI 10.1016/0013-4694(85)91051-X; FREIL DD, 1992, J PHYSL, V450, P217; Geiger J., 1990, ADENOSINE ADENOSINE; GREENE RW, 1985, BRIT J PHARMACOL, V85, P163, DOI 10.1111/j.1476-5381.1985.tb08843.x; GREENE RW, 1991, PROG NEUROBIOL, V36, P329, DOI 10.1016/0301-0082(91)90005-L; GU JG, 1992, J NEUROCHEM, V58, P1699, DOI 10.1111/j.1471-4159.1992.tb10043.x; HALLIWELL JV, 1982, BRAIN RES, V250, P71, DOI 10.1016/0006-8993(82)90954-4; HORNE J, 1992, EXPERIENTIA, V48, P941, DOI 10.1007/BF01919141; KAMONDI A, 1992, J NEUROPHYSIOL, V68, P1359, DOI 10.1152/jn.1992.68.4.1359; KUBA K, 1980, J PHYSL, V298, P547; LUEBKE JI, 1993, J NEUROPHYSIOL, V70, P2128, DOI 10.1152/jn.1993.70.5.2128; LUEBKE JI, 1992, P NATL ACAD SCI USA, V89, P743, DOI 10.1073/pnas.89.2.743; MADSEN PL, 1991, J APPL PHYSIOL, V70, P2597, DOI 10.1152/jappl.1991.70.6.2597; MAQUET P, 1992, BRAIN RES, V571, P149, DOI 10.1016/0006-8993(92)90522-B; MAYER ML, 1983, J PHYSIOL-LONDON, V340, P19, DOI 10.1113/jphysiol.1983.sp014747; MCCORMICK DA, 1990, J PHYSIOL-LONDON, V431, P291, DOI 10.1113/jphysiol.1990.sp018331; MCGINTY D, 1990, TRENDS NEUROSCI, V13, P480, DOI 10.1016/0166-2236(90)90081-K; MCILWAIN H, 1986, J NEUROBIOL, V17, P39, DOI 10.1002/neu.480170105; MCPHERSON PS, 1991, NEURON, V7, P17, DOI 10.1016/0896-6273(91)90070-G; NEERING IR, 1984, NATURE, V309, P158, DOI 10.1038/309158a0; PAPE HC, 1992, J PHYSIOL-LONDON, V447, P729, DOI 10.1113/jphysiol.1992.sp019026; PONS F, 1980, J NEUROCHEM, V34, P1319, DOI 10.1111/j.1471-4159.1980.tb09977.x; PULL I, 1972, BIOCHEM J, V130, P975, DOI 10.1042/bj1300975; RAINNIE DG, UNPUB; SATTIN A, 1970, MOL PHARMACOL, V6, P13; SCHRADER J, 1980, PFLUG ARCH EUR J PHY, V387, P245, DOI 10.1007/BF00580977; SEMBA K, 1989, PROG BRAIN RES, V79, P37; SNYDER SH, 1985, ANNU REV NEUROSCI, V8, P103; STERIADE M, 1990, J NEUROSCI, V10, P2541; STERIADE M, 1990, J NEUROSCI, V10, P2560; STERIADE M, 1988, NEUROSCIENCE, V25, P47, DOI 10.1016/0306-4522(88)90006-1; STERIADE M, 1993, SCIENCE, V262, P679, DOI 10.1126/science.8235588; VANWYLEN DGL, 1986, J CEREBR BLOOD F MET, V6, P522, DOI 10.1038/jcbfm.1986.97; VINCENT SR, 1983, NEUROSCI LETT, V43, P31, DOI 10.1016/0304-3940(83)90124-6; VIRUS RM, 1990, NEUROPSYCHOPHARMACOL, V3, P243; WINN HR, 1980, CIRC RES, V47, P568, DOI 10.1161/01.RES.47.4.568; WU PH, 1984, NEUROCHEM INT, V6, P613, DOI 10.1016/0197-0186(84)90043-3; YANIK G, 1987, BRAIN RES, V403, P177, DOI 10.1016/0006-8993(87)90141-7	48	262	268	0	13	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	1994	263	5147					689	692		10.1126/science.8303279	http://dx.doi.org/10.1126/science.8303279			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8303279	Green Accepted			2022-12-01	WOS:A1994MU96400052
J	HUTSON, HR; ANGLIN, D; PRATTS, MJ				HUTSON, HR; ANGLIN, D; PRATTS, MJ			ADOLESCENTS AND CHILDREN INJURED OR KILLED IN DRIVE-BY SHOOTINGS IN LOS-ANGELES	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FIREARM	Background. Drive-by shootings by violent street gangs contribute to early morbidity and mortality among adolescents and children in Los Angeles. This study attempted to determine the frequency of this problem and the population at greatest risk, We also studied the most frequently injured areas of the body, the seasons in which the most shootings occurred, the most common sites for drive-by shootings, and the types of firearms used. Methods. We retrospectively reviewed the files of the Gang Information Section of the Los Angeles Police Department to identify all drive-by shootings in Los Angeles in 1991 in which a child or adolescent under the age of 18 was shot at, injured, or killed. Results. A total of 677 adolescents and children were shot at, among whom 429 (63 percent) had gunshot wounds and 36 (5.3 percent) died from their injuries. Three hundred three of those with gunshot wounds (71 percent) were gang members. Arms and legs were the areas of the body most commonly injured. Handguns were the most frequently used type of firearm. All the homicide victims were African American or Hispanic, and 97 percent were boys. African American and Hispanic children and adolescents, especially male gang members, had a significantly higher risk than their Asian and white counterparts of injury and death from drive-by shootings in Los Angeles (P<0.001). Conclusions. Drive-by shootings involving adolescents and children are frequent in Los Angeles. Although Los Angeles may be an atypical case, understanding why violent street gangs form, preventing causes of violence, and limiting access to firearms are essential steps in preventing this serious problem.			HUTSON, HR (corresponding author), UNIV SO CALIF,LOS ANGELES CTY MED CTR,DEPT EMERGENCY MED,RM 1011,1200 N STATE ST,LOS ANGELES,CA 90033, USA.							BAR JH, 1984, BIOSTATISTICAL ANAL; CHRISTOFFEL KK, 1991, PEDIATRICS, V88, P294; DEAN AG, 1990, EPIINFO VERSION 5 WO; GROVES BM, 1993, JAMA-J AM MED ASSOC, V269, P262, DOI 10.1001/jama.269.2.262; HUTSON HR, 1992, ANN EMERG MED, V21, P1234; JACKSON RK, 1991, UNDERSTANDING STREET; JUAREZ PD, 1992, SUBSTANCE ABUSE GANG, P43; KELLERMANN AL, 1991, ANNU REV PUBL HEALTH, V12, P17; KLEIN MW, 1991, CRIMINOLOGY, V29, P701; MEEHAN PJ, 1992, AM J DIS CHILD, V146, P683, DOI 10.1001/archpedi.1992.02160180041014; Miller WB., 1990, GANGS AM, P263; MORALES A, 1992, SUBSTANCE ABUSE GANG, P105; PROTHROWSTITH D, 1991, DEADLY CONSEQUENCES, P11; Pynoos R.S., 1988, J TRAUMA STRESS, V1, P445, DOI [DOI 10.1002/JTS.2490010406, https://doi.org/10.1002/jts.2490010406]; TERET SP, 1992, JAMA-J AM MED ASSOC, V267, P3073, DOI 10.1001/jama.267.22.3073; Vigil J.D., 1988, BARRIO GANGS STREET; 1992, PEDIATRICS, V89, P784; 1990, 8 LOS ANG POL DEP OR; 1993, INTELLIGENCE OPERATI, P2; 1992, PUBLICATION BUREAU C, V16; 1991, PUBLIC HLTH REP, V106, P225	21	44	44	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 3	1994	330	5					324	327		10.1056/NEJM199402033300506	http://dx.doi.org/10.1056/NEJM199402033300506			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU489	8277953				2022-12-01	WOS:A1994MU48900006
J	RUNYON, BA				RUNYON, BA			CARE OF PATIENTS WITH ASCITES	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							SPONTANEOUS BACTERIAL PERITONITIS; BLOOD CULTURE BOTTLES; CHRONIC LIVER-DISEASE; LARGE-VOLUME PARACENTESIS; CIRRHOTIC-PATIENTS; INTRAVENOUS ALBUMIN; TENSE ASCITES; REFRACTORY ASCITES; BACTERIOLOGICAL DIAGNOSIS; THERAPEUTIC PARACENTESIS		UNIV IOWA,COLL MED,DEPT INTERNAL MED,IOWA CITY,IA 52242	University of Iowa								AGUADO JM, 1990, J CLIN GASTROENTEROL, V12, P550, DOI 10.1097/00004836-199010000-00013; AKRIVIADIS EA, 1990, GASTROENTEROLOGY, V98, P127, DOI 10.1016/0016-5085(90)91300-U; ALBILLOS A, 1990, GASTROENTEROLOGY, V98, P134, DOI 10.1016/0016-5085(90)91301-L; ANTILLON MR, 1991, GASTROENTEROLOGY, V101, P1455, DOI 10.1016/0016-5085(91)90116-3; Arroyo V, 1989, GASTROENTEROL INT, V2, P195; ASCIONE A, 1990, GASTROENTEROL INT, V3, P120; BERNARDI M, 1985, GUT, V26, P629, DOI 10.1136/gut.26.6.629; BOBADILLA M, 1989, J CLIN MICROBIOL, V27, P2145, DOI 10.1128/JCM.27.10.2145-2147.1989; BORIES P, 1986, J HEPATOL, V3, P212, DOI 10.1016/S0168-8278(86)80028-9; BOYER TD, 1979, GASTROENTEROLOGY, V77, P215; BRUNO S, 1992, BRIT MED J, V304, P1655, DOI 10.1136/bmj.304.6843.1655; CADRANEL JF, 1992, INT J ARTIF ORGANS, V15, P432, DOI 10.1177/039139889201500711; CAMERON JL, 1976, ANN SURG, V184, P587, DOI 10.1097/00000658-197611000-00009; CASTELLOTE J, 1990, AM J GASTROENTEROL, V85, P1605; Chetty R, 1990, Cytopathology, V1, P233, DOI 10.1111/j.1365-2303.1990.tb00352.x; COHN JN, 1988, AM J CARDIOL, V62, pA25, DOI 10.1016/S0002-9149(88)80081-X; CONN HO, 1993, HEPATOLOGY, V17, P148, DOI 10.1002/hep.1840170125; CORREIA JP, 1975, MED CLIN N AM, V59, P963, DOI 10.1016/S0025-7125(16)31995-2; DAMICO G, 1986, DIGEST DIS SCI, V31, P468, DOI 10.1007/BF01320309; DASKALOPOULOS G, 1987, GASTROENTEROLOGY, V92, P1859, DOI 10.1016/0016-5085(87)90616-0; FOGEL MR, 1981, J CLIN GASTROENTEROL, V3, P73, DOI 10.1097/00004836-198100031-00016; GARRISON RN, 1986, ANN SURG, V203, P644, DOI 10.1097/00000658-198606000-00009; GATTA A, 1991, HEPATOLOGY, V14, P231, DOI 10.1016/0270-9139(91)91408-S; GINES P, 1988, GASTROENTEROLOGY, V94, P1493, DOI 10.1016/0016-5085(88)90691-9; GINES P, 1987, GASTROENTEROLOGY, V93, P234, DOI 10.1016/0016-5085(87)91007-9; GINES P, 1987, HEPATOLOGY, V7, P122, DOI 10.1002/hep.1840070124; GINES P, 1991, NEW ENGL J MED, V325, P829, DOI 10.1056/NEJM199109193251201; GOLDBERG BB, 1970, RADIOLOGY, V96, P15, DOI 10.1148/96.1.15; HOEFS JC, 1983, J LAB CLIN MED, V102, P260; Kammerer J, 1982, Med Chir Dig, V11, P243; KAO HW, 1985, HEPATOLOGY, V5, P403, DOI 10.1002/hep.1840050310; KOCEN RS, 1963, LANCET, V1, P527; MAATHUIS JB, 1978, J ENDOCRINOL, V76, P123, DOI 10.1677/joe.0.0760123; MAUK PM, 1988, ARCH INTERN MED, V148, P1577, DOI 10.1001/archinte.148.7.1577; MCVAY PA, 1991, TRANSFUSION, V31, P164, DOI 10.1046/j.1537-2995.1991.31291142949.x; PEREZAYUSO RM, 1983, GASTROENTEROLOGY, V84, P961; PINTO PC, 1988, HEPATOLOGY, V8, P207, DOI 10.1002/hep.1840080202; PINZELLO G, 1983, HEPATOLOGY, V3, P545; PLANAS R, 1990, GASTROENTEROLOGY, V99, P1736, DOI 10.1016/0016-5085(90)90481-F; POCKROS PJ, 1986, GASTROENTEROLOGY, V90, P1827, DOI 10.1016/0016-5085(86)90249-0; POCKROS PJ, 1992, GASTROENTEROLOGY, V103, P1302, DOI 10.1016/0016-5085(92)91520-E; REYNOLDS TB, 1960, NEW ENGL J MED, V263, P734, DOI 10.1056/NEJM196010132631505; RUNYON BA, 1988, HEPATOLOGY, V8, P1104, DOI 10.1002/hep.1840080521; RUNYON BA, 1990, J CLIN MICROBIOL, V28, P2811, DOI 10.1128/JCM.28.12.2811-2812.1990; RUNYON BA, 1988, J CLIN GASTROENTEROL, V10, P410, DOI 10.1097/00004836-198808000-00013; RUNYON BA, 1992, ANN INTERN MED, V117, P215, DOI 10.7326/0003-4819-117-3-215; RUNYON BA, 1986, GASTROENTEROLOGY, V91, P1343, DOI 10.1016/0016-5085(86)90185-X; RUNYON BA, 1986, HEPATOLOGY, V6, P1443, DOI 10.1002/hep.1840060649; RUNYON BA, 1986, J HEPATOL, V3, P219, DOI 10.1016/S0168-8278(86)80029-0; RUNYON BA, 1988, GASTROENTEROLOGY, V95, P1351, DOI 10.1016/0016-5085(88)90372-1; RUNYON BA, 1987, ARCH INTERN MED, V147, P73, DOI 10.1001/archinte.147.1.73; RUNYON BA, 1986, ARCH INTERN MED, V146, P2259, DOI 10.1001/archinte.146.11.2259; RUNYON BA, 1991, HEPATOLOGY, V13, P929, DOI 10.1002/hep.1840130521; RUNYON BA, 1989, GASTROENTEROLOGY, V97, P158, DOI 10.1016/0016-5085(89)91430-3; RUNYON BA, 1987, J CLIN GASTROENTEROL, V9, P172, DOI 10.1097/00004836-198704000-00012; RUNYON BA, 1992, HEPATOLOGY, V16, pA85; RUNYON BA, 1991, TXB GASTROENTEROLOGY, P846; Runyon BA, 1991, TXB GASTROENTEROLOGY, P2455; SHEAR L, 1970, NEW ENGL J MED, V282, P1391, DOI 10.1056/NEJM197006182822502; SIERSEMA PD, 1992, J CLIN MICROBIOL, V30, P667, DOI 10.1128/JCM.30.3.667-669.1992; SMART HL, 1990, J HEPATOL, V10, P191, DOI 10.1016/0168-8278(90)90051-R; SORIANO G, 1991, GASTROENTEROLOGY, V100, P477, DOI 10.1016/0016-5085(91)90219-B; STANLEY MM, 1989, NEW ENGL J MED, V321, P1632, DOI 10.1056/NEJM198912143212403; STARZL TE, 1989, NEW ENGL J MED, V321, P1014, DOI 10.1056/NEJM198910123211505; STARZL TE, 1989, NEW ENGL J MED, V321, P1092, DOI 10.1056/NEJM198910193211606; SUNGAILA I, 1992, GASTROENTEROLOGY, V102, P1680, DOI 10.1016/0016-5085(92)91730-R; TITO L, 1990, GASTROENTEROLOGY, V98, P146, DOI 10.1016/0016-5085(90)91303-N; YAMADA S, 1970, GASTROENTEROLOGY, V59, P833	68	242	260	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 3	1994	330	5					337	342		10.1056/NEJM199402033300508	http://dx.doi.org/10.1056/NEJM199402033300508			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU489	8277955				2022-12-01	WOS:A1994MU48900008
J	CARO, TM; LAURENSON, MK				CARO, TM; LAURENSON, MK			ECOLOGICAL AND GENETIC-FACTORS IN CONSERVATION - A CAUTIONARY TALE	SCIENCE			English	Article							ACINONYX-JUBATUS; POPULATION; CHEETAHS; BOTTLENECKS; PREVALENCE; RHINOCEROS; PATTERNS		GAME CONSERVANCY, UPLAND RES GRP, NEWTONMORE PH20 1BE, INVERNESS, SCOTLAND		CARO, TM (corresponding author), UNIV CALIF DAVIS, DEPT WILDLIFE & FISHERIES BIOL, DAVIS, CA 95616 USA.							Allendorf F.W., 1986, P57; ALLENDORF FW, 1991, INTRO EVOLUTIONARY E, P57; AMMANN K, 1987, BEHAV ECOL SOCIOBIOL, V20, P351; Burney D. A., 1980, THESIS U NAIROBI KEN; CARO TM, 1993, ZOO BIOL, V12, P19, DOI 10.1002/zoo.1430120105; CARO TM, IN PRESS CHEETAHS SE; DINERSTEIN E, 1990, CONSERV BIOL, V4, P417, DOI 10.1111/j.1523-1739.1990.tb00316.x; EHRLICH P R, 1987, Conservation Biology, V1, P122, DOI 10.1111/j.1523-1739.1987.tb00021.x; EVERMANN JF, 1993, ZOO BIOL, V12, P125, DOI 10.1002/zoo.1430120111; FRAMEG, 1981, SWIFT ENDURING CHEET; FRANCE RL, 1993, CONSERV BIOL, V7, P184, DOI 10.1046/j.1523-1739.1993.07010184.x; Franklin I.R., 1980, CONSERVATION BIOL EV, P135; GREENWOOD PJ, 1978, NATURE, V271, P52, DOI 10.1038/271052a0; HARCOURT S, 1991, NATURE, V354, P10, DOI 10.1038/354010a0; HEENEY JL, 1990, J VIROL, V64, P1964, DOI 10.1128/JVI.64.5.1964-1972.1990; HILL JL, 1974, SCIENCE, V186, P1042, DOI 10.1126/science.186.4168.1042; HORZINEK M, 1978, AM J VET RES, V40, P1387; Lacy R.C., 1989, P83; LANDE R, 1988, SCIENCE, V241, P1455, DOI 10.1126/science.3420403; LAURENSON MK, 1992, RES EXPLOR, V8, P64; LAURENSON MK, IN PRESS SERENGETI, V2; LAURENSON MK, IN PRESS J ZOOL; LAURENSON MK, IN PRESS ANIM BEHAV; LAURENSON MK, UNPUB; LEADERWILLIAMS N, 1990, J APPL ECOL, V27, P1055, DOI 10.2307/2404395; LEBERG PL, 1993, CONSERV BIOL, V7, P194, DOI 10.1046/j.1523-1739.1993.07010194.x; LOUDON A.S.I., 1985, S ZOOLOGICAL SOC LON, V54, P183; LOVEJOY TE, 1990, J APPL ECOL, V27, P257; MARKER L, 1989, ZOO BIOL, V8, P3, DOI 10.1002/zoo.1430080103; MARKERKRAUS L, 1990, INT CHEETAH STUDBOOK; MYERS N, 1975, INT UNION CONSERV NA, V8; NEVO E, 1978, THEOR POPUL BIOL, V13, P121, DOI 10.1016/0040-5809(78)90039-4; NEWMAN A, 1985, J MAMMAL, V66, P256, DOI 10.2307/1381238; OBRIEN SJ, 1985, SCIENCE, V227, P1428, DOI 10.1126/science.2983425; OBRIEN SJ, 1983, SCIENCE, V221, P459, DOI 10.1126/science.221.4609.459; OBRIEN SJ, 1987, P NATL ACAD SCI USA, V84, P508, DOI 10.1073/pnas.84.2.508; OLMSTED RA, 1992, J VIROL, V66, P6008, DOI 10.1128/JVI.66.10.6008-6018.1992; PACKER C, 1991, CONSERV BIOL, V5, P219, DOI 10.1111/j.1523-1739.1991.tb00127.x; PIMM SL, 1989, TRENDS ECOL EVOL, V4, P176, DOI 10.1016/0169-5347(89)90123-7; RALLS K, 1983, BIOL CONSERV, V25, P209, DOI 10.1016/0006-3207(83)90037-X; RALLS K, 1979, SCIENCE, V206, P1101, DOI 10.1126/science.493997; RALLS K, 1988, Conservation Biology, V2, P185, DOI 10.1111/j.1523-1739.1988.tb00169.x; RIBBLE DO, 1992, CAN J ZOOL, V70, P820, DOI 10.1139/z92-116; SAVIDGE JA, 1987, ECOLOGY, V68, P660, DOI 10.2307/1938471; Schonewald-Cox C., 1983, GENETICS CONSERVATIO; SHAFFER ML, 1981, BIOSCIENCE, V31, P131, DOI 10.2307/1308256; SIMBERLOFF D, 1988, ANNU REV ECOL SYST, V19, P473, DOI 10.1146/annurev.ecolsys.19.1.473; SPENCER JA, 1991, J WILDLIFE DIS, V27, P578, DOI 10.7589/0090-3558-27.4.578; STANDER PE, 1991, THESIS CAMBRIDGE U; SUNQUIST F, 1992, WILDL CONS, V95, P38; WESTERN D, 1989, CONSERVATION 21ST CE; WILDT DE, 1993, ZOO BIOL, V12, P45, DOI 10.1002/zoo.1430120107; WILSON E O, 1992; Wright S., 1977, EVOLUTION GENETICS P, V3	54	254	266	1	115	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 28	1994	263	5146					485	486		10.1126/science.8290956	http://dx.doi.org/10.1126/science.8290956			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT966	8290956				2022-12-01	WOS:A1994MT96600021
J	LUTZ, GJ; ROME, LC				LUTZ, GJ; ROME, LC			BUILT FOR JUMPING - THE DESIGN OF THE FROG MUSCULAR SYSTEM	SCIENCE			English	Article							TWITCH MUSCLE-FIBERS; CONTRACTILE PROPERTIES; SWIMMING CARP; RANA-PIPIENS; TEMPERATURE; PERFORMANCE; COMPENSATION; VARIETIES; VELOCITY; EXTENT	Frogs must generate a high level of mechanical power when they jump. The muscular system of frogs that jump is presumably designed to deliver these high powers. The length changes and activation pattern that muscles undergo during jumping were measured, and isolated muscle bundles were driven through this in vivo pattern. During jumping muscles generated maximum power. Specifically the muscle fibers (i) operated at optimal sarcomere lengths, (ii) operated at optimal shortening velocities, and (iii) were maximally activated during power generation. Thus, many different parameters must have evolved in concert to produce a system capable of this explosive jumping movement.	UNIV PENN,DEPT BIOL,PHILADELPHIA,PA 19104; MARINE BIOL LAB,WOODS HOLE,MA 02543	University of Pennsylvania; Marine Biological Laboratory - Woods Hole					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR038404, R01AR038404] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR38404] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALEXANDER RM, 1982, J ZOOL, V198, P293, DOI 10.1111/j.1469-7998.1982.tb02077.x; BAGNI MA, 1988, BIOPHYS J, V54, P1105, DOI 10.1016/S0006-3495(88)83046-7; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; CALOW LJ, 1973, J ZOOL, V171, P293; EDMAN KAP, 1988, J PHYSIOL-LONDON, V395, P679, DOI 10.1113/jphysiol.1988.sp016941; FEDAK MA, 1982, J EXP BIOL, V79, P23; GORDON AM, 1966, J PHYSIOL-LONDON, V184, P170, DOI 10.1113/jphysiol.1966.sp007909; Hill AV, 1938, PROC R SOC SER B-BIO, V126, P136, DOI 10.1098/rspb.1938.0050; HIRANO M, 1984, J EXP BIOL, V108, P429; HUXLEY AF, 1954, NATURE, V173, P971, DOI 10.1038/173971a0; HUXLEY H, 1954, NATURE, V173, P973, DOI 10.1038/173973a0; JULIAN FJ, 1986, J PHYSIOL-LONDON, V370, P181, DOI 10.1113/jphysiol.1986.sp015929; LANNERGREN J, 1987, J MUSCLE RES CELL M, V8, P260, DOI 10.1007/BF01574594; LANNERGREN J, 1982, ACTA PHYSIOL SCAND, V114, P523, DOI 10.1111/j.1748-1716.1982.tb07020.x; LIEBER RL, 1992, ACTA ANAT, V145, P289; LUTZ GJ, 1988, NATURE, V355, P824; MARSH RL, 1992, NATURE, V357, P411, DOI 10.1038/357411a0; RENAUD JM, 1983, CAN J ZOOL, V61, P1284, DOI 10.1139/z83-172; RENAUD JM, 1984, J EXP BIOL, V108, P57; ROME LC, 1990, J EXP BIOL, V154, P163; ROME LC, 1993, SCIENCE, V261, P340, DOI 10.1126/science.8332898; ROME LC, 1991, AM J PHYSIOL, V260, pC289, DOI 10.1152/ajpcell.1991.260.2.C289; SMITH RS, 1973, J ANAT, V116, P1; Woledge RC., 1985, ENERGETIC ASPECTS MU	24	179	188	4	65	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 21	1994	263	5145					370	372		10.1126/science.8278808	http://dx.doi.org/10.1126/science.8278808			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT034	8278808				2022-12-01	WOS:A1994MT03400031
J	THOMAS, S; ACTON, C; NIXON, J; BATTISTUTTA, D; PITT, WR; CLARK, R				THOMAS, S; ACTON, C; NIXON, J; BATTISTUTTA, D; PITT, WR; CLARK, R			EFFECTIVENESS OF BICYCLE HELMETS IN PREVENTING HEAD-INJURY IN CHILDREN - CASE-CONTROL STUDY	BRITISH MEDICAL JOURNAL			English	Article								Objective-To examine the risk of injury to the head and the effect of wearing helmets in bicycle accidents among children. Design-Case-control study by questionnaire completed by the children and their carers. Setting-Two large children's hospitals in Brisbane, Australia. Subjects-445 children presenting with bicycle related injuries during 15 April 1991 to 30 June 1992. The cases comprised 102 children who had sustained injury to the upper head including the skull, forehead and scalp or loss of consciousness. The controls were 278 cyclists presenting with injuries other than to the head or face. A further 65 children with injuries to the face were considered as an extra comparison group. Main outcome measures-Cause and type of injury, wearing of helmet. Results-Most children (230) were injured after losing control and falling from their bicycle. Only 31 had contact with another moving vehicle. Children with head injury were significantly more likely to have made contact with a moving vehicle than control children (19 (19%) v 12 (4%), P<0.001). Head injuries were more likely to occur on paved surfaces than on grass, gravel, or dirt. Wearing a helmet reduced the risk of head injury by 63% (95% confidence interval 34% to 80%) and of loss of consciousness by 86% (62% to 95%). Conclusions-The risk of head injury in bicycle accidents is reduced among children wearing a helmet. Current helmet design maximises protection in the type of accident most commonly occurring in this study. Legislation enforcing helmet use among children should be considered.	QUEENSLAND RADIUM INST,HERSTON,QLD 4029,AUSTRALIA; QUEENSLAND INST MED RES,EPIDEMIOL UNIT,HERSTON,QLD 4029,AUSTRALIA; UNIV QUEENSLAND,DEPT CHILD HLTH,HERSTON,QLD 4029,AUSTRALIA; MATER CHILDRENS HOSP,BRISBANE,QLD 4101,AUSTRALIA; ROYAL CHILDRENS HOSP,HERSTON,QLD 4029,AUSTRALIA	QIMR Berghofer Medical Research Institute; University of Queensland; Royal Children's Hospital Brisbane								DIX W, 1992, 6 MONTHS REV COMPULS; NIXON J, 1987, BRIT MED J, V294, P1267, DOI 10.1136/bmj.294.6582.1267; PITT WR, 1994, BRIT MED J, V308, P177, DOI 10.1136/bmj.308.6922.177; SACKS JJ, 1991, JAMA-J AM MED ASSOC, V266, P3016, DOI 10.1001/jama.266.21.3016; Schlesselman J.J., 1982, CASE CONTROL STUDIES; THOMPSON RS, 1989, NEW ENGL J MED, V320, P1361, DOI 10.1056/NEJM198905253202101; TRIPPE HR, 1992, BRIT MED J, V305, P843, DOI 10.1136/bmj.305.6858.843; 1989, 24810 AUSTR BUR STAT, P28; 1986, 206311986 STAND AS 1; 1989, BRIT STANDARDS SPECI	10	130	132	0	12	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	1994	308	6922					173	176		10.1136/bmj.308.6922.173	http://dx.doi.org/10.1136/bmj.308.6922.173			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR974	8312768	Green Published			2022-12-01	WOS:A1994MR97400019
J	TORGERSON, DJ; DONALDSON, C				TORGERSON, DJ; DONALDSON, C			AN ECONOMIC-VIEW OF HIGH COMPLIANCE AS A SCREENING OBJECTIVE	BMJ-BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER; TRIAL	Accepted wisdom holds that high compliance is essential for a screening programme to be successful. Indeed, a reason that the national breast screening programme is not routinely offered to women aged 65 or more is on the grounds of predicted poor compliance by older women. Increasing compliance is often associated with increased costs. These costs represent a lost opportunity for screening alternative target populations. We question the need for screening programmes to achieve high compliance, and we argue that a screening programme can be efficient with very low levels of compliance. Adopting compliance as a screening objective and as a measure of the success of screening may be detrimental to the efficiency of a screening programme.			TORGERSON, DJ (corresponding author), UNIV ABERDEEN, HLTH ECON RES UNIT, ABERDEEN AB9 2ZD, SCOTLAND.		Torgerson, David/L-4566-2019	Torgerson, David/0000-0002-1667-4275; Donaldson, Cam/0000-0003-4670-5340				CHAMBERLAIN J, 1993, BRIT MED J, V307, P353, DOI 10.1136/bmj.307.6900.353; CHAMBERLAIN J, 1988, LANCET, V2, P411; CLARK RA, 1992, AM J ROENTGENOL, V158, P527, DOI 10.2214/ajr.158.3.1738989; CONSTANZA ME, 1992, CANCER S, V69, P1925; MOONEY G, 1986, CHOICES HLTH CARE PR; PILL R, 1988, J ROY COLL GEN PRACT, V38, P53; TABAR L, 1989, J EPIDEMIOL COMMUN H, V43, P107, DOI 10.1136/jech.43.2.107; Townsend P., 1988, INEQUALITIES HLTH; WILLIAMS EMI, 1989, BMJ-BRIT MED J, V299, P158, DOI 10.1136/bmj.299.6692.158; WILLIAMS EMI, 1990, J PUBLIC HEALTH MED, V12, P51, DOI 10.1093/oxfordjournals.pubmed.a042506; 1989, GENERAL PRACTICE NAT; 1990, CONSOLIDATED GUIDANC; 1986, BREAST CANCER SCREEN	13	39	39	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JAN 8	1994	308	6921					117	119		10.1136/bmj.308.6921.117	http://dx.doi.org/10.1136/bmj.308.6921.117			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR173	8298385	Green Published			2022-12-01	WOS:A1994MR17300022
J	YANG, JH; CEDERGREN, R; NADALGINARD, B				YANG, JH; CEDERGREN, R; NADALGINARD, B			CATALYTIC ACTIVITY OF AN RNA DOMAIN DERIVED FROM THE U6-U4 RNA COMPLEX	SCIENCE			English	Article							SMALL NUCLEAR-RNA; BASE-PAIRING INTERACTION; PRECURSOR MESSENGER-RNA; SELF-CLEAVAGE REACTION; SPLICING REACTION; U6 SNRNA; INTRONS; YEAST; SPLICEOSOME; BINDING	U6 RNA contains two regions that are essential for proper splicing of nuclear precursor messenger RNA (pre-mRNA). A comparison of putative secondary structures of the U6-U4 RNA complexes from different phyla revealed a conserved domain that is similar to the catalytic hammerhead RNA motif. Although no catalytic activity was detected in the mammalian U6-U4 RNA complexes, two nucleotide changes in U6 RNA and one in U4 RNA conferred cleavage activity to the complex. Furthermore, the highly conserved domain of the wild-type complex, without the accompanying flanking regions, cleaved an RNA substrate and exhibited other characteristics of the hammerhead ribozyme. The possible involvement of this structure in pre-mRNA splicing is also discussed.	HARVARD UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, MOLEC & CELLULAR CARDIOL LAB, BOSTON, MA 02115 USA; CHILDRENS HOSP MED CTR, DEPT CARDIOL, BOSTON, MA 02115 USA; UNIV MONTREAL, DEPT BIOCHIM, MONTREAL H3C 3J7, QUEBEC, CANADA	Harvard University; Harvard Medical School; Harvard University; Boston Children's Hospital; Universite de Montreal					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR036865] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR36865-08] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BARK C, 1985, MOL CELL BIOL, V5, P943, DOI 10.1128/MCB.5.5.943; BINDEREIF A, 1990, EMBO J, V9, P251, DOI 10.1002/j.1460-2075.1990.tb08102.x; CECH TR, 1986, CELL, V44, P207, DOI 10.1016/0092-8674(86)90751-8; CEDERGREN R, 1987, FEBS LETT, V226, P63, DOI 10.1016/0014-5793(87)80551-3; CELANDER DW, 1991, SCIENCE, V251, P401, DOI 10.1126/science.1989074; EPSTEIN LM, 1987, CELL, V48, P535, DOI 10.1016/0092-8674(87)90204-2; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; FORSTER AC, 1987, CELL, V49, P211, DOI 10.1016/0092-8674(87)90562-9; GUTHRIE C, 1988, ANNU REV GENET, V22, P397; HAMPEL A, 1990, NUCLEIC ACIDS RES, V18, P299, DOI 10.1093/nar/18.2.299; Innis M. A., 1990, PCR PROTOCOLS GUIDE, P3; JARRELL KA, 1988, MOL CELL BIOL, V8, P2361, DOI 10.1128/MCB.8.6.2361; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MARCINIEC T, 1989, ACTA BIOCHIM POL, V36, P183; MCPHEETERS DS, 1992, CELL, V71, P819, DOI 10.1016/0092-8674(92)90557-S; MICHEL F, 1989, GENE, V82, P5, DOI 10.1016/0378-1119(89)90026-7; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; PERREAULT JP, 1991, BIOCHEMISTRY-US, V30, P4020, DOI 10.1021/bi00230a029; REID SS, 1990, BIOCHEMISTRY-US, V29, P6025, DOI 10.1021/bi00477a021; RUFFNER DE, 1990, BIOCHEMISTRY-US, V29, P10695, DOI 10.1021/bi00499a018; RUFFNER DE, 1990, NUCLEIC ACIDS RES, V18, P6025, DOI 10.1093/nar/18.20.6025; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SHARP PA, 1985, CELL, V42, P397, DOI 10.1016/0092-8674(85)90092-3; SHELDON CC, 1989, NUCLEIC ACIDS RES, V17, P5679, DOI 10.1093/nar/17.14.5679; SMITH D, 1992, J BIOL CHEM, V267, P2429; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; TANI T, 1991, GENE DEV, V5, P1022, DOI 10.1101/gad.5.6.1022; UCHIMARU T, 1993, FASEB J, V7, P137, DOI 10.1096/fasebj.7.1.8422960; UHLENBECK OC, 1987, NATURE, V328, P596, DOI 10.1038/328596a0; USMAN N, 1987, J AM CHEM SOC, V109, P7845, DOI 10.1021/ja00259a037; WASSARMAN BJ, 1990, CELL, V61, P685; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; YANG JH, 1992, BIOCHEMISTRY-US, V31, P5005, DOI 10.1021/bi00136a013; YANG JH, 1990, BIOCHEMISTRY-US, V29, P11156, DOI 10.1021/bi00503a002; YEAN SL, 1991, MOL CELL BIOL, V11, P5571, DOI 10.1128/MCB.11.11.5571	37	6	6	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 7	1994	263	5143					77	81		10.1126/science.8272868	http://dx.doi.org/10.1126/science.8272868			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ301	8272868				2022-12-01	WOS:A1994MQ30100033
J	LI, JJ; HERSKOWITZ, I				LI, JJ; HERSKOWITZ, I			ISOLATION OF ORC6, A COMPONENT OF THE YEAST ORIGIN RECOGNITION COMPLEX BY A ONE-HYBRID SYSTEM	SCIENCE			English	Article							DNA-REPLICATION; CELL-CYCLE; SACCHAROMYCES-CEREVISIAE; SUBCELLULAR-LOCALIZATION; PROTEIN; ACTIVATION; SEQUENCES; MUTANTS; GENE	Here a method is described to identify genes encoding proteins that recognize a specific DNA sequence. A bank of random protein segments tagged with a transcriptional activation domain is screened for proteins that can activate a reporter gene containing the sequence in its promoter. This strategy was used to identify an essential protein that interacts in vivo with the yeast origin of DNA replication. Matches between its predicted amino acid sequence and peptide sequence obtained from the 50-kilodalton subunit of the yeast origin recognition complex (ORC) established that the gene isolated here, ORC6, encodes this subunit. These observations provide evidence that ORC recognizes yeast replication origins in vivo.	UNIV CALIF SAN FRANCISCO, DEPT BIOCHEM & BIOPHYS, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco					NIAID NIH HHS [AI18738] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI018738, R01AI018738] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREWS BJ, 1993, SCIENCE, V261, P1543, DOI 10.1126/science.8372349; Ausubel F.M., 1989, SHORT PROTOCOLS MOL; BELL SP, 1993, SCIENCE, V262, P1844, DOI 10.1126/science.8266072; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; BROACH JR, 1982, COLD SPRING HARB SYM, V47, P1165, DOI 10.1101/SQB.1983.047.01.132; CAMPBELL JL, 1991, MOL CELLULAR BIOL YE, V1, P41; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CHEN YR, 1992, P NATL ACAD SCI USA, V89, P10459, DOI 10.1073/pnas.89.21.10459; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CHRISTIANSON TW, 1992, GENE, V110, P119, DOI 10.1016/0378-1119(92)90454-W; DEPAMPHILIS ML, 1993, ANNU REV BIOCHEM, V62, P29; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; FANGMAN WL, 1991, ANNU REV CELL BIOL, V7, P375, DOI 10.1146/annurev.cb.07.110191.002111; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; Guthrie C, 1991, GUIDE YEAST GENETICS; HARTWELL LH, 1976, J MOL BIOL, V104, P803, DOI 10.1016/0022-2836(76)90183-2; Hartwell LH, 1981, MOL BIOL YEAST SACCH, P97; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; HICKS JB, 1976, GENETICS, V83, P245; HODGMAN TC, 1988, NATURE, V333, P22, DOI 10.1038/333022b0; HOGAN E, 1992, P NATL ACAD SCI USA, V89, P3098, DOI 10.1073/pnas.89.7.3098; KELLY TJ, 1988, J BIOL CHEM, V263, P17889; Kornberg A., 1992, DNA REPLICATION; Li J. P. H., UNPUB; LINDER P, 1989, NATURE, V337, P121, DOI 10.1038/337121a0; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MARIANS KJ, 1992, ANNU REV BIOCHEM, V61, P673, DOI 10.1146/annurev.bi.61.070192.003325; Nigg E A, 1991, Semin Cell Biol, V2, P261; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; STILLMAN B, 1989, ANNU REV CELL BIOL, V5, P197; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; VANHOUTEN JV, 1990, MOL CELL BIOL, V10, P3917, DOI 10.1128/MCB.10.8.3917; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WANG MM, 1993, NATURE, V364, P121, DOI 10.1038/364121a0; WEST RW, 1984, MOL CELL BIOL, V4, P2467, DOI 10.1128/MCB.4.11.2467; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541	40	351	409	3	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1993	262	5141					1870	1874		10.1126/science.8266075	http://dx.doi.org/10.1126/science.8266075			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266075				2022-12-01	WOS:A1993MM51100035
J	NOGUCHI, M; NAKAMURA, Y; RUSSELL, SM; ZIEGLER, SF; TSANG, M; CAO, XQ; LEONARD, WJ				NOGUCHI, M; NAKAMURA, Y; RUSSELL, SM; ZIEGLER, SF; TSANG, M; CAO, XQ; LEONARD, WJ			INTERLEUKIN-2 RECEPTOR GAMMA-CHAIN - A FUNCTIONAL COMPONENT OF THE INTERLEUKIN-7 RECEPTOR	SCIENCE			English	Article							CELL GROWTH-FACTOR; T-CELLS; SIGNAL TRANSDUCTION; FETAL THYMOCYTES; SUPERFAMILY; EXPRESSION; CLONING; SUBUNIT; GP130	The interleukin-2 receptor gamma chain (IL-2Rgamma) is a necessary component of functional IL-2 receptors. IL-2Rgamma mutations result in X-linked severe combined immunodeficiency (XSCID) in humans, a disease characterized by the presence of few or no T cells. In contrast, SCID patients with IL-2 deficiency and IL-2-deficient mice have normal numbers of T cells, suggesting that IL-2Rgamma is part of more than one cytokine receptor. By using chemical cross-linking, IL-2Rgamma was shown to be physically associated with the IL-7 receptor. The presence of IL-2Rgamma augmented both IL-7 binding affinity and the efficiency of internalization of IL-7. These findings may help explain the defects of XSCID. Given its role in more than one cytokine receptor system, the common gamma chain (gamma(c) is proposed as the designation for IL-2Rgamma.	NHLBI,PULM & MOLEC IMMUNOL SECT,BETHESDA,MD 20892; IMMUNEX CORP,SEATTLE,WA 98101	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); Immunex Corporation			Leonard, Warren/AAA-1397-2022; Russell, Sarah M/B-9341-2009	Russell, Sarah M/0000-0001-5826-9641				ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; CAO XQ, 1993, P NATL ACAD SCI USA, V90, P8464, DOI 10.1073/pnas.90.18.8464; CHAZEN GD, 1989, P NATL ACAD SCI USA, V86, P5923, DOI 10.1073/pnas.86.15.5923; COOPER MD, 1989, FUNDAMENTAL IMMUNOLO, P1034; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; FOXWELL BMJ, 1993, EUR J IMMUNOL, V23, P85, DOI 10.1002/eji.1830230114; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; Gelfand E W, 1983, Birth Defects Orig Artic Ser, V19, P65; GOODWIN RG, 1990, CELL, V60, P940; GRABSTEIN KH, 1993, J EXP MED, V178, P257, DOI 10.1084/jem.178.1.257; HARADA N, 1992, J BIOL CHEM, V267, P22752; JENKINSON EJ, 1987, NATURE, V329, P160, DOI 10.1038/329160a0; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, CELL, V66, P1174; LEONARD WJ, 1992, INTERLEUKIN 2, P29; LONDEI M, 1990, EUR J IMMUNOL, V20, P425, DOI 10.1002/eji.1830200228; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.iy.10.040192.001455; MORRISSEY PJ, 1989, J EXP MED, V169, P707, DOI 10.1084/jem.169.3.707; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; Murray R, 1989, Int Immunol, V1, P526, DOI 10.1093/intimm/1.5.526; NAMEN AE, 1988, NATURE, V333, P571, DOI 10.1038/333571a0; NAMEN AE, 1988, J EXP MED, V167, P988, DOI 10.1084/jem.167.3.988; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, UNPUB; RAULET DH, 1985, NATURE, V314, P101, DOI 10.1038/314101a0; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SHARON M, 1986, SCIENCE, V234, P859, DOI 10.1126/science.3095922; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TAKESHITA T, 1990, INT IMMUNOL, V2, P477, DOI 10.1093/intimm/2.5.477; TENTORI L, 1988, J EXP MED, V168, P1741, DOI 10.1084/jem.168.5.1741; UCKUN FM, 1991, P NATL ACAD SCI USA, V88, P6323, DOI 10.1073/pnas.88.14.6323; WATSON JD, 1989, J IMMUNOL, V143, P1215; WEINBERG K, 1990, NEW ENGL J MED, V322, P1718, DOI 10.1056/NEJM199006143222406	36	823	845	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 17	1993	262	5141					1877	1880		10.1126/science.8266077	http://dx.doi.org/10.1126/science.8266077			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266077	Green Submitted			2022-12-01	WOS:A1993MM51100037
J	KEE, F; TIRET, L; ROBO, JY; NICAUD, V; MCCRUM, E; EVANS, A; CAMBIEN, F				KEE, F; TIRET, L; ROBO, JY; NICAUD, V; MCCRUM, E; EVANS, A; CAMBIEN, F			RELIABILITY OF REPORTED FAMILY HISTORY OF MYOCARDIAL-INFARCTION	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; INDEPENDENT RISK FACTOR; ARTERY DISEASE; PARENTAL HISTORY; SUSCEPTIBILITY; POLYMORPHISM; HEALTH; ATTACK; MEN	Objective-To assess the reliability of reported family histories of myocardial infarction. Design-A case-control study in which reported histories of first degree relatives were validated from death certificates, general practitioners' records, and hospital notes. Setting-Participants enrolled in the Belfast centre of the World Health Organisation's study monitoring trends and determinants in cardiovascular disease (MONICA). Subjects-200 men who survived myocardial infarction and 200 age matched controls drawn randomly from the population. Main outcome measures-The sensitivity, specificity, positive predictive value, and proportion of overall agreement with validated records of reported family histories of myocardial infarction in first degree relatives; odds ratios for myocardial infarction, given at least one reported relative or at least one verified relative being affected. Results-349 of the 400 probands provided detailed family histories, reporting on 2812 first degree relatives. The overall sensitivity, specificity, and positive predictive value of reported histories were 67.3%, 96.5%, and 70.5% for cases and 68.5%, 97.7%, and 73.8% for controls. The K coefficients were modest: 0.65 for cases and 0.68 for controls. The odds ratios for myocardial infarction, given at least one affected relative, were not substantially inflated by recall bias. Some recall bias was evident for the probands' reports of their siblings' histories of myocardial infarction, the odds ratio for a reported history being 1.67 (95% confidence interval 1.09 to 2.57) and for the validated history 1.54 (1.01 to 2.37). Conclusions-Although the relative risk of disease is correctly estimated, the predictive accuracy of a casual family history of myocardial infarction may limit the effectiveness of targeted screening programmes. They may, however, complement other strategies based on genetic testing.	HOP BROUSSAIS,INSERM,U258,F-75674 PARIS 14,FRANCE; BANQUE ADN RECH CARDIOVASC,INSERM,SC7,F-75005 PARIS,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Europeen Georges-Pompidou - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm)	KEE, F (corresponding author), QUEENS UNIV BELFAST,DEPT EPIDEMIOL & PUBL HLTH,MONICA PROJECT,BELFAST BT12 6BJ,ANTRIM,NORTH IRELAND.							CAMBIEN F, 1992, NATURE, V359, P641, DOI 10.1038/359641a0; CICCHETTI DV, 1990, J CLIN EPIDEMIOL, V43, P551, DOI 10.1016/0895-4356(90)90159-M; COLDITZ GA, 1991, AM J CARDIOL, V67, P933, DOI 10.1016/0002-9149(91)90163-F; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; FLEISS JL, 1987, STATISTICAL METHODS; HELLER RF, 1983, J EPIDEMIOL COMMUN H, V37, P29, DOI 10.1136/jech.37.1.29; HERMANN N, 1985, AM J EPIDEMIOL, V121, P937; HUNT SC, 1986, J CHRON DIS, V39, P809, DOI 10.1016/0021-9681(86)90083-4; KHAW KT, 1986, CIRCULATION, V74, P239, DOI 10.1161/01.CIR.74.2.239; KHOURY MJ, 1989, AM J EPIDEMIOL, V129, P183, DOI 10.1093/oxfordjournals.aje.a115107; KHOURY MJ, 1990, EPIDEMIOL REV, V12, P41, DOI 10.1093/oxfordjournals.epirev.a036061; LAUER RM, 1991, CIRCULATION, V84, P1445, DOI 10.1161/01.CIR.84.3.1445; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MERTENS TE, 1993, LANCET, V342, P418, DOI 10.1016/0140-6736(93)92820-J; MYERS RH, 1990, AM HEART J, V120, P963, DOI 10.1016/0002-8703(90)90216-K; NAPIER JA, 1972, AM J PUBLIC HEALTH N, V62, P30, DOI 10.2105/AJPH.62.1.30; NELSON LM, 1990, EPIDEMIOL REV, V12, P71, DOI 10.1093/oxfordjournals.epirev.a036063; OLAV H, 1977, AM J EPIDEMIOL, V105, P192; PARRA HJ, 1992, ARTERIOSCLER THROMB, V12, P701, DOI 10.1161/01.ATV.12.6.701; PATTERSON CC, 1990, ULSTER MED J, V59, P177; PERKINS KA, 1986, AM J EPIDEMIOL, V124, P182, DOI 10.1093/oxfordjournals.aje.a114377; PHILLIPS AN, 1988, EUR HEART J, V9, P243, DOI 10.1093/oxfordjournals.eurheartj.a062492; RISSANEN AM, 1984, ATHEROSCLEROSIS, V53, P37, DOI 10.1016/0021-9150(84)90103-5; RISSANEN AM, 1979, AM J CARDIOL, V44, P60, DOI 10.1016/0002-9149(79)90251-0; RONCAGLIONI MC, 1992, CIRCULATION, V85, P2065, DOI 10.1161/01.CIR.85.6.2065; ROSE G, 1964, BRIT J PREV SOC MED, V18, P75; ROSE G, 1990, BRIT MED J, V301, P1031, DOI 10.1136/bmj.301.6759.1031; SINGER F, 1991, AM HEART J, V121, P947, DOI 10.1016/0002-8703(91)90222-4; SLACK J., 1966, J MED GENET, V3, P239, DOI 10.1136/jmg.3.4.239; SNOWDEN CB, 1982, AM J EPIDEMIOL, V115, P217, DOI 10.1093/oxfordjournals.aje.a113293; TENKATE LP, 1982, AM J CARDIOL, V50, P945, DOI 10.1016/0002-9149(82)90400-3; THELLE DS, 1979, AM J EPIDEMIOL, V110, P708, DOI 10.1093/oxfordjournals.aje.a112851	32	120	120	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1993	307	6918					1528	1530		10.1136/bmj.307.6918.1528	http://dx.doi.org/10.1136/bmj.307.6918.1528			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML869	8274922	Bronze, Green Published			2022-12-01	WOS:A1993ML86900021
J	DERMAN, AI; PRINZ, WA; BELIN, D; BECKWITH, J				DERMAN, AI; PRINZ, WA; BELIN, D; BECKWITH, J			MUTATIONS THAT ALLOW DISULFIDE BOND FORMATION IN THE CYTOPLASM OF ESCHERICHIA-COLI	SCIENCE			English	Article							THIOREDOXIN REDUCTASE; ALKALINE-PHOSPHATASE; GLUTATHIONE; CLONING; GENE; IDENTIFICATION; GLUTAREDOXIN; STABILITY; SECRETION; UROKINASE	Disulfide bonds are rarely found in cytoplasmic proteins. Mutations were selected for in Escherichia coli that allow disulfide bond formation in the cytoplasm. In the presence of these mutations, export-defective versions of alkaline phosphatase and mouse urokinase were able to fold into their enzymatically active conformations in the cytoplasm because their disulfide bonds were formed. The mutations were mapped to the gene for thioredoxin reductase and diminish or eliminate the activity of this enzyme. Thioredoxin itself was found to be unnecessary for this disulfide bond formation. Thioredoxin reductase, but not thioredoxin, is thus implicated in keeping cysteines reduced in cytoplasmic proteins.	HARVARD UNIV, SCH MED, DEPT MICROBIOL & MOLEC GENET, BOSTON, MA 02115 USA; UNIV GENEVA, MED CTR, DEPT PATHOL, CH-1211 GENEVA 4, SWITZERLAND	Harvard University; Harvard Medical School; University of Geneva								BARDWELL JCA, 1993, P NATL ACAD SCI USA, V90, P1038, DOI 10.1073/pnas.90.3.1038; BARDWELL JCA, 1991, CELL, V67, P581, DOI 10.1016/0092-8674(91)90532-4; BEEBE JS, 1990, J BIOL CHEM, V265, P312; BELIN D, 1984, EMBO J, V3, P1901, DOI 10.1002/j.1460-2075.1984.tb02065.x; BELIN D, 1985, EUR J BIOCHEM, V148, P225, DOI 10.1111/j.1432-1033.1985.tb08829.x; BERGMAN LW, 1979, J BIOL CHEM, V254, P5690; BOYD D, 1987, P NATL ACAD SCI USA, V84, P8525, DOI 10.1073/pnas.84.23.8525; Branden C, 1991, INTRO PROTEIN STRUCT, P5; CHAU MH, 1992, J MOL BIOL, V31, P4445; DAILEY FE, 1993, P NATL ACAD SCI USA, V90, P1043, DOI 10.1073/pnas.90.3.1043; DELANEY JM, 1992, J BACTERIOL, V174, P3824, DOI 10.1128/JB.174.11.3824-3825.1992; DERMAN AI, 1993, EMBO J, V12, P879, DOI 10.1002/j.1460-2075.1993.tb05728.x; DERMAN AI, 1991, J BACTERIOL, V173, P7719, DOI 10.1128/jb.173.23.7719-7722.1991; DOIG AJ, 1991, J MOL BIOL, V217, P389, DOI 10.1016/0022-2836(91)90551-G; DUBOSE RF, 1991, EVOLUTION AT THE MOLECULAR LEVEL, P58; FRAENKEL DG, 1965, J BACTERIOL, V90, P837, DOI 10.1128/JB.90.4.837-842.1965; FUCHS J, 1977, J BACTERIOL, V129, P967, DOI 10.1128/JB.129.2.967-972.1977; GILBERT HF, 1990, ADV ENZYMOL RAMB, V63, P69; HALLER BL, 1984, J BACTERIOL, V159, P1060, DOI 10.1128/JB.159.3.1060-1062.1984; HEPPEL LA, 1962, J BIOL CHEM, V237, P841; HOLMGREN A, 1984, METHOD ENZYMOL, V107, P295; HOLMGREN A, 1979, J BIOL CHEM, V254, P3664; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOLMGREN A, 1986, THIOREDOXIN GLUTARED, P1; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; KAMITANI S, 1992, EMBO J, V11, P57, DOI 10.1002/j.1460-2075.1992.tb05027.x; KIM EE, 1990, CLIN CHIM ACTA, V186, P175, DOI 10.1016/0009-8981(90)90035-Q; LUCKEY M, 1991, J BIOL CHEM, V266, P1866; LUNDSTROM J, 1990, J BIOL CHEM, V265, P9114; MICHAELIS S, 1983, J BACTERIOL, V154, P366, DOI 10.1128/JB.154.1.366-374.1983; MOORE EC, 1964, J BIOL CHEM, V239, P3453; NEURATH H, 1984, SCIENCE, V224, P350, DOI 10.1126/science.6369538; ODONNELL ME, 1986, THIOREDOXIN GLUTARED, P131; PIZER LI, 1963, J BIOL CHEM, V238, P3934; POLLITT S, 1983, J BACTERIOL, V153, P27, DOI 10.1128/JB.153.1.27-32.1983; ROEDER W, 1979, MOL GEN GENET, V176, P361, DOI 10.1007/BF00333098; RUSSEL M, 1988, J BIOL CHEM, V263, P9015; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; RUSSEL M, 1986, THIOREDOXIN GLUTARED, P331; Schulz G. E., 1979, PRINCIPLES PROTEIN S, P53; SEDIVY JM, 1984, J BACTERIOL, V158, P1048, DOI 10.1128/JB.158.3.1048-1053.1984; TORRIANI A, 1960, BIOCHIM BIOPHYS ACTA, V38, P460, DOI 10.1016/0006-3002(60)91281-6; TUGGLE CK, 1985, J BACTERIOL, V162, P448, DOI 10.1128/JB.162.1.448-450.1985; WANNER BL, 1987, CELLULAR MOL BIOL, V2, P1326	44	380	414	2	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 10	1993	262	5140					1744	1747		10.1126/science.8259521	http://dx.doi.org/10.1126/science.8259521			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	8259521				2022-12-01	WOS:A1993ML22000045
J	PEIFER, M				PEIFER, M			CANCER, CATENINS, AND CUTICLE PATTERN - A COMPLEX CONNECTION	SCIENCE			English	Editorial Material							SEGMENT POLARITY GENE; BETA-CATENIN; E-CADHERIN; PROTEIN; DROSOPHILA; PLAKOGLOBIN; HOMOLOG; PHOSPHORYLATION; IDENTIFICATION; VINCULIN				PEIFER, M (corresponding author), UNIV N CAROLINA,DEPT BIOL,CHAPEL HILL,NC 27599, USA.		Peifer, Mark/A-1152-2010	Peifer, Mark/0000-0003-1412-3987				Behrens J, 1992, Semin Cell Biol, V3, P169; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BRADLEY RS, IN PRESS J CELL BIOL; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HAMAGUCHI M, 1993, EMBO J, V12, P307, DOI 10.1002/j.1460-2075.1993.tb05658.x; HERRENKNECHT K, 1991, P NATL ACAD SCI USA, V88, P9156, DOI 10.1073/pnas.88.20.9156; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; KNUDSEN KA, 1992, J CELL BIOL, V118, P671, DOI 10.1083/jcb.118.3.671; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MCCREA PD, 1993, J CELL BIOL, V123, P477, DOI 10.1083/jcb.123.2.477; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; NAGAFUCHI A, 1991, CELL, V65, P849, DOI 10.1016/0092-8674(91)90392-C; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; ODA H, 1993, J CELL BIOL, V121, P1133, DOI 10.1083/jcb.121.5.1133; PEIFER M, 1993, J CELL SCI, V105, P993; PEIFER M, 1993, DEVELOPMENT, V118, P1191; PEIFER M, 1992, J CELL BIOL, V118, P681, DOI 10.1083/jcb.118.3.681; PEIFER M, IN PRESS DEVELOPMENT; PEIFER M, UNPUB; PIEPENHAGEN PA, 1993, J CELL SCI, V104, P751; Reynolds Alice, COMMUNICATION; RIGGLEMAN B, 1989, GENE DEV, V3, P96, DOI 10.1101/gad.3.1.96; RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518; SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519; TAKEICHI M, COMMUNICATION; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x	27	69	72	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 10	1993	262	5140					1667	1668		10.1126/science.8259511	http://dx.doi.org/10.1126/science.8259511			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	8259511				2022-12-01	WOS:A1993ML22000027
J	HAY, JC; MARTIN, TFJ				HAY, JC; MARTIN, TFJ			PHOSPHATIDYLINOSITOL TRANSFER PROTEIN REQUIRED FOR ATP-DEPENDENT PRIMING OF CA2+-ACTIVATED SECRETION	NATURE			English	Article								ELUCIDATION of the reactions responsible for the calcium-regulated fusion of secretory granules with the plasma membrane in secretory cells would be facilitated by the identification of participant proteins having known biochemical activities. The successful characterization of cytosolic1-3 and vesicle 4,5 proteins that may function in calcium-regulated secretion has not yet revealed the molecular events underlying this process. Regulated secretion consists of sequential priming and triggering steps which depend on ATP and Ca2+, respectively, and require distinct cytosolic proteins6. Characterization of priming-specific factors (PEP proteins) should enable the ATP-requiring reactions to be identified. Here we show that one of the mammalian priming factors (PEP3) is identical to phosphatidylinositol transfer protein (PITP)7. The physiological role of PITP was previously unknown. We also find that SEC14p, the yeast phosphatidylinositol transfer protein which is essential for constitutive secretion8-10, can substitute for PEP3/PITP in priming. Our results indicate that a role for phospholipid transfer proteins is conserved in the constitutive and regulated secretory pathways.	UNIV WISCONSIN, PROGRAM CELL & MOLEC BIOL, 1117 W JOHNSON ST, MADISON, WI 53706 USA; UNIV WISCONSIN, DEPT ZOOL, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison								AITKEN JF, 1990, J BIOL CHEM, V265, P4711; ANDERSON RA, 1985, NATURE, V318, P295, DOI 10.1038/318295a0; BANKAITIS VA, 1989, J CELL BIOL, V108, P1271, DOI 10.1083/jcb.108.4.1271; BANKAITIS VA, 1990, NATURE, V347, P561, DOI 10.1038/347561a0; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CLEVES AE, 1991, CELL, V64, P789, DOI 10.1016/0092-8674(91)90508-V; DAUM G, 1984, BIOCHIM BIOPHYS ACTA, V794, P385, DOI 10.1016/0005-2760(84)90004-3; DICKESON SK, 1989, J BIOL CHEM, V264, P16557; DICORLETO PE, 1979, J BIOL CHEM, V254, P7795; EBERHARD DA, 1990, BIOCHEM J, V268, P15, DOI 10.1042/bj2680015; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; HAY JC, 1992, J CELL BIOL, V119, P139, DOI 10.1083/jcb.119.1.139; HELMKAMP GM, 1974, J BIOL CHEM, V249, P6382; HEUKESHOVEN J, 1985, ELECTROPHORESIS, V6, P103, DOI 10.1002/elps.1150060302; HUSEBYE ES, 1988, BIOCHIM BIOPHYS ACTA, V968, P261, DOI 10.1016/0167-4889(88)90015-8; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; MARTIN TFJ, 1989, METHOD ENZYMOL, V168, P225; MORGAN A, 1992, NATURE, V355, P833, DOI 10.1038/355833a0; PHILLIPS JH, 1973, BIOCHEM J, V136, P579, DOI 10.1042/bj1360579; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; SZOLDERITS G, 1989, BIOCHIM BIOPHYS ACTA, V986, P301, DOI 10.1016/0005-2736(89)90481-1; VANPARIDON PA, 1987, BIOCHIM BIOPHYS ACTA, V898, P172, DOI 10.1016/0005-2736(87)90035-6; WALENT JH, 1992, J CELL, V70, P765; WHITTERS EA, 1993, J CELL BIOL, V122, P79, DOI 10.1083/jcb.122.1.79; WU YN, 1992, BIOCHEM J, V285, P697, DOI 10.1042/bj2850697	30	309	314	1	4	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 9	1993	366	6455					572	575		10.1038/366572a0	http://dx.doi.org/10.1038/366572a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	8255295				2022-12-01	WOS:A1993ML21800072
J	PETTERSON, B; NELSON, KB; WATSON, L; STANLEY, F				PETTERSON, B; NELSON, KB; WATSON, L; STANLEY, F			TWINS, TRIPLETS, AND CEREBRAL-PALSY IN BIRTHS IN WESTERN-AUSTRALIA IN THE 1980S	BRITISH MEDICAL JOURNAL			English	Article							MULTIPLE BIRTHS; PERINATAL-MORTALITY; TRENDS; EPIDEMIOLOGY	Objectives-To examine the rate of cerebral palsy in twins and triplets in births from 1980 to 1989 in Western Australia and to identify factors associated with increase in risk. Design-Pluralities for all births in Western Australia were identified through the standardised midwives' notification system, and cases of cerebral palsy were identified from the Western Australian cerebral palsy register. Main outcome measures-Multiple births, cerebral palsy, excluding postneonatal cause. Results-The prevalence of cerebral palsy in triplets, of 28 per 1000 survivors to 1 year (95% confidence interval 11 to 63) exceeded that in twins (7.3; 5.2 to 10) and singletons (1.6; 1.4 to 1.8). Although twins and triplets were more likely than singletons to be low in birth weight, their risks of cerebral palsy if low in birth weight were similar. In contrast, in normal birthweight categories twins had a higher rate of cerebral palsy (4.2; 2.2 to 7.7) than singletons (1.1; 1.0 to 1.3). The prevalence of cerebral palsy was similar in twins of unlike sex pairs, all of whom are dizygotic, and in like sex pairs. A twin pair in which one member died in utero was at higher risk of cerebral palsy: 96 per 1000 twin pairs (36 to 218) compared with 12 (8.2 to 17) for twin pregnancies in which both survived. There was a similar but non-significant trend for death of one triplet to be associated with increased risk of cerebral palsy in the survivors of the set. Conclusion-Triplet pregnancies produced a child with cerebral palsy 47 times more often than singleton pregnancies did and twin pregnancies eight times more often. Eighty six per cent of cerebral palsy in multiple births was in twins. As multiple births are increasing mainly because of personal and medical decisions the increased risk of cerebral palsy in multiple births is of concern.	NINCDS,NEUROEPIDEMIOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Neurological Disorders & Stroke (NINDS)	PETTERSON, B (corresponding author), PRINCESS MARGARET HOSP CHILDREN,WESTERN AUSTRALIAN RES INST CHILD HLTH,POB BOX D184,PERTH,WA 6001,AUSTRALIA.							BAARLETT WM, 1972, STATISTICS W AUSTR D; Botting B, 1990, 3 4 MORE STUDY TRIPL; BOTTING BJ, 1987, ARCH DIS CHILD, V62, P941, DOI 10.1136/adc.62.9.941; BRESLOW NE, 1980, SCI PUBLICATIONS, V32; BUCKENS P, 1993, AM J OBSTET GYNECOL, V168, P937; FLEISS JL, 1980, STATISTICAL METHODS, P14; GEE V, 1992, PERINATAL STATISTICS; GRETHER JK, 1985, IN PRESS PEDIATRICS; KIELY JL, 1992, AM J DIS CHILD, V146, P862, DOI 10.1001/archpedi.1992.02160190094029; KIELY JL, 1990, B NEW YORK ACAD MED, V66, P618; KLEINBAUM DG, 1982, EPIDEMIOLOGIC RES PR, P299; LEVENE MI, 1992, BRIT J OBSTET GYNAEC, V99, P607, DOI 10.1111/j.1471-0528.1992.tb13831.x; LEVENE MI, 1991, ARCH DIS CHILD-FETAL, V66, P1, DOI 10.1136/adc.66.1_Spec_No.1; MCCARTHY BJ, 1981, AM J OBSTET GYNECOL, V141, P252; MCKIMMIE M, 1993, W ASUSTR, V17, P15; MORDEL N, 1992, J PERINAT MED, V20, P117, DOI 10.1515/jpme.1992.20.2.117; PETTERSON B, 1990, AM J MED GENET, V37, P346, DOI 10.1002/ajmg.1320370311; ROSENTHAL E, 1992, NY TIMES        0526; RYDHSTROM H, 1993, J REPROD MED, V38, P142; SCHELLER JM, 1992, AM J DIS CHILD, V146, P1110, DOI 10.1001/archpedi.1992.02160210112036; SPELLACY WN, 1990, OBSTET GYNECOL, V75, P168; STANLEY F J, 1985, Neuroepidemiology, V4, P146, DOI 10.1159/000110226; STANLEY FJ, 1992, BRIT MED J, V304, P1658, DOI 10.1136/bmj.304.6843.1658; STANLEY FJ, 1979, PERINATAL MORTALITY; STANLEY RJ, 1980, LIVEBIRTHS PERINATAL; TAFFEL SM, 1992, VITAL HLTH STAT, V21, P1; WEBB S, 1987, MED J AUSTRALIA, V147, P151, DOI 10.5694/j.1326-5377.1987.tb133330.x	27	254	260	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 13	1993	307	6914					1239	1243		10.1136/bmj.307.6914.1239	http://dx.doi.org/10.1136/bmj.307.6914.1239			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH001	8281055	Green Published, Bronze			2022-12-01	WOS:A1993MH00100018
J	VELAZQUEZ, H; PERAZELLA, MA; WRIGHT, FS; ELLISON, DH				VELAZQUEZ, H; PERAZELLA, MA; WRIGHT, FS; ELLISON, DH			RENAL MECHANISM OF TRIMETHOPRIM-INDUCED HYPERKALEMIA	ANNALS OF INTERNAL MEDICINE			English	Article						HYPERKALEMIA; TRIMETHOPRIM; SODIUM CHANNELS; POTASSIUM; KIDNEY TUBULES, DISTAL	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; POTASSIUM SECRETION; LUMINAL INFLUENCES; SULFAMETHOXAZOLE; THERAPY; VIRUS; MANIFESTATIONS; INFECTION; PNEUMONIA; CHLORIDE	Objectives: 1) To determine the incidence and severity of hyperkalemia during trimethoprim therapy. 2) To test the hypothesis that trimethoprim inhibits renal potassium excretion by blocking sodium channels in the mammalian distal nephron. Patients: Thirty consecutive patients who were treated with trimethoprim-containing drugs. All patients included in the study had the acquired immunodeficiency syndrome (AIDS). Experimental animals: Thirty-nine male Sprague-Dawley rats receiving normal rat chow and tap water (allowed free access). Intervention: Humans: high dose (20 mg/kg per day) of trimethoprim therapy. Rats: trimethoprim (9.6 mg/h, per kg body weight) was infused intravenously or into the renal distal tubules (1 mmol/L). Measurements: Humans: Serum and urine electrolyte levels, serum creatinine, renin, aldosterone, and cortisol levels were measured, and the transtubular potassium gradient was calculated. Rats: The effects of trimethoprim infusion on urinary sodium, chloride, and potassium concentration and urine volume were measured. Sodium, chloride, potassium, and inulin concentrations were measured in fluid samples obtained from kidney distal tubules. The voltage across the wall of the distal tubule was measured. Results: Humans: Trimethoprim increased the serum potassium concentration by 0.6 mmol/L (95% CI, 0.29 to 0.95 mmol/L) despite normal adrenocortical function and glomerular filtration rate. Serum potassium levels greater than 5 mmol/L were observed during trimethoprim treatment in 15 of 30 patients. Rats: Intravenous trimethoprim inhibited renal potassium excretion by 40% (CI, 21% to 60%) and increased renal sodium excretion by 46% (CI, 9% to 83%). Trimethoprim (1 mmol/L) in tubule fluid inhibited distal tubule potassium secretion by 59% (CI, 26% to 92%) and depolarized the lumen-negative transepithelial voltage by 66% (CI, 46% to 85%). Conclusions: Trimethoprim (an organic cation) acts like amiloride and blocks apical membrane sodium channels in the mammalian distal nephron. As a consequence, the transepithelial voltage is reduced and potassium secretion is inhibited. Decreased renal potassium excretion secondary to these direct effects on kidney tubules leads to hyperkalemia in a substantial number of patients being treated with trimethoprim-containing drugs.	DEPT VET AFFAIRS MED CTR, W HAVEN, CT 06516 USA	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System	VELAZQUEZ, H (corresponding author), YALE UNIV, SCH MED, DEPT MED NEPHROL, 333 CEDAR ST, 2073 LMP, NEW HAVEN, CT 06510 USA.		, David/X-5730-2019	Ellison, David/0000-0003-2915-265X				BERNS JS, 1991, J AM SOC NEPHROL, V1, P1061; CHOI M J, 1992, Journal of the American Society of Nephrology, V3, P325; ELANSARY EH, 1983, BRIT MED J, V286, P1861, DOI 10.1136/bmj.286.6381.1861-a; ELLISON DH, 1985, AM J PHYSIOL, V248, pF638, DOI 10.1152/ajprenal.1985.248.5.F638; FONSECA PD, 1991, EUR J PHARM-MOLEC PH, V207, P337, DOI 10.1016/0922-4106(91)90008-6; GOOD DW, 1979, AM J PHYSIOL, V236, pF192, DOI 10.1152/ajprenal.1979.236.2.F192; GOOD DW, 1980, AM J PHYSIOL, V239, pF289, DOI 10.1152/ajprenal.1980.239.3.F289; GREENBERG S, 1992, Journal of the American Society of Nephrology, V3, P327; GRINSPOON SK, 1992, NEW ENGL J MED, V327, P1360, DOI 10.1056/NEJM199211053271906; KALIN MF, 1987, AM J MED, V82, P1035, DOI 10.1016/0002-9343(87)90171-9; KAUFMAN AM, 1983, MT SINAI J MED, V50, P238; LACHAAL M, 1989, AM J MED, V87, P260, DOI 10.1016/S0002-9343(89)80147-0; LEE BL, 1989, ANN INTERN MED, V110, P606, DOI 10.7326/0003-4819-110-8-606; LOOSE DS, 1983, J CLIN INVEST, V71, P1495, DOI 10.1172/JCI110903; MARKS JB, 1991, AM J MED SCI, V302, P110, DOI 10.1097/00000441-199108000-00009; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; MERENICH JA, 1990, J CLIN ENDOCR METAB, V70, P566, DOI 10.1210/jcem-70-3-566; OKUSA MD, 1991, AM J PHYSIOL, V260, pF459, DOI 10.1152/ajprenal.1991.260.3.F459; PORETSKY L, 1990, MT SINAI J MED, V57, P236; STRAUSS KW, 1991, ARCH INTERN MED, V151, P1441, DOI 10.1001/archinte.151.7.1441; VELAZQUEZ H, 1982, AM J PHYSIOL, V242, pF46, DOI 10.1152/ajprenal.1982.242.1.F46; VELAZQUEZ H, 1986, AM J PHYSIOL, V250, P1013, DOI 10.1152/ajprenal.1986.250.6.F1013; WEST ML, 1986, MINER ELECTROL METAB, V12, P234; ZETTLE RM, 1987, AM J NEPHROL, V7, P360, DOI 10.1159/000167502; 1992, PHYSICIANS DESK REFE	25	136	140	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1993	119	4					296	301		10.7326/0003-4819-119-4-199308150-00008	http://dx.doi.org/10.7326/0003-4819-119-4-199308150-00008			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV525	8328738				2022-12-01	WOS:A1993LV52500008
J	SORKIN, A; CARPENTER, G				SORKIN, A; CARPENTER, G			INTERACTION OF ACTIVATED EGF RECEPTORS WITH COATED PIT ADAPTINS	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; MEDIATED ENDOCYTOSIS; PLASMA-MEMBRANE; HUMAN-FIBROBLASTS; DOWN-REGULATION; CLATHRIN; INTERNALIZATION; PROTEINS; BINDING	The epidermal growth factor (EGF) receptor interacts with plasma membrane-associated adapter proteins during endocytosis through coated pits. Almost 50 percent of the total pool of alpha-adaptins was coimmunoprecipitated with the EGF receptor when A-431 cells were treated with EGF at 37-degrees-C, but not at 4-degrees-C. Partial proteolysis of alpha-adaptin suggested that the amino-terminal domain is the region that associates with the EGF receptor. The extent of receptor-adaptin association was increased in cells depleted of potassium to block endocytosis. These data suggest that receptor-adaptin association occurs in intact cells before coated pits are fully assembled.	VANDERBILT UNIV, MED CTR, SCH MED, DEPT MED, NASHVILLE, TN 37232 USA	Vanderbilt University	SORKIN, A (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA.			Sorkin, Alexander/0000-0002-4446-1920	NATIONAL CANCER INSTITUTE [R01CA024071] Funding Source: NIH RePORTER; NCI NIH HHS [CA24071] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BRODSKY FM, 1988, SCIENCE, V242, P1396, DOI 10.1126/science.2904698; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CARPENTER G, 1987, ANNU REV BIOCHEM, V56, P881, DOI 10.1146/annurev.bi.56.070187.004313; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HEUSER JE, 1989, J CELL BIOL, V108, P389, DOI 10.1083/jcb.108.2.389; KAMATA N, 1986, CANCER RES, V46, P1648; KEEN JH, 1990, ANNU REV BIOCHEM, V59, P415, DOI 10.1146/annurev.biochem.59.1.415; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LARKIN JM, 1986, J CELL BIOL, V103, P2619, DOI 10.1083/jcb.103.6.2619; MAHAFFEY DT, 1989, J CELL BIOL, V108, P1615, DOI 10.1083/jcb.108.5.1615; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; ROBINSON M S, 1992, Trends in Cell Biology, V2, P293, DOI 10.1016/0962-8924(92)90118-7; ROBINSON MS, 1987, J CELL BIOL, V104, P887, DOI 10.1083/jcb.104.4.887; SCHMID SL, 1992, BIOESSAYS, V14, P589, DOI 10.1002/bies.950140903; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1991, J BIOL CHEM, V266, P23453; SORKIN A, 1991, J BIOL CHEM, V266, P8355; SORKIN A, UNPUB; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VIGERS GPA, 1986, EMBO J, V5, P2079, DOI 10.1002/j.1460-2075.1986.tb04469.x; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WILEY HS, 1991, J BIOL CHEM, V266, P11083; ZAREMBA S, 1985, J CELL BIOCHEM, V28, P47, DOI 10.1002/jcb.240280108	31	238	243	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 30	1993	261	5121					612	615		10.1126/science.8342026	http://dx.doi.org/10.1126/science.8342026			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	8342026				2022-12-01	WOS:A1993LP72800040
J	WARNE, PH; VICIANA, PR; DOWNWARD, J				WARNE, PH; VICIANA, PR; DOWNWARD, J			DIRECT INTERACTION OF RAS AND THE AMINO-TERMINAL REGION OF RAF-1 IN-VITRO	NATURE			English	Article							PROTEIN-KINASE-C; SIGNAL TRANSDUCTION; BINDING; DOMAIN; GAP; EXPRESSION; ACTIVATION; MUTATIONS; GROWTH; CELLS	THE Ras proteins are key regulators of the growth of eukaryotic cells, but their direct target enzymes, or 'effectors', are unknown1. The protein encoded by the c-raf-1 proto-oncogene is thought to function downstream of p21ras because disruption of Raf blocks signalling by Ras in a number of systems2-5. Here we report that the amino-terminal cysteine-rich regulatory region of p74c-raf-1 expressed as a glutathione-S-transferase (GST) fusion protein binds directly to Ras with relatively high affinity (50 nM). The binding is strictly dependent on the Ras protein being in the active GTP-bound conformation rather than the inactive GDP-bound state. Raf-GST interacts with wild-type and oncogenic Ras (Val 12) but fails to interact with a biologically inert effector mutant of Ras (Ala 38) and a dominant negative mutant (Asn 17). A peptide based on the effector region of Ras inhibits the interaction. Raf-GST acts as a potent competitive inhibitor of the GTPase-activating proteins p120GAP and neurofibromin. In addition, Raf itself displays weak GTPase-stimulating activity towards Ras. It is therefore likely that Raf is a direct effector of Ras.	IMPERIAL CANC RES FUND,44 LINCOLNS INN FIELDS,LONDON WC2A 3PX,ENGLAND	Cancer Research UK			Downward, Julian/A-3251-2012	Downward, Julian/0000-0002-2331-4729				AHMED S, 1991, BIOCHEM J, V280, P233, DOI 10.1042/bj2800233; Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; BOURNE HR, 1992, NATURE, V358, P541, DOI 10.1038/358541a0; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; DICKSON B, 1992, NATURE, V360, P600, DOI 10.1038/360600a0; DOWNWARD J, 1992, BIOESSAYS, V14, P177, DOI 10.1002/bies.950140308; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; FARNSWORTH CL, 1991, CELL, V64, P625, DOI 10.1016/0092-8674(91)90246-U; HALL A, 1990, SCIENCE, V249, P635, DOI 10.1126/science.2116664; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; MARSHALL CJ, 1991, TRENDS GENET, V7, P91, DOI 10.1016/0168-9525(91)90278-X; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; ONO Y, 1989, P NATL ACAD SCI USA, V86, P3099, DOI 10.1073/pnas.86.9.3099; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313	18	667	681	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 22	1993	364	6435					352	355		10.1038/364352a0	http://dx.doi.org/10.1038/364352a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	8332195				2022-12-01	WOS:A1993LN57000062
J	HAMMER, J; VALSASNINI, P; TOLBA, K; BOLIN, D; HIGELIN, J; TAKACS, B; SINIGAGLIA, F				HAMMER, J; VALSASNINI, P; TOLBA, K; BOLIN, D; HIGELIN, J; TAKACS, B; SINIGAGLIA, F			PROMISCUOUS AND ALLELE-SPECIFIC ANCHORS IN HLA-DR-BINDING PEPTIDES	CELL			English	Article							MHC CLASS-II; T-CELL EPITOPES; MOLECULES; HLA-DR1; IDENTIFICATION; RECOGNITION; LIBRARIES; LIGANDS; COMPLEX; HLA-B27	The major histocompatibility complex (MHC) class II molecules are highly polymorphic membrane glycoproteins that bind peptide fragments of proteins and display them for recognition by CD4+ T cells. To understand the effect of human MHC class II polymorphism on peptide-MHC interaction, we have isolated M13 phage from a large M13 peptide display library by selection with DRB1*0401 and DRB1*1101 molecules, as recently described for DRB1*0101. Sequence analysis of the peptide-encoding region of DR-bound phage led to the identification of position-specific anchor residues, defining motifs for peptide binding to DR molecules. The three DR motifs share two anchor residues at relative positions 1 and 4, while allele-specific anchor residues have been identified at position 6. These results provide a biophysical basis for both the promiscuity and the specificity of peptide recognition by DR molecules.	F HOFFMANN LA ROCHE & CO LTD, DEPT PHARMACEUT RES NEW TECHNOL, CH-4002 BASEL, SWITZERLAND; F HOFFMANN LA ROCHE & CO LTD, DEPT INFLAMMAT & AUTOIMMUNE DIS, CH-4002 BASEL, SWITZERLAND	Roche Holding; Roche Holding	HAMMER, J (corresponding author), ROCHE MILANO RIC, VIA OLGETTINA 58, I-20132 MILAN, ITALY.							BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BUSCH R, 1990, INT IMMUNOL, V2, P443, DOI 10.1093/intimm/2.5.443; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; CWIRLA SE, 1990, P NATL ACAD SCI USA, V87, P6378, DOI 10.1073/pnas.87.16.6378; DEMOTZ S, 1993, EUR J IMMUNOL, V23, P425, DOI 10.1002/eji.1830230219; DEVLIN JJ, 1990, SCIENCE, V249, P404, DOI 10.1126/science.2143033; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; HAMMER J, 1992, J EXP MED, V176, P1007, DOI 10.1084/jem.176.4.1007; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; KOURILSKY P, 1989, CELL, V56, P327, DOI 10.1016/0092-8674(89)90233-X; KROPSHOFER H, 1992, J EXP MED, V175, P1799, DOI 10.1084/jem.175.6.1799; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MOLLER G, 1987, IMMUNOL REV, V98; ONG B, 1991, P NATL ACAD SCI USA, V88, P7343, DOI 10.1073/pnas.88.16.7343; OSULLIVAN D, 1991, J IMMUNOL, V147, P2663; PANINABORDIGNON P, 1989, EUR J IMMUNOL, V19, P2237, DOI 10.1002/eji.1830191209; ROTHBARD JB, 1988, CELL, V52, P515, DOI 10.1016/0092-8674(88)90464-3; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SETTE A, 1987, NATURE, V328, P395, DOI 10.1038/328395a0; SHEIRLE A, 1992, J IMMUNOL, V149, P1994; SINIGAGLIA F, 1988, NATURE, V336, P778, DOI 10.1038/336778a0; SINIGAGLIA F, 1991, METHOD ENZYMOL, V203, P370; VANBLEEK GM, 1990, NATURE, V348, P213	28	375	415	0	3	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 16	1993	74	1					197	203		10.1016/0092-8674(93)90306-B	http://dx.doi.org/10.1016/0092-8674(93)90306-B			7	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8334703				2022-12-01	WOS:A1993LN62500019
J	KISHIHARA, K; PENNINGER, J; WALLACE, VA; KUNDIG, TM; KAWAI, K; WAKEHAM, A; TIMMS, E; PFEFFER, K; OHASHI, PS; THOMAS, ML; FURLONGER, C; PAIGE, CJ; MAK, TW				KISHIHARA, K; PENNINGER, J; WALLACE, VA; KUNDIG, TM; KAWAI, K; WAKEHAM, A; TIMMS, E; PFEFFER, K; OHASHI, PS; THOMAS, ML; FURLONGER, C; PAIGE, CJ; MAK, TW			NORMAL B-LYMPHOCYTE DEVELOPMENT BUT IMPAIRED T-CELL MATURATION IN CD45-EXON6 PROTEIN-TYROSINE-PHOSPHATASE DEFICIENT MICE	CELL			English	Article							LEUKOCYTE-COMMON ANTIGEN; PRE-MESSENGER-RNA; SIGNAL TRANSDUCTION; SELECTIVE EXPRESSION; SURFACE-ANTIGENS; BONE-MARROW; KINASE-C; RECEPTOR; CD45; ACTIVATION	The transmembrane tyrosine phosphatase CD45 is expressed in multiple isoforms on all nucleated hematopoietic cells, resulting from alternative splicing of variable exons. We generated mice with a mutation in the variable CD45 exon 6, using homologous recombination. In mice homozygous for the CD45-exon6 mutation, B cells and most T cells did not express CD45. Development of B cells appeared normal, although Igmu-induced proliferation was completely abrogated. Thymocyte maturation was blocked at the transitional stage from immature CD4+CD8+ to mature CD4+ or CD8+ cells, and only a few T cells could be detected in peripheral lymphoid organs. Clonal deletion of superantigen-reactive T cells still occurred. Cytotoxic T cell responses to lymphocytic choriomeningitis virus were absent in CD45-exon6-/- mice. These data imply that CD45 is differentially required for the development and function of B and T lymphocytes.	UNIV TORONTO, AMGEN INST, TORONTO M4X 1K9, ONTARIO, CANADA; UNIV TORONTO, ONTARIO CANC INST, DEPT MED BIOPHYS & IMMUNOL, TORONTO M4X 1K9, ONTARIO, CANADA; WELLESLEY COLL HOSP, RES INST, TORONTO M4Y 1J3, ONTARIO, CANADA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, HOWARD HUGHES MED INST, ST LOUIS, MO 63110 USA	University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; Howard Hughes Medical Institute; Washington University (WUSTL)			Kawai, Kazuhiro/D-4998-2011; Penninger, Josef M/I-6860-2013	Kawai, Kazuhiro/0000-0001-9375-0713; Penninger, Josef M/0000-0002-8194-3777; Pfeffer, Klaus/0000-0002-5652-6330; Ohashi, Pamela S./0000-0003-2915-9317				ACHAORBEA H, 1991, IMMUNOL TODAY, V12, P356, DOI 10.1016/0167-5699(91)90066-3; AKBAR AN, 1988, J IMMUNOL, V140, P2171; ALESMARTINEZ JE, 1991, IMMUNOL TODAY, V12, P201, DOI 10.1016/0167-5699(91)90054-W; ALEXANDER D, 1992, IMMUNOL TODAY, V13, P477, DOI 10.1016/0167-5699(92)90021-X; ALSINET E, 1990, EUR J IMMUNOL, V20, P2801, DOI 10.1002/eji.1830201240; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; BIJSTERBOSCH MK, 1985, CELL, V41, P999, DOI 10.1016/S0092-8674(85)80080-5; BIRKELAND ML, 1989, P NATL ACAD SCI USA, V86, P6734, DOI 10.1073/pnas.86.17.6734; BLACKMAN M, 1990, SCIENCE, V248, P1335, DOI 10.1126/science.1972592; BROXMEYER HE, 1991, J EXP MED, V174, P447, DOI 10.1084/jem.174.2.447; BRUNSWICK M, 1991, P NATL ACAD SCI USA, V88, P1311, DOI 10.1073/pnas.88.4.1311; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CERROTINI JC, 1974, ADV IMMUNOL, V18, P67; CHARBONNEAU H, 1992, ANNU REV CELL BIOL, V8, P463, DOI 10.1146/annurev.cellbio.8.1.463; CHARBONNEAU H, 1988, P NATL ACAD SCI USA, V85, P7182, DOI 10.1073/pnas.85.19.7182; COLLINS LS, 1987, J IMMUNOL, V138, P1082; CUMANO A, 1990, EUR J IMMUNOL, V20, P2183, DOI 10.1002/eji.1830201006; CUMANO A, 1992, EMBO J, V11, P593, DOI 10.1002/j.1460-2075.1992.tb05091.x; FISCHER EH, 1991, SCIENCE, V253, P401, DOI 10.1126/science.1650499; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207; FRANKEL WN, 1991, NATURE, V349, P526, DOI 10.1038/349526a0; FUNGLEUNG WP, 1991, J EXP MED, V174, P1425, DOI 10.1084/jem.174.6.1425; FUNGLEUNG WP, 1991, CELL, V65, P443, DOI 10.1016/0092-8674(91)90462-8; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; HATHCOCK KS, 1992, J IMMUNOL, V148, P19; HERMAN A, 1991, ANNU REV IMMUNOL, V9, P745, DOI 10.1146/annurev.iy.09.040191.003525; HORGAN KJ, 1990, EUR J IMMUNOL, V20, P1111, DOI 10.1002/eji.1830200525; HOVIS RR, 1993, SCIENCE, V260, P544, DOI 10.1126/science.8475387; HUNTER T, 1989, CELL, V58, P1013, DOI 10.1016/0092-8674(89)90496-0; HURLEY TR, 1993, MOL CELL BIOL, V13, P1651, DOI 10.1128/MCB.13.3.1651; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; JOHNSON NA, 1989, J BIOL CHEM, V264, P6220; JONG R, 1991, J IMMUNOL, V146, P2088; JULIUS MH, 1984, EUR J IMMUNOL, V14, P753, DOI 10.1002/eji.1830140816; JUSTEMENT LB, 1991, SCIENCE, V252, P1839, DOI 10.1126/science.1648262; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KEEGAN AD, 1992, IMMUNOL TODAY, V13, P63, DOI 10.1016/0167-5699(92)90136-U; KINCADE PW, 1981, J IMMUNOL, V127, P2262; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; KLAUSNER RD, 1991, CELL, V64, P875, DOI 10.1016/0092-8674(91)90310-U; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; LANSDORP PM, 1990, J EXP MED, V172, P363, DOI 10.1084/jem.172.1.363; LEFRANCOIS L, 1987, J IMMUNOL, V139, P3718; LEHMANNGRUBE F, 1971, VIROL MONOGR, V10, P1; LEIST TP, 1987, J IMMUNOL, V138, P2278; LEVIN SD, 1993, EMBO J, V12, P1671, DOI 10.1002/j.1460-2075.1993.tb05812.x; LUQMAN M, 1992, J IMMUNOL, V149, P2300; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MCFARLAND EDC, 1993, P NATL ACAD SCI USA, V90, P1402, DOI 10.1073/pnas.90.4.1402; MELCHERS F, 1993, IMMUNOL TODAY, V14, P60, DOI 10.1016/0167-5699(93)90060-X; MITTLER RS, 1987, J IMMUNOL, V138, P3159; MIZUGUCHI J, 1986, J IMMUNOL, V21, P2373; MOLINA TJ, 1992, NATURE, V357, P161, DOI 10.1038/357161a0; MUSTELIN T, 1990, ONCOGENE, V5, P809; NOMURA J, 1991, INT IMMUNOL, V3, P117, DOI 10.1093/intimm/3.2.117; OSTERGAARD HL, 1989, P NATL ACAD SCI USA, V86, P8959, DOI 10.1073/pnas.86.22.8959; PENNINGER J, 1993, SCIENCE, V260, P358, DOI 10.1126/science.8469988; PILARSKI LM, 1989, EUR J IMMUNOL, V19, P589, DOI 10.1002/eji.1830190403; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; RETH M, 1992, ANNU REV IMMUNOL, V10, P97, DOI 10.1146/annurev.immunol.10.1.97; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAGA Y, 1990, P NATL ACAD SCI USA, V87, P3728, DOI 10.1073/pnas.87.10.3728; SAUTER H, 1987, P NATL ACAD SCI USA, V84, P4989, DOI 10.1073/pnas.84.14.4989; SHIROO M, 1992, EMBO J, V11, P4887, DOI 10.1002/j.1460-2075.1992.tb05595.x; SIEH M, 1993, EMBO J, V12, P315, DOI 10.1002/j.1460-2075.1993.tb05659.x; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; STREULI M, 1989, EMBO J, V8, P787, DOI 10.1002/j.1460-2075.1989.tb03439.x; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; THOMAS ML, 1989, ANNU REV IMMUNOL, V7, P339, DOI 10.1146/annurev.iy.07.040189.002011; TONKS NK, 1988, BIOCHEMISTRY-US, V27, P8696; TROWBRIDGE IS, 1978, J EXP MED, V148, P313, DOI 10.1084/jem.148.1.313; TSAI AYM, 1989, MOL CELL BIOL, V9, P4550, DOI 10.1128/MCB.9.10.4550; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VOLAREVIC S, 1993, SCIENCE, V260, P541, DOI 10.1126/science.8475386; WALLACE VA, 1992, J EXP MED, V176, P1657, DOI 10.1084/jem.176.6.1657; WEAVER CT, 1991, MOL CELL BIOL, V11, P4415, DOI 10.1128/MCB.11.9.4415; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WELLS FB, 1993, J EXP MED, V177, P1061, DOI 10.1084/jem.177.4.1061	83	464	475	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 16	1993	74	1					143	156		10.1016/0092-8674(93)90302-7	http://dx.doi.org/10.1016/0092-8674(93)90302-7			14	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8334701				2022-12-01	WOS:A1993LN62500015
J	SKOLNIK, EY; BATZER, A; LI, N; LEE, CH; LOWENSTEIN, E; MOHAMMADI, M; MARGOLIS, B; SCHLESSINGER, J				SKOLNIK, EY; BATZER, A; LI, N; LEE, CH; LOWENSTEIN, E; MOHAMMADI, M; MARGOLIS, B; SCHLESSINGER, J			THE FUNCTION OF GRB2 IN LINKING THE INSULIN-RECEPTOR TO RAS SIGNALING PATHWAYS	SCIENCE			English	Article							MAP KINASE; PROTEIN; ACTIVATION	Insulin-induced activation of extracellular signal-regulated kinases [ERKs, also known as mitogen-activated protein (MAP) kinases] is mediated by Ras. Insulin activates Ras primarily by increasing the rate of guanine nucleotide-releasing activity. Here, we show that insulin-induced activation of ERKs was enhanced by stable overexpression of growth factor receptor-bound protein 2 (GRB2) but not by overexpression of GRB2 proteins with point mutations in the Src homology 2 and 3 domains. Moreover, a dominant negative form of Ras (with Ser17 substituted with Asn) blocked insulin-induced activation of ERKs in cells that overexpressed GRB2. GRB2 overexpression led to increased formation of a complex between the guanine nucleotide-releasing factor Sos (the product of the mammalian homolog of son of sevenless gene) and GRB2. In response to insulin stimulation, this complex bound to tyrosine-phosphorylated IRS-1 (insulin receptor substrate-1) and Shc. In contrast to the activated epidermal growth factor receptor that binds the GRB2-Sos complex directly, activation of the insulin receptor results in the interaction of GRB2-Sos with IRS-1 and Shc, thus linking the insulin receptor to Ras signaling pathways.			SKOLNIK, EY (corresponding author), NYU MED CTR, DEPT PHARMACOL, 550 1ST AVE, NEW YORK, NY 10016 USA.		Mohammadi, Moosa/ABA-6745-2020; Lee, Chi-Hon/G-9190-2012	Mohammadi, Moosa/0000-0003-2434-9437; Lee, Chi-Hon/0000-0002-6138-711X	NIDDK NIH HHS [DK01927] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K11DK001927] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BATTENSPERGER K, 1993, SCIENCE, V260, P1950; BONFINI L, 1992, SCIENCE, V255, P603, DOI 10.1126/science.1736363; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BOULTON TG, 1991, CELL REGUL, V2, P257; BOWTELL D, 1992, P NATL ACAD SCI USA, V89, P6511, DOI 10.1073/pnas.89.14.6511; BUDAY L, 1993, CELL, V73, P611, DOI 10.1016/0092-8674(93)90146-H; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DEVRIESSMITS AMM, 1992, NATURE, V357, P602, DOI 10.1038/357602a0; EGAN SE, 1993, NATURE, V363, P45, DOI 10.1038/363045a0; FARNSWORTH CL, 1991, MOL CELL BIOL, V11, P4822, DOI 10.1128/MCB.11.10.4822; GALE NW, 1993, NATURE, V363, P88, DOI 10.1038/363088a0; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; JAYE M, 1988, EMBO J, V7, P963, DOI 10.1002/j.1460-2075.1988.tb02902.x; KELLY KL, 1993, J BIOL CHEM, V268, P4391; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; OLIVIER JP, 1993, CELL, V73, P179, DOI 10.1016/0092-8674(93)90170-U; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SATOH T, 1992, J BIOL CHEM, V267, P24149; SCHWEIGHOFFER F, 1993, MOL CELL BIOL, V13, P39, DOI 10.1128/MCB.13.1.39; SIMON MA, 1993, CELL, V73, P169, DOI 10.1016/0092-8674(93)90169-Q; SIMON MA, 1991, CELL, V67, P701, DOI 10.1016/0092-8674(91)90065-7; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SKOLNIK EY, UNPUB; SUN XJ, 1991, NATURE, V352, P73, DOI 10.1038/352073a0; SUN XJ, 1992, J BIOL CHEM, V267, P22662; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	45	577	587	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 25	1993	260	5116					1953	1955		10.1126/science.8316835	http://dx.doi.org/10.1126/science.8316835			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ349	8316835				2022-12-01	WOS:A1993LJ34900046
J	GAGLIARDINI, V; FERNANDEZ, PA; LEE, RKK; DREXLER, HCA; ROTELLO, RJ; FISHMAN, MC; YUAN, J				GAGLIARDINI, V; FERNANDEZ, PA; LEE, RKK; DREXLER, HCA; ROTELLO, RJ; FISHMAN, MC; YUAN, J			PREVENTION OF VERTEBRATE NEURONAL DEATH BY THE CRMA GENE	SCIENCE			English	Article							PROGRAMMED CELL-DEATH; PROTEIN-PRECURSOR; RNA-SYNTHESIS; BCL-2; INTERLEUKIN-1; EXPRESSION; SURVIVAL	Interleukin-1beta converting enzyme (ICE) is a mammalian homolog of CED-3, a protein required for programmed cell death in the nematode Caenorhabditis elegans. The activity of ICE can be specifically inhibited by the product of crmA, a cytokine response modifier gene encoded by cowpox virus. Microinjection of the crmA gene into chicken dorsal root ganglion neurons was found to prevent cell death induced by deprivation of nerve growth factor. Thus, ICE is likely to participate in neuronal death in vertebrates.	MASSACHUSETTS GEN HOSP, CARDIOVASC RES CTR, 149 13TH ST, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School			Drexler, Hannes/AAI-3449-2020	Gagliardini, Valeria/0000-0001-9471-0764				ALLSOPP TE, 1993, CELL, V73, P295, DOI 10.1016/0092-8674(93)90230-N; BUXBAUM JD, 1992, P NATL ACAD SCI USA, V89, P10075, DOI 10.1073/pnas.89.21.10075; DAVIES AM, 1987, DEVELOPMENT, V101, P185; FORLONI G, 1992, MOL BRAIN RES, V16, P128, DOI 10.1016/0169-328X(92)90202-M; GAGLIARDINI V, UNPUB; GARCIA I, 1992, SCIENCE, V258, P302, DOI 10.1126/science.1411528; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; HARLOW E, 1988, ANTIBODIES LAB MANUA, P92; HOCKENBERY DM, 1991, P NATL ACAD SCI USA, V88, P6961, DOI 10.1073/pnas.88.16.6961; MARTIN DP, 1988, J CELL BIOL, V106, P829, DOI 10.1083/jcb.106.3.829; MAYAWAKI A, 1990, NEURON, V5, P1114; MIURA M, 1993, CELL, V75, P653, DOI 10.1016/0092-8674(93)90486-A; NUNEZ G, 1990, J IMMUNOL, V144, P3602; OPPENHEIM RW, 1990, DEV BIOL, V138, P104, DOI 10.1016/0012-1606(90)90180-Q; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; VAUX DL, 1988, NATURE, V335, P440, DOI 10.1038/335440a0; VAUX DL, 1992, SCIENCE, V258, P1955, DOI 10.1126/science.1470921; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	21	631	679	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 11	1994	263	5148					826	828		10.1126/science.8303301	http://dx.doi.org/10.1126/science.8303301			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV866	8303301				2022-12-01	WOS:A1994MV86600041
J	FERBER, I; SCHONRICH, G; SCHENKEL, J; MELLOR, AL; HAMMERLING, GJ; ARNOLD, B				FERBER, I; SCHONRICH, G; SCHENKEL, J; MELLOR, AL; HAMMERLING, GJ; ARNOLD, B			LEVELS OF PERIPHERAL T-CELL TOLERANCE INDUCED BY DIFFERENT DOSES OF TOLEROGEN	SCIENCE			English	Article							TRANSGENIC MICE; MONOCLONAL-ANTIBODIES; VIRUS-INFECTION; INDUCTION; ANTIGEN; THYMOCYTES; EXPRESSION; RECEPTORS; MECHANISM; PROTEIN	Antigen-specific immunosuppression requires an understanding of the parameters that control peripheral T cell tolerance. A liver-specific inducible promoter was used to drive the expression of the major histocompatibility complex antigen K(b) in transgenic mice. Minute amounts of K(b), expressed exclusively on hepatocytes, induced tolerance by partial down-regulation of the T cell receptor (TCR) on the self-reactive CD8+ cells. Contact of these tolerant T cells with high concentrations of K(b) after induction led to complete down-regulation of TCR. Thus, tolerant T cells are susceptible to further tolerogenic signals and reach different levels of tolerance depending on antigen dose.	DEUTSCH KREBSFORSCHUNGSZENTRUM, DEPT SOMAT GENET, TUMOR IMMUNOL PROGRAM, NEUENHEIMER FELD 280, D-69120 HEIDELBERG, GERMANY; KERNFORSCHUNGSZENTRUM KARLSRUHE, INST GENET, D-76021 KARLSRUHE, GERMANY; NATL INST MED RES, DIV MOLEC IMMUNOL, LONDON NW7 1AA, ENGLAND	Helmholtz Association; German Cancer Research Center (DKFZ); Helmholtz Association; Karlsruhe Institute of Technology; MRC National Institute for Medical Research				Schonrich, Gunther/0000-0002-5346-5704				ADORINI L, 1993, IMMUNOL TODAY, V14, P285, DOI 10.1016/0167-5699(93)90047-O; CILIBERTO G, 1987, EMBO J, V6, P4017, DOI 10.1002/j.1460-2075.1987.tb02745.x; COBBOLD SP, 1992, IMMUNOL REV, V129, P165, DOI 10.1111/j.1600-065X.1992.tb01423.x; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; FIELDS LE, 1992, P NATL ACAD SCI USA, V89, P5730, DOI 10.1073/pnas.89.13.5730; GEIGER T, 1992, P NATL ACAD SCI USA, V89, P2985, DOI 10.1073/pnas.89.7.2985; HEATH WR, 1992, NATURE, V359, P547, DOI 10.1038/359547a0; HUA C, 1986, J IMMUNOL, V136, P1937; KAPPLER JW, 1987, CELL, V49, P263, DOI 10.1016/0092-8674(87)90567-8; KAST WM, 1988, EUR J IMMUNOL, V18, P2105; KISIELOW P, 1988, NATURE, V333, P742, DOI 10.1038/333742a0; Kohler G., 1981, IMMUNE SYSTEM, V2, P202; KUBO RT, 1989, J IMMUNOL, V142, P2736; LANZAVECCHIA A, 1993, SCIENCE, V260, P937, DOI 10.1126/science.8493532; LEDBETTER JA, 1979, IMMUNOL REV, V47, P63, DOI 10.1111/j.1600-065X.1979.tb00289.x; LO D, 1986, NATURE, V319, P672, DOI 10.1038/319672a0; LO D, 1992, EUR J IMMUNOL, V22, P1013, DOI 10.1002/eji.1830220421; MURPHY KM, 1990, SCIENCE, V250, P1720, DOI 10.1126/science.2125367; OHASHI PS, 1991, CELL, V65, P305, DOI 10.1016/0092-8674(91)90164-T; OLDSTONE MBA, 1991, CELL, V65, P319, DOI 10.1016/0092-8674(91)90165-U; SCHONRICH G, 1992, INT IMMUNOL, V4, P581, DOI 10.1093/intimm/4.5.581; SCHONRICH G, 1991, CELL, V65, P293, DOI 10.1016/0092-8674(91)90163-S; Seglen P O, 1976, Methods Cell Biol, V13, P29, DOI 10.1016/S0091-679X(08)61797-5; SIMPSON SJ, 1993, INT IMMUNOL, V5, P189, DOI 10.1093/intimm/5.2.189; YAGITA H, 1989, P NATL ACAD SCI USA, V86, P645, DOI 10.1073/pnas.86.2.645	25	205	208	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	FEB 4	1994	263	5147					674	676		10.1126/science.8303275	http://dx.doi.org/10.1126/science.8303275			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8303275				2022-12-01	WOS:A1994MU96400046
J	REBAR, EJ; PABO, CO				REBAR, EJ; PABO, CO			ZINC-FINGER PHAGE - AFFINITY SELECTION OF FINGERS WITH NEW DNA-BINDING SPECIFICITIES	SCIENCE			English	Article							RECOGNITION; PROTEIN; SEQUENCES; DOMAINS	A phage display system was developed and used to select zinc finger proteins with altered DNA-binding specificities. The three zinc fingers of the Zif268 protein were expressed on the surface of filamentous phage, and a library of variants was prepared by randomizing critical amino acids in the first zinc finger. Affinity selections, using DNA sites with base changes in the region recognized by the first finger, yielded Zif268 variants that bound tightly and specifically to the new sites. This phage system provides a tool for the study of protein-DNA interactions and may offer a general method for selecting zinc finger proteins that recognize desired target sites on double-stranded DNA.			REBAR, EJ (corresponding author), MIT,DEPT BIOL,CAMBRIDGE,MA 02139, USA.							CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DESJARLAIS JR, 1993, P NATL ACAD SCI USA, V90, P2256, DOI 10.1073/pnas.90.6.2256; DESJARLAIS JR, 1992, P NATL ACAD SCI USA, V89, P7345, DOI 10.1073/pnas.89.16.7345; FAIRALL L, 1993, NATURE, V366, P483, DOI 10.1038/366483a0; HOESS RH, 1993, CURR OPIN STRUC BIOL, V3, P572, DOI 10.1016/0959-440X(93)90085-Y; HOESS RH, 1993, CURR OPIN STRUCT BIO, V217, P228; JACOBS GH, 1992, EMBO J, V11, P4507, DOI 10.1002/j.1460-2075.1992.tb05552.x; JAMIESON A, IN PRESS BIOCHEMISTR; KLEVIT RE, 1991, SCIENCE, V253, P1367, DOI 10.1126/science.1896847; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; PARMLEY SF, 1988, GENE, V73, P305, DOI 10.1016/0378-1119(88)90495-7; PAVLETICH NP, 1993, SCIENCE, V261, P1701, DOI 10.1126/science.8378770; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PELLEGRINO GR, 1991, P NATL ACAD SCI USA, V88, P671, DOI 10.1073/pnas.88.2.671; SCOTT JK, 1990, SCIENCE, V249, P386, DOI 10.1126/science.1696028; SMITH GP, 1993, METHOD ENZYMOL, V217, P228	16	364	477	1	30	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 4	1994	263	5147					671	673		10.1126/science.8303274	http://dx.doi.org/10.1126/science.8303274			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8303274				2022-12-01	WOS:A1994MU96400045
J	SATARIANO, WA; RAGLAND, DR				SATARIANO, WA; RAGLAND, DR			THE EFFECT OF COMORBIDITY ON 3-YEAR SURVIVAL OF WOMEN WITH PRIMARY BREAST-CANCER	ANNALS OF INTERNAL MEDICINE			English	Article						BREAST NEOPLASMS; COMORBIDITY; MASS SCREENING; NEOPLASM STAGING; AGE FACTORS	OLDER WOMEN; CLINICAL-TRIALS; QUALITY	Objective: To determine the effect of comorbidity and stage of disease on 3-year survival in women with primary breast cancer. Design: Longitudinal, observational study. Setting: Metropolitan Detroit. Patients: 936 women ages 40 to 84 years. Measurements: Data on stage of breast cancer, treatment type, and comorbidity were obtained from Metropolitan Detroit Cancer Surveillance System (MDCSS) files and medical records. Personal interviews were the source of information on social and behavioral factors. Vital status and cause of death were obtained from MDCSS files. Results: Patients who had 3 or more of 7 selected comorbid conditions had a 20-fold higher rate of mortality from causes other than breast cancer and a 4-fold higher rate of all-cause mortality when compared with patients who had no comorbid conditions. The effects of comorbidity were independent of age, disease stage, tumor size, histologic type, type of treatment, race, and social and behavioral factors. Moreover, women with severe comorbid conditions had uniformly higher mortality rates, and early diagnosis in these women conferred no survival advantage. Conclusion: Comorbidity in patients with breast cancer appears to be a strong predictor of 3-year survival, independent of the effects of breast cancer stage. This finding suggests that trials assessing the efficacy of screening should routinely include measures of comorbidity.			SATARIANO, WA (corresponding author), UNIV CALIF BERKELEY, GRAD SCH PUBL HLTH, EPIDEMIOL PROGRAM, BERKELEY, CA 94720 USA.		Ragland, David R/G-6302-2017	Ragland, David R/0000-0002-8996-1320	NCI NIH HHS [N01 CN-55423] Funding Source: Medline; NIA NIH HHS [R01-AG04969] Funding Source: Medline; DIVISION OF CANCER PREVENTION AND CONTROL [N01CN055423] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG004969] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); DIVISION OF CANCER PREVENTION AND CONTROL(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BASSETT MT, 1986, AM J PUBLIC HEALTH, V76, P1400, DOI 10.2105/AJPH.76.12.1400; BERKMAN LF, 1983, HLTH WAYS LIVING ALA, P83; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; COHEN HJ, 1992, J GERONTOL, V47, P134; COSTANZA ME, 1992, CANCER, V69, P1925, DOI 10.1002/1097-0142(19920401)69:7+<1925::AID-CNCR2820691709>3.0.CO;2-U; COX DR, 1972, J R STAT SOC B, V34, P187; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; GURALNIK JM, 1989, ADV DATA VITAL HLTH; MANDELBLATT JS, 1992, ANN INTERN MED, V116, P722, DOI 10.7326/0003-4819-116-9-722; MOINPOUR CM, 1989, J NATL CANCER I, V81, P485, DOI 10.1093/jnci/81.7.485; MOR V, 1992, J GERONTOL, V47, P43; RIES LAG, 1991, NIH912789 PUB; SATARIANO WA, 1992, J GERONTOL, V47, P24; Satariano WA, 1989, CANC ELDERLY APPROAC, P71; SHAMBAUGH EM, 1977, SUMMARY STAGING GUID; SKEEL RT, 1989, J NATL CANCER I, V81, P472, DOI 10.1093/jnci/81.7.472; YOUNG JL, 1981, NCI MONOGRAPH, V57; 1989, J AM GERIATR SOC, V37, P883	18	550	553	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1994	120	2					104	110		10.7326/0003-4819-120-2-199401150-00002	http://dx.doi.org/10.7326/0003-4819-120-2-199401150-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ671	8256968				2022-12-01	WOS:A1994MQ67100002
J	HINZ, U; GIEBEL, B; CAMPOSORTEGA, JA				HINZ, U; GIEBEL, B; CAMPOSORTEGA, JA			THE BASIC-HELIX-LOOP-HELIX DOMAIN OF DROSOPHILA LETHAL OF SCUTE PROTEIN IS SUFFICIENT FOR PRONEURAL FUNCTION AND ACTIVATES NEUROGENIC GENES	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; SENSORY ORGAN DEVELOPMENT; X-A RATIO; ACHAETE-SCUTE; SEX DETERMINATION; DNA-BINDING; LATERAL INHIBITION; ENHANCER DETECTION; MOLECULAR ANALYSIS; WING DISK	The development of most epidermal sensory organs in Drosophila is controlled by achaete and scute, two of the genes of the achaete-scute complex (AS-C). The genes of the AS-C encode members of the basic-helix-loop-helix (bHLH) class of transcriptional regulators, and their activity defines proneural cell clusters in the imaginal discs from which sensory organ mother cells are singled out by a process of lateral inhibition. Ectopic expression of lethal of scute, another member of the AS-C, normally dispensable for sensory organ development in the adult, promotes this process independently of the activity of the other AS-C genes. This demonstrates a high degree of functional redundancy of the products of the AS-C. Furthermore, neurogenic genes are activated in ectopic proneural clusters, allowing development of epidermal progenitor cells. Finally, the bHLH domain is necessary and sufficient to mediate the proneural function, to activate neurogenic genes, and to allow lateral inhibition.			HINZ, U (corresponding author), UNIV COLOGNE, INST ENTWICKLUNGSBIOL, D-50923 COLOGNE, GERMANY.		Giebel, Bernd/AAH-1083-2021	Giebel, Bernd/0000-0003-2446-948X				ALONSO MC, 1988, EMBO J, V7, P2585, DOI 10.1002/j.1460-2075.1988.tb03108.x; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BALCELLS L, 1988, EMBO J, V7, P3899, DOI 10.1002/j.1460-2075.1988.tb03276.x; BELLEN HJ, 1989, GENE DEV, V3, P1288, DOI 10.1101/gad.3.9.1288; BOULIANNE GL, 1991, EMBO J, V10, P2975, DOI 10.1002/j.1460-2075.1991.tb07848.x; BRAND AH, 1993, DEVELOPMENT, V118, P401; BRAND M, 1990, ROUX ARCH DEV BIOL, V198, P275, DOI 10.1007/BF00377394; Bryant P.J., 1978, P230; CABRERA CV, 1990, DEVELOPMENT, V109, P733; CABRERA CV, 1992, DEVELOPMENT, V115, P893; CABRERA CV, 1991, EMBO J, V10, P2965, DOI 10.1002/j.1460-2075.1991.tb07847.x; CAMPOSORTEGA JA, 1992, ROUX ARCH DEV BIOL, V201, P1, DOI 10.1007/BF00188770; CAMPOSORTEGA JA, 1993, IN PRESS DEV DROSOPH; CAMPUZANO S, 1985, CELL, V40, P327, DOI 10.1016/0092-8674(85)90147-3; CAMPUZANO S, 1992, TRENDS GENET, V8, P202, DOI 10.1016/0168-9525(92)90234-U; CAUDY M, 1988, CELL, V55, P1061, DOI 10.1016/0092-8674(88)90250-4; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CHEN EY, 1985, DNA-J MOLEC CELL BIO, V4, P165, DOI 10.1089/dna.1985.4.165; CRONMILLER C, 1988, GENE DEV, V2, P1666, DOI 10.1101/gad.2.12a.1666; CUBAS P, 1992, EMBO J, V11, P3385, DOI 10.1002/j.1460-2075.1992.tb05417.x; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DAMBLYCHAUDIERE C, 1987, GENE DEV, V1, P297, DOI 10.1101/gad.1.3.297; DAMBLYCHAUDIERE C, 1988, ROUX ARCH DEV BIOL, V197, P419, DOI 10.1007/BF00398993; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DECELIS JF, 1991, ROUX ARCH DEV BIOL, V200, P64, DOI 10.1007/BF00637186; DELIDAKIS C, 1992, P NATL ACAD SCI USA, V89, P8731, DOI 10.1073/pnas.89.18.8731; DOMINGUEZ M, 1993, EMBO J, V12, P2049, DOI 10.1002/j.1460-2075.1993.tb05854.x; ELLIS HM, 1990, CELL, V61, P27, DOI 10.1016/0092-8674(90)90212-W; ERICKSON JW, 1991, SCIENCE, V251, P1071, DOI 10.1126/science.1900130; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; Garcia-Bellido A, 1975, Ciba Found Symp, V0, P161; GARCIABELLIDO A, 1978, GENETICS, V88, P469; GARCIABELLIDO A, 1979, GENETICS, V91, P491; GARRELL J, 1990, CELL, V61, P39, DOI 10.1016/0092-8674(90)90213-X; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GONZALEZ F, 1989, EMBO J, V8, P3553, DOI 10.1002/j.1460-2075.1989.tb08527.x; HARTENSTEIN V, 1989, DEVELOPMENT, V107, P389; HUANG F, 1991, DEVELOPMENT, V111, P1087; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; JIMENEZ F, 1979, NATURE, V282, P310, DOI 10.1038/282310a0; JIMENEZ F, 1987, J NEUROGENET, V4, P179, DOI 10.3109/01677068709102340; KLAMBT C, 1989, EMBO J, V8, P203, DOI 10.1002/j.1460-2075.1989.tb03365.x; KNUST E, 1987, EMBO J, V6, P4113, DOI 10.1002/j.1460-2075.1987.tb02757.x; KNUST E, 1992, GENETICS, V132, P505; LASKI FA, 1986, CELL, V44, P7, DOI 10.1016/0092-8674(86)90480-0; LEVIS R, 1985, SCIENCE, V229, P558, DOI 10.1126/science.2992080; LEYNS L, 1989, ROUX ARCH DEV BIOL, V198, P227, DOI 10.1007/BF00375909; Lindsley D.L., 1992, GENOME DROSOPHILA ME; MARTINBERMUDO MD, 1991, DEVELOPMENT, V113, P445; MARTINBERMUDO MD, 1993, DEVELOPMENT, V118, P1003; MARTINEZ C, 1991, SCIENCE, V251, P1485, DOI 10.1126/science.1900954; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; MURRE C, 1989, CELL, V58, P537, DOI 10.1016/0092-8674(89)90434-0; NUSSLEINVOLHARD C, 1984, ROUX ARCH DEV BIOL, V193, P267, DOI 10.1007/BF00848156; OKANE CJ, 1987, P NATL ACAD SCI USA, V84, P9123, DOI 10.1073/pnas.84.24.9123; PARKHURST SM, 1990, CELL, V63, P1179, DOI 10.1016/0092-8674(90)90414-A; PARKHURST SM, 1993, DEVELOPMENT, V117, P737; ROBERTSON HM, 1988, GENETICS, V118, P461; RODRIGUEZ I, 1990, EMBO J, V9, P3583, DOI 10.1002/j.1460-2075.1990.tb07569.x; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; RUEL L, 1993, NATURE, V362, P557, DOI 10.1038/362557a0; RUIZGOMEZ M, 1987, GENE DEV, V1, P1238, DOI 10.1101/gad.1.10.1238; RUIZGOMEZ M, 1993, EMBO J, V12, P1121, DOI 10.1002/j.1460-2075.1993.tb05753.x; RUSHLOW CA, 1989, EMBO J, V8, P3095, DOI 10.1002/j.1460-2075.1989.tb08461.x; SIMPSON P, 1990, DEVELOPMENT, V109, P509; SKEATH JB, 1991, GENE DEV, V5, P984, DOI 10.1101/gad.5.6.984; SKEATH JB, 1992, GENE DEV, V6, P2606, DOI 10.1101/gad.6.12b.2606; SPRADLING AC, 1983, CELL, V34, P47, DOI 10.1016/0092-8674(83)90135-6; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TORRES M, 1989, EMBO J, V8, P3079, DOI 10.1002/j.1460-2075.1989.tb08459.x; TORRES M, 1991, DEVELOPMENT, V113, P715; VANDOREN M, 1992, GENE DEV, V6, P2592, DOI 10.1101/gad.6.12b.2592; VANDOREN M, 1991, DEVELOPMENT, V113, P245; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; VILLARES R, 1987, CELL, V50, P415, DOI 10.1016/0092-8674(87)90495-8; WAGNERBERNHOLZ JT, 1991, GENE DEV, V5, P2467, DOI 10.1101/gad.5.12b.2467	78	284	285	0	2	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	1994	76	1					77	87		10.1016/0092-8674(94)90174-0	http://dx.doi.org/10.1016/0092-8674(94)90174-0			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287481				2022-12-01	WOS:A1994MR49500008
J	TURNER, R				TURNER, R			BIG-BROTHER IS LOOKING AFTER YOUR HEALTH	BRITISH MEDICAL JOURNAL			English	Article											TURNER, R (corresponding author), E RIDING HLTH,KINGSTON HULL HU10 6DT,ENGLAND.								0	1	1	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1623	1624		10.1136/bmj.307.6919.1623	http://dx.doi.org/10.1136/bmj.307.6919.1623			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292961	Green Published, Bronze			2022-12-01	WOS:A1993MN10700029
J	KONDO, M; TAKESHITA, T; ISHII, N; NAKAMURA, M; WATANABE, S; ARAI, K; SUGAMURA, K				KONDO, M; TAKESHITA, T; ISHII, N; NAKAMURA, M; WATANABE, S; ARAI, K; SUGAMURA, K			SHARING OF THE INTERLEUKIN-2 (IL-2) RECEPTOR GAMMA-CHAIN BETWEEN RECEPTORS FOR IL-2 AND IL-4	SCIENCE			English	Article							T-CELLS; BETA-CHAIN; MONOCLONAL-ANTIBODIES; EXPRESSION CLONING; B-CELLS; GM-CSF; GENERATION; DEFICIENT; MOLECULE; SUBUNIT	The gamma chain of the interleukin-2 (IL-2) receptor is an indispensable subunit for IL-2 binding and intracellular signal transduction. A monoclonal antibody to the gamma chain, TUGm2, inhibited IL-2 binding to the functional IL-2 receptors and also inhibited IL-4-induced cell growth and the high-affinity binding of IL-4 to the CTLL-2 mouse T cell line. Another monoclonal antibody, TUGm3, which reacted with the gamma chain cross-linked with IL-2, also immunoprecipitated the gamma chain when cross-linked with IL-4. These results suggest that the IL-2 receptor gamma chain is functionally involved in the IL-4 receptor complex.	TOHOKU UNIV,SCH MED,DEPT MICROBIOL,SENDAI,MIYAGI 980,JAPAN; UNIV TOKYO,INST MED SCI,DEPT MOLEC & DEV BIOL,TOKYO 108,JAPAN	Tohoku University; University of Tokyo			Takeshita, Toshikazu/AAL-1382-2021	Ishii, Naoto/0000-0002-0549-8245				ASAO H, 1993, P NATL ACAD SCI USA, V90, P4127, DOI 10.1073/pnas.90.9.4127; BECKMANN MP, 1990, J IMMUNOL, V144, P4212; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DISANTO JP, 1990, J EXP MED, V171, P1697, DOI 10.1084/jem.171.5.1697; FERNANDEZBOTRAN R, 1989, J EXP MED, V169, P379, DOI 10.1084/jem.169.2.379; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HARADA N, 1990, P NATL ACAD SCI USA, V87, P857, DOI 10.1073/pnas.87.3.857; KARASUYAMA H, 1990, J EXP MED, V172, P969, DOI 10.1084/jem.172.3.969; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KONDO M, UNPUB; KOPF M, 1993, NATURE, V362, P245, DOI 10.1038/362245a0; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; KUMAKI S, 1993, BIOCHEM BIOPH RES CO, V193, P356, DOI 10.1006/bbrc.1993.1631; LEE HK, 1990, J IMMUNOL, V144, P3431; MARTINEZ OM, 1990, J IMMUNOL, V144, P2211; MINAMI Y, 1993, ANNU REV IMMUNOL, V11, P245, DOI 10.1146/annurev.iy.11.040193.001333; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.iy.10.040192.001455; MOSLEY B, 1989, CELL, V59, P335, DOI 10.1016/0092-8674(89)90295-X; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; SCHORLE H, 1991, NATURE, V352, P621, DOI 10.1038/352621a0; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; TAGA T, 1993, FASEB J, V7, P3387; TAKESHITA T, 1989, J EXP MED, V169, P1323, DOI 10.1084/jem.169.4.1323; TAKESHITA T, 1992, J IMMUNOL, V148, P2154; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANAKA T, 1991, J IMMUNOL, V147, P2222; TANAKA Y, 1990, INT J CANCER, V46, P675, DOI 10.1002/ijc.2910460421; TATENO M, 1984, J EXP MED, V159, P1105, DOI 10.1084/jem.159.4.1105; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; YOKOTA T, 1988, IMMUNOL REV, V102, P137, DOI 10.1111/j.1600-065X.1988.tb00744.x; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	32	774	814	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 17	1993	262	5141					1874	1877		10.1126/science.8266076	http://dx.doi.org/10.1126/science.8266076			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266076				2022-12-01	WOS:A1993MM51100036
J	ZHOU, Z; ELLEDGE, SJ				ZHOU, Z; ELLEDGE, SJ			DUN1 ENCODES A PROTEIN-KINASE THAT CONTROLS THE DNA-DAMAGE RESPONSE IN YEAST	CELL			English	Article							SACCHAROMYCES-CEREVISIAE; RIBONUCLEOTIDE REDUCTASE; CELL-CYCLE; SMALL SUBUNIT; GENE; IDENTIFICATION; EXPRESSION; TRANSCRIPTION; MUTAGENESIS; AGENTS	DNA damage induces the expression of many genes proposed to enhance DNA repair capacities. We investigated the mechanism by which DNA damage induces transcription of RNR3, a subunit of ribonucleotide reductase. Five complementation groups of DNA-damage uninducible (dun) mutants were identified. Each is sensitive to DNA damage. dun1 mutants are also defective for RNR1 and RNR2 induction but are proficient for induction of other genes, defining the existence of at least two distinct DNA damage induction pathways. DUN1 encodes a nuclear protein kinase that is also a phosphoprotein. Phosphorylation of Dun1 increases in response to DNA damage in a Dun1-dependent manner, suggesting an increase in autophosphorylation activity. These results establish the existence of a eukaryotic SOS response regulated by protein phosphorylation.	BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA; BAYLOR COLL MED, INST MOLEC GENET, HOUSTON, TX 77030 USA	Baylor College of Medicine; Baylor College of Medicine	ZHOU, Z (corresponding author), BAYLOR COLL MED, HOWARD HUGHES INST, HOUSTON, TX 77030 USA.				NIGMS NIH HHS [GM44664] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM044664, R01GM044664] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BOULET A, 1989, EMBO J, V8, P1849, DOI 10.1002/j.1460-2075.1989.tb03580.x; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; ELLEDGE SJ, 1989, MOL CELL BIOL, V9, P4932, DOI 10.1128/MCB.9.11.4932; ELLEDGE SJ, 1993, BIOESSAYS, V15, P333, DOI 10.1002/bies.950150507; ELLEDGE SJ, 1992, P NATL ACAD SCI USA, V89, P2907, DOI 10.1073/pnas.89.7.2907; ELLEDGE SJ, 1990, GENE DEV, V4, P740, DOI 10.1101/gad.4.5.740; ELLEDGE SJ, 1987, MOL CELL BIOL, V7, P2783, DOI 10.1128/MCB.7.8.2783; ELLEDGE SJ, 1989, MOL CELL BIOL, V9, P5373, DOI 10.1128/MCB.9.12.5373; Friedberg E.C., 1991, MOL CELLULAR BIOL TE, P147; Gale E. F., 1981, MOL BASIS ANTIBIOTIC, V2nd; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HERRLICH P, 1992, REV PHYSIOL BIOCH P, V119, P187; HITTELMAN WN, 1974, CANCER RES, V34, P3433; HURD HK, 1987, MOL CELL BIOL, V7, P3673, DOI 10.1128/MCB.7.10.3673; JONES DA, 1991, FEBS LETT, V289, P105, DOI 10.1016/0014-5793(91)80919-T; KASTAN MB, 1992, CELL, V71, P587, DOI 10.1016/0092-8674(92)90593-2; KELEHER CA, 1992, CELL, V68, P709, DOI 10.1016/0092-8674(92)90146-4; LEVIN NA, 1993, GENETICS, V133, P799; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; OZKAYNAK E, 1984, NATURE, V312, P663, DOI 10.1038/312663a0; Radman M., 1974, MOL ENV ASPECTS MUTA, P128; ROSE MD, 1990, METHODS YEAST GENETI; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; SASSANFAR M, 1990, J MOL BIOL, V212, P79, DOI 10.1016/0022-2836(90)90306-7; SCHILD D, 1990, P NATL ACAD SCI USA, V87, P2916, DOI 10.1073/pnas.87.8.2916; SEIFERT HS, 1986, P NATL ACAD SCI USA, V83, P735, DOI 10.1073/pnas.83.3.735; SIKORSKI RS, 1989, GENETICS, V122, P19; TAN JL, 1991, J BIOL CHEM, V266, P16044; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; TREGER JM, 1990, MOL CELL BIOL, V10, P3174, DOI 10.1128/MCB.10.6.3174; TREGER JM, 1988, MOL CELL BIOL, V8, P1132, DOI 10.1128/MCB.8.3.1132; WALKER GC, 1985, ANNU REV BIOCHEM, V54, P425, DOI 10.1146/annurev.bi.54.070185.002233; WEINERT TA, 1993, GENETICS, V134, P63; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0; ZHOU Z, 1992, GENETICS, V131, P851	36	291	302	2	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 17	1993	75	6					1119	1127		10.1016/0092-8674(93)90321-G	http://dx.doi.org/10.1016/0092-8674(93)90321-G			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	8261511				2022-12-01	WOS:A1993MM89300010
J	MERMEL, LA; MAKI, DG				MERMEL, LA; MAKI, DG			DETECTION OF BACTEREMIA IN ADULTS - CONSEQUENCES OF CULTURING AN INADEQUATE VOLUME OF BLOOD	ANNALS OF INTERNAL MEDICINE			English	Article						BACTEREMIA; BACTERIOLOGICAL TECHNIQUES; CELLS, CULTURED; SENSITIVITY AND SPECIFICITY; QUALITY ASSURANCE, HEALTH; CARE	LYSIS-CENTRIFUGATION; CLINICAL-EVALUATION; FUNGEMIA; SYSTEM; MEDIA; YIELD; PLUS	The yield of blood cultures depends on the volume of blood cultured. We recently discovered that 15% of blood-culture specimens from adults in our hospital were being collected in 3.5-mL pediatric tubes and that another 5%, drawn in 10-mL adult tubes, contained less than 5 mL of blood. A comparison of 829 matched pairs of standard-volume (mean, 8.7 mL) and low-volume (mean, 2.7 mL) blood cultures showed that standard-volume cultures had a substantially higher detection rate for bloodstream infection than did low-volume cultures (92% compared with 69%; difference, 23% [95% CI, 9% to 37%]; P < 0.001). Our data, together with an analysis of previous studies, show that the yield of blood cultures in adults increases approximately 3% per millilitre of blood cultured. A survey of 158 U.S. clinical microbiology laboratory directors in the American Society of Clinical Pathologists showed that only 20% of 71 responding laboratories record the volume of blood submitted for culture and that the practice of culturing suboptimal volumes of blood from adults is widespread. Clinical laboratories should routinely monitor the volume of blood cultured as a quality-assurance measure. Blood-culture specimens from adults should not be drawn using small pediatric tubes.	UNIV WISCONSIN HOSP & CLIN, MADISON, WI USA	University of Wisconsin System; University of Wisconsin Madison			Mermel, Leonard/Z-1475-2019					ARONSON MD, 1987, ANN INTERN MED, V106, P246, DOI 10.7326/0003-4819-106-2-246; ARPI M, 1989, EUR J CLIN MICROBIOL, V8, P838, DOI 10.1007/BF02185857; BRANNON P, 1985, J CLIN MICROBIOL, V22, P951, DOI 10.1128/JCM.22.6.951-954.1985; BROWN DFJ, 1990, J CLIN PATHOL, V43, P777, DOI 10.1136/jcp.43.9.777; BRYAN CS, 1986, AM J EPIDEMIOL, V123, P113, DOI 10.1093/oxfordjournals.aje.a114205; DORN GL, 1976, J CLIN MICROBIOL, V3, P258; HALL MM, 1976, J CLIN MICROBIOL, V3, P643; HENRY NK, 1983, J CLIN MICROBIOL, V17, P864, DOI 10.1128/JCM.17.5.864-869.1983; ILSTRUP DM, 1983, DIAGN MICR INFEC DIS, V1, P107, DOI 10.1016/0732-8893(83)90039-1; ISENBERG HD, 1985, MANUAL CLIN MICROBIO, P73; KELLOGG JA, 1984, J CLIN MICROBIOL, V20, P618, DOI 10.1128/JCM.20.4.618-623.1984; KOONTZ FP, 1991, DIAGN MICR INFEC DIS, V14, P111, DOI 10.1016/0732-8893(91)90044-G; LO P, 1991, 30TH INT C ANT AG CH; PLORDE JJ, 1985, J CLIN MICROBIOL, V22, P292, DOI 10.1128/JCM.22.2.292-295.1985; RELLER LB, 1982, CUMULATIVE TECHNIQUE, P1; SALVENTI JF, 1979, J CLIN MICROBIOL, V9, P248; SANDVEN P, 1981, ACTA PATH MICRO IM B, V89, P149; SHANSON DC, 1984, J CLIN PATHOL, V37, P568, DOI 10.1136/jcp.37.5.568; STRAND CL, 1988, BLOODSTREAM INFECTIO, P7; TARRAND JJ, 1991, J CLIN MICROBIOL, V29, P2245, DOI 10.1128/JCM.29.10.2245-2249.1991; TELENTI A, 1991, MAYO CLIN PROC, V66, P1120, DOI 10.1016/S0025-6196(12)65791-7; TENNEY JH, 1982, J CLIN MICROBIOL, V15, P558, DOI 10.1128/JCM.15.4.558-561.1982; WASHINGTON JA, 1986, REV INFECT DIS, V8, P792; WEINSTEIN MP, 1983, REV INFECT DIS, V5, P54; WICHER K, 1984, J CLIN MICROBIOL, V20, P668, DOI 10.1128/JCM.20.4.668-671.1984; 1990, HOSPITAL INFECT  AUG, P1; 1990, MMWR, V39, P31	27	173	187	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1993	119	4					270	272		10.7326/0003-4819-119-4-199308150-00003	http://dx.doi.org/10.7326/0003-4819-119-4-199308150-00003			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV525	8328734				2022-12-01	WOS:A1993LV52500003
J	HANDEL, TM; WILLIAMS, SA; DEGRADO, WF				HANDEL, TM; WILLIAMS, SA; DEGRADO, WF			METAL-ION DEPENDENT MODULATION OF THE DYNAMICS OF A DESIGNED PROTEIN	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; 4-HELIX BUNDLE PROTEIN; MOLTEN GLOBULE STATE; FOLDING INTERMEDIATE; STRUCTURAL CHARACTERIZATION; SECONDARY STRUCTURE; HYDROGEN-EXCHANGE; ALPHA-LACTALBUMIN; DENOVO DESIGN; CYTOCHROME-C	The peptide a 4 is a designed four-helix bundle that contains a highly simplified hydrophobic core composed exclusively of leucine residues; its tertiary structure is therefore largely dictated by hydrophobic forces. This small protein adopts a structure with properties intermediate between those of the native and molten globule states of proteins: it is compact, globular, and has very stable helices, but its apolar side chains are mobile and not as well packed as in many natural proteins. To induce a more native-like state, two Zn2+-binding sites were introduced into the protein, thereby replacing some of the nonspecific hydrophobic interactions with more geometrically restrictive metal-ligand interactions. In the metal-bound state, this protein has properties that approach those of native proteins. Thus, hydrophobic interactions alone are sufficient to drive polypeptide chain folding nearly to completion, but specific interactions are required for a unique structure.	UNIV PENN,REG LASER & BIOTECHNOL LAB,PHILADELPHIA,PA 19104; UNIV PENN,DEPT BIOCHEM & BIOPHYS,JOHNSON RES FDN,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania	HANDEL, TM (corresponding author), DUPONT MERCK PHARMACEUT CO,POB 80328,WILMINGTON,DE 19880, USA.		Williams, Scott/AAG-7029-2020					AKKE M, 1991, J MOL BIOL, V220, P173, DOI 10.1016/0022-2836(91)90389-N; AKKE M, 1992, BIOCHEMISTRY-US, V31, P1011, DOI 10.1021/bi00119a009; ALEXANDER P, 1992, BIOCHEMISTRY-US, V31, P3597, DOI 10.1021/bi00129a007; BABU YS, 1988, J MOL BIOL, V204, P191, DOI 10.1016/0022-2836(88)90608-0; BALDWIN R L, 1991, Current Biology, V1, P218, DOI 10.1016/0960-9822(91)90061-Z; BALDWIN RL, 1986, P NATL ACAD SCI USA, V83, P8069, DOI 10.1073/pnas.83.21.8069; BRIGGS MS, 1992, P NATL ACAD SCI USA, V89, P2017, DOI 10.1073/pnas.89.6.2017; BYCROFT M, 1990, NATURE, V346, P488, DOI 10.1038/346488a0; CHEN BL, 1989, BIOCHEMISTRY-US, V28, P685, DOI 10.1021/bi00428a041; DEGRADO WF, 1987, COLD SPRING HARB SYM, V52, P521, DOI 10.1101/SQB.1987.052.01.059; DEGRADO WF, 1989, SCIENCE, V243, P622, DOI 10.1126/science.2464850; DeGrado WF, 1991, CURR OPIN STRUC BIOL, V1, P984, DOI 10.1016/0959-440X(91)90095-B; DILL KA, 1991, ANNU REV BIOCHEM, V60, P795, DOI 10.1146/annurev.bi.60.070191.004051; DILL KA, 1990, BIOCHEMISTRY-US, V29, P7133, DOI 10.1021/bi00483a001; GODZIK A, IN PRESS P NATL ACAD; GOTO Y, 1989, BIOCHEMISTRY-US, V28, P945, DOI 10.1021/bi00429a004; HAHN KW, 1990, SCIENCE, V248, P1544, DOI 10.1126/science.2360048; HANDEL T, 1990, J AM CHEM SOC, V112, P6710, DOI 10.1021/ja00174a039; HECHT MH, 1990, SCIENCE, V249, P884, DOI 10.1126/science.2392678; HO SP, 1987, J AM CHEM SOC, V109, P6751, DOI 10.1021/ja00256a032; HUGHSON FM, 1990, SCIENCE, V249, P1544, DOI 10.1126/science.2218495; IKEGUCHI M, 1986, BIOCHEMISTRY-US, V25, P6965, DOI 10.1021/bi00370a034; JENG MF, 1990, BIOCHEMISTRY-US, V29, P10433, DOI 10.1021/bi00498a001; KAISER ET, 1984, SCIENCE, V223, P249, DOI 10.1126/science.6322295; KUWAJIMA K, 1989, PROTEINS, V6, P87, DOI 10.1002/prot.340060202; LANGSETMO K, 1991, BIOCHEMISTRY-US, V30, P7609, DOI 10.1021/bi00244a033; LU JR, 1992, BIOCHEMISTRY-US, V31, P4749, DOI 10.1021/bi00135a002; MATOUSCHEK A, 1992, J MOL BIOL, V224, P837, DOI 10.1016/0022-2836(92)90565-2; MCGREGOR MJ, 1987, J MOL BIOL, V198, P295, DOI 10.1016/0022-2836(87)90314-7; MICHAEL SF, 1992, P NATL ACAD SCI USA, V89, P4796, DOI 10.1073/pnas.89.11.4796; MORII H, 1991, PROTEINS, V11, P133, DOI 10.1002/prot.340110206; MULQUEEN PM, 1982, ARCH BIOCHEM BIOPHYS, V215, P28, DOI 10.1016/0003-9861(82)90275-2; MURPHY KP, 1990, SCIENCE, V247, P559, DOI 10.1126/science.2300815; MUTTER M, 1989, ANGEW CHEM INT EDIT, V28, P535, DOI 10.1002/anie.198905353; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSTERHOUT JJ, 1992, J AM CHEM SOC, V114, P331, DOI 10.1021/ja00027a043; PRIVALOV PL, 1990, CRIT REV BIOCHEM MOL, V25, P281, DOI 10.3109/10409239009090612; PTITSYN OB, 1987, J PROTEIN CHEM, V6, P273; PTITSYN OB, 1990, FEBS LETT, V262, P20, DOI 10.1016/0014-5793(90)80143-7; RADFORD SE, 1992, NATURE, V358, P302, DOI 10.1038/358302a0; RALEIGH DP, 1992, J AM CHEM SOC, V114, P10079, DOI 10.1021/ja00051a061; REGAN L, 1990, BIOCHEMISTRY-US, V29, P10878, DOI 10.1021/bi00501a003; REGAN L, 1988, SCIENCE, V241, P76; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; RODER H, 1988, NATURE, V335, P700, DOI 10.1038/335700a0; SANTORO MM, 1988, BIOCHEMISTRY-US, V27, P8063, DOI 10.1021/bi00421a014; SEMISOTNOV GV, 1991, BIOPOLYMERS, V31, P119, DOI 10.1002/bip.360310111; STEINER RF, 1984, BIOPOLYMERS, V22, P1121; STRYER LUBERT, 1965, J MOL BIOL, V13, P482; SZEBENYI DME, 1986, J BIOL CHEM, V261, P8761; UDGAONKAR JB, 1988, NATURE, V335, P694, DOI 10.1038/335694a0; Wuthrich K., 1986, NMR PROTEINS NUCL AC	52	268	274	2	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 13	1993	261	5123					879	885		10.1126/science.8346440	http://dx.doi.org/10.1126/science.8346440			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR897	8346440				2022-12-01	WOS:A1993LR89700028
J	ALPER, J				ALPER, J			ECHO-PLANAR MRI - LEARNING TO READ MINDS	SCIENCE			English	Editorial Material																		COHEN MS, 1992, MAGNETIC RESONANCE, V26; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; STEHLING MK, 1991, SCIENCE, V254, P43, DOI 10.1126/science.1925560	3	3	3	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 30	1993	261	5121					556	556		10.1126/science.8342018	http://dx.doi.org/10.1126/science.8342018			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	LP728	8342018				2022-12-01	WOS:A1993LP72800026
J	SOLESSIO, E; ENGBRETSON, GA				SOLESSIO, E; ENGBRETSON, GA			ANTAGONISTIC CHROMATIC MECHANISMS IN PHOTORECEPTORS OF THE PARIETAL EYE OF LIZARDS	NATURE			English	Article							PINEAL ORGAN; CELLS	PHOTORECEPTORS are the first in the chain of neurons that process visual information. In lateral eyes of vertebrates, light hyperpolarizes rod and cone photoreceptors that synapse onto bipolar and horizontal cells in the first synaptic layer of the retina. The sign of the photoreceptor signal is either conserved or inverted in bipolar cells, resulting in chromatically dependent depolarizing and hyperpolarizing responses to visual stimuli. Visual information is then conveyed to the second synaptic layer for encoding and transmission to the brain by ganglion cells. The parietal (third) eve of lizards does not contain bipolar cells or other interneurons. Photoreceptors synapse directly onto ganglion cells1-4 and yet, even in the absence of interneurons, antagonistic chromatic mechanisms modulate the ganglion cell responses5,6. We report here that chromatic antagonism in the third eye originates in the chromatically dependent hyperpolarizing and depolarizing response of the photoreceptors to light. We also suggest that the antagonistic nature of these photoresponses may provide lizards with a mechanism for the enhanced detection of dawn and dusk.	SYRACUSE UNIV,DEPT BIOENGN & NEUROSCI,SYRACUSE,NY 13244	Syracuse University	SOLESSIO, E (corresponding author), SYRACUSE UNIV,INST SENSORY RES,SYRACUSE,NY 13244, USA.							AHMED J, IN PRESS VISION RES; BAYLOR DA, 1970, J PHYSIOL-LONDON, V207, P77, DOI 10.1113/jphysiol.1970.sp009049; DODT E, 1968, VISION RES, V8, P61, DOI 10.1016/0042-6989(68)90064-3; DODT E, 1973, HDB SENSORY PHYSL, P113; EAKIN RM, 1973, 3 EYE; EKSTROM P, 1988, NEUROSCIENCE, V25, P1061, DOI 10.1016/0306-4522(88)90059-0; ELDRED WD, 1978, VISION RES, V18, P29, DOI 10.1016/0042-6989(78)90073-1; ENGBRETSON GA, 1981, J COMP NEUROL, V198, P155, DOI 10.1002/cne.901980113; ENGBRETSON GA, 1990, VISUAL NEUROSCI, V5, P395, DOI 10.1017/S0952523800000481; HAMASAKI DI, 1969, PFLUG ARCH EUR J PHY, V313, P19, DOI 10.1007/BF00586325; HAMDORF K, 1979, BIOPHYS STRUCT MECH, V5, P137, DOI 10.1007/BF00535444; JENISON GL, 1979, BRAIN RES, V168, P615, DOI 10.1016/0006-8993(79)90315-9; KORF HW, 1981, CELL TISSUE RES, V219, P567; MILLER WH, 1962, SCIENCE, V135, P316, DOI 10.1126/science.135.3500.316; MINKE B, 1973, J GEN PHYSIOL, V62, P87, DOI 10.1085/jgp.62.1.87; NOLTE J, 1972, J GEN PHYSIOL, V59, P186, DOI 10.1085/jgp.59.2.186; PETIT A, 1968, Z ZELLFORSCH MIK ANA, V92, P70, DOI 10.1007/BF00339404; PORTER WP, 1989, SOLRAD SINE CLEAR SK; PU GA, 1981, J NEUROPHYSIOL, V46, P1018, DOI 10.1152/jn.1981.46.5.1018; TABATA M, 1975, VISION RES, V15, P737, DOI 10.1016/0042-6989(75)90293-X; YAU KW, 1989, ANNU REV NEUROSCI, V12, P289, DOI 10.1146/annurev.neuro.12.1.289	21	94	96	0	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 29	1993	364	6436					442	445		10.1038/364442a0	http://dx.doi.org/10.1038/364442a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP640	8332214				2022-12-01	WOS:A1993LP64000054
J	OMICHINSKI, JG; CLORE, GM; SCHAAD, O; FELSENFELD, G; TRAINOR, C; APPELLA, E; STAHL, SJ; GRONENBORN, AM				OMICHINSKI, JG; CLORE, GM; SCHAAD, O; FELSENFELD, G; TRAINOR, C; APPELLA, E; STAHL, SJ; GRONENBORN, AM			NMR STRUCTURE OF A SPECIFIC DNA COMPLEX OF ZN-CONTAINING DNA-BINDING DOMAIN OF GATA-1	SCIENCE			English	Article							NUCLEAR-MAGNETIC-RESONANCE; ERYTHROID TRANSCRIPTION FACTOR; RESTRAINED MOLECULAR-DYNAMICS; PUTATIVE ZINC FINGER; OVERHAUSER ENHANCEMENT MEASUREMENTS; 3-DIMENSIONAL SOLUTION STRUCTURE; INTERPROTON DISTANCE RESTRAINTS; NITROGEN REGULATORY GENE; DOUBLE-HELICAL FRAGMENTS; CRYSTAL-STRUCTURE	The three-dimensional solution structure of a complex between the DNA binding domain of the chicken erythroid transcription factor GATA-1 and its cognate DNA site has been determined with multidimensional heteronuclear magnetic resonance spectroscopy. The DNA binding domain consists of a core which contains a zinc coordinated by four cysteines and alpha carboxyl-terminal tail. The core is composed of two irregular antiparallel beta sheets and an ot helix, followed by a long loop that leads into the carboxyl-terminal tail. The amino-terminal part of the core, including the helix, is similar in structure, although not in sequence, to the amino-terminal zinc module of the glucocorticoid receptor DNA binding domain. In the other regions, the structures of these two DNA binding domains are entirely different. The DNA target site in contact with the protein spans eight base pairs. The helix and the loop connecting the two antiparallel beta sheets interact with the major groove of the DNA. The carboxyl-terminal tail, which is an essential determinant of specific binding, wraps around into the minor groove. The complex resembles a hand holding a rope with the palm and fingers representing the protein core and the thumb, the carboxyl-terminal tail. The specific interactions between GATA-1 and DNA in the major groove are mainly hydrophobic in nature, which accounts for the preponderance of thymines in the target site. A large number of interactions are observed with the phosphate backbone.	NIDDKD, CHEM PHYS LAB, BLDG 5, BETHESDA, MD 20892 USA; NIDDKD, MOLEC BIOL LAB, BETHESDA, MD 20892 USA; NCI, CELL BIOL LAB, BETHESDA, MD 20892 USA; NIH, OFF DIRECTOR, PROT EXPRESS LAB, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA			Clore, G Marius/L-2546-2018; Clore, G. Marius/A-3511-2008	Clore, G Marius/0000-0003-3809-1027; Clore, G. Marius/0000-0003-3809-1027; Gronenborn, Angela M/0000-0001-9072-3525				ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; ARNOTT S, 1982, COLD SPRING HARB SYM, V47, P53, DOI 10.1101/SQB.1983.047.01.008; BALEJA JD, 1992, NATURE, V356, P450, DOI 10.1038/356450a0; BAX A, 1993, ACCOUNTS CHEM RES, V26, P131, DOI 10.1021/ar00028a001; BAX A, 1992, IN PRESS J AM CHEM S, V114, P6924; BERG JM, 1988, P NATL ACAD SCI USA, V85, P99, DOI 10.1073/pnas.85.1.99; BOTHNERBY AA, 1984, J AM CHEM SOC, V106, P811, DOI 10.1021/ja00315a069; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; Brunger A.T, 1993, XPLOR VERSION 31 SYS; BRUNGER AT, 1986, P NATL ACAD SCI USA, V83, P3801, DOI 10.1073/pnas.83.11.3801; CLORE G M, 1991, Journal of Biomolecular NMR, V1, P13, DOI 10.1007/BF01874566; CLORE GM, 1983, EMBO J, V2, P2109, DOI 10.1002/j.1460-2075.1983.tb01710.x; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P5671, DOI 10.1021/bi00476a004; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; CLORE GM, 1991, PROG NUCL MAG RES SP, V23, P43, DOI 10.1016/0079-6565(91)80002-J; CLORE GM, 1987, BIOCHEMISTRY-US, V26, P8012, DOI 10.1021/bi00398a069; CLORE GM, IN PRESS METHODS ENZ; CLORE GM, UNPUB; CONNOLLY ML, 1985, J MOL GRAPHICS, V3, P19, DOI 10.1016/0263-7855(85)80009-6; CUNNINGHAM TS, 1991, MOL CELL BIOL, V11, P6205, DOI 10.1128/MCB.11.12.6205; DECASTRO E, 1992, VISP 1 0 USERS GUIDE; DIAKUN GP, 1986, NATURE, V324, P698, DOI 10.1038/324698a0; DICKERSON RE, 1991, COLD SPRING HARB SYM, V30, P1254; DIEKMANN S, 1989, J MOL BIOL, V205, P787, DOI 10.1016/0022-2836(89)90324-0; EISENBERG D, 1986, NATURE, V319, P199, DOI 10.1038/319199a0; EVANS RM, 1988, CELL, V52, P1, DOI 10.1016/0092-8674(88)90522-3; EVANS T, 1989, CELL, V58, P877, DOI 10.1016/0092-8674(89)90940-9; FESIK SW, 1988, J MAGN RESON, V78, P588, DOI 10.1016/0022-2364(88)90144-8; FREEDMAN LP, 1988, NATURE, V334, P543, DOI 10.1038/334543a0; FU YH, 1990, MOL CELL BIOL, V10, P1056, DOI 10.1128/MCB.10.3.1056; GRONENBORN AM, 1989, BIOCHEMISTRY-US, V28, P5978, DOI 10.1021/bi00440a039; GRONENBORN AM, 1985, PROG NUCL MAG RES SP, V17, P1, DOI 10.1016/0079-6565(85)80004-2; HANNON R, 1991, P NATL ACAD SCI USA, V88, P3004, DOI 10.1073/pnas.88.8.3004; HARD T, 1990, SCIENCE, V249, P157, DOI 10.1126/science.2115209; HARE DR, 1983, J MOL BIOL, V171, P319, DOI 10.1016/0022-2836(83)90096-7; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; IKURA M, 1990, BIOCHEMISTRY-US, V29, P4659, DOI 10.1021/bi00471a022; IKURA M, 1990, J MAGN RESON, V86, P204, DOI 10.1016/0022-2364(90)90227-Z; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; IKURA M, 1992, J AM CHEM SOC, V114, P2433, DOI 10.1021/ja00033a019; JEENER J, 1979, J CHEM PHYS, V71, P4546, DOI 10.1063/1.438208; JONES TA, 1990, O VERSION 5 MANUAL; KEEGAN L, 1986, SCIENCE, V231, P699, DOI 10.1126/science.3080805; KELLEY C, IN PRESS DEVELOPMENT; KIM JG, 1992, MOL CELL BIOL, V12, P5632, DOI 10.1128/MCB.12.12.5632; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KLEVIT RE, 1990, PROTEINS, V7, P215, DOI 10.1002/prot.340070303; KLUG A, 1987, TRENDS BIOCHEM SCI, V12, P464, DOI 10.1016/0968-0004(87)90231-3; KOCHOYAN M, 1991, BIOCHEMISTRY-US, V30, P3371, DOI 10.1021/bi00228a004; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRAULIS PJ, 1989, BIOCHEMISTRY-US, V28, P7241, DOI 10.1021/bi00444a016; KRAULIS PJ, 1992, NATURE, V356, P448, DOI 10.1038/356448a0; KUDLA B, 1990, EMBO J, V9, P1355, DOI 10.1002/j.1460-2075.1990.tb08250.x; LEE MS, 1989, SCIENCE, V245, P635, DOI 10.1126/science.2503871; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MARION D, 1989, J AM CHEM SOC, V111, P1515, DOI 10.1021/ja00186a066; MARION D, 1989, BIOCHEMISTRY-US, V28, P6150, DOI 10.1021/bi00441a004; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MARTIN DIK, 1990, GENE DEV, V4, P1886, DOI 10.1101/gad.4.11.1886; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MINEHART PL, 1991, MOL CELL BIOL, V11, P6216, DOI 10.1128/MCB.11.12.6216; MINIE M, 1992, J CELL SCI, P15; NILGES M, 1990, BIOPOLYMERS, V29, P813, DOI 10.1002/bip.360290415; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; NILSSON L, 1986, J COMPUT CHEM, V7, P591, DOI 10.1002/jcc.540070502; OMICHINSKI JG, 1990, BIOCHEMISTRY-US, V29, P9324, DOI 10.1021/bi00492a004; OMICHINSKI JG, 1993, P NATL ACAD SCI USA, V90, P1676, DOI 10.1073/pnas.90.5.1676; OMICHINSKI JG, 1992, BIOCHEMISTRY-US, V31, P3907, DOI 10.1021/bi00131a004; ORKIN SH, 1992, BLOOD, V80, P575; PATEL DJ, 1987, ANNU REV BIOPHYS BIO, V16, P423; PAVLETICH NP, 1991, SCIENCE, V252, P809, DOI 10.1126/science.2028256; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; POWERS R, IN PRESS BIOCHEMISTR; REID BR, 1987, Q REV BIOPHYS, V20, P1, DOI 10.1017/S0033583500004212; REIHER WE, 1985, THESIS HARVARD U CAM; REITMAN M, 1988, P NATL ACAD SCI USA, V85, P6267, DOI 10.1073/pnas.85.17.6267; ROSENBERG JM, 1976, J MOL BIOL, V104, P145, DOI 10.1016/0022-2836(76)90006-1; SAKAGUCHI K, 1991, J BIOL CHEM, V266, P7306; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; SCHEEK RM, 1983, J AM CHEM SOC, V105, P2914, DOI 10.1021/ja00347a075; SCHWABE JWR, 1990, NATURE, V348, P458, DOI 10.1038/348458a0; SCHWARTZBAUER G, 1992, NUCLEIC ACIDS RES, V20, P4429, DOI 10.1093/nar/20.17.4429; SEEMAN NC, 1976, J MOL BIOL, V104, P109, DOI 10.1016/0022-2836(76)90005-X; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TRAINOR CD, 1990, NATURE, V343, P92, DOI 10.1038/343092a0; TSAI SF, 1989, NATURE, V339, P446, DOI 10.1038/339446a0; VONKITZING E, 1987, EUR BIOPHYS J BIOPHY, V15, P13, DOI 10.1007/BF00255031; VUISTER GW, INPRESS METHODS ENZY; VUISTER GW, IN PRESS J AM CHEM S; WAGNER G, 1987, J MOL BIOL, V196, P611, DOI 10.1016/0022-2836(87)90037-4; WEISS MA, 1984, P NATL ACAD SCI-BIOL, V81, P130, DOI 10.1073/pnas.81.1.130; WIDER G, 1990, J AM CHEM SOC, V112, P9015, DOI 10.1021/ja00180a076; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YANG HY, 1992, MOL CELL BIOL, V12, P4562, DOI 10.1128/MCB.12.10.4562; ZON LI, 1990, P NATL ACAD SCI USA, V87, P668, DOI 10.1073/pnas.87.2.668; ZUIDERWEG ERP, 1990, J MAGN RESON, V86, P210, DOI 10.1016/0022-2364(90)90228-2	99	413	421	0	18	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 23	1993	261	5120					438	446		10.1126/science.8332909	http://dx.doi.org/10.1126/science.8332909			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8332909				2022-12-01	WOS:A1993LN62300027
J	ADDINGTONHALL, JM; WEIR, MW; ZOLLMAN, C; MCILLMURRAY, MB				ADDINGTONHALL, JM; WEIR, MW; ZOLLMAN, C; MCILLMURRAY, MB			A NATIONAL SURVEY OF THE PROVISION OF SUPPORT SERVICES FOR PEOPLE WITH CANCER	BRITISH MEDICAL JOURNAL			English	Article									WIRRAL HLTH AUTHOR, WIRRAL, ENGLAND; BRISTOL HOSP SICK CHILDREN, ONCOL UNIT, BRISTOL, ENGLAND; ROYAL LANCASTER INFIRM, LANCASTER, ENGLAND	Bristol Royal Hospital For Children	ADDINGTONHALL, JM (corresponding author), UCL, DEPT EPIDEMIOL & PUBL HLTH, LONDON WC1E 6EA, ENGLAND.							Fallowfield L., 1992, PSYCHOL HEALTH, V6, P107; MCILLMURRAY MB, 1986, BRIT MED J, V292, P669, DOI 10.1136/bmj.292.6521.669; SMITH T, 1990, BRIT MED J, V301, P1406, DOI 10.1136/bmj.301.6766.1406; WATSON PG, 1990, CANCER NURS, V13, P2	4	12	12	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	JUN 19	1993	306	6893					1649	1650		10.1136/bmj.306.6893.1649-a	http://dx.doi.org/10.1136/bmj.306.6893.1649-a			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ337	8324434	Bronze, Green Published			2022-12-01	WOS:A1993LJ33700021
J	GERBER, HP; SEIPEL, K; GEORGIEV, O; HOFFERER, M; HUG, M; RUSCONI, S; SCHAFFNER, W				GERBER, HP; SEIPEL, K; GEORGIEV, O; HOFFERER, M; HUG, M; RUSCONI, S; SCHAFFNER, W			TRANSCRIPTIONAL ACTIVATION MODULATED BY HOMOPOLYMERIC GLUTAMINE AND PROLINE STRETCHES	SCIENCE			English	Article							FRAGILE-X SYNDROME; MAMMALIAN-CELLS; DROSOPHILA-MELANOGASTER; HUMAN-DISEASE; MUTATIONS; SEQUENCE; GENE; ANTENNAPEDIA; EXPRESSION	Many transcription factors contain proline- or glutamine-rich activation domains. Here it is shown that simple homopolymeric stretches of these amino acids can activate transcription when fused to the DNA binding domain of GAL4 factor. In vitro, activity increased with polymer length, whereas in cell transfection assays maximal activity was achieved by 10 to 30 glutamines or about 10 prolines. Similar results were obtained when glutamine stretches were placed within a [GAL4]-VP16 chimeric protein. Because these stretches are encoded by rapidly evolving triplet repeats (microsatellites), they may be the main cause for modulation of transcription factor activity and thus result ir subtle or overt genomic effects.	UNIV ZURICH,INST MOLEK BIOL 2,WINTERTHURERSTR 190,CH-8057 ZURICH,SWITZERLAND	University of Zurich				Seipel, Katja/0000-0003-3128-1573				BECKMANN JS, 1992, GENOMICS, V12, P627, DOI 10.1016/0888-7543(92)90285-Z; BELL MV, 1991, CELL, V64, P861, DOI 10.1016/0092-8674(91)90514-Y; CASKEY CT, 1992, SCIENCE, V256, P784, DOI 10.1126/science.1589758; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; GERBER HJ, UNPUB; GERBER HP, 1992, NUCLEIC ACIDS RES, V20, P5855, DOI 10.1093/nar/20.21.5855; Group T. H. D. C. R., 1993, CELL, V72, P971, DOI [10.1016/0092-8674(93)90585-E8458085, DOI 10.1016/0092-8674(93)90585-E8458085]; HANSEN RS, 1993, CELL, V73, P1403, DOI 10.1016/0092-8674(93)90365-W; KNIGHT SJL, 1993, CELL, V74, P127, DOI 10.1016/0092-8674(93)90300-F; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NORREMOLLE A, 1993, HUM MOL GENET, V2, P1475, DOI 10.1093/hmg/2.9.1475; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; RICHARDS RI, 1992, CELL, V70, P709, DOI 10.1016/0092-8674(92)90302-S; ROSS GA, 1993, TRENDS NEUROSCI, V16, P254; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SCHNEUWLY S, 1986, EMBO J, V5, P733, DOI 10.1002/j.1460-2075.1986.tb04275.x; SEIPEL K, 1992, EMBO J, V11, P4961, DOI 10.1002/j.1460-2075.1992.tb05603.x; SEIPEL K, 1993, NUCLEIC ACIDS RES, V21, P5609, DOI 10.1093/nar/21.24.5609; WESTIN G, 1987, NUCLEIC ACIDS RES, V15, P6787, DOI 10.1093/nar/15.17.6787; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; ZUHLKE C, 1993, HUM MOL GENET, V2, P1367	24	513	530	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 11	1994	263	5148					808	811		10.1126/science.8303297	http://dx.doi.org/10.1126/science.8303297			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV866	8303297				2022-12-01	WOS:A1994MV86600035
J	WEIS, K; RAMBAUD, S; LAVAU, C; JANSEN, J; CARVALHO, T; CARMOFONSECA, M; LAMOND, A; DEJEAN, A				WEIS, K; RAMBAUD, S; LAVAU, C; JANSEN, J; CARVALHO, T; CARMOFONSECA, M; LAMOND, A; DEJEAN, A			RETINOIC ACID REGULATES ABERRANT NUCLEAR-LOCALIZATION OF PML-RAR-ALPHA IN ACUTE PROMYELOCYTIC LEUKEMIA-CELLS	CELL			English	Article							THYROID-HORMONE; RECEPTOR-ALPHA; T(15-17) TRANSLOCATION; SIGNALING PATHWAYS; RESPONSE ELEMENTS; MAMMALIAN NUCLEI; CDNA CLONING; COILED BODY; RXR-BETA; GENE	Acute promyelocytic leukemia (APL) is characterized by a specific t(15; 17) translocation that fuses the retinoic acid receptor alpha (RARalpha) to a novel gene product, PML. The involvement of RARalpha is particularly intriguing in view of the efficient therapeutic effect of retinoic acid (RA) in this disease. In this report, we show that PML is specifically localized within a discrete subnuclear compartment corresponding to nuclear bodies recognized by patient autoimmune sera. In APL cells, the PML-RARalpha hybrid displays an abnormal localization and directs RXR and other nuclear antigens into aberrant structures that are tightly bound to chromatin. This suggests that the hybrid could exert a dominant negative effect by diverting a subset of proteins from their natural sites of action. Interestingly, treatment of APL cells with RA induces a complete relocalization of each of these proteins. We propose that the beneficial role of RA in promoting myeloid differentiation in APL might be related to its ability to restore a normal subnuclear organization.	INST PASTEUR,INSERM,U163,UNITE RECOMBINAISON & EXPRESS GENET,F-75724 PARIS 15,FRANCE; FAC MED LISBON,INST HISTOL,P-1699 LISBON,PORTUGAL	Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Universidade de Lisboa	WEIS, K (corresponding author), EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,D-69012 HEIDELBERG,GERMANY.		Dejean, Anne/L-5145-2018; Jansen, J.H./H-8054-2014; Weis, Karsten/F-5719-2011; Lavau, Catherine/Q-2928-2019	Jansen, J.H./0000-0001-9459-568X; Weis, Karsten/0000-0001-7224-925X; Carvalho Goncalves, Teresa/0000-0001-7061-8904; Lavau, Catherine/0000-0003-4800-1320; Lamond, Angus/0000-0001-6204-6045; Carmo-Fonseca, Maria/0000-0002-3402-7143				ALCALAY M, 1991, P NATL ACAD SCI USA, V88, P1977, DOI 10.1073/pnas.88.5.1977; ALCALAY M, 1992, P NATL ACAD SCI USA, V89, P4840, DOI 10.1073/pnas.89.11.4840; ANDRADE LEC, 1991, J EXP MED, V173, P1407, DOI 10.1084/jem.173.6.1407; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BELLINI M, 1993, EMBO J, V12, P107, DOI 10.1002/j.1460-2075.1993.tb05636.x; BORROW J, 1990, SCIENCE, V249, P1577, DOI 10.1126/science.2218500; BOUTEILLE M, 1974, CELL NUCLEUS, V1, P5; BRASCH K, 1992, EXP CELL RES, V202, P211, DOI 10.1016/0014-4827(92)90068-J; BREITMAN TR, 1981, BLOOD, V57, P1000; BRUNK BP, 1991, NATURE, V353, P351, DOI 10.1038/353351a0; BUFFO TH, 1992, EMBO J, V11, P1409; CARMOFONSECA M, 1992, J CELL BIOL, V117, P1, DOI 10.1083/jcb.117.1.1; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHOMIENNE C, 1990, BLOOD, V76, P1710; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FREEMONT PS, 1991, CELL, V64, P483, DOI 10.1016/0092-8674(91)90229-R; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; GAUB MP, 1992, EXP CELL RES, V201, P335, DOI 10.1016/0014-4827(92)90282-D; GODDARD AD, 1991, SCIENCE, V254, P1371, DOI 10.1126/science.1720570; GREEN S, 1993, NATURE, V361, P590, DOI 10.1038/361590a0; GRIGNANI F, 1993, CELL, V74, P423, DOI 10.1016/0092-8674(93)80044-F; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOEFFLER HP, 1985, CHRONIC ACUTE LEUKEM, P27; LAMOND AI, 1993, MOL BIOL REP, V18, P127, DOI 10.1007/BF00986767; Lamond Angus I., 1993, Trends in Cell Biology, V3, P198, DOI 10.1016/0962-8924(93)90214-L; LANGANGER G, 1984, J CELL BIOL, V99, P1324, DOI 10.1083/jcb.99.4.1324; LANOTTE M, 1991, BLOOD, V77, P1080; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEONHARDT H, 1992, CELL, V71, P865, DOI 10.1016/0092-8674(92)90561-P; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PATARCA R, 1988, P NATL ACAD SCI USA, V85, P2733, DOI 10.1073/pnas.85.8.2733; PEREZ A, 1993, EMBO J, V12, P3171, DOI 10.1002/j.1460-2075.1993.tb05986.x; PETTERSSON I, 1984, J BIOL CHEM, V259, P5907; RASKA I, 1991, EXP CELL RES, V195, P27, DOI 10.1016/0014-4827(91)90496-H; REDDY BA, 1992, TRENDS BIOCHEM SCI, V17, P344, DOI 10.1016/0968-0004(92)90308-V; SACHS L, 1978, NATURE, V274, P535, DOI 10.1038/274535a0; SAWYERS CL, 1991, CELL, V64, P337, DOI 10.1016/0092-8674(91)90643-D; Scheer Ulrich, 1993, Trends in Cell Biology, V3, P236, DOI 10.1016/0962-8924(93)90123-I; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; STUURMAN N, 1992, J CELL SCI, V101, P773; SZOSTECKI C, 1990, J IMMUNOL, V145, P4338; TAKAHASHI M, 1988, MOL CELL BIOL, V8, P1853, DOI 10.1128/MCB.8.4.1853; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; XIE KW, 1993, MOL CELL BIOL, V13, P6170, DOI 10.1128/MCB.13.10.6170; Xing Yigong, 1993, Trends in Cell Biology, V3, P346, DOI 10.1016/0962-8924(93)90105-A; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	61	659	666	0	13	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 28	1994	76	2					345	356		10.1016/0092-8674(94)90341-7	http://dx.doi.org/10.1016/0092-8674(94)90341-7			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	8293468				2022-12-01	WOS:A1994MU67800017
J	ROSENBAUM, DS; JACKSON, LE; SMITH, JM; GARAN, H; RUSKIN, JN; COHEN, RJ				ROSENBAUM, DS; JACKSON, LE; SMITH, JM; GARAN, H; RUSKIN, JN; COHEN, RJ			ELECTRICAL ALTERNANS AND VULNERABILITY TO VENTRICULAR ARRHYTHMIAS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ST-SEGMENT ALTERNANS; MYOCARDIAL-INFARCTION; T-WAVE; SUDDEN-DEATH; FIBRILLATION; MORPHOLOGY	Background. Although electrical alternans (alternating amplitude from beat to beat on the electrocardiogram) has been associated with ventricular arrhythmias in many clinical settings, its physiologic importance and prognostic implications remain unknown. Methods. To test the hypothesis that electrical alternans is a marker of vulnerability to ventricular arrhythmias, we developed a technique to detect subtle alternation in the morphologic features of the electrocardiogram (which would not be detectable by visual inspection of the electrocardiogram). In a group of 83 patients referred for diagnostic electrophysiologic testing, we prospectively examined whether levels of alternans predicted vulnerability to arrhythmias as defined by the outcome of electrophysiologic testing and arrhythmia-free survival. Results. Sustained ventricular arrhythmias were induced during electrophysiologic testing in 32 of the patients (39 percent). In this group, low-level electrical alternans (a beat-to-beat change in amplitude of < 15 muV) was detected over a broad range of physiologic heart rates (from 95 to 150 beats per minute) and primarily involved the ST segment and the T wave (i.e., the phase of repolarization). Alternans during repolarization was a significant and independent predictor of inducible arrhythmias on electrophysiologic testing (sensitivity, 81 percent; specificity, 84 percent; relative risk, 5.2). Of 66 patients followed for up to 20 months, 13 had arrhythmic events. Alternans affecting the T wave and inducibility of ventricular arrhythmias were significant and essentially equivalent predictors of survival without arrhythmia (P<0.001). Actuarial survival without arrhythmia at 20 months was significantly lower among the patients with T-wave alternans (19 percent) than among the patients without T-wave alternans (94 percent). Conclusions. Electrical alternans affecting the ST segment and T wave is common among patients at increased risk for ventricular arrhythmias. Subtle electrical alternans on the electrocardiogram may serve as a noninvasive marker of vulnerability to ventricular arrhythmias.	CASE WESTERN RESERVE UNIV,DEPT MED,CLEVELAND,OH 44106; MASSACHUSETTS GEN HOSP,CARDIAC UNIT,BOSTON,MA 02114; HARVARD UNIV,MIT,DIV HLTH SCI & TECHNOL,CAMBRIDGE,MA 02138	Case Western Reserve University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts Institute of Technology (MIT)	ROSENBAUM, DS (corresponding author), CASE WESTERN RESERVE UNIV,DEPT BIOMED ENGN,WICKENDEN BLDG,RM 504,CLEVELAND,OH 44106, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039291] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01-HL39291] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAM DR, 1984, J ELECTROCARDIOL, V17, P209, DOI 10.1016/S0022-0736(84)80057-6; BIGGER JT, 1984, CIRCULATION, V69, P250, DOI 10.1161/01.CIR.69.2.250; CHENG TC, 1983, ARCH INTERN MED, V143, P1052, DOI 10.1001/archinte.143.5.1052; FEIGENBAUM H, 1966, CIRCULATION, V34, P611, DOI 10.1161/01.CIR.34.4.611; FRANK E, 1956, CIRCULATION, V13, P737, DOI 10.1161/01.CIR.13.5.737; GHANI MF, 1974, CHEST, V65, P695, DOI 10.1378/chest.65.6.695; Hamburger WW, 1936, J AMER MED ASSOC, V106, P902, DOI 10.1001/jama.1936.02770110018006; HELLERSTEIN HK, 1950, AM J PHYSIOL, V160, P366, DOI 10.1152/ajplegacy.1950.160.2.366; HIEJIMA K, 1976, BRIT HEART J, V38, P767; JOYAL M, 1984, AM J CARDIOL, V54, P915, DOI 10.1016/S0002-9149(84)80233-7; KALTER HH, 1948, NY STATE J MED, V1, P1164; KLEIMAN RB, 1988, AM J CARDIOL, V62, P528, DOI 10.1016/0002-9149(88)90649-2; KLEINFELD MJ, 1977, CIRCULATION, V55, P574, DOI 10.1161/01.CIR.55.4.574; KONTA T, 1990, CIRCULATION, V82, P2185, DOI 10.1161/01.CIR.82.6.2185; KUCHAR DL, 1986, CIRCULATION, V74, P1280, DOI 10.1161/01.CIR.74.6.1280; LEBRETT K, 1990, THESIS MIT; LEPESCHKIN E, 1950, Cardiologia, V16, P278, DOI 10.1159/000164958; Lewis T, 1910, Q J MED, V4, P141; NEARING BD, 1991, SCIENCE, V252, P437, DOI 10.1126/science.2017682; PULETTI M, 1980, J ELECTROCARDIOL, V13, P297, DOI 10.1016/S0022-0736(80)80035-5; RAEDER EA, 1992, NEW ENGL J MED, V326, P271; REDDY CVR, 1984, AM J CARDIOL, V53, P390, DOI 10.1016/0002-9149(84)90487-9; RICHARDS DAB, 1991, CIRCULATION, V83, P756, DOI 10.1161/01.CIR.83.3.756; ROSENBAUM DS, 1991, CIRCULATION, V84, P1333, DOI 10.1161/01.CIR.84.3.1333; SALERNO JA, 1986, EUR HEART J, V7, P63; SCHWARTZ PJ, 1975, AM HEART J, V89, P45, DOI 10.1016/0002-8703(75)90008-3; SHIMONI Z, 1984, AM J CARDIOL, V54, P920, DOI 10.1016/S0002-9149(84)80236-2; SMITH JM, 1988, CIRCULATION, V77, P110, DOI 10.1161/01.CIR.77.1.110; USHER BW, 1972, AM HEART J, V83, P459, DOI 10.1016/0002-8703(72)90035-X; WAYNE VS, 1983, CHEST, V83, P824, DOI 10.1378/chest.83.5.824; WILBER DJ, 1988, NEW ENGL J MED, V318, P19, DOI 10.1056/NEJM198801073180105; WINKLE RA, 1980, PROG CARDIOVASC DIS, V23, P99, DOI 10.1016/0033-0620(80)90007-9	32	886	921	0	14	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 27	1994	330	4					235	241		10.1056/NEJM199401273300402	http://dx.doi.org/10.1056/NEJM199401273300402			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR496	8272084				2022-12-01	WOS:A1994MR49600002
J	MARCANTONIO, ER; GOLDMAN, L; MANGIONE, CM; LUDWIG, LE; MURACA, B; HASLAUER, CM; DONALDSON, MC; WHITTEMORE, AD; SUGARBAKER, DJ; POSS, R; HAAS, S; COOK, EF; ORAV, J; LEE, TH				MARCANTONIO, ER; GOLDMAN, L; MANGIONE, CM; LUDWIG, LE; MURACA, B; HASLAUER, CM; DONALDSON, MC; WHITTEMORE, AD; SUGARBAKER, DJ; POSS, R; HAAS, S; COOK, EF; ORAV, J; LEE, TH			A CLINICAL-PREDICTION RULE FOR DELIRIUM AFTER ELECTIVE NONCARDIAC SURGERY	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ELDERLY HOSPITALIZED-PATIENTS; SURGICAL PATIENTS; ACTIVITY SCALE; RISK-FACTORS; MORBIDITY; CONFUSION	Objective.-To develop and validate a clinical prediction rule for postoperative delirium using data available to clinicians preoperatively. Design.-Prospective cohort study. Setting.-General surgery, orthopedic surgery, and gynecology services at Brigham and Women's Hospital, Boston, Mass. Patients.-Consenting patients older than 50 years admitted for major elective noncardiac surgery between November 1, 1990, and March 15, 1992 (N=1341). Measurements.-All patients underwent preoperative evaluations, including a medical history, physical examination, laboratory tests, and assessments of physical and cognitive function using the Specific Activity Scale and the Telephone Interview for Cognitive Status. Postoperative delirium was diagnosed using the Confusion Assessment Method or using data f rom the medical record and the hospital's nursing intensity index. Patients were followed up for the duration of hospitalization to determine major complication rates, length of stay, and discharge disposition. Results.-Postoperative delirium occurred in 117 (9%) of the 1341 patients studied. Independent correlates included age 70 years or older; self-reported alcohol abuse; poor cognitive status; poor functional status; markedly abnormal preoperative serum sodium, potassium or glucose level; noncardiac thoracic surgery; and aortic aneurysm surgery. Using these seven preoperative factors, a simple predictive rule was developed. In an independent population, the rule stratified patients into groups with low (2%), medium (8%, 13%), and high (50%) rates of postoperative delirium. Patients who developed delirium had higher rates of major complications, longer lengths of stay, and higher rates of discharge to long-term care or rehabilitative facilities. Conclusions.- Using data available preoperatively, clinicians can stratify patients into risk groups for the development of delirium. Since delirium is associated with a variety of adverse outcomes, patients with substantial risk for this complication could be candidates for interventions to reduce the incidence of postoperative delirium and potentially improve overall surgical outcomes.	HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV CLIN EPIDEMIOL,75 FRANCIS ST, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED, DIV GEN MED, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT SURG, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT ORTHOPED SURG, BOSTON, MA 02115 USA; HARVARD UNIV, BRIGHAM & WOMENS HOSP, SCH MED, DEPT OBSTET & GYNECOL, BOSTON, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School			Marcantonio, Edward R/U-3929-2017	Marcantonio, Edward R/0000-0002-2911-4250; Haas, Susan/0000-0003-1077-9823	AHRQ HHS [1RO1-HS06573] Funding Source: Medline; BHP HRSA HHS [5T32PE110011-04] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality); BHP HRSA HHS		CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; DRIPPS RD, 1961, JAMA-J AM MED ASSOC, V178, P261, DOI 10.1001/jama.1961.03040420001001; EISENDRATH SJ, 1987, AM J PSYCHIAT, V144, P1062; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FRANCIS J, 1990, JAMA-J AM MED ASSOC, V263, P1097, DOI 10.1001/jama.263.8.1097; FRANCIS J, 1990, J GEN INTERN MED, V5, P65, DOI 10.1007/BF02602312; Francis Joseph, 1992, Journal of the American Geriatrics Society, V40, pSA10; GOLDMAN L, 1981, CIRCULATION, V64, P1227, DOI 10.1161/01.CIR.64.6.1227; GOLINGER RC, 1987, AM J PSYCHIAT, V144, P1218; GUSTAFSON Y, 1991, J AM GERIATR SOC, V39, P655, DOI 10.1111/j.1532-5415.1991.tb03618.x; GUSTAFSON Y, 1988, J AM GERIATR SOC, V36, P325; Hegyvary ST, 1979, USERS MANUAL RUSH ME; INOUYE SK, 1993, ANN INTERN MED, V119, P474, DOI 10.7326/0003-4819-119-6-199309150-00005; INOUYE SK, 1990, ANN INTERN MED, V113, P941, DOI 10.7326/0003-4819-113-12-941; LEE TH, 1988, AM HEART J, V115, P203, DOI 10.1016/0002-8703(88)90545-5; LEVKOFF SE, 1992, ARCH INTERN MED, V152, P334, DOI 10.1001/archinte.152.2.334; LEVKOFF SE, 1988, J AM GERIATR SOC, V36, P1099, DOI 10.1111/j.1532-5415.1988.tb04396.x; LIPOWSKI ZJ, 1989, NEW ENGL J MED, V320, P578; Lopez Oscar L, 2010, Neuroepidemiology, V34, P63, DOI 10.1159/000264678; MILLAR HR, 1981, BRIT J PSYCHIAT, V138, P17, DOI 10.1192/bjp.138.1.17; MORSE RM, 1969, AM J PSYCHIAT, V126, P388, DOI 10.1176/ajp.126.3.388; ROCKWOOD K, 1989, J AM GERIATR SOC, V37, P150, DOI 10.1111/j.1532-5415.1989.tb05874.x; ROGERS MP, 1989, INT J PSYCHIAT MED, V19, P109; SCHOR JD, 1992, JAMA-J AM MED ASSOC, V267, P827, DOI 10.1001/jama.267.6.827; SEYMOUR DG, 1983, GERONTOLOGY, V29, P262, DOI 10.1159/000213125; SIER H, 1987, JAMA-J AM MED ASSOC, V257, P1776; Sox HC, 1988, MED DECISION MAKING; THOMAS RI, 1988, ARCH GEN PSYCHIAT, V45, P937; WILLIAMSRUSSO P, 1992, J AM GERIATR SOC, V40, P759, DOI 10.1111/j.1532-5415.1992.tb01846.x; 1987, DIAGNOSTIC STATISTIC	30	627	654	1	26	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 12	1994	271	2					134	139		10.1001/jama.271.2.134	http://dx.doi.org/10.1001/jama.271.2.134			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ083	8264068				2022-12-01	WOS:A1994MQ08300023
J	BELL, SP; KOBAYASHI, R; STILLMAN, B				BELL, SP; KOBAYASHI, R; STILLMAN, B			YEAST ORIGIN RECOGNITION COMPLEX FUNCTIONS IN TRANSCRIPTION SILENCING AND DNA-REPLICATION	SCIENCE			English	Article							MATING-TYPE LOCUS; SODIUM DODECYL-SULFATE; SACCHAROMYCES-CEREVISIAE; GENE-EXPRESSION; CHROMOSOMAL ORIGIN; REPRESSION; ACTIVATION; SEPARATION; SEQUENCES; ELEMENTS	The genes encoding two of the subunits of the Saccharomyces cerevisiae origin recognition complex (ORC) have been isolated. Characterization of a temperature-sensitive mutation in the gene encoding the 72-kD subunit of ORC (ORC2) indicates that this protein complex functions early in the DNA replication process. Moreover, ORC derived from orc2ts cells is defective for DNA binding. Others have shown a defect in orc2ts cells in transcriptional silencing at the silent mating-type loci. Consistent with this finding, ORC specifically binds to each of the four mating-type silencers identified in yeast. These findings support the hypothesis that ORC acts as an initiator protein at yeast origins of DNA replication and suggest that ORC also functions in the determination of transcriptional domains.			BELL, SP (corresponding author), COLD SPRING HARBOR LAB, COLD SPRING HARBOR, NY 11724 USA.			Stillman, Bruce/0000-0002-9453-4091; Bell, Stephen/0000-0002-2876-610X	NCI NIH HHS [CA13106] Funding Source: Medline; NIAID NIH HHS [AI20460] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P01CA013106] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI020460, R37AI020460] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM J, 1984, J MOL BIOL, V176, P307, DOI 10.1016/0022-2836(84)90492-3; AXELROD A, 1991, MOL CELL BIOL, V11, P1080, DOI 10.1128/MCB.11.2.1080; Baker T, 1991, DNA REPLICATION, V2; BELL SG, UNPUB; BELL SP, 1992, NATURE, V357, P128, DOI 10.1038/357128a0; BRAND AH, 1987, CELL, V51, P709, DOI 10.1016/0092-8674(87)90094-8; BROACH JR, 1982, COLD SPRING HARB SYM, V47, P1165, DOI 10.1101/SQB.1983.047.01.132; BROWN DD, 1984, CELL, V37, P359, DOI 10.1016/0092-8674(84)90366-0; CALLAN HG, 1973, COLD SPRING HARB SYM, V38, P195; Campbell JL, 1991, MOL CELLULAR BIOL YE, P41; DESHPANDE AM, 1992, MOL CELL BIOL, V12, P4305, DOI 10.1128/MCB.12.10.4305; DHAR V, 1989, MOL CELL BIOL, V9, P3524, DOI 10.1128/MCB.9.8.3524; DIFFLEY JFX, 1992, NATURE, V357, P169, DOI 10.1038/357169a0; DUBEY DD, 1991, MOL CELL BIOL, V11, P5346, DOI 10.1128/MCB.11.10.5346; EDGAR LG, 1988, CELL, V53, P589, DOI 10.1016/0092-8674(88)90575-2; FANGMAN WL, 1992, CELL, V71, P363, DOI 10.1016/0092-8674(92)90505-7; FELDMAN JB, 1984, J MOL BIOL, V178, P815, DOI 10.1016/0022-2836(84)90313-9; FOSS M, 1993, SCIENCE, V262, P1838, DOI 10.1126/science.8266071; HATTON KS, 1988, MOL CELL BIOL, V8, P2149, DOI 10.1128/MCB.8.5.2149; HENNESSY KM, 1990, GENE DEV, V4, P2252, DOI 10.1101/gad.4.12b.2252; JACOB F, 1963, COLD SPRING HARB SYM, V28, P329, DOI 10.1101/SQB.1963.028.01.048; KAWASAKI H, 1990, ANAL BIOCHEM, V186, P264, DOI 10.1016/0003-2697(90)90077-M; KAWASAKI H, 1990, ANAL BIOCHEM, V191, P332, DOI 10.1016/0003-2697(90)90227-Z; KITSBERG D, 1993, NATURE, V364, P459, DOI 10.1038/364459a0; LAURENSON P, 1992, MICROBIOL REV, V56, P543, DOI 10.1128/MMBR.56.4.543-560.1992; LI JJ, 1993, SCIENCE, V262, P1870, DOI 10.1126/science.8266075; MARAHRENS Y, 1992, SCIENCE, V255, P817, DOI 10.1126/science.1536007; MCNALLY FJ, 1991, MOL CELL BIOL, V11, P5648, DOI 10.1128/MCB.11.11.5648; MILLER AM, 1984, NATURE, V312, P247, DOI 10.1038/312247a0; NASH R, 1988, EMBO J, V7, P4335, DOI 10.1002/j.1460-2075.1988.tb03332.x; NEWLON CS, 1988, MICROBIOL REV, V52, P568, DOI 10.1128/MMBR.52.4.568-601.1988; NEWLON CS, IN PRESS CURRENT OPI; PILLUS L, 1989, CELL, V59, P637, DOI 10.1016/0092-8674(89)90009-3; RENAULD H, 1993, GENE DEV, V7, P1133, DOI 10.1101/gad.7.7a.1133; RIVIER DH, 1992, SCIENCE, V256, P659, DOI 10.1126/science.1585179; STINCHCOMB DT, 1979, NATURE, V282, P39, DOI 10.1038/282039a0; VILLARREAL LP, 1991, MICROBIOL REV, V55, P512, DOI 10.1128/MMBR.55.3.512-542.1991; WOLFFE AP, 1991, J CELL SCI, V99, P201	38	378	383	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 17	1993	262	5141					1844	1849		10.1126/science.8266072	http://dx.doi.org/10.1126/science.8266072			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266072				2022-12-01	WOS:A1993MM51100027
J	KINNERSLEY, P; WILKINSON, CE; SRINIVASAN, J				KINNERSLEY, P; WILKINSON, CE; SRINIVASAN, J			PNEUMOCOCCAL VACCINATION AFTER SPLENECTOMY - SURVEY OF HOSPITAL AND PRIMARY-CARE RECORDS	BRITISH MEDICAL JOURNAL			English	Article									UNIV WALES COLL MED,DEPT GEN PRACTICE,CARDIFF CF4 4XN,S GLAM,WALES; LLANDOUGH HOSP,DEPT MED,PENARTH CF6 1XX,S GLAM,WALES	Cardiff University								AMMANN AJ, 1977, NEW ENGL J MED, V297, P897, DOI 10.1056/NEJM197710272971701; [Anonymous], MMWR MORB MORTAL WKL; SIDDINS M, 1990, AUST NZ J SURG, V60, P183, DOI 10.1111/ans.1990.60.3.183; 1990, DRUG THER B, V28, P31; 1992, IMMUNISATION INFECTI	5	41	42	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1993	307	6916					1398	1399		10.1136/bmj.307.6916.1398	http://dx.doi.org/10.1136/bmj.307.6916.1398			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK420	8274893	Green Published, Bronze			2022-12-01	WOS:A1993MK42000022
J	MEADE, TW; COOPER, JA; PEART, WS				MEADE, TW; COOPER, JA; PEART, WS			PLASMA-RENIN ACTIVITY AND ISCHEMIC-HEART-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							HYPERTENSION	Background. An earlier prospective study reported an association between high levels of plasma renin activity (as measured by the renin-sodium profile) and the incidence of myocardial infarction in patients with hypertension. We have investigated the relation between plasma renin activity and ischemic heart disease in the Northwick Park Heart Study. Methods. The study included 803 white men 40 to 64 years of age selected from industrial workers in London. Plasma renin activity and established risk factors for ischemic heart disease were measured at entry, which was between 1972 and 1978. Ascertainment of the primary clinical end points of fatal or nonfatal myocardial infarction and sudden death from coronary causes was carried out until the end of 1991. Results. In an analysis of the 86 first coronary events, we found an independent relation between higher systolic blood pressure and coronary end points (relative risk per 1 SD increase in blood pressure, 1.47; 95 percent confidence interval, 1.16 to 1.85; P<0.001), but no relation between plasma renin activity and coronary end points (relative risk per 1 SD increase in the level of plasma renin activity, 1.04; 95 percent confidence interval, 0.84 to 1.30). In the 242 men who had hypertension of a degree similar to that of the subjects in the earlier prospective study of the renin profile, and in whom 44 of the 86 coronary events occurred, the relative risk of those in the highest as compared with the lowest third for plasma renin activity was 1.26 (95 percent confidence interval, 0.63 to 2.56). Conclusions. Our results suggest that there is no association between plasma renin activity and myocardial infarction or sudden death from coronary causes, at least in normotensive men.			MEADE, TW (corresponding author), ST BARTHOLOMEWS HOSP,COLL MED,WOLFSON INST PREVENT MED,MRC,EPIDEMIOL & MED CARE UNIT,LONDON EC1M 6BQ,ENGLAND.							ALDERMAN MH, 1991, NEW ENGL J MED, V324, P1098, DOI 10.1056/NEJM199104183241605; ARMITAGE P, 1971, STATISTICAL METHODS; BROWN JJ, 1966, BMJ-BRIT MED J, V1, P505, DOI 10.1136/bmj.1.5486.505; BRUNNER HR, 1972, NEW ENGL J MED, V286, P441, DOI 10.1056/NEJM197203022860901; HANENSON IB, 1959, CIRCULATION, V20, P498, DOI 10.1161/01.CIR.20.4.498; HOPKINS A, 1988, BMDP STATISTICAL SOF, P719; MEADE TW, 1983, CLIN SCI, V64, P273, DOI 10.1042/cs0640273; MEADE TW, 1986, LANCET, V2, P533, DOI 10.1016/S0140-6736(86)90111-X; 1977, PUBLIC HLTH EUROPE, V5	9	89	89	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1993	329	9					616	619		10.1056/NEJM199308263290905	http://dx.doi.org/10.1056/NEJM199308263290905			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU217	8341336				2022-12-01	WOS:A1993LU21700005
J	STRUHL, G; FITZGERALD, K; GREENWALD, I				STRUHL, G; FITZGERALD, K; GREENWALD, I			INTRINSIC ACTIVITY OF THE LIN-12 AND NOTCH INTRACELLULAR DOMAINS IN-VIVO	CELL			English	Article							PERIPHERAL NERVOUS-SYSTEM; EPIDERMAL GROWTH-FACTOR; CELL-CELL-INTERACTIONS; CAENORHABDITIS-ELEGANS; C-ELEGANS; DROSOPHILA-MELANOGASTER; TRANSMEMBRANE PROTEIN; LATERAL INHIBITION; EARLY NEUROGENESIS; HOMOLOGOUS GENES	The lin-12 gene of C. elegans and the Notch gene of D. melanogaster encode structurally related transmembrane proteins that mediate intercellular signaling. We show that truncated forms of these proteins consisting of only the intracellular domains cause cell fate transformations associated with constitutive activity in their respective organisms. This activity does not depend on endogenous gene function. Our results indicate that the intracellular domains of Lin-12 and Notch have intrinsic activity and that the principal role of the extracellular domains in the intact proteins is to regulate this activity. Our results also suggest that equivalent truncated forms of lin-12/Notch family members in vertebrates, including known oncogenes, are similarly active.	COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; PRINCETON UNIV,DEPT MOLEC BIOL,PRINCETON,NJ 08544	Columbia University; Princeton University	STRUHL, G (corresponding author), COLUMBIA UNIV COLL PHYS & SURG,DEPT GENET & DEV,HOWARD HUGHES MED INST,NEW YORK,NY 10032, USA.				NIGMS NIH HHS [GM37602] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037602] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUSTIN J, 1989, CELL, V58, P565, DOI 10.1016/0092-8674(89)90437-6; BOND BJ, 1986, MOL CELL BIOL, V6, P2080, DOI 10.1128/MCB.6.6.2080; BREEDEN L, 1987, NATURE, V329, P651, DOI 10.1038/329651a0; BRENNER S, 1974, GENETICS, V77, P71; CABRERA CV, 1992, DEVELOPMENT, V115, P893; CABRERA CV, 1987, CELL, V50, P425, DOI 10.1016/0092-8674(87)90496-X; CAGAN RL, 1989, GENE DEV, V3, P1099, DOI 10.1101/gad.3.8.1099; CHOU TB, 1992, GENETICS, V131, P643; COFFMAN C, 1990, SCIENCE, V249, P1438, DOI 10.1126/science.2402639; COFFMAN CR, 1993, CELL, V73, P659, DOI 10.1016/0092-8674(93)90247-N; CORBIN V, 1991, CELL, V67, P311, DOI 10.1016/0092-8674(91)90183-Y; CUBAS P, 1991, GENE DEV, V5, P996, DOI 10.1101/gad.5.6.996; DECELIS JF, 1991, P NATL ACAD SCI USA, V88, P632, DOI 10.1073/pnas.88.2.632; ELLISEN LW, 1991, CELL, V66, P649, DOI 10.1016/0092-8674(91)90111-B; FEHON RG, 1991, J CELL BIOL, V113, P657, DOI 10.1083/jcb.113.3.657; FEHON RG, 1990, CELL, V61, P523, DOI 10.1016/0092-8674(90)90534-L; FERGUSON EL, 1985, GENETICS, V110, P17; FIRE A, 1986, EMBO J, V5, P2673, DOI 10.1002/j.1460-2075.1986.tb04550.x; FREYD G, 1991, THESIS MIT CAMBRIDGE; GALLAHAN D, 1987, J VIROL, V61, P66, DOI 10.1128/JVI.61.1.66-74.1987; GHYSEN A, 1989, TRENDS GENET, V5, P251, DOI 10.1016/0168-9525(89)90097-8; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; GREENSPAN R J, 1990, New Biologist, V2, P595; GREENWALD I, 1985, CELL, V43, P583, DOI 10.1016/0092-8674(85)90230-2; GREENWALD I, 1990, NATURE, V346, P197, DOI 10.1038/346197a0; GREENWALD I, 1992, CELL, V68, P271, DOI 10.1016/0092-8674(92)90470-W; GREENWALD IS, 1983, CELL, V34, P435, DOI 10.1016/0092-8674(83)90377-X; HARTENSTEIN AY, 1992, DEVELOPMENT, V116, P1203; HARTENSTEIN V, 1990, DEV BIOL, V142, P13, DOI 10.1016/0012-1606(90)90147-B; HEITZLER P, 1991, CELL, V64, P1083, DOI 10.1016/0092-8674(91)90263-X; HELD LI, 1991, BIOESSAYS, V13, P633, DOI 10.1002/bies.950131203; HOPPE PE, 1986, CELL, V46, P773, DOI 10.1016/0092-8674(86)90353-3; HOPPE PE, 1990, DEVELOPMENT, V109, P875; HORVITZ HR, 1991, NATURE, V351, P535, DOI 10.1038/351535a0; JHAPPAN C, 1992, GENE DEV, V6, P345, DOI 10.1101/gad.6.3.345; JIMENEZ F, 1990, NEURON, V5, P81, DOI 10.1016/0896-6273(90)90036-F; JIMENEZ F, 1982, ROUX ARCH DEVEL BIOL, V191, P62; JOHANSEN KM, 1989, J CELL BIOL, V109, P2427, DOI 10.1083/jcb.109.5.2427; KIDD S, 1986, MOL CELL BIOL, V6, P3094, DOI 10.1128/MCB.6.9.3094; KIMBLE J, 1981, DEV BIOL, V87, P286, DOI 10.1016/0012-1606(81)90152-4; KIMBLE J, 1979, DEV BIOL, V81, P208; LAMBIE E, 1990, DEVELOPMENT, V112, P231; LEHMANN R, 1983, ROUX ARCH DEV BIOL, V192, P62, DOI 10.1007/BF00848482; LIS JT, 1983, CELL, V35, P403, DOI 10.1016/0092-8674(83)90173-3; MANGO SE, 1991, NATURE, V352, P811, DOI 10.1038/352811a0; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MICHIELS F, 1989, EMBO J, V8, P1559, DOI 10.1002/j.1460-2075.1989.tb03540.x; MULLER HJ, 1932, P INT C GENET, V6, P213; PALKA J, 1990, DEVELOPMENT, V109, P167; Poulson DF, 1940, J EXP ZOOL, V83, P271, DOI 10.1002/jez.1400830207; REBAY I, 1991, CELL, V67, P687, DOI 10.1016/0092-8674(91)90064-6; ROBBINS J, 1992, J VIROL, V66, P2594, DOI 10.1128/JVI.66.4.2594-2599.1992; ROGERS S, 1986, SCIENCE, V234, P364, DOI 10.1126/science.2876518; ROMANI S, 1989, GENE DEV, V3, P997, DOI 10.1101/gad.3.7.997; RUBIN GM, 1983, NUCLEIC ACIDS RES, V11, P6341, DOI 10.1093/nar/11.18.6341; RUOHOLA H, 1991, CELL, V66, P433, DOI 10.1016/0092-8674(81)90008-8; SCHNEIDER DS, 1991, GENE DEV, V5, P797, DOI 10.1101/gad.5.5.797; SEYDOUX G, 1989, CELL, V57, P1237, DOI 10.1016/0092-8674(89)90060-3; SEYDOUX G, 1993, IN PRESS DEV BIOL; SHELLENBARGER DL, 1978, DEV BIOL, V62, P432, DOI 10.1016/0012-1606(78)90226-9; SIMPSON P, 1990, DEVELOPMENT, V109, P509; SIMPSON P, 1989, DEVELOPMENT, V106, P57; SKEATH JB, 1992, GENE DEV, V6, P2606, DOI 10.1101/gad.6.12b.2606; STERNBERG PW, 1986, CELL, V44, P761, DOI 10.1016/0092-8674(86)90842-1; STERNBERG PW, 1989, CELL, V58, P679, DOI 10.1016/0092-8674(89)90103-7; STERNBERG PW, 1988, NATURE, V335, P551, DOI 10.1038/335551a0; STIFANI S, 1992, NAT GENET, V2, P119, DOI 10.1038/ng1092-119; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; STRUHL G, 1992, CELL, V69, P237, DOI 10.1016/0092-8674(92)90405-2; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1980, DEV BIOL, V78, P577, DOI 10.1016/0012-1606(80)90353-X; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WHARTON KA, 1985, CELL, V40, P55, DOI 10.1016/0092-8674(85)90308-3; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0	77	442	456	0	5	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					331	345		10.1016/0092-8674(93)90424-O	http://dx.doi.org/10.1016/0092-8674(93)90424-O			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343960				2022-12-01	WOS:A1993LP72600014
J	SCHIEBER, MH; HIBBARD, LS				SCHIEBER, MH; HIBBARD, LS			HOW SOMATOTOPIC IS THE MOTOR CORTEX HAND AREA	SCIENCE			English	Article							ELECTRICAL-STIMULATION; SPATIAL-ORGANIZATION; PRECENTRAL CORTEX; FINGER MOVEMENTS; AWAKE PRIMATES; MONKEY; FORELIMB; MUSCLES; REPRESENTATION; NEURONS	The primary motor cortex (M1) is thought to control movements of different body parts from somatatopically organized cortical territories. Electrical stimulation suggests, however, that territories controlling different fingers overlap. Such overlap might be artifactual or else might indicate that activation of M1 to produce a finger movement occurs over a more widespread cortical area than usually assumed. These possibilities were distinguished in monkeys moving different fingers. Recordings showed that single M1 neurons were active with movements of different fingers. Neuronal populations active with movements of different fingers overlapped extensively. Control of any finger movement thus appears to utilize a population of neurons distributed throughout the M1 hand area rather than a somatotopically segregated population.	WASHINGTON UNIV, SCH MED, DEPT NEUROSURG NEUROL, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT ANAT, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT NEUROBIOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL)	SCHIEBER, MH (corresponding author), WASHINGTON UNIV, SCH MED, DEPT NEUROL, ST LOUIS, MO 63110 USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS027686] Funding Source: NIH RePORTER; NINDS NIH HHS [R01-NS27686] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANDERSEN P, 1975, PROC R SOC SER B-BIO, V188, P31, DOI 10.1098/rspb.1975.0002; ASANUMA H, 1972, EXP BRAIN RES, V14, P243, DOI 10.1007/BF00816161; BUYS EJ, 1986, J PHYSIOL-LONDON, V381, P529, DOI 10.1113/jphysiol.1986.sp016342; DEFELIPE J, 1986, J NEUROSCI, V6, P3749, DOI 10.1523/jneurosci.06-12-03749.1986; DONOGHUE JP, 1992, EXP BRAIN RES, V89, P1; FETZ EE, 1980, J NEUROPHYSIOL, V44, P751, DOI 10.1152/jn.1980.44.4.751; FISH J, 1992, EXP BRAIN RES, V91, P327; FLANDERS M, 1992, J NEUROPHYSIOL, V67, P1264, DOI 10.1152/jn.1992.67.5.1264; GEORGOPOULOS AP, 1986, SCIENCE, V233, P1416, DOI 10.1126/science.3749885; GOULD HJ, 1986, J COMP NEUROL, V247, P297, DOI 10.1002/cne.902470303; HIBBARD LS, 1988, J NEUROSCI METH, V26, P55, DOI 10.1016/0165-0270(88)90129-X; Humphrey D R, 1982, Electroencephalogr Clin Neurophysiol Suppl, V36, P393; HUMPHREY DR, 1986, FED PROC, V45, P2687; HUNTLEY GW, 1991, J NEUROPHYSIOL, V66, P390, DOI 10.1152/jn.1991.66.2.390; KWAN HC, 1978, J NEUROPHYSIOL, V41, P1120, DOI 10.1152/jn.1978.41.5.1120; LEMON RN, 1981, J PHYSIOL-LONDON, V311, P521, DOI 10.1113/jphysiol.1981.sp013602; Leyton ASF, 1917, Q J EXP PHYSIOL, V11, P135, DOI 10.1113/expphysiol.1917.sp000240; O'Donnell T. J., 1981, Computer Graphics, V15, P133, DOI 10.1145/965161.806799; Penfield W, 1937, BRAIN, V60, P389, DOI 10.1093/brain/60.4.389; Penfield W., 1950, CEREBRAL CORTEX MAN; REED D, 1983, MOTOR CONTROL MECHAN, P347; SATO KC, 1989, J NEUROPHYSIOL, V62, P959, DOI 10.1152/jn.1989.62.4.959; SCHIEBER MH, 1990, TRENDS NEUROSCI, V13, P440, DOI 10.1016/0166-2236(90)90093-P; SCHIEBER MH, 1991, J NEUROPHYSIOL, V65, P1381, DOI 10.1152/jn.1991.65.6.1381; SERLIN DM, 1993, ACTA ANAT, V146, P255; SHINODA Y, 1981, NEUROSCI LETT, V23, P7, DOI 10.1016/0304-3940(81)90182-8; STRICK PL, 1978, BRAIN RES, V154, P366, DOI 10.1016/0006-8993(78)90707-2; WANNIER TMJ, 1989, NEUROSCI LETT, V98, P63, DOI 10.1016/0304-3940(89)90374-1; WATERS RS, 1990, SOMATOSENS MOT RES, V7, P485, DOI 10.3109/08990229009144721; WONG YC, 1978, J NEUROPHYSIOL, V41, P1107, DOI 10.1152/jn.1978.41.5.1107; WOOLSEY CN, 1979, J NEUROSURG, V51, P476, DOI 10.3171/jns.1979.51.4.0476; WOOLSEY CN, 1950, RES PUBL ASSOC RES N, V30, P238	32	318	319	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 23	1993	261	5120					489	492		10.1126/science.8332915	http://dx.doi.org/10.1126/science.8332915			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8332915				2022-12-01	WOS:A1993LN62300042
J	STATHAM, H; GREEN, J				STATHAM, H; GREEN, J			SERUM SCREENING FOR DOWNS-SYNDROME - SOME WOMENS EXPERIENCES	BRITISH MEDICAL JOURNAL			English	Article							AMNIOCENTESIS	Objectives-To describe the experiences of a small group of women who had positive results after serum screening for Down's syndrome. Design-Semistructured telephone interviews and correspondence with women after a positive screening result (four women) negative amniocentesis results (eight), or termination of a pregnancy with a confirmed abnormality (eight). Subjects-20 women who contacted Support After Termination For Abnormality about their experiences of serum screening for Down's syndrome. Main outcome measures-Women's knowledge and understanding of the test; staff misconceptions; communication of results; how women coped with the diagnostic process; attitudes to the test and to termination of abnormal fetuses. Results-All women were made anxious by their positive screening test, no matter how they were told. The women's experiences suggested that medical staff were unclear about the implications of screening tests and how to interpret risk. Even after receipt of negative amniocentesis results some women remained anxious. Staff did not always recognise women's concerns while awaiting amniocentesis results. Conclusions-The way in which serum screening is being implemented does not always meet the needs of women with positive results. Some of the problems were not specific to screening for Down's syndrome. When screening tests are introduced policies should be adopted to ensure appropriate support for participants.			STATHAM, H (corresponding author), UNIV CAMBRIDGE,CTR FAMILY RES,CAMBRIDGE CB2 3RF,ENGLAND.							CLARKE A, 1993, BRIT MED J, V306, P209, DOI 10.1136/bmj.306.6871.209-a; CUCKLE HS, 1988, LANCET, V2, P851; FARRANT W, 1980, BRIT MED J, V281, P452, DOI 10.1136/bmj.281.6237.452; GREEN J, 1990, CRITICAL REV PSYCHOL; GREEN J, 1993, PREGNANCY TESTING TI; KEATINGE RM, 1991, BRIT MED J, V303, P54, DOI 10.1136/bmj.303.6793.54-d; MARTEAU TM, 1988, BRIT MED J, V297, P1469, DOI 10.1136/bmj.297.6661.1469-b; MARTEAU TM, 1989, BRIT J OBSTET GYNAEC, V96, P739, DOI 10.1111/j.1471-0528.1989.tb03295.x; MARTEAU TM, 1992, BMJ, V305, P1434; ROELOFSEN EEC, 1993, J REPROD INFANT PSYC, V11, P41; SHELDON TA, 1991, BRIT MED J, V302, P1133, DOI 10.1136/bmj.302.6785.1133; SPENCER K, 1992, BRIT MED J, V305, P769, DOI 10.1136/bmj.305.6856.769; WALD N, 1992, LANCET, V340, P494, DOI 10.1016/0140-6736(92)91822-P; WALD NJ, 1992, BMJ-BRIT MED J, V305, P391, DOI 10.1136/bmj.305.6850.391	14	74	75	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1993	307	6897					174	176		10.1136/bmj.307.6897.174	http://dx.doi.org/10.1136/bmj.307.6897.174			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN184	8343748	Bronze, Green Published			2022-12-01	WOS:A1993LN18400023
J	KOLANUS, W; ROMEO, C; SEED, B				KOLANUS, W; ROMEO, C; SEED, B			T-CELL ACTIVATION BY CLUSTERED TYROSINE KINASES	CELL			English	Article							BASOPHILIC LEUKEMIA-CELLS; AMINO-TERMINAL DOMAIN; RECEPTOR ZETA-CHAIN; FC-GAMMA-RII; ANTIGEN RECEPTOR; SIGNAL TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; LYMPHOCYTES-T; SRC-FAMILY; CYTOPLASMIC TAIL	Many cellular recognition events in the immune system are initiated by aggregation of cell surface receptors that lack intrinsic protein-tyrosine kinase activity. Receptor-associated kinases related to the src proto-oncogene product have been found to be essential for cellular activation and may interact with the cytoplasmic domains of the antigen receptor chains. We show here that anti-CD16 antibody-mediated clustering of chimeric transmembrane proteins bearing a CD16 extracellular domain and a Src family kinase intracellular domain is not sufficient to initiate a cellular activation signal in T cells, whereas clustering of similar chimeras bearing Syk or ZAP-70 kinase sequences triggers calcium mobilization. Aggregation of the Syk chimera alone, or coaggregation of chimeras bearing Fyn and ZAP-70 kinases, suffices to initiate cytolytic effector function. The pattern of tyrosine phosphorylation induced by clustering of the Syk chimera is similar to the pattern induced by aggregation of T cell receptor.	MIT, DEPT MOLEC BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	KOLANUS, W (corresponding author), HARVARD UNIV, SCH MED, DEPT GENET, BOSTON, MA 02115 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI027849, R37AI027849] Funding Source: NIH RePORTER; NIAID NIH HHS [AI27849] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM N, 1990, MOL CELL BIOL, V10, P5197, DOI 10.1128/MCB.10.10.5197; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; Balk S, 1989, Immunol Ser, V45, P411; BANIYASH M, 1988, J BIOL CHEM, V263, P9874; BAUER A, 1991, P NATL ACAD SCI USA, V88, P3842, DOI 10.1073/pnas.88.9.3842; BELL GM, 1992, MOL CELL BIOL, V12, P5548, DOI 10.1128/MCB.12.12.5548; BOLEN JB, 1991, ADV CANCER RES, V57, P103; BURKHARDT AL, 1991, P NATL ACAD SCI USA, V88, P7410, DOI 10.1073/pnas.88.16.7410; CAMPBELL MA, 1992, MOL CELL BIOL, V12, P2315, DOI 10.1128/MCB.12.5.2315; CAMPBELL MA, 1990, EMBO J, V9, P2125, DOI 10.1002/j.1460-2075.1990.tb07381.x; CARTER RH, 1991, P NATL ACAD SCI USA, V88, P2745, DOI 10.1073/pnas.88.7.2745; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CLARK EA, 1989, ADV CANCER RES, V52, P81; CLARK MR, 1992, SCIENCE, V258, P123, DOI 10.1126/science.1439759; CLAYTON LK, 1991, P NATL ACAD SCI USA, V88, P5202, DOI 10.1073/pnas.88.12.5202; COOKE M P, 1989, New Biologist, V1, P66; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; DAVIDSON D, 1992, J EXP MED, V175, P1483, DOI 10.1084/jem.175.6.1483; DEFRANCO AL, 1992, EUR J BIOCHEM, V210, P381, DOI 10.1111/j.1432-1033.1992.tb17432.x; EISEMAN E, 1992, NATURE, V355, P78; FANGER MW, 1989, IMMUNOL TODAY, V10, P92, DOI 10.1016/0167-5699(89)90234-X; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; GASSMANN M, 1992, EUR J IMMUNOL, V22, P283, DOI 10.1002/eji.1830220142; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GOLD MR, 1990, NATURE, V345, P810, DOI 10.1038/345810a0; GOLDSMITH MA, 1987, P NATL ACAD SCI USA, V84, P6879, DOI 10.1073/pnas.84.19.6879; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHCROFT JE, 1992, J BIOL CHEM, V267, P8613; HUTCHCROFT JE, 1991, J BIOL CHEM, V266, P14846; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; JIN YJ, 1990, P NATL ACAD SCI USA, V87, P3319, DOI 10.1073/pnas.87.9.3319; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KARNITZ L, 1992, MOL CELL BIOL, V12, P4521, DOI 10.1128/MCB.12.10.4521; KOGA Y, 1986, EUR J IMMUNOL, V16, P1643, DOI 10.1002/eji.1830161229; KOLANUS W, 1992, EMBO J, V11, P4861, DOI 10.1002/j.1460-2075.1992.tb05592.x; KROCZEK RA, 1986, NATURE, V322, P181, DOI 10.1038/322181a0; LANE PJL, 1991, J IMMUNOL, V146, P715; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LETOURNEUR F, 1991, P NATL ACAD SCI USA, V88, P8905, DOI 10.1073/pnas.88.20.8905; LI W, 1992, MOL CELL BIOL, V12, P3176, DOI 10.1128/MCB.12.7.3176; LUO KX, 1992, MOL CELL BIOL, V12, P4724, DOI 10.1128/MCB.12.10.4724; MULLER AJ, 1992, MOL CELL BIOL, V12, P5087, DOI 10.1128/MCB.12.11.5087; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; PARK DJ, 1991, J BIOL CHEM, V266, P24237; PARK DJ, 1991, P NATL ACAD SCI USA, V88, P5453, DOI 10.1073/pnas.88.12.5453; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; RABINOVITCH PS, 1986, J IMMUNOL, V137, P952; RAVETCH JV, 1991, ANNU REV IMMUNOL, V9, P457, DOI 10.1146/annurev.iy.09.040191.002325; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SECRIST JP, 1991, J BIOL CHEM, V266, P12135; SECRIST JP, 1993, J BIOL CHEM, V268, P5886; SHAW AS, 1989, CELL, V59, P627, DOI 10.1016/0092-8674(89)90008-1; SHEN L, 1989, MOL IMMUNOL, V26, P959, DOI 10.1016/0161-5890(89)90114-4; STANLEY JB, 1990, J IMMUNOL, V145, P2189; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; SUGIE K, 1991, P NATL ACAD SCI USA, V88, P9132, DOI 10.1073/pnas.88.20.9132; TANIGUCHI T, 1991, J BIOL CHEM, V266, P15790; THOMAS PM, 1992, J BIOL CHEM, V267, P12317; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; TURNER JM, 1990, CELL, V60, P755, DOI 10.1016/0092-8674(90)90090-2; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WEBB DSA, 1990, SCIENCE, V249, P1295, DOI 10.1126/science.1697984; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1991, ANNU REV GENET, V25, P487, DOI 10.1146/annurev.ge.25.120191.002415; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISS A, 1984, J EXP MED, V160, P1284, DOI 10.1084/jem.160.5.1284; WONG S, 1992, ONCOGENE, V7, P2407; YAMANASHI Y, 1991, SCIENCE, V251, P192, DOI 10.1126/science.1702903; YEH ETH, 1987, J IMMUNOL, V138, P91; Yokoyama W M, 1989, Year Immunol, V4, P110; ZIONCHECK TF, 1988, J BIOL CHEM, V263, P19195; ZIONCHECK TF, 1986, J BIOL CHEM, V261, P5637	88	344	357	0	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 16	1993	74	1					171	183		10.1016/0092-8674(93)90304-9	http://dx.doi.org/10.1016/0092-8674(93)90304-9			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8334702				2022-12-01	WOS:A1993LN62500017
J	ROME, LC; SWANK, D; CORDA, D				ROME, LC; SWANK, D; CORDA, D			HOW FISH POWER SWIMMING	SCIENCE			English	Article							MUSCLE POWER; OUTPUT; CARP; TEMPERATURE; LOCOMOTION	It is thought that fish generate the power needed for steady swimming with their anterior musculature, whereas the posterior musculature only transmits forces to the tail and does negative work. Isolated red muscle bundles driven through the length changes and stimulation pattern that muscles normally undergo during steady swimming showed the opposite pattern. Most of the power for swimming came from muscle in the posterior region of the fish, and relatively little came from the anterior musculature. In addition, the contractile properties of the muscle along the length of the fish are significantly adapted to enhance power generation.	UNIV PENN,DEPT PHYSIOL,PHILADELPHIA,PA 19104; MARINE BIOL LAB,WOODS HOLE,MA 02543; WOODS HOLE OCEANOG INST,COASTAL RES CTR,WOODS HOLE,MA 02543	University of Pennsylvania; Marine Biological Laboratory - Woods Hole; Woods Hole Oceanographic Institution	ROME, LC (corresponding author), UNIV PENN,DEPT BIOL,PHILADELPHIA,PA 19104, USA.				NIAMS NIH HHS [AR38404] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR038404, R01AR038404] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTRINGHAM JD, 1990, J EXP BIOL, V148, P395; ALTRINGHAM JD, 1990, J EXP BIOL, V151, P453; HESS F, 1984, J EXP BIOL, V109, P229; Hill AV, 1938, PROC R SOC SER B-BIO, V126, P136, DOI 10.1098/rspb.1938.0050; JOSEPHSON RK, 1989, J EXP BIOL, V147, P533; JOSEPHSON RK, 1985, J EXP BIOL, V114, P493; LIGHTHILL MJ, 1971, PROC R SOC SER B-BIO, V179, P125, DOI 10.1098/rspb.1971.0085; MARSH RL, 1992, NATURE, V357, P411, DOI 10.1038/357411a0; ROME LC, 1990, J EXP BIOL, V154, P163; ROME LC, 1988, NATURE, V335, P824, DOI 10.1038/335824a0; ROME LC, 1992, J EXP BIOL, V163, P281; ROME LC, 1992, J EXP BIOL, V163, P259; ROME LC, 1991, AM J PHYSIOL, V260, pC289, DOI 10.1152/ajpcell.1991.260.2.C289; ROME LC, 1992, J EXP BIOL, V171, P261; ROME LC, 1984, AM J PHYSIOL, V247, pR272, DOI 10.1152/ajpregu.1984.247.2.R272; ROME LC, IN PRESS J BIOMECH; SCHMIDTNIELSEN K, 1972, SCIENCE, V177, P222, DOI 10.1126/science.177.4045.222; TANG J, 1992, J EXP BIOL, V166, P33; VANLEEUWEN JL, 1990, J ZOOL, V220, P123; WAINWRIGHT S, 1983, FISH BIOMECHANICS, pCH3	20	185	187	1	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 16	1993	261	5119					340	343		10.1126/science.8332898	http://dx.doi.org/10.1126/science.8332898			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM678	8332898				2022-12-01	WOS:A1993LM67800032
J	GUARIGLIA, C; PADOVANI, A; PANTANO, P; PIZZAMIGLIO, L				GUARIGLIA, C; PADOVANI, A; PANTANO, P; PIZZAMIGLIO, L			UNILATERAL NEGLECT RESTRICTED TO VISUAL-IMAGERY	NATURE			English	Article							CEREBRAL HEMISPHERES; MENTAL-IMAGERY; SPACE	DISORDERS in perceiving and exploring the visual space contralateral to a brain lesion have been frequently described. Many patients with hemi-neglect for extrapersonal space also show neglect in a representational domain when the task requires imagining a well-known piazza from a given vantage point1,2 or comparing two visual images3-5. Cognitive6 and psychophysiological7 studies show a functional parallelism between the perceptual and imaginative domain7, indicating that spatial perception and imagery share the same neural substrata. Here we describe a patient with a persistent disorder in visual imagery for familiar piazzas in the absence of any neglect for stimuli located in a far8 or near9 space or on his own body10. Contrary to previous cases involving imagery disorders, computerized tomography scans showed a lesion confined to the right frontal lobe, suggesting the role of the frontal lobe in some specific types of mental imagery.	UNIV ROMA LA SAPIENZA,DEPT PSYCHOL,VIA MARSI 78,I-00185 ROME,ITALY; UNIV ROMA LA SAPIENZA,DEPT NEUROL,I-00185 ROME,ITALY; CLIN S LUCIA,I-00179 ROME,ITALY	Sapienza University Rome; Sapienza University Rome			Padovani, Alessandro/B-7594-2011; Padovani, Alessandro/ABI-7312-2020; guariglia, cecilia/J-9898-2018; Patrizia, Pantano/C-8214-2009	Padovani, Alessandro/0000-0002-0119-3639; Patrizia, Pantano/0000-0001-9659-8294; guariglia, cecilia/0000-0001-7474-6030				BISIACH E, 1978, CORTEX, V14, P129, DOI 10.1016/S0010-9452(78)80016-1; BISIACH E, 1979, BRAIN, V102, P609, DOI 10.1093/brain/102.3.609; BISIACH E, 1987, NEUROPHYSIOLOGICAL N; DEVREESE LP, 1991, NEUROPSYCHOLOGIA, V29, P1, DOI 10.1016/0028-3932(91)90090-U; Ekstrom R.B., 1976, KIT FACTOR REFERENCE; Farah M J, 1989, J Cogn Neurosci, V1, P302, DOI 10.1162/jocn.1989.1.4.302; FARAH MJ, 1984, COGNITION, V18, P245, DOI 10.1016/0010-0277(84)90026-X; Finke R.A., 1989, PRINCIPLES MENTAL IM; GROSSI D, 1989, BRAIN COGNITION, V10, P18, DOI 10.1016/0278-2626(89)90072-9; GUARIGLIA C, 1992, NEUROPSYCHOLOGIA, V30, P1001, DOI 10.1016/0028-3932(92)90051-M; HALLIGAN PW, 1991, NATURE, V350, P498, DOI 10.1038/350498a0; Halligan PW, 1992, NEUROPSYCHOL REHABIL, V2, P125; KINSBOURNE M, 1962, J NEUROL NEUROSUR PS, V25, P339, DOI 10.1136/jnnp.25.4.339; KOSSLYN SM, 1987, PSYCHOL REV, V94, P148, DOI 10.1037/0033-295X.94.2.148; OGDEN JA, 1985, NEUROPSYCHOLOGIA, V23, P273, DOI 10.1016/0028-3932(85)90112-5; PIZZAMIGLIO L, 1990, CORTEX, V56, P551; RIZZOLATTI G, 1983, BRAIN, V106, P655, DOI 10.1093/brain/106.3.655; TEGNER R, 1991, BRAIN, V114, P1943, DOI 10.1093/brain/114.4.1943; Zoccolotti P., 1991, NEUROPSYCHOL REHABIL, V1, P33, DOI [10.1080/09602019108401378, DOI 10.1080/09602019108401378]	19	161	163	0	10	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 15	1993	364	6434					235	237		10.1038/364235a0	http://dx.doi.org/10.1038/364235a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM683	8321319				2022-12-01	WOS:A1993LM68300056
J	STOECKLE, MY; DOUGLAS, RG				STOECKLE, MY; DOUGLAS, RG			INFECTIOUS-DISEASES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									MERCK & CO INC,WHITE HOUSE STN,NJ	Merck & Company	STOECKLE, MY (corresponding author), CORNELL UNIV,MED CTR,COLL MED,NEW YORK,NY 10021, USA.		Stoeckle, Mark/D-3729-2011	Stoeckle, Mark/0000-0002-8280-4795				[Anonymous], 1992, MMWR MORB MORTAL WKL, V41, P1; BECKSAGUE C, 1992, JAMA-J AM MED ASSOC, V268, P1280, DOI 10.1001/jama.268.10.1280; EDLIN BR, 1992, NEW ENGL J MED, V326, P1514, DOI 10.1056/NEJM199206043262302; KAHN JO, 1992, NEW ENGL J MED, V327, P581, DOI 10.1056/NEJM199208273270901; KOEHLER JE, 1992, NEW ENGL J MED, V327, P1625, DOI 10.1056/NEJM199212033272303; LIVORNESE LL, 1992, ANN INTERN MED, V117, P112, DOI 10.7326/0003-4819-117-2-112; NEU HC, 1992, SCIENCE, V257, P1064, DOI 10.1126/science.257.5073.1064; RELMAN DA, 1992, NEW ENGL J MED, V327, P293, DOI 10.1056/NEJM199207303270501; SPERA RV, 1992, JAMA-J AM MED ASSOC, V268, P2563, DOI 10.1001/jama.268.18.2563; TAPPERO JW, 1993, JAMA-J AM MED ASSOC, V269, P770, DOI 10.1001/jama.269.6.770; 1992, CITY HLTH INFO, V11, P1; 1992, MMWR MORB MORTAL WKL, V41, P61; 1993, CLIN ALERT	13	1	1	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					223	224		10.1001/jama.270.2.223	http://dx.doi.org/10.1001/jama.270.2.223			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315739				2022-12-01	WOS:A1993LL36800025
J	TIITINEN, H; SINKKONEN, J; REINIKAINEN, K; ALHO, K; LAVIKAINEN, J; NAATANEN, R				TIITINEN, H; SINKKONEN, J; REINIKAINEN, K; ALHO, K; LAVIKAINEN, J; NAATANEN, R			SELECTIVE ATTENTION ENHANCES THE AUDITORY 40-HZ TRANSIENT-RESPONSE IN HUMANS	NATURE			English	Article							EVOKED-POTENTIALS	STUDIES of human auditory1-3 and somatosensory3 modalities have shown that there is an oscillatory response in the gamma-band (at about 40 Hz) frequency which is elicited by either steady state1-3 or transient4 stimulation. The auditory 40-Hz response is generated at least partially in the auditory cortex4,5 as a result of thalamocortical interaction6 and may serve perceptual integration7,8 and conscious perception9. A connection to selective attention has been implied in human10 and animal11 studies, although the evidence is inconclusive12. Moreover, fundamental differences between the human and animal 40-Hz responses13 prohibit generalization. Furthermore, most experiments have used steady-state stimulation during which the brain does not regain its resting state between stimuli as it does when transient stimulation is used14. Here we study the effect of selective attention on the auditory gamma-band (40-Hz) transient response using subjects listening to tone pips presented in one ear while ignoring a concurrent sequence of tone pips in the other ear. The 40-Hz response was larger when subjects paid attention to stimuli rather than ignored them. This attention effect was most pronounced over the frontal and central scalp areas. Our results demonstrate a physiological correlate of selective attention in the 40-Hz transient response in humans.			TIITINEN, H (corresponding author), UNIV HELSINKI,DEPT PSYCHOL,COGNIT PSYCHOPHYSIOL RES UNIT,RITARIKATU 5,SF-00170 HELSINKI 17,FINLAND.		Alho, Kimmo/G-2997-2013	Alho, Kimmo/0000-0001-8563-2792				DAUBECHIES I, 1990, IEEE T INFORM THEORY, V36, P961, DOI 10.1109/18.57199; ENGEL AK, 1992, TRENDS NEUROSCI, V15, P218, DOI 10.1016/0166-2236(92)90039-B; Gabor D., 1946, IEEE J I ELECT ENG, V93, P429, DOI DOI 10.1049/JI-3-2.1946.0074; GALAMBOS R, 1982, ANN NY ACAD SCI, V388, P722, DOI 10.1111/j.1749-6632.1982.tb50841.x; GALAMBOS R, 1981, P NATL ACAD SCI-BIOL, V78, P2643, DOI 10.1073/pnas.78.4.2643; GALAMBOS R, 1991, INDDUCED RHYTHMS BRA, P201; GRAY CM, 1989, NATURE, V338, P334, DOI 10.1038/338334a0; HARTER MR, 1984, VARIATIES ATTENTION; HILLYARD SA, 1984, CURRENT TRENDS EVE S, V40, P61; KAUFMAN L, 1990, AUDITORY EVOKED MAGN, P283; LINDEN RD, 1987, ELECTROEN CLIN NEURO, V66, P145, DOI 10.1016/0013-4694(87)90184-2; LLINAS RR, 1991, NEUROSCIENCE, V44, P521, DOI 10.1016/0306-4522(91)90075-Y; MAKEIG S, 1989, Society for Neuroscience Abstracts, V15, P113; MAKELA JP, 1987, ELECTROEN CLIN NEURO, V66, P539, DOI 10.1016/0013-4694(87)90101-5; OATMAN LC, 1971, EXP NEUROL, V32, P341, DOI 10.1016/0014-4886(71)90003-3; PANTEV C, 1991, P NATL ACAD SCI USA, V88, P8996, DOI 10.1073/pnas.88.20.8996; RIBARY U, 1991, P NATL ACAD SCI USA, V88, P11037, DOI 10.1073/pnas.88.24.11037; RIBARY U, 1989, ADV BIOMAGNETISM, P311; RIBARY U, 1988, EUR J NEUROSCI S, V1; ROUGEUL A, 1979, ELECTROEN CLIN NEURO, V46, P310, DOI 10.1016/0013-4694(79)90205-0; Sheer D.E., 1984, SELF REGULATION BRAI, P64, DOI DOI 10.1007/978-3-642-69379-3_6; Skinner JE, 1977, ATTENTION VOLUNTARY, P30	22	493	499	1	27	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 1	1993	364	6432					59	60		10.1038/364059a0	http://dx.doi.org/10.1038/364059a0			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK818	8316297				2022-12-01	WOS:A1993LK81800056
J	VONGS, A; KAKUTANI, T; MARTIENSSEN, RA; RICHARDS, EJ				VONGS, A; KAKUTANI, T; MARTIENSSEN, RA; RICHARDS, EJ			ARABIDOPSIS-THALIANA DNA METHYLATION MUTANTS	SCIENCE			English	Article							SEQUENCE SPECIFICITY; TRANSPOSABLE ELEMENTS; CHROMATIN STRUCTURE; GENE-EXPRESSION; MAIZE; METHYLTRANSFERASES; INACTIVATION; CELLS; AC	Three DNA hypomethylation mutants of the flowering plant Arabidopsis thaliana were isolated by screening mutagenized populations for plants containing centromeric repetitive DNA arrays susceptible to digestion by a restriction endonuclease that was sensitive to methylated cytosines. The mutations are recessive, and at least two are alleles of a single locus, designated DDM1 (for decrease in DNA methylation). Amounts of 5-methylcytosine were reduced over 70 percent in ddm1 mutants. Despite this reduction in DNA methylation levels, ddm1 mutants developed normally and exhibited no striking morphological phenotypes. However, the ddm1 mutations are associated with a segregation distortion phenotype. The ddm1 mutations were used to demonstrate that de novo DNA methylation in vivo is slow.	COLD SPRING HARBOR LAB,COLD SPRING HARBOR,NY 11724	Cold Spring Harbor Laboratory			Richards, Eric/E-6866-2012	Richards, Eric/0000-0002-8665-7470				BENNETZEN JL, 1987, MOL GEN GENET, V208, P45, DOI 10.1007/BF00330420; BESTOR TH, 1992, EMBO J, V11, P2611, DOI 10.1002/j.1460-2075.1992.tb05326.x; BESTOR TH, 1983, P NATL ACAD SCI-BIOL, V80, P5559, DOI 10.1073/pnas.80.18.5559; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BOYES J, 1991, CELL, V64, P1123, DOI 10.1016/0092-8674(91)90267-3; BUSSLINGER M, 1983, CELL, V34, P197, DOI 10.1016/0092-8674(83)90150-2; CAMPELL BR, 1992, GENE, V112, P225, DOI 10.1016/0378-1119(92)90380-8; CEDAR H, 1988, CELL, V53, P3, DOI 10.1016/0092-8674(88)90479-5; CEDAR H, 1979, NUCLEIC ACIDS RES, V6, P2125, DOI 10.1093/nar/6.6.2125; CHANDLER VL, 1986, P NATL ACAD SCI USA, V83, P1767, DOI 10.1073/pnas.83.6.1767; CHOMET PS, 1987, EMBO J, V6, P295, DOI 10.1002/j.1460-2075.1987.tb04753.x; FEDOROFF NV, 1989, CELL, V56, P181, DOI 10.1016/0092-8674(89)90891-X; GRUENBAUM Y, 1982, NATURE, V295, P620, DOI 10.1038/295620a0; GRUENBAUM Y, 1981, NATURE, V292, P860, DOI 10.1038/292860a0; HARE JT, 1985, P NATL ACAD SCI USA, V82, P7350, DOI 10.1073/pnas.82.21.7350; HOLLIDAY R, 1987, SCIENCE, V238, P163, DOI 10.1126/science.3310230; JONES PA, 1985, CELL, V40, P485, DOI 10.1016/0092-8674(85)90192-8; LEWIS J, 1991, FEBS LETT, V285, P155, DOI 10.1016/0014-5793(91)80795-5; LI E, 1992, CELL, V69, P915, DOI 10.1016/0092-8674(92)90611-F; LINN F, 1990, MOL GEN GENET, V222, P329, DOI 10.1007/BF00633837; LYTTLE TW, 1991, ANNU REV GENET, V25, P511, DOI 10.1146/annurev.ge.25.120191.002455; MALUSZYNSKA J, 1991, PLANT J, V1, P159, DOI 10.1111/j.1365-313X.1991.00159.x; MARTIENSSEN R, 1990, GENE DEV, V4, P331, DOI 10.1101/gad.4.3.331; MARTINEZZAPATER JM, 1986, MOL GEN GENET, V204, P417, DOI 10.1007/BF00331018; MATZKE MA, 1989, EMBO J, V8, P643, DOI 10.1002/j.1460-2075.1989.tb03421.x; NELSON M, 1991, NUCLEIC ACIDS RES, V19, P2045, DOI 10.1093/nar/19.suppl.2045; PRUITT RE, 1986, J MOL BIOL, V187, P169, DOI 10.1016/0022-2836(86)90226-3; RICHARDS EA, UNPUB; RICHARDS EJ, 1992, NUCLEIC ACIDS RES, V20, P4039, DOI 10.1093/nar/20.15.4039; SCHWARTZ D, 1986, MOL GEN GENET, V205, P476, DOI 10.1007/BF00338085; SELIG S, 1988, EMBO J, V7, P419, DOI 10.1002/j.1460-2075.1988.tb02829.x; SELKER EU, 1990, TRENDS BIOCHEM SCI, V15, P103, DOI 10.1016/0968-0004(90)90193-F; SELKER EU, 1990, ANNU REV GENET, V24, P579, DOI 10.1146/annurev.ge.24.120190.003051; SWAIN JL, 1987, CELL, V50, P719, DOI 10.1016/0092-8674(87)90330-8; VENOLIA L, 1982, P NATL ACAD SCI-BIOL, V79, P2352, DOI 10.1073/pnas.79.7.2352; VONGS A, UNPUB	36	525	547	0	39	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 25	1993	260	5116					1926	1928		10.1126/science.8316832	http://dx.doi.org/10.1126/science.8316832			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ349	8316832				2022-12-01	WOS:A1993LJ34900038
J	SUOMINEN, J; VIERULA, M				SUOMINEN, J; VIERULA, M			SEMEN QUALITY OF FINNISH MEN	BRITISH MEDICAL JOURNAL			English	Article											SUOMINEN, J (corresponding author), UNIV TURKU,DEPT MED BIOL,SF-20520 TURKU 52,FINLAND.							CARLSEN E, 1992, BRIT MED J, V305, P609, DOI 10.1136/bmj.305.6854.609; IIROLA T, 1991, J DUODECIM, V107, P1069; LEIKKOLA A, 1955, THESIS U TURKU TURKU; NIKKANEN V, 1979, ANDROLOGIA, V11, P123; Saaranen M, 1986, 5 P WORLD C HUM REPR, P298; SUOMINEN J, 1983, INT J ANDROL, V6, P405, DOI 10.1111/j.1365-2605.1983.tb00555.x; TAKALA ME, 1958, THESIS U TURKU TURKU; WICHMANN L, 1992, THESIS U TAMPERE	8	64	70	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1579	1579		10.1136/bmj.306.6892.1579	http://dx.doi.org/10.1136/bmj.306.6892.1579			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329920	Bronze, Green Published			2022-12-01	WOS:A1993LH12800020
J	CHALFIE, M; TU, Y; EUSKIRCHEN, G; WARD, WW; PRASHER, DC				CHALFIE, M; TU, Y; EUSKIRCHEN, G; WARD, WW; PRASHER, DC			GREEN FLUORESCENT PROTEIN AS A MARKER FOR GENE-EXPRESSION	SCIENCE			English	Article							TOUCH RECEPTOR NEURONS; BETA-TUBULIN GENE; CAENORHABDITIS-ELEGANS; RNA-POLYMERASE; C-ELEGANS; NEMATODE; VECTORS; SYSTEM; MEC-7	A complementary DNA for the Aequorea victoria green fluorescent protein (GFP) produces a fluorescent product when expressed in prokaryotic (Escherichia coli) or eukaryotic (Caenorhabditis elegans) cells. Because exogenous substrates and cofactors are not required for this fluorescence, GFP expression can be used to monitor gene expression and protein localization in living organisms.	RUTGERS STATE UNIV,COOK COLL,DEPT BIOCHEM & MICROBIOL,NEW BRUNSWICK,NJ 08903; WOODS HOLE OCEANOG INST,DEPT BIOL,WOODS HOLE,MA 02543	Rutgers State University New Brunswick; Woods Hole Oceanographic Institution	CHALFIE, M (corresponding author), COLUMBIA UNIV,DEPT BIOL SCI,NEW YORK,NY 10027, USA.		Albers, Pieter/I-2563-2017		NIGMS NIH HHS [GM31997] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRENNER S, 1974, GENETICS, V77, P71; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; CODY CW, 1993, BIOCHEMISTRY-US, V32, P1212, DOI 10.1021/bi00056a003; COXON A, COMMUNICATION; CUTLER ML, UNPUB; DUGGAN A, UNPUB; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; GOULD SJ, 1988, ANAL BIOCHEM, V175, P5, DOI 10.1016/0003-2697(88)90353-3; HAMELIN M, 1992, EMBO J, V11, P2885, DOI 10.1002/j.1460-2075.1992.tb05357.x; HEIM R, COMMUNICATION; KUMAGAI A, 1991, CELL, V64, P903, DOI 10.1016/0092-8674(91)90315-P; LANINI L, COMMUNICATION; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; MILLER JP, 1979, SCIENCE, V206, P702, DOI 10.1126/science.386514; MITANI S, 1993, DEVELOPMENT, V119, P773; MORIN JG, 1971, J CELL PHYSIOL, V77, P313, DOI 10.1002/jcp.1040770305; MORISE H, 1974, BIOCHEMISTRY-US, V13, P2656, DOI 10.1021/bi00709a028; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; PRENDERGAST F, COMMUNICATION; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; Sanbrook J, 1989, MOL CLONING LABORATO; SAVAGE C, 1989, GENE DEV, V3, P870, DOI 10.1101/gad.3.6.870; SHIMOMURA O, 1962, J CELL COMPAR PHYSL, V59, P223, DOI 10.1002/jcp.1030590302; SHIMOMURA O, 1979, FEBS LETT, V104, P220, DOI 10.1016/0014-5793(79)80818-2; SILHAVY TJ, 1985, MICROBIOL REV, V49, P398, DOI 10.1128/MMBR.49.4.398-418.1985; STEWART GSAB, 1992, J GEN MICROBIOL, V138, P1289, DOI 10.1099/00221287-138-7-1289; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; WALTHALL WW, 1988, SCIENCE, V239, P643, DOI 10.1126/science.3340848; WANG SS, COMMUNICATION; WARD WE, COMMUNICATION; WARD WW, 1980, PHOTOCHEM PHOTOBIOL, V31, P611, DOI 10.1111/j.1751-1097.1980.tb03755.x; WAY JC, 1988, CELL, V54, P5, DOI 10.1016/0092-8674(88)90174-2; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056	35	5065	5885	81	2305	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 11	1994	263	5148					802	805		10.1126/science.8303295	http://dx.doi.org/10.1126/science.8303295			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV866	8303295				2022-12-01	WOS:A1994MV86600033
J	HEEMSKERK, J; DINARDO, S				HEEMSKERK, J; DINARDO, S			DROSOPHILA HEDGEHOG ACTS AS A MORPHOGEN IN CELLULAR PATTERNING	CELL			English	Article							SEGMENT-POLARITY GENE; DORSAL-VENTRAL PATTERN; WINGLESS GENE; SPATIAL-DISTRIBUTION; LARVAL EPIDERMIS; ENGRAILED LOCUS; BICOID PROTEIN; PATCHED GENE; BETA FAMILY; FLOOR PLATE	The patterning of cell types in embryogenesis is specified by signals emanating from specialized organizer regions. We demonstrate that engrailed-expressing cells in the Drosophila epidermis have organizer properties. These cells influence the pattern of cell type differentiation across the segment. We show that this function is mediated by the hedgehog (hh) gene. The results of modulating the levels of hh in the embryo suggest that hh acts as a morphogen, specifying distinct cell fates by a concentration-dependent mechanism. We present a model that integrates the role of hh with that of the wingless signal in establishing the segmental array of cell type diversity.	ROCKEFELLER UNIV, NEW YORK, NY 10021 USA; COLUMBIA UNIV, DEPT PHYSIOL, NEW YORK, NY 10032 USA	Rockefeller University; Columbia University				DiNardo, Stephen/0000-0003-4131-5511	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM045747] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM45747] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARIAS AM, 1988, DEVELOPMENT, V103, P157; BAKER NE, 1988, DEV BIOL, V125, P96, DOI 10.1016/0012-1606(88)90062-0; BAKER NE, 1987, EMBO J, V6, P1765, DOI 10.1002/j.1460-2075.1987.tb02429.x; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BEJSOVEC A, 1991, DEVELOPMENT, V113, P471; BEJSOVEC A, 1993, DEVELOPMENT, V119, P501; BOUROUIS M, 1990, EMBO J, V9, P2877, DOI 10.1002/j.1460-2075.1990.tb07477.x; CABRERA CV, 1987, CELL, V50, P659, DOI 10.1016/0092-8674(87)90039-0; Campos-Ortega JA., 1997, EMBRYONIC DEV DROSOP; CARROLL SB, 1988, GENE DEV, V2, P883, DOI 10.1101/gad.2.7.883; CUMBERLEDGE S, 1993, NATURE, V363, P549, DOI 10.1038/363549a0; DINARDO S, 1988, NATURE, V332, P604, DOI 10.1038/332604a0; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; DRIEVER W, 1989, NATURE, V340, P363, DOI 10.1038/340363a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FERGUSON EL, 1992, DEVELOPMENT, V114, P583; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; FJOSE A, 1985, NATURE, V313, P284, DOI 10.1038/313284a0; GONZALEZ F, 1991, MECH DEVELOP, V35, P43, DOI 10.1016/0925-4773(91)90040-D; GREEN JBA, 1990, NATURE, V347, P391, DOI 10.1038/347391a0; HAMA C, 1990, GENE DEV, V4, P1079, DOI 10.1101/gad.4.7.1079; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HEEMSKERK J, 1991, NATURE, V352, P404, DOI 10.1038/352404a0; HIDALGO A, 1990, DEVELOPMENT, V110, P291; HOOPER JE, 1989, CELL, V59, P751, DOI 10.1016/0092-8674(89)90021-4; INGHAM PW, 1993, NATURE, V366, P560, DOI 10.1038/366560a0; INGHAM PW, 1993, DEVELOPMENT, V117, P283; INGHAM PW, 1991, NATURE, V353, P184, DOI 10.1038/353184a0; KASSIS JA, 1992, P NATL ACAD SCI USA, V89, P1919, DOI 10.1073/pnas.89.5.1919; KORNBERG T, 1985, CELL, V40, P45, DOI 10.1016/0092-8674(85)90307-1; KRAUSS S, 1993, CELL, V75, P1431, DOI 10.1016/0092-8674(93)90628-4; LAWRENCE PA, 1966, J EXP BIOL, V44, P607; LAWRENCE PA, 1987, NATURE, V328, P440, DOI 10.1038/328440a0; LAWRENCE PA, 1973, DEV SYSTEMS INSECTS, P157; LEE JJ, 1992, CELL, V71, P33, DOI 10.1016/0092-8674(92)90264-D; LOCKE M, 1960, J EXP BIOL, V37, P398; LOCKE M, 1959, J EXP BIOL, V36, P459; LOHSSCHARDIN M, 1979, DEV BIOL, V73, P239, DOI 10.1016/0012-1606(79)90065-4; MA CY, 1993, CELL, V75, P927, DOI 10.1016/0092-8674(93)90536-Y; MARTINEZARIAS A, 1959, TRENDS GENET, V5, P262; MEER SVD, 1977, DROS INF SERV, V52, P160; MOHLER J, 1992, DEVELOPMENT, V115, P957; MOHLER J, 1988, GENETICS, V120, P1061; NAKANO Y, 1989, NATURE, V341, P508, DOI 10.1038/341508a0; NOORDERMEER J, 1992, DEVELOPMENT, V116, P711; Nubler-Jung Katharina, 1979, Wilehm Roux Arch Dev Biol, V186, P211, DOI 10.1007/BF00848590; NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0; ORENIC T, 1987, DEV BIOL, V124, P50, DOI 10.1016/0012-1606(87)90458-1; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PATEL NH, 1989, CELL, V58, P955, DOI 10.1016/0092-8674(89)90947-1; PEIFER M, 1990, CELL, V63, P1167, DOI 10.1016/0092-8674(90)90413-9; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PLACZEK M, 1993, DEVELOPMENT, V117, P205; POOLE SJ, 1985, CELL, V40, P37, DOI 10.1016/0092-8674(85)90306-X; PREAT T, 1990, NATURE, V347, P87, DOI 10.1038/347087a0; RIDDLE RD, 1993, CELL, V75, P1401, DOI 10.1016/0092-8674(93)90626-2; RIJSEWIJK F, 1987, CELL, V50, P649, DOI 10.1016/0092-8674(87)90038-9; SAMPEDRO J, 1993, DEVELOPMENT, V117, P677; SIEGFRIED E, 1990, NATURE, V345, P825, DOI 10.1038/345825a0; Slack J. M. W, 1991, EGG EMBRYON REGIONAL; Spemann H., 1938, EMBRYONIC DEV INDUCT; SPENCER FA, 1982, CELL, V28, P451, DOI 10.1016/0092-8674(82)90199-4; STRUHL G, 1993, CELL, V72, P527, DOI 10.1016/0092-8674(93)90072-X; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; STUMPF HF, 1968, J EXP BIOL, V49, P49; TABATA T, 1992, GENE DEV, V6, P2635, DOI 10.1101/gad.6.12b.2635; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TAYLOR AM, 1993, MECH DEVELOP, V42, P89, DOI 10.1016/0925-4773(93)90101-3; TICKLE C, 1981, NATURE, V289, P295, DOI 10.1038/289295a0; TICKLE C, 1975, NATURE, V254, P199, DOI 10.1038/254199a0; VANDENHEUVEL M, 1989, CELL, V59, P739, DOI 10.1016/0092-8674(89)90020-2; VINCENT JP, 1992, CELL, V68, P923, DOI 10.1016/0092-8674(92)90035-B; Wieschaus E., 1986, P199; WOLPERT L, 1969, J THEOR BIOL, V25, P1, DOI 10.1016/S0022-5193(69)80016-0; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O	78	206	221	0	12	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	FEB 11	1994	76	3					449	460		10.1016/0092-8674(94)90110-4	http://dx.doi.org/10.1016/0092-8674(94)90110-4			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	8313468				2022-12-01	WOS:A1994MX20700007
J	ROSSLE, M; HAAG, K; OCHS, A; SELLINGER, M; NOLDGE, G; PERARNAU, JM; BERGER, E; BLUM, U; GABELMANN, A; HAUENSTEIN, K; LANGER, M; GEROK, W				ROSSLE, M; HAAG, K; OCHS, A; SELLINGER, M; NOLDGE, G; PERARNAU, JM; BERGER, E; BLUM, U; GABELMANN, A; HAUENSTEIN, K; LANGER, M; GEROK, W			THE TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC STENT-SHUNT PROCEDURE FOR VARICEAL BLEEDING	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DISTAL SPLENORENAL SHUNT; SIDE PORTACAVAL-SHUNT; PROSPECTIVE RANDOMIZED TRIAL; ALCOHOLIC LIVER-DISEASE; LONG-TERM MANAGEMENT; ENDOSCOPIC SCLEROTHERAPY; ESOPHAGEAL-VARICES; FOLLOW-UP; INJECTION SCLEROTHERAPY; ELECTIVE TREATMENT	Background. Transjugular placement of an intrahepatic stent is a new technique to establish a portosystemic shunt for treatment of portal hypertension. A puncture needle is advanced in a catheter through the inferior vena cava into a hepatic vein; then an intrahepatic branch of the portal vein is punctured and an expandable stent of metallic mesh is implanted to establish the shunt. Methods. We attempted the stent-shunt procedure in 100 of 112 consecutive patients with variceal bleeding due to cirrhosis, who were then followed for a mean (+/-SD) of 12+/-6 months. Of the 100 patients, 22 had Child-Pugh class C cirrhosis, 10 were treated on an emergency basis, and 68 had alcoholic cirrhosis. The shunt was established with use of Palmaz stents expanded to 8 to 12 mm in diameter. Results. Technical success was achieved in 93 percent of the patients. The mean (+/-SD) time for the procedure was 1.2+/-0.3 hours. The shunt reduced the portal venous pressure gradient by 57 percent. Major complications were hemorrhage (intraabdominal bleeding in six patients, biliary bleeding in four, and bleeding in the liver capsule in three) and migration of the stent into the pulmonary artery (in two patients). At follow-up, stenosis of the shunt was evident in 21 patients and occlusion in 10 patients; 10 of these 31 patients had variceal rebleeding. Stenoses and occlusions of the shunt were all treated successfully by redilation, thrombolysis, or implantation of an additional stent. Hepatic encephalopathy (stages I to III) developed in 25 percent of the patients. The proportion of patients with shunts who remained free of variceal rebleeding was 92 percent at six months and 82 percent at one year. The 30-day mortality was 3 percent. The cumulative one-year survival was 85 percent. Conclusions. These results suggest that the transjugular placement of an intrahepatic portosystemic stent is an effective and safe treatment for variceal hemorrhage in patients with portal hypertension due to cirrhosis.	UNIV FREIBURG,RADIOL CLIN,W-7800 FREIBURG,GERMANY; HOP BON SECOURS,METZ,FRANCE	University of Freiburg; CHR Metz-Thionville	ROSSLE, M (corresponding author), UNIV FREIBURG,MED KLIN,HUGSTETTERSTR 55,D-79106 FREIBURG,GERMANY.							BURGENER FA, 1984, FORTSCHR RONTG NEUEN, V141, P327; CELLO JP, 1987, NEW ENGL J MED, V316, P11, DOI 10.1056/NEJM198701013160103; COLAPINTO RF, 1982, CAN MED ASSOC J, V126, P267; CONN HO, 1977, AM J DIG DIS, V22, P541, DOI 10.1007/BF01072510; DIMAGNO EP, 1985, MAYO CLIN PROC, V60, P149, DOI 10.1016/S0025-6196(12)60211-0; FISCHER JE, 1981, ANN SURG, V194, P531, DOI 10.1097/00000658-198110000-00016; FLEIG WE, 1987, HEPATOLOGY, V7, P355, DOI 10.1002/hep.1840070224; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GORDON JD, 1987, CAN J SURG, V30, P45; GRACE ND, 1988, HEPATOLOGY, V8, P1475, DOI 10.1002/hep.1840080602; GUSBERG RJ, 1992, DIGEST DIS, V10, P84, DOI 10.1159/000171391; HARLEY HAJ, 1986, GASTROENTEROLOGY, V91, P802, DOI 10.1016/0016-5085(86)90679-7; HENDERSON JM, 1990, ANN INTERN MED, V112, P262, DOI 10.7326/0003-4819-112-4-262; HENDERSON JM, 1984, WORLD J SURG, V8, P722, DOI 10.1007/BF01655769; INK O, 1992, HEPATOLOGY, V16, P912, DOI 10.1002/hep.1840160410; LABERGE JM, 1993, RADIOLOGY, V187, P413, DOI 10.1148/radiology.187.2.8475283; LANGER B, 1985, GASTROENTEROLOGY, V88, P424, DOI 10.1016/0016-5085(85)90502-5; MILLIKAN WJ, 1985, ANN SURG, V201, P712; PAGLIARO L, 1989, GASTROENTEROL INT, V2, P71; PALMAZ JC, 1985, AM J ROENTGENOL, V145, P821, DOI 10.2214/ajr.145.4.821; PERARNAU JM, 1991, PRESSE MED, V20, P1770; PLANAS R, 1991, GASTROENTEROLOGY, V100, P1078, DOI 10.1016/0016-5085(91)90285-S; PUGH RNH, 1973, BRIT J SURG, V60, P646, DOI 10.1002/bjs.1800600817; RESNICK RH, 1974, GASTROENTEROLOGY, V67, P843; REYNOLDS TB, 1981, GASTROENTEROLOGY, V80, P1005; RICHTER GM, 1990, CARDIOVASC INTER RAD, V13, P200, DOI 10.1007/BF02575474; RICHTER GM, 1990, RADIOLOGY, V174, P1027, DOI 10.1148/radiology.174.3.174-3-1027; RIKKERS LF, 1984, AM J SURG, V147, P89, DOI 10.1016/0002-9610(84)90040-0; RIKKERS LF, 1987, ANN SURG, V206, P261, DOI 10.1097/00000658-198709000-00004; ROBERTS JP, 1991, TRANSPLANTATION, V52, P160, DOI 10.1097/00007890-199107000-00036; ROSCH J, 1987, RADIOLOGY, V162, P481; ROSCH J, 1969, RADIOLOGY, V92, P1112; ROSSLE M, 1989, DEUT MED WOCHENSCHR, V114, P1511, DOI 10.1055/s-2008-1066789; ROSSLE M, 1988, HEPATOLOGY, V8, P1348; ROSSLE M, 1992, DIGEST SURG, V9, P6, DOI 10.1159/000172049; SARFEH IJ, 1986, ANN SURG, V204, P356, DOI 10.1097/00000658-198610000-00003; SCHOMERUS H, 1981, DIGEST DIS SCI, V26, P622, DOI 10.1007/BF01367675; SPINA GP, 1988, AM J SURG, V155, P564, DOI 10.1016/S0002-9610(88)80411-2; SPINA GP, 1990, ANN SURG, V211, P178, DOI 10.1097/00000658-199002000-00010; STIEGMANN GV, 1992, NEW ENGL J MED, V326, P1527, DOI 10.1056/NEJM199206043262304; TERBLANCHE J, 1989, ANN SURG, V210, P725, DOI 10.1097/00000658-198912000-00006; TERES J, 1987, HEPATOLOGY, V7, P430, DOI 10.1002/hep.1840070303; WARREN WD, 1986, ANN SURG, V203, P454, DOI 10.1097/00000658-198605000-00002; WESTABY D, 1990, HEPATOLOGY, V11, P353, DOI 10.1002/hep.1840110304	44	657	670	1	21	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 20	1994	330	3					165	171		10.1056/NEJM199401203300303	http://dx.doi.org/10.1056/NEJM199401203300303			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ863	8264738				2022-12-01	WOS:A1994MQ86300003
J	LUNDE, H; HEDNER, T; SAMUELSSON, O; LOTVALL, J; ANDREN, L; LINDHOLM, L; WIHOLM, BE				LUNDE, H; HEDNER, T; SAMUELSSON, O; LOTVALL, J; ANDREN, L; LINDHOLM, L; WIHOLM, BE			DYSPNEA, ASTHMA, AND BRONCHOSPASM IN RELATION TO TREATMENT WITH ANGIOTENSIN-CONVERTING ENZYME-INHIBITORS	BRITISH MEDICAL JOURNAL			English	Article							BRONCHIAL HYPERREACTIVITY; COUGH; CAPTOPRIL; ENALAPRIL; BRADYKININ; RESPONSES	Objective-To evaluate the occurrence of asthma and dyspnoea precipitated or worsened by angiotensin converting enzyme inhibitors. Design-Summary of reports of adverse respiratory reaction in relation to treatment with angiotensin converting enzyme inhibitors that were submitted to Swedish Adverse Drug Reactions Advisory Committee and to World Health Organisation's international drug information system until 1992. Sales of angiotensin converting enzyme inhibitors in Sweden were also summarised. Subjects-Patients receiving angiotensin converting enzyme inhibitors who reported adverse respiratory reactions. Main outcome measures-Clinical characteristics of adverse reactions of asthma, bronchospasm, and dyspnoea. Results-In Sweden 424 adverse respiratory reactions were reported, of which most (374) were coughing. However, 36 patients had adverse drug reactions diagnosed as asthma, bronchospasm, or dyspnoea. In 33 of these cases the indication for treatment with angiotensin converting enzyme inhibitors was hypertension, in only three heart failure. The respiratory symptoms occurred in about half of the patients within the first two weeks of treatment, and about one third needed hospitalisation or drug treatment. Dyspnoea symptoms occurred in conjunction with other symptoms from the airways or skin in 23 out of the 36 cases. In the WHO database there were 318 reports of asthma or bronchospasm, 516 reports of dyspnoea, and 7260 reports of cough in relation to 11 different angiotensin converting enzyme inhibitors. Conclusion-Symptoms of airway obstruction in relation to treatment with angiotensin converting enzyme inhibitors seem to be a rare but potentially serious reaction generally occurring within the first few weeks of treatment.	GOTHENBURG UNIV,SAHLGRENS HOSP,DEPT NEPHROL,S-41345 GOTHENBURG,SWEDEN; SWEDISH MED PROD AGCY,UPPSALA,SWEDEN; LUND UNIV,HLTH SCI CTR,DALBY,SWEDEN	Sahlgrenska University Hospital; University of Gothenburg; Medical Products Agency; Lund University	LUNDE, H (corresponding author), GOTHENBURG UNIV,SAHLGRENS HOSP,DEPT CLIN PHARMACOL,S-41345 GOTHENBURG,SWEDEN.			Lotvall, Jan/0000-0001-9195-9249				BERKIN KE, 1989, EUR RESPIR J, V2, P198; BUCKNALL CE, 1988, BRIT MED J, V296, P86, DOI 10.1136/bmj.296.6615.86; COULTER DM, 1987, BRIT MED J, V294, P1521, DOI 10.1136/bmj.294.6586.1521; DUSSER DJ, 1988, J PHARMACOL EXP THER, V244, P531; GOH T C, 1991, SMJ Singapore Medical Journal, V32, P183; HEDNER T, 1992, BRIT MED J, V304, P941, DOI 10.1136/bmj.304.6832.941; INMAN WHW, 1988, BRIT MED J, V297, P826, DOI 10.1136/bmj.297.6652.826; KAUFMAN J, 1989, CHEST, V95, P544, DOI 10.1378/chest.95.3.544; KAUFMAN J, 1992, CHEST, V101, P922, DOI 10.1378/chest.101.4.922; KRANE NK, 1987, GERIATRICS, V42, P45; LINDGREN BR, 1989, CHEST, V95, P1225, DOI 10.1378/chest.95.6.1225; LOTVALL JO, 1991, EUR J PHARMACOL, V200, P211, DOI 10.1016/0014-2999(91)90574-A; MUE S, 1990, CLIN THER, V12, P335; POPA V, 1987, AM REV RESPIR DIS, V136, P999, DOI 10.1164/ajrccm/136.4.999; RISKA H, 1987, J CARDIOVASC PHARM, V10, pS79, DOI 10.1097/00005344-198706110-00030; SEMPLE PF, 1986, NEW ENGL J MED, V314, P61; SIMONSSON BG, 1973, RESPIRATION, V30, P378, DOI 10.1159/000193051; SKIDGEL RA, 1987, CLIN EXP HYPERTENS A, V9, P243, DOI 10.3109/10641968709164184; WIHOLM BE, 1984, ACTA MED SCAND S, V683, P107; 1989, INT MONITORING ADVER	20	54	55	2	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 1	1994	308	6920					18	21		10.1136/bmj.308.6920.18	http://dx.doi.org/10.1136/bmj.308.6920.18			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ096	8298346	Green Published			2022-12-01	WOS:A1994MQ09600023
J	KANDELSLEWIS, S; SERAPHIN, B				KANDELSLEWIS, S; SERAPHIN, B			ROLE OF U6 SNRNA IN 5' SPLICE-SITE SELECTION	SCIENCE			English	Article							PRE-MESSENGER-RNA; BASE-PAIRING INTERACTION; SMALL NUCLEAR-RNA; U1 SNRNA; SACCHAROMYCES-CEREVISIAE; TACTAAC BOX; YEAST; U2; MUTATIONS; GENE	Two models describing the interaction between U6 small nuclear RNA (snRNA) and the 5' splice site of introns have been proposed on the basis of cross-linking experiments. Here it is shown that a conserved sequence present in U6 snRNA forms base pairs with conserved nucleotides at the 5' splice junction and that this interaction is involved in 5' splice site choice. These results demonstrate a specific function for U6 snRNA in splicing and suggest that U6 snRNA has a proofreading role during splice site selection. A model is presented in which this new interaction, in concert with previously described interactions between U6 snRNA, U2 snRNA, and the pre-messenger RNA, would position the branch point near the 5' splice site for the catalysis of the first splicing step.	EUROPEAN MOLEC BIOL LAB,MEYERHOFSTR 1,D-69117 HEIDELBERG,GERMANY	European Molecular Biology Laboratory (EMBL)				Seraphin, Bertrand/0000-0002-5168-1921				BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; FOUSER LA, 1986, CELL, V45, P81, DOI 10.1016/0092-8674(86)90540-4; GUARENTE L, 1981, P NATL ACAD SCI-BIOL, V78, P2199, DOI 10.1073/pnas.78.4.2199; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JACQUIER A, 1985, CELL, V43, P423, DOI 10.1016/0092-8674(85)90172-2; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LESSER CF, 1993, SCIENCE, V262, P1982, DOI 10.1126/science.8266093; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; Moore M., 1993, RNA WORLD, P303; NEWMAN AJ, 1992, CELL, V68, P743, DOI 10.1016/0092-8674(92)90149-7; PARKER R, 1985, CELL, V41, P107, DOI 10.1016/0092-8674(85)90065-0; PARKER R, 1987, CELL, V49, P229, DOI 10.1016/0092-8674(87)90564-2; REICH CI, 1992, CELL, V69, P1159, DOI 10.1016/0092-8674(92)90637-R; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; SANTALUCIA J, 1991, BIOCHEMISTRY-US, V30, P8242, DOI 10.1021/bi00247a021; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; SERAPHIN B, 1993, CELL, V73, P803, DOI 10.1016/0092-8674(93)90258-R; SERAPHIN B, 1989, GENE, V82, P145, DOI 10.1016/0378-1119(89)90039-5; SERAPHIN B, 1988, EMBO J, V7, P2533, DOI 10.1002/j.1460-2075.1988.tb03101.x; SERAPHIN B, 1990, CELL, V63, P619, DOI 10.1016/0092-8674(90)90457-P; SIKORSKI RS, 1989, GENETICS, V122, P19; SILICIANO PG, 1988, GENE DEV, V2, P1258, DOI 10.1101/gad.2.10.1258; SONTHEIMER EJ, 1993, SCIENCE, V262, P1989, DOI 10.1126/science.8266094; STEPHENS RM, 1992, J MOL BIOL, V228, P1124, DOI 10.1016/0022-2836(92)90320-J; TEEM JL, 1983, P NATL ACAD SCI-BIOL, V80, P4403, DOI 10.1073/pnas.80.14.4403; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WU J, 1989, GENE DEV, V3, P1553, DOI 10.1101/gad.3.10.1553; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0; WYATT JR, 1992, GENE DEV, V6, P2542, DOI 10.1101/gad.6.12b.2542; ZHUANG Y, 1989, GENE DEV, V3, P1545, DOI 10.1101/gad.3.10.1545	35	246	247	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					2035	2039		10.1126/science.8266100	http://dx.doi.org/10.1126/science.8266100			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266100				2022-12-01	WOS:A1993MN10800039
J	DARBY, SC; KENDALL, GM; FELL, TP; DOLL, R; GOODILL, AA; CONQUEST, AJ; JACKSON, DA; HAYLOCK, RGE				DARBY, SC; KENDALL, GM; FELL, TP; DOLL, R; GOODILL, AA; CONQUEST, AJ; JACKSON, DA; HAYLOCK, RGE			FURTHER FOLLOW-UP OF MORTALITY AND INCIDENCE OF CANCER IN MEN FROM THE UNITED-KINGDOM WHO PARTICIPATED IN THE UNITED-KINGDOM ATMOSPHERIC NUCLEAR-WEAPON TESTS AND EXPERIMENTAL PROGRAMS	BRITISH MEDICAL JOURNAL			English	Article								Objectives-To study the long term effects of participation in the United Kingdom's atmospheric nuclear weapon tests and experimental programmes and to test hypotheses generated by an earlier report, including the possibility that participation in tests caused small hazards of leukaemia and multiple myeloma. Design-Follow up study of mortality and cancer incidence. Subjects-21 358 servicemen and civilians from the United Kingdom who participated in the tests and a control group of 22 333 non-participants. Main outcome measures-Numbers of deaths; standardised mortality ratios; relative risks of mortality from all causes and 27 types of cancer. Results-During seven further years of follow up the numbers of deaths observed in participants were fewer than expected from national rates for all causes, all neoplasms, leukaemia, and multiple myeloma (standardised mortality ratios 0.86, 0.85, 0.57, and 0.46); death rates were lower than in controls (relative risks 0.99, 0.96, 0.57, and 0.57; 90% confidence intervals all included 1.00). In the period more than 10 years after the initial participation in tests the relative risk of death in participants compared with controls was near unity for all causes (relative risk 0.99 (0.95 to 1.04)) and all neoplasms (0.95 (0.87 to 1.04)); it was raised for bladder cancer (2.69 (1.42 to 5.20)) and reduced for cancers of the mouth, tongue, and pharynx (0.45 (0.22 to 0.93)) and for lung cancer (0.85 (0.73 to 0.99)). For leukaemia mortality was equal to that expected from national rates but greater than in controls for both the whole follow up period (1.75 (1.01 to 3.06)) and the period 2-25 years after the tests (3.38 (1.45 to 8.25)). Conclusion-Participation in nuclear weapon tests had no detectable effect on expectation of life or on subsequent risk of developing cancer or other fatal diseases. The excess of leukaemia in participants compared with controls seems to be principally due to a chance deficit in the controls, but the possibility that participation in the tests may have caused a small risk of leukaemia in the early years afterwards cannot be ruled out.	NATL RADIOL PROTECT BOARD,DIDCOT OX11 0RQ,OXON,ENGLAND; UNIV OXFORD,RADCLIFFE INFIRM,HARKNESS LAB,IMPERIAL CANC RES FUND,CANC STUDIES UNIT,OXFORD OX2 6HE,ENGLAND	Radcliffe Infirmary; University of Oxford	DARBY, SC (corresponding author), UNIV OXFORD,IMPERIAL CANC RES FUND,CANC EPIDEMIOL UNIT,GIBSON BLDG,OXFORD,ENGLAND.							[Anonymous], 1988, SOURCES EFFECTS RISK; [Anonymous], 1990, HLTH EFFECTS EXPOSUR; DARBY SC, 1988, BRIT MED J, V296, P332, DOI 10.1136/bmj.296.6618.332; DARBY SC, 1988, NRPB R214 REP; DARBY SC, IN PRESS MORTALITY C; PEARCE N, 1990, BRIT MED J, V300, P1161, DOI 10.1136/bmj.300.6733.1161; 1993, DOCUMENTS NRPB, V4, P15; [No title captured]; 1990, ICRP PUBLICATION, V60	9	40	43	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1993	307	6918					1530	1535		10.1136/bmj.307.6918.1530	http://dx.doi.org/10.1136/bmj.307.6918.1530			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML869	8274923	Green Published, Bronze			2022-12-01	WOS:A1993ML86900022
J	SU, LK; VOGELSTEIN, B; KINZLER, KW				SU, LK; VOGELSTEIN, B; KINZLER, KW			ASSOCIATION OF THE APC TUMOR-SUPPRESSOR PROTEIN WITH CATENINS	SCIENCE			English	Article							CELL CELL-ADHESION; E-CADHERIN; TYROSINE PHOSPHORYLATION; POSSIBLE INVOLVEMENT; CYTOPLASMIC DOMAIN; COLORECTAL-CANCER; EPITHELIAL-CELLS; ALPHA-CATENIN; IDENTIFICATION; UVOMORULIN	Mutations of APC appear to initiate sporadic and inherited forms of human colorectal cancer. Although these mutations have been well characterized, little is known about the function of the APC gene product. Two cellular proteins that associate with APC were identified by nucleotide sequence analysis and peptide mapping as the E-cadherin-associated proteins alpha- and beta-catenin. A 27-residue fragment of APC containing a 15-amino acid repeat was sufficient for the interaction with the catenins. These results suggest an important link between tumor initiation and cell adhesion.	JOHNS HOPKINS UNIV,SCH MED,DEPT ONCOL,BALTIMORE,MD 21231	Johns Hopkins University					NCI NIH HHS [CA-57345] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R37CA057345, R01CA057345] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEHRENS J, 1989, J CELL BIOL, V108, P2435, DOI 10.1083/jcb.108.6.2435; BEHRENS J, 1993, J CELL BIOL, V120, P757, DOI 10.1083/jcb.120.3.757; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; BUTZ S, 1992, SCIENCE, V257, P1142, DOI 10.1126/science.257.5073.1142-a; FRIXEN UH, 1991, J CELL BIOL, V113, P173, DOI 10.1083/jcb.113.1.173; GEIGER B, 1992, ANNU REV CELL BIOL, V8, P307, DOI 10.1146/annurev.cb.08.110192.001515; GRODEN J, 1991, CELL, V66, P589, DOI 10.1016/0092-8674(81)90021-0; HARLOW E, 1988, ANTIBODIES LABORATOR; HIRANO S, 1992, CELL, V70, P293, DOI 10.1016/0092-8674(92)90103-J; HIRANO S, 1987, J CELL BIOL, V105, P2501, DOI 10.1083/jcb.105.6.2501; JOSLYN G, 1991, CELL, V66, P601, DOI 10.1016/0092-8674(81)90022-2; KEMLER R, 1993, TRENDS GENET, V9, P317, DOI 10.1016/0168-9525(93)90250-L; KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562; MATSUYOSHI N, 1992, J CELL BIOL, V118, P703, DOI 10.1083/jcb.118.3.703; MCCREA PD, 1991, SCIENCE, V254, P1359, DOI 10.1126/science.1962194; MIYOSHI Y, 1992, P NATL ACAD SCI USA, V89, P4452, DOI 10.1073/pnas.89.10.4452; Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229; MORTON RA, 1993, CANCER RES, V53, P3585; NAGAFUCHI A, 1989, CELL REGUL, V1, P37, DOI 10.1091/mbc.1.1.37; NELSON WJ, 1990, J CELL BIOL, V110, P349, DOI 10.1083/jcb.110.2.349; NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563; OZAWA M, 1989, EMBO J, V8, P1711, DOI 10.1002/j.1460-2075.1989.tb03563.x; OZAWA M, 1990, P NATL ACAD SCI USA, V87, P4246, DOI 10.1073/pnas.87.11.4246; PEYRIERAS N, 1985, P NATL ACAD SCI USA, V82, P8067, DOI 10.1073/pnas.82.23.8067; POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0; POWELL SM, IN PRESS N ENGL J ME; RANSOHOFF DF, 1991, NEW ENGL J MED, V325, P37; RON D, 1992, BIOTECHNIQUES, V13, P866; ROULEAU GA, 1993, NATURE, V363, P515, DOI 10.1038/363515a0; Sambrook J., 1989, MOL CLONING LAB MANU; SHIMOYAMA Y, 1989, CANCER RES, V49, P2128; SHIMOYAMA Y, 1992, CANCER RES, V52, P5770; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SMITH KJ, 1993, P NATL ACAD SCI USA, V90, P2846, DOI 10.1073/pnas.90.7.2846; Su L., UNPUB; SU LK, 1992, SCIENCE, V256, P668, DOI 10.1126/science.1350108; SU LK, 1993, CANCER RES, V53, P2728; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TROFATTER JA, 1993, CELL, V72, P791, DOI 10.1016/0092-8674(93)90406-G; TSUKITA S, 1991, J CELL BIOL, V113, P867, DOI 10.1083/jcb.113.4.867; VLEMINCKX K, 1991, CELL, V66, P107, DOI 10.1016/0092-8674(91)90143-M; VOLBERG T, 1992, EMBO J, V11, P1733, DOI 10.1002/j.1460-2075.1992.tb05225.x	42	1138	1169	0	25	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 10	1993	262	5140					1734	1737		10.1126/science.8259519	http://dx.doi.org/10.1126/science.8259519			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	8259519				2022-12-01	WOS:A1993ML22000042
J	JONES, A; REGAN, M; LEDINGHAM, J; PATTRICK, M; MANHIRE, A; DOHERTY, M				JONES, A; REGAN, M; LEDINGHAM, J; PATTRICK, M; MANHIRE, A; DOHERTY, M			IMPORTANCE OF PLACEMENT OF INTRAARTICULAR STEROID INJECTIONS	BRITISH MEDICAL JOURNAL			English	Article							OSTEOARTHRITIS; KNEE		MALMO GEN HOSP,S-21401 MALMO,SWEDEN		JONES, A (corresponding author), CITY HOSP NOTTINGHAM,RHEUMATOL UNIT,NOTTINGHAM NG5 1PD,ENGLAND.			Doherty, Michael/0000-0002-5763-8326				DOHERTY M, 1988, ANN RHEUM DIS, V47, P190, DOI 10.1136/ard.47.3.190; JONES A, 1992, ANN RHEUM DIS, V51, P243, DOI 10.1136/ard.51.2.243; MCALINDON T, 1990, BRIT J RHEUMATOL, V29, P471; RITCHIE DM, 1968, Q J MED, V37, P393; STOKER DJ, 1991, BRIT MED J, V303, P123	5	294	303	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1993	307	6915					1329	1330		10.1136/bmj.307.6915.1329	http://dx.doi.org/10.1136/bmj.307.6915.1329			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH556	8257889	Bronze, Green Published			2022-12-01	WOS:A1993MH55600023
J	REECE, RJ; PTASHNE, M				REECE, RJ; PTASHNE, M			DETERMINANTS OF BINDING-SITE SPECIFICITY AMONG YEAST C6 ZINC CLUSTER PROTEINS	SCIENCE			English	Article							DNA-BINDING; SACCHAROMYCES-CEREVISIAE; REGULATORY GENE; NUCLEOTIDE-SEQUENCE; GAL4; FINGER; ACTIVATOR; ADJACENT; INDUCTION; COMPLEX	Related DNA binding proteins often recognize similar DNA sites but can distinguish among them with the use of different protein-DNA contacts. Here, it is shown that members of the C6 zinc cluster family of yeast transcriptional activators distinguish related DNA sites by a different mechanism. The DNA binding site for each of these proteins contains identical nucleotide triplets (CGG ... CCG) but differs in the spacings between the triplets. It is shown that zinc clusters of these proteins work interchangeably to recognize the conserved triplets and that the region 19 amino acids to the carboxyl-terminal side of the zinc cluster, comprising the linker and the beginning of a dimerization element as inferred from the GAL4 crystal structure, directs the protein to its preferred site.	HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA	Harvard University					NIGMS NIH HHS [GM32308] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032308] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BALEJA JD, 1992, NATURE, V356, P450, DOI 10.1038/356450a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAREY M, 1989, J MOL BIOL, V209, P423, DOI 10.1016/0022-2836(89)90007-7; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CORTON JC, 1989, NATURE, V340, P724, DOI 10.1038/340724a0; DERIJCKE M, 1992, MOL CELL BIOL, V12, P68, DOI 10.1128/MCB.12.1.68; FAIRALL L, 1992, J MOL BIOL, V226, P349, DOI 10.1016/0022-2836(92)90952-G; FRIDEN P, 1987, MOL CELL BIOL, V7, P2708, DOI 10.1128/MCB.7.8.2708; FRIDEN P, 1988, MOL CELL BIOL, V8, P2690, DOI 10.1128/MCB.8.7.2690; KAMMERER B, 1984, J MOL BIOL, V180, P239, DOI 10.1016/S0022-2836(84)80002-9; KIM J, 1988, CURR GENET, V14, P319, DOI 10.1007/BF00419988; KRAULIS PJ, 1992, NATURE, V356, P448, DOI 10.1038/356448a0; MARCZAK JE, 1991, MOL CELL BIOL, V11, P2609, DOI 10.1128/MCB.11.5.2609; MARMORSTEIN R, 1992, NATURE, V356, P408, DOI 10.1038/356408a0; MESSENGUY F, 1986, EUR J BIOCHEM, V157, P77, DOI 10.1111/j.1432-1033.1986.tb09640.x; PFEIFER K, 1989, CELL, V56, P291, DOI 10.1016/0092-8674(89)90903-3; REECE RJ, UNPUB; ROY A, 1990, MOL CELL BIOL, V10, P5257, DOI 10.1128/MCB.10.10.5257; SALMERON JM, 1986, NUCLEIC ACIDS RES, V14, P7767, DOI 10.1093/nar/14.19.7767; SIDDIQUI AH, 1988, MOL CELL BIOL, V8, P4634, DOI 10.1128/MCB.8.11.4634; TAO P, 1990, P NATL ACAD SCI USA, V87, P2077, DOI 10.1073/pnas.87.6.2077; TURCOTTE B, 1992, GENE DEV, V6, P2001, DOI 10.1101/gad.6.10.2001; WITTE MM, 1990, MOL CELL BIOL, V10, P5128, DOI 10.1128/MCB.10.10.5128	23	155	159	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 13	1993	261	5123					909	911		10.1126/science.8346441	http://dx.doi.org/10.1126/science.8346441			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR897	8346441				2022-12-01	WOS:A1993LR89700037
J	ALPER, J				ALPER, J			EEG+MRI - A SUM GREATER-THAN THE PARTS	SCIENCE			English	Editorial Material																		GEVINS A, 1993, IN PRESS BRAIN TOPOG; GEVINS A, 1993, IN PRESS EEG CLIN NE; THATCHER RW, 1993, JUN P SOC MAGN RES M, V1; THATCHER RW, 1993, FUNCTIONAL NEUROSCIE	4	3	4	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 30	1993	261	5121					559	559		10.1126/science.8342019	http://dx.doi.org/10.1126/science.8342019			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	8342019				2022-12-01	WOS:A1993LP72800027
J	HAMER, DH; HU, S; MAGNUSON, VL; HU, N; PATTATUCCI, AML				HAMER, DH; HU, S; MAGNUSON, VL; HU, N; PATTATUCCI, AML			A LINKAGE BETWEEN DNA MARKERS ON THE X-CHROMOSOME AND MALE SEXUAL ORIENTATION	SCIENCE			English	Article							GENETICALLY COMPLEX TRAITS; AFFECTED RELATIVE PAIRS; MALE HOMOSEXUALITY; STRATEGIES; IDENTITY; POWER; POLYMORPHISM; RFLP; MEN	The role of genetics in male sexual orientation was investigated by pedigree and linkage analyses on 114 families of homosexual men. Increased rates of same-sex orientation were found in the maternal uncles and male cousins of these subjects, but not in their fathers or paternal relatives, suggesting the possibility of sex-linked transmission in a portion of the population. DNA linkage analysis of a selected group of 40 families in which there were two gay brothers and no indication of nonmaternal transmission revealed a correlation between homosexual orientation and the inheritance of polymorphic markers on the X chromosome in approximately 64 percent of the sib-pairs tested. The linkage to markers on Xq28, the subtelomeric region of the long arm of the sex chromosome, had a multipoint lod score of 4.0 (P = 10(-5)), indicating a statistical confidence level of more than 99 percent that at least one subtype of male sexual orientation is genetically influenced.			HAMER, DH (corresponding author), NCI,BIOCHEM LAB,BETHESDA,MD 20892, USA.		Hamer, Dean H/L-1248-2015	Hamer, Dean H/0000-0002-6211-5781				ALLEN LS, 1992, P NATL ACAD SCI USA, V89, P7199, DOI 10.1073/pnas.89.15.7199; BAILEY JM, 1993, AM J PSYCHIAT, V150, P272; BAILEY JM, 1993, ARCH GEN PSYCHIAT, V50, P217; BAILEY JM, 1991, ARCH GEN PSYCHIAT, V48, P1089; BAILEY JM, 1991, ARCH SEX BEHAV, V20, P277, DOI 10.1007/BF01541847; Bell AP, 1978, HOMOSEXUALITIES STUD; BISHOP DT, 1990, AM J HUM GENET, V46, P254; BLACKWELDER W C, 1985, Genetic Epidemiology, V2, P85, DOI 10.1002/gepi.1370020109; BUHRICH N, 1991, BEHAV GENET, V21, P75, DOI 10.1007/BF01067668; DUBERMAAN M, 1989, HIDDEN HIST RECLAIMI; FREIJE D, 1992, SCIENCE, V258, P1784, DOI 10.1126/science.1465614; FREIJE D, 1992, AM J HUM GENET, V51, P66; FREUND K, 1977, ARCH SEX BEHAV, V6, P507, DOI 10.1007/BF01541155; FRIEDMAN RM, 1986, PSYCHOANAL REV, V73, P483; GOLDIN LR, 1988, GENET EPIDEMIOL, V5, P35, DOI 10.1002/gepi.1370050104; GORSKI RA, 1991, BRAIN ENDOCRINOLOGY, P71; HENRY GEORGE, 1941, SEX VARIANTS STUDY H; HUGNOT JP, 1991, NUCLEIC ACIDS RES, V19, P3159, DOI 10.1093/nar/19.11.3159; ISAY R, 1989, BEING HOMOSEXUAL; JOHNSON AM, 1992, NATURE, V360, P410, DOI 10.1038/360410a0; KINSEY AC, 1948, SEXUAL BEHAVIOR HUMA; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; KURDIHAIDAR B, 1990, AM J HUM GENET, V47, P1013; LAHIRI DK, 1991, NUCLEIC ACIDS RES, V19, P5444, DOI 10.1093/nar/19.19.5444; LANDER E, 1988, GENOME ANAL PRACTICA, P171; LANDER ES, 1986, P NATL ACAD SCI USA, V83, P7353, DOI 10.1073/pnas.83.19.7353; LEVAY S, 1991, SCIENCE, V253, P1034, DOI 10.1126/science.1887219; MCEWEN BS, 1991, J STEROID BIOCHEM, V39, P223, DOI 10.1016/0960-0760(91)90067-F; McKusick V.A., 1992, MENDELIAN INHERITANC; MEYERBAHLBURG HF, 1982, CLILN ENDOCRINOL MET, V11, P6861; Ott J., 1991, ANAL HUMAN GENETIC L; PILLARD RC, 1986, ARCH GEN PSYCHIAT, V43, P808; PILLARD RC, 1990, HOMOSEXUALITY HETERO, P88; RISCH N, 1992, HUM HERED, V42, P77, DOI 10.1159/000154047; RISCH N, 1990, AM J HUM GENET, V46, P229; RISCH N, 1990, AM J HUM GENET, V46, P242; RISCH N, 1990, AM J HUM GENET, V46, P222; ROUSE AL, 1977, HOMOSEXUALS HIST; Schow R., 1991, PECULIAR PEOPLE MORM; Spong J. S., 1988, LIVING SIN; SUAREZ BK, 1978, ANN HUM GENET, V42, P87, DOI 10.1111/j.1469-1809.1978.tb00933.x; SURIN VL, 1990, NUCLEIC ACIDS RES, V18, P3432, DOI 10.1093/nar/18.11.3432; SWAAB DF, 1990, BRAIN RES, V537, P141, DOI 10.1016/0006-8993(90)90350-K; THOMSON G, 1986, AM J HUM GENET, V39, P207; Tripp C. A., 1987, HOMOSEXUAL MATRIX; WEINRICH J, 1987, SEXUAL LANDSCAPES; WEISSENBACH J, 1992, NATURE, V359, P794, DOI 10.1038/359794a0; WHITAM FL, 1986, MALE HOMOSEXUALITY 4; YU S, 1992, AM J HUM GENET, V50, P968; ZUGER B, 1989, ARCH SEX BEHAV, V18, P155, DOI 10.1007/BF01543121; 1992, NATURE, V360, P407	51	562	578	10	332	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 16	1993	261	5119					321	327		10.1126/science.8332896	http://dx.doi.org/10.1126/science.8332896			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM678	8332896	Green Submitted			2022-12-01	WOS:A1993LM67800027
J	WANG, MM; REED, RR				WANG, MM; REED, RR			MOLECULAR-CLONING OF THE OLFACTORY NEURONAL TRANSCRIPTION FACTOR OLF-1 BY GENETIC SELECTION IN YEAST	NATURE			English	Article							DNA-BINDING; SIGNAL TRANSDUCTION; MYC HOMOLOGY; PROTEIN; EXPRESSION; ENHANCER; SYSTEM; MYOD; SITE; IDENTIFICATION	A novel genetic selection in yeast has been used to isolate a complementary DNA for the transcriptional activator, Olf-1, which binds to the regulatory sequences of several olfactory-specific genes. The Olf-1 protein, expressed exclusively in the olfactory receptor neurons and their precursors, contains a new helix-loop-helix motif and functions as an apparent homodimer. Olf-1 may be the first member of a family of related proteins that may direct cellular differentiation in a variety of neuronal tissues.			WANG, MM (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,HOWARD HUGHES MED INST,725 N WOLFE ST,BALTIMORE,MD 21205, USA.							ANTHONYCAHILL SJ, 1992, SCIENCE, V255, P979, DOI 10.1126/science.1312255; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; BENEZRA R, 1990, CELL, V61, P49, DOI 10.1016/0092-8674(90)90214-Y; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; DAVIS RL, 1987, CELL, V51, P987, DOI 10.1016/0092-8674(87)90585-X; DAVIS RL, 1990, CELL, V60, P733, DOI 10.1016/0092-8674(90)90088-V; DHALLAN RS, 1990, NATURE, V347, P184, DOI 10.1038/347184a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EED RR, 1992, NEURON, V8, P205; ENGLAND BP, 1990, J BIOL CHEM, V265, P5086; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GIETZ D, 1992, NUCLEIC ACIDS RES, V20, P1425, DOI 10.1093/nar/20.6.1425; GORMAN CM, 1990, DNA PROTEIN ENG TECH, V2, P3; GRAZIADEI PPC, 1978, OLFACTORY SYSTEM MOD, P131; GRUENEBERG DA, 1992, SCIENCE, V257, P1089, DOI 10.1126/science.257.5073.1089; HAGMAN J, 1993, GENE DEV, V7, P760, DOI 10.1101/gad.7.5.760; HENTHORN P, 1990, SCIENCE, V247, P467, DOI 10.1126/science.2105528; JONES DT, 1989, SCIENCE, V244, P790, DOI 10.1126/science.2499043; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KUDRYCKI K, 1993, MOL CELL BIOL, V13, P3002, DOI 10.1128/MCB.13.5.3002; LASSAR AB, 1989, CELL, V58, P823, DOI 10.1016/0092-8674(89)90935-5; LEVY NS, 1991, J STEROID BIOCHEM, V39, P633, DOI 10.1016/0960-0760(91)90262-4; LUDWIG J, 1990, FEBS LETT, V270, P24, DOI 10.1016/0014-5793(90)81226-E; MONTIGRAZIADEI GA, 1979, NEURAL GROWTH DIFFER, P373; RODGERS KE, 1987, P NATL ACAD SCI USA, V84, P1704; SIKORSKI RS, 1989, GENETICS, V122, P19; SINGH H, 1988, CELL, V52, P415, DOI 10.1016/S0092-8674(88)80034-5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TAPSCOTT SJ, 1988, SCIENCE, V242, P405, DOI 10.1126/science.3175662; VERHAAGEN J, 1989, J NEUROSCI, V9, P683; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; VORONOVA A, 1990, P NATL ACAD SCI USA, V87, P4722, DOI 10.1073/pnas.87.12.4722; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILSON TE, 1991, SCIENCE, V252, P1296, DOI 10.1126/science.1925541	39	363	393	1	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 8	1993	364	6433					121	126		10.1038/364121a0	http://dx.doi.org/10.1038/364121a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL367	8321284				2022-12-01	WOS:A1993LL36700040
J	JONES, A; PECKETT, W; CLARK, E; SHARPE, C; KRIMHOLTZ, S; RUSSELL, M; GOODWIN, T				JONES, A; PECKETT, W; CLARK, E; SHARPE, C; KRIMHOLTZ, S; RUSSELL, M; GOODWIN, T			NURSES KNOWLEDGE OF THE RESUSCITATION STATUS OF PATIENTS AND ACTION IN THE EVENT OF CARDIORESPIRATORY ARREST	BRITISH MEDICAL JOURNAL			English	Article							ORDERS		MT VERNON HOSP,NORTHWOOD HA6 2RN,MIDDX,ENGLAND; HILLINGDON HOSP,MIDDLESEX UB8 3ON,ENGLAND				Sharpe, Claire/B-5619-2015	Sharpe, Claire/0000-0003-1704-8492				AARONS EJ, 1991, BRIT MED J, V303, P1504, DOI 10.1136/bmj.303.6816.1504; ASPLUND K, 1990, J INTERN MED, V228, P139; KAMER RS, 1990, AM J MED, V88, P108, DOI 10.1016/0002-9343(90)90457-O; TUNSTALLPEDOE H, 1992, BRIT MED J, V304, P1347, DOI 10.1136/bmj.304.6838.1347; 1984, CODE PROFESSIONAL CO	5	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1577	1578		10.1136/bmj.306.6892.1577	http://dx.doi.org/10.1136/bmj.306.6892.1577			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329918	Bronze, Green Published			2022-12-01	WOS:A1993LH12800018
J	WU, TC; LICHTEN, M				WU, TC; LICHTEN, M			MEIOSIS-INDUCED DOUBLE-STRAND BREAK SITES DETERMINED BY YEAST CHROMATIN STRUCTURE	SCIENCE			English	Article							MEIOTIC GENE CONVERSION; SYNAPTONEMAL COMPLEX-FORMATION; RECOMBINATION INITIATION SITE; SACCHAROMYCES-CEREVISIAE; CHROMOSOME-III; ARG4 LOCUS; DNA; PROMOTER; SEQUENCE; MAP	Double-strand DNA breaks (DSBs) occur at recombination hotspots during Saccharomyces cerevisiae meiosis and are thought to initiate exchange at these loci. Analysis of DSB sites in three regions of the yeast genome indicated that breaks occur at or near many potential transcription promoters and that DSBs initiate most, if not all, meiotic recombination. DSB sites displayed deoxyribonuclease I hypersensitivity in chromatin from mitotic and meiotic cells, and changes in chromatin structure produced parallel changes in the occurrence of DSBs. Thus, features of chromatin structure that are established before meiosis play a role in determining where meiotic recombination events initiate.	NCI,DIV CANC BIOL DIAGN & CTR,BIOCHEM LAB,BLDG 37,ROOM 4D14,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)			Lichten, Michael/C-5795-2013	Lichten, Michael/0000-0001-9707-2956				ALANI E, 1990, CELL, V61, P419, DOI 10.1016/0092-8674(90)90524-I; ALMER A, 1986, EMBO J, V5, P2689, DOI 10.1002/j.1460-2075.1986.tb04552.x; BEACHAM IR, 1984, GENE, V29, P271, DOI 10.1016/0378-1119(84)90056-8; BERGMAN L, COMMUNICATION; BERGMAN LW, 1983, J BIOL CHEM, V268, P7223; BERTON MT, 1990, J EXP MED, V172, P375, DOI 10.1084/jem.172.1.375; BISHOP DK, 1992, CELL, V69, P439, DOI 10.1016/0092-8674(92)90446-J; BORTS RH, 1986, GENETICS, V113, P551; BRUNK CF, 1979, ANAL BIOCHEM, V92, P497, DOI 10.1016/0003-2697(79)90690-0; CAO L, 1990, CELL, V61, P1089, DOI 10.1016/0092-8674(90)90072-M; Davisson M. T., 1981, Genetic variants and strains of the laboratory mouse., P283; DEMASSY B, 1993, EMBO J, V12, P1459, DOI 10.1002/j.1460-2075.1993.tb05789.x; DONISKELLER H, 1987, CELL, V51, P319, DOI 10.1016/0092-8674(87)90158-9; FASCHER KD, 1993, J MOL BIOL, V231, P658, DOI 10.1006/jmbi.1993.1317; GAME JC, 1992, DEV GENET, V13, P485, DOI 10.1002/dvg.1020130610; GOLDWAY M, 1993, GENETICS, V133, P159; GOYON C, 1993, MOL CELL BIOL, V13, P373, DOI 10.1128/MCB.13.1.373; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; LICHTEN M, 1990, P NATL ACAD SCI USA, V87, P7653, DOI 10.1073/pnas.87.19.7653; LOWARY PT, 1989, P NATL ACAD SCI USA, V86, P8266, DOI 10.1073/pnas.86.21.8266; Malone R., COMMUNICATION; MORTIMER RK, 1989, YEAST, V5, P321, DOI 10.1002/yea.320050503; NAG DK, 1993, MOL CELL BIOL, V13, P2324, DOI 10.1128/MCB.13.4.2324; NAG DK, 1990, GENETICS, V125, P753; NASMYTH KA, 1982, CELL, V30, P567, DOI 10.1016/0092-8674(82)90253-7; NICOLAS A, 1989, NATURE, V338, P35, DOI 10.1038/338035a0; OLIVER SG, 1992, NATURE, V357, P38, DOI 10.1038/357038a0; Oshima Y, 1982, MOL BIOL YEAST SACCH, P159; PADMORE R, 1991, CELL, V66, P1239, DOI 10.1016/0092-8674(91)90046-2; ROCCO V, 1993, YEAST, V9, P1111, DOI 10.1002/yea.320091012; ROCCO V, 1992, P NATL ACAD SCI USA, V89, P12068, DOI 10.1073/pnas.89.24.12068; SCHULTES NP, 1990, GENETICS, V126, P813; SCHULTES NP, 1991, MOL CELL BIOL, V11, P322, DOI 10.1128/MCB.11.1.322; SCHULTES NP, COMMUNICATION; SUN H, 1991, CELL, V64, P1155, DOI 10.1016/0092-8674(91)90270-9; SUN H, 1989, NATURE, V338, P87, DOI 10.1038/338087a0; SYMINGTON LS, 1991, GENETICS, V128, P717; THOMAS BJ, 1991, CELL, V64, P1, DOI 10.1016/0092-8674(91)90199-9; THON G, 1992, GENETICS, V131, P287; WHITE MA, 1992, CURR GENET, V21, P109, DOI 10.1007/BF00318468; WU TC, UNPUB; ZENVIRTH D, 1992, EMBO J, V11, P3441, DOI 10.1002/j.1460-2075.1992.tb05423.x	42	373	383	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 28	1994	263	5146					515	518		10.1126/science.8290959	http://dx.doi.org/10.1126/science.8290959			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT966	8290959				2022-12-01	WOS:A1994MT96600031
J	PHILLIPS, DM				PHILLIPS, DM			IMAGES IN CLINICAL MEDICINE - CLOSTRIDIUM-DIFFICILE	NEW ENGLAND JOURNAL OF MEDICINE			English	Note											PHILLIPS, DM (corresponding author), POPULAT COUNCIL,NEW YORK,NY 10021, USA.								0	1	1	0	0	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 27	1994	330	4					256	256						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR496	8272087				2022-12-01	WOS:A1994MR49600005
J	RAJAGOPALAN, S; XU, YH; BRENNER, MB				RAJAGOPALAN, S; XU, YH; BRENNER, MB			RETENTION OF UNASSEMBLED COMPONENTS OF INTEGRAL MEMBRANE-PROTEINS BY CALNEXIN	SCIENCE			English	Article							T-CELL RECEPTOR; PRE-GOLGI DEGRADATION; ENDOPLASMIC-RETICULUM; ANTIGEN RECEPTORS; COMPLEX; BINDING; IDENTIFICATION; GLYCOPROTEINS; MOLECULES; REQUIRES	Quality control mechanisms prevent the cell surface expression of incompletely assembled multisubunit receptors such as the T cell receptor (TCR). The molecular chaperone function of calnexin (IP90, p88), a 90-kilodalton protein that resides in the endoplasmic reticulum (ER), in the retention of representative chains of the TCR-CD3 complex in the ER was tested. Truncation mutants of calnexin, when transiently expressed in COS cells, were exported from the ER and either accumulated in the Golgi or progressed to the cell surface. CD3 epsilon chains cotransfected with the forms of calnexin that were not retained in the ER exited the ER and colocalized with calnexin. Since engineered calnexin determined the intracellular localization of the proteins associated with it, it is concluded that calnexin interacts with incompletely assembled TCR components and retains them in the ER.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,ELECTRON MICROSCOPY & STRUCT MOLEC BIOL LAB,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School	RAJAGOPALAN, S (corresponding author), HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT RHEUMATOL & IMMUNOL,LYMPHOCYTE BIOL SECT,BOSTON,MA 02115, USA.							ALARCON B, 1988, J BIOL CHEM, V263, P2953; BONIFACINO JS, 1989, J CELL BIOL, V109, P73, DOI 10.1083/jcb.109.1.73; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; GALVIN K, 1992, P NATL ACAD SCI USA, V89, P8452, DOI 10.1073/pnas.89.18.8452; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GOLD DP, 1986, NATURE, V321, P431, DOI 10.1038/321431a0; HALL C, 1991, INT IMMUNOL, V3, P359, DOI 10.1093/intimm/3.4.359; HOCHSTENBACH F, 1988, J EXP MED, V168, P761, DOI 10.1084/jem.168.2.761; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; JACKSON MR, 1990, EMBO J, V9, P3153, DOI 10.1002/j.1460-2075.1990.tb07513.x; KLAUSNER RD, 1990, ANNU REV CELL BIOL, V6, P403, DOI 10.1146/annurev.cb.06.110190.002155; KOCH G, 1986, J CELL SCI, V86, P217; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MALLABIABARRENA A, 1992, NATURE, V357, P593, DOI 10.1038/357593a0; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; RAJAGOPALAN S, UNPUB; RIDGWAY ND, 1992, J CELL BIOL, V116, P307, DOI 10.1083/jcb.116.2.307; SRIVASTAVA PK, 1986, P NATL ACAD SCI USA, V83, P3407, DOI 10.1073/pnas.83.10.3407; WADA I, 1991, J BIOL CHEM, V266, P19599; WATKINS S, 1991, HISTOCHEM J, V22, P507; WILEMAN T, 1990, J CELL BIOL, V110, P973, DOI 10.1083/jcb.110.4.973; WILLIAMS MA, 1990, J CELL BIOL, V111, P955, DOI 10.1083/jcb.111.3.955	27	226	227	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 21	1994	263	5145					387	390		10.1126/science.8278814	http://dx.doi.org/10.1126/science.8278814			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT034	8278814				2022-12-01	WOS:A1994MT03400037
J	LEVINE, JJ; ILOWITE, NT				LEVINE, JJ; ILOWITE, NT			SCLERODERMA-LIKE ESOPHAGEAL DISEASE IN CHILDREN BREAST-FED BY MOTHERS WITH SILICONE BREAST IMPLANTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN ADJUVANT DISEASE; AUGMENTATION MAMMOPLASTY; SYSTEMIC-SCLEROSIS	Objective.-To determine whether breast-fed children of mothers with silicone implants are at increased risk for the development of sclerodermalike esophageal involvement compared with children not exposed to silicone implants. Design.-Case-control study. Setting.-Referral-based pediatric gastroenterology clinic. Patients.-Eleven children (mean age, 6.0 years; range, 1.5 to 13 years; six boys and five girls) referred for abdominal pain who were born to mothers who had silicone breast implants (eight breast-fed children and three bottle-fed) were compared with 17 patients (mean age, 10.7 years; range, 2 to 18 years; 11 boys and six girls) with abdominal pain who were not exposed to silicone implants. Methods.-All children underwent esophageal manometry and upper intestinal endoscopy with esophageal biopsy and were tested for antinuclear antibody and autoantibodies to Scl-70, centromere, ribonucleoprotein, Sm, Ro, La, and phospholipid. Results.-Six of the eight breast-fed children from mothers with silicone implants had significantly abnormal esophageal motility with nearly absent peristalsis in the distal two thirds of the esophagus and decreased lower sphincter pressure. Upper esophageal pressures and motility were normal. Compared with controls, the breast-fed children had significantly decreased lower sphincter pressure and abnormal esophageal wave propagation. These manometric abnormalities were not seen in the three bottle-fed children. There was no difference in the expression of autoantibodies in the breast-fed children compared with the bottle-fed children or controls. Conclusions.-A relationship appears to exist between breast-feeding by mothers with silicone implants and abnormal esophageal motility. Studies evaluating larger numbers of children are needed to determine the extent of the risk.	ALBERT EINSTEIN COLL MED,LONG ISL JEWISH MED CTR,SCHNEIDER CHILDRENS HOSP,DIV RHEUMATOL,NEW HYDE PK,NY 11042	Northwell Health; North Shore University Hospital; Steven & Alexandra Cohen Children's Medical Center of New York; Yeshiva University	LEVINE, JJ (corresponding author), ALBERT EINSTEIN COLL MED,LONG ISL JEWISH MED CTR,SCHNEIDER CHILDRENS HOSP,NEW HYDE PK,NY 11042, USA.			Levine, Jeremiah/0000-0002-7676-538X				BRIDGES AJ, 1993, ANN INTERN MED, V118, P929, DOI 10.7326/0003-4819-118-12-199306150-00003; BROZENA SJ, 1988, ARCH DERMATOL, V124, P1383, DOI 10.1001/archderm.124.9.1383; CAULFIELD M, 1989, J PEDIATR-US, V115, P339, DOI 10.1016/S0022-3476(89)80829-7; CUCCHIARA S, 1986, J PEDIATR-US, V108, P907, DOI 10.1016/S0022-3476(86)80925-8; DUGOWSON CE, 1992, ARTHRITIS RHEUM, V35, pS66; FLICK JA, 1988, PEDIATRICS, V82, P107; GARRETT JM, 1971, MAYO CLIN PROC, V46, P92; GOLDBLUM RM, 1992, LANCET, V340, P510, DOI 10.1016/0140-6736(92)91710-P; GOLDMAN JA, 1992, ARTHRITIS RHEUM, V35, pS65; GRAY RG, 1977, ARTHRITIS RHEUM, V20, P35, DOI 10.1002/art.1780200106; KLEIN HA, 1992, GASTROENTEROLOGY, V102, P1551, DOI 10.1016/0016-5085(92)91713-E; LAWTON AR, 1989, IMMUNOLOGIC DISORDER, P1; LUGANO EM, 1984, AM REV RESPIR DIS, V129, P767, DOI 10.1164/arrd.1984.129.5.767; REIMER G, 1990, RHEUM DIS CLIN N AM, V16, P169; REISER KM, 1979, TOXICOLOGY, V13, P51, DOI 10.1016/S0300-483X(79)80010-4; RODNAN GP, 1962, JAMA-J AM MED ASSOC, V180, P665, DOI 10.1001/jama.1962.03050210027006; SANDERSON IR, 1993, GASTROENTEROLOGY, V104, P622, DOI 10.1016/0016-5085(93)90436-G; SERGOTT TJ, 1986, PLAST RECONSTR SURG, V78, P104, DOI 10.1097/00006534-198607000-00018; SPIERA H, 1988, JAMA-J AM MED ASSOC, V260, P236, DOI 10.1001/jama.260.2.236; VARGA J, 1989, ANN INTERN MED, V111, P377, DOI 10.7326/0003-4819-111-5-377; VARGAS A, 1979, PLAST RECONSTR SURG, V64, P252, DOI 10.1097/00006534-197908000-00025	21	70	71	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	1994	271	3					213	216		10.1001/jama.271.3.213	http://dx.doi.org/10.1001/jama.271.3.213			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ645	8277548				2022-12-01	WOS:A1994MQ64500035
J	KOUCHOUKOS, NT; DAVILAROMAN, VG; SPRAY, TL; MURPHY, SF; PERRILLO, JB				KOUCHOUKOS, NT; DAVILAROMAN, VG; SPRAY, TL; MURPHY, SF; PERRILLO, JB			REPLACEMENT OF THE AORTIC ROOT WITH A PULMONARY AUTOGRAFT IN CHILDREN AND YOUNG-ADULTS WITH AORTIC-VALVE DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FOLLOW-UP; HOMOGRAFT	Background. The optimal substitute for severely diseased aortic valves in children and young adults is unknown. The use of a mechanical prosthesis requires permanent treatment of the patient with anticoagulants and is associated with thromboembolic and hemorrhagic complications. Aortic-valve allografts and porcine bioprostheses, which do not necessitate anticoagulant therapy, may deteriorate and have limited durability. Methods. We therefore evaluated the use of the autologous pulmonary valve (i.e., the patient's own pulmonary valve) and the adjacent pulmonary artery as a replacement for the aortic valve and aortic sinuses in 33 patients. Five of the patients were from 8 to 16 years of age, and 28 were from 20 to 47 years of age. The pulmonary valve and the main pulmonary artery were used to replace the diseased aortic valve and the adjacent aorta. The coronary arteries were detached from the aorta and implanted into the pulmonary artery. The pulmonary valve and artery were replaced with a cryopreserved pulmonary allograft. Results. There were no deaths during follow-up of up to 48 months (mean, 21 months). There were no episodes of infective endocarditis, and no reoperations on the aortic root were necessary. Also, there was no evidence on echocardiography of progressive dilatation of the autografts. With color-flow Doppler imaging, 22 patients were found to have only trivial regurgitation or none, 9 patients to have mild regurgitation, and no patients to have moderate or severe regurgitation across the autograft at the most recent follow-up visit. The mean peak velocity of flow across the autograft was 1.3 m per second (upper limit of normal, 1.8), indicating the absence of stenosis. One patient required reoperation for stenosis of the pulmonary allograft. Conclusions. Although the pulmonary-autograft procedure is more complex than simple aortic-valve replacement, it has been safely applied in selected patients, including young adults. Intermediate follow-up indicates satisfactory function of the autografts, with no dilatation or progressive valvular regurgitation. Pulmonary-root autografts may thus be the best available substitute for diseased aortic valves in children and young adults.	WASHINGTON UNIV,SCH MED,DIV CARDIOTHORAC SURG,ST LOUIS,MO 63110; WASHINGTON UNIV,SCH MED,DIV CARDIOL,ST LOUIS,MO 63110	Washington University (WUSTL); Washington University (WUSTL)								ALKHAJA N, 1991, EUR J CARDIO-THORAC, V5, P635, DOI 10.1016/1010-7940(91)90119-5; BARRATTBOYES BG, 1987, CIRCULATION, V75, P768, DOI 10.1161/01.CIR.75.4.768; EDMUNDS LH, 1987, ANN THORAC SURG, V44, P430, DOI 10.1016/S0003-4975(10)63816-7; ELKINS RC, 1992, ANN SURG, V216, P363, DOI 10.1097/00000658-199209000-00016; GEENS M, 1971, J THORAC CARDIOV SUR, V62, P262, DOI 10.1016/S0022-5223(19)42082-5; GEROSA G, 1991, J THORAC CARDIOV SUR, V102, P51; GEROSA G, 1991, ANN THORAC SURG, V51, P424, DOI 10.1016/0003-4975(91)90858-N; GORCZYNSKI A, 1982, THORAX, V37, P535, DOI 10.1136/thx.37.7.535; KOUCHOUKOS NT, 1991, ANN SURG, V214, P308, DOI 10.1097/00000658-199109000-00013; PERRY GJ, 1987, J AM COLL CARDIOL, V9, P952, DOI 10.1016/S0735-1097(87)80254-1; RADLEYSMITH R, 1982, AM J CARDIOL, V49, P1035, DOI 10.1016/0002-9149(82)92546-2; ROMAN MJ, 1989, AM J CARDIOL, V64, P507, DOI 10.1016/0002-9149(89)90430-X; ROSS D, 1992, EUR J CARDIO-THORAC, V6, P113, DOI 10.1016/1010-7940(92)90115-E; ROSS D, 1991, ANN THORAC SURG, V52, P1346, DOI 10.1016/0003-4975(91)90032-L; ROSS DN, 1967, LANCET, V2, P956; Schenck Margaret H., 1993, Journal of the American College of Cardiology, V21, p81A; SIEVERS HH, 1993, J THORAC CARDIOV SUR, V105, P775; STELZER P, 1989, CIRCULATION, V80, P209; WEERASENA N, 1992, EUR J CARDIO-THORAC, V6, P350, DOI 10.1016/1010-7940(92)90171-S	19	216	226	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	1994	330	1					1	6		10.1056/NEJM199401063300101	http://dx.doi.org/10.1056/NEJM199401063300101			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP649	8259138				2022-12-01	WOS:A1994MP64900001
J	OSMOND, C; BARKER, DJP; WINTER, PD; FALL, CHD; SIMMONDS, SJ				OSMOND, C; BARKER, DJP; WINTER, PD; FALL, CHD; SIMMONDS, SJ			EARLY GROWTH AND DEATH FROM CARDIOVASCULAR-DISEASE IN WOMEN	BRITISH MEDICAL JOURNAL			English	Article							ISCHEMIC-HEART-DISEASE; BLOOD-PRESSURE; INFANT GROWTH; FETAL; GLUCOSE; WEIGHT; LIFE	Objective-To determine whether the link suggested between growth in utero and during infancy and death from cardiovascular disease in men is also present in women. Design-Follow up study of women and men whose birth weight and weight at 1 year of age had been recorded. Setting-Hertfordshire, England. Subjects-5585 women and 10141 men born during 1911-30. Main outcome measures-Standardised mortality ratios for cardiovascular disease. Results-Among women and men death rates from cardiovascular disease fell progressively between the low and high birth weights groups (chi2=4.3, p=0.04 for women, chi2=8.5, p<0.005 for men). Cardiovascular deaths in men but not women were also strongly related to weight at 1 year, falling progressively between the low and high weight groups (chi2=27.5, p<0.0001). The highest cardiovascular death rates in women were among those with below average birth weight but above average weight at 1 year. In men the highest rates were among those with below average birth weight and below average weight at 1 year. Conclusion-Relations between cardiovascular disease and birth weight are similar in men and women. In men cardiovascular disease is also related to weight gain in infancy.	UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,ENGLAND	University of Southampton				Osmond, Clive/0000-0002-9054-4655				ATHENS M, 1993, DIABETES, V42, pA61; BARKER DJP, 1993, DIABETOLOGIA, V36, P62, DOI 10.1007/BF00399095; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; Barker DJP, 1992, FETAL INFANT ORIGINS; BERRY G, 1983, BIOMETRICS, V39, P173, DOI 10.2307/2530817; BURGOYNE PS, 1993, DEVELOPMENT, V117, P341; EDWARDS CRW, 1993, LANCET, V341, P355, DOI 10.1016/0140-6736(93)90148-A; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; FOWDEN AL, 1989, J DEV PHYSIOL, V12, P173; GLUCKMAN PD, 1992, J PEDIATR-US, V121, P920, DOI 10.1016/S0022-3476(05)80342-7; HALES CN, 1992, DIABETOLOGIA, V35, P595, DOI 10.1007/BF00400248; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HARDING J, 1992, EARLY HUM DEV, V29, P193, DOI 10.1016/0378-3782(92)90149-B; HOLMES GE, 1977, AM J DIS CHILD, V3, P1078; LANGLEY SC, IN PRESS CLIN SCI; LAW CM, 1993, BRIT MED J, V306, P24, DOI 10.1136/bmj.306.6869.24; LEWIS DS, IN PRESS BIOL NEONAT; MARTYN CN, 1993, J EPIDEMIOL COMMUN H, V47, P76, DOI 10.1136/jech.47.1.76; MCCANCE DR, 1993, DIABETOLOGIA, V36, pA4; PEDERSEN JF, 1980, BRIT MED J, V281, P1253, DOI 10.1136/bmj.281.6250.1253; PERSSON E, 1992, ACTA PHYSIOL SCAND, V145, P195, DOI 10.1111/j.1748-1716.1992.tb09356.x; PHILLIPS DIW, 1993, ACTA ENDOCRINOL-COP, V129, P134, DOI 10.1530/acta.0.1290134; PHILLIPS DIW, IN PRESS DIABETOLOGI; PHIPPS K, 1993, DIABETOLOGIA, V36, P225, DOI 10.1007/BF00399954; ROBINSON S, 1992, DIABETOLOGIA, V35, P444, DOI 10.1007/BF02342441; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; VILLAR J, 1984, PEDIATRICS, V74, P783; WIDDOWSON EM, 1963, PROC R SOC SER B-BIO, V158, P329, DOI 10.1098/rspb.1963.0051; WILLIAMS S, 1992, J CLIN EPIDEMIOL, V45, P1257, DOI 10.1016/0895-4356(92)90167-L	33	541	553	1	15	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1993	307	6918					1519	1524		10.1136/bmj.307.6918.1519	http://dx.doi.org/10.1136/bmj.307.6918.1519			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML869	8274920	Green Published, Bronze			2022-12-01	WOS:A1993ML86900019
J	HESS, DT; PATTERSON, SI; SMITH, DS; SKENE, JHP				HESS, DT; PATTERSON, SI; SMITH, DS; SKENE, JHP			NEURONAL GROWTH CONE COLLAPSE AND INHIBITION OF PROTEIN FATTY ACYLATION BY NITRIC-OXIDE	NATURE			English	Article							LONG-TERM POTENTIATION; SYNAPTOSOMAL-ASSOCIATED PROTEIN; SOLUBLE GUANYLATE-CYCLASE; INTERCELLULAR MESSENGER; NERVOUS-SYSTEM; NMDA RECEPTORS; COMPLEX; STIMULATION; CEREBELLUM; GLUTAMATE	NITRIC oxide, a free-radical gas produced endogenously by several mammalian cell types1-6, has been implicated as a diffusible intercellular messenger subserving use-dependent modification of synaptic efficacy in the mature central nervous system7-10. It has been suggested on theoretical grounds that nitric oxide might play an analogous role during the establishment of ordered connections by developing neurons11. We report here that nitric oxide rapidly and reversibly inhibits growth of neurites of rat dorsal root ganglion neurons in vitro. In addition, we show that exposure to nitric oxide inhibits thioester-linked long-chain fatty acylation of neuronal proteins, possibly through a direct modification of substrate cysteine thiols. Our results demonstrate a potential role for nitric oxide in the regulation of process outgrowth and remodelling during neuronal development, which may be effected at least in part through modulation of dynamic protein fatty acylation in neuronal growth cones.	DUKE UNIV,MED CTR,DEPT NEUROBIOL,DURHAM,NC 27710	Duke University	HESS, DT (corresponding author), VANDERBILT UNIV,MED CTR,SCH MED,DEPT CELL BIOL,NASHVILLE,TN 37232, USA.		Smith, Deanna/AFU-2285-2022	Smith, Deanna/0000-0002-3014-641X				BOHME E, 1984, ADV CYCLIC NUCL PROT, V17, P259; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BOTTENSTEIN JE, 1983, ADV CELL NEUROBIOL, V4, P333; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CONSTANTINEPATON M, 1990, ANNU REV NEUROSCI, V13, P129, DOI 10.1146/annurev.neuro.13.1.129; GALLY JA, 1990, P NATL ACAD SCI USA, V87, P3574; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; HESS DT, 1992, J NEUROSCI, V12, P4634; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; JUGUELIN H, 1984, ANAL BIOCHEM, V142, P329, DOI 10.1016/0003-2697(84)90472-X; KAUFMAN JF, 1984, J BIOL CHEM, V259, P7230; KNOWLES RG, 1989, P NATL ACAD SCI USA, V86, P5159, DOI 10.1073/pnas.86.13.5159; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; LINDSAY RM, 1988, J NEUROSCI, V8, P2394; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; MANZONI O, 1992, NEURON, V8, P653, DOI 10.1016/0896-6273(92)90087-T; ODELL TJ, 1991, P NATL ACAD SCI USA, V88, P11285, DOI 10.1073/pnas.88.24.11285; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PATTERSON PH, 1988, NEURON, V1, P263, DOI 10.1016/0896-6273(88)90074-8; PATTERSON SI, IN PRESS J CELL BIOL; SCHUMAN EM, 1991, SCIENCE, V254, P1503, DOI 10.1126/science.1720572; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; SKENE JHP, 1986, SCIENCE, V233, P783, DOI 10.1126/science.3738509; SKENE JHP, 1989, J CELL BIOL, V108, P613, DOI 10.1083/jcb.108.2.613; SMITH DS, 1990, NEUR ABSTR, V16, P1163; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; WALTER J, 1990, TRENDS NEUROSCI, V13, P447, DOI 10.1016/0166-2236(90)90097-T	31	290	294	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 9	1993	366	6455					562	565		10.1038/366562a0	http://dx.doi.org/10.1038/366562a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	8255294				2022-12-01	WOS:A1993ML21800069
J	KERBL, K; CLAYMAN, RV; MCDOUGALL, EM; KAVOUSSI, LR				KERBL, K; CLAYMAN, RV; MCDOUGALL, EM; KAVOUSSI, LR			MINIMALLY INVASIVE SURGERY .4. LAPAROSCOPIC NEPHRECTOMY	BRITISH MEDICAL JOURNAL			English	Article								Since the first clinical operation in June 1990 laparoscopic nephrectomy for benign renal disease has become widely accepted. Although tle laparoscopic operation takes much longer than open surgery, there are considerable reductions in the length of postoperative hospital stay and the time taken to return to normal activities and to full recovery. Major complications were relatively common in early operations, but with more experience morbidity has been reduced. Laparoscopic nephrectomy for malignant renal disease is still controversial, largely because of the fear of release of malignant tissue into the abdominal cavity during the morcellation and retrieval of the diseased kidney. To prevent this, the kidney is removed intact through a 5-7 cm incision. Long term follow up is needed, however, before we will know whether the laparoscopic procedure is effective in preventing recurrence of cancer. New developments have improved various technical aspects of the operation, but stringent assessment of new techniques is necessary so that the medical community can decide which procedures should become routine practice.	WASHINGTON UNIV,SCH MED,DEPT SURG,DIV UROL,4960 CHILDRENS PL,ST LOUIS,MO 63110; JOHNS HOPKINS UNIV,DEPT UROL,BALTIMORE,MD 21224	Washington University (WUSTL); Johns Hopkins University								CLAYMAN R V, 1990, Journal of Endourology, V4, P247, DOI 10.1089/end.1990.4.247; COPTCOAT MJ, 1992, MINIM INVAS THER S1, V1, pB25; EHRLICH RM, 1992, J ENDOUROL, V6, P463, DOI 10.1089/end.1992.6.463; GAUR DD, 1993, J UROLOGY, V149, P103, DOI 10.1016/S0022-5347(17)36012-3; GAUR DD, 1992, J UROLOGY, V148, P1137, DOI 10.1016/S0022-5347(17)36842-8; IKARI O, 1990, J UROLOGY, V144, P966, DOI 10.1016/S0022-5347(17)39634-9; KERBL K, 1993, J UROLOGY, V149, P1437, DOI 10.1016/S0022-5347(17)36408-X; KERBL K, 1993, J ENDOUROL, V7, P23, DOI 10.1089/end.1993.7.23; Matsuda T, 1992, Hinyokika Kiyo, V38, P759; RASSWEILER J, 1992, J ENDOUROL, V6, pS58; SMITH AD, 1992, MINIM INVAS THER S1, V1, pB21; Weinberg J. J., 1988, J ENDOUROL, V2, P355	12	12	14	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1993	307	6917					1488	1489		10.1136/bmj.307.6917.1488	http://dx.doi.org/10.1136/bmj.307.6917.1488			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK797	8281096	Green Published, Bronze			2022-12-01	WOS:A1993MK79700033
J	CAMPBELL, D; COX, D; CRUM, J; FOSTER, K; CHRISTIE, P; BREWSTER, D				CAMPBELL, D; COX, D; CRUM, J; FOSTER, K; CHRISTIE, P; BREWSTER, D			INITIAL EFFECTS OF THE GROUNDING OF THE TANKER BRAER ON HEALTH IN SHETLAND	BRITISH MEDICAL JOURNAL			English	Article							PETROLEUM-HYDROCARBONS; MIST	Objective-To determine if the oil spillage from the tanker Braer had any immediate health effects on the exposed resident population. Design-Cohort study with a comparison against controls, exposure status being assigned on the basis of geographical location. Setting-Rural Shetland. Subjects-All those resident on or after 5 january 1993 (day 0) within 4.5 km of the site of tanker's grounding. Controls matched for sex and age were drawn from a general practice list 95 km distant. Outcome measures-Demographic details; smoking and alcohol consumption; perception of health and reported presence or absence of specific symptoms; peak expiratory flow; results of haematology, liver and renal function tests, and blood and urine toxicology. Results-Of subjects contacted, 420 (66%) exposed people and 92 (68%) controls were studied; 56 non-attenders were surveyed. Principal health effects arose on days 1 and 2 and were headache, throat irritation, and itchy eyes. No significant differences between those exposed and controls were found for any of the biological markers. Toxicological studies did not show any exposures that are known to affect human health. Conclusions-The study confirmed the anecdotal reports of certain acute symptoms. No evidence of pulmonary, haematological, renal, or hepatic damage was detected at the population level. Toxicological samples from exposed people did not find levels known to affect human health. Further studies are required to ascertain whether there have been any long term effects on the population.	SHETLAND HLTH BOARD,SHETLAND ZE1 0RB,SCOTLAND; GRAMPIAN AREA HLTH BOARD,ABERDEEN AB9 1RE,SCOTLAND; COMMON SERV AGCY SCOTTISH HLTH SERV,EDINBURGH EH5 3SQ,SCOTLAND		CAMPBELL, D (corresponding author), RUCHILL HOSP,ENVIRONM HLTH SCOTLAND UNIT,GLASGOW G20 9NB,SCOTLAND.			Brewster, David/0000-0002-5346-5608				BELL GM, 1989, TOLUENE TOXICITY REV, V20, P34; BELL GM, 1992, XYLENES TOXICITY REV, V26, P25; BINGHAM E, 1979, J ENVIRON PATHOL TOX, V3, P483; CAMPBELL DM, 1993, BRIT MED J, V306, P519, DOI 10.1136/bmj.306.6876.519-a; CHRISTIE B, 1993, BRIT MED J, V306, P230; DALYELL T, 1993, NEW SCI         0220, P50; Dean A. G., 1990, EPI INFO VERSION 5 W; DELZELL E, 1988, OCCUP MED, V3, P455; FIELDER RJ, 1982, BENZENE TOXICITY REV, V4, P11; GOLDSTEI.DH, 1970, ARCH ENVIRON HEALTH, V21, P600, DOI 10.1080/00039896.1970.10667302; GORMAN RW, 1991, HLTH HAZARD EVALUATI; JARVHOLM B, 1982, J OCCUP ENVIRON MED, V24, P473; KING RW, 1988, OCCUP MED, V3, P409; MACFARLAND HN, 1988, OCCUP MED, V3, P445; MENEZ JF, 1978, PENN AR BED, V94, P367; PEARCE F, 1993, NEW SCI         0130, P11; SMITH G, 1993, HERALD          0109, V1, P5; SMITH HM, 1968, BUREAU MINES B, V642, P136; ZEDECK MS, 1980, J ENVIRON PATHOL TOX, V3, P537; 1993, OCCUPATIONAL EXPOSUR; 1990, WATER POLLUTION LOWE; 1989, WATER POLLUTION LOWE	22	56	56	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 13	1993	307	6914					1251	1255		10.1136/bmj.307.6914.1251	http://dx.doi.org/10.1136/bmj.307.6914.1251			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH001	8281057	Bronze, Green Published			2022-12-01	WOS:A1993MH00100021
J	QUILL, TE				QUILL, TE			DOCTOR, I WANT TO DIE - WILL YOU HELP ME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HOPELESSLY ILL PATIENTS; ASSISTED SUICIDE; PHYSICIANS RESPONSIBILITY; RATIONAL SUICIDE; EUTHANASIA; CARE; DEATH; PAIN		UNIV ROCHESTER, SCH MED, PROGRAM BIOPSYCHOSOC STUDIES, ROCHESTER, NY 14627 USA	University of Rochester	QUILL, TE (corresponding author), GENESEE HOSP, DEPT MED, ROCHESTER, NY 14607 USA.							ALLEBECK P, 1989, J CLIN EPIDEMIOL, V42, P611, DOI 10.1016/0895-4356(89)90003-6; ANGELL M, 1988, NEW ENGL J MED, V319, P1348, DOI 10.1056/NEJM198811173192010; ARIES P, 1982, HOUR OF OUR DEATH; BREITBART W, 1989, ONCOLOGY, P49; BRODY H, 1992, NEW ENGL J MED, V327, P1384, DOI 10.1056/NEJM199211053271912; CASSEL CK, 1990, NEW ENGL J MED, V323, P750, DOI 10.1056/NEJM199009133231110; CASSEL EJ, 1982, NEW ENGL J MED, V306, P639, DOI 10.1056/NEJM198203183061104; CONWELL Y, 1991, NEW ENGL J MED, V325, P1100, DOI 10.1056/NEJM199110103251511; Fisher R., 2011, GETTING YES NEGOTIAT; FOLEY KM, 1985, NEW ENGL J MED, V313, P84, DOI 10.1056/NEJM198507113130205; GARFIELD C, 1978, PSYCHOSOCIAL CARE DY; GAYLIN W, 1988, JAMA-J AM MED ASSOC, V259, P2139; Gomez Carlos F., 1991, REGULATING DEATH EUT; JECKER NS, 1991, J AM GERIATR SOC, V39, P831, DOI 10.1111/j.1532-5415.1991.tb02708.x; KANE RL, 1985, JAMA-J AM MED ASSOC, V253, P2683, DOI 10.1001/jama.253.18.2683; KERR IG, 1988, ANN INTERN MED, V108, P554, DOI 10.7326/0003-4819-108-4-554; Kubler-Ross E., 1969, DEATH DYING, DOI DOI 10.4324/9780203010495; MACKENZIE TB, 1987, INT J PSYCHIAT MED, V17, P3; MEIER DE, 1983, J AM GERIATR SOC, V31, P294, DOI 10.1111/j.1532-5415.1983.tb04874.x; NOVACK DH, 1987, J GEN INTERN MED, V2, P346, DOI 10.1007/BF02596174; ORENTLICHER D, 1989, JAMA-J AM MED ASSOC, V262, P1844, DOI 10.1001/jama.262.13.1844; QUILL TE, 1983, ANN INTERN MED, V98, P228, DOI 10.7326/0003-4819-98-2-228; QUILL TE, 1990, ARCH INTERN MED, V150, P1857, DOI 10.1001/archinte.150.9.1857; QUILL TE, 1991, NEW ENGL J MED, V324, P691, DOI 10.1056/NEJM199103073241010; QUILL TE, 1992, NEW ENGL J MED, V327, P1380, DOI 10.1056/NEJM199211053271911; Quill TE, 1993, DEATH DIGNITY MAKING; RHYMES J, 1990, JAMA-J AM MED ASSOC, V264, P369, DOI 10.1001/jama.264.3.369; RICHMAN J, 1992, SUICIDE LIFE-THREAT, V22, P130; SINGER PA, 1990, NEW ENGL J MED, V322, P1881, DOI 10.1056/NEJM199006283222610; SUCHMAN AL, 1988, ANN INTERN MED, V108, P125, DOI 10.7326/0003-4819-108-1-125; TWYEROSS RG, 1984, SYMPTOM CONTROL FAR; van der Maas PJ, 1991, LANCET, V338, P669, DOI 10.1016/0140-6736(91)91241-L; WANZER SH, 1984, NEW ENGL J MED, V310, P955, DOI 10.1056/NEJM198404123101505; WANZER SH, 1989, NEW ENGL J MED, V320, P844, DOI 10.1056/NEJM198903303201306; ZIMMERMAN JM, 1981, HOSPICE COMPLETE CAR; 1987, HASTINGS CTR REPORT; 1992, JAMA-J AM MED ASSOC, V267, P2229	37	96	96	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	AUG 18	1993	270	7					870	873		10.1001/jama.270.7.870	http://dx.doi.org/10.1001/jama.270.7.870			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR612	8340988				2022-12-01	WOS:A1993LR61200035
J	WITTHUHN, BA; QUELLE, FW; SILVENNOINEN, O; YI, TL; TANG, B; MIURA, O; IHLE, JN				WITTHUHN, BA; QUELLE, FW; SILVENNOINEN, O; YI, TL; TANG, B; MIURA, O; IHLE, JN			JAK2 ASSOCIATES WITH THE ERYTHROPOIETIN RECEPTOR AND IS TYROSINE-PHOSPHORYLATED AND ACTIVATED FOLLOWING STIMULATION WITH ERYTHROPOIETIN	CELL			English	Article							SIGNAL TRANSDUCTION; CYTOPLASMIC REGION; PROTEIN-KINASE; DNA-BINDING; TRANSCRIPTION FACTOR; HEMATOPOIETIC-CELLS; IL-2 RECEPTOR; BETA-CHAIN; FAMILY; GROWTH	Erythropoietin (EPO) regulates the proliferation and differentiation of erythroid cells through interaction with its receptor (EPOR). Although EPOR is a member of the cytokine receptor superfamily and lacks a kinase domain, EPO induces tyrosine phosphorylation, which is correlated with gene transcription and mitogenesis. Here we demonstrate that EPO induces tyrosine phosphorylation of JAK2 kinase and activates its in vitro autophosphorylation. Using EPOR mutants, phosphorylation and activation of kinase activity correlate with the induction of mitogenesis. Furthermore, JAK2 physically associates with a membrane-proximal region of the EPOR cytoplasmic domain that is required for biological activity. The results support the hypothesis that JAK2 is the kinase that couples EPO binding to tyrosine phosphorylation and mitogenesis.	NYU MED CTR, DEPT PHARMACOL, NEW YORK, NY 10016 USA; TOKYO MED & DENT UNIV, DEPT MED 1, TOKYO 113, JAPAN	New York University; Tokyo Medical & Dental University (TMDU)	WITTHUHN, BA (corresponding author), ST JUDE CHILDRENS RES HOSP, DEPT BIOCHEM, MEMPHIS, TN 38101 USA.		witthuhn, bruce/GSE-3193-2022	Miura, Osamu/0000-0002-0981-3054; Quelle, Frederick/0000-0002-1184-6170	NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042932] Funding Source: NIH RePORTER; NCI NIH HHS [P30 CA21765] Funding Source: Medline; NIDDK NIH HHS [R01 DK42932] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BORELLINI F, 1991, J BIOL CHEM, V266, P15850; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAMEN J, 1992, BLOOD, V80, P1923; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DUSANTERFOURT I, 1992, J BIOL CHEM, V267, P10670; EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x; FERRARI S, 1990, CELL GROWTH DIFFER, V1, P543; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FRACKELTON AR, 1983, MOL CELL BIOL, V3, P1343, DOI 10.1128/MCB.3.8.1343; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HARPUR AG, 1992, ONCOGENE, V7, P1347; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1991, SCIENCE, V252, P1523, DOI 10.1126/science.2047859; HAYNES JR, 1988, MOL CELL BIOL, V8, P2419, DOI 10.1128/MCB.8.6.2419; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; IHLE JN, 1993, IN PRESS SEM IMMUNOL; ISFORT R, 1988, J BIOL CHEM, V263, P19203; KRANTZ SB, 1991, BLOOD, V77, P419; LINNEKIN D, 1992, P NATL ACAD SCI USA, V89, P6237, DOI 10.1073/pnas.89.14.6237; MANO H, 1993, ONCOGENE, V8, P417; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MIURA O, 1991, MOL CELL BIOL, V11, P4895, DOI 10.1128/MCB.11.10.4895; MIURA O, 1993, MOL CELL BIOL, V13, P1788, DOI 10.1128/MCB.13.3.1788; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; PARTANEN J, 1990, P NATL ACAD SCI USA, V87, P8913, DOI 10.1073/pnas.87.22.8913; QUELLE FW, 1991, J BIOL CHEM, V266, P609; QUELLE FW, 1992, J BIOL CHEM, V267, P17055; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TORIGOE T, 1992, BLOOD, V80, P617; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VEALS SA, 1992, MOL CELL BIOL, V12, P3315, DOI 10.1128/MCB.12.8.3315; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; WATANABE S, 1993, MOL CELL BIOL, V13, P1440, DOI 10.1128/MCB.13.3.1440; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WILKS AF, 1989, P NATL ACAD SCI USA, V86, P1603, DOI 10.1073/pnas.86.5.1603; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391; YOSHIMURA A, 1990, NATURE, V348, P647, DOI 10.1038/348647a0; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706	53	1092	1129	3	43	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 30	1993	74	2					227	236		10.1016/0092-8674(93)90414-L	http://dx.doi.org/10.1016/0092-8674(93)90414-L			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343951				2022-12-01	WOS:A1993LP72600004
J	KITSBERG, D; SELIG, S; BRANDEIS, M; SIMON, I; KESHET, I; DRISCOLL, DJ; NICHOLLS, RD; CEDAR, H				KITSBERG, D; SELIG, S; BRANDEIS, M; SIMON, I; KESHET, I; DRISCOLL, DJ; NICHOLLS, RD; CEDAR, H			ALLELE-SPECIFIC REPLICATION TIMING OF IMPRINTED GENE REGIONS	NATURE			English	Article							GROWTH FACTOR-II; HUMAN H19 GENE; PRADER-WILLI; INSITU HYBRIDIZATION; DNA METHYLATION; X-CHROMOSOME; TME LOCUS; MOUSE; EXPRESSION; ANGELMAN	SEVERAL lines of evidence suggest that the paternal and maternal genomes may have different expression patterns in the developing organism1 and this has been confirmed by the identification of endogenous genes that are parentally imprinted in the mouse2-5. little is known about the precise mechanisms involved in the process, but structural differences between the two alleles must somehow provide cis-acting signals for directing parental-specific transcription. Cell-cycle replication time is one parameter that has been shown to be associated with both tissue-specific gene expression6,7 and the allele-specific transcription patterns of the X chromosomes in female cells8. For this reason we have examined the replication timing patterns for the chromosomal regions containing the imprinted genes Igf2, Igf2r, Hl9 and Snrpn in the mouse. At all of these sites, and their corresponding positions in the human genome, the two homologous alleles replicate asynchronously and it is always the paternal allele that is early-replicating. Thus imprinted genes appear to be embedded in large DNA domains with differential replication patterns, which may provide a structural imprint for parental identity.	UNIV FLORIDA,COLL MED,DIV GENET,GAINESVILLE,FL 32610; UNIV FLORIDA,COLL MED,DEPT NEUROSCI,GAINESVILLE,FL 32610; UNIV FLORIDA,COLL MED,DEPT PEDIAT,GAINESVILLE,FL 32610	State University System of Florida; University of Florida; State University System of Florida; University of Florida; State University System of Florida; University of Florida	KITSBERG, D (corresponding author), HEBREW UNIV JERUSALEM,SCH MED,DEPT CELLULAR BIOCHEM,IL-91010 JERUSALEM,ISRAEL.			Simon, Itamar/0000-0002-8517-1903				BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BARTOLOMEI MS, 1991, NATURE, V351, P153, DOI 10.1038/351153a0; BELL G, 1982, P NATL ACAD SCI USA, V82, P6450; CHEN TR, 1981, AM J MED GENET, V9, P61, DOI 10.1002/ajmg.1320090111; CONNER BJ, 1983, P NATL ACAD SCI-BIOL, V80, P278, DOI 10.1073/pnas.80.1.278; DECHIARA TM, 1991, CELL, V64, P849, DOI 10.1016/0092-8674(91)90513-X; DITTRICH B, 1992, HUM GENET, V90, P313; DRISCOLL DJ, 1992, GENOMICS, V13, P917, DOI 10.1016/0888-7543(92)90001-9; DRISCOLL MC, 1989, P NATL ACAD SCI USA, V86, P7470, DOI 10.1073/pnas.86.19.7470; DROUIN R, 1990, CHROMOSOMA, V99, P272; FOREJT J, 1992, CELL, V70, P443, DOI 10.1016/0092-8674(92)90168-C; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; GOLDMAN MA, 1984, SCIENCE, V224, P686, DOI 10.1126/science.6719109; HAAS OA, 1992, NATURE, V359, P414, DOI 10.1038/359414a0; HOLMQUIST GP, 1987, AM J HUM GENET, V40, P151; IZUMIKAWA Y, 1991, HUM GENET, V87, P1, DOI 10.1007/BF01213082; JOHNSON DR, 1974, GENETICS, V76, P795; JUNIEN C, 1991, CYTOGENET CELL GENET, V58, P459, DOI 10.1159/000133171; Kuwano Akira, 1992, Human Molecular Genetics, V1, P417, DOI 10.1093/hmg/1.6.417; LEFF SE, 1992, NAT GENET, V2, P1; LICHTER P, 1990, SCIENCE, V247, P64, DOI 10.1126/science.2294592; NICHOLLS RD, 1993, P NATL ACAD SCI USA, V90, P2050, DOI 10.1073/pnas.90.5.2050; NICHOLLS RD, 1992, SEMINARS DEV BIOL, V3, P139; OGAWA O, 1993, NATURE, V362, P749, DOI 10.1038/362749a0; OZCELIK T, 1992, NAT GENET, V2, P2; RACHMILEWITZ J, 1992, FEBS LETT, V309, P25, DOI 10.1016/0014-5793(92)80731-U; RANIER S, 1993, NATURE, V362, P747; REIK W, 1989, NATURE, V338, P112, DOI 10.1038/338112a0; RINCHIK EM, 1993, NATURE, V361, P72, DOI 10.1038/361072a0; RINCHIK EM, 1992, MAMM GENOME, V3, pS104, DOI 10.1007/BF00648425; ROTWEIN P, 1990, DNA CELL BIOL, V9, P725, DOI 10.1089/dna.1990.9.725; SAUNDERS AM, 1990, GENOMICS, V8, P525, DOI 10.1016/0888-7543(90)90040-2; SELIG S, 1992, EMBO J, V11, P1217, DOI 10.1002/j.1460-2075.1992.tb05162.x; SHOELSON S, 1983, NATURE, V302, P540, DOI 10.1038/302540a0; SOLTER D, 1988, ANNU REV GENET, V22, P127; SUGAWARA O, 1985, CYTOGENET CELL GENET, V39, P210, DOI 10.1159/000132137; TAKAGI N, 1973, EXP CELL RES, V78, P127, DOI 10.1016/0014-4827(73)90046-3; ZEMEL S, 1992, NAT GENET, V2, P61, DOI 10.1038/ng0992-61; ZHANG YH, 1992, NAT GENET, V1, P40, DOI 10.1038/ng0492-40	39	342	346	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 29	1993	364	6436					459	463		10.1038/364459a0	http://dx.doi.org/10.1038/364459a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP640	8332218				2022-12-01	WOS:A1993LP64000060
J	EKELUND, H; FINNSTROM, O; GUNNARSKOG, J; KALLEN, B; LARSSON, Y				EKELUND, H; FINNSTROM, O; GUNNARSKOG, J; KALLEN, B; LARSSON, Y			ADMINISTRATION OF VITAMIN-K TO NEWBORN-INFANTS AND CHILDHOOD-CANCER	BRITISH MEDICAL JOURNAL			English	Article							REGISTRY	Objectives-To investigate whether childhood cancer is associated with intramuscular administration of vitamin K to newborn infants. Design-Routines for administration of vitamin K to infants born after normal deliveries during 1973-89 were obtained from maternity hospitals. Occurrence of cancer up to the end of 1991 was identified by comparing these records with the national cancer registry. Adherence to the routine method of administering vitamin K was checked with the medical records of a sample of 396 infants (196 who had developed childhood cancer and 200 controls). Setting-All maternity hospitals in Sweden. Subjects-1 384 424 full term infants born after non-instrumental deliveries, 1 085 654 of whom were born in units where vitamin K was routinely given by intramuscular injection and 272 080 of whom were born where it was given orally. Main outcome measures-Odds ratios for cancer after intramuscular administration of vitamin K versus oral administration after stratification for year of birth. Results-Adherence to routine method of administering vitamin K was 92% in the 235 cases where individual information could be found. The risk of cancer after intramuscular administration of vitamim K was not elevated compared with that after oral administration: odds ratios of 1.01 (95% confidence interval 0.88 to 1.17) for all childhood cancers and 0.90 (0.70 to 1.16) for childhood leukaemia. Conclusions-The alleged association between intramuscular vitamin K prophylaxis to newborn infants and childhood cancer could not be verified in the present study of full term infants born after non-instrumental delivery.	LUND UNIV,DEPT EMBRYOL,BISKOPSGATAN 7,S-22362 LUND,SWEDEN; NATL BOARD HLTH,DEPT PUBL HLTH & EPIDEMIOL,S-10601 STOCKHOLM,SWEDEN; LINKOPING UNIV HOSP,DEPT PAEDIAT,S-58185 LINKOPING,SWEDEN	Lund University; National Board of Health & Welfare; Linkoping University								CNATTINGIUS S, 1990, SCAND J SOC MED, V18, P143, DOI 10.1177/140349489001800209; Ericson A, 1991, Acta Obstet Gynecol Scand, V70, P111, DOI 10.3109/00016349109006191; FORSBERG JG, 1990, APMIS, V98, P37, DOI 10.1111/j.1699-0463.1990.tb00999.x; GOLDING J, 1990, BRIT J CANCER, V62, P304, DOI 10.1038/bjc.1990.283; GOLDING J, 1992, BRIT MED J, V305, P341, DOI 10.1136/bmj.305.6849.341; HULL D, 1992, BRIT MED J, V305, P326, DOI 10.1136/bmj.305.6849.326; HULL D, 1992, BMJ, V305, P709; PERSHAGEN G, 1992, INT J EPIDEMIOL, V21, P1, DOI 10.1093/ije/21.1.1; ZACK M, 1991, CANCER RES, V51, P3696; 1989, CANCER REGISTRY CANC	10	82	83	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1993	307	6896					89	91		10.1136/bmj.307.6896.89	http://dx.doi.org/10.1136/bmj.307.6896.89			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM585	8343734	Bronze, Green Published			2022-12-01	WOS:A1993LM58500020
J	JACKSON, R; BARHAM, P; BILLS, J; BIRCH, T; MCLENNAN, L; MACMAHON, S; MALING, T				JACKSON, R; BARHAM, P; BILLS, J; BIRCH, T; MCLENNAN, L; MACMAHON, S; MALING, T			MANAGEMENT OF RAISED BLOOD-PRESSURE IN NEW-ZEALAND - A DISCUSSION DOCUMENT	BRITISH MEDICAL JOURNAL			English	Article							CORONARY HEART-DISEASE; STROKE	A report to the National Advisory Committee on Core Health and Disability Support Services, New Zealand, on the management of raised blood pressure recommends that decisions to treat raised blood pressure should be based primarily on the estimated absolute risk of cardiovascular disease rather than on blood pressure alone. In general, patients with a blood pressure of 150-170 mm Hg systolic or 90-100 mm Hg diastolic, or both, should be given treatment to lower blood pressure if the risk of a major cardiovascular disease event in 10 years is more than about 20%. The results of clinical trials indicate that, at this level of absolute risk, 150 people would require treatment to reduce the annual number of cardiovascular events by about one. Implementation of these recommendations may result in a smaller proportion of people aged under 60, particularly women, receiving treatment but an increased proportion of older people treated. In the absence of specific contraindications, low dose diuretics and low dose beta blockers should be considered for first line treatment, since for only these drug groups is there direct evidence of reduced risk of stroke and coronary disease in people with raised blood pressure.	UNIV AUCKLAND,DEPT GEN PRACTICE,GOODFELLOW UNIT,AUCKLAND,NEW ZEALAND; ROTHERHAM MED CTR,CANTERBURY,NEW ZEALAND; HOKIANGA HLTH SERV,RAWENE,NEW ZEALAND; WAITANGIRUA HLTH CTR,WELLINGTON,NEW ZEALAND; UNIV AUCKLAND,DEPT MED,CLIN TRIALS RES UNIT,AUCKLAND,NEW ZEALAND; UNIV OTAGO,WELLINGTON SCH MED,DEPT MED,DUNEDIN,NEW ZEALAND	University of Auckland; University of Auckland; University of Otago	JACKSON, R (corresponding author), UNIV AUCKLAND,SCH MED,DEPT COMMUNITY HLTH,PRIVATE BAG 92019,AUCKLAND,NEW ZEALAND.			Jackson, Rod/0000-0001-5914-6934; Maling, Tim/0000-0002-5994-479X				ANDERSON KM, 1991, CIRCULATION, V83, P356, DOI 10.1161/01.CIR.83.1.356; CARLSEN JE, 1990, BRIT MED J, V300, P975, DOI 10.1136/bmj.300.6730.975; COLLINS R, 1990, LANCET, V335, P827, DOI 10.1016/0140-6736(90)90944-Z; CRUICKSHANK JM, 1987, LANCET, V1, P581; KAWACHI I, 1990, SOC SCI MED, V31, P1239, DOI 10.1016/0277-9536(90)90130-K; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; PFEFFER MA, 1992, NEW ENGL J MED, V327, P669, DOI 10.1056/NEJM199209033271001; RUSSEL D, 1991, LIFE NZ SURVEY COMMI; 1988, EUR HEART J, V9, P8; 1989, BMJ, V298, P694; 1988, ARCH INTERN MED, V148, P1023; 1989, J HYPERTENS, V7, P689	12	230	233	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 10	1993	307	6896					107	110		10.1136/bmj.307.6896.107	http://dx.doi.org/10.1136/bmj.307.6896.107			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM585	8343706	Green Published, Bronze			2022-12-01	WOS:A1993LM58500029
J	SCHRODER, RR; MANSTEIN, DJ; JAHN, W; HOLDEN, H; RAYMENT, I; HOLMES, KC; SPUDICH, JA				SCHRODER, RR; MANSTEIN, DJ; JAHN, W; HOLDEN, H; RAYMENT, I; HOLMES, KC; SPUDICH, JA			3-DIMENSIONAL ATOMIC MODEL OF F-ACTIN DECORATED WITH DICTYOSTELIUM MYOSIN-S1	NATURE			English	Article							HEAVY-CHAIN; MUSCLE; FILAMENTS	ELUCIDATION of the molecular contacts between actin and myosin is central to understanding the force-generating process in muscle and other cells. Actin, a highly conserved globular protein found in all eukaryotes, polymerizes into filaments (F-actin) for most of its biological functions. Myosins, which are more diverse in sequence, share a conserved globular head of about 900 amino acids in length (subfragment-1 or S1) at the N-terminal end of the molecule. S1 contains all the elements necessary for mechanochemical force transduction in vitro1,2. Here we report an atomic model for the actomyosin complex produced by combining the atomic X-ray structure of F-actin3,4 and chicken myosin S1(5) with a three-dimensional reconstruction from electron micrographs of frozen-hydrated F-actin decorated with recombinant Dictyostelium myosin S1. The accuracy of the reconstruction shows the position of actin and myosin molecules unambiguously.	NATL INST MED RES,LONDON NW7 1AA,ENGLAND; UNIV WISCONSIN,INST ENZYME RES,MADISON,WI 53705; UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53705; STANFORD UNIV,MED CTR,SCH MED,BECKMAN CTR,DEPT BIOCHEM,STANFORD,CA 94305	MRC National Institute for Medical Research; University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Stanford University	SCHRODER, RR (corresponding author), MAX PLANCK INST MED RES,DEPT BIOPHYS,JAHNSTR 29,W-6900 HEIDELBERG,GERMANY.		rayment, ivan/A-2720-2008; Manstein, Dietmar J. J/M-1034-2013; Manstein, Dietmar J./AAG-2640-2019; Schröder, Rasmus R/S-6220-2016	rayment, ivan/0000-0001-9279-7835; Manstein, Dietmar J. J/0000-0003-0763-0147; Manstein, Dietmar J./0000-0003-0763-0147; Holmes, Kenneth/0000-0001-8894-9453				BRENNER B, 1982, P NATL ACAD SCI-BIOL, V79, P7288, DOI 10.1073/pnas.79.23.7288; BRZESKA H, 1990, J BIOL CHEM, V265, P16138; GEEVES MA, 1992, PHILOS T ROY SOC B, V336, P63, DOI 10.1098/rstb.1992.0045; GEISTERFERLOWRANCE AAT, 1990, CELL, V62, P999, DOI 10.1016/0092-8674(90)90274-I; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; JONES TA, 1985, METHOD ENZYMOL, V115, P157; KISHINO A, 1988, NATURE, V334, P74, DOI 10.1038/334074a0; KRON SJ, 1986, P NATL ACAD SCI USA, V83, P6272, DOI 10.1073/pnas.83.17.6272; LORENZ M, IN PRESS J MOL BIOL; MAITA T, 1991, J BIOCHEM, V110, P75, DOI 10.1093/oxfordjournals.jbchem.a123546; MANSTEIN DJ, 1989, SCIENCE, V246, P656, DOI 10.1126/science.2530629; MILLIGAN RA, 1990, NATURE, V348, P217, DOI 10.1038/348217a0; MOORE PB, 1970, J MOL BIOL, V50, P279, DOI 10.1016/0022-2836(70)90192-0; ONISHI H, 1990, J BIOL CHEM, V265, P19362; RAYMENT I, IN PRESS SCIENCE; RITCHIE MD, IN PRESS P NATN ACAD; SCHRODER RR, 1990, J STRUCT BIOL, V105, P28, DOI 10.1016/1047-8477(90)90095-T; SCHRODER RR, IN PRESS 51ST P MSA; SMITH MF, 1992, J MOL BIOL, V226, P763, DOI 10.1016/0022-2836(92)90631-S; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; TOYOSHIMA YY, 1987, NATURE, V328, P536, DOI 10.1038/328536a0; TROUNG T, 1992, J BIOL CHEM, V267, P9767	22	289	290	0	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 8	1993	364	6433					171	174		10.1038/364171a0	http://dx.doi.org/10.1038/364171a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL367	8321290				2022-12-01	WOS:A1993LL36700057
J	TALBOT, WS; SWYRYD, EA; HOGNESS, DS				TALBOT, WS; SWYRYD, EA; HOGNESS, DS			DROSOPHILA TISSUES WITH DIFFERENT METAMORPHIC RESPONSES TO ECDYSONE EXPRESS DIFFERENT ECDYSONE RECEPTOR ISOFORMS	CELL			English	Article							IMAGINAL DISKS; INDUCIBLE GENE; ESTROGEN-RECEPTOR; RETINOIC ACID; DNA-BINDING; EARLY PUFF; ENCODES 2; C-JUN; MELANOGASTER; PROTEIN	In D. melanogaster a pulse of the steroid hormone ecdysone triggers the larval-to-adult metamorphosis, a complex process in which this hormone induces imaginal tissues to generate adult structures and larval tissues to degenerate. We show that the EcR gene encodes three ecdysone receptor isoforms (EcR-A, EcR-B1, and EcR-B2) that have common DNA- and hormone-binding domains but different N-terminal regions. We have used isoform-specific monoclonal antibodies to show that at the onset of metamorphosis different ecdysone target tissues express different isoform combinations in a manner consistent with the proposition that the different metamorphic responses of these tissues require different combinations of the EcR isoforms. We have also determined temporal developmental profiles of the EcR isoforms and their mRNAs in whole animals, showing that different isoforms predominate at different developmental stages that are marked by a pulse of ecdysone.	STANFORD UNIV, MED CTR, SCH MED, DEPT BIOCHEM, STANFORD, CA 94305 USA; STANFORD UNIV, MED CTR, SCH MED, DEPT DEV BIOL, STANFORD, CA 94305 USA	Stanford University; Stanford University								ASHBURNER M, 1973, COLD SPRING HARB SYM, V38, P655; ASHBURNER M, 1989, DROSOPHILA LABORATOR; BATE M, 1991, DEVELOPMENT, V112, P755; Bodenstein D., 1950, BIOL DROSOPHILA, P275; BURTIS KC, 1990, CELL, V61, P85, DOI 10.1016/0092-8674(90)90217-3; BURTIS KC, 1985, THESIS STANFORD U ST; CHERBAS L, 1986, J MOL BIOL, V189, P617, DOI 10.1016/0022-2836(86)90492-4; CHRISTOPHERSON KS, 1992, P NATL ACAD SCI USA, V89, P6314, DOI 10.1073/pnas.89.14.6314; CONDIC ML, 1991, DEVELOPMENT, V111, P23; DESBOIS C, 1991, CELL, V67, P731, DOI 10.1016/0092-8674(91)90068-A; DEUTSCH J, 1989, DEV GENET, V10, P220, DOI 10.1002/dvg.1020100311; DIBELLO PR, 1991, GENETICS, V129, P385; DOUCAS V, 1991, EMBO J, V10, P2237, DOI 10.1002/j.1460-2075.1991.tb07760.x; FRISTROM JW, 1977, AM ZOOL, V17, P671; FRISTROM JW, 1973, DEV BIOL, V33, P441, DOI 10.1016/0012-1606(73)90149-8; GIBSON G, 1990, CELL, V62, P1087, DOI 10.1016/0092-8674(90)90386-S; GUAY PS, 1991, GENETICS, V129, P169; JOHNSON FB, 1990, GENE DEV, V4, P1044, DOI 10.1101/gad.4.6.1044; KARIM FD, 1992, EMBO J, V11, P4083, DOI 10.1002/j.1460-2075.1992.tb05501.x; KARIM FD, 1991, GENE DEV, V5, P1067, DOI 10.1101/gad.5.6.1067; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; KOELLE MR, 1992, P NATL ACAD SCI USA, V89, P6167, DOI 10.1073/pnas.89.13.6167; KOELLE MR, 1992, THESIS STANFORD U ST; KOELLE MR, 1993, IN PRESS P NATL ACAD, V90; KUTOH E, 1992, MOL CELL BIOL, V12, P4960, DOI 10.1128/MCB.12.11.4960; LOPEZ AJ, 1991, P NATL ACAD SCI USA, V88, P9924, DOI 10.1073/pnas.88.22.9924; MADHAVAN MM, 1977, ROUX ARCH DEV BIOL, V183, P269, DOI 10.1007/BF00848459; MANIATIS T, 1978, CELL, V15, P687, DOI 10.1016/0092-8674(78)90036-3; MANN RS, 1990, CELL, V60, P597, DOI 10.1016/0092-8674(90)90663-Y; MOSES K, 1989, NATURE, V340, P531, DOI 10.1038/340531a0; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; OCONNELL P, 1984, NUCLEIC ACIDS RES, V12, P5495, DOI 10.1093/nar/12.13.5495; ORO AE, 1992, DEVELOPMENT, V115, P449; PAINESAUNDERS S, 1990, DEV BIOL, V140, P337, DOI 10.1016/0012-1606(90)90084-V; PONTA H, 1990, CELL, V62, P1189; RICHARDS G, 1981, MOL CELL ENDOCRINOL, V21, P181, DOI 10.1016/0303-7207(81)90013-7; RICHARDS G, 1982, ROUX ARCH DEV BIOL, V191, P103, DOI 10.1007/BF00848447; RIDDIFORD LM, 1993, IN PRESS DEV DROSOPH; RIDDIHOUGH G, 1987, EMBO J, V6, P3729, DOI 10.1002/j.1460-2075.1987.tb02707.x; RIMM DL, 1989, GENE, V75, P323, DOI 10.1016/0378-1119(89)90278-3; ROSELAND CR, 1979, ROUX ARCH DEV BIOL, V186, P235, DOI 10.1007/BF00848591; RUTHER U, 1983, EMBO J, V2, P1791, DOI 10.1002/j.1460-2075.1983.tb01659.x; SAKURAI S, 1989, GEN COMP ENDOCR, V75, P204, DOI 10.1016/0016-6480(89)90072-5; Sakurai S., 1990, P83; Sambrook J., 1989, MOL CLONING LAB MANU; SCHULE R, 1991, P NATL ACAD SCI USA, V88, P6092, DOI 10.1073/pnas.88.14.6092; SEGRAVES WA, 1990, GENE DEV, V4, P204, DOI 10.1101/gad.4.2.204; SEGRAVES WA, 1991, CELL, V67, P225, DOI 10.1016/0092-8674(91)90172-U; SEGRAVES WA, 1988, THESIS STANFORD U ST; TALBOT WS, 1993, THESIS STANFORD U ST; THOMAS HE, 1993, NATURE, V362, P471, DOI 10.1038/362471a0; THUMMEL CS, 1990, CELL, V61, P101, DOI 10.1016/0092-8674(90)90218-4; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TORA L, 1988, NATURE, V333, P185, DOI 10.1038/333185a0; URNESS LD, 1990, CELL, V63, P47, DOI 10.1016/0092-8674(90)90287-O; YANGYEN HF, 1990, CELL, V62, P1205, DOI 10.1016/0092-8674(90)90396-V; YAO TP, 1992, CELL, V71, P63, DOI 10.1016/0092-8674(92)90266-F; ZHANG XK, 1991, MOL CELL BIOL, V11, P6016, DOI 10.1128/MCB.11.12.6016	59	493	510	1	24	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 2	1993	73	7					1323	1337		10.1016/0092-8674(93)90359-X	http://dx.doi.org/10.1016/0092-8674(93)90359-X			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LL209	8324824	Bronze			2022-12-01	WOS:A1993LL20900008
J	KOHL, NE; MOSSER, SD; DESOLMS, SJ; GIULIANI, EA; POMPLIANO, DL; GRAHAM, SL; SMITH, RL; SCOLNICK, EM; OLIFF, A; GIBBS, JB				KOHL, NE; MOSSER, SD; DESOLMS, SJ; GIULIANI, EA; POMPLIANO, DL; GRAHAM, SL; SMITH, RL; SCOLNICK, EM; OLIFF, A; GIBBS, JB			SELECTIVE-INHIBITION OF RAS-DEPENDENT TRANSFORMATION BY A FARNESYLTRANSFERASE INHIBITOR	SCIENCE			English	Article							MURINE SARCOMA-VIRUS; PROTEIN FARNESYLTRANSFERASE; GERANYLGERANYLTRANSFERASE; TRANSFERASE; SEQUENCE; HARVEY; ISOPRENYLATION; IDENTIFICATION; REQUIREMENT; CEREVISIAE	To acquire transforming potential, the precursor of the Ras oncoprotein must undergo farnesylation of the cysteine residue located in a carboxyl-terminal tetrapeptide. Inhibitors of the enzyme that catalyzes this modification, farnesyl protein transferase (FPTase), have therefore been suggested as anticancer agents for tumors in which Ras contributes to transformation. The tetrapeptide analog L-731,735 is a potent and selective inhibitor of FPTase in vitro. A prodrug of this compound, L-731,734, inhibited Ras processing in cells transformed with v-ras. L-731,734 decreased the ability of v-ras-transformed cells to form colonies in soft agar but had no effect on the efficiency of colony formation of cells transformed by either the v-raf or v-mos oncogenes. The results demonstrate selective inhibition of ras-dependent cell transformation with a synthetic organic inhibitor of FPTase.	MERCK RES LABS,DEPT CANC RES,W POINT,PA 19486; MERCK RES LABS,DEPT MED CHEM,W POINT,PA 19486	Merck & Company; Merck & Company								BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BOS JL, 1989, CANCER RES, V49, P4682; BROWN MS, 1992, P NATL ACAD SCI USA, V89, P8313, DOI 10.1073/pnas.89.17.8313; CAPON DJ, 1983, NATURE, V302, P33, DOI 10.1038/302033a0; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; COX AD, 1992, MOL CELL BIOL, V12, P2606, DOI 10.1128/MCB.12.6.2606; COX A D, 1992, Critical Reviews in Oncogenesis, V3, P365; DECLUE JE, 1991, CANCER RES, V51, P712; DHAR R, 1984, NUCLEIC ACIDS RES, V12, P3611, DOI 10.1093/nar/12.8.3611; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FUJIYAMA A, 1987, EMBO J, V6, P223, DOI 10.1002/j.1460-2075.1987.tb04742.x; FURTH ME, 1982, J VIROL, V43, P294, DOI 10.1128/JVI.43.1.294-304.1982; GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P2674, DOI 10.1073/pnas.81.9.2674; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HEIMBROOK D, UNPUB; HORIUCHI H, 1991, J BIOL CHEM, V266, P16981; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JOLY A, 1991, J BIOL CHEM, V266, P13495; KARKAS JD, UNPUB; KATO K, 1992, P NATL ACAD SCI USA, V89, P6403, DOI 10.1073/pnas.89.14.6403; KOHL NE, UNPUB; KOHN N, UNPUB; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MOSSER SD, UNPUB; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; POWERS S, 1986, CELL, V47, P413, DOI 10.1016/0092-8674(86)90598-2; POWERS S, 1984, CELL, V36, P607, DOI 10.1016/0092-8674(84)90340-4; PRENDERGAST GC, UNPUB; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; SCHABER MD, 1990, J BIOL CHEM, V265, P14701; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SHIH TY, 1982, J BIOL CHEM, V257, P1767; SINENSKY M, 1990, J BIOL CHEM, V265, P19937; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1991, ONCOGENE, V6, P2297; WILLUMSEN BM, 1984, EMBO J, V3, P2581, DOI 10.1002/j.1460-2075.1984.tb02177.x; WILSO FR, UNPUB; YOKOYAMA K, 1991, P NATL ACAD SCI USA, V88, P5302, DOI 10.1073/pnas.88.12.5302; YOSHIDA Y, 1991, BIOCHEM BIOPH RES CO, V175, P720, DOI 10.1016/0006-291X(91)91625-M	47	619	732	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUN 25	1993	260	5116					1934	1937		10.1126/science.8316833	http://dx.doi.org/10.1126/science.8316833			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LJ349	8316833				2022-12-01	WOS:A1993LJ34900041
J	NEWMAN, RD; ZU, SX; WUHIB, T; LIMA, AAM; GUERRANT, RL; SEARS, CL				NEWMAN, RD; ZU, SX; WUHIB, T; LIMA, AAM; GUERRANT, RL; SEARS, CL			HOUSEHOLD EPIDEMIOLOGY OF CRYPTOSPORIDIUM-PARVUM INFECTION IN AN URBAN-COMMUNITY IN NORTHEAST BRAZIL	ANNALS OF INTERNAL MEDICINE			English	Article							DAY-CARE-CENTER; ACQUIRED IMMUNODEFICIENCY SYNDROME; PERSISTENT DIARRHEA; ESCHERICHIA-COLI; IMMUNOGLOBULIN-M; OUTBREAK; TRANSMISSION; CHILDREN; IMMUNOCOMPETENT; ADHERENCE	Objective: To examine the transmission of Cryptosporidium infection in households with an identified person with cryptosporidiosis. Design: Prospective cohort study. Setting: An urban slum in Fortaleza, Brazil. Participants: Thirty-one households with a child less than 3 years of age (index case) who was positive for Cryptosporidium parvum using acid-fast and auramine-stained stool smears. Measurements: Three stool samples (at 0, 2, and 6 weeks after identification of the index case) and two serum samples (0 and 6 weeks) were collected from each family member in households with an index case of Cryptosporidium infection. Results: Forty-five percent of index cases of Cryptosporidium infection were associated with persistent (>14 days) diarrhea. Secondary cases of Cryptosporidium infection were identified either by stool examination or seroconversion in 18 (58%) of 31 households involving 30 persons, yielding an overall transmission rate of 19%. Of the 202 persons in this study with at least one serum sample available for analysis, 191 (94.6%) had evidence of antibodies (either IgM or IgG) to Cryptosporidium. Conclusions: Cryptosporidium parvum is highly transmissible and infective in the family setting, with transmission rates similar to other highly infectious enteric pathogens such as Shigella species. These data are cause for added concern because of the rapidly increasing rate of seropositivity for human immunodeficiency virus.	JOHNS HOPKINS UNIV, SCH MED, DIV INFECT DIS, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DIV GASTROENTEROL, BALTIMORE, MD 21205 USA; UNIV FED CEARA, UNIDADE PESQUISAS CLIN, FORTALEZA, CEARA, BRAZIL; UNIV VIRGINIA, SCH MED, DIV GEOG & INTERNAL MED, CHARLOTTESVILLE, VA 22908 USA	Johns Hopkins University; Johns Hopkins University; Universidade Federal do Ceara; University of Virginia			Sears, Cynthia L/AAJ-6704-2020; Lima, Aldo AM/D-8251-2018	Sears, Cynthia L/0000-0003-4059-1661; Lima, Aldo AM/0000-0002-0299-1747	NCPDCID CDC HHS [ICIDR PO1-A126512 02] Funding Source: Medline	NCPDCID CDC HHS		ADDISS DG, 1991, PEDIATR INFECT DIS J, V10, P907, DOI 10.1097/00006454-199112000-00005; ALPERT G, 1986, PEDIATRICS, V77, P152; BROWN EAE, 1989, PUBLIC HEALTH, V103, P3, DOI 10.1016/S0033-3506(89)80095-2; COMBEE CL, 1986, PEDIATR INFECT DIS J, V5, P528, DOI 10.1097/00006454-198609000-00008; Current W.L., 1990, P31; CURRENT WL, 1983, NEW ENGL J MED, V308, P1252, DOI 10.1056/NEJM198305263082102; DANTONIO RG, 1985, ANN INTERN MED, V103, P886, DOI 10.7326/0003-4819-103-6-886; DRYJANSKI J, 1986, AM J MED, V80, P751, DOI 10.1016/0002-9343(86)90839-9; EGGER M, 1990, ARCH DIS CHILD, V65, P445, DOI 10.1136/adc.65.4.445; FAYER R, 1990, INFECT IMMUN, V58, P2962, DOI 10.1128/IAI.58.9.2962-2965.1990; GAGGERO A, 1992, J CLIN MICROBIOL, V30, P3294, DOI 10.1128/JCM.30.12.3294-3297.1992; HANNAH J, 1988, PUBLIC HEALTH, V102, P539, DOI 10.1016/S0033-3506(88)80023-4; HAYES EB, 1989, NEW ENGL J MED, V320, P1372, DOI 10.1056/NEJM198905253202103; HEIJBEL H, 1987, PEDIATR INFECT DIS J, V6, P532, DOI 10.1097/00006454-198706000-00009; HOJLYNG N, 1986, J CLIN MICROBIOL, V23, P1109; KOCH KL, 1985, ANN INTERN MED, V102, P593, DOI 10.7326/0003-4819-102-5-593; KOTLER DP, 1990, ANN INTERN MED, V113, P444; LAUGHON BE, 1988, GASTROENTEROLOGY, V94, P984, DOI 10.1016/0016-5085(88)90557-4; LEMON SM, 1980, INFECT IMMUN, V28, P927; LIMA AAM, 1992, ACTA PAEDIATR, V81, P39, DOI 10.1111/j.1651-2227.1992.tb12370.x; MALLA N, 1987, INDIAN J MED RES, V86, P722; MIRON D, 1991, PEDIATR INFECT DIS J, V10, P438, DOI 10.1097/00006454-199106000-00004; NATARO JP, 1987, PEDIATR INFECT DIS J, V6, P829, DOI 10.1097/00006454-198709000-00008; NEWMAN RD, 1993, AM J TROP MED HYG, V49, P270, DOI 10.4269/ajtmh.1993.49.270; Nwanyanwu O C, 1989, Tex Med, V85, P40; PAPE JW, 1987, AM J TROP MED HYG, V36, P333, DOI 10.4269/ajtmh.1987.36.333; PATTISON JR, 1975, LANCET, V1, P185; PERERA J, 1990, Ceylon Medical Journal, V35, P11; RAHMAN M, 1990, AM J TROP MED HYG, V42, P127, DOI 10.4269/ajtmh.1990.42.127; REIF JS, 1989, AM J PUBLIC HEALTH, V79, P1528, DOI 10.2105/AJPH.79.11.1528; RIBEIRO CD, 1986, BRIT MED J, V292, P377, DOI 10.1136/bmj.292.6517.377; Schlager T A, 1988, Infect Dis Clin North Am, V2, P607; SCHORLING JB, 1990, AM J EPIDEMIOL, V132, P144, DOI 10.1093/oxfordjournals.aje.a115626; Sher A., 1989, Fundamental Immunology., P957; SMITH PD, 1988, ANN INTERN MED, V108, P328, DOI 10.7326/0003-4819-108-3-328; SOAVE R, 1985, ARCH INTERN MED, V145, P70, DOI 10.1001/archinte.145.1.70; TERRY S, 1993, NY TIMES MAGAZI 0926, P42; Ungar B. L. P., 1990, Cryptosporidiosis of man and animals., P59; UNGAR BLP, 1989, ARCH INTERN MED, V149, P894, DOI 10.1001/archinte.149.4.894; UNGAR BLP, 1986, J INFECT DIS, V153, P570, DOI 10.1093/infdis/153.3.570; WANKE CA, 1991, PEDIATR INFECT DIS J, V10, P746, DOI 10.1097/00006454-199110000-00006; WEIKEL CS, 1985, J INFECT DIS, V151, P963, DOI 10.1093/infdis/151.5.963; WILSON R, 1981, J INFECT DIS, V143, P130, DOI 10.1093/infdis/143.1.130; ZIERDT WS, 1984, J CLIN MICROBIOL, V20, P860, DOI 10.1128/JCM.20.5.860-861.1984; 1984, LANCET, V1, P734	45	104	110	0	10	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1994	120	6					500	505		10.7326/0003-4819-120-6-199403150-00009	http://dx.doi.org/10.7326/0003-4819-120-6-199403150-00009			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB625	8311373				2022-12-01	WOS:A1994NB62500009
J	TAYLOR, AK; SAFANDA, JF; FALL, MZ; QUINCE, C; LANG, KA; HULL, CE; CARPENTER, I; STALEY, LW; HAGERMAN, RJ				TAYLOR, AK; SAFANDA, JF; FALL, MZ; QUINCE, C; LANG, KA; HULL, CE; CARPENTER, I; STALEY, LW; HAGERMAN, RJ			MOLECULAR PREDICTORS OF COGNITIVE INVOLVEMENT IN FEMALE CARRIERS OF FRAGILE-X SYNDROME	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MENTAL-RETARDATION; CHROMOSOME INACTIVATION; HETEROZYGOUS CARRIERS; ABNORMAL METHYLATION; DNA; GENE; INSTABILITY; FREQUENCY; REPEAT; WOMEN	Objective.-Fragile X syndrome is caused by a mutation involving expansion of a CGG trinucleotide repeat segment in the fragile X mentaL retardation-1 (FMR1) gene on the long arm of the X chromosome. This study was undertaken to determine the relative impact of three molecular characteristics of the FMR1 mutation-number of CGG repeats, methylation status, and X inactivation ratio-on the cognitive involvement of female carriers of fragile X syndrome. Design.-Retrospective study with new DNA analysis of known female carriers of fragile X syndrome. Setting.-Molecular studies were conducted in a university-based DNA diagnostic laboratory. Patients were originally ascertained through a regional fragile X clinic in a university-affiliated pediatric hospital. Patients.-Forty-eight female carriers of fragile X syndrome were studied, including 22 with a premutation (a small expansion to approximately 50 to 200 CGG repeats), 23 with a full mutation (a full expansion to >200 CGG repeats), and three with both types of mutations (mosaics). Results.-Median IQ score was significantly lower for females with a full mutation than for females with a premutation. No significant relationship was found between IQ score and number of CGG repeats or percentage methylation of the mutant allele within each mutation category. In addition, no significant relationship was found between IQ score and the proportion of normal FMR1 alleles on the active X chromosome in the carrier female group as a whole or in either mutation subgroup. Comparisons of leukocytes and saliva-borne epithelial cells in certain full-mutation carriers revealed striking differences in FMR1 mutation sizes. Conclusions.-Mutation category remains the most important predictor of affectedness in female carriers of fragile X syndrome. Our data do not support use of the proportion of normal FMR1 alleles on the active X chromosome as a predictor of cognitive involvement in female carriers with full mutations. Individual tissue-specific differences exist in the heterogeneous sizes of full mutations and in the presence of premutation/full-mutation mosaicism.	CHILDRENS HOSP,CHILD DEV UNIT,DENVER,CO 80218	Children's Hospital Colorado	TAYLOR, AK (corresponding author), UNIV COLORADO,HLTH SCI CTR,DEPT PEDIAT,DNA DIAGNOST LAB,C-233,4200 E 9TH AVE,DENVER,CO 80262, USA.				NIMH NIH HHS [MH45916] Funding Source: Medline; PHS HHS [MCJ000252] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH045916] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALLEN RC, 1992, AM J HUM GENET, V51, P1229; BRAINARD SS, 1991, AM J MED GENET, V38, P505, DOI 10.1002/ajmg.1320380273; BROWN WT, 1993, JAMA-J AM MED ASSOC, V270, P1569, DOI 10.1001/jama.270.13.1569; CONLEY ME, 1986, NEW ENGL J MED, V315, P564, DOI 10.1056/NEJM198608283150907; DEVYS D, 1992, AM J MED GENET, V43, P208, DOI 10.1002/ajmg.1320430134; FRYNS JP, 1984, HUM GENET, V65, P400, DOI 10.1007/BF00291567; FRYNS JP, 1986, AM J MED GENET, V23, P157, DOI 10.1002/ajmg.1320230110; FU YH, 1991, CELL, V67, P1047, DOI 10.1016/0092-8674(91)90283-5; Hagerman R, 1991, FRAGILE X SYNDROME D, P3; Hagerman R. J., 1991, FRAGILE X SYNDROME D, P173; HAGERMAN RJ, 1992, PEDIATRICS, V89, P395; HAGERMAN RJ, 1989, AM J MED GENET, V30, P377; HANZLIK AJ, 1993, NAT GENET, V3, P44, DOI 10.1038/ng0193-44; HINDS HL, 1993, NAT GENET, V3, P36, DOI 10.1038/ng0193-36; HULL C, 1993, AM J DIS CHILD, V147, P1236, DOI 10.1001/archpedi.1993.02160350110017; KNOLL JH, 1984, AM J HUM GENET, V36, P640; KREMER EJ, 1991, SCIENCE, V252, P1711, DOI 10.1126/science.1675488; MAZZOCCO MMM, 1992, J AM ACAD CHILD PSY, V31, P1141, DOI 10.1097/00004583-199211000-00025; MAZZOCCO MMM, 1992, AM J MED GENET, V43, P78, DOI 10.1002/ajmg.1320430112; McGavran L., 1992, American Journal of Human Genetics, V51, pA84; MIEZEJESKI CM, 1992, 1992 INTERNATIONAL FRAGILE X CONFERENCE PROCEEDINGS, P85; MIGEON BR, 1992, AM J MED GENET, V43, P291, DOI 10.1002/ajmg.1320430145; NIELSEN KB, 1983, HUM GENET, V64, P240, DOI 10.1007/BF00279401; OBERLE I, 1991, SCIENCE, V252, P1097, DOI 10.1126/science.252.5009.1097; PERGOLIZZI RG, 1992, LANCET, V339, P271, DOI 10.1016/0140-6736(92)91334-5; PIERETTI M, 1991, CELL, V66, P817, DOI 10.1016/0092-8674(91)90125-I; PRCHAL JT, 1980, BLOOD, V56, P1048; PUCK JM, 1992, AM J HUM GENET, V50, P742; REISS AL, 1993, AM J HUM GENET, V52, P884; REISS AL, 1988, ARCH GEN PSYCHIAT, V45, P25; REISS AL, 1993, 10 S U WASH SEATTL; ROUSSEAU F, 1991, J MED GENET, V28, P830, DOI 10.1136/jmg.28.12.830; ROUSSEAU F, 1991, NEW ENGL J MED, V325, P1673, DOI 10.1056/NEJM199112123252401; SHERMAN SL, 1984, ANN HUM GENET, V48, P21, DOI 10.1111/j.1469-1809.1984.tb00830.x; SNOW K, 1993, AM J HUM GENET, V53, P1217; SOBESKY WE, IN PRESS J AM ACAD C; STALEY LW, 1993, AM J DIS CHILD, V147, P723, DOI 10.1001/archpedi.1993.02160310025011; SUTLIFFE JS, 1992, HUM MOL GENET, V1, P397; UCHIDA IA, 1982, AM J HUM GENET, V34, P286; VERKERK AJMH, 1991, CELL, V65, P905, DOI 10.1016/0092-8674(91)90397-H; WEBB TP, 1986, J MED GENET, V23, P396, DOI 10.1136/jmg.23.5.396; WILHELM D, 1988, AM J MED GENET, V30, P407, DOI 10.1002/ajmg.1320300141; WOHRLE D, 1993, NAT GENET, V4, P140, DOI 10.1038/ng0693-140; WORHLE D, 1992, HUM GENET, V29, P114; YU S, 1992, AM J HUM GENET, V50, P968; YU S, 1991, SCIENCE, V252, P1179, DOI 10.1126/science.252.5009.1179; [No title captured]; [No title captured]	48	126	126	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	1994	271	7					507	514		10.1001/jama.271.7.507	http://dx.doi.org/10.1001/jama.271.7.507			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV423	8301764				2022-12-01	WOS:A1994MV42300032
J	LI, Y; FLANAGAN, PM; TSCHOCHNER, H; KORNBERG, RD				LI, Y; FLANAGAN, PM; TSCHOCHNER, H; KORNBERG, RD			RNA POLYMERASE-II INITIATION-FACTOR INTERACTIONS AND TRANSCRIPTION START SITE SELECTION	SCIENCE			English	Article							SACCHAROMYCES-CEREVISIAE; SCHIZOSACCHAROMYCES-POMBE; TATA ELEMENTS; FACTOR-B; YEAST; GENE; PURIFICATION; SEQUENCE; PROMOTER; CLONING	An RNA polymerase II transcription system was resolved and reconstituted from extracts of Schizosaccharomyces pombe. Exchange with components of a Saccharomyces cerevisiae visiae system was undertaken to reveal the factor or factors responsible for the difference in location of the transcription start site, about 30 base pairs and 40 to 120 base pairs downstream of the TATA box in S. pombe and S. cerevisiae, respectively. Two components, counterparts of human transcription factor IIF (TFIIF) and TFIIH, could be exchanged individually between systems without effect on the start site. Three components, counterparts of human TFIIB, TFIIE, and RNA polymerase II, could not be exchanged individually but Gould be swapped in the pairs TFIIE-TFIIH and TFIIB-RNA polymerase II, which demonstrates that there are functional interactions between these components. Moreover, exchange of the latter pair shifted the starting position, which shows that TFIIB and RNA polymerase II are solely responsible for determining the start site of transcription.	STANFORD UNIV,MED CTR,SCH MED,DEPT CELL BIOL,STANFORD,CA 94305	Stanford University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036659, R37GM036659] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM36659] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BENOIST C, 1981, NATURE, V290, P304, DOI 10.1038/290304a0; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; CAVALLINI B, 1988, NATURE, V334, P77, DOI 10.1038/334077a0; CHASMAN DI, 1993, P NATL ACAD SCI USA, V90, P8174, DOI 10.1073/pnas.90.17.8174; CHEN W, 1985, EMBO J, V4, P3273, DOI 10.1002/j.1460-2075.1985.tb04077.x; CONAWAY JW, COMMUNICATION; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; EDWARDS AM, 1990, P NATL ACAD SCI USA, V87, P2122, DOI 10.1073/pnas.87.6.2122; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FEAVER WJ, 1989, IN PRESS CELL, V56, P549; FEAVER WJ, UNPUB; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FLANAGANPM, 1992, P NATL ACAD SCI USA, V89, P7659; FURTERGRAVES EM, 1990, MOL GEN GENET, V223, P407, DOI 10.1007/BF00264447; FURTERGRAVES EM, 1991, MOL CELL BIOL, V11, P4121, DOI 10.1128/MCB.11.8.4121; GAURENTE L, 1987, ANNU REV GENET, V21, P425; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HAHN S, 1989, CELL, V58, P1173, DOI 10.1016/0092-8674(89)90515-1; HAHN S, 1985, P NATL ACAD SCI USA, V82, P8562, DOI 10.1073/pnas.82.24.8562; HENRY NL, UNPUB; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; LI WZ, 1991, MOL CELL BIOL, V11, P666, DOI 10.1128/MCB.11.2.666; LU H, 1992, NATURE, V358, P641, DOI 10.1038/358641a0; LUE NF, 1993, P NATL ACAD SCI USA, V90, P8018, DOI 10.1073/pnas.90.17.8018; MALDONADO E, 1990, MOL CELL BIOL, V10, P6335, DOI 10.1128/MCB.10.12.6335; Maniatis T., 1982, MOL CLONING; NAGAWA F, 1985, P NATL ACAD SCI USA, V82, P8557, DOI 10.1073/pnas.82.24.8557; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; SAYRE MH, 1992, J BIOL CHEM, V267, P23383; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SERIZAWA H, UNPUB; TOYAMA R, 1990, FEBS LETT, V268, P217, DOI 10.1016/0014-5793(90)81012-D; TSCHOCHNER H, 1992, P NATL ACAD SCI USA, V89, P11292, DOI 10.1073/pnas.89.23.11292; WINSTON F, 1992, TRENDS GENET, V8, P387, DOI 10.1016/0168-9525(92)90300-S	36	115	119	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 11	1994	263	5148					805	807		10.1126/science.8303296	http://dx.doi.org/10.1126/science.8303296			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV866	8303296				2022-12-01	WOS:A1994MV86600034
J	LOVEJOY, B; CLEASBY, A; HASSELL, AM; LONGLEY, K; LUTHER, MA; WEIGL, D; MCGEEHAN, G; MCELROY, AB; DREWRY, D; LAMBERT, MH; JORDAN, SR				LOVEJOY, B; CLEASBY, A; HASSELL, AM; LONGLEY, K; LUTHER, MA; WEIGL, D; MCGEEHAN, G; MCELROY, AB; DREWRY, D; LAMBERT, MH; JORDAN, SR			STRUCTURE OF THE CATALYTIC DOMAIN OF FIBROBLAST COLLAGENASE COMPLEXED WITH AN INHIBITOR	SCIENCE			English	Article							C-TERMINAL DOMAIN; BINDING; METALLOPROTEINASES; STROMELYSIN; THERMOLYSIN; FAMILY	Collagenase is a zinc-dependent endoproteinase and is a member of the matrix metalloproteinase (MMP) family of enzymes. The MMPs participate in connective tissue remodeling events and aberrant regulation has been associated with several pathologies. The 2.4 angstrom resolution structure of the inhibited enzyme revealed that, in addition to the catalytic zinc, there is a second zinc ion and a calcium ion which play a major role in stabilizing the tertiary structure of collagenase. Despite scant sequence homology, collagenase shares structural homology with two other endoproteinases, bacterial thermolysin and crayfish astacin. The detailed description of protein-inhibitor interactions present in the structure will aid in the design of compounds that selectively inhibit individual members of the MMP family. Such inhibitors will be useful in examining the function of MMPs in pathological processes.	GLAXO GRP RES LTD,GREENFORD UB0 6HE,MIDDX,ENGLAND	GlaxoSmithKline	LOVEJOY, B (corresponding author), GLAXO RES INST,RES TRIANGLE PK,NC 27709, USA.			Drewry, David Harold/0000-0001-5973-5798				ALLAN JA, 1991, J CELL SCI, V99, P789; BECHERER JD, 1991, J CELL BIOCH G S, V15; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BODE W, 1992, NATURE, V358, P164, DOI 10.1038/358164a0; BROWN FK, IN PRESS J MED CHEM; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; FUREY W, 1990, AM CRYSTALLOGR ASS 2, V18, P73; GOLDBERG GI, 1986, J BIOL CHEM, V261, P6600; GOMISRUTH FX, 1993, J MOL BIOL, V229, P945, DOI 10.1006/jmbi.1993.1098; HASSELL AM, IN PRESS J MOL BIOL; HENDERSON B, 1990, Drugs of the Future, V15, P495; KABSCH W, 1978, ACTA CRYSTALLOGR A, V34, P827, DOI 10.1107/S0567739478001680; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LOWRY CL, 1992, PROTEINS, V12, P42, DOI 10.1002/prot.340120106; MATHEWS BW, 1988, ACCOUNTS CHEM RES, V21, P333; MATTHEWS BW, 1972, NATURE-NEW BIOL, V238, P37, DOI 10.1038/newbio238037a0; MCCACHREN SS, 1991, ARTHRITIS RHEUM-US, V34, P1085; MCGEEHAN G, 1992, PLANT PHYSIOL, V99, P1179, DOI 10.1104/pp.99.3.1179; MCGEEHAN GM, UNPUB; MONZINGO AF, 1984, BIOCHEMISTRY-US, V23, P5724, DOI 10.1021/bi00319a010; MULLER D, 1988, BIOCHEM J, V253, P187, DOI 10.1042/bj2530187; MURPHY G, 1992, J BIOL CHEM, V267, P9612; SALOWE SP, 1992, BIOCHEMISTRY-US, V31, P4535, DOI 10.1021/bi00134a001; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	24	306	314	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 21	1994	263	5145					375	377		10.1126/science.8278810	http://dx.doi.org/10.1126/science.8278810			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT034	8278810				2022-12-01	WOS:A1994MT03400033
J	MARSDEN, AFA; CAFFREY, P; APARICIO, JF; LOUGHRAN, MS; STAUNTON, J; LEADLAY, PF				MARSDEN, AFA; CAFFREY, P; APARICIO, JF; LOUGHRAN, MS; STAUNTON, J; LEADLAY, PF			STEREOSPECIFIC ACYL TRANSFERS ON THE ERYTHROMYCIN-PRODUCING POLYKETIDE SYNTHASE	SCIENCE			English	Article							METHYLMALONYL-COA EPIMERASE; SACCHAROPOLYSPORA-ERYTHRAEA; MACROLIDE BIOSYNTHESIS; PROPIONIBACTERIUM-SHERMANII; MULTIFUNCTIONAL ENZYME; STEREOCHEMISTRY; ANTIBIOTICS; POLYETHER	During assembly of complex polyketide antibiotics like erythromycin A, molecular recognition by the multienzyme polyketide synthase controls the stereochemical outcome as each successive methylmalonyl-coenzyme A (CoA) extender unit is added. Acylation of the purified erythromycin-producing polyketide synthase has shown that all six acyltransferase domains have identical stereospecificity for their normal substrate (2S)-methylmalonyl-CoA. In contrast, the configuration of the methyl-branched centers in the products, that are derived from (2S)-methylmalonyl-CoA, is different. Stereoselection during the chain building process must, therefore, involve additional epimerization steps.	UNIV CAMBRIDGE,CAMBRIDGE CTR MOLEC RECOGNIT,CAMBRIDGE CB2 1QW,ENGLAND; UNIV CAMBRIDGE,DEPT BIOCHEM,CAMBRIDGE CB2 1QW,ENGLAND; UNIV CAMBRIDGE,CAMBRIDGE CTR MOLEC RECOGNIT,CAMBRIDGE CB2 1EW,ENGLAND; UNIV CAMBRIDGE,CHEM LAB,DEPT ORGAN CHEM,CAMBRIDGE CB2 1EW,ENGLAND	University of Cambridge; University of Cambridge; University of Cambridge; University of Cambridge			Aparicio, Jesús F./K-8686-2014; Caffrey, Patrick/B-1409-2008	Aparicio, Jesús F./0000-0003-4242-4701; Leadlay, Peter/0000-0002-3247-509X				APARICIO JF, IN PRESS J BIOL CHEM; BEVITT DJ, 1992, EUR J BIOCHEM, V204, P39, DOI 10.1111/j.1432-1033.1992.tb16603.x; BULSING JM, 1984, J CHEM SOC CHEM COMM, V19, P1301; CAFFREY P, 1992, FEBS LETT, V304, P225, DOI 10.1016/0014-5793(92)80624-P; CANE DE, 1987, J AM CHEM SOC, V109, P1255, DOI 10.1021/ja00238a051; CANE DE, 1986, J AM CHEM SOC, V108, P4957, DOI 10.1021/ja00276a042; CANE DE, 1983, J AM CHEM SOC, V105, P3594, DOI 10.1021/ja00349a040; CANE DE, 1993, J AM CHEM SOC, V115, P522, DOI 10.1021/ja00055a023; CELMER WD, 1965, J AM CHEM SOC, V87, P1801, DOI 10.1021/ja01086a038; CORTES J, 1990, NATURE, V348, P176, DOI 10.1038/348176a0; DONADIO S, 1993, P NATL ACAD SCI USA, V90, P7119, DOI 10.1073/pnas.90.15.7119; DONADIO S, 1991, SCIENCE, V252, P675, DOI 10.1126/science.2024119; Fersht A. R., 1985, ENZYME STRUCTURE MEC, P347; FULLER JQ, 1983, BIOCHEM J, V213, P643, DOI 10.1042/bj2130643; HOPWOOD DA, 1990, ANNU REV GENET, V24, P37, DOI 10.1146/annurev.ge.24.120190.000345; HOPWOOD DA, IN PRESS CURR TOP BI; LEADLAY PF, 1981, BIOCHEM J, V197, P413, DOI 10.1042/bj1970413; MARSDEN AFA, UNPUB; MCALPINE JB, 1987, J ANTIBIOT, V40, P1115, DOI 10.7164/antibiotics.40.1115; OHAGAN D, 1989, NAT PROD REP, V6, P205, DOI 10.1039/np9890600205; ROBERTS GA, 1993, EUR J BIOCHEM, V214, P305, DOI 10.1111/j.1432-1033.1993.tb17925.x; SEDGWICK B, 1977, EUR J BIOCHEM, V75, P481, DOI 10.1111/j.1432-1033.1977.tb11550.x; SHERMAN MM, 1987, BIOCHEMISTRY-US, V26, P438, DOI 10.1021/bi00376a015; SOOD GR, 1984, J CHEM SOC CHEM COMM, V21, P1421; STAUNTON J, 1991, ANGEW CHEM INT EDIT, V30, P1302, DOI 10.1002/anie.199113021; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; YUE S, 1987, J AM CHEM SOC, V109, P1253, DOI 10.1021/ja00238a050	27	156	162	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 21	1994	263	5145					378	380		10.1126/science.8278811	http://dx.doi.org/10.1126/science.8278811			3	Multidisciplinary Sciences	Index Chemicus (IC); Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT034	8278811				2022-12-01	WOS:A1994MT03400034
J	EDERY, I; RUTILA, JE; ROSBASH, M				EDERY, I; RUTILA, JE; ROSBASH, M			PHASE-SHIFTING OF THE CIRCADIAN CLOCK BY INDUCTION OF THE DROSOPHILA PERIOD PROTEIN	SCIENCE			English	Article							MESSENGER-RNA LEVELS; VISUAL-SYSTEM; GENE-PRODUCT; MELANOGASTER; MUTANTS; RHYTHMS; ADULT	Virtually all organisms manifest circadian (24-hour) rhythms, governed by an ill-defined endogenous pacemaker or clock. Several lines of evidence suggest that the Drosophila melanogaster period gene product PER is a clock component. If PER were central to the time-keeping mechanism, a transient increase in its concentration would cause a stable shift in the phase of the clock. Therefore, transgenic flies bearing a heat-inducible copy of PER were subjected to temperature pulses. This treatment caused long-lasting phase shifts in the locomotor activity circadian rhythm, a result that supports the contention that PER is a bona fide clock component.	BRANDEIS UNIV,DEPT BIOL,HOWARD HUGHES MED INST,WALTHAM,MA 02254	Brandeis University; Howard Hughes Medical Institute								CITRI Y, 1987, NATURE, V326, P42, DOI 10.1038/326042a0; DUSHAY MS, 1990, GENETICS, V125, P557; Edmunds L.N., 1988, CELLULAR MOL BASES B; EWER J, 1988, NATURE, V333, P82, DOI 10.1038/333082a0; EWER J, 1990, J NEUROGENET, V7, P31, DOI 10.3109/01677069009084151; HALL JC, 1987, TRENDS GENET, V3, P185, DOI 10.1016/0168-9525(87)90231-9; HAMBLEN M, 1986, J NEUROGENET, V3, P249, DOI 10.3109/01677068609106855; HAMBLENCOYLE MJ, 1992, J INSECT BEHAV, V5, P417, DOI 10.1007/BF01058189; HARDIN PE, 1990, NATURE, V343, P536, DOI 10.1038/343536a0; HARDIN PE, 1992, P NATL ACAD SCI USA, V89, P11711, DOI 10.1073/pnas.89.24.11711; Hastings J.W., 1991, NEURAL INTEGRATIVE A, P435; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; Johnson Carl Hirschie, 1992, P209; KHALSA SBS, 1992, P NATL ACAD SCI USA, V89, P10862, DOI 10.1073/pnas.89.22.10862; KONOPKA RJ, 1971, P NATL ACAD SCI USA, V68, P2112, DOI 10.1073/pnas.68.9.2112; LIU X, 1992, J NEUROSCI, V12, P2735; MCGARRY TJ, 1985, CELL, V42, P903, DOI 10.1016/0092-8674(85)90286-7; ROSBASH M, 1989, NEURON, V3, P387, DOI 10.1016/0896-6273(89)90199-2; RUBIN GM, 1985, TRENDS NEUROSCI, V8, P231, DOI 10.1016/0166-2236(85)90094-3; SIWICKI KK, 1988, NEURON, V1, P141, DOI 10.1016/0896-6273(88)90198-5; Takahashi J S, 1991, Curr Opin Neurobiol, V1, P556, DOI 10.1016/S0959-4388(05)80028-5; YOUNG MW, 1989, NEURONAL CELLULAR OS, P529; ZERR DM, 1990, J NEUROSCI, V10, P2749	23	120	120	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 14	1994	263	5144					237	240		10.1126/science.8284676	http://dx.doi.org/10.1126/science.8284676			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ879	8284676				2022-12-01	WOS:A1994MQ87900039
J	HOGQUIST, KA; JAMESON, SC; HEATH, WR; HOWARD, JL; BEVAN, MJ; CARBONE, FR				HOGQUIST, KA; JAMESON, SC; HEATH, WR; HOWARD, JL; BEVAN, MJ; CARBONE, FR			T-CELL RECEPTOR ANTAGONIST PEPTIDES INDUCE POSITIVE SELECTION	CELL			English	Article							CLASS-I MOLECULES; THYMIC SELECTION; TRANSGENIC MICE; ANTIGEN; BINDING; MHC; THYMOCYTES; CD8; BETA-2-MICROGLOBULIN; RECOGNITION	We have used organ culture of fetal thymic lobes from T cell receptor (TCR) transgenic beta2M(-/-) mice to study the role of peptides in positive selection. The TCR used was from a CD8+ T cell specific for ovalbumin 257-264 in the context of K(b). Several peptides with the ability to induce positive selection were identified. These peptide-selected thymocytes have the same phenotype as mature CD8+ T cells and can respond to antigen. Those peptides with the ability to induce positive selection were all variants of the antigenic peptide and were identified as TCR antagonist peptides for this receptor. One peptide tested, E1, induced positive selection on the beta2M(-/-) background but negative selection on the beta2M(+/-) background. These results show that the process of positive selection is exquisitely peptide specific and sensitive to extremely low ligand density and support the notion that low efficacy ligands mediate positive selection.	UNIV WASHINGTON,HOWARD HUGHES MED INST,DEPT IMMUNOL,SEATTLE,WA 98195; ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,PARKVILLE,VIC 3050,AUSTRALIA; MONASH UNIV,SCH MED,DEPT PATHOL & IMMUNOL,PRAHRAN,VIC 3181,AUSTRALIA	Howard Hughes Medical Institute; University of Washington; University of Washington Seattle; Royal Melbourne Hospital; Walter & Eliza Hall Institute; Monash University			Eckhardt, Erik/G-1567-2010; Jameson, Stephen C/D-9892-2013; Carbone, Francis/ABF-2141-2020	Jameson, Stephen C/0000-0001-9137-1146; Heath, William/0000-0001-9670-259X; Hogquist, Kristin/0000-0001-9963-5687	NIAID NIH HHS [AI-28902] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALEXANDER J, 1993, J IMMUNOL, V150, P1; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; BENDELAC A, 1992, J EXP MED, V175, P731, DOI 10.1084/jem.175.3.731; CARBONE FR, 1992, INT IMMUNOL, V4, P861, DOI 10.1093/intimm/4.8.861; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; EVAVOLD BD, 1993, J IMMUNOL, V150, P3131; GREGOIRE C, 1991, P NATL ACAD SCI USA, V88, P8077, DOI 10.1073/pnas.88.18.8077; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JACOBS H, 1990, EUR J IMMUNOL, V20, P2333, DOI 10.1002/eji.1830201024; JAMESON SC, 1993, J EXP MED, V177, P1541, DOI 10.1084/jem.177.6.1541; Janeway Charles A. Jr., 1992, Current Biology, V2, P591, DOI 10.1016/0960-9822(92)90163-5; Jenkinson E J, 1990, Semin Immunol, V2, P51; JOYCE S, 1991, ANTIGEN PROCESSING R, P109; KAYE J, 1992, J IMMUNOL, V148, P3342; KELLY JM, 1993, IN PRESS EUR J IMMUN, V10; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; LEE NA, 1992, J EXP MED, V175, P1013, DOI 10.1084/jem.175.4.1013; MANNIE MD, 1991, J THEOR BIOL, V151, P169, DOI 10.1016/S0022-5193(05)80360-1; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; OGQUIST KA, 1993, J EXP MED, V177, P1469; RACIOPPI L, 1993, J EXP MED, V177, P1047, DOI 10.1084/jem.177.4.1047; ROBEY EA, 1992, CELL, V69, P1089, DOI 10.1016/0092-8674(92)90631-L; ROTHENBERG EV, 1992, ADV IMMUNOL, V51, P85, DOI 10.1016/S0065-2776(08)60487-3; SCHUMACHER TNM, 1990, CELL, V62, P563, DOI 10.1016/0092-8674(90)90020-F; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; SHERMAN LA, 1992, SCIENCE, V258, P815, DOI 10.1126/science.1439792; SLOANLANCASTER J, 1993, NATURE, V363, P156, DOI 10.1038/363156a0; SPAIN LM, 1992, J EXP MED, V176, P213, DOI 10.1084/jem.176.1.213; SWAT W, 1991, NATURE, V351, P150, DOI 10.1038/351150a0; SWAT W, 1993, EUR J IMMUNOL, V23, P739, DOI 10.1002/eji.1830230326; VANBLEEK GM, 1991, P NATL ACAD SCI USA, V88, P11032, DOI 10.1073/pnas.88.24.11032; VEIS DJ, 1993, J IMMUNOL, V151, P2546; VITIELLO A, 1990, SCIENCE, V250, P1423, DOI 10.1126/science.2124002; VONBOEHMER H, 1990, ANNU REV IMMUNOL, V8, P531, DOI 10.1146/annurev.iy.08.040190.002531; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0; ZUGIC JN, 1990, NATURE, V344, P65	36	2237	2275	2	64	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 14	1994	76	1					17	27		10.1016/0092-8674(94)90169-4	http://dx.doi.org/10.1016/0092-8674(94)90169-4			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287475				2022-12-01	WOS:A1994MR49500003
J	SASAKI, H; HOGAN, BLM				SASAKI, H; HOGAN, BLM			HNF-3-BETA AS A REGULATOR OF FLOOR PLATE DEVELOPMENT	CELL			English	Article							C-KIT RECEPTOR; CENTRAL-NERVOUS-SYSTEM; GENE FORK-HEAD; TRANSCRIPTION FACTORS; EARLY NEUROGENESIS; MESSENGER-RNA; SPINAL-CORD; SI-LOCUS; DROSOPHILA; EXPRESSION	The transcription factor gene HNF-3beta is expressed in the ventral midline of the mouse embryonic neural tube, including the floor plate, a structure important for dorsoventral patterning and axonal guidance. To assess HNF-3beta function, the gene has been ectopically expressed in the midbrain/hindbrain of transgenic embryos using an En-2 promoter/enhancer. By 18.5 days postcoitum, transgenic brains show a range of abnormalities, including absent inferior colliculus and reduced cerebellum. Earlier, several genes normally expressed in the floor plate (BMP-1, Steel factor, and HNF-3alpha) are induced within the same ectopic dorsal domain as HNF-3beta, and autoactivation of the endogenous HNF-3beta is observed. Conversely, expression of the dorsal gene Pax-3 is suppressed. Ectopic dorsal neuronal differentiation and abnormal dorsal axonal projections are also seen. These results suggest that HNF-3beta is an important regulator of floor plate development in vivo.	VANDERBILT UNIV, MED CTR, SCH MED, DEPT CELL BIOL, NASHVILLE, TN 37232 USA	Vanderbilt University	SASAKI, H (corresponding author), VANDERBILT UNIV, MED CTR, SCH MED, HOWARD HUGHES MED INST, NASHVILLE, TN 37232 USA.							ALTABA ARI, 1992, DEVELOPMENT, V116, P81; ALTABA ARI, 1993, P NATL ACAD SCI USA, V90, P8268, DOI 10.1073/pnas.90.17.8268; ALTMAN J, 1984, ADV ANATOMY EMBRYOLO; [Anonymous], [No title captured]; ARTINGER KB, 1992, DEVELOPMENT, V116, P877; BASLER K, 1993, CELL, V73, P687, DOI 10.1016/0092-8674(93)90249-P; BERNHARDT RR, 1992, NEURON, V8, P869, DOI 10.1016/0896-6273(92)90201-N; BOVOLENTA P, 1991, DEVELOPMENT, V113, P625; CABRERA CV, 1992, DEVELOPMENT, V115, P893; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLARKE JDW, 1991, DEVELOPMENT, V112, P499; DAVIS CA, 1988, GENE DEV, V2, P361, DOI 10.1101/gad.2.3.361; DIRKSEN ML, 1992, GENE DEV, V6, P599, DOI 10.1101/gad.6.4.599; DODD J, 1993, CELL CELL SIGNALING, P81; ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3; FAHRNER K, 1987, EMBO J, V6, P1265, DOI 10.1002/j.1460-2075.1987.tb02363.x; GOULDING MD, 1991, EMBO J, V10, P1135, DOI 10.1002/j.1460-2075.1991.tb08054.x; GOULDING MD, 1993, DEVELOPMENT, V117, P1001; GROSSNIKLAUS U, 1992, GENE DEV, V6, P1030, DOI 10.1101/gad.6.6.1030; HALPERN ME, 1993, CELL, V75, P99, DOI 10.1016/0092-8674(93)90682-G; HATTA K, 1992, NEURON, V9, P629, DOI 10.1016/0896-6273(92)90027-B; HATTA K, 1991, NATURE, V350, P339, DOI 10.1038/350339a0; HIROTA S, 1992, MOL BRAIN RES, V15, P47, DOI 10.1016/0169-328X(92)90150-A; Hogan B., 1986, MANIPULATING MOUSE E; HROMAS R, 1993, BLOOD, V81, P2854; HUANG E, 1990, CELL, V63, P225, DOI 10.1016/0092-8674(90)90303-V; INOUYE M, 1976, Congenital Anomalies, V16, P171; JESSELL TM, 1989, CIBA F SYMP, V144, P255; JESSELL TM, 1992, HARVEY LECT, V86, P87; KESHET E, 1991, EMBO J, V10, P2425, DOI 10.1002/j.1460-2075.1991.tb07782.x; KINTNER C, 1992, ANNU REV NEUROSCI, V15, P251, DOI 10.1146/annurev.neuro.15.1.251; KNOCHEL S, 1992, MECH DEVELOP, V38, P157, DOI 10.1016/0925-4773(92)90007-7; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUZIORA MA, 1988, CELL, V55, P477, DOI 10.1016/0092-8674(88)90034-7; LAI E, 1990, GENE DEV, V4, P1427, DOI 10.1101/gad.4.8.1427; LAI E, 1991, GENE DEV, V5, P416, DOI 10.1101/gad.5.3.416; LAIRD PW, 1991, NUCLEIC ACIDS RES, V19, P4293, DOI 10.1093/nar/19.15.4293; LOGAN C, 1993, DEVELOPMENT, V117, P905; MATSUI Y, 1990, NATURE, V347, P667, DOI 10.1038/347667a0; McMahon A P, 1993, Curr Opin Neurobiol, V3, P4, DOI 10.1016/0959-4388(93)90027-V; MILLER LM, 1993, GENE DEV, V7, P933, DOI 10.1101/gad.7.6.933; NAGAMINE CM, 1990, GENE DEV, V4, P63, DOI 10.1101/gad.4.1.63; NISHI M, 1988, NATURE, V331, P267, DOI 10.1038/331267a0; OBERDICK J, 1988, NEURON, V1, P367, DOI 10.1016/0896-6273(88)90186-9; PANI L, 1992, MOL CELL BIOL, V12, P552, DOI 10.1128/MCB.12.2.552; PLACZEK M, 1990, DEVELOPMENT, V110, P19; PLACZEK M, 1990, SCIENCE, V250, P985, DOI 10.1126/science.2237443; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; SASAKI H, 1993, DEVELOPMENT, V118, P47; SCHIER AF, 1992, NATURE, V356, P804, DOI 10.1038/356804a0; SCHOENWOLF GC, 1990, DEVELOPMENT, V109, P243; SLACK JMW, 1992, DEVELOPMENT, V114, P285; STRAHLE U, 1993, GENE DEV, V7, P1436, DOI 10.1101/gad.7.7b.1436; TAKAHASHI Y, 1992, P NATL ACAD SCI USA, V89, P10237, DOI 10.1073/pnas.89.21.10237; TESSIERLAVIGNE M, 1988, NATURE, V336, P775, DOI 10.1038/336775a0; WALL NA, 1993, J CELL BIOL, V120, P493, DOI 10.1083/jcb.120.2.493; WEIGEL D, 1990, CELL, V63, P455, DOI 10.1016/0092-8674(90)90439-L; WEIGEL D, 1989, CELL, V57, P645, DOI 10.1016/0092-8674(89)90133-5; YAMADA T, 1991, CELL, V64, P635, DOI 10.1016/0092-8674(91)90247-V; YAMADA T, 1993, CELL, V73, P673, DOI 10.1016/0092-8674(93)90248-O; ZHU GF, 1993, MOL CELL BIOL, V13, P1779, DOI 10.1128/MCB.13.3.1779	61	271	273	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	1994	76	1					103	115		10.1016/0092-8674(94)90176-7	http://dx.doi.org/10.1016/0092-8674(94)90176-7			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287471				2022-12-01	WOS:A1994MR49500010
J	LUTTICKEN, C; WEGENKA, UM; YUAN, JP; BUSCHMANN, J; SCHINDLER, C; ZIEMIECKI, A; HARPUR, AG; WILKS, AF; YASUKAWA, K; TAGA, T; KISHIMOTO, T; BARBIERI, G; PELLEGRINI, S; SENDTNER, M; HEINRICH, PC; HORN, F				LUTTICKEN, C; WEGENKA, UM; YUAN, JP; BUSCHMANN, J; SCHINDLER, C; ZIEMIECKI, A; HARPUR, AG; WILKS, AF; YASUKAWA, K; TAGA, T; KISHIMOTO, T; BARBIERI, G; PELLEGRINI, S; SENDTNER, M; HEINRICH, PC; HORN, F			ASSOCIATION OF TRANSCRIPTION FACTOR APRF AND PROTEIN-KINASE JAK1 WITH THE INTERLEUKIN-6 SIGNAL TRANSDUCER GP130	SCIENCE			English	Article							TYROSINE PHOSPHORYLATION; INTERFERON-ALPHA; IFN-GAMMA; RECEPTOR; ACTIVATION; AFFINITY	Interleukin-6 (IL-6), leukemia inhibitory factor, oncostatin M, interleukin-11, and ciliary neurotrophic factor bind to receptor complexes that share the signal transducer gp130. Upon binding, the ligands rapidly activate DNA binding of acute-phase response factor (APRF), a protein antigenically related to the p91 subunit of the interferon-stimulated gene factor-3alpha (ISGF-3alpha). These cytokines caused tyrosine phosphorylation of APRF and ISGF-3alpha p91. Protein kinases of the Jak family were also rapidly tyrosine phosphorylated, and both APRF and Jak1 associated with gp130. These data indicate that Jak family protein kinases may participate in IL-6 signaling and that APRF may be activated in a complex with gp130.	RHEIN WESTFAL TH AACHEN,INST BIOCHEM,PAUWELSSTR 30,D-52057 AACHEN,GERMANY; COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,NEW YORK,NY 10032; UNIV BERN,CLIN & EXPTL CANC RES LAB,CH-3004 BERN,SWITZERLAND; ROYAL MELBOURNE HOSP,LUDWIG INST CANC RES,PARKVILLE,VIC 3050,AUSTRALIA; TOSOH CORP,BIOTECHNOL RES LAB,KANAGAWA 252,JAPAN; OSAKA UNIV,INST MOLEC & CELLULAR BIOL,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT MED 3,SUITA,OSAKA 565,JAPAN; INST PASTEUR,INSERM,U276,F-75724 PARIS 15,FRANCE; MAX PLANCK INST PSYCHIAT,D-82152 MARTINSRIED,GERMANY	RWTH Aachen University; Columbia University; University of Bern; Ludwig Institute for Cancer Research; Royal Melbourne Hospital; Tosoh Corporation; Osaka University; Osaka University; Institut National de la Sante et de la Recherche Medicale (Inserm); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Max Planck Society			Pellegrini, Sandra -/G-5546-2015; Kishimoto, Tadamitsu/C-8470-2009; Sendtner, Michael/J-1542-2012; Sendtner, Michael/M-8137-2014; Pellegrini, Sandra/Y-6351-2019; Barbieri, Giovanna/AAH-3645-2019; Wilks, Andrew F/R-5542-2019	Pellegrini, Sandra -/0000-0001-5837-7589; Sendtner, Michael/0000-0002-4737-2974; Sendtner, Michael/0000-0002-4737-2974; Pellegrini, Sandra/0000-0001-5837-7589; BARBIERI, GIOVANNA/0000-0002-5895-1795; Wilks, Andrew F/0000-0002-8554-2399				ARGETSINGER LS, 1993, CELL, V74, P237, DOI 10.1016/0092-8674(93)90415-M; BAZAN JF, 1991, NEURON, V7, P197, DOI 10.1016/0896-6273(91)90258-2; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; COOPER JA, 1983, METHOD ENZYMOL, V99, P387; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DECKER T, 1991, EMBO J, V10, P927, DOI 10.1002/j.1460-2075.1991.tb08026.x; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; FU XY, 1993, CELL, V74, P1135, DOI 10.1016/0092-8674(93)90734-8; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HIBI M, 1992, CELL S, V69, P1121; KESSLER DS, 1990, GENE DEV, V4, P1753, DOI 10.1101/gad.4.10.1753; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LUTTICKEN C, UNPUB; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; PATTERSON PH, 1993, CELL, V72, P123, DOI 10.1016/S0092-8674(05)80032-7; PELLEGRINI S, 1993, TRENDS BIOCHEM SCI, V18, P338, DOI 10.1016/0968-0004(93)90070-4; RUFFJAMISON S, 1993, SCIENCE, V261, P1733, DOI 10.1126/science.8378774; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SILVENNOINEN O, 1993, P NATL ACAD SCI USA, V90, P8429, DOI 10.1073/pnas.90.18.8429; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; WEGENKA UM, UNPUB; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1993, CELL, V74, P227, DOI 10.1016/0092-8674(93)90414-L; YOSHIMURA A, 1992, MOL CELL BIOL, V12, P706, DOI 10.1128/MCB.12.2.706; YUAN J, IN PRESS MOL CELL BI	32	741	770	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 7	1994	263	5143					89	92		10.1126/science.8272872	http://dx.doi.org/10.1126/science.8272872			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ301	8272872				2022-12-01	WOS:A1994MQ30100037
J	VANDENHEUVEL, S; HARLOW, E				VANDENHEUVEL, S; HARLOW, E			DISTINCT ROLES FOR CYCLIN-DEPENDENT KINASES IN CELL-CYCLE CONTROL	SCIENCE			English	Article							PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; CATALYTIC SUBUNIT; CDC28 MUTATION; ACTIVATION; MITOSIS; FAMILY; YEAST; PHASE; GENE	The key cell-cycle regulator Cdc2 belongs to a family of cyclin-dependent kinases in higher eukaryotes. Dominant-negative mutations were used to address the requirement for kinases of this family in progression through the human cell cycle. A dominant-negative Cdc2 mutant arrested cells at the G2 to M phase transition, whereas mutants of the cyclin-dependent kinases Cdk2 and Cdk3 caused a G1 block. The mutant phenotypes were specifically rescued by the corresponding wild-type kinases. These data reveal that Cdk3, in addition to Cdc2 and Cdk2, executes a distinct and essential function in the mammalian cell cycle.			VANDENHEUVEL, S (corresponding author), MASSACHUSETTS GEN HOSP,CTR CANC,BOSTON,MA 02129, USA.		van den Heuvel, Sander J.L./B-8892-2011	van den Heuvel, Sander J.L./0000-0001-9015-7463				Ausubel FM, 1988, CURRENT PROTOCOLS MO, V1; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DRAETTA G, 1988, CELL, V54, P17, DOI 10.1016/0092-8674(88)90175-4; DUCOMMUN B, 1991, MOL CELL BIOL, V11, P6177, DOI 10.1128/MCB.11.12.6177; DUCOMMUN B, 1991, EMBO J, V10, P3311, DOI 10.1002/j.1460-2075.1991.tb04895.x; DULIC V, 1992, SCIENCE, V257, P1958, DOI 10.1126/science.1329201; ELLEDGE SJ, 1991, EMBO J, V10, P2653, DOI 10.1002/j.1460-2075.1991.tb07808.x; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FORSBURG SL, 1991, ANNU REV CELL BIOL, V7, P227, DOI 10.1146/annurev.cb.07.110191.001303; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1987, P NATL ACAD SCI USA, V84, P388, DOI 10.1073/pnas.84.2.388; HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46; HERSKOWITZ I, 1987, NATURE, V329, P219, DOI 10.1038/329219a0; HINDS PW, 1992, CELL, V70, P993, DOI 10.1016/0092-8674(92)90249-C; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOFF A, 1992, SCIENCE, V257, P1689, DOI 10.1126/science.1388288; LAPIDOTLIESON Y, 1992, P NATL ACAD SCI USA, V89, P579, DOI 10.1073/pnas.89.2.579; LEES E, 1992, GENE DEV, V6, P1874, DOI 10.1101/gad.6.10.1874; LEW J, 1992, J BIOL CHEM, V267, P25922; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MENDENHALL MD, 1988, P NATL ACAD SCI USA, V85, P4426, DOI 10.1073/pnas.85.12.4426; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MEYERSON M, IN PRESS MOL CELL BI; MEYERSON M, UNPUB; NINOMIYATSUJI J, 1991, P NATL ACAD SCI USA, V88, P9006, DOI 10.1073/pnas.88.20.9006; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PINES J, 1990, New Biologist, V2, P389; PINES J, 1989, CELL, V58, P833, DOI 10.1016/0092-8674(89)90936-7; PINES J, 1990, NATURE, V346, P760, DOI 10.1038/346760a0; REED SI, 1990, P NATL ACAD SCI USA, V87, P5697, DOI 10.1073/pnas.87.15.5697; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; ROSENBLATT J, 1992, P NATL ACAD SCI USA, V89, P2824, DOI 10.1073/pnas.89.7.2824; TAYLOR SS, 1993, TRENDS BIOCHEM SCI, V18, P84, DOI 10.1016/0968-0004(93)80001-R; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; TSAI LH, 1993, ONCOGENE, V8, P1593; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSAI LH, IN PRESS DEVELOPMENT; VANDENHEUVEL S, UNPUB; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; ZHU L, 1993, GENE DEV, V7, P1111, DOI 10.1101/gad.7.7a.1111	45	995	1017	0	36	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					2050	2054		10.1126/science.8266103	http://dx.doi.org/10.1126/science.8266103			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266103				2022-12-01	WOS:A1993MN10800043
J	BROWN, EM; GAMBA, G; RICCARDI, D; LOMBARDI, M; BUTTERS, R; KIFOR, O; SUN, A; HEDIGER, MA; LYTTON, J; HEBERT, SC				BROWN, EM; GAMBA, G; RICCARDI, D; LOMBARDI, M; BUTTERS, R; KIFOR, O; SUN, A; HEDIGER, MA; LYTTON, J; HEBERT, SC			CLONING AND CHARACTERIZATION OF AN EXTRACELLULAR CA2+-SENSING RECEPTOR FROM BOVINE PARATHYROID	NATURE			English	Article							METABOTROPIC GLUTAMATE RECEPTOR; CALCIUM CONCENTRATIONS; DIVALENT-CATIONS; XENOPUS OOCYTES; CELLS; SEQUENCE; EXPRESSION; CA-2+; PROTEINS; HORMONE	MAINTENANCE of a stable internal environment within complex organisms requires specialized cells that sense changes in the extracellular concentration of specific ions (such as Ca2+). Although the molecular nature of such ion sensors is unknown, parathyroid cells possess a cell surface Ca2+-sensing mechanism that also recognizes trivalent and polyvalent cations (such as neomycin) and couples by changes in phosphoinositide turnover and cytosolic Ca2+ to regulation of parathyroid hormone secretion1-4. The latter restores normocalcaemia by acting on kidney and bone2. We now report the cloning of complementary DNA encoding an extracellular Ca2+-sensing receptor from bovine parathyroid with pharmacological and functional properties nearly identical to those of the native receptor. The novel approximately 120K receptor shares limited similarity with the metabotropic glutamate receptors5 and features a large extracellular domain, containing clusters of acidic amino-acid residues possibly involved in calcium binding, coupled to a seven-membrane-spanning domain like those in the G-protein-coupled receptor superfamily.	HARVARD UNIV,SCH MED,CTR STUDY KIDNEY DIS,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DEPT MED,DIV RENAL,MOLEC PHYSIOL & BIOPHYS LAB,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital	BROWN, EM (corresponding author), BRIGHAM & WOMENS HOSP,DEPT MED,DIV ENDOCRINE HYPERTENS,BOSTON,MA 02115, USA.		Centeno, Patricia Pacios/O-8368-2016; Riccardi, Daniela/A-4674-2010; Gamba, Gerardo/P-4873-2016	Riccardi, Daniela/0000-0002-7322-3163; Hediger, Matthias/0000-0003-1946-027X; Gamba, Gerardo/0000-0002-4378-9043; Lytton, Jonathan/0000-0003-4770-2512				ABE T, 1992, J BIOL CHEM, V267, P13361; BAIMBRIDGE KG, 1992, TRENDS NEUROSCI, V15, P303, DOI 10.1016/0166-2236(92)90081-I; BROWN EM, 1991, ENDOCRINOLOGY, V128, P3047, DOI 10.1210/endo-128-6-3047; BROWN EM, 1991, J BONE MINER RES, V6, P1217; BROWN EM, 1991, PHYSIOL REV, V71, P371, DOI 10.1152/physrev.1991.71.2.371; BROWN EM, 1990, ENDOCRINOLOGY, V127, P1064, DOI 10.1210/endo-127-3-1064; DASCAL N, 1987, CRIT REV BIOCHEM MOL, V22, P317, DOI 10.3109/10409238709086960; DRICKAMER K, 1993, CURR OPIN STRUC BIOL, V3, P393, DOI 10.1016/S0959-440X(05)80112-5; FLIEGEL L, 1987, P NATL ACAD SCI USA, V84, P1167, DOI 10.1073/pnas.84.5.1167; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HAWKINS D, 1989, ENDOCRINOLOGY, V124, P838, DOI 10.1210/endo-124-2-838; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; HOUAMED KM, 1991, SCIENCE, V252, P1318, DOI 10.1126/science.1656524; HUMES HD, 1986, KIDNEY, P1491; JUHLIN C, 1990, J BIOL CHEM, V265, P8275; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KEMP BE, 1992, METHOD ENZYMOL, V207, P121; KOZAK M, 1991, J BIOL CHEM, V266, P19867; LECHLEITER J, 1991, SCIENCE, V252, P123, DOI 10.1126/science.2011747; MASU M, 1991, NATURE, V349, P760, DOI 10.1038/349760a0; MORIARTY TM, 1989, J BIOL CHEM, V264, P13524; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; NEMETH EF, 1986, FEBS LETT, V203, P15, DOI 10.1016/0014-5793(86)81427-2; NEMETH EF, 1990, CELL CALCIUM, V11, P323, DOI 10.1016/0143-4160(90)90033-Q; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; SCHOEPP DD, 1993, TRENDS PHARMACOL SCI, V14, P13, DOI 10.1016/0165-6147(93)90107-U; SHOBACK DM, 1988, ENDOCRINOLOGY, V123, P382, DOI 10.1210/endo-123-1-382; SPRENGEL R, 1990, MOL ENDOCRINOL, V4, P525, DOI 10.1210/mend-4-4-525; TANABE Y, 1992, NEURON, V8, P169, DOI 10.1016/0896-6273(92)90118-W; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683	30	2168	2310	1	141	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 9	1993	366	6455					575	580		10.1038/366575a0	http://dx.doi.org/10.1038/366575a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	8255296				2022-12-01	WOS:A1993ML21800073
J	LANDI, G; DALESSANDRO, R; DOSSI, BC; RICCI, S; SIMONE, IL; CICCONE, A				LANDI, G; DALESSANDRO, R; DOSSI, BC; RICCI, S; SIMONE, IL; CICCONE, A			GUILLAIN-BARRE-SYNDROME AFTER EXOGENOUS GANGLIOSIDES IN ITALY	BRITISH MEDICAL JOURNAL			English	Article							THERAPY		POLICLIN S ORSOLA,SERV NEUROL,BOLOGNA,ITALY; OSPED INFERMI,DIV NEUROL,RIMINI,ITALY; OSPED POLICLIN PERUGIA,NEUROL CLIN,PERUGIA,ITALY; UNIV BARI,IST CLIN MALATTIE NERVOSE & MENTALI,I-70124 BARI,ITALY	IRCCS Azienda Ospedaliero-Universitaria di Bologna; Hospital of Rimini; Universita degli Studi di Bari Aldo Moro	LANDI, G (corresponding author), OSPED POLICLIN,NEUROL CLIN,I-20122 MILAN,ITALY.		Ciccone, Alfonso/AAB-6942-2022; Simone, sabella laura/K-9755-2018	Ciccone, Alfonso/0000-0002-4590-3575; Simone, Isabella Laura/0000-0002-7429-3091				FIGUERAS A, 1992, BRIT MED J, V305, P1330, DOI 10.1136/bmj.305.6865.1330; GRANIERI E, 1991, NEUROEPIDEMIOLOGY, V10, P161, DOI 10.1159/000110265; LATOV N, 1991, LANCET, V338, P757, DOI 10.1016/0140-6736(91)91475-A; RASCHETTI R, 1992, LANCET, V340, P60, DOI 10.1016/0140-6736(92)92481-T; VANDERMECHE FGA, 1992, NEW ENGL J MED, V326, P1123, DOI 10.1056/NEJM199204233261705	5	53	59	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1993	307	6917					1463	1464		10.1136/bmj.307.6917.1463	http://dx.doi.org/10.1136/bmj.307.6917.1463			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK797	8281088	Green Published, Bronze			2022-12-01	WOS:A1993MK79700024
J	CORDER, EH; SAUNDERS, AM; STRITTMATTER, WJ; SCHMECHEL, DE; GASKELL, PC; SMALL, GW; ROSES, AD; HAINES, JL; PERICAKVANCE, MA				CORDER, EH; SAUNDERS, AM; STRITTMATTER, WJ; SCHMECHEL, DE; GASKELL, PC; SMALL, GW; ROSES, AD; HAINES, JL; PERICAKVANCE, MA			GENE DOSE OF APOLIPOPROTEIN-E TYPE-4 ALLELE AND THE RISK OF ALZHEIMERS-DISEASE IN LATE-ONSET FAMILIES	SCIENCE			English	Article							LINKAGE; LOCUS; CHROMOSOME-14; PROTEIN	The apolipoprotein E type 4 allele (APOE-epsilon4) is genetically associated with the common late onset familial and sporadic forms of Alzheimer's disease (AD). Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE-epsilon4 alleles in 42 families with late onset AD. Thus APOE-epsilon4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE-epsilon4 was virtually sufficient to cause AD by age 80.	DUKE UNIV,MED CTR,JOSEPH & KATHLEEN BRYAN ALZHEIMERS DIS RES CTR,DEPT MED,DURHAM,NC 27710; DUKE UNIV,MED CTR,JOSEPH & KATHLEEN BRYAN ALZEHEIMERS DIS RES CTR,DEPT NEUROL,DURHAM,NC 27710; DUKE UNIV,MED CTR,JOSEPH & KATHLEEN BRYAN ALZEHEIMERS DIS RES CTR,DEPT NEUROBIOL,DURHAM,NC 27710; VET ADM MED CTR,DURHAM,NC 27705; UNIV CALIF LOS ANGELES,CTR HLTH SCI,NEUROPSYCHIAT INST & HOSP,LOS ANGELES,CA 90024; MASSACHUSETTS GEN HOSP,MOLEC NEUROGENET UNIT,BOSTON,MA 02129	Duke University; Duke University; Duke University; US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California Los Angeles; Harvard University; Massachusetts General Hospital			Zito, Giancarlo/F-9008-2010; Kennedy, Kristen M/B-4699-2008; Haines, Jonathan/C-3374-2012	Kennedy, Kristen M/0000-0001-5373-9026; Haines, Jonathan/0000-0002-4351-4728				CORDER EH, UNPUB; Cox DR., 1984, ANAL SURVIVAL DATA; FARID NR, 1979, J CLIN INVEST, V63, P108, DOI 10.1172/JCI109263; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GREENBERG DA, 1993, AM J HUM GENET, V52, P135; KOCH GG, 1985, ANAL CATEGORICAL DAT; LANGDON N, 1984, LANCET, V2, P1178; Miller R.G., 1981, SURVIVAL ANAL; NAMBA Y, 1991, BRAIN RES, V541, P163, DOI 10.1016/0006-8993(91)91092-F; PERICAKVANCE MA, 1991, AM J HUM GENET, V48, P1034; PERICAKVANCE MA, 1988, EXP NEUROL, V102, P271, DOI 10.1016/0014-4886(88)90220-8; SAUNDERS AM, IN PRESS NEUROLOGY; SCHELLENBERG GD, 1992, SCIENCE, V258, P668, DOI 10.1126/science.1411576; SCHMECHEL DE, IN PRESS; STGEORGEHYSLOP P, 1992, NAT GENET, V2, P330, DOI 10.1038/ng1292-330; STGEORGEHYSLOP PH, 1987, SCIENCE, V235, P885, DOI 10.1126/science.2880399; STRITTMATTER WJ, 1993, P NATL ACAD SCI USA, V90, P1977, DOI 10.1073/pnas.90.5.1977; STRITTMATTER WJ, IN PRESS P NATL ACAD; WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084; WISNIEWSKI T, 1992, NEUROSCI LETT, V135, P235, DOI 10.1016/0304-3940(92)90444-C; 1991, SAS P217 SAS I INC T; 1985, SAS USERS GUIDE STAT; 1988, SAS STAT USERS GUIDE	23	6902	7094	20	676	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 13	1993	261	5123					921	923		10.1126/science.8346443	http://dx.doi.org/10.1126/science.8346443			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR897	8346443				2022-12-01	WOS:A1993LR89700041
J	MCMAHON, HT; USHKARYOV, YA; EDELMANN, L; LINK, E; BINZ, T; NIEMANN, H; JAHN, R; SUDHOF, TC				MCMAHON, HT; USHKARYOV, YA; EDELMANN, L; LINK, E; BINZ, T; NIEMANN, H; JAHN, R; SUDHOF, TC			CELLUBREVIN IS A UBIQUITOUS TETANUS-TOXIN SUBSTRATE HOMOLOGOUS TO A PUTATIVE SYNAPTIC VESICLE FUSION PROTEIN	NATURE			English	Article							MEMBRANE-PROTEIN; SYNAPTOPHYSIN; MICROVESICLES; PC12-CELLS; GENES	TETANUS toxin inhibits neurotransmitter release by selectively blocking fusion of synaptic vesicles1,2. Recently tetanus toxin was shown to proteolytically degrade synaptobrevin II (also named VAMP-2), a synaptic vesicle-specific protein3,4, in vitro and in nerve terminals5,6. As targets of tetanus toxin, synaptobrevins probably function in the exocytotic fusion of synaptic vesicles. Here we describe a new synaptobrevin homologue, cellubrevin, that is present in all cells and tissues tested and demonstrate that it is a membrane trafficking protein of a constitutively recycling pathway. Like synaptobrevin II, cellubrevin is proteolysed by tetanus toxin light chain in vitro and after transfection. Our results suggest that constitutive and regulated vesicular pathways use homologous proteins for membrane trafficking, probably for membrane fusion at the plasma membrane, indicating a greater mechanistic and evolutionary similarity between these pathways than previously thought.	UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED INST,DALLAS,TX 75235; UNIV TEXAS,SW MED CTR,DEPT MED GENET,DALLAS,TX 75235; YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06510; YALE UNIV,DEPT CELL BIOL,NEW HAVEN,CT 06510; YALE UNIV,DEPT PHARMACOL,NEW HAVEN,CT 06510; FED RES CTR VIRUS DIS ANIM,W-7400 TUBINGEN,GERMANY	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Howard Hughes Medical Institute; Yale University; Yale University; Yale University			Ushkaryov, Yuri/AAQ-2985-2020	Ushkaryov, Yuri/0000-0002-5712-8297; Jahn, Reinhard/0000-0003-1542-3498				ARCHER BT, 1990, J BIOL CHEM, V265, P17267; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BURGER PM, 1989, NEURON, V3, P715, DOI 10.1016/0896-6273(89)90240-7; BURGESS TL, 1987, ANNU REV CELL BIOL, V3, P243, DOI 10.1146/annurev.cellbio.3.1.243; BURGESS TL, 1991, A REV CELL BIOL, V1, P388; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; DOTTI CG, 1990, CELL, V62, P63, DOI 10.1016/0092-8674(90)90240-F; EISEL U, 1986, EMBO J, V5, P2495, DOI 10.1002/j.1460-2075.1986.tb04527.x; ELFERINK LA, 1989, J BIOL CHEM, V264, P11061; FAIRWEATHER NF, 1986, NUCLEIC ACIDS RES, V14, P7809, DOI 10.1093/nar/14.19.7809; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; Hubbard AL, 1989, CURR OPIN CELL BIOL, V1, P675, DOI 10.1016/0955-0674(89)90033-1; Huttner W B, 1991, Curr Opin Neurobiol, V1, P388, DOI 10.1016/0959-4388(91)90058-F; JOHNSTON PA, 1989, EMBO J, V8, P2863, DOI 10.1002/j.1460-2075.1989.tb08434.x; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; LINSTEDT AD, 1991, NEURON, V7, P309, DOI 10.1016/0896-6273(91)90269-6; MARSAL J, 1989, P NATL ACAD SCI USA, V86, P372, DOI 10.1073/pnas.86.1.372; MAYCOX PR, 1992, J CELL BIOL, V118, P1379, DOI 10.1083/jcb.118.6.1379; REGNIERVIGOUROUX A, 1991, EMBO J, V10, P3589, DOI 10.1002/j.1460-2075.1991.tb04925.x; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; Simpson L.L., 1989, BOTULINUM NEUROTOXIN; SMYTHE E, 1991, EUR J BIOCHEM, V202, P689, DOI 10.1111/j.1432-1033.1991.tb16424.x; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; SUDHOF TC, 1990, J BIOL CHEM, V265, P1988; SUDHOF TC, 1989, NEURON, V2, P1474; TRIMBLE WS, 1988, P NATL ACAD SCI USA, V85, P4538, DOI 10.1073/pnas.85.12.4538; TRIMBLE WS, 1991, A REV NEUROSCI, V14, P665; [No title captured]	29	430	439	1	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 22	1993	364	6435					346	349		10.1038/364346a0	http://dx.doi.org/10.1038/364346a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	8332193				2022-12-01	WOS:A1993LN57000060
J	GORE, JM; DALEN, JE				GORE, JM; DALEN, JE			CARDIOVASCULAR-DISEASE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article									UNIV ARIZONA,ARIZONA HLTH SCI CTR,TUCSON,AZ 85724	University of Arizona; University of Arizona Health Sciences	GORE, JM (corresponding author), UNIV MASSACHUSETTS,SCH MED,WORCESTER,MA 01605, USA.							DALEN JE, 1992, CHEST S, V102, P3035; GIBBONS RJ, 1993, NEW ENGL J MED, V328, P685, DOI 10.1056/NEJM199303113281003; GRINES CL, 1993, NEW ENGL J MED, V328, P673, DOI 10.1056/NEJM199303113281001; HOBSON RW, 1993, NEW ENGL J MED, V328, P221, DOI 10.1056/NEJM199301283280401; HULLEY SB, 1993, JAMA-J AM MED ASSOC, V269, P1416, DOI 10.1001/jama.269.11.1416; LAROSA JC, 1992, CIRCULATION, V85, P1229, DOI 10.1161/01.CIR.85.3.1229; RAMSAY LE, 1991, BMJ-BRIT MED J, V303, P953, DOI 10.1136/bmj.303.6808.953; WEINTRAUB WS, 1993, AM J CARDIOL, V71, P511, DOI 10.1016/0002-9149(93)90504-6; ZIJLSTRA F, 1993, NEW ENGL J MED, V328, P680, DOI 10.1056/NEJM199303113281002; 1993, CIRCULATION, V87, P323; 1993, LANCET, V341, P573; 1989, ARCH INTERN MED, V149, P2650	12	1	1	1	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 14	1993	270	2					190	192		10.1001/jama.270.2.190	http://dx.doi.org/10.1001/jama.270.2.190			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL368	8315725				2022-12-01	WOS:A1993LL36800011
J	TRAIL, PA; WILLNER, D; LASCH, SJ; HENDERSON, AJ; HOFSTEAD, S; CASAZZA, AM; FIRESTONE, RA; HELLSTROM, I; HELLSTROM, KE				TRAIL, PA; WILLNER, D; LASCH, SJ; HENDERSON, AJ; HOFSTEAD, S; CASAZZA, AM; FIRESTONE, RA; HELLSTROM, I; HELLSTROM, KE			CURE OF XENOGRAFTED HUMAN CARCINOMAS BY BR96-DOXORUBICIN IMMUNOCONJUGATES	SCIENCE			English	Article							MONOCLONAL-ANTIBODIES; LEWIS-A; ANTIGENS; ADRIAMYCIN; INVIVO; CANCER; METHOTREXATE; IMMUNOTOXINS; EXPRESSION; STABILITY	Immunoconjugates (BR96-DOX) were prepared between chimeric monoclonal antibody BR96 and the anticancer drug doxorubicin. The monoclonal antibody binds an antigen related to Lewis Y that is abundantly expressed at the surface of cells from many human carcinomas; it has a high degree of tumor selectivity and is internalized after binding. BR96-DOX induced complete regressions and cures of xenografted human lung, breast, and colon carcinomas growing subcutaneously in athymic mice and cured 70 percent of mice bearing extensive metastases of a human lung carcinoma. Also, BR96-DOX cured 94 percent of athymic rats with subcutaneous human lung carcinoma, even though the rats, like humans and in contrast to mice, expressed the BR96 target antigen in normal tissues.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,WALLINGFORD,CT 06492; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121	Bristol-Myers Squibb; Bristol-Myers Squibb	TRAIL, PA (corresponding author), BRISTOL MYERS SQUIBB PHARMACEUT RES INST,PRINCETON,NJ 08543, USA.							ARNON R, 1982, IMMUNOL REV, V62, P5, DOI 10.1111/j.1600-065X.1982.tb00387.x; BLAKEY DC, 1988, MONOCLONAL ANTIBODY, V45, P50; BRASLAWSKY GR, 1990, CANCER RES, V50, P6608; CARTER SK, 1975, J NATL CANCER I, V55, P1265, DOI 10.1093/jnci/55.6.1265; DILLMAN RO, 1988, CANCER RES, V48, P6097; EICHLER HG, 1991, BIOTHERAPY, V3, P11; FELL HP, 1989, P NATL ACAD SCI USA, V86, P8507, DOI 10.1073/pnas.86.21.8507; FREIREICH EMIL J., 1966, CANCER CHEMOTHERAP REP, V50, P219; FRIEDMAN PN, 1993, J IMMUNOL, V150, P3054; GARRIGUES J, 1993, AM J PATHOL, V142, P607; GOODMAN GE, 1990, J CLIN ONCOL, V8, P1083, DOI 10.1200/JCO.1990.8.6.1083; HELLSTROM I, 1990, CANCER RES, V50, P2183; HELLSTROM I, UNPUB; Hellstrom K., 1991, BIOL THERAPY CANCER, P35; HURWITZ E, 1992, CANCER IMMUNOL IMMUN, V35, P186, DOI 10.1007/BF01756186; KANEKO T, 1991, BIOCONJUGATE CHEM, V2, P133, DOI 10.1021/bc00009a001; KULKARNI PN, 1981, CANCER RES, V41, P2700; LLOYD KO, 1983, IMMUNOGENETICS, V17, P537, DOI 10.1007/BF00696877; ORNTOFT TF, 1989, INT J CANCER, V43, P774, DOI 10.1002/ijc.2910430505; PASTAN I, 1986, CELL, V47, P641, DOI 10.1016/0092-8674(86)90506-4; PIETERSZ GA, 1992, IMMUNOL REV, V129, P57, DOI 10.1111/j.1600-065X.1992.tb01419.x; POUR PM, 1988, CANCER RES, V48, P5422; SAKAMOTO J, 1989, CANCER RES, V49, P745; SHIH LB, 1988, INT J CANCER, V41, P832, DOI 10.1002/ijc.2910410610; THORPE PE, 1987, CANCER RES, V47, P5924; TRAIL PA, 1992, CANCER RES, V52, P5693; TRAIL PA, UNPUB; VITETTA ES, 1987, SCIENCE, V238, P1098, DOI 10.1126/science.3317828; WAWRZYNCZAK EJ, 1991, BRIT J CANCER, V64, P624, DOI 10.1038/bjc.1991.374; WORRELL NR, 1986, ANTI-CANCER DRUG DES, V1, P179; YANG HM, 1988, P NATL ACAD SCI USA, V85, P1189, DOI 10.1073/pnas.85.4.1189; YOUNG RC, 1981, NEW ENGL J MED, V305, P139, DOI 10.1056/NEJM198107163050305	32	420	523	4	56	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 9	1993	261	5118					212	215		10.1126/science.8327892	http://dx.doi.org/10.1126/science.8327892			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL596	8327892				2022-12-01	WOS:A1993LL59600041
J	SCHINDELIN, H; MARAHIEL, MA; HEINEMANN, U				SCHINDELIN, H; MARAHIEL, MA; HEINEMANN, U			UNIVERSAL NUCLEIC ACID-BINDING DOMAIN REVEALED BY CRYSTAL-STRUCTURE OF THE BACILLUS-SUBTILIS MAJOR COLD-SHOCK PROTEIN	NATURE			English	Article							ESCHERICHIA-COLI; DNA-BINDING; SECONDARY STRUCTURE; RIBONUCLEOPROTEIN; RESOLUTION; SEQUENCE	THE cold-shock response in both Escherichia coli and Bacillus subtilis is induced by an abrupt downshift in growth temperature. It leads to the increased production of the major cold-shock proteins, CS7.4 and CspB, respectively1-3. CS7.4 is a transcriptional activator of two genes4,5. CS7.4 and CspB share 43 per cent sequence identity with the nucleic acid-binding domain of the eukaryotic gene-regulatory Y-box factors6. This cold-shock domain is conserved from bacteria to man7 and contains the RNA-binding RNP1 sequence motif8. As a prototype of the cold-shock domain, the structure of CspB has been determined here from two crystal forms. In both, CspB is present as an antiparallel five-stranded beta-barrel. Three consecutive beta-strands, the central one containing the RNP1 motif, create a surface rich in aromatic and basic residues that are presumably involved in nucleic acid binding. Preferential binding of CspB to single-stranded DNA is observed in gel retardation experiments.	PHILIPPS UNIV MARBURG,BIOCHEMIE FB CHEM,D-35043 MARBURG,GERMANY	Philipps University Marburg	SCHINDELIN, H (corresponding author), FREE UNIV BERLIN,INST KRISTALLOG,TAKUSTR 6,D-14195 BERLIN,GERMANY.		Heinemann, Udo/S-3379-2016; Schindelin, Hermann/Q-2697-2019; Heinemann, Udo/AAH-4766-2019	Heinemann, Udo/0000-0002-8191-3850; Heinemann, Udo/0000-0002-8191-3850				BRAYER GD, 1983, J MOL BIOL, V169, P565, DOI 10.1016/S0022-2836(83)80065-5; BRENNAN CA, 1991, J BIOL CHEM, V266, P17296; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; CRAWFORD DR, 1987, DEVELOPMENT, V101, P741; FOLKERS PJM, 1991, EUR J BIOCHEM, V202, P349, DOI 10.1111/j.1432-1033.1991.tb16382.x; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; GOLDSTEIN J, 1990, P NATL ACAD SCI USA, V87, P283, DOI 10.1073/pnas.87.1.283; HYNES TR, 1991, PROTEINS, V10, P92, DOI 10.1002/prot.340100203; JONES PG, 1987, J BACTERIOL, V169, P2092, DOI 10.1128/jb.169.5.2092-2095.1987; JONES PG, 1992, J BACTERIOL, V174, P5798, DOI 10.1128/jb.174.18.5798-5802.1992; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDSMAN D, 1992, NUCLEIC ACIDS RES, V20, P2861, DOI 10.1093/nar/20.11.2861; LATEANA A, 1991, P NATL ACAD SCI USA, V88, P10907, DOI 10.1073/pnas.88.23.10907; MERRIL CR, 1981, SCIENCE, V211, P1437, DOI 10.1126/science.6162199; MERRILL BM, 1988, J BIOL CHEM, V263, P3307; MURRAY MT, 1991, J CELL BIOL, V12, P1; MURZIN AG, 1993, EMBO J, V12, P861, DOI 10.1002/j.1460-2075.1993.tb05726.x; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; Pope M.T., 1983, HETEROPOLY ISOPOLY O; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; Richardson J S, 1981, Adv Protein Chem, V34, P167, DOI 10.1016/S0065-3233(08)60520-3; SCHINDELIN H, 1992, PROTEINS, V14, P120, DOI 10.1002/prot.340140113; SCHNUCHEL A, 1993, NATURE, V364; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WILLIMSKY G, 1992, J BACTERIOL, V174, P6326, DOI 10.1128/JB.174.20.6326-6335.1992; WISTOW G, 1990, NATURE, V344, P823, DOI 10.1038/344823c0; WOLFFE AP, 1992, NEW BIOL, V4, P290; 1979, CCP4 SERC DAR LAB CO	30	325	330	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 8	1993	364	6433					164	168		10.1038/364164a0	http://dx.doi.org/10.1038/364164a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL367	8321288				2022-12-01	WOS:A1993LL36700055
J	FOISNER, R; GERACE, L				FOISNER, R; GERACE, L			INTEGRAL MEMBRANE-PROTEINS OF THE NUCLEAR-ENVELOPE INTERACT WITH LAMINS AND CHROMOSOMES, AND BINDING IS MODULATED BY MITOTIC PHOSPHORYLATION	CELL			English	Article							INTERMEDIATE FILAMENT PROTEINS; PORE COMPLEX; CHROMATIN INVITRO; XENOPUS EGGS; CDC2 KINASE; B-RECEPTOR; MITOSIS; ANTIBODIES; INTERPHASE; FRACTION	Lamina-associated polypeptides (LAPs) 1A, 1B, 1C, and 2 are integral membrane proteins of the nuclear envelope associated with the nuclear lamina. Using in vitro assays, we show that LAPs 1A and 1B specifically bind to both lamins A and C and lamin B1, while LAP 2 associates only with lamin B1. LAP 2 also binds to mitotic chromosomes. The LAPs are phosphorylated during mitosis, and phosphorylation of LAP 2 by mitotic cytosol inhibits its binding to both lamin B1 and chromosomes. During late anaphase, LAP 2 associates with chromosomes prior to assembly of most lamins. Together, these data suggest that LAP 2 may have a key role in initial events of nuclear envelope reassembly, and that both LAP 2 and LAP 1 may be involved in attaching lamins to the nuclear envelope.	Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute			Foisner, Roland/AAD-1833-2019	Foisner, Roland/0000-0003-4734-4647				AEBI U, 1986, NATURE, V323, P560, DOI 10.1038/323560a0; BAILER SM, 1991, J CELL BIOL, V114, P389, DOI 10.1083/jcb.114.3.389; BENAVENTE R, 1986, J CELL BIOL, V103, P1847, DOI 10.1083/jcb.103.5.1847; BENAVENTE R, 1989, EUR J CELL BIOL, V50, P209; BOMAN AL, 1992, J CELL BIOL, V116, P281, DOI 10.1083/jcb.116.2.281; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRANTON D, 1981, CELL, V24, P24, DOI 10.1016/0092-8674(81)90497-9; BURKE B, 1990, EXP CELL RES, V186, P169, DOI 10.1016/0014-4827(90)90223-W; BURKE B, 1986, CELL, V44, P639, DOI 10.1016/0092-8674(86)90273-4; Burke B, 1990, CURR OPIN CELL BIOL, V2, P514, DOI 10.1016/0955-0674(90)90136-3; DABAUVALLE MC, 1991, J CELL BIOL, V112, P1073, DOI 10.1083/jcb.112.6.1073; DESSEV G N, 1992, Current Opinion in Cell Biology, V4, P430, DOI 10.1016/0955-0674(92)90008-Z; DWYER N, 1976, J CELL BIOL, V70, P581, DOI 10.1083/jcb.70.3.581; ERLANDSON RA, 1971, J CELL SCI, V8, P353; FOISNER R, 1988, J CELL BIOL, V106, P723, DOI 10.1083/jcb.106.3.723; FRANKE WW, 1987, CELL, V48, P3, DOI 10.1016/0092-8674(87)90345-X; GERACE L, 1982, J CELL BIOL, V95, P826, DOI 10.1083/jcb.95.3.826; GERACE L, 1992, Current Opinion in Cell Biology, V4, P637, DOI 10.1016/0955-0674(92)90083-O; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; GERACE L, 1988, ANNU REV CELL BIOL, V4, P335, DOI 10.1146/annurev.cb.04.110188.002003; GLASS JR, 1990, J CELL BIOL, V111, P1047, DOI 10.1083/jcb.111.3.1047; HAREL A, 1989, J CELL SCI, V94, P463; HOGER TH, 1991, EXP CELL RES, V197, P280, DOI 10.1016/0014-4827(91)90434-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUDERUS MEE, 1992, CELL, V70, P949, DOI 10.1016/0092-8674(92)90245-8; MATSUURA S, 1981, J CELL BIOL, V91, P212, DOI 10.1083/jcb.91.1.212; MEIER J, 1991, J CELL SCI, V98, P271; MURRAY RG, 1965, J CELL BIOL, V26, P601, DOI 10.1083/jcb.26.2.601; NEWPORT JW, 1990, J CELL BIOL, V111, P2247, DOI 10.1083/jcb.111.6.2247; NIGG E A, 1992, Current Opinion in Cell Biology, V4, P105, DOI 10.1016/0955-0674(92)90066-L; Nigg EA, 1989, CURR OPIN CELL BIOL, V1, P435, DOI 10.1016/0955-0674(89)90002-1; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; PADAN R, 1990, J BIOL CHEM, V265, P7808; PADDY MR, 1990, CELL, V62, P89, DOI 10.1016/0092-8674(90)90243-8; PETER M, 1990, CELL, V61, P591, DOI 10.1016/0092-8674(90)90471-P; PETER M, 1991, EMBO J, V10, P1535, DOI 10.1002/j.1460-2075.1991.tb07673.x; PFALLER R, 1991, CELL, V65, P209, DOI 10.1016/0092-8674(91)90155-R; POWELL L, 1990, J CELL BIOL, V111, P2225, DOI 10.1083/jcb.111.6.2225; ROBBINS E, 1964, J CELL BIOL, V21, P429, DOI 10.1083/jcb.21.3.429; SENIOR A, 1988, J CELL BIOL, V107, P2029, DOI 10.1083/jcb.107.6.2029; SHOEMAN RL, 1990, J BIOL CHEM, V265, P9055; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143; STICK R, 1988, J CELL BIOL, V107, P397, DOI 10.1083/jcb.107.2.397; ULITZUR N, 1992, J CELL BIOL, V119, P17, DOI 10.1083/jcb.119.1.17; VIGERS GPA, 1991, J CELL BIOL, V112, P545, DOI 10.1083/jcb.112.4.545; WORMAN HJ, 1990, J CELL BIOL, V111, P1535, DOI 10.1083/jcb.111.4.1535; WORMAN HJ, 1988, P NATL ACAD SCI USA, V85, P8531, DOI 10.1073/pnas.85.22.8531; YUAN J, 1991, J BIOL CHEM, V266, P9211	48	457	467	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 2	1993	73	7					1267	1279		10.1016/0092-8674(93)90355-T	http://dx.doi.org/10.1016/0092-8674(93)90355-T			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LL209	8324822				2022-12-01	WOS:A1993LL20900004
J	VERA, JC; RIVAS, CI; FISCHBARG, J; GOLDE, DW				VERA, JC; RIVAS, CI; FISCHBARG, J; GOLDE, DW			MAMMALIAN FACILITATIVE HEXOSE TRANSPORTERS MEDIATE THE TRANSPORT OF DEHYDROASCORBIC ACID	NATURE			English	Article							BORDER MEMBRANE-VESICLES; XENOPUS-LAEVIS OOCYTES; L-ASCORBATE TRANSPORT; GLUCOSE-TRANSPORTER; FUNCTIONAL EXPRESSION; LEUKOCYTES; KIDNEY; FIBROBLASTS; DEFICIENCY; INTESTINE	ALTHOUGH vitamin C is critical to human physiology1-5, it is not clear how it is taken up into cells. The kinetics of cell and tissue accumulation of ascorbic acid in vitro indicate that the process is mediated by specific transporters at the cell membrane6. Some experimental observations have linked the transport of ascorbic acid with hexose transport systems in mammalian cells, although no clear information is available regarding the specific role(s) of these transporters, if any, in this process7-16. Here we use the Xenopus laevis oocyte expression system to show that the mammalian facilitative hexose transporters are efficient transporters of the oxidized form of vitamin C (dehydroascorbic acid). Two transport pathways, one with low affinity and one with high affinity for dehydroascorbic acid, were found in oocytes expressing the mammalian transporters, and these oocytes accumulated vitamin C against a concentration gradient when supplied with dehydroascorbic acid. We obtained similar results in experiments using normal human neutrophils. These observations indicate that mammalian facilitative hexose transporters are a physiologically significant pathway for the uptake and accumulation of vitamin C by cells, and suggest a mechanism for the accumulation of ascorbic acid against a concentration gradient.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PHYSIOL & CELLULAR BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT OPHTHALMOL,NEW YORK,NY 10032	Columbia University; Columbia University	VERA, JC (corresponding author), MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC PHARMACOL & THERAPEUT,1275 YORK AVE,NEW YORK,NY 10021, USA.		Alshali, Rasha A/K-8051-2012					BERGSTEN P, 1990, J BIOL CHEM, V265, P2584; BIANCHI J, 1986, AM J PHYSIOL, V250, pG461, DOI 10.1152/ajpgi.1986.250.4.G461; BIGLEY R, 1983, DIABETES, V32, P545, DOI 10.2337/diabetes.32.6.545; BIGLEY RH, 1974, J EXP MED, V139, P1084, DOI 10.1084/jem.139.5.1084; BIRNBAUM MJ, 1986, P NATL ACAD SCI USA, V83, P5784, DOI 10.1073/pnas.83.16.5784; Crandon JH, 1940, NEW ENGL J MED, V223, P353, DOI 10.1056/NEJM194009052231001; DHARIWAL KR, 1991, AM J CLIN NUTR, V54, P712, DOI 10.1093/ajcn/54.4.712; ENGLARD S, 1986, ANNU REV NUTR, V6, P365, DOI 10.1146/annurev.nu.06.070186.002053; HODGES RE, 1969, AM J CLIN NUTR, V22, P535; HODGES RE, 1971, AM J CLIN NUTR, V24, P432; INGERMANN RL, 1986, AM J PHYSIOL, V250, pC637, DOI 10.1152/ajpcell.1986.250.4.C637; JUNG CY, 1977, J BIOL CHEM, V252, P5456; MCLENNAN S, 1988, DIABETES, V37, P359, DOI 10.2337/diabetes.37.3.359; MOSER U, 1984, INT J VITAM NUTR RES, V54, P47; OKA Y, 1990, NATURE, V345, P550, DOI 10.1038/345550a0; PADH H, 1990, BIOCHEM CELL BIOL, V68, P1166, DOI 10.1139/o90-173; PADH H, 1987, BIOCHIM BIOPHYS ACTA, V901, P283, DOI 10.1016/0005-2736(87)90125-8; RAGHOEBAR M, 1987, LIFE SCI, V40, P499, DOI 10.1016/0024-3205(87)90117-2; ROSE RC, 1988, BIOCHIM BIOPHYS ACTA, V947, P335, DOI 10.1016/0304-4157(88)90014-7; ROSE RC, 1986, AM J PHYSIOL, V250, pF627, DOI 10.1152/ajprenal.1986.250.4.F627; SILIPRANDI L, 1979, BIOCHIM BIOPHYS ACTA, V552, P129, DOI 10.1016/0005-2736(79)90252-9; THORENS B, 1988, CELL, V55, P281, DOI 10.1016/0092-8674(88)90051-7; TOGGENBURGER G, 1981, BIOCHIM BIOPHYS ACTA, V646, P433, DOI 10.1016/0005-2736(81)90312-6; VERA JC, 1990, MOL CELL BIOL, V10, P743, DOI 10.1128/MCB.10.2.743; VERA JC, 1989, MOL CELL BIOL, V9, P4187, DOI 10.1128/MCB.9.10.4187; WASKHO P, 1992, J BIOL CHEM, V267, P23568; WEASHKO P, 1989, J BIOL CHEM, V284, P18996; WHEELER TJ, 1985, ANNU REV PHYSIOL, V47, P503, DOI 10.1146/annurev.ph.47.030185.002443; WILSON JX, 1989, J MEMBRANE BIOL, V111, P83, DOI 10.1007/BF01869211; WINKLER BS, 1987, BIOCHIM BIOPHYS ACTA, V925, P258, DOI 10.1016/0304-4165(87)90190-5; WUNDERLING M, 1986, BIOL CHEM H-S, V367, P1047, DOI 10.1515/bchm3.1986.367.2.1047	31	430	437	0	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 1	1993	364	6432					79	82		10.1038/364079a0	http://dx.doi.org/10.1038/364079a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK818	8316303				2022-12-01	WOS:A1993LK81800063
J	KARIO, K; MATSUO, T				KARIO, K; MATSUO, T			RELATION BETWEEN SIALIC-ACID CONCENTRATIONS AND THE HEMOSTATIC SYSTEM IN THE ELDERLY	BRITISH MEDICAL JOURNAL			English	Article									HYOGO PREFECTURAL AWAJI HOSP,DEPT INTERNAL MED,SUMOTO,HYOGO 656,JAPAN		KARIO, K (corresponding author), AWAJI HOKUTAN PUBL CLIN,DEPT INTERNAL MED,HOKUTAN,HYOGO 65616,JAPAN.							LINDBERG G, 1991, BRIT MED J, V303, P1306, DOI 10.1136/bmj.303.6813.1306; LINDBERG G, 1991, BRIT MED J, V302, P143, DOI 10.1136/bmj.302.6769.143; MEADE T W, 1987, Blood Reviews, V1, P2, DOI 10.1016/0268-960X(87)90013-0; SUGAHARA K, 1980, CLIN CHIM ACTA, V108, P493, DOI 10.1016/0009-8981(80)90360-5; WAKABAYASHI I, 1992, BRIT MED J, V305, P562, DOI 10.1136/bmj.305.6853.562	5	19	19	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1993	306	6893					1650	1651		10.1136/bmj.306.6893.1650	http://dx.doi.org/10.1136/bmj.306.6893.1650			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LJ337	8324435	Bronze, Green Published			2022-12-01	WOS:A1993LJ33700022
J	FROEHLING, DA; SILVERSTEIN, MD; MOHR, DN; BEATTY, CW				FROEHLING, DA; SILVERSTEIN, MD; MOHR, DN; BEATTY, CW			DOES THIS DIZZY PATIENT HAVE A SERIOUS FORM OF VERTIGO	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PAROXYSMAL POSITIONAL VERTIGO; AMBULATORY CARE; DIZZINESS; NYSTAGMUS		MAYO CLIN & MAYO FDN,DIV AREA GEN INTERNAL MED,200 1ST ST SW,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT HLTH SCI RES,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT OTORHINOLARYNGOL,ROCHESTER,MN 55905	Mayo Clinic; Mayo Clinic; Mayo Clinic								Aantaa E, 1979, Acta Otorhinolaryngol Belg, V33, P401; ADAMS RD, 1985, PRINCIPLES NEUROLOGY, P216; ADAMS RD, 1985, PRINCIPLES NEUROLOGY, P552; ALFORD B R, 1972, Transactions of the American Academy of Ophthalmology and Oto-Laryngology, V76, P1462; Baloh R W, 1979, Am J Otolaryngol, V1, P1, DOI 10.1016/S0196-0709(79)80002-2; BALOH RW, 1987, NEUROLOGY, V37, P371, DOI 10.1212/WNL.37.3.371; Barber H O, 1973, Otolaryngol Clin North Am, V6, P169; BERKOWITZ BW, 1985, ARCH NEUROL-CHICAGO, V42, P874, DOI 10.1001/archneur.1985.04060080056016; DIX MR, 1952, P ROY SOC MED, V45, P341, DOI 10.1177/003591575204500604; DRACHMAN DA, 1972, NEUROLOGY, V22, P323, DOI 10.1212/WNL.22.4.323; FISHER CM, 1967, ARCHIV OTOLARYNGOL, V85, P529; Frederic M W, 1973, Otolaryngol Clin North Am, V6, P267; FROEHLING DA, 1991, MAYO CLIN PROC, V66, P596, DOI 10.1016/S0025-6196(12)60518-7; HARBERT F, 1970, ARCH OPHTHALMOL-CHIC, V84, P298; HARNER SG, 1981, NEUROSURGERY, V9, P373, DOI 10.1227/00006123-198110000-00004; HERR RD, 1989, ANN EMERG MED, V18, P664, DOI 10.1016/S0196-0644(89)80524-4; JACKSON GG, 1971, J INFECT DIS, V124, pS130, DOI 10.1093/infdis/124.Supplement_1.S130; KATSARKAS A, 1978, J OTOLARYNGOL, V7, P320; KELLY JP, 1985, PRINCIPLES NEURAL SC, P591; KROENKE K, 1989, AM J MED, V86, P262, DOI 10.1016/0002-9343(89)90293-3; KROENKE K, 1992, ANN INTERN MED, V117, P898, DOI 10.7326/0003-4819-117-11-898; LACHMAN J, 1967, NEUROLOGY, V17, P376, DOI 10.1212/WNL.17.4.376; LEHRER J F, 1987, Comprehensive Therapy, V13, P31; LELIEVER WC, 1981, LARYNGOSCOPE, V91, P1; MAGARIAN GJ, 1982, MEDICINE, V61, P219, DOI 10.1097/00005792-198207000-00002; MOHR DN, 1986, WESTERN J MED, V145, P645; MYLEN CO, 1950, J LARYNGOL OTOL, V64, P295; NEDZELSKI JM, 1986, J OTOLARYNGOL, V15, P101; NYLEN CO, 1939, ACTA OTO-LARYNGOL, V33, P5; OLSSON JE, 1987, OTOLARYNG CLIN N AM, V20, P83; PLUM F, 1980, DIAGNOSIS STUPOR COM, P58; Pulec J L, 1973, Otolaryngol Clin North Am, V6, P25; ROWLAND LP, 1985, PRINCIPLES NEURAL SC, P599; SCHUKNECHT HF, 1969, ARCH OTOLARYNGOL, V90, P765; Silvoniemi P, 1988, Acta Otolaryngol Suppl, V453, P1; SLATER R, 1979, J NEUROL NEUROSUR PS, V42, P363, DOI 10.1136/jnnp.42.4.363; THOMAS JE, 1981, MAYO CLIN PROC, V56, P17; VERNICK DM, 1987, OFFICE PRACTICE MED, P291; WATSON P, 1981, CAN J NEUROL SCI, V8, P133, DOI 10.1017/S0317167100043031; WOODWELL DA, 1992, ADV DATA, V209, P1; 1981, CLIN EXAMINATIONS NE, P63; 1986, WEBSTERS 3RD NEW INT, P664	42	39	39	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 2	1994	271	5					385	388		10.1001/jama.271.5.385	http://dx.doi.org/10.1001/jama.271.5.385			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR983	8283588				2022-12-01	WOS:A1994MR98300035
J	FENG, JA; JOHNSON, RC; DICKERSON, RE				FENG, JA; JOHNSON, RC; DICKERSON, RE			HIN RECOMBINASE BOUND TO DNA - THE ORIGIN OF SPECIFICITY IN MAJOR AND MINOR-GROOVE INTERACTIONS	SCIENCE			English	Article							REPRESSOR-OPERATOR COMPLEX; CRYSTAL-STRUCTURE; BINDING DOMAIN; STRAND EXCHANGE; TRP REPRESSOR; RESOLUTION; PROTEIN; RECOGNITION; HOMEODOMAIN; ENHANCER	The structure of the 52-amino acid DNA-binding domain of prokaryotic Hin recombinase, complexed with a DNA recombination half-site, has been solved by x-ray crystallography at 2.3 angstrom resolution. The Hin domain consists of a three-alpha-helix bundle, with the carboxyl-terminal helix inserted into the major groove of DNA, and two flanking extended polypeptide chains that contact bases in the minor groove. The overall structure displays features resembling both a prototypical bacterial helix-turn-helix and the eukaryotic homeodomain, and in many respects is an intermediate between these two DNA-binding binding motifs. In addition, a new structural motif is seen: the six-amino acid carboxyl-terminal peptide of the Hin domain runs along the minor groove at the edge of the recombination site, with the peptide backbone facing the floor of the groove and side chains extending away toward the exterior. The x-ray structure provides an almost complete explanation for DNA mutant binding studies in the Hin system and for DNA specificity observed in the Hin-related family of DNA invertases.	UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90024; UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90024	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038509, R01GM038509, P01GM031299] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-38509, GM-31299] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AFFOLTER M, 1991, CELL, V64, P879, DOI 10.1016/0092-8674(91)90311-L; AGGARWAL AK, 1988, SCIENCE, V242, P899, DOI 10.1126/science.3187531; ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; BRUIST MF, 1987, SCIENCE, V235, P777, DOI 10.1126/science.3027895; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; COLL M, 1987, P NATL ACAD SCI USA, V84, P8385, DOI 10.1073/pnas.84.23.8385; DEKKER N, 1993, NATURE, V362, P852, DOI 10.1038/362852a0; DREW HR, 1981, P NATL ACAD SCI-BIOL, V78, P2179, DOI 10.1073/pnas.78.4.2179; FENG JA, 1993, J MOL BIOL, V232, P982, DOI 10.1006/jmbi.1993.1443; GLASGOW AC, 1989, J BIOL CHEM, V264, P10072; GLASGOW AC, 1989, MOBILE DNA, P637; GRZESKOWIAK K, 1991, J BIOL CHEM, V266, P8861; HARAN TE, 1992, EMBO J, V11, P3021, DOI 10.1002/j.1460-2075.1992.tb05372.x; HARRISON SC, 1990, ANNU REV BIOCHEM, V59, P933, DOI 10.1146/annurev.biochem.59.1.933; HEICHMAN KA, 1991, GENE DEV, V5, P1622, DOI 10.1101/gad.5.9.1622; HEICHMAN KA, 1990, SCIENCE, V249, P511, DOI 10.1126/science.2166334; HUGHES KT, 1992, EMBO J, V11, P2695, DOI 10.1002/j.1460-2075.1992.tb05335.x; JOHNSON RC, 1985, CELL, V41, P781, DOI 10.1016/S0092-8674(85)80059-3; JOHNSON RC, 1989, EMBO J, V8, P1581, DOI 10.1002/j.1460-2075.1989.tb03542.x; Johnson RC, 1991, CURR OPIN GENET DEV, V1, P404, DOI 10.1016/S0959-437X(05)80307-7; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KISSINGER CR, 1990, CELL, V63, P579, DOI 10.1016/0092-8674(90)90453-L; KOPKA ML, 1985, J MOL BIOL, V183, P553, DOI 10.1016/0022-2836(85)90171-8; KOPKA ML, 1985, P NATL ACAD SCI USA, V82, P1376, DOI 10.1073/pnas.82.5.1376; KOSTREWA D, 1991, NATURE, V349, P178, DOI 10.1038/349178a0; MACK DP, 1990, BIOCHEMISTRY-US, V29, P6561, DOI 10.1021/bi00480a003; MONDRAGON A, 1991, J MOL BIOL, V219, P321, DOI 10.1016/0022-2836(91)90568-Q; MOSKOWITZ IPG, 1991, GENE DEV, V5, P1635, DOI 10.1101/gad.5.9.1635; NELSON HCM, 1987, NATURE, V330, P221, DOI 10.1038/330221a0; OGATA K, 1992, P NATL ACAD SCI USA, V89, P6428, DOI 10.1073/pnas.89.14.6428; OTTING G, 1990, EMBO J, V9, P3085, DOI 10.1002/j.1460-2075.1990.tb07505.x; OTWINOWSKI Z, 1988, NATURE, V335, P321, DOI 10.1038/335321a0; PRIVE GG, 1991, J MOL BIOL, V217, P117; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; ROULD MA, 1992, ACTA CRYSTALLOGR A, V48, P751, DOI 10.1107/S0108767392003404; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SLUKA JP, 1990, BIOCHEMISTRY-US, V29, P6551, DOI 10.1021/bi00480a002; SLUKA JP, 1987, SCIENCE, V238, P1129, DOI 10.1126/science.3120311; SOMERS WS, 1992, NATURE, V359, P387, DOI 10.1038/359387a0; STEITZ TA, 1990, Q REV BIOPHYS, V23, P205, DOI 10.1017/S0033583500005552; SUZUKI M, 1989, EMBO J, V8, P797, DOI 10.1002/j.1460-2075.1989.tb03440.x; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WOLBERGER C, 1991, CELL, V67, P517, DOI 10.1016/0092-8674(91)90526-5; YUAN HS, 1991, P NATL ACAD SCI USA, V88, P9558, DOI 10.1073/pnas.88.21.9558; ZHANG KYJ, 1990, ACTA CRYSTALLOGR A, V46, P377, DOI 10.1107/S0108767389012158	49	178	187	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 21	1994	263	5145					348	355		10.1126/science.8278807	http://dx.doi.org/10.1126/science.8278807			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT034	8278807				2022-12-01	WOS:A1994MT03400025
J	LAM, PYS; JADHAV, PK; EYERMANN, CJ; HODGE, CN; RU, Y; BACHELER, LT; MEEK, JL; OTTO, MJ; RAYNER, MM; WONG, YN; CHANG, CH; WEBER, PC; JACKSON, DA; SHARPE, TR; ERICKSONVIITANEN, S				LAM, PYS; JADHAV, PK; EYERMANN, CJ; HODGE, CN; RU, Y; BACHELER, LT; MEEK, JL; OTTO, MJ; RAYNER, MM; WONG, YN; CHANG, CH; WEBER, PC; JACKSON, DA; SHARPE, TR; ERICKSONVIITANEN, S			RATIONAL DESIGN OF POTENT, BIOAVAILABLE, NONPEPTIDE CYCLIC UREAS AS HIV PROTEASE INHIBITORS	SCIENCE			English	Article							HUMAN IMMUNODEFICIENCY VIRUS-1; HOST GUEST COMPLEXATION; CRYSTAL-STRUCTURE; TYPE-1 PROTEASE; PROTEINASE; RESOLUTION; BINDING; ISOSTERE; LIGAND; AIDS	Mechanistic information and structure-based design methods have been used to design a series of nonpeptide cyclic ureas that are potent inhibitors of human immunodeficiency virus (HIV) protease and HIV replication. A fundamental feature of these inhibitors is the cyclic urea carbonyl oxygen that mimics the hydrogen-bonding features of a key structural water molecule. The success of the design in both displacing and mimicking the structural water molecule was confirmed by x-ray crystallographic studies. Highly selective, preorganized inhibitors with relatively low molecular weight and high oral bioavailability were synthesized.	DUPONT MERCK PHARMACEUT CO, DEPT CHEM & PHYS SCI, WILMINGTON, DE 19880 USA	DuPont	LAM, PYS (corresponding author), DUPONT MERCK PHARMACEUT CO, DEPT VIROL RES, WILMINGTON, DE 19880 USA.							ALLEN FH, 1991, J CHEM INF COMP SCI, V31, P187, DOI 10.1021/ci00002a004; ANDREETTI GD, 1974, CRYST STRUCT COMMUN, V3, P145; BABINE RE, 1992, BIOORG MED CHEM LETT, V2, P541, DOI 10.1016/S0960-894X(01)81194-X; BACHELER L, IN PRESS ANTIVIRAL C; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BLANEY JM, DGEOM590 QUANT CHEM; BLUNDELL TL, 1990, TRENDS BIOCHEM SCI, V15, P425, DOI 10.1016/0968-0004(90)90280-O; BONE R, 1991, J AM CHEM SOC, V113, P9382, DOI 10.1021/ja00024a061; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; BURES MG, 1990, TETRAHEDRON COMP MET, V3, P673; CALABRESE JC, UNPUB; CHENG YSE, 1990, P NATL ACAD SCI USA, V87, P9660, DOI 10.1073/pnas.87.24.9660; CRAM DJ, 1986, TETRAHEDRON, V42, P1607, DOI 10.1016/S0040-4020(01)87577-3; CRAM DJ, 1988, SCIENCE, V240, P760, DOI 10.1126/science.3283937; CRAM DJ, 1984, J AM CHEM SOC, V106, P7150, DOI 10.1021/ja00335a049; CRAM DJ, 1985, J AM CHEM SOC, V107, P3657, DOI 10.1021/ja00298a041; DEBOUCK C, 1992, AIDS RES HUM RETROV, V8, P153, DOI 10.1089/aid.1992.8.153; DESJARLAIS RL, 1990, P NATL ACAD SCI USA, V87, P6644, DOI 10.1073/pnas.87.17.6644; DREYER GB, 1993, BIOCHEMISTRY-US, V32, P937, DOI 10.1021/bi00054a027; DREYER GB, 1992, BIOCHEMISTRY-US, V31, P6646, DOI 10.1021/bi00144a004; DUEWEKE TJ, 1993, P NATL ACAD SCI USA, V90, P4713, DOI 10.1073/pnas.90.10.4713; ERICKSON J, 1990, SCIENCE, V249, P527, DOI 10.1126/science.2200122; ERICKSONVIITANEN S, 1989, AIDS RES HUM RETROV, V5, P577, DOI 10.1089/aid.1989.5.577; EYERMANN CJ, UNPUB; FITZGERALD PMD, 1990, J BIOL CHEM, V265, P14209; GETMAN DP, 1993, J MED CHEM, V36, P288, DOI 10.1021/jm00054a014; GHOSH AK, 1993, J MED CHEM, V36, P292, DOI 10.1021/jm00054a015; GREENLEE WJ, 1990, MED RES REV, V10, P173, DOI 10.1002/med.2610100203; GUTSCHINA A, 1990, FEBS LETT, V269, P269; HOLMES DS, 1993, BIOORG MED CHEM LETT, V3, P503, DOI 10.1016/S0960-894X(01)81216-6; IKEDA S, 1992, J AM CHEM SOC, V114, P7604, DOI 10.1021/ja00045a067; IWAKURA Y, 1992, AIDS, V6, P1069, DOI 10.1097/00002030-199210000-00002; JADHAV PK, 1991, Patent No. 9118866; JASKOLSKI M, 1991, BIOCHEMISTRY-US, V30, P1600, DOI 10.1021/bi00220a023; JOHNSON F, 1968, CHEM REV, V68, P375, DOI 10.1021/cr60254a001; JONAK G, UNPUB; KEMPF DJ, 1993, J MED CHEM, V36, P320, DOI 10.1021/jm00055a003; KLEINERT HD, 1992, SCIENCE, V257, P1940, DOI 10.1126/science.1411510; KUNTZ ID, 1982, J MOL BIOL, V161, P269, DOI 10.1016/0022-2836(82)90153-X; LAI MHT, 1993, J ACQ IMMUN DEF SYND, V6, P24; LAM PM, UNPUB; LAM PYS, 1993, Patent No. 9307128; LAPATTO R, 1989, NATURE, V342, P299, DOI 10.1038/342299a0; March J., 1985, ADV ORGANIC CHEM REA, P125; MARTIN JA, 1992, ANTIVIR RES, V17, P265, DOI 10.1016/0166-3542(92)90022-W; MARTIN YC, 1992, J MED CHEM, V35, P2145, DOI 10.1021/jm00090a001; MILLER M, 1989, SCIENCE, V246, P1149, DOI 10.1126/science.2686029; MUIRHEAD GJ, 1992, P BRIT PHARM SOC, P170; NORBECK DW, 1991, ANNU REP MED CHEM, V26, P141; OTTO MJ, 1993, 2ND INT WORKSH HIV D; OTTO MJ, 1992, 8TH INT C AIDS AMST, V1, P203; PLATTNER JJ, 1990, DRUG DISCOVERY TECHN, P92; RAYNER M, UNPUB; RICH DH, 1992, J MED CHEM, V35, P3803, DOI 10.1021/jm00099a008; RIPKA WC, 1993, 2ND P INT C CHEM INF, P303; ROSENBERG SH, 1993, J MED CHEM, V36, P449, DOI 10.1021/jm00056a005; SCHATZL H, 1991, ARCH VIROL, V120, P71, DOI 10.1007/BF01310950; SHAW TM, 1992, P BRIT PHARM SOC, P167; SMALLHEER JM, 1993, IN PRESS ANTIVIRAL C, V4, P27; SWAIN AL, 1990, P NATL ACAD SCI USA, V87, P8805, DOI 10.1073/pnas.87.22.8805; THANKI N, 1992, PROTEIN SCI, V1, P1061, DOI 10.1002/pro.5560010811; THOMPSON WJ, 1993, J AM CHEM SOC, V115, P801, DOI 10.1021/ja00055a069; TIMASHEFF SN, 1992, BIOCHEMISTRY-US, V31, P9857, DOI 10.1021/bi00156a001; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5633; TOMASSELLI AG, 1991, CHEM TODAY       MAY, P6; TUCKER TJ, 1992, J MED CHEM, V35, P2525, DOI 10.1021/jm00092a002; VANDRIE JH, 1989, J COMPUT AID MOL DES, V3, P225, DOI 10.1007/BF01533070; WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722; WILLIAMS PEO, 1992, P BRIT PHARM SOC, P156; WLODAWER A, 1993, ANNU REV BIOCHEM, V62, P543, DOI 10.1146/annurev.bi.62.070193.002551; WLODAWER A, 1989, SCIENCE, V245, P616, DOI 10.1126/science.2548279; YARCHOAN R, 1993, TRENDS PHARMACOL SCI, V14, P196, DOI 10.1016/0165-6147(93)90208-2	72	855	910	0	49	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	1994	263	5145					380	384		10.1126/science.8278812	http://dx.doi.org/10.1126/science.8278812			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	MT034	8278812				2022-12-01	WOS:A1994MT03400035
J	CHAPMAN, S; YACH, D; SALOOJEE, Y; SIMPSON, D				CHAPMAN, S; YACH, D; SALOOJEE, Y; SIMPSON, D			ALL AFRICA CONFERENCE ON TOBACCO CONTROL	BRITISH MEDICAL JOURNAL			English	Article								Although the health hazards of smoking are now generally accepted in most Western countries, the arguments have not had much impact on poorer nations. A conference on tobacco control held in Harare, Zimbabwe, in November last year was the largest to tackle this problem. The conference heard how threats of epidemics of tobacco related disease in the distant future held little weight with governments of countries that often already had massive public health problems. More immediate effects needed to be emphasised. Speakers gave three cogent arguments; firstly, the loss of capacity for foreign trade in essential goods, since most African countries are net importers of tobacco; secondly, the extensive deforestation which is occurring to fuel the flue curing of tobacco; thirdly, evidence from Papua New Guinea that raising taxation on tobacco provides governments with increased income for many years before a decrease begins.	UNIV SYDNEY,DEPT COMMUNITY MED,SYDNEY,NSW 2006,AUSTRALIA; S AFRICAN MRC,ESSENTIAL HLTH RES GRP,PRETORIA,SOUTH AFRICA; TOBACCO ACT GRP,JOHANNESBURG,SOUTH AFRICA; INT AGCY TOBACCO & HLTH,LONDON,ENGLAND	University of Sydney; South African Medical Research Council			Chapman, Simon/D-4114-2009					CHAPMAN S, 1990, AM J PUBLIC HEALTH, V80, P537, DOI 10.2105/AJPH.80.5.537; WALKER ARP, 1993, CANCER J - FRANCE, V6, P180; WINKFIELD R, 1992, FARMER ZIMBABWE 0917; Yach D, 1992, TOB CONTROL, V1, P272, DOI DOI 10.1136/TC.1.4.272]; 1992, WORLD HTLH STATISTIC; 1992, CANCER INCIDENCE 5 C; 1993, FARMER ZIMBAWE  1104, P12; 1993, TOBACCO REPORTER JUL, P68	8	11	12	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	1994	308	6922					189	191		10.1136/bmj.308.6922.189	http://dx.doi.org/10.1136/bmj.308.6922.189			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR974	8312774	Green Published			2022-12-01	WOS:A1994MR97400026
J	SKINNER, M; LEWIS, WD; JONES, LA; KASIRSKY, J; KANE, K; JU, ST; JENKINS, R; FALK, RH; SIMMS, RW; COHEN, AS				SKINNER, M; LEWIS, WD; JONES, LA; KASIRSKY, J; KANE, K; JU, ST; JENKINS, R; FALK, RH; SIMMS, RW; COHEN, AS			LIVER-TRANSPLANTATION AS A TREATMENT FOR FAMILIAL AMYLOIDOTIC POLYNEUROPATHY	ANNALS OF INTERNAL MEDICINE			English	Note							VARIANT		BOSTON CITY HOSP, DEPT MED, BOSTON, MA 02118 USA; NEW ENGLAND DEACONESS HOSP, DIV HEPATOBILIARY SURG & LIVER TRANSPLANTAT, BOSTON, MA 02215 USA	Boston Medical Center				Simms, Robert/0000-0002-0101-1807	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR020613, R01AR040414] Funding Source: NIH RePORTER; NCRR NIH HHS [RR 533] Funding Source: Medline; NIAMS NIH HHS [AR 20613, AR 40414] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALTLAND K, 1986, ELECTROPHORESIS, V7, P529, DOI 10.1002/elps.1150071110; Benson MD, 1989, METABOLIC BASIS INHE, P2439; COHEN AS, 1990, ARQ MEDICIN, P25; EWING DJ, 1982, BRIT MED J, V285, P916, DOI 10.1136/bmj.285.6346.916; HOLMGREN G, 1993, LANCET, V341, P1113, DOI 10.1016/0140-6736(93)93127-M; SKARE JC, 1991, CLIN GENET, V39, P6	6	83	85	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1994	120	2					133	134		10.7326/0003-4819-120-2-199401150-00006	http://dx.doi.org/10.7326/0003-4819-120-2-199401150-00006			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ671	8256972				2022-12-01	WOS:A1994MQ67100006
J	BASSING, CH; YINGLING, JM; HOWE, DJ; WANG, TW; HE, WW; GUSTAFSON, ML; SHAH, P; DONAHOE, PK; WANG, XF				BASSING, CH; YINGLING, JM; HOWE, DJ; WANG, TW; HE, WW; GUSTAFSON, ML; SHAH, P; DONAHOE, PK; WANG, XF			A TRANSFORMING GROWTH-FACTOR-BETA TYPE-I RECEPTOR THAT SIGNALS TO ACTIVATE GENE-EXPRESSION	SCIENCE			English	Article							CELL-PROLIFERATION; FAMILY	Transforming growth factor beta (TGF-beta) is a multifunctional factor that regulates many aspects of cellular functions. TGF-beta signals through a heteromeric complex of the type I and type II TGF-beta receptors. However, the molecular mechanism of signal transduction by this receptor complex remains unresolved. The type II receptor belongs to a transmembrane receptor serine-threonine kinase family. A new member of this receptor family (R4) was identified and shown to be a functional TGF-beta type I receptor on the basis of its ability to restore a TGF-beta-induced gene response in mutant cell lines lacking endogenous type I receptor. Both ligand binding and signaling of the R4 protein were dependent on the presence of a functional type II receptor. The type I receptor has an intrinsic serine-threonine kinase activity, which was essential for signal transduction.	DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; MASSACHUSETTS GEN HOSP, PEDIAT SURG RES LAB, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT SURG, BOSTON, MA 02114 USA; HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA	Duke University; Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [T32HD007396] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045746] Funding Source: NIH RePORTER; NICHD NIH HHS [NICHD T32HD07396] Funding Source: Medline; NIDDK NIH HHS [DK45746] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSSON S, 1989, J BIOL CHEM, V264, P8222; ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; BASSING CH, UNPUB; BOYD FT, 1989, J BIOL CHEM, V264, P2272; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; LAIHO M, 1990, J BIOL CHEM, V265, P18518; LIN HY, 1992, CELL, V68, P1; LYONS RM, 1990, EUR J BIOCHEM, V187, P467, DOI 10.1111/j.1432-1033.1990.tb15327.x; MASSAGUE J, 1992, CELL, V69, P1067, DOI 10.1016/0092-8674(92)90627-O; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATTHEWS LS, 1991, CELL, V65, P973; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P421; SEGARANI P, IN PRESS BIOCH BIOPH; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S	18	290	303	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 7	1994	263	5143					87	89		10.1126/science.8272871	http://dx.doi.org/10.1126/science.8272871			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ301	8272871				2022-12-01	WOS:A1994MQ30100036
J	OHSUMI, K; KATAGIRI, C; KISHIMOTO, T				OHSUMI, K; KATAGIRI, C; KISHIMOTO, T			CHROMOSOME CONDENSATION IN XENOPUS MITOTIC EXTRACTS WITHOUT HISTONE H1	SCIENCE			English	Article							NUCLEOSOME ASSEMBLY INVITRO; TOPOISOMERASE-II; EGG EXTRACTS; CELL-CYCLE; SPERM NUCLEI; G2 PHASE; PHOSPHORYLATION; CHROMATIN; PROTEIN; H-1	The contribution of histone H1 to mitotic chromosome condensation was examined with the use of a cell-free extract from Xenopus eggs, which transforms condensed sperm nuclei into metaphase chromosomes. When H1 was removed from the extract, the resultant metaphase chromosomes were indistinguishable from those formed in complete extract. Nucleosomal spacing was the same for both. Thus, H1 is not required for the structural reorganization that leads to condensed metaphase chromosomes in this egg extract.	HOKKAIDO UNIV,GRAD SCH SCI,DIV BIOL SCI,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University	OHSUMI, K (corresponding author), TOKYO INST TECHNOL,FAC BIOSCI,CELL & DEV BIOL LAB,4259 NAGATSUTA,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN.							ADACHI Y, 1991, CELL, V64, P137, DOI 10.1016/0092-8674(91)90215-K; BRADBURY EM, 1974, NATURE, V247, P257, DOI 10.1038/247257a0; BRADBURY EM, 1992, BIOESSAYS, V14, P9; CHURCHILL MEA, 1991, TRENDS BIOCHEM SCI, V16, P92, DOI 10.1016/0968-0004(91)90040-3; DILWORTH SM, 1987, CELL, V51, P1009, DOI 10.1016/0092-8674(87)90587-3; FLYNN JM, 1980, DEV BIOL, V75, P222, DOI 10.1016/0012-1606(80)90157-8; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HILL CS, 1991, EMBO J, V10, P1939, DOI 10.1002/j.1460-2075.1991.tb07720.x; HIRANO T, 1993, J CELL BIOL, V120, P601, DOI 10.1083/jcb.120.3.601; ITOH T, 1993, DEV GROWTH DIFFER, V35, P59; KLEINSCHMIDT JA, 1990, EMBO J, V9, P1309, DOI 10.1002/j.1460-2075.1990.tb08240.x; KLEINSCHMIDT JA, 1983, J CELL BIOL, V97, P838, DOI 10.1083/jcb.97.3.838; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGAN TA, 1989, MOL CELL BIOL, V9, P3860, DOI 10.1128/MCB.9.9.3860; LOHKA MJ, 1985, J CELL BIOL, V101, P518, DOI 10.1083/jcb.101.2.518; LOHKA MJ, 1984, DEV BIOL, V103, P434, DOI 10.1016/0012-1606(84)90331-2; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MUELLER RD, 1985, J BIOL CHEM, V260, P5081; MURRAY AW, 1989, NATURE, V339, P275, DOI 10.1038/339275a0; NEWPORT J, 1987, CELL, V48, P219, DOI 10.1016/0092-8674(87)90425-9; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; OHSUMI K, 1991, DEV BIOL, V147, P110, DOI 10.1016/S0012-1606(05)80011-9; OHSUMI K, 1991, DEV BIOL, V148, P295, DOI 10.1016/0012-1606(91)90338-4; OHSUMI K, 1988, GAMETE RES, V20, P1, DOI 10.1002/mrd.1120200102; OHSUMI K, UNPUB; OOKATA K, 1992, EMBO J, V11, P1763, DOI 10.1002/j.1460-2075.1992.tb05228.x; PHILPOTT A, 1992, CELL, V69, P759, DOI 10.1016/0092-8674(92)90288-N; RISLEY MS, 1981, DEV BIOL, V84, P79, DOI 10.1016/0012-1606(81)90372-9; ROBERGE M, 1990, J CELL BIOL, V111, P1753, DOI 10.1083/jcb.111.5.1753; RODRIGUEZCAMPOS A, 1989, J MOL BIOL, V209, P135, DOI 10.1016/0022-2836(89)90177-0; ROTH SY, 1992, TRENDS BIOCHEM SCI, V17, P93, DOI 10.1016/0968-0004(92)90243-3; Sambrook J., 1989, MOL CLONING; SMITH RC, 1988, GENE DEV, V2, P1284, DOI 10.1101/gad.2.10.1284; THNG JPH, 1990, CELL, V63, P313, DOI 10.1016/0092-8674(90)90164-A; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; UEMURA T, 1987, CELL, V50, P917, DOI 10.1016/0092-8674(87)90518-6; van Holde K E, 1988, CHROMATIN	37	139	146	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					2033	2035		10.1126/science.8266099	http://dx.doi.org/10.1126/science.8266099			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266099				2022-12-01	WOS:A1993MN10800038
J	PETTIT, MJ; SCHWARK, HD				PETTIT, MJ; SCHWARK, HD			RECEPTIVE-FIELD REORGANIZATION IN DORSAL COLUMN NUCLEI DURING TEMPORARY DENERVATION	SCIENCE			English	Article							PRIMARY SOMATOSENSORY CORTEX; PRIMARY AFFERENT-FIBERS; FELINE CUNEATE NUCLEUS; DIGIT DENERVATION; RAT; CAT; DEAFFERENTATION; PLASTICITY; NEURONS	Altered sensory input can result in the reorganization of somatosensory maps in the cerebral cortex and thalamus, but the extent to which reorganization occurs at lower levels of the somatosensory system is unknown. In cat dorsal column nuclei (DCN), the injection of local anesthetic into the receptive fields of DCN neurons resulted in the emergence of a new receptive field in all 13 neurons studied. New receptive fields emerged rapidly (within minutes), sometimes accompanied by changes in adaptation rates and stimulus selectivity, suggesting that the new fields arose from the unmasking of previously ineffective inputs. Receptive field reorganization was not imposed by descending cortical inputs to the DCN, because comparable results were obtained in 10 additional cells when the somatosensory and motor cortex were removed before recording. These results suggest that mechanisms underlying somatotopic reorganization exist at the earliest stages of somatosensory processing. Such mechanisms may participate in adaptive responses of the nervous system to injury or continuously changing sensory stimulation.	UNIV N TEXAS,DEPT BIOL SCI,DENTON,TX 76203	University of North Texas System; University of North Texas Denton					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R29NS025729] Funding Source: NIH RePORTER; NINDS NIH HHS [NS 25729] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BYRNE JA, 1991, BRAIN RES, V565, P218, DOI 10.1016/0006-8993(91)91652-H; CALFORD MB, 1991, J NEUROPHYSIOL, V65, P178, DOI 10.1152/jn.1991.65.2.178; CALFORD MB, 1991, P ROY SOC B-BIOL SCI, V243, P269, DOI 10.1098/rspb.1991.0041; DOSTROVSKY JO, 1976, EXP NEUROL, V52, P480, DOI 10.1016/0014-4886(76)90219-3; EYSEL UT, 1981, EXP BRAIN RES, V41, P256; FYFFE REW, 1986, J NEUROPHYSIOL, V56, P1284, DOI 10.1152/jn.1986.56.5.1284; FYFFE REW, 1986, J NEUROPHYSIOL, V56, P1268, DOI 10.1152/jn.1986.56.5.1268; GARRAGHTY PE, 1991, NEUROREPORT, V2, P747, DOI 10.1097/00001756-199112000-00004; GILBERT CD, 1992, NATURE, V356, P150, DOI 10.1038/356150a0; HALLIGAN PW, 1993, NEUROREPORT, V4, P233, DOI 10.1097/00001756-199303000-00001; KAAS JH, 1991, ANNU REV NEUROSCI, V14, P137, DOI 10.1146/annurev.neuro.14.1.137; KALASKA J, 1982, BRAIN RES, V236, P35, DOI 10.1016/0006-8993(82)90032-4; KUYPERS HGJ, 1964, J ANAT, V98, P143; LANDRY P, 1981, J COMP NEUROL, V199, P345, DOI 10.1002/cne.901990304; MCMAHON SB, 1983, EXP NEUROL, V80, P195, DOI 10.1016/0014-4886(83)90016-X; MERZENICH MM, 1988, NEUROBIOLOGY NEOCORT, P41; MOGILNER A, 1993, P NATL ACAD SCI USA, V90, P3593, DOI 10.1073/pnas.90.8.3593; Nakahama H, 1966, Prog Brain Res, V21, P180; NICOLELIS MAL, 1993, NATURE, V361, P533, DOI 10.1038/361533a0; RAMACHANDRAN VS, 1992, NEUROREPORT, V3, P583, DOI 10.1097/00001756-199207000-00009; SCHWARK HD, 1992, EXP BRAIN RES, V91, P425; SNOW PJ, 1988, SOMATOSENS MOT RES, V5, P349, DOI 10.3109/07367228809144636; WAITE PME, 1984, J PHYSIOL-LONDON, V352, P425, DOI 10.1113/jphysiol.1984.sp015301; WEINBERG RJ, 1990, J COMP NEUROL, V300, P113, DOI 10.1002/cne.903000108	24	101	102	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					2054	2056		10.1126/science.8266104	http://dx.doi.org/10.1126/science.8266104			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266104				2022-12-01	WOS:A1993MN10800044
J	SHRIVASTAVA, A; SALEQUE, S; KALPANA, GV; ARTANDI, S; GOFF, SP; CALAME, K				SHRIVASTAVA, A; SALEQUE, S; KALPANA, GV; ARTANDI, S; GOFF, SP; CALAME, K			INHIBITION OF TRANSCRIPTIONAL REGULATOR YIN-YANG-1 BY ASSOCIATION WITH C-MYC	SCIENCE			English	Article							SERUM RESPONSE FACTOR; DNA-BINDING; PROTEIN; MAX; YY1; IDENTIFICATION; PROMOTER; ACTIVATION; REPRESSOR; ONCOGENES	Yin-Yang-1 (YY1) regulates the transcription of many genes, including the oncogenes c-fos and c-myc. Depending on the context, YY1 acts as a transcriptional repressor, a transcriptional activator, or a transcriptional initiator. The yeast two-hybrid system was used to screen a human complementary DNA (cDNA) library for proteins that associate with YY1, and a c-myc cDNA was isolated. Affinity chromatography confirmed that YY1 associates with c-Myc but not with Max. In cotransfections, c-Myc inhibits both the repressor and the activator functions of YY1, which suggests that one way c-Myc acts is by modulating the activity of YY1.	COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,HOWARD HUGHES MED INST,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT MICROBIOL,NEW YORK,NY 10032	Columbia University; Columbia University; Howard Hughes Medical Institute; Columbia University				Kalpana, Ganjam/0000-0003-4111-0604	NATIONAL CANCER INSTITUTE [R01CA038571] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029361] Funding Source: NIH RePORTER; NCI NIH HHS [CA 38571] Funding Source: Medline; NIGMS NIH HHS [GM29361] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMATI B, 1992, NATURE, V359, P423, DOI 10.1038/359423a0; BAUKNECHT T, 1992, EMBO J, V11, P4607, DOI 10.1002/j.1460-2075.1992.tb05563.x; BLACKWOOD EM, 1992, GENE DEV, V6, P71, DOI 10.1101/gad.6.1.71; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; DALLAFAVERA R, ORIGINS HUMAN CANCER, P543; DANG CV, 1988, MOL CELL BIOL, V8, P4048, DOI 10.1128/MCB.8.10.4048; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLANAGAN JR, 1992, MOL CELL BIOL, V12, P38, DOI 10.1128/MCB.12.1.38; GILL G, 1987, CELL, V51, P121, DOI 10.1016/0092-8674(87)90016-X; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GRIGNANI F, 1990, EMBO J, V9, P3913, DOI 10.1002/j.1460-2075.1990.tb07612.x; GUALBERTO A, 1992, MOL CELL BIOL, V12, P4209, DOI 10.1128/MCB.12.9.4209; HARIHARAN N, 1989, GENE DEV, V3, P1789, DOI 10.1101/gad.3.11.1789; HARIHARAN N, 1991, P NATL ACAD SCI USA, V88, P9799, DOI 10.1073/pnas.88.21.9799; KAKKIS E, 1989, NATURE, V339, P718, DOI 10.1038/339718a0; KRETZNER L, 1992, NATURE, V359, P426, DOI 10.1038/359426a0; LEE TC, 1992, P NATL ACAD SCI USA, V89, P9814, DOI 10.1073/pnas.89.20.9814; LUBAN J, 1993, CELL, V73, P1067, DOI 10.1016/0092-8674(93)90637-6; LUSCHER B, 1989, EMBO J, V8, P1111, DOI 10.1002/j.1460-2075.1989.tb03481.x; LUSCHER B, 1990, GENE DEV, V4, P2025, DOI 10.1101/gad.4.12a.2025; MARCU KB, 1992, ANNU REV BIOCHEM, V61, P809, DOI 10.1146/annurev.bi.61.070192.004113; PACIUCCI R, 1991, MOL CELL BIOL, V11, P1334, DOI 10.1128/MCB.11.3.1334; PARK K, 1991, P NATL ACAD SCI USA, V88, P9804, DOI 10.1073/pnas.88.21.9804; PENN LJZ, 1990, MOL CELL BIOL, V10, P4961, DOI 10.1128/MCB.10.9.4961; PRENDERGAST GC, 1991, CELL, V65, P395, DOI 10.1016/0092-8674(91)90457-A; RALSTON R, 1983, NATURE, V306, P803, DOI 10.1038/306803a0; RIGGS KJ, 1991, MOL CELL BIOL, V11, P1765, DOI 10.1128/MCB.11.3.1765; RIGGS KJ, 1993, MOL CELL BIOL, V13, P7487, DOI 10.1128/MCB.13.12.7487; ROY AL, 1993, NATURE, V365, P359, DOI 10.1038/365359a0; RUSTGI AK, 1991, NATURE, V352, P541, DOI 10.1038/352541a0; SETO E, 1991, NATURE, V354, P241, DOI 10.1038/354241a0; SHENK T, COMMUNICATION; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SRTANDI S, 1993, METHODS MOL GENET, V1, P267; STONE J, 1987, MOL CELL BIOL, V7, P1697, DOI 10.1128/MCB.7.5.1697; VINCENT CK, 1993, MOL CELL BIOL, V13, P1264, DOI 10.1128/MCB.13.2.1264	36	243	250	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 17	1993	262	5141					1889	1892		10.1126/science.8266081	http://dx.doi.org/10.1126/science.8266081			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266081				2022-12-01	WOS:A1993MM51100041
J	LAUNER, LJ; HOFMAN, A; GROBBEE, DE				LAUNER, LJ; HOFMAN, A; GROBBEE, DE			RELATION BETWEEN BIRTH-WEIGHT AND BLOOD-PRESSURE - LONGITUDINAL-STUDY OF INFANTS AND CHILDREN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							ADULT LIFE; CARDIOVASCULAR-DISEASE; PLACENTAL SIZE; HYPERTENSION; CHILDHOOD; GROWTH; BROMPTON; HEART; FETAL; RISK	Objective-To study the relation between birth weight and systolic blood pressure in infancy and early childhood. Design-Longitudinal study of infants from birth to 4 years of age. Setting-A middle class community in the Netherlands. Participants--476 Dutch infants born in 1980 to healthy women after uncomplicated pregnancies. Main outcome measures-Systolic blood pressure and body weight measured at birth and at 3 months and 4 years of age; the relation between systolic blood pressure and birth weight as estimated by multiple regression models that include current weight and previous blood pressure and control for gestational age, length at birth, and sex. Results-Complete data were available on 392 infants. At 4 years of age the relation between blood pressure and birth weight appeared to be U shaped; low and high birthweight infants had raised blood pressure. Current weight and previous blood pressure were also positively associated with blood pressure at that age. Low birthweight infants (birth weight <3100 g) had a greater gain in blood pressure and weight in early infancy. High birthweight infants (birth weight greater-than-or-equal-to 3700 g) had high blood pressure at birth, and weight and blood pressure tended to remain high thereafter. Conclusions-Even among normal infants there seem to be subgroups defined by birth weight in which blood pressure is regulated differently. Future investigations are needed to examine the physiological basis of these differences. Studies of correlates of adult disease related to birth weight should investigate mechanisms related to increased risk separately in infants of low and high birth weight.			LAUNER, LJ (corresponding author), ERASMUS UNIV ROTTERDAM, SCH MED, DEPT EPIDEMIOL & BIOSTAT, 3000 DR ROTTERDAM, NETHERLANDS.		Launer, Lenore J/A-8218-2010; Grobbee, Diederick/C-7651-2014	Grobbee, Diederick/0000-0003-4472-4468				[Anonymous], 1987, PEDIATRICS, V79, P1; BARKER DJP, 1989, LANCET, V2, P577; BARKER DJP, 1989, BRIT MED J, V298, P564, DOI 10.1136/bmj.298.6673.564; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BERENSON GS, 1989, SEMIN NEPHROL, V9, P236; BINKIN NJ, 1988, PEDIATRICS, V82, P828; DAVIES DP, 1979, ARCH DIS CHILD, V54, P703, DOI 10.1136/adc.54.9.703; DESWIET M, 1992, BRIT MED J, V304, P23, DOI 10.1136/bmj.304.6818.23; DESWIET M, 1980, PEDIATRICS, V65, P1028; ELFORD J, 1991, INT J EPIDEMIOL, V20, P833, DOI 10.1093/ije/20.4.833; GARN SM, 1985, AM J CLIN NUTR, V42, P57, DOI 10.1093/ajcn/42.1.57; HEATH D, 1990, BRIT MED J, V301, P441; HOFMAN A, 1983, JAMA-J AM MED ASSOC, V250, P370, DOI 10.1001/jama.250.3.370; OUNSTED MK, 1985, ARCH DIS CHILD, V60, P631, DOI 10.1136/adc.60.7.631; PARKER DJP, 1992, J EPIDEMIOL COMMUN H, V46, P8, DOI 10.1136/jech.46.1.8; SCHACHTER J, 1982, AM J EPIDEMIOL, V116, P29, DOI 10.1093/oxfordjournals.aje.a113400; SEIDMAN DS, 1991, BMJ-BRIT MED J, V302, P1235, DOI 10.1136/bmj.302.6787.1235; STRACHAN DP, 1990, BRIT MED J, V301, P552, DOI 10.1136/bmj.301.6751.552; VOORS AW, 1980, HYPERTENSION, V2, pI102, DOI 10.1161/01.HYP.2.4_Pt_2.I102; WHINCUP PH, 1989, BMJ-BRIT MED J, V299, P587, DOI 10.1136/bmj.299.6699.587; ZINNER SH, 1985, HYPERTENSION, V7, P411, DOI 10.1161/01.HYP.7.3_Pt_1.411; 1985, SAS USERS GUIDE STAT	22	111	117	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 4	1993	307	6917					1451	1454		10.1136/bmj.307.6917.1451	http://dx.doi.org/10.1136/bmj.307.6917.1451			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK797	8281086	Green Published, Green Submitted, Bronze			2022-12-01	WOS:A1993MK79700019
J	GIARDINA, C; LIS, JT				GIARDINA, C; LIS, JT			DNA MELTING ON YEAST RNA POLYMERASE-II PROMOTERS	SCIENCE			English	Article							COMPLEX-FORMATION; TRANSCRIPTION; INITIATION; INVIVO; GENES; SACCHAROMYCES; SEQUENCES; MECHANISM; PROTEINS; CLONING	Transcription-dependent DNA melting on the yeast GAL1 and GAL10 promoters was found to be more closely correlated with the TATA box than the transcription start site. On both these genes, melting begins about 20 base pairs downstream of the TATA box. Physical and genetic analyses suggest that RNA polymerase II associates with this region. Thus, the distance between promoter melting and the TATA box in yeast may be similar to that in higher eukaryotes, even though transcription initiates in a region about 10 to 90 base pairs farther downstream in yeast.	CORNELL UNIV,DEPT BIOCHEM MOLEC & CELL BIOL,ITHACA,NY 14853	Cornell University								ABOULELA F, 1992, J BIOL CHEM, V267, P1776; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; CAVALLINI B, 1989, P NATL ACAD SCI USA, V86, P9803, DOI 10.1073/pnas.86.24.9803; CORDEN J, 1980, SCIENCE, V209, P1406, DOI 10.1126/science.6251548; GIARDINA C, 1992, GENE DEV, V6, P2190, DOI 10.1101/gad.6.11.2190; GILEADI O, 1992, SCIENCE, V257, P1389, DOI 10.1126/science.1445600; GRIMES E, 1991, NUCLEIC ACIDS RES, V19, P6113, DOI 10.1093/nar/19.22.6113; JOHNSTON M, 1984, MOL CELL BIOL, V4, P1440, DOI 10.1128/MCB.4.8.1440; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; RANISH JA, 1992, SCIENCE, V255, P1127, DOI 10.1126/science.1546313; RUBIN CM, 1980, NUCLEIC ACIDS RES, V8, P4613, DOI 10.1093/nar/8.20.4613; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; STJOHN TP, 1981, J MOL BIOL, V152, P285, DOI 10.1016/0022-2836(81)90244-8; STRUHL K, 1987, CELL, V49, P295, DOI 10.1016/0092-8674(87)90277-7; SUH WC, 1993, SCIENCE, V259, P358, DOI 10.1126/science.8420002; TRECO DA, 1989, CURRENT PROTOCOLS MO; VONHIPPEL PH, 1984, ANNU REV BIOCHEM, V53, P389, DOI 10.1146/annurev.bi.53.070184.002133; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WANG WD, 1992, GENE DEV, V6, P1716, DOI 10.1101/gad.6.9.1716; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	24	124	126	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 6	1993	261	5122					759	762		10.1126/science.8342041	http://dx.doi.org/10.1126/science.8342041			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ730	8342041				2022-12-01	WOS:A1993LQ73000039
J	HODGKINSON, CA; MOORE, KJ; NAKAYAMA, A; STEINGRIMSSON, E; COPELAND, NG; JENKINS, NA; ARNHEITER, H				HODGKINSON, CA; MOORE, KJ; NAKAYAMA, A; STEINGRIMSSON, E; COPELAND, NG; JENKINS, NA; ARNHEITER, H			MUTATIONS AT THE MOUSE MICROPHTHALMIA LOCUS ARE ASSOCIATED WITH DEFECTS IN A GENE ENCODING A NOVEL BASIC-HELIX-LOOP-HELIX-ZIPPER PROTEIN	CELL			English	Article							DNA-BINDING; SPLEEN-CELLS; INSERTIONAL MUTATION; WAARDENBURG SYNDROME; MYC ONCOGENE; C-FOS; MICE; DIFFERENTIATION; MOTIF; TRANSCRIPTION	Mice with mutations at the microphthalmia (mi) locus have some or all of the following defects: loss of pigmentation, reduced eye size, failure of secondary bone resorption, reduced numbers of mast cells, and early onset of deafness. Using a transgenic insertional mutation at this locus, we have identified a gene whose expression is disrupted in transgenic animals. This gene encodes a novel member of the basic-helix-loop-helix-leucine zipper (bHLH-ZIP) protein family of transcription factors, is altered in mice carrying two independent mi alleles (mi and mi(ws)), and is expressed in the developing eye, ear, and skin, all anatomical sites affected by mi. The multiple spontaneous and induced mutations available at mi provide a unique biological resource for studying the role of a bHLH-ZIP protein in mammalian development.	NCI,FREDERICK CANC RES & DEV CTR,BASIC RES PROGRAM,ADV BIOSCI LABS,MAMMALIAN GENET LAB,FREDERICK,MD 21702	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	HODGKINSON, CA (corresponding author), NINCDS,VIRAL & MOLEC PATHOGENESIS LAB,BETHESDA,MD 20892, USA.			Hodgkinson, Colin/0000-0002-5365-8119; Arnheiter, Heinz/0000-0003-2537-1134; Steingrimsson, Eirikur/0000-0001-5826-7486	OFFICE OF THE DIRECTOR, NCI [N01CO074101] Funding Source: NIH RePORTER; NCI NIH HHS [N01-CO-74101] Funding Source: Medline	OFFICE OF THE DIRECTOR, NCI(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARNHEITER H, 1990, CELL, V62, P51, DOI 10.1016/0092-8674(90)90239-B; ASHER JH, 1990, J MED GENET, V27, P618, DOI 10.1136/jmg.27.10.618; AYER DE, 1993, CELL, V72, P211, DOI 10.1016/0092-8674(93)90661-9; BALDWIN CT, 1992, NATURE, V355, P637, DOI 10.1038/355637a0; BALNAR MA, 1992, SCIENCE, V256, P1014; BECKMANN H, 1990, GENE DEV, V4, P167, DOI 10.1101/gad.4.2.167; BENNETT DC, 1989, DEVELOPMENT, V105, P379; BEXEVANIS AD, 1993, CURR OPIN GENE DEV, V3, P278; BLACKWOOD EM, 1991, SCIENCE, V251, P1211, DOI 10.1126/science.2006410; BOSWELL HS, 1990, EXP HEMATOL, V18, P794; CARR CS, 1990, MOL CELL BIOL, V10, P4384, DOI 10.1128/MCB.10.8.4384; CASANOVA JL, 1990, NUCLEIC ACIDS RES, V18, P4028, DOI 10.1093/nar/18.13.4028; Chromczynski P, 1987, ANAL BIOCHEM, V162, P156; COLE MD, 1986, ANNU REV GENET, V20, P361, DOI 10.1146/annurev.ge.20.120186.002045; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DUBREUIL P, 1991, P NATL ACAD SCI USA, V88, P2341, DOI 10.1073/pnas.88.6.2341; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FARRER LA, 1992, J MED GENET, V27, P618; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; FISHER DE, 1991, GENE DEV, V5, P2342, DOI 10.1101/gad.5.12a.2342; FISHER DE, 1993, CELL, V72, P467, DOI 10.1016/0092-8674(93)90122-7; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GARRELL J, 1991, BIOESSAYS, V13, P493, DOI 10.1002/bies.950131002; Green MC., 1989, GENETIC VARIANTS STR, P12; GREGOR PD, 1990, GENE DEV, V4, P1730, DOI 10.1101/gad.4.10.1730; GRUNEBERG H, 1953, J GENET, V51, P359, DOI 10.1007/BF03023302; HARA Y, 1990, MOL BRAIN RES, V8, P319, DOI 10.1016/0169-328X(90)90045-F; HERO I, 1991, INVEST OPHTH VIS SCI, V32, P2622; Hertwig P., 1942, ZEITSCHR INDUKT ABSTAMM U VERERBUNGSL, V80, P220, DOI 10.1007/BF01741984; HOLLANDER WF, 1968, GENETICS, V60, P189; HU YF, 1990, GENE DEV, V4, P167; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JOHNSON RS, 1992, CELL, V71, P577, DOI 10.1016/0092-8674(92)90592-Z; KADESCH T, 1993, CELL GROWTH DIFFER, V4, P49; KONYUKHOV BV, 1968, SOV GENET, V4, P1457; LAMOREUX ML, 1992, J HERED, V83, P435, DOI 10.1093/oxfordjournals.jhered.a111247; LERNER AB, 1986, J INVEST DERMATOL, V87, P299, DOI 10.1111/1523-1747.ep12524353; LERNER AB, 1986, MOUSE NEWS LETT, V74, P125; MARKS SC, 1981, AM J ANAT, V161, P1, DOI 10.1002/aja.1001610102; MINER JH, 1991, MOL CELL BIOL, V11, P2842, DOI 10.1128/MCB.11.5.2842; MULLER G, 1950, Z MIKROSK ANAT FORSC, V56, P520; MURRE C, 1989, CELL, V56, P777, DOI 10.1016/0092-8674(89)90682-X; PACKER SO, 1967, J EXP ZOOL, V165, P21, DOI 10.1002/jez.1401650103; PRENDERGAST GC, 1992, TRENDS GENET, V8, P91, DOI 10.1016/0168-9525(92)90196-B; ROMAN C, 1992, MOL CELL BIOL, V12, P817, DOI 10.1128/MCB.12.2.817; Sambrook J., 1989, MOL CLONING LAB MANU; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; Silvers WK., 1979, COAT COLORS MICE, DOI [10.1007/978-1-4612-6164-3, DOI 10.1007/978-1-4612-6164-3]; SINGH G, 1991, GENE DEV, V5, P2245, DOI 10.1101/gad.5.12a.2245; SOUTHARD JL, 1974, MOUSE NEWS LETT, V51, P23; STEEL KP, 1992, DEVELOPMENT, V115, P1111; STELZNER KF, 1966, MOUSE NEWS LETT, V34, P41; STELZNER KF, 1964, MOUSE NEWS LETT, V31, P40; TACHIBANA M, 1992, MOL CELL NEUROSCI, V3, P433, DOI 10.1016/1044-7431(92)90055-7; TASASBEHJI M, 1993, NAT GENET, V3, P26; TASSABEHJI M, 1992, NATURE, V355, P635, DOI 10.1038/355635a0; WALKER DG, 1975, SCIENCE, V190, P784, DOI 10.1126/science.1105786; WALKER DG, 1975, SCIENCE, V190, P785, DOI 10.1126/science.1198094; WANG ZQ, 1992, NATURE, V360, P741, DOI 10.1038/360741a0; WOLFE HG, 1964, GENET RES, V46, P309; WOYCHIK RP, 1990, NATURE, V346, P850, DOI 10.1038/346850a0; YOSHITAKA E, 1992, BLOOD, V80, P1454; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	63	928	964	4	56	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					395	404		10.1016/0092-8674(93)90429-T	http://dx.doi.org/10.1016/0092-8674(93)90429-T			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343963				2022-12-01	WOS:A1993LP72600019
J	HAMELIN, M; ZHOU, YW; SU, MW; SCOTT, IM; CULOTTI, JG				HAMELIN, M; ZHOU, YW; SU, MW; SCOTT, IM; CULOTTI, JG			EXPRESSION OF THE UNC-5 GUIDANCE RECEPTOR IN THE TOUCH NEURONS OF C-ELEGANS STEERS THEIR AXONS DORSALLY	NATURE			English	Article							EMBRYONIC CELL LINEAGES; CAENORHABDITIS-ELEGANS; GUIDES CELL; MIGRATIONS; GENETICS; IMMUNOGLOBULIN; NEMATODE; PROTEIN	GROWTH cones in developing nervous systems encounter a sequence of extracellular cues during migration1,2. In theory, a growth cone can navigate by selectively expressing or activating surface receptor(s) that recognize extracellular cues appropriate to each migratory phase. Using the simple Caenorhabditis elegans nervous system, we attempted to demonstrate that path selection by migrating growth cones can be predictably altered by ectopic expression of a single receptor. The unc-5 gene of C. elegans encodes a unique receptor of the immunoglobulin superfamily (UNC-5), required cell-autonomously to guide growth cone and mesodermal cell migrations in a dorsal direction on the epidermis3,4. We report here that the UNC-5 receptor induces dorsally oriented axon trajectories when ectopically expressed in the touch receptor neurons which normally extend pioneer axons longitudinally or ventrally on the epidermis5. These errant trajectories depend on unc-6, which encodes a putative epidermal path cue6, just as normal dorsally oriented axon trajectories do (such as those of certain motor neurons4), suggesting that UNC-5 acts to reorient the touch cell growth cones by using its normal guidance mechanisms. These results support previous evidence that UNC-5 and UNC-6 play instructive roles in guiding growth cone migrations on the epidermis in C elegans4, and indicate that pioneering growth cones, which normally migrate in different directions may use equivalent intracellular signalling mechanisms for guidance.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,TORONTO M5G 1X5,ONTARIO,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO M5S 1A8,ONTARIO,CANADA; MERCK RES LABS,RAHWAY,NJ 07065	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; Merck & Company			Culotti, Joseph/G-6467-2013	Culotti, Joseph/0000-0001-6325-4612				BRENNER S, 1974, GENETICS, V77, P71; BRENNER S, 1973, BRIT MED BULL, V29, P269, DOI 10.1093/oxfordjournals.bmb.a071019; CHALFIE M, 1981, DEV BIOL, V82, P358, DOI 10.1016/0012-1606(81)90459-0; DODD J, 1988, SCIENCE, V242, P692, DOI 10.1126/science.3055291; FIRE A, 1990, GENE, V93, P189, DOI 10.1016/0378-1119(90)90224-F; HAMELIN M, 1992, EMBO J, V11, P2885, DOI 10.1002/j.1460-2075.1992.tb05357.x; HARRELSON AL, 1988, SCIENCE, V242, P700, DOI 10.1126/science.3187519; HEDGECOCK EM, 1987, DEVELOPMENT, V100, P365; HEDGECOCK EM, 1990, NEURON, V2, P61; ISHII N, 1992, NEURON, V9, P873, DOI 10.1016/0896-6273(92)90240-E; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; LEUNGHAGESTEIJN CY, 1992, CELL, V71, P289, DOI 10.1016/0092-8674(92)90357-I; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; WHITE JG, 1976, PHILOS T R SOC B, V275, P327, DOI 10.1098/rstb.1976.0086	16	202	211	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 22	1993	364	6435					327	330		10.1038/364327a0	http://dx.doi.org/10.1038/364327a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	8332188				2022-12-01	WOS:A1993LN57000054
J	NELSEN, B; TIAN, G; ERMAN, B; GREGOIRE, J; MAKI, R; GRAVES, B; SEN, R				NELSEN, B; TIAN, G; ERMAN, B; GREGOIRE, J; MAKI, R; GRAVES, B; SEN, R			REGULATION OF LYMPHOID-SPECIFIC IMMUNOGLOBULIN-MU HEAVY-CHAIN GENE ENHANCER BY ETS-DOMAIN PROTEINS	SCIENCE			English	Article							TISSUE-SPECIFIC EXPRESSION; TRANSGENIC MICE; BINDING SITES; DNA; TRANSCRIPTION; REARRANGEMENT; ONCOGENE; SEQUENCE; LINEAGE; COMPLEX	The enhancer for the immunoglobulin mu heavy chain gene (IgH) activates a heterologous gene at the pre-B cell stage of B lymphocyte differentiation. A lymphoid-specific element, muB, is necessary for enhancer function in pre-B cells. A muB binding protein is encoded by the PU.1/Spi-1 proto-oncogene. Another sequence element, muA, was identified in the mu enhancer that binds the product of the ets-1 proto-oncogene. The muA motif was required for muB-dependent enhancer activity, which suggests that a minimal B cell-specific enhancer is composed of both the PU.1 and Ets-1 binding sites. Co-expression of both PU.1 and Ets-1 in nonlymphoid cells trans-activated reporter plasmids that contained the minimal mu enhancer. These results implicate two members of the Ets family in the activation of IgH gene expression.	BRANDEIS UNIV,ROSENSTIEL BASIC MED SCI RES CTR,WALTHAM,MA 02254; BRANDEIS UNIV,DEPT BIOL,WALTHAM,MA 02254; UNIV UTAH,SCH MED,DEPT CELLULAR VIRAL & MOLEC BIOL,SALT LAKE CITY,UT 84132; LA JOLLA CANC RES FDN,CANC RES CTR,LA JOLLA,CA 92037	Brandeis University; Brandeis University; Utah System of Higher Education; University of Utah; Sanford Burnham Prebys Medical Discovery Institute			erman, burak/F-5900-2015; erman, batu/AAE-1963-2020	erman, burak/0000-0002-2496-6059; 	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038925, K04GM000563, R01GM038925, R01GM038663, R29GM038663] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38925, GM38663, 1K04GM00563] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JM, 1985, NATURE, V318, P533, DOI 10.1038/318533a0; ALT FW, 1986, IMMUNOL REV, V89, P5, DOI 10.1111/j.1600-065X.1986.tb01470.x; ARONHEIM A, 1991, NUCLEIC ACIDS RES, V19, P3893, DOI 10.1093/nar/19.14.3893; BHAT NK, 1987, P NATL ACAD SCI USA, V84, P3161, DOI 10.1073/pnas.84.10.3161; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; CORDLE SR, 1991, MOL CELL BIOL, V11, P1734, DOI 10.1128/MCB.11.3.1734; EPHRUSSI A, 1985, SCIENCE, V227, P134, DOI 10.1126/science.3917574; FERRIER P, 1990, EMBO J, V9, P117, DOI 10.1002/j.1460-2075.1990.tb08087.x; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GNTER CV, 1990, GENE DEV, V4, P677; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HIPSKIND RA, 1991, NATURE, V354, P531, DOI 10.1038/354531a0; HO IC, 1990, SCIENCE, V250, P814, DOI 10.1126/science.2237431; KARIM FD, 1990, GENE DEV, V4, P1451, DOI 10.1101/gad.4.9.1451; KILEDJIAN M, 1988, MOL CELL BIOL, V8, P145, DOI 10.1128/MCB.8.1.145; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; KREIDER BL, 1992, SCIENCE, V255, P1700, DOI 10.1126/science.1372755; LANGDON WY, 1986, CELL, V47, P11, DOI 10.1016/0092-8674(86)90361-2; LENARDO M, 1987, SCIENCE, V236, P1573, DOI 10.1126/science.3109035; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P3155, DOI 10.1128/MCB.10.6.3155; LO K, 1991, MOL CELL BIOL, V11, P5229, DOI 10.1128/MCB.11.10.5229; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MURRE C, 1991, MOL CELL BIOL, V11, P1156, DOI 10.1128/MCB.11.2.1156; NELSEN B, 1988, MOL CELL BIOL, V8, P3526, DOI 10.1128/MCB.8.8.3526; NELSEN B, 1990, MOL CELL BIOL, V10, P3145, DOI 10.1128/MCB.10.6.3145; NELSEN B, 1992, ANN REV CYTOL, V133, P121; NELSEN B, UNPUB; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; REIK W, 1987, EUR J IMMUNOL, V17, P465, DOI 10.1002/eji.1830170405; RUEZINSKY D, 1991, GENE DEV, V5, P29, DOI 10.1101/gad.5.1.29; SCHLISSEL M, 1991, GENE DEV, V5, P1367, DOI 10.1101/gad.5.8.1367; SCHMIDT EV, 1988, P NATL ACAD SCI USA, V85, P6047, DOI 10.1073/pnas.85.16.6047; SELDEN RF, 1986, MOL CELL BIOL, V6, P3173, DOI 10.1128/MCB.6.9.3173; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; SUSSMAN DJ, 1984, MOL CELL BIOL, V4, P1641, DOI 10.1128/MCB.4.8.1641; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; TSAO BP, 1988, NUCLEIC ACIDS RES, V16, P3239, DOI 10.1093/nar/16.8.3239; WEINTRAUB H, 1991, SCIENCE, V251, P761, DOI 10.1126/science.1846704; WILSON RB, 1991, MOL CELL BIOL, V11, P6185, DOI 10.1128/MCB.11.12.6185; YANCOPOULOS GD, 1985, CELL, V40, P271, DOI 10.1016/0092-8674(85)90141-2	42	210	211	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					82	86		10.1126/science.8316859	http://dx.doi.org/10.1126/science.8316859			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	8316859				2022-12-01	WOS:A1993LK43400036
J	VESSEY, MP; VILLARDMACKINTOSH, L; PAINTER, R				VESSEY, MP; VILLARDMACKINTOSH, L; PAINTER, R			EPIDEMIOLOGY OF ENDOMETRIOSIS IN WOMEN ATTENDING FAMILY-PLANNING CLINICS	BRITISH MEDICAL JOURNAL			English	Article								Objective-To describe the epidemiology of endometriosis in women attending family planning clinics with special reference to contraceptive methods. Design-Non-randomised cohort study with follow up of subjects for up to 23 years. Disease was measured by first hospital admission rates since endometriosis can be diagnosed with accuracy only at laparotomy or laparoscopy. Setting-17 family planning centres in England and Scotland. Subjects-17 032 married white women aged 25-39 years at entry during 1968-74 who were taking oral contraceptives or using an intrauterine device or diaphragm. About 99% of the women approached agreed to participate and annual loss to follow up was about 0.3%. Main outcome measures-Diagnosis of endometriosis, age, parity, and history of contraceptive use. Results-Endometriosis was significantly related to age, peaking at ages 40-44 (chi2 for heterogeneity=30.9, p<0.001). Endometriosis was not linked to duration of taking oral contraceptives. Nevertheless, the risk of endometriosis was low in women currently taking oral contraceptives (relative risk 0.4; 95% confidence interval 0.2 to 0.7), but higher in women who had formerly taken them (1.8; 1.0 to 3.1 in women who had stopped 25-48 months previously) compared with women who had never taken the pill. A similar pattern was seen for use of intrauterine devices (relative risk 0.4 (0.2 to 0.7) in current users and 1.4 (0.4 to 3.2) in users 49-72 months previously compared with never users). No association was found between endometriosis and use of the diaphragm. Conclusions-Oral contraceptives seem to temporarily suppress endometriosis. Endometriosis may be diagnosed late in women using intrauterine devices as pain and bleeding occur with both.			VESSEY, MP (corresponding author), RADCLIFFE INFIRM,DEPT PUBL HLTH & PRIMARY CARE,OXFORD OX2 6HE,ENGLAND.							BUTTRAM VC, 1979, FERTIL STERIL, V31, P347; CRAMER DW, 1986, JAMA-J AM MED ASSOC, V255, P1904; KIRSHON B, 1988, OBSTET GYNECOL, V71, P829; MAHMOOD TA, 1991, HUM REPROD, V6, P544, DOI 10.1093/oxfordjournals.humrep.a137377; MOEN MH, 1987, ACTA OBSTET GYN SCAN, V66, P451, DOI 10.3109/00016348709022053; OBERMEYER CM, 1986, AM J EPIDEMIOL, V124, P762, DOI 10.1093/oxfordjournals.aje.a114452; RAMCHARAN S, 1981, 81564 NAT I HLTH CTR, V3; VESSEY M, 1976, Journal of Biosocial Science, V8, P373; 1974, ORAL CONTRACEPTIVES	9	150	157	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 16	1993	306	6871					182	184		10.1136/bmj.306.6871.182	http://dx.doi.org/10.1136/bmj.306.6871.182			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	KH513	8338516	Bronze, Green Published			2022-12-01	WOS:A1993KH51300022
J	LURIE, P; BISHAW, M; CHESNEY, MA; COOKE, M; FERNANDES, MEL; HEARST, N; KATONGOLEMBIDDE, E; KOETSAWANG, S; LINDAN, CP; MANDEL, J; MHLOYI, M; COATES, TJ				LURIE, P; BISHAW, M; CHESNEY, MA; COOKE, M; FERNANDES, MEL; HEARST, N; KATONGOLEMBIDDE, E; KOETSAWANG, S; LINDAN, CP; MANDEL, J; MHLOYI, M; COATES, TJ			ETHICAL, BEHAVIORAL, AND SOCIAL ASPECTS OF HIV VACCINE TRIALS IN DEVELOPING-COUNTRIES	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							AIDS VACCINES; CLINICAL-TRIALS; ISSUES; AFRICA; RESEARCHERS; PREVENTION	Issue.-Several investigators are preparing to conduct efficacy trials of human immunodeficiency virus (HIV) vaccines in the developing world. Failure to adequately address the unique ethical, behavioral, and social issues that surround vaccine testing in that setting will jeopardize the success of these trials and future acquired immunodeficiency syndrome (AIDS) research in the host nation. Description of the Project.-Twelve investigators from Africa, Asia, North America, and South America reviewed previous experience with HIV trials in developing countries and explored potential solutions to these issues. Conclusions.-Host country scientists, government officials, and media must be actively involved in all aspects of the trials. Minimum prerequisites for conducting the trial include the following: (1) researching vaccines active against developing world HIV isolates; (2) establishing and maintaining an adequate technological infrastructure; (3) assessing the feasibility of recruitment in countries where the existence of HIV may be denied; (4) designing methods to obtain informed consent from each individual subject, rather than exclusively from family members or community elders; (5) creating locally appropriate instruments to measure risk behavior; (6) identifying a behavioral intervention for placebo and treatment groups; (7) making available laboratory methods to distinguish between natural HIV infection and vaccine-induced seropositivity; and (8) guaranteeing that an effective vaccine is available free of charge to the placebo group and at affordable prices to other host country residents.	UNIV ADDIS ABABA,INST DEV RES,ADDIS ABABA,ETHIOPIA; FAMILY HLTH INT AIDSCAP,SAO PAULO,BRAZIL; UGANDA CANC INST,KAMPALA,UGANDA; MAHIDOL UNIV,SIRARAJ FAMILY HLTH RES CTR,BANGKOK 10700,THAILAND; UNIV ZIMBABWE,HARARE,ZIMBABWE	Addis Ababa University; Mahidol University; University of Zimbabwe	LURIE, P (corresponding author), UNIV CALIF SAN FRANCISCO,CTR AIDS PREVENT STUDIES,74 NEW MONTGOMERY ST,6TH FLOOR,SAN FRANCISCO,CA 94105, USA.				NATIONAL INSTITUTE OF MENTAL HEALTH [T32MH019105, P50MH042459] Funding Source: NIH RePORTER; NIMH NIH HHS [MH 19105, MH 42459] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AJAYI OO, 1980, J MED ETHICS, V6, P61, DOI 10.1136/jme.6.2.61; ALLEN S, 1992, JAMA-J AM MED ASSOC, V268, P3338, DOI 10.1001/jama.268.23.3338; ANKRAH EM, 1989, SOC SCI MED, V29, P265, DOI 10.1016/0277-9536(89)90275-X; [Anonymous], BLAMING OTHERS PREJU; BARRICK B, 1988, 4TH INT C AIDS STOCK; BARRY M, 1990, NEW ENGL J MED, V322, P201; BARRY M, 1992, NEW ENGL J MED, V327, P1103; BLOWER SM, 1993, 9TH INT C AIDS BERL; CHEYNE J, 1989, REV INFECT DIS S3, V11, P5617; CHRISTAKIS NA, 1988, HASTINGS CTR REP JUN, P31; COHEN J, 1991, SCIENCE, V251, P1312, DOI 10.1126/science.2003218; COHEN J, 1993, SCIENCE, V259, P752, DOI 10.1126/science.8430324; COHEN J, 1992, SCIENCE, V258, P883, DOI 10.1126/science.1439797; COHEN J, 1992, SCIENCE, V258, P536, DOI 10.1126/science.1411563; COHEN J, 1992, SCIENCE, V258, P211, DOI 10.1126/science.1411518; Enel Patricia, 1992, AIDS Public Policy J, V7, P50; ESPARZA J, 1993, 9TH INT C AIDS BERL; GRANT RM, 1992, 8TH INT C AIDS AMST; IJSSELMUIDEN CB, 1992, NEW ENGL J MED, V326, P830, DOI 10.1056/NEJM199203193261212; KATZENSTEIN DA, 1988, AIDS, V2, P151; KOFF WC, 1988, SCIENCE, V241, P426, DOI 10.1126/science.3293212; KOFF WC, 1992, 8TH INT C AIDS AMST; KONOTEYAHULU FID, 1987, LANCET, V2, P206; LAMPTEY P, 1992, 8TH INT C AIDS AMST; LEBLOND RF, 1992, 8TH INT C AIDS AMST; Macklin R, 1986, Law Med Health Care, V14, P273; MARINER WK, 1989, AM J PUBLIC HEALTH, V79, P86, DOI 10.2105/AJPH.79.1.86; MARMOR M, 1993, 9 INT C AIDS BERL; MARWICK C, 1991, JAMA-J AM MED ASSOC, V265, P2648; MATTHEWS TJ, 1988, SCI AM, V4, P120; MELTON GB, 1988, AM PSYCHOL, V43, P573, DOI 10.1037/0003-066X.43.7.573; MERZ B, 1987, JAMA-J AM MED ASSOC, V258, P1433, DOI 10.1001/jama.258.11.1433; NDINYAACHOLA JO, 1991, E AFR MED J, V68, P735; OSBORN JE, 1992, 8 INT C AIDS AMST; SCHILD GC, 1990, LANCET, V335, P1081, DOI 10.1016/0140-6736(90)92645-X; SCHOEPF BG, 1991, SOC SCI MED, V33, P749, DOI 10.1016/0277-9536(91)90374-L; SERWADDA D, 1990, LANCET, V335, P842, DOI 10.1016/0140-6736(90)90946-3; SOUTEYRAND Y, 1992, 8TH INT C AIDS AMST; TACKET CO, 1990, J INFECT DIS, V161, P356, DOI 10.1093/infdis/161.2.356; ULIN PR, 1992, SOC SCI MED, V34, P63, DOI 10.1016/0277-9536(92)90068-2; VERMUND SH, 1992, 8 INT C AIDS AMST; WALTERS L, 1988, SCIENCE, V239, P597, DOI 10.1126/science.3340846; WINKELSTEIN W, 1992, AUG FUT HIV VACC SAN; 1991, ETHICAL CONDUCT AIDS; 1992, NIH GUIDE GRANTS CON, V21, P3; 1978, US DHEW OS780012 NAT; 1990, PRACTICAL TECHNICAL; 1989, STATEMENT CONSULTATI	49	70	70	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 26	1994	271	4					295	301		10.1001/jama.271.4.295	http://dx.doi.org/10.1001/jama.271.4.295			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MR221	8295289				2022-12-01	WOS:A1994MR22100026
J	BAUREN, G; WIESLANDER, L				BAUREN, G; WIESLANDER, L			SPLICING OF BALBIANI RING-1 GENE PREMESSENGER RNA OCCURS SIMULTANEOUSLY WITH TRANSCRIPTION	CELL			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; CHIRONOMUS-TENTANS; ELECTROPHORETIC SEPARATION; INTERVENING SEQUENCES; SITE SELECTION; INVITRO; POLYADENYLATION; VISUALIZATION; SPLICEOSOMES; LOCALIZATION	The 40 kb Balbiani ring 1 (BR1) gene is at a given moment transcribed by, on average, 120 RNA polymerases. Here we directly assay the excision of introns both in the nascent and in the released nucleoplasmic BR1 pre-mRNAs, isolated by microdissection. We show that intron 3, located 3 kb from the 5' end of the pre-mRNA, is excised simultaneous with transcription. Within 2.5 min of transcription time, 50% of the pre-mRNA molecules have lost the intron. Intron 4, located 600 bases from the polyadenylation site, is excised cotranscriptionally in 5%-10% of the molecules and after or during release to the nucleoplasm in the remaining molecules. Our results demonstrate that spliceosome assembly is a cotranscriptional process in vivo and that splicing may occur during transcription but also after completed transcription, depending on the position of the intron.	KAROLINSKA INST,MED NOBEL INST,DEPT CELL & MOLEC BIOL,S17177 STOCKHOLM,SWEDEN	Karolinska Institutet			Wieslander, Lars/B-4670-2016	Wieslander, Lars/0000-0003-3271-6946				AEBI M, 1987, TRENDS GENET, V3, P102, DOI 10.1016/0168-9525(87)90193-4; AMERO SA, 1992, P NATL ACAD SCI USA, V89, P8409, DOI 10.1073/pnas.89.18.8409; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BEYER AL, 1988, GENE DEV, V2, P754, DOI 10.1101/gad.2.6.754; CARMOFONSECA M, 1991, EMBO J, V10, P1863, DOI 10.1002/j.1460-2075.1991.tb07712.x; DANEHOLT B, 1972, NATURE-NEW BIOL, V240, P229, DOI 10.1038/newbio240229a0; DARNELL JE, 1982, NATURE, V297, P365, DOI 10.1038/297365a0; DREYFUSS G, 1988, TRENDS BIOCHEM SCI, V13, P86, DOI 10.1016/0968-0004(88)90046-1; DREYFUSS G, 1990, EUCARYOTIC NUCLEUS S, V2, P477; EDSTROM JE, 1978, CHROMOSOMA, V66, P33, DOI 10.1007/BF00285814; EGYHAZI E, 1975, P NATL ACAD SCI USA, V72, P947, DOI 10.1073/pnas.72.3.947; FAKAN S, 1986, J CELL BIOL, V103, P1153, DOI 10.1083/jcb.103.4.1153; FOE VE, 1976, CELL, V9, P131, DOI 10.1016/0092-8674(76)90059-3; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; GALL JG, 1991, SCIENCE, V252, P1499, DOI 10.1126/science.1828621; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HAWKINS JD, 1988, NUCLEIC ACIDS RES, V16, P9893, DOI 10.1093/nar/16.21.9893; HOOG C, 1986, NUCLEIC ACIDS RES, V14, P703, DOI 10.1093/nar/14.2.703; HUANG S, 1992, Current Biology, V2, P188, DOI 10.1016/0960-9822(92)90516-D; JIMENEZGARCIA LF, 1993, CELL, V73, P47, DOI 10.1016/0092-8674(93)90159-N; KEOHAVONG P, 1982, NUCLEIC ACIDS RES, V10, P1215, DOI 10.1093/nar/10.4.1215; KONARSKA MM, 1986, CELL, V46, P845, DOI 10.1016/0092-8674(86)90066-8; LAMB MM, 1979, CELL, V17, P835, DOI 10.1016/0092-8674(79)90324-6; Lambert B, 1975, Methods Cell Biol, V10, P17, DOI 10.1016/S0091-679X(08)60728-1; LAMOND AI, 1993, CURR BIOL, V3, P62, DOI 10.1016/0960-9822(93)90154-G; LANG KM, 1987, MOL CELL BIOL, V7, P3428, DOI 10.1128/MCB.7.10.3428; LANG KM, 1985, EMBO J, V4, P1991, DOI 10.1002/j.1460-2075.1985.tb03882.x; LEMAIRE MF, 1990, MOL CELL BIOL, V10, P6059, DOI 10.1128/MCB.10.11.6059; LEWIN B, 1980, CELL, V22, P324, DOI 10.1016/0092-8674(80)90340-2; LONNROTH A, 1992, EXP CELL RES, V199, P292, DOI 10.1016/0014-4827(92)90437-D; LUHRMANN R, 1990, BIOCHIM BIOPHYS ACTA, V1087, P265, DOI 10.1016/0167-4781(90)90001-I; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MARIMAN ECM, 1983, J MOL BIOL, V163, P239, DOI 10.1016/0022-2836(83)90005-0; MATTAJ IW, 1993, FASEB J, V7, P47, DOI 10.1096/fasebj.7.1.8422974; MATUNIS EL, 1993, J CELL BIOL, V121, P219, DOI 10.1083/jcb.121.2.219; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MCKNIGHT SL, 1979, CELL, V17, P551; MICHAUD S, 1993, GENE DEV, V7, P10018; NEVINS JR, 1983, ANNU REV BIOCHEM, V52, P441, DOI 10.1146/annurev.bi.52.070183.002301; NIWA M, 1990, GENE DEV, V4, P1552, DOI 10.1101/gad.4.9.1552; NIWA M, 1991, GENE DEV, V5, P2086, DOI 10.1101/gad.5.11.2086; NYMAN U, 1986, J CELL BIOL, V102, P137, DOI 10.1083/jcb.102.1.137; OSHEIM YN, 1985, CELL, V43, P143, DOI 10.1016/0092-8674(85)90019-4; PAULSSON G, 1992, J MOL BIOL, V225, P349, DOI 10.1016/0022-2836(92)90926-B; PINOLROMA S, 1988, GENE DEV, V2, P215, DOI 10.1101/gad.2.2.215; REED R, 1988, CELL, V53, P949, DOI 10.1016/S0092-8674(88)90489-8; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; RIO D C, 1992, Current Opinion in Cell Biology, V4, P444, DOI 10.1016/0955-0674(92)90010-A; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; RUBY SW, 1991, TRENDS GENET, V7, P79; SAMBROOK J, 1989, MOL CLONING LABORATG; SASS H, 1984, J MOL BIOL, V180, P911, DOI 10.1016/0022-2836(84)90263-8; SKOGLUND U, 1983, CELL, V34, P847, DOI 10.1016/0092-8674(83)90542-1; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; ULLU E, 1993, MOL CELL BIOL, V13, P720, DOI 10.1128/MCB.13.1.720; VAZQUEZNIN GH, 1990, CHROMOSOMA, V99, P44, DOI 10.1007/BF01737288; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WASSARMAN KM, 1993, GENE DEV, V7, P647, DOI 10.1101/gad.7.4.647; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; WIESLANDER L, 1979, ANAL BIOCHEM, V98, P305, DOI 10.1016/0003-2697(79)90145-3; WU ZG, 1991, J CELL BIOL, V113, P465, DOI 10.1083/jcb.113.3.465; XING YG, 1993, SCIENCE, V259, P1326, DOI 10.1126/science.8446901; [No title captured]	65	240	242	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 14	1994	76	1					183	192		10.1016/0092-8674(94)90182-1	http://dx.doi.org/10.1016/0092-8674(94)90182-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287477				2022-12-01	WOS:A1994MR49500016
J	LI, M; MOYLE, H; SUSSKIND, MM				LI, M; MOYLE, H; SUSSKIND, MM			TARGET OF THE TRANSCRIPTIONAL ACTIVATION FUNCTION OF PHAGE-LAMBDA CL-PROTEIN	SCIENCE			English	Article							COLI RNA-POLYMERASE; ESCHERICHIA-COLI; SIGMA-70 SUBUNIT; POSITIVE CONTROL; PROMOTER RECOGNITION; PRM PROMOTER; REPRESSOR; MUTATIONS; INITIATION; SPECIFICITY	Activation of transcription initiation by the cl protein of phage lambda is thought to be mediated by a direct interaction between cl and RNA polymerase at the P(RM) promoter. Two negatively charged amino acid residues in the DNA binding domain of cl play a key role in activation, suggesting that these residues contact RNA polymerase. The subunit of RNA polymerase involved was identified by selecting polymerase mutants that restored the activation function of a mutant form of cl protein. Although previous studies suggest that several activators interact with the alpha subunit of RNA polymerase, the results here suggest that cl interacts with the sigma subunit. An arginine to histidine change near the carboxyl terminus of sigma specifically suppresses an aspartic acid to asparagine change in the activation region of cl. This finding supports the direct-contact model and suggests that a cluster of positively charged residues near the carboxyl terminus of sigma is the target of the negatively charged activation region of cl.	UNIV SO CALIF,DEPT BIOL SCI,LOS ANGELES,CA 90089	University of Southern California					NIGMS NIH HHS [GM36811] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036811] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BUSHMAN FD, 1989, CELL, V58, P1163, DOI 10.1016/0092-8674(89)90514-X; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; EBRIGHT R, UNPUB; FONG RSC, 1988, IN PRESS J MOL BIOL, V200, P735; GARDELLA T, 1989, J MOL BIOL, V206, P579, DOI 10.1016/0022-2836(89)90567-6; GRANA D, 1985, GENETICS, V110, P1; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P2236, DOI 10.1073/pnas.79.7.2236; HAWLEY DK, 1983, CELL, V32, P327, DOI 10.1016/0092-8674(83)90452-X; HAWLEY DK, 1982, J MOL BIOL, V157, P493, DOI 10.1016/0022-2836(82)90473-9; HAYWARD RB, UNPUB; HOCHSCHILD A, 1983, CELL, V32, P319, DOI 10.1016/0092-8674(83)90451-8; HOCHSCHILD A, UNPUB; HU JC, 1985, MOL GEN GENET, V199, P7, DOI 10.1007/BF00327502; HWANG JJ, 1988, J MOL BIOL, V200, P735, DOI 10.1016/0022-2836(88)90484-6; ISHIHAMA A, 1993, J BACTERIOL, V175, P2483, DOI 10.1128/JB.175.9.2483-2489.1993; JORDAN SR, 1988, SCIENCE, V242, P893, DOI 10.1126/science.3187530; KEENER J, 1993, P NATL ACAD SCI USA, V90, P1751, DOI 10.1073/pnas.90.5.1751; MAKINO K, 1993, GENE DEV, V7, P149, DOI 10.1101/gad.7.1.149; MEYER BJ, 1980, J MOL BIOL, V139, P195, DOI 10.1016/0022-2836(80)90304-6; Miller JH., 1972, EXPT MOL GENETICS; PTASHNE M, 1992, GENETIC SWITCH GENE; RUSSO FD, 1992, J BIOL CHEM, V267, P14515; SIEGELE DA, 1989, J MOL BIOL, V206, P591, DOI 10.1016/0022-2836(89)90568-8; SIEGELE DA, 1988, J MOL BIOL, V203, P29, DOI 10.1016/0022-2836(88)90088-5; SILVERSTONE AE, 1972, MOL GEN GENET, V118, P223, DOI 10.1007/BF00333459; SMITH HO, 1964, P NATL ACAD SCI USA, V52, P356, DOI 10.1073/pnas.52.2.356; TSAI SP, 1989, J GEN MICROBIOL, V135, P2561; WALDBURGER C, 1990, J MOL BIOL, V215, P267, DOI 10.1016/S0022-2836(05)80345-6	28	151	152	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 7	1994	263	5143					75	77		10.1126/science.8272867	http://dx.doi.org/10.1126/science.8272867			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ301	8272867				2022-12-01	WOS:A1994MQ30100032
J	SASAKI, YC; SUZUKI, Y; ISHIBASHI, T				SASAKI, YC; SUZUKI, Y; ISHIBASHI, T			FLUORESCENT X-RAY INTERFERENCE FROM A PROTEIN MONOLAYER	SCIENCE			English	Article							SURFACE	Fluorescent x-ray interference patterns have been observed from monolayers of both a metal-containing protein (ferritin) and a nonmetal-containing protein [bovine serum albumin (BSA)] bound on a gold substrate. These interference patterns have been used to determine structure data. The nonmetal-containing protein was first reacted with metal ions by means of a chelate compound to place the necessary chromophore in the molecule. The size of the ferritin core measured by a scanning electron microscope agrees with the value obtained from the x-ray interference experiments. In the BSA molecule, the measured interference fringe is consistent with the model in which the short axes of BSA molecules are perpendicular to the surface substrate.			SASAKI, YC (corresponding author), HITACHI LTD,ADV RES LAB,HATOYAMA,SAITAMA 35003,JAPAN.		SASAKI, Yuji/N-6880-2016	SASAKI, Yuji/0000-0003-3403-237X				BEDZYK MJ, 1989, PHYS REV LETT, V62, P1376, DOI 10.1103/PhysRevLett.62.1376; Born M., 1980, PRINCIPLES OPTICS EL, V6th, P55; CHATTERJ.A, 1965, J MOL BIOL, V11, P432, DOI 10.1016/S0022-2836(65)80068-7; FROMHERZ P, 1971, NATURE, V231, P267, DOI 10.1038/231267a0; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; HNATOWICH DJ, 1982, INT J APPL RADIAT IS, V33, P327, DOI 10.1016/0020-708X(82)90144-2; HUTTON JT, 1985, PHYS REV B, V31, P6420, DOI 10.1103/PhysRevB.31.6420; Kossel W, 1935, Z PHYS, V94, P139, DOI 10.1007/BF01330803; SASAKI Y, 1990, APPL PHYS A-MATER, V50, P397, DOI 10.1007/BF00323597; SASAKI YC, 1993, PHYS REV B, V48, P7724, DOI 10.1103/PhysRevB.48.7724; TOMIOKA Y, 1990, CHEM PHYS LETT, V174, P433, DOI 10.1016/S0009-2614(90)87175-Q; von Laue M, 1935, ANN PHYS-BERLIN, V23, P705	12	21	21	0	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 7	1994	263	5143					62	64		10.1126/science.8272866	http://dx.doi.org/10.1126/science.8272866			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ301	8272866				2022-12-01	WOS:A1994MQ30100027
J	LIU, HP; STYLES, CA; FINK, GR				LIU, HP; STYLES, CA; FINK, GR			ELEMENTS OF THE YEAST PHEROMONE RESPONSE PATHWAY REQUIRED FOR FILAMENTOUS GROWTH OF DIPLOIDS	SCIENCE			English	Article							PROTEIN-KINASE; SACCHAROMYCES-CEREVISIAE; USTILAGO-MAYDIS; SIGNALING COMPONENTS; CONSTITUTIVE MUTANTS; GAMMA-SUBUNITS; FISSION YEAST; GENES; STE12; TRANSCRIPTION	Transmission of an external signal from receptors to downstream targets is often mediated by a conserved set of protein kinases that act in sequence (a kinase cascade). In haploid strains of Saccharomyces cerevisiae, a signal initiated by peptide pheromones is transmitted through this kinase cascade to a transcription factor STE12, which is required for the expression of many mating-specific genes. Here it was shown that in diploids some of the same kinases and STE12 are required for filamentous growth, but the pheromone receptors and guanosine triphosphate-binding protein are not required for filament formation. Thus, a similar kinase cascade is activated by different signals in haploids and diploids and mediates different developmental outcomes in the two cell types.	MIT,WHITEHEAD INST BIOMED RES,CAMBRIDGE,MA 02142	Massachusetts Institute of Technology (MIT); Whitehead Institute					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035010, R37GM035010] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM 35010] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANUETT F, 1992, TRENDS GENET, V8, P174, DOI 10.1016/0168-9525(92)90091-H; BANUETT F, 1989, P NATL ACAD SCI USA, V86, P5878, DOI 10.1073/pnas.86.15.5878; BENDER A, 1991, CELL, V65, P1203; BLINDER D, 1989, CELL, V56, P479, DOI 10.1016/0092-8674(89)90250-X; BOLKER M, 1992, CELL, V68, P441, DOI 10.1016/0092-8674(92)90182-C; CHALEFF DT, 1985, MOL CELL BIOL, V5, P1878, DOI 10.1128/MCB.5.8.1878; CHANT J, 1991, CELL, V65, P1213, DOI 10.1016/0092-8674(91)90016-R; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; DOLAN JW, 1989, P NATL ACAD SCI USA, V86, P5703, DOI 10.1073/pnas.86.15.5703; DOLAN JW, 1990, GENE DEV, V4, P492, DOI 10.1101/gad.4.4.492; ELION EA, 1991, COLD SH Q B, V56, P41; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ERREDE B, 1989, GENE DEV, V3, P1349, DOI 10.1101/gad.3.9.1349; FIELDS S, 1985, CELL, V42, P923, DOI 10.1016/0092-8674(85)90288-0; GILLISSEN B, 1992, CELL, V68, P647, DOI 10.1016/0092-8674(92)90141-X; GIMENO CJ, 1992, SCIENCE, V257, P626, DOI 10.1126/science.1496375; GIMENO CJ, 1992, CELL, V68, P1077, DOI 10.1016/0092-8674(92)90079-R; LEBERER E, 1992, EMBO J, V11, P4815, DOI 10.1002/j.1460-2075.1992.tb05587.x; NADINDAVIS SA, 1988, EMBO J, V7, P985, DOI 10.1002/j.1460-2075.1988.tb02905.x; NAKAYAMA N, 1985, EMBO J, V4, P2643, DOI 10.1002/j.1460-2075.1985.tb03982.x; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; RAMER SW, 1993, P NATL ACAD SCI USA, V90, P452, DOI 10.1073/pnas.90.2.452; RHODES N, 1990, GENE DEV, V4, P1862, DOI 10.1101/gad.4.11.1862; Sprague GF, 1992, MOL CELLULAR BIOL YE, V2, P657; STEVENSON BJ, 1992, GENE DEV, V6, P1293, DOI 10.1101/gad.6.7.1293; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; TRUEHEART J, 1987, MOL CELL BIOL, V7, P2316, DOI 10.1128/MCB.7.7.2316; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WHITEWAY M, 1989, CELL, V56, P467, DOI 10.1016/0092-8674(89)90249-3; WRIGHT RM, 1993, CURR GENET, V23, P388, DOI 10.1007/BF00312623	31	420	432	0	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 10	1993	262	5140					1741	1744		10.1126/science.8259520	http://dx.doi.org/10.1126/science.8259520			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML220	8259520				2022-12-01	WOS:A1993ML22000044
J	JEPPESEN, P; TURNER, BM				JEPPESEN, P; TURNER, BM			THE INACTIVE X-CHROMOSOME IN FEMALE MAMMALS IS DISTINGUISHED BY A LACK OF HISTONE-H4 ACETYLATION, A CYTOGENETIC MARKER FOR GENE-EXPRESSION	CELL			English	Article							HUMAN METAPHASE CHROMOSOMES; HUMAN-CELLS; XIST GENE; HETEROCHROMATIN; ANTIBODIES; ISLANDS; LOCALIZATION; REPLICATION; ISOFORMS; NUCLEUS	We have immunolabeled human and mouse metaphase chromosomes with antibodies specific for the acetylated isoforms of histone H4. All chromosomes were labeled in regions corresponding to conventional R bands (regions enriched in coding DNA), except for a single chromosome in female cells, which was largely unlabeled and which we have identified as the inactive X (Xi). Three sharply defined immunofluorescent bands, enhanced by butyrate pretreatment, were observed in homologous positions on the human and mouse Xi, showing limited, regional persistence of H4 acetylation. Two of these bands are in cytogenetic regions known to contain genes expressed on Xi. We propose that H4 hyperacetylation defines regions of the genome containing potentially transcriptionally active chromatin, while virtual absence of H4 acetylation defines both constitutive and facultative heterochromatin.	UNIV BIRMINGHAM,SCH MED,DEPT ANAT,BIRMINGHAM B15 2TT,W MIDLANDS,ENGLAND	University of Birmingham	JEPPESEN, P (corresponding author), WESTERN GEN HOSP,MRC,HUMAN GENET UNIT,EDINBURGH EH4 2XU,MIDLOTHIAN,SCOTLAND.							ASHWORTH A, 1991, NATURE, V351, P406, DOI 10.1038/351406a0; BARR ML, 1949, NATURE, V163, P676, DOI 10.1038/163676a0; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BORSANI G, 1991, NATURE, V351, P325, DOI 10.1038/351325a0; BROCKDORFF N, 1991, NATURE, V351, P329, DOI 10.1038/351329a0; BROCKDORFF N, 1992, CELL, V71, P515, DOI 10.1016/0092-8674(92)90519-I; BROWN CJ, 1991, NATURE, V349, P82, DOI 10.1038/349082a0; BROWN CJ, 1991, NATURE, V349, P38, DOI 10.1038/349038a0; BROWN CJ, 1992, CELL, V71, P527, DOI 10.1016/0092-8674(92)90520-M; BROWN CJ, 1990, AM J HUM GENET, V46, P273; CSORDAS A, 1990, BIOCHEM J, V265, P23, DOI 10.1042/bj2650023; DAVIES K, 1991, NATURE, V349, P15, DOI 10.1038/349015a0; DAVIES KE, 1991, CYTOGENET CELL GENET, V58, P853, DOI 10.1159/000133183; DAVISSON M T, 1987, Genomics, V1, P213, DOI 10.1016/0888-7543(87)90047-4; DUTRILLAUX B, 1971, CR ACAD SCI D NAT, V272, P2638; FISHER EMC, 1990, CELL, V63, P1205, DOI 10.1016/0092-8674(90)90416-C; GRANT SG, 1988, ANNU REV GENET, V22, P199, DOI 10.1146/annurev.ge.22.120188.001215; HEBBES TR, 1992, NUCLEIC ACIDS RES, V20, P1017, DOI 10.1093/nar/20.5.1017; HOLMQUIST GP, 1987, AM J HUM GENET, V40, P151; JEPPESEN P, 1992, CHROMOSOMA, V101, P322, DOI 10.1007/BF00346011; KANDA N, 1973, EXP CELL RES, V80, P463, DOI 10.1016/0014-4827(73)90324-8; LAFRENIERE RG, 1991, GENOMICS, V11, P352, DOI 10.1016/0888-7543(91)90143-3; LATT SA, 1973, P NATL ACAD SCI USA, V70, P3395, DOI 10.1073/pnas.70.12.3395; LUCCHESI JC, 1987, ADV GENET, V24, P271; LYON MF, 1986, NATURE, V320, P313, DOI 10.1038/320313b0; LYON MF, 1961, NATURE, V190, P372, DOI 10.1038/190372a0; MATTEI MG, 1981, HUM GENET, V56, P401, DOI 10.1007/BF00274702; MILLER OJ, 1974, NATURE, V251, P636, DOI 10.1038/251636a0; MORISHIMA A, 1962, P NATL ACAD SCI USA, V48, P756, DOI 10.1073/pnas.48.5.756; RASTAN S, 1990, GENET RES, V56, P99, DOI 10.1017/S0016672300035163; RASTAN S, 1992, GENET RES, V8, P169; RIGGS AD, 1992, TRENDS GENET, V8, P169, DOI 10.1016/0168-9525(92)90219-T; SAUNDERS WS, 1993, J CELL SCI, V104, P573; SAVAGE JRK, 1984, J MED GENET, V21, P204, DOI 10.1136/jmg.21.3.204; SCHNEIDERGADICKE A, 1989, CELL, V57, P1247, DOI 10.1016/0092-8674(89)90061-5; SINGH PB, 1991, NUCLEIC ACIDS RES, V19, P789, DOI 10.1093/nar/19.4.789; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; THORNE AW, 1990, EUR J BIOCHEM, V193, P701, DOI 10.1111/j.1432-1033.1990.tb19390.x; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; TURNER BM, 1989, EUR J BIOCHEM, V179, P131, DOI 10.1111/j.1432-1033.1989.tb14530.x; TURNER BM, 1989, FEBS LETT, V253, P141, DOI 10.1016/0014-5793(89)80947-0; TURNER BM, 1990, J CELL SCI, V96, P335; TURNER BM, 1989, EXP CELL RES, V182, P206, DOI 10.1016/0014-4827(89)90292-9; TURNER BM, 1991, J CELL SCI, V99, P13	44	601	606	1	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					281	289		10.1016/0092-8674(93)90419-Q	http://dx.doi.org/10.1016/0092-8674(93)90419-Q			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343956				2022-12-01	WOS:A1993LP72600009
J	COLOTTA, F; RE, F; MUZIO, M; BERTINI, R; POLENTARUTTI, N; SIRONI, M; GIRI, JG; DOWER, SK; SIMS, JE; MANTOVANI, A				COLOTTA, F; RE, F; MUZIO, M; BERTINI, R; POLENTARUTTI, N; SIRONI, M; GIRI, JG; DOWER, SK; SIMS, JE; MANTOVANI, A			INTERLEUKIN-1 TYPE-II RECEPTOR - A DECOY TARGET FOR IL-1 THAT IS REGULATED BY IL-4	SCIENCE			English	Article							POLYMORPHONUCLEAR LEUKOCYTES; MOLECULAR-PROPERTIES; ENDOTHELIAL-CELLS; BINDING-SITES; T-CELLS; B-CELLS; EXPRESSION; IDENTIFICATION; PURIFICATION; LYMPHOCYTES	Interleukin-1 (IL-1) interacts with cells through two types of binding molecules, IL-1 type I receptor (IL-1R I) and IL-1R II. The function of IL-1R II is unknown. In studies using monoclonal antibodies, IL-1 prolonged the in vitro survival of polymorphonuclear cells (PMN) through IL-1R I, and IL-4 antagonized the action of IL-1 by inducing expression and release of IL-1R II. Dexamethasone also induced expression and release of the IL-1R II in PMN. These results, together with the effect of antibodies to IL-1R on IL-1-induced production of cytokines in monocytes, indicate that IL-1 acts on myelomonocytic cells through IL-1R I and that IL-1R II inhibits IL-1 activity by acting as a decoy target for IL-1. The existence of multiple pathways of regulation emphasizes the need for tight control of IL-1 action.	IMMUNEX RES & DEV CORP,DEPT IMMUNOL,SEATTLE,WA 98101		COLOTTA, F (corresponding author), MARIO NEGRI INST PHARMACOL RES,CTR DANIELA & CATULLO BORGOMAINERIO,VIA ERITREA 62,I-20157 MILAN,ITALY.		Muzio, Marta/J-9360-2018; Mantovani, Alberto/HCI-7449-2022; sironi, marina/AAB-5757-2020	Muzio, Marta/0000-0002-7761-759X; Mantovani, Alberto/0000-0001-5578-236X; sironi, marina/0000-0002-3342-1149; Colotta, Francesco/0000-0001-8601-2309; Sims, John/0000-0002-5667-9185; dower, steve/0000-0002-4675-4225				AKAHOSHI T, 1988, J EXP MED, V167, P924, DOI 10.1084/jem.167.3.924; BENJAMIN D, 1990, J BIOL CHEM, V265, P9943; BENSIMON C, 1989, J IMMUNOL, V143, P1168; BIRD TA, 1988, J BIOL CHEM, V263, P12063; BIRD TA, 1986, NATURE, V324, P263, DOI 10.1038/324263a0; BORASCHI D, 1991, BLOOD, V78, P1262; BORMSTYK K, 1989, P NATL ACAD SCI USA, V86, P8034; CHIN J, 1987, J EXP MED, V165, P70, DOI 10.1084/jem.165.1.70; CHIZZONITE R, 1989, P NATL ACAD SCI USA, V86, P8029, DOI 10.1073/pnas.86.20.8029; COLOTTA F, 1992, BLOOD, V80, P2012; COLOTTA F, 1993, BLOOD, V81, P1347; COLOTTA F, 1992, J IMMUNOL, V148, P760; COLOTTA F, 1987, J EXP MED, V165, P122; DINARELLO CA, 1991, BLOOD, V77, P1627; DOWER SK, 1985, J EXP MED, V162, P501, DOI 10.1084/jem.162.2.501; DOWER SK, 1986, NATURE, V324, P266, DOI 10.1038/324266a0; GIRI JG, 1990, J BIOL CHEM, V265, P17416; GRANOWITZ EV, 1991, J BIOL CHEM, V266, P14147; HORUK R, 1987, J BIOL CHEM, V262, P16275; KILIAN PL, 1986, J IMMUNOL, V136, P4509; KOCH KC, 1992, EUR J IMMUNOL, V22, P153, DOI 10.1002/eji.1830220123; LOPEZ AF, 1986, J CLIN INVEST, V78, P1220, DOI 10.1172/JCI112705; LORD PCW, 1991, J CLIN INVEST, V87, P1312, DOI 10.1172/JCI115134; MATSUSHIMA K, 1986, J IMMUNOL, V136, P4496; MCMAHAN CJ, 1991, EMBO J, V10, P2821, DOI 10.1002/j.1460-2075.1991.tb07831.x; PAUL WE, 1991, BLOOD, V77, P1859; RHYNE JA, 1988, CLIN IMMUNOL IMMUNOP, V48, P354, DOI 10.1016/0090-1229(88)90029-3; SCAPIGLIATI G, 1989, FEBS LETT, V243, P394, DOI 10.1016/0014-5793(89)80169-3; SIMS JE, 1988, SCIENCE, V241, P585, DOI 10.1126/science.2969618; SIRONI M, 1989, J IMMUNOL, V142, P549; SPRIGGS MK, 1992, CYTOKINE, V4, P90, DOI 10.1016/1043-4666(92)90042-P; SPRIGGS MK, 1992, CELL, V71, P145, DOI 10.1016/0092-8674(92)90273-F; SPRIGGS MK, 1992, CELL, V71, P153; SPRIGGS MK, 1990, J BIOL CHEM, V265, P2249; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; SYMONS JA, 1991, J EXP MED, V174, P1251, DOI 10.1084/jem.174.5.1251; TIKU K, 1986, J IMMUNOL, V136, P3677; URDAL DL, 1988, J BIOL CHEM, V263, P2870; YAMAGUCHI Y, 1991, BLOOD, V78, P2542	39	869	897	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 23	1993	261	5120					472	475		10.1126/science.8332913	http://dx.doi.org/10.1126/science.8332913			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN623	8332913				2022-12-01	WOS:A1993LN62300036
J	ALLEN, JC; SCHAFFER, WM; ROSKO, D				ALLEN, JC; SCHAFFER, WM; ROSKO, D			CHAOS REDUCES SPECIES EXTINCTION BY AMPLIFYING LOCAL-POPULATION NOISE	NATURE			English	Article							SPACE-LIMITED SUBPOPULATIONS; ECOLOGICAL-SYSTEMS; TIME-SERIES; DYNAMICS; MODELS; RARITY; GROWTH	IN the mid-1970s, theoretical ecologists were responsible for stimulating interest in nonlinear dynamics and chaos1-3. Ironically, the importance of chaos in ecology itself remains controversial4-17. Proponents of ecological chaos point to its ubiquity in mathematical models and to various empirical findings15,16,18. Sceptics12,19,20 maintain that the models are unrealistic and that the experimental evidence is equally consistent with stochastic models. More generally, it has been argued9,11,21-23 that interdemic selection and/or enhanced rates of species extinction will eliminate populations and species that evolve into chaotic regions of parameter space. Fundamental to this opinion is the belief24,25 that violent oscillations and low minimum population densities are inevitable correlates of the chaotic state. In fact, rarity is not a necessary consequence of complex dynamical behaviour26,27. But even when chaos is associated with frequent rarity, its consequences to survival are necessarily deleterious only in the case of species composed of a single population. Of course, the majority of real world species (for example, most insects) consist of multiple populations weakly coupled by migration, and in this circumstance chaos can actually reduce the probability of extinction. Here we show that although low densities lead to more frequent extinction at the local level28, the decorrelating effect of chaotic oscillations reduces the degree of synchrony among populations and thus the likelihood that all are simultaneously extinguished.	UNIV ARIZONA,DEPT ECOL & EVOLUTIONARY BIOL,TUCSON,AZ 85721	University of Arizona	ALLEN, JC (corresponding author), UNIV FLORIDA,DEPT ENTOMOL & NEMATOL,GAINESVILLE,FL 32611, USA.							BERRYMAN AA, 1989, TRENDS ECOL EVOL, V4, P26, DOI 10.1016/0169-5347(89)90014-1; BERRYMAN AA, 1991, CHAOS INSECT ECOLOGY, P23; CASDAGLI M, 1989, PHYSICA D, V35, P335, DOI 10.1016/0167-2789(89)90074-2; Collet P., 1980, ITERATED MAPS INTERV; CRUTCHFIELD JP, 1982, PHYS REP, V92, P45, DOI 10.1016/0370-1573(82)90089-8; ELLNER S, 1991, VA EXP STAF INF SERI, V9193, P63; Gilpin M.E., 1991, METAPOPULATION DYNAM; HASSELL MP, 1991, NATURE, V353, P255, DOI 10.1038/353255a0; HASSELL MP, 1976, J ANIM ECOL, V45, P473; IWASA Y, 1986, THEOR POPUL BIOL, V30, P194, DOI 10.1016/0040-5809(86)90033-X; Lichtenberg AJ, 1983, REGULAR STOCHASTIC M, P515; LOGAN JA, 1992, ANNU REV ENTOMOL, V37, P455, DOI 10.1146/annurev.en.37.010192.002323; LOMNICKI A, 1989, TRENDS ECOL EVOL, V4, P239; MANI GS, 1989, TRENDS ECOL EVOL, V4, P239; MAY RM, 1974, SCIENCE, V186, P645, DOI 10.1126/science.186.4164.645; MAY RM, 1976, AM NAT, V110, P573, DOI 10.1086/283092; MAY RM, 1976, NATURE, V261, P459, DOI 10.1038/261459a0; MILTON JG, 1990, THEOR POPUL BIOL, V37, P273, DOI 10.1016/0040-5809(90)90040-3; MORRIS WF, 1990, ECOLOGY, V71, P1849, DOI 10.2307/1937593; MUELLER LD, 1981, ECOLOGY, V62, P1148, DOI 10.2307/1937278; NISBET R, 1989, TRENDS ECOL EVOL, V4, P238, DOI 10.1016/0169-5347(89)90168-7; PHILIPPI TE, 1987, ECOLOGY, V68, P154, DOI 10.2307/1938815; PIMM SL, 1988, AM NAT, V132, P757, DOI 10.1086/284889; RICKER W. E., 1954, JOUR FISH RES BD CANADA, V11, P559; ROGERS TD, 1984, MATH BIOSCI, V72, P13, DOI 10.1016/0025-5564(84)90058-0; ROUGHGARDEN J, 1986, THEOR POPUL BIOL, V29, P235, DOI 10.1016/0040-5809(86)90010-9; RUELLE D, 1990, P ROY SOC LOND A MAT, V427, P241, DOI 10.1098/rspa.1990.0010; RUELLE D, 1979, BIFURCATION THEORY A, V316, P408; SCHAFFER WM, 1986, TRENDS ECOL EVOL, V1, P58, DOI 10.1016/0169-5347(86)90018-2; SUGIHARA G, 1990, NATURE, V344, P734, DOI 10.1038/344734a0; THOMAS WR, 1980, ECOLOGY, V61, P13; TILLMAN D, 1991, NATURE, V353, P653; TURCHIN P, 1990, NATURE, V344, P660, DOI 10.1038/344660a0; TURCHIN P, 1991, VA EXP STAF INF, V9193, P39; VANDERMEER J, 1982, ECOLOGY, V63, P1167, DOI 10.2307/1937252; VANDERMEER J, 1982, THEOR POPUL BIOL, V22, P17, DOI 10.1016/0040-5809(82)90033-8; YORKE JA, 1979, AM J EPIDEMIOL, V109, P103, DOI 10.1093/oxfordjournals.aje.a112666	37	271	282	1	31	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 15	1993	364	6434					229	232		10.1038/364229a0	http://dx.doi.org/10.1038/364229a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM683	8321317				2022-12-01	WOS:A1993LM68300054
J	CRUM, JE				CRUM, JE			PEAK EXPIRATORY FLOW-RATE IN SCHOOLCHILDREN LIVING CLOSE TO BRAER OIL-SPILL	BRITISH MEDICAL JOURNAL			English	Article																		GODFREY S, 1970, British Journal of Diseases of the Chest, V64, P15, DOI 10.1016/S0007-0971(70)80045-6; READ C, 1991, AIR POLLUTION CHILD	2	21	21	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1993	307	6895					23	24		10.1136/bmj.307.6895.23	http://dx.doi.org/10.1136/bmj.307.6895.23			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL369	8343663	Green Published, Bronze			2022-12-01	WOS:A1993LL36900020
J	BROWN, JH; JARDETZKY, TS; GORGA, JC; STERN, LJ; URBAN, RG; STROMINGER, JL; WILEY, DC				BROWN, JH; JARDETZKY, TS; GORGA, JC; STERN, LJ; URBAN, RG; STROMINGER, JL; WILEY, DC			3-DIMENSIONAL STRUCTURE OF THE HUMAN CLASS-II HISTOCOMPATIBILITY ANTIGEN HLA-DR1	NATURE			English	Article							MHC CLASS-II; NONOBESE DIABETIC MICE; T-CELL RECOGNITION; HLA-DR; CRYSTALLOGRAPHIC REFINEMENT; SURFACE EXPRESSION; PEPTIDE ANTIGENS; MOLECULAR-BASIS; BINDING SITE; BETA-CHAIN	The three-dimensional structure of the class II histocompatibility glycoprotein HLA-DR1 from human B-cell membranes has been determined by X-ray crystallography and is similar to that of class I HLA. Peptides are bound in an extended conformation that projects from both ends of an 'open-ended' antigen-binding groove. A prominent non-polar pocket into which an 'anchoring' peptide side chain fits is near one end of the binding groove. A dimer of the class II alphabeta heterodimers is seen in the crystal forms of HLA-DR1, suggesting class II HLA dimerization as a mechanism for initiating the cytoplasmic signalling events in T-cell activation.	HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, 7 DIVIN AVE, CAMBRIDGE, MA 02138 USA; CHILDRENS HOSP PITTSBURGH, DEPT PEDIAT, PITTSBURGH, PA 15213 USA; HARVARD UNIV, HOWARD HUGHES MED INST, CAMBRIDGE, MA 02138 USA	Harvard University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Harvard University; Howard Hughes Medical Institute								ALEXANDER J, 1993, J IMMUNOL, V150, P1; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; BJORKMAN PJ, 1987, NATURE, V329, P512, DOI 10.1038/329512a0; BLUM M, 1987, J APPL CRYSTALLOGR, V20, P235, DOI 10.1107/S0021889887086783; BRAUNSTEIN NS, 1987, P NATL ACAD SCI USA, V84, P2921, DOI 10.1073/pnas.84.9.2921; BRAUNSTEIN NS, 1990, J IMMUNOL, V145, P1635; BRICOGNE G, 1976, ACTA CRYSTALLOGR A, V32, P832, DOI 10.1107/S0567739476001691; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BUSCH R, 1991, J IMMUNOL, V147, P1292; CAMMAROTA G, 1992, NATURE, V356, P799, DOI 10.1038/356799a0; CHICZ RM, 1993, J EXP MED, V178, P27, DOI 10.1084/jem.178.1.27; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; COLMAN PM, 1988, ADV IMMUNOL, V43, P99; DEMAGISTRIS MT, 1992, CELL, V68, P625, DOI 10.1016/0092-8674(92)90139-4; DEMOTZ S, 1993, EUR J IMMUNOL, V23, P425, DOI 10.1002/eji.1830230219; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FALK K, 1991, NATURE, V351, P290, DOI 10.1038/351290a0; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; GARRETT TPJ, 1989, NATURE, V342, P692, DOI 10.1038/342692a0; GELUK A, 1992, J IMMUNOL, V149, P2864; GLAICHENHAUS N, 1991, CELL, V64, P511, DOI 10.1016/0092-8674(91)90235-Q; GORGA JC, 1991, RES IMMUNOL, V142, P401, DOI 10.1016/0923-2494(91)90038-K; GORGA JC, 1987, J BIOL CHEM, V262, P16087; GORGA JC, 1992, CRIT REV IMMUNOL, V11, P305; GRIFFITH IJ, 1988, J EXP MED, V167, P541, DOI 10.1084/jem.167.2.541; GUO HC, 1992, NATURE, V360, P364, DOI 10.1038/360364a0; HAMMER J, 1992, J EXP MED, V176, P1007, DOI 10.1084/jem.176.4.1007; HARRISON SC, 1968, J APPL CRYSTALLOGR, V1, P84, DOI 10.1107/S0021889868005054; HODEL A, 1992, ACTA CRYSTALLOGR A, V48, P851, DOI 10.1107/S0108767392006044; HORN GT, 1988, P NATL ACAD SCI USA, V85, P6012, DOI 10.1073/pnas.85.16.6012; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; JANEWAY CA, 1989, COLD SH Q B, V54, P657; JARDETZKY TS, 1990, EMBO J, V9, P1797, DOI 10.1002/j.1460-2075.1990.tb08304.x; JENCKS WP, 1981, P NATL ACAD SCI-BIOL, V78, P4046, DOI 10.1073/pnas.78.7.4046; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KAPPES D, 1988, ANNU REV BIOCHEM, V57, P991, DOI 10.1146/annurev.bi.57.070188.005015; KAYE J, 1984, J EXP MED, V159, P1397, DOI 10.1084/jem.159.5.1397; KLINMAN NR, 1972, J EXP MED, V136, P241, DOI 10.1084/jem.136.2.241; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; KRIEGER JI, 1991, J IMMUNOL, V146, P2331; KROPSHOFER H, 1991, BIOCHEMISTRY-US, V30, P9177, DOI 10.1021/bi00102a008; KWONG PD, 1990, P NATL ACAD SCI USA, V87, P6423, DOI 10.1073/pnas.87.16.6423; LUND T, 1990, NATURE, V345, P727, DOI 10.1038/345727a0; MADDEN DR, 1991, NATURE, V353, P321, DOI 10.1038/353321a0; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MATSUI K, 1991, SCIENCE, V254, P1788, DOI 10.1126/science.1763329; MIYAZAKI T, 1990, NATURE, V345, P722, DOI 10.1038/345722a0; NABAVI N, 1992, NATURE, V360, P266, DOI 10.1038/360266a0; NEWTONNASH DK, 1993, J IMMUNOL, V150, P1813; PECCOUD J, 1990, EMBO J, V9, P4215, DOI 10.1002/j.1460-2075.1990.tb07869.x; RACIOPPI L, 1993, J EXP MED, V177, P1047, DOI 10.1084/jem.177.4.1047; RACIOPPI L, 1991, J IMMUNOL, V147, P3718; ROCHE PA, 1991, NATURE, V354, P392, DOI 10.1038/354392a0; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SAPER MA, 1991, J MOL BIOL, V219, P277, DOI 10.1016/0022-2836(91)90567-P; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SETTE A, 1989, J IMMUNOL, V143, P3289; SIDNEY J, 1992, J IMMUNOL, V149, P2634; SILVER ML, 1992, NATURE, V360, P367, DOI 10.1038/360367a0; SLATTERY RM, 1990, NATURE, V345, P724, DOI 10.1038/345724a0; SPRINGER TA, 1977, NATURE, V268, P213, DOI 10.1038/268213a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; STUART D, 1984, ACTA CRYSTALLOGR A, V40, P713, DOI 10.1107/S0108767384001471; SUSSMAN JL, 1978, J MOL BIOL, V123, P607, DOI 10.1016/0022-2836(78)90209-7; TENG TY, 1990, J APPL CRYSTALLOGR, V23, P387, DOI 10.1107/S0021889890005568; TIWARI J, 1985, DISEASE ASS; TODD JA, 1988, SCIENCE, V240, P1003, DOI 10.1126/science.3368786; WETTS TH, 1993, IMMUN, V150, P2192	69	2129	2197	4	80	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 1	1993	364	6432					33	39		10.1038/364033a0	http://dx.doi.org/10.1038/364033a0			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK818	8316295				2022-12-01	WOS:A1993LK81800048
J	SCHMID, D; BAICI, A; GEHRING, H; CHRISTEN, P				SCHMID, D; BAICI, A; GEHRING, H; CHRISTEN, P			KINETICS OF MOLECULAR CHAPERONE ACTION	SCIENCE			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; ATPASE ACTIVITY; DNAK	Molecular chaperones of the Hsp70 type transiently sequester unfolded segments of proteins and promote their correct folding. Target peptides were labeled with an environmentally sensitive fluorophore so that their binding to the molecular chaperone DnaK of Escherichia coli could be followed in real time. The two-step process was characterized by relaxation times of 27 seconds and 200 seconds with 2 mu M DnaK and 0.1 mu M ligand at 25 degrees C. In the presence of adenosine triphosphate, the formation of the complex was greatly accelerated and appeared to be a single-exponential process with a relaxation time of 0.4 second. The binding-release cycle of DnaK thus occurs in the time range of polypeptide chain elongation and folding and is too fast to be stoichiometrically coupled to the adenosine triphosphatase activity of the chaperone (turnover number, 0.13 per minute at 30 degrees C).	UNIV ZURICH,INST BIOCHEM,CH-8057 ZURICH,SWITZERLAND; UNIV SPITAL ZURICH,CH-8091 ZURICH,SWITZERLAND	University of Zurich; University of Zurich; University Zurich Hospital				Baici, Antonio/0000-0002-2980-0541				BANECKI B, 1992, J BIOL CHEM, V267, P25051; BERGMEYER HU, 1985, METHODS ENZYMATIC AN, V7; BRAND L, 1972, ANNU REV BIOCHEM, V41, P843, DOI 10.1146/annurev.bi.41.070172.004211; FLAHERTY KM, 1990, NATURE, V346, P623, DOI 10.1038/346623a0; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LINDQUIST S, 1988, ANNU REV GENET, V22, P631, DOI 10.1146/annurev.ge.22.120188.003215; MCCARTY JS, 1991, P NATL ACAD SCI USA, V88, P9513, DOI 10.1073/pnas.88.21.9513; MULLEN DG, 1987, INT J PEP PROTEIN RE, V30, P705; PALLEROS DR, 1992, J BIOL CHEM, V267, P5279; PELHAM HRB, 1986, CELL, V46, P959, DOI 10.1016/0092-8674(86)90693-8; PRENDERGAST FG, 1983, J BIOL CHEM, V258, P7541; ROTHMAN JE, 1989, CELL, V59, P591, DOI 10.1016/0092-8674(89)90005-6; SCHMID D, 1992, EUR J BIOCHEM, V208, P699, DOI 10.1111/j.1432-1033.1992.tb17237.x; SCHMID DS, UNPUB; ZYLICZ M, 1983, P NATL ACAD SCI-BIOL, V80, P6431, DOI 10.1073/pnas.80.21.6431	17	417	427	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 18	1994	263	5149					971	973		10.1126/science.8310296	http://dx.doi.org/10.1126/science.8310296			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX165	8310296				2022-12-01	WOS:A1994MX16500037
J	ZINSMAIER, KE; EBERLE, KK; BUCHNER, E; WALTER, N; BENZER, S				ZINSMAIER, KE; EBERLE, KK; BUCHNER, E; WALTER, N; BENZER, S			PARALYSIS AND EARLY DEATH IN CYSTEINE STRING PROTEIN MUTANTS OF DROSOPHILA	SCIENCE			English	Article							MELANOGASTER; BRAIN; EXOCYTOSIS; MEMBRANE; MUTATION; BINDING; RETINA	Multimeric complexes of synaptic vesicle and terminal membrane proteins are important components of the neurotransmitter release mechanism. The csp gene of Drosophila encodes proteins homologous to synaptic vesicle proteins in Torpedo. Monoclonal antibodies demonstrate different distributions of isoforms at distinct subsets of terminals. Deletion of the csp gene in Drosophila causes a temperature-sensitive block of synaptic transmission, followed by paralysis and premature death.	INST ZOOL,CH-8057 ZURICH,SWITZERLAND; THEODOR BOVERI INST BIOWISSENSCH,D-97074 WURZBURG,GERMANY		ZINSMAIER, KE (corresponding author), CALTECH,DIV BIOL 15629,PASADENA,CA 91125, USA.		Walter, Nils/P-3163-2019	Walter, Nils/0000-0002-7301-1275				BIER E, 1989, GENE DEV, V3, P1273, DOI 10.1101/gad.3.9.1273; BONINI NM, 1993, CELL, V72, P379, DOI 10.1016/0092-8674(93)90115-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; COOMBE PE, 1986, J NEUROGENET, V3, P135, DOI 10.3109/01677068609106845; COOMBE PE, 1986, J COMP PHYSIOL A, V159, P655, DOI 10.1007/BF00612038; DIANTONIO A, 1993, CELL, V73, P1281, DOI 10.1016/0092-8674(93)90356-U; GREENGARD P, 1993, SCIENCE, V259, P780, DOI 10.1126/science.8430330; GUNDERSEN CB, 1992, NEURON, V9, P527, DOI 10.1016/0896-6273(92)90190-O; JESSELL TM, 1993, CELL, V72, P1, DOI 10.1016/S0092-8674(05)80025-X; KELLY LE, 1981, COMP BIOCHEM PHYS B, V69, P61, DOI 10.1016/0305-0491(81)90209-1; KELLY RB, 1993, CELL, V72, P43, DOI 10.1016/S0092-8674(05)80027-3; KOENIG JH, 1989, J NEUROSCI, V9, P3844; KRUEGER BK, 1979, J MEMBRANE BIOL, V50, P287, DOI 10.1007/BF01868894; KURIHARA T, 1992, MEMBRANE BIOGENESIS, P309; LEVERTY T, 1986, RUBIN LAB MANUAL; LITTLETON JT, 1993, DEVELOPMENT, V118, P1077; LITTLETON JT, 1993, CELL, V74, P1125, DOI 10.1016/0092-8674(93)90733-7; MASTROGIACOMO A, 1994, SCIENCE, V263, P981, DOI 10.1126/science.7906056; MEINERTZHAGEN IA, 1991, J COMP NEUROL, V305, P232, DOI 10.1002/cne.903050206; NAKANE PK, 1974, J HISTOCHEM CYTOCHEM, V22, P1077; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OCONNOR VM, 1993, FEBS LETT, V326, P255, DOI 10.1016/0014-5793(93)81802-7; OHKI R, 1992, J BIOL CHEM, V267, P13180; PAK WL, 1975, HDB GENETICS, P703; PFLUGFELDER GO, 1990, GENETICS, V126, P91; Pirrotta V., 1986, DROSOPHILA PRACTICAL, P83; REIFEGERSTE R, 1993, J NEUROSCI, V13, P2186; ROBERTSON HM, 1988, GENETICS, V118, P461; Sambrook J., 1989, MOL CLONING LAB MANU; SILVER PA, 1993, CELL, V16, P5; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Spradling AC, 1986, P ELEMENT MEDIATED T, P175; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; Thomas P, 1992, Curr Opin Neurobiol, V2, P308, DOI 10.1016/0959-4388(92)90120-A; TSANG SS, 1993, BIOTECHNIQUES, V14, P380; ZINSMAIER KE, 1990, J NEUROGENET, V7, P15, DOI 10.3109/01677069009084150; ZIPURSKY SL, 1984, CELL, V36, P15, DOI 10.1016/0092-8674(84)90069-2	38	325	326	0	9	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 18	1994	263	5149					977	980		10.1126/science.8310297	http://dx.doi.org/10.1126/science.8310297			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX165	8310297				2022-12-01	WOS:A1994MX16500039
J	JOLY, M; KAZLAUSKAS, A; FAY, FS; CORVERA, S				JOLY, M; KAZLAUSKAS, A; FAY, FS; CORVERA, S			DISRUPTION OF PDGF RECEPTOR TRAFFICKING BY MUTATION OF ITS PI-3 KINASE BINDING-SITES	SCIENCE			English	Article							EPIDERMAL GROWTH-FACTOR; GTPASE-ACTIVATING PROTEIN; TYROSINE KINASES; SIGNAL TRANSDUCTION; PHOSPHATIDYLINOSITOL 3-KINASE; INTERNALIZATION; CELLS; PHOSPHORYLATION; INSULIN; VISUALIZATION	Human platelet-derived growth factor receptors (PDGFRs) expressed in human Hep G2 cells internalized and concentrated in a juxtanuclear region near the Golgi network within 10 minutes after the cells were treated with PDGF. A PDGFR mutant (F5) that lacks high-affinity binding sites for the Src homology 2 domain-containing proteins phosphatidylinositol-3 kinase (PI-3 kinase), Ras guanosine triphosphatase activating protein, phospholipase C-gamma, and a phosphotyrosine phosphatase (Syp) remained at the cell periphery. Restoration of the PI-3 kinase binding sites on F5 completely restored the ability of the receptor to concentrate intracellularly. A PDGFR mutant lacking only PI-3 kinase binding sites failed to concentrate intracellularly. Thus, PI-3 kinase binding sites appear both necessary and sufficient for the normal endocytic trafficking of the activated PDGFR.	UNIV MASSACHUSETTS,SCH MED,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605; NATL JEWISH HOSP IMMUNOL & RESP MED,DENVER,CO 80206; UNIV MASSACHUSETTS,SCH MED,DEPT CELL BIOL,WORCESTER,MA 01605; UNIV MASSACHUSETTS,SCH MED,BIOMED IMAGING GRP,WORCESTER,MA 01605	University of Massachusetts System; University of Massachusetts Worcester; National Jewish Health; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK040330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM048339] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK40330] Funding Source: Medline; NIGMS NIH HHS [GM48339] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BACKER JM, 1989, J BIOL CHEM, V264, P1694; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CARRINGTON WA, 1990, NONINVASIVE TECHNIQU, P53; COUGHLIN SR, 1989, SCIENCE, V243, P1191; FANTL W, 1992, CELL, V69, P13; GENSHENG F, 1993, SCIENCE, V259, P1607; GOLDSTEIN JL, 1985, ANNU REV CELL BIOL, V1, P1, DOI 10.1146/annurev.cb.01.110185.000245; GORDEN P, 1978, SCIENCE, V200, P782, DOI 10.1126/science.644321; HAIGLER H, 1978, P NATL ACAD SCI USA, V75, P3317, DOI 10.1073/pnas.75.7.3317; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; KASHISHIAN A, 1992, EMBO J, V11, P1373, DOI 10.1002/j.1460-2075.1992.tb05182.x; KAZLAUSKAS A, 1992, MOL CELL BIOL, V12, P2534, DOI 10.1128/MCB.12.6.2534; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KUMIJAN DA, 1989, P NATL ACAD SCI USA, V86, P8232; KYPTA RM, 1990, CELL, V62, P481, DOI 10.1016/0092-8674(90)90013-5; MARSHALL S, 1980, ENDOCRINOLOGY, V107, P1937, DOI 10.1210/endo-107-6-1937; MORAN MF, 1991, MOL CELL BIOL, V11, P1804, DOI 10.1128/MCB.11.4.1804; NILSSON J, 1983, P NATL ACAD SCI-BIOL, V80, P5592, DOI 10.1073/pnas.80.18.5592; NISHIMURA R, 1993, MOL CELL BIOL, V13, P6889, DOI 10.1128/MCB.13.11.6889; OTSU M, 1991, CELL, V65, P91, DOI 10.1016/0092-8674(91)90411-Q; PAZIN MJ, 1992, TRENDS BIOCHEM SCI, V17, P374, DOI 10.1016/0968-0004(92)90003-R; RONNSTRAND L, 1988, J BIOL CHEM, V263, P10429; ROSENFELD ME, 1985, J CELL PHYSL, V121, P263; SCHLESSINGER J, 1978, P NATL ACAD SCI USA, V75, P2659, DOI 10.1073/pnas.75.6.2659; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SORKIN A, 1991, J CELL BIOL, V112, P469, DOI 10.1083/jcb.112.3.469; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; STOSCHECK CM, 1984, J CELL PHYSIOL, V120, P296, DOI 10.1002/jcp.1041200306; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VALIUS B, 1993, CELL, V73, P321; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217	33	293	295	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 4	1994	263	5147					684	687		10.1126/science.8303278	http://dx.doi.org/10.1126/science.8303278			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8303278				2022-12-01	WOS:A1994MU96400050
J	GOTTESFELD, JM; WOLF, VJ; DANG, T; FORBES, DJ; HARTL, P				GOTTESFELD, JM; WOLF, VJ; DANG, T; FORBES, DJ; HARTL, P			MITOTIC REPRESSION OF RNA POLYMERASE-III TRANSCRIPTION IN-VITRO MEDIATED BY PHOSPHORYLATION OF A TFIIIB COMPONENT	SCIENCE			English	Article							TATA-BINDING PROTEIN; CELL-CYCLE CONTROL; XENOPUS; COMPLEX; MITOSIS; P34CDC2; GENES; DNA; ACTIVATION; PROMOTERS	Interphase cytosol extracts prepared from Xenopus laevis eggs are active in RNA polymerase III (Pol III) transcription. Addition of recombinant B1 cyclin to these extracts activates mitotic protein kinases that repress transcription. Affinity-purified p34cdc2-cyclin B kinase (mitosis-promoting factor) is sufficient to effect this repression in a simplified Pol III transcription system. This mitotic repression involves the direct phosphorylation of a component of the Pol III transcription initiation factor TFIIIB, which consists of the TATA box-binding protein (TBP) and associated Pol III-specific factors. The transcriptional activity of the TFIIIB-TBP fraction can be modulated in vitro by phosphorylation with mitotic kinases and by dephosphorylation with immobilized alkaline phosphatase.	UNIV CALIF SAN DIEGO, DEPT BIOL, LA JOLLA, CA 92093 USA	University of California System; University of California San Diego	GOTTESFELD, JM (corresponding author), SCRIPPS RES INST, DEPT MOLEC BIOL, LA JOLLA, CA 92037 USA.			Gottesfeld, Joel/0000-0002-4643-5777	NIGMS NIH HHS [GM26453, GM33279, R01 GM033279] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033279, R01GM026453] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAN VJ, 1991, J CELL BIOL, V113, P347, DOI 10.1083/jcb.113.2.347; ALMOUZNI G, 1990, EMBO J, V9, P573, DOI 10.1002/j.1460-2075.1990.tb08145.x; ALMOUZNI G, 1991, MOL CELL BIOL, V11, P655, DOI 10.1128/MCB.11.2.655; BRIZUELA L, 1987, EMBO J, V6, P3507, DOI 10.1002/j.1460-2075.1987.tb02676.x; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CORMACK BP, 1992, CELL, V69, P685, DOI 10.1016/0092-8674(92)90232-2; DUNPHY WG, 1988, CELL, V54, P423, DOI 10.1016/0092-8674(88)90205-X; EDGAR BA, 1986, CELL, V44, P871, DOI 10.1016/0092-8674(86)90009-7; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; FINK K, 1977, EUR J BIOCHEM, V80, P93, DOI 10.1111/j.1432-1033.1977.tb11860.x; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; HARTL P, 1993, J CELL BIOL, V120, P613, DOI 10.1083/jcb.120.3.613; HASHIMOTO S, 1992, NUCLEIC ACIDS RES, V20, P3788, DOI 10.1093/nar/20.14.3788; HIRANO T, 1991, J CELL BIOL, V115, P1479, DOI 10.1083/jcb.115.6.1479; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; INOSTROZA JA, 1992, CELL, V70, P477; JOHNSON TC, 1965, J CELL BIOL, V27, P565, DOI 10.1083/jcb.27.3.565; JOHNSTON LH, 1987, NUCLEIC ACIDS RES, V15, P5017, DOI 10.1093/nar/15.13.5017; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KELLER HJ, 1990, MOL CELL BIOL, V10, P5166, DOI 10.1128/MCB.10.10.5166; KELLER HJ, 1992, J BIOL CHEM, V267, P18190; KIMMELMAN D, 1987, CELL, V48, P399; LERESCHE A, UNPUB; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; MIAKELYE R, 1985, CELL, V41, P165, DOI 10.1016/0092-8674(85)90071-6; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; PETERSON RC, 1980, CELL, V20, P131, DOI 10.1016/0092-8674(80)90241-X; PRESCOTT DM, 1962, EXP CELL RES, V26, P260, DOI 10.1016/0014-4827(62)90176-3; RUPERT S, 1993, NATURE, V362, P175; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SEGALL J, 1980, J BIOL CHEM, V255, P1986; SHERMOEN AW, 1991, CELL, V67, P303, DOI 10.1016/0092-8674(91)90182-X; SIMMEN KA, 1992, NUCLEIC ACIDS RES, V20, P5889, DOI 10.1093/nar/20.22.5889; SMITH DR, 1984, CELL, V37, P645, DOI 10.1016/0092-8674(84)90396-9; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; SMYTHE C, 1991, METHOD CELL BIOL, V35, P449; SOLOMON MJ, 1990, CELL, V63, P1013, DOI 10.1016/0092-8674(90)90504-8; STUTZ F, 1989, GENE DEV, V3, P1190, DOI 10.1101/gad.3.8.1190; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TAYLOR JH, 1960, ANN NY ACAD SCI, V90, P409, DOI 10.1111/j.1749-6632.1960.tb23259.x; TAYODA T, 1992, ANAL BIOCHEM, V203, P340; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WHITE RJ, 1992, P NATL ACAD SCI USA, V89, P1949, DOI 10.1073/pnas.89.5.1949; WOLF VJ, UNPUB	45	123	125	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 7	1994	263	5143					81	84		10.1126/science.8272869	http://dx.doi.org/10.1126/science.8272869			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ301	8272869				2022-12-01	WOS:A1994MQ30100034
J	LOWELL, BB; SSUSULIC, V; HAMANN, A; LAWITTS, JA; HIMMSHAGEN, J; BOYER, BB; KOZAK, LP; FLIER, JS				LOWELL, BB; SSUSULIC, V; HAMANN, A; LAWITTS, JA; HIMMSHAGEN, J; BOYER, BB; KOZAK, LP; FLIER, JS			DEVELOPMENT OF OBESITY IN TRANSGENIC MICE AFTER GENETIC ABLATION OF BROWN ADIPOSE-TISSUE	NATURE			English	Article							MITOCHONDRIAL UNCOUPLING PROTEIN; COLD-ACCLIMATED RATS; TOXIN-A-CHAIN; MOLECULAR-CLONING; BETA-3-ADRENERGIC RECEPTOR; INDUCED THERMOGENESIS; BLOOD-FLOW; EXPRESSION; FAT; ANIMALS	BROWN adipose tissue, because of its capacity for uncoupled mitochondrial respiration 1,2, has been implicated as an important site of facultative energy expenditure3-5. This has led to speculation that this tissue normally functions to prevent obesity3-5. Attempts to ablate or denervate brown adipose tissue surgically have been uninformative because it exists in diffuse depots and has substantial capacity for regeneration and hypertrophy6. Here we have used a transgenic toxigene approach7,8 to create two lines of transgenic mice with primary deficiency of brown adipose tissue. At 16 days, both lines have decreased brown fat and obesity, In one line, brown fat subsequently regenerates and obesity resolves. In the other line, the deficiency persists and obesity, with its morbid complications, advances. Obesity develops in the absence of hyperphagia, indicating that brown fat deficient mice have increased metabolic efficiency. As obesity progresses, transgenic animals develop hyperphagia. This study supports a critical role for brown adipose tissue in the nutritional homeostasis of mice.	BETH ISRAEL HOSP,HARVARD THORNDIKE LAB,DEPT MED,BOSTON,MA 02215; BETH ISRAEL HOSP,DEPT PATHOL,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02115; UNIV OTTAWA,FAC MED,DEPT BIOCHEM,OTTAWA K1H 8M5,ONTARIO,CANADA; JACKSON LAB,BAR HARBOR,ME 04609	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Ottawa; Jackson Laboratory	LOWELL, BB (corresponding author), CHARLES A DANA RES INST,BOSTON,MA 02215, USA.		Flier, jeffrey/AAG-6223-2019					BERGMEYER HU, 1974, METHODS ENZYMATIC AN; BLOOM JD, 1992, J MED CHEM, V35, P3081, DOI 10.1021/jm00094a025; BOYER BB, 1991, MOL CELL BIOL, V11, P4147, DOI 10.1128/MCB.11.8.4147; BRAY GA, 1979, PHYSIOL REV, V59, P719, DOI 10.1152/physrev.1979.59.3.719; Breitman M. L., 1992, Transgenic animals., P127; BREITMAN ML, 1987, SCIENCE, V238, P1563, DOI 10.1126/science.3685993; BREITMAN ML, 1990, MOL CELL BIOL, V10, P474, DOI 10.1128/MCB.10.2.474; CAMERON DP, 1978, CLIN EXP PHARMACOL P, V5, P41, DOI 10.1111/j.1440-1681.1978.tb00650.x; COLEMAN DL, 1978, DIABETOLOGIA, V14, P141, DOI 10.1007/BF00429772; DAVIS TRA, 1960, AM J PHYSIOL, V198, P471, DOI 10.1152/ajplegacy.1960.198.3.471; DESAUTELS M, 1978, CAN J BIOCHEM CELL B, V56, P378, DOI 10.1139/o78-060; DUBUC PU, 1976, METABOLISM, V25, P1567, DOI 10.1016/0026-0495(76)90109-8; FOSTER DO, 1979, CAN J PHYSIOL PHARM, V57, P257, DOI 10.1139/y79-039; GRANNEMAN JG, 1991, MOL PHARMACOL, V40, P895; HIMMSHAGEN J, 1989, PROG LIPID RES, V28, P67, DOI 10.1016/0163-7827(89)90009-X; HOLLOWAY BR, 1991, BRIT J PHARMACOL, V104, P97, DOI 10.1111/j.1476-5381.1991.tb12391.x; JACOBSSON A, 1985, J BIOL CHEM, V260, P6250; KLAUS S, 1991, INT J BIOCHEM, V23, P791, DOI 10.1016/0020-711X(91)90062-R; MA SWY, 1986, CAN J PHYSIOL PHARM, V64, P1252, DOI 10.1139/y86-211; MAXWELL F, 1987, MOL CELL BIOL, V7, P1576, DOI 10.1128/MCB.7.4.1576; MAXWELL IH, 1986, CANCER RES, V46, P4660; MUZZIN P, 1991, J BIOL CHEM, V266, P24053; NAHMIAS C, 1991, EMBO J, V10, P3721, DOI 10.1002/j.1460-2075.1991.tb04940.x; NICHOLLS DG, 1984, PHYSIOL REV, V64, P1, DOI 10.1152/physrev.1984.64.1.1; PALMITER RD, 1987, CELL, V50, P435, DOI 10.1016/0092-8674(87)90497-1; ROTHWELL NJ, 1989, AM J PHYSIOL, V257, pR253, DOI 10.1152/ajpregu.1989.257.2.R253; ROTHWELL NJ, 1979, NATURE, V281, P31, DOI 10.1038/281031a0; SALMON DMW, 1985, INT J OBESITY, V9, P443; TRAYHURN P, 1986, BIOCHEM SOC T, V14, P236, DOI 10.1042/bst0140236	29	869	916	3	57	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 23	1993	366	6457					740	742		10.1038/366740a0	http://dx.doi.org/10.1038/366740a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN264	8264795				2022-12-01	WOS:A1993MN26400027
J	YAGI, T; AIZAWA, S; TOKUNAGA, T; SHIGETANI, Y; TAKEDA, N; IKAWA, Y				YAGI, T; AIZAWA, S; TOKUNAGA, T; SHIGETANI, Y; TAKEDA, N; IKAWA, Y			A ROLE FOR FYN TYROSINE KINASE IN THE SUCKLING BEHAVIOR OF NEONATAL MICE	NATURE			English	Article							OLFACTORY-BULB; RAT-BRAIN; LOCALIZATION; PROTEIN; GENE; MAIN	NON-RECEPTOR-TYPE tyrosine kinases of the Src family, such as Src, Yes and Fyn, are strongly expressed in the brain and have been suggested to have an important function in the central nervous system1-5. We generated Fyn-deficient mice by inserting the beta-galactosidase gene (lacZ) into the fyn gene. The homozygous Fyn-mutant neonates from homozygous Fyn-deficient parents died because of a suckling problem. Neonates were, however, able to suckle milk normally when die homozygous mother's mammary glands had been activated by suckling of a heterozygous or wild-type pup. In these homozygous pups, the modified glomerular complex of the olfactory bulb, which had been suggested to play a role in perceiving pheromones, was abnormal in shape and reduced in size, and the hippocampal cell-layer was undulated. These results suggest that Fyn may be involved in the initial step of instinctive suckling behaviour in neonates.	INST PHYS & CHEM RES,TSUKUBA LIFE SCI CTR,MOLEC ONCOL LAB,IBARAKI 305,JAPAN; TOKYO MED & DENT UNIV,SCH MED,DEPT BIOCHEM,TOKYO 113,JAPAN	RIKEN; Tokyo Medical & Dental University (TMDU)								BLASS EM, 1980, SCIENCE, V210, P15, DOI 10.1126/science.6997992; CARTWRIGHT CA, 1988, P NATL ACAD SCI USA, V85, P3348, DOI 10.1073/pnas.85.10.3348; Diem K, 1968, WISSENSCHAFTLICHE TA; GRANT SGN, 1992, SCIENCE, V258, P1903, DOI 10.1126/science.1361685; GREER CA, 1982, J NEUROSCI, V2, P1744; KATAGIRI T, 1989, MOL CELL BIOL, V9, P4914, DOI 10.1128/MCB.9.11.4914; OJIMA H, 1988, ANAT EMBRYOL, V178, P481, DOI 10.1007/BF00305035; PEDERSEN PE, 1986, J COMP NEUROL, V252, P555, DOI 10.1002/cne.902520411; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; TEICHER MH, 1980, BRAIN RES, V194, P530, DOI 10.1016/0006-8993(80)91237-8; UMEMORI H, 1992, MOL BRAIN RES, V16, P303, DOI 10.1016/0169-328X(92)90239-8; YAGI T, 1993, ANAL BIOCHEM, V214, P77, DOI 10.1006/abio.1993.1459; YAGI T, 1990, P NATL ACAD SCI USA, V87, P9918, DOI 10.1073/pnas.87.24.9918; YAGI T, IN PRESS ONCOGENE; YAGI T, 1993, ANAL BIOCHEM, V214, P68; ZHAO YH, 1991, ONCOGENE, V6, P1725	16	144	146	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 23	1993	366	6457					742	745		10.1038/366742a0	http://dx.doi.org/10.1038/366742a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN264	8264796				2022-12-01	WOS:A1993MN26400028
J	CHEN, ZX; SILVA, H; KLESSIG, DF				CHEN, ZX; SILVA, H; KLESSIG, DF			ACTIVE OXYGEN SPECIES IN THE INDUCTION OF PLANT SYSTEMIC ACQUIRED-RESISTANCE BY SALICYLIC-ACID	SCIENCE			English	Article							SIGNAL TRANSDUCTION; BINDING PROTEIN; RECEPTOR; ASPIRIN; TOBACCO; GENE; ANTIBODIES; SYRINGAE; CATALASE; DISEASE	A complementary DNA encoding a salicylic acid (SA)-binding protein has been cloned. Its properties suggest involvement in SA-mediated induction of systemic acquired resistance (SAR) in plants. The sequence of the protein is similar to that of catalases and the protein exhibits catalase activity. Salicylic acid specifically inhibited the catalase activity in vitro and induced an increase in H2O2 concentrations in vivo. H2O2 or compounds, such as SA, that inhibit catalases or enhance the generation of H2O2, induced expression of defense-related genes associated with SAR. Thus, the action of SA in SAR is likely mediated by elevated amounts of H2O2.	RUTGERS UNIV,WAKSMAN INST,PISCATAWAY,NJ 08855	Rutgers State University New Brunswick			Chen, Zhixiang/U-1015-2017; Silva, Herman P/C-7252-2012	Chen, Zhixiang/0000-0002-5472-4560; Silva, Herman P/0000-0003-1007-7442				ABAD P, 1988, ANTIVIR RES, V9, P315, DOI 10.1016/0166-3542(88)90026-5; ALEXANDER D, 1993, P NATL ACAD SCI USA, V90, P7327, DOI 10.1073/pnas.90.15.7327; APOSTOL I, 1989, PLANT PHYSIOL, V90, P109, DOI 10.1104/pp.90.1.109; BAKER CJ, 1993, PLANT PHYSIOL, V102, P1341, DOI 10.1104/pp.102.4.1341; BRADLEY DJ, 1992, CELL, V70, P21, DOI 10.1016/0092-8674(92)90530-P; BROGLIE K, 1991, SCIENCE, V254, P1194, DOI 10.1126/science.254.5035.1194; CHANG C, 1993, SCIENCE, V262, P539, DOI 10.1126/science.8211181; CHEN Z, UNPUB; CHEN ZX, 1991, P NATL ACAD SCI USA, V88, P8179, DOI 10.1073/pnas.88.18.8179; CHEN ZX, 1993, P NATL ACAD SCI USA, V90, P9533, DOI 10.1073/pnas.90.20.9533; Chester KS, 1933, Q REV BIOL, V8, P275, DOI 10.1086/394440; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DOHERTY HM, 1988, PHYSIOL MOL PLANT P, V33, P377, DOI 10.1016/0885-5765(88)90004-5; GAFFNEY T, 1993, SCIENCE, V261, P754, DOI 10.1126/science.261.5122.754; HAVIR EA, 1987, PLANT PHYSIOL, V84, P450, DOI 10.1104/pp.84.2.450; Hennig J., UNPUB; KIEBER JJ, 1993, CELL, V72, P427, DOI 10.1016/0092-8674(93)90119-B; KUC J, 1982, BIOSCIENCE, V32, P854, DOI 10.2307/1309008; KULAEVA ON, 1990, FEBS LETT, V261, P410, DOI 10.1016/0014-5793(90)80604-H; LEGENDRE L, 1993, PLANT PHYSIOL, V102, P233, DOI 10.1104/pp.102.1.233; MALAMY J, 1990, SCIENCE, V250, P1002, DOI 10.1126/science.250.4983.1002; MAUCH F, 1988, PLANT PHYSIOL, V88, P935; NAPIER RM, 1991, TRENDS BIOCHEM SCI, V16, P72; ORLANDI EW, 1992, PHYSIOL MOL PLANT P, V40, P173, DOI 10.1016/0885-5765(92)90058-4; PRASAD PV, 1991, P NATL ACAD SCI USA, V88, P5479, DOI 10.1073/pnas.88.13.5479; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; RASMUSSEN JB, 1991, PLANT PHYSIOL, V97, P1342, DOI 10.1104/pp.97.4.1342; RAZ V, 1993, PLANT CELL, V5, P523, DOI 10.1105/tpc.5.5.523; ROSS AF, 1961, VIROLOGY, V14, P340, DOI 10.1016/0042-6822(61)90319-1; ROTROSEN D, 1987, ANNU REV IMMUNOL, V5, P127, DOI 10.1146/annurev.immunol.5.1.127; SANCHEZCASAS P, UNPUB; SCANDALIOS JG, 1980, MOL GEN GENET, V179, P33, DOI 10.1007/BF00268443; Schreck R, 1991, Trends Cell Biol, V1, P39, DOI 10.1016/0962-8924(91)90072-H; STEIN JC, 1993, PLANT PHYSIOL, V101, P1103, DOI 10.1104/pp.101.3.1103; SUTHERLAND MW, 1991, PHYSIOL MOL PLANT P, V39, P79, DOI 10.1016/0885-5765(91)90020-I; VANLOON LC, 1983, NETH J PLANT PATHOL, V89, P265, DOI 10.1007/BF01995261; VIGERS AJ, 1991, MOL PLANT MICROBE IN, V4, P315, DOI 10.1094/MPMI-4-315; WARD ER, 1991, PLANT CELL, V3, P1085, DOI 10.1105/tpc.3.10.1085; WEISSMANN G, 1991, SCI AM, V264, P84, DOI 10.1038/scientificamerican0191-84; WHITE RF, 1979, VIROLOGY, V99, P410, DOI 10.1016/0042-6822(79)90019-9; WOLOSHUK CP, 1991, PLANT CELL, V3, P619, DOI 10.1105/tpc.3.6.619; YOSHIKAWA M, 1993, NATURWISSENSCHAFTEN, V80, P417, DOI 10.1007/BF01168337	42	907	1086	5	133	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 17	1993	262	5141					1883	1886		10.1126/science.8266079	http://dx.doi.org/10.1126/science.8266079			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM511	8266079				2022-12-01	WOS:A1993MM51100039
J	BRENNAN, M; RUNGANGA, J; BARBARA, JAJ; CONTRERAS, M; TEDDER, RS; GARSON, JA; TUKE, PW; MORTIMER, PP; MCALPINE, L; TOSSWILL, JHC				BRENNAN, M; RUNGANGA, J; BARBARA, JAJ; CONTRERAS, M; TEDDER, RS; GARSON, JA; TUKE, PW; MORTIMER, PP; MCALPINE, L; TOSSWILL, JHC			PREVALENCE OF ANTIBODIES TO HUMAN T-CELL LEUKEMIA-LYMPHOMA VIRUS IN BLOOD-DONORS IN NORTH LONDON	BRITISH MEDICAL JOURNAL			English	Article							I-ASSOCIATED MYELOPATHY; HTLV-I; LEUKEMIA-VIRUS; INFECTION; TRANSFUSION; TRANSMISSION; RISK	Objectives-To determine the prevalence of antibodies to the human T cell leukaemia/lymphoma viruses (HTLV-I and HTLV-II) in blood donors in north London in order to assess the economic impact and the logistic effects that routine screening would have on the blood supply. Design-All donations collected by the north London blood transfusion centre between January 1991 and June 1991 were screened for antibodies to HTLV-I and HTLV-II by modified, improved Fujirebio gel particle agglutination test. Positive samples were titrated and retested as necessary. Subjects-96 720 unpaid volunteers, who gave 105 730 consecutive donations of blood and plasma. Setting-North London blood transfusion centre. Main outcome measure-Observed numbers of donors confirmed to be seropositive for HTLV by reference laboratories. Results-Of 2622 (2.5%) initially reactive samples, 414 (0.4% of all samples) gave a titre of greater-than-or-equal-to 1 in 16 on the modified agglutination test. Thirty five of the 414 serum samples yielded positive results on one of two enzyme linked immunosorbent assays (ELISA (Cambridge Biotech and Abbot)), and none of these results were confirmed by either reference laboratory. Five samples yielded positive results on both ELISAs and all five of these were confirmed to contain antibodies to HTLV. One of the five contained antibodies to HTLV-II and the others antibodies to HTLV-I. Four seropositive donors were white women whose only risk factor for infection was sexual contact. The fifth (positive for antibodies to HTLV-II) was an Anglo-Caribbean man who admitted to previous misuse of intravenous drugs. Conclusion-The prevalence of antibodies to HTLV in blood donors in north London was one in 19 344 (0.005%). Up to 100 donors a year might be identified in the United Kingdom as being infected with HTLV, although prevalence in different regions may vary considerably.	UCL, SCH MED, DEPT MED MICROBIOL, DIV VIROL, LONDON W1P 6DB, ENGLAND; CENT PUBL HLTH LAB, PHLS, VIRUS REFERENCE LAB, LONDON NW9 5HT, ENGLAND	University of London; University College London; UCL Medical School; Public Health England	BRENNAN, M (corresponding author), N LONDON BLOOD TRANSFUS CTR, COLINDALE AVE, LONDON NW9 5BG, ENGLAND.		Garson, Jeremy A/C-5357-2008	Tedder, Richard/0000-0002-9672-5721; Garson, Jeremy/0000-0003-0553-0126				BARBARA JAJ, 1989, MED LAB SCI, V46, P135; CANNAVAGGIO M, 1990, TRANSFUSION, V30, P780; CHEN YC, 1989, BLOOD, V74, P388; COUROUCE AM, 1993, AIDS, V7, P841, DOI 10.1097/00002030-199306000-00013; ERLICH G, 1990, PCR PROTOCOLS GUIDE; FUJINO R, 1991, JPN J CANCER RES, V82, P367, DOI 10.1111/j.1349-7006.1991.tb01856.x; HALL WW, 1993, FOCUS HIV; HJELLE B, 1992, LANCET, V339, P645, DOI 10.1016/0140-6736(92)90797-7; KAPLAN JE, 1990, J ACQ IMMUN DEF SYND, V3, P1096; KIYOKAWA T, 1991, LANCET, V338, P312, DOI 10.1016/0140-6736(91)90450-4; LEE H, 1989, SCIENCE, V244, P471, DOI 10.1126/science.2655084; MCALPINE L, 1992, AIDS, V6, P387, DOI 10.1097/00002030-199204000-00005; MEYTES D, 1990, LANCET, V336, P1553; MINAMOTO GY, 1988, NEW ENGL J MED, V318, P219, DOI 10.1056/NEJM198801283180405; MURPHY EL, 1989, INT J CANCER, V43, P250, DOI 10.1002/ijc.2910430214; OKOCHI K, 1984, VOX SANG, V46, P245, DOI 10.1111/j.1423-0410.1984.tb00083.x; OSAME M, 1986, LANCET, V2, P104; PILLONEL J, 1993, GAZETTE TRANSFUSION, V84, P15; SALKER R, 1990, LANCET, V336, P317, DOI 10.1016/0140-6736(90)91856-6; SANDLER S G, 1991, Transfusion Medicine Reviews, V5, P93, DOI 10.1016/S0887-7963(91)70197-1; TAJIMA K, 1982, GANN, V73, P893; TOSWILL J, 1989, LANCET, V2, P328; TUKE PW, 1992, J VIROL METHODS, V40, P163, DOI 10.1016/0166-0934(92)90065-L; WILLIAMS AE, 1990, TRANSFUSION TODAY, V7, P5; 1988, LANCET, V1, P217	25	55	56	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	NOV 13	1993	307	6914					1235	1239		10.1136/bmj.307.6914.1235	http://dx.doi.org/10.1136/bmj.307.6914.1235			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH001	8281054	Green Published, Bronze			2022-12-01	WOS:A1993MH00100017
J	GREENBERG, S; REISER, IW; CHOU, SY; PORUSH, JG				GREENBERG, S; REISER, IW; CHOU, SY; PORUSH, JG			TRIMETHOPRIM-SULFAMETHOXAZOLE INDUCES REVERSIBLE HYPERKALEMIA	ANNALS OF INTERNAL MEDICINE			English	Article						TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; HYPERKALEMIA; POTASSIUM; ACQUIRED IMMUNODEFICIENCY SYNDROME; PNEUMONIA, PNEUMOCYSTIS-CARINII	ACQUIRED-IMMUNODEFICIENCY-SYNDROME; PNEUMOCYSTIS-CARINII PNEUMONIA; IMMUNE-DEFICIENCY SYNDROME; CO-TRIMOXAZOLE; INTERSTITIAL NEPHRITIS; ADVERSE REACTIONS; MINERALOCORTICOID DEFICIENCY; HIV INFECTION; NEPHROTOXICITY; CREATININE	Objective: To determine the effect of trimethoprim-sulfamethoxazole (Tmp-Smx) on serum potassium concentration. Design: Retrospective cohort study. Setting: An urban teaching hospital. Patients: Fifty-one persons hospitalized for symptomatic infection with human immunodeficiency virus (HIV). Twenty-five patients who were taking high-dose Tmp-Smx (trimethoprim 20 mg/kg per day; sulfamethoxazole, 100 mg/kg per day) for Pneumocystis carinii pneumonia were the study group. Twenty-six patients who had not received the drug were the control group. Patients who received potassium supplements, those taking medications known to alter potassium homeostasis or renal function, or those with a serum creatinine level more than 186 mumol/L were excluded. Measurements and Main Results: Serum potassium concentration in the study group was 4.1 +/- 0.1 mmol/L (mean +/- SE) and increased by 1.1 mmol/L (CI, 0.8 to 1.5 mmol/L) (P < 0.0001) 9.8 +/- 0.5 days after starting Tmp-Smx therapy. Patients followed longitudinally showed a progressive increase in serum potassium levels during therapy and a progressive decline after discontinuing Tmp-Smx. Blood urea nitrogen and serum creatinine levels increased mildly from 4.3 +/- 0.5 mmol/L and 85 +/- 6 mumol/L to 6.4 +/- 0.7 mmol/L and 113 +/- 8 mumol/L, respectively. The serum potassium level in the control group was 4.3 +/- 0.1 mmol/L and remained unchanged during hospitalization. Conclusions: High-dose Tmp-Smx therapy used for the treatment of P. carinii pneumonia in HIV-infected patients leads to an increase in the serum potassium concentration and may result in life-threatening hyperkalemia. Patients receiving high doses of Tmp-Smx require close monitoring of their serum potassium concentration, particularly 7 to 10 days after the start of therapy.	BROOKDALE HOSP MED CTR, DIV NEPHROL & HYPERTENS, BROOKLYN, NY 11212 USA									APPEL GB, 1977, NEW ENGL J MED, V296, P784, DOI 10.1056/NEJM197704072961404; BERGLUND F, 1975, J UROLOGY, V114, P802, DOI 10.1016/S0022-5347(17)67149-0; CHOI M J, 1992, Journal of the American Society of Nephrology, V3, P325; CRYST C, 1988, AM J NEPHROL, V8, P483, DOI 10.1159/000167666; GORDIN FM, 1984, ANN INTERN MED, V100, P495, DOI 10.7326/0003-4819-100-4-495; GREENE LW, 1984, ANN INTERN MED, V101, P497, DOI 10.7326/0003-4819-101-4-497; GUY RJC, 1989, BRIT MED J, V298, P496, DOI 10.1136/bmj.298.6672.496; JAFFE HS, 1983, LANCET, V2, P1109; JICK H, 1982, REV INFECT DIS, V4, P426; KALIN MF, 1987, AM J MED, V82, P1035, DOI 10.1016/0002-9343(87)90171-9; LACHAAL M, 1989, AM J MED, V87, P260, DOI 10.1016/S0002-9343(89)80147-0; LAWSON DH, 1978, AM J MED SCI, V275, P53, DOI 10.1097/00000441-197801000-00005; LAWSON DH, 1982, REV INFECT DIS, V4, P429; LINTON AL, 1980, ANN INTERN MED, V93, P735, DOI 10.7326/0003-4819-93-5-735; MEDINA I, 1990, NEW ENGL J MED, V323, P776, DOI 10.1056/NEJM199009203231202; MEMBRENO L, 1987, J CLIN ENDOCR METAB, V65, P482, DOI 10.1210/jcem-65-3-482; MURPHY CF, 1989, BRIT MED J, V298, P1181, DOI 10.1136/bmj.298.6681.1181-b; REVERT L, 1988, SEMIN NEPHROL, V8, P82; RICHMOND JM, 1979, LANCET, V1, P493; SCHOENFELD P, 1990, AM J KIDNEY DIS, V16, P14, DOI 10.1016/S0272-6386(12)80780-3; SENEY FD, 1990, AM J KIDNEY DIS, V16, P1; SHOUVAL D, 1978, LANCET, V1, P244; SMITH EJ, 1980, JAMA-J AM MED ASSOC, V244, P360, DOI 10.1001/jama.244.4.360; VAZIRI ND, 1985, J NATL MED ASSOC, V77, P369; VELAZQUEZ H, 1992, Journal of the American Society of Nephrology, V3, P322	25	88	92	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1993	119	4					291	295		10.7326/0003-4819-119-4-199308150-00007	http://dx.doi.org/10.7326/0003-4819-119-4-199308150-00007			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV525	8328737				2022-12-01	WOS:A1993LV52500007
J	NAUJOKAS, MF; MORIN, M; ANDERSON, MS; PETERSON, M; MILLER, J				NAUJOKAS, MF; MORIN, M; ANDERSON, MS; PETERSON, M; MILLER, J			THE CHONDROITIN SULFATE FORM OF INVARIANT CHAIN CAN ENHANCE STIMULATION OF T-CELL RESPONSES THROUGH INTERACTION WITH CD44	CELL			English	Article							MHC CLASS-II; MAJOR HISTOCOMPATIBILITY COMPLEX; LYMPHOCYTE HOMING RECEPTOR; HLA-DR MOLECULES; PANCREATIC BETA-CELLS; ANTIGEN PRESENTATION; TRANSGENIC MICE; MONOCLONAL-ANTIBODIES; B-CELL; SURFACE EXPRESSION	Invariant chain (Ii) is a nonpolymorphic glycoprotein that associates with major histocompatibility complex class II molecules and has been shown to mediate several functions in class II-restricted antigen presentation. A small proportion of Ii is modified by the addition of chondroitin sulfate (Ii-CS), and this form of Ii is associated with class II on the surface of antigen-presenting cells. In this report we show that expression of Ii-CS dramatically enhanced the ability of class II-positive EL4 transfectants to stimulate class II-dependent allogeneic and mitogenic T cell responses. Antibody blocking studies and the ability of CD44 to bind directly to Ii-CS suggest that Ii-CS can function as an accessory molecule during T cell responses through interactions with CD44.	UNIV CHICAGO,COMM IMMUNOL,CHICAGO,IL 60637	University of Chicago	NAUJOKAS, MF (corresponding author), UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637, USA.				NIDDK NIH HHS [DK42857] Funding Source: Medline; NIGMS NIH HHS [GM07281, GM42071] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042857] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007281, R01GM042071] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACCOLLA RS, 1985, J IMMUNOL, V134, P3265; ALLISON J, 1988, NATURE, V333, P529, DOI 10.1038/333529a0; ANDERSON MS, 1992, P NATL ACAD SCI USA, V89, P2282, DOI 10.1073/pnas.89.6.2282; ARCH R, 1992, SCIENCE, V257, P682, DOI 10.1126/science.1496383; ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BERTOLINO P, 1991, INT IMMUNOL, V3, P435, DOI 10.1093/intimm/3.5.435; BHATTACHARYA A, 1981, J IMMUNOL, V127, P2488; BIKOFF EK, 1992, J IMMUNOL, V149, P1; BLUM JS, 1988, P NATL ACAD SCI USA, V85, P3975, DOI 10.1073/pnas.85.11.3975; BOHME J, 1989, SCIENCE, V244, P1179, DOI 10.1126/science.2499048; BUTTERFIELD K, 1989, J EXP MED, V169, P1461, DOI 10.1084/jem.169.4.1461; CONRAD P, 1992, J IMMUNOL, V149, P1833; CRESSWELL P, 1985, P NATL ACAD SCI USA, V82, P8188, DOI 10.1073/pnas.82.23.8188; DAMLE NK, 1992, J IMMUNOL, V148, P1985; DELLABONA P, 1990, CELL, V62, P1115, DOI 10.1016/0092-8674(90)90388-U; DENNING SM, 1990, J IMMUNOL, V144, P7; DIALYNAS DP, 1983, J IMMUNOL, V131, P2445; DOUGHERTY GJ, 1991, J EXP MED, V174, P1, DOI 10.1084/jem.174.1.1; FELL HP, 1992, J BIOL CHEM, V267, P15552; GOLDSTEIN LA, 1989, CELL, V56, P1063, DOI 10.1016/0092-8674(89)90639-9; GUAGLIARDI L, 1990, NATURE, V345, P172; HAYNES BF, 1989, IMMUNOL TODAY, V10, P423, DOI 10.1016/0167-5699(89)90040-6; HE Q, 1992, J CELL BIOL, V119, P1711, DOI 10.1083/jcb.119.6.1711; HEATH WR, 1989, NATURE, V341, P749, DOI 10.1038/341749a0; HOLT GD, 1985, J IMMUNOL, V135, P399; HUET S, 1989, J IMMUNOL, V143, P798; JALKANEN S, 1992, J CELL BIOL, V116, P817, DOI 10.1083/jcb.116.3.817; JONES PP, 1979, MOL IMMUNOL, V16, P51, DOI 10.1016/0161-5890(79)90027-0; KAPPLER JW, 1981, J EXP MED, V153, P1198, DOI 10.1084/jem.153.5.1198; KOCH N, 1982, EUR J IMMUNOL, V12, P909, DOI 10.1002/eji.1830121103; KOCH N, 1987, EMBO J, V6, P1677, DOI 10.1002/j.1460-2075.1987.tb02417.x; KOCH N, 1982, NATURE, V299, P644, DOI 10.1038/299644a0; KOOPMAN G, 1993, J EXP MED, V177, P897, DOI 10.1084/jem.177.4.897; KOULOVA L, 1991, J EXP MED, V173, P759, DOI 10.1084/jem.173.3.759; KVIST S, 1982, CELL, V29, P61, DOI 10.1016/0092-8674(82)90090-3; LAMB CA, 1991, P NATL ACAD SCI USA, V88, P5998, DOI 10.1073/pnas.88.14.5998; LAYET C, 1991, P NATL ACAD SCI USA, V88, P2346, DOI 10.1073/pnas.88.6.2346; LIU ZR, 1992, J EXP MED, V175, P1663, DOI 10.1084/jem.175.6.1663; LO D, 1989, J EXP MED, V170, P87, DOI 10.1084/jem.170.1.87; LO D, 1988, CELL, V53, P159, DOI 10.1016/0092-8674(88)90497-7; LOMBARDI G, 1989, J IMMUNOL, V142, P753; LOSS GE, 1993, J IMMUNOL, V150, P3187; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MARRACK P, 1990, SCIENCE, V248, P705, DOI 10.1126/science.2185544; MARRACK P, 1988, NATURE, V332, P840, DOI 10.1038/332840a0; MEHRINGER JH, 1991, J IMMUNOL, V146, P920; MILLER J, 1988, P NATL ACAD SCI USA, V85, P1359, DOI 10.1073/pnas.85.5.1359; MILLER J, 1986, J EXP MED, V164, P1478, DOI 10.1084/jem.164.5.1478; MILLER J, 1990, J IMMUNOL, V144, P334; MIYAKE K, 1990, J EXP MED, V171, P477, DOI 10.1084/jem.171.2.477; MOST J, 1992, J IMMUNOL, V148, P1635; MUELLER DL, 1989, ANNU REV IMMUNOL, V7, P445, DOI 10.1146/annurev.iy.07.040189.002305; MURAKAMI S, 1990, J IMMUNOL, V145, P3618; MURAKAMI S, 1991, J IMMUNOL, V146, P1422; MURPHY KM, 1989, P NATL ACAD SCI USA, V86, P10034, DOI 10.1073/pnas.86.24.10034; NABAVI N, 1992, NATURE, V360, P266, DOI 10.1038/360266a0; NADIMI F, 1991, EUR J IMMUNOL, V21, P1255, DOI 10.1002/eji.1830210524; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NEWCOMB JR, 1993, J IMMUNOL, V150, P499; NORTON SD, 1992, J IMMUNOL, V149, P1556; OZATO K, 1980, J IMMUNOL, V124, P533; PETERSON M, 1990, NATURE, V345, P172, DOI 10.1038/345172a0; PETERSON M, 1992, NATURE, V357, P596, DOI 10.1038/357596a0; PIERRES M, 1981, IMMUNOGENETICS, V14, P481, DOI 10.1007/BF00350120; RATH S, 1992, EUR J IMMUNOL, V22, P2121, DOI 10.1002/eji.1830220824; RAZIWOLF Z, 1992, P NATL ACAD SCI USA, V89, P4210, DOI 10.1073/pnas.89.9.4210; ROCHE PA, 1990, NATURE, V345, P615, DOI 10.1038/345615a0; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROSAMOND S, 1988, J IMMUNOL, V139, P1946; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SANT AJ, 1985, J IMMUNOL, V135, P416; SANT AJ, 1985, J EXP MED, V162, P1916, DOI 10.1084/jem.162.6.1916; SARMIENTO M, 1980, J IMMUNOL, V125, P2665; SCHAIFF WT, 1991, J IMMUNOL, V147, P603; SCREATON GR, 1992, P NATL ACAD SCI USA, V89, P12160, DOI 10.1073/pnas.89.24.12160; SEKALY RP, 1986, J EXP MED, V164, P1490, DOI 10.1084/jem.164.5.1490; SHIMIZU Y, 1989, J IMMUNOL, V143, P2457; SHIMONKEVITZ R, 1983, J EXP MED, V158, P303, DOI 10.1084/jem.158.2.303; SIVAK LE, 1987, J IMMUNOL, V138, P1319; STAMENKOVIC I, 1991, EMBO J, V10, P343, DOI 10.1002/j.1460-2075.1991.tb07955.x; STOCKINGER B, 1989, CELL, V56, P683, DOI 10.1016/0092-8674(89)90590-4; SY MS, 1991, J EXP MED, V174, P859, DOI 10.1084/jem.174.4.859; TAN P, 1993, J EXP MED, V177, P165, DOI 10.1084/jem.177.1.165; TEYTON L, 1990, NATURE, V348, P39, DOI 10.1038/348039a0; WATTS TH, 1984, P NATL ACAD SCI-BIOL, V81, P7564, DOI 10.1073/pnas.81.23.7564; WEBB DSA, 1990, SCIENCE, V249, P1295, DOI 10.1126/science.1697984; YAGI JJ, 1990, J IMMUNOL, V144, P892	89	215	217	0	7	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					257	268		10.1016/0092-8674(93)90417-O	http://dx.doi.org/10.1016/0092-8674(93)90417-O			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343954				2022-12-01	WOS:A1993LP72600007
J	HUGHES, DA; ASHWORTH, A; MARSHALL, CJ				HUGHES, DA; ASHWORTH, A; MARSHALL, CJ			COMPLEMENTATION OF BYR1 IN FISSION YEAST BY MAMMALIAN MAP KINASE KINASE REQUIRES COEXPRESSION OF RAF KINASE	NATURE			English	Article							NERVE GROWTH-FACTOR; PROTEIN-KINASE; SCHIZOSACCHAROMYCES-POMBE; SIGNAL TRANSDUCTION; GENE; ACTIVATION; FUS3; CEREVISIAE; TYROSINE; KSS1	INTRACELLULAR signalling from receptor tyrosine kinases in mammalian cells involves the activation of a signal cascade which includes p21ras and the protein kinases p74raf-1, MAP kinase kinase and MAP kinases1-8. In the yeasts Schizosaccharomyces pombe and Saccharomyces cerevisiae the response to mating pheromones requires the Spk1 and KSS1/FUS3 kinases, which have sequence homology to Vertebrate MAP kinases9-12. The recent cloning of complementary DNAs for mammalian13-15 and frog16 MAP kinase kinases has shown that they are homologous to the S. pombe Byr1 (ref. 17) and S. cerevisiae STE7 (ref. 18) kinases, which have been proposed to function upstream of Spk1 and KSS1/FUS3, respectively19-22. We have investigated whether these apparently similar kinase pathways are functionally conserved between vertebrates and S. pombe. We report here that expression of mammalian MAP kinase kinase alone fails to complement a byr1 mutant of S. pombe. When coexpressed with Raf kinase, however, MAP kinase kinase is activated by phosphorylation and the mating defect of the byr1 mutant is rescued. This suggests that the pathways are functionally homologous and that Raf kinase may directly phosphorylate and activate MAP kinase kinase.			HUGHES, DA (corresponding author), INST CANC RES, CHESTER BEATTY LABS, CELL & MOLEC BIOL SECT, LONDON SW3 6JB, ENGLAND.							ASHWORTH A, 1992, ONCOGENE, V7, P2555; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; COURCHESNE WE, 1989, CELL, V58, P1107, DOI 10.1016/0092-8674(89)90509-6; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; EGEL R, 1971, PLANTA, V98, P89, DOI 10.1007/BF00387025; ELION EA, 1991, P NATL ACAD SCI USA, V88, P9392, DOI 10.1073/pnas.88.21.9392; ELION EA, 1990, CELL, V60, P649, DOI 10.1016/0092-8674(90)90668-5; ERREDE B, 1993, NATURE, V362, P261, DOI 10.1038/362261a0; GARTNER A, 1992, GENE DEV, V6, P1280, DOI 10.1101/gad.6.7.1280; GOMEZ N, 1991, NATURE, V353, P170, DOI 10.1038/353170a0; GOTOH Y, IN PRESS MOL CELL BI; GRIMM C, 1988, MOL GEN GENET, V215, P81, DOI 10.1007/BF00331307; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; KOSAKO H, 1993, EMBO J, V12, P787, DOI 10.1002/j.1460-2075.1993.tb05713.x; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MATSUDA S, 1993, J BIOL CHEM, V268, P3277; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NADINDAVIS SA, 1988, EMBO J, V7, P985, DOI 10.1002/j.1460-2075.1988.tb02905.x; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; NEIMAN AM, 1993, MOL BIOL CELL, V4, P107, DOI 10.1091/mbc.4.1.107; ROBERTS TM, 1992, NATURE, V360, P534, DOI 10.1038/360534a0; SEGER R, 1992, J BIOL CHEM, V267, P25628; SMITS AMM, 1992, NATURE, V357, P602; STYRKARSDOTTIR U, 1992, MOL GEN GENET, V235, P122, DOI 10.1007/BF00286189; TEAGUE MA, 1986, P NATL ACAD SCI USA, V83, P7371, DOI 10.1073/pnas.83.19.7371; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TODA T, 1991, GENE DEV, V5, P60, DOI 10.1101/gad.5.1.60; TRAVERSE S, 1992, BIOCHEM J, V288, P351, DOI 10.1042/bj2880351; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; WANG Y, 1991, MOL CELL BIOL, V11, P3554, DOI 10.1128/MCB.11.7.3554; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O	35	61	79	0	3	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 22	1993	364	6435					349	352		10.1038/364349a0	http://dx.doi.org/10.1038/364349a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	8332194				2022-12-01	WOS:A1993LN57000061
J	OLSEN, RJ; LYNCH, P; COYLE, MB; CUMMINGS, J; BOKETE, T; STAMM, WE				OLSEN, RJ; LYNCH, P; COYLE, MB; CUMMINGS, J; BOKETE, T; STAMM, WE			EXAMINATION GLOVES AS BARRIERS TO HAND CONTAMINATION IN CLINICAL-PRACTICE	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							POLYVINYL-CHLORIDE GLOVES; SURGICAL GLOVES; LATEX; PERMEABILITY; VINYL; INFECTION; VIRUS; INTEGRITY; SURGERY; CARE	Objective.-To test the effectiveness of vinyl and latex gloves as barriers to hand contamination with gram-negative organisms and enterococci during routine hospital procedures. Design and Interventions.-We studied 137 procedures during which a health care workers gloved hand contacted a patient's mucous membrane and was thus potentially contaminated with gram-negative rods or enterococci. Quantitative hand cultures were obtained from each health care worker before and after the gloved contact using a modified glove juice method, and the exterior glove surface was also quantitatively cultured after patient contact. Used gloves were then tested for leaks using the American Society for Testing and Materials' watertight test. Setting.-Harborview Medical Center, a 330-bed city-county hospital and level I regional trauma and burn center, is both a teaching facility affiliated with the University of Washington and the major provider of care to indigent and uninsured persons in Seattle-King County, Washington. Patients and Other Participants.-Respiratory therapists performing endotracheal tube care on intubated intensive care unit patients, registered nurses performing digital rectal stimulation for bowel training on patients with spinal cord injury in the rehabilitation ward, and dentists performing routine dental examinations and procedures on healthy outpatients in the dental clinic. Main Outcome Measure and Results.-Eighty-six of the 135 gloves cultured had gram-negative rods or enterococci on the external surface after use and were thus sources of potential hand contamination. Microbial contamination of the health care worker's hands occurred in 11 (13%; 95% confidence interval, 6% to 20%) of these 86 events, and was more frequent with vinyl (10 of 42) than latex (one of 44) gloves (P<.01). After use, glove leaks were also more frequent in vinyl gloves (26 of 61) than with latex gloves (six of 70) (P<.001). Even when leaks were present, gloves prevented hand contamination in 77% of instances and quantitative counts of microorganisms contaminating hands were 2 to 4 logs less than counts on external glove surfaces. Health care workers reported awareness of the presence of glove leaks in only seven (22%) of the 32 events in which leaks were subsequently demonstrated. Conclusions.-Under conditions of routine use, gloves effectively function as a protective barrier even when leaks are present. Latex gloves were less frequently associated with leaks and hand contamination. Since hand contamination occurred after 13% of exposures and cannot be readily identified by health care workers, routine hand washing should be done after each patient contact.	UNIV WASHINGTON, HARBORVIEW MED CTR, DEPT CLIN MICROBIOL, SEATTLE, WA 98104 USA; UNIV WASHINGTON, HARBORVIEW MED CTR, DEPT INFECT DIS, SEATTLE, WA 98104 USA; UNIV WASHINGTON, HARBORVIEW MED CTR, DEPT EPIDEMIOL, SEATTLE, WA 98104 USA; NATL HLTH INST, GABORONE, BOTSWANA	Harborview Medical Center; University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle; Harborview Medical Center; University of Washington; University of Washington Seattle								BERG GA, 1987, BRIT J CLIN PRACT, V41, P903; CONNOR TH, 1984, AM J HOSP PHARM, V41, P676, DOI 10.1093/ajhp/41.4.676; DEGROOTKOSOLCHAROEN J, 1989, AM J INFECT CONTROL, V17, P196, DOI 10.1016/0196-6553(89)90128-4; DIENSTAG JL, 1982, AM J EPIDEMIOL, V115, P26, DOI 10.1093/oxfordjournals.aje.a113277; DODDS RDA, 1990, BRIT J SURG, V77, P219, DOI 10.1002/bjs.1800770228; GERHARDT GG, 1989, ZBL HYG UMWELTMED, V188, P336; JOHNSON S, 1990, AM J MED, V88, P137, DOI 10.1016/0002-9343(90)90462-M; KLEIN BS, 1989, NEW ENGL J MED, V320, P1714, DOI 10.1056/NEJM198906293202603; KLEIN RC, 1990, BIOTECHNIQUES, V9, P196; KORNIEWICZ DM, 1990, J CLIN MICROBIOL, V28, P787, DOI 10.1128/JCM.28.4.787-788.1990; KORNIEWICZ DM, 1989, NURS RES, V38, P144; KOTILAINEN HR, 1989, ARCH INTERN MED, V149, P2749, DOI 10.1001/archinte.149.12.2749; LAIDLAW JL, 1984, AM J HOSP PHARM, V41, P2618, DOI 10.1093/ajhp/41.12.2618; LARSON EL, 1980, J CLIN MICROBIOL, V12, P355, DOI 10.1128/JCM.12.3.355-360.1980; LYNCH P, 1990, AM J INFECT CONTROL, V18, P1, DOI 10.1016/0196-6553(90)90204-6; PUGLIESE G, 1991, UNIVERSAL PRECAUTION, P400; STOIKES ME, 1987, AM J HOSP PHARM, V44, P1341, DOI 10.1093/ajhp/44.6.1341; YANGCO BG, 1989, INFECT CONT HOSP EP, V10, P553, DOI 10.1086/645950; 1977, ANN BOOK ASTM STANDA, P1; 1990, FED REG         1212, V55, P51254; 1987, MMWR MORB MORTAL S25, V36, P1; 1990, M2AA4 NAT COMM CLIN; 1991, FED REG         1206, V56, P64003	23	138	140	0	10	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60654-0946 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1993	270	3					350	353		10.1001/jama.270.3.350	http://dx.doi.org/10.1001/jama.270.3.350			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM435	8315779				2022-12-01	WOS:A1993LM43500030
J	GREEN, WN; CLAUDIO, T				GREEN, WN; CLAUDIO, T			ACETYLCHOLINE-RECEPTOR ASSEMBLY - SUBUNIT FOLDING AND OLIGOMERIZATION OCCUR SEQUENTIALLY	CELL			English	Article							GATED ION CHANNELS; ENDOPLASMIC-RETICULUM; MONOCLONAL-ANTIBODIES; GAMMA-SUBUNIT; TORPEDO-CALIFORNICA; ALPHA-SUBUNIT; PROTEIN; CELLS; TRANSPORT; FIBROBLASTS	The temperature sensitivity of nicotinic acetylcholine receptors (AChRs) from T. californica was used to identify steps in AChR subunit folding and oligomerization. Assembly intermediates were isolated by lowering to an assembly-permissive temperature. The earliest identifiable assembly intermediates, alphabetagamma trimers, form minutes after subunit synthesis. Alphabetagammadelta tetramers are formed slowly by the addition of delta subunits to trimers, and finally a second alpha subunit is added to form alpha2betagammadelta pentamers. Between these oligomerization steps, subunits fold as monitored by alpha-bungarotoxin-binding site formation, appearance of antigenic epitopes, changes in apparent molecular weight, and changes in detergent solubility. Subunit folding requires specific combinations of subunits and correlates in time with subunit additions, suggesting that these subunit folding events contribute to subunit recognition site formation during assembly.	YALE UNIV, SCH MED, DEPT CELLULAR & MOLEC PHYSIOL, NEW HAVEN, CT 06510 USA	Yale University					NHLBI NIH HHS [HL38156] Funding Source: Medline; NINDS NIH HHS [NS21714] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL038156] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021714] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BETZ H, 1990, NEURON, V5, P383, DOI 10.1016/0896-6273(90)90077-S; BLOUNT P, 1990, J CELL BIOL, V111, P2601, DOI 10.1083/jcb.111.6.2601; CLAUDIO T, 1989, J CELL BIOL, V108, P2277, DOI 10.1083/jcb.108.6.2277; CLAUDIO T, 1977, ARCH BIOCHEM BIOPHYS, V181, P484, DOI 10.1016/0003-9861(77)90254-5; CLAUDIO T, 1987, SCIENCE, V238, P1688, DOI 10.1126/science.3686008; CLAUDIO T, 1989, FRONTIERS MOL BIOL M, P63; CONROY WG, 1990, J BIOL CHEM, V265, P21642; DOMS RW, 1987, J CELL BIOL, V105, P1957, DOI 10.1083/jcb.105.5.1957; GARDNER PD, 1990, NUCLEIC ACIDS RES, V18, P6714, DOI 10.1093/nar/18.22.6714; Gething M J, 1990, Semin Cell Biol, V1, P65; GOLDENBERG DP, 1988, ANNU REV BIOPHYS BIO, V17, P481; GREEN WN, 1991, NEURON, V7, P659, DOI 10.1016/0896-6273(91)90378-D; GU Y, 1991, J CELL BIOL, V114, P799, DOI 10.1083/jcb.114.4.799; GULLICK WJ, 1983, BIOCHEMISTRY-US, V22, P3312, DOI 10.1021/bi00283a003; HARTMAN SC, 1988, P NATL ACAD SCI USA, V85, P8047, DOI 10.1073/pnas.85.21.8047; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; KUROSAKI T, 1987, FEBS LETT, V214, P253, DOI 10.1016/0014-5793(87)80065-0; LODISH HF, 1988, J BIOL CHEM, V263, P2107; MERLIE JP, 1983, CELL, V34, P747, DOI 10.1016/0092-8674(83)90531-7; PAULSON HL, 1991, J CELL BIOL, V113, P1371, DOI 10.1083/jcb.113.6.1371; PAULSON HL, 1990, J CELL BIOL, V110, P1705, DOI 10.1083/jcb.110.5.1705; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; POPOT JL, 1984, PHYSIOL REV, V64, P1162, DOI 10.1152/physrev.1984.64.4.1162; ROSE JK, 1988, ANNU REV CELL BIOL, V4, P257, DOI 10.1146/annurev.cellbio.4.1.257; ROSS AF, 1991, J CELL BIOL, V113, P623, DOI 10.1083/jcb.113.3.623; SAEDI MS, 1991, J CELL BIOL, V112, P1007, DOI 10.1083/jcb.112.5.1007; SINE SM, 1991, J BIOL CHEM, V266, P19369; SMITH MM, 1987, J BIOL CHEM, V262, P4367; STROUD RM, 1990, BIOCHEMISTRY-US, V29, P11009, DOI 10.1021/bi00502a001; SUMIKAWA K, 1989, MOL BRAIN RES, V5, P183, DOI 10.1016/0169-328X(89)90034-X; TZARTOS SJ, 1980, P NATL ACAD SCI-BIOL, V77, P755, DOI 10.1073/pnas.77.2.755; UNWIN N, 1989, NEURON, V3, P665, DOI 10.1016/0896-6273(89)90235-3; WAN KK, 1985, BIOCHEMISTRY-US, V24, P1212, DOI 10.1021/bi00326a024; YONG G, 1989, J CELL BIOL, V109, P729, DOI 10.1083/jcb.109.2.729	36	128	128	0	0	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 16	1993	74	1					57	69		10.1016/0092-8674(93)90294-Z	http://dx.doi.org/10.1016/0092-8674(93)90294-Z			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8334706				2022-12-01	WOS:A1993LN62500007
J	WU, DQ; LAROSA, GJ; SIMON, MI				WU, DQ; LAROSA, GJ; SIMON, MI			G-PROTEIN-COUPLED SIGNAL-TRANSDUCTION PATHWAYS FOR INTERLEUKIN-8	SCIENCE			English	Article							ACTIVATING PROTEIN; COMPLEMENTARY-DNA; RECEPTOR; ALPHA; CLONING; FAMILY; CELLS	Interleukin-8 (IL-8) is one of the major mediators of the inflammatory response. The pathways by which IL-8 activates inositide-specific phospholipase C (PLC) were investigated by co-expression of different components of the guanosine triphosphate binding protein (G protein) pathway in COS-7 cells. Two distinct IL-8 receptors reconstituted ligand-dependent activation of endogenous PLC when transfected together with the G protein alpha subunits Galpha14, Galpha15, or Galpha16. However, reconstitution was not observed with cells that overexpressed Galpha(q) or Galpha11. Furthermore, IL-8 receptors interacted with endogenous pertussis toxin-sensitive G proteins or with the recombinant G protein G(i) to release free betagamma subunits that could then specifically activate the beta2 isoform of PLC. These findings suggest that IL-8 acts through signal-transducing pathways that are limited to specific heterotrimeric G proteins and effectors. These may provide suitable targets for the development of anti-inflammatory agents.	CALTECH, DIV BIOL, 147-75, PASADENA, CA 91125 USA; REPLIGEN CORP, DEPT MOLEC BIOL, CAMBRIDGE, MA 02132 USA	California Institute of Technology								AMATRUDA T, UNPUB; AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; CAMPS M, 1992, NATURE, V360, P684, DOI 10.1038/360684a0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.biochem.56.1.615; GOLDSMITH P, 1988, J BIOL CHEM, V263, P6476; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HUBER AR, 1991, SCIENCE, V254, P99, DOI 10.1126/science.1718038; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554; KRIZ R, 1990, CIBA F SYMP, V150, P112; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LARSEN CG, 1989, SCIENCE, V243, P1464, DOI 10.1126/science.2648569; LEE CH, 1992, J BIOL CHEM, V267, P16044; LEE J, 1992, J BIOL CHEM, V267, P16283; MURPHY PM, 1987, FEBS LETT, V221, P81, DOI 10.1016/0014-5793(87)80356-3; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PARK D, 1992, J BIOL CHEM, V267, P16048; SHENKER A, 1991, J BIOL CHEM, V266, P9309; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SMRCKA AV, 1991, SCIENCE, V251, P804, DOI 10.1126/science.1846707; TAYLOR SJ, 1991, NATURE, V350, P516, DOI 10.1038/350516a0; THELEN M, 1988, FASEB J, V2, P2702, DOI 10.1096/fasebj.2.11.2840318; THOMAS KM, 1991, J BIOL CHEM, V266, P14839; THOMAS KM, 1990, J BIOL CHEM, V265, P20061; WALDO GL, 1991, J BIOL CHEM, V266, P14217; WANGE RL, 1991, J BIOL CHEM, V266, P11409; WILKIE TM, 1992, NAT GENET, V1, P85, DOI 10.1038/ng0592-85; WU D, IN PRESS P NATL ACAD; Wu D., UNPUB; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811	35	349	363	1	4	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUL 2	1993	261	5117					101	103		10.1126/science.8316840	http://dx.doi.org/10.1126/science.8316840			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	8316840				2022-12-01	WOS:A1993LK43400042
J	PELOSI, AJ; APPLEBY, L				PELOSI, AJ; APPLEBY, L			PERSONALITY AND FATAL DISEASES	BRITISH MEDICAL JOURNAL			English	Article							NOVATION BEHAVIOR-THERAPY; CORONARY HEART-DISEASE; PROPHYLACTIC TREATMENT; CANCER; PREDICTOR		UNIV HOSP S MANCHESTER,MANCHESTER M20 8LR,LANCS,ENGLAND	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	PELOSI, AJ (corresponding author), HAIRMYRES HOSP,GLASGOW G75 8RG,SCOTLAND.			Pelosi, Anthony/0000-0002-5501-2661				BINIK YM, 1991, BEHAV RES THER, V29, P33, DOI 10.1016/S0005-7967(09)80004-1; Eysenck H.J., 1991, SMOKING PERSONALITY; EYSENCK HJ, 1991, AM J EPIDEMIOL, V133, P429, DOI 10.1093/oxfordjournals.aje.a115907; EYSENCK HJ, 1992, BRIT MED J, V305, P457, DOI 10.1136/bmj.305.6851.457; EYSENCK HJ, 1991, BEHAV RES THER, V29, P17, DOI 10.1016/S0005-7967(09)80003-X; EYSENCK HJ, 1991, PSYCHOL INQ, V2, P297, DOI DOI 10.1207/S15327965PLI0203_21; Eysenck HJ., 1991, PSYCHOL INQ, V2, P221, DOI DOI 10.1207/S15327965P1I0203_1; Fox B. H., 1991, PSYCHOL INQ, V2, P242; FOX BH, 1988, TOPICS HLTH PSYCHOL, P37; GALLACHER JEJ, 1992, PSYCHOLOGIST, P360; GROSSARTHMATICEK R, 1991, BEHAV RES THER, V29, P1; GROSSARTHMATICEK R, 1988, PERS INDIV DIFFER, V9, P479, DOI 10.1016/0191-8869(88)90125-0; GROSSARTHMATICEK R, 1991, BEHAV RES THER, V29, P343, DOI 10.1016/0005-7967(91)90070-J; KISSEN DM, 1962, J PSYCHOSOM RES, V6, P123, DOI 10.1016/0022-3999(62)90062-4; Lee PN., 1991, PSYCHOL INQ, V2, P251; PELOSI AJ, 1992, BRIT MED J, V304, P1295, DOI 10.1136/bmj.304.6837.1295; QUANDERBLAZNIK J, 1991, PERS INDIV DIFFER, V12, P125, DOI 10.1016/0191-8869(91)90095-S; SCHMALE AH, 1971, SOC SCI MED, V5, P95, DOI 10.1016/0037-7856(71)90090-4; SCHMITZ PG, 1992, PERS INDIV DIFFER, V13, P683, DOI 10.1016/0191-8869(92)90239-L; TEMOSHOK L, 1991, PSYCHOL INQUIRY, V2, P277; van der Ploeg HM, 1991, PSYCHOL INQ, V2, P280; 1991, PSYCHOL INQUIRY, V2, P233	22	10	10	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1993	306	6893					1666	1667		10.1136/bmj.306.6893.1666	http://dx.doi.org/10.1136/bmj.306.6893.1666			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LJ337	8324440	Bronze, Green Published			2022-12-01	WOS:A1993LJ33700030
J	DAVID, J; PRIORWILLEARD, PFS				DAVID, J; PRIORWILLEARD, PFS			RESUSCITATION SKILLS OF MRCP CANDIDATES	BRITISH MEDICAL JOURNAL			English	Article									ROYAL BERKSHIRE HOSP,DEPT MED,READING RG3 1AG,BERKS,ENGLAND	Royal Berkshire Hospital	DAVID, J (corresponding author), BATTLE HOSP,DEPT MED,READING RG3 1AG,BERKS,ENGLAND.							MCINTYRE AS, 1993, J ROY COLL PHYS LOND, V27, P34; THWAITES BC, 1992, J ROY COLL PHYS LOND, V26, P265; TUNSTALLPEDOE H, 1992, BRIT MED J, V304, P1347, DOI 10.1136/bmj.304.6838.1347; WYNNE G, 1992, J ROY COLL PHYS LOND, V26, P372; 1987, J R COLL PHYSICIANS, V21, P2	5	31	31	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1578	1579		10.1136/bmj.306.6892.1578	http://dx.doi.org/10.1136/bmj.306.6892.1578			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329919	Green Published, Bronze			2022-12-01	WOS:A1993LH12800019
J	ROSTOKER, G; DESVAUXBELGHITI, D; PILATTE, Y; PETITPHAR, M; PHILIPPON, C; DEFORGES, L; TERZIDIS, H; INTRATOR, L; ANDRE, C; ADNOT, S; BONIN, P; BIERLING, P; REMY, P; LAGRUE, G; LANG, P; WEIL, B				ROSTOKER, G; DESVAUXBELGHITI, D; PILATTE, Y; PETITPHAR, M; PHILIPPON, C; DEFORGES, L; TERZIDIS, H; INTRATOR, L; ANDRE, C; ADNOT, S; BONIN, P; BIERLING, P; REMY, P; LAGRUE, G; LANG, P; WEIL, B			HIGH-DOSE IMMUNOGLOBULIN THERAPY FOR SEVERE IGA NEPHROPATHY AND HENOCH-SCHONLEIN PURPURA	ANNALS OF INTERNAL MEDICINE			English	Article						PURPURA, SCHONLEIN-HENOCH; GLOMERULONEPHRITIS, IGA; PROTEINURIA; HEMATURIA	CHRONIC-RENAL-FAILURE; IMMUNE-COMPLEXES; GAMMA-GLOBULIN; INTRAVENOUS IMMUNOGLOBULIN; PRIMARY GLOMERULONEPHRITIS; NATURAL-HISTORY; LUPUS NEPHRITIS; A NEPHROPATHY; POLYMERIC IGA; SERUM	Objective: To determine if polyvalent IgG is promising therapy for severe IgA nephropathy. Design: Open prospective cohort study. Setting: Referral nephrology unit. Patients: 11 adult patients with severe IgA nephropathy (9 who had idiopathic disease and 2 who had Henoch-Schanlein purpura) and indicators of poor prognosis. Intervention: Patients were given high-dose immunoglobulins (2 g/kg each month) for 3 successive months, followed by intramuscular immunoglobulins (preparation content, 16.5%; 0.35 mL/kg every 15 days) for another 6 months. Measurements: Histologic changes were analyzed by comparing pre- and post-therapy renal biopsy specimens blindly, using an activity index (14-point scale), a sclerosis index (10-point scale), and a semiquantitative immunofluorescence test of immune deposits. Proteinuria, hematuria, leukocyturia, enzymuria, and global renal function (creatinine and polyfructosan clearances) were evaluated before and after intervention. Results: Proteinuria (median level before intervention, 5.20 g/d; median level after intervention, 2.25 g/d), hematuria, and leukocyturia decreased substantially. The decrease in glomerular filtration rate was greatly slowed or stopped (median rate of decline in glomerular filtration before, -3.78 mL/min per month; after, 0 mL/min per month). The histologic index of activity (median index before, 5; after, 2) and the staining intensity of glomerular IgA and C3 deposits also decreased. Immunoglobulin therapy was well tolerated. Conclusions: Immunoglobulin therapy may be effective in treating severe IgA nephropathy and protecting renal function. However, prospective controlled trials must confirm these preliminary results.	HOP HENRI MONDOR, INSERM, U139, F-94010 CRETEIL, FRANCE; HOP HENRI MONDOR, HISTOL ANAT PATHOL LAB, F-94010 CRETEIL, FRANCE; HOP HENRI MONDOR, BIOCHIM LAB, F-94010 CRETEIL, FRANCE; HOP HENRI MONDOR, BACTERIOL VIROL LAB, F-94010 CRETEIL, FRANCE; HOP HENRI MONDOR, IMMUNOL LAB, F-94010 CRETEIL, FRANCE; HOP HENRI MONDOR, EXPLORAT FONCTIONNELLES RENALES LAB, F-94010 CRETEIL, FRANCE; HOP HENRI MONDOR, CTR DEPT TRANFUS SANGUINE, F-94010 CRETEIL, FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	ROSTOKER, G (corresponding author), HOP HENRI MONDOR, SERV NEPHROL, 51 AVE GEN DE LATTRE DE TASSIGNY, F-94010 CRETEIL, FRANCE.		Pilatte, Yannick/N-4422-2018; Rostoker, Guy/K-1432-2019; Pilatte, Yannick/AAD-1943-2019	Rostoker, Guy/0000-0002-4383-3825; 				ALAMARTINE E, 1990, CLIN NEPHROL, V34, P45; ANDREOLI SP, 1989, PEDIATR NEPHROL, V3, P248, DOI 10.1007/BF00858524; BALLARDIE F, 1991, IMMUNOLOGY RENAL DIS, P183; BARANDUN S, 1986, CLIN USE INTRAVENOUS, P63; BASTA M, 1989, J CLIN INVEST, V84, P1974, DOI 10.1172/JCI114387; BENE MC, 1983, J CLIN INVEST, V71, P1342, DOI 10.1172/JCI110886; BERGER J, 1969, TRANSPL P, V1, P939; CLARKSON A, 1993, IGA NEPHROPATHY 25TH, V104, P189; COCKCROFT DW, 1976, NEPHRON, V16, P31, DOI 10.1159/000180580; DAMICO G, 1987, Q J MED, V64, P709; DUNNILL MS, 1984, PATHOLOGICAL BASIS R, P112; DURANDY A, 1981, J CLIN INVEST, V67, P867, DOI 10.1172/JCI110104; EMANCIPATOR SN, 1990, KIDNEY INT, V38, P1216, DOI 10.1038/ki.1990.337; EMANCIPATOR SN, 1985, CLIN NEPHROL, V24, P161; FRIDMAN WH, 1986, MOL IMMUNOL, V23, P1141, DOI 10.1016/0161-5890(86)90144-6; GENKINS G, 1979, JPLASMAPHERESIS IMMU, P144; GONZALEZCABRERO J, 1987, CLIN EXP IMMUNOL, V68, P694; HAMMARSTROM L, 1992, CLIN APPLICATIONS IN, P117; HOGG RJ, 1985, AM J KIDNEY DIS, V5, P157; HORII Y, 1989, J IMMUNOL, V143, P3949; IMAI H, 1987, J IMMUNOL METHODS, V103, P239, DOI 10.1016/0022-1759(87)90295-X; ISAACS JD, 1990, NEPHROL DIAL TRANSPL, V5, P619, DOI 10.1093/ndt/5.8.619; JAYNE DRW, 1991, LANCET, V337, P1137, DOI 10.1016/0140-6736(91)92797-6; JULIAN B, 1992, IGA NEPHROPATHY 25TH, V104, P198; KIM M, 1992, AUGP INT S IGA NEPHR; LAGRUE G, 1975, J UROL NEPHROL, V81, P655; LAI KN, 1991, CLIN EXP IMMUNOL, V85, P240; LAI KN, 1987, AM J KIDNEY DIS, V10, P66, DOI 10.1016/S0272-6386(87)80014-8; LAI KN, 1986, CLIN NEPHROL, V26, P174; LAI KN, 1988, TRANSPLANT P, V20, P297; LEE SMK, 1982, HUM PATHOL, V13, P314, DOI 10.1016/S0046-8177(82)80221-9; LIN CY, 1989, NEPHRON, V53, P303, DOI 10.1159/000185772; MAGIL AB, 1987, NEPHRON, V47, P246, DOI 10.1159/000184518; MANOHAR N, 1990, 11TH P INT C NEPHR T, pA105; MEILLET D, 1987, CLIN EXP IMMUNOL, V69, P142; MERSKEY C, 1966, BLOOD-J HEMATOL, V28, P1; MIYAKAWA S, 1986, Jikeikai Medical Journal, V33, P241; NYDEGGER U E, 1991, P27; ODONOGHUE DJ, 1991, J CLIN INVEST, V88, P1522, DOI 10.1172/JCI115462; OLIVIERA D, 1992, IMMUNOLOGICAL ASPECT, P87; PALLA R, 1991, CLIN NEPHROL, V35, P98; PECHADRE JC, 1977, REV EEG NEUROPHYSIOL, V7, P443, DOI 10.1016/S0370-4475(77)80049-X; REMUZZI G, 1987, KIDNEY INT, V32, P292, DOI 10.1038/ki.1987.206; ROSSI F, 1989, J IMMUNOL, V143, P4104; ROSTOKER G, 1991, NEPHRON, V59, P561, DOI 10.1159/000186644; ROSTOKER G, 1989, CLIN EXP IMMUNOL, V75, P30; ROSTOKER G, 1991, LANCET, V338, P54, DOI 10.1016/0140-6736(91)90043-O; ROSTOKER G, 1992, CLIN EXP IMMUNOL, V90, P305; SCHENA FP, 1990, AM J MED, V89, P209; SCHENA FP, 1989, CLIN EXP IMMUNOL, V77, P15; SCHWARTZ D, 1984, METHODES STATISTIQUE, P245; SCOTT MG, 1990, HUMAN IGG SUBCLASSES, P161; SINICO RA, 1986, J IMMUNOL, V137, P536; SUNDBLAD A, 1991, EUR J IMMUNOL, V21, P1155, DOI 10.1002/eji.1830210510; TOMINO Y, 1984, CLIN EXP IMMUNOL, V58, P42; van den Wall Bake A W, 1988, Clin Exp Immunol, V72, P321; WALDO FB, 1989, AM J KIDNEY DIS, V13, P55, DOI 10.1016/S0272-6386(89)80117-9; WALKER RG, 1990, CLIN NEPHROL, V34, P103; WALSER M, 1990, KIDNEY INT, V37, P1195, DOI 10.1038/ki.1990.103; WIENER E, 1990, HUMAN IGG SUBCLASSES, P135; WIGHT JP, 1992, NEPHROL DIAL TRANSPL, V7, P379; WOO KT, 1987, CLIN NEPHROL, V28, P304; YOSHIKAWA N, 1990, CLIN NEPHROL, V33, P160	63	121	127	0	4	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	MAR 15	1994	120	6					476	484		10.7326/0003-4819-120-6-199403150-00005	http://dx.doi.org/10.7326/0003-4819-120-6-199403150-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	NB625	8311370				2022-12-01	WOS:A1994NB62500005
J	MURPHY, DJ; BURROWS, D; SANTILLI, S; KEMP, AW; TENNER, S; KRELING, B; TENO, J				MURPHY, DJ; BURROWS, D; SANTILLI, S; KEMP, AW; TENNER, S; KRELING, B; TENO, J			THE INFLUENCE OF THE PROBABILITY OF SURVIVAL ON PATIENTS PREFERENCES REGARDING CARDIOPULMONARY-RESUSCITATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							LIFE-SUSTAINING TREATMENTS; HOSPITAL CARDIAC-ARREST; ADVANCE DIRECTIVES; ELDERLY OUTPATIENTS; MEDICAL-CARE; ATTITUDES; OUTCOMES; OLDER; PHYSICIANS; DECISIONS	Background. Studies suggest that a majority of elderly patients would want to undergo cardiopulmonary resuscitation (CPR) if they had a cardiac arrest. Yet few studies have examined their preferences after clinicians have informed them about the outcomes of CPR. Methods. To study older patients' preferences regarding CPR, we interviewed as many ambulatory patients as possible in one geriatrics practice in Denver from August 1, 1991, through July 31, 1992. Results. A total of 371 patients at least 60 years of age were eligible; 287 completed the interview (mean age, 77 years; range, 60 to 99). When asked about their wishes if they had cardiac arrest during an acute illness, 41 percent opted for CPR before learning the probability of survival to discharge. After learning the probability of survival (10 to 17 percent), 22 percent opted for CPR. Only 6 percent of patients 86 years of age or older opted for CPR under these conditions. When asked about a chronic illness in which the life expectancy was less than one year, 11 percent of the 287 patients opted for CPR before learning the. probability of survival to discharge. After teaming the probability of survival (0 to 5 percent), 5 percent said they would want CPR. Conclusions. Older patients readily understand prognostic information, which influences their preferences with respect to CPR. Most do not want to undergo CPR once a clinician explains the probability of survival after the procedure.	GEORGE WASHINGTON UNIV,DEPT HLTH CARE SCI,WASHINGTON,DC; GEORGE WASHINGTON UNIV,INTENS CARE UNIT RES UNIT,WASHINGTON,DC	George Washington University; George Washington University	MURPHY, DJ (corresponding author), PRESBYTERIAN ST LUKES MED CTR,SENIOR CITIZENS HLTH CTR,1801 HIGH ST,DENVER,CO 80218, USA.		Murphy, Denis J/ABC-1734-2020					APPLEBAUM GE, 1990, J AM GERIATR SOC, V38, P197, DOI 10.1111/j.1532-5415.1990.tb03490.x; AWOKE S, 1992, J AM GERIATR SOC, V40, P593, DOI 10.1111/j.1532-5415.1992.tb02109.x; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; BONNIN MJ, 1993, JAMA-J AM MED ASSOC, V270, P1457, DOI 10.1001/jama.270.12.1457; BRUNETTI LL, 1991, J GEN INTERN MED, V6, P323, DOI 10.1007/BF02597430; COGEN R, 1992, ARCH INTERN MED, V152, P1885, DOI 10.1001/archinte.152.9.1885; COHENMANSFIELD J, 1992, GERONTOLOGIST, V32, P89, DOI 10.1093/geront/32.1.89; DANIS M, 1991, NEW ENGL J MED, V324, P882, DOI 10.1056/NEJM199103283241304; DEGROSS JM, 1990, SOUTHERN MED J, V83, P733, DOI 10.1097/00007611-199007000-00001; DOUKAS DJ, 1993, J CLIN ETHIC, V4, P41; EMANUEL LL, 1989, JAMA-J AM MED ASSOC, V261, P3288, DOI 10.1001/jama.261.22.3288; EMANUEL LL, 1991, NEW ENGL J MED, V324, P889, DOI 10.1056/NEJM199103283241305; EVERHART MA, 1990, CHEST, V97, P159, DOI 10.1378/chest.97.1.159; FINUCANE TE, 1988, J GEN INTERN MED, V3, P322, DOI 10.1007/BF02595788; FRANKL D, 1989, AM J MED, V86, P645, DOI 10.1016/0002-9343(89)90436-1; JECKER NS, 1993, J CLIN ETHIC, V4, P16; Kielstein Rita, 1993, Kennedy Institute of Ethics Journal, V3, P303; LONGSTRETH WT, 1990, JAMA-J AM MED ASSOC, V264, P2109, DOI 10.1001/jama.264.16.2109; MALLOY TR, 1992, J AM GERIATR SOC, V40, P1255, DOI 10.1111/j.1532-5415.1992.tb03652.x; MICHELSON C, 1991, GERONTOLOGIST, V31, P358, DOI 10.1093/geront/31.3.358; MILLER DL, 1993, ARCH INTERN MED, V153, P1999, DOI 10.1001/archinte.153.17.1999; MILLER DL, 1992, ARCH INTERN MED, V152, P578, DOI 10.1001/archinte.152.3.578; MOWER MR, 1993, ARCH INTERN MED, V153, P375; MURPHY DJ, 1988, JAMA-J AM MED ASSOC, V260, P2098, DOI 10.1001/jama.260.14.2098; MURPHY DJ, 1990, JAMA-J AM MED ASSOC, V264, P2103, DOI 10.1001/jama.264.16.2103; MURPHY DJ, 1989, ANN INTERN MED, V111, P199, DOI 10.7326/0003-4819-111-3-199; OCONNOR AM, 1989, J CLIN EPIDEMIOL, V42, P119, DOI 10.1016/0895-4356(89)90085-1; PEARLMAN RA, 1993, J CLIN ETHIC, V4, P33; QUILL TE, 1992, ARCH INTERN MED, V152, P569, DOI 10.1001/archinte.152.3.569; SACHS GA, 1992, J AM GERIATR SOC, V40, P269, DOI 10.1111/j.1532-5415.1992.tb02081.x; SCHNEIDERMAN LJ, 1992, ARCH INTERN MED, V152, P2114, DOI 10.1001/archinte.152.10.2114; SCHONWETTER RS, 1993, J GEN INTERN MED, V8, P295, DOI 10.1007/BF02600139; SCHONWETTER RS, 1991, J AM GERIATR SOC, V39, P372, DOI 10.1111/j.1532-5415.1991.tb02902.x; SECKLER AB, 1991, ANN INTERN MED, V115, P92, DOI 10.7326/0003-4819-115-2-92; SEHGAL A, 1992, JAMA-J AM MED ASSOC, V267, P59, DOI 10.1001/jama.267.1.59; SHMERLING RH, 1988, J GEN INTERN MED, V3, P317, DOI 10.1007/BF02595786; TAFFET GE, 1988, JAMA-J AM MED ASSOC, V260, P2069, DOI 10.1001/jama.260.14.2069; TORIAN LV, 1992, ARCH INTERN MED, V152, P1659; TRESCH DD, 1988, AM J CARDIOL, V61, P1120, DOI 10.1016/0002-9149(88)90141-5; TRESCH DD, 1989, AM J MED, V86, P145, DOI 10.1016/0002-9343(89)90259-3; TRESCH DD, 1990, AM J CARDIOL, V65, P453, DOI 10.1016/0002-9149(90)90809-F; TRIAN LV, 1992, ARCH INTERNMED, V152, P561; UHLMANN RF, 1989, WESTERN J MED, V150, P705; WAGNER A, 1984, NEW ENGL J MED, V310, P1129, DOI 10.1056/NEJM198404263101732; 1987, CRUNC STATISTICAL PA	45	437	441	0	7	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	1994	330	8					545	549		10.1056/NEJM199402243300807	http://dx.doi.org/10.1056/NEJM199402243300807			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MX436	8302322				2022-12-01	WOS:A1994MX43600007
J	JACKSON, MR; COHENDOYLE, MF; PETERSON, PA; WILLIAMS, DB				JACKSON, MR; COHENDOYLE, MF; PETERSON, PA; WILLIAMS, DB			REGULATION OF MHC CLASS-I TRANSPORT BY THE MOLECULAR CHAPERONE, CALNEXIN (P88, IP90)	SCIENCE			English	Article							IMMUNOGLOBULIN HEAVY-CHAIN; ENDOPLASMIC-RETICULUM MEMBRANE; BINDING-PROTEIN; HISTOCOMPATIBILITY MOLECULES; SURFACE EXPRESSION; HLA-A; PEPTIDE; ANTIGEN; BETA-2-MICROGLOBULIN; EMPTY	Assembled class I histocompatibility molecules, consisting of heavy chain, beta2-microglobulin, and peptide ligand, are transported rapidly to the cell surface. In contrast, the intracellular transport of free heavy chains or peptide-deficient heavy chain-beta2-microglobulin heterodimers is impaired. A 90-kilodalton membrane-bound chaperone of the endoplasmic reticulum (ER), termed calnexin, associates quantitatively with newly synthesized class I heavy chains, but the functions of calnexin in this interaction are unknown. Class I subunits were expressed alone or in combination with calnexin in Drosophila melanogaster cells. Calnexin retarded the intracellular transport of both peptide-deficient heavy chain-beta2-microglobulin heterodimers and free heavy chains. Calnexin also impeded the rapid intracellular degradation of free heavy chains. The ability of calnexin to protect and retain class I assembly intermediates is likely to contribute to the efficient intracellular formation of class I-peptide complexes.	UNIV TORONTO, DEPT BIOCHEM, MED SCI BLDG, TORONTO M5S 1A8, ONTARIO, CANADA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	University of Toronto; Scripps Research Institute								AHLUWALIA N, 1992, J BIOL CHEM, V267, P10914; ALLEN H, 1986, P NATL ACAD SCI USA, V83, P7447, DOI 10.1073/pnas.83.19.7447; BOLE DG, 1986, J CELL BIOL, V102, P1558, DOI 10.1083/jcb.102.5.1558; CLICK EM, 1992, COLD SPRING HARB SYM, V57, P571, DOI 10.1101/SQB.1992.057.01.063; COHENDOYLE MF, UNPUB; DAAR AS, 1984, TRANSPLANTATION, V38, P287, DOI 10.1097/00007890-198409000-00018; DAVID V, 1993, J BIOL CHEM, V268, P9585; DEGEN E, 1992, J EXP MED, V175, P1653, DOI 10.1084/jem.175.6.1653; DEGEN E, 1991, J CELL BIOL, V112, P1099, DOI 10.1083/jcb.112.6.1099; GALVIN K, 1992, P NATL ACAD SCI USA, V89, P8452, DOI 10.1073/pnas.89.18.8452; HENDERSHOT L, 1987, J CELL BIOL, V104, P761, DOI 10.1083/jcb.104.3.761; HENDERSHOT LM, 1990, J CELL BIOL, V111, P829, DOI 10.1083/jcb.111.3.829; HOCHSTENBACH F, 1992, P NATL ACAD SCI USA, V89, P4734, DOI 10.1073/pnas.89.10.4734; JACKSON MR, 1992, P NATL ACAD SCI USA, V89, P12117, DOI 10.1073/pnas.89.24.12117; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KRANGEL MS, 1979, CELL, V18, P979, DOI 10.1016/0092-8674(79)90210-1; LIE WR, 1991, J EXP MED, V173, P449, DOI 10.1084/jem.173.2.449; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MARGOLESE L, 1993, J BIOL CHEM, V268, P17959; NEEFJES JJ, 1993, SCIENCE, V261, P769, DOI 10.1126/science.8342042; ORTIZNAVARRETE V, 1991, P NATL ACAD SCI USA, V88, P3594, DOI 10.1073/pnas.88.9.3594; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; POWIS SJ, 1991, NATURE, V354, P528, DOI 10.1038/354528a0; SEGE K, 1981, BIOCHEMISTRY-US, V20, P4223; SHEPHERD JC, 1993, CELL, V74, P577, DOI 10.1016/0092-8674(93)80058-M; SMITH MH, 1986, MOL IMMUNOL, V23, P1077, DOI 10.1016/0161-5890(86)90006-4; TOWNSEND A, 1990, CELL, V62, P285, DOI 10.1016/0092-8674(90)90366-M; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39; WADA I, 1991, J BIOL CHEM, V266, P19599; WILLIAMS DB, 1989, J IMMUNOL, V142, P2796; YANG Y, 1992, J BIOL CHEM, V267, P11669	32	245	252	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 21	1994	263	5145					384	387		10.1126/science.8278813	http://dx.doi.org/10.1126/science.8278813			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT034	8278813				2022-12-01	WOS:A1994MT03400036
J	MAULE, WF				MAULE, WF			SCREENING FOR COLORECTAL-CANCER BY NURSE ENDOSCOPISTS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FLEXIBLE FIBEROPTIC SIGMOIDOSCOPY; POLYPS; RISK; EXPERIENCE; PHYSICIANS; MORTALITY; ADENOMAS; RECTUM; COLON; SIZE	Background. Case-control studies have demonstrated that screening by sigmoidoscopy is effective in reducing mortality from colorectal cancer. If nurses performed screening examinations, more patients could be screened and, at current income levels, at a lower cost. Methods. Two registered nurses and two licensed practical nurses learned to perform examinations with the flexible fiberoptic sigmoidoscope in order to screen patients for colorectal tumors. They performed 1881 independent examinations of outpatients more than 45 years of age. During the same period, 730 examinations were performed by two gastroenterologists in similar patients. Results. The mean depth of insertion of the sigmoidoscope was slightly but significantly greater in the patients examined by the physicians than in those examined by the nurses (48 vs. 46 cm in men, P = 0.003; 41 vs. 38 cm in women, P = 0.002). Adenomas were found in 14 percent of the men and 8 percent of the women examined (P = 0.001). Nine cancers were found in men and four in women. There were no significant differences between the nurses and the physicians in the proportion of examinations that were positive for adenomas or cancer. No complications occurred during the initial examinations or during 894 follow-up sigmoidoscopic procedures. Among the patients whose initial examination results were normal, more of those examined by nurses returned for follow-up sigmoidoscopy after 12 months or more (45 percent, vs. 30 percent of those examined by physicians; P = 0.001). Conclusions. Nurses can carry out screening by flexible sigmoidoscopy as accurately and safely as experienced gastroenterologists.			MAULE, WF (corresponding author), OCHSNER CLIN BATON ROUGE, DEPT MED, GASTROENTEROL SECT, 16777 MED CTR DR, BATON ROUGE, LA 70816 USA.							ANASTASI A, 1968, PSYCHOL TESTING, P486; ATKIN WS, 1992, NEW ENGL J MED, V326, P658, DOI 10.1056/NEJM199203053261002; BORING CC, 1993, CA-CANCER J CLIN, V43, P7, DOI 10.3322/canjclin.43.1.7; CASS OW, 1993, ANN INTERN MED, V118, P40, DOI 10.7326/0003-4819-118-1-199301010-00008; GOLDBLOOM R, 1989, CAN MED ASSOC J, V141, P209; HAWES R, 1986, AM J MED, V80, P465, DOI 10.1016/0002-9343(86)90721-7; HIXSON LJ, 1990, JNCI-J NATL CANCER I, V82, P1769, DOI 10.1093/jnci/82.22.1769; HOFF G, 1985, SCAND J GASTROENTERO, V20, P356, DOI 10.3109/00365528509091664; KATON RM, 1985, FLEXIBLE SIGMOIDOSCO; MARKS G, 1979, DIS COLON RECTUM, V22, P162, DOI 10.1007/BF02586809; MUTO T, 1975, CANCER, V36, P2251, DOI 10.1002/cncr.2820360944; NEWCOMB PA, 1992, JNCI-J NATL CANCER I, V84, P1572, DOI 10.1093/jnci/84.20.1572; NIVATVONGS S, 1980, NEW ENGL J MED, V303, P380, DOI 10.1056/NEJM198008143030707; OBRIEN MJ, 1990, GASTROENTEROLOGY, V98, P371, DOI 10.1016/0016-5085(90)90827-N; ROSEVELT J, 1984, DIGEST DIS SCI, V29, P161, DOI 10.1007/BF01317059; SCHERTZ RD, 1989, GASTROINTEST ENDOSC, V35, P316, DOI 10.1016/S0016-5107(89)72800-5; SCHROY PC, 1988, GASTROINTEST ENDOSC, V34, P390, DOI 10.1016/S0016-5107(88)71402-9; SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001; SELBY JV, 1989, JAMA-J AM MED ASSOC, V261, P94; SPENCER RJ, 1984, MAYO CLIN PROC, V59, P305, DOI 10.1016/S0025-6196(12)61425-6; TRAUL DG, 1983, DIS COLON RECTUM, V26, P161, DOI 10.1007/BF02560161; VENNES JA, 1992, GASTROINTEST ENDOSC, V38, P746; WEISSMAN GS, 1987, CA-CANCER J CLIN, V37, P26, DOI 10.3322/canjclin.37.1.26; WINAWER SJ, 1992, CANCER, V70, P1236, DOI 10.1002/1097-0142(19920901)70:3+<1236::AID-CNCR2820701508>3.0.CO;2-4; WINAWER SJ, 1984, ADV INTERNAL MED, V30, P471; WINNAN G, 1980, NEW ENGL J MED, V302, P1011, DOI 10.1056/NEJM198005013021806; 1987, ANN INTERN MED, V107, P589; 1989, SUMMARY CURRENT GUID; 1990, SCREENING COLORECTAL; 1987, WORKING GUIDELINES E; 1989, CAN MED ASSOC J, V141, P1126	31	156	157	1	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JAN 20	1994	330	3					183	187		10.1056/NEJM199401203300307	http://dx.doi.org/10.1056/NEJM199401203300307			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ863	8264742				2022-12-01	WOS:A1994MQ86300007
J	SCHWARTZ, B; FRIES, S; FITZGIBBON, AM; LIPMAN, H				SCHWARTZ, B; FRIES, S; FITZGIBBON, AM; LIPMAN, H			PEDIATRICIANS DIAGNOSTIC-APPROACH TO PHARYNGITIS AND IMPACT OF CLIA 1988 ON OFFICE DIAGNOSTIC-TESTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE RHEUMATIC-FEVER; GROUP-A STREPTOCOCCI; PHYSICIANS OFFICE; THROAT-CULTURES; PENICILLIN THERAPY; SORE THROATS; ACCURACY; PENNSYLVANIA; LABORATORIES; PERFORMANCE	Objective.-To determine the factors associated with an optimal diagnostic approach to a child with pharyngitis, characterize off ice laboratory methods for throat swab culture and group A streptococcal rapid antigen testing, and assess the potential impact of the Clinical Laboratory Improvement Amendments (CLIA) of 1988 on the performance of these tests. Design and Setting.-Mailed survey to all board-certified primary care pediatricians from seven western states with telephone follow-up for nonrespondents. Outcome Measures.-Differences in practice characteristics and use of office laboratory tests for physicians who usually (>80%) diagnose pharyngitis using a recommended approach vs those who follow this approach less often (<50%); characteristics of physicians who indicate that they intend to discontinue office throat culture because of CLIA and those who will continue to perform this test also are compared. Results.-Responses from 531 pediatricians were analyzed. Forty-four percent diagnosed pharyngitis appropriately for more than 80% of patients, and 17% did so for fewer than 50%. Optimal diagnosis was significantly more common among physicians who cultured throat swabs in their office (relative risk, 1.40; 95% confidence interval, 1.19 to 1.66) and less common among solo practitioners (relative risk, 0.71; 95% confidence interval, 0.56 to 0.88). Factors that may decrease the sensitivity of off ice throat culture include short duration of incubation (59%), lack of quality control (51%), and limited education of the persons reading results (6%). With implementation of CLIA, 24% of pediatricians reported that they already have discontinued or will discontinue off ice throat culture, and 23% have discontinued or will discontinue antigen detection testing for group A streptococci. Those most likely to stop off ice culture include solo practitioners and practitioners who do not currently perform quality control of culture methods. Conclusions.-Office culture for group A streptococci is strongly associated with an optimal diagnostic approach. Implementation of CLIA regulations may substantially decrease the number of physicians who perform this test. The balance between potential improvements in the quality of office culture with CLIA implementation and the decreased availability of this test needs to be assessed.	BOULDER MED CTR,BOULDER,CO; BIOTEXT,BOULDER,CO		SCHWARTZ, B (corresponding author), CTR DIS CONTROL & PREVENT,CHILDHOOD & RESP DIS BRANCH,MAILSTOP C-09,ATLANTA,GA 30333, USA.							ARTHUR JD, 1984, POSTGRAD MED, V75, P241, DOI 10.1080/00325481.1984.11697969; BLOCH MJ, 1988, JAMA-J AM MED ASSOC, V260, P230, DOI 10.1001/jama.260.2.230; CRAWLEY R, 1986, JAMA-J AM MED ASSOC, V255, P374, DOI 10.1001/jama.255.3.374; DAJANI AS, 1989, PEDIATR INFECT DIS J, V8, P263; FACKLAM RR, 1987, J CLIN MICROBIOL, V25, P504, DOI 10.1128/JCM.25.3.504-508.1987; GERBER MA, 1986, DIAGN MICR INFEC DIS, V4, pS5, DOI 10.1016/S0732-8893(86)80038-4; GERBER MA, 1989, PEDIATR INFECT DIS J, V8, P820, DOI 10.1097/00006454-198911000-00032; GORDIS L, 1976, PEDIATRICS, V57, P422; HARBECK RJ, 1993, J CLIN MICROBIOL, V31, P839, DOI 10.1128/JCM.31.4.839-844.1993; HUCK W, 1989, J CLIN MICROBIOL, V27, P1715, DOI 10.1128/JCM.27.8.1715-1718.1989; KELLOGG JA, 1986, JAMA-J AM MED ASSOC, V255, P2638, DOI 10.1001/jama.255.19.2638; KELLOGG JA, 1990, J CLIN MICROBIOL, V28, P165, DOI 10.1128/JCM.28.2.165-169.1990; KROBER MS, 1985, JAMA-J AM MED ASSOC, V253, P1271, DOI 10.1001/jama.253.9.1271; LIEU TA, 1988, PEDIATR INFECT DIS J, V7, P847; LIEU TA, 1990, PEDIATRICS, V85, P246; LUNZ ME, 1987, JAMA-J AM MED ASSOC, V258, P361, DOI 10.1001/jama.258.3.361; MACKNIN ML, 1988, PEDIATR INFECT DIS J, V7, P735, DOI 10.1097/00006454-198810000-00016; MEIER FA, 1990, ARCH INTERN MED, V150, P1696, DOI 10.1001/archinte.150.8.1696; NELSON JD, 1984, PEDIATR INFECT DIS J, V3, P10, DOI 10.1097/00006454-198401000-00004; PEDDECORD KM, 1980, AM J CLIN PATHOL, V73, P380; POSES RM, 1985, JAMA-J AM MED ASSOC, V254, P925, DOI 10.1001/jama.254.7.925; RANDOLPH MF, 1985, J PEDIATR-US, V106, P870, DOI 10.1016/S0022-3476(85)80228-6; REDD SC, 1988, PEDIATRICS, V82, P576; REED BD, 1990, ARCH INTERN MED, V150, P1727, DOI 10.1001/archinte.150.8.1727; ROSENSTEIN BJ, 1970, J PEDIATR-US, V76, P606, DOI 10.1016/S0022-3476(70)80413-9; SCHUMAN AJ, 1993, CONT PEDIAT, V1, P50; SHULMAN ST, 1989, PEDIATR INFECT DIS J, V8, P816, DOI 10.1097/00006454-198911000-00031; SNELLMAN LW, 1993, PEDIATRICS, V91, P1166; TIEN PC, 1992, 32ND INT C ANT AG CH, P367; TODD JK, 1982, PEDIATR INFECT DIS J, V1, P265, DOI 10.1097/00006454-198207000-00017; VEASY LG, 1987, NEW ENGL J MED, V316, P421, DOI 10.1056/NEJM198702193160801; WAGNER DL, 1992, JAMA-J AM MED ASSOC, V267, P695; WALD ER, 1987, PEDIATRICS, V80, P371; WALLACE MR, 1989, JAMA-J AM MED ASSOC, V262, P2557, DOI 10.1001/jama.262.18.2557; 1991, RED BOOK, P438; [No title captured]	36	38	39	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 19	1994	271	3					234	238		10.1001/jama.271.3.234	http://dx.doi.org/10.1001/jama.271.3.234			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ645	8277551				2022-12-01	WOS:A1994MQ64500039
J	SKALHEGG, BS; TASKEN, K; HANSSON, V; HUITFELDT, HS; JAHNSEN, T; LEA, T				SKALHEGG, BS; TASKEN, K; HANSSON, V; HUITFELDT, HS; JAHNSEN, T; LEA, T			LOCATION OF CAMP-DEPENDENT PROTEIN-KINASE TYPE-I WITH THE TCR-CD3 COMPLEX	SCIENCE			English	Article							T-CELL RECEPTOR; REGULATORY SUBUNIT; HUMAN TESTIS; TYROSINE PHOSPHORYLATION; ADENOSINE-MONOPHOSPHATE; SURFACE MOLECULES; IDENTIFICATION; BINDING; SITE; ACTIVATION	Selective activation of cyclic adenosine 3',5'-monophosphate (cAMP)-dependent protein kinase type I (cAKI), but not type II, is sufficient to mediate inhibition of T cell replication induced through the antigen-specific T cell receptor-CD3 (TCR-CD3) complex. Immunocytochemistry and immunoprecipitation studies of the molecular mechanism by which cAKI inhibits TCR-CD3-dependent T cell replication demonstrated that regulatory subunit Ialpha, along with its associated kinase activity, translocated to and interacted with the TCR-CD3 complex during T cell activation and capping. Regulatory subunit IIalpha did not. When stimulated by cAMP, the cAKI localized to the TCR-CD3 complex may release kinase activity that, through phosphorylation, might uncouple the TCR-CD3 complex from intracellular signaling systems.	NATL HOSP NORWAY,INST IMMUNOL & RHEUMATOL,N-0027 OSLO,NORWAY; NATL INST PUBL HLTH,N-0462 OSLO,NORWAY; NATL HOSP NORWAY,INST PATHOL,IMMUNOHISTOCHEM & IMMUNOPATHOL LAB,N-0027 OSLO,NORWAY	University of Oslo; National Hospital Norway; University of Oslo; National Hospital Norway	SKALHEGG, BS (corresponding author), UNIV OSLO,INST MED BIOCHEM,N-0317 OSLO,NORWAY.		Skålhegg, Bjørn Steen/AAZ-2976-2021	Skålhegg, Bjørn Steen/0000-0002-3481-8084; Tasken, Kjetil/0000-0003-2841-4697				ANASTASSIOU ED, 1992, J IMMUNOL, V148, P2845; BEEBE SJ, 1988, METHOD ENZYMOL, V159, P118; BOOKER GW, 1993, CELL, V73, P813, DOI 10.1016/0092-8674(93)90259-S; CICCHETTI P, 1992, SCIENCE, V257, P803, DOI 10.1126/science.1379745; COOPER JA, 1984, J BIOL CHEM, V259, P7835; HUNTER T, 1982, J BIOL CHEM, V257, P4843; KAMMER GM, 1988, P NATL ACAD SCI USA, V85, P792, DOI 10.1073/pnas.85.3.792; KHAN AA, 1992, SCIENCE, V257, P815, DOI 10.1126/science.1323146; KLAUSNER RD, 1987, J BIOL CHEM, V262, P12654; LANOTTE M, 1991, J CELL PHYSIOL, V146, P73, DOI 10.1002/jcp.1041460110; LEDBETTER JA, 1986, J IMMUNOL, V137, P3299; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOHMANN SM, 1984, P NATL ACAD SCI-BIOL, V81, P6723, DOI 10.1073/pnas.81.21.6723; PARK DJ, 1992, J BIOL CHEM, V267, P1496; PATSCHINSKY T, 1982, P NATL ACAD SCI-BIOL, V79, P973, DOI 10.1073/pnas.79.4.973; ROZAKISADCOCK M, 1993, NATURE, V363, P83, DOI 10.1038/363083a0; SANDBERG M, 1987, BIOCHEM BIOPH RES CO, V149, P939, DOI 10.1016/0006-291X(87)90499-2; SANDBERG M, 1990, BIOCHEM BIOPH RES CO, V167, P323, DOI 10.1016/0006-291X(90)91768-N; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SKALHEGG BS, 1992, J BIOL CHEM, V267, P5374; SKALHEGG BS, 1992, J BIOL CHEM, V267, P15707; SKALHEGG BS, UNPUB; TAKAYAMA H, 1988, J BIOL CHEM, V263, P2330; TASKEN K, 1993, J BIOL CHEM, V268, P21276; TAYLOR RB, 1971, NATURE-NEW BIOL, V233, P225, DOI 10.1038/newbio233225a0; YU HT, 1992, SCIENCE, V258, P1665, DOI 10.1126/science.1280858	26	186	191	0	6	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 7	1994	263	5143					84	87		10.1126/science.8272870	http://dx.doi.org/10.1126/science.8272870			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ301	8272870				2022-12-01	WOS:A1994MQ30100035
J	WARREN, WS; RICHTER, W; ANDREOTTI, AH; FARMER, BT				WARREN, WS; RICHTER, W; ANDREOTTI, AH; FARMER, BT			GENERATION OF IMPOSSIBLE CROSS-PEAKS BETWEEN BULK WATER AND BIOMOLECULES IN SOLUTION NMR	SCIENCE			English	Article							MULTIPLE SPIN ECHOES; NUCLEAR-MAGNETIC-RESONANCE; FIELD; LIQUIDS	Intermolecular multiple-quantum coherences between bulk water and a glycoprotein fragment at modest concentration (20 mM) have been experimentally produced and detected, although such coherences are inconceivable in the normal theoretical framework of nuclear magnetic resonance. A density matrix treatment explains these results by including the long-range dipolar interaction between spins and by discarding the high-temperature approximation. These results imply that peak intensities (critical for structural determinations) can be distorted in many gradient experiments, and show that magic-angle gradients provide substantial improvements with reduced gradient strengths. They also suggest methods for contrast enhancement in magnetic resonance imaging.	BRISTOL MYERS SQUIBB CO,PHARMACEUT RES INST,PRINCETON,NJ 08543	Bristol-Myers Squibb	WARREN, WS (corresponding author), PRINCETON UNIV,DEPT CHEM,PRINCETON,NJ 08544, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035253] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAX A, 1980, CHEM PHYS LETT, V69, P567, DOI 10.1016/0009-2614(80)85130-X; BEDFORD AS, 1991, J MAGN RESON, V93, P516, DOI 10.1016/0022-2364(91)90080-D; BOWTELL R, 1990, J MAGN RESON, V88, P643, DOI 10.1016/0022-2364(90)90297-M; BOWTELL R, 1992, J MAGN RESON, V100, P1, DOI 10.1016/0022-2364(92)90361-A; DEVILLE G, 1979, PHYS REV B, V19, P5666, DOI 10.1103/PhysRevB.19.5666; EINZEL D, 1984, PHYS REV LETT, V53, P2312, DOI 10.1103/PhysRevLett.53.2312; HE QH, 1993, J CHEM PHYS, V98, P6779, DOI 10.1063/1.464770; KORBER H, 1991, J MAGN RESON, V93, P589, DOI 10.1016/0022-2364(91)90085-8; MATSUURA H, 1988, J BIOL CHEM, V263, P3314; MAUDSLEY AA, 1978, CHEM PHYS LETT, V55, P9, DOI 10.1016/0009-2614(78)85120-3; MCCOY MA, 1990, J CHEM PHYS, V93, P858, DOI 10.1063/1.459457; WARREN WS, 1992, J CHEM PHYS, V96, P1659, DOI 10.1063/1.462156; WEITEKAMP DP, 1983, ADV MAGN RESON, V11, P111	13	343	355	3	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					2005	2009		10.1126/science.8266096	http://dx.doi.org/10.1126/science.8266096			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266096				2022-12-01	WOS:A1993MN10800029
J	SCANLON, TJ; LUBEN, RN; SCANLON, FL; SINGLETON, N				SCANLON, TJ; LUBEN, RN; SCANLON, FL; SINGLETON, N			IS FRIDAY THE 13TH BAD FOR YOUR HEALTH	BRITISH MEDICAL JOURNAL			English	Article							SUPERNATURAL BELIEFS	Objective-To, examine the relation between health, behaviour, and superstition surrounding Friday 13th in the United Kingdom. Design-Retrospective study of paired data comparing driving and shopping patterns and accidents. Subjects-Drivers, shoppers, and residents. Setting-South West Thames region. Main outcome measures-Numbers of vehicles on motorways; numbers of shoppers in supermarkets; and hospital admissions due to accidents. Results-There were consistently and significantly fewer vehicles on the southern section of the M25 on Friday the 13th compared with Friday the 6th. The numbers of shoppers were not significantly different on the two days. Admissions due to transport accidents were significantly increased on Friday 13th (total 65 v 45; p < 0.05). Conclusions-Friday 13th is unlucky for some. The risk of hospital admission as a result of a transport accident may be increased by as much as 52%. Staving at home is recommended.			SCANLON, TJ (corresponding author), MID DOWNS HLTH AUTHOR,DEPT PUBL HLTH,HAYWARDS HEATH RH16 4BE,W SUSSEX,ENGLAND.		Luben, Robert N/H-5519-2015	Luben, Robert N/0000-0002-5088-6343				Aderinokun G A, 1991, Afr Dent J, V5, P26; Burleigh E, 1990, Med Anthropol, V12, P419; GOUTEUX JP, 1992, B SOC PATHOL EXOT, V85, P256; LaPiere RT, 1934, SOC FORCES, V13, P230, DOI 10.2307/2570339; LEYGUES M, 1989, SOC SCI MED, V28, P1255, DOI 10.1016/0277-9536(89)90344-4; Lorie P., 1992, SUPERSTITIONS; MAHDIHASSAN S, 1990, AM J CHINESE MED, V18, P87, DOI 10.1142/S0192415X90000125; RADFORD A, 1961, ENCYCLOPEDIA SUPERSI	8	26	26	0	7	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 18	1993	307	6919					1584	1586		10.1136/bmj.307.6919.1584	http://dx.doi.org/10.1136/bmj.307.6919.1584			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292946	Green Published, Bronze			2022-12-01	WOS:A1993MN10700009
J	CHOY, B; GREEN, MR				CHOY, B; GREEN, MR			EUKARYOTIC ACTIVATORS FUNCTION DURING MULTIPLE STEPS OF PREINITIATION COMPLEX ASSEMBLY	NATURE			English	Article							RNA POLYMERASE-II; TRANSCRIPTION FACTOR ATF; TATA-BINDING-PROTEIN; GAL4 DERIVATIVES; TFIID COMPLEX; INVITRO; MECHANISM; DNA; DOMAIN; PROMOTERS	Eukaryotic activator proteins (activators) stimulate transcription by increasing assembly of the preinitiation complex. We have developed methods to quantify the stable assembly of general transcription factors into transcriptional complexes in response to activators. We show that activators function during at least two stages of preinitiation complex assembly: first, to recruit the general transcription factor TFIIB, and then at a second step, after TFIIB entry. It is at this second step that the TATA-box binding protein associated factors act. This step also seems to be critical for activators to stimulate transcription synergistically.			CHOY, B (corresponding author), UNIV MASSACHUSETTS,MED CTR,PROGRAM MOLEC MED,373 PLANTAT ST,WORCESTER,MA 01605, USA.							ARIAS JA, 1989, J BIOL CHEM, V264, P3223; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; CARCAMO J, 1989, J BIOL CHEM, V264, P7704; CAREY M, 1990, NATURE, V345, P361, DOI 10.1038/345361a0; CAREY MF, 1986, J BIOL CHEM, V261, P4309; COLGAN J, 1993, NATURE, V362, P549, DOI 10.1038/362549a0; CRESS WD, 1991, SCIENCE, V251, P87, DOI 10.1126/science.1846049; FLANAGAN PM, 1991, NATURE, V350, P436, DOI 10.1038/350436a0; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GINIGER E, 1987, NATURE, V330, P670, DOI 10.1038/330670a0; HA H, 1993, GENE DEV, V7, P1021; HAGEMEIER C, 1992, J VIROL, V66, P4452, DOI 10.1128/JVI.66.7.4452-4456.1992; HAHN S, 1993, NATURE, V363, P672, DOI 10.1038/363672a0; HAI T, 1988, CELL, V54, P1043, DOI 10.1016/0092-8674(88)90119-5; HAWLEY D, 1991, TRENDS BIOCHEM SCI, V16, P317, DOI 10.1016/0968-0004(91)90130-N; HERNANDEZ N, 1993, GENE DEV, V7, P1291, DOI 10.1101/gad.7.7b.1291; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HORIKOSHI M, 1988, CELL, V54, P665, DOI 10.1016/S0092-8674(88)80011-4; HORIKOSHI M, 1988, CELL, V54, P1033, DOI 10.1016/0092-8674(88)90118-3; HORIKOSHI N, 1991, P NATL ACAD SCI USA, V88, P5124, DOI 10.1073/pnas.88.12.5124; ING NH, 1992, J BIOL CHEM, V267, P17617; INGLES CJ, 1991, NATURE, V351, P588, DOI 10.1038/351588a0; JOHNSON FB, 1992, GENE DEV, V6, P2177, DOI 10.1101/gad.6.11.2177; KAO CC, 1990, SCIENCE, V248, P1646, DOI 10.1126/science.2194289; KATAGIRI F, 1990, GENE DEV, V4, P1899, DOI 10.1101/gad.4.11.1899; LEE WS, 1991, CELL, V67, P365, DOI 10.1016/0092-8674(91)90188-5; LIEBERMAN PM, 1991, GENE DEV, V5, P2441, DOI 10.1101/gad.5.12b.2441; LIN YS, 1990, NATURE, V345, P359, DOI 10.1038/345359a0; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1991, NATURE, V353, P569, DOI 10.1038/353569a0; MEISTERERNST M, 1991, CELL, V66, P981, DOI 10.1016/0092-8674(91)90443-3; MEISTERERNST M, 1991, CELL, V67, P557, DOI 10.1016/0092-8674(91)90530-C; PARVIN JD, 1992, CELL, V68, P1135, DOI 10.1016/0092-8674(92)90084-P; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1992, J BIOL CHEM, V267, P679; ROBERTS SGE, 1993, NATURE, V363, P741, DOI 10.1038/363741a0; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; STRINGER KF, 1990, NATURE, V345, P783, DOI 10.1038/345783a0; SUNDSETH R, 1992, J BIOL CHEM, V267, P7845; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THOMPSON NE, 1990, J BIOL CHEM, V265, P7069; TRUANT R, 1993, J BIOL CHEM, V268, P2284; WAMPLER SL, 1992, GENE DEV, V6, P1542, DOI 10.1101/gad.6.8.1542; WANG WD, 1992, SCIENCE, V255, P450, DOI 10.1126/science.1310361; WHITE J, 1992, EMBO J, V11, P2229, DOI 10.1002/j.1460-2075.1992.tb05282.x; WORKMAN JL, 1990, EMBO J, V9, P1299, DOI 10.1002/j.1460-2075.1990.tb08239.x; ZAWEL L, 1993, PROG NUCLEIC ACID RE, V44, P67, DOI 10.1016/S0079-6603(08)60217-2; ZHU H, 1992, P NATL ACAD SCI USA, V89, P5291, DOI 10.1073/pnas.89.12.5291	50	264	267	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 9	1993	366	6455					531	536		10.1038/366531a0	http://dx.doi.org/10.1038/366531a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	ML218	8255291				2022-12-01	WOS:A1993ML21800060
J	KEE, F; GAFFNEY, B; CURRIE, S; OREILLY, D				KEE, F; GAFFNEY, B; CURRIE, S; OREILLY, D			ACCESS TO CORONARY CATHETERIZATION - FAIR SHARES FOR ALL	BRITISH MEDICAL JOURNAL			English	Article							ARTERY DISEASE; HEART-DISEASE; ANGIOGRAPHY; PROBABILITY; DEPRIVATION; MORBIDITY; MORTALITY; PATTERNS; RATIOS; BIAS	Objective-To determine the effects of patient's sex and area's material deprivation on utilisation rates of coronary catheterisation and angiography in the investigation of ischaemic heart disease. Design-Retrospective analysis of routinely collected hospital statistics. Setting-Acute hospitals throughout Northern Ireland. Subjects-24179 episodes of patients discharged from hospital with a primary diagnosis of ischaemic heart disease and 1270 episodes relating to patients with an underlying diagnosis of ischaemic heart disease who had either coronary catheterisation or angiography. Main outcome measures-Age standardised admission rates for heart disease and age standardised utilisation rates for catheterisation or angiography, or both, for 566 electoral wards ranked by Townsend ''deprivation'' scores. Results-Catheterisation-angiography rates in men were over fivefold those of women, ranging from 85.5/100000 v 16/100000 in patients from ''well off'' areas to 123/100000 v 22/100000 for patients from deprived areas. After admission rates for heart disease were controlled for, the overall rate ratio for women was 0.48 (95% confidence interval 0.38 to 0.60). After differential admission rates for heart disease and other potential clinical confounders were controlled for, the investigation rates of patients from the least and most ''deprived'' areas were not significantly different (rate ratio 1.04 (0.87 to 1.25)). Conclusion-Although investigation rates were significantly lower in women than in men, further clinical data would be required before labelling this underutilisation as evidence of bias. There was no significant difference in invasive investigation rates for heart disease in areas of varying deprivation or affluence.	QUEENS UNIV,DEPT EPIDEMIOL & PUBL HLTH,KINGSTON K7L 3N6,ONTARIO,CANADA; NORTHERN HLTH & SOC SERV BOARD,BALLYMENA BT42 19B,NORTH IRELAND; EASTERN HLTH & SOCIAL SERV BOARD,DEPT PUBL HLTH MED,BELFAST,NORTH IRELAND	Queens University - Canada								Bernstein S J, 1993, Int J Technol Assess Health Care, V9, P3; BERNSTEIN SJ, 1993, JAMA-J AM MED ASSOC, V269, P766, DOI 10.1001/jama.269.6.766; BICKELL NA, 1992, ANN INTERN MED, V116, P791, DOI 10.7326/0003-4819-116-10-791; BOBBIO M, 1992, MED DECIS MAKING, V12, P197, DOI 10.1177/0272989X9201200305; CHASSIN MR, 1987, JAMA-J AM MED ASSOC, V258, P2543, DOI 10.1001/jama.258.18.2543; CROMBIE IK, 1990, BRIT HEART J, V64, P199; CROMBIE IK, 1989, BRIT HEART J, V61, P172; CURTIS SE, 1990, J EPIDEMIOL COMMUN H, V44, P62, DOI 10.1136/jech.44.1.62; ELDER AT, 1991, BRIT MED J, V303, P950, DOI 10.1136/bmj.303.6808.950; FEIBACH NH, 1990, JAMA-J AM MED ASSOC, V263, P1092; FINDLAY IN, 1991, BRIT HEART J, V66, P70; GARBER CE, 1992, J CLIN EPIDEMIOL, V45, P715, DOI 10.1016/0895-4356(92)90048-R; GRAY D, 1990, LANCET, V335, P1317, DOI 10.1016/0140-6736(90)91196-H; KREIGER N, 1992, AM J PUBLIC HEALTH, V92, P703; LERNER DJ, 1986, AM HEART J, V111, P383, DOI 10.1016/0002-8703(86)90155-9; MAYS N, 1989, J EPIDEMIOL COMMUN H, V43, P191, DOI 10.1136/jech.43.2.191; ORENCIA A, 1993, JAMA-J AM MED ASSOC, V269, P2392, DOI 10.1001/jama.269.18.2392; PARK RE, 1989, AM J PUBLIC HEALTH, V79, P445, DOI 10.2105/AJPH.79.4.445; PETTICREW M, 1993, BMJ-BRIT MED J, V306, P1164, DOI 10.1136/bmj.306.6886.1164; PRICE CE, 1992, J EPIDEMIOL COMMUN H, V46, P58, DOI 10.1136/jech.46.1.58; SOX HC, 1990, AM J MED, V89, P7, DOI 10.1016/0002-9343(90)90090-Z; TOFLER GH, 1993, AM J CARDIOL, V71, P1031, DOI 10.1016/0002-9149(93)90568-W; Townsend P, 1988, HLTH DEPRIVATION INE; TUNIS SR, 1993, ARCH INTERN MED, V153, P991, DOI 10.1001/archinte.153.8.991; WILLIAMS RB, 1992, JAMA-J AM MED ASSOC, V267, P520, DOI 10.1001/jama.267.4.520; 1992, REGIONAL STRATEGIC F; 1990, SPATIAL SOCIAL VARIA	27	62	62	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1993	307	6915					1305	1307		10.1136/bmj.307.6915.1305	http://dx.doi.org/10.1136/bmj.307.6915.1305			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH556	8257883	Green Published, Bronze			2022-12-01	WOS:A1993MH55600017
J	HOELDTKE, RD; STREETEN, DHP				HOELDTKE, RD; STREETEN, DHP			TREATMENT OF ORTHOSTATIC HYPOTENSION WITH ERYTHROPOIETIN	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RECOMBINANT-HUMAN-ERYTHROPOIETIN; PLASMA NOREPINEPHRINE; HYPERTENSION; EPINEPHRINE	Background and Methods. Patients with orthostatic hypotension caused by autonomic neuropathy frequently have a decreased red-cell mass. This would be expected to compromise their effective circulating blood volume and aggravate the orthostatic hypotension. We studied the effect of increasing the red-cell mass with erythropoietin, given subcutaneously in a dose of 50 U per kilogram of body weight three times a week for 6 to 10 weeks to eight patients with orthostatic hypotension - four men, one teenage boy, and three women (age range, 17 to 68 years). Four patients had type I diabetes mellitus and autonomic neuropathy, three patients had pure autonomic failure, and one patient had sympathotonic orthostatic hypotension. Seven patients received fludrocortisone (0.1 or 0.2 mg per day) before, during, and after the trial of erythropoietin. The red-cell volume, plasma volume, and hemodynamic response to orthostatic stress were measured before and after therapy. Results. Erythropoietin increased the mean (+/-SD) hematocrit from 0.34+/-0.04 to 0.45+/-0.04 (P<0.005) and increased the red-cell volume from 16.8+/-3.9 to 25.3+/-3.1 ml per kilogram (P<0.005), but had no effect on plasma volume. The systolic blood pressure increased from 81+/-11 to 100+/-24 mm Hg (P<0.01) and the diastolic blood pressure increased from 46+/-10 to 63+/-18 mm Hg (P<0.01) while the patients were standing. The average systolic and diastolic blood pressure while the patients were supine did not increase significantly, although hypertension in the supine position developed in three patients. Orthostatic dizziness improved during treatment in six of the eight patients. Conclusions. In patients with orthostatic hypotension, increasing the red-cell volume with erythropoietin elevates blood pressure while standing. Possible long-term adverse effects are not known.	W VIRGINIA UNIV,DEPT MED,MORGANTOWN,WV 26506; SUNY HLTH SCI CTR,DEPT MED,SYRACUSE,NY	West Virginia University; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center	HOELDTKE, RD (corresponding author), TEMPLE UNIV,DEPT MED,PHILADELPHIA,PA 19122, USA.				NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES [R01AM032239] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000349] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG003055, R37AG003055] Funding Source: NIH RePORTER; NCRR NIH HHS [RR-00349] Funding Source: Medline; NIADDK NIH HHS [AM-32239] Funding Source: Medline; NIA NIH HHS [AG-03055] Funding Source: Medline	NAT INST OF ARTHRITIS, DIABETES, DIGESTIVE &KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIADDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BASKIN S, 1990, NEW ENGL J MED, V323, P999; BERSON SA, 1953, J CLIN INVEST, V32, P746, DOI 10.1172/JCI102789; BIAGGIONI I, 1993, J CLIN ENDOCR METAB, V76, P580, DOI 10.1210/jc.76.3.580; BIAGGIONI I, 1991, CLIN RES, V30, P300; CHOBANIAN AV, 1979, NEW ENGL J MED, V301, P68, DOI 10.1056/NEJM197907123010202; CHOKROVERTY S, 1969, BRAIN, V92, P743, DOI 10.1093/brain/92.4.743; EGRIE JC, 1987, J IMMUNOL METHODS, V99, P235, DOI 10.1016/0022-1759(87)90133-5; EWING DJ, 1980, ANN INTERN MED, V92, P308, DOI 10.7326/0003-4819-92-2-308; HEIDENREICH S, 1991, KIDNEY INT, V39, P259, DOI 10.1038/ki.1991.31; HOELDTKE RD, 1989, NEUROLOGY, V39, P34, DOI 10.1212/WNL.39.1.34; HOELDTKE RD, 1991, J CLIN ENDOCR METAB, V73, P132, DOI 10.1210/jcem-73-1-132; HOELDTKE RD, 1992, MUSCLE NERVE, V15, P926, DOI 10.1002/mus.880150810; International Committee for Standardization in Hematology, 1973, British Journal of Haematology, V25, P801, DOI 10.1111/j.1365-2141.1973.tb01792.x; LONDON GM, 1989, KIDNEY INT, V36, P878, DOI 10.1038/ki.1989.274; MARTIN W, 1986, BRIT J PHARMACOL, V89, P563, DOI 10.1111/j.1476-5381.1986.tb11157.x; NUSYNOWITZ ML, 1974, AM J ROENTGENOL, V120, P549, DOI 10.2214/ajr.120.3.549; PEULER JD, 1977, LIFE SCI, V21, P625, DOI 10.1016/0024-3205(77)90070-4; SLATON PE, 1967, J CLIN ENDOCR METAB, V27, P37, DOI 10.1210/jcem-27-1-37; STREETEN DHP, 1990, J CLIN INVEST, V86, P1582, DOI 10.1172/JCI114878; WATSON E, 1981, LIFE SCI, V28, P493, DOI 10.1016/0024-3205(81)90142-9; WILCOX CS, 1983, AUTONOMIC FAILURE TX, P115	21	166	169	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1993	329	9					611	615		10.1056/NEJM199308263290904	http://dx.doi.org/10.1056/NEJM199308263290904			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU217	8341335	Green Published			2022-12-01	WOS:A1993LU21700004
J	NELSON, JL; HUGHES, KA; SMITH, AG; NISPEROS, BB; BRANCHAUD, AM; HANSEN, JA				NELSON, JL; HUGHES, KA; SMITH, AG; NISPEROS, BB; BRANCHAUD, AM; HANSEN, JA			MATERNAL-FETAL DISPARITY IN HLA CLASS-II ALLOANTIGENS AND THE PREGNANCY-INDUCED AMELIORATION OF RHEUMATOID-ARTHRITIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ELUTED GAMMA-GLOBULINS; SUPPRESSOR T-CELLS; ANKYLOSING-SPONDYLITIS; SEQUENCE-ANALYSIS; ANTIBODIES; HLA-DR4; DISEASE; POLYMORPHISM; ASSOCIATION; MOLECULES	Background. Rheumatoid arthritis frequently remits during pregnancy, for unknown reasons. Since an immune response to paternally inherited fetal HLA can occur during normal pregnancy and since rheumatoid arthritis is an autoimmune disorder with a known HLA class II antigen association, we tested the hypothesis that maternal-fetal disparity in HLA alloantigens might be associated with the pregnancy-induced remission of rheumatoid arthritis. Methods. We studied 57 pregnancies of 41 women with rheumatoid arthritis, 18 prospectively and 39 retrospectively. Serologic and DNA techniques were used to study HLA class I and II antigens. For newborns, typing was performed from cord-blood samples obtained at delivery. For four young children, typing was performed from DNA extracted from hair samples. Results. We found significantly more maternal-fetal disparity in HLA-DR and DQ antigens in pregnancies characterized by the remission or improvement of rheumatoid arthritis than in pregnancies characterized by active disease. Further studies using DNA-typing techniques to define allelic variants of HLA-DR and DQ antigens confirmed this observation. Maternal-fetal disparity in alleles of HLA-DRB1, DQA, and DQB occurred in 26 of 34 pregnancies characterized by remission or improvement (76 percent), as compared with 3 of 12 pregnancies characterized by active arthritis (25 percent) (odds ratio, 9.7; P = 0.003). The difference between the two groups was most marked for alleles of HLA-DQA. Conclusions. Amelioration of rheumatoid arthritis during pregnancy is associated with a disparity in HLA class II antigens between mother and fetus. These findings suggest that the maternal immune response to paternal HLA antigens may have a role in the pregnancy-induced remission of rheumatoid arthritis.			NELSON, JL (corresponding author), FRED HUTCHINSON CANC RES CTR, DIV CLIN RES, HUMAN IMMUNOGENET PROGRAM, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR039153, R29AR039282] Funding Source: NIH RePORTER; NIAMS NIH HHS [R29 AR39282, AR39153] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; BIJLSMA JWJ, 1992, AM J REPROD IMMUNOL, V28, P231, DOI 10.1111/j.1600-0897.1992.tb00800.x; BROWN JH, 1988, NATURE, V332, P845, DOI 10.1038/332845a0; BROWN JH, 1988, NATURE, V333, P786, DOI 10.1038/333786a0; CALIN A, 1989, ARTHRITIS RHEUM, V32, P1221, DOI 10.1002/anr.1780321006; COMBE B, 1985, AM J MED, V78, P920, DOI 10.1016/0002-9343(85)90213-X; GILBERT M, 1964, JAMA-J AM MED ASSOC, V190, P235; HANSEN JA, 1990, CRIT REV IMMUNOL, V10, P307; HARRIS ED, 1990, NEW ENGL J MED, V322, P1277, DOI 10.1056/nejm199005033221805; Hench P.S., 1938, P STAFF M MAYO CLIN, V13, P161; LOKE YW, 1991, CURR OPIN IMMUNOL, V3, P762, DOI 10.1016/0952-7915(91)90110-M; MOREL C, 1990, HUM IMMUNOL, V29, P64, DOI 10.1016/0198-8859(90)90070-6; MORINPAPUNEN L, 1984, MED BIOL, V62, P323; MOYNIER M, 1987, ARTHRITIS RHEUM, V30, P375, DOI 10.1002/art.1780300403; NEELY NT, 1977, TEX MED, V73, P59; NELSON JL, 1991, CRIT REV IMMUNOL, V10, P454; NISHIMURA Y, 1983, NATURE, V302, P67, DOI 10.1038/302067a0; OKA M, 1958, Acta Rheumatol Scand, V4, P243; OSTENSEN M, 1983, ARTHRITIS RHEUM, V26, P1155, DOI 10.1002/art.1780260915; OSTENSEN M, 1983, SCAND J RHEUMATOL, V12, P315, DOI 10.3109/03009748309098556; OTTENHOFF THM, 1986, NATURE, V322, P462, DOI 10.1038/322462a0; PAYNE R, 1957, ARCH INTERN MED, V99, P587, DOI 10.1001/archinte.1957.00260040087010; Persellin R H, 1976, Bull Rheum Dis, V27, P922; PERSELLIN R H, 1982, Arthritis and Rheumatism, V25, pS6; PETERSDORF EW, 1991, IMMUNOGENETICS, V33, P267; PETERSDORF EW, 1991, TISSUE ANTIGENS, V38, P169, DOI 10.1111/j.1399-0039.1991.tb01891.x; PINALS RS, 1981, ARTHRITIS RHEUM, V24, P1308, DOI 10.1002/art.1780241012; Ray JG., 1977, DHEW PUBLICATION; REDMAN CWG, 1987, IMMUNOREGULATION FET, P210; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SALGAME P, 1991, P NATL ACAD SCI USA, V88, P2598, DOI 10.1073/pnas.88.6.2598; SANY J, 1982, ARTHRITIS RHEUM, V25, P17, DOI 10.1002/art.1780250103; SCHARF SJ, 1986, SCIENCE, V233, P1076, DOI 10.1126/science.3461561; STEINMAN L, 1981, P NATL ACAD SCI-BIOL, V78, P7111, DOI 10.1073/pnas.78.11.7111; SUCIUFOCA N, 1983, P NATL ACAD SCI-BIOL, V80, P830, DOI 10.1073/pnas.80.3.830; VANZEBEN D, 1991, ARTHRITIS RHEUM, V34, P822, DOI 10.1002/art.1780340707; VONBEROLDINGEN CH, 1989, PCR TECHNOLOGY PRINC, P20; WALDOR MK, 1983, P NATL ACAD SCI-BIOL, V80, P2713, DOI 10.1073/pnas.80.9.2713; WEYAND CM, 1992, ANN INTERN MED, V117, P801, DOI 10.7326/0003-4819-117-10-801; WINCHESTER R, 1992, RHEUM DIS CLIN N AM, V18, P761; WOLFSON W Q, 1951, J Mich State Med Soc, V50, P1019; WOOLEY PH, 1985, J IMMUNOL, V134, P2366; ZEGER SL, 1986, BIOMETRICS, V42, P121, DOI 10.2307/2531248	44	241	257	0	6	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	AUG 12	1993	329	7					466	471		10.1056/NEJM199308123290704	http://dx.doi.org/10.1056/NEJM199308123290704			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LR443	8332151				2022-12-01	WOS:A1993LR44300004
J	FISHBEYN, VA; NORTON, JA; BENYA, RV; PISEGNA, JR; VENZON, DJ; METZ, DC; JENSEN, RT				FISHBEYN, VA; NORTON, JA; BENYA, RV; PISEGNA, JR; VENZON, DJ; METZ, DC; JENSEN, RT			ASSESSMENT AND PREDICTION OF LONG-TERM CURE IN PATIENTS WITH THE ZOLLINGER-ELLISON SYNDROME - THE BEST APPROACH	ANNALS OF INTERNAL MEDICINE			English	Article						ZOLLINGER-ELLISON SYNDROME; GASTRINOMA; SECRETIN; GASTRIC ACIDITY DETERMINATION; GASTRIN	ISLET CELL TUMORS; GASTRINOMAS; MANAGEMENT; RESECTION; LOCALIZATION; DIAGNOSIS; ANGIOGRAPHY; EXCISION; SECRETIN; SURGERY	Objective: To identify the best method for determining freedom from disease after gastrinoma resection and for predicting long-term disease-free status in patients with the Zollinger-Ellison syndrome. Design: Prospective study in consecutive patients. Setting: Referral-based clinical research center. Patients: Eighty-one consecutive patients with the Zollinger-Ellison syndrome who underwent surgical exploration for gastrinoma resection. Intervention: Patients were evaluated after gastrinoma resection, before discharge, 3 to 6 months after surgery, and yearly thereafter. Evaluation included secretin provocative testing and fasting serum gastrin determinations. Follow-up examinations after the initial postoperative evaluations included a clinical assessment, acid secretion studies, a calcium provocative test, and various imaging studies. Measurements and Main Results. Most patients (96%) had gastrinomas. Freedom from disease was defined by improved symptoms, reduced acid output and antisecretory drug requirements, and a normal gastrin level, normal imaging studies, and negative gastrin provocative studies. Fifty-two percent of patients (n = 42) were disease-free immediately after surgery, 44% at 3 to 6 months, 42% at 1 year, and 35% by 5 years (mean follow-up, 39 months). The secretin provocative test was the first test to become positive in 45% of patients with a recurrence, the serum gastrin determination was the first test to become positive in 36%, and both tests became positive at the same time in 18%. No recurrence was first detected by imaging studies or by calcium provocative testing. Fasting serum gastrin levels and secretin provocative test results at different postoperative times can be used to predict the probability of a patient remaining disease free at 3 years. Patients with a normal gastrin level and a normal secretin provocative test immediately after surgery had a 3-year disease-free probability of 75%, and normal results on both tests at 6 months, 1 year, and 2 years yielded respective probabilities of 88%, 95%, and 100%. Conclusions: Both the secretin provocative test and fasting serum gastrin determination are necessary for the early diagnosis of cases of recurrent disease after gastrinoma resection. The calcium provocative test and imaging studies do not detect any recurrences first. Fasting serum gastrin determinations and secretin provocative testing at different postoperative times can be used to predict the probability of a patient remaining disease free at 3 years.	NIH, BLDG 10, ROOM 9C-103, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA			Venzon, David J/B-3078-2008		NIDDK NIH HHS [P30 DK041301] Funding Source: Medline; RRD VA [I01 RX000194] Funding Source: Medline; BLRD VA [I01 BX004560] Funding Source: Medline	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); RRD VA; BLRD VA		ANDERSEN DK, 1989, ANN SURG, V210, P685, DOI 10.1097/00000658-198912000-00001; BARDRAM L, 1988, GASTROINTESTINAL APU; BONFILS S, 1989, GASTROENTEROL INT, V2, P9; BROWN WB, 1977, BIOMEDICAL INTRO, P150; CREUTZFELDT W, 1975, HUM PATHOL, V6, P47, DOI 10.1016/S0046-8177(75)80109-2; DAWSONSANDERS B, 1990, BASIC CLIN BIOSTATIC; DELCORE R, 1988, ANN SURG, V208, P291, DOI 10.1097/00000658-198809000-00006; DEVENEY CW, 1983, ANN SURG, V198, P546, DOI 10.1097/00000658-198310000-00015; DIEPSTRATEN A, 1990, BRIT J SURG, V77, P1403, DOI 10.1002/bjs.1800771226; ELLISON EC, 1987, AM J MED, V82, P17, DOI 10.1016/0002-9343(87)90423-2; ELLISON EH, 1964, ANN SURG, V160, P512, DOI 10.1097/00000658-196409000-00013; FELDMAN M, 1987, GASTROENTEROLOGY, V93, P59, DOI 10.1016/0016-5085(87)90314-3; FOX PS, 1974, SURG CLIN N AM, V54, P395; FRUCHT H, 1989, RADIOLOGY, V171, P713, DOI 10.1148/radiology.171.3.2655004; FRUCHT H, 1989, ANN INTERN MED, V111, P713, DOI 10.7326/0003-4819-111-9-713; FRUCHT H, 1991, DIGEST DIS SCI, V36, P394, DOI 10.1007/BF01298865; FRUCHT H, 1990, GASTROENTEROLOGY, V99, P1622, DOI 10.1016/0016-5085(90)90466-E; HAHNE W F, 1991, Gastroenterology, V100, pA79; HOWARD TJ, 1990, ANN SURG, V211, P9, DOI 10.1097/00000658-199001000-00002; IMAMURA M, 1989, ANN SURG, V210, P710, DOI 10.1097/00000658-198912000-00004; JENSEN RT, 1983, ANN INTERN MED, V98, P59, DOI 10.7326/0003-4819-98-1-59; JENSEN RT, 1986, EXOCRINE PANCREAS BI, P727; JENSEN RT, 1991, TXB GASTROENTEROLOGY, P1912; JENSEN RT, 1991, STOMACH, P341; LONDON JF, 1991, RADIOLOGY, V178, P763, DOI 10.1148/radiology.178.3.1994415; MATON PN, 1989, GASTROENTEROL CLIN N, V18, P847; MATON PN, 1987, GASTROENTEROLOGY, V92, P913, DOI 10.1016/0016-5085(87)90964-4; MCCARTHY DM, 1980, NEW ENGL J MED, V302, P1344, DOI 10.1056/NEJM198006123022404; MIGNON M, 1986, WORLD J SURG, V10, P703, DOI 10.1007/BF01655562; NORTON JA, 1986, ANN SURG, V203, P352, DOI 10.1097/00000658-198604000-00003; NORTON JA, 1986, ANN SURG, V204, P468, DOI 10.1097/00000658-198610000-00015; NORTON JA, 1988, ANN SURG, V207, P160, DOI 10.1097/00000658-198802000-00008; NORTON JA, 1991, WORLD J SURG, V15, P151, DOI 10.1007/BF01658992; NORTON JA, 1992, ANN SURG, V215, P8, DOI 10.1097/00000658-199201000-00012; PIPELEERSMARICHAL M, 1990, NEW ENGL J MED, V322, P723, DOI 10.1056/NEJM199003153221103; PISEGNA JR, 1992, GASTROENTEROLOGY, V102, P767, DOI 10.1016/0016-5085(92)90157-T; RAUFMAN JP, 1983, GASTROENTEROLOGY, V84, P108; ROCHE A, 1982, RADIOLOGY, V145, P621, DOI 10.1148/radiology.145.3.6292994; ROTHMAN KJ, 1978, J CHRON DIS, V31, P557, DOI 10.1016/0021-9681(78)90043-7; SAEED ZA, 1989, GASTROENTEROLOGY, V96, P1393, DOI 10.1016/0016-5085(89)90504-0; STABILE BE, 1984, AM J SURG, V147, P25, DOI 10.1016/0002-9610(84)90029-1; STADIL F, 1979, CLIN ENDOCRINOL META, V8, P433, DOI 10.1016/S0300-595X(79)80051-1; THOMPSON JC, 1975, SURG GYNECOL OBSTET, V140, P721; THOMPSON NW, 1989, ANN SURG, V209, P396, DOI 10.1097/00000658-198904000-00002; VINAYEK R, 1990, GASTROENTEROLOGY, V99, P10, DOI 10.1016/0016-5085(90)91223-S; VINAYEK R, 1986, AM J MED, V81, P49, DOI 10.1016/0002-9343(86)90600-5; WANK SA, 1987, GASTROENTEROLOGY, V92, P905, DOI 10.1016/0016-5085(87)90963-2; WOLFE MM, 1985, ANN INTERN MED, V103, P215, DOI 10.7326/0003-4819-103-2-215; WOLFE MM, 1987, NEW ENGL J MED, V317, P1200, DOI 10.1056/NEJM198711053171907; ZOLLINGER RM, 1980, ANN SURG, V192, P422, DOI 10.1097/00000658-198009000-00018	50	112	113	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 1	1993	119	3					199	206		10.7326/0003-4819-119-3-199308010-00004	http://dx.doi.org/10.7326/0003-4819-119-3-199308010-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU903	8323088	Green Accepted			2022-12-01	WOS:A1993LU90300004
J	THOMPSON, CM; KOLESKE, AJ; CHAO, DM; YOUNG, RA				THOMPSON, CM; KOLESKE, AJ; CHAO, DM; YOUNG, RA			A MULTISUBUNIT COMPLEX-ASSOCIATED WITH THE RNA POLYMERASE-II CTD AND TATA-BINDING PROTEIN IN YEAST	CELL			English	Article							TRANSCRIPTION FACTOR-IIF; C-TERMINAL DOMAIN; SACCHAROMYCES-CEREVISIAE; PREINITIATION COMPLEX; LARGEST SUBUNIT; HEPTAPEPTIDE REPEAT; INITIATION-FACTOR; ESCHERICHIA-COLI; TFIID COMPLEX; ACTIVATION	We report genetic and biochemical evidence that the RNA polymerase II carboxy-terminal domain (CTD) interacts with a large multisubunit complex that contains TATA-binding protein (TBP) and is an integral part of the transcription initiation complex. The isolation and characterization of extragenic suppressors of S. cerevisiae RNA polymerase II CTD truncation mutations led us to identify SRB2, SRB4, SRB5, and SRB6 as genes involved in CTD function in vivo. SRB2 was previously isolated and shown to encode a 23 kd TBP-binding protein. The four SRB proteins and a portion of cellular TBP are components of a high molecular weight multisubunit complex that is tightly bound to RNA polymerase II. This SRB-TBP complex binds specifically to recombinant CTD protein. In vitro transcription and template commitment assays confirm that SRB2 and SRB5 are components of a functional preinitiation complex and are required for efficient transcription initiation.	MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	THOMPSON, CM (corresponding author), WHITEHEAD INST BIOMED RES, 9 CAMBRIDGE CTR, CAMBRIDGE, MA 02142 USA.		Young, Richard A/F-6495-2012	Young, Richard A/0000-0001-8855-8647; Chao, David/0000-0001-9198-337X				ALANI E, 1987, GENETICS, V116, P541, DOI 10.1534/genetics.112.541.test; ALLISON LA, 1988, MOL CELL BIOL, V8, P321, DOI 10.1128/MCB.8.1.321; ALLISON LA, 1989, P NATL ACAD SCI USA, V86, P2794, DOI 10.1073/pnas.86.8.2794; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1016/S0022-2836(05)80360-2; BARTOLOMEI MS, 1988, MOL CELL BIOL, V8, P330, DOI 10.1128/MCB.8.1.330; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; BOEKE JD, 1987, METHOD ENZYMOL, V154, P164; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P5086, DOI 10.1128/MCB.8.12.5086; BUERMEYER AB, 1992, MOL CELL BIOL, V12, P2250, DOI 10.1128/MCB.12.5.2250; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1991, P NATL ACAD SCI USA, V88, P7509, DOI 10.1073/pnas.88.17.7509; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURTON ZF, 1988, MOL CELL BIOL, V8, P1602, DOI 10.1128/MCB.8.4.1602; CADENA DL, 1987, J BIOL CHEM, V262, P12468; CHASMAN DI, 1989, MOL CELL BIOL, V9, P4746, DOI 10.1128/MCB.9.11.4746; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; COMAI L, 1992, CELL, V68, P965, DOI 10.1016/0092-8674(92)90039-F; CONAWAY RC, 1991, P NATL ACAD SCI USA, V88, P6205, DOI 10.1073/pnas.88.14.6205; CONAWAY RC, 1992, J BIOL CHEM, V267, P8464; CORDEN JL, 1990, TRENDS BIOCHEM SCI, V15, P383, DOI 10.1016/0968-0004(90)90236-5; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; ELLEDGE SJ, 1988, GENE, V70, P303, DOI 10.1016/0378-1119(88)90202-8; FEAVER WJ, 1991, J BIOL CHEM, V266, P19000; FLANAGAN PM, 1990, J BIOL CHEM, V265, P11105; FLORES O, 1988, J BIOL CHEM, V263, P10812; FLORES O, 1991, P NATL ACAD SCI USA, V88, P9999, DOI 10.1073/pnas.88.22.9999; GERARD M, 1991, J BIOL CHEM, V266, P20940; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; HA I, 1991, NATURE, V352, P689, DOI 10.1038/352689a0; HANAHAN D, 1991, METHOD ENZYMOL, V204, P63; HARLOW E, 1989, ANTIBODIES LABORATOR; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KELLEHER RJ, 1992, GENE DEV, V6, P296, DOI 10.1101/gad.6.2.296; KOLESKE AJ, 1992, CELL, V69, P883, DOI 10.1016/0092-8674(92)90298-Q; KOLODZIEJ PA, 1990, MOL CELL BIOL, V10, P1915, DOI 10.1128/MCB.10.5.1915; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAYBOURN PJ, 1990, J BIOL CHEM, V265, P13165; LIAO SM, 1991, GENE DEV, V5, P2431, DOI 10.1101/gad.5.12b.2431; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; LU H, 1991, P NATL ACAD SCI USA, V88, P10004, DOI 10.1073/pnas.88.22.10004; LUE NF, 1989, SCIENCE, V246, P661, DOI 10.1126/science.2510298; NONET M, 1987, MOL CELL BIOL, V7, P1602, DOI 10.1128/MCB.7.5.1602; NONET M, 1987, CELL, V50, P909, DOI 10.1016/0092-8674(87)90517-4; NONET ML, 1989, GENETICS, V123, P715; PETERSON CL, 1991, CELL, V64, P1135, DOI 10.1016/0092-8674(91)90268-4; PETERSON MG, 1990, SCIENCE, V248, P1625, DOI 10.1126/science.2363050; PHILIPPSEN P, 1991, METHOD ENZYMOL, V194, P169; PINTO I, 1992, CELL, V68, P977, DOI 10.1016/0092-8674(92)90040-J; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SAADOGO M, 1990, ANNU REV BIOCHEM, V59, P711; Sambrook J., 1989, MOL CLONING LAB MANU; SAMUELS M, 1982, J BIOL CHEM, V267, P679; SAYRE MH, 1992, J BIOL CHEM, V267, P23376; SCAFE C, 1990, NATURE, V347, P491, DOI 10.1038/347491a0; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SERIZAWA H, 1992, P NATL ACAD SCI USA, V89, P7476, DOI 10.1073/pnas.89.16.7476; SHARP PA, 1991, NATURE, V351, P16, DOI 10.1038/351016d0; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; TAGGART AKP, 1992, CELL, V71, P1015, DOI 10.1016/0092-8674(92)90396-T; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; THOMPSON NE, 1989, J BIOL CHEM, V264, P11511; TIMMERS HTM, 1991, GENE DEV, V5, P1946, DOI 10.1101/gad.5.11.1946; TSCHOCHNER H, 1992, P NATL ACAD SCI USA, V89, P11292, DOI 10.1073/pnas.89.23.11292; USHEVA A, 1992, CELL, V69, P871, DOI 10.1016/0092-8674(92)90297-P; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V; WOONTNER M, 1991, MOL CELL BIOL, V11, P4555, DOI 10.1128/MCB.11.9.4555; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6; ZEHRING WA, 1988, P NATL ACAD SCI USA, V85, P3698, DOI 10.1073/pnas.85.11.3698; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	80	403	416	0	11	CELL PRESS	CAMBRIDGE	600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 2	1993	73	7					1361	1375		10.1016/0092-8674(93)90362-T	http://dx.doi.org/10.1016/0092-8674(93)90362-T			15	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LL209	8324825				2022-12-01	WOS:A1993LL20900011
J	JAMES, GL; GOLDSTEIN, JL; BROWN, MS; RAWSON, TE; SOMERS, TC; MCDOWELL, RS; CROWLEY, CW; LUCAS, BK; LEVINSON, AD; MARSTERS, JC				JAMES, GL; GOLDSTEIN, JL; BROWN, MS; RAWSON, TE; SOMERS, TC; MCDOWELL, RS; CROWLEY, CW; LUCAS, BK; LEVINSON, AD; MARSTERS, JC			BENZODIAZEPINE PEPTIDOMIMETICS - POTENT INHIBITORS OF RAS FARNESYLATION IN ANIMAL-CELLS	SCIENCE			English	Article							P21RAS PROTEIN FARNESYLTRANSFERASE; NON-PEPTIDE LIGANDS; POSTTRANSLATIONAL MODIFICATION; ALPHA-SUBUNIT; EXPRESSION; TRANSFORMATION; REQUIREMENT; ISOPRENOIDS; RESOLUTION; RECEPTORS	Oncogenic Ras proteins transform animal cells to a malignant phenotype only when modified by farnesyl residues attached to cysteines near their carboxyl termini. The farnesyltransferase that catalyzes this reaction recognizes tetrapeptides of the sequence CAAX, where C is cysteine, A is an aliphatic amino acid, and X is a carboxyl-terminal methionine or serine. Replacement of the two aliphatic residues with a benzodiazepine-based mimic of a peptide turn generated potent inhibitors of farnesyltransferase [50 percent inhibitory concentration (IC50) < 1 nM]. Unlike tetrapeptides, the benzodiazepine peptidomimetics enter cells and block attachment of farnesyl to Ras, nuclear lamins, and several other proteins. At micromolar concentrations, these inhibitors restored a normal growth pattern to Ras-transformed cells. The benzodiazepine peptidomimetics may be useful in the design of treatments for tumors in which oncogenic Ras proteins contribute to abnormal growth, such as that of the colon, lung, and pancreas.	GENENTECH INC, DEPT BIOORGAN CHEM, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT CELL GENET, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech	JAMES, GL (corresponding author), UNIV TEXAS, SW MED CTR, DEPT MOLEC GENET, DALLAS, TX 75235 USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN FH, 1979, ACTA CRYSTALLOGR B, V35, P2331, DOI 10.1107/S0567740879009249; Ball J B, 1990, J Mol Recognit, V3, P55, DOI 10.1002/jmr.300030202; BARANY G, 1980, PEPTIDES ANAL SYNTHE, V2, P1; BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BARSAGI D, 1987, J CELL PHYSIOL, P69; BOCK MG, 1987, J ORG CHEM, V52, P3232, DOI 10.1021/jo00391a010; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; BROWN MS, 1992, P NATL ACAD SCI USA, V89, P8313, DOI 10.1073/pnas.89.17.8313; BROWN MS, 1978, J BIOL CHEM, V253, P1121; BUNDGAARD H, 1985, DESIGN PRODRUGS, P1; CASEY PJ, 1989, P NATL ACAD SCI USA, V86, P8323, DOI 10.1073/pnas.86.21.8323; CASEY PJ, 1991, P NATL ACAD SCI USA, V88, P8631, DOI 10.1073/pnas.88.19.8631; CHEN WJ, 1991, CELL, V66, P327, DOI 10.1016/0092-8674(91)90622-6; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; COX A D, 1992, Critical Reviews in Oncogenesis, V3, P365; EVANS BE, 1988, J MED CHEM, V31, P2235, DOI 10.1021/jm00120a002; Farmer P. S., 1980, DRUG DESIGN, VX, P119; FARNSWORTH CC, 1989, J BIOL CHEM, V264, P20422; FARNSWORTH CC, 1990, SCIENCE, V247, P320, DOI 10.1126/science.2296721; FAUST J, 1987, J BIOL CHEM, V262, P1996; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERAMISCO JR, 1985, NATURE, V314, P639, DOI 10.1038/314639a0; FREIDINGER RM, 1989, TRENDS PHARMACOL SCI, V10, P270, DOI 10.1016/0165-6147(89)90026-6; GIBBS JB, 1991, CELL, V65, P1, DOI 10.1016/0092-8674(91)90352-Y; GIBBS JB, 1993, J BIOL CHEM, V268, P7617; GOLDSTEIN JL, 1991, J BIOL CHEM, V266, P15575; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HARA M, 1993, P NATL ACAD SCI USA, V90, P2281, DOI 10.1073/pnas.90.6.2281; HEILMEYER LMG, 1992, P NATL ACAD SCI USA, V89, P9554, DOI 10.1073/pnas.89.20.9554; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; JAMES GE, UNPUB; KIM CM, 1992, J BIOL CHEM, V267, P23113; KITTS PA, 1990, NUCLEIC ACIDS RES, V18, P5667, DOI 10.1093/nar/18.19.5667; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Luckow VA, 1992, BACULOVIRUS EXPRESSI; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MOORES SL, 1991, J BIOL CHEM, V266, P14603; MORGAN BA, 1989, ANNU REP MED CHEM, V24, P243; OMURA S, 1993, J ANTIBIOT, V46, P222, DOI 10.7164/antibiotics.46.222; POMPLIANO DL, 1992, BIOCHEMISTRY-US, V31, P3800, DOI 10.1021/bi00130a010; REESE JH, 1991, MOL CELL BIOCHEM, V104, P109; REISS Y, 1990, Methods (Orlando), V1, P241, DOI 10.1016/S1046-2023(05)80323-8; REISS Y, 1992, J BIOL CHEM, V267, P6403; REISS Y, 1991, P NATL ACAD SCI USA, V88, P732, DOI 10.1073/pnas.88.3.732; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RILLING HC, 1990, SCIENCE, V247, P318, DOI 10.1126/science.2296720; SCHAFER WR, 1992, ANNU REV GENET, V26, P209, DOI 10.1146/annurev.ge.26.120192.001233; SCHAFER WR, 1989, SCIENCE, V245, P379, DOI 10.1126/science.2569235; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SEEBURG PH, 1984, NATURE, V312, P71, DOI 10.1038/312071a0; SHIOMI K, 1993, J ANTIBIOT, V46, P229, DOI 10.7164/antibiotics.46.229; SMITH MR, 1986, NATURE, V320, P540, DOI 10.1038/320540a0; STACEY DW, 1991, MOL CELL BIOL, V11, P4053, DOI 10.1128/MCB.11.8.4053; STEVENS RC, 1990, BIOCHEMISTRY-US, V29, P7691, DOI 10.1021/bi00485a019; TAKAI Y, 1992, INT REV CYTOL, V133, P187, DOI 10.1016/S0074-7696(08)61861-6; VANDERPYL D, 1992, J ANTIBIOT, V45, P1802; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055	60	618	701	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JUN 25	1993	260	5116					1937	1942		10.1126/science.8316834	http://dx.doi.org/10.1126/science.8316834			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)	Science & Technology - Other Topics	LJ349	8316834				2022-12-01	WOS:A1993LJ34900042
J	NORDENTOFT, M; BREUM, L; MUNCK, LK; NORDESTGAARD, AG; HUNDING, A; BJAELDAGER, PAL				NORDENTOFT, M; BREUM, L; MUNCK, LK; NORDESTGAARD, AG; HUNDING, A; BJAELDAGER, PAL			HIGH MORTALITY BY NATURAL AND UNNATURAL CAUSES - A 10-YEAR FOLLOW-UP-STUDY OF PATIENTS ADMITTED TO A POISONING TREATMENT CENTER AFTER SUICIDE ATTEMPTS	BRITISH MEDICAL JOURNAL			English	Article							MODELS; DEATH	Objective-To describe mortality by suicide and other causes of death in a group of patients who attempted suicide, and to identify predictive factors. Design-10 year follow up study based on records of suicide attempters in 1980. Setting-Poisoning treatment centre at a general hospital. Subjects-974 patients aged 15 and over referred to the poisoning treatment centre after deliberate self poisoning. Main outcome measures-Death by different causes registered in the Danish death cause register. Results-In 10 years of follow up 306 patients died: 103 by suicide, 131 from natural causes, and 31 by accidents; five were murdered, and in 36 cases the cause of death was uncertain. The standard mortality ratio was 550. Cause specific standardised mortality rates were 2960 for suicide, 236 for natural causes, 1256 for accidents, and 5459 for uncertain causes. In a Cox regression analysis, high risk factors for subsequent suicide were: more than one previous suicide attempt (relative risk 2.25), living alone (2.28), and age (1.03 per year). Predictors of death by natural causes were receiving a pension (1.69), drug misuse (2.72), more than one previous suicide attempt (2.25), age (1.06 per year), and male sex (2.49). The group of patients fulfilling at least one high risk criterion for later suicide differed significantly from the rest of the patient group in incidence of suicide, but both sensitivity and specificity were low. Conclusions-Most patients who attempted suicide were at high risk of succeeding because the risk factors, though significant, are not very specific. A strategy to prevent suicide must be directed toward the majority of those who attempt suicide.	BISPEBJERG HOSP,DEPT MED C,COPENHAGEN,DENMARK; BISPEBJERG HOSP,CTR POISONING TREATMENT,COPENHAGEN,DENMARK; UNIV COPENHAGEN,INST CHEM,DK-1168 COPENHAGEN,DENMARK	University of Copenhagen; Bispebjerg Hospital; University of Copenhagen; Bispebjerg Hospital; University of Copenhagen	NORDENTOFT, M (corresponding author), UNIV COPENHAGEN,BISPEBJERG HOSP,DEPT PSYCHIAT,DK-2400 COPENHAGEN NV,DENMARK.		Nordentoft, Merete/AAH-3253-2019	Nordentoft, Merete/0000-0003-4895-7023; Munck, Lars Kristian/0000-0002-5014-8260				ANDERSEN PK, 1988, STATISTISK ANAL OVER; Bjaeldager P A, 1983, Ugeskr Laeger, V145, P2833; BRATFOS O, 1971, ACTA PSYCHIAT SCAND, V38, P38; BRESLOW NE, 1975, J CHRON DIS, V28, P289, DOI 10.1016/0021-9681(75)90010-7; COX DR, 1972, J R STAT SOC B, V34, P187; CULLBERG J, 1988, ACTA PSYCHIAT SCAND, V77, P598, DOI 10.1111/j.1600-0447.1988.tb05173.x; DAHLGREN KG, 1977, SUICIDE LIFE-THREAT, V7, P75; EGMOND EJ, 1989, SUICIDE ITS PREVENTI; EKEBERG O, 1991, ACTA PSYCHIAT SCAND, V83, P432, DOI 10.1111/j.1600-0447.1991.tb05570.x; ETTLINGER RW, 1975, ACTA PSYCHIATR SCA S, V260, P84; GOODWIN JS, 1987, JAMA-J AM MED ASSOC, V258, P3125, DOI 10.1001/jama.258.21.3125; HAWTON K, 1988, BRIT J PSYCHIAT, V152, P359, DOI 10.1192/bjp.152.3.359; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Kreitman N., 1977, PARASUICIDE; LESTER D, 1992, ACTA PSYCHIAT SCAND, V85, P15, DOI 10.1111/j.1600-0447.1992.tb01435.x; NIELSEN B, 1990, ACTA PSYCHIAT SCAND, V81, P250, DOI 10.1111/j.1600-0447.1990.tb06490.x; PAERREGAARD G, 1975, SUICIDE, V5, P140; RYGNESTAD T, 1988, ACTA PSYCHIAT SCAND, V77, P328, DOI 10.1111/j.1600-0447.1988.tb05129.x; SUNDQVISTSTENSM.UB, 1988, OPUSC MED, V3, P71; SUOKAS J, 1991, ACTA PSYCHIAT SCAND, V84, P545, DOI 10.1111/j.1600-0447.1991.tb03191.x; 1982, CAUSES DEATH DENMARK; 1981, COPENHAGEN STATISTIC; 1991, WHO1990 WORLD HLTH S; 1991, 1989 DAN NAT BUR STA	24	184	184	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 19	1993	306	6893					1637	1641		10.1136/bmj.306.6893.1637	http://dx.doi.org/10.1136/bmj.306.6893.1637			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LJ337	8324430	Green Published, Bronze			2022-12-01	WOS:A1993LJ33700016
J	SWAI, ABM; LUTALE, JL; MCLARTY, DG				SWAI, ABM; LUTALE, JL; MCLARTY, DG			PROSPECTIVE-STUDY OF INCIDENCE OF JUVENILE DIABETES-MELLITUS OVER 10 YEARS IN DAR-ES-SALAAM, TANZANIA	BRITISH MEDICAL JOURNAL			English	Article							TROPICAL AFRICA; EPIDEMIOLOGY; CHILDHOOD; IDDM	Objective-To ascertain the annual incidence of diabetes requiring treatment with insulin in children and adolescents aged 0-19 years in Dar es Salaam, Tanzania, during a 10 year period from 1 january 1982 to 31 December 1991. Design-Prospective registration at a major urban hospital of all patients with newly diagnosed diabetes who were resident in Dar es Salaam. Setting-Muhimbili Medical Centre, Dar es Salaam, Tanzania. Patients-86 patients: 45 male, 41 female. Results-The annual incidence of juvenile diabetes for both sexes was 1.5 per 100000 population aged 0-19 years (95% confidence interval 1.3 to 1.7). Incidence per 100 000 population per year increased with age: 0.6 (0.0 to 0.13) in the age group 0-4 years, 0.5 (0.3 to 0.7) at 5-9 years, 2.2 (1.8 to 2.6) at 10-14 years, and 3.4 (2.9 to 3.9) at 15-19 years. Conclusion-Juvenile diabetes mellitus is fairly rare in sub-Saharan Africa. If environmental factors such as infection and material deprivation were important determinants of insulin dependent diabetes in Africans, as they may be in Europeans, much higher rates would have been expected unless genetic factors possibly exert a protective role. The eightfold greater incidence in African Americans than in Tanzanians may be related to greater genetic admixture in African Americans with people from countries in Europe with a high incidence.			SWAI, ABM (corresponding author), UNIV DAR ES SALAAM,MUHIMBILI MED CTR,DEPT MED,POB 65001,DAR ES SALAAM,TANZANIA.							BRAHAMS D, 1990, LANCET, V335, P652, DOI 10.1016/0140-6736(90)90427-7; BRAHAMS D, 1990, LANCET, V335, P595, DOI 10.1016/0140-6736(90)90366-D; CROW YJ, 1991, BRIT MED J, V303, P158, DOI 10.1136/bmj.303.6795.158; Diabetes Epidemiology Research International Group, 1988, DIABETES, V37, P1113; EKOE JM, 1992, INT TXB DIABETES MEL, P129; ELAMIN A, 1989, DIABETES CARE, V12, P430, DOI 10.2337/diacare.12.6.430; MAKAME MH, 1992, DIABETIC MED, V9, P571, DOI 10.1111/j.1464-5491.1992.tb01841.x; MCLARTY DG, 1989, DIABETIC MED, V6, P762, DOI 10.1111/j.1464-5491.1989.tb01275.x; METCALFE MA, 1991, BRIT MED J, V302, P443, DOI 10.1136/bmj.302.6774.443; PAPOZ L, 1991, ACTA DIABETOL, V28, P140, DOI 10.1007/BF00579716; REWERS M, 1988, World Health Statistics Quarterly, V41, P179; RWIZA HT, 1986, DIABETIC MED, V3, P1811; SWAI ABM, 1990, BMJ-BRIT MED J, V300, P1103, DOI 10.1136/bmj.300.6732.1103; TROWELL HC, 1981, W DISEASES THEIR EME, P25; TULL ES, 1991, DIABETES CARE, V14, P558, DOI 10.2337/diacare.14.7.558; TULL ES, 1992, DIABETIC MED, V9, P13	16	48	49	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1570	1572		10.1136/bmj.306.6892.1570	http://dx.doi.org/10.1136/bmj.306.6892.1570			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329915	Bronze, Green Published			2022-12-01	WOS:A1993LH12800015
J	LIPES, MA; ROSENZWEIG, A; TAN, KN; TANIGAWA, G; LADD, D; SEIDMAN, JG; EISENBARTH, GS				LIPES, MA; ROSENZWEIG, A; TAN, KN; TANIGAWA, G; LADD, D; SEIDMAN, JG; EISENBARTH, GS			PROGRESSION TO DIABETES IN NONOBESE DIABETIC (NOD) MICE WITH TRANSGENIC T-CELL RECEPTORS	SCIENCE			English	Article							POLYMERASE CHAIN-REACTION; VARIABLE REGION GENES; BETA-CHAIN; I-E; CLONAL DELETION; LYMPHOCYTE-T; EXPRESSION; MOLECULES; ANTIBODY; ANTIGEN	The T cell receptor (TCR) requirements in the pathogenesis of insulin-dependent diabetes were examined with transgenic NOD mice bearing nondisease-related TCR alpha and beta chains. In both TCRbeta and TCRalphabeta transgenic NOD mice the beta chain transgene was expressed by >98% of peripheral T cells. The alpha chain transgene was also highly expressed. Insulitis developed in both sets of transgenic animals with most of the lymphocytes in the lesion expressing the transgenic beta chain and with depletion of the endogenous TCR V(beta) genes. Nonetheless, NOD animals transgenic for TCRbeta and TCRalphabeta developed diabetes similar to controls. Thus, skewing the TCR repertoire did not diminish autoimmune susceptibility in NOD mice.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,DEPT PATHOL,DIV PEDIAT ONCOL,BOSTON,MA 02115; HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,BOSTON,MA 02115; HARVARD UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT GENET,BOSTON,MA 02115; MASSACHUSETTS GEN HOSP,CARDIAC UNIT,BOSTON,MA 02114	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; Harvard University; Massachusetts General Hospital	LIPES, MA (corresponding author), JOSLIN DIABET CTR,DIV RES,BOSTON,MA 02215, USA.							BARTH RK, 1985, NATURE, V316, P517, DOI 10.1038/316517a0; BEHLKE MA, 1986, P NATL ACAD SCI USA, V83, P767, DOI 10.1073/pnas.83.3.767; BEHLKE MA, 1985, SCIENCE, V229, P566, DOI 10.1126/science.3875151; BILL J, 1989, J EXP MED, V169, P1405, DOI 10.1084/jem.169.4.1405; BOHME J, 1990, SCIENCE, V249, P293, DOI 10.1126/science.2115690; CANDEIAS S, 1991, P NATL ACAD SCI USA, V88, P6167, DOI 10.1073/pnas.88.14.6167; CASTANO L, 1990, ANNU REV IMMUNOL, V8, P647, DOI 10.1146/annurev.iy.08.040190.003243; CHIEN YH, 1984, NATURE, V309, P322, DOI 10.1038/309322a0; EISENBARTH GS, 1982, P NATL ACAD SCI-BIOL, V79, P5066, DOI 10.1073/pnas.79.16.5066; FENTON RG, 1988, SCIENCE, V241, P1089, DOI 10.1126/science.2970670; GLIMCHER LH, 1982, J EXP MED, V156, P640, DOI 10.1084/jem.156.2.640; HANENBERG H, 1989, DIABETOLOGIA, V32, P126, DOI 10.1007/BF00505185; HASKINS K, 1984, J EXP MED, V160, P452, DOI 10.1084/jem.160.2.452; KANAGAWA O, 1989, CELL IMMUNOL, V119, P412, DOI 10.1016/0008-8749(89)90255-4; KIM HS, 1988, NUCLEIC ACIDS RES, V16, P8887, DOI 10.1093/nar/16.18.8887; KRANZ DM, 1984, P NATL ACAD SCI-BIOL, V81, P573, DOI 10.1073/pnas.81.2.573; LEIDEN JM, 1986, MOL CELL BIOL, V6, P3207, DOI 10.1128/MCB.6.9.3207; LEO O, 1987, P NATL ACAD SCI USA, V84, P1374, DOI 10.1073/pnas.84.5.1374; LIPES MA, 1988, P NATL ACAD SCI USA, V85, P9704, DOI 10.1073/pnas.85.24.9704; LOH EY, 1989, SCIENCE, V243, P217, DOI 10.1126/science.2463672; LUND T, 1990, NATURE, V345, P727, DOI 10.1038/345727a0; MALISSEN M, 1984, CELL, V37, P1101, DOI 10.1016/0092-8674(84)90444-6; MCDUFFIE M, 1991, DIABETES, V40, P1555, DOI 10.2337/diabetes.40.11.1555; MCINTYRE BW, 1983, CELL, V34, P739, DOI 10.1016/0092-8674(83)90530-5; NAKANO N, 1991, J EXP MED, V173, P1091, DOI 10.1084/jem.173.5.1091; NISHIMOTO H, 1987, NATURE, V328, P432, DOI 10.1038/328432a0; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; OREILLY LA, 1991, EUR J IMMUNOL, V21, P1171, DOI 10.1002/eji.1830210512; REICH EP, 1989, NATURE, V341, P326, DOI 10.1038/341326a0; REICH EP, 1991, NATURE, V352, P88, DOI 10.1038/352088a0; REINHERZ EL, 1983, P NATL ACAD SCI-BIOL, V80, P4104, DOI 10.1073/pnas.80.13.4104; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SHIZURU JA, 1991, J EXP MED, V174, P633, DOI 10.1084/jem.174.3.633; WALKER R, 1988, DIABETES, V37, P1301, DOI 10.2337/diabetes.37.9.1301; WHITE J, 1989, J IMMUNOL, V143, P1822; WOODLAND D, 1990, SCIENCE, V247, P964, DOI 10.1126/science.1968289	36	57	58	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 19	1993	259	5098					1165	1169		10.1126/science.8267690	http://dx.doi.org/10.1126/science.8267690			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	KM917	8267690				2022-12-01	WOS:A1993KM91700040
J	SVENSSON, PJ; DAHLBACK, B				SVENSSON, PJ; DAHLBACK, B			RESISTANCE TO ACTIVATED PROTEIN-C AS A BASIS FOR VENOUS THROMBOSIS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLOOD-COAGULATION; C4B-BINDING PROTEIN; DEFICIENCY; DISEASE; DISORDERS	Background. In three families with various forms of venous thrombosis, we observed an apparently inherited poor response to the anticoagulant activated protein C (APC). The condition was due to a deficiency in a previously unrecognized anticoagulant factor that functioned as a cofactor to activated protein C. Methods. We conducted the present study to determine the prevalence of resistance to APC in patients with venous thrombosis. We compared 104 consecutive patients with venous thrombosis confirmed by objective tests with 130 controls. in addition, 211 members of 34 families of persons with resistance to APC were studied. The anticoagulant response to APC was measured with a modified version of the activated partial-thromboplastin time test; the results were expressed as APC ratios. Results. Forty-five percent of patients had a family history of thrombosis. A significant (P<0.001) difference in APC ratios was observed between the controls and the patients with thrombosis. For 33 percent of patients, the APC ratio was below the 5th percentile of the control values, although the results of the family studies suggested that the prevalence of APC resistance may be even higher (approximately 40 percent) in the patients with thrombosis. The inherited nature of the defect was confirmed in a majority of cases, and the family studies suggested the mode of inheritance to be autosomal dominant. The thrombosis-free survival of APC-resistant family members was significantly less than that of non-APC-resistant family members. Conclusions. There was a high prevalence of APC resistance among young persons with a history of venous thrombosis, and this resistance appeared to be inherited as an autosomal dominant trait.	LUND UNIV,MALMO GEN HOSP,DEPT CLIN CHEM,S-21401 MALMO,SWEDEN; LUND UNIV,MALMO GEN HOSP,DEPT COAGULAT DISORDERS,S-21401 MALMO,SWEDEN; LUND UNIV,MALMO GEN HOSP,DEPT MED,S-21401 MALMO,SWEDEN	Lund University; Lund University; Lund University				Dahlback, Bjorn/0000-0003-1546-0328				ALLAART CF, 1993, LANCET, V341, P134, DOI 10.1016/0140-6736(93)90003-Y; BAUER KA, 1991, SEMIN HEMATOL, V28, P10; BRIET E, 1988, PROTEIN C RELATED PR, P203; Broekmans AW, 1988, PROTEIN C RELATED PR, V3, P160; COMP PC, 1984, NEW ENGL J MED, V311, P1525, DOI 10.1056/NEJM198412133112401; DAHLBACK B, 1993, P NATL ACAD SCI USA, V90, P1004, DOI 10.1073/pnas.90.3.1004; DAHLBACK B, 1993, THROMB HAEMOSTASIS, V69, P978; DAHLBACK B, 1991, THROMB HAEMOSTASIS, V66, P49; DAHLBACK B, 1994, P NATL ACAD SCI USA, V91, P1396, DOI 10.1073/pnas.91.4.1396; DAHLBACK B, 1994, MOL BASIS BLOOD DISE, P599; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; ESMON CT, 1989, J BIOL CHEM, V264, P4743; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; GALLUS AS, 1973, LANCET, V2, P805; GRIFFIN JH, 1993, BLOOD, V82, P1989; GRIFFIN JH, 1981, J CLIN INVEST, V68, P1370, DOI 10.1172/JCI110385; GRUBER A, 1992, BLOOD, V79, P2340; HEIJBOER H, 1990, NEW ENGL J MED, V323, P1512, DOI 10.1056/NEJM199011293232202; KANE WH, 1988, BLOOD, V71, P539; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; MALM J, 1992, THROMB HAEMOSTASIS, V68, P7; MALM J, 1988, BRIT J HAEMATOL, V68, P437, DOI 10.1111/j.1365-2141.1988.tb04232.x; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MARLAR RA, 1990, SEMIN THROMB HEMOST, V16, P299, DOI 10.1055/s-2007-1002683; MILETICH JP, 1993, CELL, V72, P477, DOI 10.1016/0092-8674(93)90063-V; RAPAPORT SI, 1989, BLOOD, V73, P359; SCHWARZ HP, 1984, BLOOD, V64, P1297; TABERNERO MD, 1991, AM J HEMATOL, V36, P249, DOI 10.1002/ajh.2830360405	28	1134	1157	0	6	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 24	1994	330	8					517	522		10.1056/NEJM199402243300801	http://dx.doi.org/10.1056/NEJM199402243300801			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MX436	8302317				2022-12-01	WOS:A1994MX43600001
J	HARKINS, TT; GRISSOM, CB				HARKINS, TT; GRISSOM, CB			MAGNETIC-FIELD EFFECTS ON B-12 ETHANOLAMINE AMMONIA-LYASE - EVIDENCE FOR A RADICAL MECHANISM	SCIENCE			English	Article							BOND-DISSOCIATION ENERGY; CO-C BOND; BIOLOGICAL CATALYSIS; REACTION CENTERS; ADENOSYLCOBALAMIN; THERMOLYSIS; ENZYMES; SPIN; INTERMEDIATE; COENZYME-B12	A change in radical pair recombination rates is one of the few mechanisms by which a magnetic field can interact with a biological system. The kinetic parameter V-max/K-m (where K-m is the Michaelis constant) for the coenzyme B-12-dependent enzyme ethanolamine ammonia lyase was decreased 25 percent by a static magnetic field near 0.1 tesla (1000 gauss) with unlabeled ethanolamine and decreased 60 percent near 0.15 tesla with perdeuterated ethanolamine. This effect is likely caused by a magnetic field-induced change in intersystem crossing rates between the singlet and triplet spin states in the {cob(II)alamin:5'-deoxyadenosyl radical} spin-correlated radical pair.	UNIV UTAH,DEPT CHEM,SALT LAKE CITY,UT 84112	Utah System of Higher Education; University of Utah					NIEHS NIH HHS [ES05728] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES005728] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BABIOR BM, 1969, J BIOL CHEM, V244, P449; BABIOR BM, 1971, J BIOL CHEM, V246, P6064; BABLOR BM, 1991, B12, pCH10; BLANKENSHIP RE, 1981, ACCOUNTS CHEM RES, V14, P163, DOI 10.1021/ar00066a001; BOXER SG, 1982, J AM CHEM SOC, V104, P1452, DOI 10.1021/ja00369a062; BUCHACHENKO AL, 1991, ACCOUNTS CHEM RES, V24, P177, DOI 10.1021/ar00006a004; CHAGOVETZ AM, 1993, J AM CHEM SOC, V115, P12152, DOI 10.1021/ja00078a063; CLELAND WW, 1982, CRC CR REV BIOCH MOL, V13, P385; DIZIOL P, 1980, EUR J BIOCHEM, V106, P211; DOLPHIN D, 1991, B12, V2; DOLPHIN D, 1991, B12, V1; DOUBLEDAY C, 1989, ACCOUNTS CHEM RES, V22, P199, DOI 10.1021/ar00162a001; FAUST LP, 1992, ARCH BIOCHEM BIOPHYS, V294, P50, DOI 10.1016/0003-9861(92)90135-J; FINKE RG, 1984, INORG CHEM, V23, P3041, DOI 10.1021/ic00188a002; GENO MK, 1987, J CHEM SOC CHEM COMM, P1052, DOI 10.1039/c39870001052; HALPERN J, 1985, SCIENCE, V227, P869, DOI 10.1126/science.2857503; HARKINS TT, 1993, MAY AM SOC BIOCH MOL; HAY BP, 1987, J AM CHEM SOC, V109, P8012, DOI 10.1021/ja00260a011; HAY BP, 1986, J AM CHEM SOC, V108, P4820, DOI 10.1021/ja00276a020; HAYASHI H, 1990, PHOTOCHEM PHOTOBIOL, V1, P59; HOFF AJ, 1977, BIOCHIM BIOPHYS ACTA, V460, P547, DOI 10.1016/0005-2728(77)90094-9; HOLLAWAY MR, 1978, EUR J BIOCHEM, V82, P143, DOI 10.1111/j.1432-1033.1978.tb12005.x; HUMMEL K, 1989, J MOL CATAL, V54, P11; KAPLAN BH, 1968, J BIOL CHEM, V243, P1787; KIM SH, 1984, J AM CHEM SOC, V106, P8317; MCLAUCHLAN KA, 1991, MOL PHYS, V73, P241, DOI 10.1080/00268979100101181; OBRIEN RJ, 1985, J BIOL CHEM, V260, P6131; PRATT JM, 1985, CHEM SOC REV, V14, P161, DOI 10.1039/cs9851400161; ROBINTSON B, 1992, BIOCHEMISTRY-US, V31, P138; SALIKHOV KM, 1983, CHEM PHYS, V82, P163, DOI 10.1016/0301-0104(83)85354-3; SCHEPLER KL, 1975, BIOCHIM BIOPHYS ACTA, V397, P510, DOI 10.1016/0005-2744(75)90141-2; Schneider Z., 1987, COMPREHENSIVE B12; STEINER UE, 1989, CHEM REV, V89, P51, DOI 10.1021/cr00091a003; STEINER UE, 1990, PHOTOCHEM PHOTOBIOL, V4, P1; STUBBE J, 1988, BIOCHEMISTRY-US, V27, P3893, DOI 10.1021/bi00411a001; STUBBE JA, 1989, ANNU REV BIOCHEM, V58, P257; TURRO NJ, 1983, P NATL ACAD SCI USA, V80, P609, DOI 10.1073/pnas.80.2.609; TURRO NJ, 1984, ISOTOPES ORGANIC CHE; VANAG VK, 1988, IZV AN SSSR BIOL+, V2, P215; WEAVER JC, 1990, SCIENCE, V247, P459, DOI 10.1126/science.2300806; WESTERHOFF HV, 1986, P NATL ACAD SCI USA, V83, P4734, DOI 10.1073/pnas.83.13.4734	41	177	180	1	23	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 18	1994	263	5149					958	960		10.1126/science.8310292	http://dx.doi.org/10.1126/science.8310292			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MX165	8310292				2022-12-01	WOS:A1994MX16500032
J	AVINS, AL; WOODS, WJ; LINDAN, CP; HUDES, ES; CLARK, W; HULLEY, SB				AVINS, AL; WOODS, WJ; LINDAN, CP; HUDES, ES; CLARK, W; HULLEY, SB			HIV-INFECTION AND RISK BEHAVIORS AMONG HETEROSEXUALS IN ALCOHOL TREATMENT PROGRAMS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; ADDICTION SEVERITY INDEX; SEXUAL-BEHAVIOR; HOMOSEXUAL MEN; SAN-FRANCISCO; DRUG-USE; AIDS; COHORT; POPULATION; BELIEFS	Objective.-To measure the prevalence of human immunodeficiency virus (HIV) infection and high-risk behaviors among heterosexuals in alcohol treatment. Design.-Cross-sectional survey. Setting.-Five public alcohol treatment centers. Subjects.-Consecutive, sample of 888 heterosexual clients entering treatment between October 1990 and December 1991. Respondents were 51% black, 10% Hispanic, 33% white, and 76% male. The overall response rate was 68%. Measurements.-Structured interview and serotesting for HIV antibodies. Results.-The overall seroprevalence of HIV infection was 5% (95% confidence interval, 3% to 6%). There were no significant differences in rates of infection by age, gender, or race. The prevalence of infection in heterosexual respondents without a history of injection drug use was 3% in men and 4% in women, several times higher than published estimates from a similar community-based heterosexual sample. Unsafe sexual practices were common: 54% of respondents reported multiple sexual partners in the previous year, 97% of nonmonogamous respondents did not use condoms during all sexual encounters, and few respondents consistently asked new sexual partners about previous high-risk behaviors. Conclusions.-There is a substantial prevalence of HIV infection among heterosexual clients in San Francisco (Calif) alcohol treatment programs, much of which is not associated with injection drug use. Because of this and the high prevalence of unsafe sexual behaviors, there is a relatively high likelihood of heterosexual spread of HIV among the large population of clients seeking treatment for alcohol dependency. Interventions to prevent HIV spread should become a standard part of alcohol treatment programs.	SAN FRANCISCO GEN HOSP,DIV GEN INTERNAL MED,SAN FRANCISCO,CA 94110; SAN FRANCISCO DEPT PUBL HLTH,COMMUNITY SUBST ABUSE SERV,SAN FRANCISCO,CA 94105	San Francisco General Hospital Medical Center; San Francisco Department of Public Health	AVINS, AL (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT EPIDEMIOL & BIOSTAT,DIV CLIN EPIDEMIOL,74 NEW MONTGOMERY ST,SAN FRANCISCO,CA 94105, USA.				NIAAA NIH HHS [AA08328] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA008328] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		AVINS AL, 1993, AIDS, V7, P109, DOI 10.1097/00002030-199301000-00017; BAGASRA O, 1989, ALCOHOL CLIN EXP RES, V13, P636, DOI 10.1111/j.1530-0277.1989.tb00396.x; BAGASRA O, 1993, J INFECT DIS, V167, P789, DOI 10.1093/infdis/167.4.789; BAGNALL G, 1990, AIDS Care, V2, P309, DOI 10.1080/09540129008257746; BLYTH CR, 1986, J AM STAT ASSOC, V81, P843, DOI 10.2307/2289018; CATANIA JA, 1990, PSYCHOL BULL, V108, P339, DOI 10.1037/0033-2909.108.3.339; CRITCHLOW B, 1986, AM PSYCHOL, V41, P751, DOI 10.1037/0003-066X.41.7.751; CROWE LC, 1989, PSYCHOL BULL, V105, P374, DOI 10.1037/0033-2909.105.3.374; DONOVAN JE, 1985, J CONSULT CLIN PSYCH, V53, P890, DOI 10.1037/0022-006X.53.6.890; FULLILOVE MT, 1992, WESTERN J MED, V157, P32; HEARST N, 1988, JAMA-J AM MED ASSOC, V259, P2428, DOI 10.1001/jama.259.16.2428; HINGSON R, 1993, AM J PREV MED, V9, P62, DOI 10.1016/S0749-3797(18)30770-0; HINGSON RW, 1990, AM J PUBLIC HEALTH, V80, P295, DOI 10.2105/AJPH.80.3.295; HOLMES KK, 1990, AM J PUBLIC HEALTH, V80, P858, DOI 10.2105/AJPH.80.7.858; JACOBSON JM, 1992, J STUD ALCOHOL, V53, P76, DOI 10.15288/jsa.1992.53.76; LEIGH BC, 1990, J SEX RES, V27, P199, DOI 10.1080/00224499009551552; MAHLER J, IN PRESS AM J ADDICT; MCCUSKER J, 1990, J ACQ IMMUN DEF SYND, V3, P729; MCLELLAN AT, 1985, J NERV MENT DIS, V173, P412, DOI 10.1097/00005053-198507000-00005; MCLELLAN AT, 1980, J NERV MENT DIS, V168, P26, DOI 10.1097/00005053-198001000-00006; OSTROW DG, 1990, AIDS, V4, P759, DOI 10.1097/00002030-199008000-00007; PENKOWER L, 1991, AM J PUBLIC HEALTH, V81, P194, DOI 10.2105/AJPH.81.2.194; SCHLEIFER S, 1990, HOSP COMMUNITY PSYCH, V248, P249; SIEGEL K, 1989, SOC SCI MED, V28, P561, DOI 10.1016/0277-9536(89)90250-5; Snedecor G. W, 1989, STAT METHODS, V8th; STALL R, 1990, MED ANTHROPOL Q, V4, P115, DOI 10.1525/maq.1990.4.1.02a00070; STALL R, 1986, HEALTH EDUC QUART, V13, P359, DOI 10.1177/109019818601300407; TROCKI KF, 1991, J ACQ IMMUN DEF SYND, V4, P981; VALDISERRI RO, 1988, AM J PUBLIC HEALTH, V78, P801, DOI 10.2105/AJPH.78.7.801; WESTERBERG VS, 1992, AM J EPIDEMIOL, V135, P719, DOI 10.1093/oxfordjournals.aje.a116358; WESTERMEYER J, 1990, AM J DRUG ALCOHOL AB, V16, P47, DOI 10.3109/00952999009001571; ZUCKER RA, 1981, J STUD ALCOHOL, V42, P457, DOI 10.15288/jsa.1981.42.457; 1991, MMWR MORB MORTAL WKL, V40, P358; 1989, STATISTICAL ANAL SYS; 1993, STATA PC	35	101	102	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	1994	271	7					515	518		10.1001/jama.271.7.515	http://dx.doi.org/10.1001/jama.271.7.515			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MV423	8301765				2022-12-01	WOS:A1994MV42300033
J	DYKE, T; BROWN, N				DYKE, T; BROWN, N			HYPOXIA IN CHILDHOOD PNEUMONIA - BETTER DETECTION AND MORE OXYGEN NEEDED IN DEVELOPING-COUNTRIES	BRITISH MEDICAL JOURNAL			English	Article							PAPUA-NEW-GUINEA; SIGNS	Even though hypoxia is a major risk factor for death in children with acute respiratory infection in developing countries, oxygen is not part of first line treatment. Because oxygen is not readily available in developing countries it tends to be given to the most seriously ill children, whose outcome is poor. Oxygen might be useful if given earlier in the course of the disease. Clinical signs are not clear cut, however, though the presence of cyanosis and grunting together with a raised respiratory rate can significantly increase the detection of hypoxaemia. A simple oximeter would make detection easier, and oxygen concentrators are more cost effective than bottled oxygen. Ideally oxygen should be given to children in the early stages of clinical pneumonia to prevent deterioration.	UNIV PAPUA NEW GUINEA,FAC MED,DEPT PAEDIAT,BOROKO,PAPUA N GUINEA	University of Papua New Guinea	DYKE, T (corresponding author), UNIV PAPUA NEW GUINEA,FAC MED,DEPT COMMUNITY MED,POB 5623,BOROKO,PAPUA N GUINEA.							CHANTAROJANASIR.T, 1987, TXB PAEDIATRIC INTEN, V1, P199; DOBSON MB, 1991, ANAESTHESIA, V46, P217, DOI 10.1111/j.1365-2044.1991.tb09413.x; Garenne Michel, 1992, World Health Statistics Quarterly, V45, P180; ODEMPSEY TJD, 1993, BRIT MED J, V306, P1342, DOI 10.1136/bmj.306.6888.1342; ONYANGO FE, 1993, BRIT MED J, V306, P612, DOI 10.1136/bmj.306.6878.612; REULAND DS, 1991, J PEDIATR-US, V119, P900, DOI 10.1016/S0022-3476(05)83040-9; SHANN F, 1988, LANCET, V2, P1238; SPOONER V, 1989, J TROP PEDIATRICS, V35, P295, DOI 10.1093/tropej/35.6.295; WANG EEL, 1992, AM REV RESPIR DIS, V145, P106, DOI 10.1164/ajrccm/145.1.106; 1991, TECHNICAL BASIS WHO; 1993, MANUAL STANDARD TREA	11	23	24	0	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 8	1994	308	6921					119	120		10.1136/bmj.308.6921.119	http://dx.doi.org/10.1136/bmj.308.6921.119			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MR173	8298386	Green Published			2022-12-01	WOS:A1994MR17300023
J	HENDRY, WF; AHERN, RP; COLE, PJ				HENDRY, WF; AHERN, RP; COLE, PJ			WAS YOUNGS SYNDROME CAUSED BY EXPOSURE TO MERCURY IN CHILDHOOD	BMJ-BRITISH MEDICAL JOURNAL			English	Article							OBSTRUCTIVE AZOOSPERMIA; DISEASE	Objective-To determine whether the incidence of chronic sinusitis, bronchitis, or bronchiectasis in men with obstructive azoospermia (Young's syndrome) has fallen in men born after 1955 when calomel (mercurous chloride) was removed from teething powders and worm medication in the United Kingdom. Design-A prospective study of aetiological factors in subfertile men with epididymal obstruction operated on between 1975 and 1993. Setting-Central London. Subjects-274 men with obstructive azoospermia undergoing epididymovasostomy; date of birth was recorded and illness in childhood, persistent nasal or respiratory symptoms, and previous urinary or genital infection were asked about. Main outcome measure-Site of epididymal block and association with possible aetiological factors, related to date of birth. Results-146 men had hold up in the head of the epididymis (capital blocks): 119 (82%) had Young's syndrome, and 11 gave a definite history of pink disease (mercury intoxication) in childhood. 128 had obstruction lower down towards the tail of the epididymis (caudal blocks): 64 (50%) had a history of genital or urinary infection, and only three had Young's syndrome; none had had pink disease. The incidence of Young's syndrome fell significantly from 114 (50%) of 227 men born up to 1955 to eight (17%) of 47 men born since then. Conclusions-The decline in incidence of Young's syndrome in those born after 1955 is similar to that observed with pink disease, suggesting that both conditions may have had a similar aetiology-mercury intoxication.	ROYAL MARSDEN HOSP, DEPT COMP & INFORMAT, LONDON SW3 6JJ, ENGLAND; ROYAL BROMPTON NATL HEART & LUNG INST, HOST DEF UNIT, LONDON SW3 6LY, ENGLAND	Royal Marsden NHS Foundation Trust; Imperial College London	HENDRY, WF (corresponding author), ST BARTHOLOMEWS HOSP, DEPT UROL, LONDON EC1A 7BE, ENGLAND.			A'Hern, Roger/0000-0003-0593-8391				BARLOW SM, 1982, REPRODUCTIVE HAZARDS, P386; BARRETT FR, 1957, MED J AUSTRALIA, V2, P242; Bidstrup PL., 1964, TOXICITY MERCURY ITS; Brown J R, 1967, Med Serv J Can, V23, P786; CHAMBERLAIN JL, 1963, CLIN PEDIATR, V2, P439, DOI 10.1177/000992286300200808; CLEMENTS FW, 1960, MED J AUSTRALIA, V1, P922; COLOVER T, 1956, BRIT MED J, V1, P897; DATHAN JG, 1965, BMJ-BRIT MED J, V1, P1181, DOI 10.1136/bmj.1.5443.1181; FORD WCL, 1982, PROGR MALE CONTRACEP, P159; GODLEE F, 1992, BRIT MED J, V305, P333; GOLDWATER LJ, 1972, MERCURY HIST QUICKSI, P182; GREENSTONE MA, 1988, THORAX, V43, P153, DOI 10.1136/thx.43.2.153; GUILLON G, 1972, C NATL SOC FERTIL ST, P391; HANDELSMAN DJ, 1984, NEW ENGL J MED, V310, P3, DOI 10.1056/NEJM198401053100102; HENDRY WF, 1978, BRIT J UROL, V50, P598, DOI 10.1111/j.1464-410X.1978.tb06221.x; HENDRY WF, 1990, ANN ROY COLL SURG, V72, P396; HENDRY WF, 1983, BRIT J UROL, V55, P785, DOI 10.1111/j.1464-410X.1983.tb03426.x; HOLSTEIN A F, 1976, P23; HOLZEL A, 1952, LANCET, V262, P441; HUGHES TM, 1987, J UROLOGY, V137, P1238, DOI 10.1016/S0022-5347(17)44467-3; KEW J, 1993, BRIT MED J, V306, P506, DOI 10.1136/bmj.306.6876.506; LELANNOU D, 1980, ANN UROL, V14, P94; LOGAN WPD, 1949, LANCET, V256, P608; MITCHINSON MJ, 1975, J PATHOL, V115, P57, DOI 10.1002/path.1711150110; MOHAMED MK, 1986, J ANDROL, V7, P11; NEVILLE E, 1983, THORAX, V38, P929, DOI 10.1136/thx.38.12.929; PAVIA D, 1981, CHEST, V80, P892, DOI 10.1378/chest.80.6.892; SCHANKER HMJ, 1985, ARCH INTERN MED, V145, P2201, DOI 10.1001/archinte.145.12.2201; SCHRAG SD, 1985, REPROD TOXICOL, P301; WARKANY J, 1966, AM J DIS CHILD, V112, P147; WARKANY J, 1948, LANCET, V1, P8929; YOUNG D, 1970, J REPROD FERTIL, V23, P541	32	39	40	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 18	1993	307	6919					1579	1582		10.1136/bmj.307.6919.1579	http://dx.doi.org/10.1136/bmj.307.6919.1579			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN107	8292944	Green Published, Bronze			2022-12-01	WOS:A1993MN10700007
J	WU, JY; MANIATIS, T				WU, JY; MANIATIS, T			SPECIFIC INTERACTIONS BETWEEN PROTEINS IMPLICATED IN SPLICE-SITE SELECTION AND REGULATED ALTERNATIVE SPLICING	CELL			English	Article							PRE-MESSENGER-RNA; RIBONUCLEOPROTEIN AUXILIARY FACTOR; BIOCHEMICAL-CHARACTERIZATION; DROSOPHILA ENCODES; BINDING PROTEINS; ASSEMBLY PATHWAY; FACTOR SC35; INVITRO; GENE; U1	Specific recognition and pairing of the 5' and 3' splice sites are critical steps in pre-mRNA splicing. We report that the splicing factors SC35 and SF2/ASF specifically interact with both the integral U1 small nuclear ribonucleoprotein snRNP U1-70K) and with the 35 kd subunit of the splicing factor U2AF (U2AF35). Previous studies indicated that the U1 snRNP binds specifically to the 5' splice site, while U2AF35-U2AF65 heterodimer binds to the 3' splice site. Together, these observations suggest that SC35 and other members of the SR family of splicing factors may function in splice site selection by acting as a bridge between components bound to the 5' and 3' splice sites. Interestingly, SC35, SF2/ASF, and U2AF35 also interact with the Drosophila splicing regulators Transformer (Tra) and Transformer-2 (Tra2), suggesting that protein-protein interactions mediated by SR proteins may also play an important role in regulating alternative splicing.			WU, JY (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA.				NATIONAL CANCER INSTITUTE [R01CA114197] Funding Source: NIH RePORTER; NATIONAL EYE INSTITUTE [R01EY014576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM070967] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA114197-01A2] Funding Source: Medline; NEI NIH HHS [R01 EY014576-03] Funding Source: Medline; NIGMS NIH HHS [R01 GM070967-02] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS MD, 1992, NATURE, V355, P632, DOI 10.1038/355632a0; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BILLINGS PB, 1982, J IMMUNOL, V128, P1176; BLANAR MA, 1992, SCIENCE, V256, P1014, DOI 10.1126/science.1589769; COLICELLI J, 1989, P NATL ACAD SCI USA, V86, P3599, DOI 10.1073/pnas.86.10.3599; DRIVAS GT, 1990, MOL CELL BIOL, V10, P1793, DOI 10.1128/MCB.10.4.1793; FAN CM, 1991, NATURE, V354, P395, DOI 10.1038/354395a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; FU XD, 1993, NATURE, V365, P82, DOI 10.1038/365082a0; FU XD, 1990, NATURE, V343, P437, DOI 10.1038/343437a0; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GE H, 1990, CELL, V62, P25, DOI 10.1016/0092-8674(90)90236-8; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HOFFMAN BE, 1992, GENE DEV, V6, P2554, DOI 10.1101/gad.6.12b.2554; HOFFMAN DW, 1991, P NATL ACAD SCI USA, V88, P2495, DOI 10.1073/pnas.88.6.2495; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; HUANG ZJ, 1993, NATURE, V364, P259, DOI 10.1038/364259a0; INOUE K, 1992, P NATL ACAD SCI USA, V89, P8092, DOI 10.1073/pnas.89.17.8092; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KENAN DJ, 1991, TRENDS BIOCHEM SCI, V16, P214, DOI 10.1016/0968-0004(91)90088-D; KIM YJ, 1993, MOL CELL BIOL, V13, P174, DOI 10.1128/MCB.13.1.174; KRAINER AR, 1990, GENE DEV, V4, P1158, DOI 10.1101/gad.4.7.1158; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1990, CELL, V62, P35, DOI 10.1016/0092-8674(90)90237-9; LAMM GM, 1993, BIOCHIM BIOPHYS ACTA, V1173, P247, DOI 10.1016/0167-4781(93)90122-T; LI H, 1991, CELL, V67, P335, DOI 10.1016/0092-8674(91)90185-2; MCKEOWN M, 1987, CELL, V48, P489, DOI 10.1016/0092-8674(87)90199-1; MICHAUD S, 1993, GENE DEV, V7, P1008, DOI 10.1101/gad.7.6.1008; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; Moore M., 1993, RNA WORLD, P303; NAGAI K, 1990, NATURE, V348, P515, DOI 10.1038/348515a0; PINTO AL, 1989, P NATL ACAD SCI USA, V86, P8742, DOI 10.1073/pnas.86.22.8742; QUERY CC, 1989, CELL, V57, P89, DOI 10.1016/0092-8674(89)90175-X; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; RUBY SW, 1991, TRENDS GENET, V7, P79; RYNER LC, 1991, GENE DEV, V5, P2071, DOI 10.1101/gad.5.11.2071; SPRITZ RA, 1987, NUCLEIC ACIDS RES, V15, P10373, DOI 10.1093/nar/15.24.10373; TAZI J, 1993, NATURE, V363, P283, DOI 10.1038/363283a0; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; TIAN M, 1993, CELL, V74, P105, DOI 10.1016/0092-8674(93)90298-5; VIALARD J, 1990, J VIROL, V64, P37, DOI 10.1128/JVI.64.1.37-50.1990; WOPPMANN A, 1990, NUCLEIC ACIDS RES, V18, P4427, DOI 10.1093/nar/18.15.4427; WOPPMANN A, 1993, NUCLEIC ACIDS RES, V21, P2815, DOI 10.1093/nar/21.12.2815; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAMORE PD, 1991, EMBO J, V10, P207, DOI 10.1002/j.1460-2075.1991.tb07937.x; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0; ZAMORE PD, 1989, P NATL ACAD SCI USA, V86, P9243, DOI 10.1073/pnas.86.23.9243; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHANG M, 1992, P NATL ACAD SCI USA, V89, P8769, DOI 10.1073/pnas.89.18.8769	57	641	658	1	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	DEC 17	1993	75	6					1061	1070		10.1016/0092-8674(93)90316-I	http://dx.doi.org/10.1016/0092-8674(93)90316-I			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	8261509				2022-12-01	WOS:A1993MM89300005
J	SCRAGG, R; MITCHELL, EA; TAYLOR, BJ; STEWART, AW; FORD, RPK; THOMPSON, JMD; ALLEN, EM; BECROFT, DMO				SCRAGG, R; MITCHELL, EA; TAYLOR, BJ; STEWART, AW; FORD, RPK; THOMPSON, JMD; ALLEN, EM; BECROFT, DMO			BED SHARING, SMOKING, AND ALCOHOL IN THE SUDDEN-INFANT-DEATH-SYNDROME	BMJ-BRITISH MEDICAL JOURNAL			English	Article							PASSIVE SMOKING; HONG-KONG; NICOTINE; COTININE; CHILDREN; URINE	Objectives-To investigate why sharing the bed with an infant is a not consistent risk factor for the sudden infant death syndrome in ethnic subgroups in New Zealand and to see if the risk of sudden infant death associated with this practice is related to other factors, particularly maternal smoking and alcohol consumption. Design-Nationwide case-control study. Setting-Region of New Zealand with 78% of all births during 1987-90. Subjects-Home interviews were completed with parents of 393 (81.0% of total) infants who died from the sudden infant death syndrome in the postneonatal age group, and 1592 (88.4% of total) controls who were a representative sample of all hospital births in the study region. Results-Maternal smoking interacted with infant bed sharing on the risk of sudden infant death. Compared with infants not exposed to either risk factor, the relative risk for infants of mothers who smoked was 3.94 (95% confidence interval 2.47 to 6.27) for bed sharing in the last two weeks and 4.55 (2.63 to 7.88) for bed sharing in the last sleep, after other confounders were controlled for. The results for infants of non-smoking mothers were inconsistent with the relative risk being significantly increased for usual bed sharing in the last two weeks (1.73; 1.11 to 2.70) but not for bed sharing in the last sleep (0.98; 0.44 to 2.18). Neither maternal alcohol consumption nor the thermal resistance of the infant's clothing and bedding interacted with bed sharing to increase the risk of sudden infant death, and alcohol was not a risk factor by itself. Conclusion-Infant bed sharing is associated with a significantly raised risk of the sudden infant death syndrome, particularly among infants of mothers who smoke. The interaction between maternal smoking and bed sharing suggests that a mechanism involving passive smoking, rather than the previously proposed mechanisms of overlaying and hyperthermia, increases the risk of sudden infant death from bed sharing.	UNIV OTAGO, DUNEDIN, NEW ZEALAND	University of Otago	SCRAGG, R (corresponding author), UNIV AUCKLAND, DEPT COMMUNITY HLTH, AUCKLAND, NEW ZEALAND.		Taylor, Barry j/G-1410-2010	Taylor, Barry/0000-0002-6450-8677; Scragg, Robert/0000-0003-0013-2620				BALARAJAN R, 1989, BRIT MED J, V298, P716, DOI 10.1136/bmj.298.6675.716; BASS M, 1986, NEW ENGL J MED, V315, P100, DOI 10.1056/NEJM198607103150206; BRESLOW NE, 1985, AM J EPIDEMIOL, V122, P149, DOI 10.1093/oxfordjournals.aje.a114074; CARPENTER RG, 1972, SUDDEN UNEXPECTED DE, P7; DAVIES DP, 1985, LANCET, V2, P1346; ELLEY WB, 1976, NEW ZEAL J EDUC STUD, V11, P25; FLEMING PJ, 1990, BRIT MED J, V301, P85, DOI 10.1136/bmj.301.6743.85; FORD RPK, 1993, IN PRESS INT J EPIDE; GANTLEY M, 1993, BRIT MED J, V306, P16, DOI 10.1136/bmj.306.6869.16; GREENBERG RA, 1984, NEW ENGL J MED, V310, P1075, DOI 10.1056/NEJM198404263101703; HOFFMAN HJ, 1988, ANN NY ACAD SCI, V533, P13, DOI 10.1111/j.1749-6632.1988.tb37230.x; KEMP JS, 1991, NEW ENGL J MED, V324, P1858, DOI 10.1056/NEJM199106273242605; LEE NNY, 1989, BRIT MED J, V298, P721, DOI 10.1136/bmj.298.6675.721; LOZOFF B, 1984, PEDIATRICS, V74, P171; LUCK W, 1985, J PEDIATR-US, V107, P816, DOI 10.1016/S0022-3476(85)80427-3; LUKE JL, 1978, J FORENSIC SCI, V23, P379; MACLURE M, 1992, AM J EPIDEMIOL, V135, P96; McKenna J J, 1986, Med Anthropol, V10, P9; MCKENNA JJ, 1993, SLEEP, V16, P263, DOI 10.1093/sleep/16.3.263; MITCHELL EA, 1991, NEW ZEAL MED J, V104, P71; MITCHELL EA, 1993, PEDIATRICS, V91, P893; MITCHELL EA, 1992, J PAEDIATR CHILD H, V28, pS3, DOI 10.1111/j.1440-1754.1992.tb02729.x; MITCHELL EA, 1993, BMJ-BRIT MED J, V306, P13, DOI 10.1136/bmj.306.6869.13; MORLEY CJ, 1991, ARCH DIS CHILD, V66, P100, DOI 10.1136/adc.66.1.100; MOSKOWITZ WB, 1990, CIRCULATION, V81, P586, DOI 10.1161/01.CIR.81.2.586; RINTAHAKA RJ, 1986, FORENSIC SCI INT, V30, P219, DOI 10.1016/0379-0738(86)90017-4; ROTHMANK, 1986, MODERN EPIDEMIOLOGY; SHIONO PH, 1986, JAMA-J AM MED ASSOC, V255, P82; 1987, SAS USERS GUIDE STAT	29	227	231	0	10	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 20	1993	307	6915					1312	1318		10.1136/bmj.307.6915.1312	http://dx.doi.org/10.1136/bmj.307.6915.1312			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH556	8257885	Bronze, Green Published			2022-12-01	WOS:A1993MH55600019
J	WANNER, C; RADER, D; BARTENS, W; KRAMER, J; BREWER, HB; SCHOLLMEYER, P; WIELAND, H				WANNER, C; RADER, D; BARTENS, W; KRAMER, J; BREWER, HB; SCHOLLMEYER, P; WIELAND, H			ELEVATED PLASMA LIPOPROTEIN(A) IN PATIENTS WITH THE NEPHROTIC SYNDROME	ANNALS OF INTERNAL MEDICINE			English	Article						NEPHROTIC SYNDROME; LIPOPROTEIN-(A); CORONARY ARTERIOSCLEROSIS; APOLIPOPROTEIN-A; THROMBOSIS	LP(A) GLYCOPROTEIN PHENOTYPES; CARDIOVASCULAR-DISEASE; SIZE HETEROGENEITY; GLYCEMIC CONTROL; RISK FACTOR; APOLIPOPROTEIN(A); SERUM; ATHEROSCLEROSIS; TRANSPLANTATION; HEMODIALYSIS	Objective: To examine the influence of the nephrotic syndrome on lipoprotein(a) [Lp(a)], a plasma lipoprotein associated with atherosclerotic cardiovascular disease independently of low-density lipoproteins. Factors that modulate plasma Lp(a) concentrations are poorly understood. Patients: A total of 62 patients: 47 with primary kidney disease and 15 with diabetic nephropathy. Measurements: Lipoprotein(a) levels were determined by enzyme-linked immunosorbent assay. Because apo(a) phenotype has a significant effect on Lp(a) levels, apo(a) isoforms were determined by sodium dodecyl sulfate-polyacrylamide gel electrophoresis, Western blotting, and immunoblotting; the data were compared with a healthy control group. Results: Nephrotic patients had significantly higher Lp(a) levels (mean, +/- SE, 69 +/- 10 mg/dL; median, 46 mg/dL, <0.01) compared with 91 healthy controls (mean, 18 +/- 2 mg/dL; median 9 mg/dL). Sixty percent of the patients and 18% of the controls had values greater than 30 mg/dL. Lipoprotein(a) levels correlated significantly with apolipoprotein B, serum cholesterol, and low-density lipoprotein cholesterol but showed no correlation with creatinine, albumin, or proteinuria. Within all apo(a) isoform classes, higher concentrations of Lp(a) were seen in the nephrotic patients compared with controls (P < 0.05). Finally, in nine patients with primary kidney disease and elevated Lp(a) levels, remission of the nephrotic syndrome was induced using immunosuppressive drugs and Lp(a) values decreased dramatically (pretreatment mean, 90 +/- 15 mg/dL versus remission mean, 31 +/- 8 mg/dL). A decrease in Lp(a) levels was also observed when patients with diabetic nephropathy progressed to end-stage renal disease (nephropathy mean, 56 +/- 11 mg/dL versus dialysis mean, 34 +/- 4 10 mg/dL; n = 7). Conclusions. Most patients with the nephrotic syndrome have Lp(a) concentrations that are substantially elevated compared with controls of the same apo(a) isoform. Because Lp(a) concentrations are substantially reduced when remission of the nephrotic syndrome is induced, it is likely that the nephrotic syndrome results directly in elevation of Lp(a) by an as yet unknown mechanism. The high levels of Lp(a) in the nephrotic syndrome could cause glomerular injury as well as increase the risk for atherosclerosis and thrombotic events associated with this disorder.	NHLBI, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)	WANNER, C (corresponding author), UNIV HOSP FREIBURG, DEPT MED, DIV NEPHROL, HUGSTETTERSTR 55, W-7800 FREIBURG, GERMANY.							ALTMAN DG, 1989, BRIT MED J, P20; APPEL GB, 1985, NEW ENGL J MED, V312, P1544, DOI 10.1056/NEJM198506133122404; BLACK IW, 1992, CLIN CHEM, V38, P353; BOERWINKLE E, 1989, HUM GENET, V82, P73, DOI 10.1007/BF00288277; BRUCKERT E, 1990, JAMA-J AM MED ASSOC, V263, P35, DOI 10.1001/jama.1990.03440010033016; Cameron J, 1988, NEPHROTIC SYNDROME, P849; CAMPBELL MJ, 1989, BRIT MED J, P71; CRESSMAN MD, 1992, CIRCULATION, V86, P475, DOI 10.1161/01.CIR.86.2.475; CURRY RC, 1977, AM J MED, V63, P183, DOI 10.1016/0002-9343(77)90231-5; FLESS GM, 1989, J LIPID RES, V30, P651; FUJITA T, 1992, NEPHRON, V61, P122, DOI 10.1159/000186854; GAUBATZ JW, 1990, J LIPID RES, V31, P603; HAFFNER SM, 1992, METABOLISM, V41, P116, DOI 10.1016/0026-0495(92)90136-X; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; JENKINS AJ, 1991, DIABETES, V40, P787, DOI 10.2337/diabetes.40.6.787; KARADI I, 1989, CLIN CHEM, V35, P2121; KNIGHT BL, 1991, ATHEROSCLEROSIS, V87, P227, DOI 10.1016/0021-9150(91)90025-X; KOSCHINSKY ML, 1990, BIOCHEMISTRY-US, V29, P640, DOI 10.1021/bi00455a007; KRAFT HG, 1989, J CLIN INVEST, V83, P137, DOI 10.1172/JCI113849; KREMPLER F, 1980, J CLIN INVEST, V65, P1483, DOI 10.1172/JCI109813; LACKNER C, 1991, J CLIN INVEST, V87, P2153, DOI 10.1172/JCI115248; LOSCALZO J, 1990, ARTERIOSCLEROSIS, V10, P672, DOI 10.1161/01.ATV.10.5.672; MALLICK NP, 1981, NEPHRON, V27, P54, DOI 10.1159/000182024; MARSH JB, 1960, METABOLISM, V9, P946; MBEWU AD, 1990, ATHEROSCLEROSIS, V85, P1, DOI 10.1016/0021-9150(90)90177-K; MCLEAN JW, 1987, NATURE, V330, P132, DOI 10.1038/330132a0; MILES LA, 1990, THROMB HAEMOSTASIS, V63, P331; MOORHEAD JF, 1982, LANCET, V2, P1309; ORDONEZ JD, 1990, KIDNEY INT, V37, P243; PARRA HJ, 1987, CLIN CHEM, V33, P721; RADER DJ, 1993, J CLIN INVEST, V91, P443, DOI 10.1172/JCI116221; SATO H, 1993, KIDNEY INT, V43, P430, DOI 10.1038/ki.1993.63; SCANU AM, 1990, J CLIN INVEST, V85, P1709, DOI 10.1172/JCI114625; SIMONET WS, 1990, J BIOL CHEM, V265, P10809; STAPRANS I, 1980, BIOCHIM BIOPHYS ACTA, V617, P514, DOI 10.1016/0005-2760(80)90017-X; THOMAS ME, 1992, NEPHROL DIAL TRANSPL, V7, P597, DOI 10.1093/ndt/7.7.597; UTERMANN G, 1989, SCIENCE, V246, P904, DOI 10.1126/science.2530631; UTERMANN G, 1989, P NATL ACAD SCI USA, V86, P4171, DOI 10.1073/pnas.86.11.4171; UTERMANN G, 1987, J CLIN INVEST, V80, P458, DOI 10.1172/JCI113093; WASS VJ, 1979, LANCET, V2, P664; WEBB AT, 1992, NEPHROL DIAL TRANSPL, V7, P636; WIELAND H, 1982, CLIN CHEM, V28, P1335	42	151	152	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	AUG 15	1993	119	4					263	269		10.7326/0003-4819-119-4-199308150-00002	http://dx.doi.org/10.7326/0003-4819-119-4-199308150-00002			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV525	8328733				2022-12-01	WOS:A1993LV52500002
J	FORREST, S				FORREST, S			GENETIC ALGORITHMS - PRINCIPLES OF NATURAL-SELECTION APPLIED TO COMPUTATION	SCIENCE			English	Article								A genetic algorithm is a form of evolution that occurs on a computer. Genetic algorithms are a search method that can be used for both solving problems and modeling evolutionary systems. With various mapping techniques and an appropriate measure of fitness, a genetic algorithm can be tailored to evolve a solution for many types of problems, including optimization of a function or determination of the proper order of a sequence. Mathematical analysis has begun to explain how genetic algorithms work and how best to use them. Recently, genetic algorithms have been used to model several natural evolutionary systems, including immune systems.			FORREST, S (corresponding author), UNIV NEW MEXICO, DEPT COMP SCI, ALBUQUERQUE, NM 87131 USA.							[Anonymous], 1991, HDB GENETIC ALGORITH; ANTONISSE HJ, 1987, 2ND P INT C GEN ALG, P69; Axelrod R., 1987, GENETIC ALGORITHMS S; AXELROD R, 1986, AM POLIT SCI REV, P80; Back T, 1993, EVOL COMPUT, V1, P1, DOI 10.1162/evco.1993.1.1.1; BEAN JC, IN PRESS J COMPUT; BELEW RK, 1991, 4TH P INT C GEN ALG; BERGMAN A, 1992, PHYSICA D, V56, P57, DOI 10.1016/0167-2789(92)90050-W; Bethke A., 1980, THESIS U MICHIGAN AN; Booker L. B, 1993, FDN GENETIC ALGORITH, V2, P29; BOOKER LB, IN PRESS BASIC PARAD, V1; BOX GEP, 1957, APPLIED STATISTICS, V6, P81; Davidor Y., 1991, WORLD SCI SERIES ROB; DAVIS L, 1987, 2ND P INT C GEN ALG, P252; Davis L., 1991, HDB GENETIC ALGORITH, DOI DOI 10.1.1.87.3586; Dawkins R, 1989, ARTIF LIFE, P201; DeJong K, 1975, THESIS U MICHIGAN AN; FARMER JD, 1986, PHYSICA D, V22, P187, DOI 10.1016/0167-2789(86)90240-X; FOGEL DB, 1990, BIOL CYBERN, V63, P111, DOI 10.1007/BF00203032; Fogel LJ., 1966, ARTIF INTELL; FORREST S, IN PRESS EVOL COMPUT; FORREST S, IN PRESS MACH LEARN; GLOVER DE, 1987, GENETIC ALGORITHMS S, P12; Goldberg D. E., 1991, Complex Systems, V5, P139; Goldberg D. E., 1992, Complex Systems, V6, P333; Goldberg D. E., 1989, Complex Systems, V3, P153; Goldberg D. E., 1989, COMPLEX SYST, V3, P493, DOI DOI 10.1007/978-1-4757-3643-4; Goldberg D.E., 1985, P INT C GENETIC ALGO, P154; GOLDBERG DE, IN PRESS COMMUN ACM; GOLDBERG DE, 1989, GENETIC ALGORITHSM S; Grefenstette J., 1995, P 1 INT C GEN ALG TH, P160; GREFENSTETTE JJ, 1987, 2ND P INT C GEN ALG; GREFENSTETTE JJ, 1989, 3RD P INT C GEN ALG; GREFENSTETTE JJ, 1985, P INT C GENETIC ALGO; HIGHTOWER R, IN PRESS 2ND EUR C A; HILLIS WD, 1990, PHYSICA D, V42, P228, DOI 10.1016/0167-2789(90)90076-2; Holland J., 1962, J ACM, V3, P297; Holland J, 1992, ADAPTATION NATURAL A; Holland J. H., 1986, INDUCTION PROCESSES; HOLLAND JH, IN PRESS INTEGRATIVE; HOLLAND JH, 1988, EVOLUTION LEARNING C; Koza J.R, 1997, GENETIC PROGRAMMING; Liepins G. E., 1990, Journal of Experimental and Theoretical Artificial Intelligence, V2, P101, DOI 10.1080/09528139008953717; MANDERICK B, 1991, 4TH P INT C GEN ALG; MUHLENBEIN H, 1988, PARALLEL COMPUT, V7, P65, DOI 10.1016/0167-8191(88)90098-1; PACKARD NH, 1990, COMPLEX SYST, V4; Rechenberg I, 1965, CYBERNETIC SOLUTION, V1122; ROS JP, 1993, FDN GENETIC ALGORITH, V2, P257; SCHAFER CG, 1987, 2ND P INT C GEN ALG, P50; SCHAFER JD, 1989, 3RD P INT C GEN ALGO; SCHAFFER JD, 1989, 3RD P INT C GEN ALG; Schaffer JD., 1985, P 1 INT C GEN ALG, P93, DOI 10.1017/CBO9781107415324.004; SCHRAUDOLPH NN, 1992, MACH LEARN, V9, P9, DOI 10.1007/BF00993252; SIMS K, 1991, COMP GRAPH, V25, P319, DOI 10.1145/127719.122752; SMITH D, 1985, P INT C GENETIC ALGO, P202; Smith R. E., 1992, Complex Systems, V6, P251; SMITH RE, IN PRESS EVOL COMPUT; SYSWERDA G, 1989, 3RD P INT C GEN ALGO; Tanese R., 1989, DISTRIBUTED GENETIC; ULDER NLJ, 1991, LECT NOTES COMPUT SC, V496, P109, DOI 10.1007/BFb0029740; Walsh JL, 1923, AM J MATH, V45, P5, DOI 10.2307/2387224; Wilson S. W., 1987, Machine Learning, V2, P199, DOI 10.1023/A:1022655214215; [No title captured]	63	570	598	1	107	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	AUG 13	1993	261	5123					872	878		10.1126/science.8346439	http://dx.doi.org/10.1126/science.8346439			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR897	8346439				2022-12-01	WOS:A1993LR89700027
J	RONCHI, E; TREISMAN, J; DOSTATNI, N; STRUHL, G; DESPLAN, C				RONCHI, E; TREISMAN, J; DOSTATNI, N; STRUHL, G; DESPLAN, C			DOWN-REGULATION OF THE DROSOPHILA MORPHOGEN BICOID BY THE TORSO RECEPTOR-MEDIATED SIGNAL-TRANSDUCTION CASCADE	CELL			English	Article							SEGMENTATION GENE HUNCHBACK; HEAD DEVELOPMENT; TYROSINE KINASE; TRANSCRIPTIONAL ACTIVATOR; ORTHODENTICLE GENE; ANTERIOR PATTERN; TERMINAL ANLAGEN; EMPTY SPIRACLES; GAP GENE; EMBRYO	Anterior body pattern in Drosophila is specified by the graded distribution of the bicoid protein (bcd), which activates subordinate genes in distinct anterior domains. Subsequently, transcription of these target genes is repressed at the anterior pole owing to the activity of the receptor tyrosine kinase torso (tor). We show that both activation by bcd and repression by tor can be reproduced by a minimal promoter containing only bcd-binding sites upstream of a naive transcriptional start site. Repression requires the D-raf kinase and is associated with phosphorylation of bcd protein. Repression does not require either tailless or huckebein, which were previously thought to constitute the sole zygotic output of the tor signaling system. Finally, addition of a heterologous transcriptional activation domain to bcd renders the protein insensitive to tor-mediated repression. We propose that phosphorylation resulting from the activity of the tor signal transduction cascade down-regulates transcriptional activation by the bcd morphogen.	COLUMBIA UNIV COLL PHYS & SURG,CTR NEUROBIOL & BEHAV,HOWARD HUGHES MED INST,NEW YORK,NY 10032	Columbia University; Howard Hughes Medical Institute	RONCHI, E (corresponding author), ROCKEFELLER UNIV,HOWARD HUGHES MED INST,NEW YORK,NY 10021, USA.			Desplan, Claude/0000-0002-6914-1413; Treisman, Jessica/0000-0002-7453-107X				AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BERLETH T, 1988, EMBO J, V7, P1749, DOI 10.1002/j.1460-2075.1988.tb03004.x; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRONNER G, 1991, MECH DEVELOP, V35, P205, DOI 10.1016/0925-4773(91)90019-3; CASANOVA J, 1989, GENE DEV, V3, P2025, DOI 10.1101/gad.3.12b.2025; CASANOVA J, 1990, DEVELOPMENT, V110, P621; CHOU TB, 1992, GENETICS, V131, P643; COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; DOUGAN S, 1992, NATURE, V360, P347, DOI 10.1038/360347a0; DRIEVER W, 1988, CELL, V54, P83, DOI 10.1016/0092-8674(88)90182-1; DRIEVER W, 1989, NATURE, V337, P138, DOI 10.1038/337138a0; DRIEVER W, 1988, CELL, V54, P95, DOI 10.1016/0092-8674(88)90183-3; FINKELSTEIN R, 1990, GENE DEV, V4, P1516, DOI 10.1101/gad.4.9.1516; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; FRIGERIO G, 1986, CELL, V47, P735, DOI 10.1016/0092-8674(86)90516-7; FROHNHOFER HG, 1986, NATURE, V324, P120, DOI 10.1038/324120a0; GOLIC KG, 1991, SCIENCE, V252, P958, DOI 10.1126/science.2035025; GROSSNIKLAUS U, 1992, GENE DEV, V6, P1030, DOI 10.1101/gad.6.6.1030; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; KLINGLER M, 1988, NATURE, V335, P275, DOI 10.1038/335275a0; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; LIS JT, 1983, CELL, V35, P403, DOI 10.1016/0092-8674(83)90173-3; MARK GE, 1987, MOL CELL BIOL, V7, P2134, DOI 10.1128/MCB.7.6.2134; MELNICK MB, 1993, DEVELOPMENT, V118, P127; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; NUSSLEINVOLHARD C, 1991, DEVELOPMENT S1, V13, P1; OHARE K, 1983, CELL, V34, P25, DOI 10.1016/0092-8674(83)90133-2; PERRIMON N, 1984, DEV BIOL, V105, P404, DOI 10.1016/0012-1606(84)90297-5; PIGNONI F, 1992, DEVELOPMENT, V115, P239; PIGNONI F, 1990, CELL, V62, P151, DOI 10.1016/0092-8674(90)90249-E; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHRODER C, 1988, EMBO J, V7, P2881, DOI 10.1002/j.1460-2075.1988.tb03145.x; SPRENGER F, 1989, NATURE, V338, P478, DOI 10.1038/338478a0; STEVENS LM, 1990, NATURE, V346, P660, DOI 10.1038/346660a0; STJOHNSTON D, 1992, CELL, V68, P201; STRECKER TR, 1991, P NATL ACAD SCI USA, V88, P5824, DOI 10.1073/pnas.88.13.5824; STRUHL G, 1989, CELL, V57, P1259, DOI 10.1016/0092-8674(89)90062-7; TAUTZ D, 1988, NATURE, V332, P281, DOI 10.1038/332281a0; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; TREISMAN J, 1989, CELL, V59, P553; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; WALLDORF U, 1992, EMBO J, V11, P2247, DOI 10.1002/j.1460-2075.1992.tb05284.x; WEIGEL D, 1990, SCIENCE, V248, P495, DOI 10.1126/science.2158673; WIESCHAUS E, 1984, ROUX ARCH DEV BIOL, V193, P296, DOI 10.1007/BF00848158	45	90	91	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 30	1993	74	2					347	355		10.1016/0092-8674(93)90425-P	http://dx.doi.org/10.1016/0092-8674(93)90425-P			9	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LP726	8343961				2022-12-01	WOS:A1993LP72600015
J	KLEIN, D; ONO, H; OHUIGIN, C; VINCEK, V; GOLDSCHMIDT, T; KLEIN, J				KLEIN, D; ONO, H; OHUIGIN, C; VINCEK, V; GOLDSCHMIDT, T; KLEIN, J			EXTENSIVE MHC VARIABILITY IN CICHLID FISHES OF LAKE MALAWI	NATURE			English	Article							MAJOR HISTOCOMPATIBILITY COMPLEX; EVOLUTION; GENES	LAKE Malawi in East Africa harbours 500-1,000 endemic species of cichlid fishes, all presumably derived by adaptive radiation from a single founding population within the past two million years1-3. The species of this 'flock' differ strikingly in their ecology and behaviour4, moderately in their external morphology1 and very little in their molecular characteristics5,6. Here we describe high sequence variability of class II major histocompatibility complex genes in a sample of species from Lake Malawi. The variability provides a set of molecular markers for studying adaptive radiation and should be useful for estimating the size of the population that founded the species flock.	MAX PLANCK INST BIOL,IMMUNGENET ABT,W-7400 TUBINGEN,GERMANY; LEIDEN UNIV,ZOOL LAB,ECOL MORPHOL RES GRP,2300 RA LEIDEN,NETHERLANDS; YOKOHAMA CITY UNIV,SCH MED,DEPT DERMATOL,KANAZAWA KU,YOKOHAMA 236,JAPAN	Max Planck Society; Leiden University; Leiden University - Excl LUMC; Yokohama City University	KLEIN, D (corresponding author), UNIV MIAMI,DEPT MICROBIOL & IMMUNOL,MIAMI,FL 33101, USA.							Eccles D. H., 1989, MALAWIAN CICHLID FIS; Fryer G., 1972, CICHLID FISHES GREAT; FRYER GEOFFREY, 1959, PROC ZOOL SOC LONDON, V132, P153; KIMURA M, 1980, J MOL EVOL, V16, P111, DOI 10.1007/BF01731581; KLEIN J, 1986, CRC CR REV IMMUNOL, V6, P295; Klein J., 1986, NATURAL HIST MAJOR H; Kornfield I., 1991, P103; Lewis D., 1986, GUIDE FISHES LAKE MA; MACKAYE KR, 1982, ZOOL J LINN SOC-LOND, V76, P91; ONO H, 1992, P NATL ACAD SCI USA, V89, P11886, DOI 10.1073/pnas.89.24.11886; ONO H, IN PRESS MOL BIOL EV; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; ZHU ZF, 1991, MOL BIOL EVOL, V8, P563	14	124	130	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 22	1993	364	6435					330	334		10.1038/364330a0	http://dx.doi.org/10.1038/364330a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	8332189				2022-12-01	WOS:A1993LN57000055
J	NIGHTINGALE, SL				NIGHTINGALE, SL			INTERNATIONAL-CONFERENCE ON HARMONIZING TECHNICAL REQUIREMENTS FOR DRUG APPROVALS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																		1993, FED REG         0512, V58, P28194	1	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 21	1993	270	3					302	302		10.1001/jama.270.3.302	http://dx.doi.org/10.1001/jama.270.3.302			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM435	8315763				2022-12-01	WOS:A1993LM43500006
J	RIDSDALE, L; EVANS, A; JERRETT, W; MANDALIA, S; OSLER, K; VORA, H				RIDSDALE, L; EVANS, A; JERRETT, W; MANDALIA, S; OSLER, K; VORA, H			PATIENTS WITH FATIGUE IN GENERAL-PRACTICE - A PROSPECTIVE-STUDY	BMJ-BRITISH MEDICAL JOURNAL			English	Article								Objective-To describe the characteristics of patients attending their general practitioners and complaining of fatigue or being ''tired all the time.'' Design-Prospective study of cohort aged 16 years and older with follow up at two weeks and by questionnaires at two and six months. Subjects-220 patients (164 women) with mean age 43 years and an age-sex matched comparison group. Settings-Doctors and patients in four practices in Lancashire, Mid Glamorgan, Suffolk, and Surrey. Main outcome measure-General clinical data, results from standard group of laboratory tests, fatigue questionnaire, and 12 item general health questionnaire. Results-Over twice as many patients with fatigue had high scores on the health questionnaire compared with the comparison group (156 (75%) v 69 (34%)). Results of laboratory tests were abnormal and contributed to the diagnosis in 19 patients. 59 out of 102 patients who responded had high fatigue scores six months later. Patients with persistent fatigue were more likely to have a history of anxiety or depression and to have had fatigue for more than three months on entry to the study. Conclusions-Women are particularly at risk of fatigue. The outcome is better if patients have had symptoms for three months or less or there is no history of emotional illness.	UNIV LEEDS, ST JAMES HOSP, DEPT GEN PRACTICE, LEEDS LS9 7TF, W YORKSHIRE, ENGLAND; OLD SCH SURG, PONTYCLUN, M GLAM, WALES; THE SURGERY, SUFFOLK IP16 4ES, ENGLAND	Saint James's University Hospital; University of Leeds	RIDSDALE, L (corresponding author), UNITED MED & DENT SCH GUYS & ST THOMAS HOSP, DEPT GEN PRACTICE, LONDON SE11 6SP, ENGLAND.			Ridsdale, Leone/0000-0002-2234-2859				CATHEBRAS PJ, 1992, J GEN INTERN MED, V7, P276, DOI 10.1007/BF02598083; CHALDER T, 1993, J PSYCHOSOM RES, V37, P147, DOI 10.1016/0022-3999(93)90081-P; Goldberg DPW, 1988, USERS GUIDE GEN HLTH; Hannay D R, 1978, J R Coll Gen Pract, V28, P492; JERRETT WA, 1981, PRACTITIONER, V225, P731; Morrell D C, 1976, J R Coll Gen Pract, V26, P398; MORRELL DC, 1972, J ROY COLL GEN PRACT, V22, P295; RIDSDALE L, 1991, BRIT MED J, V303, P1490, DOI 10.1136/bmj.303.6816.1490; VALDINI A, 1989, FAM PRACT, V6, P286, DOI 10.1093/fampra/6.4.286; VALDINI AF, 1988, J FAM PRACTICE, V26, P33; WESSELY S, 1989, J NEUROL NEUROSUR PS, V52, P940, DOI 10.1136/jnnp.52.8.940	11	85	85	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	JUL 10	1993	307	6896					103	106		10.1136/bmj.307.6896.103	http://dx.doi.org/10.1136/bmj.307.6896.103			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM585	8343705	Bronze, Green Published			2022-12-01	WOS:A1993LM58500027
J	MOZES, E; KOHN, LD; HAKIM, F; SINGER, DS				MOZES, E; KOHN, LD; HAKIM, F; SINGER, DS			RESISTANCE OF MHC CLASS-I-DEFICIENT MICE TO EXPERIMENTAL SYSTEMIC LUPUS-ERYTHEMATOSUS	SCIENCE			English	Article							T-CELLS; INDUCTION; IDIOTYPE	Experimental systemic lupus erythematosus (SLE) can be induced in mice by immunization with a human monoclonal antibody to DNA that bears a common idiotype (16/6Id). These mice generate antibodies to 16/6Id, antibodies to DNA, and antibodies directed against nuclear antigens. Subsequently, manifestations of SLE develop, including leukopenia, proteinuria, and immune complex deposits in the kidney. In contrast, after immunization with 16/6Id, mice lacking major histocompatibility complex (MHC) class I molecules generated antibodies to 16/6Id but did not generate antibodies to DNA or to nuclear antigen. Furthermore, they did not develop any of the above clinical manifestations. These results reveal an unexpected function of MHC class I in the induction of autoimmune SLE.	NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892; NIDDKD,BIOCHEM & METAB LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								FRICKE H, 1991, IMMUNOLOGY, V73, P421; KOLLER BH, 1990, SCIENCE, V248, P1227, DOI 10.1126/science.2112266; MENDLOVIC S, 1990, IMMUNOLOGY, V69, P228; MENDLOVIC S, 1989, EUR J IMMUNOL, V19, P729, DOI 10.1002/eji.1830190424; MENDLOVIC S, 1988, P NATL ACAD SCI USA, V85, P2260, DOI 10.1073/pnas.85.7.2260; MOZES E, UNPUB; RUIZ P, UNPUB; SHOENFELD Y, 1983, J EXP MED, V158, P718, DOI 10.1084/jem.158.3.718; SINGER DS, 1990, CRIT REV IMMUNOL, V10, P235; SPRIGGS MK, 1992, P NATL ACAD SCI USA, V89, P6070, DOI 10.1073/pnas.89.13.6070; TALAL N, 1977, AUTOIMMUNITY GENETIC; TARLETON RL, 1992, NATURE, V356, P338, DOI 10.1038/356338a0; ZIJLSTRA M, 1990, NATURE, V344, P742, DOI 10.1038/344742a0	13	107	107	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 2	1993	261	5117					91	93		10.1126/science.8316860	http://dx.doi.org/10.1126/science.8316860			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK434	8316860				2022-12-01	WOS:A1993LK43400038
J	SIMONS, AM; PHILLIPS, DH; COLEMAN, DV				SIMONS, AM; PHILLIPS, DH; COLEMAN, DV			DAMAGE TO DNA IN CERVICAL EPITHELIUM RELATED TO SMOKING TOBACCO	BRITISH MEDICAL JOURNAL			English	Article							CIGARETTE-SMOKING; UTERINE CERVIX; ADDUCTS; COTININE; SMOKERS; SENSITIVITY; NEOPLASIA; TISSUES; CANCER; CELLS	Objective-To determine whether tobacco smoking causes increased DNA modification (adducts) in human cervical epithelium. Design-Comparison of DNA adducts measured by the technique of postlabelling with phosphorus-32 in normal ectocervical epithelium of smokers and non-smokers. A questionnaire on smoking habit and a urinary cotinine assay were used to identify smokers and non-smokers. Setting-Cytology unit in large teaching hospital. Subjects-39 women (11 current smokers, seven former smokers, and 21 who had never smoked) undergoing gynaecological treatment (colposcopy or hysterectomy). Nineteen members of staff who did not smoke as controls. Interventions-Biopsy of normal ectocervical epithelium. Urine sample. Main outcome measures-Measurement of DNA adducts in cervical epithelial tissue of smokers and non-smokers. Smoking habit derived from results of questionnaire and urinary cotinine:creatinine ratio. Proportion of adducts in women with abnormal and normal results of cervical smear test. Results-DNA samples from smokers (identified from questionnaire) had significantly higher median proportions of DNA adducts that non-smokers (4.62 (95% confidence interval 4.04 to 7.74) v 3.47 (2.84 to 4.78) adducts/10(8) nucleotides; p=0.048). Exclusion of women whose urinary cotinine:creatinine ratio did not confirm their self reported smoking habit (smoker or non-smoker) increased this difference (4.7 (3.85 to 8.08) v 3.52 (2.32 to 4.95) adducts/10(8) nucleotides; p=0.03). Women who had abnormal results of cervical smear tests had significantly higher proportions of adducts than those with normal results (4.7 (3.90 to 8.13) v 3.47 (3.06 to 5.36) adducts/10(8) nucleotides; p=0.03). Conclusions-Tobacco smoking by women leads to increased modification of DNA in cervical epithelium, suggesting biochemical evidence consistent with smoking as a cause of cervical cancer.	ST MARYS HOSP,SCH MED,IMPERIAL COLL,FAC MED,CYTOL & CYTOGENET UNIT,LONDON W2 1PG,ENGLAND; INST CANC RES,HADDOW LABS,SUTTON SM2 5NG,SURREY,ENGLAND	Imperial College London; University of London; Institute of Cancer Research - UK				Phillips, David/0000-0001-8509-3485				BENOWITZ NL, 1983, CLIN PHARMACOL THER, V34, P604, DOI 10.1038/clpt.1983.222; BRISSON J, 1988, AM J EPIDEMIOL, V128, P337, DOI 10.1093/oxfordjournals.aje.a114973; CUZICK J, 1990, INT J CANCER, V45, P673, DOI 10.1002/ijc.2910450417; DUNN BP, 1991, INT J CANCER, V48, P485, DOI 10.1002/ijc.2910480403; FEYERABEND C, 1980, ANALYST, V105, P998, DOI 10.1039/an9800500998; GUPTA RC, 1982, CARCINOGENESIS, V3, P1081, DOI 10.1093/carcin/3.9.1081; GUPTA RC, 1985, CANCER RES, V45, P5656; HOFFMANN D, 1990, HDB EXPT PHARM, V94, P63; MCCANN MF, 1992, CANCER EPIDEM BIOMAR, V1, P125; MILLER EC, 1981, CANCER-AM CANCER SOC, V47, P2327, DOI 10.1002/1097-0142(19810515)47:10<2327::AID-CNCR2820471003>3.0.CO;2-Z; PHILLIPS DH, 1990, LANCET, V335, P417, DOI 10.1016/0140-6736(90)90257-6; PHILLIPS DH, 1988, NATURE, V336, P790, DOI 10.1038/336790a0; PHILLIPS DH, 1990, INT J CANCER, V46, P569, DOI 10.1002/ijc.2910460403; RANDERATH E, 1989, J NATL CANCER I, V81, P341, DOI 10.1093/jnci/81.5.341; REDDY MV, 1986, CARCINOGENESIS, V7, P1543, DOI 10.1093/carcin/7.9.1543; SASCO AJ, 1991, LANCET, V338, P123, DOI 10.1016/0140-6736(91)90119-A; SASSON IM, 1985, NEW ENGL J MED, V312, P315; SCHOKET B, 1990, J INVEST DERMATOL, V94, P241, DOI 10.1111/1523-1747.ep12874576; SILLETT RW, 1978, BRIT MED J, V2, P1185, DOI 10.1136/bmj.2.6146.1185; WILCOX RG, 1979, BRIT MED J, V2, P1026, DOI 10.1136/bmj.2.6197.1026; WINKELSTEIN W, 1990, AM J EPIDEMIOL, V131, P945, DOI 10.1093/oxfordjournals.aje.a115614; 1992, 5TH ROYAL COLL PHYS; 1986, MONOGRAPH EVALUATION, V38; 1986, TEENAGE GIRLS SMOKIN; 1991, OPCS MONITOR	25	92	95	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	MAY 29	1993	306	6890					1444	1448		10.1136/bmj.306.6890.1444	http://dx.doi.org/10.1136/bmj.306.6890.1444			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LE935	8257490	Green Published, Bronze			2022-12-01	WOS:A1993LE93500017
J	WANG, EH; TJIAN, R				WANG, EH; TJIAN, R			PROMOTER-SELECTIVE TRANSCRIPTIONAL DEFECT IN CELL-CYCLE MUTANT TS13 RESCUED BY HTAF(II)250	SCIENCE			English	Article							DNA-BINDING PROTEIN; TATA-LESS PROMOTER; TFIID COMPLEX; REPLICATION; GENE; PROGRESSION; EXPRESSION; COACTIVATORS; ACTIVATION; REQUIRES	The TAF(II)250 subunit of the human transcription factor IID (TFIID) rescues the temperature-sensitive hamster cell line ts13 and overcomes a G1 arrest. Investigation of the transcriptional properties of ts13 nuclear extracts in vitro showed that activation by the site-specific regulators Sp1 and Gal4VP16 is temperature sensitive in ts13 extracts, whereas basal transcription remains unaffected. This transcriptional defect can be rescued by purified human TFIID or by expression of wild-type TAF(II)250 in ts13 cells. Expression from the cyclin A but not c-fos promoter is temperature sensitive in these mutant cells. Thus, the mutation in TAF(II)250 appears to have gene-specific effects that may lead to the ts13 cell cycle phenotype.			WANG, EH (corresponding author), UNIV CALIF BERKELEY,HOWARD HUGHES MED INST,DEPT MOLEC & CELL BIOL,BERKELEY,CA 94720, USA.							DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; GILMAN MZ, 1986, MOL CELL BIOL, V6, P4305, DOI 10.1128/MCB.6.12.4305; GIRARD F, 1991, CELL, V67, P1169, DOI 10.1016/0092-8674(91)90293-8; GOODRICH JA, 1993, CELL, V75, P519, DOI 10.1016/0092-8674(93)90386-5; GORMAN CM, 1989, VIROLOGY, V171, P377, DOI 10.1016/0042-6822(89)90605-3; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HIPSKIND RA, 1991, J BIOL CHEM, V266, P19583; HISATAKE K, 1993, NATURE, V362, P179, DOI 10.1038/362179a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KOKUBO T, 1993, P NATL ACAD SCI USA, V90, P5896, DOI 10.1073/pnas.90.13.5896; LIN YS, 1988, CELL, V54, P65; LIU HT, 1985, J BIOL CHEM, V260, P3269; LOBO SM, 1992, CELL, V71, P1029, DOI 10.1016/0092-8674(92)90397-U; MCKINNEY JD, 1991, TRENDS BIOCHEM SCI, V16, P430, DOI 10.1016/0968-0004(91)90170-Z; NEUMANN JR, 1987, BIOTECHNIQUES, V5, P444; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SEKIGUCHI T, 1988, EMBO J, V7, P1683, DOI 10.1002/j.1460-2075.1988.tb02996.x; SEKIGUCHI T, 1987, EXP CELL RES, V169, P395, DOI 10.1016/0014-4827(87)90200-X; SEKIGUCHI T, 1991, MOL CELL BIOL, V11, P3317, DOI 10.1128/MCB.11.6.3317; SEKIGUCHI T, COMMUNICATION; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; TALAVERA A, 1977, J CELL PHYSIOL, V92, P425, DOI 10.1002/jcp.1040920310; TANESE N, 1991, GENE DEV, V5, P2212, DOI 10.1101/gad.5.12a.2212; USTAV M, 1991, EMBO J, V10, P449, DOI 10.1002/j.1460-2075.1991.tb07967.x; WANG EG, UNPUB; WEINZIERL ROJ, 1993, NATURE, V362, P511, DOI 10.1038/362511a0; YANG L, 1991, NATURE, V353, P628, DOI 10.1038/353628a0; ZHOU Q, 1992, GENE DEV, V6, P1964, DOI 10.1101/gad.6.10.1964	32	151	154	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 11	1994	263	5148					811	814		10.1126/science.8303298	http://dx.doi.org/10.1126/science.8303298			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MV866	8303298				2022-12-01	WOS:A1994MV86600036
J	BROOKS, A; LITHGOW, GJ; JOHNSON, TE				BROOKS, A; LITHGOW, GJ; JOHNSON, TE			MORTALITY-RATES IN A GENETICALLY HETEROGENEOUS POPULATION OF CAENORHABDITIS-ELEGANS	SCIENCE			English	Article							LIFE-SPAN	Age-specific mortality rates in isogenic populations of the nematode Caenorhabditis elegans increase exponentially throughout life. In genetically heterogeneous populations, age-specific mortality increases exponentially until about 17 days and then remains constant until the last death occurs at about 60 days. This period of constant age-specific mortality results from genetic heterogeneity. Subpopulations differ in mean life-span, but they all exhibit near exponential, albeit different, rates of increase in age-specific mortality. Thus, much of the observed heterogeneity in mortality rates later in life could result from genetic heterogeneity and not from an inherent effect of aging.	UNIV COLORADO,INST BEHAV GENET,BOULDER,CO 80309; UNIV COLORADO,DEPT PSYCHOL,BOULDER,CO 80309	University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder				/0000-0001-7147-8237	NIA NIH HHS [K04-AG00369, R01-AG08332, R01-AG10248] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG008332, K04AG000369, R01AG010248] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BROCK DB, 1990, HDB BIOL AGING, P3; BROOKS A, 1991, HEREDITY, V67, P19, DOI 10.1038/hdy.1991.60; Brooks A, UNPUB; CAREY JR, 1992, SCIENCE, V258, P457, DOI 10.1126/science.1411540; CASSEL CK, 1992, HEALTH AFFAIR, V11, P87, DOI 10.1377/hlthaff.11.2.87; Charlesworth B., 1994, EVOLUTION AGE STRUCT; CURTSINGER JW, 1992, SCIENCE, V258, P461, DOI 10.1126/science.1411541; FABIAN TJ, IN PRESS J GERONTOL; FABIAN TJ, UNPUB; FINCH CE, 1990, SCIENCE, V249, P902, DOI 10.1126/science.2392680; Finch CE., 1990, LONGEVITY SENESCENCE; FRIES JF, 1988, PERSPECT BIOL MED, V31, P407; Gavrilov L.A., 1991, BIOL LIFE SPAN QUANT; GOMPERTZ B, 1825, PHILOS T R SOC LON A, V57, P289; JOHNSON TE, 1988, EXP GERONTOL, V23, P281, DOI 10.1016/0531-5565(88)90031-9; JOHNSON TE, 1982, P NATL ACAD SCI-BIOL, V79, P6603, DOI 10.1073/pnas.79.21.6603; JOHNSON TE, 1990, SCIENCE, V249, P908, DOI 10.1126/science.2392681; JOHNSON TE, 1987, P NATL ACAD SCI USA, V84, P3777, DOI 10.1073/pnas.84.11.3777; Kirkwood T., 1985, HDB BIOL AGING, P2743; KOWALD A, 1993, SCIENCE, V260, P1664, DOI 10.1126/science.8503014; NORUSSIS MJ, 1990, SPSS PC PLUS ADV STA; NORUSSIS MJ, 1990, SPSS PC PLUS 4 0 BAS; Rose MR, 1991, EVOLUTIONARY BIOL AG; SACHER GA, 1977, HDB BIOL AGING, P582; Tabachnick B.G., 2019, USING MULTIVARIATE S, V7th, DOI DOI 10.1037/022267; WITTEN M, 1988, MECH AGEING DEV, V46, P175, DOI 10.1016/0047-6374(88)90124-8; 1990, SAS STAT USERS GUIDE, V2, P936	27	145	153	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 4	1994	263	5147					668	671		10.1126/science.8303273	http://dx.doi.org/10.1126/science.8303273			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8303273				2022-12-01	WOS:A1994MU96400044
J	FULHORST, CF; HARDY, JL; ELDRIDGE, BF; PRESSER, SB; REEVES, WC				FULHORST, CF; HARDY, JL; ELDRIDGE, BF; PRESSER, SB; REEVES, WC			NATURAL VERTICAL TRANSMISSION OF WESTERN EQUINE ENCEPHALOMYELITIS VIRUS IN MOSQUITOS	SCIENCE			English	Article							CALIFORNIA; CULICIDAE; DIPTERA	The mechanism by which western equine encephalomyelitis (WEE) virus and other mosquito-borne alphaviruses (Togaviridae) survive during periods of vector inactivity is unknown. Recently, three strains of WEE virus were isolated from adult Aedes dorsalis collected as larvae from a salt marsh in a coastal region of California. This provides evidence of vertical transmission of WEE virus in mosquitoes in nature. Vertical transmission in Ae. dorsalis and closely related mosquito species may be an important mechanism for the maintenance of WEE virus in temperate regions in North America where horizontal transmission of the virus is seasonal.	UNIV CALIF BERKELEY,SCH PUBL HLTH,BERKELEY,CA 94720; UNIV CALIF DAVIS,DEPT ENTOMOL,DAVIS,CA 95616	University of California System; University of California Berkeley; University of California System; University of California Davis					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI003028, R01AI026154, R22AI003028] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-03028, AI-26154] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		CAMPBELL GL, 1991, AM J TROP MED HYG, V44, P244, DOI 10.4269/ajtmh.1991.44.244; CHAMBERLAIN R, 1961, ANNU REV ENTOMOL, V6, P371, DOI 10.1146/annurev.en.06.010161.002103; ELDRIDGE BF, 1991, J MED ENTOMOL, V28, P645, DOI 10.1093/jmedent/28.5.645; HARDY JL, 1987, AM J TROP MED HYG, V37, pS18, DOI 10.4269/ajtmh.1987.37.18S; HAYES RO, 1962, AM J HYG, V75, P183, DOI 10.1093/oxfordjournals.aje.a120242; KAY BH, 1982, AUST J EXP BIOL MED, V60, P339, DOI 10.1038/icb.1982.37; LINDSEY HS, 1976, J CLIN MICROBIOL, V4, P503; OVENDEN JR, 1984, J MED ENTOMOL, V21, P292, DOI 10.1093/jmedent/21.3.292; Reeves WC., 1990, EPIDEMIOLOGY CONTROL; Reisen W.K.M.T., 1988, ARBOVIRUSES EPIDEMIO, P89; ROSEN L, 1987, AM J TROP MED HYG, V37, pS69, DOI 10.4269/ajtmh.1987.37.69S; STONES PB, CITED INDIRECTLY; TIKASINGH E. S., 1966, AMER J TROP MED HYG, V15, P219	13	39	42	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	FEB 4	1994	263	5147					676	678		10.1126/science.8303276	http://dx.doi.org/10.1126/science.8303276			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MU964	8303276				2022-12-01	WOS:A1994MU96400047
J	STUDITSKY, VM; CLARK, DJ; FELSENFELD, G				STUDITSKY, VM; CLARK, DJ; FELSENFELD, G			A HISTONE OCTAMER CAN STEP AROUND A TRANSCRIBING POLYMERASE WITHOUT LEAVING THE TEMPLATE	CELL			English	Article							RNA-POLYMERASE; NUCLEOSOME CORE; CHROMATIN STRUCTURE; ELONGATION COMPLEXES; DNA-TEMPLATE; TRANSCRIPTION; GENE; DISPLACEMENT; RESOLUTION; EXPRESSION	The mechanism by which nucleosome cores are displaced and re-formed during transcription in vitro has been investigated. A nucleosome core was assembled on a short linear DNA template (227 bp) containing an SP6 RNA polymerase promoter and a nucleosome-positioning sequence. Transcription induced the translocation of the nucleosome core over 75 or 80 bp to two positions at the other end of the template, blocking the promoter. At low rNTP concentrations, transfer occurred only on the same template molecule, even in the presence of large excesses of competitor DNA. On a longer template (262 bp), nucleosome core position after transcription depended on its position before transcription. The data suggest that the octamer transfers without dissociation from DNA and provide strong evidence for a translocation mechanism in which DNA ahead of the polymerase uncoils from the octamer as the DNA behind coils around it. In this way, the octamer steps around the transcribing polymerase.			STUDITSKY, VM (corresponding author), NIAID,MOLEC BIOL LAB,BETHESDA,MD 20892, USA.		Studitsky, Vasily/A-9382-2014					ADAMS CC, 1993, CELL, V72, P305, DOI 10.1016/0092-8674(93)90109-4; AUSIO J, 1989, J MOL BIOL, V206, P451, DOI 10.1016/0022-2836(89)90493-2; BJORKROTH B, 1988, CHROMOSOMA, V96, P333, DOI 10.1007/BF00330699; BRESNICK EH, 1992, NUCLEIC ACIDS RES, V20, P273, DOI 10.1093/nar/20.2.273; BROWN JE, 1986, NUCLEIC ACIDS RES, V14, P3521, DOI 10.1093/nar/14.8.3521; CLARK DJ, 1992, CELL, V71, P11, DOI 10.1016/0092-8674(92)90262-B; CLARK DJ, 1991, EMBO J, V10, P387, DOI 10.1002/j.1460-2075.1991.tb07960.x; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DEBERNARDIN W, 1986, J MOL BIOL, V191, P469, DOI 10.1016/0022-2836(86)90142-7; EICKBUSH TH, 1978, BIOCHEMISTRY-US, V17, P4955, DOI 10.1021/bi00616a016; FELSENFELD G, 1992, NATURE, V355, P219, DOI 10.1038/355219a0; HEUMANN H, 1988, EMBO J, V7, P4379, DOI 10.1002/j.1460-2075.1988.tb03336.x; KAMAKAKA RT, 1990, CELL, V11, P1941; KORNBERG RD, 1991, CELL, V67, P833, DOI 10.1016/0092-8674(91)90354-2; KORNBERG RD, 1992, ANNU REV CELL BIOL, V8, P563, DOI 10.1146/annurev.cellbio.8.1.563; KOTANI H, 1987, NUCLEIC ACIDS RES, V15, P2653, DOI 10.1093/nar/15.6.2653; LEE MS, 1991, EMBO J, V10, P607, DOI 10.1002/j.1460-2075.1991.tb07988.x; LINN SC, 1991, MOL CELL BIOL, V11, P1508, DOI 10.1128/MCB.11.3.1508; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; LOHR D, 1983, NUCLEIC ACIDS RES, V11, P6755, DOI 10.1093/nar/11.19.6755; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; LORCH Y, 1988, CELL, V55, P743, DOI 10.1016/0092-8674(88)90128-6; LOSA R, 1987, CELL, V50, P801, DOI 10.1016/0092-8674(87)90338-2; McKnight S L, 1978, Cold Spring Harb Symp Quant Biol, V42 Pt 2, P741; MEERSSEMAN G, 1992, EMBO J, V11, P2951, DOI 10.1002/j.1460-2075.1992.tb05365.x; MINEHART PL, 1991, MOL CELL BIOL, V11, P6216, DOI 10.1128/MCB.11.12.6216; MORSE RH, 1989, EMBO J, V8, P2343, DOI 10.1002/j.1460-2075.1989.tb08362.x; MORSE RH, 1992, TRENDS BIOCHEM SCI, V17, P23, DOI 10.1016/0968-0004(92)90422-6; NACHEVA GA, 1989, CELL, V58, P27, DOI 10.1016/0092-8674(89)90399-1; NAM SC, 1988, J BIOL CHEM, V263, P18123; ONEILL TE, 1993, P NATL ACAD SCI USA, V90, P6203, DOI 10.1073/pnas.90.13.6203; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; SASTRY SS, 1991, J MOL BIOL, V221, P1091, DOI 10.1016/0022-2836(91)80114-A; STEIN AD, 1977, P NATL ACAD SCI USA, V74, P2480; THOMA F, 1979, J CELL BIOL, V83, P403, DOI 10.1083/jcb.83.2.403; THOMA F, 1991, TRENDS GENET, V7, P175, DOI 10.1016/0168-9525(91)90429-T; THOMAS JO, 1975, P NATL ACAD SCI USA, V72, P2626, DOI 10.1073/pnas.72.7.2626; VANHOLDE KE, 1992, J BIOL CHEM, V267, P2837; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; WOLFFE AP, 1988, EMBO J, V7, P1071, DOI 10.1002/j.1460-2075.1988.tb02915.x; WU C, 1979, CELL, V16, P807, DOI 10.1016/0092-8674(79)90096-5; YOUNG RA, 1991, ANNU REV BIOCHEM, V60, P689, DOI 10.1146/annurev.bi.60.070191.003353	42	201	204	1	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 28	1994	76	2					371	382		10.1016/0092-8674(94)90343-3	http://dx.doi.org/10.1016/0092-8674(94)90343-3			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MU678	8293470				2022-12-01	WOS:A1994MU67800019
J	SCHULZ, VP; ZAKIAN, VA				SCHULZ, VP; ZAKIAN, VA			THE SACCHAROMYCES PIF1 DNA HELICASE INHIBITS TELOMERE ELONGATION AND DE-NOVO TELOMERE FORMATION	CELL			English	Article							MITOCHONDRIAL-DNA; BINDING-PROTEIN; NUCLEOTIDE-SEQUENCE; CHROMATIN STRUCTURE; YEAST TELOMERES; CHROMOSOME LOSS; CEREVISIAE; RAP1; RECOMBINATION; MUTANTS	A screen to detect yeast mutants that frequently lost expression of subtelomeric genes identified two mutations in PIF1, a gene known to encode a 5' to 3' DNA helicase. The loss of expression of subtelomeric genes in pif1 cells was due to deletion of the subtelomeric regions of the chromosomes and the generation of new telomeres at proximal sites. In pif1 mutants, de novo telomere formation usually occurred at sites with very little homology to telomeric DNA. De novo telomere formation after HO-induced chromosome breakage also occurred at elevated frequencies in pif1 cells. Moreover, mutations in PIF1 caused all telomeres to lengthen. These results suggest that the PIF1 helicase is an inhibitor of both de novo telomere formation and telomere elongation.	UNIV WASHINGTON, DEPT GENET, SEATTLE, WA 98195 USA; UNIV WASHINGTON, DEPT PATHOL, SEATTLE, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	SCHULZ, VP (corresponding author), FRED HUTCHINSON CANC RES CTR, 1124 COLUMBIA ST, SEATTLE, WA 98104 USA.			Schulz, Vincent/0000-0001-6333-4284	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM026938, R01GM043265, R01GM026938] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM43265, GM26938] Funding Source: Medline; PHS HHS [G0057] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BLACKBURN EH, 1992, ANNU REV BIOCHEM, V61, P113, DOI 10.1146/annurev.bi.61.070192.000553; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; BUCHMAN AR, 1988, MOL CELL BIOL, V8, P5086, DOI 10.1128/MCB.8.12.5086; CARSON MJ, 1985, CELL, V42, P249, DOI 10.1016/S0092-8674(85)80120-3; CHAN CSM, 1983, CELL, V33, P563, DOI 10.1016/0092-8674(83)90437-3; CHANG ACY, 1978, J BACTERIOL, V134, P1141, DOI 10.1128/JB.134.3.1141-1156.1978; CONRAD MN, 1990, CELL, V63, P739, DOI 10.1016/0092-8674(90)90140-A; DELANGE T, 1992, EMBO J, V11, P717, DOI 10.1002/j.1460-2075.1992.tb05104.x; DUTCHER SK, 1981, MOL CELL BIOL, V1, P245, DOI 10.1128/MCB.1.3.245; FOURY F, 1987, EMBO J, V6, P1441, DOI 10.1002/j.1460-2075.1987.tb02385.x; FOURY F, 1983, P NATL ACAD SCI-BIOL, V80, P5345, DOI 10.1073/pnas.80.17.5345; FOURY F, 1985, EMBO J, V4, P3525, DOI 10.1002/j.1460-2075.1985.tb04112.x; FRIEDBERG EC, 1992, CELL, V71, P887, DOI 10.1016/0092-8674(92)90384-O; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; GREIDER CW, 1991, MOL CELL BIOL, V11, P4572, DOI 10.1128/MCB.11.9.4572; HARDY CFJ, 1992, GENE DEV, V6, P801, DOI 10.1101/gad.6.5.801; HARTWELL LH, 1985, GENETICS, V110, P381; HENIKOFF S, 1990, METHOD ENZYMOL, V183, P111; HENIKOFF S, 1987, GENETICS, V117, P711; HERSKOWITZ I, 1991, METHOD ENZYMOL, V194, P132; HILL J, 1991, NUCLEIC ACIDS RES, V19, P5791, DOI 10.1093/nar/19.20.5791; KLEIN F, 1992, J CELL BIOL, V117, P935, DOI 10.1083/jcb.117.5.935; KOSHLAND D, 1985, CELL, V40, P393, DOI 10.1016/0092-8674(85)90153-9; KYRION G, 1992, MOL CELL BIOL, V12, P5159, DOI 10.1128/MCB.12.11.5159; LAHAYE A, 1991, EMBO J, V10, P997, DOI 10.1002/j.1460-2075.1991.tb08034.x; LAWRENCE CW, 1991, METHOD ENZYMOL, V194, P273; LEA DE, 1949, J GENET, V49, P264, DOI 10.1007/BF02986080; LONGTINE MS, 1989, CURR GENET, V16, P225, DOI 10.1007/BF00422108; LUNDBLAD V, 1989, CELL, V57, P633, DOI 10.1016/0092-8674(89)90132-3; LUSTIG AJ, 1990, SCIENCE, V250, P549, DOI 10.1126/science.2237406; LUSTIG AJ, 1986, P NATL ACAD SCI USA, V83, P1398, DOI 10.1073/pnas.83.5.1398; MORTIMER RK, 1981, P NATL ACAD SCI-BIOL, V78, P5778, DOI 10.1073/pnas.78.9.5778; PANASENKO SM, 1977, SCIENCE, V196, P187, DOI 10.1126/science.322281; PLUTA AF, 1989, NATURE, V337, P429, DOI 10.1038/337429a0; PLUTA AF, 1984, P NATL ACAD SCI-BIOL, V81, P1475, DOI 10.1073/pnas.81.5.1475; ROSE AM, 1992, MOL CELL BIOL, V12, P5652, DOI 10.1128/MCB.12.12.5652; ROSE MD, 1987, GENE, V60, P237, DOI 10.1016/0378-1119(87)90232-0; RUDIN N, 1988, MOL CELL BIOL, V8, P3918, DOI 10.1128/MCB.8.9.3918; RUNGE KW, 1991, MOL CELL BIOL, V11, P2919, DOI 10.1128/MCB.11.6.2919; RUNGE KW, 1989, MOL CELL BIOL, V9, P1488, DOI 10.1128/MCB.9.4.1488; Sambrook J., 1989, MOL CLONING LAB MANU; SANDELL LL, 1993, CELL, V75, P729, DOI 10.1016/0092-8674(93)90493-A; SANGER F, 1982, J MOL BIOL, V162, P729, DOI 10.1016/0022-2836(82)90546-0; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SIKORSKI RS, 1989, GENETICS, V122, P19; STRATHERN JN, 1991, GENETICS, V127, P61; SUSSEL L, 1991, P NATL ACAD SCI USA, V88, P7749, DOI 10.1073/pnas.88.17.7749; VANDYCK E, 1992, EMBO J, V11, P3421, DOI 10.1002/j.1460-2075.1992.tb05421.x; WALTON JD, 1986, CELL, V46, P857, DOI 10.1016/0092-8674(86)90067-X; WATSON JD, 1972, NATURE-NEW BIOL, V239, P197, DOI 10.1038/newbio239197a0; WELLINGER RJ, 1989, P NATL ACAD SCI USA, V86, P973, DOI 10.1073/pnas.86.3.973; WELLINGER RJ, 1993, CELL, V72, P51, DOI 10.1016/0092-8674(93)90049-V; WHITE CI, 1990, EMBO J, V9, P663, DOI 10.1002/j.1460-2075.1990.tb08158.x; WRIGHT JH, 1992, GENE DEV, V6, P197, DOI 10.1101/gad.6.2.197; YU GL, 1991, CELL, V67, P823, DOI 10.1016/0092-8674(91)90077-C; ZAKIAN VA, 1982, MOL CELL BIOL, V2, P221, DOI 10.1128/MCB.2.3.221; ZAKIAN VA, 1989, ANNU REV GENET, V23, P579, DOI 10.1146/annurev.genet.23.1.579	57	292	296	0	16	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JAN 14	1994	76	1					145	155		10.1016/0092-8674(94)90179-1	http://dx.doi.org/10.1016/0092-8674(94)90179-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287473				2022-12-01	WOS:A1994MR49500013
J	MONTMAYEUR, JP; BORRELLI, E				MONTMAYEUR, JP; BORRELLI, E			TARGETING OF G-ALPHA(I2) TO THE GOLGI BY ALTERNATIVE SPLICED CARBOXYL-TERMINAL REGION	SCIENCE			English	Article							GTP-BINDING PROTEINS; SENSITIVE G-PROTEIN; SIGNAL TRANSDUCTION; BREFELDIN-A; BETA-COP; MEMBRANES; CELLS; TRANSPORT; APPARATUS; GENE	Heterotrimeric guanosine triphosphate (GTP)-binding proteins (G proteins) may participate pate in membrane traffic events. A complementary DNA (cDNA) was isolated from a mouse pituitary cDNA library that corresponded to an alternatively spliced form of the gene encoding the G protein alpha subunit Galpha(i2). The cDNA was identical to that encoding Galpha(i2) except that the region encoding for the carboxyl-terminal 24 amino acids was replaced by a longer region encoding 35 amino acids that have no sequence similarity with Galpha(i2) or other members of the G protein family. This alternative spliced product and the corresponding protein (sG(i2)) were present in several tissues. Specific antibodies revealed that sG(i2) was localized in the Golgi apparatus, suggesting a role in membrane transport. Thus, alternative splicing may generate from a single gene two G protein alpha subunits with differential cellular localization and function.	FAC MED STRASBOURG,GENET MOLEC EUCARYOTES LAB,CNRS,INSERM,U184,11 RUE HUMANN,F-67000 STRASBOURG,FRANCE	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg			Montmayeur, Jean-Pierre R/A-5723-2009; Borrelli, Emiliana/M-8994-2018	Montmayeur, Jean-Pierre/0000-0002-0942-1114				ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; BARBER JR, 1987, MOL CELL BIOL, V7, P2201, DOI 10.1128/MCB.7.6.2201; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BURGOYNE RD, 1992, TRENDS BIOCHEM SCI, V17, P87; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; COLOMBO MI, 1992, SCIENCE, V255, P1695, DOI 10.1126/science.1348148; CONKLIN BR, 1993, NATURE, V363, P274, DOI 10.1038/363274a0; DONALDSON JG, 1991, J CELL BIOL, V112, P579, DOI 10.1083/jcb.112.4.579; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DRATZ EA, 1993, NATURE, V363, P276, DOI 10.1038/363276a0; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; ERCOLANI L, 1990, P NATL ACAD SCI USA, V87, P4635, DOI 10.1073/pnas.87.12.4635; FOULKES NS, 1991, CELL, V64, P739, DOI 10.1016/0092-8674(91)90503-Q; HEPLER JR, 1992, TRENDS BIOCHEM SCI, V17, P383, DOI 10.1016/0968-0004(92)90005-T; HESS SD, 1993, SCIENCE, V259, P1169, DOI 10.1126/science.8438167; JONES DT, 1987, J BIOL CHEM, V262, P14241; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; KTISTAKIS NT, 1992, NATURE, V356, P344, DOI 10.1038/356344a0; MCKENZIE FR, 1988, BIOCHEM J, V249, P653, DOI 10.1042/bj2490653; MONTMAYEUR JP, 1991, P NATL ACAD SCI USA, V88, P3135, DOI 10.1073/pnas.88.8.3135; MONTMAYEUR JP, 1991, FEBS LETT, V278, P239, DOI 10.1016/0014-5793(91)80125-M; MONTMAYEUR JP, 1993, MOL ENDOCRINOL, V7, P161, DOI 10.1210/me.7.2.161; MONTMAYEUR JP, UNPUB; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; Pfeffer S R, 1992, Trends Cell Biol, V2, P41, DOI 10.1016/0962-8924(92)90161-F; PIMPLIKAR SW, 1993, NATURE, V362, P4536; ROSENWALD AG, 1992, BIOCHEMISTRY-US, V31, P3581, DOI 10.1021/bi00129a005; SCHWANINGER R, 1992, J CELL BIOL, V119, P1077, DOI 10.1083/jcb.119.5.1077; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; SULLIVAN KA, 1987, NATURE, V330, P758, DOI 10.1038/330758a0; SULLIVAN KA, 1986, P NATL ACAD SCI USA, V83, P6687, DOI 10.1073/pnas.83.18.6687; WEINSTEIN LS, 1988, FEBS LETT, V232, P333, DOI 10.1016/0014-5793(88)80764-6; WILSON BS, 1993, P NATL ACAD SCI USA, V90, P1681, DOI 10.1073/pnas.90.5.1681	35	60	60	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 7	1994	263	5143					95	98		10.1126/science.8272874	http://dx.doi.org/10.1126/science.8272874			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ301	8272874				2022-12-01	WOS:A1994MQ30100039
J	WIMMER, EA; JACKLE, H; PFEIFLE, C; COHEN, SM				WIMMER, EA; JACKLE, H; PFEIFLE, C; COHEN, SM			A DROSOPHILA HOMOLOG OF HUMAN SP1 IS A HEAD-SPECIFIC SEGMENTATION GENE	NATURE			English	Article							BOX-BINDING-PROTEINS; TRANSCRIPTIONAL ACTIVATION; EMPTY SPIRACLES; HOMEOBOX GENES; EXPRESSION; PROMOTER; DOMAINS; REPRESSION; SEQUENCE; PATTERN	SEGMENTATION in Drosophila is based on a cascade of hierarchical gene interactions initiated by maternally deposited morphogens that define the spatially restricted domains of gap gene expression at blastoderm (reviewed in ref. 1). Although segmentation of the embryonic head is morphologically obscured, the repeated patterns of expression of the segment polarity genes reflect the formation of seven head segments2,3; two of these depend on the segmentation and homeotic genes used in the trunk, whereas the others form as a result of the activity of the head-specific genes orthodenticle (otd), empty spiracles (ems) and buttonhead (btd). The genes ems and otd encode homeodomain proteins. suggesting that they may function as transcription factors4-6. They are expressed in overlapping stripes in the early embryonic head of Drosophila, and their vertebrate homologues, otx and emx, are expressed in overlapping domains in the anterior central nervous system of the mouse embryo7,8. We show here that btd is expressed in a stripe covering the head anlagen of the segments affected in btd lack-of-function mutants and that btd encodes a zinc-finger-type transcription factor with sequence and functional similarity to the prototype mammalian transcription factor Sp1 (ref. 9). When expressed in the spatial pattern of btd, a transgene providing Sp1 activity can support development of the mandibular segment in the head of btd mutant embryos. A ubiquitous transcription factor from humans can therefore replace an essential component of the genetic circuitry required to specify the development of a particular head segment in the fly.	MAX PLANCK INST BIOPHYS CHEM,MOLEK ENTWICKLUNGSBIOL ABT,D-37018 GOTTINGEN,GERMANY	Max Planck Society	WIMMER, EA (corresponding author), BAYLOR COLL MED,HOWARD HUGHES MED INST,DEPT CELL BIOL,HOUSTON,TX 77030, USA.		Wimmer, Ernst A./I-3333-2019; Cohen, Stephen M/G-9930-2011	Wimmer, Ernst A./0000-0002-2480-2804; Cohen, Stephen M/0000-0003-2858-9163				CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; COHEN S, 1991, TRENDS GENET, V7, P267; COHEN SM, 1990, NATURE, V346, P482, DOI 10.1038/346482a0; COUREY AJ, 1989, CELL, V59, P827, DOI 10.1016/0092-8674(89)90606-5; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; DALTON D, 1989, GENE DEV, V3, P1940, DOI 10.1101/gad.3.12a.1940; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNLACHT BD, 1991, CELL, V66, P563, DOI 10.1016/0092-8674(81)90019-2; FINKELSTEIN R, 1990, NATURE, V346, P485, DOI 10.1038/346485a0; GARZA D, 1989, SCIENCE, V246, P641, DOI 10.1126/science.2510296; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HEBERLEIN U, 1988, NATURE, V331, P410, DOI 10.1038/331410a0; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOHEISEL JD, 1991, J MOL BIOL, V220, P903, DOI 10.1016/0022-2836(91)90362-A; IMATAKA H, 1992, EMBO J, V11, P3663, DOI 10.1002/j.1460-2075.1992.tb05451.x; JONES FS, 1992, P NATL ACAD SCI USA, V89, P2091, DOI 10.1073/pnas.89.6.2091; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; KRASNOW MA, 1989, CELL, V57, P1031, DOI 10.1016/0092-8674(89)90341-3; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SAUER F, 1991, NATURE, V353, P563, DOI 10.1038/353563a0; SCHMIDTOTT U, 1992, DEVELOPMENT, V116, P111; SIMEONE A, 1992, EMBO J, V11, P2541, DOI 10.1002/j.1460-2075.1992.tb05319.x; SIMEONE A, 1992, NATURE, V358, P687, DOI 10.1038/358687a0; STJOHNSTON D, 1992, CELL, V68, P201; TAUTZ D, 1989, CHROMOSOMA, V98, P81, DOI 10.1007/BF00291041; Thummel CS, 1992, DROS INF SERV, V71, P150; WALLDORF U, 1992, EMBO J, V11, P2247, DOI 10.1002/j.1460-2075.1992.tb05284.x	29	141	145	1	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	DEC 16	1993	366	6456					690	694		10.1038/366690a0	http://dx.doi.org/10.1038/366690a0			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MM265	8259212				2022-12-01	WOS:A1993MM26500071
J	BARKER, DJP; MARTYN, CN; OSMOND, C; HALES, CN; FALL, CHD				BARKER, DJP; MARTYN, CN; OSMOND, C; HALES, CN; FALL, CHD			GROWTH IN-UTERO AND SERUM-CHOLESTEROL CONCENTRATIONS IN ADULT LIFE	BRITISH MEDICAL JOURNAL			English	Article							INFANT GROWTH; FETAL; LIPOPROTEINS; METABOLISM; CHILDREN; PLASMA; DIET; AGE	Objective-To see whether reduced rates of fetal growth are related to raised serum cholesterol concentrations in adult life. Design-Follow up study of men and women whose size at birth had been recorded. Setting-Jessop and Northern General Hospitals, Sheffield. Subjects-219 men and women born in the Jessop Hospital during 1939-40. Main outcome measures-Serum concentrations of total cholesterol, low density lipoprotein cholesterol, and apolipoprotein B. Results-Men and women who had had a small abdominal circumference at birth had raised serum concentrations of total and low density lipoprotein cholesterol and apolipoprotein B. This was independent of the duration of gestation. Serum concentrations of total cholesterol fell by 0.25 mmol/l (95% confidence interval 0.09 to 0.42) with each 1 in (2-54 cm) increase in abdominal circumference. The corresponding figure for serum low density lipoprotein cholesterol was 0.26 mmol/l (0.11 to 0.42) and for serum apolipoprotein B 0.04 g/l (0.02 to 0.07). Small head and chest circumferences at birth and short length were each associated with raised serum low density lipoprotein cholesterol concentrations but the trends disappeared in a simultaneous regression with abdominal circumference at birth. The association between abdominal circumference at birth and low density lipoprotein cholesterol concentration was independent of social class, current body weight, cigarette smoking, and alcohol consumption. Conclusion-Raised serum cholesterol concentrations in adult life are associated with impaired growth during late gestation, when fetal undernutrition has a disproportionate effect on liver growth. Impaired liver growth may permanently alter low density lipoprotein cholesterol metabolism.	UNIV CAMBRIDGE,ADDENBROOKES HOSP,DEPT CLIN BIOCHEM,CAMBRIDGE CB2 2QR,ENGLAND	Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge	BARKER, DJP (corresponding author), UNIV SOUTHAMPTON,SOUTHAMPTON GEN HOSP,MRC,ENVIRONM EPIDEMIOL UNIT,SOUTHAMPTON S09 4XY,ENGLAND.			Osmond, Clive/0000-0002-9054-4655	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALLAIN CC, 1974, CLIN CHEM, V20, P470; ANDERSEN GE, 1979, ACTA PAEDIATR SCAND, V68, P165, DOI 10.1111/j.1651-2227.1979.tb04983.x; BARKER DJP, 1992, BMJ-BRIT MED J, V304, P148, DOI 10.1136/bmj.304.6820.148; BARKER DJP, 1993, BRIT MED J, V306, P422, DOI 10.1136/bmj.306.6875.422; BARKER DJP, 1993, LANCET, V341, P938, DOI 10.1016/0140-6736(93)91224-A; BARKER DJP, 1990, BRIT MED J, V301, P259, DOI 10.1136/bmj.301.6746.259; BHATNAGAR D, 1991, ANN CLIN BIOCHEM, V28, P427, DOI 10.1177/000456329102800501; CAMPBELL S, 1977, BRIT J OBSTET GYNAEC, V84, P165, DOI 10.1111/j.1471-0528.1977.tb12550.x; CARR BR, 1982, J CLIN ENDOCR METAB, V55, P447, DOI 10.1210/jcem-55-3-447; DICKE JM, 1987, CLIN OBSTETRICS, P421; FALL CHD, 1992, BRIT MED J, V304, P801, DOI 10.1136/bmj.304.6830.801; FOSSATI P, 1982, CLIN CHEM, V28, P2077; FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499; Gruenwald P, 1974, CIBA F S, V27, P3; HAHN P, 1973, J NUTR, V103, P690, DOI 10.1093/jn/103.5.690; HAHN P, 1989, ATHEROSCLEROSIS PEDI, P155; HALES CN, 1991, BMJ-BRIT MED J, V303, P1019, DOI 10.1136/bmj.303.6809.1019; HASSAN AS, 1982, AM J CLIN NUTR, V35, P546, DOI 10.1093/ajcn/35.3.546; INNIS SM, 1983, J NUTR, V113, P2464, DOI 10.1093/jn/113.12.2464; Keys A., 1980, SCIENCE, DOI DOI 10.1126/SCIENCE.208.4448.1138; LABARTHE DR, 1991, ANNU REV PUBL HEALTH, V12, P519, DOI 10.1146/annurev.pu.12.050191.002511; LEWIS B, 1983, BMJ-BRIT MED J, V287, P1161, DOI 10.1136/bmj.287.6400.1161; LIE AF, 1976, CLIN CHEM, V22, P11627; LOPESVIRELLA MF, 1977, CLIN CHEM, V23, P882; MCCANCE RA, 1974, PROC R SOC SER B-BIO, V185, P1, DOI 10.1098/rspb.1974.0001; MCNAMARA DJ, 1972, J BIOL CHEM, V247, P5805; MOTT GE, 1990, J NUTR, V120, P243, DOI 10.1093/jn/120.3.243; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; SPORIK R, 1991, ARCH DIS CHILD, V66, P134, DOI 10.1136/adc.66.1.134; WALD NJ, 1992, CORONARY HEART DIS E, P358; 1986, LANCET, V2, P991	31	461	475	0	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1993	307	6918					1524	1527		10.1136/bmj.307.6918.1524	http://dx.doi.org/10.1136/bmj.307.6918.1524			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML869	8274921	Bronze, Green Published			2022-12-01	WOS:A1993ML86900020
J	HALL, CG; SANCHO, J; TERHORST, C				HALL, CG; SANCHO, J; TERHORST, C			RECONSTITUTION OF T-CELL RECEPTOR ZETA-MEDIATED CALCIUM MOBILIZATION IN NONLYMPHOID CELLS	SCIENCE			English	Article							PROTEIN-TYROSINE KINASE; ANTIGEN RECEPTOR; SIGNAL TRANSDUCTION; PHOSPHOLIPASE C-GAMMA-1; MOLECULAR-CLONING; PHOSPHATASE CD45; ACTIVATION; PHOSPHORYLATION; CHAIN; STIMULATION	T cell antigen receptor (TCR) activation involves interactions between receptor subunits and nonreceptor protein tyrosine kinases (PTKs). Early steps in signaling through the zeta chain of the TCR were examined in transfected COS-1 cells. Coexpression of the PTK p59fynT, but not p56lck, with zeta or with a homodimeric TCRbeta-zeta fusion protein produced tyrosine phosphorylation of both zeta and phospholipase C (PLC)-gamma1, as well as calcium ion mobilization in response to receptor cross-linking. CD45 coexpression enhanced these effects. No requirement for the PTKZAP-70 was observed. Thus, p59fynT may link zeta directly to the PLC-gamma1 activation pathway.			HALL, CG (corresponding author), HARVARD UNIV,BETH ISRAEL HOSP,SCH MED,DIV IMMUNOL,BOSTON,MA 02215, USA.		Sancho, Jaime/O-3228-2013; Sancho, Jaime/K-5989-2019	Sancho, Jaime/0000-0003-3852-7951; Sancho, Jaime/0000-0003-3852-7951	NCI NIH HHS [CA 01486] Funding Source: Medline; NIAID NIH HHS [AI 15066] Funding Source: Medline; NATIONAL CANCER INSTITUTE [K08CA001486] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI015066, R56AI015066] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ABRAHAM KM, 1991, P NATL ACAD SCI USA, V88, P3977, DOI 10.1073/pnas.88.9.3977; APPLEBY MW, 1992, CELL, V70, P751, DOI 10.1016/0092-8674(92)90309-Z; ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BARBER EK, 1989, P NATL ACAD SCI USA, V86, P3277, DOI 10.1073/pnas.86.9.3277; BERRIDGE MJ, 1993, NATURE, V361, P315, DOI 10.1038/361315a0; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COOKE MP, 1991, CELL, V65, P281, DOI 10.1016/0092-8674(91)90162-R; ENGEL I, 1992, SCIENCE, V256, P1318, DOI 10.1126/science.1598575; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; HALL CA, UNPUB; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; JUNE CH, 1990, J IMMUNOL, V144, P1591; JUNE CH, 1990, P NATL ACAD SCI USA, V87, P7722, DOI 10.1073/pnas.87.19.7722; KORETZKY GA, 1990, NATURE, V346, P66, DOI 10.1038/346066a0; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; KOYASU S, 1992, J BIOL CHEM, V267, P3375; Ledbetter J A, 1990, Semin Immunol, V2, P99; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MASLINSKI W, UNPUB; MUSTELIN T, 1990, SCIENCE, V247, P1584, DOI 10.1126/science.2138816; PERLMUTTER RM, 1988, J CELL BIOCHEM, V38, P117, DOI 10.1002/jcb.240380206; PINGEL JT, 1989, CELL, V58, P1055, DOI 10.1016/0092-8674(89)90504-7; QIAN DP, 1993, J BIOL CHEM, V268, P4488; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SAMELSON LE, 1986, CELL, V46, P1083, DOI 10.1016/0092-8674(86)90708-7; SANCHO J, 1993, EUR J IMMUNOL, V23, P1636, DOI 10.1002/eji.1830230736; SANCHO J, 1992, J BIOL CHEM, V267, P7871; SEFTON BM, 1991, ANNU REV CELL BIOL, V7, P257, DOI 10.1146/annurev.cellbio.7.1.257; SEMBA K, 1986, P NATL ACAD SCI USA, V83, P5459, DOI 10.1073/pnas.83.15.5459; STEIN PL, 1992, CELL, V70, P741, DOI 10.1016/0092-8674(92)90308-Y; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WEBER JR, 1992, J EXP MED, V176, P373, DOI 10.1084/jem.176.2.373; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1991, P NATL ACAD SCI USA, V88, P5484, DOI 10.1073/pnas.88.13.5484; WEISSMAN AM, 1988, SCIENCE, V239, P1018, DOI 10.1126/science.3278377; WILEMAN T, 1990, CELL REGUL, V1, P907, DOI 10.1091/mbc.1.12.907; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0	45	80	83	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 13	1993	261	5123					915	918		10.1126/science.8346442	http://dx.doi.org/10.1126/science.8346442			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LR897	8346442				2022-12-01	WOS:A1993LR89700039
J	JARAMILLO, F; MARKIN, VS; HUDSPETH, AJ				JARAMILLO, F; MARKIN, VS; HUDSPETH, AJ			AUDITORY ILLUSIONS AND THE SINGLE HAIR CELL	NATURE			English	Article							DISTORTION PRODUCTS F2-F1; BASILAR-MEMBRANE; MECHANOELECTRICAL TRANSDUCTION; BULLFROGS SACCULUS; COMBINATION TONES; CHANNELS; ADAPTATION; RESPONSES; COCHLEA; BUNDLES	LIKE our other senses, the auditory system can produce illusions. Prominent among these are distortion products1-5: when listening to two tones, one of frequency f1 and the second of a higher frequency f2, an individual may hear not only these primary tones, but also a difference tone of frequency f2-f1, a sum tone of frequency f2+f1, and combination tones of frequencies such as 2f1-f2 and 2f2-f1. Discovered by Tartini early in the eighteenth century6,7, these illusory sounds are sufficiently conspicuous that they were employed to carry melodies in classical compositions. Distortion products originate within the cochlea, where they manifest themselves in the basilar membrane's vibration8. Here we demonstrate distortion products in individual hair cells of the bullfrog's sacculus, where they emerge from a nonlinearity inherent in the mechanoelectrical transduction process. In addition to offering an explanation for cochlear distortion products, our results suggest that the mechanical properties of hair bundles significantly influence the basilar membrane's motion.			JARAMILLO, F (corresponding author), UNIV TEXAS,SW MED CTR,CTR BASIC NEUROSCI RES,DALLAS,TX 75235, USA.							ASHMORE JF, 1987, J PHYSIOL-LONDON, V388, P323, DOI 10.1113/jphysiol.1987.sp016617; ASSAD JA, 1991, NEURON, V7, P985, DOI 10.1016/0896-6273(91)90343-X; BENSER ME, IN PRESS HEARING RES; BROWNELL WE, 1985, SCIENCE, V227, P194, DOI 10.1126/science.3966153; COREY DP, 1983, J NEUROSCI, V3, P962; COREY DP, 1979, BIOPHYS J, V26, P499, DOI 10.1016/S0006-3495(79)85267-4; COREY DP, 1983, J NEUROSCI, V3, P942; CRAWFORD AC, 1985, J PHYSIOL-LONDON, V364, P359, DOI 10.1113/jphysiol.1985.sp015750; CRAWFORD AC, 1989, J PHYSIOL-LONDON, V419, P405, DOI 10.1113/jphysiol.1989.sp017878; DENK W, 1992, HEARING RES, V60, P89, DOI 10.1016/0378-5955(92)90062-R; GILLESPIE PG, 1993, P NATL ACAD SCI USA, V90, P2710, DOI 10.1073/pnas.90.7.2710; GOLDSTEIN JL, 1967, J ACOUST SOC AM, V41, P676, DOI 10.1121/1.1910396; GUMMER AW, 1981, J ACOUST SOC AM, V70, P1298, DOI 10.1121/1.387144; HALL JL, 1972, J ACOUST SOC AM, V51, P1863, DOI 10.1121/1.1913045; HOLTON T, 1986, J PHYSIOL-LONDON, V375, P195, DOI 10.1113/jphysiol.1986.sp016113; HOWARD J, 1987, P NATL ACAD SCI USA, V84, P3064, DOI 10.1073/pnas.84.9.3064; HOWARD J, 1988, ANNU REV BIOPHYS BIO, V17, P99; HOWARD J, 1988, NEURON, V1, P189, DOI 10.1016/0896-6273(88)90139-0; HUDSPETH AJ, 1989, NATURE, V341, P397, DOI 10.1038/341397a0; HUMES LE, 1980, J ACOUST SOC AM, V67, P2073, DOI 10.1121/1.384451; JARAMILLO F, 1993, P NATL ACAD SCI USA, V90, P1330, DOI 10.1073/pnas.90.4.1330; JARAMILLO F, 1991, NEURON, V7, P409, DOI 10.1016/0896-6273(91)90293-9; KROESE ABA, 1989, HEARING RES, V37, P203, DOI 10.1016/0378-5955(89)90023-3; MILLER CE, 1985, J ACOUST SOC AM, V77, P1465, DOI 10.1121/1.392041; OHMORI H, 1987, J PHYSIOL-LONDON, V387, P589, DOI 10.1113/jphysiol.1987.sp016590; OLSON ES, 1991, J ACOUST SOC AM, V89, P1262, DOI 10.1121/1.400535; PICKLES JO, 1984, HEARING RES, V15, P103, DOI 10.1016/0378-5955(84)90041-8; RHODE WS, 1967, J ACOUST SOC AM, V42, P185, DOI 10.1121/1.1910547; ROBERTS WM, 1988, ANNU REV CELL BIOL, V4, P63, DOI 10.1146/annurev.cellbio.4.1.63; ROBLES L, 1991, NATURE, V349, P413, DOI 10.1038/349413a0; Ruggero M A, 1992, Curr Opin Neurobiol, V2, P449, DOI 10.1016/0959-4388(92)90179-O; RUSSELL IJ, 1992, P ROY SOC B-BIOL SCI, V250, P217, DOI 10.1098/rspb.1992.0152; SIEGEL JH, 1982, J NEUROPHYSIOL, V47, P303, DOI 10.1152/jn.1982.47.2.303; SMOORENBURG GF, 1972, J ACOUST SOC AM, V52, P615, DOI 10.1121/1.1913152; SMOORENBURG GF, 1972, J ACOUST SOC AM, V52, P603, DOI 10.1121/1.1913151; TARTINI G, 1967, PRINCIPJ ARMONIA MUS, P4; WALKER DP, 1978, STUDIES MUSICAL SCI, P136; ZUREK PM, 1979, SCIENCE, V205, P600, DOI 10.1126/science.451625	38	102	102	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	AUG 5	1993	364	6437					527	529		10.1038/364527a0	http://dx.doi.org/10.1038/364527a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	8336792				2022-12-01	WOS:A1993LQ66700054
J	TSUJINO, S; SHANSKE, S; DIMAURO, S				TSUJINO, S; SHANSKE, S; DIMAURO, S			MOLECULAR-GENETIC HETEROGENEITY OF MYOPHOSPHORYLASE DEFICIENCY (MCARDLES-DISEASE)	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							MUSCLE PHOSPHORYLASE-DEFICIENCY; GLYCOGEN-PHOSPHORYLASE; SEQUENCE-ANALYSIS; HUMAN-LIVER; RESOLUTION	Background and Methods. Myophosphorylase deficiency (McArdle's disease) is one of the most common causes of exercise intolerance, muscle cramps, and recurrent myoglobinuria. The myophosphorylase gene has been sequenced and assigned to chromosome 11, but the molecular basis of McArdle's disease is not known. We sequenced complementary DNA in 4 patients and studied genomic DNA by restriction-endonuclease analysis in 40 patients with McArdle's disease. Results. Sequence analysis revealed three distinct point mutations: the substitution of thymine for cytosine at codon 49 in exon 1, changing an encoded arginine to a stop codon; the substitution of adenine for guanine at codon 204 in exon 5, changing glycine to serine; and the substitution of cytosine for adenine at codon 542 in exon 14, changing lysine to threonine. Analysis of restriction-fragment-length polymorphisms of appropriate fragments of genomic DNA after amplification with the polymerase chain reaction showed that 18 patients were homozygous for the stop-codon mutation, 6 had different mutations in the two alleles (compound heterozygotes), and 11 were presumed to be compound heterozygotes for a known mutation and an unknown one; only 5 patients had none of the three mutations. All three mutations were present in various combinations in five members of a family in which transmission appeared to be autosomal dominant. Conclusions. McArdle's disease is genetically heterogeneous, but the most common mutation is the substitution of thymine for cytosine at codon 49. These results suggest that in about 90 percent of patients the diagnosis of McArdle's disease can be made from a patient's leukocytes, thus avoiding the need for muscle biopsy.	COLUMBIA PRESBYTERIAN MED CTR, COLL PHYS & SURG 4420, 630 W 168TH ST, NEW YORK, NY 10032 USA; COLUMBIA PRESBYTERIAN MED CTR, H HOUSTON MERRITT CLIN RES CTR MUSCULAR DYSTROPHY, NEW YORK, NY 10032 USA	Columbia University; NewYork-Presbyterian Hospital; Columbia University; NewYork-Presbyterian Hospital					NINDS NIH HHS [NS-11766] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS011766, P01NS011766] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BEGRADER P, 1993, P NATL ACAD SCI USA, V90, P482; BURKE J, 1987, PROTEINS, V2, P177, DOI 10.1002/prot.340020303; CHUI LA, 1976, ARCH NEUROL-CHICAGO, V33, P636, DOI 10.1001/archneur.1976.00500090042008; Dahl H.-H. M., 1992, Human Mutation, V1, P97, DOI 10.1002/humu.1380010203; DELAMAZA M, 1980, NEUROLOGY, V30, P402; DIMAURO S, 1978, NEUROLOGY, V28, P1124, DOI 10.1212/WNL.28.11.1124; DIMAURO S, 1986, MYOLOGY, P1585; GAUTRON S, 1987, J CLIN INVEST, V79, P275, DOI 10.1172/JCI112794; GLISIN V, 1974, BIOCHEMISTRY-US, V13, P2633, DOI 10.1021/bi00709a025; LEBO RV, 1990, HUM GENET, V86, P17; LEBO RV, 1984, SCIENCE, V225, P57, DOI 10.1126/science.6587566; LEWIS SF, 1986, J APPL PHYSIOL, V61, P391, DOI 10.1152/jappl.1986.61.2.391; MASHIMA Y, 1992, AM J HUM GENET, V51, P81; MCARDLE B, 1951, CLIN SCI, V10, P12; MCCONCHIE SM, 1990, BIOCHIM BIOPHYS ACTA, V1096, P26, DOI 10.1016/0925-4439(90)90008-D; MILSTEIN JM, 1989, J CHILD NEUROL, V4, P186, DOI 10.1177/088307388900400305; MIRANDA AF, 1979, NEUROLOGY, V29, P1538, DOI 10.1212/WNL.29.11.1538; MOMMAERTS WFHM, 1959, P NATL ACAD SCI USA, V45, P791, DOI 10.1073/pnas.45.6.791; NEWGARD CB, 1988, J BIOL CHEM, V263, P3850; NEWGARD CB, 1986, P NATL ACAD SCI USA, V83, P8132, DOI 10.1073/pnas.83.21.8132; PAPADIMITRIOU A, 1990, J NEUROL, V237, P267, DOI 10.1007/BF00314633; SCHIMRIG.K, 1967, KLIN WOCHENSCHR, V45, P1, DOI 10.1007/BF01745732; SCHMID R, 1959, J CLIN INVEST, V38, P2044, DOI 10.1172/JCI103983; SCHMIDT B, 1987, NEUROLOGY, V37, P1558, DOI 10.1212/WNL.37.9.1558; SERVIDEI S, 1988, ANN NEUROL, V24, P774, DOI 10.1002/ana.410240612; SHANSKE S, 1987, J BIOL CHEM, V262, P14612; SPRANG S, 1979, J MOL BIOL, V131, P523, DOI 10.1016/0022-2836(79)90006-8; TARONI F, 1992, P NATL ACAD SCI USA, V89, P8429, DOI 10.1073/pnas.89.18.8429	28	172	174	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	JUL 22	1993	329	4					241	245		10.1056/NEJM199307223290404	http://dx.doi.org/10.1056/NEJM199307223290404			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LM682	8316268				2022-12-01	WOS:A1993LM68200004
J	ZHANG, XF; SETTLEMAN, J; KYRIAKIS, JM; TAKEUCHISUZUKI, E; ELLEDGE, SJ; MARSHALL, MS; BRUDER, JT; RAPP, UR; AVRUCH, J				ZHANG, XF; SETTLEMAN, J; KYRIAKIS, JM; TAKEUCHISUZUKI, E; ELLEDGE, SJ; MARSHALL, MS; BRUDER, JT; RAPP, UR; AVRUCH, J			NORMAL AND ONCOGENIC P21(RAS) PROTEINS BIND TO THE AMINO-TERMINAL REGULATORY DOMAIN OF C-RAF-1	NATURE			English	Article							S6 KINASE-II; XENOPUS OOCYTES; SIGNAL TRANSDUCTION; SUPPRESSOR ACTIVITY; RAS-P21 GTPASE; RAS; ACTIVATION; SERINE; RAF-1; GROWTH	In higher eukaryotes, the Ras and Raf-1 proto-oncoproteins transduce growth and differentiation signals initiated by tyrosine kinases. The Ras polypeptide and the amino-terminal regulatory domain of Raf-1(residues 1-257) are shown to interact, directly in vitro and in a yeast expression system. Raf-1(1-257) binds GTP-Ras in preference to GDP-Ras, and inhibits Ras-GAP activity. Mutations in and around the Ras effector domain impair Ras binding to Raf-1(1-257) and Ras transforming activity in parallel.	HARVARD UNIV, SCH MED, DIABET UNIT, 149 13TH ST, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, MED SERV, BOSTON, MA 02129 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02129 USA; MASSACHUSETTS GEN HOSP E, CTR CANC, BOSTON, MA 02129 USA; BAYLOR COLL MED, DEPT BIOCHEM, HOUSTON, TX 77030 USA; NCI, FREDERICK CANC RES & DEV CTR, VIRAL CARCINOGENESIS LAB, FREDERICK, MD 21702 USA; INDIANA UNIV, SCH MED, DEPT MED, HEMATOL ONCOL SECT, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Baylor College of Medicine; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute								AHN NG, 1991, J BIOL CHEM, V266, P4220; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO, pCH13; BARRETT CB, 1992, J BIOL CHEM, V267, P4408; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; CAMPA MJ, 1991, BIOCHEM BIOPH RES CO, V174, P1, DOI 10.1016/0006-291X(91)90475-M; CHIEN CT, 1991, P NATL ACAD SCI USA, V88, P9578, DOI 10.1073/pnas.88.21.9578; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; GIBBS JB, 1989, MICROBIOL REV, V53, P171, DOI 10.1128/MMBR.53.2.171-185.1989; GOMEZ N, 1991, NATURE, V351, P69; GROVE JR, IN PRESS BIOCHEMISTR; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HANCOCK JF, 1989, CELL, V57, P1167, DOI 10.1016/0092-8674(89)90054-8; HATA Y, 1990, J BIOL CHEM, V265, P7104; HATTORI G, J BIOL CHEM, V267, P20346; HEIDECKER G, 1992, ADV CANCER RES, V58, P53, DOI 10.1016/S0065-230X(08)60290-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HULEIHEL M, 1986, MOL CELL BIOL, V6, P2655, DOI 10.1128/MCB.6.7.2655; ITOH T, 1993, J BIOL CHEM, V268, P3025; KITAYAMA H, 1990, P NATL ACAD SCI USA, V87, P4284, DOI 10.1073/pnas.87.11.4284; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOLCH W, 1991, NATURE, V349, P426, DOI 10.1038/349426a0; KOSAKO H, 1992, EMBO J, V11, P2903, DOI 10.1002/j.1460-2075.1992.tb05359.x; KOVACINA KS, 1990, J BIOL CHEM, V265, P12115; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; KYRIAKIS JM, IN PRESS J BIOL CHEM; LEEVERS SJ, 1992, EMBO J, V11, P569, DOI 10.1002/j.1460-2075.1992.tb05088.x; MARSHALL MS, 1991, MOL CELL BIOL, V11, P3997, DOI 10.1128/MCB.11.8.3997; MARSHALL MS, 1993, ONCOGENE, V8, P425; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; PAGE MJ, 1989, J BIOL CHEM, V264, P19147; PIZON V, 1988, NUCLEIC ACIDS RES, V16, P7719, DOI 10.1093/nar/16.15.7719; PIZON V, 1988, ONCOGENE, V3, P201; POMERANCE M, 1992, J BIOL CHEM, V267, P16155; QUILLIAM LA, 1990, MOL CELL BIOL, V10, P2901, DOI 10.1128/MCB.10.6.2901; RAPP UR, 1988, COLD SPRING HARB SYM, V53, P173, DOI 10.1101/SQB.1988.053.01.023; ROBBINS DJ, 1992, P NATL ACAD SCI USA, V89, P6924, DOI 10.1073/pnas.89.15.6924; SATOH T, 1992, J BIOL CHEM, V267, P24149; SHIBUYA EK, 1992, P NATL ACAD SCI USA, V89, P9831, DOI 10.1073/pnas.89.20.9831; STANTON VP, 1989, MOL CELL BIOL, V9, P639, DOI 10.1128/MCB.9.2.639; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TROPPMAIR J, 1992, ONCOGENE, V7, P1867; TSUDA L, 1993, CELL, V72, P407, DOI 10.1016/0092-8674(93)90117-9; WOOD KW, 1992, J CELL, V68, P1041	48	802	822	0	12	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	JUL 22	1993	364	6435					308	313		10.1038/364308a0	http://dx.doi.org/10.1038/364308a0			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LN570	8332187				2022-12-01	WOS:A1993LN57000047
J	BRUNGER, AT; CLORE, GM; GRONENBORN, AM; SAFFRICH, R; NILGES, M				BRUNGER, AT; CLORE, GM; GRONENBORN, AM; SAFFRICH, R; NILGES, M			ASSESSING THE QUALITY OF SOLUTION NUCLEAR-MAGNETIC-RESONANCE STRUCTURES BY COMPLETE CROSS-VALIDATION	SCIENCE			English	Article							DISTANCE GEOMETRY; 3-DIMENSIONAL STRUCTURE; MACROMOLECULAR STRUCTURES; PROTEIN CONFORMATIONS; MOLECULAR-DYNAMICS; TRYPSIN-INHIBITOR; REFINEMENT; SPECTROSCOPY; CONSTRAINTS; RESTRAINTS	Structure determination of macromolecules in solution by nuclear magnetic resonance (NMR) spectroscopy involves the fitting of atomic models to the observed nuclear Over-hauser effect (NOE) data. Complete cross-validation has been used to define reliable and unbiased criteria for the quality of solution NMR structures. The method is based on the partitioning of NOE data into test sets and the cross-validation of statistical quantities for each of the test sets. A high correlation between cross-validated measures of fit, such as distance bound violations and NMR R values, and the quality of solution NMR structures was observed. Less complete data resulted in poorer satisfaction of the cross-validated measures of fit. Optimization of cross-validated measures of fit will likely produce solution NMR structures with maximal information content.	NIDDKD,CHEM PHYS LAB,BETHESDA,MD 20892; YALE UNIV,DEPT MOLEC BIOPHYS & BIOCHEM,NEW HAVEN,CT 06511; EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK); Yale University; European Molecular Biology Laboratory (EMBL)	BRUNGER, AT (corresponding author), YALE UNIV,HOWARD HUGHES MED INST,NEW HAVEN,CT 06511, USA.		Clore, G. Marius/A-3511-2008; Clore, G Marius/L-2546-2018; Nilges, Michael/E-4803-2011	Clore, G. Marius/0000-0003-3809-1027; Clore, G Marius/0000-0003-3809-1027; Nilges, Michael/0000-0002-1451-8092; Gronenborn, Angela M/0000-0001-9072-3525; Brunger, Axel/0000-0001-5121-2036; Saffrich, Rainer/0000-0002-0547-4550				BONVIN AMJ, 1993, COMPUTER SIMULATION, V2; BROOKS BR, 1983, J COMPUT CHEM, V4, P187, DOI 10.1002/jcc.540040211; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; BRUNGER AT, 1991, ANNU REV PHYS CHEM, V42, P197, DOI 10.1146/annurev.pc.42.100191.001213; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; BRUNGER AT, IN PRESS Q REV BIOPH; CLORE GM, 1986, EMBO J, V5, P2729, DOI 10.1002/j.1460-2075.1986.tb04557.x; CLORE GM, 1993, J MOL BIOL, V231, P82, DOI 10.1006/jmbi.1993.1259; CLORE GM, 1991, BIOCHEMISTRY-US, V30, P2315, DOI 10.1021/bi00223a005; CLORE GM, 1991, SCIENCE, V252, P1390, DOI 10.1126/science.2047852; CLORE GM, 1991, ANNU REV BIOPHYS BIO, V20, P29, DOI 10.1146/annurev.biophys.20.1.29; EFRON B, 1988, SIAM REV, V30, P421, DOI 10.1137/1030093; Efron B., 1982, JACKKNIFE BOOTSTRAP; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Ernst R. R., 1987, PRINCIPLES NUCL MAGN; GONZALEZ C, 1991, J MAGN RESON, V91, P659, DOI 10.1016/0022-2364(91)90397-C; GRONENBORN AM, 1991, SCIENCE, V253, P657, DOI 10.1126/science.1871600; HAVEL TF, 1985, J MOL BIOL, V182, P281, DOI 10.1016/0022-2836(85)90346-8; HAVEL TF, 1983, B MATH BIOL, V45, P665; Hendrickson W. A., 1991, MACROMOLECULAR STRUC; HENDRICKSON WA, 1985, METHOD ENZYMOL, V115, P252; HOLAK TA, 1989, J MOL BIOL, V210, P635, DOI 10.1016/0022-2836(89)90137-X; IKURA M, 1992, SCIENCE, V256, P632, DOI 10.1126/science.1585175; James TL, 1991, CURR OPIN STRUC BIOL, V1, P1042, DOI 10.1016/0959-440X(91)90104-2; KUSZEWSKI J, 1992, J BIOMOL NMR, V2, P33, DOI 10.1007/BF02192799; NILGES M, 1991, J MOL BIOL, V219, P499, DOI 10.1016/0022-2836(91)90189-D; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; OSHIRO CM, 1991, BIOPOLYMERS, V31, P1049, DOI 10.1002/bip.360310905; POWERS R, 1992, SCIENCE, V256, P1673, DOI 10.1126/science.256.5064.1673; SMITH LJ, 1992, J MOL BIOL, V224, P899, DOI 10.1016/0022-2836(92)90457-U; STONE M, 1974, J R STAT SOC B, V36, P111, DOI 10.1111/j.2517-6161.1974.tb00994.x; THERIAULT Y, 1993, NATURE, V361, P88, DOI 10.1038/361088a0; THOMAS PD, 1991, P NATL ACAD SCI USA, V88, P1237, DOI 10.1073/pnas.88.4.1237; TORDA AE, 1990, J MOL BIOL, V214, P223, DOI 10.1016/0022-2836(90)90157-H; TORDA AE, 1989, CHEM PHYS LETT, V157, P289, DOI 10.1016/0009-2614(89)87249-5; WHITE SA, 1992, BIOCHEMISTRY-US, V31, P1610, DOI 10.1021/bi00121a005; WILLIAMSON MP, 1985, J MOL BIOL, V182, P295, DOI 10.1016/0022-2836(85)90347-X; WITHKA JM, 1992, J MAGN RESON, V98, P611, DOI 10.1016/0022-2364(92)90014-X; WUTHRICH K, 1983, J MOL BIOL, V169, P949, DOI 10.1016/S0022-2836(83)80144-2; Wuthrich K., 1986, NMR PROTEINS NUCL AC; YIP P, 1989, J MAGN RESON, V83, P643, DOI 10.1016/0022-2364(89)90360-0; YIP PF, 1989, CHEM PHYS LETT, V161, P50, DOI 10.1016/S0009-2614(89)87030-7	43	148	148	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 16	1993	261	5119					328	331		10.1126/science.8332897	http://dx.doi.org/10.1126/science.8332897			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM678	8332897				2022-12-01	WOS:A1993LM67800028
J	THOMAS, JD; SIDERAS, P; SMITH, CIE; VORECHOVSKY, I; CHAPMAN, V; PAUL, WE				THOMAS, JD; SIDERAS, P; SMITH, CIE; VORECHOVSKY, I; CHAPMAN, V; PAUL, WE			COLOCALIZATION OF X-LINKED AGAMMAGLOBULINEMIA AND X-LINKED IMMUNODEFICIENCY GENES	SCIENCE			English	Article							B-CELLS; IMMUNE-DEFICIENCY; LYMPHOCYTES-B; SRC GENE; 5' EXONS; C-SRC; MICE; MUTATION; PROTEIN; MOUSE	Mice that bear the X-linked immunodeficiency (xid) mutation have a B lymphocyte-specific defect resulting in an inability to make antibody responses to polysaccharide antigens. A backcross of 1114 progeny revealed the colocalization of xid with Bruton's agammaglobulinemia tyrosine kinase (btk) gene, which is implicated in the human immune deficiency, X-linked agammaglobulinemia. Mice that carry xid have a missense mutation that alters a highly conserved arginine near the amino-terminus of the btk protein, Btk. Because this region of Btk lies outside any obvious kinase domain, the xid mutation may define another aspect of tyrosine kinase function.	NIAID,IMMUNOL LAB,BETHESDA,MD 20892; KAROLINSKA INST,NOVUM,CTR BIOTECHNOL,S-14157 HUDDINGE,SWEDEN; UMEA UNIV,APPL CELL & MOLEC BIOL UNIT,S-90187 UMEA,SWEDEN; NEW YORK STATE DEPT HLTH,ROSWELL PK MEM INST,DEPT MOLEC BIOL,BUFFALO,NY 14263	National Institutes of Health (NIH) - USA; NIH National Institute of Allergy & Infectious Diseases (NIAID); Karolinska Institutet; Umea University; Roswell Park Cancer Institute				Sideras, Paschalis/0000-0003-0701-1258; SMITH, C. I. Edvard/0000-0003-1907-3392	NHGRI NIH HHS [HG00277] Funding Source: Medline; NIGMS NIH HHS [GM33160] Funding Source: Medline; NATIONAL HUMAN GENOME RESEARCH INSTITUTE [R01HG000277] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM033160] Funding Source: NIH RePORTER	NHGRI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HUMAN GENOME RESEARCH INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Human Genome Research Institute (NHGRI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BEN-NERIAH Y, 1986, CELL, V44, P577, DOI 10.1016/0092-8674(86)90267-9; BERNING AK, 1980, J IMMUNOL, V124, P1875; BONA C, 1980, J EXP MED, V151, P224, DOI 10.1084/jem.151.1.224; BROWN S, IN PRESS MAMM GENOME; COLIGAN JE, 1992, CURRENT PROTOCOLS IM, V1, pCH3; COLIGAN JE, 1992, CURRENT PROTOCOLS IM, V1, pCH2; COLLINS FS, 1992, NAT GENET, V1, P3, DOI 10.1038/ng0492-3; CONLEY ME, 1992, ANNU REV IMMUNOL, V10, P215; COOKE MF, 1988, NEW BIOL, V1, P66; CROSS FR, 1984, MOL CELL BIOL, V4, P1824; DESIDERIO S, 1993, NATURE, V361, P202, DOI 10.1038/361202a0; DIETRICH W, 1992, GENETICS, V131, P4232; DIUGUID DL, 1989, BLOOD, V74, P193; DORAI T, 1991, MOL CELL BIOL, V11, P4165, DOI 10.1128/MCB.11.8.4165; FORRESTER LM, 1987, J EXP MED, V165, P949, DOI 10.1084/jem.165.4.949; GREEN MC, 1991, HDB GENETICALLY STAN, P14; KAMPS MP, 1985, P NATL ACAD SCI USA, V82, P4625, DOI 10.1073/pnas.82.14.4625; KATO JY, 1986, MOL CELL BIOL, V6, P4155, DOI 10.1128/MCB.6.12.4155; KUSUMI K, IN PRESS MAMM GENOME; LORENZO F, 1993, BRIT J HAEMATOL, V83, P152, DOI 10.1111/j.1365-2141.1993.tb04646.x; MANO, 1993, ONCOGENE, V8, P417; MOND JJ, 1982, J EXP MED, V155, P924, DOI 10.1084/jem.155.3.924; MOYERS JS, 1993, MOL CELL BIOL, V13, P2391, DOI 10.1128/MCB.13.4.2391; NAHM MH, 1983, J EXP MED, V158, P920, DOI 10.1084/jem.158.3.920; PRIOR L, 1992, AM J HUM GENET, V51, P143; ROSSI JM, 1992, P NATL ACAD SCI USA, V89, P2456, DOI 10.1073/pnas.89.6.2456; SAIKI RK, 1986, NATURE, V324, P163, DOI 10.1038/324163a0; SCHER I, 1982, ADV IMMUNOL, V33, P1, DOI 10.1016/S0065-2776(08)60834-2; SIDERAS P, UNPUB; SILICIANO JD, 1992, P NATL ACAD SCI USA, V89, P11194, DOI 10.1073/pnas.89.23.11194; SPRENT J, 1984, J EXP MED, V160, P335, DOI 10.1084/jem.160.1.335; STEPHENSON DA, 1988, NUCLEIC ACIDS RES, V16, P1642, DOI 10.1093/nar/16.4.1642; SUGRUE MM, 1990, J NEUROSCI, V10, P2513; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; VANETTEN RA, 1989, CELL, V58, P669, DOI 10.1016/0092-8674(89)90102-5; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; VINCENT WS, 1989, GENE DEV, V3, P334, DOI 10.1101/gad.3.3.334; WORTIS HH, 1982, J EXP MED, V155, P903, DOI 10.1084/jem.155.3.903; YI TL, 1991, MOL CELL BIOL, V11, P2391, DOI 10.1128/MCB.11.5.2391; [No title captured]	40	576	584	0	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 16	1993	261	5119					355	358		10.1126/science.8332900	http://dx.doi.org/10.1126/science.8332900			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LM678	8332900				2022-12-01	WOS:A1993LM67800037
J	CULLEN, KE; KLADDE, MP; SEYFRED, MA				CULLEN, KE; KLADDE, MP; SEYFRED, MA			INTERACTION BETWEEN TRANSCRIPTION REGULATORY REGIONS OF PROLACTIN CHROMATIN	SCIENCE			English	Article							COOPERATIVE BINDING; GENE-REGULATION; DNA LOOP; ENHANCER; ACTIVATION; PROMOTER; ELEMENTS; ESTROGEN; DISTANCE; PROTEIN	The regulation of transcription requires complex interactions between proteins bound to DNA sequences that are often separated by hundreds of base pairs. As demonstrated by a nuclear ligation assay, the distal enhancer and the proximal promoter regions of the rat prolactin gene were found to be juxtaposed. By acting through its receptor bound to the distal enhancer, estrogen stimulated the interaction between the distal and proximal regulatory regions two- to threefold compared to control values. Thus, the chromatin structure of the prolactin gene may facilitate the occurrence of protein-protein interactions between transcription factors bound to widely separated regulatory elements.	VANDERBILT UNIV,DEPT MOLEC BIOL,NASHVILLE,TN 37235; UNIV WISCONSIN,DEPT BIOCHEM,MADISON,WI 53706	Vanderbilt University; University of Wisconsin System; University of Wisconsin Madison					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [T32HD007048] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK042731] Funding Source: NIH RePORTER; NICHD NIH HHS [T32HD07048] Funding Source: Medline; NIDDK NIH HHS [DK42731] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BRENT R, 1985, CELL, V43, P729, DOI 10.1016/0092-8674(85)90246-6; CAMPER SA, 1985, J BIOL CHEM, V260; CAREY M, 1990, SCIENCE, V247, P710, DOI 10.1126/science.2405489; CRENSHAW EB, 1989, GENE DEV, V3, P959, DOI 10.1101/gad.3.7.959; CULLEN KE, UNPUB; DAY RN, 1989, MOL ENDOCRINOL, V3, P3, DOI 10.1210/mend-3-1-3; DUNAWAY M, 1989, NATURE, V341, P657, DOI 10.1038/341657a0; DUNN TM, 1984, P NATL ACAD SCI-BIOL, V81, P5017, DOI 10.1073/pnas.81.16.5017; ELLISTON JF, 1990, MOL CELL BIOL, V10, P6607, DOI 10.1128/MCB.10.12.6607; ELSHOLTZ HP, 1986, SCIENCE, V234, P1552, DOI 10.1126/science.3491428; FELSENFELD G, 1986, CELL, V44, P375, DOI 10.1016/0092-8674(86)90456-3; GRALLA JD, 1989, CELL, V57, P193, DOI 10.1016/0092-8674(89)90955-0; GRIFFITH J, 1986, NATURE, V322, P750, DOI 10.1038/322750a0; HANN S, 1986, J MOL BIOL, V188, P355; HOCHSCHILD A, 1986, CELL, V44, P681, DOI 10.1016/0092-8674(86)90833-0; HOPE IA, 1986, CELL, V46, P885, DOI 10.1016/0092-8674(86)90070-X; LAYBOURN PJ, 1992, SCIENCE, V257, P1682, DOI 10.1126/science.1388287; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; MASTRANGELO IA, 1991, P NATL ACAD SCI USA, V88, P5670, DOI 10.1073/pnas.88.13.5670; MAURER RA, 1982, J BIOL CHEM, V257, P2133; MAURER RA, 1987, MOL CELL BIOL, V7, P4247, DOI 10.1128/MCB.7.12.4247; MUKHERJEE S, 1988, CELL, V52, P375, DOI 10.1016/S0092-8674(88)80030-8; PTASHNE M, 1990, NATURE, V346, P329, DOI 10.1038/346329a0; PTASHNE M, 1986, NATURE, V322, P697, DOI 10.1038/322697a0; ROTHBERG I, 1991, NUCLEIC ACIDS RES, V19, P5713, DOI 10.1093/nar/19.20.5713; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SCHLEIF R, 1987, NATURE, V327, P369, DOI 10.1038/327369a0; SEYFRED MA, 1990, MOL ENDOCRINOL, V4, P1226, DOI 10.1210/mend-4-8-1226; SEYFRED MA, 1989, MOL ENDOCRINOL, V3, P305, DOI 10.1210/mend-3-2-305; SU W, 1991, GENE DEV, V5, P820, DOI 10.1101/gad.5.5.820; SUPOWIT SC, 1984, P NATL ACAD SCI-BIOL, V81, P2975, DOI 10.1073/pnas.81.10.2975; THEVENY B, 1987, NATURE, V329, P79, DOI 10.1038/329079a0; THOMAS GH, 1988, EMBO J, V7, P2191, DOI 10.1002/j.1460-2075.1988.tb03058.x; WANG JC, 1988, SCIENCE, V240, P300, DOI 10.1126/science.3281259; WATERMAN ML, 1988, MOL ENDOCRINOL, V2, P14, DOI 10.1210/mend-2-1-14	35	157	160	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 9	1993	261	5118					203	206		10.1126/science.8327891	http://dx.doi.org/10.1126/science.8327891			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL596	8327891				2022-12-01	WOS:A1993LL59600038
J	ANDREWS, K				ANDREWS, K			PATIENTS IN THE PERSISTENT VEGETATIVE STATE - PROBLEMS IN THEIR LONG-TERM MANAGEMENT	BRITISH MEDICAL JOURNAL			English	Article								Physicians responsible for the long term management of patients in the persistent vegetative state face several problems. These include deciding whether tube feeding is treatment or nutritional care, whether withdrawal of tube feeding is an appropriate form of management, what clinical advantage there is in active treatment; at what level of awareness can a patient be said to have a quality of life; and who should determine a patient's right to die. These problems are determined more by social, legal, emotional, cultural, religious, and economic forces than by clinical facts.	ROYAL HOSP & HOME,RES SERV,LONDON SW15 3SW,ENGLAND		ANDREWS, K (corresponding author), ROYAL HOSP & HOME,MED SERV,LONDON SW15 3SW,ENGLAND.							ANDREWS K, 1993, BRIT MED J, V306, P1597, DOI 10.1136/bmj.306.6892.1597	1	24	24	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1600	1602		10.1136/bmj.306.6892.1600	http://dx.doi.org/10.1136/bmj.306.6892.1600			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329927	Bronze, Green Published			2022-12-01	WOS:A1993LH12800028
J	ORLEANS, CT; RESCH, N; NOLL, E; KEINTZ, MK; RIMER, BK; BROWN, TV; SNEDDEN, TM				ORLEANS, CT; RESCH, N; NOLL, E; KEINTZ, MK; RIMER, BK; BROWN, TV; SNEDDEN, TM			USE OF TRANSDERMAL NICOTINE IN A STATE-LEVEL PRESCRIPTION PLAN FOR THE ELDERLY - A FIRST LOOK AT REAL-WORLD PATCH USERS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SMOKING-CESSATION; CIGARETTE-SMOKING; CONTROLLED TRIAL; INTERVENTION; PROGRAMS; THERAPY; SMOKERS; CARE; HELP; DEPENDENCE	Objective.-To assess transdermal nicotine use patterns and outcomes in a population of low-income older smokers. Design.-A 6-month telephone follow-up survey of smokers filling prescriptions for transdermal nicotine in the first 3 months of 1992. Setting.-Pennsylvania's Pharmaceutical Assistance Plan for the Elderly, the nation's largest state-level prescription plan for the elderly. Population.-A total of 1070 noninstitutionalized male and female smokers aged 65 through 74 years. Main Outcome Measures.-Self-reported physician/pharmacist advice and adjunctive treatments, concomitant smoking, and 6-month smoking abstinence. Results.-Respondents were predominantly long-term heavy smokers. They used nicotine patches for an average of 5 weeks, with few reporting use beyond 3 months or recalling bothersome side effects. Most of those with previous quit attempts rated quitting with the patch ''easier.'' The 29% self-reported 6-month quit rate observed is encouraging. However, compliance with patch use guidelines was far from ideal in this high-risk population: only 54% of respondents received any initial advice or materials from their physicians or pharmacists, fewer than 2% took part in a formal clinic or one-to-one treatment program, and almost half (47%) smoked while using the patch, including 20% who smoked every day. Concomitant smoking was strongly associated with failure to achieve abstinence (P<.001). More frequent contact with physicians and/or pharmacists was associated with less concomitant smoking (P<.001) and higher quit rates (P=.005). Conclusions.-This survey offers an important first look at problems and prospects for nicotine patch therapy in older adults, with implications for other groups as well. Prospective studies are needed to clarify optimal treatment regimens and adjuncts.	DUKE COMPREHENS CANC CTR, DURHAM, NC USA; COMMONWEALTH PENN DEPT AGING, HARRISBURG, PA USA	Duke University	ORLEANS, CT (corresponding author), FOX CHASE CANC CTR, 510 TOWNSHIP LINE RD, CHELTENHAM, PA 19012 USA.				NATIONAL CANCER INSTITUTE [P50CA034856, P01CA034856] Funding Source: NIH RePORTER; NCI NIH HHS [CA34856] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELIN T, 1989, LANCET, V1, P7; BANDURA A, 1985, COGNITION PSYCHOTHER; BENOWITZ NL, 1993, DRUGS, V45, P157, DOI 10.2165/00003495-199345020-00001; BENOWITZ NL, IN PRESS J AM COLL C; BERRY GL, 1988, AM J PUBLIC HEALTH, V78, P157, DOI 10.2105/AJPH.78.2.157; BUCHKREMER G, 1991, PHARMACOPSYCHIATRY, V24, P96, DOI 10.1055/s-2007-1014448; COHEN SJ, 1987, AM J PUBLIC HEALTH, V77, P313, DOI 10.2105/AJPH.77.3.313; CURRY SJ, 1991, J CONSULT CLIN PSYCH, V59, P318, DOI 10.1037/0022-006X.59.2.318; DAUGHTON DM, 1991, ARCH INTERN MED, V151, P749, DOI 10.1001/archinte.151.4.749; DENEEF P, 1991, J FAM PRACTICE, V32, P607; FAGERSTROM KO, 1978, ADDICT BEHAV, V3, P235, DOI 10.1016/0306-4603(78)90024-2; FINCHAM J E, 1992, American Pharmacy, V32, P62; FIORE MC, 1990, JAMA-J AM MED ASSOC, V263, P2760, DOI 10.1001/jama.263.20.2760; FIORE MC, 1992, JAMA-J AM MED ASSOC, V268, P2687, DOI 10.1001/jama.268.19.2687; FIORE MC, IN PRESS CHEST; GLYNN TJ, 1990, JAMA-J AM MED ASSOC, V263, P2795, DOI 10.1001/jama.263.20.2795; GLYNN TJ, 1991, NCI NIH913104 PUBL; GORODETZKY CC, 1992, JULY US FOOD DRUG AD; HENNINGFIELD JE, 1988, NICOTINE REPLACEMENT, P35; HERMANSON B, 1988, NEW ENGL J MED, V319, P1365, DOI 10.1056/NEJM198811243192101; HIGGINS MW, 1993, JAMA-J AM MED ASSOC, V269, P2741, DOI 10.1001/jama.269.21.2741; Hirsch J D, 1990, Am Pharm, VNS30, P20; HUGHES JR, 1993, J CONSULT CLIN PSYCH, V61, P751, DOI 10.1037/0022-006X.61.5.751; HURT RD, 1990, MAYO CLIN PROC, V65, P1529, DOI 10.1016/S0025-6196(12)62186-7; KOTTKE TE, 1988, JAMA-J AM MED ASSOC, V259, P2882, DOI 10.1001/jama.1988.03720190050031; LICHTENSTEIN E, 1992, J CONSULT CLIN PSYCH, V60, P518, DOI 10.1037/0022-006X.60.4.518; MULLER P, 1990, LUNG, V168, P445, DOI 10.1007/BF02718163; OCKENE J, 1992, HEALTH PSYCHOL, V11, P119, DOI 10.1037//0278-6133.11.5.277; ORLEANS CT, 1991, J CONSULT CLIN PSYCH, V59, P439, DOI 10.1037/0022-006X.59.3.439; ORLEANS CT, 1991, HEALTH PSYCHOL, V10, P343, DOI 10.1037/0278-6133.10.5.343; ORLEANS CT, 1990, SMOKING PATTERNS QUI; ORLEANS CT, 1993, NICOTINE ADDICTION P, P181; PALMER KJ, 1992, DRUGS, V44, P498, DOI 10.2165/00003495-199244030-00011; POMERLEAU CS, 1990, ADDICT BEHAV, V15, P73, DOI 10.1016/0306-4603(90)90009-M; PROCHASKA JO, 1993, HEALTH PSYCHOL, V12, P399, DOI 10.1037/0278-6133.12.5.399; RANKIN K, 1992, DRUGS STORE NEW 0316, P21; RENNARD S, 1991, JAMA-J AM MED ASSOC, V266, P3133; RENNARD S, 1991, CHEST, V100, pS5; RIMER BK, 1990, CHEST, V97, P547, DOI 10.1378/chest.97.3.547; RIMER BK, IN PRESS HLTH ED RES; ROGERS RL, 1985, JAMA-J AM MED ASSOC, V253, P2970, DOI 10.1001/jama.253.20.2970; ROWE JW, 1985, NEW ENGL J MED, V312, P827, DOI 10.1056/NEJM198503283121305; SACHS DP, IN PRESS ARCH INTERN; SALIVE ME, 1992, AM J PUBLIC HEALTH, V82, P1268, DOI 10.2105/AJPH.82.9.1268; SCHAUFFLER HH, 1993, HEALTH EDUC QUART, V20, P185, DOI 10.1177/109019819302000211; SCHOENBACH VJ, 1992, HEALTH EDUC RES, V7, P369, DOI 10.1093/her/7.3.369; SLADE J, 1992, TOBACCO CONTROL S, V1, pS10; SOUMERAI SB, 1990, HEALTH AFFAIR, V9, P36, DOI 10.1377/hlthaff.9.3.36; STUART B, 1991, ANAL DETERMINANTS CO, P1; STUART B, 1991, PROFILES PRESCRIPTIO, P2; TAYLOR CB, 1990, ANN INTERN MED, V113, P118, DOI 10.7326/0003-4819-113-2-118; TONNESEN P, 1991, NEW ENGL J MED, V325, P311, DOI 10.1056/NEJM199108013250503; Tonnesen P, 1992, J SMOKING RELATED DI, V3, P241; VELICER WF, 1992, PSYCHOL BULL, V111, P23, DOI 10.1037/0033-2909.111.1.23; WEINER JP, 1991, HEALTH AFFAIR, V10, P140, DOI 10.1377/hlthaff.10.1.140; 1992, MMWR MORB MORTAL WKL, V41, P354; 1992, NATIONAL COUNCIL PAT, V55, P6; 1986, NIH862687 NCI PUBL; 1992, NICOTINE SUBSTITUTIO; 1990, CDC908416 US DEP HLT; 1991, LIT HLTH US SELECTED; 1992, NICODERM PRODUCT INS; 1989, CDC898411 US DEP HLT; 1992, HABITROL PRODUCT INS	64	102	104	1	12	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	1994	271	8					601	607		10.1001/jama.271.8.601	http://dx.doi.org/10.1001/jama.271.8.601			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW477	8301792				2022-12-01	WOS:A1994MW47700023
J	CLINTON, JJ				CLINTON, JJ			MANAGING EARLY HIV-INFECTION	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 16	1994	271	7					492	492		10.1001/jama.271.7.492	http://dx.doi.org/10.1001/jama.271.7.492			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV423	8301749				2022-12-01	WOS:A1994MV42300006
J	KLEBER, HD				KLEBER, HD			OUR CURRENT APPROACH TO DRUG-ABUSE - PROGRESS, PROBLEMS, PROPOSALS	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							ALTERNATIVES; LEGALIZATION; PROHIBITION				KLEBER, HD (corresponding author), COLUMBIA UNIV, CTR ADDICT & SUBSTANCE ABUSE, NEW YORK, NY 10019 USA.							ELLICKSON PL, IN PRESS HDB DRUG AB; FARRELL M, 1990, BRIT J ADDICT, V85, P5; GLADWELL M, 1993, WASH POST       0607, pA1; HOMER JB, 1993, J DRUG ISSUES, V23, P281, DOI 10.1177/002204269302300208; INCIARDI A, 1992, WAR DRUGS, V2, P233; INCIARDI JA, 1989, AM BEHAV SCI, V32, P259, DOI 10.1177/0002764289032003006; JOHNSTON LD, 1992, MONITORING FUTURE AN; KAPLAN J, 1988, PUBLIC INTEREST, P32; KAPLAN J, 1983, HARDEST DRUG HEROIN; KLEBER HD, 1993, 1993 SEN COM LAB HUM; Kleiman M., 1993, ECONOMIST       0612, P8; Kleiman M, 1992, EXCESS DRUG POLICY R; Kleiman M., 1990, HOFSTRA LAW REV, V18, P527; LANDRY DW, 1993, SCIENCE, V259, P1899, DOI 10.1126/science.8456315; MCAULIFFE WE, 1990, J HEALTH POLIT POLIC, V15, P357, DOI 10.1215/03616878-15-2-357; MCLELLAN AT, 1993, J SUBST ABUSE TREAT, V10, P243, DOI 10.1016/0740-5472(93)90071-9; Musto D F, 1989, Wilson Q, V13, P59; Musto David F., 1992, V166, P7; MUSTO DF, 1987, AM DISEASE ORIGINS N; NADELMANN EA, 1989, SCIENCE, V245, P939, DOI 10.1126/science.2772647; NADELMANN EA, 1992, DAEDALUS, V121, P85; PENTZ MA, 1989, JAMA-J AM MED ASSOC, V261, P3259, DOI 10.1001/jama.261.22.3259; REUTER P, 1992, ANN AM ACAD POLIT SS, V521, P151, DOI 10.1177/0002716292521001009; SHIMADA S, 1991, SCIENCE, V254, P576, DOI 10.1126/science.1948034; STERNBERG L, 1991, SAP PREVENTION MONOG, V8, P13; Szasz T, 1992, NUESTRO DERECHO DROG; WILSON JQ, 1990, COMMENTARY       FEB, P21; 1992, DRUG ABUSE WARNING N; 1993, NATIONAL HOUSEHOLD S; 1989, NATIONAL DRUG CONTRO; 1991, MANDATORY MINIMUM SE	31	24	25	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	FEB 3	1994	330	5					361	365		10.1056/NEJM199402033300514	http://dx.doi.org/10.1056/NEJM199402033300514			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU489	8277959				2022-12-01	WOS:A1994MU48900014
J	STRAUS, WL; OSTROFF, SM; JERNIGAN, DB; KIEHN, TE; SORDILLO, EM; ARMSTRONG, D; BOONE, N; SCHNEIDER, N; KILBURN, JO; SILCOX, VA; LABOMBARDI, V; GOOD, RC				STRAUS, WL; OSTROFF, SM; JERNIGAN, DB; KIEHN, TE; SORDILLO, EM; ARMSTRONG, D; BOONE, N; SCHNEIDER, N; KILBURN, JO; SILCOX, VA; LABOMBARDI, V; GOOD, RC			CLINICAL AND EPIDEMIOLOGIC CHARACTERISTICS OF MYCOBACTERIUM-HAEMOPHILUM, AN EMERGING PATHOGEN IN IMMUNOCOMPROMISED PATIENTS	ANNALS OF INTERNAL MEDICINE			English	Article							ACQUIRED-IMMUNODEFICIENCY-SYNDROME; VIRUS INFECTION; CUTANEOUS MANIFESTATIONS; AIDS; LYMPHADENITIS; HEMOPHILUM	Objective:To describe 13 infections caused by Mycobacterium haemophilum. Design: Identification of patients by microbiologic record review, followed by medical record review and a case-control study. Setting: Seven metropolitan hospitals in New York. Patients: All patients with M. haemophilum infections diagnosed between January 1989 and September 1991 and followed through September 1992. Surviving patients were enrolled in the case-control study. Results: Infection with M. haemophilum causes disseminated cutaneous lesions, bacteremia, and diseases of the bones, joints, lymphatics, and the lungs. Improper culture techniques may delay laboratory diagnosis, and isolates may be identified incorrectly as other mycobacterial species. Persons with profound deficits in cell-mediated immunity have an increased risk for infection. These include persons with human immunodeficiency virus infection or lymphoma and those receiving medication to treat immunosuppression after organ transplant. Various antimycobacterial regimens have been used with apparent success to treat M. haemophilum infection. However, standards for defining antimicrobial susceptibility to the organism do not exist. Conclusions: Clinicians should consider this pathogen when evaluating an immunocompromised patient with cutaneous ulcerating lesions, joint effusions, or osteomyelitis. Microbiologists must be familiar with the fastidious growth requirements of this organism and screen appropriate specimens for mycobacteria using an acid-fast stain. If acid-fast bacilli are seen, M. haemophilum should be considered as the infecting organism as well as other mycobacteria, and appropriate media and incubation conditions should be used.	MEM SLOAN KETTERING CANC CTR, INFECT DIS SERV, NEW YORK, NY 10021 USA; ST LUKES ROOSEVELT HOSP, DEPT MICROBIOL, NEW YORK, NY 10025 USA; ST VINCENTS HOSP & MED CTR, DEPT MICROBIOL, NEW YORK, NY 10011 USA	Memorial Sloan Kettering Cancer Center; Mount Sinai St. Luke's; Mount Sinai West; Saint Vincents Hospital Manhattan	STRAUS, WL (corresponding author), CTR DIS CONTROL & PREVENT, DIV BACTERIAL & MYCOT DIS, MAILSTOP C-09, ATLANTA, GA 30333 USA.		Sordillo, Emilia Mia/AAF-3012-2021	Sordillo, Emilia Mia/0000-0001-7787-3051				ARMSTRONG KL, 1992, J PEDIATR-US, V121, P202, DOI 10.1016/S0022-3476(05)81188-6; ASCHOFF J, 1958, NATURWISSENSCHAFTEN, V45, P477, DOI 10.1007/BF00635546; BARBER TW, 1990, MEDICINE, V69, P375, DOI 10.1097/00005792-199011000-00005; BECHERER P, 1992, CLIN INFECT DIS, V14, P793, DOI 10.1093/clinids/14.3.793; BRANGER B, 1985, CLIN NEPHROL, V23, P46; BUTLER WR, 1992, 92ND GEN M AM SOC MI, P177; CLARK RP, 1985, MAN HIS THERMAL ENV, P1; DAVIS BR, 1982, ANN INTERN MED, V97, P723, DOI 10.7326/0003-4819-97-5-723; DAWSON DJ, 1981, MED J AUSTRALIA, V2, P289, DOI 10.5694/j.1326-5377.1981.tb128321.x; DAWSON DJ, 1980, J CLIN MICROBIOL, V11, P190, DOI 10.1128/JCM.11.2.190-192.1980; DEVER LL, 1992, CLIN INFECT DIS, V14, P1195, DOI 10.1093/clinids/14.6.1195; DOVER JS, 1991, ARCH DERMATOL, V127, P1383, DOI 10.1001/archderm.127.9.1383; DOVER JS, 1991, ARCH DERMATOL, V127, P1549, DOI 10.1001/archderm.127.10.1549; FELDMAN RA, 1974, ANN INTERN MED, V80, P445, DOI 10.7326/0003-4819-80-4-445; GOSLEE S, 1976, AM REV RESPIR DIS, V113, P287; GOUBY A, 1988, J MED MICROBIOL, V25, P299, DOI 10.1099/00222615-25-4-299; HAWKINS CC, 1986, ANN INTERN MED, V105, P184, DOI 10.7326/0003-4819-105-2-184; HOLTON J, 1991, J INFECTION, V23, P303, DOI 10.1016/0163-4453(91)93080-V; HOPEWELL PC, 1985, CHEST, V87, P104, DOI 10.1378/chest.87.1.104; HORSBURGH CR, 1991, NEW ENGL J MED, V324, P1332, DOI 10.1056/NEJM199105093241906; KAYE BR, 1989, ANN INTERN MED, V111, P158, DOI 10.7326/0003-4819-111-2-158; Kent PT, 1985, PUBLIC HLTH MYCOBACT, P1; KIEHN TE, 1993, EUR J CLIN MICROBIOL, V12, P114, DOI 10.1007/BF01967586; KRISTJANSSON M, 1991, REV INFECT DIS, V13, P906; MALES BM, 1987, J CLIN MICROBIOL, V25, P2367; MCBRIDE JA, 1992, AM J CLIN PATHOL, V98, P282; MEZO A, 1979, PATHOLOGY, V11, P377, DOI 10.3109/00313027909059014; MOULSDALE MT, 1983, TUBERCLE, V64, P29, DOI 10.1016/0041-3879(83)90047-8; RIES KM, 1990, NEW ENGL J MED, V322, P633; ROGERS PL, 1988, AM J MED, V84, P640, DOI 10.1016/0002-9343(88)90150-7; RYAN CG, 1983, J CLIN MICROBIOL, V18, P976, DOI 10.1128/JCM.18.4.976-977.1983; SAUBOLLE MA, 1991, 91ST ANN M AM SOC MI, P391; SOMPOLINSKY D, 1978, INT J SYST BACTERIOL, V28, P67, DOI 10.1099/00207713-28-1-67; THIBERT L, 1990, J CLIN MICROBIOL, V28, P621, DOI 10.1128/JCM.28.3.621-623.1990; Thibert L, 1988, Can Dis Wkly Rep, V14, P196; VADNEY FS, 1985, J CLIN MICROBIOL, V22, P884, DOI 10.1128/JCM.22.5.884-885.1985; WALDER BK, 1976, AUSTRALAS J DERMATOL, V17, P94, DOI 10.1111/j.1440-0960.1976.tb00798.x; WAYNE LG, 1992, CLIN MICROBIOL REV, V5, P1; WOLINSKY E, 1968, AM REV RESPIR DIS, V97, P1032; YARRISH RL, 1992, AIDS, V6, P557, DOI 10.1097/00002030-199206000-00006	40	87	87	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	JAN 15	1994	120	2					118	125		10.7326/0003-4819-120-2-199401150-00004	http://dx.doi.org/10.7326/0003-4819-120-2-199401150-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MQ671	8256970				2022-12-01	WOS:A1994MQ67100004
J	WAWER, MJ; SEWANKAMBO, NK; BERKLEY, S; SERWADDA, D; MUSGRAVE, SD; GRAY, RH; MUSAGARA, M; STALLINGS, RY; KONDELULE, JK				WAWER, MJ; SEWANKAMBO, NK; BERKLEY, S; SERWADDA, D; MUSGRAVE, SD; GRAY, RH; MUSAGARA, M; STALLINGS, RY; KONDELULE, JK			INCIDENCE OF HIV-1 INFECTION IN A RURAL REGION OF UGANDA	BRITISH MEDICAL JOURNAL			English	Article							RISK-FACTORS; DISTRICT	Objective-To determine the incidence of infection with HIV-1 and the risk factors associated with seroconversion in three geographical strata of a rural Ugandan district. Design-Serological, sociodemographic, and behavioural surveys of everyone aged 13 or more in 21 randomly selected communities at baseline and one year later. Setting-Rural population of Rakai district, southwestern Uganda, residing in main road trading centres, secondary trading villages, and agricultural villages. Subjects-In 1989, 1292 adults provided a blood sample and interview data; one year later, 778 survivors (77%) who had been seronegative at baseline provided follow up data. Main outcome measures-Incidence of HIV infection in relation to individual characteristics and risk factors, including place of residence. Results-Incidence of HIV infection in all adults was 2.1/100 person years of observation (SE 0.5 (95% confidence interval 1.1 to 3.1)); in people aged 15-39 the incidence was 3.2/100 person years. Incidence was highest in men and women aged 20-24 (9.2/100 person years (3.9) and 6.8/100 person years (2-9) respectively). Risk factors significantly associated with seroconversion were age 24 and under and two or more sexual partners. Between the surveys the proportion of all respondents reporting high risk behaviour (two or more partners) significantly increased from 8.9% to 12.3%. Conclusions-Despite preventive programmes and substantial knowledge about AIDS the incidence of HIV infection remains high in this rural population. Prevention aimed at vulnerable rural communities is urgently needed to contain the HIV epidemic.	MAKERERE UNIV,DEPT MED,KAMPALA,UGANDA; MAKERERE UNIV,INST PUBL HLTH,KAMPALA,UGANDA; ROCKEFELLER FDN,DIV HLTH SCI,NEW YORK,NY 10036; UGANDA VIRUS RES INST,RAKAI PROJECT,COLUMBIA UNIV OFF,ENTEBBE,UGANDA; JOHNS HOPKINS UNIV,SCH PUBL HLTH,DEPT POPULAT DYNAM,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,SCH PUBL HLTH,DEPT INT HLTH,BALTIMORE,MD 21218	Makerere University; Makerere University; Uganda Virus Research Institute; Johns Hopkins University; Johns Hopkins University	WAWER, MJ (corresponding author), COLUMBIA UNIV,SCH PUBL HLTH,CTR POPULAT & FAMILY HLTH,60 HAVEN AVE,NEW YORK,NY 10032, USA.			Sewankambo, Nelson/0000-0001-9362-053X	NIAID NIH HHS [R01-AI29314] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI029314] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLAN S, 1991, JAMA-J AM MED ASSOC, V266, P1657; BERKLEY SF, 1989, J INFECT DIS, V160, P22, DOI 10.1093/infdis/160.1.22; Hosmer D, 2013, APPL LOGISTIC REGRES; ORUBULOYE IO, 1991, STUD FAMILY PLANN, V22, P61, DOI 10.2307/1966777; SERWADDA D, 1992, AIDS, V6, P983, DOI 10.1097/00002030-199209000-00012; WAWER MJ, 1991, BRIT MED J, V303, P1303, DOI 10.1136/bmj.303.6813.1303; 1991, WORLD DEV REPORT; 1987, RELEASE 6 04	8	84	85	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JAN 15	1994	308	6922					171	173		10.1136/bmj.308.6922.171	http://dx.doi.org/10.1136/bmj.308.6922.171			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	MR974	8312767	Green Published			2022-12-01	WOS:A1994MR97400018
J	BOJESTIG, M; ARNQVIST, HJ; HERMANSSON, G; KARLBERG, BE; LUDVIGSSON, J				BOJESTIG, M; ARNQVIST, HJ; HERMANSSON, G; KARLBERG, BE; LUDVIGSSON, J			DECLINING INCIDENCE OF NEPHROPATHY IN INSULIN-DEPENDENT DIABETES-MELLITUS	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							BLOOD-GLUCOSE CONTROL; MICROVASCULAR COMPLICATIONS; GLYCEMIC CONTROL; KIDNEY-FUNCTION; MICROALBUMINURIA; PROTEINURIA; IDDM	Background. The high relative mortality among patients with insulin-dependent diabetes mellitus results mainly from diabetic nephropathy. The cumulative incidence of nephropathy of 25 to 30 percent among patients who had had diabetes for 25 years remained stable from 1950 to the early 1980s. In a population study, we assessed recent trends in the incidence of diabetic nephropathy. Methods. We studied all 213 patients in whom insulin-dependent diabetes mellitus was diagnosed before the age of 15 years between 1961 and 1980 in a district in southeastern Sweden. Ninety-two percent of the patients were followed from the onset of diabetes to 1991 or to death. Patients with persistent albuminuria (positive Albustix test) were considered to have diabetic nephropathy. Glycosylated hemoglobin was measured periodically in all patients, beginning in 1980. Results. The cumulative incidence of persistent albuminuria after 25 years of diabetes decreased from 30.0 percent among the patients in whom diabetes developed in the period 1961 to 1965 to 8.9 percent among those in whom it developed from 1966 to 1970 (P = 0.01). After 20 years of diabetes, the cumulative incidence decreased from 28.0 percent among the patients in whom diabetes developed from 1961 to 1965 to 5.8 percent among those in whom it developed from 1971 to 1975 (P = 0.01). Persistent albuminuria has not yet developed in any patient in whom diabetes was diagnosed in the period 1976 to 1980. The average glycosylated hemoglobin value decreased from 7.4 percent in the period 1980 to 1985 to 7.0 percent from 1986 to 1991 (P<0.001). The mean glycosylated hemoglobin value was higher in the patients with persistent albuminuria than the patients with no albuminuria (8.1 percent vs. 7.1 percent, P<0.001). Conclusions. During the past decade the cumulative incidence of diabetic nephropathy, as manifested by persistent albuminuria, among patients who have had diabetes for 25 years has decreased substantially, probably as a result of improved glycemic control.	EKSJO NASSJO HOSP,DEPT INTERNAL MED,EKSJO,SWEDEN; LINKOPING UNIV HOSP,DEPT INTERNAL MED,S-58185 LINKOPING,SWEDEN; LINKOPING UNIV HOSP,DEPT PEDIAT,S-58185 LINKOPING,SWEDEN	Linkoping University; Linkoping University			Ludvigsson, Johnny/AAI-2051-2020	Ludvigsson, Johnny/0000-0003-1695-5234				ANDERSEN AR, 1983, DIABETOLOGIA, V25, P496; BANGSTAD HJ, 1989, DIABETES RES CLIN EX, V12, P71; BORCHJOHNSEN K, 1985, DIABETOLOGIA, V28, P590, DOI 10.1007/BF00281993; BORCHJOHNSEN K, 1992, KIDNEY INT, V41, P719, DOI 10.1038/ki.1992.112; CHASE HP, 1989, JAMA-J AM MED ASSOC, V261, P1155, DOI 10.1001/jama.261.8.1155; DANTONIO JA, 1989, DIABETES CARE, V12, P694, DOI 10.2337/diacare.12.10.694; FELDTRASMUSSEN B, 1991, DIABETOLOGIA, V34, P164, DOI 10.1007/BF00418270; HANSSEN KF, 1992, DIABETIC MED, V9, P697, DOI 10.1111/j.1464-5491.1992.tb01876.x; KLEIN R, 1991, ARCH INTERN MED, V151, P1344, DOI 10.1001/archinte.151.7.1344; KOFOEDENEVOLDSEN A, 1987, DIABETES, V36, P205, DOI 10.2337/diabetes.36.2.205; KROLEWSKI AS, 1988, NEW ENGL J MED, V318, P140, DOI 10.1056/NEJM198801213180303; KROLEWSKI AS, 1987, NEW ENGL J MED, V317, P1390; KROLEWSKI AS, 1985, AM J MED, V78, P785, DOI 10.1016/0002-9343(85)90284-0; Ludvigsson J., 1976, METABOLIC CONTROL JU; MARRE M, 1988, BMJ-BRIT MED J, V297, P1092, DOI 10.1136/bmj.297.6656.1092; MATHIESEN ER, 1989, DIABETOLOGIA, V32, P884, DOI 10.1007/BF00297455; MOGENSEN CE, 1987, KIDNEY INT, V31, P673, DOI 10.1038/ki.1987.50; NORGAARD K, 1989, DIABETIC MED, V6, P325, DOI 10.1111/j.1464-5491.1989.tb01173.x; ORCHARD TJ, 1990, DIABETES, V39, P1116, DOI 10.2337/diabetes.39.9.1116; PARVING HH, 1989, BMJ-BRIT MED J, V299, P533, DOI 10.1136/bmj.299.6698.533; REICHARD P, 1991, J INTERN MED, V230, P101, DOI 10.1111/j.1365-2796.1991.tb00415.x; VIBERTI GC, 1992, DIABETES CARE, V15, P1216, DOI 10.2337/diacare.15.9.1216; WANG PH, 1993, LANCET, V341, P1306, DOI 10.1016/0140-6736(93)90816-Y; 1990, SPSS MACINTOSH OPERA; 1990, AM J KIDNEY DIS S2, V16, P22	25	362	371	0	1	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	JAN 6	1994	330	1					15	18		10.1056/NEJM199401063300103	http://dx.doi.org/10.1056/NEJM199401063300103			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MP649	8259139				2022-12-01	WOS:A1994MP64900003
J	BYRNE, C; VERNON, P; COHEN, JJ				BYRNE, C; VERNON, P; COHEN, JJ			EFFECT OF AGE AND DIAGNOSIS ON SURVIVAL OF OLDER PATIENTS BEGINNING CHRONIC DIALYSIS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								Objective.-To assess the survival of elderly patients in the United States beginning chronic dialysis for end-stage renal disease caused by diabetes mellitus, hypertension, glomerulonephritis, polycystic kidney disease, and other causes. Design.-A secondary analysis of data obtained from the Health Care Financing Administration. Patients.-All Medicare end-stage renal disease patients 55 years of age or older (n=95 394) who began chronic dialysis treatment in the US between 1982 and 1987. Main Outcome Measures.-The l-, 3-, and 5-year survival rates for each of six age strata and, within each strata, for each of the four most frequent causes of renal failure. Results.-Survival rates of dialysis patients fell precipitously, and much more rapidly for the study group than for the general population, as a function of advancing age. Older patients with diabetic nephropathy fared particularly badly, such that no patients with diabetic nephropathy aged 85 years or more survived 5 years. Conclusions.-Mortality rates of patients older than 55 years beginning chronic dialysis treatment increased dramatically as age at initiation of dialysis increased. Clinically meaningful survival data should prove useful to persons making decisions about the initiation of chronic dialysis.	SUNY STONY BROOK,SCH MED,STONY BROOK,NY 11794; NEW YORK STATE DEPT HLTH,STONY BROOK,NY	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook								[Anonymous], 1988, MED GOALS AGEING SOC; BLAGG CR, 1991, AM J KIDNEY DIS, V17, P458, DOI 10.1016/S0272-6386(12)80641-X; CALLAHAN D, 1990, WHAT KIND LIFE LIMIT; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; INGLEHART JK, 1993, NEW ENGL J MED, V328, P366; LO B, 1986, ARCH INTERN MED, V146, P1613, DOI 10.1001/archinte.146.8.1613; LOWRANCE DC, 1993, AM J KIDNEY DIS, V21, P679; LOWRIE EG, 1990, AM J KIDNEY DIS, V15, P458, DOI 10.1016/S0272-6386(12)70364-5; RETTIG RA, 1976, LAW CONTEMP PROBL, V40, P196, DOI 10.2307/1191314; RUBIN R, 1991, AM KIDNEY FUND NEWSL, V7, P1; RUBIN R, 1991, AM KIDNEY FUND NEWSL, V7, P3; SLEPIAN F, 1991, AM KIDNEY FUND NEWSL, V7, P1; 1988, PHS881104 US DEP HLT; 1993, USRDS1993 NIH NAT I; 1989, SAS SAT USERS GUIDE, V2; 1991, MONOGRAPH SERIES, V1	16	67	68	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JAN 5	1994	271	1					34	36						3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MN725	8258884				2022-12-01	WOS:A1994MN72500027
J	HIGUCHI, M; SINGLE, FN; KOHLER, M; SOMMER, B; SPRENGEL, R; SEEBURG, PH				HIGUCHI, M; SINGLE, FN; KOHLER, M; SOMMER, B; SPRENGEL, R; SEEBURG, PH			RNA EDITING OF AMPA RECEPTOR SUBUNIT GLUR-B - A BASE-PAIRED INTRON-EXON STRUCTURE DETERMINES POSITION AND EFFICIENCY	CELL			English	Article							SELECTIVE GLUTAMATE RECEPTORS; CENTRAL-NERVOUS-SYSTEM; FUNCTIONAL EXPRESSION; MODIFYING ACTIVITY; MOLECULAR-CLONING; ION FLOW; CHANNELS; CELLS; PERMEABILITY; SUBTYPES	A functionally critical position (Q/R site) of the AMPA receptor subunit GluR-B is controlled by RNA editing that operates in the nucleus, since in brain and clonal cell lines of neural origin, unspliced GluR-B transcripts occur edited in the Q/R site CAG codon and, additionally, in intronic adenosines. Transfection of GluR-B gene constructs into PC12 cells revealed that the proximal part of the intron downstream of the unedited exonic site is required for Q/R site editing. This intron portion contains an imperfect inverted repeat preceding a 10 nt sequence with exact complementarity to the exon centered on the unedited codon. Single nucleotide substitutions in this short intronic sequence or its exonic complement curtailed Q/R site editing, which was recovered by restoring complementarity in the respective partner strand. Base conversion in the channel-coding region of GluR-B directed by base paired sequences may be executed by a ubiquitous nuclear adenosine deaminase specific for double-stranded RNA.			HIGUCHI, M (corresponding author), UNIV HEIDELBERG,CTR MOLEC BIOL,IM NEUENHEIMER FELD 282,D-69120 HEIDELBERG,GERMANY.							BASS BL, 1993, RNA WORLD, P383; BASS BL, 1992, DEV BIOL, V3, P425; BOULTER J, 1990, SCIENCE, V249, P1033, DOI 10.1126/science.2168579; BURNASHEV N, 1992, NEURON, V8, P189, DOI 10.1016/0896-6273(92)90120-3; BURNASHEV N, 1992, SCIENCE, V256, P1566, DOI 10.1126/science.1317970; CATTANEO R, 1991, ANNU REV GENET, V25, P71, DOI 10.1146/annurev.ge.25.120191.000443; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHU G, 1987, NUCLEIC ACIDS RES, V15, P1311, DOI 10.1093/nar/15.3.1311; HOLLMANN M, 1989, NATURE, V342, P643, DOI 10.1038/342643a0; HOLLMANN M, 1991, SCIENCE, V252, P851, DOI 10.1126/science.1709304; HONORE T, 1989, MED RES REV, V9, P1, DOI 10.1002/med.2610090102; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; IINO M, 1990, J PHYSIOL-LONDON, V424, P151, DOI 10.1113/jphysiol.1990.sp018060; JONAS P, 1993, IN PRESS NATURE; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; Kim U, 1993, Semin Cell Biol, V4, P285, DOI 10.1006/scel.1993.1034; KIMELMAN D, 1989, CELL, V59, P687, DOI 10.1016/0092-8674(89)90015-9; KOHLER M, 1993, NEURON, V10, P491, DOI 10.1016/0896-6273(93)90336-P; LAMBOLEZ B, 1992, NEURON, V9, P247, DOI 10.1016/0896-6273(92)90164-9; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MULLIS KB, 1987, METHOD ENZYMOL, V155, P355; NICOLL RA, 1990, PHYSIOL REV, V70, P513, DOI 10.1152/physrev.1990.70.2.513; OGINO Y, 1992, J NEUROCHEM, V58, P46, DOI 10.1111/j.1471-4159.1992.tb09275.x; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; POLSON AG, 1991, BIOCHEMISTRY-US, V30, P11507, DOI 10.1021/bi00113a004; POWELL LM, 1987, CELL, V50, P831, DOI 10.1016/0092-8674(87)90510-1; SAMBROOK S, 1989, MOL CLONING LABORATO; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SEEBURG PH, 1993, TRENDS NEUROSCI, V16, P359, DOI 10.1016/0166-2236(93)90093-2; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WAGNER RW, 1990, MOL CELL BIOL, V10, P5586, DOI 10.1128/MCB.10.10.5586; WISDEN W, 1993, J NEUROSCI, V13, P3582; Wisden W, 1993, Curr Opin Neurobiol, V3, P291, DOI 10.1016/0959-4388(93)90120-N; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	36	523	549	0	10	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 31	1993	75	7					1361	1370		10.1016/0092-8674(93)90622-W	http://dx.doi.org/10.1016/0092-8674(93)90622-W			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MP869	8269514				2022-12-01	WOS:A1993MP86900014
J	BERGOFFEN, J; SCHERER, SS; WANG, S; SCOTT, MO; BONE, LJ; PAUL, DL; CHEN, K; LENSCH, MW; CHANCE, PF; FISCHBECK, KH				BERGOFFEN, J; SCHERER, SS; WANG, S; SCOTT, MO; BONE, LJ; PAUL, DL; CHEN, K; LENSCH, MW; CHANCE, PF; FISCHBECK, KH			CONNEXIN MUTATIONS IN X-LINKED CHARCOT-MARIE-TOOTH DISEASE	SCIENCE			English	Article							GAP JUNCTION PROTEIN; SENSORY NEUROPATHY; HEREDITARY MOTOR; GENE; LOCALIZATION; TYPE-1A; EXPRESSION; LINKAGE; CLONING; GJB1	X-linked Charcot-Marie-Tooth disease (CMTX) is a form of hereditary neuropathy with demyelination. Recently, this disorder was mapped to chromosome Xq13.1. The gene for the gap junction protein connexin32 is located in the same chromosomal segment, which led to its consideration as a candidate gene for CMTX. With the use of Northern (RNA) blot and immunohistochemistry technique, it was found that connexin32 is normally expressed in myelinated peripheral nerve. Direct sequencing of the connexin32 gene showed seven different mutations in affected persons from eight CMTX families. These findings, a demonstration of inherited defects in a gap junction protein, suggest that connexin32 plays an important role in peripheral nerve.	UNIV PENN,SCH MED,DEPT NEUROL,PHILADELPHIA,PA 19104; CHILDRENS HOSP PHILADELPHIA,DIV GENET,PHILADELPHIA,PA 19104; HARVARD UNIV,SCH MED,DEPT NEUROBIOL,BOSTON,MA 02115	University of Pennsylvania; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; Harvard University; Harvard Medical School			Chance, Phillip/AAX-5826-2020		NIGMS NIH HHS [GM37751] Funding Source: Medline; NINDS NIH HHS [NS01565, NS08075] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037751] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS008075, K08NS001565, P01NS008075] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		AKERT K, 1976, CELL TISSUE RES, V165, P281; BECKETT J, 1986, J NEUROGENET, V3, P225, DOI 10.3109/01677068609106852; BELLIVEAU DJ, 1991, DEV GENET, V12, P308, DOI 10.1002/dvg.1020120408; BENNETT MVL, 1991, NEURON, V6, P305, DOI 10.1016/0896-6273(91)90241-Q; BERGOFFEN J, 1993, AM J HUM GENET, V53, P977; BERGOFFEN J, 1993, AM J HUM GENET, V52, P312; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORCOS IA, 1992, GENOMICS, V13, P479, DOI 10.1016/0888-7543(92)90278-Z; DAHL G, 1992, BIOPHYS J, V62, P172, DOI 10.1016/S0006-3495(92)81803-9; DERMIETZEL R, 1993, TRENDS NEUROSCI, V16, P186, DOI 10.1016/0166-2236(93)90151-B; FAIN PR, IN PRESS AM J HUM GE; FISCHBECK KH, 1986, ANN NEUROL, V20, P527, DOI 10.1002/ana.410200414; FRIEDMAN B, 1992, NEURON, V9, P295, DOI 10.1016/0896-6273(92)90168-D; FRYNS JP, 1980, HUM GENET, V55, P413, DOI 10.1007/BF00290228; GABRIEL G, 1986, ACTA NEUROPATHOL, V72, P62, DOI 10.1007/BF00687948; GAL A, 1985, HUM GENET, V70, P38, DOI 10.1007/BF00389456; HAHN AF, 1990, BRAIN, V113, P1511, DOI 10.1093/brain/113.5.1511; HAYASAKA K, 1993, NAT GENET, V5, P31, DOI 10.1038/ng0993-31; KULKENS T, 1993, NAT GENET, V5, P35, DOI 10.1038/ng0993-35; KUMAR NM, 1986, J CELL BIOL, V103, P767, DOI 10.1083/jcb.103.3.767; MILKS LC, 1988, EMBO J, V7, P2967, DOI 10.1002/j.1460-2075.1988.tb03159.x; OTT J, 1974, AM J HUM GENET, V26, P588; PATEL PI, 1992, NAT GENET, V1, P159, DOI 10.1038/ng0692-159; PAUL DL, 1986, J CELL BIOL, V103, P123, DOI 10.1083/jcb.103.1.123; RAIMONDI E, 1992, CYTOGENET CELL GENET, V60, P210, DOI 10.1159/000133339; ROA BB, 1993, NEW ENGL J MED, V329, P96, DOI 10.1056/NEJM199307083290205; ROZEAR MP, 1987, NEUROLOGY, V37, P1460, DOI 10.1212/WNL.37.9.1460; TIMMERMAN V, 1992, NAT GENET, V1, P176; VALENTIJN LJ, 1992, NAT GENET, V2, P288, DOI 10.1038/ng1292-288; VALENTIJN LJ, 1992, NAT GENET, V1, P166, DOI 10.1038/ng0692-166	30	911	947	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	DEC 24	1993	262	5142					2039	2042		10.1126/science.8266101	http://dx.doi.org/10.1126/science.8266101			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266101				2022-12-01	WOS:A1993MN10800040
J	YU, YT; MARONEY, PA; NILSEN, TW				YU, YT; MARONEY, PA; NILSEN, TW			FUNCTIONAL RECONSTITUTION OF U6 SNRNA IN NEMATODE CIS-SPLICING AND TRANSSPLICING - U6 CAN SERVE AS BOTH A BRANCH ACCEPTOR AND A 5'-EXON	CELL			English	Article							PRE-MESSENGER-RNA; SMALL NUCLEAR-RNA; SPLICEOSOME ASSEMBLY PATHWAY; BASE-PAIRING INTERACTION; YEAST; INVITRO; U2; SITE; RIBONUCLEOPROTEIN; U4	Maturation of nuclear pre-mRNAs in nematodes requires both cis- and trans-splicing. Both processing pathways involve analogous two-step phosphotransfer reactions and both are dependent upon the integrity of U6 snRNA. We have developed a functional reconstitution assay to assess the U6 snRNA sequence requirements for cis- and trans-splicing. Branch formation between the splicing substrates and U6 snRNA was observed. The frequency of this event was greatly enhanced when a highly conserved sequence in U6 snRNA was altered by mutation. In cis- and trans-splicing reactions reconstituted with this mutant U6 snRNA the liberated exon of U6 proceeded through the second step of splicing using the appropriate splice acceptor sites. These results demonstrate covalent interactions between a U snRNA required for splicing and a splicing substrate, and they provide evidence for an unexpected degree of catalytic flexibility within the spliceosome.			YU, YT (corresponding author), CASE WESTERN RESERVE UNIV,SCH MED,CTR MOLEC PARASITOL,DEPT MOLEC BIOL & MICROBIOL,CLEVELAND,OH 44106, USA.				NIAID NIH HHS [AI-28799] Funding Source: Medline; NIGMS NIH HHS [GM-31528] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028799] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031528] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Baserga S., 1993, RNA WORLD, P359; BROW DA, 1988, NATURE, V334, P213, DOI 10.1038/334213a0; BROW DA, 1989, NATURE, V337, P14, DOI 10.1038/337014a0; DATTA B, 1993, MOL CELL BIOL, V13, P5377, DOI 10.1128/MCB.13.9.5377; DATTA B, 1991, NATURE, V352, P821, DOI 10.1038/352821a0; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FABRIZIO P, 1989, GENE DEV, V3, P2137, DOI 10.1101/gad.3.12b.2137; FABRIZIO P, 1992, NUCLEIC ACIDS RES, V20, P3659, DOI 10.1093/nar/20.14.3659; FABRIZIO P, 1990, SCIENCE, V250, P404, DOI 10.1126/science.2145630; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; GUTHRIE C, 1989, AM ZOOL, V29, P557; GUTHRIE C, 1991, SCIENCE, V253, P157, DOI 10.1126/science.1853200; HANNON GJ, 1991, J BIOL CHEM, V266, P22792; HANNON GJ, 1990, CELL, V61, P1247, DOI 10.1016/0092-8674(90)90689-C; HAUSNER TP, 1990, GENE DEV, V4, P2146, DOI 10.1101/gad.4.12a.2146; JAMISON SF, 1992, MOL CELL BIOL, V12, P4279, DOI 10.1128/MCB.12.10.4279; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MADHANI HD, 1992, CELL, V71, P803, DOI 10.1016/0092-8674(92)90556-R; MADHANI HD, 1990, GENE DEV, V4, P2264, DOI 10.1101/gad.4.12b.2264; MARONEY PA, 1990, EMBO J, V9, P3667, DOI 10.1002/j.1460-2075.1990.tb07578.x; MICHAUD S, 1993, GENE DEV, V7, P1008, DOI 10.1101/gad.7.6.1008; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; Moore M., 1993, RNA WORLD, P303; MOORE MJ, 1993, NATURE, V365, P364, DOI 10.1038/365364a0; NILSEN TW, 1993, ANNU REV MICROBIOL, V47, P413, DOI 10.1146/annurev.mi.47.100193.002213; ROSBASH M, 1991, TRENDS BIOCHEM SCI, V16, P187, DOI 10.1016/0968-0004(91)90073-5; RUSKIN B, 1985, SCIENCE, V229, P135, DOI 10.1126/science.2990042; SAWA H, 1992, P NATL ACAD SCI USA, V89, P11269, DOI 10.1073/pnas.89.23.11269; SAWA H, 1992, GENE DEV, V6, P244, DOI 10.1101/gad.6.2.244; Steitz J. A., 1988, STRUCTURE FUNCTION M, P115; STEITZ JA, 1992, SCIENCE, V257, P888, DOI 10.1126/science.1386941; STEITZ TA, 1993, P NATL ACAD SCI USA, V90, P6498, DOI 10.1073/pnas.90.14.6498; TAKAHASHI Y, 1993, MOL CELL BIOL, V13, P5613, DOI 10.1128/MCB.13.9.5613; TANI T, 1991, GENE DEV, V5, P1022, DOI 10.1101/gad.5.6.1022; TANI T, 1989, NATURE, V337, P87, DOI 10.1038/337087a0; TSCHUDI C, 1990, CELL, V61, P459, DOI 10.1016/0092-8674(90)90527-L; VANKAN P, 1990, EMBO J, V9, P3397, DOI 10.1002/j.1460-2075.1990.tb07541.x; VANKAN P, 1992, EMBO J, V11, P335, DOI 10.1002/j.1460-2075.1992.tb05056.x; VIERA J, 1987, METHOD ENZYMOL, V153, P3; WASSARMAN DA, 1992, SCIENCE, V257, P1918, DOI 10.1126/science.1411506; WEBER LA, 1978, METHOD CELL BIOL, V9, P215; WEINER AM, 1993, CELL, V72, P161, DOI 10.1016/0092-8674(93)90654-9; WOLFF T, 1992, EMBO J, V11, P345, DOI 10.1002/j.1460-2075.1992.tb05057.x; WOLFF T, 1993, GENE DEV, V7, P1377, DOI 10.1101/gad.7.7b.1377; WOLFF T, 1993, IN PRESS P NATL ACAD; WU J, 1991, NATURE, V352, P818, DOI 10.1038/352818a0	46	54	55	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	DEC 17	1993	75	6					1049	1059		10.1016/0092-8674(93)90315-H	http://dx.doi.org/10.1016/0092-8674(93)90315-H			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MM893	8261508				2022-12-01	WOS:A1993MM89300004
J	TASHIRO, K; TADA, H; HEILKER, R; SHIROZU, M; NAKANO, T; HONJO, T				TASHIRO, K; TADA, H; HEILKER, R; SHIROZU, M; NAKANO, T; HONJO, T			SIGNAL SEQUENCE TRAP - A CLONING STRATEGY FOR SECRETED PROTEINS AND TYPE-I MEMBRANE-PROTEINS	SCIENCE			English	Article							STROMAL CELL CLONE; MOLECULAR-CLONING; DIFFERENTIATION; CDNA; EXPRESSION; RECEPTOR; GROWTH; IDENTIFICATION; CULTURE; INVITRO	A method was developed to clone, without the use of specific functional assays, complementary DNAs (cDNAs) that carry specific amino-terminal signal sequences, such as those encoding intercellular signal-transducing molecules and receptors. The vector used in this system directed the cell surface expression of interleukin-2 receptor fusion proteins when inserts with signal sequences were cloned in-frame with the correct orientation. An expression cDNA library was constructed from a bone marrow stromal cell line, which contained 5' portion-enriched cDNAs (the average size was 400 base pairs). Two cDNAs that encoded putative cytokine molecules, stromal cell-derived factor-1alpha (SDF-1alpha) and SDF-1beta, which belong to the intercrine-macrophage inflammatory protein superfamily, were cloned.	KYOTO UNIV,FAC MED,DEPT MED CHEM,SAKYO KU,KYOTO 606,JAPAN	Kyoto University			Honjo, Tasuku/N-4470-2016					BROXMEYER HE, 1990, BLOOD, V76, P1110; COLLINS SJ, 1977, NATURE, V270, P347, DOI 10.1038/270347a0; GIGUERE V, 1987, NATURE, V330, P624, DOI 10.1038/330624a0; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; IKEDA T, 1991, J BONE MINER RES, V6, P1013; JAINCHIL.JL, 1969, J VIROL, V4, P549, DOI 10.1128/JVI.4.5.549-553.1969; KATAMINE S, 1984, NATURE, V309, P369, DOI 10.1038/309369a0; Kinashi T, 1989, INT IMMUNOL, V1, P11, DOI 10.1093/intimm/1.1.11; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE KH, 1991, J EXP MED, V173, P1257, DOI 10.1084/jem.173.5.1257; MORITA M, 1991, BLOOD, V77, P1766; NAGATA S, 1986, NATURE, V319, P415, DOI 10.1038/319415a0; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; NISHIKAWA SI, 1988, EUR J IMMUNOL, V18, P1767, DOI 10.1002/eji.1830181117; OGAWA M, 1988, EMBO J, V7, P1337, DOI 10.1002/j.1460-2075.1988.tb02949.x; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PALACIOS R, 1987, EMBO J, V6, P3687, DOI 10.1002/j.1460-2075.1987.tb02702.x; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; RALPH P, 1973, J IMMUNOL, V110, P1470; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; Sambrook J., 1989, MOL CLONING LAB MANU; SHIROZU M, UNPUB; Sideras P, 1989, Int Immunol, V1, P631, DOI 10.1093/intimm/1.6.631; SUDO T, 1989, J EXP MED, V170, P333, DOI 10.1084/jem.170.1.333; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; TASHIRO K, 1991, IMMUNOL LETT, V28, P147, DOI 10.1016/0165-2478(91)90113-O; UCHIYAMA T, 1981, J IMMUNOL, V126, P1393; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WOLPE SD, 1989, FASEB J, V3, P2565, DOI 10.1096/fasebj.3.14.2687068	31	628	753	1	24	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 30	1993	261	5121					600	603		10.1126/science.8342023	http://dx.doi.org/10.1126/science.8342023			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	8342023				2022-12-01	WOS:A1993LP72800036
J	HELLINGER, FJ				HELLINGER, FJ			THE LIFETIME COST OF TREATING A PERSON WITH HIV	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MEDICAL-CARE COSTS; AIDS; EXPERIENCE; FORECASTS	Objective.-To estimate the cost (total charges for services) of medical care for persons with human immunodeficiency virus (HIV) from the time of infection until death. Design and Setting.-Data from the AIDS (acquired immunodeficiency syndrome) Cost and Service Utilization Survey were used. Patients.-Data from interviews conducted during the spring and early summer of 1992 with 1164 respondents with HIV were analyzed. The respondents were recruited at 26 sites (hospitals, clinics, and physicians' offices) in 10 cities. Billing data from a survey of providers also were used. Outcome Measures.-Estimates of the mean occupancy time in each of four disease stages were obtained from the San Francisco Men's Health Study. These estimates were multiplied by the monthly cost in each stage and summed to derive a synthetic estimate of the lifetime medical care costs of treating a person with HIV. Results.-It is estimated herein that the lifetime cost of treating a person with HIV from the time of infection until death is approximately $119 000. The estimated cost of care from HIV infection until the development of AIDS is $50 000, while the estimated cost from Al DS development until death is approximately $69 000. These estimates define upper bounds because they assume persons receive treatment continuously from the moment of infection until death. Conclusions.-This study found that the cost of treating a person with AIDS, which has risen rapidly in the past, has fallen as a result of a reduction in the use of inpatient hospital services.			HELLINGER, FJ (corresponding author), US PHS,AGCY HLTH CARE POLICY & RES,CTR GEN HLTH SERV EXTRAMURAL RES,ROCKVILLE,MD 20852, USA.							ANDRULIS DP, 1987, JAMA-J AM MED ASSOC, V258, P1343; ANDRULIS DP, 1989, JAMA-J AM MED ASSOC, V262, P784, DOI 10.1001/jama.262.6.784; BACCHETTI P, 1989, NATURE, V338, P251, DOI 10.1038/338251a0; BARTLETT JG, 1992, 1992 1993 RECOMMENDA; BENNETT CL, 1992, J ACQ IMMUN DEF SYND, V5, P1; BENNETT CL, 1991, J ACQ IMMUN DEF SYND, V4, P197; EISENHANDLER J, 1992, AIDS UPDATE; GREEN J, 1990, JAMA-J AM MED ASSOC, V264, P1261, DOI 10.1001/jama.264.10.1261; HELLINGER FJ, 1992, INQUIRY-J HEALTH CAR, V29, P356; HELLINGER FJ, 1991, INQUIRY-J HEALTH CAR, V28, P213; HELLINGER FJ, 1990, PUBLIC HEALTH REP, V105, P1; ROTHENBERG R, 1987, NEW ENGL J MED, V317, P1297, DOI 10.1056/NEJM198711193172101; SATTEN GA, 1992, 8TH INT C AIDS AMST; SCITOVSKY AA, 1989, MILBANK Q, V67, P318, DOI 10.2307/3350143; STONE VE, 1992, JAMA-J AM MED ASSOC, V268, P2655, DOI 10.1001/jama.268.19.2655; 1992, DISTRICT COLUMBIA CO; 1992, AIDS NEW YORK STATE; 1990, AIDS NEW YORK STATE	18	241	243	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	JUL 28	1993	270	4					474	478		10.1001/jama.270.4.474	http://dx.doi.org/10.1001/jama.270.4.474			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LN426	8320787				2022-12-01	WOS:A1993LN42600027
J	TIAN, M; MANIATIS, T				TIAN, M; MANIATIS, T			A SPLICING ENHANCER COMPLEX CONTROLS ALTERNATIVE SPLICING OF DOUBLESEX PREMESSENGER RNA	CELL			English	Article							NUCLEAR RIBONUCLEOPROTEIN-PARTICLES; SITE SELECTION; DROSOPHILA-MELANOGASTER; BINDING PROTEINS; CONSERVED FAMILY; SEXUAL-DIFFERENTIATION; MAMMALIAN SPLICEOSOME; EXON SEQUENCES; 70K PROTEIN; FACTOR SC35	Female-specific splicing of Drosophila doublesex (dsx) pre-mRNA is regulated by the products of the transformer (tra) and transformer 2 (tra2) genes. In this paper we show that Tra and Tra2 act by recruiting general splicing factors to a regulatory element located downstream of a female-specific 3' splice site. Remarkably, Tra, Tra2, and members of the serine/arginine-rich (SR) family of general splicing factors are sufficient to commit dsx pre-mRNA to female-specific splicing, and individual SR proteins differ significantly in their ability to participate in commitment complex formation. Characterization of the proteins associated with affinity purified complex formed on dsx pre-mRNA reveals the presence of Tra, Tra2, SR proteins, and additional unidentified components. We conclude that Tra, Tra2, and SR proteins are essential components of a splicing enhancer complex.			TIAN, M (corresponding author), HARVARD UNIV, DEPT BIOCHEM & MOLEC BIOL, CAMBRIDGE, MA 02138 USA.							ABMAYR SM, 1988, P NATL ACAD SCI USA, V85, P7216, DOI 10.1073/pnas.85.19.7216; AMREIN H, 1988, CELL, V55, P1025, DOI 10.1016/0092-8674(88)90247-4; BAKER BS, 1980, GENETICS, V94, P383; BAKER BS, 1989, NATURE, V340, P521, DOI 10.1038/340521a0; BANZIULIS RJ, 1989, GENE DEV, P431; BARDWELL VJ, 1990, NUCLEIC ACIDS RES, V18, P6587, DOI 10.1093/nar/18.22.6587; BENNETT M, 1992, MOL CELL BIOL, V12, P3165, DOI 10.1128/MCB.12.7.3165; BENNETT M, 1992, GENE DEV, V6, P1986, DOI 10.1101/gad.6.10.1986; BINGHAM PM, 1988, TRENDS GENET, V4, P134, DOI 10.1016/0168-9525(88)90136-9; BLACK DL, 1992, CELL, V69, P795, DOI 10.1016/0092-8674(92)90291-J; BOGGS RT, 1987, CELL, V50, P739, DOI 10.1016/0092-8674(87)90332-1; BURTIS KC, 1989, CELL, V56, P997, DOI 10.1016/0092-8674(89)90633-8; CHOU TB, 1987, EMBO J, V6, P4095, DOI 10.1002/j.1460-2075.1987.tb02755.x; FU XD, 1992, P NATL ACAD SCI USA, V89, P11224, DOI 10.1073/pnas.89.23.11224; FU XD, 1992, P NATL ACAD SCI USA, V89, P1725, DOI 10.1073/pnas.89.5.1725; FU XD, 1992, SCIENCE, V256, P535, DOI 10.1126/science.1373910; GE H, 1991, CELL, V66, P373, DOI 10.1016/0092-8674(91)90626-A; GORALSKI TJ, 1989, CELL, V56, P1011, DOI 10.1016/0092-8674(89)90634-X; GOTT JM, 1991, BIOCHEMISTRY-US, V30, P6290, DOI 10.1021/bi00239a030; GRABOWSKI PJ, 1986, SCIENCE, V233, P1294, DOI 10.1126/science.3638792; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HEDLEY ML, 1991, CELL, V65, P579, DOI 10.1016/0092-8674(91)90090-L; HOFFMAN BE, 1992, GENE DEV, V6, P2554, DOI 10.1101/gad.6.12b.2554; HOSHIJIMA K, 1991, SCIENCE, V252, P833, DOI 10.1126/science.1902987; INOUE K, 1992, P NATL ACAD SCI USA, V89, P8092, DOI 10.1073/pnas.89.17.8092; KIM YJ, 1992, GENE DEV, V6, P2569, DOI 10.1101/gad.6.12b.2569; KRAINER AR, 1991, CELL, V66, P383, DOI 10.1016/0092-8674(91)90627-B; KRAINER AR, 1985, CELL, V42, P725, DOI 10.1016/0092-8674(85)90269-7; KRAMER A, 1988, GENE DEV, V2, P1155, DOI 10.1101/gad.2.9.1155; MANCEBO R, 1990, MOL CELL BIOL, V10, P2492, DOI 10.1128/MCB.10.6.2492; MANIATIS T, 1991, SCIENCE, V251, P33, DOI 10.1126/science.1824726; MAYEDA A, 1992, P NATL ACAD SCI USA, V89, P1301, DOI 10.1073/pnas.89.4.1301; MICHAUD S, 1991, GENE DEV, V5, P2534, DOI 10.1101/gad.5.12b.2534; NADALGINARD B, 1991, ADV ENZYME REGUL, V31, P261, DOI 10.1016/0065-2571(91)90017-G; NAGOSHI RN, 1990, GENE DEV, V4, P89, DOI 10.1101/gad.4.1.89; NIWA M, 1992, NATURE, V360, P277, DOI 10.1038/360277a0; NIWA M, 1991, GENE DEV, V5, P2086, DOI 10.1101/gad.5.11.2086; NOTHIGER R, 1987, GENET RES, V50, P113, DOI 10.1017/S001667230002351X; REED R, 1988, CELL, V53, P949, DOI 10.1016/S0092-8674(88)90489-8; REED R, 1986, CELL, V46, P681, DOI 10.1016/0092-8674(86)90343-0; REED R, 1990, P NATL ACAD SCI USA, V87, P8031, DOI 10.1073/pnas.87.20.8031; Rio Donald C., 1992, Gene Expression, V2, P1; ROBBERSON BL, 1990, MOL CELL BIOL, V10, P84, DOI 10.1128/MCB.10.1.84; ROTH MB, 1991, J CELL BIOL, V115, P587, DOI 10.1083/jcb.115.3.587; RYNER LC, 1991, GENE DEV, V5, P2071, DOI 10.1101/gad.5.11.2071; SIEBEL CW, 1992, GENE DEV, V6, P1386, DOI 10.1101/gad.6.8.1386; SIEBEL CW, 1990, SCIENCE, V248, P1200, DOI 10.1126/science.2161558; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; Steinmann-Zwicky M, 1990, Adv Genet, V27, P189; THEISSEN H, 1986, EMBO J, V5, P3209, DOI 10.1002/j.1460-2075.1986.tb04631.x; TIAN M, 1992, SCIENCE, V256, P237, DOI 10.1126/science.1566072; VALCARCEL J, 1993, NATURE, V362, P171, DOI 10.1038/362171a0; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; ZAHLER AM, 1992, GENE DEV, V6, P837, DOI 10.1101/gad.6.5.837; ZAHLER AM, 1993, SCIENCE, V260, P219, DOI 10.1126/science.8385799; ZAMORE PD, 1992, NATURE, V355, P609, DOI 10.1038/355609a0	56	313	321	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	JUL 16	1993	74	1					105	114		10.1016/0092-8674(93)90298-5	http://dx.doi.org/10.1016/0092-8674(93)90298-5			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8334698				2022-12-01	WOS:A1993LN62500011
J	HAMMOND, SA; BOLLINGER, RC; TOBERY, TW; SILICIANO, RF				HAMMOND, SA; BOLLINGER, RC; TOBERY, TW; SILICIANO, RF			TRANSPORTER-INDEPENDENT PROCESSING OF HIV-1 ENVELOPE PROTEIN FOR RECOGNITION BY CD8+ T-CELLS	NATURE			English	Article							TOXIC LYMPHOCYTES-T; MAJOR HISTOCOMPATIBILITY COMPLEX; CLASS-II REGION; ENDOPLASMIC-RETICULUM; ANTIGEN PRESENTATION; SIGNAL SEQUENCE; VIRUS; MHC; EXPRESSION; GENE	CD8+ cytolytic T lymphocytes (CTL) identify virally infected cells by recognizing processed viral antigen in association with class I major histocompatibility complex (MHC) molecules on infected cells1-4. Processing begins in the cytosol5-7 with the generation of peptides, possibly by a protease complex with MHC-encoded subunits, known as the proteasome8-11. Transport of the resulting cytosolic peptides into the endoplasmic reticulum for association with class I molecules is essential and probably involves a heterodimer of the MHC-encoded proteins, Tap-1 and Tap-2(12-17). The site of processing of viral envelope proteins is uncertain. These proteins are not present in the cytosol because of cotranslational translocation into the endoplasmic reticulum. We show here that the HIV-1 envelope (env) protein is processed in infected cells by a novel Tap-1/Tap-2-independent pathway that seems to be localized to the endoplasmic reticulum.			HAMMOND, SA (corresponding author), JOHNS HOPKINS UNIV,SCH MED,DEPT MED,BALTIMORE,MD 21205, USA.			Bollinger, Robert/0000-0002-6798-6834				ALDRICH CJ, 1992, J IMMUNOL, V149, P3773; ANDERSON K, 1991, J EXP MED, V174, P489, DOI 10.1084/jem.174.2.489; BROWN MG, 1991, NATURE, V353, P355, DOI 10.1038/353355a0; BUONOCORE L, 1990, NATURE, V345, P625, DOI 10.1038/345625a0; CALLAHAN KC, IN PRESS J IMMUN; CERUNDOLO V, 1990, NATURE, V345, P449, DOI 10.1038/345449a0; CHESEBRO B, 1988, J VIROL, V62, P3779, DOI 10.1128/JVI.62.10.3779-3788.1988; CRISE B, 1990, J VIROL, V64, P5585, DOI 10.1128/JVI.64.11.5585-5593.1990; DEMARS R, 1985, P NATL ACAD SCI USA, V82, P8183, DOI 10.1073/pnas.82.23.8183; DEVERSON EV, 1990, NATURE, V348, P738, DOI 10.1038/348738a0; EARL PL, 1991, J VIROL, V65, P31, DOI 10.1128/JVI.65.1.31-41.1991; EARL PL, 1990, J VIROL, V64, P2448, DOI 10.1128/JVI.64.5.2448-2451.1990; FOLZ RJ, 1987, BIOCHEM BIOPH RES CO, V146, P870, DOI 10.1016/0006-291X(87)90611-5; GERMAIN RN, 1986, NATURE, V322, P687, DOI 10.1038/322687a0; GLYNNE R, 1991, NATURE, V353, P357, DOI 10.1038/353357a0; GOODING LR, 1983, J IMMUNOL, V131, P2580; HAFFAR OK, 1990, J VIROL, V64, P3100, DOI 10.1128/JVI.64.6.3100-3103.1990; HAMMOND SA, 1992, J EXP MED, V176, P1531, DOI 10.1084/jem.176.6.1531; HENDERSON RA, 1992, SCIENCE, V255, P1264, DOI 10.1126/science.1546329; HOSKEN NA, 1990, SCIENCE, V248, P367, DOI 10.1126/science.2326647; JARDETZKY TS, 1991, NATURE, V353, P326, DOI 10.1038/353326a0; KELLY A, 1992, NATURE, V355, P641, DOI 10.1038/355641a0; KLEIJMEER MJ, 1992, NATURE, V357, P342, DOI 10.1038/357342a0; KOENIG S, 1988, P NATL ACAD SCI USA, V85, P8638, DOI 10.1073/pnas.85.22.8638; KVIST S, 1990, NATURE, V348, P446, DOI 10.1038/348446a0; LIE WR, 1990, NATURE, V344, P439, DOI 10.1038/344439a0; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; LJUNGGREN HG, 1990, NATURE, V346, P476, DOI 10.1038/346476a0; MONACO JJ, 1990, SCIENCE, V250, P1723, DOI 10.1126/science.2270487; MONACO JJ, 1984, NATURE, V309, P797, DOI 10.1038/309797a0; MOORE MW, 1988, CELL, V54, P777, DOI 10.1016/S0092-8674(88)91043-4; MORRISON LA, 1986, J EXP MED, V163, P903, DOI 10.1084/jem.163.4.903; OHLEN C, 1990, J IMMUNOL, V145, P52; ORENTAS RJ, 1990, SCIENCE, V248, P1234, DOI 10.1126/science.2190315; ORTIZNAVARRETE V, 1991, NATURE, V353, P662, DOI 10.1038/353662a0; OTTEN GR, 1992, J IMMUNOL, V148, P3723; PLATA F, 1987, NATURE, V328, P348, DOI 10.1038/328348a0; POLYDEFKIS M, 1990, J EXP MED, V171, P875, DOI 10.1084/jem.171.3.875; SALTER RD, 1985, IMMUNOGENETICS, V21, P235, DOI 10.1007/BF00375376; SPIES T, 1990, NATURE, V348, P744, DOI 10.1038/348744a0; TOWNSEND A, 1989, NATURE, V340, P443, DOI 10.1038/340443a0; TOWNSEND ARM, 1986, NATURE, V324, P575, DOI 10.1038/324575a0; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; TROWSDALE J, 1990, NATURE, V348, P741, DOI 10.1038/348741a0; VANBINNENDIJK RS, 1992, J EXP MED, V176, P119, DOI 10.1084/jem.176.1.119; WALKER BD, 1987, NATURE, V328, P345, DOI 10.1038/328345a0; WEI ML, 1992, NATURE, V356, P443, DOI 10.1038/356443a0; WILLEY RL, 1988, P NATL ACAD SCI USA, V85, P9580, DOI 10.1073/pnas.85.24.9580; WILSTROM L, 1991, J CELL BIOL, V113, P997; YEWDELL JW, 1988, SCIENCE, V239, P637, DOI 10.1126/science.3257585	50	97	97	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 8	1993	364	6433					158	161		10.1038/364158a0	http://dx.doi.org/10.1038/364158a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL367	8321286				2022-12-01	WOS:A1993LL36700053
J	HOWARD, RJ; LILLIS, C; TUCK, SM				HOWARD, RJ; LILLIS, C; TUCK, SM			CONTRACEPTIVES, COUNSELING, AND PREGNANCY IN WOMEN WITH SICKLE-CELL DISEASE	BRITISH MEDICAL JOURNAL			English	Article							DIAGNOSIS	Sickle cell disease is listed in the manufacturers' data sheets in the United Kingdom as a contraindication to the use of most combined contraceptive pills; the result is confused advice on family planning to a group of women who are at substantial risk from both planned and unplanned pregnancy. A study in north London on the use of contraceptives by women with sickle cell disease indicates that the use of combined oral contraceptives is common. Although medical staff usually advised against pregnancy, such advice was almost always ignored. Over half of the women surveyed had some knowledge about antenatal diagnosis. Family planning advice should be an integral part of the care of women with sickle cell disease. In the absence of specific data to the contrary all methods of contraception may be considered, although with appropriate caution.			HOWARD, RJ (corresponding author), UNIV LONDON,ROYAL FREE HOSP,DEPT OBSTET & GYNAECOL,LONDON NW3 2QG,ENGLAND.							ANIONWU EN, 1987, J MED GENET, V25, P769; CHARACHE S, 1985, CLIN HAEMATOL, V14, P729; DECEULAER K, 1982, LANCET, V2, P229; EVANS DK, 1984, BR J FAM PLANN, V10, P80; FLEISSIG A, 1991, BRIT MED J, V302, P147, DOI 10.1136/bmj.302.6769.147; FOSTER HW, 1981, SOUTHERN MED J, V74, P543, DOI 10.1097/00007611-198105000-00009; FREIE HMP, 1983, ACTA OBSTET GYN SCAN, V62, P211, DOI 10.3109/00016348309155794; Greenwald J G, 1971, Conn Med, V35, P231; HARGUS EP, 1977, AM J OBSTET GYNECOL, V129, P697, DOI 10.1016/0002-9378(77)90656-1; HAYNES RL, 1967, JAMA-J AM MED ASSOC, V200, P186; LOUDEN N, 1991, HDB FAMILY PLANNING; LOUKOPOULOS D, 1990, ANN NY ACAD SCI, V612, P226; LUTCHER CL, 1986, CLIN RES, V34, pA217; MORRISON J C, 1979, Clinical Obstetrics and Gynecology, V22, P819, DOI 10.1097/00003081-197912000-00005; PERKINS RP, 1971, NEW ENGL J MED, V285, P296; PETROU M, 1990, ANN NY ACAD SCI, V612, P251; ROWLEY PT, 1991, AM J HUM GENET, V48, P439; SAMUELSREID JH, 1984, J NATL MED ASSOC, V76, P879; SERGEANT GR, 1983, BMJ, V287, P628; SMITH T, 1990, BRIT MED J, V300, P1154, DOI 10.1136/bmj.300.6733.1154; TUCK SM, 1983, BRIT J OBSTET GYNAEC, V90, P112, DOI 10.1111/j.1471-0528.1983.tb08893.x	21	29	30	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 26	1993	306	6894					1735	1737		10.1136/bmj.306.6894.1735	http://dx.doi.org/10.1136/bmj.306.6894.1735			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LK367	8343632	Bronze, Green Published			2022-12-01	WOS:A1993LK36700026
J	DOYAL, L; WILSHER, D				DOYAL, L; WILSHER, D			WITHHOLDING CARDIOPULMONARY-RESUSCITATION - PROPOSALS FOR FORMAL GUIDELINES	BRITISH MEDICAL JOURNAL			English	Article							DECISIONS; SURVIVAL; ORDERS; ETHICS; DNR	Working with members of the Royal London Trust and its medical council, Len Doyal and Daniel Wilsher have composed a set of guidelines governing the making of decisions to withhold resuscitation from patients. The guidelines describe the procedures that should be followed when giving orders for non-resuscitation and the clinical, legal, and moral criteria that should be satisfied before such orders arc issued. The authors hope that these guidelines will be of help to those responsible for the creation of hospitals' policies for non-resuscitation.	ST BARTHOLOMEWS HOSP,COLL MED,JOINT DEPT HUMAN SCI & MED ETH,LONDON E1 2AD,ENGLAND	University of London; Queen Mary University London	DOYAL, L (corresponding author), UNIV LONDON LONDON HOSP,COLL MED,JOINT DEPT HUMAN SCI & MED ETH,LONDON E1 2AD,ENGLAND.							AARONS EJ, 1991, BRIT MED J, V303, P1504, DOI 10.1136/bmj.303.6816.1504; [Anonymous], 1989, ALL ER, V2, P782; BEDELL SE, 1983, NEW ENGL J MED, V309, P569, DOI 10.1056/NEJM198309083091001; DOYAL LT, IN PRESS SURGERY NEW; EVANS TR, 1990, ABS RESUSCITATION, P66; GEORGE AL, 1989, AM J MED, V87, P28; Great Britain. England. Court of Appeal Civil Division, 1990, All Engl Law Rep, V[1990] 3, P930; HOLMBERG S, 1992, RESUSCITATION, V24, P239, DOI 10.1016/0300-9572(92)90184-E; KENNEDY I, 1990, MED LAW TEST MATERIA, P936; LOEWY EH, 1991, J MED ETHICS, V17, P156, DOI 10.1136/jme.17.3.156; Re T, 1992, WLR, V3, P782; SAUNDERS J, 1992, J ROY COLL PHYS LOND, V26, P254; SCHADE SG, 1989, J MED ETHICS, V15, P186, DOI 10.1136/jme.15.4.186; TOMLINSON T, 1990, JAMA-J AM MED ASSOC, V264, P1276, DOI 10.1001/jama.264.10.1276; TOMLINSON T, 1988, NEW ENGL J MED, V318, P43, DOI 10.1056/NEJM198801073180109; WALKER RM, 1991, JAMA-J AM MED ASSOC, V266, P2407, DOI 10.1001/jama.266.17.2407; 1993, BMLR, V9, P20; 1983, DECIDING FOREGO LIFE, P231; 1993, DECISIONS RELATING C; 1991, 1990 1991 HLTH SERV, P12; 1991, PLCMO9122 DEP HLTH	21	64	64	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1593	1596		10.1136/bmj.306.6892.1593	http://dx.doi.org/10.1136/bmj.306.6892.1593			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329925	Green Published, Bronze			2022-12-01	WOS:A1993LH12800025
J	HELGREN, ME; SQUINTO, SP; DAVIS, HL; PARRY, DJ; BOULTON, TG; HECK, CS; ZHU, Y; YANCOPOULOS, GD; LINDSAY, RM; DISTEFANO, PS				HELGREN, ME; SQUINTO, SP; DAVIS, HL; PARRY, DJ; BOULTON, TG; HECK, CS; ZHU, Y; YANCOPOULOS, GD; LINDSAY, RM; DISTEFANO, PS			TROPHIC EFFECT OF CILIARY NEUROTROPHIC FACTOR ON DENERVATED SKELETAL-MUSCLE	CELL			English	Article							DIGITORUM LONGUS MUSCLE; RAT SOLEUS MUSCLE; NERVE EXTRACT; NEURONOTROPHIC FACTOR; SCIATIC-NERVE; CHOLINERGIC DIFFERENTIATION; ACETYLCHOLINE RECEPTORS; EMBRYONIC MOTONEURONS; SIGNAL TRANSDUCER; PERIPHERAL-NERVE	The actions and receptor for ciliary neurotrophic factor (CNTF) are largely restricted to cells of the nervous system, although one of the CNTF receptor components, CNTFR alpha, is expressed by skeletal muscle. Here we show that the other CNTF receptor components, LIFR beta and gp130, are also expressed by skeletal muscle and that expression of all three CNTF receptor components is greatly increased in denervated muscle. In vivo, administration of CNTF activates these receptors on skeletal muscle by inducing receptor phosphorylation and immediate-early gene responses. Furthermore, CNTF reduces the denervation-induced atrophy of muscle and attenuates the reduced twitch and tetanic tensions that result from muscle denervation. Our findings reveal that, in addition to its known neurotrophic actions, CNTF exerts myotrophic effects by attenuating the morphological and functional changes associated with denervation of rat skeletal muscle.	UNIV OTTAWA,PHYSIOTHERAPY PROGRAM,OTTAWA,ON,CANADA; UNIV OTTAWA,DEPT PHYSIOL,OTTAWA,ON,CANADA; UNIV WESTERN ONTARIO,DEPT PHYSIOTHERAPY,LONDON,ON,CANADA	University of Ottawa; University of Ottawa; Western University (University of Western Ontario)	HELGREN, ME (corresponding author), REGENERON PHARMACEUT INC,777 OLD SAW MILL RIVER RD,TARRYTOWN,NY 10591, USA.		Lindsay, Ronald/GQP-8001-2022					ADLER R, 1979, SCIENCE, V204, P1434, DOI 10.1126/science.451576; ALOE L, 1975, ARCH ITAL BIOL, V113, P236; ARAKAWA Y, 1990, J NEUROSCI, V10, P3507; BARBIN G, 1984, J NEUROCHEM, V43, P1468, DOI 10.1111/j.1471-4159.1984.tb05410.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRIMIJOIN S, 1988, NERVE MUSCLE CELL TR, P23; CALCUTT NA, 1992, BRAIN RES, V575, P320, DOI 10.1016/0006-8993(92)90097-S; CAMERON NE, 1992, EXP PHYSIOL, V77, P89, DOI 10.1113/expphysiol.1992.sp003585; CARD DJ, 1977, EXP NEUROL, V54, P251, DOI 10.1016/0014-4886(77)90268-0; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVEY B, 1978, EXP NEUROL, V59, P168; DAVIS HL, 1985, BRAIN RES, V343, P176, DOI 10.1016/0006-8993(85)91174-6; DAVIS HL, 1981, EXP NEUROL, V72, P582, DOI 10.1016/0014-4886(81)90007-8; DAVIS HL, 1980, EXP NEUROL, V69, P124, DOI 10.1016/0014-4886(80)90148-X; DAVIS HL, 1983, EXP NEUROL, V80, P383, DOI 10.1016/0014-4886(83)90290-X; DAVIS HL, 1985, EXP NEUROL, V89, P159, DOI 10.1016/0014-4886(85)90273-0; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; Davis S, 1993, Curr Opin Neurobiol, V3, P20, DOI 10.1016/0959-4388(93)90030-3; FISCHBACH GD, 1969, J PHYSIOL-LONDON, V201, P305, DOI 10.1113/jphysiol.1969.sp008757; FITTS RH, 1986, J APPL PHYSIOL, V60, P1946, DOI 10.1152/jappl.1986.60.6.1946; FLORINI JR, 1987, MUSCLE NERVE, V10, P577, DOI 10.1002/mus.880100702; FORGERNG, 1993, J NEUROSCI, V13, P4720; FRIEDMAN B, 1992, NEURON, V9, P295, DOI 10.1016/0896-6273(92)90168-D; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; GURNEY ME, 1992, J NEUROSCI, V12, P3241, DOI 10.1523/JNEUROSCI.12-08-03241.1992; HELD IR, 1983, J NEUROSCI, V3, P2054; HENDERSON CE, 1983, NATURE, V302, P609, DOI 10.1038/302609a0; HILL MA, 1986, DEV BRAIN RES, V24, P305, DOI 10.1016/0165-3806(86)90201-4; HOUENOU LJ, 1991, J NEUROSCI, V11, P2829; IP NY, 1991, J NEUROSCI, V11, P3124; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; IP NY, 1993, EUR J NEUROSCI, V5, P25, DOI 10.1111/j.1460-9568.1993.tb00201.x; IP NY, 1993, NEURON, V10, P89, DOI 10.1016/0896-6273(93)90245-M; JOHNSON DJ, 1982, EXP NEUROL, V76, P414, DOI 10.1016/0014-4886(82)90218-7; JOLESZ F, 1981, ANNU REV PHYSIOL, V43, P531, DOI 10.1146/annurev.ph.43.030181.002531; LIN LFH, 1989, SCIENCE, V246, P1023, DOI 10.1126/science.2587985; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; MANTHORPE M, 1986, BRAIN RES, V367, P282, DOI 10.1016/0006-8993(86)91603-3; MARTINOU JC, 1992, NEURON, V8, P737, DOI 10.1016/0896-6273(92)90094-T; MASIAKOWSKI P, 1991, J NEUROCHEM, V57, P1003, DOI 10.1111/j.1471-4159.1991.tb08250.x; MATHERS DA, 1978, J PHYSIOL-LONDON, V282, P105, DOI 10.1113/jphysiol.1978.sp012451; MESSING A, 1992, NEURON, V8, P507, DOI 10.1016/0896-6273(92)90279-M; MIDDLEMAS DS, 1991, MOL CELL BIOL, V11, P143, DOI 10.1128/MCB.11.1.143; NIEDERLE B, 1978, ANAT EMBRYOL, V153, P9, DOI 10.1007/BF00569846; PESTRONK A, 1976, NATURE, V260, P352, DOI 10.1038/260352a0; RASSENDREN FA, 1992, P NATL ACAD SCI USA, V89, P7194, DOI 10.1073/pnas.89.15.7194; RENDE M, 1992, GLIA, V5, P25, DOI 10.1002/glia.440050105; RILEY DA, 1973, EXP NEUROL, V40, P391, DOI 10.1016/0014-4886(73)90082-4; SAADAT S, 1989, J CELL BIOL, V108, P1807, DOI 10.1083/jcb.108.5.1807; SCHIAFFINO S, 1989, J MUSCLE RES CELL M, V10, P197, DOI 10.1007/BF01739810; SCHMALBRUCH H, 1985, SKELETAL MUSCLE; SENDTNER M, 1992, NATURE, V358, P502, DOI 10.1038/358502a0; SENDTNER M, 1992, J CELL BIOL, V118, P139, DOI 10.1083/jcb.118.1.139; SENDTNER M, 1990, NATURE, V345, P440, DOI 10.1038/345440a0; SPECTOR SA, 1985, J NEUROSCI, V5, P2177; STAHL N, 1993, J BIOL CHEM, V268, P7628; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STOCKLI KA, 1989, NATURE, V342, P920, DOI 10.1038/342920a0; TAGA T, 1992, P NATL ACAD SCI USA, V89, P10998, DOI 10.1073/pnas.89.22.10998; TEMPLETON GH, 1984, J APPL PHYSIOL, V56, P278, DOI 10.1152/jappl.1984.56.2.278; THOENEN H, 1991, TRENDS NEUROSCI, V14, P165, DOI 10.1016/0166-2236(91)90097-E; UCHITEL O, 1978, BRAIN RES, V153, P539, DOI 10.1016/0006-8993(78)90338-4; VARON SS, 1978, ANNU REV NEUROSCI, V1, P327, DOI 10.1146/annurev.ne.01.030178.001551; WILLIAMS LR, 1984, INT J DEV NEUROSCI, V2, P177, DOI 10.1016/0736-5748(84)90009-1; WITZMANN FA, 1982, J APPL PHYSIOL, V53, P335, DOI 10.1152/jappl.1982.53.2.335; WONG V, 1993, EUR J NEUROSCI, V5, P466, DOI 10.1111/j.1460-9568.1993.tb00513.x	69	209	221	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	FEB 11	1994	76	3					493	504		10.1016/0092-8674(94)90113-9	http://dx.doi.org/10.1016/0092-8674(94)90113-9			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MX207	8313470				2022-12-01	WOS:A1994MX20700010
J	DAVIS, DL; DINSE, GE; HOEL, DG				DAVIS, DL; DINSE, GE; HOEL, DG			DECREASING CARDIOVASCULAR-DISEASE AND INCREASING CANCER AMONG WHITES IN THE UNITED-STATES FROM 1973 THROUGH 1987 - GOOD-NEWS AND BAD-NEWS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INDUSTRIALIZED COUNTRIES; TRENDS; MORTALITY; PERIOD; MODELS; RATES; AGE	Objective.-Trends in cancer mortality, cardiovascular mortality, and cancer incidence are assessed among US whites to determine whether aging of the population and smoking patterns completely account for increased cancer rates from 1973 through 1987. Design.-For mortality, percentage changes in age-specific rates were calculated. For cancer incidence, trends in age-specific rates across time periods and birth cohorts were assessed for several sites. Main Outcome Measures.-National US cardiovascular and cancer mortality rates and incidence rates for smoking-related cancer, breast cancer, and all other types of cancer in 1 0% of the US population covered by the National Cancer Institute's Surveillance, Epidemiology, and End Results Program were analyzed. Results.-From 1973 through 1987, cardiovascular mortality decreased 42% in the age group 0 to 54 years and decreased 33% in the age group 55 to 84 years; concurrently, cancer mortality decreased 17% in the younger group but increased 12% in the older group. By 1987, even though proportionally fewer people in the older age groups died, relatively more of them died of cancer. Men born in the 1940s had twice as much cancer as those born in 1888 through 1897 and more than twice as much cancer not linked to smoking; women born during this period had 50% and 30% more of these same cancers, respectively. Rates of smoking-related cancers in recent cohorts of women were five to six times greater than in those born in 1888 th rough 1897, while rates in men declined. Recent cohorts of women also had more than twice as much breast cancer as those born in 1888 through 1897. Conclusions.-In recent US birth cohorts, our model found that increases in cancer have occurred that are not solely linked to aging of the population and smoking patterns. In light of these results and similar findings in Sweden, changes in carcinogenic hazards in addition to smoking are likely to have occurred and need to be studied further.	NIEHS, STAT & BIOMATH BRANCH, RES TRIANGLE PK, NC 27709 USA; MED UNIV S CAROLINA, HOLLINGS CANC CTR, CHARLESTON, SC 29425 USA; MED UNIV S CAROLINA, DEPT BIOMETRY & EPIDEMIOL, CHARLESTON, SC 29425 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS); Medical University of South Carolina; Medical University of South Carolina	DAVIS, DL (corresponding author), DEPT HLTH & HUMAN SERV, OFF ASSISTANT SECRETARY HLTH, 200 INDEPENDENCE AVE SW, WASHINGTON, DC 20201 USA.							ADAMI HO, 1993, LANCET, V341, P773, DOI 10.1016/0140-6736(93)90557-W; ADAMI HO, 1992, ACTA ONCOL, V31, P1; BAKER RJ, 1978, GLIM SYSTEM; BRESLOW NE, 1984, APPL STAT-J ROY ST C, V33, P38; BRODER S, 1991, ORIGINS HUMAN CANNCE; CLAYTON D, 1987, STAT MED, V6, P449, DOI 10.1002/sim.4780060405; DAVIS DL, 1990, LANCET, V336, P474, DOI 10.1016/0140-6736(90)92020-I; DAVIS DL, 1993, ENVIRON HEALTH PERSP, V100, P39, DOI 10.2307/3431519; DOLL R, 1991, AM J EPIDEMIOL, V134, P675, DOI 10.1093/oxfordjournals.aje.a116143; FEUER EJ, 1992, AM J EPIDEMIOL, V136, P1423, DOI 10.1093/oxfordjournals.aje.a116463; HOEL DG, 1992, JNCI-J NATL CANCER I, V84, P313, DOI 10.1093/jnci/84.5.313; HOLFORD TR, 1991, J CLIN EPIDEMIOL, V44, P29, DOI 10.1016/0895-4356(91)90198-I; HOLFORD TR, 1983, BIOMETRICS, V39, P311, DOI 10.2307/2531004; JICK H, 1979, NEW ENGL J MED, V300, P218, DOI 10.1056/NEJM197902013000502; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; LOPEZ AD, 1990, ANN NY ACAD SCI, V609, P58, DOI 10.1111/j.1749-6632.1990.tb32057.x; RIES LAG, 1990, NCI NIH902789 PUBL; 1982, HLTH CONSEQUENCES SM; 1991, CANCER FACTS FIGURES; 1991, NCI MONOGRAPH, V1	20	70	71	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 9	1994	271	6					431	437		10.1001/jama.271.6.431	http://dx.doi.org/10.1001/jama.271.6.431			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MU491	8295317				2022-12-01	WOS:A1994MU49100029
J	COHEN, C; PARRY, DAD				COHEN, C; PARRY, DAD			ALPHA-HELICAL COILED COILS - MORE FACTS AND BETTER PREDICTIONS	SCIENCE			English	Article							FIBROUS PROTEINS; HEPTAD REPEAT; TROPOMYOSIN; SPECTRIN; MOTIF		MASSEY UNIV, DEPT PHYS & BIOPHYS, PALMERSTON NORTH, NEW ZEALAND	Massey University	COHEN, C (corresponding author), BRANDEIS UNIV, ROSENSTIEL BASIC MED SCI RES CTR, WALTHAM, MA 02254 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR017346, R37AR017346] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR17346] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; COHEN C, 1986, TRENDS BIOCHEM SCI, V11, P245, DOI 10.1016/0968-0004(86)90186-6; COHEN C, 1990, PROTEINS, V7, P1, DOI 10.1002/prot.340070102; CONWAY JF, 1990, INT J BIOL MACROMOL, V12, P328, DOI 10.1016/0141-8130(90)90023-4; CONWAY JF, 1991, INT J BIOL MACROMOL, V13, P14, DOI 10.1016/0141-8130(91)90004-E; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; LUPAS A, 1991, SCIENCE, V252, P1162, DOI 10.1126/science.252.5009.1162; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MCLACHLAN AD, 1976, J MOL BIOL, V103, P271, DOI 10.1016/0022-2836(76)90313-2; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; Parry D A, 1991, J Mol Recognit, V4, P63, DOI 10.1002/jmr.300040205; PARRY DAD, 1982, BIOSCIENCE REP, V2, P1017, DOI 10.1007/BF01122170; PARRY DAD, 1992, BIOPHYS J, V61, P858, DOI 10.1016/S0006-3495(92)81893-3; PARRY DAD, 1991, AIP CONF PROC, V226, P367; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; PRESTA LG, 1988, SCIENCE, V240, P1632, DOI 10.1126/science.2837824; RICHARDSON JS, 1988, SCIENCE, V240, P1648, DOI 10.1126/science.3381086; SEO J, 1993, PROTEINS, V15, P223, DOI 10.1002/prot.340150302; WARD CW, 1980, AUST J BIOL SCI, V33, P449; WILEY DC, UNPUB; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097	24	159	167	0	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	JAN 28	1994	263	5146					488	489		10.1126/science.8290957	http://dx.doi.org/10.1126/science.8290957			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT966	8290957				2022-12-01	WOS:A1994MT96600023
J	BANERJEE, A; DUBNAU, E; QUEMARD, A; BALASUBRAMANIAN, V; UM, KS; WILSON, T; COLLINS, D; DELISLE, G; JACOBS, WR				BANERJEE, A; DUBNAU, E; QUEMARD, A; BALASUBRAMANIAN, V; UM, KS; WILSON, T; COLLINS, D; DELISLE, G; JACOBS, WR			INHA, A GENE ENCODING A TARGET FOR ISONIAZID AND ETHIONAMIDE IN MYCOBACTERIUM-TUBERCULOSIS	SCIENCE			English	Article							MYCOLIC ACID SYNTHESIS; ESCHERICHIA-COLI; RESISTANCE; AURUM; CHEMOTHERAPY; TRIMETHOPRIM; MECHANISMS; SMEGMATIS; EXTRACTS	Isoniazid (isonicotinic acid hydrazide, INH) is one of the most widely used antituberculosis drugs, yet its precise target of action on Mycobacterium tuberculosis is unknown. A missense mutation within the mycobacterial inhA gene was shown to confer resistance to both INH and ethionamide (ETH) in M. smegmatis and in M. bovis. The wild-type inhA gene also conferred INH and ETH resistance when transferred on a multicopy plasmid vector to M. smegmatis and M. bovis BCG. The InhA protein shows significant sequence conservation with the Escherichia coli enzyme EnvM, and cell-free assays indicate that it may be involved in mycolic acid biosynthesis. These results suggest that InhA is likely a primary target of action for INH and ETH.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, HOWARD HUGHES MED INST, 1300 MORRIS PK, BRONX, NY 10461 USA; MINIST AGR & FISHERIES, WALLACEVILLE ANIM RES CTR, UPPER HUTT, NEW ZEALAND	Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; AgResearch - New Zealand				Quemard, Annaik/0000-0002-5545-3424; Jacobs, William/0000-0003-3321-3080	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI030189] Funding Source: NIH RePORTER; NIAID NIH HHS [UO1AI30189, AI27160] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Balasubramanian V., UNPUB; Banerjee A., UNPUB; Barany F, 1991, PCR Methods Appl, V1, P5, DOI 10.1101/gr.1.1.5; BEGGS WH, 1970, AM REV RESPIR DIS, V102, P94; BERGLER H, 1992, J GEN MICROBIOL, V138, P2093, DOI 10.1099/00221287-138-10-2093; BERNSTEIN J, 1952, AM REV TUBERC PULM, V65, P357; BESLILE JT, 1991, J BACTERIOL, V173, P6991; BRANDEN C, 1991, INTRO PROTEIN STRUCT, P141; Brennan P J, 1970, Ir J Med Sci, V3, P371, DOI 10.1007/BF02956904; CANETTI G, 1965, AM REV RESPIR DIS, V92, P687; CODERRE JA, 1983, P NATL ACAD SCI-BIOL, V80, P2132, DOI 10.1073/pnas.80.8.2132; COHN ML, 1954, AM REV TUBERC PULM, V70, P641; COMBS DL, 1990, ANN INTERN MED, V112, P397, DOI 10.7326/0003-4819-76-3-112-6-397; FOX HH, 1952, SCIENCE, V116, P129, DOI 10.1126/science.116.3006.129; FRIEDEN TR, 1993, NEW ENGL J MED, V328, P521, DOI 10.1056/NEJM199302253280801; GOPINATHAN KP, 1981, CURR SCI INDIA, V50, P216; GREY D, 1979, CHEMOTHERAPY, V25, P147, DOI 10.1159/000237834; GRUMBACH F, 1961, Rev Tuberc Pneumol (Paris), V25, P1365; HOK TT, 1964, AM REV RESPIR DIS, V90, P468; JACOBS WR, 1991, METHOD ENZYMOL, V204, P537; KALPANA GV, 1991, P NATL ACAD SCI USA, V88, P5433, DOI 10.1073/pnas.88.12.5433; LACAVE C, 1990, BIOCHIM BIOPHYS ACTA, V1045, P58, DOI 10.1016/0005-2760(90)90203-A; Lefford M J, 1966, Tubercle, V47, P198, DOI 10.1016/S0041-3879(66)80036-3; LOPEZMARIN LM, 1991, BIOCHIM BIOPHYS ACTA, V1086, P22, DOI 10.1016/0005-2760(91)90150-G; MIDDLEBROOK G, 1954, AM REV TUBERC PULM, V69, P471; MIDDLEBROOK G, 1952, AM REV TUBERC PULM, V65, P765; Murray C. J. L., 1993, DIS CONTROL PRIORITI, P233; MURRAY CJL, 1990, B INT UNION TUBER, V65, P24; NAG DK, 1988, GENE, V64, P135, DOI 10.1016/0378-1119(88)90487-8; OFFE HA, 1952, Z NATURFORSCH B, V7, P462; PANSY F, 1952, AM REV TUBERC PULM, V65, P761; PERRIENS JH, 1991, AM REV RESPIR DIS, V144, P750, DOI 10.1164/ajrccm/144.4.750; QUEMARD A, 1991, ANTIMICROB AGENTS CH, V35, P1035, DOI 10.1128/AAC.35.6.1035; RABUSSAY D, 1969, FEBS LETT, V5, P104, DOI 10.1016/0014-5793(69)80305-4; SAROJA D, 1973, ANTIMICROB AGENTS CH, V4, P643, DOI 10.1128/AAC.4.6.643; SMALL PM, COMMUNICATION; SMALL PM, 1966, TUBERCLE, V47, P109; SNAPPER SB, 1990, MOL MICROBIOL, V4, P1911, DOI 10.1111/j.1365-2958.1990.tb02040.x; SNIDER DE, 1992, NEW ENGL J MED, V326, P703, DOI 10.1056/NEJM199203053261011; STOECKLE MY, 1993, J INFECT DIS, V168, P1063, DOI 10.1093/infdis/168.4.1063; TAKAYAMA K, 1972, ANTIMICROB AGENTS CH, V2, P29, DOI 10.1128/AAC.2.1.29; TELENTI A, 1993, LANCET, V341, P647, DOI 10.1016/0140-6736(93)90417-F; THEN RL, 1982, REV INFECT DIS, V4, P261; TURNOWSKY F, 1989, J BACTERIOL, V171, P6555, DOI 10.1128/jb.171.12.6555-6565.1989; WILSON T, UNPUB; Winder F. G., 1982, The biology of the mycobacteria. Volume 1, P353; WINDER F G, 1970, Journal of General Microbiology, V63, P41; WINDER FG, 1971, J GEN MICROBIOL, V66, P379, DOI 10.1099/00221287-66-3-379; YOUATT J, 1969, AM REV RESPIR DIS, V99, P729; ZHANG Y, 1992, NATURE, V358, P591, DOI 10.1038/358591a0; ZHANG Y, 1993, MOL MICROBIOL, V8, P521, DOI 10.1111/j.1365-2958.1993.tb01596.x; 1991, PROGRAM MANUAL GCG P	52	1137	1210	1	97	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	1994	263	5144					227	230		10.1126/science.8284673	http://dx.doi.org/10.1126/science.8284673			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ879	8284673				2022-12-01	WOS:A1994MQ87900035
J	ADELSON, EH				ADELSON, EH			PERCEPTUAL ORGANIZATION AND THE JUDGMENT OF BRIGHTNESS	SCIENCE			English	Article							LIGHTNESS	The perceived brightness of a gray patch depends on the surrounding context. For example, a medium-gray patch appears darker when placed on a bright background and brighter when placed on a dark background. Models to explain these effects are usually based on simple low-level mechanisms. A new set of brightness illusions cannot be explained by such models. In these illusions, the brightness percept is strongly influenced by the perceptual organization of the stimuli. Simple modifications of the stimuli that should have little effect on low-level mechanisms greatly alter the strength of the illusion. These effects may be ascribed to more complex mechanisms occurring later in the visual system.	MIT, DEPT BRAIN & COGNIT SCI, CAMBRIDGE, MA 02139 USA	Massachusetts Institute of Technology (MIT)	ADELSON, EH (corresponding author), MIT, MEDIA LAB, CAMBRIDGE, MA 02139 USA.			Sanchez-Fernandez, Gregorio Esteban/0000-0002-6059-7182				ADELSON EH, 1991, CHANNELS IN THE VISUAL NERVOUS SYSTEM : NEUROPHYSIOLOGY, PSYCHOPHYSICS AND MODELS, P195; AREND LE, 1987, J OPT SOC AM A, V4, P2281, DOI 10.1364/JOSAA.4.002281; Barrow H., 1978, COMPUTER VISION SYST, V2, P2; Cornsweet T., 1970, VISUAL PERCEPTION; Evans Ralph M., 1948, INTRO COLOR; GILCHRIST A, 1983, PERCEPT PSYCHOPHYS, V33, P425, DOI 10.3758/BF03202893; GILCHRIST AL, 1977, SCIENCE, V195, P185, DOI 10.1126/science.831266; Horn B., 1974, COMPUT GRAPH IMAGE P, V3, P277, DOI DOI 10.1016/0146-664X(74)90022-7; KERSTEN D, 1991, COMPUTATIONAL MODELS; KNILL DC, 1991, NATURE, V351, P228, DOI 10.1038/351228a0; LAND EH, 1971, J OPT SOC AM, V61, P1, DOI 10.1364/JOSA.61.000001; METELLI F, 1974, SCI AM, V230, P91, DOI 10.1038/scientificamerican0474-90; Sinha P., 1993, [1993] Proceedings Fourth International Conference on Computer Vision, P156, DOI 10.1109/ICCV.1993.378224	13	356	359	5	51	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 24	1993	262	5142					2042	2044		10.1126/science.8266102	http://dx.doi.org/10.1126/science.8266102			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MN108	8266102				2022-12-01	WOS:A1993MN10800041
J	BENGTSSON, C; BJORKELUND, C; LAPIDUS, L; LISSNER, L				BENGTSSON, C; BJORKELUND, C; LAPIDUS, L; LISSNER, L			ASSOCIATIONS OF SERUM-LIPID CONCENTRATIONS AND OBESITY WITH MORTALITY IN WOMEN - 20 YEAR FOLLOW-UP OF PARTICIPANTS IN PROSPECTIVE POPULATION STUDY IN GOTHENBURG, SWEDEN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CARDIOVASCULAR-DISEASE; RISK; FRAMINGHAM; DEATH; PHASE	Objective-To examine association of different measures of serum lipid concentr Design-Prospective observational study initiated in 1968-9, follow up examination after 12 years, and follow up study based on death certificates after 20 years. Setting-Gothenburg, Sweden. Subjects-1462 randomly selected women aged 38-60 at start of study. Main outcome measures-Total mortality and death from myocardial infarction as predicted by serum cholesterol and triglyceride concentrations, body mass index, and ratio of circumference of waist to circumference of hips. Results-170 women died during follow up, 26 from myocardial infarction. Serum triglyceride concentration and waist:hip ratio were significantly associated with both end points (relative risk of total mortality for highest quarter of triglyceride concentration v lower three quarters 1.86 (95% confidence interval 1.30 to 2.67); relative risk for waist:hip ratio 1.67 (1.18 to 2.36)). These associations remained after adjustment for background variables. Serum cholesterol concentration and body mass index were initially associated with death from myocardial infarction, but association was lost after adjustment for background variables. Serum triglyceride concentration and waist:hip ratio were independently predictive of both end points (logistic regression coefficient for total mortality for triglyceride 0.514 (SE 0.150), p=0.0006; coefficient for waist:hip ratio 7.130 (1.92), p=0.0002) whereas the other two risk factors were not (coefficient for total mortality for cholesterol concentration -0.102 (0.079), p=0.20; coefficient for body mass index -0.051 (0.027), p=0.05). Conclusions-Lipid risk profile appears to be different in men and women given that serum triglyceride concentration was an independent risk factor for mortality while serum cholesterol concentration was not. Consistent with previous observations in men, localisation of adipose tissue was more important than obesity per se as risk factor in women.	GOTHENBURG UNIV, DEPT PRIMARY HLTH CARE, S-41124 GOTHENBURG, SWEDEN; GOTHENBURG UNIV, DEPT MED, S-41124 GOTHENBURG, SWEDEN	University of Gothenburg; University of Gothenburg								BENGTSSON C, 1989, SCAND J SOC MED, V17, P141, DOI 10.1177/140349488901700203; BENGTSSON C, 1978, SCAND J SOC MED, V6, P49, DOI 10.1177/140349487800600201; BENGTSSON C, 1973, ACTA MED SCAND, P311; BENGTSSON C, 1973, ACTA MED SCAND     S, P549; BOTTIGER LE, 1982, ACTA MED SCAND, V211, P437; BRADLEY PJ, 1982, INT J OBESITY, V6, P43; CASTELLI WP, 1986, AM HEART J, V112, P432, DOI 10.1016/0002-8703(86)90296-6; HARTZ A, 1990, INT J OBESITY, V14, P657; JOHANSSON S, 1988, ARTERIOSCLEROSIS, V8, P742, DOI 10.1161/01.ATV.8.6.742; KANNEL WB, 1971, ANN INTERN MED, V74, P1, DOI 10.7326/0003-4819-74-1-1; KEYS A, 1984, PREV MED, V13, P141, DOI 10.1016/0091-7435(84)90047-1; LAPIDUS L, 1985, ACTA MED SCAND, V217, P481; LAPIDUS L, 1984, BMJ-BRIT MED J, V289, P1257, DOI 10.1136/bmj.289.6454.1257; LEVINE JB, 1964, CLIN CHIM ACTA, V10, P381, DOI 10.1016/0009-8981(64)90073-7; LOFLAND HB, 1964, ANAL BIOCHEM, V9, P393, DOI 10.1016/0003-2697(64)90199-X; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; THOMPSON CJ, 1991, ARTERIOSCLER THROMB, V11, P327, DOI 10.1161/01.ATV.11.2.327; 1983, SPRI122 SWED PLANN R	19	117	121	1	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 27	1993	307	6916					1385	1388		10.1136/bmj.307.6916.1385	http://dx.doi.org/10.1136/bmj.307.6916.1385			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK420	8274890	Green Published, Bronze			2022-12-01	WOS:A1993MK42000018
J	LOWRY, WS; ATKINSON, RJ				LOWRY, WS; ATKINSON, RJ			TUMOR-SUPPRESSOR GENES AND RISK OF METASTASIS IN OVARIAN-CANCER	BRITISH MEDICAL JOURNAL			English	Article											LOWRY, WS (corresponding author), QUEENS UNIV BELFAST,DEPT ONCOL,BELFAST BT9 7BL,ANTRIM,NORTH IRELAND.							ANDERSON MC, 1987, OVARIAN CANCERS WAY, P63; ECCLES DM, 1992, ONCOGENE, V7, P2069	2	4	4	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	AUG 28	1993	307	6903					542	542		10.1136/bmj.307.6903.542	http://dx.doi.org/10.1136/bmj.307.6903.542			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LV180	8267754	Green Published, Bronze			2022-12-01	WOS:A1993LV18000019
J	TONEY, MD; HOHENESTER, E; COWAN, SW; JANSONIUS, JN				TONEY, MD; HOHENESTER, E; COWAN, SW; JANSONIUS, JN			DIALKYLGLYCINE DECARBOXYLASE STRUCTURE - BIFUNCTIONAL ACTIVE-SITE AND ALKALI-METAL SITES	SCIENCE			English	Article							MITOCHONDRIAL ASPARTATE-AMINOTRANSFERASE; MACROMOLECULAR CRYSTALLOGRAPHY; REFINEMENT; ENZYME; RESOLUTION; BINDING; FORMS; ACID	The structure of the bifunctional, pyridoxal phosphate-dependent enzyme dialkylglycine decarboxylase was determined to 2.1-angstrom resolution. Model building suggests that a single cleavage site catalyzes both decarboxylation and transamination by maximizing stereoelectronic advantages and providing electrostatic and general base catalysis. The enzyme contains two binding sites for alkali metal ions. One is located near the active site and accounts for the dependence of activity on potassium ions. The other is located at the carboxyl terminus of an alpha helix. These sites help show how proteins can specifically bind alkali metals and how these ions can exert functional effects.	UNIV BASEL,BIOCTR,DEPT STRUCT BIOL,KLINGELBERGSTR 70,CH-4056 BASEL,SWITZERLAND	University of Basel					NIGMS NIH HHS [GM13854] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM013854, R01GM013854] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASLESTAD HG, 1968, PYRIDOXAL CATALYSIS, P479; ANTSON AA, 1993, BIOCHEMISTRY-US, V32, P4195, DOI 10.1021/bi00067a006; ASHLEY JA, 1993, J AM CHEM SOC, V115, P2515, DOI 10.1021/ja00059a061; BAILEY GB, 1967, BIOCHEMISTRY-US, V6, P1526, DOI 10.1021/bi00857a039; BRAUNSHTEIN AE, 1953, BIOKHIMIYA, V18, P393; BRUNGER AT, 1990, XPLOR MANUAL; CARSON M, 1987, J MOL GRAPHICS, V5, P103, DOI 10.1016/0263-7855(87)80010-3; CRAM DJ, 1986, ANGEW CHEM INT EDIT, V25, P1039, DOI 10.1002/anie.198610393; Dobler M., 1981, IONOPHORES THEIR STR; DUNATHAN HC, 1966, P NATL ACAD SCI USA, V55, P712, DOI 10.1073/pnas.55.4.712; EISENMAN G, 1987, ANNU REV BIOPHYS BIO, V16, P205; FORD GC, 1980, P NATL ACAD SCI-BIOL, V77, P2559, DOI 10.1073/pnas.77.5.2559; GALLAGHER T, 1989, J BIOL CHEM, V264, P12737; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P1; GROS P, 1989, J MOL BIOL, V210, P347, DOI 10.1016/0022-2836(89)90336-7; GURSKY O, 1992, BIOPHYS J, V61, P604, DOI 10.1016/S0006-3495(92)81865-9; IZATT RM, 1985, CHEM REV, V85, P271, DOI 10.1021/cr00068a003; Jansonius J.N., 1987, BIOL MACROMOLECULES, P187; JONES TA, 1990, MANUAL O; KAO JPY, 1989, J BIOL CHEM, V264, P8179; KELLER JW, 1990, J BIOL CHEM, V265, P5531; LESLIE AGW, 1986, CCP4 NEWSLETTER, V18, P33; MARLIER JF, 1986, J AM CHEM SOC, V108, P4896, DOI 10.1021/ja00276a031; MCPHALEN CA, 1992, J MOL BIOL, V225, P495, DOI 10.1016/0022-2836(92)90935-D; MCPHALEN CA, 1990, P NATL ACAD SCI USA, V87, P5648; MESSERSCHMIDT A, 1987, J APPL CRYSTALLOGR, V20, P306, DOI 10.1107/S002188988708662X; METZLER DE, 1954, J AM CHEM SOC, V76, P648, DOI 10.1021/ja01632a004; MUIRHEAD H, 1987, BIOL MACROMOL, V3, P143; OLEARY MH, 1988, ACCOUNTS CHEM RES, V21, P450, DOI 10.1021/ar00156a003; PANTOLIANO MW, 1988, BIOCHEMISTRY-US, V27, P8311, DOI 10.1021/bi00422a004; SUELTER CH, 1970, SCIENCE, V168, P789, DOI 10.1126/science.168.3933.789; TONEY MD, 1991, J MOL BIOL, V222, P873, DOI 10.1016/0022-2836(91)90580-Y; TONEY MD, 1989, SCIENCE, V243, P1485, DOI 10.1126/science.2538921; TONEY MD, 1993, BIOCHEMISTRY-US, V32, P1471, DOI 10.1021/bi00057a010; TRONRUD DE, 1987, ACTA CRYSTALLOGR A, V43, P489, DOI 10.1107/S0108767387099124; Vogtle F., 1985, HOST GUEST COMPLEX C; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WATANABE N, 1989, J BIOCHEM, V105, P1, DOI 10.1093/oxfordjournals.jbchem.a122600; 1979, CCP4 SERC UK COLL CO	39	195	196	1	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	AUG 6	1993	261	5122					756	759		10.1126/science.8342040	http://dx.doi.org/10.1126/science.8342040			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ730	8342040				2022-12-01	WOS:A1993LQ73000038
J	PEPPERKOK, R; SCHEEL, J; HORSTMANN, H; HAURI, HP; GRIFFITHS, G; KREIS, TE				PEPPERKOK, R; SCHEEL, J; HORSTMANN, H; HAURI, HP; GRIFFITHS, G; KREIS, TE			BETA-COP IS ESSENTIAL FOR BIOSYNTHETIC MEMBRANE-TRANSPORT FROM THE ENDOPLASMIC-RETICULUM TO THE GOLGI-COMPLEX IN-VIVO	CELL			English	Article							CLATHRIN-COATED VESICLES; BREFELDIN-A; PROTEIN-TRANSPORT; VESICULAR TRANSPORT; SECRETORY PATHWAY; CAPILLARY MICROINJECTION; INTERMEDIATE COMPARTMENT; ELECTRON-MICROSCOPY; GUANINE-NUCLEOTIDE; BINDING PROTEIN	Microinjection of antibodies against a synthetic peptide of a non-clathrin-coated vesicle-associated coat protein, beta-COP, blocks transport of a temperature-sensitive vesicular stomatitis virus glycoprotein (ts-O45-G) to the cell surface. Transport is inhibited upon release of the viral glycoprotein from temperature blocks at 39.5-degrees-C (endoplasmic reticulum [ER]) and 15-degrees-C (intermediate compartment), but not at 20-degrees-C (trans-Golgi network). Ts-O45-G is arrested in tubular membrane structures containing p53 at the interface of the ER and the Golgi stack. This is consistent with inhibition of acquisition of endoglycosidase H resistance of ts-O45-G in injected cells. Secretion of endogenous proteins and maturation of cathepsin D are also inhibited. These data provide in vivo evidence that beta-COP has an important function in biosynthetic membrane traffic in mammalian cells.	EUROPEAN MOLEC BIOL LAB,W-6900 HEIDELBERG,GERMANY; BIOCENTER,DEPT PHARMACOL,CH-4065 BASEL,SWITZERLAND	European Molecular Biology Laboratory (EMBL)				Pepperkok, Rainer/0000-0002-9762-3583				AHLE S, 1988, EMBO J, V7, P919, DOI 10.1002/j.1460-2075.1988.tb02897.x; ALLAN VJ, 1986, J CELL BIOL, V103, P2229, DOI 10.1083/jcb.103.6.2229; ANSORGE W, 1988, J BIOCHEM BIOPH METH, V16, P283, DOI 10.1016/0165-022X(88)90062-0; BLOOM GS, 1989, J BIOL CHEM, V264, P16083; DOMS RW, 1989, J CELL BIOL, V109, P61, DOI 10.1083/jcb.109.1.61; DONALDSON JG, 1992, NATURE, V360, P350, DOI 10.1038/360350a0; DONALDSON JG, 1990, J CELL BIOL, V111, P2295, DOI 10.1083/jcb.111.6.2295; DONALDSON JG, 1992, P NATL ACAD SCI USA, V89, P6408, DOI 10.1073/pnas.89.14.6408; DONALDSON JG, 1991, SCIENCE, V254, P1197, DOI 10.1126/science.1957170; DUDEN R, 1991, CELL, V64, P649, DOI 10.1016/0092-8674(91)90248-W; GIESELMANN V, 1985, J BIOL CHEM, V260, P3215; GODA Y, 1991, J CELL BIOL, V112, P823, DOI 10.1083/jcb.112.5.823; GRIFFITHS G, 1985, J CELL BIOL, V101, P949, DOI 10.1083/jcb.101.3.949; GRIFFITHS G, 1986, SCIENCE, V234, P438, DOI 10.1126/science.2945253; HELMS JB, 1992, NATURE, V360, P352, DOI 10.1038/360352a0; HENDRICKS LC, 1992, EUR J CELL BIOL, V58, P202; HOSOBUCHI M, 1992, NATURE, V360, P603, DOI 10.1038/360603a0; KAISER CA, 1990, CELL, V61, P723, DOI 10.1016/0092-8674(90)90483-U; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KREIS T E, 1992, Current Opinion in Cell Biology, V4, P609, DOI 10.1016/0955-0674(92)90079-R; KREIS TE, 1987, EMBO J, V6, P2597, DOI 10.1002/j.1460-2075.1987.tb02550.x; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KREIS TE, 1986, CELL, V46, P929, DOI 10.1016/0092-8674(86)90075-9; LEO AH, 1993, MODERN TECHNIQUES BI, P157; LIPPINCOTTSCHWARTZ J, 1989, CELL, V56, P801, DOI 10.1016/0092-8674(89)90685-5; LOTTI LV, 1992, J CELL BIOL, V118, P43, DOI 10.1083/jcb.118.1.43; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; MATSUI W, 1990, BIOCHEMISTRY-US, V29, P10791, DOI 10.1021/bi00500a011; MELANCON P, 1987, CELL, V51, P1053, DOI 10.1016/0092-8674(87)90591-5; MELLMAN I, 1992, CELL, V68, P829, DOI 10.1016/0092-8674(92)90027-A; NOVICK P, 1980, CELL, V21, P205, DOI 10.1016/0092-8674(80)90128-2; OPRINS A, 1993, J CELL BIOL, V121, P49, DOI 10.1083/jcb.121.1.49; ORCI L, 1989, CELL, V56, P357, DOI 10.1016/0092-8674(89)90239-0; ORCI L, 1986, CELL, V46, P171, DOI 10.1016/0092-8674(86)90734-8; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cellbio.6.1.151; PEPPERKOK R, 1988, EXP CELL RES, V178, P369, DOI 10.1016/0014-4827(88)90406-5; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; RAMBOURG A, 1990, EUR J CELL BIOL, V51, P189; Rasure J., 1990, International Journal of Imaging Systems and Technology, V2, P183, DOI 10.1002/ima.1850020304; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; ROBINSON MS, 1992, CELL, V69, P129, DOI 10.1016/0092-8674(92)90124-U; ROSA P, 1989, J CELL BIOL, V109, P17, DOI 10.1083/jcb.109.1.17; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; SCHEEL J, 1991, J BIOL CHEM, V266, P18141; SCHEEL J, 1990, J CELL SCI, V96, P711; SCHWEIZER A, 1988, J CELL BIOL, V107, P1643, DOI 10.1083/jcb.107.5.1643; SCHWEIZER A, 1990, EUR J CELL BIOL, V53, P185; STENBECK G, 1992, FEBS LETT, V314, P195, DOI 10.1016/0014-5793(92)80973-K; VANGENDEREN IL, 1991, J CELL BIOL, V115, P1009, DOI 10.1083/jcb.115.4.1009; VAUX D, 1990, NATURE, V345, P495, DOI 10.1038/345495a0; WATERS MG, 1991, NATURE, V349, P248, DOI 10.1038/349248a0; WONG DH, 1992, J CELL BIOL, V117, P1171, DOI 10.1083/jcb.117.6.1171	53	308	311	0	9	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JUL 16	1993	74	1					71	82		10.1016/0092-8674(93)90295-2	http://dx.doi.org/10.1016/0092-8674(93)90295-2			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	LN625	8334707				2022-12-01	WOS:A1993LN62500008
J	PORTER, K; WALL, PG; EVANS, BG				PORTER, K; WALL, PG; EVANS, BG			FACTORS ASSOCIATED WITH LACK OF AWARENESS OF HIV-INFECTION BEFORE DIAGNOSIS OF AIDS	BRITISH MEDICAL JOURNAL			English	Article							PNEUMOCYSTIS-CARINII PNEUMONIA; CONTROLLED TRIAL; ZIDOVUDINE; COHORT	Objective-To identify characteristics of people likely to be unaware of their HIV infection before diagnosis of AIDS defining disease. Design-Survey of continuing surveillance of voluntarily reported AIDS cases. Subjects-4127 adults with AIDS diagnosed during 1989-92 and reported to the Public Health Laboratory Service AIDS Centre. Setting-England and Wales. Main outcome measure-Lack of prolonged awareness of infection before diagnosis of AIDS, defined as an interval of nine months or less between first positive test result and diagnosis of AIDS. Results-Of 3556 adults with known dates of first positive HIV test result and AIDS diagnosis, 1742 (49%) had been unaware of their infection for up to nine months before AIDS was diagnosed. Lack of awareness was independently and positively associated with infection through heterosexual contact (odds ratio 4.46, 95% confidence interval 3.15 to 6.33), AIDS reported outside the Thames regions (1.64, 1.38 to 1.96), and being non-white (1.99, 1.51 to 2.61). Women were less likely to be unaware than men (0.50, 0.33 to 0.76), and people diagnosed in 1992 were least likely to be unaware (0.48, 0.39 to 0.60). Those aged 25-49 years at diagnosis were less likely to be unaware than those aged 15-24 years and those aged 50 and over. Conclusions-People with certain characteristics are more likely than others to be unaware of their HIV infection before AIDS is diagnosed and are therefore less likely to receive prophylaxis. Methods for educating this heterogeneous group need to be investigated.			PORTER, K (corresponding author), PUBL HLTH LAB SERV,CTR AIDS,CTR COMMUNICABLE DIS SURVEILLANCE,LONDON NW9 5EQ,ENGLAND.			Porter, Kholoud/0000-0002-9226-6206				ABOULKER JP, 1993, LANCET, V341, P889, DOI 10.1016/0140-6736(93)93096-J; BAUM MK, 1991, J ACQ IMMUN DEF SYND, V4, P1122; BECK EJ, 1992, INT J STD AIDS, V3, P182, DOI 10.1177/095646249200300305; DEMARTINO M, 1992, AIDS, V6, P991, DOI 10.1097/00002030-199209000-00013; DROTMAN DP, 1989, ANN INTERN MED, V110, P680, DOI 10.7326/0003-4819-110-9-680; FISCHL MA, 1990, ANN INTERN MED, V112, P727, DOI 10.7326/0003-4819-112-10-727; GRAHAM NMH, 1991, LANCET, V338, P265, DOI 10.1016/0140-6736(91)90414-K; GRAHAM NMH, 1991, J ACQ IMMUN DEF SYND, V4, P267; HAMILTON JD, 1992, NEW ENGL J MED, V326, P437, DOI 10.1056/NEJM199202133260703; HIRSCHEL B, 1991, NEW ENGL J MED, V324, P1079, DOI 10.1056/NEJM199104183241602; KLEIN RS, 1992, 8 P INT C AIDS AMST; KUO JM, 1991, AM J EPIDEMIOL, V133, P1050, DOI 10.1093/oxfordjournals.aje.a115814; PAYNE C, 1983, GLIM SYSTEM MANUAL R; RAGNI MV, 1992, J ACQ IMMUN DEF SYND, V5, P120; REGEVIK N, 1992, 8 P INT C AIDS AMST; VOLBERDING PA, 1990, NEW ENGL J MED, V322, P941, DOI 10.1056/NEJM199004053221401; 1991, COMMUNICABLE DISEASE, V5, pR51; 1992, IMMUNISATION INFECTI; 1991, LANCET, V337, P253; 1992, MMWR, V41, pRR4	20	59	60	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 3	1993	307	6895					20	23		10.1136/bmj.307.6895.20	http://dx.doi.org/10.1136/bmj.307.6895.20			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	LL369	8343662	Bronze, Green Published			2022-12-01	WOS:A1993LL36900019
J	ELIOPOULOS, C; KLEIN, J; PHAN, MK; KNIE, B; GREENWALD, M; CHITAYAT, D; KOREN, G				ELIOPOULOS, C; KLEIN, J; PHAN, MK; KNIE, B; GREENWALD, M; CHITAYAT, D; KOREN, G			HAIR CONCENTRATIONS OF NICOTINE AND COTININE IN WOMEN AND THEIR NEWBORN-INFANTS	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Note							FOLLOW-UP; PREGNANCY; EXPOSURE; SMOKING; CIGARETTES; METABOLISM; MARIJUANA; BEHAVIOR; ALCOHOL; COCAINE	Background.-To date, no biological markers have been identified that can predict the extent of fetal exposure to the toxic constituents of cigarette smoke. A variety of xenobiotic agents have been shown to accumulate in growing hair. Patients and Methods.-We measured maternal and neonatal hair concentrations of nicotine and cotinine in 94 mother-infant pairs. Mothers who were active smokers, nonsmokers, and passive smokers and their infants were included. Results.-Mothers who were active smokers (n=36) had mean (SEM) hair concentrations of 19.2 (4.9) ng/mg for nicotine and 6.3 (4.0) ng/mg for cotinine, significantly higher than concentrations in nonsmokers (n=35) (1.2 [0.4] ng/mg for nicotine and 0.3 [0.06] ng/mg for cotinine, P<.0001). Infants of smokers had mean hair concentrations of 2.4 (0.9) ng/mg for nicotine (range, 0 to 27.3 ng/mg) and 2.8 (0.8) ng/mg for cotinine (range, 0 to 12.2 ng/mg), significantly higher than concentrations in infants of nonsmokers (0.4 [0.09] ng/mg for nicotine and 0.26 [0.04] ng/mg for cotinine, P<.01). Mothers with passive smoke exposure and their infants (n=23) had significantly higher hair concentrations of nicotine (3.2 [0.8] ng/mg for mothers and 0.28 [0.05] ng/mg for infants) and cotinine (0.9 [0.3] ng/mg for mothers and 0.6 [0.15] ng/mg for infants) than nonsmoking mothers and their infants (P<.01). There was a significant correlation between maternal and neonatal hair concentrations of nicotine (r=.49, P<.001) or cotinine (r=.85, P=.0001). Conclusions.-This is the first biochemical evidence that infants of passive smokers are at risk of measurable exposure to cigarette smoke. Hair accumulation of cigarette smoke constituents reflects long-term systemic exposure to these toxins and therefore may be well correlated with perinatal risks.	HOSP SICK CHILDREN, MOTHERISK PROGRAM, TORONTO M5G 1X8, ON, CANADA; HOSP SICK CHILDREN, DEPT PEDIAT, TORONTO, ON, CANADA; HOSP SICK CHILDREN, DIV CLIN PHARMACOL & TOXICOL, TORONTO M5G 1X8, ON, CANADA; HOSP SICK CHILDREN, DIV CLIN GENET, TORONTO, ON, CANADA; HOSP SICK CHILDREN, RES INST, TORONTO M5G 1X8, ON, CANADA; YORK FINCH GEN HOSP, DEPT PEDIAT, N YORK, ON, CANADA; YORK FINCH GEN HOSP, DEPT PHARMACOL, N YORK, ON, CANADA; UNIV TORONTO, TORONTO GEN HOSP, TORONTO M5G 1L7, ON, CANADA	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University Toronto Affiliates; University Health Network Toronto; Toronto General Hospital			Koren, Gideon/AAG-7726-2019	Koren, Gideon/0000-0002-9234-0875				ABEL EL, 1984, J PSYCHOACTIVE DRUGS, V16, P327, DOI 10.1080/02791072.1984.10472303; BENOWITZ NL, 1982, J PHARMACOL EXP THER, V221, P368; FELDMAN Y, 1989, TERATOLOGY, V40, P37, DOI 10.1002/tera.1420400106; FORMAN R, 1992, LIFE SCI, V50, P1333, DOI 10.1016/0024-3205(92)90284-V; FORMAN R, IN PRESS CLIN INVEST; FRIED PA, 1992, J DEV BEHAV PEDIATR, V13, P383; FRIED PA, 1992, NEUROTOXICOL TERATOL, V14, P299, DOI 10.1016/0892-0362(92)90036-A; GRAHAM K, 1989, JAMA-J AM MED ASSOC, V262, P3328, DOI 10.1001/jama.262.23.3328; HALEY NJ, 1983, AM J PUBLIC HEALTH, V73, P1204, DOI 10.2105/AJPH.73.10.1204; HALEY NJ, 1985, CLIN CHEM, V31, P1598; ISHIYAMA I, 1983, J FORENSIC SCI, V28, P380; KINTZ P, 1993, J FORENSIC SCI, V38, P119; KLEIN J, 1993, NEW ENGL J MED, V328, P66, DOI 10.1056/NEJM199301073280116; KOREN G, 1991, REPROD TOXICOL, V5, P397, DOI 10.1016/0890-6238(91)90002-W; KYEREMATEN GA, 1991, DRUG METAB REV, V23, P3, DOI 10.3109/03602539109029754; LANGONE JJ, 1973, BIOCHEMISTRY-US, V12, P5025, DOI 10.1021/bi00748a032; LONGO LD, 1977, AM J OBSTET GYNECOL, V129, P69, DOI 10.1016/0002-9378(77)90824-9; MAKIN J, 1991, NEUROTOXICOL TERATOL, V13, P5, DOI 10.1016/0892-0362(91)90021-N; MARSH DO, 1981, CLIN TOXICOL, V18, P1311, DOI 10.3109/00099308109035071; MARTIN TR, 1986, AM J EPIDEMIOL, V124, P633, DOI 10.1093/oxfordjournals.aje.a114436; Pilotti A, 1980, Acta Physiol Scand Suppl, V479, P13; RUSH D, 1989, ANN NY ACAD SCI, V562, P74, DOI 10.1111/j.1749-6632.1989.tb21008.x; STILLMAN RJ, 1986, FERTIL STERIL, V46, P545; TRIEBIG G, 1984, PREV MED, V13, P570, DOI 10.1016/S0091-7435(84)80007-9; 1989, CDC898411 US DEP HLT, P71	25	127	130	0	4	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	FEB 23	1994	271	8					621	623		10.1001/jama.271.8.621	http://dx.doi.org/10.1001/jama.271.8.621			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MW477	8301796				2022-12-01	WOS:A1994MW47700027
J	HOPPER, JL; SEEMAN, E				HOPPER, JL; SEEMAN, E			THE BONE-DENSITY OF FEMALE TWINS DISCORDANT FOR TOBACCO USE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CIGARETTE-SMOKING; POSTMENOPAUSAL WOMEN; MINERAL DENSITY; HIP FRACTURE; OSTEOPOROSIS; MASS; AGE; RISK; ESTROGENS; OBESITY	Background. Smoking is recognized as a risk factor for vertebral, forearm, and hip fractures. Since bone density is an important determinant of bone strength, we conducted a study to ascertain whether a deficit in bone density is associated with tobacco use and, if so, to identify the responsible mechanisms. Methods. We conducted a cross-sectional study of bone density at the lumbar spine and the femoral neck and shaft in 41 pairs of female twins (21 monozygotic pairs), 27 to 73 years of age (mean, 49), who were discordant for at least 5 pack-years of smoking (mean, 23; maximum, 64). Bone density was measured by dual-photon absorptiometry. The difference in bone density between the members of a pair was expressed as a percentage of the mean value for the pair. Results. For every 10 pack-years of smoking, the bone density of the twin who smoked more heavily was 2.0 percent lower at the lumbar spine (P = 0.01), 0.9 percent lower at the femoral neck (P = 0.25), and 1.4 percent lower at the femoral shaft (P = 0.04). These results were not confounded by measured lifestyle factors. In the 20 pairs who were discordant by 20 or more pack-years (mean, 35), the (mean +/- SE) within-pair differences in bone density at the three sites were 9.3 +/- 3.1 percent (P = 0.008), 5.8 +/- 2.9 percent (P = 0.06), and 6.5 +/- 3.2 percent (P = 0.05), respectively. Smoking was associated with higher serum concentrations of follicle-stimulating hormone (P = 0.02) and luteinizing hormone (P = 0.03) and lower serum concentrations of parathyroid hormone (P = 0.05). Differences in spinal bone density between members of a pair were associated with differences in the serum concentrations of parathyroid hormone (P = 0.01) and calcium (P = 0.05) and urinary pyridinoline excretion (P = 0.06), a marker of bone resorption. Conclusions. Women who smoke one pack of cigarettes each day throughout adulthood will, by the time of menopause, have an average deficit of 5 to 10 percent in bone density, which is sufficient to increase the risk of fracture.	UNIV MELBOURNE,AUSTIN HOSP,DEPT MED,ENDOCRINE UNIT,HEIDELBERG,VIC 3084,AUSTRALIA; UNIV MELBOURNE,FAC MED,EPIDEMIOL UNIT,PARKVILLE,VIC 3052,AUSTRALIA	Austin Research Institute; Florey Institute of Neuroscience & Mental Health; University of Melbourne; University of Melbourne			Seeman, Ego/AAC-3656-2019	Seeman, Ego/0000-0002-9692-048X				BROWN JB, 1976, METHODS HORMONE ANAL, P446; CARTER DR, 1977, J BONE JOINT SURG AM, V59, P954, DOI 10.2106/00004623-197759070-00021; DANIELL HW, 1976, ARCH INTERN MED, V136, P298, DOI 10.1001/archinte.136.3.298; DELMAS PD, 1983, J CLIN INVEST, V71, P1316, DOI 10.1172/JCI110882; EYRE DR, 1984, ANAL BIOCHEM, V137, P380, DOI 10.1016/0003-2697(84)90101-5; HUI SL, 1988, J CLIN INVEST, V81, P1804, DOI 10.1172/JCI113523; JARDINE R, 1984, Genetic Epidemiology, V1, P89, DOI 10.1002/gepi.1370010202; JENSEN J, 1985, NEW ENGL J MED, V313, P973, DOI 10.1056/NEJM198510173131602; KASRIEL J, 1976, J BIOSOC SCI, V8, P263, DOI 10.1017/S0021932000010737; KRALL EA, 1991, J BONE MINER RES, V6, P331; KROLNER B, 1982, CLIN SCI, V62, P329, DOI 10.1042/cs0620329; LINDQUIST O, 1979, ACTA MED SCAND, V205, P73; LONGCOPE C, 1988, J CLIN ENDOCR METAB, V67, P379, DOI 10.1210/jcem-67-2-379; MACMAHON B, 1982, NEW ENGL J MED, V307, P1062, DOI 10.1056/NEJM198210213071707; MAZESS RB, 1988, J BONE MINER RES, V3, P13; MAZESS RB, 1982, CLIN ORTHOPAEDICS, V165, P239; MCCULLAGH P, 1989, MONOGRAPHS STATISTIC, V37; MELTON LJ, 1988, J CLIN EPIDEMIOL, V41, P985; MONTGOMERY DC, 1982, INTRO LINEAR REGRESS, P367; NOBBS BT, 1975, CLIN CHIM ACTA, V64, P219, DOI 10.1016/0009-8981(75)90206-5; POCOCK NA, 1987, J CLIN INVEST, V80, P706, DOI 10.1172/JCI113125; POCOCK NA, 1989, BONE, V10, P329, DOI 10.1016/8756-3282(89)90128-2; RIGGS BL, 1986, NEW ENGL J MED, V314, P1676, DOI 10.1056/NEJM198606263142605; RIGOTTI NA, 1989, NEW ENGL J MED, V320, P931, DOI 10.1056/NEJM198904063201409; SEEMAN E, 1983, AM J MED, V75, P977, DOI 10.1016/0002-9343(83)90878-1; SLEMENDA CW, 1989, J BONE MINER RES, V4, P737, DOI 10.1002/jbmr.5650040513; SMITH DM, 1973, J CLIN INVEST, V52, P2800, DOI 10.1172/JCI107476; WICKHAM CAC, 1989, BMJ-BRIT MED J, V299, P889, DOI 10.1136/bmj.299.6704.889; 1989, DHHS CDC898411 DEP H	29	291	302	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	FEB 10	1994	330	6					387	392		10.1056/NEJM199402103300603	http://dx.doi.org/10.1056/NEJM199402103300603			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MV279	8284003				2022-12-01	WOS:A1994MV27900003
J	SCHLUPP, I; MARLER, C; RYAN, MJ				SCHLUPP, I; MARLER, C; RYAN, MJ			BENEFIT TO MALE SAILFIN MOLLIES OF MATING WITH HETEROSPECIFIC FEMALES	SCIENCE			English	Article							SEXUAL SELECTION; MATE CHOICE; BODY SIZE; POECILIA; FISH; EVOLUTION; STABILITY; FORMOSA; COPY	Female gynogens reproduce clonally but rely on sperm from heterospecific males to initiate embryogenesis. lt has been assumed that males gain no benefit from such matings; thus, selection should favor males that avoid them. Here it is shown that males gain a benefit by mating with female gynogens in an asexual-sexual complex of fish. The sexual females increase their preference for males whom they observe consorting with female gynogens. Thus, gynogenetic species might persist because selection favors males to be sexually parasitized.	UNIV TEXAS, DEPT ZOOL, AUSTIN, TX 78712 USA	University of Texas System; University of Texas Austin			Schlupp, Ingo/C-3913-2012; Marler, Catherine/D-1285-2011; Marler, Catherine/AAB-6883-2020	Schlupp, Ingo/0000-0002-2460-5667; Marler, Catherine/0000-0002-2783-1029	NIMH NIH HHS [F32 MH10204] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [F32MH010204] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		AVISE JC, 1991, EVOLUTION, V45, P1530, DOI 10.1111/j.1558-5646.1991.tb02657.x; Balsano J.S., 1989, P277; BALSANO JS, 1981, ENVIRON BIOL FISH, V6, P39, DOI 10.1007/BF00001798; BASOLO A, 1990, ANIM BEHAV, V40, P339; BASOLO AL, 1990, SCIENCE, V250, P808, DOI 10.1126/science.250.4982.808; Bell G., 1982, MASTERPIECE NATURE; BISCHOFF RJ, 1985, BEHAV ECOL SOCIOBIOL, V17, P253, DOI 10.1007/BF00300143; CLUTTONBROCK T, 1993, BEHAV ECOL, V4, P191, DOI 10.1093/beheco/4.3.191; COYNE JA, 1992, NATURE, V355, P511, DOI 10.1038/355511a0; Darwin C., 1959, ORIGIN SPECIES; Dawley Robert M., 1989, New York State Museum Bulletin, V466, P1; Dobzhansky T, 1937, GENETICS ORIGIN SPEC; DUGATKIN LA, 1992, AM NAT, V139, P1384, DOI 10.1086/285392; GIBSON RM, 1992, TRENDS ECOL EVOL, V7, P229, DOI 10.1016/0169-5347(92)90050-L; GODIN JGJ, 1992, P R SOC LONDON B, V249, P179; GOLDSCHMIDT T, 1993, ANIM BEHAV, V45, P541, DOI 10.1006/anbe.1993.1064; HEDGES SB, 1992, NATURE, V356, P708, DOI 10.1038/356708a0; Hubbs C., 1964, Bulletin of the Texas Memorial Museum, VNo. 8, P1; Hubbs CL, 1932, SCIENCE, V76, P628, DOI 10.1126/science.76.1983.628; KALLMAN KD, 1962, J GENET, V58, P7, DOI 10.1007/BF02986114; KIRKENDALL LR, 1990, EVOLUTION, V44, P698, DOI 10.1111/j.1558-5646.1990.tb05949.x; MAYNARDSMITH J, 1979, EVOLUTION SEX; MCKAY FE, 1971, ECOLOGY, V52, P778, DOI 10.2307/1936025; MCPEEK MA, 1992, BEHAV ECOL, V3, P1, DOI 10.1093/beheco/3.1.1; PRUETTJONES S, 1992, AM NAT, V140, P1000, DOI 10.1086/285452; QUATTRO JM, 1992, P NATL ACAD SCI USA, V89, P348, DOI 10.1073/pnas.89.1.348; RYAN MJ, 1987, SCIENCE, V236, P595, DOI 10.1126/science.236.4801.595; RYAN MJ, 1990, BEHAV ECOL SOCIOBIOL, V26, P231; RYAN MJ, UNPUB; SCHARTL M, 1991, P NATL ACAD SCI USA, V88, P8759, DOI 10.1073/pnas.88.19.8759; SCHLUPP I, 1991, ETHOLOGY, V88, P215, DOI 10.1111/j.1439-0310.1991.tb00276.x; SCHULTZ RJ, 1971, AM ZOOL, V11, P351; SMITH JM, 1992, NATURE, V356, P661, DOI 10.1038/356661a0; SPOLSKY CM, 1992, NATURE, V356, P706, DOI 10.1038/356706a0; STENSETH NC, 1985, EVOLUTION, V39, P294, DOI 10.1111/j.1558-5646.1985.tb05667.x; Turner B.J., 1982, Progress in Clinical and Biological Research, V96, P265; Vrijenhoek R.C., 1989, P386; WADE MJ, 1990, P NATL ACAD SCI USA, V87, P5749, DOI 10.1073/pnas.87.15.5749; Williams G.C., 1975, Journal Cell Biol, VNo. 8, pi; WOODHEAD AD, 1985, J FISH BIOL, V27, P593, DOI 10.1111/j.1095-8649.1985.tb03204.x	40	187	188	1	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 21	1994	263	5145					373	374		10.1126/science.8278809	http://dx.doi.org/10.1126/science.8278809			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MT034	8278809				2022-12-01	WOS:A1994MT03400032
J	BILDERBACK, DH; HOFFMAN, SA; THIEL, DJ				BILDERBACK, DH; HOFFMAN, SA; THIEL, DJ			NANOMETER SPATIAL-RESOLUTION ACHIEVED IN HARD X-RAY-IMAGING AND LAUE DIFFRACTION EXPERIMENTS	SCIENCE			English	Article							SINGLE-CRYSTAL; OPTICS	Tapered glass capillaries have successfully condensed hard x-ray beams to ultrasmall dimensions providing unprecedented spatial resolution for the characterization of materials. A spatial resolution of 50 nanometers was obtained while imaging a lithographically prepared gold pattern with x-rays in the energy range of 5 to 8 kiloelectron volts. This is the highest resolution scanning x-ray image made to date with hard x-rays. With a beam 360 nanometers in diameter, Laue diffraction was observed from the smallest sample volume ever probed by x-ray diffraction, 5 x 10(-3) cubic micrometers.	CORNELL UNIV,SCH APPL & ENGN PHYS,ITHACA,NY 14853	Cornell University	BILDERBACK, DH (corresponding author), CORNELL UNIV,CORNELL HIGH ENERGY SYNCHROTRON SOURCE,ITHACA,NY 14853, USA.				NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR001646] Funding Source: NIH RePORTER; NCRR NIH HHS [RR01646-10] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		ANDERSON EH, 1992, XRAY MICROSCOPY, V3, P75; ANDREWS SJ, 1987, ACTA CRYSTALLOGR A, V43, P70, DOI 10.1107/S0108767387099872; ARNOLD E, 1992, NATURE, V357, P85, DOI 10.1038/357085a0; BILDERBACK DH, 1981, P SOC PHOTO-OPT INST, V315, P90; BROWN KT, 1986, ADV MICROPIPETTE TEC, pCH6; CARPENTER DA, 1988, MICROBEAM ANAL, P391; Chapman H N, 1990, J Xray Sci Technol, V2, P117, DOI 10.3233/XST-1990-2203; COOKE D, 1990, NATURE, V346, P802, DOI 10.1038/346802a0; ENGSTROM P, 1991, NUCL INSTRUM METH A, V302, P547, DOI 10.1016/0168-9002(91)90373-X; HOFFMAN SA, IN PRESS OPT ENG; KUMAKHOV MA, 1990, PHYS REP, V191, P289, DOI 10.1016/0370-1573(90)90135-O; OHSUMI K, 1991, J APPL CRYSTALLOGR, V24, P340, DOI 10.1107/S0021889891002133; ROSSMANN MG, 1985, NATURE, V317, P145, DOI 10.1038/317145a0; SKELTON EF, 1991, SCIENCE, V253, P1123, DOI 10.1126/science.253.5024.1123; STERN EA, 1988, APPL OPTICS, V27, P5135, DOI 10.1364/AO.27.005135; THIEL DJ, 1992, NUCL INSTRUM METH A, V317, P597, DOI 10.1016/0168-9002(92)91006-U; TRANQUADA JM, 1989, NATURE, V337, P720, DOI 10.1038/337720a0; YUN WB, 1993, P SOC PHOTO-OPT INS, V1740, P117, DOI 10.1117/12.138694; 1990, LBL28001 UC411 U CAL, P4	19	190	195	0	20	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JAN 14	1994	263	5144					201	203		10.1126/science.8284671	http://dx.doi.org/10.1126/science.8284671			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ879	8284671				2022-12-01	WOS:A1994MQ87900025
J	HARRISON, CJ; BOHM, AA; NELSON, HCM				HARRISON, CJ; BOHM, AA; NELSON, HCM			CRYSTAL-STRUCTURE OF THE DNA-BINDING DOMAIN OF THE HEAT-SHOCK TRANSCRIPTION FACTOR	SCIENCE			English	Article							MOLECULAR-CLONING; PROTEIN; GENES; RECOGNITION; EXPRESSION; ANGLE; UNIT	The structure of the DNA binding domain, determined at 1.8 angstrom resolution, contains a three-helix bundle that is capped by a four-stranded antiparallel beta sheet. This structure is a variant of the helix-turn-helix motif, typified by catabolite activator protein. In the heat shock transcription factor, the first helix of the motif (alpha2) has an alpha-helical bulge and a proline-induced kink. The angle between the two helices of the motif (alpha2 and alpha3) is about 20-degrees smaller than the average for canonical helix-turn-helix proteins. Nevertheless, the relative positions of the first and third helices of the bundle (alpha1 and alpha3) are conserved. It is proposed here that the first helix of the three-helix bundle be considered a component of the helix-turn-helix motif.	UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, BERKELEY, CA 94720 USA; LAWRENCE BERKELEY LAB, DIV STRUCT BIOL, BERKELEY, CA 94720 USA	University of California System; University of California Berkeley; United States Department of Energy (DOE); Lawrence Berkeley National Laboratory					NIGMS NIH HHS [GM44086, GM08295] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008295, R01GM044086] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABBOTT J, 1993, BIOCHEMISTRY-US, V32, P9649, DOI 10.1021/bi00088a017; ABERG A, 1993, NATURE, V361, P276, DOI 10.1038/361276a0; ASSAMUNT N, 1993, CELL, V73, P193, DOI 10.1016/0092-8674(93)90171-L; BARLOW DJ, 1988, J MOL BIOL, V201, P601, DOI 10.1016/0022-2836(88)90641-9; BROWN JL, 1993, J BACTERIOL, V175, P6908, DOI 10.1128/jb.175.21.6908-6915.1993; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1992, XPLOR VERSION 3 ONE; CESKA TA, 1993, EMBO J, V12, P1805, DOI 10.1002/j.1460-2075.1993.tb05828.x; CHOTHIA C, 1975, NATURE, V254, P304, DOI 10.1038/254304a0; CLARK KL, 1993, NATURE, V364, P412, DOI 10.1038/364412a0; CLOS J, 1990, CELL, V63, P1085, DOI 10.1016/0092-8674(90)90511-C; COSTA RH, 1989, MOL CELL BIOL, V9, P1415, DOI 10.1128/MCB.9.4.1415; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; FUJITA A, 1989, GENE, V85, P321; GALLO GJ, 1993, MOL CELL BIOL, V13, P749, DOI 10.1128/MCB.13.2.749; HARRISON SC, 1991, NATURE, V353, P715, DOI 10.1038/353715a0; HEINZ DW, 1993, NATURE, V361, P561, DOI 10.1038/361561a0; HEINZ DW, IN PRESS PROTEIN ENG; HUBL S, UNPUB; JAKOBSEN BK, 1991, EMBO J, V10, P369, DOI 10.1002/j.1460-2075.1991.tb07958.x; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KEEFE LJ, 1993, P NATL ACAD SCI USA, V90, P3275, DOI 10.1073/pnas.90.8.3275; LAI E, 1993, P NATL ACAD SCI USA, V90, P10421, DOI 10.1073/pnas.90.22.10421; LEITING B, 1993, EMBO J, V12, P1797, DOI 10.1002/j.1460-2075.1993.tb05827.x; LIUJOHNSON HN, 1986, CELL, V47, P995, DOI 10.1016/0092-8674(86)90814-7; MORIMOTO RI, 1993, SCIENCE, V259, P1409, DOI 10.1126/science.8451637; MORIMOTO RI, 1992, J BIOL CHEM, V267, P21987; NAKAI A, 1993, MOL CELL BIOL, V13, P1983, DOI 10.1128/MCB.13.4.1983; PABO CO, 1993, ANNU REV BIOCHEM, V74, P773; PERISIC O, 1989, CELL, V59, P797, DOI 10.1016/0092-8674(89)90603-X; RABINDRAN SK, 1991, P NATL ACAD SCI USA, V88, P6906, DOI 10.1073/pnas.88.16.6906; RAMAKRISHNAN V, 1993, NATURE, V362, P219, DOI 10.1038/362219a0; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; RYE HS, 1993, J BIOL CHEM, V268, P25229; SARGE KD, 1991, GENE DEV, V5, P1902, DOI 10.1101/gad.5.10.1902; SCHARF KD, 1990, EMBO J, V9, P4495, DOI 10.1002/j.1460-2075.1990.tb07900.x; SCHIERING N, 1991, NATURE, V352, P168, DOI 10.1038/352168a0; SCHUETZ TJ, 1991, P NATL ACAD SCI USA, V88, P6911, DOI 10.1073/pnas.88.16.6911; SCHULTZ SC, 1991, SCIENCE, V253, P1001, DOI 10.1126/science.1653449; SORGER PK, 1991, CELL, V65, P363, DOI 10.1016/0092-8674(91)90452-5; SORGER PK, 1989, CELL, V59, P807, DOI 10.1016/0092-8674(89)90604-1; SORGER PK, 1988, CELL, V54, P855, DOI 10.1016/S0092-8674(88)91219-6; STEIGEMANN W, 1982, PROTEIN PACKAGE CRYS; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TERWILLIGER TC, 1987, ACTA CRYSTALLOGR A, V43, P1, DOI 10.1107/S0108767387099999; WANG BC, 1985, METHOD ENZYMOL, V115, P90; WIEDERRECHT G, 1988, CELL, V54, P841, DOI 10.1016/S0092-8674(88)91197-X; WILSON KP, 1992, P NATL ACAD SCI USA, V89, P9257, DOI 10.1073/pnas.89.19.9257; XIAO H, 1991, CELL, V64, P585, DOI 10.1016/0092-8674(91)90242-Q	52	222	232	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	JAN 14	1994	263	5144					224	227		10.1126/science.8284672	http://dx.doi.org/10.1126/science.8284672			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	MQ879	8284672				2022-12-01	WOS:A1994MQ87900034
J	WESTAWAY, D; DEARMOND, SJ; CAYETANOCANLAS, J; GROTH, D; FOSTER, D; YANG, SL; TORCHIA, M; CARLSON, GA; PRUSINER, SB				WESTAWAY, D; DEARMOND, SJ; CAYETANOCANLAS, J; GROTH, D; FOSTER, D; YANG, SL; TORCHIA, M; CARLSON, GA; PRUSINER, SB			DEGENERATION OF SKELETAL-MUSCLE, PERIPHERAL-NERVES, AND THE CENTRAL-NERVOUS-SYSTEM IN TRANSGENIC MICE OVEREXPRESSING WILD-TYPE PRION PROTEINS	CELL			English	Article							RECEPTOR-INDUCING ACTIVITY; CREUTZFELDT-JAKOB DISEASE; ACETYLCHOLINE-RECEPTOR; SCRAPIE; GENE; BRAIN; EXPRESSION; SUBUNIT; ACID	Prion diseases of humans and animals are known to be caused by infection with prions containing PrP(Sc) or mutation of the prion protein (PrP) gene. During transgenetic studies, we discovered that uninoculated older mice harboring high copy numbers of wild-type (wt) PrP transgenes derived from Syrian hamsters (SHa), sheep (She), and PrP-B mice developed truncal ataxia, hindlimb paralysis, and tremors. These transgenic (Tg) mice exhibited a profound necrotizing myopathy involving skeletal muscle, a demyelinating polyneuropathy, and focal vacuolation of the central nervous system. Development of disease was dependent on transgene dosage. For example, half of all Tg(SHaPrP+/+)7 mice homozygous for the SHaPrP transgene array developed disease by approximately 460 days of age, while no hemizygous Tg(SHaPrP+/0)7 mice became ill before 650 days. The novel neurologic syndrome found in older Tg(wtPrP) mice implies that overexpression of wtPrP(C) is pathogenic and widens the spectrum of prion diseases.	UNIV CALIF SAN FRANCISCO,DEPT PATHOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT BIOCHEM & BIOPHYS,SAN FRANCISCO,CA 94143; MCLAUGHLIN RES INST,GREAT FALLS,MT 59405	University of California System; University of California San Francisco; University of California System; University of California San Francisco; McLaughlin Research Institute for Biomedical Sciences, Inc.	WESTAWAY, D (corresponding author), UNIV CALIF SAN FRANCISCO,DEPT NEUROL,SAN FRANCISCO,CA 94143, USA.							BAZAN JF, 1987, PROTEIN ENG, V1, P125, DOI 10.1093/protein/1.2.125; BECK E, 1964, BRAIN, V87, P153, DOI 10.1093/brain/87.1.153; BEER J, 1991, ALZHEIMERS DISEASE : BASIC MECHANISMS, DIAGNOSIS AND THERAPEUTIC STRATEGIES, P473; BENDHEIM PE, 1992, NEUROLOGY, V42, P149, DOI 10.1212/WNL.42.1.149; BOSANQUET FD, 1956, LANCET, V2, P737; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; CARLSON GA, 1993, GENETICS, V133, P979; CASHMAN NR, 1990, CELL, V61, P185, DOI 10.1016/0092-8674(90)90225-4; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COTE F, 1993, CELL, V73, P35, DOI 10.1016/0092-8674(93)90158-M; DAVIS RL, 1991, TXB NEUROPATHOLOGY, P486; DEARMOND SJ, 1992, PROG BRAIN RES, V94, P437; DUBOVITZ V, 1985, MUSCLE BIOPSY PRACTI, P14; FALLS DL, 1990, COLD SH Q B, V55, P397; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FOROLONI G, 1993, NATURE, V362, P543; GOLDMANN W, 1990, P NATL ACAD SCI USA, V87, P2476, DOI 10.1073/pnas.87.7.2476; HARRIS DA, 1988, P NATL ACAD SCI USA, V85, P1983, DOI 10.1073/pnas.85.6.1983; HARRIS DA, 1991, P NATL ACAD SCI USA, V88, P7664, DOI 10.1073/pnas.88.17.7664; HSIAO K, 1989, NATURE, V338, P342, DOI 10.1038/338342a0; HSIAO KK, 1990, SCIENCE, V250, P1587, DOI 10.1126/science.1980379; HULLAND T. J., 1958, JOUR COMP PATHOL AND THERAP, V68, P264, DOI 10.1016/S0368-1742(58)80027-2; KASCSAK RJ, 1987, J VIROL, V61, P3688, DOI 10.1128/JVI.61.12.3688-3693.1987; KUNCL RW, 1989, ACTA NEUROPATHOL, V78, P615, DOI 10.1007/BF00691288; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUPSKI JR, 1991, CELL, V66, P219, DOI 10.1016/0092-8674(91)90613-4; MANSON J, 1992, DEVELOPMENT, V115, P117; MARTINOU JC, 1991, P NATL ACAD SCI USA, V88, P7669, DOI 10.1073/pnas.88.17.7669; NEUFELD MY, 1992, MUSCLE NERVE, V15, P1234, DOI 10.1002/mus.880151103; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; OLSSON JE, 1992, NEURON, V9, P815, DOI 10.1016/0896-6273(92)90236-7; PALMITER RD, 1986, ANNU REV GENET, V20, P465, DOI 10.1146/annurev.ge.20.120186.002341; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1993, P NATL ACAD SCI USA, V90, P10608, DOI 10.1073/pnas.90.22.10608; PRUSINER SB, 1990, CELL, V63, P673, DOI 10.1016/0092-8674(90)90134-Z; PRUSINER SB, 1992, BIOCHEMISTRY-US, V31, P12278; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; ROSENTHAL NP, 1976, ARCH NEUROL-CHICAGO, V33, P252, DOI 10.1001/archneur.1976.00500040036005; ROY S, 1992, CAN J NEUROL SCI, V19, P453, DOI 10.1017/S0317167100041639; SCOTT M, 1989, CELL, V59, P847, DOI 10.1016/0092-8674(89)90608-9; SERBAN D, 1990, NEUROLOGY, V40, P110, DOI 10.1212/WNL.40.1.110; SPARKES RS, 1986, P NATL ACAD SCI USA, V83, P7358, DOI 10.1073/pnas.83.19.7358; STAHL N, 1992, BIOCHEMISTRY-US, V31, P5043, DOI 10.1021/bi00136a600; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; TARABOULOS A, 1992, P NATL ACAD SCI USA, V89, P7620, DOI 10.1073/pnas.89.16.7620; VIRELIZIER JL, 1975, INFECT IMMUN, V12, P1127, DOI 10.1128/IAI.12.5.1127-1140.1975; WESTAWAY D, 1991, NEURON, V7, P59, DOI 10.1016/0896-6273(91)90074-A; WESTAWAY D, 1989, TRENDS NEUROSCI, V12, P221, DOI 10.1016/0166-2236(89)90126-4; XU ZS, 1993, CELL, V73, P23, DOI 10.1016/0092-8674(93)90157-L	50	309	325	1	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138	0092-8674			CELL	Cell	JAN 14	1994	76	1					117	129		10.1016/0092-8674(94)90177-5	http://dx.doi.org/10.1016/0092-8674(94)90177-5			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	MR495	8287472				2022-12-01	WOS:A1994MR49500011
J	SCHUTZ, R; SAVARIT, D; KADJO, JC; BATTER, V; KONE, NV; LARUCHE, G; BONDURAND, A; DECOCK, KM				SCHUTZ, R; SAVARIT, D; KADJO, JC; BATTER, V; KONE, NV; LARUCHE, G; BONDURAND, A; DECOCK, KM			EXCLUDING BLOOD-DONORS AT HIGH-RISK OF HIV-INFECTION IN A WEST-AFRICAN CITY	BRITISH MEDICAL JOURNAL			English	Article							TRANSFUSION; KINSHASA; ZAIRE	Objective-To examine the potential impact of deferral of blood donors at high risk of HIV infection in a west African city where blood is screened for HIV antibodies but no other special measures are taken to protect the blood supply. Design-Cross sectional study. Setting-National Blood Transfusion Centre and Project RETRO-CI, an international collaborative AIDS research project, Abidjan, Cote d'Ivoire. Subjects-1257 male first time blood donors. Interventions-Blood donors were interviewed about demographic and behavioural characteristics and tested for HIV antibodies by enzyme immunoassay and, if positive, synthetic peptide based tests. Main outcome measures-HIV antibody status in relation to presence of behavioural risk factors; calculation of sensitivity, specificity, and predictive values of specific criteria for excluding HIV infected donors. Results-The overall prevalence of HIV infection was 11.4%. The most important risk factors for HIV positivity were prostitute contact and being aged 30-39 years. For identifying seropositive donors individual criteria had sensitivity, specificity, and positive predictive values ranging from 15% to 98%, 38% to 91%, and 17% to 30% respectively. Prostitute contact in the past five years would have excluded 31% of all donors and 73% of HIV infected donors. 27% of those excluded would have been HIV positive. Conclusions--The widespread assumption that donor deferral is not feasible in sub-Saharan Africa needs reassessment. In Abidjan this approach was well accepted and potentially effective. Donor deferral requires evaluation as a strategy for improving blood safety in resource poor areas with high rates of HIV infection.	CTR NATL TRANSFUS SANGUINE,ABIDJAN,COTE IVOIRE; PROJET SANTE ABIDJAN,ABIDJAN,COTE IVOIRE; PROJET RETRO CI,ABIDJAN,COTE IVOIRE; CTR DIS CONTROL & PREVENT,NATL CTR INFECT DIS,DIV HIV AIDS,ATLANTA,GA	Centers for Disease Control & Prevention - USA								BERKLEY SF, 1989, J INFECT DIS, V160, P22, DOI 10.1093/infdis/160.1.22; CHIN J, 1989, B WORLD HEALTH ORGAN, V67, P1; DECOCK KM, 1990, AIDS, V4, P875, DOI 10.1097/00002030-199009000-00007; DIALLO MO, 1992, AIDS, V6, P581, DOI 10.1097/00002030-199206000-00010; DOLL LS, 1991, TRANSFUSION, V31, P704, DOI 10.1046/j.1537-2995.1991.31892023494.x; GREENBERG AE, 1988, JAMA-J AM MED ASSOC, V259, P545, DOI 10.1001/jama.259.4.545; JAGER H, 1991, AIDS, V5, pS163; LACKRITZ EM, 1992, LANCET, V340, P524, DOI 10.1016/0140-6736(92)91719-O; MANN J, 1992, AIDS WORLD, P421; NTITA I, 1991, AIDS, V5, P437, DOI 10.1097/00002030-199104000-00013; PIOT P, 1990, HDB AIDS PREVENTION, P1; RYDER RW, 1992, AIDS, V6, P1395, DOI 10.1097/00002030-199211000-00026; SAVARIT D, 1992, BRIT MED J, V305, P498, DOI 10.1136/bmj.305.6852.498; SETBON M, 1993, MONDE           0506	14	31	32	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 11	1993	307	6918					1517	1519		10.1136/bmj.307.6918.1517	http://dx.doi.org/10.1136/bmj.307.6918.1517			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	ML869	8274919	Green Published, Bronze			2022-12-01	WOS:A1993ML86900018
J	JATOI, I; BAUM, M				JATOI, I; BAUM, M			AMERICAN AND EUROPEAN RECOMMENDATIONS FOR SCREENING MAMMOGRAPHY IN YOUNGER WOMEN - A CULTURAL DIVIDE	BRITISH MEDICAL JOURNAL			English	Article							BREAST-CANCER; AGE 50; MORTALITY; TRIAL	The American Cancer Society advocates mammoraphy screening for all women from age 40, whereas in Europe it is not recommended for women below the age of 50. Randomised prospective studies have failed to show a significant benefit from screening women aged under 50 and five potentially harmful effects of screening should be considered: lead time, overdiagnosis, radiation exposure, false positive results, and cost. Younger women must be properly informed about the potential for harm as well as for benefit before screening.	ROYAL MARSDEN HOSP,ACAD DEPT SURG,LONDON SW3 6JJ,ENGLAND	Royal Marsden NHS Foundation Trust								ANDERSSON I, 1988, BRIT MED J, V297, P943, DOI 10.1136/bmj.297.6654.943; BAUER TL, 1991, SURG GYNECOL OBSTET, V173, P482; EDDY DM, 1988, JAMA-J AM MED ASSOC, V259, P1512, DOI 10.1001/jama.259.10.1512; MILLER AB, 1992, CAN MED ASSOC J, V147, P1459; MILLER AB, 1993, LANCET, V341, P439, DOI 10.1016/0140-6736(93)93033-W; NIELSEN M, 1987, BRIT J CANCER, V56, P814, DOI 10.1038/bjc.1987.296; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; Payer Lynn, 1989, MED CULTURE; REIDY J, 1988, BRIT MED J, V297, P932, DOI 10.1136/bmj.297.6654.932; ROBERTS MM, 1990, LANCET, V335, P241; Shapiro S, 1988, PERIODIC SCREENING B; STACEYCLEAR A, 1992, LANCET, V340, P991; SWIFT M, 1991, NEW ENGL J MED, V325, P1831, DOI 10.1056/NEJM199112263252602; TABAR L, 1985, LANCET, V1, P829, DOI 10.1016/S0140-6736(85)92204-4; IN PRESS BREAST; 1991, LANCET, V337, P1575	16	26	26	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1993	307	6917					1481	1483		10.1136/bmj.307.6917.1481	http://dx.doi.org/10.1136/bmj.307.6917.1481			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MK797	8281094	Green Published			2022-12-01	WOS:A1993MK79700031
J	STENSVOLD, I; TVERDAL, A; URDAL, P; GRAFFIVERSEN, S				STENSVOLD, I; TVERDAL, A; URDAL, P; GRAFFIVERSEN, S			NONFASTING SERUM TRIGLYCERIDE CONCENTRATION AND MORTALITY FROM CORONARY HEART-DISEASE AND ANY CAUSE IN MIDDLE-AGED NORWEGIAN WOMEN	BMJ-BRITISH MEDICAL JOURNAL			English	Article							RISK FACTOR; CARDIOVASCULAR RISK; MEN; INSULIN	Objective-To study the association between non-fasting serum triglyceride concentrations and mortality in women from coronary and cardiovascular disease and all causes. Design-Follow up by ambulatory teams of men and women who underwent cardiovascular screening for a mean of 14.6 years. Setting-National health screening service in Norway. Subjects-25 058 men and 24 535 women aged 35-49 years. Main outcome measure-Predictive value of non-fasting serum triglyceride concentrations. Results-At initial screening total serum cholesterol concentration, serum triglyceride concentration, blood pressure, height, and weight were measured, and self reported information about smoking habits, physical activity, and time since last meal were recorded. During subsequent follow up 108 women died from coronary heart disease, 238 from cardiovascular diseases, and 931 from all causes. In women mortality increased steadily with increasing triglyceride concentration for all three causes of death. With the proportional hazards model and adjustment for age, systolic blood pressure, total cholesterol concentration, time since last meal, and number of cigarettes a day the relative risk between triglyceride concentration greater-than-or-equal-to 3.5 mmol/l and <1.5 mmol/l was 4.7 (95% confidence interval 2.5 to 8.9) for deaths from coronary heart disease, 3.0 (1.9 to 4.8) for deaths from cardiovascular disease, 2.3 (1.8 to 2.9) for total deaths in all women. Conclusions-A raised non-fasting concentration of triglycerides is an independent risk factor for mortality from coronary heart disease, cardiovascular disease, and any cause mortality among middle aged Norwegian women in contrast to what is seen in men.	UNIV OSLO, ULLEVAL HOSP, DEPT CLIN CHEM, OSLO 1, NORWAY; NATL HLTH SCREENING SERV, DEPT HLTH INFORMAT, N-0033 OSLO, NORWAY	University of Oslo	STENSVOLD, I (corresponding author), NATL HLTH SCREENING SERV, COMP SERV, POB 8155 DEP, N-0033 OSLO, NORWAY.			Tverdal, Aage/0000-0002-2909-5678				AUSTIN MA, 1989, AM J EPIDEMIOL, V129, P249, DOI 10.1093/oxfordjournals.aje.a115130; AUSTIN MA, 1986, LANCET, V2, P592; Bjartveit K, 1979, Acta Med Scand Suppl, V634, P1; CARLSON LA, 1985, ACTA MED SCAND, V218, P207; COSTONGS GMPJ, 1985, J CLIN CHEM CLIN BIO, V23, P7; Dixon W. J., 1990, BMDP STATISTICAL SOF; FOLSOM AR, 1991, ATHEROSCLEROSIS, V91, P191, DOI 10.1016/0021-9150(91)90167-2; FONTBONNE A, 1991, CIRCULATION, V84, P1442, DOI 10.1161/01.CIR.84.3.1442; FREEDMAN DS, 1988, AM J EPIDEMIOL, V127, P1118, DOI 10.1093/oxfordjournals.aje.a114906; GIANTURCO SH, 1991, CURR OPIN LIPIDOL, V2, P324; HALL WH, 1993, JAMA-J AM MED ASSOC, V269, P505; HAMSTEN A, 1991, CURRENT OPINION LIPI, V2, P26; HULLEY SB, 1980, NEW ENGL J MED, V302, P1383, DOI 10.1056/NEJM198006193022503; KASHYAP ML, 1991, CURRENT OPINION LIPI, V2, P379; LAPIDUS L, 1985, ACTA MED SCAND, V217, P481; NATVIG H, 1968, SCAND J CLIN LAB INV, VS 22, P1; REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595; STENSVOLD I, 1992, EUR HEART J, V13, P1155, DOI 10.1093/oxfordjournals.eurheartj.a060331; TVERDAL A, 1989, AM J EPIDEMIOL, V129, P458, DOI 10.1093/oxfordjournals.aje.a115157; WESTLUND K, 1972, SCAND J CLIN LAB INV, V30, P1; 1973, INT CLASSIFICATION D; 1988, CARDIOVASCULAR DISEA; 1986, INT CLASSIFICATION D	23	112	114	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 20	1993	307	6915					1318	1322		10.1136/bmj.307.6915.1318	http://dx.doi.org/10.1136/bmj.307.6915.1318			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	MH556	8257886	Bronze, Green Published			2022-12-01	WOS:A1993MH55600020
J	NOVACK, DH				NOVACK, DH			ADRIENNE	ANNALS OF INTERNAL MEDICINE			English	Editorial Material											NOVACK, DH (corresponding author), RHODE ISL HOSP, 593 EDDY ST, PROVIDENCE, RI 02903 USA.								0	2	2	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	SEP 1	1993	119	5					424	425		10.7326/0003-4819-119-5-199309010-00013	http://dx.doi.org/10.7326/0003-4819-119-5-199309010-00013			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LZ476	8338298				2022-12-01	WOS:A1993LZ47600013
J	BENNETT, PR; KIM, CL; COLIN, Y; WARWICK, RM; CHERIFZAHAR, B; FISK, NM; CARTRON, JP				BENNETT, PR; KIM, CL; COLIN, Y; WARWICK, RM; CHERIFZAHAR, B; FISK, NM; CARTRON, JP			PRENATAL DETERMINATION OF FETAL RHD TYPE BY DNA AMPLIFICATION	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							FETOMATERNAL HEMORRHAGE; EARLY AMNIOCENTESIS; 1ST TRIMESTER; MANAGEMENT; PREGNANCY; CLONING	Background. An RhD-negative woman whose partner is heterozygous may have preexisting anti-RhD antibodies that may or may not affect a subsequent fetus, depending on whether it is heterozygous. A safe method of determining fetal RhD type early in pregnancy would eliminate the risks to an RhD-negative fetus of fetal-blood sampling or serial amniocenteses. Methods. We determined the RhD type in 15 fetuses using the polymerase chain reaction in amniotic cells and serologic methods in fetal blood collected simultaneously. In another 15 fetuses, the RhD type determined from chorionic-villus samples was compared with that identified by typing of DNA from the fetus itself. Results. RhD typing of DNA from amniotic cells correctly indicated the serologic type in every fetus. Of 10 fetuses with RhD-negative mothers, 4 were identified as RhD-negative and 6 as RhD-positive. Of five fetuses with RhD-positive mothers, four were identified as RhD-positive and one as RhD-negative. There was also complete agreement between the results of RhD typing of DNA from chorionic-villus samples and the results of typing of DNA from fetal tissue. Eleven fetuses were RhD-positive, and four were RhD-negative. Four RhD-positive fetuses had RhD-negative mothers. Three RhD-negative fetuses had RhD-positive mothers. There was no contamination by maternal RhD-positive DNA of the samples from RhD-negative fetuses. Conclusions. Determining fetal RhD type in amniotic cells without invading the fetomaternal circulation is a reliable method that will be valuable in the management of Rh alloimmunization.	INST NATL TRANSFUS SANGUINE,INSERM,U76,PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm)	BENNETT, PR (corresponding author), QUEEN CHARLOTTES & CHELSEA HOSP,ROYAL POSTGRAD MED SCH,INST OBSTET & GYNAECOL,LONDON W6 OXG,ENGLAND.		Fisk, Nicholas M/B-2126-2009; colin, yves/O-1910-2017; le van kim, caroline/O-7030-2017	Fisk, Nicholas M/0000-0003-0031-7975; colin, yves/0000-0001-5196-4254; Cherif-Zahar, Baya/0000-0002-4965-7252; le van kim, caroline/0000-0002-3251-1310; Bennett, Phillip/0000-0002-6253-4919				[Anonymous], 1991, LANCET, V337, P1491; AVENT ND, 1990, BIOCHEM J, V271, P821, DOI 10.1042/bj2710821; BLAKEMORE KJ, 1986, AM J OBSTET GYNECOL, V155, P988, DOI 10.1016/0002-9378(86)90332-7; BLANCHARD D, 1988, BLOOD, V72, P1424; BOWMAN JM, 1965, PEDIATRICS, V35, P815; BURTON BK, 1992, OBSTET GYNECOL, V79, P726; BYRNE D, 1991, ULTRASOUND OBST GYN, V1, P235, DOI 10.1046/j.1469-0705.1991.01040235.x; Canadian Collaborative CVS-Amniocentesis Clinical Trial Group, 1989, LANCET, V1, P1; CHERIFZAHAR B, 1991, HUM GENET, V86, P398, DOI 10.1007/BF00201843; CHERIFZAHAR B, 1990, P NATL ACAD SCI USA, V87, P6243, DOI 10.1073/pnas.87.16.6243; CLARKE CA, 1987, BRIT MED J, V294, P1001, DOI 10.1136/bmj.294.6578.1001; COLIN Y, 1991, BLOOD, V78, P2747; FUHRMAN HC, 1987, PRENATAL DIAG, V7, P17, DOI 10.1002/pd.1970070104; GEMKE RJBJ, 1986, BRIT J HAEMATOL, V64, P689, DOI 10.1111/j.1365-2141.1986.tb02230.x; HANDYSIDE AH, 1992, NEW ENGL J MED, V327, P905, DOI 10.1056/NEJM199209243271301; HANSON FW, 1992, AM J OBSTET GYNECOL, V166, P1707, DOI 10.1016/0002-9378(92)91560-W; KANHAI HH, 1987, AM J OBSTET GYNECOL, V156, P120, DOI 10.1016/0002-9378(87)90219-5; KIM CL, 1992, BLOOD, V80, P1074; KIM CL, 1992, P NATL ACAD SCI USA, V89, P10925; MARSH WL, 1974, SCIENCE, V183, P966, DOI 10.1126/science.183.4128.966; NICOLAIDES K H, 1986, Fetal Therapy, V1, P185; NICOLINI U, 1988, BRIT MED J, V297, P1379, DOI 10.1136/bmj.297.6660.1379; POISSONNIER MH, 1989, AM J OBSTET GYNECOL, V161, P709, DOI 10.1016/0002-9378(89)90386-4; PRICE JO, 1991, AM J OBSTET GYNECOL, V165, P1731, DOI 10.1016/0002-9378(91)90024-L; Race RR., 1975, BLOOD GROUPS MAN; RODECK CH, 1989, BRIT J OBSTET GYNAEC, V96, P759, DOI 10.1111/j.1471-0528.1989.tb03312.x; WARREN RC, 1985, LANCET, V1, P691	27	208	232	0	5	MASS MEDICAL SOC	BOSTON	10 SHATTUCK, BOSTON, MA 02115	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	AUG 26	1993	329	9					607	610		10.1056/NEJM199308263290903	http://dx.doi.org/10.1056/NEJM199308263290903			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LU217	8341334				2022-12-01	WOS:A1993LU21700003
J	TRAUTWEIN, C; CAELLES, C; VANDERGEER, P; HUNTER, T; KARIN, M; CHOJKIER, M				TRAUTWEIN, C; CAELLES, C; VANDERGEER, P; HUNTER, T; KARIN, M; CHOJKIER, M			TRANSACTIVATION BY NF-IL6 LAP IS ENHANCED BY PHOSPHORYLATION OF ITS ACTIVATION DOMAIN	NATURE			English	Article							HEPATOCYTE-STIMULATING FACTOR; NECROSIS FACTOR-ALPHA; ACUTE PHASE RESPONSE; PROTEIN-KINASE; C-JUN; NUCLEAR-PROTEIN; PHORBOL ESTERS; C/EBP; CELLS; GENE	ONE of the members of the bZIP family of transcriptional activators1-5 is NF-IL6/LAP (IL-6 DBP, C/EBPbeta, CRP2). NF-IL6/LAP protein is highly expressed in liver nuclei2, where it has been implicated as a master regulator of the acute-phase response1,3,6,7, induced by interleukin-6 (IL-6) and other inflammatory mediators3,8. Also, NF-IL6/LAP is involved in the activation of the IL-6 promoter in response to IL-1 and bacterial lipopolysaccharide1,6. The control of NF-IL6/LAP expression and activity is complex and poorly understood. Under some conditions the NF-IL6/LAP gene is transcriptionally activated by IL-1 and lipopolysaccharide1, whereas in other instances, its binding to cognate DNA sequences is enhanced by cytokines1,3. Additionally, the ability of constitutively expressed NF-IL6/LAP to activate transcription is strongly augmented by IL-6, through an unknown signalling pathway. We now show that stimulation of the protein kinase C pathway increases the phosphorylation of Ser 105 within the activation domain of NF-IL6/LAP, and enhances its transcriptional efficacy.	UNIV CALIF SAN DIEGO, DEPT PHARMACOL, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, DEPT MED, LA JOLLA, CA 92093 USA; UNIV CALIF SAN DIEGO, CTR MOLEC GENET, LA JOLLA, CA 92093 USA; VET AFFAIRS MED CTR, LA JOLLA, CA 92093 USA; SALK INST BIOL STUDIES, LA JOLLA, CA 92186 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego; US Department of Veterans Affairs; Veterans Health Administration (VHA); Salk Institute								AKIRA S, 1990, EMBO J, V9, P1897, DOI 10.1002/j.1460-2075.1990.tb08316.x; BINETRUY B, 1991, NATURE, V351, P122, DOI 10.1038/351122a0; BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRENNER DA, 1989, NATURE, V337, P661, DOI 10.1038/337661a0; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CASTAGNA M, 1982, J BIOL CHEM, V257, P7847; DARLINGTON GJ, 1986, J CELL BIOL, V103, P787, DOI 10.1083/jcb.103.3.787; DESCOMBES P, 1991, CELL, V67, P569, DOI 10.1016/0092-8674(91)90531-3; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EVANS E, 1987, J BIOL CHEM, V262, P10850; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GONZALEZ GA, 1989, CELL, V59, P675, DOI 10.1016/0092-8674(89)90013-5; HENSEL G, 1989, LYMPHOKINE RES, V8, P347; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; ISSHIKI H, 1990, MOL CELL BIOL, V10, P2757, DOI 10.1128/MCB.10.6.2757; JAMES G, 1992, J CELL BIOL, V116, P863, DOI 10.1083/jcb.116.4.863; LI L, 1992, CELL, V71, P1181, DOI 10.1016/S0092-8674(05)80066-2; METCALF D, 1985, LEUKEMIA RES, V9, P35, DOI 10.1016/0145-2126(85)90020-7; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; MUELLER CR, 1990, CELL, V61, P279, DOI 10.1016/0092-8674(90)90808-R; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; NISHIZAWA M, 1990, J BIOL CHEM, V265, P5897; POLI V, 1990, CELL, V63, P643, DOI 10.1016/0092-8674(90)90459-R; POLI V, 1989, P NATL ACAD SCI USA, V86, P8202, DOI 10.1073/pnas.86.21.8202; RAY A, 1988, P NATL ACAD SCI USA, V85, P6701, DOI 10.1073/pnas.85.18.6701; SADOWSKI I, 1989, NUCLEIC ACIDS RES, V17, P7539, DOI 10.1093/nar/17.18.7539; SEELENTAG WK, 1987, EMBO J, V6, P2261, DOI 10.1002/j.1460-2075.1987.tb02499.x; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; WILLIAMS SC, 1991, GENE DEV, V5, P1553, DOI 10.1101/gad.5.9.1553	31	333	339	0	1	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	AUG 5	1993	364	6437					544	547		10.1038/364544a0	http://dx.doi.org/10.1038/364544a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LQ667	8336793				2022-12-01	WOS:A1993LQ66700060
J	VEAUTE, X; FUCHS, RPP				VEAUTE, X; FUCHS, RPP			GREATER SUSCEPTIBILITY TO MUTATIONS IN LAGGING-STRAND OF DNA-REPLICATION IN ESCHERICHIA-COLI THAN IN LEADING-STRAND	SCIENCE			English	Article							POLYMERASE-III HOLOENZYME; FRAMESHIFT MUTAGENESIS; SEQUENCES; SYSTEM	Models of DNA replication in Escherichia coli involve an asymmetric DNA polymerase complex that replicates concurrently the leading and the lagging strands of double-stranded DNA. The effect of asymmetry on mutagenesis was tested with pairs of plasmids containing the unidirectional ColE1 origin of replication and a single lesion located in the leading or lagging strand. The lesion used was the covalent adduct that the chemical carcinogen N-2-acetylaminofluorene (AAF) forms with the C-8 position of guanine. Whether SOS was induced or not, mutations arose at about a 20-fold higher frequency when the AAF adduct was located in the lagging strand than when in the leading strand.			VEAUTE, X (corresponding author), CNRS,INST BIOL MOLEC & CELLULAIRE,UNITE PROPRE RECH CANCEROGENESE & MUTAGENESE MOLEC & STRUCT,F-67084 STRASBOURG,FRANCE.							BACKMAN K, 1978, COLD SPRING HARB SYM, V43, P69; BURNOUF D, 1989, P NATL ACAD SCI USA, V86, P4147, DOI 10.1073/pnas.86.11.4147; FUCHS RPP, 1981, NATURE, V294, P657, DOI 10.1038/294657a0; JOHANSON KO, 1984, J BIOL CHEM, V259, P4589; Kaderlik R. K., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P152; KOFFELSCHWARTZ N, 1989, MOL GEN GENET, V215, P306, DOI 10.1007/BF00339733; KOFFELSCHWARTZ N, 1984, J MOL BIOL, V177, P33, DOI 10.1016/0022-2836(84)90056-1; LAHUE RS, 1989, SCIENCE, V245, P160, DOI 10.1126/science.2665076; LAMBERT IB, 1992, P NATL ACAD SCI USA, V89, P1310, DOI 10.1073/pnas.89.4.1310; MAENHAUTMICHEL G, 1992, MOL GEN GENET, V235, P373, DOI 10.1007/BF00279383; MAKI H, 1988, J BIOL CHEM, V263, P6570; MARIANS KT, 1992, ANN REV BIOCH, V61, P67; ROBERTS JD, 1991, P NATL ACAD SCI USA, V88, P3465, DOI 10.1073/pnas.88.8.3465; TOMIZAWA JI, 1974, P NATL ACAD SCI USA, V71, P2260, DOI 10.1073/pnas.71.6.2260; TRINH TQ, 1991, NATURE, V352, P544, DOI 10.1038/352544a0; VEAUTE X, IN PRESS P NATL ACAD; VIEIRA J, 1982, GENE, V19, P259, DOI 10.1016/0378-1119(82)90015-4	17	112	113	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005	0036-8075			SCIENCE	Science	JUL 30	1993	261	5121					598	600		10.1126/science.8342022	http://dx.doi.org/10.1126/science.8342022			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LP728	8342022				2022-12-01	WOS:A1993LP72800035
J	LI, J; TAYLOR, B				LI, J; TAYLOR, B			FACTORS AFFECTING UPTAKE OF MEASLES, MUMPS, AND RUBELLA IMMUNIZATION	BRITISH MEDICAL JOURNAL			English	Article							IMMUNIZATION POLICY; CHILDREN; DISTRICT; RATES	Objective-To study factors affecting uptake of measles, mumps, and rubella immunisation. Design-Cohort study using data from computerised child health systems. Setting-10 health districts in North East Thames and North West Thames regions. Subjects-7841 children born in January to March 1990 and resident in the districts up till the end of October 1991. Main outcome measures-Overall uptake of measles, mumps, and rubella immunisation, variation of uptake among groups of children, and odds ratio of being vaccinated against measles, mumps, and rubella. Results-The overall uptake rate of measles, mumps, and rubella immunisation for the study cohort in the 10 districts was 82%. Wide variation was identified among children with different demographic characteristics. Lower uptake was associated with absent or incomplete primary immunisation, including omission of pertussis vaccine. Other factors affecting uptake included the type of resident district, birth order, where registered for immunisation (general practitioner or clinic), and one parent family status. Conclusions-Many districts have difficulties in meeting the 90% target for measles, mumps, and rubella immunisation, mainly because of the characteristics of their local population. To increase overall coverage, the health service should target families with adverse factors, especially those whose children have missed previous immunisations.			LI, J (corresponding author), ROYAL FREE HOSP,SCH MED,DEPT COMMUNITY CHILD HLTH,LONDON NW3 2QG,ENGLAND.							BEGG NT, 1985, BRIT MED J, V291, P1370, DOI 10.1136/bmj.291.6506.1370; CAMPBELL AGM, 1983, ARCH DIS CHILD, V58, P3, DOI 10.1136/adc.58.1.3; HERTOGS D, 1989, PUBLIC HEALTH, V103, P421, DOI 10.1016/S0033-3506(89)80051-4; HODES DT, 1990, PUBLIC HEALTH, V104, P27, DOI 10.1016/S0033-3506(05)80342-7; HULL D, 1987, J ROY COLL PHYS LOND, V21, P28; JARMAN B, 1988, BRIT MED J, V296, P1775, DOI 10.1136/bmj.296.6639.1775; JARMAN B, 1983, BRIT MED J, V286, P1704; JEFFERIES S, 1991, J PUBLIC HEALTH MED, V13, P312; JEFFERSON N, 1987, BRIT MED J, V294, P423, DOI 10.1136/bmj.294.6569.423; LI J, 1991, BRIT MED J, V303, P1035, DOI 10.1136/bmj.303.6809.1035; Li J, 1993, Health Trends, V25, P16; MARKS JS, 1979, PEDIATRICS, V64, P304; MILLER C, 1986, LANCET, V2, P732; NICOLL A, 1989, BRIT MED J, V299, P808, DOI 10.1136/bmj.299.6703.808; PECKHAM C, 1989, PECKHAM REPORT NATIO; RILEY DJ, 1991, BRIT MED J, V302, P31, DOI 10.1136/bmj.302.6767.31; TCHIE LD, 1992, BMJ, V304, P816; WALKER D, 1986, BRIT MED J, V292, P1501, DOI 10.1136/bmj.292.6534.1501; White J M, 1992, Commun Dis Rep CDR Rev, V2, pR96; WHITE JM, 1992, BRIT MED J, V304, P682, DOI 10.1136/bmj.304.6828.682; 1991, CM 1523; 1985, SAS USERS GUIDE STAT; 1990, IMMUNISATION INFECTI; 1986, LANCET, V2, P671; 1988, IMMUNISATION INFECTI	25	48	48	1	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUL 17	1993	307	6897					168	171		10.1136/bmj.307.6897.168	http://dx.doi.org/10.1136/bmj.307.6897.168			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LN184	8343745	Green Published, Bronze			2022-12-01	WOS:A1993LN18400020
J	STEVENS, CF; WANG, YY				STEVENS, CF; WANG, YY			REVERSAL OF LONG-TERM POTENTIATION BY INHIBITORS OF HEME OXYGENASE	NATURE			English	Article							DENTATE GYRUS; TRANSMISSION; HIPPOCAMPUS; ZINC; RAT	EVIDENCE that carbon monoxide can serve as an intercellular messenger in brain1-3, a role much like that demonstrated for nitric oxide in various tissues4, prompted us to investigate whether carbon monoxide participates in long-term potentiation (LTP), the cellular mechanism that may underlie certain forms of learning and memory. Although LTP is triggered in the postsynaptic neuron, at least some fraction of LTP is expressed presynaptically as an increase in the quantity of neurotransmitter released5-14. Thus, a retrograde signal must form the communication link between the postsynaptic site of induction and the presynaptic site of expression. To test whether carbon monoxide might act as a retrograde signal in LTP, we have investigated the effect on LTP of inhibitors of the enzyme haem oxygenase-2, which catalyses the production of carbon monoxide in the brain. We find that these inhibitors prevent the induction of LTP and have no effect on one form of long-term depression. Furthermore, they will reverse LTP that is already established.			STEVENS, CF (corresponding author), SALK INST BIOL STUDIES,HOWARD HUGHES MED INST,10010 N TORREY PINES RD,LA JOLLA,CA 92037, USA.							BASKYS A, 1991, NEUROSCI LETT, V127, P169, DOI 10.1016/0304-3940(91)90786-S; BEKKERS JM, 1990, NATURE, V346, P724, DOI 10.1038/346724a0; BLISS TVP, 1986, J PHYSIOL-LONDON, V377, P391, DOI 10.1113/jphysiol.1986.sp016193; BLOOMER JR, 1983, GASTROENTEROLOGY, V95, P663; CULOTTA E, 1992, SCIENCE, V258, P1862, DOI 10.1126/science.1361684; DUDEK SM, 1992, P NATL ACAD SCI USA, V89, P4363, DOI 10.1073/pnas.89.10.4363; EWING JF, 1992, MOL CELL NEUROSCI, V3, P559, DOI 10.1016/1044-7431(92)90068-D; IGNARRO LJ, 1984, J BIOL CHEM, V259, P6201; KULLMANN DM, 1992, NATURE, V357, P240, DOI 10.1038/357240a0; LARKMAN A, 1992, NATURE, V360, P70, DOI 10.1038/360070a0; LIAO D, 1992, NEURON, V9, P1089, DOI 10.1016/0896-6273(92)90068-O; MAINES MD, 1981, BIOCHIM BIOPHYS ACTA, V673, P339, DOI 10.1016/0304-4165(81)90465-7; MALGAROLI A, 1992, NATURE, V357, P134, DOI 10.1038/357134a0; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MALINOW R, 1990, NATURE, V346, P177, DOI 10.1038/346177a0; MALINOW R, 1991, SCIENCE, V252, P722, DOI 10.1126/science.1850871; MARKS GS, 1991, TRENDS PHARMACOL SCI, V12, P185, DOI 10.1016/0165-6147(91)90544-3; MAYER ML, 1989, J PHYSIOL-LONDON, V415, P351, DOI 10.1113/jphysiol.1989.sp017725; MULKEY RM, 1992, NEURON, V9, P967, DOI 10.1016/0896-6273(92)90248-C; VERMA A, 1993, SCIENCE, V259, P381, DOI 10.1126/science.7678352; VORONIN LL, 1988, SYNAPTIC PLASTICITY, P27; VREMAN HJ, 1991, AM J MED SCI, V302, P335, DOI 10.1097/00000441-199112000-00002; ZHOU M, IN PRESS SCIENCE	23	256	260	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 8	1993	364	6433					147	149		10.1038/364147a0	http://dx.doi.org/10.1038/364147a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LL367	8321285				2022-12-01	WOS:A1993LL36700049
J	SLATER, SJ; COX, KJA; LOMBARDI, JV; HO, C; KELLY, MB; RUBIN, E; STUBBS, CD				SLATER, SJ; COX, KJA; LOMBARDI, JV; HO, C; KELLY, MB; RUBIN, E; STUBBS, CD			INHIBITION OF PROTEIN-KINASE-C BY ALCOHOLS AND ANESTHETICS	NATURE			English	Article							GENERAL-ANESTHETICS; LOCAL-ANESTHETICS; MOLECULAR MECHANISMS; ACTIVATION; SITE; MEMBRANES; ALKANOLS; TORPEDO; BINDING	DESPITE almost a century of research, the mechanism of anaesthesia remains obscure and there is still no agreement on the location of the site(s) of action1-7. Because the potencies of general anaesthetics increase in proportion to their solubility in olive oil, this led to a consensus that the site is within the cell membrane 8-10. This led to theories that lipid bilayer perturbation was the primary event, which was then transmitted to a membrane protein11. But at the concentrations used clinically, such perturbations are small3. A plausible site would be in or on ion channels at the synapse, where a number of modulatory effects have been described6. A possible location for such a site would be at the protein-lipid interface5,12,13. We report here that anaesthetics inhibit protein kinase C, a key component in signal transduction. The potency is a linear function of the octanol-water partition coefficient (the Meyer-Overton rule of anaesthesia). The effect was obtained in a lipid-free assay, implicating a hydrophobic site in the protein, supporting the contention that a (membrane) protein may be a target for anaesthetic interactions14-17. In a lipid-dependent assay, a potential role of lipids in the protein-site model was demonstrated. The inhibition was absent in the isolated catalytic domain, suggesting that the site of inhibition is on the regulatory subunit, which is unique to protein kinase C.	THOMAS JEFFERSON UNIV,DEPT PATHOL & CELL BIOL,PHILADELPHIA,PA 19107	Jefferson University				Lombardi, Joseph/0000-0002-2665-8084				ALIFIMOFF JK, 1989, BRIT J PHARMACOL, V96, P9, DOI 10.1111/j.1476-5381.1989.tb11777.x; BELL RM, 1991, J BIOL CHEM, V266, P4661; CURRY S, 1990, BIOCHEMISTRY-US, V29, P4641, DOI 10.1021/bi00471a020; DLUZEWSKI AR, 1983, MOL ASPECTS MED, V6, P459, DOI 10.1016/0098-2997(83)90001-8; FRANKS NP, 1982, NATURE, V300, P487, DOI 10.1038/300487a0; FRANKS NP, 1985, NATURE, V316, P349, DOI 10.1038/316349a0; FRANKS NP, 1984, NATURE, V310, P599, DOI 10.1038/310599a0; FRASER DM, 1990, BIOCHEMISTRY-US, V29, P2664, DOI 10.1021/bi00463a007; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HAYDON DA, 1977, NATURE, V268, P356, DOI 10.1038/268356a0; INOUE M, 1977, J BIOL CHEM, V252, P7610; Kitano T, 1986, Methods Enzymol, V124, P349; LEE MH, 1986, J BIOL CHEM, V261, P4867; LEO A, 1971, CHEM REV, V71, P525, DOI 10.1021/cr60274a001; MATTHEWS R, 1992, SCIENCE, V255, P156, DOI 10.1126/science.1553540; Meyer H, 1901, ARCH EXP PATHOL PHAR, V46, P338, DOI 10.1007/BF01978064; MEYER H, 1989, ARCH EXP PATHOL PH, V42, P109; MIKAWA K, 1990, J INT MED RES, V18, P153, DOI 10.1177/030006059001800209; MILLER KW, 1985, INT REV NEUROBIOL, V27, P1, DOI 10.1016/S0074-7742(08)60555-3; MOSS GWJ, 1991, P NATL ACAD SCI USA, V88, P134, DOI 10.1073/pnas.88.1.134; Overton E., 1901, STUDIEN NARKOSE; RICHARDS CD, 1978, NATURE, V276, P775, DOI 10.1038/276775a0; RUBIN E, 1991, ANN NY ACAD SCI, V625; SEEMAN P, 1972, PHARMACOL REV, V24, P583; STUBBS CD, 1984, BIOCHIM BIOPHYS ACTA, V775, P374, DOI 10.1016/0005-2736(84)90193-7; TAS PWL, 1991, BIOCHIM BIOPHYS ACTA, V1091, P401, DOI 10.1016/0167-4889(91)90206-D; TRUDELL JR, 1991, ANN NY ACAD SCI, V625, P743, DOI 10.1111/j.1749-6632.1991.tb33907.x; TRUDELL JR, 1973, BIOCHIM BIOPHYS ACTA, V291, P321, DOI 10.1016/0005-2736(73)90485-9; WOOD SC, 1991, MOL PHARMACOL, V39, P332	29	219	220	3	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 1	1993	364	6432					82	84		10.1038/364082a0	http://dx.doi.org/10.1038/364082a0			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK818	8316305				2022-12-01	WOS:A1993LK81800064
J	TINGLEY, WG; ROCHE, KW; THOMPSON, AK; HUGANIR, RL				TINGLEY, WG; ROCHE, KW; THOMPSON, AK; HUGANIR, RL			REGULATION OF NMDA RECEPTOR PHOSPHORYLATION BY ALTERNATIVE SPLICING OF THE C-TERMINAL DOMAIN	NATURE			English	Article							ACETYLCHOLINE-RECEPTOR; PROTEIN-KINASE; SEQUENCES	THE NMDA (N-methyl D-aspartate) receptors in the brain play a critical role in synaptic plasticity, synaptogenesis and excitotoxicity1-3. Molecular cloning has demonstrated that NMDA receptors consist of several homologous subunits (NMDAR1, 2A-2D)4-7. A variety of studies have suggested that protein phosphorylation of NMDA receptors may regulate their function7-12 and play a role in many forms of synaptic plasticity such as long-term potentiation13,14. We have examined the phosphorylation of the NMDA receptor subunit NMDAR1 (NR1) by protein kinase C (PKC) in cells transiently expressing recombinant NR1 and in primary cultures of cortical neurons. PKC phosphorylation occurs on several distinct sites on the NR1 subunit. Most of these sites are contained within a single alternatively spliced exon in the C-terminal domain, which has previously been proposed to be on the extracellular side of the membrane4,5,15. These results demonstrate that alternative splicing of the NR1 messenger RNA regulates its phosphorylation by PKC, and that mRNA splicing is a novel mechanism for regulating the sensitivity of glutamate receptors to protein phosphorylation. These results also provide evidence that the C-terminal domain of the NR1 protein is located intracellularly, suggesting that the proposed transmembrane topology model for glutamate receptors may be incorrect.	JOHNS HOPKINS UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT NEUROSCI,BALTIMORE,MD 21205	Howard Hughes Medical Institute; Johns Hopkins University			Roche, Katherine/W-9893-2019	Roche, Katherine/0000-0001-7282-6539				BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHEN L, 1991, NEURON, V7, P319, DOI 10.1016/0896-6273(91)90270-A; CHOI DW, 1990, REV NEUROSCI, V13, P171; CLAUDIO T, 1983, P NATL ACAD SCI-BIOL, V80, P1111, DOI 10.1073/pnas.80.4.1111; CONSTANTINEPATO.M, 1990, REV NEUROSCI, V13, P129; DURANDD GM, 1992, P NATN ACADD SCI US, V89, P1; GASIC GP, 1992, ANNU REV PHYSIOL, V54, P507, DOI 10.1146/annurev.physiol.54.1.507; HIRANO AA, 1988, J NEUROCHEM, V50, P1447, DOI 10.1111/j.1471-4159.1988.tb03029.x; HUGANIR RL, 1984, P NATL ACAD SCI-BIOL, V81, P6968, DOI 10.1073/pnas.81.22.6968; KELSO SR, 1992, J PHYSIOL-LONDON, V449, P705, DOI 10.1113/jphysiol.1992.sp019110; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUTSUWADA T, 1992, NATURE, V358, P36, DOI 10.1038/358036a0; MARKRAM H, 1992, J PHYSIOL-LONDON, V457, P491, DOI 10.1113/jphysiol.1992.sp019389; MARTIN LJ, 1993, NEUROSCIENCE, V53, P327, DOI 10.1016/0306-4522(93)90199-P; MOLNAR E, 1993, NEUROSCIENCE, V53, P307, DOI 10.1016/0306-4522(93)90198-O; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MURPHY TH, 1990, DEV BRAIN RES, V57, P146, DOI 10.1016/0165-3806(90)90195-5; NAKANISHI S, 1992, SCIENCE, V258, P597, DOI 10.1126/science.1329206; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; RAYMOND LA, 1993, TRENDS NEUROSCI, V16, P147, DOI 10.1016/0166-2236(93)90123-4; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; Sambrook J., 1989, MOL CLONING LAB MANU; SCHOFIELD PR, 1987, NATURE, V328, P221, DOI 10.1038/328221a0; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; SWOPE SL, 1992, FASEB J, V6, P2514, DOI 10.1096/fasebj.6.8.1375568; URUSHIHARA H, 1992, J BIOL CHEM, V267, P11697	28	372	387	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON, ENGLAND N1 9XW	0028-0836			NATURE	Nature	JUL 1	1993	364	6432					70	73		10.1038/364070a0	http://dx.doi.org/10.1038/364070a0			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	LK818	8316301				2022-12-01	WOS:A1993LK81800060
J	ANDREWS, K				ANDREWS, K			RECOVERY OF PATIENTS AFTER 4 MONTHS OR MORE IN THE PERSISTENT VEGETATIVE STATE	BRITISH MEDICAL JOURNAL			English	Article							SEVERE HEAD-INJURY; TRAUMATIC COMA; PROGNOSIS	A retrospective review was made of the case notes of 43 consecutive patients admitted to a unit specialising in the rehabilitation of people in the persistent vegetative state. Eleven of these patients regained awareness four months or more after suffering brain damage. The time to the first reported incidence of eye tracking was between four months and three years, and the time to the first response to command was between four and 12 months. Only one patient was eventually unable to communicate, six could use non-verbal methods of indicating at least a yes or no response, and four were able to speak. Six patients remained totally dependent while two became independent in daily activities. Four patients became independent in feeding, three required help, and four remained on gastrostomy feeding. Thus some patients can regain awareness after more than four months in a vegetative state, and, although few reach full independence, most can achieve an improved quality of life within the limitations of their disabilities. The recovery period is prolonged and may continue for several years. Even patients with profound brain damage should be offered the opportunity of a specialist rehabilitation programme.	ROYAL HOSP & HOME,RES SERV,LONDON SW15 3SW,ENGLAND		ANDREWS, K (corresponding author), ROYAL HOSP & HOME,MED SERV,LONDON SW15 3SW,ENGLAND.							ARTS WFM, 1985, J NEUROL NEUROSUR PS, V48, P1300, DOI 10.1136/jnnp.48.12.1300; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BRAAKMAN R, 1988, ACTA NEUROCHIR, V95, P49, DOI 10.1007/BF01793082; BRICOLO A, 1980, J NEUROSURG, V52, P625, DOI 10.3171/jns.1980.52.5.0625; CRAIG CW, 1986, J NEUROSURG, V65, P9; HAIG AJ, 1990, ARCH PHYS MED REHAB, V71, P1081; HANSOTIA PL, 1985, ARCH NEUROL-CHICAGO, V42, P1048, DOI 10.1001/archneur.1985.04060100030015; HEIDEN JS, 1983, PHYS THER, V63, P1946, DOI 10.1093/ptj/63.12.1946; HIGASHI K, 1977, J NEUROL NEUROSUR PS, V40, P876, DOI 10.1136/jnnp.40.9.876; HIGASHI K, 1981, J NEUROL NEUROSUR PS, V44, P552, DOI 10.1136/jnnp.44.6.552; JENNETT B, 1991, BMJ-BRIT MED J, V302, P1256, DOI 10.1136/bmj.302.6787.1256; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; JENNETT B, 1972, LANCET, V1, P734; JENNETT B, 1992, BRIT MED J, V305, P1305, DOI 10.1136/bmj.305.6865.1305; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; Levy D E, 1978, Ann N Y Acad Sci, V315, P293, DOI 10.1111/j.1749-6632.1978.tb50347.x; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LYLE DM, 1986, J NEUROSURG, V65, P15, DOI 10.3171/jns.1986.65.1.0015; MAHONEY WJ, 1983, PEDIATRICS, V71, P756; MAY PG, 1968, DIS NERV SYST, V29, P837; NAJENSON T, 1978, SCAND J REHABIL MED, V10, P15; Roberts AH., 1979, SEVERE ACCIDENTAL HE; ROSENBERG GA, 1977, ANN NEUROL, V2, P167, DOI 10.1002/ana.410020215; ROSIN AJ, 1978, SCAND J REHABIL MED, V10, P33; SAZBON L, 1992, BRAIN INJURY, V4, P359; STEINBOCK B, 1989, HASTINGS CENT REP, V19, P14, DOI 10.2307/3562294; TANHEHCO J, 1982, ARCH PHYS MED REHAB, V63, P36; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300; [No title captured]; 1993, BMA NEWS REV, V19, P9	30	63	64	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON, ENGLAND WC1H 9JR	0959-8138			BRIT MED J	Br. Med. J.	JUN 12	1993	306	6892					1597	1600		10.1136/bmj.306.6892.1597	http://dx.doi.org/10.1136/bmj.306.6892.1597			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LH128	8329926	Green Published, Bronze			2022-12-01	WOS:A1993LH12800027
J	NESS, RB; HARRIS, T; COBB, J; FLEGAL, KM; KELSEY, JL; BALANGER, A; STUNKARD, AJ; DAGOSTINO, RB				NESS, RB; HARRIS, T; COBB, J; FLEGAL, KM; KELSEY, JL; BALANGER, A; STUNKARD, AJ; DAGOSTINO, RB			NUMBER OF PREGNANCIES AND THE SUBSEQUENT RISK OF CARDIOVASCULAR-DISEASE	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; YOUNG-WOMEN; REPRODUCTIVE HISTORY; FAT DISTRIBUTION; WHITE WOMEN; FRAMINGHAM; OBESITY; PARITY; HEALTH	Background. Whether increasing parity or gravidity is a risk factor for corona Methods. We tested the association between the number of pregnancies and a variety of cardiovascular end points in two groups of women who had completed childbearing. One group comprised 2357 women who were followed for 28 years through the Framingham Heart Study, and the other 2533 women followed for at least 12 years through the first National Health and Nutrition Examination Survey National Epidemiologic Follow-up Study (NHEFS). Results. The rates of coronary heart disease were higher among multigravid women than among women who had never been pregnant, in both the Framingham Heart Study and the NHEFS, but in both studies, the higher rates were statistically significant only in women with six or more pregnancies. For the women in the Framingham Study, the rate ratio adjusted for age and educational level in the group with six or more pregnancies (as compared with women who had never been pregnant) was 1.6 (95 percent confidence interval, 1.1 to 2.2). For the women in the NHEFS, the same adjusted rate ratio was 1.5 (95 percent confidence interval, 1.1 to 1.9). Adjustments for other known cardiovascular risk factors, including weight, did not markedly alter this risk. The rate of total cardiovascular disease was also significantly higher among multigravid women in the Framingham Study than in the women who had never been pregnant. Conclusions. In two prospective American studies, having six or more pregnancies was associated with a small but consistent increase in the risk of coronary heart disease and cardiovascular disease. Whether gravidity itself or some other unmeasured factor accounts for the increase in risk that we observed requires further investigation.	UNIV PENN, CLIN EPIDEMIOL UNIT, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT PSYCHIAT, PHILADELPHIA, PA 19104 USA; UNIV PENN, DEPT MED, DEPT EMERGENCY, PHILADELPHIA, PA 19104 USA; CTR DIS CONTROL & PREVENT, NATL CTR HLTH STAT, HYATTSVILLE, MD USA; STANFORD UNIV, DEPT HLTH RES & POLICY, SAN FRANCISCO, CA USA; BOSTON UNIV, DEPT MATH, STAT UNIT, BOSTON, MA 02215 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); Stanford University; Boston University			Flegal, Katherine M/A-4608-2013	Flegal, Katherine/0000-0002-0838-469X	NCI NIH HHS [5T32CA09529] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009529] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ABELL LL, 1952, J BIOL CHEM, V195, P357; BEARD CM, 1984, AM J EPIDEMIOL, V120, P108, DOI 10.1093/oxfordjournals.aje.a113859; BENGTSSON C, 1973, ACTA MED SCAND, V549, P75; BERAL V, 1985, J EPIDEMIOL COMMUN H, V39, P343, DOI 10.1136/jech.39.4.343; BROADHEAD WE, 1983, AM J EPIDEMIOL, V117, P521, DOI 10.1093/oxfordjournals.aje.a113575; COLDITZ GA, 1987, AM J EPIDEMIOL, V126, P861, DOI 10.1093/oxfordjournals.aje.a114723; COX DR, 1972, J R STAT SOC B, V34, P187; CUPPLES LA, 1989, MIH893039 PUBL; Dawber TR., 1980, FRAMINGHAM STUDY EPI, DOI DOI 10.4159/HARVARD.9780674492097; DEALVAREZ RR, 1959, AM J OBSTET GYNECOL, V77, P743, DOI 10.1016/S0002-9378(16)36790-4; DENTONKELAAR I, 1990, INT J OBESITY, V14, P753; EAVENSON E, 1966, J AM OIL CHEM SOC, V43, P652, DOI 10.1007/BF02682563; EVANS DJ, 1984, J CLIN INVEST, V74, P1515, DOI 10.1172/JCI111565; FAHRAEUS L, 1985, OBSTET GYNECOL, V66, P468; Feinleib M, 1985, Natl Cancer Inst Monogr, V67, P59; FLEGAL KM, 1990, AM J EPIDEMIOL, V132, P766; FORSTER JL, 1986, PREV MED, V15, P685, DOI 10.1016/0091-7435(86)90073-3; GORDON T, 1977, ANN INTERN MED, V87, P393, DOI 10.7326/0003-4819-87-4-393; HAYNES SG, 1980, AM J PUBLIC HEALTH, V70, P133, DOI 10.2105/AJPH.70.2.133; HELIOVAARA M, 1981, J EPIDEMIOL COMMUN H, V35, P197, DOI 10.1136/jech.35.3.197; HOLLINGSWORTH DR, 1983, AM J OBSTET GYNECOL, V146, P417, DOI 10.1016/0002-9378(83)90822-0; KANNEL WB, 1976, ANN INTERN MED, V85, P447, DOI 10.7326/0003-4819-85-4-447; KAYE SA, 1990, INT J OBESITY, V14, P583; KEYS A, 1972, J CHRON DIS, V25, P329, DOI 10.1016/0021-9681(72)90027-6; KORN EL, 1991, AM J PUBLIC HEALTH, V81, P1166, DOI 10.2105/AJPH.81.9.1166; KRITZSILVERSTEIN D, 1989, NEW ENGL J MED, V321, P1214, DOI 10.1056/NEJM198911023211802; LAVECCHIA C, 1987, AM J OBSTET GYNECOL, V157, P1108, DOI 10.1016/S0002-9378(87)80271-5; LISSNER L, 1991, NEW ENGL J MED, V324, P1839, DOI 10.1056/NEJM199106273242602; MACHLIN SR, 1989, STAT MED, V8, P997, DOI 10.1002/sim.4780080810; MANN JI, 1975, BMJ-BRIT MED J, V2, P241, DOI 10.1136/bmj.2.5965.241; MANN JI, 1976, BRIT J PREV SOC MED, V30, P94; MANTEL N, 1963, J AM STAT ASSOC, V58, P690; Nelson N, 1944, J BIOL CHEM, V153, P375; OLIVER MF, 1974, BMJ-BRIT MED J, V4, P253, DOI 10.1136/bmj.4.5939.253; POTTER JM, 1979, AM J OBSTET GYNECOL, V133, P165, DOI 10.1016/0002-9378(79)90469-1; PYKE DA, 1956, LANCET, V270, P818; RITTERBRAND AB, 1963, CIRCULATION, V27, P237, DOI 10.1161/01.CIR.27.2.237; STEPHENS RC, 1978, J GERONTOLOGICAL SOC, V1, P33; STOKES J, 1987, CIRCULATION, V75, P65; VANSTIPHOUT WAHJ, 1987, AM J EPIDEMIOL, V126, P922; WINKELSTEIN W, 1964, AM HEART J, V67, P481, DOI 10.1016/0002-8703(64)90094-8; WINKELSTEIN W Jr, 1958, J Chronic Dis, V7, P273, DOI 10.1016/0021-9681(58)90085-7; 1977, VITAL HLTH STATI 10B, V1; 1974, DHEW NIH75628 PUBL; 1988, DHHS PHS881122 NAT C, V2; 1987, VITAL HLTH STATIS 22, V1; 1973, VITAL HLTH STATI 10A, V1	47	224	228	0	9	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	MAY 27	1993	328	21					1528	1533		10.1056/NEJM199305273282104	http://dx.doi.org/10.1056/NEJM199305273282104			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	LC941	8267704				2022-12-01	WOS:A1993LC94100004
